PDC_property	GDC_property	shared_terms	num_shared_terms	PDC_terms_only	GDC_terms_only
aliquot_is_ref			0/2 (both/PDC)	False|True	
analyte_type	analyte_type	DNA|EBV Immortalized Normal|FFPE DNA|FFPE RNA|GenomePlex (Rubicon) Amplified DNA|Nuclei RNA|RNA|Repli-G (Qiagen) DNA|Repli-G Pooled (Qiagen) DNA|Repli-G X (Qiagen) DNA|Total RNA|cfDNA	12/13 (both/PDC)	Protein	
analyte_type_id	analyte_type_id	D|E|G|H|R|S|T|W|X|Y	10/10 (both/PDC)		
pool			0/2 (both/PDC)	False|True	
status	status		0/2 (both/PDC)	Disqualified|Qualified	Approved|Rescinded
status			0/2 (both/PDC)	Disqualified|Qualified	
experiment_type			0/3 (both/PDC)	Label Free|TMT|iTRAQ	
experimental_protocol_type	experimental_protocol_type	Allprep FFPE DNA|Allprep RNA Extraction|Chemical Lysis DNA Extraction|Genomplex|HighPure miRNA (Allprep DNA) FFPE RNA|Pre-extracted DNA received by TSS|Repli-G|Repli-G X|Total RNA|aDNA Preparation Type|mirVana (Allprep DNA) RNA|nRNA - Melanoma Protocol	12/12 (both/PDC)		
normal_tumor_genotype_snp_match	normal_tumor_genotype_snp_match	False|Not Allowed To Collect|Not Reported|True|Unknown	5/5 (both/PDC)		
case_is_ref			0/2 (both/PDC)	False|True	
consent_type	consent_type	Consent Exemption|Consent Waiver|Consent by Death|Informed Consent	4/4 (both/PDC)		
disease_type	disease_type	Acinar Cell Neoplasms|Adenomas and Adenocarcinomas|Adnexal and Skin Appendage Neoplasms|Basal Cell Neoplasms|Blood Vessel Tumors|Chronic Myeloproliferative Disorders|Complex Epithelial Neoplasms|Complex Mixed and Stromal Neoplasms|Cystic, Mucinous and Serous Neoplasms|Ductal and Lobular Neoplasms|Epithelial Neoplasms, NOS|Fibroepithelial Neoplasms|Fibromatous Neoplasms|Germ Cell Neoplasms|Giant Cell Tumors|Gliomas|Granular Cell Tumors and Alveolar Soft Part Sarcomas|Hodgkin Lymphoma|Immunoproliferative Diseases|Leukemias, NOS|Lipomatous Neoplasms|Lymphatic Vessel Tumors|Lymphoid Leukemias|Malignant Lymphomas, NOS or Diffuse|Mast Cell Tumors|Mature B-Cell Lymphomas|Mature T- and NK-Cell Lymphomas|Meningiomas|Mesonephromas|Mesothelial Neoplasms|Miscellaneous Bone Tumors|Miscellaneous Tumors|Mucoepidermoid Neoplasms|Myelodysplastic Syndromes|Myeloid Leukemias|Myomatous Neoplasms|Myxomatous Neoplasms|Neoplasms of Histiocytes and Accessory Lymphoid Cells|Neoplasms, NOS|Nerve Sheath Tumors|Neuroepitheliomatous Neoplasms|Nevi and Melanomas|Not Applicable|Not Reported|Odontogenic Tumors|Osseous and Chondromatous Neoplasms|Other Hematologic Disorders|Other Leukemias|Paragangliomas and Glomus Tumors|Plasma Cell Tumors|Precursor Cell Lymphoblastic Lymphoma|Soft Tissue Tumors and Sarcomas, NOS|Specialized Gonadal Neoplasms|Squamous Cell Neoplasms|Synovial-like Neoplasms|Thymic Epithelial Neoplasms|Transitional Cell Papillomas and Carcinomas|Trophoblastic neoplasms|Unknown	59/113 (both/PDC)	Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Adrenocortical Carcinoma|Bladder Urothelial Carcinoma|Brain Lower Grade Glioma|Breast Invasive Carcinoma|Burkitt Lymphoma|Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma|Cholangiocarcinoma|Chromophobe Renal Cell Carcinoma|Chronic Lymphocytic Leukemia|Clear Cell Renal Cell Carcinoma|Clear Cell Sarcoma of the Kidney|Colon Adenocarcinoma|Early Onset Gastric Cancer|Esophageal Carcinoma|Glioblastoma|Glioblastoma Multiforme|HIV+ Tumor Molecular Characterization Project - Cervical Cancer|HIV+ Tumor Molecular Characterization Project - Lung Cancer|Head and Neck Squamous Cell Carcinoma|Hepatocellular Carcinoma|High-Risk Wilms Tumor|Kidney Chromophobe|Kidney Renal Clear Cell Carcinoma|Kidney Renal Papillary Cell Carcinoma|Liver Hepatocellular Carcinoma|Lung Adenocarcinoma|Lung Squamous Cell Carcinoma|Lymphoid Neoplasm Diffuse Large B-cell Lymphoma|Mesothelioma|Multiple Myeloma|Neuroblastoma|Oral Squamous Cell Carcinoma|Osteosarcoma|Other|Ovarian Serous Cystadenocarcinoma|Pancreatic Adenocarcinoma|Pancreatic Ductal Adenocarcinoma|Papillary Renal Cell Carcinoma|Pediatric/AYA Brain Tumors|Pheochromocytoma and Paraganglioma|Prostate Adenocarcinoma|Rectum Adenocarcinoma|Rhabdoid Tumor|Sarcoma|Skin Cutaneous Melanoma|Stomach Adenocarcinoma|Testicular Germ Cell Tumors|Thymoma|Thyroid Carcinoma|Uterine Carcinosarcoma|Uterine Corpus Endometrial Carcinoma|Uveal Melanoma	
index_date	index_date	Diagnosis|First Patient Visit|First Treatment|Initial Genomic Sequencing|Recurrence|Sample Procurement|Study Enrollment	7/7 (both/PDC)		
lost_to_followup	lost_to_followup	False|True|Unknown	3/3 (both/PDC)		
primary_site	primary_site	Accessory sinuses|Adrenal gland|Anus and anal canal|Base of tongue|Bladder|Bones, joints and articular cartilage of limbs|Bones, joints and articular cartilage of other and unspecified sites|Brain|Breast|Bronchus and lung|Colon|Connective, subcutaneous and other soft tissues|Corpus uteri|Esophagus|Eye and adnexa|Floor of mouth|Gallbladder|Gum|Heart, mediastinum, and pleura|Hematopoietic and reticuloendothelial systems|Hypopharynx|Kidney|Larynx|Lip|Liver and intrahepatic bile ducts|Lymph nodes|Meninges|Nasal cavity and middle ear|Nasopharynx|Not Reported|Oropharynx|Other and ill-defined digestive organs|Other and ill-defined sites|Other and ill-defined sites in lip, oral cavity and pharynx|Other and ill-defined sites within respiratory system and intrathoracic organs|Other and unspecified female genital organs|Other and unspecified major salivary glands|Other and unspecified male genital organs|Other and unspecified parts of biliary tract|Other and unspecified parts of mouth|Other and unspecified parts of tongue|Other and unspecified urinary organs|Other endocrine glands and related structures|Ovary|Palate|Pancreas|Penis|Peripheral nerves and autonomic nervous system|Placenta|Pyriform sinus|Rectum|Retroperitoneum and peritoneum|Skin|Small intestine|Spinal cord, cranial nerves, and other parts of central nervous system|Stomach|Testis|Thymus|Tonsil|Trachea|Unknown|Ureter|Uterus, NOS|Vagina|Vulva	65/88 (both/PDC)	Bile Duct|Blood|Bone|Bone Marrow|Cervix|Cervix uteri|Colorectal|Eye|Head and Neck|Liver|Lung|Nervous System|Not Applicable|Parotid gland|Pleura|Prostate|Prostate gland|Rectosigmoid junction|Renal pelvis|Soft Tissue|Thyroid|Thyroid gland|Uterus	Cervix Uteri|Parotid Gland|Prostate Gland|Rectosigmoid Region|Renal Pelvis|Thyroid Gland
cause_of_death	cause_of_death	Not Reported|Spinal Muscular Atrophy|Toxicity|Unknown	4/11 (both/PDC)	Cancer Related|Cardiovascular Disorder, NOS|End-stage Renal Disease|Infection|Not Cancer Related|Renal Disorder, NOS|Surgical Complications	Cardiovascular Disorder|Chronic Kidney Disease, Stage 5|Infectious Disorder|Kidney Disorder|Non-Cancer Related Death|Related to Cancer|Surgical Complication
cause_of_death_source	cause_of_death_source	Autopsy|Death Certificate|Medical Record|Not Reported|Social Security Death Index|Unknown	6/6 (both/PDC)		
country_of_residence_at_enrollment	country_of_residence_at_enrollment	Afghanistan|Albania|Algeria|Andorra|Angola|Anguilla|Antigua and Barbuda|Argentina|Armenia|Aruba|Australia|Austria|Azerbaijan|Bahamas|Bahrain|Bangladesh|Barbados|Belarus|Belgium|Belize|Benin|Bermuda|Bhutan|Bolivia|Bosnia and Herzegovina|Botswana|Brazil|Brunei|Bulgaria|Burkina Faso|Burundi|Cambodia|Cameroon|Canada|Cape Verde|Cayman Islands|Central African Republic|Chad|Chile|China|Colombia|Comoros|Congo|Cook Islands|Costa Rica|Cote d'Ivoire|Croatia|Cuba|Curacao|Cyprus|Czech Republic (Czechia)|Democratic Republic of the Congo|Denmark|Djibouti|Dominica|Dominican Republic|Ecuador|Egypt|El Salvador|Equatorial Guinea|Eritrea|Estonia|Eswatini|Ethiopia|Falkland Islands (Malvinas)|Faroe Islands|Federated States of Micronesia|Fiji|Finland|France|French Guiana|French Polynesia|Gabon|Gambia|Georgia|Germany|Ghana|Gibraltar|Greece|Greenland|Grenada|Guadeloupe|Guam|Guatemala|Guernsey|Guinea|Guinea-Bissau|Guyana|Haiti|Holy See|Honduras|Hong Kong|Hungary|Iceland|India|Indonesia|Iran|Iraq|Ireland|Isle of Man|Israel|Italy|Jamaica|Japan|Jersey|Jordan|Kazakhstan|Kenya|Kiribati|Kosovo|Kuwait|Kyrgyzstan|Laos|Latvia|Lebanon|Lesotho|Liberia|Libya|Liechtenstein|Lithuania|Luxembourg|Macau|Madagascar|Malawi|Malaysia|Maldives|Mali|Malta|Marshall Islands|Martinique|Mauritania|Mauritius|Mayotte|Mexico|Moldova|Monaco|Mongolia|Montenegro|Montserrat|Morocco|Mozambique|Myanmar|Namibia|Nauru|Nepal|Netherlands|New Caledonia|New Zealand|Nicaragua|Niger|Nigeria|Niue|North Korea|North Macedonia|Northern Mariana Islands|Norway|Oman|Pakistan|Palau|Panama|Papua New Guinea|Paraguay|Peru|Philippines|Poland|Portugal|Puerto Rico|Qatar|Reunion|Romania|Russia|Rwanda|Saint Helena, Ascension and Tristan da Cunha|Saint Kitts and Nevis|Saint Lucia|Saint Pierre and Miquelon|Saint Vincent and the Grenadines|Samoa|San Marino|Sao Tome and Principe|Saudi Arabia|Senegal|Serbia|Seychelles|Sierra Leone|Singapore|Slovakia|Slovenia|Solomon Islands|Somalia|South Africa|South Korea|South Sudan|Spain|Sri Lanka|State of Palestine|Sudan|Suriname|Sweden|Switzerland|Syria|Taiwan|Tajikistan|Tanzania|Thailand|Timor-Leste|Togo|Tokelau|Tonga|Trinidad and Tobago|Tunisia|Turkey|Turkmenistan|Tuvalu|Uganda|Ukraine|United Arab Emirates|United Kingdom|United States|Uruguay|Uzbekistan|Vanuatu|Venezuela|Vietnam|Virgin Islands, British|Virgin Islands, U.S.|Wallis and Futuna|Western Sahara|Yemen|Zambia|Zimbabwe	231/232 (both/PDC)	Svalbard & Jan Mayen Islands	Svalbard and Jan Mayen
ethnicity	ethnicity	Unknown|not allowed to collect|not reported	3/5 (both/PDC)	hispanic or latino|not hispanic or latino	Hispanic or Latino|Not Hispanic or Latino|unknown
gender	gender	not reported|unknown	2/5 (both/PDC)	female|male|unspecified	Female|Male|Unspecified
premature_at_birth	premature_at_birth	False|Not Reported|True|Unknown	4/4 (both/PDC)		
race	race	Unknown|not allowed to collect|not reported|other|white	5/9 (both/PDC)	american indian or alaska native|asian|black or african american|native hawaiian or other pacific islander	American Indian or Alaska Native|Asian|Black or African American|Native Hawaiian or Other Pacific Islander|unknown
vital_status	vital_status	Alive|Dead|Not Reported|Unknown	4/4 (both/PDC)		lost to follow-up
adrenal_hormone	adrenal_hormone	False|Not Reported|True	3/3 (both/PDC)		
ajcc_clinical_m	ajcc_clinical_m	Not Allowed To Collect|Not Reported|Unknown	3/10 (both/PDC)	M0|M1|M1a|M1b|M1c|MX|cM0 (i+)	M0 Stage Finding|M1 Stage Finding|M1a Stage Finding|M1b Stage Finding|M1c Stage Finding|MX Stage Finding|cM0 (i+) Stage Finding
ajcc_clinical_n	ajcc_clinical_n	N0 (i+)|N0 (mol+)|Not Allowed To Collect|Not Reported|Unknown	5/27 (both/PDC)	N0|N0 (i-)|N0 (mol-)|N1|N1a|N1b|N1bI|N1bII|N1bIII|N1bIV|N1c|N1mi|N2|N2a|N2b|N2c|N3|N3a|N3b|N3c|N4|NX	N0 (i+) Stage Finding|N0 (mol+) Stage Finding|N0 Stage Finding|N1 Stage Finding|N1a Stage Finding|N1b Stage Finding|N1bI Stage Finding|N1bII Stage Finding|N1bIII Stage Finding|N1bIV Stage Finding|N1c Stage Finding|N1mi Stage Finding|N2 Stage Finding|N2a Stage Finding|N2b Stage Finding|N2c Stage Finding|N3 Stage Finding|N3a Stage Finding|N3b Stage Finding|N3c Stage Finding|N4 Stage Finding|NX Stage Finding
ajcc_clinical_stage	figo_stage	Not Allowed To Collect|Not Reported|Stage 0|Stage I|Stage IA1|Stage IA2|Stage IB|Stage IB1|Stage IB2|Stage IC|Stage II|Stage IIA|Stage IIA1|Stage IIA2|Stage IIB|Stage IIC|Stage III|Stage IIIA|Stage IIIB|Stage IIIC|Stage IIIC1|Stage IIIC2|Stage IV|Stage IVA|Stage IVB|Unknown	26/38 (both/PDC)	Stage 0a|Stage 0is|Stage IA|Stage IA3|Stage IB Cervix|Stage II Cervix|Stage IIA Cervix|Stage IIC1|Stage IS|Stage IVC|Stage Tis|Stage X	FIGO Stage IA|FIGO Stage IC1|FIGO Stage IC2|FIGO Stage IC3|FIGO Stage IIIA1(i)|FIGO Stage IIIA1(ii)|FIGO Stage IIIA2|Stage IIIA1
ajcc_clinical_t	ajcc_clinical_t	Not Allowed To Collect|Not Reported|T1b1|T1b2|T2a1|T2a2|Unknown	7/37 (both/PDC)	T0|T1|T1a|T1a1|T1a2|T1b|T1c|T1mi|T2|T2a|T2b|T2c|T2d|T3|T3a|T3b|T3c|T3d|T4|T4a|T4b|T4c|T4d|T4e|TX|Ta|Tis|Tis (DCIS)|Tis (LCIS)|Tis (Paget's)	Breast Cancer pTis (DCIS) TNM Finding v8|Breast Cancer pTis (LCIS) TNM Finding v6 and v7|Cervical Cancer pT1a1 TNM Finding v8|Cervical Cancer pT1a2 TNM Finding v8|Choroidal and Ciliary Body Melanoma pT4e TNM Finding v8|Paget Disease of the Breast without Invasive Carcinoma|T0 Stage Finding|T1 Stage Finding|T1a Stage Finding|T1b Stage Finding|T1c Stage Finding|T1mi Stage Finding|T2 Stage Finding|T2a Stage Finding|T2b Stage Finding|T2c Stage Finding|T2d Stage Finding|T3 Stage Finding|T3a Stage Finding|T3b Stage Finding|T3c Stage Finding|T3d Stage Finding|T4 Stage Finding|T4a Stage Finding|T4b Stage Finding|T4c Stage Finding|T4d Stage Finding|TX Stage Finding|Ta Stage Finding|Tis Stage Finding
ajcc_pathologic_m	ajcc_pathologic_m	M1d|M2|Not Allowed To Collect|Not Reported|Unknown	5/12 (both/PDC)	M0|M1|M1a|M1b|M1c|MX|cM0 (i+)	M0 Stage Finding|M1 Stage Finding|M1a Stage Finding|M1b Stage Finding|M1c Stage Finding|MX Stage Finding|cM0 (i+) Stage Finding
ajcc_pathologic_n	ajcc_pathologic_n	N0 (i+)|N0 (mol+)|Not Allowed To Collect|Not Reported|Unknown	5/27 (both/PDC)	N0|N0 (i-)|N0 (mol-)|N1|N1a|N1b|N1bI|N1bII|N1bIII|N1bIV|N1c|N1mi|N2|N2a|N2b|N2c|N3|N3a|N3b|N3c|N4|NX	N0 (i+) Stage Finding|N0 (mol+) Stage Finding|N0 Stage Finding|N1 Stage Finding|N1a Stage Finding|N1b Stage Finding|N1bI Stage Finding|N1bII Stage Finding|N1bIII Stage Finding|N1bIV Stage Finding|N1c Stage Finding|N1mi Stage Finding|N2 Stage Finding|N2a Stage Finding|N2b Stage Finding|N2c Stage Finding|N3 Stage Finding|N3a Stage Finding|N3b Stage Finding|N3c Stage Finding|N4 Stage Finding|NX Stage Finding
ajcc_pathologic_stage	ajcc_pathologic_stage	Not Reported|Stage 0|Stage 0a|Stage 0is|Stage I|Stage IA1|Stage IA2|Stage IA3|Stage IB|Stage IB1|Stage IB2|Stage IC|Stage II|Stage IIA|Stage IIA1|Stage IIA2|Stage IIB|Stage IIC|Stage III|Stage IIIA|Stage IIIA1|Stage IIIB|Stage IIIC|Stage IIIC1|Stage IIIC2|Stage IIID|Stage IV|Stage IVA|Stage IVB|Stage IVC|Stage X|Unknown	32/36 (both/PDC)	Stage IA|Stage IIIA2|Stage IS|Stage Tis	FIGO Stage IA|FIGO Stage IIIA2|Stage Is|Tis Stage Finding
ajcc_pathologic_t	ajcc_pathologic_t	Not Allowed To Collect|Not Reported|T1b1|T1b2|T2a1|T2a2|Unknown	7/37 (both/PDC)	T0|T1|T1a|T1a1|T1a2|T1b|T1c|T1mi|T2|T2a|T2b|T2c|T2d|T3|T3a|T3b|T3c|T3d|T4|T4a|T4b|T4c|T4d|T4e|TX|Ta|Tis|Tis (DCIS)|Tis (LCIS)|Tis (Paget's)	Breast Cancer pTis (DCIS) TNM Finding v8|Breast Cancer pTis (LCIS) TNM Finding v6 and v7|Cervical Cancer pT1a1 TNM Finding v8|Cervical Cancer pT1a2 TNM Finding v8|Choroidal and Ciliary Body Melanoma pT4e TNM Finding v8|Paget Disease of the Breast without Invasive Carcinoma|T0 Stage Finding|T1 Stage Finding|T1a Stage Finding|T1b Stage Finding|T1c Stage Finding|T1mi Stage Finding|T2 Stage Finding|T2a Stage Finding|T2b Stage Finding|T2c Stage Finding|T2d Stage Finding|T3 Stage Finding|T3a Stage Finding|T3b Stage Finding|T3c Stage Finding|T3d Stage Finding|T4 Stage Finding|T4a Stage Finding|T4b Stage Finding|T4c Stage Finding|T4d Stage Finding|TX Stage Finding|Ta Stage Finding|Tis Stage Finding
ajcc_staging_system_edition	ajcc_staging_system_edition	1st|2nd|3rd|4th|5th|Not Reported|Unknown	7/10 (both/PDC)	6th|7th|8th	AJCC v6 Stage|AJCC v7 Stage|AJCC v8 Stage
anaplasia_present	anaplasia_present	False|Not Reported|True|Unknown	4/4 (both/PDC)		
anaplasia_present_type	anaplasia_present_type	Absent|Diffuse|Equivocal|Focal|Not Reported|Present|Sclerosis|Unknown	8/8 (both/PDC)		
ann_arbor_b_symptoms	ann_arbor_b_symptoms	False|Not Allowed To Collect|Not Reported|True|Unknown	5/5 (both/PDC)		
ann_arbor_b_symptoms_described	ann_arbor_b_symptoms_described	Fever|Night Sweats|Other|Weight Loss	4/4 (both/PDC)		
ann_arbor_clinical_stage	figo_stage	Not Reported|Stage I|Stage II|Stage III|Stage IV|Unknown	6/6 (both/PDC)		FIGO Stage IA|FIGO Stage IC1|FIGO Stage IC2|FIGO Stage IC3|FIGO Stage IIIA1(i)|FIGO Stage IIIA1(ii)|FIGO Stage IIIA2|Not Allowed To Collect|Stage 0|Stage IA1|Stage IA2|Stage IB|Stage IB1|Stage IB2|Stage IC|Stage IIA|Stage IIA1|Stage IIA2|Stage IIB|Stage IIC|Stage IIIA|Stage IIIA1|Stage IIIB|Stage IIIC|Stage IIIC1|Stage IIIC2|Stage IVA|Stage IVB
ann_arbor_extranodal_involvement	ann_arbor_extranodal_involvement	False|Not Allowed To Collect|Not Reported|True|Unknown	5/5 (both/PDC)		
ann_arbor_pathologic_stage	ajcc_pathologic_stage	Not Reported|Stage I|Stage II|Stage III|Stage IV|Unknown	6/6 (both/PDC)		FIGO Stage IA|FIGO Stage IIIA2|Stage 0|Stage 0a|Stage 0is|Stage IA1|Stage IA2|Stage IA3|Stage IB|Stage IB1|Stage IB2|Stage IC|Stage IIA|Stage IIA1|Stage IIA2|Stage IIB|Stage IIC|Stage IIIA|Stage IIIA1|Stage IIIB|Stage IIIC|Stage IIIC1|Stage IIIC2|Stage IIID|Stage IVA|Stage IVB|Stage IVC|Stage Is|Stage X|Tis Stage Finding
best_overall_response	best_overall_response	AJ-Adjuvant Therapy|DU-Disease Unchanged|MX-Mixed Response|Non-CR/Non-PD-Non-CR/Non-PD|PA-Palliative Therapy|PB-Palliative Benefit|PR-Partial Response|PSR-Pseudoresponse|SPD-Surgical Progression|TE-Too Early|VGPR-Very Good Partial Response|sCR-Stringent Complete Response	12/26 (both/PDC)	CPD-Clinical Progression|CR-Complete Response|CRU-Complete Response Unconfirmed|IMR-Immunoresponse|IPD-Immunoprogression|MR-Minimal/Marginal Response|NPB-No Palliative Benefit|NR-No Response|PD-Progressive Disease|PPD-Pseudoprogression|RD-Responsive Disease|RP-Response|RPD-Radiographic Progressive Disease|SD-Stable Disease	Complete Remission|Complete Response Unconfirmed|Disease Progression|Disease Response|Immunoprogression|Immunoresponse|Minor Response|No Palliative Benefit|No Response|Progressive Neoplastic Disease|Pseudoprogression|Radiographic Progressive Disease|Responsive Disease|Stable Disease
burkitt_lymphoma_clinical_variant	burkitt_lymphoma_clinical_variant	Not Allowed To Collect|Not Reported|Unknown	3/8 (both/PDC)	Endemic|Immunodeficiency-associated, adult|Immunodeficiency-associated, pediatric|Sporadic, adult|Sporadic, pediatric	Endemic Burkitt Lymphoma|Immunodeficiency-Related Burkitt Lymphoma|Sporadic Burkitt Lymphoma
child_pugh_classification	child_pugh_classification	Not Reported|Unknown	2/13 (both/PDC)	A|A5|A6|B|B7|B8|B9|C|C10|C11|C12	Child-Pugh Class A|Child-Pugh Class A5|Child-Pugh Class A6|Child-Pugh Class B|Child-Pugh Class B7|Child-Pugh Class B8|Child-Pugh Class B9|Child-Pugh Class C|Child-Pugh Class C10|Child-Pugh Class C11|Child-Pugh Class C12
classification_of_tumor	classification_of_tumor	Not Allowed To Collect|Premalignant|Progression|Unknown|not reported|other	6/9 (both/PDC)	metastasis|primary|recurrence	Metastatic Neoplasm|Primary Neoplasm|Recurrent Neoplasm
cog_liver_stage	figo_stage	Not Reported|Stage I|Stage II|Stage III|Stage IV|Unknown	6/6 (both/PDC)		FIGO Stage IA|FIGO Stage IC1|FIGO Stage IC2|FIGO Stage IC3|FIGO Stage IIIA1(i)|FIGO Stage IIIA1(ii)|FIGO Stage IIIA2|Not Allowed To Collect|Stage 0|Stage IA1|Stage IA2|Stage IB|Stage IB1|Stage IB2|Stage IC|Stage IIA|Stage IIA1|Stage IIA2|Stage IIB|Stage IIC|Stage IIIA|Stage IIIA1|Stage IIIB|Stage IIIC|Stage IIIC1|Stage IIIC2|Stage IVA|Stage IVB
cog_neuroblastoma_risk_group	cog_neuroblastoma_risk_group	High Risk|Intermediate Risk|Low Risk|Not Reported|Unknown	5/5 (both/PDC)		
cog_renal_stage	figo_stage	Not Reported|Stage I|Stage II|Stage III|Stage IV|Unknown	6/6 (both/PDC)		FIGO Stage IA|FIGO Stage IC1|FIGO Stage IC2|FIGO Stage IC3|FIGO Stage IIIA1(i)|FIGO Stage IIIA1(ii)|FIGO Stage IIIA2|Not Allowed To Collect|Stage 0|Stage IA1|Stage IA2|Stage IB|Stage IB1|Stage IB2|Stage IC|Stage IIA|Stage IIA1|Stage IIA2|Stage IIB|Stage IIC|Stage IIIA|Stage IIIA1|Stage IIIB|Stage IIIC|Stage IIIC1|Stage IIIC2|Stage IVA|Stage IVB
cog_rhabdomyosarcoma_risk_group	cog_rhabdomyosarcoma_risk_group	High Risk|Intermediate Risk|Low Risk|Not Reported|Unknown	5/5 (both/PDC)		
eln_risk_classification	eln_risk_classification	Adverse|Favorable|Intermediate|Not Reported|Unknown	5/5 (both/PDC)		
enneking_msts_grade	enneking_msts_grade	Not Reported|Unknown	2/4 (both/PDC)	High Grade (G2)|Low Grade (G1)	Enneking High Surgical Grade|Enneking Low Surgical Grade
enneking_msts_metastasis	enneking_msts_metastasis	Not Reported|Unknown	2/4 (both/PDC)	No Metastasis (M0)|Regional or Distant Metastasis (M1)	Enneking Metastasis M0|Enneking Metastasis M1
enneking_msts_stage	figo_stage	Not Reported|Stage IB|Stage IIA|Stage IIB|Stage III|Unknown	6/7 (both/PDC)	Stage IA	FIGO Stage IA|FIGO Stage IC1|FIGO Stage IC2|FIGO Stage IC3|FIGO Stage IIIA1(i)|FIGO Stage IIIA1(ii)|FIGO Stage IIIA2|Not Allowed To Collect|Stage 0|Stage I|Stage IA1|Stage IA2|Stage IB1|Stage IB2|Stage IC|Stage II|Stage IIA1|Stage IIA2|Stage IIC|Stage IIIA|Stage IIIA1|Stage IIIB|Stage IIIC|Stage IIIC1|Stage IIIC2|Stage IV|Stage IVA|Stage IVB
enneking_msts_tumor_site	enneking_msts_tumor_site	Not Reported|Unknown	2/4 (both/PDC)	Extracompartmental (T2)|Intracompartmental (T1)	Extracompartmental Tumor|Intracompartmental Tumor
esophageal_columnar_dysplasia_degree	esophageal_columnar_dysplasia_degree	High Grade Dysplasia|Low Grade Dysplasia|Not Reported|Unknown	4/6 (both/PDC)	Indefinite for Dysplasia|Negative/ No Dysplasia	Dysplasia Negative|Indefinite Dysplasia
esophageal_columnar_metaplasia_present	esophageal_columnar_metaplasia_present	False|Not Reported|True|Unknown	4/4 (both/PDC)		
figo_stage	figo_stage	Not Allowed To Collect|Not Reported|Stage 0|Stage I|Stage IA1|Stage IA2|Stage IB|Stage IB1|Stage IB2|Stage IC|Stage II|Stage IIA|Stage IIA1|Stage IIA2|Stage IIB|Stage IIC|Stage III|Stage IIIA|Stage IIIA1|Stage IIIB|Stage IIIC|Stage IIIC1|Stage IIIC2|Stage IV|Stage IVA|Stage IVB|Unknown	27/34 (both/PDC)	Stage IA|Stage IC1|Stage IC2|Stage IC3|Stage IIIA2|Stage IIIAi|Stage IIIAii	FIGO Stage IA|FIGO Stage IC1|FIGO Stage IC2|FIGO Stage IC3|FIGO Stage IIIA1(i)|FIGO Stage IIIA1(ii)|FIGO Stage IIIA2
figo_staging_edition_year	figo_staging_edition_year	1988|1995|2009	3/3 (both/PDC)		
first_symptom_prior_to_diagnosis	first_symptom_prior_to_diagnosis	Altered Mental Status|Not Reported|Sensory Changes|Unknown	4/8 (both/PDC)	Headaches|Motor or Movement Changes|Seizures|Visual Changes	Headache|Motor / Movement Change|Seizure|Visual Change
gastric_esophageal_junction_involvement	gastric_esophageal_junction_involvement	False|Not Reported|True|Unknown	4/4 (both/PDC)		
gleason_grade_group	gleason_grade_group	Not Reported	1/6 (both/PDC)	Group 1|Group 2|Group 3|Group 4|Group 5	Gleason Grade Group 1|Gleason Grade Group 2|Gleason Grade Group 3|Gleason Grade Group 4|Gleason Grade Group 5
gleason_grade_tertiary	gleason_grade_tertiary		0/2 (both/PDC)	Pattern 4|Pattern 5	Gleason Pattern 4|Gleason Pattern 5
goblet_cells_columnar_mucosa_present	goblet_cells_columnar_mucosa_present	False|Not Reported|True|Unknown	4/4 (both/PDC)		
hpv_positive_type	hpv_positive_type	16|18|26|31|33|35|39|45|51|52|53|56|58|59|63|66|68|70|73|82|Not Reported|Other|Unknown	23/23 (both/PDC)		
hpv_positive_type			0/23 (both/PDC)	16|18|26|31|33|35|39|45|51|52|53|56|58|59|63|66|68|70|73|82|Not Reported|Other|Unknown	
igcccg_stage	figo_stage	Not Reported|Unknown	2/5 (both/PDC)	Good Prognosis|Intermediate Prognosis|Poor Prognosis	FIGO Stage IA|FIGO Stage IC1|FIGO Stage IC2|FIGO Stage IC3|FIGO Stage IIIA1(i)|FIGO Stage IIIA1(ii)|FIGO Stage IIIA2|Not Allowed To Collect|Stage 0|Stage I|Stage IA1|Stage IA2|Stage IB|Stage IB1|Stage IB2|Stage IC|Stage II|Stage IIA|Stage IIA1|Stage IIA2|Stage IIB|Stage IIC|Stage III|Stage IIIA|Stage IIIA1|Stage IIIB|Stage IIIC|Stage IIIC1|Stage IIIC2|Stage IV|Stage IVA|Stage IVB
inpc_grade	inpc_grade	Not Reported|Unknown	2/5 (both/PDC)	Differentiating|Poorly Differentiated|Undifferentiated	Differentiating Neuroblastoma|Poorly Differentiated Neuroblastoma|Undifferentiated Neuroblastoma
inpc_histologic_group	inpc_histologic_group	Favorable|Not Reported|Unfavorable|Unknown	4/4 (both/PDC)		
inrg_stage	figo_stage	Not Reported|Unknown	2/6 (both/PDC)	L1|L2|M|Ms	FIGO Stage IA|FIGO Stage IC1|FIGO Stage IC2|FIGO Stage IC3|FIGO Stage IIIA1(i)|FIGO Stage IIIA1(ii)|FIGO Stage IIIA2|Not Allowed To Collect|Stage 0|Stage I|Stage IA1|Stage IA2|Stage IB|Stage IB1|Stage IB2|Stage IC|Stage II|Stage IIA|Stage IIA1|Stage IIA2|Stage IIB|Stage IIC|Stage III|Stage IIIA|Stage IIIA1|Stage IIIB|Stage IIIC|Stage IIIC1|Stage IIIC2|Stage IV|Stage IVA|Stage IVB
inss_stage	figo_stage	Not Reported|Unknown	2/8 (both/PDC)	Stage 1|Stage 2A|Stage 2B|Stage 3|Stage 4|Stage 4S	FIGO Stage IA|FIGO Stage IC1|FIGO Stage IC2|FIGO Stage IC3|FIGO Stage IIIA1(i)|FIGO Stage IIIA1(ii)|FIGO Stage IIIA2|Not Allowed To Collect|Stage 0|Stage I|Stage IA1|Stage IA2|Stage IB|Stage IB1|Stage IB2|Stage IC|Stage II|Stage IIA|Stage IIA1|Stage IIA2|Stage IIB|Stage IIC|Stage III|Stage IIIA|Stage IIIA1|Stage IIIB|Stage IIIC|Stage IIIC1|Stage IIIC2|Stage IV|Stage IVA|Stage IVB
international_prognostic_index	international_prognostic_index	High Risk|Low Risk	2/4 (both/PDC)	High-Intermediate Risk|Low-Intermediate Risk	International Prognostic Index High-Intermediate Risk Group|International Prognostic Index Low-Intermediate Risk Group
irs_group	irs_group	Not Reported|Unknown	2/13 (both/PDC)	Group I|Group II|Group III|Group IIIa|Group IIIb|Group IIa|Group IIb|Group IIc|Group IV|Group Ia|Group Ib	Intergroup Rhabdomyosarcoma Group I|Intergroup Rhabdomyosarcoma Group II|Intergroup Rhabdomyosarcoma Group III|Intergroup Rhabdomyosarcoma Group IIIa|Intergroup Rhabdomyosarcoma Group IIIb|Intergroup Rhabdomyosarcoma Group IIa|Intergroup Rhabdomyosarcoma Group IIb|Intergroup Rhabdomyosarcoma Group IIc|Intergroup Rhabdomyosarcoma Group IV|Intergroup Rhabdomyosarcoma Group Ia|Intergroup Rhabdomyosarcoma Group Ib
irs_stage	figo_stage	Not Reported|Unknown	2/6 (both/PDC)	1|2|3|4	FIGO Stage IA|FIGO Stage IC1|FIGO Stage IC2|FIGO Stage IC3|FIGO Stage IIIA1(i)|FIGO Stage IIIA1(ii)|FIGO Stage IIIA2|Not Allowed To Collect|Stage 0|Stage I|Stage IA1|Stage IA2|Stage IB|Stage IB1|Stage IB2|Stage IC|Stage II|Stage IIA|Stage IIA1|Stage IIA2|Stage IIB|Stage IIC|Stage III|Stage IIIA|Stage IIIA1|Stage IIIB|Stage IIIC|Stage IIIC1|Stage IIIC2|Stage IV|Stage IVA|Stage IVB
ishak_fibrosis_score	ishak_fibrosis_score	Not Reported|Unknown	2/7 (both/PDC)	0 - No Fibrosis|1,2 - Portal Fibrosis|3,4 - Fibrous Septa|5 - Nodular Formation and Incomplete Cirrhosis|6 - Established Cirrhosis	Ishak Score 0|Ishak Score 1-2|Ishak Score 3-4|Ishak Score 5|Ishak Score 6
iss_stage	figo_stage	Not Reported|Unknown	2/5 (both/PDC)	I|II|III	FIGO Stage IA|FIGO Stage IC1|FIGO Stage IC2|FIGO Stage IC3|FIGO Stage IIIA1(i)|FIGO Stage IIIA1(ii)|FIGO Stage IIIA2|Not Allowed To Collect|Stage 0|Stage I|Stage IA1|Stage IA2|Stage IB|Stage IB1|Stage IB2|Stage IC|Stage II|Stage IIA|Stage IIA1|Stage IIA2|Stage IIB|Stage IIC|Stage III|Stage IIIA|Stage IIIA1|Stage IIIB|Stage IIIC|Stage IIIC1|Stage IIIC2|Stage IV|Stage IVA|Stage IVB
largest_extrapelvic_peritoneal_focus	largest_extrapelvic_peritoneal_focus	Microscopic|Not Reported|Unknown	3/5 (both/PDC)	Macroscopic (2cm or less)|Macroscopic (greater than 2cm)	Lesion with Diameter Greater than 2cm|Lesion with Diameter of 2cm or Less
last_known_disease_status	last_known_disease_status	Distant met recurrence/progression|Loco-regional recurrence/progression|Not Allowed To Collect|not reported	4/8 (both/PDC)	Biochemical evidence of disease without structural correlate|Tumor free|Unknown tumor status|With tumor	Biochemical Evidence of Disease without Structural Correlate|Tumor Free|Unknown Tumor Status|With Tumor
laterality	laterality	Bilateral|Left|Midline|Not Reported|Right|Unilateral|Unknown	7/7 (both/PDC)		
lymphatic_invasion_present	lymphatic_invasion_present	False|Not Reported|True|Unknown	4/4 (both/PDC)		
margins_involved_site	margins_involved_site	Gerota Fascia|Parenchyma|Perinephric Fat|Renal|Renal Capsule|Renal Sinus|Renal Vein|Ureter	8/8 (both/PDC)		
masaoka_stage	figo_stage	Stage I|Stage III	2/6 (both/PDC)	Stage IIa|Stage IIb|Stage IVa|Stage IVb	FIGO Stage IA|FIGO Stage IC1|FIGO Stage IC2|FIGO Stage IC3|FIGO Stage IIIA1(i)|FIGO Stage IIIA1(ii)|FIGO Stage IIIA2|Not Allowed To Collect|Not Reported|Stage 0|Stage IA1|Stage IA2|Stage IB|Stage IB1|Stage IB2|Stage IC|Stage II|Stage IIA|Stage IIA1|Stage IIA2|Stage IIB|Stage IIC|Stage IIIA|Stage IIIA1|Stage IIIB|Stage IIIC|Stage IIIC1|Stage IIIC2|Stage IV|Stage IVA|Stage IVB|Unknown
medulloblastoma_molecular_classification	medulloblastoma_molecular_classification	Not Reported|Unknown	2/6 (both/PDC)	Non-WNT/non-SHH Activated|Not Determined|SHH-Activated|WNT-Activated	Medulloblastoma, Non-WNT/Non-SHH|Medulloblastoma, Not Otherwise Specified|Medulloblastoma, SHH-Activated|Medulloblastoma, WNT-Activated
metastasis_at_diagnosis	metastasis_at_diagnosis	Distant Metastasis|Not Reported|Regional Metastasis|Unknown	4/6 (both/PDC)	Metastasis, NOS|No Metastasis	Metastasis|Metastasis Negative
metastasis_at_diagnosis_site	metastasis_at_diagnosis_site	Abdomen|Adrenal Gland|Ascites|Bladder|Bone|Bone Marrow|Brain|Bronchus|Central Nervous System|Cerebrospinal Fluid|Colon|Distant Nodes|Distant Organ|Esophagus|Gastrointestinal Tract|Head, Face or Neck, NOS|Heart|Kidney|Liver|Lung|Lymph Node, NOS|Lymph Node, Regional|Lymph Node, Subcarinal|Mediastinum|Neck|Not Reported|Omentum|Ovary|Pancreas|Pelvis|Peritoneal Cavity|Peritoneum|Pleura|Retroperitoneum|Scalp|Skin|Small Intestine|Soft Tissue|Spinal Cord|Unknown|Urethra|Uterine Adnexa|Vertebral Canal	43/47 (both/PDC)	Groin|Lymph Node, Axillary|Lymph Node, Inguinal|Vulva, NOS	Axillary Lymph Node|Inguinal Lymph Node|Inguinal Region|Vulva
method_of_diagnosis	method_of_diagnosis	Autopsy|Biopsy|Blood Draw|Bone Marrow Aspirate|Core Biopsy|Cystoscopy|Cytology|Diagnostic Imaging|Enucleation|Excisional Biopsy|Exoresection|Fine Needle Aspiration|Incisional Biopsy|Laparoscopy|Laparotomy|Not Allowed To Collect|Not Reported|Other|Pap Smear|Thoracentesis|Unknown	21/28 (both/PDC)	Debulking|Dilation and Curettage Procedure|Imaging|Pathologic Review|Physical Exam|Surgical Resection|Ultrasound Guided Biopsy	Dilation and Curettage|Excision|Imaging Technique|Pathologic Examination|Physical Examination|Tumor Debulking|Ultrasound-Guided Biopsy
micropapillary_features	micropapillary_features	Absent|Not Reported|Present|Unknown	4/4 (both/PDC)		
mitosis_karyorrhexis_index	mitosis_karyorrhexis_index	High|Intermediate|Low|Not Reported|Unknown	5/5 (both/PDC)		
morphology	morphology	8001/0|8005/3|8020/6|8035/3|8040/1|8040/3|8041/34|8041/6|8046/6|8070/33|8086/3|8140/33|8149/0|8163/3|8173/3|8174/3|8175/3|8191/0|8213/3|8230/2|8240/6|8241/3|8245/1|8246/6|8249/6|8265/3|8281/3|8310/6|8311/1|8311/6|8313/1|8313/3|8316/3|8330/0|8332/3|8333/3|8335/3|8341/3|8342/3|8343/3|8346/3|8347/3|8370/1|8380/0|8380/6|8381/3|8401/3|8408/1|8413/3|8430/1|8441/6|8443/0|8444/1|8452/3|8453/0|8453/3|8461/6|8463/1|8470/2|8471/1|8482/6|8500/6|8501/2|8507/2|8507/3|8508/3|8509/3|8512/3|8513/3|8514/3|8521/1|8522/1|8522/6|8523/3|8524/3|8525/3|8530/3|8541/3|8552/3|8560/0|8594/1|8623/1|8631/0|8631/3|8633/1|8634/1|8634/3|8640/3|8641/0|8642/1|8670/3|8720/6|8761/0|8761/3|8800/6|8801/6|8804/6|8806/6|8825/3|8827/1|8898/1|8902/3|8904/0|8920/6|8934/3|8950/6|8960/1|8966/0|8967/0|8974/1|8975/1|8981/3|8983/0|8983/3|9014/1|9014/3|9015/1|9015/3|9045/3|9055/0|9064/2|9072/3|9123/0|9124/3|9133/3|9161/0|9171/0|9180/6|9184/3|9230/3|9290/3|9396/3|9440/6|9501/0|9502/0|9502/3|9582/0|9654/3|9655/3|9728/3|9751/1|9752/1|9753/1|9754/3|9760/3|9967/3|Not Reported|Unknown	148/1152 (both/PDC)	8000/0|8000/1|8000/3|8000/6|8000/9|8001/1|8001/3|8002/3|8003/3|8004/3|8005/0|8010/0|8010/2|8010/3|8010/6|8010/9|8011/0|8011/3|8012/3|8013/3|8014/3|8015/3|8020/3|8021/3|8022/3|8023/3|8030/3|8031/3|8032/3|8033/3|8034/3|8040/0|8041/3|8042/3|8043/3|8044/3|8045/3|8046/3|8050/0|8050/2|8050/3|8051/0|8051/3|8052/0|8052/2|8052/3|8053/0|8060/0|8070/2|8070/3|8070/6|8071/2|8071/3|8072/3|8073/3|8074/3|8075/3|8076/2|8076/3|8077/0|8077/2|8078/3|8080/2|8081/2|8082/3|8083/3|8084/3|8085/3|8090/1|8090/3|8091/3|8092/3|8093/3|8094/3|8095/3|8096/0|8097/3|8098/3|8100/0|8101/0|8102/0|8102/3|8103/0|8110/0|8110/3|8120/0|8120/1|8120/2|8120/3|8121/0|8121/1|8121/3|8122/3|8123/3|8124/3|8130/1|8130/2|8130/3|8131/3|8140/0|8140/1|8140/2|8140/3|8140/6|8141/3|8142/3|8143/3|8144/3|8145/3|8146/0|8147/0|8147/3|8148/0|8148/2|8150/0|8150/1|8150/3|8151/0|8151/3|8152/1|8152/3|8153/1|8153/3|8154/3|8155/1|8155/3|8156/1|8156/3|8158/1|8160/0|8160/3|8161/0|8161/3|8162/3|8163/0|8163/2|8170/0|8170/3|8171/3|8172/3|8180/3|8190/0|8190/3|8200/0|8200/3|8201/2|8201/3|8202/0|8204/0|8210/0|8210/2|8210/3|8211/0|8211/3|8212/0|8213/0|8214/3|8215/3|8220/0|8220/3|8221/0|8221/3|8230/3|8231/3|8240/1|8240/3|8242/1|8242/3|8243/3|8244/3|8245/3|8246/3|8247/3|8248/1|8249/3|8250/1|8250/2|8250/3|8251/0|8251/3|8252/3|8253/3|8254/3|8255/3|8256/3|8257/3|8260/0|8260/3|8261/0|8261/2|8261/3|8262/3|8263/0|8263/2|8263/3|8264/0|8270/0|8270/3|8271/0|8272/0|8272/3|8280/0|8280/3|8281/0|8290/0|8290/3|8300/0|8300/3|8310/0|8310/3|8311/3|8312/3|8313/0|8314/3|8315/3|8317/3|8318/3|8319/3|8320/3|8321/0|8322/0|8322/3|8323/0|8323/3|8324/0|8325/0|8330/1|8330/3|8331/3|8333/0|8334/0|8336/0|8337/3|8339/3|8340/3|8343/2|8344/3|8345/3|8350/3|8360/1|8361/0|8370/0|8370/3|8371/0|8372/0|8373/0|8374/0|8375/0|8380/1|8380/2|8380/3|8381/0|8381/1|8382/3|8383/3|8384/3|8390/0|8390/3|8391/0|8392/0|8400/0|8400/1|8400/3|8401/0|8402/0|8402/3|8403/0|8403/3|8404/0|8405/0|8406/0|8407/0|8407/3|8408/0|8408/3|8409/0|8409/3|8410/0|8410/3|8420/0|8420/3|8430/3|8440/0|8440/3|8441/0|8441/2|8441/3|8442/1|8450/0|8450/3|8451/1|8452/1|8453/2|8454/0|8460/0|8460/2|8460/3|8461/0|8461/3|8462/1|8470/0|8470/3|8471/0|8471/3|8472/1|8473/1|8474/1|8474/3|8480/0|8480/1|8480/3|8480/6|8481/3|8482/3|8490/3|8490/6|8500/2|8500/3|8501/3|8502/3|8503/0|8503/2|8503/3|8504/0|8504/2|8504/3|8505/0|8506/0|8509/2|8510/3|8519/2|8520/2|8520/3|8521/3|8522/2|8522/3|8540/3|8542/3|8543/3|8550/0|8550/1|8550/3|8551/3|8560/3|8561/0|8562/3|8570/3|8571/3|8572/3|8573/3|8574/3|8575/3|8576/3|8580/0|8580/1|8580/3|8581/1|8581/3|8582/1|8582/3|8583/1|8583/3|8584/1|8584/3|8585/1|8585/3|8586/3|8587/0|8588/3|8589/3|8590/1|8591/1|8592/1|8593/1|8600/0|8600/3|8601/0|8602/0|8610/0|8620/1|8620/3|8621/1|8622/1|8630/0|8630/1|8630/3|8631/1|8632/1|8640/1|8650/0|8650/1|8650/3|8660/0|8670/0|8671/0|8680/0|8680/1|8680/3|8681/1|8682/1|8683/0|8690/1|8691/1|8692/1|8693/1|8693/3|8700/0|8700/3|8710/3|8711/0|8711/3|8712/0|8713/0|8714/3|8720/0|8720/2|8720/3|8721/3|8722/0|8722/3|8723/0|8723/3|8725/0|8726/0|8727/0|8728/0|8728/1|8728/3|8730/0|8730/3|8740/0|8740/3|8741/2|8741/3|8742/2|8742/3|8743/3|8744/3|8745/3|8746/3|8750/0|8760/0|8761/1|8762/1|8770/0|8770/3|8771/0|8771/3|8772/0|8772/3|8773/3|8774/3|8780/0|8780/3|8790/0|8800/0|8800/3|8800/9|8801/3|8802/3|8803/3|8804/3|8805/3|8806/3|8810/0|8810/1|8810/3|8811/0|8811/1|8811/3|8812/0|8812/3|8813/0|8813/3|8814/3|8815/0|8815/1|8815/3|8820/0|8821/1|8822/1|8823/0|8824/0|8824/1|8825/0|8825/1|8826/0|8830/0|8830/1|8830/3|8831/0|8832/0|8832/3|8833/3|8834/1|8835/1|8836/1|8840/0|8840/3|8841/1|8842/0|8842/3|8850/0|8850/1|8850/3|8851/0|8851/3|8852/0|8852/3|8853/3|8854/0|8854/3|8855/3|8856/0|8857/0|8857/3|8858/3|8860/0|8861/0|8862/0|8870/0|8880/0|8881/0|8890/0|8890/1|8890/3|8891/0|8891/3|8892/0|8893/0|8894/0|8894/3|8895/0|8895/3|8896/3|8897/1|8900/0|8900/3|8901/3|8903/0|8905/0|8910/3|8912/3|8920/3|8921/3|8930/0|8930/3|8931/3|8932/0|8933/3|8935/0|8935/1|8935/3|8936/0|8936/1|8936/3|8940/0|8940/3|8941/3|8950/3|8951/3|8959/0|8959/1|8959/3|8960/3|8963/3|8964/3|8965/0|8970/3|8971/3|8972/3|8973/3|8980/3|8982/0|8982/3|8990/0|8990/1|8990/3|8991/3|9000/0|9000/1|9000/3|9010/0|9011/0|9012/0|9013/0|9014/0|9015/0|9016/0|9020/0|9020/1|9020/3|9030/0|9040/0|9040/3|9041/3|9042/3|9043/3|9044/3|9050/0|9050/3|9051/0|9051/3|9052/0|9052/3|9053/3|9054/0|9055/1|9060/3|9061/3|9062/3|9063/3|9064/3|9065/3|9070/3|9071/3|9073/1|9080/0|9080/1|9080/3|9081/3|9082/3|9083/3|9084/0|9084/3|9085/3|9086/3|9090/0|9090/3|9091/1|9100/0|9100/1|9100/3|9101/3|9102/3|9103/0|9104/1|9105/3|9110/0|9110/1|9110/3|9120/0|9120/3|9121/0|9122/0|9125/0|9130/0|9130/1|9130/3|9131/0|9132/0|9133/1|9135/1|9136/1|9137/3|9140/3|9141/0|9142/0|9150/0|9150/1|9150/3|9160/0|9161/1|9170/0|9170/3|9172/0|9173/0|9174/0|9174/1|9175/0|9180/0|9180/3|9181/3|9182/3|9183/3|9185/3|9186/3|9187/3|9191/0|9192/3|9193/3|9194/3|9195/3|9200/0|9200/1|9210/0|9210/1|9220/0|9220/1|9220/3|9221/0|9221/3|9230/0|9231/3|9240/3|9241/0|9242/3|9243/3|9250/1|9250/3|9251/1|9251/3|9252/0|9252/3|9260/3|9261/3|9262/0|9270/0|9270/1|9270/3|9271/0|9272/0|9273/0|9274/0|9275/0|9280/0|9281/0|9282/0|9290/0|9300/0|9301/0|9302/0|9302/3|9310/0|9310/3|9311/0|9312/0|9320/0|9321/0|9322/0|9330/0|9330/3|9340/0|9341/1|9341/3|9342/3|9350/1|9351/1|9352/1|9360/1|9361/1|9362/3|9363/0|9364/3|9365/3|9370/3|9371/3|9372/3|9373/0|9380/3|9381/3|9382/3|9383/1|9384/1|9385/3|9390/0|9390/1|9390/3|9391/3|9392/3|9393/3|9394/1|9395/3|9400/3|9401/3|9410/3|9411/3|9412/1|9413/0|9420/3|9421/1|9423/3|9424/3|9425/3|9430/3|9431/1|9432/1|9440/3|9441/3|9442/1|9442/3|9444/1|9445/3|9450/3|9451/3|9460/3|9470/3|9471/3|9472/3|9473/3|9474/3|9475/3|9476/3|9477/3|9478/3|9480/3|9490/0|9490/3|9491/0|9492/0|9493/0|9500/3|9501/3|9503/3|9504/3|9505/1|9505/3|9506/1|9507/0|9508/3|9509/1|9510/0|9510/3|9511/3|9512/3|9513/3|9514/1|9520/3|9521/3|9522/3|9523/3|9530/0|9530/1|9530/3|9531/0|9532/0|9533/0|9534/0|9535/0|9537/0|9538/1|9538/3|9539/1|9539/3|9540/0|9540/1|9540/3|9541/0|9542/3|9550/0|9560/0|9560/1|9560/3|9561/3|9562/0|9570/0|9571/0|9571/3|9580/0|9580/3|9581/3|9590/3|9591/3|9596/3|9597/3|9650/3|9651/3|9652/3|9653/3|9659/3|9661/3|9662/3|9663/3|9664/3|9665/3|9667/3|9670/3|9671/3|9673/3|9675/3|9678/3|9679/3|9680/3|9684/3|9687/3|9688/3|9689/3|9690/3|9691/3|9695/3|9698/3|9699/3|9700/3|9701/3|9702/3|9705/3|9708/3|9709/3|9712/3|9714/3|9716/3|9717/3|9718/3|9719/3|9724/3|9725/3|9726/3|9727/3|9729/3|9731/3|9732/3|9733/3|9734/3|9735/3|9737/3|9738/3|9740/1|9740/3|9741/1|9741/3|9742/3|9750/3|9751/3|9755/3|9756/3|9757/3|9758/3|9759/3|9761/3|9762/3|9764/3|9765/1|9766/1|9767/1|9768/1|9769/1|9800/3|9801/3|9805/3|9806/3|9807/3|9808/3|9809/3|9811/3|9812/3|9813/3|9814/3|9815/3|9816/3|9817/3|9818/3|9820/3|9823/3|9826/3|9827/3|9831/3|9832/3|9833/3|9834/3|9835/3|9836/3|9837/3|9840/3|9860/3|9861/3|9863/3|9865/3|9866/3|9867/3|9869/3|9870/3|9871/3|9872/3|9873/3|9874/3|9875/3|9876/3|9891/3|9895/3|9896/3|9897/3|9898/1|9898/3|9910/3|9911/3|9920/3|9930/3|9931/3|9940/3|9945/3|9946/3|9948/3|9950/3|9960/3|9961/3|9962/3|9963/3|9964/3|9965/3|9966/3|9970/1|9971/1|9971/3|9975/3|9980/3|9982/3|9983/3|9984/3|9985/3|9986/3|9987/3|9989/3|9991/3|9992/3	ALK-Positive Large B-Cell Lymphoma|Abdominal (Mesenteric) Fibromatosis|Acinar Cell Adenoma|Acinar Cell Carcinoma|Acinar Cell Neoplasm|Acral Lentiginous Melanoma|Acute Basophilic Leukemia|Acute Biphenotypic Leukemia|Acute Erythroid Leukemia|Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Megakaryoblastic Leukemia|Acute Monocytic Leukemia|Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1|Acute Myeloid Leukemia Not Otherwise Specified|Acute Myeloid Leukemia with Maturation|Acute Myeloid Leukemia with Minimal Differentiation|Acute Myeloid Leukemia with Myelodysplasia-Related Changes|Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11|Acute Myeloid Leukemia with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM|Acute Myeloid Leukemia with t(6;9) (p23;q34.1); DEK-NUP214|Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A|Acute Myeloid Leukemia without Maturation|Acute Myelomonocytic Leukemia|Acute Panmyelosis with Myelofibrosis|Acute Promyelocytic Leukemia with PML-RARA|Adamantinoma|Adamantinomatous Craniopharyngioma|Adenocarcinoma|Adenocarcinoma In Situ|Adenocarcinoma In Situ in Adenomatous Polyp|Adenocarcinoma In Situ in Tubulovillous Adenoma|Adenocarcinoma In Situ in Villous Adenoma|Adenocarcinoma in Adenomatous Polyp|Adenocarcinoma in Adenomatous Polyposis Coli|Adenocarcinoma in Multiple Adenomatous Polyps|Adenocarcinoma in Tubulovillous Adenoma|Adenocarcinoma in Villous Adenoma|Adenocarcinoma with Apocrine Metaplasia|Adenocarcinoma with Cartilaginous and Osseous Metaplasia|Adenocarcinoma with Neuroendocrine Differentiation|Adenocarcinoma with Spindle Cell Metaplasia|Adenocarcinoma with Squamous Metaplasia|Adenocarcinoma, Endocervical Type|Adenoid Cystic Carcinoma|Adenoma|Adenomatoid Odontogenic Tumor|Adenomatoid Tumor|Adenomatous Polyp|Adenomyoma|Adenosarcoma|Adenosquamous Carcinoma|Adnexal Carcinoma|Adrenal Cortex Adenoma|Adrenal Cortex Carcinoma|Adrenal Cortex Clear Cell Adenoma|Adrenal Cortex Compact Cell Adenoma|Adrenal Cortex Glomerulosa Cell Adenoma|Adrenal Cortex Mixed Cell Adenoma|Adrenal Gland Myelolipoma|Adrenal Gland Pheochromocytoma|Adrenal Rest Tumor|Adult Cystic Nephroma|Adult Pleomorphic Rhabdomyosarcoma|Adult T-Cell Leukemia/Lymphoma|Adult Type Granulosa Cell Tumor|Aggressive NK-Cell Leukemia|Aggressive Osteoblastoma|Alpha Heavy Chain Disease|Alveolar Adenoma|Alveolar Rhabdomyosarcoma|Alveolar Soft Part Sarcoma|Amelanotic Melanoma|Ameloblastic Fibro-Odontoma|Ameloblastic Fibrodentinoma|Ameloblastic Fibroma|Ameloblastic Fibrosarcoma|Ameloblastoma|Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with High Grade Dysplasia|Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with Low Grade Dysplasia|Anal Canal Cloacogenic Carcinoma|Anal Glands Adenocarcinoma|Anaplastic (Malignant) Meningioma|Anaplastic Astrocytoma|Anaplastic Ependymoma|Anaplastic Ganglioglioma|Anaplastic Large Cell Lymphoma, ALK-Positive|Anaplastic Oligodendroglioma|Angiocentric Glioma|Angiocentric Immunoproliferative Lesion|Angiofibroma|Angioimmunoblastic T-Cell Lymphoma|Angiokeratoma|Angioleiomyoma|Angiolipoma|Angiomatoid Fibrous Histiocytoma|Angiomatous Meningioma|Angiomyofibroblastoma|Angiomyolipoma|Angiomyosarcoma|Angiomyxoma|Angiosarcoma|Aorticopulmonary Paraganglioma|Apocrine Adenoma|Askin Tumor|Astroblastoma|Astrocytoma|Atypical Adenoma|Atypical Carcinoid Tumor|Atypical Choroid Plexus Papilloma|Atypical Endometrial Hyperplasia|Atypical Fibroxanthoma|Atypical Lipomatous Tumor|Atypical Meningioma|Atypical Teratoid/Rhabdoid Tumor|B Acute Lymphoblastic Leukemia|B Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy|B Lymphoblastic Leukemia/Lymphoma with Hypodiploidy|B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1|B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)|B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH|B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1|B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged|B Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified|B-Cell Prolymphocytic Leukemia|Balloon Cell Melanoma|Balloon Cell Nevus|Basal Cell Neoplasm|Basaloid Carcinoma|Basaloid Squamous Cell Carcinoma|Basophilic Adenocarcinoma|Benign Epithelial Neoplasm|Benign Fibrous Histiocytoma|Benign Hemangioendothelioma|Benign Hemangiopericytoma|Benign Leydig Cell Tumor|Benign Mesenchymoma|Benign Mesonephroma|Benign Muscle Neoplasm|Benign Neoplasm|Benign Odontogenic Neoplasm|Benign Paraganglioma|Benign Phyllodes Tumor|Benign Sertoli Cell Tumor|Benign Soft Tissue Neoplasm|Benign Stromal Tumor|Benign Synovial Neoplasm|Benign Thymoma|Bile Duct Adenoma|Bile Duct Mucinous Cystic Neoplasm|Bile Duct Mucinous Cystic Neoplasm with an Associated Invasive Carcinoma|Biphasic Mesothelioma|Biphasic Synovial Sarcoma|Bizarre Leiomyoma|Bladder Papillary Urothelial Neoplasm of Low Malignant Potential|Blue Nevus|Bone Desmoplastic Fibroma|Borderline Ovarian Brenner Tumor/Atypical Proliferative Ovarian Brenner Tumor|Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor|Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor|Borderline Ovarian Serous Tumor-Micropapillary Variant/Non-Invasive Low Grade Ovarian Serous Carcinoma|Borderline Papillary Cystadenoma|Borderline Papillary Mucinous Cystadenoma|Borderline Papillary Serous Cystadenoma|Borderline Phyllodes Tumor|Borderline Serous Cystadenoma|Bowen Disease of the Skin|Breast Fibroadenoma|Breast Giant Fibroadenoma|Breast Intracanalicular Fibroadenoma|Breast Juvenile Fibroadenoma|Breast Pericanalicular Fibroadenoma|Brenner Tumor|Burkitt Leukemia|Burkitt Lymphoma|Calcifying Cystic Odontogenic Tumor|Calcifying Epithelial Odontogenic Tumor|Capillary Hemangioma|Carcinoid Tumor|Carcinoid Tumor of Uncertain Malignant Potential|Carcinoma|Carcinoma In Situ|Carcinoma Simplex|Carcinoma ex Pleomorphic Adenoma|Carcinomatosis|Carcinosarcoma|Carotid Body Paraganglioma|Cavernous Hemangioma|Cavernous Lymphangioma|Cellular Blue Nevus|Cellular Fibroma|Cellular Leiomyoma|Cementoblastoma|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 2|Central Neurocytoma|Cerebellar Sarcoma|Ceruminous Adenocarcinoma|Cholangiocarcinoma|Chondroblastic Osteosarcoma|Chondroblastoma|Chondroid Chordoma|Chondroid Lipoma|Chondroma|Chondromatosis|Chondromyxoid Fibroma|Chondrosarcoma|Chordoid Glioma of the Third Ventricle|Chordoma|Choriocarcinoma|Choriocarcinoma Combined with Other Germ Cell Elements|Choroid Plexus Carcinoma|Choroid Plexus Papilloma|Chromophobe Renal Cell Carcinoma|Chronic Eosinophilic Leukemia, Not Otherwise Specified|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Clear Cell Adenocarcinoma|Clear Cell Adenofibroma|Clear Cell Adenoma|Clear Cell Chondrosarcoma|Clear Cell Meningioma|Clear Cell Neoplasm|Clear Cell Odontogenic Carcinoma|Clear Cell Sarcoma of Soft Tissue|Clear Cell Sarcoma of the Kidney|Collecting Duct Carcinoma|Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Combined Carcinoid and Adenocarcinoma|Combined Hepatocellular Carcinoma and Cholangiocarcinoma|Combined Lung Small Cell Carcinoma|Comedocarcinoma|Complex Odontoma|Composite Lymphoma|Compound Nevus|Compound Odontoma|Conventional Osteosarcoma|Craniopharyngioma|Cribriform Carcinoma|Cutaneous Nodular Melanoma|Cylindroma|Cystadenocarcinoma|Cystadenoma|Cystic Hygroma|Cystic Partially Differentiated Kidney Nephroblastoma|Cystic Tumor of the Atrioventricular Node|Dedifferentiated Chondrosarcoma|Dedifferentiated Chordoma|Dedifferentiated Liposarcoma|Dermal Nevus|Dermatofibrosarcoma Protuberans|Dermoid Cyst|Desmoid-Type Fibromatosis|Desmoplastic Infantile Astrocytoma|Desmoplastic Melanoma|Desmoplastic Small Round Cell Tumor|Desmoplastic/Nodular Medulloblastoma|Differentiated Retinoblastoma|Diffuse Centroblastic-Centrocytic Lymphoma|Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Arising in HHV8-Positive Multicentric Castleman Disease|Diffuse Midline Glioma, H3 K27M-Mutant|Diffuse Retinoblastoma|Diffuse Sclerosing Variant Thyroid Gland Papillary Carcinoma|Diffuse Type Adenocarcinoma|Digestive System Mixed Adenoneuroendocrine Carcinoma|Digital Papillary Adenocarcinoma|Ductal Breast Carcinoma In Situ|Ductal Breast Carcinoma In Situ and Lobular Carcinoma In Situ|Dysembryoplastic Neuroepithelial Tumor|Dysgerminoma|Dysplastic Cerebellar Gangliocytoma|Dysplastic Nevus|Ectomesenchymoma|Ectopic Hamartomatous Thymoma|Elastofibroma|Embryonal Carcinoma|Embryonal Rhabdomyosarcoma|Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified|Endometrial Endometrioid Adenocarcinoma, Ciliated Variant|Endometrial Endometrioid Adenocarcinoma, Secretory Variant|Endometrial Stromal Nodule|Endometrioid Adenocarcinoma|Endometrioid Stromal Sarcoma|Enterochromaffin-Like Cell Neuroendocrine Tumor G1|Enteroglucagonoma|Enteropathy-Associated T-Cell Lymphoma|Ependymoma|Epithelial Neoplasm|Epithelial Synovial Sarcoma|Epithelial-Myoepithelial Carcinoma|Epithelioid Cell Melanoma|Epithelioid Cell Nevus|Epithelioid Cell Type Gastrointestinal Stromal Tumor|Epithelioid Hemangioendothelioma|Epithelioid Hemangioma|Epithelioid Leiomyosarcoma|Epithelioid Malignant Peripheral Nerve Sheath Tumor|Epithelioid Mesothelioma|Epithelioid Sarcoma|Epithelioid Trophoblastic Tumor|Essential Thrombocythemia|Ewing Sarcoma|External Auditory Canal Ceruminous Adenoma|Extra-Adrenal Paraganglioma|Extramammary Paget Disease|Extraosseous Plasmacytoma|Familial Adenomatous Polyposis|Fascial Fibroma|Fascial Fibrosarcoma|Female Reproductive System Adenofibroma|Fetal Rhabdomyoma|Fibrillary Astrocytoma|Fibroblastic Liposarcoma|Fibroblastic Osteosarcoma|Fibroblastic Reticular Cell Tumor|Fibrofolliculoma|Fibrolamellar Carcinoma|Fibrolipoma|Fibroma|Fibromyxoid Tumor|Fibromyxolipoma|Fibrosarcoma|Fibrous Meningioma|Flat Adenoma|Follicular Dendritic Cell Sarcoma|Follicular Lymphoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Functioning Endocrine Neoplasm|Gangliocytoma|Ganglioglioma|Ganglioneuroblastoma|Ganglioneuroma|Ganglioneuromatosis|Gastric Parietal Cell Adenocarcinoma|Gastrin-Producing Neuroendocrine Tumor|Gastrointestinal Stromal Tumor|Gemistocytic Astrocytoma|Genital Rhabdomyoma|Germinoma|Ghost Cell Odontogenic Carcinoma|Giant Cell Carcinoma|Giant Cell Fibroblastoma|Giant Cell Glioblastoma|Giant Cell Sarcoma|Giant Cell Tumor of Bone|Giant Cell Tumor of Soft Tissue|Giant Cell and Spindle Cell Carcinoma|Giant Congenital Nevus|Gigantiform Cementoma|Glandular Papilloma|Glandular Papillomatosis|Glassy Cell Carcinoma|Glioblastoma|Glioblastoma, IDH-Mutant|Gliofibroma|Gliomatosis Cerebri|Gliosarcoma|Glomangioma|Glomangiomyoma|Glomus Tumor|Glycogen-Rich Carcinoma|Gonadoblastoma|Grade 1 Follicular Lymphoma|Grade 1 Nodular Sclerosis Classic Hodgkin Lymphoma|Grade 2 Follicular Lymphoma|Grade 2 Nodular Sclerosis Classic Hodgkin Lymphoma|Grade 3 Follicular Lymphoma|Granular Cell Carcinoma|Granular Cell Tumor|Granulosa Cell-Theca Cell Tumor|Hairy Cell Leukemia|Halo Nevus|Heavy Chain Disease|Hemangioblastic Meningioma|Hemangioblastoma|Hemangioendothelioma|Hemangioma|Hemangiopericytoma|Hemolymphangioma|Hepatoblastoma|Hepatocellular Adenoma|Hepatocellular Carcinoma|Hepatoid Adenocarcinoma|Hepatosplenic T-Cell Lymphoma|Hereditary Leiomyomatosis and Renal Cell Carcinoma|Hibernoma|Hidradenocarcinoma|Hidradenoma Papilliferum|Hidrocystoma|High Grade Glandular Intraepithelial Neoplasia|High Grade Squamous Intraepithelial Neoplasia|High Grade Surface Osteosarcoma|High Risk Gastrointestinal Stromal Tumor|Hilar Cholangiocarcinoma|Histiocytic Sarcoma|Histiocytoma|Hodgkin Lymphoma|Hodgkin's Granuloma|Human Papillomavirus-Related Squamous Cell Carcinoma|Hydatidiform Mole|Hydroa Vacciniforme-Like Lymphoproliferative Disorder|Immature Teratoma|Immunoblastic Lymphoma|Indolent Systemic Mastocytosis|Infantile Fibrosarcoma|Inflammatory Myofibroblastic Tumor|Interdigitating Dendritic Cell Sarcoma|Intermediate Immature Teratoma|Intestinal-Type Adenocarcinoma|Intimal Sarcoma|Intracystic Papillary Breast Carcinoma|Intracystic Papilloma|Intraductal Cribriform Breast Adenocarcinoma|Intraductal Papillary Adenocarcinoma with Invasion|Intraductal Papillary Breast Carcinoma|Intraductal Papilloma|Intraductal Papillomatosis|Intraepidermal Epithelioma of Jadassohn|Intramuscular Hemangioma|Intramuscular Lipoma|Intrathyroid Thymic Carcinoma|Intravascular Large B-Cell Lymphoma|Invasive Ductal Carcinoma, Not Otherwise Specified|Invasive Ductal and Lobular Carcinoma|Invasive Hydatidiform Mole|Inverted Squamous Cell Papilloma|Inverted Transitional Cell Papilloma|Islet Cell Adenoma|Jugulotympanic Paraganglioma|Junctional Nevus|Juvenile Myelomonocytic Leukemia|Juvenile Type Granulosa Cell Tumor|Juxtaglomerular Cell Tumor|Kaposi Sarcoma|Keratinizing Squamous Cell Carcinoma|Kidney Wilms Tumor|Lactating Adenoma|Lactotroph Adenoma|Langerhans Cell Histiocytosis|Langerhans Cell Sarcoma|Large Cell Carcinoma|Large Cell Medulloblastoma|Large Cell Neuroendocrine Carcinoma|Leiomyoma|Leiomyomatosis|Leiomyosarcoma|Lentigo Maligna|Lentigo Maligna Melanoma|Leukemia|Leydig Cell Tumor|Linitis Plastica|Lipid-Rich Carcinoma|Lipoadenoma|Lipoblastomatosis|Lipoma|Liposarcoma|Lobular Breast Carcinoma|Lobular Breast Carcinoma In Situ|Low Grade Central Osteosarcoma|Low Grade Endometrioid Stromal Sarcoma|Low Grade Glandular Intraepithelial Neoplasia|Low Grade Squamous Intraepithelial Neoplasia|Low Risk Gastrointestinal Stromal Tumor|Low-CSD Melanoma|Low-Grade Appendix Mucinous Neoplasm|Lung Adenocarcinoma with Mixed Bronchioloalveolar and Invasive Components|Lung Colloid Adenocarcinoma|Lung Large Cell Carcinoma with Rhabdoid Phenotype|Lung Non-Mucinous Adenocarcinoma In Situ|Lymphangioleiomyoma|Lymphangioleiomyomatosis|Lymphangioma|Lymphangiosarcoma|Lymphoblastic Lymphoma|Lymphocyte-Depleted Classic Hodgkin Lymphoma|Lymphocyte-Rich Classic Hodgkin Lymphoma|Lymphoid Leukemia|Lymphoma|Lymphoplasmacytic Lymphoma|Lymphoproliferative Disorder|Malignancy in Giant Cell Tumor of Bone|Malignant Adrenal Gland Pheochromocytoma|Malignant Cell|Malignant Extra-Adrenal Paraganglioma|Malignant Gastrinoma|Malignant Giant Cell Neoplasm|Malignant Glioma|Malignant Glomus Tumor|Malignant Granular Cell Tumor|Malignant Granulosa Cell Tumor|Malignant Hemangiopericytoma|Malignant Histiocytosis|Malignant Leydig Cell Tumor|Malignant Mastocytosis|Malignant Mediastinal Germ Cell Tumor with Associated Hematologic Malignancy|Malignant Melanoma in Precancerous Melanosis|Malignant Mesenchymoma|Malignant Mesothelioma|Malignant Mixed Tumor of the Salivary Gland|Malignant Muscle Neoplasm|Malignant Myoepithelioma|Malignant Neoplasm|Malignant Neoplasm, Uncertain Whether Primary or Metastatic|Malignant Odontogenic Neoplasm|Malignant Ovarian Brenner Tumor|Malignant Ovarian Thecoma|Malignant PEComa|Malignant Pancreatic Glucagonoma|Malignant Pancreatic Insulinoma|Malignant Paraganglioma|Malignant Peripheral Nerve Sheath Tumor|Malignant Peripheral Nerve Sheath Tumor with Perineurial Differentiation|Malignant Phyllodes Tumor|Malignant Sertoli Cell Tumor|Malignant Solitary Fibrous Tumor|Malignant Somatostatinoma|Malignant Spindle Cell Neoplasm|Malignant Struma Ovarii|Malignant Tenosynovial Giant Cell Tumor|Malignant Teratoma|Malignant Thymoma|Malignant Triton Tumor|Malignant Trophoblastic Teratoma|Malignant Tumor, Small Cell Type|Malignant Type A Thymoma|Malignant Type AB Thymoma|Malignant Type B1 Thymoma|Malignant Type B2 Thymoma|Malignant Vipoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Mast Cell Leukemia|Mast Cell Sarcoma|Mastocytoma|Mature Teratoma|Medullary Carcinoma, Not Otherwise Specified|Medulloblastoma|Medulloblastoma, Non-WNT/Non-SHH|Medulloblastoma, WNT-Activated|Medulloepithelioma|Medullomyoblastoma with Myogenic Differentiation|Melanocytoma of the Eyeball|Melanoma|Melanoma Arising from Blue Nevus|Melanoma in Junctional Nevus|Melanotic Neuroectodermal Tumor|Melanotic Neurofibroma|Meningeal Melanocytoma|Meningeal Melanocytosis|Meningeal Melanomatosis|Meningeal Sarcomatosis|Meningioma|Meningiomatosis|Meningothelial Meningioma|Merkel Cell Carcinoma|Mesenchymal Chondrosarcoma|Mesenchymoma|Mesonephric Adenocarcinoma|Mesonephric Neoplasm|Metanephric Adenofibroma|Metanephric Adenoma|Metaplastic Carcinoma|Metastasizing Ameloblastoma|Metastatic Adenocarcinoma|Metastatic Carcinoma|Metastatic Neoplasm|Metastatic Signet Ring Cell Carcinoma|Metastatic Squamous Cell Carcinoma|Microcystic Adenoma|Microcystic Adnexal Carcinoma|Microinvasive Squamous Cell Carcinoma|Micropapillary Transitional Cell Carcinoma|Minimally Invasive Lung Adenocarcinoma|Minimally Invasive Lung Mucinous Adenocarcinoma|Minimally Invasive Lung Non-Mucinous Adenocarcinoma|Mixed Cell Adenocarcinoma|Mixed Cell Adenoma|Mixed Cellularity Classic Hodgkin Lymphoma|Mixed Ductal-Neuroendocrine Carcinoma of the Pancreas|Mixed Embryonal Carcinoma and Teratoma|Mixed Epithelioid and Spindle Cell Melanoma|Mixed Germ Cell Tumor|Mixed Glioma|Mixed Liposarcoma|Mixed Mesodermal (Mullerian) Tumor|Mixed Mucinous and Non-Mucinous Bronchioloalveolar Carcinoma|Mixed Phenotype Acute Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1|Mixed Phenotype Acute Leukemia with t(v;11q23.3); KMT2A Rearranged|Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified|Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified|Mixed Testicular Sex Cord-Stromal Tumor|Moderately Differentiated Ovarian Sertoli-Leydig Cell Tumor|Monoclonal Gammopathy of Undetermined Significance|Mucin-Producing Adenocarcinoma|Mucinous Adenocarcinoma|Mucinous Adenocarcinoma, Endocervical Type|Mucinous Adenofibroma|Mucinous Cystadenocarcinoma|Mucinous Cystadenoma|Mucoepidermoid Carcinoma|Mucosal Lentiginous Melanoma|Multicystic Mesothelioma|Multiple Adenomatous Polyps|Multiple Endocrine Neoplasia|Multiple Osteochondromas|Mycosis Fungoides|Myelodysplastic Syndrome|Myelodysplastic Syndrome with Excess Blasts|Myelodysplastic Syndrome with Isolated del(5q)|Myelodysplastic Syndrome with Multilineage Dysplasia|Myelodysplastic Syndrome with Ring Sideroblasts|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Myeloid Leukemia|Myeloid Leukemia Associated with Down Syndrome|Myeloid Sarcoma|Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement|Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement|Myeloproliferative Neoplasm|Myoepithelial Tumor|Myofibroblastoma|Myofibroma|Myofibromatosis|Myxofibrosarcoma|Myxoid Chondrosarcoma|Myxoid Leiomyosarcoma|Myxoid Liposarcoma|Myxoinflammatory Fibroblastic Sarcoma|Myxoma|Myxopapillary Ependymoma|Myxosarcoma|NUT Carcinoma|Nasal Type Extranodal NK/T-Cell Lymphoma|Nasopharyngeal-Type Undifferentiated Carcinoma|Neoplasm of the Diffuse Neuroendocrine System|Neoplasm, Uncertain Whether Benign or Malignant|Neoplastic Cell|Nerve Sheath Myxoma|Neuroblastoma|Neuroendocrine Carcinoma|Neurofibroma|Neurofibromatosis|Neuroma|Neuronevus|Nipple Adenoma|Nodular Hidradenoma|Nodular Lymphocyte Predominant Hodgkin Lymphoma|Nodular Sclerosis Classic Hodgkin Lymphoma|Nodular Sclerosis Classic Hodgkin Lymphoma, Cellular Phase|Non-Hodgkin Lymphoma|Non-Invasive Papillary Squamous Cell Carcinoma|Non-Invasive Papillary Transitional Cell Carcinoma|Non-Keratinizing Large Cell Squamous Cell Carcinoma|Non-Keratinizing Sinonasal Squamous Cell Carcinoma|Non-Keratinizing Small Cell Squamous Cell Carcinoma|Non-Small Cell Carcinoma|Nongerminomatous Germ Cell Tumor|Nonpigmented Nevus|Odontoameloblastoma|Odontogenic Fibroma|Odontogenic Myxoma|Odontogenic Neoplasm|Odontoma|Olfactory Neuroblastoma|Olfactory Neurocytoma|Olfactory Neurogenic Tumor|Oligodendroblastoma|Oligodendroglioma|Oncocytic Adenoma|Ossifying Fibroma|Ossifying Fibromyxoid Tumor|Osteoblastoma|Osteochondroma|Osteoid Osteoma|Osteoma|Osteosarcoma|Ovarian Endometrioid Adenofibroma|Ovarian Gynandroblastoma|Ovarian Hilus Cell Tumor|Ovarian Luteinized Thecoma|Ovarian Sclerosing Stromal Tumor|Ovarian Seromucinous Carcinoma|Ovarian Sex Cord-Stromal Tumor|Ovarian Steroid Cell Tumor|Ovarian Stromal Luteoma|Ovarian Stromal Tumor with Minor Sex Cord Elements|Oxyphilic Adenocarcinoma|Pacinian Neurofibroma|Paget Disease and Intraductal Carcinoma of the Breast|Paget Disease of the Breast|Pancreatic Acinar Cell Cystadenocarcinoma|Pancreatic Insulinoma|Pancreatic Intraductal Papillary-Mucinous Neoplasm with High Grade Dysplasia|Pancreatic Neuroendocrine Carcinoma|Pancreatic Neuroendocrine Neoplasm|Pancreatoblastoma|Papillary Adenocarcinoma|Papillary Carcinoma|Papillary Carcinoma In Situ|Papillary Craniopharyngioma|Papillary Cystadenocarcinoma|Papillary Cystadenoma|Papillary Cystic Neoplasm|Papillary Eccrine Adenoma|Papillary Ependymoma|Papillary Glioneuronal Tumor|Papillary Intralymphatic Angioendothelioma|Papillary Meningioma|Papillary Mucinous Cystadenocarcinoma|Papillary Mucinous Cystadenoma|Papillary Serous Cystadenocarcinoma|Papillary Serous Cystadenoma|Papillary Squamous Cell Carcinoma|Papillary Transitional Cell Carcinoma|Papillary Tumor of the Pineal Region|Papilloma|Parachordoma|Paraganglioma|Parasympathetic Paraganglioma|Parathyroid Gland Chief Cell Adenoma|Parathyroid Gland Water-Clear Cell Adenoma|Parosteal Osteosarcoma|Partial Hydatidiform Mole|Penile Carcinoma In Situ|Perineurioma|Periosteal Chondroma|Periosteal Chondrosarcoma|Periosteal Fibroma|Periosteal Fibrosarcoma|Periosteal Osteosarcoma|Peripheral Odontogenic Fibroma|Peripheral Primitive Neuroectodermal Tumor|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Philadelphia-Negative Myelogenous Leukemia|Pigmented Adrenal Cortex Adenoma|Pigmented Dermatofibrosarcoma Protuberans|Pigmented Nevus|Pilocytic Astrocytoma|Pilomatrical Carcinoma|Pilomatricoma|Pilomyxoid Astrocytoma|Pineal Parenchymal Cell Neoplasm|Pineoblastoma|Pineocytoma|Pituicytoma|Pituitary Gland Acidophil Adenoma|Pituitary Gland Acidophil Carcinoma|Pituitary Gland Adenoma|Pituitary Gland Basophil Adenoma|Pituitary Gland Carcinoma|Pituitary Gland Chromophobe Adenoma|Pituitary Gland Mixed Acidophil-Basophil Adenoma|Placental-Site Gestational Trophoblastic Tumor|Plasma Cell Leukemia|Plasma Cell Myeloma|Plasmablastic Lymphoma|Plasmacytoma|Pleomorphic Adenoma|Pleomorphic Carcinoma|Pleomorphic Lipoma|Pleomorphic Liposarcoma|Pleomorphic Lobular Breast Carcinoma In Situ|Pleomorphic Xanthoastrocytoma|Pleural Solitary Fibrous Tumor|Pleuropulmonary Blastoma|Plexiform Fibrohistiocytic Tumor|Plexiform Neurofibroma|Polar Spongioblastoma|Polycythemia Vera|Polygonal Cell Carcinoma|Polymorphic Post-Transplant Lymphoproliferative Disorder|Poorly Differentiated Thyroid Gland Carcinoma|Porocarcinoma|Poroma|Post-Transplant Lymphoproliferative Disorder|Precancerous Melanosis|Primary Amyloidosis|Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder|Primary Cutaneous Follicle Center Lymphoma|Primary Cutaneous Gamma-Delta T-Cell Lymphoma|Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Primary Effusion Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Primary Myelofibrosis|Primitive Neuroectodermal Tumor|Proliferating Trichilemmal Tumor|Proliferative Nodules in Congenital Melanocytic Nevus|Prolymphocytic Leukemia|Protoplasmic Astrocytoma|Psammomatous Meningioma|Pseudoglandular Squamous Cell Carcinoma|Pseudomyxoma Peritonei|Pulmonary Adenomatosis|Pulmonary Blastoma|Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Translocation|Refractory Anemia|Refractory Anemia with Excess Blasts in Transformation|Refractory Neutropenia|Refractory Thrombocytopenia|Regressing Melanoma|Renal Cell Carcinoma|Retinoblastoma|Retinocytoma|Rhabdoid Tumor|Rhabdomyoma|Rhabdomyosarcoma|Round Cell Liposarcoma|Salivary Gland Basal Cell Adenocarcinoma|Salivary Gland Basal Cell Adenoma|Salivary Gland Monomorphic Adenoma|Sarcoma|Sarcomatoid Carcinoma|Sarcomatoid Mesothelioma|Sarcomatoid Renal Cell Carcinoma|Sarcomatoid Transitional Cell Carcinoma|Sarcomatosis|Schwannoma|Schwannomatosis|Scirrhous Adenocarcinoma|Scirrhous Hepatocellular Carcinoma|Sebaceous Adenoma|Sebaceous Carcinoma|Secretory Breast Carcinoma|Seminoma|Serous Adenofibroma|Serous Cystadenocarcinoma|Serous Cystadenoma|Serous Surface Papillary Carcinoma|Serous Surface Papilloma|Serous Tubal Intraepithelial Carcinoma|Sertoli Cell Tumor|Sezary Syndrome|Signet Ring Cell Carcinoma|Sinonasal Schneiderian Papilloma|Skin Adenoid Basal Cell Carcinoma|Skin Appendage Adenoma|Skin Basal Cell Carcinoma|Skin Basosquamous Cell Carcinoma|Skin Fibroepithelial Basal Cell Carcinoma|Skin Fibrous Histiocytoma|Skin Infiltrating Basal Cell Carcinoma|Skin Metatypical Carcinoma|Skin Nodular Basal Cell Carcinoma|Small Cell Carcinoma|Small Cell Carcinoma, Fusiform Cell Type|Small Cell Intermediate Cell Carcinoma|Small Cell Osteosarcoma|Small Cell Sarcoma|Small Lymphocytic Lymphoma|Smooth Muscle Neoplasm|Solid Carcinoma|Solid Papillary Breast Carcinoma|Solitary Fibrous Tumor|Somatostatin-Producing Neuroendocrine Tumor|Spindle Cell Hemangioma|Spindle Cell Lipoma|Spindle Cell Melanoma|Spindle Cell Rhabdomyosarcoma|Spindle Cell Sarcoma|Spindle Cell Squamous Cell Carcinoma|Spindle Cell Synovial Sarcoma|Spiradenocarcinoma|Spiradenoma|Spitz Nevus|Splenic Marginal Zone Lymphoma|Spongioneuroblastoma|Spontaneously Regressing Retinoblastoma|Squamous Cell Carcinoma|Squamous Cell Carcinoma In Situ with Questionable Stromal Invasion|Squamous Cell Carcinoma with Horn Formation|Squamous Cell Carcinoma, Clear Cell Type|Squamous Cell Papilloma|Squamous Odontogenic Tumor|Squamous Papillomatosis|Stage 0 Cutaneous Melanoma AJCC v6 and v7|Stage 0 Squamous Cell Carcinoma|Stage 0 Transitional Cell Carcinoma|Stromal Neoplasm|Stromal Sarcoma|Struma Ovarii|Strumal Carcinoid|Subcutaneous Panniculitis-Like T-Cell Lymphoma|Subependymal Giant Cell Astrocytoma|Subependymoma|Superficial Multifocal Basal Cell Carcinoma|Superficial Spreading Adenocarcinoma|Sweat Gland Adenoma|Sweat Gland Carcinoma|Sweat Gland Neoplasm|Sympathetic Paraganglioma|Synovial Sarcoma|Syringocystadenoma Papilliferum|Syringofibroadenoma|Syringoma|Systemic EBV-Positive T-Cell Lymphoma of Childhood|T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma|T-Cell Large Granular Lymphocyte Leukemia|T-Cell Prolymphocytic Leukemia|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Telangiectatic Osteosarcoma|Tenosynovial Giant Cell Tumor|Teratoma|Teratoma with Somatic-Type Malignancy|Testicular Seminoma with High Mitotic Index|Testicular Spermatocytic Tumor|Thecoma|Therapy-Related Myelodysplastic Syndrome|Therapy-Related Myeloid Neoplasm|Thymic Carcinoma|Thymoma|Thymoma Type A|Thymoma Type AB|Thymoma Type B1|Thymoma Type B2|Thymoma Type B3|Thyroid Gland Follicular Carcinoma|Thyroid Gland Follicular Carcinoma, Encapsulated Angioinvasive|Thyroid Gland Hyalinizing Trabecular Tumor|Thyroid Gland Macrofollicular Adenoma|Thyroid Gland Medullary Carcinoma with Amyloid Stroma|Thyroid Gland Microfollicular Adenoma|Thyroid Gland Noninvasive Follicular Neoplasm with Papillary-Like Nuclear Features|Thyroid Gland Spindle Cell Tumor with Thymus-Like Differentiation|Thyroid Gland Well-Differentiated Tumor of Uncertain Malignant Potential|Trabecular Adenocarcinoma|Trabecular Adenoma|Traditional Serrated Adenoma|Transient Abnormal Myelopoiesis Associated with Down Syndrome|Transitional Cell Carcinoma|Transitional Cell Papilloma|Transitional Meningioma|Trichilemmal Carcinoma|Trichilemmoma|Trichoblastoma|Trichofolliculoma|Tubular Adenocarcinoma|Tubular Adenoma|Tubulovillous Adenoma|Tumorlet|Type A Spindle Cell Melanoma|Type B Spindle Cell Melanoma|Unclassified Testicular Sex Cord-Stromal Tumor|Undifferentiated (Embryonal) Sarcoma|Undifferentiated Carcinoma|Undifferentiated Pleomorphic Sarcoma|Undifferentiated Pleomorphic Sarcoma with Osteoclast-Like Giant Cells|Undifferentiated Retinoblastoma|Undifferentiated Sarcoma, Not Otherwise Specified|Urothelial Papilloma|VIP-Producing Neuroendocrine Tumor|Venous Hemangioma|Verrucous Carcinoma|Verrucous Hemangioma|Verrucous Papilloma|Villous Adenocarcinoma|Villous Adenoma|Waldenstrom Macroglobulinemia|Warthin Tumor|Water-Clear Cell Adenocarcinoma|Well Differentiated Liposarcoma|Yolk Sac Tumor
non_nodal_regional_disease	non_nodal_regional_disease	Absent|Indeterminate|Not Reported|Present|Unknown	5/5 (both/PDC)		
non_nodal_tumor_deposits	non_nodal_tumor_deposits	False|Not Reported|True|Unknown	4/4 (both/PDC)		
ovarian_specimen_status	ovarian_specimen_status	Not Reported|Ovarian Capsule Fragmented|Ovarian Capsule Intact|Ovarian Capsule Ruptured|Unknown	5/5 (both/PDC)		
ovarian_surface_involvement	ovarian_surface_involvement	Absent|Indeterminate|Not Reported|Present|Unknown	5/5 (both/PDC)		
perineural_invasion_present	perineural_invasion_present	False|Not Reported|True|Unknown	4/4 (both/PDC)		
peripancreatic_lymph_nodes_positive	peripancreatic_lymph_nodes_positive	Not Reported|Unknown	2/5 (both/PDC)	0|1-3|4 or More	Four or More Positive Lymph Nodes|One to Three Positive Lymph Nodes|Zero
peritoneal_fluid_cytological_status	peritoneal_fluid_cytological_status	Malignant|Non-Malignant|Not Reported|Unknown|Unsatisfactory	5/6 (both/PDC)	Atypical	Cytologic Atypia
pregnant_at_diagnosis	pregnant_at_diagnosis	False|Not Reported|True|Unknown	4/4 (both/PDC)		
primary_diagnosis	primary_diagnosis	ACTH-producing tumor|Acquired tufted hemangioma|Acute myeloid leukemia, t(15:17)(g22;q11-12)|Acute progressive histiocytosis X|Adenocarcinoma, cribriform comedo-type|Adenocarcinoma, pancreatobiliary type|Adenomatosis, NOS|Adenomyoepithelioma|Adenomyoepithelioma with carcinoma|Adenomyoma|Adenosarcoma|Adult rhabdomyoma|Aggressive digital papillary adenoma|Aleukemic granulocytic leukemia|Aleukemic monocytic leukemia|Aleukemic myelogenous leukemia|Aleukemic myeloid leukemia|Alpha cell tumor, NOS|Ameloblastic fibro-odontosarcoma|Ameloblastic fibrodentinosarcoma|Ameloblastic odontosarcoma|Anal intraepithelial neoplasia, low grade|Anaplastic large cell lymphoma, T cell and Null cell type|Angioblastic meningioma|Angiokeratoma|Angioleiomyoma|Angiomyofibroblastoma|Angiomyolipoma|Angiomyosarcoma|Angiomyxoma|Angiosarcoma|Apocrine adenocarcinoma|Argentaffinoma, NOS|Argentaffinoma, malignant|Astroblastoma|Atypical hyperplasia/Endometrioid intraepithelial neoplasm|Atypical medullary carcinoma|Atypical proliferating clear cell tumor|Atypical proliferative mucinous tumor|B cell lymphoma, NOS|Biliary intraepithelial neoplasia, high grade|Biliary intraepithelial neoplasia, low grade|Biphenotypic sinonasal sarcoma|Bronchial adenoma, carcinoid|Bronchial adenoma, cylindroid|Calcifying nested epithelial stromal tumor|Canalicular adenoma|Capillary lymphangioma|Carcinofibroma|Carcinoid tumor, NOS, of appendix|Carcinoid tumor, argentaffin, NOS|Carcinoid tumor, argentaffin, malignant|Carcinoid, NOS, of appendix|Carcinoma with osteoclast-like giant cells|Carcinoma with other types mesenchymal differentiation|Carcinomatosis|Carcinosarcoma, embryonal|Cholangiocarcinoma|Chondroblastoma, malignant|Chondrosarcoma grade 2/3|Choriocarcinoma combined with teratorna|Chronic erythremia|Chronic myelomonocytic leukemia, Type 1|Chronic myelomonocytic leukemia, Type II|Classical Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis|Classical Hodgkin lymphoma, lymphocyte depletion, reticular|Clear cell adenocarcinofibroma|Clear cell adenofibroma of borderline malignancy|Clear cell cystadenocarcinofibroma|Clear cell cystadenofibroma of borderline malignancy|Clear cell cystadenoma|Clear cell cystic tumor of borderline malignancy|Clear cell sarcoma, of tendons and aponeuroses|Columnar cell papilloma|Combined small cell-large carcinoma|Comedocarcinoma, noninfiltrating|Composite Hodgkin and non-Hodgkin lymphoma|Congenital generalized fibromatosis|Congenital peribronchial myofibroblastic tumor|Craniopharyngioma|Cribriform carcinoma in situ|Cribriform comedo-type carcinoma|Cylindrical cell papilloma|Cyst-associated renal cell carcinoma|Cystic hypersecretory carcinoma|Cystic mesothelioma, benign|DCIS, comedo type|Differentiated penile intraepithelial neoplasia|Diktyoma, benign|Duct carcinoma, desmoplastic type|Ductal carcinoma in situ, comedo type|Ductal carcinoma in situ, micropapillary|Ductal carcinoma in situ, solid type|Dysgerminoma|EC cell carcinoid|Eccrine adenocarcinoma|Ectomesenchymoma|Elastofibroma|Embryonal adenoma|Embryonal carcinoma, polyembryonal type|Embryonal rhabdomyosarcoma, pleomorphic|Encapsulated follicular variant of papillary thyroid carcinoma, NOS (EFVPTC, NOS)|Enchondroma|Endometrioid adenofibroma, malignant|Endometrioid adenoma, NOS|Endometrioid cystadenofibroma, malignant|Endometrioid cystadenoma, NOS|Enteric adenocarcinoma|Enterochromaffin cell carcinoid|Epithelioid hemangioendothelioma, malignant|Epithelioma, malignant|Erythroleukemia|Esthesioneurocytoma|Fibrofolliculoma|Fibrolipoma|Fibromatosis-like metaplastic carcinoma|Fibromyxolipoma|Fibrous papule of nose|Flat intraepithelial glandular neoplasia, high grade|Flat intraepithelial neoplasia, high grade|Follicular adenocarcinoma, moderately differentiated|Follicular adenocarcinoma, trabecular|Follicular carcinoma, encapsulated|Follicular carcinoma, minimally invasive|Follicular carcinoma, moderately differentiated|Follicular carcinoma, trabecular|Folliculome lipidique|Gangliocytoma|Ganglioneuroblastoma|Ganglioneuroma|Ganglioneuromatosis|Gastrointestinal pacemaker cell tumor|Germinoma|Glioblastoma|Gliofibroma|Gliosarcoma|Glomangioma|Glomangiomyoma|Glucagon-like peptide-producing tumor|Glucagonoma, NOS|Glycogenic rhabdomyoma|Gonadoblastoma|Granulosa cell tumor, sarcomatoid|Hemangiopericytic meningioma|Hemolymphangioma|Hepatoblastoma|Hepatoblastoma, epithelioid|Hepatocellular carcinoma, clear cell type|Hepatocellular carcinoma, pleomorphic type|Hepatocellular carcinoma, sarcomatoid|Hepatocellular carcinoma, spindle cell variant|Hibernoma|Hidradenocarcinoma|Hidrocystoma|High-grade neuroendocrine carcinoma|High-grade serous carcinoma|Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis|Hodgkin lymphoma, lymphocyte depletion, reticular|Hypernephroid tumor|Immunoproliferative disease, NOS|Infiltrating duct and colloid carcinoma|Infiltrating duct and cribriform carcinoma|Infiltrating duct and mucinous carcinoma|Infiltrating duct and tubular carcinoma|Infiltrating duct mixed with other types of carcinoma|Infiltrating lobular mixed with other types of carcinoma|Inflammatory adenocarcinoma|Inflammatory carcinoma|Intermediate and giant congenital nevus|Intracystic papillary neoplasm with associated invasive carcinoma|Intracystic papillary neoplasm with high grade intraepithelial neoplasia|Intracystic papillary tumor with high grade dysplasia|Intracystic papillary tumor with high grade entraepithelial neoplasia|Intracystic papillary tumor with high grade intraepithelial neoplasia|Intraductal carcinoma, clinging|Intraductal carcinoma, solid type|Intraductal micropapillary carcinoma|Intraductal papillary mucinous neoplasm with an associated invasive carcinoma|Intraductal papillary neoplasm with high grade dysplasia|Intraductal papillary tumor with high grade dysplasia|Intraductal papillary tumor with high grade intraepithelial neoplasia|Intraductal papillary-mucinous adenoma|Intraductal papillary-mucinous carcinoma, invasive|Intraductal papillary-mucinous carcinoma, non-invasive|Intraductal papillary-mucinous neoplasm with low grade dysplasia|Intraductal papillary-mucinous neoplasm with moderate dysplasia|Intraductal papillary-mucinous tumor with intermediate dysplasia|Intraductal papillary-mucinous tumor with low grade dysplasia|Intraductal papillary-mucinous tumor with moderate dysplasia|Intraductal papilloma with ductal carcinoma in situ|Intraductal papilloma with lobular carcinoma in situ|Intraductal tubular-papillary neoplasm, high grade|Intraductal tubular-papillary neoplasm, low grade|Intratubular germ cell neoplasia|Intratubular malignant germ cells|Intravascular bronchial alveolar tumor|Intravascular leiomyomatosis|Invasive carcinoma of no special type|Invasive carcinoma, NST|Involuting nevus|Islet cell tumor, benign|Kupffer cell sarcoma|L-cell tumor|Large cell calcifying Sertoli cell tumor|Large granular lymphocytosis, NOS|Lepidic adenocarcinoma|Lipid-rich Sertoli cell tumor|Lipoadenoma|Lipoblastoma|Lipoblastomatosis|Low-grade serous carcinoma|Lymphangioleiomyomatosis|Lymphangiosarcoma|MPNST with glandular differentiation|MPNST with mesenchymal differentiation|Malignant chondroid syringoma|Malignant fibrous histiocytoma (MFH) of bone|Malignant lymphoma, centrocytic|Malignant lymphoma, cleaved cell, NOS|Malignant lymphoma, lymphocytic, intermediate differentiation, nodular|Malignant lymphoma, lymphocytic, poorly differentiated, diffuse|Malignant lymphoma, lymphocytic, well differentiated, nodular|Malignant lymphoma, mixed cell type, diffuse|Malignant lymphoma, mixed lymphocytic-histiocytic, diffuse|Malignant lymphoma, mixed small and large cell, diffuse|Malignant lymphoma, noncleaved cell, follicular, NOS|Malignant lymphoma, small cell, noncleaved, diffuse|Malignant lymphoma, small cleaved cell, NOS|Malignant lymphoma, small cleaved cell, diffuse|Malignant lymphoma, undifferentiated cell type, NOS|Malignant lymphoma, undifferentiated cell, non-Burkitt|Malignant melanoma in congenital melanocytic nevus|Malignant melanoma in giant pigmented nevus|Malignant midline reticulosis|Malignant mucinous adenofibroma|Malignant mucinous cystadenofibroma|Malignant myelosclerosis|Malignant serous adenofibroma|Malignant serous cystadenofibroma|Malignant tumor, clear cell type|Mammary carcinoma, in situ|Medullary adenocarcinoma|Medullary carcinoma with lymphoid stroma|Medulloepithelioma, benign|Mesothelial papilloma|Metaplastic carcinoma with chondroid differentiation|Metaplastic carcinoma with osseous differentiation|Metaplastic carcinoma with other types mesenchymal differentiation|Metastasizing leiomyoma|Micropapillary adenocarcinoma|Micropapillary carcinoma, NOS|Mixed acinar-ductal carcinoma|Mixed acinar-endocrine carcinoma|Mixed embryonal rhabdomyosarcoma and alveolar rhabdomyosarcoma|Mixed endocrine and exocrine adenocarcinoma|Mixed invasive mucinous and non-mucinous adenocarcinoma|Mixed islet cell and exocrine adenocarcinoma|Mixed medullary-follicular carcinoma|Mixed medullary-papillary carcinoma|Mixed pancreatic endocrine and exocrine tumor, malignant|Mixed pineal tumor|Mixed pineocytoma-pineoblastoma|Mixed squamous cell and glandular papilloma|Mixed type rhabdomyosarcoma|Monstrocellular sarcoma|Mucinous adenocarcinofibroma|Mucinous adenofibroma of borderline malignancy|Mucinous carcinoid|Mucinous cystadenocarcinofibroma|Mucinous cystadenocarcinoma, non-invasive|Mucinous cystadenofibroma of borderline malignancy|Mucinous cystadenoma, borderline malignancy|Mucinous cystic neoplasm with an associated invasive carcinoma|Mucinous cystic neoplasm with high-grade dysplasia|Mucinous cystic neoplasm with high-grade intraepithelial neoplasia|Mucinous cystic neoplasm with intermediate-grade dysplasia|Mucinous cystic neoplasm with intermediate-grade intraepithelial neoplasia|Mucinous cystic neoplasm with low-grade dysplasia|Mucinous cystic neoplasm with low-grade intraepithelial neoplasia|Mucinous cystic tumor of borderline malignancy|Mucinous cystic tumor with an associated invasive carcinoma|Mucinous cystic tumor with high-grade dysplasia|Mucinous cystic tumor with intermediate dysplasia|Mucinous cystic tumor with low grade dysplasia|Mucinous tumor, NOS, of low malignant potential|Mucocarcinoid tumor|Mucoepidermoid tumor|Multicystic mesothelioma, benign|Myeloid and lymphoid neoplasms with FGFR1 abnormalities|Myelomonocytic leukemia, NOS|Myofibroblastic sarcoma|Myofibroblastic tumor, peribronchial|Myofibroblastoma|Myofibroma|Myofibromatosis|Myxosarcoma|NK-cell large granular lymphocytic leukemia|Neuroendocrine tumor, grade 1|Neuroendocrine tumor, grade 2|Neuronevus|Neurotropic melanoma, malignant|Nodular hidradenoma, malignant|Non-invasive low grade serous carcinoma|Non-invasive mammary carcinoma|Nonchromaffin paraganglioma, NOS|Nonlipid reticuloendotheliosis|Not Reported|Odontoameloblastoma|Oligoastrocytoma|Oligodendroblastoma|Ossifying renal tumor|Osteochondroma|Osteofibroma|Osteosarcoma in Paget disease of bone|PP/PYY producing tumor|Paget disease and infiltrating duct carcinoma of breast|Pancreatic endocrine tumor, benign|Pancreatic endocrine tumor, malignant|Pancreatic endocrine tumor, nonfunctioning|Pancreatic microadenoma|Pancreatic peptide and pancreatic peptide-like peptide within terminal tyrosine amide producing tumor|Pancreatobiliary neoplasm, non-invasive|Pancreatobiliary-type carcinoma|Pancreatoblastoma|Papillary adenocarcinoma, follicular variant|Papillary carcinoma, encapsulated|Papillary carcinoma, follicular variant|Papillary carcinoma, oxyphilic cell|Papillary microcarcinoma|Papillotubular adenocarcinoma|Parachordoma|Periductal stromal tumor, low grade|Periosteal sarcoma, NOS|Peripheral T-cell lymphoma, pleomorphic medium and large cell|Peripheral T-cell lymphoma, pleomorphic small cell|Pineoblastoma|Pineocytoma|Pituicytoma|Plexiform fibromyxoma|Plexiform leiomyoma|Polyembryoma|Polymorphic reticulosis|Polymorphous low grade adenocarcinoma|Porocarcinoma|Primary diffuse large B-cell lymphoma of the CNS|Primary intraosseous carcinoma|Primitive polar spongioblastoma|Pseudomucinous cystadenoma, borderline malignancy|Refractory anemia without sideroblasts|Renomedullary fibroma|Renomedullary interstitial cell tumor|Reticulosarcoma, diffuse|Reticulum cell sarcoma, diffuse|Retinocytoma|Round cell sarcoma|Serotonin producing carcinoid|Serous adenocarcinofibroma|Serous adenofibroma of borderline malignancy|Serous cystadenocarcinofibroma|Serous cystadenofibroma of borderline malignancy|Serous cystadenofibroma, NOS|Serous surface papillary tumor of borderline malignancy|Serrated adenocarcinoma|Sertoli cell carcinoma|Sertoli cell tumor with lipid storage|Sertoli-Leydig cell tumor of intermediate differentiation|Sertoli-Leydig cell tumor, intermediate differentiation, with heterologous elements|Sertoli-Leydig cell tumor, poorly differentiated|Sertoli-Leydig cell tumor, poorly differentiated, with heterologous elements|Sertoli-Leydig cell tumor, retiform|Sertoli-Leydig cell tumor, retiform, with heterologous elements|Sertoli-Leydig cell tumor, sarcomatoid|Sertoli-Leydig cell tumor, well differentiated|Sex cord tumor with annular tubules|Sialoblastoma|Small congenital nevus|Solid adenocarcinoma with mucin formation|Solid carcinoma with mucin formation|Solid papillary carcinoma with invasion|Solid pseudopapillary carcinoma|Splenic lymphoma with villous lymphocytes|Spongioblastoma, NOS|Spongioneuroblastoma|Squamous cell carcinoma, HPV-negative|Steroid cell tumor, malignant|Subacute leukemia, NOS|Subacute lymphatic leukemia|Subacute lymphocytic leukemia|Subacute lymphoid leukemia|Subacute monocytic leukemia|Subependymal astrocytoma, NOS|Subependymoma|Sympathicoblastoma|Syringadenoma, NOS|Syringofibroadenoma|Teratoid medulloepithelioma|Teratoid medulloepithelioma, benign|Terminal duct adenocarcinoma|Testicular stromal tumor|Thymic carcinoma with adenoid cystic carcinoma-like features|Traditional sessile serrated adenoma|Transitional pineal tumor|Trichilemmoma|Trichofolliculoma|Tubular androblastoma with lipid storage|Tubular carcinoid|Tubulopapillary adenocarcinoma|Tumor cells, benign|Tumorlet, NOS|Typical carcinoid|Unknown|Urothelial carcinoma with divergent differentiation|Villous papilloma|Well differentiated papillary mesothelioma, benign	414/2622 (both/PDC)	AIN III|ALK positive large B-cell lymphoma|AML M6|Abdominal desmoid|Abdominal fibromatosis|Achromic nevus|Acidophil adenocarcinoma|Acidophil adenoma|Acidophil carcinoma|Acinar adenocarcinoma|Acinar adenocarcinoma, sarcomatoid|Acinar adenoma|Acinar carcinoma|Acinar cell adenoma|Acinar cell carcinoma|Acinar cell cystadenocarcinoma|Acinar cell tumor|Acinic cell adenocarcinoma|Acinic cell adenoma|Acinic cell tumor|Acoustic neuroma|Acquired cystic disease-associated renal cell carcinoma (RCC)|Acral lentiginous melanoma, malignant|Acute basophilic leukaemia|Acute bilineal leukemia|Acute biphenotypic leukemia|Acute erythremia|Acute erythremic myelosis|Acute erythroid leukaemia|Acute granulocytic leukemia|Acute leukemia, Burkitt type|Acute leukemia, NOS|Acute lymphatic leukemia|Acute lymphoblastic leukemia, L2 type, NOS|Acute lymphoblastic leukemia, NOS|Acute lymphoblastic leukemia, mature B-cell type|Acute lymphoblastic leukemia, precursor cell type|Acute lymphoblastic leukemia-lymphoma, NOS|Acute lymphocytic leukemia|Acute lymphoid leukemia|Acute megakaryoblastic leukaemia|Acute mixed lineage leukemia|Acute monoblastic and monocytic leukemia|Acute monoblastic leukemia|Acute monocytic leukemia|Acute myeloblastic leukemia|Acute myelocytic leukemia|Acute myelofibrosis|Acute myelogenous leukemia|Acute myeloid leukaemia, t(8;21)(q22;q22)|Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1|Acute myeloid leukemia with abnormal marrow eosinophils (includes all variants)|Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1|Acute myeloid leukemia with maturation|Acute myeloid leukemia with multilineage dysplasia|Acute myeloid leukemia with mutated CEBPA|Acute myeloid leukemia with mutated NPM1|Acute myeloid leukemia with myelodysplasia-related changes|Acute myeloid leukemia with prior myelodysplastic syndrome|Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214|Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1|Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL|Acute myeloid leukemia without maturation|Acute myeloid leukemia without prior myelodysplastic syndrome|Acute myeloid leukemia, AML1(CBF-alpha)/ETO|Acute myeloid leukemia, CBF-beta/MYH11|Acute myeloid leukemia, M6 type|Acute myeloid leukemia, MLL|Acute myeloid leukemia, NOS|Acute myeloid leukemia, PML/RAR-alpha|Acute myeloid leukemia, inv(16)(p13;q22)|Acute myeloid leukemia, minimal differentiation|Acute myeloid leukemia, t(16;16)(p 13;q 11)|Acute myelomonocytic leukemia|Acute myelomonocytic leukemia with abnormal eosinophils|Acute myelosclerosis, NOS|Acute myloid leukemia, 11q23 abnormalities|Acute non-lymphocytic leukemia|Acute panmyelosis with myelofibrosis|Acute panmyelosis, NOS|Acute promyelocytic leukaemia, PML-RAR-alpha|Acute promyelocytic leukaemia, t(15;17)(q22;q11-12)|Acute promyelocytic leukemia, NOS|Adamantinoma of long bones|Adamantinoma, NOS|Adamantinoma, malignant|Adenoacanthoma|Adenoameloblastoma|Adenocarcinoid tumor|Adenocarcinoma admixed with neuroendocrine carcinoma|Adenocarcinoma combined with other types of carcinoma|Adenocarcinoma in a polyp, NOS|Adenocarcinoma in adenomatous polyp|Adenocarcinoma in adenomatous polyposis coli|Adenocarcinoma in multiple adenomatous polyps|Adenocarcinoma in polypoid adenoma|Adenocarcinoma in situ in a polyp, NOS|Adenocarcinoma in situ in adenomatous polyp|Adenocarcinoma in situ in polypoid adenoma|Adenocarcinoma in situ in tubular adenoma|Adenocarcinoma in situ in tubulovillous adenoma|Adenocarcinoma in situ in villous adenoma|Adenocarcinoma in situ, NOS|Adenocarcinoma in situ, mucinous|Adenocarcinoma in situ, non-mucinous|Adenocarcinoma in tubolovillous adenoma|Adenocarcinoma in tubular adenoma|Adenocarcinoma in villous adenoma|Adenocarcinoma of anal ducts|Adenocarcinoma of anal glands|Adenocarcinoma of rete ovarii|Adenocarcinoma with apocrine metaplasia|Adenocarcinoma with cartilaginous and osseous metaplasia|Adenocarcinoma with cartilaginous metaplasia|Adenocarcinoma with mixed subtypes|Adenocarcinoma with neuroendocrine differentiation|Adenocarcinoma with osseous metaplasia|Adenocarcinoma with spindle cell metaplasia|Adenocarcinoma with squamous metaplasia|Adenocarcinoma, NOS|Adenocarcinoma, cylindroid|Adenocarcinoma, diffuse type|Adenocarcinoma, endocervical type|Adenocarcinoma, intestinal type|Adenocarcinoma, metastatic, NOS|Adenocystic carcinoma|Adenofibroma, NOS|Adenoid basal carcinoma|Adenoid cystic carcinoma|Adenolipoma|Adenolymphoma|Adenoma of nipple|Adenoma, NOS|Adenomatoid odontogenic tumor|Adenomatoid tumor, NOS|Adenomatous polyp, NOS|Adenomatous polyposis coli|Adenosquamous carcinoma|Adnexal carcinoma|Adnexal tumor, benign|Adrenal cortical adenocarcinoma|Adrenal cortical adenoma, NOS|Adrenal cortical adenoma, clear cell|Adrenal cortical adenoma, compact cell|Adrenal cortical adenoma, glomerulosa cell|Adrenal cortical adenoma, mixed cell|Adrenal cortical adenoma, pigmented|Adrenal cortical carcinoma|Adrenal cortical tumor, NOS|Adrenal cortical tumor, benign|Adrenal cortical tumor, malignant|Adrenal medullary paraganglioma|Adrenal medullary paraganglioma, malignant|Adrenal rest tumor|Adult T-cell leukemia|Adult T-cell leukemia/lymphoma (HTLV-1 positive) (includes all variants)|Adult T-cell lymphoma|Adult T-cell lymphoma/leukemia|Adult cystic teratoma|Adult granulosa cell tumor|Adult teratoma, NOS|Aggressive NK-cell leukaemia|Aggressive angiomyxoma|Aggressive fibromatosis|Aggressive osteoblastoma|Aggressive systemic mastocytosis|Agnogenic myeloid metaplasia|Aleukemic leukemia, NOS|Aleukemic lymphatic leukemia|Aleukemic lymphocytic leukemia|Aleukemic lymphoid leukemia|Alpha cell tumor, malignant|Alpha heavy chain disease|Alveolar adenocarcinoma|Alveolar adenoma|Alveolar carcinoma|Alveolar cell carcinoma|Alveolar rhabdomyosarcoma|Alveolar soft part sarcoma|Amelanotic melanoma|Ameloblastic carcinoma|Ameloblastic fibro-odontoma|Ameloblastic fibrodentinoma|Ameloblastic fibroma|Ameloblastic fibrosarcoma|Ameloblastic sarcoma|Ameloblastoma, NOS|Ameloblastoma, malignant|Anal intraepithelial neoplasia, grade III|Anaplastic astrocytoma, IDH-mutant|Anaplastic astrocytoma, IDH-wildtype|Anaplastic large B-cell lymphoma|Anaplastic large cell lymphoma, ALK negative|Anaplastic large cell lymphoma, ALK positive|Anaplastic large cell lymphoma, CD30+|Anaplastic large cell lymphoma, NOS|Anaplastic medulloblastoma|Anaplastic oligoastrocytoma|Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted|Anaplastic pleomorphic xanthroastrocytoma|Ancient schwannoma|Androblastoma, NOS|Androblastoma, benign|Androblastoma, malignant|Angioblastoma|Angiocentric T-cell lymphoma|Angiocentric glioma|Angiocentric immunoproliferative lesion|Angioendothelioma|Angioendotheliomatosis|Angiofibroma, NOS|Angioimmunoblastic T-cell lymphoma|Angioimmunoblastic lymphadenopathy|Angioimmunoblastic lymphoma|Angiolipoma, NOS|Angioma, NOS|Angiomatoid fibrous histiocytoma|Angiomatous meningioma|Angiomyoma|Angiotropic lymphoma|Aortic body paraganglioma|Aortic body tumor|Aorticopulmonary paraganglioma|Apocrine adenoma|Apocrine cystadenoma|Apudoma|Arrhenoblastoma, NOS|Arrhenoblastoma, benign|Arrhenoblastoma, malignant|Arteriovenous hemangioma|Askin tumor|Astrocytic glioma|Astrocytoma, NOS|Astrocytoma, anaplastic|Astrocytoma, low grade|Astroglioma|Atypical adenoma|Atypical carcinoid tumor|Atypical choroid plexus papilloma|Atypical chronic myeloid leukemia, BCR/ABL negative|Atypical chronic myeloid leukemia, Philadelphia chromosome (Ph1) negative|Atypical fibrous histiocytoma|Atypical fibroxanthoma|Atypical follicular adenoma|Atypical leiomyoma|Atypical lipoma|Atypical meningioma|Atypical polypoid adenomyoma|Atypical proliferating serous tumor|Atypical proliferative endometrioid tumor|Atypical proliferative papillary serous tumor|Atypical teratoid/rhabdoid tumor|B lymphoblastic leukemia/lymphoma with hyperdiploidy|B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL)|B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)|B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)|B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH|B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1|B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged|B lymphoblastic leukemia/lymphoma, NOS|B-ALL|B-cell lymphocytic leukemia/small lymphocytic lymphoma|B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma|B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma|BALT lymphoma|Balloon cell melanoma|Balloon cell nevus|Basal cell adenocarcinoma|Basal cell adenoma|Basal cell carcinoma, NOS|Basal cell carcinoma, desmoplastic type|Basal cell carcinoma, fibroepithelial|Basal cell carcinoma, micronodular|Basal cell carcinoma, morpheic|Basal cell carcinoma, nodular|Basal cell epithelioma|Basal cell tumor|Basaloid carcinoma|Basaloid squamous cell carcinoma|Basophil adenocarcinoma|Basophil adenoma|Basophil carcinoma|Basosquamous carcinoma|Bednar tumor|Bellini duct carcinoma|Benign cystic nephroma|Benign fibrous histiocytoma|Beta cell adenoma|Beta cell tumor, malignant|Bile duct adenocarcinoma|Bile duct adenoma|Bile duct carcinoma|Bile duct cystadenocarcinoma|Bile duct cystadenoma|Biliary intraepithelial neoplasia, grade 3|Biliary papillomatosis|Bizarre leiomyoma|Black adenoma|Blast cell leukemia|Blastic NK cell lymphoma|Blastic plasmacytoid dendritic cell neoplasm|Blastoma, NOS|Blue nevus, NOS|Blue nevus, malignant|Botryoid sarcoma|Bowen disease|Brenner tumor, NOS|Brenner tumor, borderline malignancy|Brenner tumor, malignant|Brenner tumor, proliferating|Bronchial adenoma, NOS|Bronchial-associated lymphoid tissue lymphoma|Bronchio-alveolar carcinoma, mixed mucinous and non-mucinous|Bronchio-alveolar carcinoma, mucinous|Bronchiolar adenocarcinoma|Bronchiolar carcinoma|Bronchiolo-alveolar adenocarcinoma, NOS|Bronchiolo-alveolar carcinoma, Clara cell|Bronchiolo-alveolar carcinoma, Clara cell and goblet cell type|Bronchiolo-alveolar carcinoma, NOS|Bronchiolo-alveolar carcinoma, goblet cell type|Bronchiolo-alveolar carcinoma, indeterminate type|Bronchiolo-alveolar carcinoma, non-mucinous|Bronchiolo-alveolar carcinoma, type II pneumocyte and goblet cell type|Bronchiolo-alveolar carcinoma; type II pneumocyte|Brooke tumor|Brown fat tumor|Burkitt cell leukemia|Burkitt lymphoma, NOS (Includes all variants)|Burkitt tumor|Burkitt-like lymphoma|C cell carcinoma|CASTLE|CIN III with severe dysplasia|CNS Embryonal tumor with rhabdoid features|CPNET|Calcifying epithelial odontogenic tumor|Calcifying epithelioma of Malherbe|Calcifying odontogenic cyst|Cancer|Capillary hemangioma|Carcinoid tumor of uncertain malignant potential|Carcinoid tumor, NOS|Carcinoid, NOS|Carcinoma in a polyp, NOS|Carcinoma in adenomatous polyp|Carcinoma in pleomorphic adenoma|Carcinoma in situ in a polyp, NOS|Carcinoma in situ in adenomatous polyp|Carcinoma in situ, NOS|Carcinoma showing thymus-like differentiation|Carcinoma showing thymus-like element|Carcinoma simplex|Carcinoma with apocrine metaplasia|Carcinoma with chondroid differentiation|Carcinoma with neuroendocrine differentiation|Carcinoma with osseous differentiation|Carcinoma with productive fibrosis|Carcinoma, NOS|Carcinoma, anaplastic, NOS|Carcinoma, diffuse type|Carcinoma, intestinal type|Carcinoma, metastatic, NOS|Carcinoma, undifferentiated, NOS|Carcinosarcoma, NOS|Carotid body paraganglioma|Carotid body tumor|Cartilaginous exostosis|Cavernous hemangioma|Cavernous lymphangioma|Cellular angiofibroma|Cellular blue nevus|Cellular ependymoma|Cellular fibroma|Cellular leiomyoma|Cellular schwannoma|Cementifying fibroma|Cemento-ossifying fibroma|Cementoblastoma, benign|Cementoma, NOS|Central neuroblastoma|Central neurocytoma|Central odontogenic fibroma|Central osteosarcoma|Central primitive neuroectodermal tumor, NOS|Cerebellar liponeurocytoma|Cerebellar sarcoma, NOS|Ceruminous adenocarcinoma|Ceruminous adenoma|Ceruminous carcinoma|Cervical intraepithelial neoplasia, grade III|Cervical intraepithelial neoplasia, low grade|Chemodectoma|Chief cell adenoma|Chloroma|Cholangioma|Chondroblastic osteosarcoma|Chondroblastoma, NOS|Chondroid chordoma|Chondroid lipoma|Chondroid syringoma|Chondroma, NOS|Chondromatosis, NOS|Chondromatous giant cell tumor|Chondromyxoid fibroma|Chondrosarcoma, NOS|Chordoid glioma|Chordoid glioma of third ventricle|Chordoid meningioma|Chordoma, NOS|Chorioadenoma|Chorioadenoma destruens|Chorioangioma|Choriocarcinoma combined with embryonal carcinoma|Choriocarcinoma combined with other germ cell elements|Choriocarcinoma, NOS|Chorioepithelioma|Chorionepithelioma|Choroid plexus carcinoma|Choroid plexus papilloma, NOS|Choroid plexus papilloma, anaplastic|Choroid plexus papilloma, malignant|Chromaffin paraganglioma|Chromaffin tumor|Chromaffinoma|Chromophobe adenocarcinoma|Chromophobe adenoma|Chromophobe carcinoma|Chromophobe cell renal carcinoma|Chronic eosinophilic leukemia, NOS|Chronic granulocytic leukemia, BCR/ABL|Chronic granulocytic leukemia, NOS|Chronic granulocytic leukemia, Philadelphia chromosome (Ph1) positive|Chronic granulocytic leukemia, t(9;22)(q34;q11)|Chronic idiopathic myelofibrosis|Chronic leukemia, NOS|Chronic lymphatic leukemia|Chronic lymphocytic leukemia|Chronic lymphocytic leukemia, B-cell type (includes all variants of BCLL)|Chronic lymphoid leukemia|Chronic lymphoproliferative disorder of NK cells|Chronic monocytic leukemia|Chronic myelocytic leukemia, NOS|Chronic myelogenous leukemia, BCR-ABL positive|Chronic myelogenous leukemia, Philadelphia chromosome (Ph 1) positive|Chronic myelogenous leukemia, t(9;22)(q34;q11)|Chronic myeloid leukemia, NOS|Chronic myelomonocytic leukemia in transformation|Chronic myelomonocytic leukemia, NOS|Chronic myeloproliferative disease, NOS|Chronic myeloproliferative disorder|Chronic neutrophilic leukemia|Cin III, NOS|Circumscribed arachnoidal cerebellar sarcoma|Classical Hodgkin lymphoma, lymphocyte depletion, NOS|Classical Hodgkin lymphoma, lymphocyte-rich|Classical Hodgkin lymphoma, mixed cellularity, NOS|Classical Hodgkin lymphoma, nodular sclerosis, NOS|Classical Hodgkin lymphoma, nodular sclerosis, cellular phase|Classical Hodgkin lymphoma, nodular sclerosis, grade 1|Classical Hodgkin lymphoma, nodular sclerosis, grade 2|Clear cell (glycogen-rich) urothelial carcinoma|Clear cell adenocarcinoma, NOS|Clear cell adenocarcinoma, mesonephroid|Clear cell adenofibroma|Clear cell adenoma|Clear cell carcinoma|Clear cell chondrosarcoma|Clear cell cystadenofibroma|Clear cell ependymoma|Clear cell hidradenoma|Clear cell meningioma|Clear cell odontogenic carcinoma|Clear cell odontogenic tumor|Clear cell sarcoma of kidney|Clear cell sarcoma, NOS|Clear cell tumor, NOS|Cloacogenic carcinoma|Codman tumor|Collecting duct carcinoma|Colloid adenocarcinoma|Colloid adenoma|Colloid carcinoma|Combined carcinoid and adenocarcinoma|Combined hepatocellular carcinoma and cholangiocarcinoma|Combined large cell neuroendocrine carcinoma|Combined small cell carcinoma|Combined small cell-adenocarcinoma|Combined small cell-squamous cell carcinoma|Combined/mixed carcinoid and adenocarcinoma|Comedocarcinoma, NOS|Common ALL|Common precursor B ALL|Complete hydatidiform mole|Complex odontoma|Composite carcinoid|Compound nevus|Compound odontoma|Condylomatous carcinoma|Congenital fibrosarcoma|Conventional central osteosarcoma|Cortical T ALL|Craniopharyngioma, adamantinomatous|Craniopharyngioma, papillary|Cribriform carcinoma, NOS|Cutaneous T-cell lymphoma, NOS|Cutaneous histiocytoma, NOS|Cutaneous lymphoma, NOS|Cutaneous mastocytosis|Cylindrical cell carcinoma|Cylindroma of skin|Cylindroma, NOS|Cystadenocarcinoma, NOS|Cystadenofibroma, NOS|Cystadenoma, NOS|Cystic astrocytoma|Cystic hygroma|Cystic lymphangioma|Cystic mesothelioma, NOS|Cystic partially differentiated nephroblastoma|Cystic teratoma, NOS|Cystic tumor of atrio-ventricular node|Cystoma, NOS|Cystosarcoma phyllodes, NOS|Cystosarcoma phyllodes, benign|Cystosarcoma phyllodes, malignant|DCIS, NOS|DCIS, papillary|DIN 3|Dabska tumor|Dedifferentiated chondrosarcoma|Dedifferentiated chordoma|Dedifferentiated liposarcoma|Deep histiocytoma|Degenerated schwannoma|Dendritic cell sarcoma, NOS|Dentinoma|Dermal and epidermal nevus|Dermal nevus|Dermatofibroma lenticulare|Dermatofibroma, NOS|Dermatofibrosarcoma protuberans, NOS|Dermatofibrosarcoma, NOS|Dermoid cyst with malignant transformation|Dermoid cyst with secondary tumor|Dermoid cyst, NOS|Dermoid, NOS|Desmoid, NOS|Desmoplastic fibroma|Desmoplastic infantile astrocytoma|Desmoplastic infantile ganglioglioma|Desmoplastic medulloblastoma|Desmoplastic melanoma, amelanotic|Desmoplastic melanoma, malignant|Desmoplastic mesothelioma|Desmoplastic nodular medulloblastoma|Desmoplastic small round cell tumor|Di Guglielmo disease|Differentiated-type vulvar intraepithelial neoplasia|Diffuse astrocytoma|Diffuse astrocytoma, IDH-mutant|Diffuse astrocytoma, IDH-wildtype|Diffuse astrocytoma, low grade|Diffuse cutaneous mastocytosis|Diffuse intraductal papillomatosis|Diffuse large B-cell lymphoma associated with chronic inflammation|Diffuse large B-cell lymphoma, NOS|Diffuse leptomeningeal glioneuronal tumor|Diffuse melanocytosis|Diffuse meningiomatosis|Diffuse midline glioma, H3 K27M-mutant|Digital papillary adenocarcinoma|Diktyoma, malignant|Duct adenocarcinoma, NOS|Duct adenoma, NOS|Duct carcinoma, NOS|Duct cell carcinoma|Ductal carcinoma in situ, NOS|Ductal carcinoma in situ, cribriform type|Ductal carcinoma in situ, papillary|Ductal carcinoma, NOS|Ductal carcinoma, cribriform type|Ductal intraepithelial neoplasia 3|Ductal papilloma|Dysembryoplastic neuroepithelial tumor|Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)|Dysplastic nevus|EBV positive diffuse large B-cell lymphoma of the elderly|ECL cell carcinoid, NOS|ECL cell carcinoid, malignant|Ecchondroma|Ecchondrosis|Eccrine acrospiroma|Eccrine cystadenoma|Eccrine dermal cylindroma|Eccrine papillary adenocarcinoma|Eccrine papillary adenoma|Eccrine poroma|Eccrine poroma, malignant|Eccrine spiradenoma|Ectopic hamartomatous thymoma|Embryonal adenocarcinoma|Embryonal carcinoma, NOS|Embryonal carcinoma, infantile|Embryonal hepatoma|Embryonal rhabdomyosarcoma, NOS|Embryonal sarcoma|Embryonal teratoma|Embryonal tumor with multilayered rosettes C19MC-altered|Embryonal tumor with multilayered rosettes, NOS|Embryonal tumor with rhabdoid features|Encapsulated papillary carcinoma|Encapsulated papillary carcinoma with invasion|Endocervical adenocarcinoma usual type|Endocrine adenomatosis|Endocrine tumor, functioning, NOS|Endodermal sinus tumor|Endolymphatic stromal myosis|Endometrial sarcoma, NOS|Endometrial stromal nodule|Endometrial stromal sarcoma, NOS|Endometrial stromal sarcoma, high grade|Endometrial stromal sarcoma, low grade|Endometrial stromatosis|Endometrioid adenocarcinoma, NOS|Endometrioid adenocarcinoma, ciliated cell variant|Endometrioid adenocarcinoma, secretory variant|Endometrioid adenocarcinoma, villoglandular|Endometrioid adenofibroma, NOS|Endometrioid adenofibroma, borderline malignancy|Endometrioid adenoma, borderline malignancy|Endometrioid carcinoma with squamous differentiation|Endometrioid carcinoma, NOS|Endometrioid cystadenocarcinoma|Endometrioid cystadenofibroma, NOS|Endometrioid cystadenofibroma, borderline malignancy|Endometrioid cystadenoma, borderline malignancy|Endometrioid tumor of low malignant potential|Endotheliomatous meningioma|Endovascular papillary angioendothelioma|Enterochromaffin-like cell carcinoid, NOS|Enterochromaffin-like cell tumor, malignant|Enteroglucagonoma, NOS|Enteroglucagonoma, malignant|Enteropathy associated T-cell lymphoma|Enteropathy type intestinal T-cell lymphoma|Eosinophil adenocarcinoma|Eosinophil adenoma|Eosinophil carcinoma|Eosinophilic granuloma|Eosinophilic leukemia|Ependymoblastoma|Ependymoma, NOS|Ependymoma, RELA fusion-positive|Ependymoma, anaplastic|Epidermoid carcinoma in situ with questionable stromal invasion|Epidermoid carcinoma in situ, NOS|Epidermoid carcinoma, NOS|Epidermoid carcinoma, keratinizing|Epidermoid carcinoma, large cell, nonkeratinizing|Epidermoid carcinoma, small cell, nonkeratinizing|Epidermoid carcinoma, spindle cell|Epithelial ependymoma|Epithelial tumor, benign|Epithelial tumor, malignant|Epithelial-myoepithelial carcinoma|Epithelioid MPNST|Epithelioid and spindle cell nevus|Epithelioid cell melanoma|Epithelioid cell nevus|Epithelioid cell sarcoma|Epithelioid glioblastoma|Epithelioid hemangioendothelioma, NOS|Epithelioid hemangioma|Epithelioid leiomyoma|Epithelioid leiomyosarcoma|Epithelioid malignant peripheral nerve sheath tumor|Epithelioid mesothelioma, NOS|Epithelioid mesothelioma, benign|Epithelioid mesothelioma, malignant|Epithelioid sarcoma|Epithelioma adenoides cysticum|Epithelioma, NOS|Epithelioma, benign|Erythremic myelosis, NOS|Esophageal glandular dysplasia (intraepithelial neoplasia), high grade|Esophageal glandular dysplasia (intraepithelial neoplasia), low grade|Esophageal intraepithelial neoplasia, high grade|Esophageal squamous intraepithelial neoplasia (dysplasia), high grade|Esophageal squamous intraepithelial neoplasia (dysplasia), low grade|Essential hemorrhagic thrombocythaemia|Essential thrombocythemia|Esthesioneuroblastoma|Esthesioneuroepithelioma|Ewing sarcoma|Ewing tumor|Extra-abdominal desmoid|Extra-adrenal paraganglioma, NOS|Extra-adrenal paraganglioma, malignant|Extracutaneous mastocytoma|Extranodal NK/T-cell lymphoma, nasal type|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extraosseous plasmacytoma|Extraventricular neurocytoma|FAB L2|FAB L3|FAB Ll|FAB M1|FAB M2, AML1(CBF-alpha)/ETO|FAB M2, NOS|FAB M2, t(8;21)(q22;q22)|FAB M3 (includes all variants)|FAB M4|FAB M4Eo|FAB M5 (includes all variants)|FAB M6|FAB M7|FAB MO|Familial polyposis coli|Fascial fibroma|Fascial fibrosarcoma|Fetal adenocarcinoma|Fetal adenoma|Fetal fat cell lipoma|Fetal lipoma, NOS|Fetal lipomatosis|Fetal rhabdomyoma|Fibrillary astrocytoma|Fibro-osteoma|Fibroadenoma, NOS|Fibroameloblastic odontoma|Fibroblastic liposarcoma|Fibroblastic meningioma|Fibroblastic osteosarcoma|Fibroblastic reticular cell tumor|Fibrochondrosarcoma|Fibroepithelial basal cell carcinoma, Pinkus type|Fibroepithelioma of Pinkus type|Fibroepithelioma, NOS|Fibroid uterus|Fibroliposarcoma|Fibroma, NOS|Fibromyoma|Fibromyxoma|Fibromyxosarcoma|Fibrosarcoma, NOS|Fibrosarcomatous dermatofibrosarcoma protuberans|Fibrous astrocytoma|Fibrous histiocytoma of tendon sheath|Fibrous histiocytoma, NOS|Fibrous meningioma|Fibrous mesothelioma, NOS|Fibrous mesothelioma, benign|Fibrous mesothelioma, malignant|Fibroxanthoma, NOS|Fibroxanthoma, malignant|Flat adenoma|Florid osseous dysplasia|Follicular adenocarcinoma, NOS|Follicular adenocarcinoma, well differentiated|Follicular adenoma|Follicular adenoma, oxyphilic cell|Follicular carcinoma, NOS|Follicular carcinoma, oxyphilic cell|Follicular carcinoma, well differentiated|Follicular dendritic cell sarcoma|Follicular dendritic cell tumor|Follicular fibroma|Follicular lymphoma, NOS|Follicular lymphoma, grade 1|Follicular lymphoma, grade 2|Follicular lymphoma, grade 3|Follicular lymphoma, grade 3A|Follicular lymphoma, grade 3B|Follicular lymphoma, small cleaved cell|Follicular thyroid carcinoma (FTC), encapsulated angioinvasive|Franklin disease|G cell tumor, NOS|G cell tumor, malignant|GANT|GIST, NOS|GIST, benign|GIST, malignant|Gamma heavy chain disease|Gangliocytic paraganglioma|Ganglioglioma, NOS|Ganglioglioma, anaplastic|Gastrin cell tumor|Gastrin cell tumor, malignant|Gastrinoma, NOS|Gastrinoma, malignant|Gastrointestinal autonomic nerve tumor|Gastrointestinal stromal sarcoma|Gastrointestinal stromal tumor, NOS|Gastrointestinal stromal tumor, benign|Gastrointestinal stromal tumor, malignant|Gastrointestinal stromal tumor, uncertain malignant potential|Gelatinous adenocarcinoma|Gelatinous carcinoma|Gemistocytic astrocytoma|Gemistocytoma|Genital rhabdomyoma|Germ cell tumor, NOS|Germ cell tumor, nonseminomatous|Germ cell tumors with associated hematological malignancy|Ghost cell odontogenic carcinoma|Giant cell and spindle cell carcinoma|Giant cell angiofibroma|Giant cell carcinoma|Giant cell fibroblastoma|Giant cell glioblastoma|Giant cell sarcoma|Giant cell sarcoma of bone|Giant cell tumor of bone, NOS|Giant cell tumor of bone, malignant|Giant cell tumor of soft parts, NOS|Giant cell tumor of tendon sheath|Giant cell tumor of tendon sheath, malignant|Giant fibroadenoma|Giant osteoid osteoma|Giant pigmented nevus, NOS|Gigantiform cementoma|Glandular intraepithelial neoplasia, grade I|Glandular intraepithelial neoplasia, grade II|Glandular intraepithelial neoplasia, grade III|Glandular intraepithelial neoplasia, high grade|Glandular intraepithelial neoplasia, low grade|Glandular papilloma|Glassy cell carcinoma|Glioblastoma multiforme|Glioblastoma with sarcomatous component|Glioblastoma, IDH wildtype|Glioblastoma, IDH-mutant|Glioma, NOS|Glioma, malignant|Gliomatosis cerebri|Glioneuroma|Glomangiosarcoma|Glomoid sarcoma|Glomus jugulare tumor, NOS|Glomus tumor, NOS|Glomus tumor, malignant|Glucagonoma, malignant|Glycogen-rich carcinoma|Goblet cell carcinoid|Gonadal stromal tumor, NOS|Gonocytoma|Granular cell adenocarcinoma|Granular cell carcinoma|Granular cell myoblastoma, NOS|Granular cell myoblastoma, malignant|Granular cell tumor of the sellar region|Granular cell tumor, NOS|Granular cell tumor, malignant|Granulocytic leukemia, NOS|Granulocytic sarcoma|Granulosa cell carcinoma|Granulosa cell tumor, NOS|Granulosa cell tumor, adult type|Granulosa cell tumor, juvenile|Granulosa cell tumor, malignant|Granulosa cell-theca cell tumor|Grawitz tumor|Gynandroblastoma|Haemangioblastoma|Haemangiosarcoma|Hairy cell leukaemia variant|Hairy cell leukemia|Hairy cell leukemia variant|Hairy nevus|Halo nevus|Hand-Schuller-Christian disease|Heavy chain disease, NOS|Hemangioblastic meningioma|Hemangioendothelial sarcoma|Hemangioendothelioma, NOS|Hemangioendothelioma, benign|Hemangioendothelioma, malignant|Hemangioma simplex|Hemangioma, NOS|Hemangiopericytoma, NOS|Hemangiopericytoma, benign|Hemangiopericytoma, malignant|Hepatoblastoma, mixed epithelial-mesenchymal|Hepatocarcinoma|Hepatocellular adenoma|Hepatocellular carcinoma, NOS|Hepatocellular carcinoma, fibrolamellar|Hepatocellular carcinoma, scirrhous|Hepatocholangiocarcinoma|Hepatoid adenocarcinoma|Hepatoid carcinoma|Hepatoid yolk sac tumor|Hepatoma, NOS|Hepatoma, benign|Hepatoma, malignant|Hepatosplenic T-cell lymphoma|Hepatosplenic gamma-delta cell lymphoma|Hereditary leiomyomatosis & RCC-associated renal cell carcinoma|Hidradenoma papilliferum|Hidradenoma, NOS|High grade surface osteosarcoma|Hilar cell tumor|Hilus cell tumor|Histiocyte-rich large B-cell lymphoma|Histiocytic medullary reticulosis|Histiocytic sarcoma|Histiocytoid hemangioma|Histiocytoma, NOS|Histiocytosis X, NOS|Hodgkin disease, NOS|Hodgkin disease, lymphocyte predominance, NOS|Hodgkin disease, lymphocyte predominance, diffuse|Hodgkin disease, lymphocytic-histiocytic predominance|Hodgkin disease, nodular sclerosis, NOS|Hodgkin disease, nodular sclerosis, lymphocyte depletion|Hodgkin disease, nodular sclerosis, lymphocyte predominance|Hodgkin disease, nodular sclerosis, mixed cellularity|Hodgkin disease, nodular sclerosis, syncytial variant|Hodgkin granuloma|Hodgkin lymphoma, NOS|Hodgkin lymphoma, lymphocyte depletion, NOS|Hodgkin lymphoma, lymphocyte predominance, nodular|Hodgkin lymphoma, lymphocyte-rich|Hodgkin lymphoma, mixed cellularity, NOS|Hodgkin lymphoma, nodular lymphocyte predominance|Hodgkin lymphoma, nodular sclerosis, NOS|Hodgkin lymphoma, nodular sclerosis, cellular phase|Hodgkin lymphoma, nodular sclerosis, grade 1|Hodgkin lymphoma, nodular sclerosis, grade 2|Hodgkin paragranuloma, NOS|Hodgkin paragranuloma, nodular|Hodgkin sarcoma|Hurthle cell adenocarcinoma|Hurthle cell adenoma|Hurthle cell carcinoma|Hurthle cell tumor|Hutchinson melanotic freckle, NOS|Hyalinizing trabecular adenoma|Hydatid mole|Hydatidiform mole, NOS|Hydroa vacciniforme-like lymphoma|Hygroma, NOS|Hypereosinophilic syndrome|Hypernephroma|Idiopathic hemorrhagic thrombocythaemia|Idiopathic thrombocythemia|Immature teratoma, NOS|Immature teratoma, malignant|Immunoblastic sarcoma|Immunocytoma|Immunoglobulin deposition disease|Immunoproliferative small intestinal disease|Indeterminate dendritic cell tumor|Indolent systemic mastocytosis|Infantile fibrosarcoma|Infantile hemangioma|Infantile myofibromatosis|Infiltrating and papillary adenocarcinoma|Infiltrating angiolipoma|Infiltrating basal cell carcinoma, NOS|Infiltrating basal cell carcinoma, non-sclerosing|Infiltrating basal cell carcinoma, sclerosing|Infiltrating duct adenocarcinoma|Infiltrating duct and lobular carcinoma|Infiltrating duct and lobular carcinoma in situ|Infiltrating duct carcinoma, NOS|Infiltrating ductular carcinoma|Infiltrating lipoma|Infiltrating lobular carcinoma and ductal carcinoma in situ|Infiltrating lobular carcinoma, NOS|Infiltrating papillary adenocarcinoma|Inflammatory liposarcoma|Inflammatory myofibroblastic tumor|Insular carcinoma|Insulinoma, NOS|Insulinoma, malignant|Interdigitating cell sarcoma|Interdigitating dendritic cell sarcoma|Interstitial cell tumor, NOS|Interstitial cell tumor, benign|Interstitial cell tumor, malignant|Intestinal T-cell lymphoma|Intestinal-type adenocarcinoma|Intimal sarcoma|Intracanalicular fibroadenoma|Intracortical osteosarcoma|Intracystic carcinoma, NOS|Intracystic papillary adenocarcinoma|Intracystic papillary adenoma|Intracystic papillary neoplasm with intermediate grade intraepithelial neoplasia|Intracystic papillary neoplasm with low grade intraepithelial neoplasia|Intracystic papilloma|Intradermal nevus|Intraductal adenocarcinoma, noninfiltrating, NOS|Intraductal and lobular carcinoma|Intraductal carcinoma and lobular carcinoma in situ|Intraductal carcinoma, NOS|Intraductal carcinoma, noninfiltrating, NOS|Intraductal papillary adenocarcinoma with invasion|Intraductal papillary adenocarcinoma, NOS|Intraductal papillary carcinoma|Intraductal papillary mucinous neoplasm (IPMN) with an associated invasive carcinoma|Intraductal papillary mucinous neoplasm with high grade dysplasia|Intraductal papillary neoplasm with associated invasive carcinoma|Intraductal papillary neoplasm with high grade intraepithelial neoplasia|Intraductal papillary neoplasm with intermediate grade neoplasia|Intraductal papillary neoplasm with low grade intraepithelial neoplasia|Intraductal papillary neoplasm, NOS|Intraductal papilloma|Intraductal papillomatosis, NOS|Intraductal tubulopapillary neoplasm|Intraepidermal carcinoma, NOS|Intraepidermal epithelioma of Jadassohn|Intraepidermal nevus|Intraepidermal squamous cell carcinoma, Bowen type|Intraepithelial carcinoma, NOS|Intraepithelial squamous cell carcinoma|Intraglandular papillary neoplasm with low grade intraepithelial neoplasia|Intramuscular hemangioma|Intramuscular lipoma|Intraneural perineurioma|Intraosseous low grade osteosarcoma|Intraosseous well differentiated osteosarcoma|Intravascular B-cell lymphoma|Intravascular large B-cell lymphoma|Invasive encapsulated follicular variant of papillary thyroid carcinoma (invasive EFVPTC)|Invasive fibroma|Invasive hydatidiform mole|Invasive lobular carcinoma|Invasive lobular carcinoma, alveolar type|Invasive lobular carcinoma, solid type|Invasive lobular carcinoma, tubulolobular variant|Invasive mammary carcinoma|Invasive micropapillary carcinoma|Invasive mole, NOS|Invasive mucinous adenocarcinoma|Islet cell adenocarcinoma|Islet cell adenoma|Islet cell adenomatosis|Islet cell carcinoma|Islet cell tumor, NOS|Jadassohn blue nevus|Jugular paraganglioma|Jugulotympanic paraganglioma|Junction nevus|Junctional nevus, NOS|Juvenile angiofibroma|Juvenile astrocytoma|Juvenile carcinoma of breast|Juvenile chronic myelomonocytic leukemia|Juvenile fibroadenoma|Juvenile hemangioma|Juvenile histiocytoma|Juvenile melanoma|Juvenile myelomonocytic leukemia|Juvenile nevus|Juxtacortical chondroma|Juxtacortical chondrosarcoma|Juxtacortical osteosarcoma|Juxtaglomerular tumor|Kaposi sarcoma|Kaposiform hemangioendothelioma|Keratotoc papilloma|Klatskin tumor|Krukenberg tumor|LCIS, NOS|Lactating adenoma|Langerhans cell granulomatosis|Langerhans cell granulomatosis, unifocal|Langerhans cell histiocytosis, NOS|Langerhans cell histiocytosis, disseminated|Langerhans cell histiocytosis, generalized|Langerhans cell histiocytosis, mono-ostotic|Langerhans cell histiocytosis, multifocal|Langerhans cell histiocytosis, poly-ostotic|Langerhans cell histiocytosis, unifocal|Langerhans cell sarcoma|Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease|Large cell (Ki-1+) lymphoma|Large cell carcinoma with rhabdoid phenotype|Large cell carcinoma, NOS|Large cell medulloblastoma|Large cell neuroendocrine carcinoma|Leiomyoblastoma|Leiomyofibroma|Leiomyoma, NOS|Leiomyomatosis, NOS|Leiomyosarcoma, NOS|Lennert lymphoma|Lentigo maligna|Lentigo maligna melanoma|Lepidic predominant adenocarcinoma|Leptomeningeal sarcoma|Letterer-Siwe disease|Leukemia, NOS|Leukemic reticuloendotheliosis|Leydig cell tumor, NOS|Leydig cell tumor, benign|Leydig cell tumor, malignant|Linitis plastica|Lipid cell tumor of ovary|Lipid-rich carcinoma|Lipid-rich urothelial carcinoma|Lipoid cell tumor of ovary|Lipoleiomyoma|Lipoma, NOS|Lipoma-like liposarcoma|Lipomatous medulloblastoma|Liposarcoma, NOS|Liposarcoma, differentiated|Liposarcoma, well differentiated|Liver cell adenoma|Liver cell carcinoma|Lobular adenocarcinoma|Lobular and ductal carcinoma|Lobular carcinoma in situ, NOS|Lobular carcinoma, NOS|Lobular carcinoma, noninfiltrating|Localized fibrous tumor|Low grade adenosquamous carcinoma|Low grade appendiceal mucinous neoplasm|Low grade cribriform cystadenocarcinoma (LGCCC)|Low-grade central osteosarcoma|Low-grade fibromyxoid sarcoma|Low-grade intramedullary osteosarcoma|Low-grade myofibroblastic sarcoma|Luteinoma|Luteoma, NOS|Lymphangioendothelial sarcoma|Lymphangioendothelioma, NOS|Lymphangioendothelioma, malignant|Lymphangioma, NOS|Lymphangiomyoma|Lymphangiomyomatosis|Lymphatic leukemic, NOS|Lymphoblastic leukemia, NOS|Lymphoblastoma|Lymphocytic leukemia, NOS|Lymphoepithelial carcinoma|Lymphoepithelioid lymphoma|Lymphoepithelioma|Lymphoepithelioma-like carcinoma|Lymphoid leukemia, NOS|Lymphoma, NOS|Lymphomatoid granulomatosis|Lymphomatoid papulosis|Lymphoplasmacyte-rich meningioma|Lymphoproliferative disease, NOS|Lymphoproliferative disorder, NOS|Lymphosarcoma cell leukemia|Lymphosarcoma, NOS|Lymphosarcoma, diffuse|M6A|M6B|MALT lymphoma|MANEC|MGUS|MPNST with rhabdomyoblastic differentiation|MPNST, NOS|Macrofollicular adenoma|Magnocellular nevus|Malignancy|Malignant cystic nephroma|Malignant eccrine spiradenoma|Malignant fibrous histiocytoma|Malignant giant cell tumor of soft parts|Malignant histiocytosis|Malignant hydatidiform mole|Malignant lymphoma, Hodgkin|Malignant lymphoma, NOS|Malignant lymphoma, centroblastic, NOS|Malignant lymphoma, centroblastic, diffuse|Malignant lymphoma, centroblastic, follicular|Malignant lymphoma, centroblasticcentrocytic, NOS|Malignant lymphoma, centroblasticcentrocytic, diffuse|Malignant lymphoma, centroblasticcentrocytic, follicular|Malignant lymphoma, convoluted cell|Malignant lymphoma, diffuse, NOS|Malignant lymphoma, follicle center, NOS|Malignant lymphoma, follicle center, follicular|Malignant lymphoma, follicular, NOS|Malignant lymphoma, histiocytic, NOS|Malignant lymphoma, histiocytic, diffuse|Malignant lymphoma, histiocytic, nodular|Malignant lymphoma, immunoblastic, NOS|Malignant lymphoma, large B-cell, NOS|Malignant lymphoma, large B-cell, diffuse, NOS|Malignant lymphoma, large B-cell, diffuse, centroblastic, NOS|Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS|Malignant lymphoma, large cell, NOS|Malignant lymphoma, large cell, cleaved and noncleaved|Malignant lymphoma, large cell, cleaved, NOS|Malignant lymphoma, large cell, cleaved, diffuse|Malignant lymphoma, large cell, diffuse, NOS|Malignant lymphoma, large cell, follicular, NOS|Malignant lymphoma, large cell, immunoblastic|Malignant lymphoma, large cell, noncleaved, NOS|Malignant lymphoma, large cell, noncleaved, diffuse|Malignant lymphoma, large cell, noncleaved, follicular|Malignant lymphoma, large cleaved cell, NOS|Malignant lymphoma, large cleaved cell, follicular|Malignant lymphoma, lymphoblastic, NOS|Malignant lymphoma, lymphocytic, NOS|Malignant lymphoma, lymphocytic, diffuse, NOS|Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse|Malignant lymphoma, lymphocytic, nodular, NOS|Malignant lymphoma, lymphocytic, poorly differentiated, nodular|Malignant lymphoma, lymphocytic, well differentiated, diffuse|Malignant lymphoma, lymphoplasmacytic|Malignant lymphoma, lymphoplasmacytoid|Malignant lymphoma, mixed cell type, follicular|Malignant lymphoma, mixed cell type, nodular|Malignant lymphoma, mixed lymphocytic-histiocytic, nodular|Malignant lymphoma, mixed small cleaved and large cell, follicular|Malignant lymphoma, nodular, NOS|Malignant lymphoma, non-Hodgkin, NOS|Malignant lymphoma, non-cleaved cell, NOS|Malignant lymphoma, noncleaved, NOS|Malignant lymphoma, noncleaved, diffuse, NOS|Malignant lymphoma, plasmacytoid|Malignant lymphoma, small B lymphocytic, NOS|Malignant lymphoma, small cell diffuse|Malignant lymphoma, small cell, NOS|Malignant lymphoma, small cleaved cell, follicular|Malignant lymphoma, small lymphocytic, NOS|Malignant lymphoma, small lymphocytic, diffuse|Malignant lymphoma, small noncleaved, Burkitt type|Malignant lymphoma, undifferentiated, Burkitt type|Malignant lymphomatous polyposis|Malignant mast cell tumor|Malignant mastocytoma|Malignant mastocytosis|Malignant melanoma in Hutchinson melanotic freckle|Malignant melanoma in junctional nevus|Malignant melanoma in precancerous melanosis|Malignant melanoma, NOS|Malignant melanoma, regressing|Malignant multilocular cystic nephroma|Malignant myoepithelioma|Malignant peripheral nerve sheath tumor|Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation|Malignant perivascular epithelial cell tumor|Malignant reticulosis, NOS|Malignant rhabdoid tumor|Malignant schwannoma with rhabdomyoblastic differentiation|Malignant schwannoma, NOS|Malignant tenosynovial giant cell tumor|Malignant teratoma, anaplastic|Malignant teratoma, intermediate|Malignant teratoma, trophoblastic|Malignant teratoma, undifferentiated|Malignant tumor, fusiform cell type|Malignant tumor, giant cell type|Malignant tumor, small cell type|Malignant tumor, spindle cell type|Mantle cell lymphoma (Includes all variants blastic, pleomorphic, small cell)|Mantle zone lymphoma|Marginal zone B-cell lymphoma, NOS|Marginal zone lymphoma, NOS|Masculinovoblastoma|Mast cell leukaemia|Mast cell sarcoma|Mast cell tumor, NOS|Mastocytoma, NOS|Matrical carcinoma|Mature T ALL|Mature T-cell lymphoma, NOS|Mature teratoma|Mediastinal (thymic) large B-cell lymphoma|Mediterranean lymphoma|Medullary carcinoma with amyloid stroma|Medullary carcinoma, NOS|Medullary osteosarcoma|Medulloblastoma with extensive nodularity|Medulloblastoma, NOS|Medulloblastoma, SHH-activated and TP53-mutant|Medulloblastoma, SHH-activated and TP53-wildtype|Medulloblastoma, WNT-activated|Medulloblastoma, classic|Medulloblastoma, group 3|Medulloblastoma, group 4|Medulloblastoma, non-WNT/non-SHH|Medullocytoma|Medulloepithelioma, NOS|Medullomyoblastoma|Megakaryocytic leukemia|Megakaryocytic myelosclerosis|Melanoameloblastoma|Melanocytic nevus|Melanocytoma, NOS|Melanocytoma, eyeball|Melanoma in situ|Melanoma, NOS|Melanoma, malignant, of soft parts|Melanotic MPNST|Melanotic medulloblastoma|Melanotic neuroectodermal tumor|Melanotic neurofibroma|Melanotic progonoma|Melanotic psammomatous MPNST|Melanotic schwannoma|Meningeal melanocytoma|Meningeal melanoma|Meningeal melanomatosis|Meningeal sarcoma|Meningeal sarcomatosis|Meningioma, NOS|Meningioma, anaplastic|Meningioma, malignant|Meningiomatosis, NOS|Meningothelial meningioma|Meningothelial sarcoma|Merkel cell carcinoma|Merkel cell tumor|Mesenchymal chondrosarcoma|Mesenchymal tumor, malignant|Mesenchymoma, NOS|Mesenchymoma, benign|Mesenchymoma, malignant|Mesenteric fibromatosis|Mesoblastic nephroma|Mesodermal mixed tumor|Mesonephric adenocarcinoma|Mesonephric adenoma|Mesonephric tumor, NOS|Mesonephroma, NOS|Mesonephroma, benign|Mesonephroma, malignant|Mesothelioma, NOS|Mesothelioma, benign|Mesothelioma, biphasic, NOS|Mesothelioma, biphasic, malignant|Mesothelioma, malignant|Metanephric adenoma|Metaplastic carcinoma of no special type|Metaplastic carcinoma, NOS|Metaplastic meningioma|Metastatic signet ring cell carcinoma|Metatypical carcinoma|MiT family translocation renal cell carcinoma|Microcystic adenoma|Microcystic adnexal carcinoma|Microcystic meningioma|Microcystic urothelial carcinoma|Microfollicular adenoma, NOS|Microglioma|Micropapillary serous carcinoma|Midline carcinoma of children and young adults with NUT rearrangement|Minimally invasive adenocarcinoma, NOS|Minimally invasive adenocarcinoma, mucinous|Minimally invasive adenocarcinoma, non-mucinous|Mixed acidophil-basophil adenoma|Mixed acidophil-basophil carcinoma|Mixed acinar-endocrine-ductal carcinoma|Mixed adenocarcinoma and epidermoid carcinoma|Mixed adenocarcinoma and squamous cell carcinoma|Mixed adenomatous and hyperplastic polyp|Mixed adenoneuroendocrine carcinoma|Mixed basal-squamous cell carcinoma|Mixed carcinoid-adenocarcinoma|Mixed cell adenocarcinoma|Mixed cell adenoma|Mixed ductal-endocrine carcinoma|Mixed embryonal carcinoma and teratoma|Mixed epithelioid and spindle cell melanoma|Mixed germ cell sex cord-stromal tumor, unclassified|Mixed germ cell tumor|Mixed glioma|Mixed hepatocellular and bile duct carcinoma|Mixed liposarcoma|Mixed meningioma|Mixed mesenchymal sarcoma|Mixed mesenchymal tumor|Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1|Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged|Mixed phenotype acute leukemia, B/myeloid, NOS|Mixed phenotype acute leukemia, T/myeloid, NOS|Mixed small cell carcinoma|Mixed subependymoma-ependymoma|Mixed teratoma and seminoma|Mixed tumor, NOS|Mixed tumor, malignant, NOS|Mixed tumor, salivary gland type, NOS|Mixed tumor, salivary gland type, malignant|Monoblastic leukemia, NOS|Monoclonal gammopathy of undetermined significance|Monoclonal gammopathy, NOS|Monocytic leukemia, NOS|Monocytoid B-cell lymphoma|Monomorphic adenoma|Mu heavy chain disease|Mucin-producing adenocarcinoma|Mucin-producing carcinoma|Mucin-secreting adenocarcinoma|Mucin-secreting carcinoma|Mucinous adenocarcinoma|Mucinous adenocarcinoma, endocervical type|Mucinous adenofibroma, NOS|Mucinous adenoma|Mucinous carcinoma|Mucinous carcinoma, gastric type|Mucinous carcinoma, intestinal type|Mucinous cystadenocarcinoma, NOS|Mucinous cystadenofibroma, NOS|Mucinous cystadenoma, NOS|Mucinous cystic tumor with moderate dysplasia|Mucinous cystoma|Mucinous tubular and spindle cell carcinoma|Mucoepidermoid carcinoma|Mucoid adenocarcinoma|Mucoid carcinoma|Mucoid cell adenocarcinoma|Mucoid cell adenoma|Mucosal lentiginous melanoma|Mucosal-associated lymphoid tissue lymphoma|Mucous adenocarcinoma|Mucous carcinoma|Mullerian adenosarcoma|Mullerian mixed tumor|Multicentric basal cell carcinoma|Multifocal superficial basal cell carcinoma|Multiple adenomatous polyps|Multiple endocrine adenomas|Multiple hemorrhagic sarcoma|Multiple meningiomas|Multiple myeloma|Multiple neurofibromatosis|Mycosis fungoides|Myelocytic leukemia, NOS|Myelodysplastic syndrome with 5q deletion (5q-) syndrome|Myelodysplastic syndrome with isolated del (5q)|Myelodysplastic syndrome, NOS|Myelodysplastic syndrome, unclassifiable|Myelodysplastic/myeloproliferative neoplasm, unclassifiable|Myelofibrosis as a result of myeloproliferative disease|Myelofibrosis with myeloid metaplasia|Myelogenous leukemia, NOS|Myeloid and lymphoid neoplasms with PDGFRA rearrangement|Myeloid leukemia associated with Down Syndrome|Myeloid leukemia, NOS|Myeloid neoplasms with PDGFRB rearrangement|Myeloid sarcoma|Myelolipoma|Myeloma, NOS|Myelomatosis|Myeloproliferative disease, NOS|Myeloproliferative neoplasm, NOS|Myelosclerosis with myeloid metaplasia|Myloproliferative neoplasm, unclassifiable|Myoepithelial adenoma|Myoepithelial carcinoma|Myoepithelial tumor|Myoepithelioma|Myofibroblastic tumor, NOS|Myoma|Myosarcoma|Myxofibroma, NOS|Myxoid chondrosarcoma|Myxoid fibroma|Myxoid leiomyosarcoma|Myxoid liposarcoma|Myxoinflammatory fibroblastic sarcoma (MIFS)|Myxolipoma|Myxoliposarcoma|Myxoma, NOS|Myxopapillary ependymoma|NK/T-cell lymphoma, nasal and nasal-type|NUT carcinoma|NUT midline carcinoma|Neoplasm, NOS|Neoplasm, benign|Neoplasm, malignant|Neoplasm, malignant, uncertain whether primary or metastatic|Neoplasm, metastatic|Neoplasm, secondary|Neoplasm, uncertain whether benign or malignant|Nephroblastoma, NOS|Nephrogenic adenofibroma|Nephroma, NOS|Nerve sheath myxoma|Nesidioblastoma|Nested urothelial carcinoma|Neurilemoma, NOS|Neurilemoma, malignant|Neurilemosarcoma|Neurinoma|Neurinomatosis|Neuroastrocytoma|Neuroblastoma, NOS|Neurocytoma|Neuroectodermal tumor, NOS|Neuroendocrine carcinoma, NOS|Neuroendocrine carcinoma, low grade|Neuroendocrine carcinoma, moderately differentiated|Neuroendocrine carcinoma, poorly differentiated|Neuroendocrine carcinoma, well-differentiated|Neuroendocrine tumor, well differentiated|Neuroepithelioma, NOS|Neurofibroma, NOS|Neurofibromatosis, NOS|Neurofibrosarcoma|Neurogenic sarcoma|Neurolipocytoma|Neuroma, NOS|Neurosarcoma|Neurothekeoma|Nevus, NOS|Nodal marginal zone lymphoma|Nodular hidradenoma|Nodular melanoma|Non-Hodgkin lymphoma, NOS|Non-invasive EFVPTC|Non-invasive FTP|Non-invasive encapsulated follicular variant of papillary thyroid carcinoma (non-invasive EFVPTC)|Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)|Non-lymphocytic leukemia, NOS|Non-small cell carcinoma|Nonchromaffin paraganglioma, malignant|Nonencapsulated sclerosing adenocarcinoma|Nonencapsulated sclerosing carcinoma|Nonencapsulated sclerosing tumor|Noninfiltrating intracystic carcinoma|Noninfiltrating intraductal papillary adenocarcinoma|Noninfiltrating intraductal papillary carcinoma|Noninvasive pancreatobiliary papillary neoplasm with high grade dysplasia|Noninvasive pancreatobiliary papillary neoplasm with high grade intraepithelial neoplasia|Noninvasive pancreatobiliary papillary neoplasm with low grade dysplasia|Noninvasive pancreatobiliary papillary neoplasm with low grade intraepithelial neoplasia|Nonpigmented nevus|Oat cell carcinoma|Odontogenic carcinoma|Odontogenic carcinosarcoma|Odontogenic fibroma, NOS|Odontogenic fibrosarcoma|Odontogenic ghost cell tumor|Odontogenic myxofibroma|Odontogenic myxoma|Odontogenic sarcoma|Odontogenic tumor, NOS|Odontogenic tumor, benign|Odontogenic tumor, malignant|Odontoma, NOS|Olfactory neuroblastoma|Olfactory neurocytoma|Olfactory neuroepithelioma|Olfactory neurogenic tumor|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted|Oligodendroglioma, NOS|Oligodendroglioma, anaplastic|Oncocytic Schneiderian papilloma|Oncocytic adenocarcinoma|Oncocytic adenoma|Oncocytic carcinoma|Oncocytoma|Orchioblastoma|Ossifying fibroma|Ossifying fibromyxoid tumor|Ossifying fibromyxoid tumor, malignant|Osteoblastic sarcoma|Osteoblastoma, NOS|Osteoblastoma, malignant|Osteocartilaginous exostosis|Osteochondromatosis, NOS|Osteochondrosarcoma|Osteofibrosarcoma|Osteogenic sarcoma, NOS|Osteoid osteoma, NOS|Osteoma, NOS|Osteosarcoma, NOS|Ovarian stromal tumor|Oxyphilic adenocarcinoma|Oxyphilic adenoma|PEComa, malignant|PIN III|PNET, NOS|PPNET|PTLD, NOS|Pacinian tumor|Paget disease and intraductal carcinoma of breast|Paget disease of breast|Paget disease, extramammary|Paget disease, mammary|Pagetoid reticulosis|Pancreatic endocrine tumor, NOS|Papillary adenocarcinoma, NOS|Papillary adenofibroma|Papillary adenoma, NOS|Papillary and follicular adenocarcinoma|Papillary and follicular carcinoma|Papillary carcinoma in situ|Papillary carcinoma of thyroid|Papillary carcinoma, NOS|Papillary carcinoma, columnar cell|Papillary carcinoma, diffuse sclerosing|Papillary carcinoma, tall cell|Papillary cystadenocarcinoma, NOS|Papillary cystadenoma lymphomatosum|Papillary cystadenoma, NOS|Papillary cystadenoma, borderline malignancy|Papillary cystic tumor|Papillary ependymoma|Papillary epidermoid carcinoma|Papillary glioneuronal tumor|Papillary hidradenoma|Papillary meningioma|Papillary mucinous cystadenocarcinoma|Papillary mucinous cystadenoma, NOS|Papillary mucinous cystadenoma, borderline malignancy|Papillary mucinous tumor of low malignant potential|Papillary neoplasm, pancreatobiliary-type, with high grade intraepithelial neoplasia|Papillary pseudomucinous cystadenocarcinoma|Papillary pseudomucinous cystadenoma, NOS|Papillary pseudomucinous cystadenoma, borderline malignancy|Papillary renal cell carcinoma|Papillary serous adenocarcinoma|Papillary serous cystadenocarcinoma|Papillary serous cystadenoma, NOS|Papillary serous cystadenoma, borderline malignancy|Papillary serous tumor of low malignant potential|Papillary squamous cell carcinoma|Papillary squamous cell carcinoma in situ|Papillary squamous cell carcinoma, non-invasive|Papillary syringadenoma|Papillary syringocystadenoma|Papillary transitional cell carcinoma|Papillary transitional cell carcinoma, non-invasive|Papillary transitional cell neoplasm of low malignant potential|Papillary tumor of the pineal region|Papillary urothelial carcinoma|Papillary urothelial carcinoma, non-invasive|Papillary urothelial neoplasm of low malignant potential|Papillocystic adenocarcinoma|Papilloma of bladder|Papilloma, NOS|Papillomatosis, NOS|Papillomatosis, glandular|Papillotubular adenoma|Parafollicular cell carcinoma|Paraganglioma, NOS|Paraganglioma, benign|Paraganglioma, malignant|Parasympathetic paraganglioma|Parietal cell adenocarcinoma|Parietal cell carcinoma|Parosteal osteosarcoma|Partial hydatidiform mole|Periapical cemental dysplasia|Periapical cemento-osseous dysplasia|Pericanalicular fibroadenoma|Perifollicular fibroma|Perineural MPNST|Perineurioma, NOS|Perineurioma, malignant|Periosteal chondroma|Periosteal chondrosarcoma|Periosteal fibroma|Periosteal fibrosarcoma|Periosteal osteosarcoma|Peripheral T-cell lymphoma, AILD (Angioimmunoblastic Lymphadenopathy with Dysproteinemia)|Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, large cell|Peripheral neuroectodermal tumor|Peripheral odontogenic fibroma|Peripheral primitive neuroectodermal tumor, NOS|Perivascular epithelioid cell tumor, malignant|Pheochromoblastoma|Pheochromocytoma, NOS|Pheochromocytoma, malignant|Phosphaturic mesenchymal tumor, malignant|Phyllodes tumor, NOS|Phyllodes tumor, benign|Phyllodes tumor, borderline|Phyllodes tumor, malignant|Pick tubular adenoma|Pigmented adenoma|Pigmented basal cell carcinoma|Pigmented dermatofibrosarcoma protuberans|Pigmented nevus, NOS|Pigmented schwannoma|Pigmented spindle cell nevus of Reed|Pilar tumor|Pilocytic astrocytoma|Piloid astrocytoma|Pilomatricoma, NOS|Pilomatricoma, malignant|Pilomatrix carcinoma|Pilomatrixoma, NOS|Pilomatrixoma, malignant|Pilomyxoid astrocytoma|Pindborg tumor|Pineal parenchymal tumor of intermediate differentiation|Pinealoma|Pinkus tumor|Pituitary adenoma, NOS|Pituitary carcinoma, NOS|Placental site trophoblastic tumor|Plasma cell leukemia|Plasma cell myeloma|Plasma cell tumor|Plasmablastic lymphoma|Plasmacytic leukemia|Plasmacytic lymphoma|Plasmacytoma of bone|Plasmacytoma, NOS|Plasmacytoma, extramedullary|Pleomorphic adenoma|Pleomorphic carcinoma|Pleomorphic cell sarcoma|Pleomorphic leiomyoma|Pleomorphic lipoma|Pleomorphic liposarcoma|Pleomorphic lobular carcinoma|Pleomorphic lobular carcinoma in situ|Pleomorphic rhabdomyosarcoma, NOS|Pleomorphic rhabdomyosarcoma, adult type|Pleomorphic xanthoastrocytoma|Pleuropulmonary blastoma|Plexiform fibrohistiocytic tumor|Plexiform hemangioma|Plexiform neurofibroma|Plexiform neuroma|Plexiform schwannoma|Pneumoblastoma|Polar spongioblastoma|Polycythemia rubra vera|Polycythemia vera|Polygonal cell carcinoma|Polymorphic post transplant lymphoproliferative disorder|Polypoid adenoma|Polyvesicular vitelline tumor|Poorly cohesive carcinoma|Post transplant lymphoproliferative disorder, NOS|Pre-B ALL|Pre-T ALL|Pre-pre-B ALL|Precancerous melanosis, NOS|Precursor B-cell lymphoblastic leukemia|Precursor B-cell lymphoblastic lymphoma|Precursor T-cell lymphoblastic leukemia|Precursor T-cell lymphoblastic lymphoma|Precursor cell lymphoblastic leukemia, NOS|Precursor cell lymphoblastic leukemia, not phenotyped|Precursor cell lymphoblastic lymphoma, NOS|Preleukemia|Preleukemic syndrome|Primary amyloidosis|Primary cutaneous CD30+ T-cell lymphoproliferative disorder|Primary cutaneous CD30+ large T-cell lymphoma|Primary cutaneous CD4-positive small/medium T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous DLBCL, leg type|Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous follicle centre lymphoma|Primary cutaneous gamma-delta T-cell lymphoma|Primary cutaneous neuroendocrine carcinoma|Primary effusion lymphoma|Primary myelofibrosis|Primary serous papillary carcinoma of peritoneum|Primitive neuroectodermal tumor, NOS|Pro-B ALL|Pro-T ALL|Prolactinoma|Proliferating trichilemmal cyst|Proliferating trichilemmal tumor|Proliferative dermal lesion in congenital nevus|Proliferative polycythemia|Prolymphocytic leukemia, B-cell type|Prolymphocytic leukemia, NOS|Prolymphocytic leukemia, T-cell type|Prostatic intraepithelial neoplasia, grade III|Protoplasmic astrocytoma|Psammomatous meningioma|Psammomatous schwannoma|Pseudomucinous adenocarcinoma|Pseudomucinous cystadenocarcinoma, NOS|Pseudomucinous cystadenoma, NOS|Pseudomyxoma peritonei|Pseudomyxoma peritonei with unknown primary site|Pseudosarcomatous carcinoma|Pulmonary adenomatosis|Pulmonary artery intimal sarcoma|Pulmonary blastoma|Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation|Queyrat erythroplasia|RAEB|RAEB I|RAEB II|RAEB-T|RARS|Racemose hemangioma|Rathke pouch tumor|Recklinghausen disease|Refractory anemia|Refractory anemia with excess blasts|Refractory anemia with excess blasts in transformation|Refractory anemia with ring sideroblasts associated with marked thrombocytosis|Refractory anemia with ringed sideroblasts|Refractory anemia with sideroblasts|Refractory cytopenia of childhood|Refractory cytopenia with multilineage dysplasia|Refractory neutropenia|Refractory thrombocytopenia|Regressing nevus|Renal carcinoma, collecting duct type|Renal cell adenocarcinoma|Renal cell carcinoma, NOS|Renal cell carcinoma, chromophobe type|Renal cell carcinoma, sarcomatoid|Renal cell carcinoma, spindle cell|Renal cell carcinoma, unclassified|Renal medullary carcinoma|Reninoma|Reserve cell carcinoma|Reticulohistiocytoma|Reticulosarcoma, NOS|Reticulum cell sarcoma, NOS|Retinal anlage tumor|Retinoblastoma, NOS|Retinoblastoma, differentiated|Retinoblastoma, diffuse|Retinoblastoma, spontaneously regressed|Retinoblastoma, undifferentiated|Retroperitoneal fibromatosis|Rhabdoid meningioma|Rhabdoid sarcoma|Rhabdoid tumor, NOS|Rhabdomyoma, NOS|Rhabdomyosarcoma with ganglionic differentiation|Rhabdomyosarcoma, NOS|Rhabdosarcoma|Rodent ulcer|Rosette-forming glioneuronal tumor|Round cell carcinoma|Round cell liposarcoma|Round cell osteosarcoma|SALT lymphoma|SETTLE|Salivary duct carcinoma|Sarcoma botryoides|Sarcoma, NOS|Sarcomatoid carcinoma|Sarcomatoid mesothelioma|Sarcomatosis, NOS|Schmincke tumor|Schneiderian carcinoma|Schneiderian papilloma, NOS|Schneiderian papilloma, inverted|Schwannoma, NOS|Scirrhous adenocarcinoma|Scirrhous carcinoma|Sclerosing epithelioid fibrosarcoma|Sclerosing hemangioma|Sclerosing hepatic carcinoma|Sclerosing liposarcoma|Sclerosing rhabdomyosarcoma|Sclerosing stromal tumor|Sclerosing sweat duct carcinoma|Sebaceous adenocarcinoma|Sebaceous adenoma|Sebaceous carcinoma|Sebaceous epithelioma|Secondary carcinoma|Secretory carcinoma of breast|Secretory meningioma|Seminoma with high mitotic index|Seminoma, NOS|Seminoma, anaplastic|Seromucinous carcinoma|Serous adenocarcinoma, NOS|Serous adenofibroma, NOS|Serous borderline tumor-micropapillary variant|Serous carcinoma, NOS|Serous cystadenocarcinoma, NOS|Serous cystadenoma, NOS|Serous cystadenoma, borderline malignancy|Serous cystoma|Serous endometrial intraepithelial carcinoma|Serous microcystic adenoma|Serous papillary cystic tumor of borderline malignancy|Serous surface papillary carcinoma|Serous surface papilloma|Serous tubal intraepithelial carcinoma|Serous tumor, NOS, of low malignant potential|Serrated adenoma|Sertoli cell adenoma|Sertoli cell tumor, NOS|Sertoli-Leydig cell tumor, NOS|Sessile serrated adenoma|Sessile serrated polyp|Sex cord tumor, NOS|Sex cord-gonadal stromal tumor, NOS|Sex cord-gonadal stromal tumor, incompletely differentiated|Sex cord-gonadal stromal tumor, mixed forms|Sezary disease|Sezary syndrome|Signet ring cell adenocarcinoma|Signet ring cell carcinoma|Sinonasal papilloma, NOS|Sinonasal papilloma, exophytic|Sinonasal papilloma, fungiform|Skin appendage adenoma|Skin appendage carcinoma|Skin appendage tumor, benign|Skin-associated lymphoid tissue lymphoma|Small cell carcinoma pulmonary type|Small cell carcinoma, NOS|Small cell carcinoma, fusiform cell|Small cell carcinoma, hypercalcemic type|Small cell carcinoma, intermediate cell|Small cell neuroendocrine carcinoma|Small cell osteosarcoma|Small cell sarcoma|Smooth muscle tumor of uncertain malignant potential|Smooth muscle tumor, NOS|Soft tissue perineurioma|Soft tissue sarcoma|Soft tissue tumor, benign|Soft tissue tumor, malignant|Solid and cystic tumor|Solid and papillary epithelial neoplasm|Solid carcinoma, NOS|Solid papillary carcinoma in situ|Solid pseudopapillary tumor|Solid teratoma|Solitary fibrous tumor|Solitary fibrous tumor, malignant|Solitary fibrous tumor/hemangiopericytoma Grade 1 (CNS)|Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS)|Solitary fibrous tumor/hemangiopericytoma Grade 3 (CNS)|Solitary mastocytoma of skin|Solitary myeloma|Solitary plasmacytoma|Somatostatin cell tumor, NOS|Somatostatin cell tumor, malignant|Somatostatinoma, NOS|Somatostatinoma, malignant|Spermatocytic seminoma|Spermatocytoma|Spindle cell angioendothelioma|Spindle cell carcinoma, NOS|Spindle cell hemangioendothelioma|Spindle cell lipoma|Spindle cell melanoma, NOS|Spindle cell melanoma, type A|Spindle cell melanoma, type B|Spindle cell nevus, NOS|Spindle cell oncocytoma|Spindle cell rhabdomyosarcoma|Spindle cell sarcoma|Spindle epithelial tumor with thymus-like differentiation|Spindle epithelial tumor with thymus-like element|Spindled mesothelioma|Spiradenoma, NOS|Spitz nevus|Splenic B-cell lymphoma/leukemia, unclassifiable|Splenic diffuse red pulp small B-cell lymphoma|Splenic marginal zone B-cell lymphoma|Splenic marginal zone lymphoma, NOS|Spongioblastoma multiforme|Spongioblastoma polare|Squamotransitional cell carcinoma|Squamous carcinoma|Squamous cell carcinoma in situ with questionable stromal invasion|Squamous cell carcinoma in situ, NOS|Squamous cell carcinoma with horn formation|Squamous cell carcinoma, HPV-positive|Squamous cell carcinoma, NOS|Squamous cell carcinoma, acantholytic|Squamous cell carcinoma, adenoid|Squamous cell carcinoma, clear cell type|Squamous cell carcinoma, keratinizing, NOS|Squamous cell carcinoma, large cell, keratinizing|Squamous cell carcinoma, large cell, nonkeratinizing, NOS|Squamous cell carcinoma, metastatic, NOS|Squamous cell carcinoma, microinvasive|Squamous cell carcinoma, nonkeratinizing, NOS|Squamous cell carcinoma, pseudoglandular|Squamous cell carcinoma, sarcomatoid|Squamous cell carcinoma, small cell, nonkeratinizing|Squamous cell carcinoma, spindle cell|Squamous cell epithelioma|Squamous cell papilloma, NOS|Squamous cell papilloma, inverted|Squamous intraepithelial neoplasia, grade I|Squamous intraepithelial neoplasia, grade II|Squamous intraepithelial neoplasia, grade III|Squamous intraepithelial neoplasia, high grade|Squamous intraepithelial neoplasia, low grade|Squamous odontogenic tumor|Squamous papilloma|Squamous papillomatosis|Stem cell leukemia|Steroid cell tumor, NOS|Stromal endometriosis|Stromal myosis, NOS|Stromal sarcoma, NOS|Stromal tumor with minor sex cord elements|Stromal tumor, NOS|Stromal tumor, benign|Struma ovarii and carcinoid|Struma ovarii, NOS|Struma ovarii, malignant|Strumal carcinoid|Subacute granulocytic leukemia|Subacute myelogenous leukemia|Subacute myeloid leukemia|Subareolar duct papillomatosis|Subcutaneous panniculitis-like T-cell lymphoma|Subependymal giant cell astrocytoma|Subependymal glioma|Subepidermal nodular fibrosis|Superficial spreading adenocarcinoma|Superficial spreading melanoma|Superficial well differentiated liposarcoma|Supratentorial PNET|Sweat gland adenocarcinoma|Sweat gland adenoma|Sweat gland carcinoma|Sweat gland tumor, NOS|Sweat gland tumor, benign|Sweat gland tumor, malignant|Sympathetic paraganglioma|Symplastic leiomyoma|Syncytial meningioma|Synovial sarcoma, NOS|Synovial sarcoma, biphasic|Synovial sarcoma, epithelioid cell|Synovial sarcoma, monophasic fibrous|Synovial sarcoma, spindle cell|Synovioma, NOS|Synovioma, benign|Synovioma, malignant|Syringocystadenoma papilliferum|Syringoma, NOS|Syringomatous carcinoma|Systemic EBV positive T-cell lymphoproliferative disease of childhood|Systemic light chain disease|Systemic mastocytosis with AHNMD|Systemic mastocytosis with associated hematological clonal non-mast cell disorder|Systemic tissue mast cell disease|T lymphoblastic leukemia/lymphoma|T-cell large granular lymphocytic leukemia|T-cell large granular lymphocytosis|T-cell lymphoma, NOS|T-cell rich large B-cell lymphoma|T-cell rich/histiocyte-rich large B-cell lymphoma|T-gamma lymphoproliferative disease|T-zone lymphoma|T/NK-cell lymphoma|Tanycytic ependymoma|Telangiectatic osteosarcoma|Tenosynovial giant cell tumor|Teratoblastoma, malignant|Teratocarcinoma|Teratoma with malignant transformation|Teratoma, NOS|Teratoma, benign|Teratoma, differentiated|Teratoma, malignant, NOS|Testicular adenoma|Theca cell tumor|Theca cell-granulosa cell tumor|Thecoma, NOS|Thecoma, luteinized|Thecoma, malignant|Therapy related myeloid neoplasm|Therapy-related acute myeloid leukemia, NOS|Therapy-related acute myeloid leukemia, alkylating agent related|Therapy-related acute myeloid leukemia, epipodophyllotoxin-related|Therapy-related myelodysplastic syndrome, NOS|Therapy-related myelodysplastic syndrome, alkylating agent related|Therapy-related myelodysplastic syndrome, epipodophyllotoxin-related|Thymic carcinoma, NOS|Thymic large B-cell lymphoma|Thymoma, NOS|Thymoma, atypical, NOS|Thymoma, atypical, malignant|Thymoma, benign|Thymoma, cortical, NOS|Thymoma, cortical, malignant|Thymoma, epithelial, NOS|Thymoma, epithelial, malignant|Thymoma, lymphocyte-rich, NOS|Thymoma, lymphocyte-rich, malignant|Thymoma, lymphocytic, NOS|Thymoma, lymphocytic, malignant|Thymoma, malignant, NOS|Thymoma, medullary, NOS|Thymoma, medullary, malignant|Thymoma, mixed type, NOS|Thymoma, mixed type, malignant|Thymoma, organoid, NOS|Thymoma, organoid, malignant|Thymoma, predominantly cortical, NOS|Thymoma, predominantly cortical, malignant|Thymoma, spindle cell, NOS|Thymoma, spindle cell, malignant|Thymoma, type A, NOS|Thymoma, type A, malignant|Thymoma, type AB, NOS|Thymoma, type AB, malignant|Thymoma, type B1, NOS|Thymoma, type B1, malignant|Thymoma, type B2, NOS|Thymoma, type B2, malignant|Thymoma, type B3, NOS|Thymoma, type B3, malignant|Thymoma, type C|Tibial adamantinoma|Trabecular adenocarcinoma|Trabecular adenoma|Trabecular carcinoma|Traditional serrated adenoma|Transient abnormal myelopoiesis|Transitional carcinoma|Transitional cell carcinoma|Transitional cell carcinoma in situ|Transitional cell carcinoma, micropapillary|Transitional cell carcinoma, sarcomatoid|Transitional cell carcinoma, spindle cell|Transitional cell papilloma, NOS|Transitional cell papilloma, benign|Transitional cell papilloma, inverted, NOS|Transitional cell papilloma, inverted, benign|Transitional meningioma|Transitional papilloma|Transitional papilloma, inverted, NOS|Transitional papilloma, inverted, benign|Trichilemmal carcinoma|Trichilemmocarcinoma|Trichodiscoma|Trichoepithelioma|Triton tumor, malignant|Trophoblastic tumor, epithelioid|True histiocytic lymphoma|Tubular adenocarcinoma|Tubular adenoma, NOS|Tubular androblastoma, NOS|Tubular carcinoma|Tubulo-papillary adenoma|Tubulocystic renal cell carcinoma|Tubulolobular carcinoma|Tubulovillous adenoma, NOS|Tumor cells, NOS|Tumor cells, malignant|Tumor cells, uncertain whether benign or malignant|Tumor embolus|Tumor, NOS|Tumor, benign|Tumor, malignant, NOS|Tumor, metastatic|Tumor, secondary|Tumorlet, benign|Turban tumor|Unclassified tumor, benign|Unclassified tumor, borderline malignancy|Unclassified tumor, malignant|Unclassified tumor, malignant, uncertain whether primary or metastatic|Unclassified tumor, uncertain whether benign or malignant|Undifferentiated epithelioid sarcoma|Undifferentiated high-grade pleomorphic sarcoma|Undifferentiated leukaemia|Undifferentiated pleomorphic sarcoma|Undifferentiated round cell sarcoma|Undifferentiated sarcoma|Undifferentiated spindle cell sarcoma|Undifferentiated uterine sarcoma|Urachal carcinoma|Urothelial carcinoma in situ|Urothelial carcinoma with squamous differentiation|Urothelial carcinoma with trophoblastic differentiation|Urothelial carcinoma, NOS|Urothelial papilloma, NOS|Urticaria pigmentosa|VAIN III|VIN III|Vaginal intraepithelial neoplasia, grade III|Vascular leiomyoma|Venous hemangioma|Verrucous carcinoma, NOS|Verrucous epidermoid carcinoma|Verrucous keratotic hemangioma|Verrucous papilloma|Verrucous squamous cell carcinoma|Villoglandular adenoma|Villoglandular carcinoma|Villous adenocarcinoma|Villous adenoma, NOS|Vipoma, NOS|Vipoma, malignant|Von Recklinghausen disease|Vulvar intraepithelial neoplasia, grade III|Waldenstrom macroglobulinemia|Warthin tumor|Warty carcinoma|Water-clear cell adenocarcinoma|Water-clear cell adenoma|Water-clear cell carcinoma|Well differentiated liposarcoma of superficial soft tissue|Well differentiated thymic carcinoma|Wilms tumor|Wolffian duct adenoma|Wolffian duct carcinoma|Wolffian duct tumor|Xanthofibroma|Yolk sac tumor|c-ALL	"ALK-Positive Large B-Cell Lymphoma|Abdominal (Mesenteric) Fibromatosis|Acinar Cell Adenoma|Acinar Cell Carcinoma|Acinar Cell Neoplasm|Acoustic Schwannoma|Acquired Cystic Disease-Associated Renal Cell Carcinoma|Acquired Progressive Lymphangioma|Acral Lentiginous Melanoma|Acute Basophilic Leukemia|Acute Bilineal Leukemia|Acute Biphenotypic Leukemia|Acute Erythroid Leukemia|Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Megakaryoblastic Leukemia|Acute Monoblastic Leukemia|Acute Monoblastic and Monocytic Leukemia|Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1|Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia Not Otherwise Specified|Acute Myeloid Leukemia with Maturation|Acute Myeloid Leukemia with Minimal Differentiation|Acute Myeloid Leukemia with Multilineage Dysplasia|Acute Myeloid Leukemia with Mutated CEBPA|Acute Myeloid Leukemia with Mutated NPM1|Acute Myeloid Leukemia with Myelodysplasia-Related Changes|Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11|Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11|Acute Myeloid Leukemia with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM|Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11|Acute Myeloid Leukemia with t(6;9) (p23;q34.1); DEK-NUP214|Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A|Acute Myeloid Leukemia without Maturation|Acute Myelomonocytic Leukemia|Acute Myelomonocytic Leukemia with Abnormal Eosinophils|Acute Panmyelosis with Myelofibrosis|Acute Promyelocytic Leukemia with PML-RARA|Acute Undifferentiated Leukemia|Adamantinoma|Adamantinomatous Craniopharyngioma|Adenocarcinoma|Adenocarcinoma In Situ|Adenocarcinoma In Situ in Adenomatous Polyp|Adenocarcinoma In Situ in Tubular Adenoma|Adenocarcinoma In Situ in Tubulovillous Adenoma|Adenocarcinoma In Situ in Villous Adenoma|Adenocarcinoma In Situ in a Polyp|Adenocarcinoma in Adenomatous Polyp|Adenocarcinoma in Adenomatous Polyposis Coli|Adenocarcinoma in Multiple Adenomatous Polyps|Adenocarcinoma in Tubular Adenoma|Adenocarcinoma in Tubulovillous Adenoma|Adenocarcinoma in Villous Adenoma|Adenocarcinoma with Apocrine Metaplasia|Adenocarcinoma with Cartilaginous Metaplasia|Adenocarcinoma with Cartilaginous and Osseous Metaplasia|Adenocarcinoma with Neuroendocrine Differentiation|Adenocarcinoma with Osseous Metaplasia|Adenocarcinoma with Spindle Cell Metaplasia|Adenocarcinoma with Squamous Metaplasia|Adenocarcinoma, Endocervical Type|Adenoid Cystic Carcinoma|Adenoma|Adenomatoid Odontogenic Tumor|Adenomatoid Tumor|Adenomatous Polyp|Adenosquamous Carcinoma|Adnexal Carcinoma|Adrenal Cortex Adenoma|Adrenal Cortex Carcinoma|Adrenal Cortex Clear Cell Adenoma|Adrenal Cortex Compact Cell Adenoma|Adrenal Cortex Glomerulosa Cell Adenoma|Adrenal Cortex Mixed Cell Adenoma|Adrenal Cortex Neoplasm|Adrenal Gland Myelolipoma|Adrenal Gland Pheochromocytoma|Adrenal Rest Tumor|Adult Cystic Nephroma|Adult Cystic Teratoma|Adult Pleomorphic Rhabdomyosarcoma|Adult T-Cell Leukemia/Lymphoma|Adult Teratoma|Adult Type Granulosa Cell Tumor|Aggressive NK-Cell Leukemia|Aggressive Osteoblastoma|Aggressive Systemic Mastocytosis|Aleukemic Chronic Lymphocytic Leukemia|Aleukemic Leukemia|Aleukemic Lymphoid Leukemia|Alkylating Agent-Related Acute Myeloid Leukemia|Alkylating Agent-Related Myelodysplastic Syndrome|Alpha Heavy Chain Disease|Alveolar Adenoma|Alveolar Rhabdomyosarcoma|Alveolar Soft Part Sarcoma|Amelanotic Melanoma|Ameloblastic Carcinoma|Ameloblastic Fibro-Odontoma|Ameloblastic Fibrodentinoma|Ameloblastic Fibroma|Ameloblastic Fibrosarcoma|Ameloblastoma|Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with High Grade Dysplasia|Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with Low Grade Dysplasia|Anal Canal Cloacogenic Carcinoma|Anal Glands Adenocarcinoma|Anal Intraepithelial Neoplasia 3|Anaplastic (Malignant) Meningioma|Anaplastic Astrocytoma|Anaplastic Astrocytoma, IDH-Mutant|Anaplastic Astrocytoma, IDH-Wildtype|Anaplastic Ependymoma|Anaplastic Ganglioglioma|Anaplastic Large Cell Lymphoma|Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Anaplastic Lymphoma|Anaplastic Medulloblastoma|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted|Anaplastic Pleomorphic Xanthoastrocytoma|Angiocentric Glioma|Angiocentric Immunoproliferative Lesion|Angiofibroma|Angioimmunoblastic T-Cell Lymphoma|Angiolipoma|Angiomatoid Fibrous Histiocytoma|Angiomatous Meningioma|Aorticopulmonary Paraganglioma|Apocrine Adenoma|Apocrine Hidrocystoma|Arteriovenous Hemangioma/Malformation|Askin Tumor|Astrocytic Tumor|Astrocytoma|Atypical Adenoma|Atypical Burkitt/Burkitt-Like Lymphoma|Atypical Carcinoid Tumor|Atypical Choroid Plexus Papilloma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Atypical Fibroxanthoma|Atypical Lipomatous Tumor|Atypical Meningioma|Atypical Polypoid Adenomyoma|Atypical Teratoid/Rhabdoid Tumor|B Acute Lymphoblastic Leukemia|B Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy|B Lymphoblastic Leukemia/Lymphoma with Hypodiploidy|B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1|B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)|B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH|B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1|B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged|B Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified|B Lymphoblastic Lymphoma|B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|B-Cell Prolymphocytic Leukemia|Balloon Cell Melanoma|Balloon Cell Nevus|Basal Cell Neoplasm|Basaloid Carcinoma|Basaloid Squamous Cell Carcinoma|Basophilic Adenocarcinoma|Benign Adrenal Cortex Neoplasm|Benign Epithelial Neoplasm|Benign Fibrous Histiocytoma|Benign Gastrointestinal Stromal Tumor|Benign Hemangioendothelioma|Benign Hemangiopericytoma|Benign Leydig Cell Tumor|Benign Mesenchymoma|Benign Mesonephroma|Benign Mixed Tumor of the Skin|Benign Muscle Neoplasm|Benign Myoepithelioma|Benign Neoplasm|Benign Odontogenic Neoplasm|Benign Paraganglioma|Benign Phyllodes Tumor|Benign Sertoli Cell Tumor|Benign Skin Appendage Neoplasm|Benign Soft Tissue Neoplasm|Benign Stromal Tumor|Benign Sweat Gland Neoplasm|Benign Synovial Neoplasm|Benign Thymoma|Bile Duct Adenocarcinoma|Bile Duct Adenoma|Bile Duct Carcinoma|Bile Duct Mucinous Cystic Neoplasm|Bile Duct Mucinous Cystic Neoplasm with an Associated Invasive Carcinoma|Bile Duct Papillary Neoplasm|Bile Duct Papillary Neoplasm with High Grade Intraepithelial Neoplasia|Bile Duct Papillary Neoplasm with Low Grade Intraepithelial Neoplasia|Biliary Intraepithelial Neoplasia-3|Biphasic Mesothelioma|Biphasic Synovial Sarcoma|Bizarre Leiomyoma|Bladder Papillary Urothelial Neoplasm of Low Malignant Potential|Bladder Urachal Carcinoma|Blastic Plasmacytoid Dendritic Cell Neoplasm|Blastoma|Blue Nevus|Bone Desmoplastic Fibroma|Borderline Ovarian Brenner Tumor/Atypical Proliferative Ovarian Brenner Tumor|Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor|Borderline Ovarian Serous Tumor-Micropapillary Variant/Non-Invasive Low Grade Ovarian Serous Carcinoma|Borderline Papillary Cystadenoma|Borderline Papillary Mucinous Cystadenoma|Borderline Papillary Serous Cystadenoma|Borderline Phyllodes Tumor|Borderline Serous Cystadenoma|Botryoid-Type Embryonal Rhabdomyosarcoma|Bowen Disease of the Skin|Breast Carcinoma with Chondroid Metaplasia|Breast Carcinoma with Osseous Metaplasia|Breast Fibroadenoma|Breast Giant Fibroadenoma|Breast Intracanalicular Fibroadenoma|Breast Juvenile Fibroadenoma|Breast Pericanalicular Fibroadenoma|Brenner Tumor|Bronchial Mucosa-Associated Lymphoid Tissue Lymphoma|Burkitt Leukemia|Burkitt Lymphoma|Calcifying Cystic Odontogenic Tumor|Calcifying Epithelial Odontogenic Tumor|Capillary Hemangioma|Carcinoid Tumor|Carcinoid Tumor of Uncertain Malignant Potential|Carcinoma|Carcinoma In Situ|Carcinoma In Situ in a Polyp|Carcinoma Simplex|Carcinoma ex Pleomorphic Adenoma|Carcinoma in a Polyp|Carcinosarcoma|Carotid Body Paraganglioma|Cavernous Hemangioma|Cavernous Lymphangioma|Cellular Angiofibroma|Cellular Blue Nevus|Cellular Ependymoma|Cellular Fibroma|Cellular Leiomyoma|Cellular Schwannoma|Cementoblastoma|Central Nervous System Embryonal Tumor with Rhabdoid Features|Central Nervous System Embryonal Tumor, Not Otherwise Specified|Central Nervous System Lymphoma|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 1|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 2|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 3|Central Neurocytoma|Centroblastic Lymphoma|Cerebellar Liponeurocytoma|Cerebellar Sarcoma|Ceruminous Adenocarcinoma|Cervical Adenocarcinoma Admixed with Neuroendocrine Carcinoma|Cervical Mucinous Adenocarcinoma, Gastric Type|Cervical Mucinous Adenocarcinoma, Intestinal-Type|Cervical Squamotransitional Carcinoma|Cervical Villoglandular Adenocarcinoma|Childhood Astrocytic Tumor|Chondroblastic Osteosarcoma|Chondroblastoma|Chondroid Chordoma|Chondroid Lipoma|Chondroma|Chondromatosis|Chondromyxoid Fibroma|Chondrosarcoma|Chordoid Glioma of the Third Ventricle|Chordoid Meningioma|Chordoma|Choriocarcinoma|Choriocarcinoma Combined with Other Germ Cell Elements|Choroid Plexus Carcinoma|Choroid Plexus Papilloma|Chromophobe Renal Cell Carcinoma|Chronic Eosinophilic Leukemia, Not Otherwise Specified|Chronic Leukemia|Chronic Lymphocytic Leukemia|Chronic Lymphoproliferative Disorder of NK-Cells|Chronic Monocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Classic Medulloblastoma|Clear Cell Adenocarcinoma|Clear Cell Adenofibroma|Clear Cell Adenoma|Clear Cell Chondrosarcoma|Clear Cell Cystadenofibroma|Clear Cell Ependymoma|Clear Cell Hidradenoma|Clear Cell Meningioma|Clear Cell Neoplasm|Clear Cell Odontogenic Carcinoma|Clear Cell Renal Cell Carcinoma|Clear Cell Sarcoma of Soft Tissue|Clear Cell Sarcoma of the Kidney|Collecting Duct Carcinoma|Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Combined Carcinoid and Adenocarcinoma|Combined Hepatocellular Carcinoma and Cholangiocarcinoma|Combined Lung Large Cell Neuroendocrine Carcinoma|Combined Lung Small Cell Carcinoma|Combined Lung Small Cell Carcinoma and Lung Adenocarcinoma|Comedocarcinoma|Common Acute Lymphoblastic Leukemia|Complete Hydatidiform Mole|Complex Odontoma|Compound Nevus|Compound Odontoma|Congenital Mesoblastic Nephroma|Conventional Osteosarcoma|Cribriform Carcinoma|Cutaneous Mastocytosis|Cutaneous Nodular Melanoma|Cylindroma|Cystadenocarcinoma|Cystadenofibroma|Cystadenoma|Cystic Hygroma|Cystic Partially Differentiated Kidney Nephroblastoma|Cystic Teratoma|Cystic Tumor of the Atrioventricular Node|Dedifferentiated Chondrosarcoma|Dedifferentiated Chordoma|Dedifferentiated Liposarcoma|Deep ""Aggressive"" Angiomyxoma|Deep Benign Fibrous Histiocytoma|Degenerated Schwannoma|Dendritic Cell Tumor, Not Otherwise Specified|Dentinogenic Ghost Cell Tumor|Dermal Nevus|Dermatofibrosarcoma Protuberans|Dermoid Cyst|Desmoid-Type Fibromatosis|Desmoplastic Infantile Astrocytoma|Desmoplastic Infantile Ganglioglioma|Desmoplastic Melanoma|Desmoplastic Mesothelioma|Desmoplastic Small Round Cell Tumor|Desmoplastic/Nodular Medulloblastoma|Differentiated Retinoblastoma|Diffuse Astrocytoma|Diffuse Astrocytoma, IDH-Mutant|Diffuse Astrocytoma, IDH-Wildtype|Diffuse Centroblastic-Centrocytic Lymphoma|Diffuse Cutaneous Mastocytosis|Diffuse Intraductal Papillomatosis|Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Arising in HHV8-Positive Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation|Diffuse Leptomeningeal Glioneuronal Tumor|Diffuse Malignant Lymphoma|Diffuse Midline Glioma, H3 K27M-Mutant|Diffuse Retinoblastoma|Diffuse Sclerosing Variant Thyroid Gland Papillary Carcinoma|Diffuse Type Adenocarcinoma|Digestive System Mixed Adenoneuroendocrine Carcinoma|Digital Papillary Adenocarcinoma|Ductal Breast Carcinoma|Ductal Breast Carcinoma In Situ|Ductal Breast Carcinoma In Situ and Invasive Lobular Carcinoma|Ductal Breast Carcinoma In Situ and Lobular Carcinoma In Situ|Dysembryoplastic Neuroepithelial Tumor|Dysplastic Cerebellar Gangliocytoma|Dysplastic Nevus|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Eccrine Hidrocystoma|Ectopic Hamartomatous Thymoma|Embryonal Carcinoma|Embryonal Rhabdomyosarcoma|Embryonal Tumor with Multilayered Rosettes, C19MC-Altered|Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified|Encapsulated Variant Thyroid Gland Papillary Carcinoma|Endocervical Adenocarcinoma, Usual Type|Endometrial Endometrioid Adenocarcinoma, Ciliated Variant|Endometrial Endometrioid Adenocarcinoma, Secretory Variant|Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation|Endometrial Stromal Nodule|Endometrioid Adenocarcinoma|Endometrioid Stromal Sarcoma|Enterochromaffin-Like Cell Neuroendocrine Tumor G1|Enteroglucagonoma|Enteropathy-Associated T-Cell Lymphoma|Eosinophilic Granuloma|Ependymoma|Ependymoma, RELA Fusion-Positive|Epipodophyllotoxin-Related Myelodysplastic Syndrome|Epithelial Neoplasm|Epithelial Synovial Sarcoma|Epithelial-Myoepithelial Carcinoma|Epithelioid Cell Melanoma|Epithelioid Cell Nevus|Epithelioid Cell Type Gastrointestinal Stromal Tumor|Epithelioid Glioblastoma|Epithelioid Hemangioendothelioma|Epithelioid Hemangioma|Epithelioid Leiomyosarcoma|Epithelioid Malignant Peripheral Nerve Sheath Tumor|Epithelioid Mesothelioma|Epithelioid Sarcoma|Epithelioid Trophoblastic Tumor|Esophageal High Grade Intraepithelial Neoplasia|Essential Thrombocythemia|Ewing Sarcoma|External Auditory Canal Ceruminous Adenoma|Extra-Adrenal Paraganglioma|Extraabdominal Fibromatosis|Extracutaneous Mastocytoma|Extramammary Paget Disease|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Extraosseous Plasmacytoma|Extraventricular Neurocytoma|Familial Adenomatous Polyposis|Fascial Fibroma|Fascial Fibrosarcoma|Female Reproductive System Adenofibroma|Fetal Rhabdomyoma|Fibrillary Astrocytoma|Fibroblastic Liposarcoma|Fibroblastic Osteosarcoma|Fibroblastic Reticular Cell Tumor|Fibrolamellar Carcinoma|Fibroma|Fibromyxoid Tumor|Fibrosarcoma|Fibrosarcomatous Dermatofibrosarcoma Protuberans|Fibrous Meningioma|Flat Adenoma|Follicular Dendritic Cell Sarcoma|Follicular Lymphoma|Follicular Variant Thyroid Gland Papillary Carcinoma, Encapsulated Subtype with Invasion|Functioning Endocrine Neoplasm|Gallbladder Papillary Neoplasm with Intermediate Grade Intraepithelial Neoplasia|Gallbladder Papillary Neoplasm with Low Grade Intraepithelial Neoplasia|Gamma Heavy Chain Disease|Ganglioglioma|Gastric Parietal Cell Adenocarcinoma|Gastrin-Producing Neuroendocrine Tumor|Gastrointestinal Autonomic Nerve Tumor|Gastrointestinal Stromal Tumor|Gastrointestinal Stromal Tumor of Uncertain Malignant Potential|Gemistocytic Astrocytoma|Genital Rhabdomyoma|Germ Cell Tumor|Ghost Cell Odontogenic Carcinoma|Giant Cell Angiofibroma|Giant Cell Carcinoma|Giant Cell Fibroblastoma|Giant Cell Glioblastoma|Giant Cell Sarcoma|Giant Cell Tumor of Bone|Giant Cell Tumor of Soft Tissue|Giant Cell and Spindle Cell Carcinoma|Giant Congenital Nevus|Gigantiform Cementoma|Glandular Papilloma|Glandular Papillomatosis|Glassy Cell Carcinoma|Glioblastoma, IDH-Mutant|Glioblastoma, IDH-Wildtype|Glioma|Gliomatosis Cerebri|Glomus Tumor|Glycogen-Rich Carcinoma|Grade 1 Follicular Lymphoma|Grade 1 Nodular Sclerosis Classic Hodgkin Lymphoma|Grade 2 Follicular Lymphoma|Grade 2 Nodular Sclerosis Classic Hodgkin Lymphoma|Grade 3 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Grade 3b Follicular Lymphoma|Grade I Neuroendocrine Carcinoma|Grade II Glandular Intraepithelial Neoplasia|Grade II Neuroendocrine Carcinoma|Grade II Squamous Intraepithelial Neoplasia|Grade III Glandular Intraepithelial Neoplasia|Grade III Prostatic Intraepithelial Neoplasia|Granular Cell Carcinoma|Granular Cell Tumor|Granular Cell Tumor of the Sellar Region|Granulocytic Sarcoma|Granulosa Cell Tumor|Granulosa Cell-Theca Cell Tumor|Hairy Cell Leukemia|Hairy Cell Leukemia Variant|Hairy Nevus|Halo Nevus|Hand-Schuller-Christian Disease|Heavy Chain Disease|Hemangioblastic Meningioma|Hemangioblastoma|Hemangioendothelioma|Hemangioma|Hemangiopericytoma|Hepatocellular Adenoma|Hepatocellular Carcinoma|Hepatoid Adenocarcinoma|Hepatosplenic T-Cell Lymphoma|Hereditary Leiomyomatosis and Renal Cell Carcinoma|Hidradenoma|Hidradenoma Papilliferum|High Grade B-Cell Lymphoma, Not Otherwise Specified|High Grade Ductal Breast Carcinoma In Situ|High Grade Esophageal Glandular Intraepithelial Neoplasia|High Grade Esophageal Squamous Intraepithelial Neoplasia|High Grade Glandular Intraepithelial Neoplasia|High Grade Squamous Intraepithelial Neoplasia|High Grade Surface Osteosarcoma|High Risk Gastrointestinal Stromal Tumor|Hilar Cholangiocarcinoma|Histiocytic Sarcoma|Histiocytoma|Hodgkin Lymphoma|Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Depletion|Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Predominance|Hodgkin's Disease, Nodular Sclerosis, Mixed Cellularity|Hodgkin's Granuloma|Hodgkin's Paragranuloma|Human Papillomavirus-Related Squamous Cell Carcinoma|Hydatidiform Mole|Hydroa Vacciniforme-Like Lymphoproliferative Disorder|Hypereosinophilic Syndrome|Immature Teratoma|Immunoblastic Lymphoma|Indeterminate Dendritic Cell Tumor|Indolent Systemic Mastocytosis|Infantile Fibrosarcoma|Infantile Hemangioma|Infiltrating Angiolipoma|Infiltrating Bladder Urothelial Carcinoma with Squamous Differentiation|Infiltrating Bladder Urothelial Carcinoma with Trophoblastic Differentiation|Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant|Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant|Infiltrating Bladder Urothelial Carcinoma, Microcystic Variant|Infiltrating Bladder Urothelial Carcinoma, Nested Variant|Infiltrating Lipoma|Infiltrating Papillary Adenocarcinoma|Inflammatory Liposarcoma|Inflammatory Myofibroblastic Tumor|Interdigitating Dendritic Cell Sarcoma|Intermediate Immature Teratoma|Intestinal-Type Adenocarcinoma|Intimal Sarcoma|Intracystic Papillary Breast Carcinoma|Intracystic Papilloma|Intraductal Carcinoma of the Minor Salivary Gland|Intraductal Cribriform Breast Adenocarcinoma|Intraductal Papillary Adenocarcinoma with Invasion|Intraductal Papillary Breast Carcinoma|Intraductal Papilloma|Intraductal Papillomatosis|Intraductal and Lobular Carcinoma|Intraepidermal Epithelioma of Jadassohn|Intramuscular Hemangioma|Intramuscular Lipoma|Intraneural Perineurioma|Intrathyroid Thymic Carcinoma|Intravascular Large B-Cell Lymphoma|Invasive Breast Carcinoma|Invasive Ductal Carcinoma, Not Otherwise Specified|Invasive Ductal and Lobular Carcinoma|Invasive Ductal and Lobular Carcinoma In Situ|Invasive Hydatidiform Mole|Invasive Lobular Breast Carcinoma|Invasive Lobular Breast Carcinoma, Alveolar Variant|Invasive Lobular Breast Carcinoma, Pleomorphic Variant|Invasive Lobular Breast Carcinoma, Solid Variant|Invasive Lobular Breast Carcinoma, Tubulolobular Variant|Invasive Lung Mucinous Adenocarcinoma|Invasive Micropapillary Breast Carcinoma|Inverted Squamous Cell Papilloma|Inverted Transitional Cell Papilloma|Islet Cell Adenoma|Jugulotympanic Paraganglioma|Junctional Nevus|Juvenile Myelomonocytic Leukemia|Juvenile Type Granulosa Cell Tumor|Juxtaglomerular Cell Tumor|Kaposi Sarcoma|Kaposiform Hemangioendothelioma|Keratinizing Squamous Cell Carcinoma|Kidney Medullary Carcinoma|Kidney Wilms Tumor|Krukenberg Tumor|L1 Acute Lymphoblastic Leukemia|L2 Acute Lymphoblastic Leukemia|Lactating Adenoma|Lactotroph Adenoma|Langerhans Cell Histiocytosis|Langerhans Cell Histiocytosis, Disseminated|Langerhans Cell Histiocytosis, Monostotic|Langerhans Cell Histiocytosis, Polyostotic|Langerhans Cell Sarcoma|Large Cell Carcinoma|Large Cell Medulloblastoma|Large Cell Neuroendocrine Carcinoma|Leiomyoma|Leiomyomatosis|Leiomyosarcoma|Lentigo Maligna|Lentigo Maligna Melanoma|Lepidic Predominant Adenocarcinoma|Leptomeningeal Sarcoma|Letterer-Siwe Disease|Leukemia|Leydig Cell Tumor|Light Chain Deposition Disease|Linitis Plastica|Lipid-Rich Carcinoma|Lipoma|Liposarcoma|Lobular Breast Carcinoma|Lobular Breast Carcinoma In Situ|Low Grade Adenosquamous Breast Carcinoma|Low Grade Central Osteosarcoma|Low Grade Cervical Intraepithelial Neoplasia|Low Grade Endometrioid Stromal Sarcoma|Low Grade Esophageal Glandular Intraepithelial Neoplasia|Low Grade Esophageal Squamous Intraepithelial Neoplasia|Low Grade Fibromyxoid Sarcoma|Low Grade Glandular Intraepithelial Neoplasia|Low Grade Myofibroblastic Sarcoma|Low Grade Squamous Intraepithelial Neoplasia|Low-CSD Melanoma|Low-Grade Appendix Mucinous Neoplasm|Lung Adenocarcinoma with Mixed Bronchioloalveolar and Invasive Components|Lung Fetal Adenocarcinoma|Lung Large Cell Carcinoma with Rhabdoid Phenotype|Lung Mucinous Adenocarcinoma In Situ|Lung Non-Mucinous Adenocarcinoma In Situ|Lung Papillary Adenoma|Lymphangioleiomyoma|Lymphangioma|Lymphoblastic Lymphoma|Lymphocyte Predominant Type Hodgkin's Disease|Lymphocyte-Depleted Classic Hodgkin Lymphoma|Lymphocyte-Rich Classic Hodgkin Lymphoma|Lymphoepithelioid Variant Peripheral T-Cell Lymphoma|Lymphoid Leukemia|Lymphoma|Lymphomatoid Granulomatosis|Lymphomatoid Papulosis|Lymphoplasmacyte-Rich Meningioma|Lymphoplasmacytic Lymphoma|Lymphoproliferative Disorder|Lymphosarcoma|Malignancy in Giant Cell Tumor of Bone|Malignant Adrenal Cortex Neoplasm|Malignant Adrenal Gland Pheochromocytoma|Malignant Cell|Malignant Enteroglucagonoma|Malignant Extra-Adrenal Paraganglioma|Malignant Gastrinoma|Malignant Gastrointestinal Stromal Tumor|Malignant Giant Cell Neoplasm|Malignant Glioma|Malignant Glomus Tumor|Malignant Granular Cell Tumor|Malignant Granulosa Cell Tumor|Malignant Hemangiopericytoma|Malignant Histiocytosis|Malignant Leydig Cell Tumor|Malignant Lymphoma Centroblastic, Follicular|Malignant Lymphoma, Convoluted|Malignant Lymphoma, Histiocytic, Diffuse|Malignant Lymphoma, Large Cell Type|Malignant Lymphoma, Large Cell, Cleaved|Malignant Lymphoma, Non-Cleaved Cell Type|Malignant Lymphoma, Non-Cleaved, Diffuse|Malignant Mastocytosis|Malignant Mediastinal Germ Cell Tumor with Associated Hematologic Malignancy|Malignant Melanoma in Precancerous Melanosis|Malignant Melanotic Peripheral Nerve Sheath Tumor|Malignant Mesenchymoma|Malignant Mesothelioma|Malignant Mixed Tumor of the Salivary Gland|Malignant Muscle Neoplasm|Malignant Myoepithelioma|Malignant Neoplasm|Malignant Neoplasm, Uncertain Whether Primary or Metastatic|Malignant Odontogenic Neoplasm|Malignant Ossifying Fibromyxoid Tumor|Malignant Ovarian Brenner Tumor|Malignant Ovarian Thecoma|Malignant PEComa|Malignant Pancreatic Glucagonoma|Malignant Pancreatic Insulinoma|Malignant Paraganglioma|Malignant Pericytic Neoplasm|Malignant Peripheral Nerve Sheath Tumor|Malignant Peripheral Nerve Sheath Tumor with Perineurial Differentiation|Malignant Phosphaturic Mesenchymal Tumor|Malignant Phyllodes Tumor|Malignant Sertoli Cell Tumor|Malignant Soft Tissue Neoplasm|Malignant Solitary Fibrous Tumor|Malignant Somatostatinoma|Malignant Spindle Cell Neoplasm|Malignant Struma Ovarii|Malignant Sweat Gland Neoplasm|Malignant Tenosynovial Giant Cell Tumor|Malignant Teratoma|Malignant Thymoma|Malignant Triton Tumor|Malignant Trophoblastic Teratoma|Malignant Tumor, Small Cell Type|Malignant Type A Thymoma|Malignant Type AB Thymoma|Malignant Type B1 Thymoma|Malignant Type B2 Thymoma|Malignant Vipoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Mast Cell Leukemia|Mast Cell Neoplasm|Mast Cell Sarcoma|Mastocytoma|Mature T-ALL|Mature Teratoma|Medullary Carcinoma, Not Otherwise Specified|Medulloblastoma|Medulloblastoma with Extensive Nodularity|Medulloblastoma with Melanotic Differentiation|Medulloblastoma, Non-WNT/Non-SHH|Medulloblastoma, Non-WNT/Non-SHH, Group 3|Medulloblastoma, Non-WNT/Non-SHH, Group 4|Medulloblastoma, SHH-Activated, TP53-Mutant|Medulloblastoma, SHH-Activated, TP53-Wildtype|Medulloblastoma, WNT-Activated|Medulloepithelioma|Medulloepithelioma Not Otherwise Specified|Medullomyoblastoma with Myogenic Differentiation|Melanocytic Nevus|Melanocytoma|Melanocytoma of the Eyeball|Melanoma|Melanoma Arising from Blue Nevus|Melanoma in Junctional Nevus|Melanotic Neuroectodermal Tumor|Melanotic Neurofibroma|Melanotic Psammomatous Malignant Peripheral Nerve Sheath Tumor|Melanotic Schwannoma|Meningeal Melanocytoma|Meningeal Melanocytosis|Meningeal Melanoma|Meningeal Melanomatosis|Meningeal Sarcoma|Meningeal Sarcomatosis|Meningioma|Meningiomatosis|Meningothelial Meningioma|Merkel Cell Carcinoma|Mesenchymal Chondrosarcoma|Mesenchymoma|Mesonephric Adenocarcinoma|Mesonephric Neoplasm|Mesothelioma|Metanephric Adenofibroma|Metanephric Adenoma|Metaplastic Carcinoma|Metaplastic Meningioma|Metastasizing Ameloblastoma|Metastatic Adenocarcinoma|Metastatic Carcinoma|Metastatic Neoplasm|Metastatic Signet Ring Cell Carcinoma|Metastatic Squamous Cell Carcinoma|MiT Family Translocation-Associated Renal Cell Carcinoma|Microcystic Adenoma|Microcystic Adnexal Carcinoma|Microcystic Meningioma|Microinvasive Squamous Cell Carcinoma|Micropapillary Serous Carcinoma|Micropapillary Transitional Cell Carcinoma|Minimally Invasive Lung Adenocarcinoma|Minimally Invasive Lung Mucinous Adenocarcinoma|Minimally Invasive Lung Non-Mucinous Adenocarcinoma|Mixed Acinar-Ductal Carcinoma of the Pancreas|Mixed Cell Adenocarcinoma|Mixed Cell Adenoma|Mixed Cellularity Classic Hodgkin Lymphoma|Mixed Ductal and Lobular Carcinoma|Mixed Ductal-Neuroendocrine Carcinoma of the Pancreas|Mixed Embryonal Carcinoma and Teratoma|Mixed Epithelial and Mesenchymal Hepatoblastoma|Mixed Epithelioid and Spindle Cell Melanoma|Mixed Germ Cell Tumor|Mixed Glioma|Mixed Liposarcoma|Mixed Mesodermal (Mullerian) Tumor|Mixed Mucinous and Non-Mucinous Bronchioloalveolar Carcinoma|Mixed Phenotype Acute Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1|Mixed Phenotype Acute Leukemia with t(v;11q23.3); KMT2A Rearranged|Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified|Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified|Mixed Teratoma and Seminoma|Mixed Testicular Sex Cord-Stromal Tumor|Mixed Tumor, Not Otherwise Specified|Monoclonal Gammopathy of Undetermined Significance|Monoclonal Immunoglobulin Deposition Disease|Mu Heavy Chain Disease|Mucin-Producing Adenocarcinoma|Mucin-Producing Carcinoma|Mucinous Adenocarcinoma|Mucinous Adenocarcinoma, Endocervical Type|Mucinous Adenofibroma|Mucinous Cystadenocarcinoma|Mucinous Cystadenofibroma|Mucinous Cystadenoma|Mucinous Tubular and Spindle Cell Carcinoma of the Kidney|Mucoepidermoid Carcinoma|Mucosal Lentiginous Melanoma|Multicystic Mesothelioma|Multifocal Lymphomatous Polyposis|Multiple Adenomatous Polyps|Multiple Endocrine Neoplasia|Multiple Osteochondromas|Mycosis Fungoides|Myelodysplastic Syndrome|Myelodysplastic Syndrome with Excess Blasts|Myelodysplastic Syndrome with Excess Blasts-1|Myelodysplastic Syndrome with Excess Blasts-2|Myelodysplastic Syndrome with Isolated del(5q)|Myelodysplastic Syndrome with Multilineage Dysplasia|Myelodysplastic Syndrome with Ring Sideroblasts|Myelodysplastic Syndrome, Unclassifiable|Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Myeloid Leukemia|Myeloid Leukemia Associated with Down Syndrome|Myeloid Sarcoma|Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement|Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement|Myeloproliferative Neoplasm|Myoepithelial Tumor|Myolipoma|Myxofibrosarcoma|Myxoid Chondrosarcoma|Myxoid Leiomyosarcoma|Myxoid Liposarcoma|Myxoinflammatory Fibroblastic Sarcoma|Myxoma|Myxopapillary Ependymoma|NUT Carcinoma|Nasal Type Extranodal NK/T-Cell Lymphoma|Nasopharyngeal-Type Undifferentiated Carcinoma|Neoplasm|Neoplasm of the Diffuse Neuroendocrine System|Neoplasm, Uncertain Whether Benign or Malignant|Neoplastic Cell|Nerve Sheath Myxoma|Nesidioblastosis|Neuroblastoma|Neuroendocrine Carcinoma|Neurofibroma|Neurofibromatosis|Neurofibromatosis Type 1|Neuroma|Nipple Adenoma|Nodal Marginal Zone Lymphoma|Nodular Hidradenoma|Nodular Lymphocyte Predominant Hodgkin Lymphoma|Nodular Sclerosis Classic Hodgkin Lymphoma|Nodular Sclerosis Classic Hodgkin Lymphoma, Cellular Phase|Nodular Sclerosis Classic Hodgkin Lymphoma, Syncytial Variant|Non-Hodgkin Lymphoma|Non-Invasive Papillary Squamous Cell Carcinoma|Non-Invasive Papillary Transitional Cell Carcinoma|Non-Keratinizing Large Cell Squamous Cell Carcinoma|Non-Keratinizing Sinonasal Squamous Cell Carcinoma|Non-Keratinizing Small Cell Squamous Cell Carcinoma|Non-Small Cell Carcinoma|Nongerminomatous Germ Cell Tumor|Nonpigmented Nevus|Odontogenic Fibroma|Odontogenic Myxofibroma|Odontogenic Myxoma|Odontogenic Neoplasm|Odontoma|Olfactory Neuroblastoma|Olfactory Neurocytoma|Olfactory Neurogenic Tumor|Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted|Oligodendroglioma, Not Otherwise Specified|Oncocytic Adenoma|Oncocytic Neoplasm|Ossifying Fibroma|Ossifying Fibromyxoid Tumor|Osteoblastic Osteosarcoma|Osteoblastoma|Osteoid Osteoma|Osteoma|Osteosarcoma|Ovarian Endometrioid Adenofibroma|Ovarian Endometrioid Cystadenofibroma|Ovarian Gynandroblastoma|Ovarian Hilus Cell Tumor|Ovarian Luteinized Thecoma|Ovarian Sclerosing Stromal Tumor|Ovarian Seromucinous Carcinoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord-Stromal Tumor|Ovarian Small Cell Carcinoma, Hypercalcemic Type|Ovarian Small Cell Carcinoma, Pulmonary-Type|Ovarian Steroid Cell Tumor|Ovarian Stromal Luteoma|Ovarian Stromal Tumor with Minor Sex Cord Elements|Oxyphilic Adenocarcinoma|Pacinian Neurofibroma|Paget Disease and Intraductal Carcinoma of the Breast|Paget Disease of the Breast|Pagetoid Reticulosis|Pancreatic Acinar Cell Cystadenocarcinoma|Pancreatic Beta Cell Adenoma|Pancreatic Insulinoma|Pancreatic Intraductal Papillary-Mucinous Neoplasm with High Grade Dysplasia|Pancreatic Intraductal Papillary-Mucinous Neoplasm with an Associated Invasive Carcinoma|Pancreatic Intraductal Tubulopapillary Neoplasm|Pancreatic Mucinous-Cystic Neoplasm with Intermediate Grade Dysplasia|Pancreatic Neuroendocrine Carcinoma|Pancreatic Neuroendocrine Neoplasm|Papillary Adenocarcinoma|Papillary Adenofibroma|Papillary Carcinoma|Papillary Carcinoma In Situ|Papillary Craniopharyngioma|Papillary Cystadenocarcinoma|Papillary Cystadenoma|Papillary Cystic Neoplasm|Papillary Eccrine Adenoma|Papillary Ependymoma|Papillary Glioneuronal Tumor|Papillary Intralymphatic Angioendothelioma|Papillary Meningioma|Papillary Mucinous Cystadenocarcinoma|Papillary Mucinous Cystadenoma|Papillary Renal Cell Carcinoma|Papillary Serous Cystadenocarcinoma|Papillary Serous Cystadenoma|Papillary Squamous Cell Carcinoma|Papillary Transitional Cell Carcinoma|Papillary Tumor of the Pineal Region|Papilloma|Papillomatosis|Paraganglioma|Parasympathetic Paraganglioma|Parathyroid Gland Chief Cell Adenoma|Parathyroid Gland Water-Clear Cell Adenoma|Parosteal Osteosarcoma|Partial Hydatidiform Mole|Penile Carcinoma In Situ|Perifollicular Fibroma|Perineurioma|Periosteal Chondroma|Periosteal Chondrosarcoma|Periosteal Fibroma|Periosteal Fibrosarcoma|Periosteal Osteosarcoma|Peripheral Odontogenic Fibroma|Peripheral Primitive Neuroectodermal Tumor|Peripheral T-Cell Lymphoma, Large Cell|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia|Philadelphia-Negative Myelogenous Leukemia|Phyllodes Tumor|Pigmented Adrenal Cortex Adenoma|Pigmented Dermatofibrosarcoma Protuberans|Pigmented Nevus|Pigmented Spindle Cell Nevus|Pilocytic Astrocytoma|Pilomatrical Carcinoma|Pilomatricoma|Pilomyxoid Astrocytoma|Pineal Parenchymal Tumor of Intermediate Differentiation|Pineal Region Neoplasm|Pituitary Gland Acidophil Adenoma|Pituitary Gland Acidophil Carcinoma|Pituitary Gland Adenoma|Pituitary Gland Basophil Adenoma|Pituitary Gland Carcinoma|Pituitary Gland Chromophobe Adenoma|Pituitary Gland Mixed Acidophil-Basophil Adenoma|Pituitary Gland Mixed Acidophil-Basophil Carcinoma|Placental Hemangioma|Placental-Site Gestational Trophoblastic Tumor|Plasma Cell Leukemia|Plasma Cell Myeloma|Plasma Cell Neoplasm|Plasmablastic Lymphoma|Plasmacytoma|Pleomorphic Adenoma|Pleomorphic Carcinoma|Pleomorphic Lipoma|Pleomorphic Liposarcoma|Pleomorphic Lobular Breast Carcinoma In Situ|Pleomorphic Rhabdomyosarcoma|Pleomorphic Xanthoastrocytoma|Pleural Solitary Fibrous Tumor|Pleuropulmonary Blastoma|Plexiform Fibrohistiocytic Tumor|Plexiform Neurofibroma|Plexiform Schwannoma|Polar Spongioblastoma|Polycythemia Vera|Polygonal Cell Carcinoma|Polymorphic Post-Transplant Lymphoproliferative Disorder|Poorly Differentiated Neuroendocrine Lesion|Poorly Differentiated Thyroid Gland Carcinoma|Poroma|Post-Transplant Lymphoproliferative Disorder|Pre T-ALL|Pre-B Acute Lymphoblastic Leukemia|Pre-Pre-B Acute Lymphoblastic Leukemia|Precancerous Melanosis|Primary Amyloidosis|Primary Cutaneous Anaplastic Large Cell Lymphoma|Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder|Primary Cutaneous CD4-Positive Small/Medium T-Cell Lymphoproliferative Disorder|Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma|Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Primary Cutaneous Follicle Center Lymphoma|Primary Cutaneous Gamma-Delta T-Cell Lymphoma|Primary Cutaneous Lymphoma|Primary Cutaneous Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Primary Effusion Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Primary Myelofibrosis|Primary Peritoneal Serous Papillary Adenocarcinoma|Primitive Neuroectodermal Tumor|Proliferating Trichilemmal Tumor|Proliferative Nodules in Congenital Melanocytic Nevus|Prolymphocytic Leukemia|Prostate Acinar Adenocarcinoma, Sarcomatoid Variant|Protoplasmic Astrocytoma|Psammomatous Meningioma|Pseudoglandular Squamous Cell Carcinoma|Pseudomyxoma Peritonei|Pulmonary Adenomatosis|Pulmonary Artery Intimal Sarcoma|Pulmonary Blastoma|Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Translocation|Pure Erythroid Leukemia|Refractory Anemia|Refractory Anemia with Excess Blasts in Transformation|Refractory Cytopenia of Childhood|Refractory Neutropenia|Refractory Thrombocytopenia|Regressing Melanoma|Regressing Nevus|Renal Cell Carcinoma|Rete Ovarii Adenocarcinoma|Reticulosarcoma|Retinoblastoma|Rhabdoid Meningioma|Rhabdoid Tumor|Rhabdomyoma|Rhabdomyosarcoma|Rosette-Forming Glioneuronal Tumor|Round Cell Liposarcoma|Salivary Duct Carcinoma|Salivary Gland Basal Cell Adenocarcinoma|Salivary Gland Basal Cell Adenoma|Salivary Gland Monomorphic Adenoma|Sarcoma|Sarcomatoid Carcinoma|Sarcomatoid Mesothelioma|Sarcomatoid Renal Cell Carcinoma|Sarcomatoid Transitional Cell Carcinoma|Sarcomatosis|Schwannoma|Schwannomatosis|Scirrhous Adenocarcinoma|Scirrhous Hepatocellular Carcinoma|Sclerosing Epithelioid Fibrosarcoma|Sclerosing Liposarcoma|Sclerosing Rhabdomyosarcoma|Sebaceous Adenoma|Sebaceous Carcinoma|Secondary Carcinoma|Secondary Neoplasm|Secretory Breast Carcinoma|Secretory Meningioma|Seminoma|Serous Adenofibroma|Serous Cystadenocarcinoma|Serous Cystadenoma|Serous Endometrial Intraepithelial Carcinoma|Serous Surface Papillary Carcinoma|Serous Surface Papilloma|Serous Tubal Intraepithelial Carcinoma|Sertoli Cell Tumor|Sessile Serrated Adenoma/Polyp|Sex Cord-Stromal Tumor|Sezary Syndrome|Signet Ring Cell Carcinoma|Sinonasal Inverted Schneiderian Papilloma|Sinonasal Oncocytic Schneiderian Papilloma|Sinonasal Schneiderian Papilloma|Skin Adenoid Basal Cell Carcinoma|Skin Appendage Adenoma|Skin Basal Cell Carcinoma|Skin Basal Cell Carcinoma with Sebaceous Differentiation|Skin Basosquamous Cell Carcinoma|Skin Fibroepithelial Basal Cell Carcinoma|Skin Fibrous Histiocytoma|Skin Infiltrating Basal Cell Carcinoma|Skin Metatypical Carcinoma|Skin Micronodular Basal Cell Carcinoma|Skin Nodular Basal Cell Carcinoma|Skin Nodulo-Ulcerative Basal Cell Carcinoma|Skin Pigmented Basal Cell Carcinoma|Skin Sclerosing/Morphoeic Basal Cell Carcinoma|Small Cell Carcinoma|Small Cell Carcinoma, Fusiform Cell Type|Small Cell Intermediate Cell Carcinoma|Small Cell Osteosarcoma|Small Cell Sarcoma|Small Lymphocytic Lymphoma|Smooth Muscle Neoplasm|Soft Tissue Perineurioma|Soft Tissue Sarcoma|Solid Carcinoma|Solid Papillary Breast Carcinoma|Solitary Fibrous Tumor|Solitary Mastocytoma of the Skin|Solitary Osseous Plasmacytoma|Solitary Plasmacytoma|Solitary Reticulohistiocytoma|Somatostatin-Producing Neuroendocrine Tumor|Spindle Cell Hemangioma|Spindle Cell Lipoma|Spindle Cell Melanoma|Spindle Cell Oncocytoma|Spindle Cell Rhabdomyosarcoma|Spindle Cell Sarcoma|Spindle Cell Squamous Cell Carcinoma|Spindle Cell Synovial Sarcoma|Spindle-Cell Predominant Trichodiscoma|Spiradenocarcinoma|Spiradenoma|Spitz Nevus|Splenic B-Cell Lymphoma/Leukemia, Unclassifiable|Splenic Diffuse Red Pulp Small B-Cell Lymphoma|Splenic Marginal Zone Lymphoma|Spontaneously Regressing Retinoblastoma|Squamous Cell Carcinoma|Squamous Cell Carcinoma In Situ with Questionable Stromal Invasion|Squamous Cell Carcinoma with Horn Formation|Squamous Cell Carcinoma, Clear Cell Type|Squamous Cell Papilloma|Squamous Odontogenic Tumor|Squamous Papillomatosis|Stage 0 Cervical Cancer AJCC v6|Stage 0 Cutaneous Melanoma AJCC v6 and v7|Stage 0 Squamous Cell Carcinoma|Stage 0 Transitional Cell Carcinoma|Stage 0 Vaginal Cancer AJCC v6|Stage 0 Vaginal Cancer AJCC v7|Stage 0 Vulvar Cancer AJCC v6|Stromal Neoplasm|Stromal Sarcoma|Struma Ovarii|Strumal Carcinoid|Subcutaneous Panniculitis-Like T-Cell Lymphoma|Subependymal Giant Cell Astrocytoma|Subepidermal Nodular Fibrosis|Superficial Multifocal Basal Cell Carcinoma|Superficial Spreading Adenocarcinoma|Supratentorial Embryonal Tumor, Not Otherwise Specified|Sweat Gland Adenoma|Sweat Gland Carcinoma|Sweat Gland Neoplasm|Sympathetic Paraganglioma|Synovial Sarcoma|Syringocystadenoma Papilliferum|Syringoma|Systemic EBV-Positive T-Cell Lymphoma of Childhood|Systemic Mastocytosis|Systemic Mastocytosis with an Associated Hematological Neoplasm|T Acute Lymphoblastic Leukemia|T Lymphoblastic Leukemia/Lymphoma|T Lymphoblastic Lymphoma|T-Cell Large Granular Lymphocyte Leukemia|T-Cell Non-Hodgkin Lymphoma|T-Cell Prolymphocytic Leukemia|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|T-Zone Variant Peripheral T-Cell Lymphoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Tanycytic Ependymoma|Telangiectatic Osteosarcoma|Tenosynovial Giant Cell Tumor|Teratoma|Teratoma with Somatic-Type Malignancy|Testicular Mixed Germ Cell-Sex Cord-Stromal Tumor, Unclassified|Testicular Seminoma with High Mitotic Index|Testicular Spermatocytic Tumor|Thecoma|Therapy-Related Acute Myeloid Leukemia|Therapy-Related Myelodysplastic Syndrome|Therapy-Related Myeloid Neoplasm|Thymic Carcinoma|Thymoma|Thymoma Type A|Thymoma Type AB|Thymoma Type B1|Thymoma Type B2|Thymoma Type B3|Thyroid Gland Follicular Adenoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Follicular Carcinoma, Encapsulated Angioinvasive|Thyroid Gland Hurthle (Oncocytic) Cell Neoplasm|Thyroid Gland Hurthle Cell Adenoma|Thyroid Gland Hyalinizing Trabecular Tumor|Thyroid Gland Macrofollicular Adenoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Medullary Carcinoma with Amyloid Stroma|Thyroid Gland Microfollicular Adenoma|Thyroid Gland Noninvasive Follicular Neoplasm with Papillary-Like Nuclear Features|Thyroid Gland Papillary Carcinoma|Thyroid Gland Papillary and Follicular Carcinoma|Thyroid Gland Spindle Cell Tumor with Thymus-Like Differentiation|Thyroid Gland Well-Differentiated Tumor of Uncertain Malignant Potential|Tibial Adamantinoma|Trabecular Adenocarcinoma|Trabecular Adenoma|Traditional Serrated Adenoma|Transient Abnormal Myelopoiesis Associated with Down Syndrome|Transitional Cell Carcinoma|Transitional Cell Papilloma|Transitional Meningioma|Trichilemmal Carcinoma|Trichoblastoma|True Histiocytic Lymphoma|Tubular Adenocarcinoma|Tubular Adenoma|Tubulocystic Renal Cell Carcinoma|Tubulovillous Adenoma|Tumor Embolism|Tumorlet|Turban Tumor|Type A Spindle Cell Melanoma|Type B Spindle Cell Melanoma|Unclassified Testicular Sex Cord-Stromal Tumor|Undifferentiated (Embryonal) Sarcoma|Undifferentiated Carcinoma|Undifferentiated Epithelioid Sarcoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone|Undifferentiated Pleomorphic Sarcoma|Undifferentiated Pleomorphic Sarcoma with Osteoclast-Like Giant Cells|Undifferentiated Retinoblastoma|Undifferentiated Round Cell Sarcoma|Undifferentiated Sarcoma, Not Otherwise Specified|Undifferentiated Spindle Cell Sarcoma|Urothelial Carcinoma|Urothelial Papilloma|Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis|Uterine Corpus Leiomyoma|Uterine Corpus Undifferentiated Sarcoma|VIP-Producing Neuroendocrine Tumor|Venous Hemangioma|Verrucous Carcinoma|Verrucous Hemangioma|Verrucous Papilloma|Villoglandular Endometrial Endometrioid Adenocarcinoma|Villous Adenocarcinoma|Villous Adenoma|Vulvar Intraepithelial Neoplasia, Differentiated Type|Waldenstrom Macroglobulinemia|Warthin Tumor|Water-Clear Cell Adenocarcinoma|Well Differentiated Liposarcoma|Well Differentiated Neuroendocrine Lesion|Wilms Tumor|Yolk Sac Tumor"
primary_gleason_grade	primary_gleason_grade		0/5 (both/PDC)	Pattern 1|Pattern 2|Pattern 3|Pattern 4|Pattern 5	Gleason Pattern 1|Gleason Pattern 2|Gleason Pattern 3|Gleason Pattern 4|Gleason Pattern 5
prior_malignancy	prior_malignancy	False|Not Allowed To Collect|True|not reported|unknown	5/5 (both/PDC)		
prior_treatment	prior_treatment	False|Not Allowed To Collect|Not Reported|True|Unknown	5/5 (both/PDC)		
progression_or_recurrence	progression_or_recurrence	False|Not Allowed To Collect|Not Reported|True|Unknown|not reported|unknown	7/7 (both/PDC)		
residual_disease	residual_disease	Not Reported|R0|RX|Unknown	4/6 (both/PDC)	R1|R2	Stage R1|Stage R2
satellite_nodule_present	satellite_nodule_present	Absent|Indeterminate|Not Reported|Present|Unknown	5/5 (both/PDC)		
secondary_gleason_grade	secondary_gleason_grade		0/5 (both/PDC)	Pattern 1|Pattern 2|Pattern 3|Pattern 4|Pattern 5	Gleason Pattern 1|Gleason Pattern 2|Gleason Pattern 3|Gleason Pattern 4|Gleason Pattern 5
site_of_resection_or_biopsy	site_of_resection_or_biopsy	Abdomen, NOS|Abdominal esophagus|Accessory sinus, NOS|Adrenal gland, NOS|Ampulla of Vater|Anterior 2/3 of tongue, NOS|Anterior floor of mouth|Anterior mediastinum|Anterior wall of bladder|Anus, NOS|Aortic body and other paraganglia|Appendix|Autonomic nervous system, NOS|Axillary tail of breast|Biliary tract, NOS|Bladder, NOS|Blood|Body of pancreas|Bone marrow|Bone of limb, NOS|Bone, NOS|Bones of skull and face and associated joints|Border of tongue|Brain stem|Breast, NOS|Cardia, NOS|Cauda equina|Cecum|Central portion of breast|Cervical esophagus|Cheek mucosa|Choroid|Clitoris|Cloacogenic zone|Colon, NOS|Commissure of lip|Conjunctiva|Connective, subcutaneous and other soft tissues of abdomen|Connective, subcutaneous and other soft tissues of head, face, and neck|Connective, subcutaneous and other soft tissues of lower limb and hip|Connective, subcutaneous and other soft tissues of pelvis|Connective, subcutaneous and other soft tissues of thorax|Connective, subcutaneous and other soft tissues of trunk, NOS|Connective, subcutaneous and other soft tissues of upper limb and shoulder|Connective, subcutaneous and other soft tissues, NOS|Cornea, NOS|Corpus uteri|Cortex of adrenal gland|Cranial nerve, NOS|Craniopharyngeal duct|Descended testis|Dorsal surface of tongue, NOS|Duodenum|Endocervix|Endometrium|Epididymis|Esophagus, NOS|Ethmoid sinus|External ear|External lip, NOS|External upper lip|Extrahepatic bile duct|Eyelid|Floor of mouth, NOS|Frontal lobe|Fundus of stomach|Gallbladder|Glottis|Gum, NOS|Hard palate|Head, face or neck, NOS|Heart|Hepatic flexure of colon|Hypopharyngeal aspect of aryepiglottic fold|Ileum|Ill-defined sites within respiratory system|Intestinal tract, NOS|Intrahepatic bile duct|Islets of Langerhans|Jejunum|Kidney, NOS|Lacrimal gland|Larynx, NOS|Lateral floor of mouth|Lateral wall of bladder|Lateral wall of oropharynx|Lingual tonsil|Liver|Long bones of lower limb and associated joints|Long bones of upper limb, scapula and associated joints|Lower limb, NOS|Lower lobe, lung|Lower third of esophagus|Lower-inner quadrant of breast|Lung, NOS|Lymph nodes of axilla or arm|Lymph nodes of inguinal region or leg|Lymph nodes of multiple regions|Major salivary gland, NOS|Mandible|Meckel diverticulum|Mediastinum, NOS|Medulla of adrenal gland|Middle third of esophagus|Mucosa of upper lip|Myometrium|Nasal cavity|Nipple|Not Reported|Olfactory nerve|Other specified parts of male genital organs|Ovary|Overlapping lesion of accessory sinuses|Overlapping lesion of biliary tract|Overlapping lesion of bladder|Overlapping lesion of bones, joints and articular cartilage|Overlapping lesion of bones, joints and articular cartilage of limbs|Overlapping lesion of brain|Overlapping lesion of brain and central nervous system|Overlapping lesion of breast|Overlapping lesion of cervix uteri|Overlapping lesion of colon|Overlapping lesion of connective, subcutaneous and other soft tissues|Overlapping lesion of corpus uteri|Overlapping lesion of digestive system|Overlapping lesion of endocrine glands and related structures|Overlapping lesion of esophagus|Overlapping lesion of eye and adnexa|Overlapping lesion of female genital organs|Overlapping lesion of floor of mouth|Overlapping lesion of heart, mediastinum and pleura|Overlapping lesion of hypopharynx|Overlapping lesion of ill-defined sites|Overlapping lesion of larynx|Overlapping lesion of lip|Overlapping lesion of lip, oral cavity and pharynx|Overlapping lesion of lung|Overlapping lesion of major salivary glands|Overlapping lesion of male genital organs|Overlapping lesion of nasopharynx|Overlapping lesion of other and unspecified parts of mouth|Overlapping lesion of palate|Overlapping lesion of pancreas|Overlapping lesion of penis|Overlapping lesion of peripheral nerves and autonomic nervous system|Overlapping lesion of rectum, anus and anal canal|Overlapping lesion of respiratory system and intrathoracic organs|Overlapping lesion of retroperitoneum and peritoneum|Overlapping lesion of skin|Overlapping lesion of small intestine|Overlapping lesion of stomach|Overlapping lesion of tongue|Overlapping lesion of tonsil|Overlapping lesion of urinary organs|Overlapping lesion of vulva|Overlapping lesions of oropharynx|Palate, NOS|Pancreas, NOS|Pancreatic duct|Pancreatic neck|Parametrium|Parathyroid gland|Paraurethral gland|Pelvic bones, sacrum, coccyx and associated joints|Pelvic lymph nodes|Pelvis, NOS|Peripheral nerves and autonomic nervous system of abdomen|Peripheral nerves and autonomic nervous system of head, face, and neck|Peripheral nerves and autonomic nervous system of lower limb and hip|Peripheral nerves and autonomic nervous system of pelvis|Peripheral nerves and autonomic nervous system of thorax|Peripheral nerves and autonomic nervous system of trunk, NOS|Peripheral nerves and autonomic nervous system of upper limb and shoulder|Peritoneum, NOS|Pineal gland|Placenta|Pleura, NOS|Postcricoid region|Posterior mediastinum|Posterior wall of bladder|Posterior wall of hypopharynx|Posterior wall of oropharynx|Prepuce|Pylorus|Pyriform sinus|Rectum, NOS|Retina|Retroperitoneum|Rib, sternum, clavicle and associated joints|Round ligament|Short bones of lower limb and associated joints|Short bones of upper limb and associated joints|Skin of lip, NOS|Skin of trunk|Skin, NOS|Soft palate, NOS|Specified parts of peritoneum|Spermatic cord|Sphenoid sinus|Spinal meninges|Spleen|Subglottis|Sublingual gland|Supraglottis|Tail of pancreas|Thorax, NOS|Thymus|Tongue, NOS|Tonsillar pillar|Trachea|Transverse colon|Undescended testis|Unknown|Upper gum|Upper limb, NOS|Upper lobe, lung|Upper respiratory tract, NOS|Upper third of esophagus|Upper-inner quadrant of breast|Upper-outer quadrant of breast|Urachus|Ureter|Urethra|Uterus, NOS|Uvula|Vallecula|Ventral surface of tongue, NOS|Ventricle, NOS|Vertebral column|Waldeyer ring	230/333 (both/PDC)	Acoustic nerve|Anal canal|Anterior surface of epiglottis|Anterior wall of nasopharynx|Ascending colon|Base of tongue, NOS|Bladder neck|Body of penis|Body of stomach|Brain, NOS|Branchial cleft|Broad ligament|Carotid body|Cerebellum, NOS|Cerebral meninges|Cerebrum|Cervix uteri|Ciliary body|Descending colon|Dome of bladder|Endocrine gland, NOS|Exocervix|External lower lip|Eye, NOS|Fallopian tube|Female genital tract, NOS|Frontal sinus|Fundus uteri|Gastric antrum|Gastrointestinal tract, NOS|Glans penis|Greater curvature of stomach, NOS|Head of pancreas|Hematopoietic system, NOS|Hypopharynx, NOS|Intra-abdominal lymph nodes|Intrathoracic lymph nodes|Isthmus uteri|Labium majus|Labium minus|Laryngeal cartilage|Lateral wall of nasopharynx|Lesser curvature of stomach, NOS|Lip, NOS|Lower gum|Lower-outer quadrant of breast|Lymph node, NOS|Lymph nodes of head, face and neck|Main bronchus|Male genital organs, NOS|Maxillary sinus|Meninges, NOS|Middle ear|Middle lobe, lung|Mouth, NOS|Mucosa of lip, NOS|Mucosa of lower lip|Nasopharynx, NOS|Nervous system, NOS|Occipital lobe|Optic nerve|Orbit, NOS|Oropharynx, NOS|Other ill-defined sites|Other specified parts of female genital organs|Other specified parts of pancreas|Parietal lobe|Parotid gland|Penis, NOS|Pharynx, NOS|Pituitary gland|Posterior wall of nasopharynx|Prostate gland|Rectosigmoid junction|Renal pelvis|Reticuloendothelial system, NOS|Retromolar area|Scrotum, NOS|Sigmoid colon|Skin of lower limb and hip|Skin of other and unspecified parts of face|Skin of scalp and neck|Skin of upper limb and shoulder|Small intestine, NOS|Spinal cord|Splenic flexure of colon|Stomach, NOS|Submandibular gland|Superior wall of nasopharynx|Temporal lobe|Testis, NOS|Thoracic esophagus|Thyroid gland|Tonsil, NOS|Tonsillar fossa|Trigone of bladder|Unknown primary site|Ureteric orifice|Urinary system, NOS|Uterine adnexa|Vagina, NOS|Vestibule of mouth|Vulva, NOS	Anal Canal|Anterior Surface of the Epiglottis|Anterior Wall of the Nasopharynx|Antrum Pylori|Appendage of the Uterus|Ascending Colon|Base of the Tongue|Bladder Neck|Bladder Trigone|Body of Stomach|Body of the Penis|Brain|Branchial Cleft Remnant|Broad Ligament|Carotid Body|Cerebellum|Cerebral Hemisphere|Cerebral Meninges|Cervix Uteri|Ciliary Body|Cochlear Nerve|Descending Colon|Dome of the Bladder|Ectocervix|Endocrine Gland|External Lower Lip|Eye|Fallopian Tube|Female Genitalia|Frontal Sinus|Fundus Uteri|Gastrointestinal Tract|Glans Penis|Greater Curvature of the Stomach|Head and Neck Lymph Node|Head of the Pancreas|Hematopoietic System|Hypopharynx|Ill-Defined Anatomic Site|Intra-Abdominal Lymph Node|Intrathoracic Lymph Node|Isthmus Uteri|Labium Majus|Labium Minus|Laryngeal Cartilage|Lateral Wall of the Nasopharynx|Lesser Curvature of the Stomach|Lip|Lower Gingiva|Lower-Outer Quadrant of the Breast|Lymph Node|Main Bronchus|Male Genitalia|Maxillary Sinus|Meninges|Middle Ear|Middle Lobe of the Right Lung|Mucosa of the Lip|Mucosa of the Lower Lip|Nasopharynx|Nervous System|Occipital Lobe|Optic Nerve|Oral Cavity|Orbit|Oropharynx|Other Specified Parts of Pancreas|Other and Unspecified Female Genital Organs ICD-O-3|Palatine Tonsil|Parietal Lobe|Parotid Gland|Penis|Pharynx|Pituitary Gland|Posterior Wall of the Nasopharynx|Primary Site Unknown|Prostate Gland|Rectosigmoid Region|Renal Pelvis|Reticuloendothelial System|Retromolar Trigone|Scrotum|Sigmoid Colon|Skin of the Face|Skin of the Lower Limb and Hip|Skin of the Scalp and Neck|Skin of the Upper Limb and Shoulder|Small Intestine|Spinal Cord|Splenic Flexure|Stomach|Submandibular Gland|Superior Wall of the Nasopharynx|Temporal Lobe|Testis|Thoracic Esophagus|Thyroid Gland|Tonsillar Fossa|Ureteric Orifice|Urinary System|Vagina|Vestibule of Mouth|Vulva
supratentorial_localization	supratentorial_localization	Cerebral Cortex|Frontal lobe|Not Reported|Spinal Cord|Unknown|White Matter	6/10 (both/PDC)	Deep Gray (e.g. Basal Ganglia, Thalamus)|Occipital lobe|Parietal lobe|Temporal lobe	Deep Gray Matter|Occipital Lobe|Parietal Lobe|Temporal Lobe
synchronous_malignancy	synchronous_malignancy	False|Not Reported|True|Unknown	4/5 (both/PDC)	Not Allowed To Collect	
tissue_or_organ_of_origin	tissue_or_organ_of_origin	Abdomen, NOS|Abdominal esophagus|Accessory sinus, NOS|Adrenal gland, NOS|Ampulla of Vater|Anterior 2/3 of tongue, NOS|Anterior floor of mouth|Anterior mediastinum|Anterior wall of bladder|Anus, NOS|Aortic body and other paraganglia|Appendix|Autonomic nervous system, NOS|Axillary tail of breast|Biliary tract, NOS|Bladder, NOS|Blood|Body of pancreas|Bone marrow|Bone of limb, NOS|Bone, NOS|Bones of skull and face and associated joints|Border of tongue|Brain stem|Breast, NOS|Cardia, NOS|Cauda equina|Cecum|Central portion of breast|Cervical esophagus|Cheek mucosa|Choroid|Clitoris|Cloacogenic zone|Colon, NOS|Commissure of lip|Conjunctiva|Connective, subcutaneous and other soft tissues of abdomen|Connective, subcutaneous and other soft tissues of head, face, and neck|Connective, subcutaneous and other soft tissues of lower limb and hip|Connective, subcutaneous and other soft tissues of pelvis|Connective, subcutaneous and other soft tissues of thorax|Connective, subcutaneous and other soft tissues of trunk, NOS|Connective, subcutaneous and other soft tissues of upper limb and shoulder|Connective, subcutaneous and other soft tissues, NOS|Cornea, NOS|Corpus uteri|Cortex of adrenal gland|Cranial nerve, NOS|Craniopharyngeal duct|Descended testis|Dorsal surface of tongue, NOS|Duodenum|Endocervix|Endometrium|Epididymis|Esophagus, NOS|Ethmoid sinus|External ear|External lip, NOS|External upper lip|Extrahepatic bile duct|Eyelid|Floor of mouth, NOS|Frontal lobe|Fundus of stomach|Gallbladder|Glottis|Gum, NOS|Hard palate|Head, face or neck, NOS|Heart|Hepatic flexure of colon|Hypopharyngeal aspect of aryepiglottic fold|Ileum|Ill-defined sites within respiratory system|Intestinal tract, NOS|Intrahepatic bile duct|Islets of Langerhans|Jejunum|Kidney, NOS|Lacrimal gland|Laryngeal commissure|Larynx, NOS|Lateral floor of mouth|Lateral wall of bladder|Lateral wall of oropharynx|Lingual tonsil|Liver|Long bones of lower limb and associated joints|Long bones of upper limb, scapula and associated joints|Lower limb, NOS|Lower lobe, lung|Lower third of esophagus|Lower-inner quadrant of breast|Lung, NOS|Lymph nodes of axilla or arm|Lymph nodes of inguinal region or leg|Lymph nodes of multiple regions|Major salivary gland, NOS|Mandible|Meckel diverticulum|Mediastinum, NOS|Medulla of adrenal gland|Middle third of esophagus|Mucosa of upper lip|Myometrium|Nasal cavity|Nipple|Not Reported|Olfactory nerve|Other specified parts of male genital organs|Ovary|Overlapping lesion of accessory sinuses|Overlapping lesion of biliary tract|Overlapping lesion of bladder|Overlapping lesion of bones, joints and articular cartilage|Overlapping lesion of bones, joints and articular cartilage of limbs|Overlapping lesion of brain|Overlapping lesion of brain and central nervous system|Overlapping lesion of breast|Overlapping lesion of cervix uteri|Overlapping lesion of colon|Overlapping lesion of connective, subcutaneous and other soft tissues|Overlapping lesion of corpus uteri|Overlapping lesion of digestive system|Overlapping lesion of endocrine glands and related structures|Overlapping lesion of esophagus|Overlapping lesion of eye and adnexa|Overlapping lesion of female genital organs|Overlapping lesion of floor of mouth|Overlapping lesion of heart, mediastinum and pleura|Overlapping lesion of hypopharynx|Overlapping lesion of ill-defined sites|Overlapping lesion of larynx|Overlapping lesion of lip|Overlapping lesion of lip, oral cavity and pharynx|Overlapping lesion of lung|Overlapping lesion of major salivary glands|Overlapping lesion of male genital organs|Overlapping lesion of nasopharynx|Overlapping lesion of other and unspecified parts of mouth|Overlapping lesion of palate|Overlapping lesion of pancreas|Overlapping lesion of penis|Overlapping lesion of peripheral nerves and autonomic nervous system|Overlapping lesion of rectum, anus and anal canal|Overlapping lesion of respiratory system and intrathoracic organs|Overlapping lesion of retroperitoneum and peritoneum|Overlapping lesion of skin|Overlapping lesion of small intestine|Overlapping lesion of stomach|Overlapping lesion of tongue|Overlapping lesion of tonsil|Overlapping lesion of urinary organs|Overlapping lesion of vulva|Overlapping lesions of oropharynx|Palate, NOS|Pancreas, NOS|Pancreatic duct|Parametrium|Parathyroid gland|Paraurethral gland|Pelvic bones, sacrum, coccyx and associated joints|Pelvic lymph nodes|Pelvis, NOS|Peripheral nerves and autonomic nervous system of abdomen|Peripheral nerves and autonomic nervous system of head, face, and neck|Peripheral nerves and autonomic nervous system of lower limb and hip|Peripheral nerves and autonomic nervous system of pelvis|Peripheral nerves and autonomic nervous system of thorax|Peripheral nerves and autonomic nervous system of trunk, NOS|Peripheral nerves and autonomic nervous system of upper limb and shoulder|Peritoneum, NOS|Pineal gland|Placenta|Pleura, NOS|Postcricoid region|Posterior mediastinum|Posterior wall of bladder|Posterior wall of hypopharynx|Posterior wall of oropharynx|Prepuce|Pylorus|Pyriform sinus|Rectum, NOS|Retina|Retroperitoneum|Rib, sternum, clavicle and associated joints|Round ligament|Short bones of lower limb and associated joints|Short bones of upper limb and associated joints|Skin of lip, NOS|Skin of trunk|Skin, NOS|Soft palate, NOS|Specified parts of peritoneum|Spermatic cord|Sphenoid sinus|Spinal meninges|Spleen|Subglottis|Sublingual gland|Supraglottis|Tail of pancreas|Thorax, NOS|Thymus|Tongue, NOS|Tonsillar pillar|Trachea|Transverse colon|Undescended testis|Unknown|Upper limb, NOS|Upper lobe, lung|Upper respiratory tract, NOS|Upper third of esophagus|Upper-inner quadrant of breast|Upper-outer quadrant of breast|Urachus|Ureter|Urethra|Uterus, NOS|Uvula|Vallecula|Ventral surface of tongue, NOS|Ventricle, NOS|Vertebral column|Waldeyer ring	229/333 (both/PDC)	Acoustic nerve|Anal canal|Anterior surface of epiglottis|Anterior wall of nasopharynx|Ascending colon|Base of tongue, NOS|Bladder neck|Body of penis|Body of stomach|Brain, NOS|Branchial cleft|Broad ligament|Carotid body|Cerebellum, NOS|Cerebral meninges|Cerebrum|Cervix uteri|Ciliary body|Descending colon|Dome of bladder|Endocrine gland, NOS|Exocervix|External lower lip|Eye, NOS|Fallopian tube|Female genital tract, NOS|Frontal sinus|Fundus uteri|Gastric antrum|Gastrointestinal tract, NOS|Glans penis|Greater curvature of stomach, NOS|Head of pancreas|Hematopoietic system, NOS|Hypopharynx, NOS|Intra-abdominal lymph nodes|Intrathoracic lymph nodes|Isthmus uteri|Labium majus|Labium minus|Laryngeal cartilage|Lateral wall of nasopharynx|Lesser curvature of stomach, NOS|Lip, NOS|Lower gum|Lower-outer quadrant of breast|Lymph node, NOS|Lymph nodes of head, face and neck|Main bronchus|Male genital organs, NOS|Maxillary sinus|Meninges, NOS|Middle ear|Middle lobe, lung|Mouth, NOS|Mucosa of lip, NOS|Mucosa of lower lip|Nasopharynx, NOS|Nervous system, NOS|Occipital lobe|Optic nerve|Orbit, NOS|Oropharynx, NOS|Other ill-defined sites|Other specified parts of female genital organs|Other specified parts of pancreas|Parietal lobe|Parotid gland|Penis, NOS|Pharynx, NOS|Pituitary gland|Posterior wall of nasopharynx|Prostate gland|Rectosigmoid junction|Renal pelvis|Reticuloendothelial system, NOS|Retromolar area|Scrotum, NOS|Sigmoid colon|Skin of lower limb and hip|Skin of other and unspecified parts of face|Skin of scalp and neck|Skin of upper limb and shoulder|Small intestine, NOS|Spinal cord|Splenic flexure of colon|Stomach, NOS|Submandibular gland|Superior wall of nasopharynx|Temporal lobe|Testis, NOS|Thoracic esophagus|Thyroid gland|Tonsil, NOS|Tonsillar fossa|Trigone of bladder|Unknown primary site|Upper Gum|Ureteric orifice|Urinary system, NOS|Uterine adnexa|Vagina, NOS|Vestibule of mouth|Vulva, NOS	Anal Canal|Anterior Surface of the Epiglottis|Anterior Wall of the Nasopharynx|Antrum Pylori|Appendage of the Uterus|Ascending Colon|Base of the Tongue|Bladder Neck|Bladder Trigone|Body of Stomach|Body of the Penis|Brain|Branchial Cleft Remnant|Broad Ligament|Carotid Body|Cerebellum|Cerebral Hemisphere|Cerebral Meninges|Cervix Uteri|Ciliary Body|Cochlear Nerve|Descending Colon|Dome of the Bladder|Ectocervix|Endocrine Gland|External Lower Lip|Eye|Fallopian Tube|Female Genitalia|Frontal Sinus|Fundus Uteri|Gastrointestinal Tract|Glans Penis|Greater Curvature of the Stomach|Head and Neck Lymph Node|Head of the Pancreas|Hematopoietic System|Hypopharynx|Ill-Defined Anatomic Site|Intra-Abdominal Lymph Node|Intrathoracic Lymph Node|Isthmus Uteri|Labium Majus|Labium Minus|Laryngeal Cartilage|Lateral Wall of the Nasopharynx|Lesser Curvature of the Stomach|Lip|Lower Gingiva|Lower-Outer Quadrant of the Breast|Lymph Node|Main Bronchus|Male Genitalia|Maxillary Sinus|Meninges|Middle Ear|Middle Lobe of the Right Lung|Mucosa of the Lip|Mucosa of the Lower Lip|Nasopharynx|Nervous System|Occipital Lobe|Optic Nerve|Oral Cavity|Orbit|Oropharynx|Other Specified Parts of Pancreas|Other and Unspecified Female Genital Organs ICD-O-3|Palatine Tonsil|Parietal Lobe|Parotid Gland|Penis|Pharynx|Pituitary Gland|Posterior Wall of the Nasopharynx|Primary Site Unknown|Prostate Gland|Rectosigmoid Region|Renal Pelvis|Reticuloendothelial System|Retromolar Trigone|Scrotum|Sigmoid Colon|Skin of the Face|Skin of the Lower Limb and Hip|Skin of the Scalp and Neck|Skin of the Upper Limb and Shoulder|Small Intestine|Spinal Cord|Splenic Flexure|Stomach|Submandibular Gland|Superior Wall of the Nasopharynx|Temporal Lobe|Testis|Thoracic Esophagus|Thyroid Gland|Tonsillar Fossa|Upper Gingiva|Ureteric Orifice|Urinary System|Vagina|Vestibule of Mouth|Vulva
tumor_confined_to_organ_of_origin	tumor_confined_to_organ_of_origin	False|Not Reported|True|Unknown	4/5 (both/PDC)	Not Allowed To Collect	
tumor_focality	tumor_focality	Multifocal|Not Reported|Unifocal|Unknown	4/4 (both/PDC)		
tumor_grade	tumor_grade	High Grade|Intermediate Grade|Low Grade|Not Reported|Unknown	5/11 (both/PDC)	G1|G2|G3|G4|GB|GX	Grade 1|Grade 2|Grade 3|Grade 4|Grade B|Grade X|not reported
tumor_regression_grade	tumor_regression_grade	0|1|2|3|Not Reported|Unknown	6/6 (both/PDC)		"0 - No Fibrosis|00|01|02|03|04|05|06|07|08|09|1,2 - Portal Fibrosis|1-3|10|10-Deacetyltaxol|100|11|11C Topotecan|11D10 AluGel Anti-Idiotype Monoclonal Antibody|12|12-Allyldeoxoartemisinin|1200 series LC/MSD SL|1200 series LC/MSD VL|13|13-Deoxydoxorubicin|14|14C BMS-275183|15|16|17|17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521|18|180|1988|1995|1st|2'-F-ara-deoxyuridine|2,6-Diaminopurine|2,6-Dimethoxyquinone|2-Deoxy-D-glucose|2-Ethylhydrazide|2-Fluoroadenine|2-Fluorofucose-containing SGN-2FF|2-Hydroxyestradiol|2-Hydroxyestrone|2-Hydroxyflutamide Depot|2-Hydroxyoleic Acid|2-Methoxyestradiol|2-Methoxyestradiol Nanocrystal Colloidal Dispersion|2-Methoxyestrone|2-O, 3-O Desulfated Heparin|2-chloroacetamide (TCEP)|2-iodobenzoate|20|2000 QTRAP|2009|21|220 GC/MS Ion Trap System|240 GC/MS Ion Trap System|2500 QTRAP|26|2D Classical Conditionally Reprogrammed Cells|2D Modified Conditionally Reprogrammed Cells|2nd|3'-C-ethynylcytidine|3'-dA Phosphoramidate NUC-7738|3,4 - Fibrous Septa|30|31|31-60 Minutes|3100|32|3200 QTRAP|33|35|3500 QTRAP|39|3D Air-Liquid Interface Organoid|3D Neurosphere|3D Organoid|3rd|4|4 or More|4'-Iodo-4'-Deoxydoxorubicin|4-Nitroestrone 3-Methyl Ether|4-Thio-2-deoxycytidine|40|4000 QTRAP|41|42|45|4700 Proteomics Analyzer|4800 Plus MALDI TOF/TOF|4800 Proteomics Analyzer|4th|5|5 - Nodular Formation and Incomplete Cirrhosis|5-Aza-4'-thio-2'-deoxycytidine|5-Fluoro-2-Deoxycytidine|50|51|52|53|56|58|5800 TOF/TOF|59|5th|6|6 - Established Cirrhosis|6-30 Minutes|6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158|60|61|6110 Quadrupole LC/MS|6120A Quadrupole LC/MS|6120B Quadrupole LC/MS|6130 Quadrupole LC/MS|6140 Quadrupole LC/MS|6150 Quadrupole LC/MS|62|6200 Series Accurate-Mass Time-of-Flight (TOF) LC/MS|6210 Time-of-Flight LC/MS|6220 Time-of-Flight LC/MS|6224 Time-of-Flight LC/MS|6230A Time-of-Flight LC/MS|6230B Time-of-Flight LC/MS|63|6310 Ion Trap LC/MS|6320 Ion Trap LC/MS|6330 Ion Trap LC/MS|6340 Ion Trap LC/MS|64|6400 Series Triple Quadrupole LC/MS|6410 Triple Quadrupole LC/MS|6420 Triple Quadrupole LC/MS|6430 Triple Quadrupole LC/MS|6460 Triple Quadrupole LC/MS|6490 Triple Quadrupole LC/MS|6495A Triple Quadrupole LC/MS|6495B Triple Quadrupole LC/MS|65|6510 Quadrupole Time-of-Flight LC/MS|6520A Quadrupole Time-of-Flight LC/MS|6520B Q-TOF LC/MS|6530A Q-TOF LC/MS|6530B Q-TOF LC/MS|6538 Q-TOF LC/MS|6540 Q-TOF LC/MS|6542 Q-TOF LC/MS|6545 Q-TOF LC/MS|6550 iFunnel Q-TOF LC/MS|6550A iFunnel Q-TOF LC/MS|6560 Q-TOF LC/MS|6570 Q-TOF LC/MS|66|68|6th|7|7-Cyanoquinocarcinol|7-Ethyl-10-Hydroxycamptothecin|7-Hydroxystaurosporine|70|7000 Triple Quadrupole GC/MS System|7000A Triple Quadrupole GC/MS|7000B Triple Quadrupole GC/MS|71|7200 GC/Q-TOF|73|7800 Quadrupole ICP-MS|7th|8|8-Azaguanine|80|8000/0|8000/1|8000/3|8000/6|8000/9|8001/0|8001/1|8001/3|8002/3|8003/3|8004/3|8005/0|8005/3|8010/0|8010/2|8010/3|8010/6|8010/9|8011/0|8011/3|8012/3|8013/3|8014/3|8015/3|8020/3|8020/6|8021/3|8022/3|8023/3|8030/3|8031/3|8032/3|8033/3|8034/3|8035/3|8040/0|8040/1|8040/3|8041/3|8041/34|8041/6|8042/3|8043/3|8044/3|8045/3|8046/3|8046/6|8050/0|8050/2|8050/3|8051/0|8051/3|8052/0|8052/2|8052/3|8053/0|8060/0|8070/2|8070/3|8070/33|8070/6|8071/2|8071/3|8072/3|8073/3|8074/3|8075/3|8076/2|8076/3|8077/0|8077/2|8078/3|8080/2|8081/2|8082/3|8083/3|8084/3|8085/3|8086/3|8090/1|8090/3|8091/3|8092/3|8093/3|8094/3|8095/3|8096/0|8097/3|8098/3|81|8100/0|8101/0|8102/0|8102/3|8103/0|8110/0|8110/3|8120/0|8120/1|8120/2|8120/3|8121/0|8121/1|8121/3|8122/3|8123/3|8124/3|8130/1|8130/2|8130/3|8131/3|8140/0|8140/1|8140/2|8140/3|8140/33|8140/6|8141/3|8142/3|8143/3|8144/3|8145/3|8146/0|8147/0|8147/3|8148/0|8148/2|8149/0|8150/0|8150/1|8150/3|8151/0|8151/3|8152/1|8152/3|8153/1|8153/3|8154/3|8155/1|8155/3|8156/1|8156/3|8158/1|8160/0|8160/3|8161/0|8161/3|8162/3|8163/0|8163/2|8163/3|8170/0|8170/3|8171/3|8172/3|8173/3|8174/3|8175/3|8180/3|8190/0|8190/3|8191/0|82|8200/0|8200/3|8201/2|8201/3|8202/0|8204/0|8210/0|8210/2|8210/3|8211/0|8211/3|8212/0|8213/0|8213/3|8214/3|8215/3|8220/0|8220/3|8221/0|8221/3|8230/2|8230/3|8231/3|8240/1|8240/3|8240/6|8241/3|8242/1|8242/3|8243/3|8244/3|8245/1|8245/3|8246/3|8246/6|8247/3|8248/1|8249/3|8249/6|8250/1|8250/2|8250/3|8251/0|8251/3|8252/3|8253/3|8254/3|8255/3|8256/3|8257/3|8260/0|8260/3|8261/0|8261/2|8261/3|8262/3|8263/0|8263/2|8263/3|8264/0|8265/3|8270/0|8270/3|8271/0|8272/0|8272/3|8280/0|8280/3|8281/0|8281/3|8290/0|8290/3|8300/0|8300/3|8310/0|8310/3|8310/6|8311/1|8311/3|8311/6|8312/3|8313/0|8313/1|8313/3|8314/3|8315/3|8316/3|8317/3|8318/3|8319/3|8320/3|8321/0|8322/0|8322/3|8323/0|8323/3|8324/0|8325/0|8330/0|8330/1|8330/3|8331/3|8332/3|8333/0|8333/3|8334/0|8335/3|8336/0|8337/3|8339/3|8340/3|8341/3|8342/3|8343/2|8343/3|8344/3|8345/3|8346/3|8347/3|8350/3|8360/1|8361/0|8370/0|8370/1|8370/3|8371/0|8372/0|8373/0|8374/0|8375/0|8380/0|8380/1|8380/2|8380/3|8380/6|8381/0|8381/1|8381/3|8382/3|8383/3|8384/3|8390/0|8390/3|8391/0|8392/0|8400/0|8400/1|8400/3|8401/0|8401/3|8402/0|8402/3|8403/0|8403/3|8404/0|8405/0|8406/0|8407/0|8407/3|8408/0|8408/1|8408/3|8409/0|8409/3|8410/0|8410/3|8413/3|8420/0|8420/3|8430/1|8430/3|8440/0|8440/3|8441/0|8441/2|8441/3|8441/6|8442/1|8443/0|8444/1|8450/0|8450/3|8451/1|8452/1|8452/3|8453/0|8453/2|8453/3|8454/0|8460/0|8460/2|8460/3|8461/0|8461/3|8461/6|8462/1|8463/1|8470/0|8470/2|8470/3|8471/0|8471/1|8471/3|8472/1|8473/1|8474/1|8474/3|8480/0|8480/1|8480/3|8480/6|8481/3|8482/3|8482/6|8490/3|8490/6|85|8500/2|8500/3|8500/6|8501/2|8501/3|8502/3|8503/0|8503/2|8503/3|8504/0|8504/2|8504/3|8505/0|8506/0|8507/2|8507/3|8508/3|8509/2|8509/3|8510/3|8512/3|8513/3|8514/3|8519/2|8520/2|8520/3|8521/1|8521/3|8522/1|8522/2|8522/3|8522/6|8523/3|8524/3|8525/3|8530/3|8540/3|8541/3|8542/3|8543/3|8550/0|8550/1|8550/3|8551/3|8552/3|8560/0|8560/3|8561/0|8562/3|8570/3|8571/3|8572/3|8573/3|8574/3|8575/3|8576/3|8580/0|8580/1|8580/3|8581/1|8581/3|8582/1|8582/3|8583/1|8583/3|8584/1|8584/3|8585/1|8585/3|8586/3|8587/0|8588/3|8589/3|8590/1|8591/1|8592/1|8593/1|8594/1|86|8600/0|8600/3|8601/0|8602/0|8610/0|8620/1|8620/3|8621/1|8622/1|8623/1|8630/0|8630/1|8630/3|8631/0|8631/1|8631/3|8632/1|8633/1|8634/1|8634/3|8640/1|8640/3|8641/0|8642/1|8650/0|8650/1|8650/3|8660/0|8670/0|8670/3|8671/0|8680/0|8680/1|8680/3|8681/1|8682/1|8683/0|8690/1|8691/1|8692/1|8693/1|8693/3|87|8700/0|8700/3|8710/3|8711/0|8711/3|8712/0|8713/0|8714/3|8720/0|8720/2|8720/3|8720/6|8721/3|8722/0|8722/3|8723/0|8723/3|8725/0|8726/0|8727/0|8728/0|8728/1|8728/3|8730/0|8730/3|8740/0|8740/3|8741/2|8741/3|8742/2|8742/3|8743/3|8744/3|8745/3|8746/3|8750/0|8760/0|8761/0|8761/1|8761/3|8762/1|8770/0|8770/3|8771/0|8771/3|8772/0|8772/3|8773/3|8774/3|8780/0|8780/3|8790/0|8800 Triple Quadrupole ICP-MS|8800/0|8800/3|8800/6|8800/9|8801/3|8801/6|8802/3|8803/3|8804/3|8804/6|8805/3|8806/3|8806/6|8810/0|8810/1|8810/3|8811/0|8811/1|8811/3|8812/0|8812/3|8813/0|8813/3|8814/3|8815/0|8815/1|8815/3|8820/0|8821/1|8822/1|8823/0|8824/0|8824/1|8825/0|8825/1|8825/3|8826/0|8827/1|8830/0|8830/1|8830/3|8831/0|8832/0|8832/3|8833/3|8834/1|8835/1|8836/1|8840/0|8840/3|8841/1|8842/0|8842/3|8850/0|8850/1|8850/3|8851/0|8851/3|8852/0|8852/3|8853/3|8854/0|8854/3|8855/3|8856/0|8857/0|8857/3|8858/3|8860/0|8861/0|8862/0|8870/0|8880/0|8881/0|8890/0|8890/1|8890/3|8891/0|8891/3|8892/0|8893/0|8894/0|8894/3|8895/0|8895/3|8896/3|8897/1|8898/1|8900/0|8900/3|8901/3|8902/3|8903/0|8904/0|8905/0|8910/3|8912/3|8920/3|8920/6|8921/3|8930/0|8930/3|8931/3|8932/0|8933/3|8934/3|8935/0|8935/1|8935/3|8936/0|8936/1|8936/3|8940/0|8940/3|8941/3|8950/3|8950/6|8951/3|8959/0|8959/1|8959/3|8960/1|8960/3|8963/3|8964/3|8965/0|8966/0|8967/0|8970/3|8971/3|8972/3|8973/3|8974/1|8975/1|8980/3|8981/3|8982/0|8982/3|8983/0|8983/3|8990/0|8990/1|8990/3|8991/3|8th|9|9-Ethyl 6-Mercaptopurine|90|9000/0|9000/1|9000/3|9010/0|9011/0|9012/0|9013/0|9014/0|9014/1|9014/3|9015/0|9015/1|9015/3|9016/0|9020/0|9020/1|9020/3|9030/0|9040/0|9040/3|9041/3|9042/3|9043/3|9044/3|9045/3|9050/0|9050/3|9051/0|9051/3|9052/0|9052/3|9053/3|9054/0|9055/0|9055/1|9060/3|9061/3|9062/3|9063/3|9064/2|9064/3|9065/3|9070/3|9071/3|9072/3|9073/1|9080/0|9080/1|9080/3|9081/3|9082/3|9083/3|9084/0|9084/3|9085/3|9086/3|9090/0|9090/3|9091/1|9100/0|9100/1|9100/3|9101/3|9102/3|9103/0|9104/1|9105/3|9110/0|9110/1|9110/3|9120/0|9120/3|9121/0|9122/0|9123/0|9124/3|9125/0|9130/0|9130/1|9130/3|9131/0|9132/0|9133/1|9133/3|9135/1|9136/1|9137/3|9140/3|9141/0|9142/0|9150/0|9150/1|9150/3|9160/0|9161/0|9161/1|9170/0|9170/3|9171/0|9172/0|9173/0|9174/0|9174/1|9175/0|9180/0|9180/3|9180/6|9181/3|9182/3|9183/3|9184/3|9185/3|9186/3|9187/3|9191/0|9192/3|9193/3|9194/3|9195/3|9200/0|9200/1|9210/0|9210/1|9220/0|9220/1|9220/3|9221/0|9221/3|9230/0|9230/3|9231/3|9240/3|9241/0|9242/3|9243/3|9250/1|9250/3|9251/1|9251/3|9252/0|9252/3|9260/3|9261/3|9262/0|9270/0|9270/1|9270/3|9271/0|9272/0|9273/0|9274/0|9275/0|9280/0|9281/0|9282/0|9290/0|9290/3|9300/0|9301/0|9302/0|9302/3|9310/0|9310/3|9311/0|9312/0|9320/0|9321/0|9322/0|9330/0|9330/3|9340/0|9341/1|9341/3|9342/3|9350/1|9351/1|9352/1|9360/1|9361/1|9362/3|9363/0|9364/3|9365/3|9370/3|9371/3|9372/3|9373/0|9380/3|9381/3|9382/3|9383/1|9384/1|9385/3|9390/0|9390/1|9390/3|9391/3|9392/3|9393/3|9394/1|9395/3|9396/3|9400/3|9401/3|9410/3|9411/3|9412/1|9413/0|9420/3|9421/1|9423/3|9424/3|9425/3|9430/3|9431/1|9432/1|9440/3|9440/6|9441/3|9442/1|9442/3|9444/1|9445/3|9450/3|9451/3|9460/3|9470/3|9471/3|9472/3|9473/3|9474/3|9475/3|9476/3|9477/3|9478/3|9480/3|9490/0|9490/3|9491/0|9492/0|9493/0|9500/3|9501/0|9501/3|9502/0|9502/3|9503/3|9504/3|9505/1|9505/3|9506/1|9507/0|9508/3|9509/1|9510/0|9510/3|9511/3|9512/3|9513/3|9514/1|9520/3|9521/3|9522/3|9523/3|9530/0|9530/1|9530/3|9531/0|9532/0|9533/0|9534/0|9535/0|9537/0|9538/1|9538/3|9539/1|9539/3|9540/0|9540/1|9540/3|9541/0|9542/3|9550/0|9560/0|9560/1|9560/3|9561/3|9562/0|9570/0|9571/0|9571/3|9580/0|9580/3|9581/3|9582/0|9590/3|9591/3|9596/3|9597/3|9650/3|9651/3|9652/3|9653/3|9654/3|9655/3|9659/3|9661/3|9662/3|9663/3|9664/3|9665/3|9667/3|9670/3|9671/3|9673/3|9675/3|9678/3|9679/3|9680/3|9684/3|9687/3|9688/3|9689/3|9690/3|9691/3|9695/3|9698/3|9699/3|9700/3|9701/3|9702/3|9705/3|9708/3|9709/3|9712/3|9714/3|9716/3|9717/3|9718/3|9719/3|9724/3|9725/3|9726/3|9727/3|9728/3|9729/3|9731/3|9732/3|9733/3|9734/3|9735/3|9737/3|9738/3|9740/1|9740/3|9741/1|9741/3|9742/3|9750/3|9751/1|9751/3|9752/1|9753/1|9754/3|9755/3|9756/3|9757/3|9758/3|9759/3|9760/3|9761/3|9762/3|9764/3|9765/1|9766/1|9767/1|9768/1|9769/1|9800/3|9801/3|9805/3|9806/3|9807/3|9808/3|9809/3|9811/3|9812/3|9813/3|9814/3|9815/3|9816/3|9817/3|9818/3|9820/3|9823/3|9826/3|9827/3|9831/3|9832/3|9833/3|9834/3|9835/3|9836/3|9837/3|9840/3|9860/3|9861/3|9863/3|9865/3|9866/3|9867/3|9869/3|9870/3|9871/3|9872/3|9873/3|9874/3|9875/3|9876/3|9891/3|9895/3|9896/3|9897/3|9898/1|9898/3|99|9910/3|9911/3|9920/3|9930/3|9931/3|9940/3|9945/3|9946/3|9948/3|9950/3|9960/3|9961/3|9962/3|9963/3|9964/3|9965/3|9966/3|9967/3|9970/1|9971/1|9971/3|9975/3|9980/3|9982/3|9983/3|9984/3|9985/3|9986/3|9987/3|9989/3|9991/3|9992/3|99mTc Bone Scintigraphy|9H-Purine-6Thio-98D|A|A081105|A081801|A2A Receptor Antagonist EOS100850|A5|A6|ACQUITY UPLC|ACQUITY UPLC H-Class|ACQUITY UPLC H-Class Bio|ACQUITY UPLC I-Class|ACQUITY UPLC Systems with 2D Technology|ACTH-producing tumor|ADF|ADH-1|AE37 Peptide/GM-CSF Vaccine|AEE788|AIN III|AJ-Adjuvant Therapy|AJCC v6 Stage|AJCC v7 Stage|AJCC v8 Stage|AKR1C3-activated Prodrug OBI-3424|AKT 1/2 Inhibitor BAY1125976|AKT Inhibitor ARQ 092|ALK Inhibitor|ALK Inhibitor ASP3026|ALK Inhibitor PLB 1003|ALK Inhibitor RO5424802|ALK Inhibitor TAE684|ALK Inhibitor WX-0593|ALK positive large B-cell lymphoma|ALK-2 Inhibitor TP-0184|ALK-FAK Inhibitor CEP-37440|ALK-Positive Large B-Cell Lymphoma|ALK/FAK/Pyk2 Inhibitor CT-707|ALK/ROS1/Met Inhibitor TQ-B3101|ALK/TRK Inhibitor TSR-011|ALK/c-Met Inhibitor  TQ-B3139|AML M6|APC8015F|APE1/Ref-1 Redox Inhibitor APX3330|API 100|API 100LC|API 150EX|API 150EX Prep|API 165|API 2000|API 300|API 3000|API 3200|API 350|API 365|API 4000|API 5000|API-US|AQUA|AR Antagonist BMS-641988|ARC Fusion Protein SL-279252|ASCAT2|ASP4132|ATAC-Seq|ATM Inhibitor M 3541|ATM Kinase Inhibitor AZD0156|ATM Kinase Inhibitor AZD1390|ATR Inhibitor RP-3500|ATR Kinase Inhibitor BAY1895344|ATR Kinase Inhibitor M1774|ATR Kinase Inhibitor M6620|ATR Kinase Inhibitor VX-803|AXIMA Assurance Linear MALDI-TOF|AXIMA CFR MALDI-TOF|AXIMA Confidence MALDI-TOF|AXIMA Performance MALDI-TOF/TOF|AXIMA-CFR plus|AXIMA-QIT|AXL Inhibitor DS-1205c|AXL Inhibitor SLC-391|AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M|AXL/ FLT3/VEGFR2 Inhibitor KC1036|Abagovomab|Abarelix|Abdomen|Abdomen, NOS|Abdomen, total|Abdominal (Mesenteric) Fibromatosis|Abdominal Distension|Abdominal Infection|Abdominal Pain|Abdominal Soft Tissue Necrosis|Abdominal Wall|Abdominal desmoid|Abdominal esophagus|Abdominal fibromatosis|Abdomino-perineal Resection of Rectum|Abducens Nerve Disorder|Abemaciclib|Abemaciclib Mesylate|Abexinostat|Abexinostat Tosylate|Abiraterone|Abiraterone Acetate|Abituzumab|Ablation, Cryo|Ablation, Ethanol Injection|Ablation, Microwave|Ablation, NOS|Ablation, Radiofrequency|Ablation, Radiosurgical|Abnormal|Abnormal Glucose Level|Absent|Absolute quantitation analysis|Acai Berry Juice|Acalabrutinib|Acalisib|Accela PDA|Acceptable treatment for TCGA tumor|Accessory Nerve Disorder|Accessory sinus, NOS|Accessory sinuses|Accidental building fire smoke|Accidental fire smoke, NOS|Accidental fire smoke, grass|Accidental forest fire smoke|Accidental vehicle fire smoke|Aceglatone|Acetabulum|Acetate|Acetylcysteine|Acetylome|Achromic nevus|Acidophil adenocarcinoma|Acidophil adenoma|Acidophil carcinoma|Acidosis|Acinar Cell Adenoma|Acinar Cell Carcinoma|Acinar Cell Neoplasm|Acinar Cell Neoplasms|Acinar adenocarcinoma|Acinar adenocarcinoma, sarcomatoid|Acinar adenoma|Acinar carcinoma|Acinar cell adenoma|Acinar cell carcinoma|Acinar cell cystadenocarcinoma|Acinar cell tumor|Acinic cell adenocarcinoma|Acinic cell adenoma|Acinic cell tumor|Acitretin|Acivicin|Aclacinomycin B|Aclarubicin|Acodazole|Acodazole Hydrochloride|Acolbifene Hydrochloride|Acoustic Nerve Disorder NOS|Acoustic Schwannoma|Acoustic nerve|Acoustic neuroma|Acquired Cystic Disease-Associated Renal Cell Carcinoma|Acquired Progressive Lymphangioma|Acquired cystic disease-associated renal cell carcinoma (RCC)|Acquired tufted hemangioma|Acquity SQD|Acquity TQD|Acquity UPLC FLR|Acquity UPLC PDA|Acral Lentiginous Melanoma|Acral lentiginous melanoma, malignant|Acridine|Acridine Carboxamide|Acronine|Actinium Ac 225 Lintuzumab|Actinium Ac 225-FPI-1434|Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591|Actinomycin C2|Actinomycin C3|Actinomycin F1|Activated Partial Thromboplastin Time Prolonged|Activin Type 2B Receptor Fc Fusion Protein STM 434|Acute Basophilic Leukemia|Acute Bilineal Leukemia|Acute Biphenotypic Leukemia|Acute Coronary Syndrome|Acute Erythroid Leukemia|Acute Kidney Injury|Acute Leukemia|Acute Leukemia of Ambiguous Lineage (ALAL)|Acute Lymphoblastic Leukemia|Acute Megakaryoblastic Leukemia|Acute Monoblastic Leukemia|Acute Monoblastic and Monocytic Leukemia|Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1|Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia Not Otherwise Specified|Acute Myeloid Leukemia with Maturation|Acute Myeloid Leukemia with Minimal Differentiation|Acute Myeloid Leukemia with Multilineage Dysplasia|Acute Myeloid Leukemia with Mutated CEBPA|Acute Myeloid Leukemia with Mutated NPM1|Acute Myeloid Leukemia with Myelodysplasia-Related Changes|Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11|Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11|Acute Myeloid Leukemia with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM|Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11|Acute Myeloid Leukemia with t(6;9) (p23;q34.1); DEK-NUP214|Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A|Acute Myeloid Leukemia without Maturation|Acute Myelomonocytic Leukemia|Acute Myelomonocytic Leukemia with Abnormal Eosinophils|Acute Panmyelosis with Myelofibrosis|Acute Promyelocytic Leukemia with PML-RARA|Acute Renal Failure|Acute Undifferentiated Leukemia|Acute basophilic leukaemia|Acute bilineal leukemia|Acute biphenotypic leukemia|Acute erythremia|Acute erythremic myelosis|Acute erythroid leukaemia|Acute granulocytic leukemia|Acute leukemia, Burkitt type|Acute leukemia, NOS|Acute lymphatic leukemia|Acute lymphoblastic leukemia (ALL)|Acute lymphoblastic leukemia, L2 type, NOS|Acute lymphoblastic leukemia, NOS|Acute lymphoblastic leukemia, mature B-cell type|Acute lymphoblastic leukemia, precursor cell type|Acute lymphoblastic leukemia-lymphoma, NOS|Acute lymphocytic leukemia|Acute lymphoid leukemia|Acute megakaryoblastic leukaemia|Acute mixed lineage leukemia|Acute monoblastic and monocytic leukemia|Acute monoblastic leukemia|Acute monocytic leukemia|Acute myeloblastic leukemia|Acute myelocytic leukemia|Acute myelofibrosis|Acute myelogenous leukemia|Acute myeloid leukaemia, t(8;21)(q22;q22)|Acute myeloid leukemia (AML)|Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1|Acute myeloid leukemia with abnormal marrow eosinophils (includes all variants)|Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1|Acute myeloid leukemia with maturation|Acute myeloid leukemia with multilineage dysplasia|Acute myeloid leukemia with mutated CEBPA|Acute myeloid leukemia with mutated NPM1|Acute myeloid leukemia with myelodysplasia-related changes|Acute myeloid leukemia with prior myelodysplastic syndrome|Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214|Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1|Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL|Acute myeloid leukemia without maturation|Acute myeloid leukemia without prior myelodysplastic syndrome|Acute myeloid leukemia, AML1(CBF-alpha)/ETO|Acute myeloid leukemia, CBF-beta/MYH11|Acute myeloid leukemia, M6 type|Acute myeloid leukemia, MLL|Acute myeloid leukemia, NOS|Acute myeloid leukemia, PML/RAR-alpha|Acute myeloid leukemia, inv(16)(p13;q22)|Acute myeloid leukemia, minimal differentiation|Acute myeloid leukemia, t(15:17)(g22;q11-12)|Acute myeloid leukemia, t(16;16)(p 13;q 11)|Acute myelomonocytic leukemia|Acute myelomonocytic leukemia with abnormal eosinophils|Acute myelosclerosis, NOS|Acute myloid leukemia, 11q23 abnormalities|Acute non-lymphocytic leukemia|Acute panmyelosis with myelofibrosis|Acute panmyelosis, NOS|Acute progressive histiocytosis X|Acute promyelocytic leukaemia, PML-RAR-alpha|Acute promyelocytic leukaemia, t(15;17)(q22;q11-12)|Acute promyelocytic leukemia, NOS|Acyclic Nucleoside Phosphonate Prodrug ABI-1968|Ad-RTS-hIL-12|Adagloxad Simolenin|Adamantinoma|Adamantinoma of long bones|Adamantinoma, NOS|Adamantinoma, malignant|Adamantinomatous Craniopharyngioma|Adavosertib|Additional - New Primary|Additional Metastatic|Adecatumumab|Adenoacanthoma|Adenoameloblastoma|Adenocarcinoid tumor|Adenocarcinoma|Adenocarcinoma In Situ|Adenocarcinoma In Situ in Adenomatous Polyp|Adenocarcinoma In Situ in Tubular Adenoma|Adenocarcinoma In Situ in Tubulovillous Adenoma|Adenocarcinoma In Situ in Villous Adenoma|Adenocarcinoma In Situ in a Polyp|Adenocarcinoma admixed with neuroendocrine carcinoma|Adenocarcinoma combined with other types of carcinoma|Adenocarcinoma in Adenomatous Polyp|Adenocarcinoma in Adenomatous Polyposis Coli|Adenocarcinoma in Multiple Adenomatous Polyps|Adenocarcinoma in Tubular Adenoma|Adenocarcinoma in Tubulovillous Adenoma|Adenocarcinoma in Villous Adenoma|Adenocarcinoma in a polyp, NOS|Adenocarcinoma in adenomatous polyp|Adenocarcinoma in adenomatous polyposis coli|Adenocarcinoma in multiple adenomatous polyps|Adenocarcinoma in polypoid adenoma|Adenocarcinoma in situ in a polyp, NOS|Adenocarcinoma in situ in adenomatous polyp|Adenocarcinoma in situ in polypoid adenoma|Adenocarcinoma in situ in tubular adenoma|Adenocarcinoma in situ in tubulovillous adenoma|Adenocarcinoma in situ in villous adenoma|Adenocarcinoma in situ, NOS|Adenocarcinoma in situ, mucinous|Adenocarcinoma in situ, non-mucinous|Adenocarcinoma in tubolovillous adenoma|Adenocarcinoma in tubular adenoma|Adenocarcinoma in villous adenoma|Adenocarcinoma of anal ducts|Adenocarcinoma of anal glands|Adenocarcinoma of rete ovarii|Adenocarcinoma with Apocrine Metaplasia|Adenocarcinoma with Cartilaginous Metaplasia|Adenocarcinoma with Cartilaginous and Osseous Metaplasia|Adenocarcinoma with Neuroendocrine Differentiation|Adenocarcinoma with Osseous Metaplasia|Adenocarcinoma with Spindle Cell Metaplasia|Adenocarcinoma with Squamous Metaplasia|Adenocarcinoma with apocrine metaplasia|Adenocarcinoma with cartilaginous and osseous metaplasia|Adenocarcinoma with cartilaginous metaplasia|Adenocarcinoma with mixed subtypes|Adenocarcinoma with neuroendocrine differentiation|Adenocarcinoma with osseous metaplasia|Adenocarcinoma with spindle cell metaplasia|Adenocarcinoma with squamous metaplasia|Adenocarcinoma, Endocervical Type|Adenocarcinoma, NOS|Adenocarcinoma, cribriform comedo-type|Adenocarcinoma, cylindroid|Adenocarcinoma, diffuse type|Adenocarcinoma, endocervical type|Adenocarcinoma, intestinal type|Adenocarcinoma, metastatic, NOS|Adenocarcinoma, pancreatobiliary type|Adenocystic carcinoma|Adenofibroma, NOS|Adenoid|Adenoid Cystic Carcinoma|Adenoid basal carcinoma|Adenoid cystic carcinoma|Adenolipoma|Adenolymphoma|Adenoma|Adenoma of nipple|Adenoma, NOS|Adenomas and Adenocarcinomas|Adenomatoid Odontogenic Tumor|Adenomatoid Tumor|Adenomatoid odontogenic tumor|Adenomatoid tumor, NOS|Adenomatosis, NOS|Adenomatous Polyp|Adenomatous Polyposis Coli|Adenomatous polyp, NOS|Adenomatous polyposis coli|Adenomyoepithelioma|Adenomyoepithelioma with carcinoma|Adenomyoma|Adenosarcoma|Adenosine A2A Receptor Antagonist AZD4635|Adenosine A2A Receptor Antagonist CS3005|Adenosine A2A Receptor Antagonist NIR178|Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999|Adenosine A2A/A2B Receptor Antagonist AB928|Adenosine A2B Receptor Antagonist PBF-1129|Adenosis (Atypical Adenomatous Hyperplasia)|Adenosquamous Carcinoma|Adenosquamous carcinoma|Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201|Adenoviral Brachyury Vaccine ETBX-051|Adenoviral Cancer Vaccine PF-06936308|Adenoviral MUC1 Vaccine ETBX-061|Adenoviral PSA Vaccine ETBX-071|Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001|Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP|Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901|Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE|Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918|Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931|Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3|Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001|Aderbasib|Adherent Cell Line|Adipose|Adjacent (< or = 2cm)|Adjuvant|Administrative Compliance|Adnexal Carcinoma|Adnexal and Skin Appendage Neoplasms|Adnexal carcinoma|Adnexal tumor, benign|Adopted Brother|Adopted Daughter|Adopted Sister|Adopted Son|Adoptive Brother|Adoptive Father|Adoptive Mother|Adoptive Sister|Adrenal|Adrenal Cortex Adenoma|Adrenal Cortex Carcinoma|Adrenal Cortex Clear Cell Adenoma|Adrenal Cortex Compact Cell Adenoma|Adrenal Cortex Glomerulosa Cell Adenoma|Adrenal Cortex Mixed Cell Adenoma|Adrenal Cortex Neoplasm|Adrenal Gland|Adrenal Gland Cancer|Adrenal Gland Myelolipoma|Adrenal Gland Pheochromocytoma|Adrenal Insufficiency|Adrenal Rest Tumor|Adrenal cortical adenocarcinoma|Adrenal cortical adenoma, NOS|Adrenal cortical adenoma, clear cell|Adrenal cortical adenoma, compact cell|Adrenal cortical adenoma, glomerulosa cell|Adrenal cortical adenoma, mixed cell|Adrenal cortical adenoma, pigmented|Adrenal cortical carcinoma|Adrenal cortical tumor, NOS|Adrenal cortical tumor, benign|Adrenal cortical tumor, malignant|Adrenal gland|Adrenal gland, NOS|Adrenal medullary paraganglioma|Adrenal medullary paraganglioma, malignant|Adrenal rest tumor|Adrenocortical Carcinoma|Adrenocortical Insufficiency|Adult Cystic Nephroma|Adult Cystic Teratoma|Adult Pleomorphic Rhabdomyosarcoma|Adult Respiratory Distress Syndrome|Adult T-Cell Leukemia/Lymphoma|Adult T-cell leukemia|Adult T-cell leukemia/lymphoma (HTLV-1 positive) (includes all variants)|Adult T-cell lymphoma|Adult T-cell lymphoma/leukemia|Adult Teratoma|Adult Type Granulosa Cell Tumor|Adult cystic teratoma|Adult granulosa cell tumor|Adult rhabdomyoma|Adult teratoma, NOS|Adverse|Adverse Event|Aerosol Gemcitabine|Aerosolized Aldesleukin|Aerosolized Liposomal Rubitecan|Afatinib|Afatinib Dimaleate|Affymetrix SNP 6.0|Afghanistan|Afimoxifene|After 60 Minutes|Afuresertib|Agatolimod Sodium|Agerafenib|Aggregated Somatic Mutation|Aggressive NK-Cell Leukemia|Aggressive NK-cell leukaemia|Aggressive Osteoblastoma|Aggressive Systemic Mastocytosis|Aggressive angiomyxoma|Aggressive digital papillary adenoma|Aggressive fibromatosis|Aggressive osteoblastoma|Aggressive systemic mastocytosis|Agilent|Agitation|Aglatimagene Besadenovec|Agnogenic myeloid metaplasia|Agonistic Anti-CD40 Monoclonal Antibody ADC-1013|Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949|Agonistic Anti-OX40 Monoclonal Antibody MEDI6469|Aircraft smoke|Akathisia|Akt Inhibitor LY2780301|Akt Inhibitor MK2206|Akt Inhibitor SR13668|Akt/ERK Inhibitor ONC201|Alacizumab Pegol|Alanine Aminotransferase Increased|Alanosine|Albania|Albumin-binding Cisplatin Prodrug BTP-114|Alcohol Consumption|Alcohol Intolerance|Alcoholic Liver Disease|Aldesleukin|Aldoxorubicin|Alectinib|Alefacept|Alemtuzumab|Alestramustine|Aleukemic Chronic Lymphocytic Leukemia|Aleukemic Leukemia|Aleukemic Lymphoid Leukemia|Aleukemic granulocytic leukemia|Aleukemic leukemia, NOS|Aleukemic lymphatic leukemia|Aleukemic lymphocytic leukemia|Aleukemic lymphoid leukemia|Aleukemic monocytic leukemia|Aleukemic myelogenous leukemia|Aleukemic myeloid leukemia|Alflutinib Mesylate|Algenpantucel-L|Algeria|Aligned Reads|Aligned Reads Index|Aliquot Ensemble Somatic Variant Merging and Masking|Alisertib|Alitretinoin|Alive|Alkaline Phosphatase Increased|Alkalosis|Alkotinib|Alkylating Agent-Related Acute Myeloid Leukemia|Alkylating Agent-Related Myelodysplastic Syndrome|Allele-specific Copy Number Segment|Allergic Reaction|Allergic Rhinitis|Allergies|Allergy, Animal, NOS|Allergy, Ant|Allergy, Bee|Allergy, Cat|Allergy, Dairy or Lactose|Allergy, Dog|Allergy, Eggs|Allergy, Food, NOS|Allergy, Fruit|Allergy, Meat|Allergy, Mold or Dust|Allergy, Nuts|Allergy, Processed Foods|Allergy, Seafood|Allergy, Wasp|Allodepleted T Cell Immunotherapeutic ATIR101|Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715|Allogeneic Anti-BCMA-CAR T-cells PBCAR269A|Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells|Allogeneic Anti-CD19 CAR T-cells ALLO-501A|Allogeneic Anti-CD19 Universal CAR-T Cells CTA101|Allogeneic Anti-CD19-CAR T-cells PBCAR0191|Allogeneic Anti-CD20 CAR T-cells LUCAR-20S|Allogeneic Anti-CD20-CAR T-cells PBCAR20A|Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22|Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100|Allogeneic CD56-positive CD3-negative Natural Killer Cells CYNK-001|Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001|Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120|Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130|Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A|Allogeneic Cellular Vaccine 1650-G|Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM|Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine|Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine|Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo|Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo|Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2|Allogeneic Irradiated Melanoma Cell Vaccine CSF470|Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307|Allogeneic Melanoma Vaccine AGI-101H|Allogeneic Natural Killer Cell Line MG4101|Allogeneic Natural Killer Cell Line NK-92|Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01|Allogeneic Renal Cell Carcinoma Vaccine MGN1601|Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19|Allosteric ErbB Inhibitor BDTX-189|Allovectin-7|Allprep FFPE DNA|Allprep RNA Extraction|Almurtide|Alobresib|Alofanib|Alopecia|Alpelisib|Alpha Galactosylceramide|Alpha Heavy Chain Disease|Alpha V Beta 1 Inhibitor ATN-161|Alpha V Beta 8 Antagonist PF-06940434|Alpha cell tumor, NOS|Alpha cell tumor, malignant|Alpha heavy chain disease|Alpha-1 Antitrypsin|Alpha-1 Antitrypsin Deficiency|Alpha-Gal AGI-134|Alpha-Glucosidase Inhibitor|Alpha-Thioguanine Deoxyriboside|Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H|Alpha-tocopheryloxyacetic Acid|Alsevalimab|Altered Mental Status|Alternate sample pipeline|Altiratinib|Altretamine|Alveolar Adenoma|Alveolar Rhabdomyosarcoma|Alveolar Ridge|Alveolar Soft Part Sarcoma|Alveolar adenocarcinoma|Alveolar adenoma|Alveolar carcinoma|Alveolar cell carcinoma|Alveolar rhabdomyosarcoma|Alveolar soft part sarcoma|Alvespimycin|Alvespimycin Hydrochloride|Alvocidib|Alvocidib Hydrochloride|Alvocidib Prodrug TP-1287|Amatuximab|Ambamustine|Ambazone|Amber|Amblyomin-X|Amcasertib|Amelanotic Melanoma|Amelanotic melanoma|Ameloblastic Carcinoma|Ameloblastic Fibro-Odontoma|Ameloblastic Fibrodentinoma|Ameloblastic Fibroma|Ameloblastic Fibrosarcoma|Ameloblastic carcinoma|Ameloblastic fibro-odontoma|Ameloblastic fibro-odontosarcoma|Ameloblastic fibrodentinoma|Ameloblastic fibrodentinosarcoma|Ameloblastic fibroma|Ameloblastic fibrosarcoma|Ameloblastic odontosarcoma|Ameloblastic sarcoma|Ameloblastoma|Ameloblastoma, NOS|Ameloblastoma, malignant|American Indian or Alaska Native|Ametantrone|Amifostine|Amino Acid Injection|Aminocamptothecin|Aminocamptothecin Colloidal Dispersion|Aminoflavone Prodrug AFP464|Aminopterin|Aminopterin Sodium|AminoxyTMT|Amivantamab|Amnesia|Amniotic Fluid|Amolimogene Bepiplasmid|Amonafide L-Malate|Ampulla Of Vater|Ampulla of Vater|Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with High Grade Dysplasia|Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with Low Grade Dysplasia|Amrubicin|Amrubicin Hydrochloride|Amsacrine|Amsacrine Lactate|Amsilarotene|Amustaline|Amustaline Dihydrochloride|Amuvatinib|Amuvatinib Hydrochloride|Anakinra|Anal Canal|Anal Canal Cloacogenic Carcinoma|Anal Cancer (all types)|Anal Fistula|Anal Glands Adenocarcinoma|Anal Hemorrhage|Anal Intraepithelial Neoplasia 3|Anal Mucositis|Anal Necrosis|Anal Pain|Anal Sphincter|Anal Stenosis|Anal Ulcer|Anal canal|Anal intraepithelial neoplasia, grade III|Anal intraepithelial neoplasia, low grade|Analysis Metadata|Anaphylaxis|Anaplastic (Malignant) Meningioma|Anaplastic Astrocytoma|Anaplastic Astrocytoma, IDH-Mutant|Anaplastic Astrocytoma, IDH-Wildtype|Anaplastic Ependymoma|Anaplastic Ganglioglioma|Anaplastic Large Cell Lymphoma|Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Anaplastic Lymphoma|Anaplastic Medulloblastoma|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted|Anaplastic Pleomorphic Xanthoastrocytoma|Anaplastic astrocytoma, IDH-mutant|Anaplastic astrocytoma, IDH-wildtype|Anaplastic large B-cell lymphoma|Anaplastic large cell lymphoma, ALK negative|Anaplastic large cell lymphoma, ALK positive|Anaplastic large cell lymphoma, CD30+|Anaplastic large cell lymphoma, NOS|Anaplastic large cell lymphoma, T cell and Null cell type|Anaplastic medulloblastoma|Anaplastic oligoastrocytoma|Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted|Anaplastic pleomorphic xanthroastrocytoma|Anastrozole|Anaxirone|Ancient schwannoma|Ancillary Treatment|Ancitabine|Ancitabine Hydrochloride|Andecaliximab|Andorra|Androblastoma, NOS|Androblastoma, benign|Androblastoma, malignant|Androgen Antagonist APC-100|Androgen Deprivation Therapy (ADT)|Androgen Receptor Antagonist BAY 1161116|Androgen Receptor Antagonist SHR3680|Androgen Receptor Antagonist TAS3681|Androgen Receptor Antagonist TRC253|Androgen Receptor Antisense Oligonucleotide AZD5312|Androgen Receptor Antisense Oligonucleotide EZN-4176|Androgen Receptor Degrader ARV-110|Androgen Receptor Degrader CC-94676|Androgen Receptor Downregulator AZD3514|Androgen Receptor Inhibitor EPI-7386|Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118|Androgen Receptor/Glucocorticoid Receptor  Antagonist CB-03-10|Andrographolide|Androstane Steroid HE3235|Anemia|Anetumab Ravtansine|Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241|Angioblastic meningioma|Angioblastoma|Angiocentric Glioma|Angiocentric Immunoproliferative Lesion|Angiocentric T-cell lymphoma|Angiocentric glioma|Angiocentric immunoproliferative lesion|Angioendothelioma|Angioendotheliomatosis|Angiofibroma|Angiofibroma, NOS|Angiogenesis Inhibitor GT-111|Angiogenesis Inhibitor JI-101|Angiogenesis/Heparanase Inhibitor PG545|Angioimmunoblastic T-Cell Lymphoma|Angioimmunoblastic T-cell lymphoma|Angioimmunoblastic lymphadenopathy|Angioimmunoblastic lymphoma|Angiokeratoma|Angioleiomyoma|Angiolipoma|Angiolipoma, NOS|Angioma, NOS|Angiomatoid Fibrous Histiocytoma|Angiomatoid fibrous histiocytoma|Angiomatous Meningioma|Angiomatous meningioma|Angiomyofibroblastoma|Angiomyolipoma|Angiomyoma|Angiomyosarcoma|Angiomyxoma|Angiopoietin-2-specific Fusion Protein PF-04856884|Angiosarcoma|Angiotropic lymphoma|Angola|Anguilla|Anhydrous Enol-oxaloacetate|Anhydrovinblastine|Aniline Mustard|Ankle|Ankle Fracture|Anlotinib Hydrochloride|Annamycin|Annamycin Liposomal|Annonaceous Acetogenins|Annotated Somatic Mutation|Anopheles gambiae|Anorectal Infection|Anorectum|Anorexia|Anorgasmia|Ansamitomicin P-3|Antacids|Antecubital Fossa|Anterior 2/3 of tongue, NOS|Anterior Resection of Rectum|Anterior Surface of the Epiglottis|Anterior Wall of the Nasopharynx|Anterior floor of mouth|Anterior mediastinum|Anterior surface of epiglottis|Anterior wall of bladder|Anterior wall of nasopharynx|Anthramycin|Anthrapyrazole|Anti c-KIT Antibody-drug Conjugate LOP628|Anti-5T4 Antibody-Drug Conjugate PF-06263507|Anti-5T4 Antibody-drug Conjugate ASN004|Anti-5T4 Antibody-drug Conjugate SYD1875|Anti-A33 Monoclonal Antibody KRN330|Anti-A5B1 Integrin Monoclonal Antibody PF-04605412|Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087|Anti-AG7 Antibody Drug Conjugate AbGn-107|Anti-AGS-16 Monoclonal Antibody AGS-16M18|Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME|Anti-AGS-8 Monoclonal Antibody AGS-8M4|Anti-ANG2 Monoclonal Antibody MEDI-3617|Anti-APRIL Monoclonal Antibody BION-1301|Anti-AXL Fusion Protein AVB-S6-500|Anti-AXL/PBD Antibody-drug Conjugate ADCT-601|Anti-B7-H3 Antibody DS-5573a|Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a|Anti-B7-H4 Monoclonal Antibody FPA150|Anti-B7H3 Antibody-drug Conjugate MGC018|Anti-BCMA Antibody SEA-BCMA|Anti-BCMA Antibody-drug Conjugate AMG 224|Anti-BCMA Antibody-drug Conjugate CC-99712|Anti-BCMA Antibody-drug Conjugate GSK2857916|Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA|Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459|Anti-BCMA/CD3 BiTE Antibody AMG 420|Anti-BCMA/CD3 BiTE Antibody AMG 701|Anti-BCMA/CD3 BiTE Antibody REGN5458|Anti-BCMA/PBD ADC MEDI2228|Anti-BTLA Monoclonal Antibody TAB004|Anti-BTN3A Agonistic Monoclonal Antibody ICT01|Anti-C-met Monoclonal Antibody SAIT301|Anti-C4.4a Antibody-Drug Conjugate BAY1129980|Anti-C5aR Monoclonal Antibody IPH5401|Anti-CA19-9 Monoclonal Antibody 5B1|Anti-CA6-DM4 Immunoconjugate SAR566658|Anti-CCR7 Antibody-drug Conjugate JBH492|Anti-CD117 Monoclonal Antibody JSP191|Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1|Anti-CD123 ADC IMGN632|Anti-CD123 Monoclonal Antibody CSL360|Anti-CD123 Monoclonal Antibody KHK2823|Anti-CD123 x Anti-CD3 Bispecific Antibody XmAb1404|Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A|Anti-CD123/CD3 BiTE Antibody SAR440234|Anti-CD123/CD3 Bispecific Antibody APVO436|Anti-CD123/CD3 Bispecific Antibody JNJ-63709178|Anti-CD137 Agonistic Monoclonal Antibody ADG106|Anti-CD137 Agonistic Monoclonal Antibody AGEN2373|Anti-CD137 Agonistic Monoclonal Antibody ATOR-1017|Anti-CD137 Agonistic Monoclonal Antibody CTX-471|Anti-CD137 Agonistic Monoclonal Antibody LVGN6051|Anti-CD157 Monoclonal Antibody MEN1112|Anti-CD166 Probody-drug Conjugate CX-2009|Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003|Anti-CD19 Antibody-drug Conjugate SGN-CD19B|Anti-CD19 Monoclonal Antibody DI-B4|Anti-CD19 Monoclonal Antibody MDX-1342|Anti-CD19 Monoclonal Antibody MEDI-551|Anti-CD19 Monoclonal Antibody XmAb5574|Anti-CD19 iCAR NK Cells|Anti-CD19-DM4 Immunoconjugate SAR3419|Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL|Anti-CD19/CD22 CAR NK Cells|Anti-CD19/CD3 BiTE Antibody AMG 562|Anti-CD19/CD3 Tetravalent Antibody AFM11|Anti-CD20 Monoclonal Antibody B001|Anti-CD20 Monoclonal Antibody BAT4306F|Anti-CD20 Monoclonal Antibody MIL62|Anti-CD20 Monoclonal Antibody PRO131921|Anti-CD20 Monoclonal Antibody SCT400|Anti-CD20 Monoclonal Antibody TL011|Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002|Anti-CD20-engineered Toxin Body MT-3724|Anti-CD20/Anti-CD3 Bispecific IgM Antibody IGM2323|Anti-CD20/CD3 Monoclonal Antibody REGN1979|Anti-CD20/CD3 Monoclonal Antibody XmAb13676|Anti-CD205 Antibody-drug Conjugate OBT076|Anti-CD22 ADC TRPH-222|Anti-CD22 Monoclonal Antibody-MMAE Conjugate DCDT2980S|Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A|Anti-CD25 Monoclonal Antibody RO7296682|Anti-CD25-PBD Antibody-drug Conjugate ADCT-301|Anti-CD26 Monoclonal Antibody YS110|Anti-CD27 Agonistic Monoclonal Antibody MK-5890|Anti-CD27L Antibody-Drug Conjugate AMG 172|Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1)|Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044|Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody JNJ-64007957|Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody PF-06863135|Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05|Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564|Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119|Anti-CD3/CD20 Bispecific Antibody GEN3013|Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424|Anti-CD3/CD7-Ricin Toxin A Immunotoxin|Anti-CD30 Monoclonal Antibody MDX-1401|Anti-CD30 Monoclonal Antibody XmAb2513|Anti-CD30/CD16A Monoclonal Antibody AFM13|Anti-CD30/DM1 Antibody-drug Conjugate F0002|Anti-CD32B Monoclonal Antibody BI-1206|Anti-CD33 Antibody-drug Conjugate IMGN779|Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564|Anti-CD33 Monoclonal Antibody BI 836858|Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633|Anti-CD33/CD3 BiTE Antibody AMG 330|Anti-CD33/CD3 BiTE Antibody AMG 673|Anti-CD33/CD3 Bispecific Antibody GEM 333|Anti-CD33/CD3 Bispecific Antibody JNJ-67571244|Anti-CD352 Antibody-drug Conjugate SGN-CD352A|Anti-CD37 Antibody-Drug Conjugate IMGN529|Anti-CD37 Bispecific Monoclonal Antibody GEN3009|Anti-CD37 MMAE Antibody-drug Conjugate AGS67E|Anti-CD37 Monoclonal Antibody BI 836826|Anti-CD38 Antibody-drug Conjugate STI-6129|Anti-CD38 Monoclonal Antibody MOR03087|Anti-CD38 Monoclonal Antibody SAR442085|Anti-CD38 Monoclonal Antibody TAK-079|Anti-CD38-targeted IgG4-attenuated IFNa TAK-573|Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257|Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342|Anti-CD39 Monoclonal Antibody SRF617|Anti-CD39 Monoclonal Antibody TTX-030|Anti-CD40 Agonist Monoclonal Antibody ABBV-927|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Anti-CD40 Monoclonal Antibody Chi Lob 7/4|Anti-CD40 Monoclonal Antibody SEA-CD40|Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042|Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428|Anti-CD40L Fc-Fusion Protein BMS-986004|Anti-CD44 Monoclonal Antibody RO5429083|Anti-CD45 Monoclonal Antibody AHN-12|Anti-CD46 Antibody-drug Conjugate FOR46|Anti-CD47 ADC SGN-CD47M|Anti-CD47 Monoclonal Antibody AO-176|Anti-CD47 Monoclonal Antibody CC-90002|Anti-CD47 Monoclonal Antibody Hu5F9-G4|Anti-CD47 Monoclonal Antibody IBI188|Anti-CD47 Monoclonal Antibody IMC-002|Anti-CD47 Monoclonal Antibody SHR-1603|Anti-CD47 Monoclonal Antibody SRF231|Anti-CD47 Monoclonal Antibody TJC4|Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801|Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A|Anti-CD52 Monoclonal Antibody ALLO-647|Anti-CD70 Antibody-Drug Conjugate MDX-1203|Anti-CD70 Antibody-drug Conjugate SGN-CD70A|Anti-CD70 CAR-expressing T Lymphocytes|Anti-CD70 Monoclonal Antibody MDX-1411|Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029|Anti-CD73 Monoclonal Antibody BMS-986179|Anti-CD73 Monoclonal Antibody CPI-006|Anti-CD73 Monoclonal Antibody NZV930|Anti-CD73 Monoclonal Antibody TJ4309|Anti-CD74 Antibody-drug Conjugate STRO-001|Anti-CD98 Monoclonal Antibody IGN523|Anti-CDH6 Antibody-drug Conjugate HKT288|Anti-CEA BiTE Monoclonal Antibody AMG211|Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody|Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2|Anti-CEACAM1 Monoclonal Antibody CM-24|Anti-CEACAM5 Antibody-Drug Conjugate SAR408701|Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47|Anti-CEACAM6 Antibody BAY1834942|Anti-CLDN6 Monoclonal Antibody ASP1650|Anti-CLEC12A/CD3 Bispecific Antibody MCLA117|Anti-CLEVER-1 Monoclonal Antibody FP-1305|Anti-CSF1 Monoclonal Antibody PD-0360324|Anti-CSF1R Monoclonal Antibody IMC-CS4|Anti-CSF1R Monoclonal Antibody SNDX-6352|Anti-CTGF Monoclonal Antibody FG-3019|Anti-CTLA-4 Monoclonal Antibody ADG116|Anti-CTLA-4 Monoclonal Antibody ADU-1604|Anti-CTLA-4 Monoclonal Antibody AGEN1181|Anti-CTLA-4 Monoclonal Antibody BCD-145|Anti-CTLA-4 Monoclonal Antibody HBM4003|Anti-CTLA-4 Monoclonal Antibody MK-1308|Anti-CTLA-4 Monoclonal Antibody ONC-392|Anti-CTLA-4 Monoclonal Antibody REGN4659|Anti-CTLA-4 Probody BMS-986288|Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217|Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841|Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015|Anti-CTLA4 Antibody Fc Fusion Protein KN044|Anti-CTLA4 Monoclonal Antibody BMS-986218|Anti-CXCR4 Monoclonal Antibody PF-06747143|Anti-Claudin18.2 Monoclonal Antibody TST001|Anti-DKK-1 Monoclonal Antibody LY2812176|Anti-DKK1 Monoclonal Antibody BHQ880|Anti-DLL3/CD3 BiTE Antibody AMG 757|Anti-DLL4 Monoclonal Antibody MEDI0639|Anti-DLL4/VEGF Bispecific Monoclonal Antibody OMP-305B83|Anti-DR5 Agonist Monoclonal Antibody TRA-8|Anti-DR5 Agonistic Antibody DS-8273a|Anti-DR5 Agonistic Monoclonal Antibody INBRX-109|Anti-Denatured Collagen Monoclonal Antibody TRC093|Anti-EGFR Monoclonal Antibody CPGJ 602|Anti-EGFR Monoclonal Antibody EMD 55900|Anti-EGFR Monoclonal Antibody GC1118|Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX|Anti-EGFR Monoclonal Antibody HLX-07|Anti-EGFR Monoclonal Antibody Mixture MM-151|Anti-EGFR Monoclonal Antibody RO5083945|Anti-EGFR Monoclonal Antibody SCT200|Anti-EGFR Monoclonal Antibody SYN004|Anti-EGFR TAP Antibody-drug Conjugate IMGN289|Anti-EGFR/CD16A Bispecific Antibody AFM24|Anti-EGFR/DM1 Antibody-drug Conjugate AVID100|Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013|Anti-EGFR/PBD Antibody-drug Conjugate ABBV-321|Anti-EGFR/c-Met Bispecific Antibody EMB-01|Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372|Anti-EGFRvIII Antibody Drug Conjugate AMG 595|Anti-EGFRvIII Immunotoxin MR1-1|Anti-EGFRvIII/CD3 BiTE Antibody AMG 596|Anti-EGP-2 Immunotoxin MOC31-PE|Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F|Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F|Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A|Anti-Ep-CAM Monoclonal Antibody ING-1|Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310|Anti-EphA2 Monoclonal Antibody DS-8895a|Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547|Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111|Anti-ErbB3 Antibody ISU104|Anti-ErbB3 Monoclonal Antibody AV-203|Anti-ErbB3 Monoclonal Antibody CDX-3379|Anti-ErbB3 Monoclonal Antibody REGN1400|Anti-ErbB3/Anti-IGF-1R Bispecific Monoclonal Antibody MM-141|Anti-FAP/Interleukin-2 Fusion Protein RO6874281|Anti-FCRH5/CD3 BiTE Antibody BFCR4350A|Anti-FGFR2 Antibody BAY1179470|Anti-FGFR3 Antibody-drug Conjugate LY3076226|Anti-FGFR4 Monoclonal Antibody U3-1784|Anti-FLT3 Antibody-drug Conjugate AGS62P1|Anti-FLT3 Monoclonal Antibody 4G8-SDIEM|Anti-FLT3 Monoclonal Antibody IMC-EB10|Anti-FLT3/CD3 BiTE Antibody AMG 427|Anti-FRA/Eribulin Antibody-drug Conjugate MORAb-202|Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002|Anti-GARP Monoclonal Antibody ABBV-151|Anti-GCC Antibody-Drug Conjugate MLN0264|Anti-GCC Antibody-Drug Conjugate TAK-164|Anti-GD2 Monoclonal Antibody MORAb-028|Anti-GD2 Monoclonal Antibody hu14.18K322A|Anti-GD2 hu3F8/Anti-CD3 huOKT3 Bispecific Antibody|Anti-GD3 Antibody-drug Conjugate PF-06688992|Anti-GITR Agonistic Monoclonal Antibody ASP1951|Anti-GITR Agonistic Monoclonal Antibody BMS-986156|Anti-GITR Agonistic Monoclonal Antibody INCAGN01876|Anti-GITR Monoclonal Antibody GWN 323|Anti-GITR Monoclonal Antibody MK-4166|Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a|Anti-GRP78 Monoclonal Antibody PAT-SM6|Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962|Anti-Globo H Monoclonal Antibody OBI-888|Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999|Anti-Glypican 3/CD3 Bispecific Antibody ERY974|Anti-GnRH Vaccine PEP223|Anti-HA Epitope Monoclonal Antibody MEDI8852|Anti-HB-EGF Monoclonal Antibody KHK2866|Anti-HBEGF Monoclonal Antibody U3-1565|Anti-HER-2 Bispecific Antibody KN026|Anti-HER2 ADC DS-8201a|Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702|Anti-HER2 Antibody-drug Conjugate A166|Anti-HER2 Antibody-drug Conjugate ARX788|Anti-HER2 Antibody-drug Conjugate BAT8001|Anti-HER2 Antibody-drug Conjugate DP303c|Anti-HER2 Antibody-drug Conjugate MEDI4276|Anti-HER2 Antibody-drug Conjugate RC48|Anti-HER2 Bi-specific Monoclonal Antibody ZW25|Anti-HER2 Bispecific Antibody-drug Conjugate ZW49|Anti-HER2 Immune Stimulator-antibody Conjugate NJH395|Anti-HER2 Monoclonal Antibody B002|Anti-HER2 Monoclonal Antibody CT-P6|Anti-HER2 Monoclonal Antibody HLX22|Anti-HER2 Monoclonal Antibody/Anti-CD137Anticalin Bispecific Fusion Protein PRS-343|Anti-HER2-DM1 ADC B003|Anti-HER2-DM1 Antibody-drug Conjugate GQ1001|Anti-HER2-vc0101 ADC PF-06804103|Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A|Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302|Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128|Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522|Anti-HER2/MMAE Antibody-drug Conjugate MRG002|Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A|Anti-HER3 Antibody-drug Conjugate U3 1402|Anti-HER3 Monoclonal Antibody GSK2849330|Anti-HGF Monoclonal Antibody TAK-701|Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968|Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1|Anti-HLA-DR Monoclonal Antibody IMMU-114|Anti-HLA-G Antibody TTX-080|Anti-ICAM-1 Monoclonal Antibody BI-505|Anti-ICOS Agonist Antibody GSK3359609|Anti-ICOS Agonist Monoclonal Antibody BMS-986226|Anti-ICOS Monoclonal Antibody KY1044|Anti-ICOS Monoclonal Antibody MEDI-570|Anti-IGF-1R Monoclonal Antibody AVE1642|Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022|Anti-IL-1 alpha Monoclonal Antibody MABp1|Anti-IL-13 Humanized Monoclonal Antibody TNX-650|Anti-IL-15 Monoclonal Antibody AMG 714|Anti-IL-8 Monoclonal Antibody BMS-986253|Anti-IL-8 Monoclonal Antibody HuMax-IL8|Anti-ILDR2 Monoclonal Antibody BAY 1905254|Anti-ILT4 Monoclonal Antibody MK-4830|Anti-IRF4 Antisense Oligonucleotide ION251|Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388|Anti-KIR Monoclonal Antibody IPH 2101|Anti-KSP/Anti-VEGF siRNAs ALN-VSP02|Anti-LAG-3 Monoclonal Antibody IBI-110|Anti-LAG-3 Monoclonal Antibody INCAGN02385|Anti-LAG-3 Monoclonal Antibody LAG525|Anti-LAG-3 Monoclonal Antibody REGN3767|Anti-LAG-3/PD-L1 Bispecific Antibody FS118|Anti-LAG3 Monoclonal Antibody BI 754111|Anti-LAG3 Monoclonal Antibody MK-4280|Anti-LAG3 Monoclonal Antibody TSR-033|Anti-LAMP1 Antibody-drug Conjugate SAR428926|Anti-LGR5 Monoclonal Antibody BNC101|Anti-LIF Monoclonal Antibody MSC-1|Anti-LILRB4 Monoclonal Antibody IO-202|Anti-LIV-1 Monoclonal Antibody-MMAE Conjugate SGN-LIV1A|Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102|Anti-Ly6E Antibody-Drug Conjugate RG 7841|Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C|Anti-MMP-9 Monoclonal Antibody GS-5745|Anti-MUC1 Monoclonal Antibody BTH1704|Anti-MUC16/CD3 BiTE Antibody REGN4018|Anti-MUC16/CD3 Bispecific Antibody REGN4018|Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A|Anti-MUC17/CD3 BiTE Antibody AMG 199|Anti-Melanin Monoclonal Antibody PTI-6D2|Anti-Met Monoclonal Antibody Mixture Sym015|Anti-Met/EGFR Monoclonal Antibody LY3164530|Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062|Anti-NRP1 Antibody ASP1948|Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A|Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso|Anti-NaPi2b Antibody-drug Conjugate XMT-1592|Anti-NaPi2b Monoclonal Antibody XMT-1535|Anti-Neuropilin-1 Monoclonal Antibody MNRP1685A|Anti-Nucleolin Aptamer AS1411|Anti-OFA Immunotherapeutic BB-MPI-03|Anti-OX40 Agonist Monoclonal Antibody ABBV-368|Anti-OX40 Agonist Monoclonal Antibody BGB-A445|Anti-OX40 Agonist Monoclonal Antibody PF-04518600|Anti-OX40 Antibody BMS 986178|Anti-OX40 Hexavalent Agonist Antibody INBRX-106|Anti-OX40 Monoclonal Antibody GSK3174998|Anti-OX40 Monoclonal Antibody IBI101|Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256|Anti-PD-1 Checkpoint Inhibitor PF-06801591|Anti-PD-1 Fusion Protein AMP-224|Anti-PD-1 Monoclonal Antibody 609A|Anti-PD-1 Monoclonal Antibody AK105|Anti-PD-1 Monoclonal Antibody AMG 404|Anti-PD-1 Monoclonal Antibody BAT1306|Anti-PD-1 Monoclonal Antibody BCD-100|Anti-PD-1 Monoclonal Antibody BI 754091|Anti-PD-1 Monoclonal Antibody CS1003|Anti-PD-1 Monoclonal Antibody F520|Anti-PD-1 Monoclonal Antibody GLS-010|Anti-PD-1 Monoclonal Antibody HLX10|Anti-PD-1 Monoclonal Antibody HX008|Anti-PD-1 Monoclonal Antibody JTX-4014|Anti-PD-1 Monoclonal Antibody LZM009|Anti-PD-1 Monoclonal Antibody MEDI0680|Anti-PD-1 Monoclonal Antibody MGA012|Anti-PD-1 Monoclonal Antibody SCT-I10A|Anti-PD-1 Monoclonal Antibody Sym021|Anti-PD-1 Monoclonal Antibody TSR-042|Anti-PD-1/Anti-CTLA4 DART Protein MGD019|Anti-PD-1/Anti-HER2 Bispecific Antibody IBI315|Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669|Anti-PD-1/Anti-LAG-3 DART Protein MGD013|Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318|Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172|Anti-PD-1/CD47 Infusion Protein HX009|Anti-PD-1/CTLA-4 Bispecific Antibody AK104|Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752|Anti-PD-1/TIM-3 Bispecific Antibody RO7121661|Anti-PD-1/VEGF Bispecific Antibody AK112|Anti-PD-L1 Monoclonal Antibody A167|Anti-PD-L1 Monoclonal Antibody BCD-135|Anti-PD-L1 Monoclonal Antibody BGB-A333|Anti-PD-L1 Monoclonal Antibody CBT-502|Anti-PD-L1 Monoclonal Antibody CK-301|Anti-PD-L1 Monoclonal Antibody CS1001|Anti-PD-L1 Monoclonal Antibody FAZ053|Anti-PD-L1 Monoclonal Antibody GR1405|Anti-PD-L1 Monoclonal Antibody HLX20|Anti-PD-L1 Monoclonal Antibody IMC-001|Anti-PD-L1 Monoclonal Antibody LY3300054|Anti-PD-L1 Monoclonal Antibody MDX-1105|Anti-PD-L1 Monoclonal Antibody MSB2311|Anti-PD-L1 Monoclonal Antibody RC98|Anti-PD-L1 Monoclonal Antibody SHR-1316|Anti-PD-L1 Monoclonal Antibody TG-1501|Anti-PD-L1 Monoclonal Antibody ZKAB001|Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105|Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046|Anti-PD-L1/CD137 Bispecific Antibody MCLA-145|Anti-PD-L1/IL-15 Fusion Protein KD033|Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244|Anti-PD1 Monoclonal Antibody AGEN2034|Anti-PD1/CTLA4 Bispecific Antibody XmAb20717|Anti-PGF Monoclonal Antibody RO5323441|Anti-PKN3 siRNA Atu027|Anti-PLGF Monoclonal Antibody TB-403|Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4|Anti-PRAME Immunotherapeutic GSK2302032A|Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C|Anti-PRL-3 Monoclonal Antibody PRL3-zumab|Anti-PSCA Monoclonal Antibody AGS-1C4D4|Anti-PSMA Monoclonal Antibody MDX1201-A488|Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704|Anti-PSMA Monoclonal Antibody-MMAE Conjugate|Anti-PSMA/CD28 Bispecific Antibody REGN5678|Anti-PSMA/CD3 Bispecific Antibody CCW702|Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081|Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414|Anti-PSMA/PBD ADC MEDI3726|Anti-PTK7/Auristatin-0101 Antibody-drug Conjugate PF-06647020|Anti-PVRIG Monoclonal Antibody COM701|Anti-RANKL Monoclonal Antibody GB-223|Anti-RANKL Monoclonal Antibody JMT103|Anti-ROR1 ADC VLS-101|Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002|Anti-Ribonucleoprotein Antibody ATRC-101|Anti-S15 Monoclonal Antibody NC318|Anti-SIRPa Monoclonal Antibody CC-95251|Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E|Anti-TAG-72 Monoclonal Antibody scFV CC-49/218|Anti-TF Monoclonal Antibody ALT-836|Anti-TGF-beta Monoclonal Antibody NIS793|Anti-TGF-beta Monoclonal Antibody SAR-439459|Anti-TGF-beta RII Monoclonal Antibody IMC-TR1|Anti-TIGIT Monoclonal Antibody AB154|Anti-TIGIT Monoclonal Antibody BGB-A1217|Anti-TIGIT Monoclonal Antibody BMS-986207|Anti-TIGIT Monoclonal Antibody COM902|Anti-TIGIT Monoclonal Antibody OMP-313M32|Anti-TIGIT Monoclonal Antibody SGN-TGT|Anti-TIM-3 Antibody BMS-986258|Anti-TIM-3 Monoclonal Antibody BGB-A425|Anti-TIM-3 Monoclonal Antibody INCAGN02390|Anti-TIM-3 Monoclonal Antibody MBG453|Anti-TIM-3 Monoclonal Antibody Sym023|Anti-TIM-3 Monoclonal Antibody TSR-022|Anti-TIM3 Monoclonal Antibody LY3321367|Anti-TIM3 Monoclonal Antibody SHR-1702|Anti-TNF Therapy|Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711|Anti-TROP2 Antibody-drug Conjugate BAT8003|Anti-TROP2 Antibody-drug Conjugate SKB264|Anti-TROP2/DXd Antibody-drug Conjugate DS-1062a|Anti-TWEAK Monoclonal Antibody RG7212|Anti-Tissue Factor Monoclonal Antibody MORAb-066|Anti-VEGF Anticalin PRS-050-PEG40|Anti-VEGF Monoclonal Antibody hPV19|Anti-VEGF/ANG2 Nanobody BI 836880|Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T|Anti-VEGFC Monoclonal Antibody VGX-100|Anti-VEGFR2 Monoclonal Antibody HLX06|Anti-VEGFR2 Monoclonal Antibody MSB0254|Anti-VEGFR3 Monoclonal Antibody IMC-3C5|Anti-VISTA Monoclonal Antibody JNJ 61610588|Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B|Anti-alpha5beta1 Integrin Antibody MINT1526A|Anti-angiopoietin Monoclonal Antibody AMG 780|Anti-c-KIT Monoclonal Antibody CDX 0158|Anti-c-MET Monoclonal Antibody LY2875358|Anti-c-Met Antibody-drug Conjugate HTI-1066|Anti-c-Met Antibody-drug Conjugate TR1801|Anti-c-Met Monoclonal Antibody ABT-700|Anti-c-Met Monoclonal Antibody ARGX-111|Anti-c-Met Monoclonal Antibody HLX55|Anti-c-fms Monoclonal Antibody AMG 820|Anti-claudin18.2 Monoclonal Antibody AB011|Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012|Anti-gpA33/CD3 Monoclonal Antibody MGD007|Anti-gremlin-1 Monoclonal Antibody UCB6114|Anti-hepcidin Monoclonal Antibody LY2787106|Anti-human GITR Monoclonal Antibody AMG 228|Anti-human GITR Monoclonal Antibody TRX518|Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A|Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181|Anti-mesothelin Antibody-drug Conjugate BMS-986148|Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100|Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A|Anti-mesothelin/MMAE Antibody-drug Conjugate RC88|Anti-myostatin Monoclonal Antibody LY2495655|Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E|Anti-nf-P2X7 Antibody Ointment BIL-010t|Anti-prolactin Receptor Antibody LFA102|Anti-sCLU Monoclonal Antibody AB-16B5|Antiangiogenic Drug Combination TL-118|Antibody-Drug Conjugate DFRF4539A|Antibody-drug Conjugate ABBV-011|Antibody-drug Conjugate ABBV-085|Antibody-drug Conjugate ABBV-155|Antibody-drug Conjugate ABBV-176|Antibody-drug Conjugate ABBV-838|Antibody-drug Conjugate ADC XMT-1536|Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014|Antibody-drug Conjugate MEDI7247|Antibody-drug Conjugate PF-06647263|Antibody-drug Conjugate PF-06664178|Antibody-drug Conjugate SC-002|Antibody-drug Conjugate SC-003|Antibody-drug Conjugate SC-004|Antibody-drug Conjugate SC-005|Antibody-drug Conjugate SC-006|Antibody-drug Conjugate SC-007|Antibody-like CD95 Receptor/Fc-fusion Protein CAN-008|Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV|Antigua and Barbuda|Antimetabolite FF-10502|Antineoplastic Agent Combination SM-88|Antineoplastic Vaccine|Antineoplastic Vaccine GV-1301|Antineoplaston A10|Antineoplaston AS2-1|Antiseizure Treatment|Antisense Oligonucleotide GTI-2040|Antisense Oligonucleotide QR-313|Antitumor B Key Active Component-alpha|Antrodia cinnamomea Supplement|Antroquinonol Capsule|Antrum|Antrum Pylori|Anus|Anus and anal canal|Anus, NOS|Anxiety|Aorta|Aortic Body|Aortic Injury|Aortic Valve Disease|Aortic body and other paraganglia|Aortic body paraganglioma|Aortic body tumor|Aorticopulmonary Paraganglioma|Aorticopulmonary paraganglioma|Apalutamide|Apatorsen|Apaziquone|Aphidicoline Glycinate|Aphonia|Apilimod Dimesylate Capsule|Apitolisib|Apnea|Apocrine Adenoma|Apocrine Hidrocystoma|Apocrine adenocarcinoma|Apocrine adenoma|Apocrine cystadenoma|Apolizumab|Apomab|Apomine|Apoptosis Inducer BZL101|Apoptosis Inducer GCS-100|Apoptosis Inducer MPC-2130|Appendage of the Uterus|Appendicitis|Appendicitis Perforated|Appendix|Applied Biosystems|Approved|Apricoxib|Aprinocarsen|Aprutumab|Aprutumab Ixadotin|Apudoma|Aqueous Fluid|Arabidopsis thaliana|Arabinoxylan Compound MGN3|Arachnoiditis|Aranose|Archexin|Archive|Arcitumomab|Arfolitixorin|Arg-C, Asp-N|Argentaffinoma, NOS|Argentaffinoma, malignant|Argentina|Arginase Inhibitor INCB001158|Arginine Butyrate|Arm|Armenia|Arnebia Indigo Jade Pearl Topical Cream|Arrhenoblastoma, NOS|Arrhenoblastoma, benign|Arrhenoblastoma, malignant|Arrhythmia|Arriba|Arsenic Trioxide|Arsenic Trioxide Capsule Formulation ORH 2014|Artemether Sublingual Spray|Artemisinin Dimer|Arterial Injury|Arteriovenous Hemangioma/Malformation|Arteriovenous hemangioma|Arteritis Infective|Artery|Artesunate|Arthralgia|Arthritis|Aruba|Arugula Seed Powder|Aryl Hydrocarbon Receptor Antagonist BAY2416964|Aryl Hydrocarbon Receptor Inhibitor IK-175|Asaley|AscatNGS|Ascending Colon|Ascending Colon Hepatic Flexure|Ascending colon|Asciminib|Ascites|Ascites Drainage|Ascrinvacumab|Ashwagandha Root Powder Extract|Asian|Askin Tumor|Askin tumor|Asp-N_ambic|Aspacytarabine|Asparaginase|Asparaginase Erwinia chrysanthemi|Aspartate Aminotransferase Increased|Aspirate|Aspiration|Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10|Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10|Asthma|Astroblastoma|Astrocytic Tumor|Astrocytic glioma|Astrocytoma|Astrocytoma, NOS|Astrocytoma, anaplastic|Astrocytoma, low grade|Astroglioma|Astuprotimut-R|Asulacrine|Asulacrine Isethionate|Asunercept|Asystole|At 211 Monoclonal Antibody 81C6|Atamestane|Ataxia|Ataxia-telangiectasia|Atelectasis|Atezolizumab|Atiprimod|Atiprimod Dihydrochloride|Atiprimod Dimaleate|Atorvastatin Calcium|Atorvastatin Sodium|Atrasentan Hydrochloride|Atrial Fibrillation|Atrial Flutter|Atrioventricular Block Complete|Atrioventricular Block First Degree|Attenuated Listeria monocytogenes CRS-100|Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001|Attenuated Measles Virus Encoding SCD Transgene TMV-018|Atuveciclib|Atypical|Atypical Adenoma|Atypical Burkitt/Burkitt-Like Lymphoma|Atypical Carcinoid Tumor|Atypical Choroid Plexus Papilloma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Atypical Endometrial Hyperplasia|Atypical Fibroxanthoma|Atypical Lipomatous Tumor|Atypical Meningioma|Atypical Polypoid Adenomyoma|Atypical Teratoid/Rhabdoid Tumor|Atypical adenoma|Atypical carcinoid tumor|Atypical choroid plexus papilloma|Atypical chronic myeloid leukemia, BCR/ABL negative|Atypical chronic myeloid leukemia, Philadelphia chromosome (Ph1) negative|Atypical fibrous histiocytoma|Atypical fibroxanthoma|Atypical follicular adenoma|Atypical hyperplasia/Endometrioid intraepithelial neoplasm|Atypical leiomyoma|Atypical lipoma|Atypical medullary carcinoma|Atypical meningioma|Atypical polypoid adenomyoma|Atypical proliferating clear cell tumor|Atypical proliferating serous tumor|Atypical proliferative endometrioid tumor|Atypical proliferative mucinous tumor|Atypical proliferative papillary serous tumor|Atypical teratoid/rhabdoid tumor|Audencel|Auditory Canal|Aunt|Auranofin|Aurora A Kinase Inhibitor LY3295668|Aurora A Kinase Inhibitor LY3295668 Erbumine|Aurora A Kinase Inhibitor MK5108|Aurora A Kinase Inhibitor TAS-119|Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076|Aurora B Serine/Threonine Kinase Inhibitor TAK-901|Aurora B/C Kinase Inhibitor GSK1070916A|Aurora Kinase Inhibitor AMG 900|Aurora Kinase Inhibitor BI 811283|Aurora Kinase Inhibitor MLN8054|Aurora Kinase Inhibitor PF-03814735|Aurora Kinase Inhibitor SNS-314|Aurora Kinase Inhibitor TTP607|Aurora Kinase/VEGFR2 Inhibitor CYC116|Aurora kinase A/B inhibitor TT-00420|Australia|Austria|Auto Spec Ultima NT|Autoimmune Atrophic Chronic Gastritis|Autoimmune Disorder|Autoimmune Lymphoproliferative Syndrome (ALPS)|Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707|Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055|Autologous AXL-targeted CAR T-cells CCT301-38|Autologous Anti-BCMA CAR T-cells PHE885|Autologous Anti-BCMA CAR-transduced T-cells KITE-585|Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11|Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T-lymphocytes JCARH125|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells CT053|Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143|Autologous Anti-CD123 CAR-T Cells|Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx|Autologous Anti-CD19 CAR T-cells IM19|Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19|Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19|Autologous Anti-CD19 CAR-CD28 T-cells ET019002|Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01|Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901|Autologous Anti-CD19 Chimeric Antigen Receptor T-cells AUTO1|Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19|Autologous Anti-CD19 T-cell Receptor T cells ET190L1|Autologous Anti-CD19 TAC-T cells TAC01-CD19|Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells|Autologous Anti-CD19/CD22 CAR T-cells AUTO3|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells|Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1|Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s|Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes|Autologous Anti-FLT3 CAR T Cells AMG 553|Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202|Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1|Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100|Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794|Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes|Autologous Anti-PSMA CAR-T Cells P-PSMA-101|Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes|Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B|Autologous BCMA-targeted CAR T Cells CC-98633|Autologous BCMA-targeted CAR T Cells LCAR-B4822M|Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528|Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F|Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022|Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001|Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3005|Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3006|Autologous CD123-4SCAR-expressing T-cells 4SCAR123|Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1|Autologous CD19-targeted CAR T Cells CC-97540|Autologous CD19-targeted CAR T Cells JWCAR029|Autologous CD19-targeted CAR-T Cells GC007F|Autologous CD19/PD-1 Bispecific CAR-T Cells|Autologous CD20-4SCAR-expressing T-cells 4SCAR20|Autologous CD22-4SCAR-expressing T-cells 4SCAR22|Autologous CD38-4SCAR-expressing T-cells 4SCAR38|Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19|Autologous Clonal Neoantigen T Cells ATL001|Autologous Deep IL-15 Primed T-cells TRQ15-01|Autologous Dendritic Cell Vaccine ACT2001|Autologous Dendritic Cell-based Immunotherapeutic AV0113|Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa|Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells|Autologous Genetically-modified MAGE-A4 C1032 T Cells|Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439|Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858|Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001|Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718|Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR|Autologous Mesenchymal Stem Cells Apceth_101|Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11|Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC|Autologous Multi-lineage Potential Cells|Autologous NKG2D CAR T-cells CYAD-02|Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01|Autologous Nectin-4/FAP-targeted CAR-T Cells|Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine|Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001|Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101|Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601|Autologous ROR2-targeted CAR T-cells CCT301-59|Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201|Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1|Autologous TCR-engineered T-cells IMA201|Autologous TCR-engineered T-cells IMA202|Autologous TCR-engineered T-cells IMA203|Autologous TCRm-expressing T-cells ET140203|Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG|Autologous Tumor Infiltrating Lymphocytes LN-144|Autologous Tumor Infiltrating Lymphocytes LN-145|Autologous Tumor Infiltrating Lymphocytes LN-145-S1|Autologous Tumor Infiltrating Lymphocytes MDA-TIL|Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T|Autonomic Nervous System|Autonomic nervous system, NOS|Autopsy|Avadomide|Avadomide Hydrochloride|Avapritinib|Avascular Necrosis|Avdoralimab|Avelumab|Aviscumine|Avitinib Maleate|Axalimogene Filolisbac|Axatilimab|Axicabtagene Ciloleucel|Axilla|Axillary Lymph Node|Axillary tail of breast|Axitinib|Axl/Mer Inhibitor INCB081776|Axl/Mer Inhibitor PF-07265807|Axumin|Azacitidine|Azapicyl|Azaribine|Azaserine|Azathioprine|Azerbaijan|Azimexon|Azintuxizumab Vedotin|Aziridinylbenzoquinone RH1|Azoospermia|Azotomycin|Azurin:50-77 Cell Penetrating Peptide p28|B|B Acute Lymphoblastic Leukemia|B Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy|B Lymphoblastic Leukemia/Lymphoma with Hypodiploidy|B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1|B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)|B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH|B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1|B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged|B Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified|B Lymphoblastic Lymphoma|B cell lymphoma, NOS|B lymphoblastic leukemia/lymphoma with hyperdiploidy|B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL)|B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)|B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)|B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH|B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1|B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged|B lymphoblastic leukemia/lymphoma, NOS|B-ALL|B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|B-Cell Prolymphocytic Leukemia|B-Raf/VEGFR-2 Inhibitor RAF265|B-cell lymphocytic leukemia/small lymphocytic lymphoma|B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma|B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma|B7|B8|B9|BAI|BALT lymphoma|BAM|BAP1 Tumor Predisposition Syndrome|BC-819 Plasmid/Polyethylenimine Complex|BCG Solution|BCG Tokyo-172 Strain Solution|BCG Vaccine|BCGSC miRNA Profiling|BCMA x CD3 T-cell Engaging Antibody CC-93269|BCMA-CD19 Compound CAR T Cells|BCMA/CD3e Tri-specific T-cell Activating Construct HPN217|BCR Auxiliary XML|BCR Biotab|BCR Notification|BCR OMF XML|BCR PPS XML|BCR SSF XML|BCR XML|BCR-ABL/KIT/AKT/ERK Inhibitor HQP1351|BED-Biochemical Evidence of Disease|BEDPE|BET Bromodomain Inhibitor ZEN-3694|BET Inhibitor ABBV-744|BET Inhibitor BAY1238097|BET Inhibitor BMS-986158|BET Inhibitor CC-90010|BET Inhibitor CPI-0610|BET Inhibitor FT-1101|BET Inhibitor GS-5829|BET Inhibitor GSK2820151|BET Inhibitor INCB054329|BET Inhibitor INCB057643|BET Inhibitor RO6870810|BET inhibitor BI 894999|BET-bromodomain Inhibitor ODM-207|BF-200 Gel Formulation|BH3 Mimetic ABT-737|BL22 Immunotoxin|BMI1 Inhibitor PTC596|BMS-184476|BMS-188797|BMS-214662|BMS-275183|BP-Cx1-Platinum Complex BP-C1|BR96-Doxorubicin Immunoconjugate|BRAF Inhibitor|BRAF Inhibitor ARQ 736|BRAF Inhibitor BGB-3245|BRAF Inhibitor PLX8394|BRAF(V600E) Kinase Inhibitor ABM-1310|BRAF(V600E) Kinase Inhibitor RO5212054|BRAF/EGFR Inhibitor BGB-283|BRAFV600/PI3K Inhibitor ASN003|BRASS|BRCA Family History|BRD4 Inhibitor PLX2853|BRD4 Inhibitor PLX51107|BTK Inhibitor ARQ 531|BTK Inhibitor CT-1530|BTK Inhibitor DTRMWXHS-12|BTK Inhibitor HZ-A-018|BTK Inhibitor ICP-022|BTK Inhibitor LOXO-305|BTK Inhibitor M7583|BTK inhibitor TG-1701|BWA|BWA with BQSR|BWA with Mark Duplicates and BQSR|BWA with Mark Duplicates and Cocleaning|BWA-aln|BWA-mem|BXQ-350 Nanovesicle Formulation|B_Allele_Freq|Babaodan Capsule|Bacillus Calmette-Guerin Substrain Connaught Live Antigen|Back|Back Pain|Bacteroides fragilis|Bactobolin|Bafetinib|Bahamas|Bahrain|Balixafortide|Balloon Cell Melanoma|Balloon Cell Nevus|Balloon cell melanoma|Balloon cell nevus|Balstilimab|Baltaleucel-T|Bangladesh|Banoxantrone|Barasertib|Barbados|Barcode incorrect|Bardoxolone|Bardoxolone Methyl|Baricitinib|Barrett's Esophagus|Basal Cell Cancer|Basal Cell Carcinoma|Basal Cell Neoplasm|Basal Cell Neoplasms|Basal cell adenocarcinoma|Basal cell adenoma|Basal cell carcinoma, NOS|Basal cell carcinoma, desmoplastic type|Basal cell carcinoma, fibroepithelial|Basal cell carcinoma, micronodular|Basal cell carcinoma, morpheic|Basal cell carcinoma, nodular|Basal cell epithelioma|Basal cell tumor|Basaloid Carcinoma|Basaloid Squamous Cell Carcinoma|Basaloid carcinoma|Basaloid squamous cell carcinoma|Base of the Tongue|Base of tongue|Base of tongue, NOS|Basophil adenocarcinoma|Basophil adenoma|Basophil carcinoma|Basophilic Adenocarcinoma|Basosquamous carcinoma|Batabulin|Batabulin Sodium|Batimastat|Bavituximab|Bazedoxifene|Bazlitoran|Bcl-2 Inhibitor APG 2575|Bcl-2 Inhibitor BCL201|Bcl-2 Inhibitor BGB-11417|Bcl-2 Inhibitor LP-108|Bcl-2 Inhibitor S65487|Bcl-Xs Adenovirus Vaccine|Bcr-Abl Kinase Inhibitor K0706|Bcr-Abl Kinase Inhibitor PF-114|Beauvericin|Becatecarin|Beckwith-Wiedemann|Bednar tumor|Beer|Behcet's Disease|Belagenpumatucel-L|Belantamab Mafodotin|Belapectin|Belarus|Belgium|Belimumab|Belinostat|Belize|Bellini duct carcinoma|Belotecan Hydrochloride|Belvarafenib|Belzutifan|Bemarituzumab|Bemcentinib|Bemisia tabaci (Gennadius)|Bempegaldesleukin|Benaxibine|Bendamustine|Bendamustine Hydrochloride|Bendamustine-containing Nanoparticle-based Formulation RXDX-107|Benign Adrenal Cortex Neoplasm|Benign Epithelial Neoplasm|Benign Fibrous Histiocytoma|Benign Gastrointestinal Stromal Tumor|Benign Hemangioendothelioma|Benign Hemangiopericytoma|Benign Leydig Cell Tumor|Benign Mesenchymoma|Benign Mesonephroma|Benign Mixed Tumor of the Skin|Benign Muscle Neoplasm|Benign Myoepithelioma|Benign Neoplasm|Benign Neoplasms|Benign Odontogenic Neoplasm|Benign Paraganglioma|Benign Phyllodes Tumor|Benign Prostatic Hyperplasia|Benign Sertoli Cell Tumor|Benign Skin Appendage Neoplasm|Benign Soft Tissue Neoplasm|Benign Stromal Tumor|Benign Sweat Gland Neoplasm|Benign Synovial Neoplasm|Benign Thymoma|Benign cystic nephroma|Benign fibrous histiocytoma|Benin|Benzaldehyde Dimethane Sulfonate|Benzoylphenylurea|Berberine Chloride|Bermekimab|Bermuda|Bersanlimab|Berubicin Hydrochloride|Berzosertib|Beta Alethine|Beta cell adenoma|Beta cell tumor, malignant|Beta-Carotene|Beta-Glucan|Beta-Glucan MM-10-001|Beta-Thioguanine Deoxyriboside|Beta-elemene|Beta-lapachone Prodrug ARQ 761|Betaglucin Gel|Betulinic Acid|Bevacizumab|Bexarotene|Bexmarilimab|Bhutan|Bi-functional Alkylating Agent VAL-083|BiTE Antibody AMG 910|Bicalutamide|Biguanide|Bilateral|Bile Duct|Bile Duct Adenocarcinoma|Bile Duct Adenoma|Bile Duct Cancer|Bile Duct Carcinoma|Bile Duct Mucinous Cystic Neoplasm|Bile Duct Mucinous Cystic Neoplasm with an Associated Invasive Carcinoma|Bile Duct Papillary Neoplasm|Bile Duct Papillary Neoplasm with High Grade Intraepithelial Neoplasia|Bile Duct Papillary Neoplasm with Low Grade Intraepithelial Neoplasia|Bile Duct Stenosis|Bile duct adenocarcinoma|Bile duct adenoma|Bile duct carcinoma|Bile duct cystadenocarcinoma|Bile duct cystadenoma|Biliary Anastomotic Leak|Biliary Disorder|Biliary Fistula|Biliary Intraepithelial Neoplasia-3|Biliary Tract Infection|Biliary intraepithelial neoplasia, grade 3|Biliary intraepithelial neoplasia, high grade|Biliary intraepithelial neoplasia, low grade|Biliary papillomatosis|Biliary tract, NOS|Bimiralisib|Binetrakin|Binimetinib|Bintrafusp Alfa|Bio-Q|BioSizing|Biochemical|Biochemical Evidence of Disease without Structural Correlate|Biochemical evidence of disease without structural correlate|Biopsy|Biopsy with Histologic Confirmation|Biospecimen|Biospecimen Supplement|Biospecimen identity unknown|Biphasic Mesothelioma|Biphasic Synovial Sarcoma|Biphenotypic sinonasal sarcoma|Birabresib|Birdseed|Birinapant|Birt-Hogg-Dube Syndrome|Bis(choline)tetrathiomolybdate|Bisantrene|Bisantrene Hydrochloride|Bisnafide|Bisnafide Dimesylate|Bispecific Antibody 2B1|Bispecific Antibody AGEN1223|Bispecific Antibody AMG 509|Bispecific Antibody GS-1423|Bispecific Antibody MDX-H210|Bispecific Antibody MDX447|Bisphosphonate Therapy|Bisthianostat|Bisulfite-Seq|Bivalent BRD4 Inhibitor AZD5153|Bizalimogene Ralaplasmid|Bizarre Leiomyoma|Bizarre leiomyoma|Bizelesin|Black Cohosh|Black Raspberry Nectar|Black adenoma|Black or African American|Bladder|Bladder Anastomotic Leak|Bladder Cancer|Bladder Infection|Bladder Neck|Bladder Papillary Urothelial Neoplasm of Low Malignant Potential|Bladder Perforation|Bladder Spasm|Bladder Trigone|Bladder Urachal Carcinoma|Bladder Urothelial Carcinoma|Bladder neck|Bladder, NOS|Blast cell leukemia|Blastic NK cell lymphoma|Blastic Plasmacytoid Dendritic Cell Neoplasm|Blastic plasmacytoid dendritic cell neoplasm|Blastoma|Blastoma, NOS|Bleomycin|Bleomycin A2|Bleomycin B2|Bleomycin Sulfate|Blinatumomab|Blinded Study, Treatment Unknown|Bloating|Blocking Release|Blood|Blood Antidiuretic Hormone Abnormal|Blood Bilirubin Increased|Blood Cancer|Blood Clots|Blood Corticotrophin Decreased|Blood Derived Cancer - Bone Marrow|Blood Derived Cancer - Bone Marrow, Post-treatment|Blood Derived Cancer - Peripheral Blood|Blood Derived Cancer - Peripheral Blood, Post-treatment|Blood Derived Liquid Biopsy|Blood Derived Normal|Blood Draw|Blood Gonadotrophin Abnormal|Blood Prolactin Abnormal|Blood Vessel|Blood Vessel Tumors|Blood and Lymphatic System Disorders - Other|Blue|Blue Nevus|Blue nevus, NOS|Blue nevus, malignant|Blueberry Powder Supplement|Blurred Vision|Boanmycin Hydrochloride|Body Odor|Body of Stomach|Body of pancreas|Body of penis|Body of stomach|Body of the Penis|Body, total|Bolivia|Bomedemstat|Bone|Bone Cancer|Bone Desmoplastic Fibroma|Bone Fracture(s)|Bone Infection|Bone Marrow|Bone Marrow Aspirate|Bone Marrow Components|Bone Marrow Components NOS|Bone Marrow Hypocellular|Bone Marrow Normal|Bone Pain|Bone marrow|Bone of limb, NOS|Bone, NOS|Bone, non-spine|Bones of skull and face and associated joints|Bones, joints and articular cartilage of limbs|Bones, joints and articular cartilage of other and unspecified sites|Border of tongue|Borderline Ovarian Brenner Tumor/Atypical Proliferative Ovarian Brenner Tumor|Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor|Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor|Borderline Ovarian Serous Tumor-Micropapillary Variant/Non-Invasive Low Grade Ovarian Serous Carcinoma|Borderline Papillary Cystadenoma|Borderline Papillary Mucinous Cystadenoma|Borderline Papillary Serous Cystadenoma|Borderline Phyllodes Tumor|Borderline Serous Cystadenoma|Boronophenylalanine-Fructose Complex|Bortezomib|Bos taurus|Bosnia and Herzegovina|Bosutinib|Bosutinib Monohydrate|Botanical Agent BEL-X-HG|Botanical Agent LEAC-102|Botryoid sarcoma|Botryoid-Type Embryonal Rhabdomyosarcoma|Botswana|Bovine Cartilage|Bowel|Bowen Disease of the Skin|Bowen disease|Bozitinib|Brachial Plexopathy|Brachytherapy, High Dose|Brachytherapy, Low Dose|Brachytherapy, NOS|Brachyury-expressing Yeast Vaccine GI-6301|Brain|Brain Cancer|Brain Lower Grade Glioma|Brain Stem|Brain stem|Brain, NOS|Branchial Cleft Remnant|Branchial cleft|Brazil|Breast|Breast Atrophy|Breast Cancer|Breast Cancer pTis (DCIS) TNM Finding v8|Breast Cancer pTis (LCIS) TNM Finding v6 and v7|Breast Carcinoma with Chondroid Metaplasia|Breast Carcinoma with Osseous Metaplasia|Breast Fibroadenoma|Breast Giant Fibroadenoma|Breast Infection|Breast Intracanalicular Fibroadenoma|Breast Invasive Carcinoma|Breast Juvenile Fibroadenoma|Breast Pain|Breast Pericanalicular Fibroadenoma|Breast, NOS|Breflate|Brenner Tumor|Brenner tumor, NOS|Brenner tumor, borderline malignancy|Brenner tumor, malignant|Brenner tumor, proliferating|Brentuximab|Brentuximab Vedotin|Brequinar|Brequinar Sodium|Briciclib Sodium|Brigatinib|Brilanestrant|Brimonidine Tartrate Nanoemulsion OCU-300|Brivanib|Brivanib Alaninate|Brivudine|Brivudine Phosphoramidate|Broad Ligament|Broad ligament|Broad-Spectrum Human Papillomavirus Vaccine V505|Broccoli Sprout/Broccoli Seed Extract Supplement|Bromacrylide|Bromebric Acid|Bromocriptine Mesylate|Bronchial Fistula|Bronchial Infection|Bronchial Mucosa-Associated Lymphoid Tissue Lymphoma|Bronchial Obstruction|Bronchial Stricture|Bronchial adenoma, NOS|Bronchial adenoma, carcinoid|Bronchial adenoma, cylindroid|Bronchial-associated lymphoid tissue lymphoma|Bronchio-alveolar carcinoma, mixed mucinous and non-mucinous|Bronchio-alveolar carcinoma, mucinous|Bronchiolar adenocarcinoma|Bronchiolar carcinoma|Bronchiole|Bronchiolo-alveolar adenocarcinoma, NOS|Bronchiolo-alveolar carcinoma, Clara cell|Bronchiolo-alveolar carcinoma, Clara cell and goblet cell type|Bronchiolo-alveolar carcinoma, NOS|Bronchiolo-alveolar carcinoma, goblet cell type|Bronchiolo-alveolar carcinoma, indeterminate type|Bronchiolo-alveolar carcinoma, non-mucinous|Bronchiolo-alveolar carcinoma, type II pneumocyte and goblet cell type|Bronchiolo-alveolar carcinoma; type II pneumocyte|Bronchitis|Bronchopleural Fistula|Bronchopulmonary Hemorrhage|Bronchospasm|Bronchus|Bronchus and lung|Brontictuzumab|Brooke tumor|Brostacillin Hydrochloride|Brostallicin|Brother|Brother-in-law|Brow|Brown|Brown fat tumor|Broxuridine|Bruceanol A|Bruceanol B|Bruceanol C|Bruceanol D|Bruceanol E|Bruceanol F|Bruceanol G|Bruceanol H|Bruceantin|Bruising|Bruker|Bruker Daltonics BioTOF series|Bruker Daltonics EVOQ series|Bruker Daltonics HCT series|Bruker Daltonics SCION series|Bruker Daltonics amaZon series|Bruker Daltonics apex series|Bruker Daltonics esquire series|Bruker Daltonics flex series|Bruker Daltonics maXis series|Bruker Daltonics micrOTOF series|Bruker Daltonics solarix series|Brunei|Bryostatin 1|Buccal Cavity|Buccal Cell Normal|Buccal Cells|Buccal Mucosa|Buccal Mucosal Resection|Budigalimab|Budotitane|Bufalin|Buffy Coat|Bulgaria|Bullous Dermatitis|Buparlisib|Burixafor|Burixafor Hydrobromide|Burkina Faso|Burkitt Leukemia|Burkitt Lymphoma|Burkitt cell leukemia|Burkitt lymphoma, NOS (Includes all variants)|Burkitt tumor|Burkitt-like lymphoma|Burn|Burning tree smoke|Burosumab|Burundi|Buserelin|Bushen Culuan Decoction|Bushen-Jianpi Decoction|Busulfan|Buthionine Sulfoximine|Buttock|Buttock Pain|C|C cell carcinoma|C-VISA BikDD:Liposome|C-myb Antisense Oligonucleotide G4460|C/EBP Beta Antagonist ST101|C10|C11|C12|C18|CAB-ROR2-ADC BA3021|CAIX Inhibitor DTP348|CAIX Inhibitor SLC-0111|CAR T-Cells AMG 119|CASTLE|CBP/beta-catenin Antagonist PRI-724|CBP/beta-catenin Modulator E7386|CCR2 Antagonist CCX872-B|CCR2 Antagonist PF-04136309|CCR2/CCR5 Antagonist BMS-813160|CCR4 Inhibitor FLX475|CD11b Agonist GB1275|CD123-CD33 Compound CAR T Cells|CD123-specific Targeting Module TM123|CD20-CD19 Compound CAR T Cells|CD28/ICOS Antagonist ALPN-101|CD4 Lymphocytes Decreased|CD4-specific Telomerase Peptide Vaccine UCPVax|CD40 Agonist Monoclonal Antibody CP-870,893|CD40 Agonistic Monoclonal Antibody APX005M|CD44 Targeted Agent SPL-108|CD44v6-specific CAR T-cells|CD47 Antagonist ALX148|CD73 Inhibitor AB680|CD73 Inhibitor LY3475070|CD80-Fc Fusion Protein ALPN-202|CD80-Fc Fusion Protein FPT155|CDC JSON|CDC7 Inhibitor TAK-931|CDC7 Kinase Inhibitor BMS-863233|CDC7 Kinase Inhibitor LY3143921 Hydrate|CDC7 Kinase Inhibitor NMS-1116354|CDK Inhibitor AT7519|CDK Inhibitor R547|CDK Inhibitor SNS-032|CDK/JAK2/FLT3 Inhibitor TG02 Citrate|CDK1 Inhibitor BEY1107|CDK1/2/4 Inhibitor AG-024322|CDK2 Inhibitor PF-07104091|CDK2/4/6/FLT3 Inhibitor FN-1501|CDK2/5/9 Inhibitor CYC065|CDK4 Inhibitor P1446A-05|CDK4/6 Inhibitor|CDK4/6 Inhibitor BPI-16350|CDK4/6 Inhibitor CS3002|CDK4/6 Inhibitor FCN-437|CDK4/6 Inhibitor G1T38|CDK4/6 Inhibitor HS-10342|CDK4/6 Inhibitor SHR6390|CDK4/6 Inhibitor TQB3616|CDK7 Inhibitor CT7001|CDK7 Inhibitor SY-1365|CDK7 Inhibitor SY-5609|CDK8/19 Inhibitor SEL 120|CDK9 Inhibitor AZD4573|CEA-MUC-1-TRICOM Vaccine CV301|CEA-targeting Agent RG6123|CEBPA-targeting saRNA MTL-CEBPA Liposome|CEL|CENP-E Inhibitor GSK-923295|CHK1 Inhibitor MK-8776|CHK1 Inhibitor PF-477736|CHP-NY-ESO-1 Peptide Vaccine IMF-001|CID|CIN III with severe dysplasia|CK1alpha/CDK7/CDK9 Inhibitor BTX-A51|CK2-targeting Synthetic Peptide CIGB-300|CL 246738|CNBr, Formic_acid|CNS Cancer|CNS Embryonal tumor with rhabdoid features|CNS, ependymoma|CNS, glioblastoma (GBM)|CNS, low grade glioma (LGG)|CNS, medulloblastoma|CNS, other|CNS, rhabdoid tumor|COPD|CPD-Clinical Progression|CPK Increased|CPNET|CR-Complete Response|CRU-Complete Response Unconfirmed|CSF-1R Inhibitor BLZ945|CSF1R Inhibitor ABSK021|CSF1R Inhibitor DCC-3014|CSF1R Inhibitor PLX73086|CSV|CT Scan|CT2584 HMS|CTLA-4-directed Probody BMS-986249|CXC Chemokine Receptor 2 Antagonist AZD5069|CXCR1/2 Inhibitor SX-682|CXCR2 Antagonist QBM076|CXCR4 Antagonist BL-8040|CXCR4 Antagonist USL311|CXCR4 Inhibitor Q-122|CXCR4 Peptide Antagonist LY2510924|CXCR4/E-selectin Antagonist GMI-1359|CYL-02 Plasmid DNA|CYP11A1 Inhibitor ODM-209|CYP11A1 inhibitor ODM-208|CYP17 Inhibitor CFG920|CYP17 Lyase Inhibitor ASN001|CYP17/Androgen Receptor Inhibitor ODM 204|CYP17/CYP11B2 Inhibitor LAE001|CaVEMan|CaVEMan Annotation|CaVEMan Variant Aggregation and Masking|Cabazitaxel|Cabiralizumab|Cabozantinib|Cabozantinib S-malate|Cactinomycin|Caenorhabditis briggsae|Caenorhabditis elegans|Caenorhabditis remanei|Caffeic Acid Phenethyl Ester|Calaspargase Pegol-mknl|Calcifying Cystic Odontogenic Tumor|Calcifying Epithelial Odontogenic Tumor|Calcifying epithelial odontogenic tumor|Calcifying epithelioma of Malherbe|Calcifying nested epithelial stromal tumor|Calcifying odontogenic cyst|Calcitriol|Calcium Channel Blockers|Calcium Release-activated Channel Inhibitor CM4620|Calcium Release-activated Channels Inhibitor RP4010|Calcium Saccharate|Calculus bovis/Moschus/Olibanum/Myrrha Capsule|Calf|Calicheamicin Gamma 1I|Cambodia|Cameroon|Camidanlumab Tesirine|Camptothecin|Camptothecin Analogue TLC388|Camptothecin Glycoconjugate BAY 38-3441|Camptothecin Sodium|Camptothecin-20(S)-O-Propionate Hydrate|Camrelizumab|Camsirubicin|Canada|Canalicular adenoma|Cancell|Cancer|Cancer Control|Cancer Peptide Vaccine S-588410|Cancer Related|Candidiasis|Canerpaturev|Canertinib Dihydrochloride|Canfosfamide|Canfosfamide Hydrochloride|Canis familiaris|Cannabidiol|Cantrixil|Cantuzumab Ravtansine|Cape Verde|Capecitabine|Capecitabine Rapidly Disintegrating Tablet|Capillary|Capillary Hemangioma|Capillary Leak Syndrome|Capillary hemangioma|Capillary lymphangioma|Capivasertib|Capmatinib|Captopril|Caracemide|Carbendazim|Carbetimer|Carbogen|Carbon C 14-pamiparib|Carbon Monoxide Diffusing Capacity Decreased|Carboplatin|Carboquone|Carboxyamidotriazole|Carboxyamidotriazole Orotate|Carboxyphenyl Retinamide|Carcinofibroma|Carcinoid Tumor|Carcinoid Tumor of Uncertain Malignant Potential|Carcinoid tumor of uncertain malignant potential|Carcinoid tumor, NOS|Carcinoid tumor, NOS, of appendix|Carcinoid tumor, argentaffin, NOS|Carcinoid tumor, argentaffin, malignant|Carcinoid, NOS|Carcinoid, NOS, of appendix|Carcinoma|Carcinoma In Situ|Carcinoma In Situ in a Polyp|Carcinoma Simplex|Carcinoma ex Pleomorphic Adenoma|Carcinoma in a Polyp|Carcinoma in a polyp, NOS|Carcinoma in adenomatous polyp|Carcinoma in pleomorphic adenoma|Carcinoma in situ in a polyp, NOS|Carcinoma in situ in adenomatous polyp|Carcinoma in situ, NOS|Carcinoma showing thymus-like differentiation|Carcinoma showing thymus-like element|Carcinoma simplex|Carcinoma with apocrine metaplasia|Carcinoma with chondroid differentiation|Carcinoma with neuroendocrine differentiation|Carcinoma with osseous differentiation|Carcinoma with osteoclast-like giant cells|Carcinoma with other types mesenchymal differentiation|Carcinoma with productive fibrosis|Carcinoma, NOS|Carcinoma, anaplastic, NOS|Carcinoma, diffuse type|Carcinoma, intestinal type|Carcinoma, metastatic, NOS|Carcinoma, undifferentiated, NOS|Carcinomatosis|Carcinosarcoma|Carcinosarcoma, NOS|Carcinosarcoma, embryonal|Cardia|Cardia, NOS|Cardiac Arrest|Cardiac Disorders - Other|Cardiac Troponin I Increased|Cardiac Troponin T Increased|Cardiovascular Disorder|Cardiovascular Disorder, NOS|Carfilzomib|Caricotamide/Tretazicar|Carina|Carlumab|Carmofur|Carmustine|Carmustine Implant|Carmustine Sustained-Release Implant Wafer|Carmustine in Ethanol|Carotid Artery|Carotid Body|Carotid Body Paraganglioma|Carotid body|Carotid body paraganglioma|Carotid body tumor|Carotuximab|Cartilage|Cartilaginous exostosis|Carubicin|Carubicin Hydrochloride|Carzelesin|Carzinophilin|Case submitted is found to be a recurrence after submission|Cataract|Cataracts|Cathelicidin LL-37|Catheter Related Infection|Cationic Liposome-Encapsulated Paclitaxel|Cationic Peptide Cream Cypep-1|Catumaxomab|Cauda equina|Cavernous Hemangioma|Cavernous Lymphangioma|Cavernous hemangioma|Cavernous lymphangioma|Cayman Islands|Cecal Hemorrhage|Cecal Infection|Cecum|Cedazuridine|Cedazuridine/Azacitidine Combination Agent ASTX030|Cedazuridine/Decitabine Combination Agent ASTX727|Cedefingol|Cediranib|Cediranib Maleate|Celecoxib|Celiac Disease|Cell|Cell Culture|Cell Culture Image|Cell Cycle Checkpoint/DNA Repair Antagonist IC83|Cell Line Derived Xenograft Tissue|Cell Lines|Cell-Line|CellRanger - 10x Chromium|CellRanger - 10x Filtered Counts|CellRanger - 10x Raw Counts|Cellular Angiofibroma|Cellular Blue Nevus|Cellular Ependymoma|Cellular Fibroma|Cellular Leiomyoma|Cellular Schwannoma|Cellular angiofibroma|Cellular blue nevus|Cellular ependymoma|Cellular fibroma|Cellular leiomyoma|Cellular schwannoma|Cemadotin|Cemadotin Hydrochloride|Cementifying fibroma|Cemento-ossifying fibroma|Cementoblastoma|Cementoblastoma, benign|Cementoma, NOS|Cemiplimab|Cenersen|Cenisertib|Center QC failed|CenterNotification|Central African Republic|Central Nervous System|Central Nervous System Embryonal Tumor with Rhabdoid Features|Central Nervous System Embryonal Tumor, Not Otherwise Specified|Central Nervous System Lymphoma|Central Nervous System Necrosis|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 1|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 2|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 3|Central Neurocytoma|Central neuroblastoma|Central neurocytoma|Central odontogenic fibroma|Central osteosarcoma|Central portion of breast|Central primitive neuroectodermal tumor, NOS|Centroblastic Lymphoma|Ceralasertib|Ceramide Nanoliposome|Cerdulatinib|Cerebellar Liponeurocytoma|Cerebellar Sarcoma|Cerebellar liponeurocytoma|Cerebellar sarcoma, NOS|Cerebellum|Cerebellum, NOS|Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480|Cereblon E3 Ubiquitin Ligase Modulating Agent CC-99282|Cereblon Modulator CC-90009|Cerebral Cortex|Cerebral Hemisphere|Cerebral Meninges|Cerebral meninges|Cerebrospinal Fluid|Cerebrospinal Fluid Leakage|Cerebrovascular Disease|Cerebrum|Cergutuzumab Amunaleukin|Ceritinib|Ceruminous Adenocarcinoma|Ceruminous adenocarcinoma|Ceruminous adenoma|Ceruminous carcinoma|Cervical Adenocarcinoma Admixed with Neuroendocrine Carcinoma|Cervical Cancer|Cervical Cancer (all types)|Cervical Cancer pT1a1 TNM Finding v8|Cervical Cancer pT1a2 TNM Finding v8|Cervical Mucinous Adenocarcinoma, Gastric Type|Cervical Mucinous Adenocarcinoma, Intestinal-Type|Cervical Spine|Cervical Squamotransitional Carcinoma|Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma|Cervical Villoglandular Adenocarcinoma|Cervical esophagus|Cervical intraepithelial neoplasia, grade III|Cervical intraepithelial neoplasia, low grade|Cervicitis Infection|Cervix|Cervix Uteri|Cervix uteri|Cesalin|Cetrelimab|Cetuximab|Cetuximab Sarotalocan|Cetuximab-IR700 Conjugate RM-1929|Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY)|Cevipabulin|Cevipabulin Fumarate|Cevipabulin Succinate|Cevostamab|ChIP-Seq|Chad|Chaparrin|Chaparrinone|Checkpoint Kinase Inhibitor AZD7762|Checkpoint Kinase Inhibitor XL844|Cheek mucosa|Cheilitis|Chemical Lysis DNA Extraction|Chemodectoma|Chemoembolization|Chemoprotectant|Chemotherapy|Chest|Chest Pain - Cardiac|Chest Wall|Chest Wall Pain|ChiNing Decoction|Chiauranib|Chief cell adenoma|Child|Child-Pugh Class A|Child-Pugh Class A5|Child-Pugh Class A6|Child-Pugh Class B|Child-Pugh Class B7|Child-Pugh Class B8|Child-Pugh Class B9|Child-Pugh Class C|Child-Pugh Class C10|Child-Pugh Class C11|Child-Pugh Class C12|Childhood Astrocytic Tumor|Chile|Chills|Chimeric Monoclonal Antibody 81C6|Chin|China|Chk1 Inhibitor CCT245737|Chk1 Inhibitor GDC-0425|Chk1 Inhibitor GDC-0575|Chlamydia|Chlamydomonas reinhardtii|Chlorambucil|Chlorodihydropyrimidine|Chloroma|Chloroquine|Chloroquinoxaline Sulfonamide|Chlorotoxin|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes|Chlorozotocin|Cholangiocarcinoma|Cholangioma|Cholecystitis|Cholelithiasis|Cholesterol High|Choline|Choline Kinase Alpha Inhibitor TCD-717|Chondroblastic Osteosarcoma|Chondroblastic osteosarcoma|Chondroblastoma|Chondroblastoma, NOS|Chondroblastoma, malignant|Chondroid Chordoma|Chondroid Lipoma|Chondroid chordoma|Chondroid lipoma|Chondroid syringoma|Chondroma|Chondroma, NOS|Chondromatosis|Chondromatosis, NOS|Chondromatous giant cell tumor|Chondromyxoid Fibroma|Chondromyxoid fibroma|Chondrosarcoma|Chondrosarcoma grade 2/3|Chondrosarcoma, NOS|Chordoid Glioma of the Third Ventricle|Chordoid Meningioma|Chordoid glioma|Chordoid glioma of third ventricle|Chordoid meningioma|Chordoma|Chordoma, NOS|Chorioadenoma|Chorioadenoma destruens|Chorioangioma|Choriocarcinoma|Choriocarcinoma Combined with Other Germ Cell Elements|Choriocarcinoma combined with embryonal carcinoma|Choriocarcinoma combined with other germ cell elements|Choriocarcinoma combined with teratorna|Choriocarcinoma, NOS|Chorioepithelioma|Chorionepithelioma|Choroid|Choroid Plexus Carcinoma|Choroid Plexus Papilloma|Choroid plexus carcinoma|Choroid plexus papilloma, NOS|Choroid plexus papilloma, anaplastic|Choroid plexus papilloma, malignant|Choroidal and Ciliary Body Melanoma pT4e TNM Finding v8|Chromaffin paraganglioma|Chromaffin tumor|Chromaffinoma|Chromomycin A3|Chromophobe Renal Cell Carcinoma|Chromophobe adenocarcinoma|Chromophobe adenoma|Chromophobe carcinoma|Chromophobe cell renal carcinoma|Chronic Eosinophilic Leukemia, Not Otherwise Specified|Chronic Fatigue Syndrome|Chronic Hepatitis|Chronic Kidney Disease|Chronic Kidney Disease, Stage 5|Chronic Leukemia|Chronic Lymphocytic Leukemia|Chronic Lymphoproliferative Disorder of NK-Cells|Chronic Monocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Myeloproliferative Disorders|Chronic Neutrophilic Leukemia|Chronic Renal Failure|Chronic Systemic Steroid Use|Chronic eosinophilic leukemia, NOS|Chronic erythremia|Chronic granulocytic leukemia, BCR/ABL|Chronic granulocytic leukemia, NOS|Chronic granulocytic leukemia, Philadelphia chromosome (Ph1) positive|Chronic granulocytic leukemia, t(9;22)(q34;q11)|Chronic idiopathic myelofibrosis|Chronic leukemia, NOS|Chronic lymphatic leukemia|Chronic lymphocytic leukemia|Chronic lymphocytic leukemia, B-cell type (includes all variants of BCLL)|Chronic lymphoid leukemia|Chronic lymphoproliferative disorder of NK cells|Chronic monocytic leukemia|Chronic myelocytic leukemia, NOS|Chronic myelogenous leukemia, BCR-ABL positive|Chronic myelogenous leukemia, Philadelphia chromosome (Ph 1) positive|Chronic myelogenous leukemia, t(9;22)(q34;q11)|Chronic myeloid leukemia, NOS|Chronic myelomonocytic leukemia in transformation|Chronic myelomonocytic leukemia, NOS|Chronic myelomonocytic leukemia, Type 1|Chronic myelomonocytic leukemia, Type II|Chronic myeloproliferative disease, NOS|Chronic myeloproliferative disorder|Chronic neutrophilic leukemia|Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement|Chylothorax|Chymotrypsin|Cibisatamab|Ciclopirox Prodrug CPX-POM|Cidan Herbal Capsule|Ciforadenant|Cigar|Cigarette|Cilengitide|Ciliary Body|Ciliary body|Ciltacabtagene Autoleucel|Cimetidine|Cin III, NOS|Cinacalcet Hydrochloride|Cinobufagin|Cinobufotalin|Cinrebafusp Alfa|Cintirorgon|Cintredekin Besudotox|Circumscribed arachnoidal cerebellar sarcoma|Cirmtuzumab|Cirrhosis|Cirrhosis, Unknown Etiology|Cisplatin|Cisplatin Liposomal|Cisplatin-E Therapeutic Implant|Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6|Citarinostat|Citatuzumab Bogatox|Citius HRT|Cixutumumab|Cladribine|Clanfenur|Clarithromycin|Class 1/4 Histone Deacetylase Inhibitor OKI-179|Classic Medulloblastoma|Classical Hodgkin lymphoma, lymphocyte depletion, NOS|Classical Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis|Classical Hodgkin lymphoma, lymphocyte depletion, reticular|Classical Hodgkin lymphoma, lymphocyte-rich|Classical Hodgkin lymphoma, mixed cellularity, NOS|Classical Hodgkin lymphoma, nodular sclerosis, NOS|Classical Hodgkin lymphoma, nodular sclerosis, cellular phase|Classical Hodgkin lymphoma, nodular sclerosis, grade 1|Classical Hodgkin lymphoma, nodular sclerosis, grade 2|Clavicle|Clear Cell Adenocarcinoma|Clear Cell Adenofibroma|Clear Cell Adenoma|Clear Cell Chondrosarcoma|Clear Cell Cystadenofibroma|Clear Cell Ependymoma|Clear Cell Hidradenoma|Clear Cell Meningioma|Clear Cell Neoplasm|Clear Cell Odontogenic Carcinoma|Clear Cell Renal Cell Carcinoma|Clear Cell Sarcoma of Soft Tissue|Clear Cell Sarcoma of the Kidney|Clear cell (glycogen-rich) urothelial carcinoma|Clear cell adenocarcinofibroma|Clear cell adenocarcinoma, NOS|Clear cell adenocarcinoma, mesonephroid|Clear cell adenofibroma|Clear cell adenofibroma of borderline malignancy|Clear cell adenoma|Clear cell carcinoma|Clear cell chondrosarcoma|Clear cell cystadenocarcinofibroma|Clear cell cystadenofibroma|Clear cell cystadenofibroma of borderline malignancy|Clear cell cystadenoma|Clear cell cystic tumor of borderline malignancy|Clear cell ependymoma|Clear cell hidradenoma|Clear cell meningioma|Clear cell odontogenic carcinoma|Clear cell odontogenic tumor|Clear cell sarcoma of kidney|Clear cell sarcoma of the kidney (CCSK)|Clear cell sarcoma, NOS|Clear cell sarcoma, of tendons and aponeuroses|Clear cell tumor, NOS|Clinical|Clinical Supplement|Clinical Trial|Clinical Trial Agent|Clinical data insufficient|Clioquinol|Clitoris|Clivatuzumab|Cloacogenic carcinoma|Cloacogenic zone|Clodronate Disodium|Clodronic Acid|Clofarabine|Clomesone|Clomiphene|Clomiphene Citrate|Clonal Hematopoiesis|Clostridium Novyi-NT Spores|Coal smoke, NOS|Cobimetinib|Cobolimab|Cobomarsen|Coccidioidomycosis|Cochlear Nerve|Codman tumor|Codrituzumab|Coenzyme Q10|Cofetuzumab Pelidotin|Cognitive Disturbance|Cohort Level Copy Number Scores|Colchicine-Site Binding Agent ABT-751|Cold Contaminant-free Iobenguane I-131|Colitis|Collecting Duct Carcinoma|Collecting duct carcinoma|Colloid adenocarcinoma|Colloid adenoma|Colloid carcinoma|Colloidal Gold-Bound Tumor Necrosis Factor|Colombia|Colon|Colon - Mucosa Only|Colon Adenocarcinoma|Colon Polyps|Colon, NOS|Colonic Fistula|Colonic Hemorrhage|Colonic Obstruction|Colonic Perforation|Colonic Stenosis|Colonic Ulcer|Colonization, Bacterial|Colonization, Fungal|Colonoscopy|Colorectal|Colorectal Cancer|Colorectal Cancer Peptide Vaccine PolyPEPI1018|Colorectal Tumor-Associated Peptides Vaccine IMA910|Coltuximab Ravtansine|Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Columnar cell papilloma|Combined Carcinoid and Adenocarcinoma|Combined Hepatocellular Carcinoma and Cholangiocarcinoma|Combined Lung Large Cell Neuroendocrine Carcinoma|Combined Lung Small Cell Carcinoma|Combined Lung Small Cell Carcinoma and Lung Adenocarcinoma|Combined Nucleotide Variation|Combined carcinoid and adenocarcinoma|Combined hepatocellular carcinoma and cholangiocarcinoma|Combined large cell neuroendocrine carcinoma|Combined small cell carcinoma|Combined small cell-adenocarcinoma|Combined small cell-large carcinoma|Combined small cell-squamous cell carcinoma|Combined/mixed carcinoid and adenocarcinoma|Combretastatin|Combretastatin A-1|Combretastatin A1 Diphosphate|Comedocarcinoma|Comedocarcinoma, NOS|Comedocarcinoma, noninfiltrating|Commensal Bacterial Strain Formulation VE800|Commissure of lip|Common ALL|Common Acute Lymphoblastic Leukemia|Common Duct|Common Variable Immunodeficiency|Common precursor B ALL|Common variable immune deficiency (CVID)|Comoros|Complete Data Freeze|Complete Genomics|Complete Hydatidiform Mole|Complete Necrosis (No Viable Tumor)|Complete Remission|Complete Response|Complete Response Unconfirmed|Complete hydatidiform mole|Complex Epithelial Neoplasms|Complex Mixed and Stromal Neoplasms|Complex Odontoma|Complex odontoma|Composite Hodgkin and non-Hodgkin lymphoma|Composite Lymphoma|Composite carcinoid|Compound Kushen Injection|Compound Nevus|Compound Odontoma|Compound nevus|Compound odontoma|Conatumumab|Conbercept|Concentrated Lingzhi Mushroom Extract|Concentration Impairment|Concurrent Chemoradiation|Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011|Conduction Disorder|Condylomatous carcinoma|Confusion|Congenital Mesoblastic Nephroma|Congenital fibrosarcoma|Congenital generalized fibromatosis|Congenital peribronchial myofibroblastic tumor|Congenital, Familial and Genetic Disorders - Other|Congestive Heart Failure (CHF)|Congo|Conjunctiva|Conjunctivitis|Conjunctivitis Infective|Connective Tissue|Connective Tissue Disorder|Connective, subcutaneous and other soft tissues|Connective, subcutaneous and other soft tissues of abdomen|Connective, subcutaneous and other soft tissues of head, face, and neck|Connective, subcutaneous and other soft tissues of lower limb and hip|Connective, subcutaneous and other soft tissues of pelvis|Connective, subcutaneous and other soft tissues of thorax|Connective, subcutaneous and other soft tissues of trunk, NOS|Connective, subcutaneous and other soft tissues of upper limb and shoulder|Connective, subcutaneous and other soft tissues, NOS|Consent Exemption|Consent Waiver|Consent by Death|Constipation|Constrictive Pericarditis|Control Analyte|Conventional Osteosarcoma|Conventional central osteosarcoma|Convincing Image Source|Cook Islands|Cooking-related smoke, NOS|Copanlisib|Copanlisib Hydrochloride|Copper Cu 64-ATSM|Copper Cu 67 Tyr3-octreotate|Copper Gluconate|Copy Number Estimate|Copy Number Segment|Copy Number Variation|Cord Blood Derived CAR T-Cells|Cord Blood-derived Expanded Natural Killer Cells PNK-007|Cordycepin|Cordycepin Triphosphate|Core Biopsy|Coriolus Versicolor Extract|Cornea, NOS|Corneal Infection|Corneal Ulcer|Coronary Artery Disease|Corpus uteri|Cortex of adrenal gland|Cortical T ALL|Corticorelin Acetate|Cortisone Acetate|Cosibelimab|Cositecan|Costa Rica|Cote d'Ivoire|Cough|Course of Therapy Completed|Cousin|Cowden Syndrome|Coxsackievirus A21|Coxsackievirus V937|CpG Oligodeoxynucleotide GNKG168|Cranial Nerve Infection|Cranial nerve, NOS|Craniopharyngeal duct|Craniopharyngioma|Craniopharyngioma, adamantinomatous|Craniopharyngioma, papillary|Creatinine Increased|Crenolanib|Crenolanib Besylate|Cribriform Carcinoma|Cribriform carcinoma in situ|Cribriform carcinoma, NOS|Cribriform comedo-type carcinoma|Crizotinib|Croatia|Crohn's Disease|Crolibulin|Cryoablation|Cryopreserved|Cryptococcal Meningitis|Cryptococcosis|Cryptogenic Organizing Pneumonia|Cryptophycin|Cryptophycin 52|Cryptosporidiosis, Chronic Intestinal|Crystalline Genistein Formulation AXP107-11|Cuba|Cufflinks|Curacao|Curcumin|Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110|Cure|Current User|Cusatuzumab|Cushingoid|Custirsen Sodium|Cutaneous Mastocytosis|Cutaneous Nodular Melanoma|Cutaneous T-cell lymphoma, NOS|Cutaneous histiocytoma, NOS|Cutaneous lymphoma, NOS|Cutaneous mastocytosis|Cyclin-dependent Kinase 8/19 Inhibitor BCD 115|Cyclin-dependent Kinase Inhibitor PF-06873600|Cyclodextrin-Based Polymer-Camptothecin CRLX101|Cyclodisone|Cycloleucine|Cyclopentenyl Cytosine|Cyclophosphamide|Cyclophosphamide Anhydrous|Cyclosporine|Cylindrical cell carcinoma|Cylindrical cell papilloma|Cylindroma|Cylindroma of skin|Cylindroma, NOS|Cyproterone|Cyproterone Acetate|Cyprus|Cyst(s)|Cyst-associated renal cell carcinoma|Cystadenocarcinoma|Cystadenocarcinoma, NOS|Cystadenofibroma|Cystadenofibroma, NOS|Cystadenoma|Cystadenoma, NOS|Cystectomy|Cystic Hygroma|Cystic Partially Differentiated Kidney Nephroblastoma|Cystic Teratoma|Cystic Tumor of the Atrioventricular Node|Cystic astrocytoma|Cystic hygroma|Cystic hypersecretory carcinoma|Cystic lymphangioma|Cystic mesothelioma, NOS|Cystic mesothelioma, benign|Cystic partially differentiated nephroblastoma|Cystic teratoma, NOS|Cystic tumor of atrio-ventricular node|Cystic, Mucinous and Serous Neoplasms|Cystitis Noninfective|Cystoma, NOS|Cystosarcoma phyllodes, NOS|Cystosarcoma phyllodes, benign|Cystosarcoma phyllodes, malignant|Cystoscopy|Cytarabine|Cytarabine Monophosphate Prodrug MB07133|Cytarabine-asparagine Prodrug BST-236|Cytidine Analog RX-3117|Cytochlor|Cytokine Release Syndrome|Cytokine-based Biologic Agent IRX-2|Cytologic Atypia|Cytology|Cytomegalovirus|Cytomegalovirus (CMV)|Czech Republic (Czechia)|D|D-methionine Formulation MRX-1024|DAB389 Epidermal Growth Factor|DACH Polymer Platinate AP5346|DACH-Platin Micelle NC-4016|DCIS, NOS|DCIS, comedo type|DCIS, papillary|DDA|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|DEXSeq|DFS|DGE|DHA-Paclitaxel|DHEA Mustard|DI-Leu16-IL2 Immunocytokine|DIA|DIN 3|DKK1-Neutralizing Monoclonal Antibody DKN-01|DM-CHOC-PEN|DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015|DNA|DNA Interference Oligonucleotide PNT2258|DNA Methylation|DNA Minor Groove Binding Agent SG2000|DNA Plasmid Encoding Interleukin-12 INO-9012|DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151|DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457|DNA Vaccine VB10.16|DNA-PK inhibitor AZD7648|DNA-PK/PI3K-delta Inhibitor BR101801|DNA-PK/TOR Kinase Inhibitor CC-115|DNA-dependent Protein Kinase Inhibitor VX-984|DNAcopy|DNMT1 Inhibitor NTX-301|DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98|DPT/BCG/Measles/Serratia/Pneumococcus Vaccine|DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine|DPX-E7 HPV Vaccine|DR5 HexaBody Agonist GEN1029|DR5-targeting Tetrameric Nanobody Agonist TAS266|DSQ II|DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555|DU-Disease Unchanged|DVT/PE|Dabrafenib|Dabrafenib Mesylate|Dabska tumor|Dacarbazine|Dacetuzumab|Daclizumab|Dacomitinib|Dacplatinum|Dactinomycin|Dactolisib|Dactolisib Tosylate|Dalantercept|Dalotuzumab|Danio rerio (zebrafish)|Daniquidone|Danusertib|Danvatirsen|Daporinad|Daratumumab|Daratumumab and Hyaluronidase-fihj|Daratumumab/rHuPH20|Darinaparsin|Darleukin|Darolutamide|Daromun|Dasatinib|Daughter|Daughter-in-law|Daunorubicin|Daunorubicin Citrate|Daunorubicin Hydrochloride|Dead|Death|Death Certificate|Death NOS|Death Neonatal|Debulking|Decitabine|Decitabine and Cedazuridine|Dedifferentiated Chondrosarcoma|Dedifferentiated Chordoma|Dedifferentiated Liposarcoma|Dedifferentiated chondrosarcoma|Dedifferentiated chordoma|Dedifferentiated liposarcoma|Deep ""Aggressive"" Angiomyxoma|Deep Benign Fibrous Histiocytoma|Deep Gray (e.g. Basal Ganglia, Thalamus)|Deep Gray Matter|Deep Parotidectomy|Deep Vein Thrombosis / Thromboembolism|Deep histiocytoma|Defactinib|Defactinib Hydrochloride|Deferoxamine|Deferoxamine Mesylate|Degarelix|Degarelix Acetate|Degenerated Schwannoma|Degenerated schwannoma|Dehydration|Delanzomib|Delayed Orgasm|Delayed Puberty|Delirium|Delolimogene Mupadenorepvec|Delta_B_Allele_Freq|Delusions|Demcizumab|Demecolcine|Democratic Republic of the Congo|Demplatin Pegraglumer|Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466|Dendritic Cell Tumor, Not Otherwise Specified|Dendritic Cell Vaccine|Dendritic Cell-Autologous Lung Tumor Vaccine|Dendritic Cell-targeting Lentiviral Vector ID-LV305|Dendritic cell sarcoma, NOS|Denenicokin|Dengue Virus Adjuvant PV-001-DV|Denibulin|Denibulin Hydrochloride|Denileukin Diftitox|Denintuzumab Mafodotin|Denmark|Denosumab|Dental Caries|Dentinogenic Ghost Cell Tumor|Dentinoma|Denys-Drash Syndrome|Deoxycytidine Analogue TAS-109|Deoxycytidine Analogue TAS-109 Hydrochloride|Depatuxizumab|Depatuxizumab Mafodotin|Depressed Level of Consciousness|Depression|Derazantinib|Derived Cell Line|Dermal|Dermal Nevus|Dermal and epidermal nevus|Dermal nevus|Dermatitis Radiation|Dermatofibroma lenticulare|Dermatofibroma, NOS|Dermatofibrosarcoma Protuberans|Dermatofibrosarcoma protuberans, NOS|Dermatofibrosarcoma, NOS|Dermatomyosis|Dermoid Cyst|Dermoid cyst with malignant transformation|Dermoid cyst with secondary tumor|Dermoid cyst, NOS|Dermoid, NOS|Descended testis|Descending Colon|Descending colon|Deslorelin|Deslorelin Acetate|Desmoid, NOS|Desmoid-Type Fibromatosis|Desmoplastic Infantile Astrocytoma|Desmoplastic Infantile Ganglioglioma|Desmoplastic Melanoma|Desmoplastic Mesothelioma|Desmoplastic Small Round Cell Tumor|Desmoplastic fibroma|Desmoplastic infantile astrocytoma|Desmoplastic infantile ganglioglioma|Desmoplastic medulloblastoma|Desmoplastic melanoma, amelanotic|Desmoplastic melanoma, malignant|Desmoplastic mesothelioma|Desmoplastic nodular medulloblastoma|Desmoplastic small round cell tumor|Desmoplastic/Nodular Medulloblastoma|Detirelix|Detorubicin|Deuteporfin|Deuterated Enzalutamide|Device Related Infection|Devimistat|Dexamethason|Dexamethasone|Dexamethasone Phosphate|Dexamethasone Sodium Phosphate|Dexanabinol|Dexrazoxane|Dexrazoxane Hydrochloride|Dezaguanine|Dezaguanine Mesylate|Dezapelisib|Di Guglielmo disease|DiART|DiLeu|Diabetes|Diabetes, NOS|Diabetes, Type I|Diabetes, Type II|Diabetic Neuropathy|Diagnosis|Diagnostic Imaging|Diagnostic Slide|Dianhydrogalactitol|Diaphragm|Diarrhea|Diarylsulfonylurea Compound ILX-295501|Diazepinomicin|Diaziquone|Diazooxonorleucine|Dibrospidium Chloride|Dichloroallyl Lawsone|Dictyostelium discoideum|Dicycloplatin|Didox|Dienogest|Diet|Diet Controlled Diabetes|Diethylnorspermine|Differential Gene Expression|Differentiated Retinoblastoma|Differentiated penile intraepithelial neoplasia|Differentiated-type vulvar intraepithelial neoplasia|Differentiating|Differentiating Neuroblastoma|Diffuse|Diffuse Astrocytoma|Diffuse Astrocytoma, IDH-Mutant|Diffuse Astrocytoma, IDH-Wildtype|Diffuse Centroblastic-Centrocytic Lymphoma|Diffuse Cutaneous Mastocytosis|Diffuse Intraductal Papillomatosis|Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma (DLBCL)|Diffuse Large B-Cell Lymphoma Arising in HHV8-Positive Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation|Diffuse Leptomeningeal Glioneuronal Tumor|Diffuse Malignant Lymphoma|Diffuse Midline Glioma, H3 K27M-Mutant|Diffuse Retinoblastoma|Diffuse Sclerosing Variant Thyroid Gland Papillary Carcinoma|Diffuse Type Adenocarcinoma|Diffuse astrocytoma|Diffuse astrocytoma, IDH-mutant|Diffuse astrocytoma, IDH-wildtype|Diffuse astrocytoma, low grade|Diffuse cutaneous mastocytosis|Diffuse intraductal papillomatosis|Diffuse large B-cell lymphoma associated with chronic inflammation|Diffuse large B-cell lymphoma, NOS|Diffuse leptomeningeal glioneuronal tumor|Diffuse melanocytosis|Diffuse meningiomatosis|Diffuse midline glioma, H3 K27M-mutant|Digestive System Mixed Adenoneuroendocrine Carcinoma|Digital Papillary Adenocarcinoma|Digital papillary adenocarcinoma|Digitoxin|Digoxin|Dihydro-5-Azacytidine|Dihydrolenperone|Dihydroorotate Dehydrogenase Inhibitor AG-636|Dihydroorotate Dehydrogenase Inhibitor BAY2402234|Diindolylmethane|Diktyoma, benign|Diktyoma, malignant|Dilation and Curettage|Dilation and Curettage Procedure|Dilpacimab|Dimethylmyleran|Dinaciclib|Dinutuximab|Dionex|Dioscorea nipponica Makino Extract DNE3|Diphencyprone|Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777|Disease Progression|Disease Response|Disqualified|Disseminated Intravascular Coagulation|Distal (>2cm)|Distant|Distant Metastasis|Distant Nodes|Distant Organ|Distant Site|Distant met recurrence/progression|Ditiocarb|Diverticulitis|Dizziness|Djibouti|Docetaxel|Docetaxel Anhydrous|Docetaxel Emulsion ANX-514|Docetaxel Formulation CKD-810|Docetaxel Lipid Microspheres|Docetaxel Nanoparticle CPC634|Docetaxel Polymeric Micelles|Docetaxel-PNP|Docetaxel-loaded Nanopharmaceutical CRLX301|Docetaxel/Ritonavir|Dociparstat sodium|Dolastatin 10|Dolastatin 15|Domatinostat|Dome of bladder|Dome of the Bladder|Domestic Partner|Dominica|Dominican Republic|Donafenib|Dopamine-Somatostatin Chimeric Molecule BIM-23A760|Dorsal surface of tongue, NOS|Dostarlimab|Double-armed TMZ-CD40L/4-1BBL Oncolytic Ad5/35 Adenovirus LOAd703|Dovitinib|Dovitinib Lactate|Downstream Data Freeze|Doxazosin|Doxercalciferol|Doxifluridine|Doxorubicin|Doxorubicin Hydrochloride|Doxorubicin Prodrug L-377,202|Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370|Doxorubicin-Eluting Beads|Doxorubicin-HPMA Conjugate|Doxorubicin-Magnetic Targeted Carrier Complex|Doxorubicin-loaded EGFR-targeting Nanocells|Drinker|Dromostanolone Propionate|Drosophila melanogaster|Drozitumab|Dry Eye|Dry Mouth|Dry Skin|Dual IGF-1R/InsR Inhibitor BMS-754807|Dual Variable Domain Immunoglobulin ABT-165|Dual-affinity B7-H3/CD3-targeted Protein MGD009|Dubermatinib|Duborimycin|Duct adenocarcinoma, NOS|Duct adenoma, NOS|Duct carcinoma, NOS|Duct carcinoma, desmoplastic type|Duct cell carcinoma|Ductal Breast Carcinoma|Ductal Breast Carcinoma In Situ|Ductal Breast Carcinoma In Situ and Invasive Lobular Carcinoma|Ductal Breast Carcinoma In Situ and Lobular Carcinoma In Situ|Ductal and Lobular Neoplasms|Ductal carcinoma in situ, NOS|Ductal carcinoma in situ, comedo type|Ductal carcinoma in situ, cribriform type|Ductal carcinoma in situ, micropapillary|Ductal carcinoma in situ, papillary|Ductal carcinoma in situ, solid type|Ductal carcinoma, NOS|Ductal carcinoma, cribriform type|Ductal intraepithelial neoplasia 3|Ductal papilloma|Dulanermin|Duligotuzumab|Duodenal Fistula|Duodenal Hemorrhage|Duodenal Infection|Duodenal Obstruction|Duodenal Perforation|Duodenal Stenosis|Duodenal Ulcer|Duodenum|Dupilumab|Duplicate case|Duplicate item|Durvalumab|Dusigitumab|Duvelisib|Duvortuxizumab|Dynemicin|Dynemicin A|Dysarthria|Dysembryoplastic Neuroepithelial Tumor|Dysembryoplastic neuroepithelial tumor|Dysesthesia|Dysgerminoma|Dysgeusia|Dyslipidemia|Dysmenorrhea|Dyspareunia|Dyspepsia|Dysphagia|Dysphasia|Dysplasia Negative|Dysplastic Cerebellar Gangliocytoma|Dysplastic Nevus|Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)|Dysplastic nevus|Dyspnea|E|E2F1 Pathway Activator ARQ 171|E4512|EA5142|EBNA-1 inhibitor VK-2019|EBV Immortalized|EBV Immortalized Normal|EBV positive diffuse large B-cell lymphoma of the elderly|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EC cell carcinoid|ECD|ECL cell carcinoid, NOS|ECL cell carcinoid, malignant|EED Inhibitor MAK683|EGFR Antagonist Hemay022|EGFR Antisense DNA BB-401|EGFR Inhibitor AZD3759|EGFR Inhibitor BIBX 1382|EGFR Inhibitor DBPR112|EGFR Inhibitor PD-168393|EGFR Inhibitor TY-9591|EGFR Mutant-selective  Inhibitor TQB3804|EGFR Mutant-specific Inhibitor BPI-7711|EGFR Mutant-specific Inhibitor CK-101|EGFR Mutant-specific Inhibitor D-0316|EGFR Mutant-specific Inhibitor ZN-e4|EGFR T790M Antagonist BPI-15086|EGFR T790M Inhibitor HS-10296|EGFR/EGFRvIII Inhibitor WSD0922-FU|EGFR/FLT3/Abl Inhibitor SKLB1028|EGFR/HER1/HER2 Inhibitor PKI166|EGFR/HER2 Inhibitor AP32788|EGFR/HER2 Inhibitor AV-412|EGFR/HER2 Inhibitor DZD9008|EGFR/HER2 Kinase Inhibitor TAK-285|EGFR/TGFb Fusion Monoclonal Antibody BCA101|EGFR/VEGFR/RET Inhibitor HA121-28|EGb761|EMD 1000|EP2/EP4 Antagonist TPST-1495|EP4 Antagonist INV-1120|EP4 Antagonist ONO-4578|ER alpha Proteolysis-targeting Chimera Protein Degrader ARV-471|ERK 1/2 Inhibitor ASTX029|ERK Inhibitor CC-90003|ERK Inhibitor GDC-0994|ERK Inhibitor LTT462|ERK Inhibitor MK-8353|ERK1/2 Inhibitor ASN007|ERK1/2 Inhibitor HH2710|ERK1/2 Inhibitor JSI-1187|ERK1/2 Inhibitor KO-947|ERK1/2 Inhibitor LY3214996|ERa36 Modulator Icaritin|ETD|EVOQ Elite|EVOQ Qube|EZH1/2 Inhibitor DS-3201|EZH1/2 Inhibitor HH2853|EZH2 Inhibitor CPI-1205|EZH2 Inhibitor PF-06821497|EZH2 Inhibitor SHR2554|EZH2 inhibitor CPI-0209|Ear|Ear Canal|Ear Pain|Ear and Labyrinth Disorders - Other|Ear, Pinna (External)|Early Onset Gastric Cancer|Ecchondroma|Ecchondrosis|Eccrine Hidrocystoma|Eccrine acrospiroma|Eccrine adenocarcinoma|Eccrine cystadenoma|Eccrine dermal cylindroma|Eccrine papillary adenocarcinoma|Eccrine papillary adenoma|Eccrine poroma|Eccrine poroma, malignant|Eccrine spiradenoma|Echinomycin|Ecromeximab|Ectocervix|Ectomesenchymoma|Ectopic Hamartomatous Thymoma|Ectopic Pregnancy|Ectopic hamartomatous thymoma|Ecuador|Eczema|Edatrexate|Edelfosine|Edema Cerebral|Edema Face|Edema Limbs|Edema Trunk|Edicotinib|Edodekin alfa|Edotecarin|Edrecolomab|Efatutazone|Efatutazone Dihydrochloride|Effusion|Efizonerimod|Eflornithine|Eflornithine Hydrochloride|Eftilagimod Alpha|Eftozanermin Alfa|Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205|Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621|Egypt|Eicosapentaenoic Acid|Ejaculation Disorder|Ejection Fraction Decreased|El Salvador|Elacestrant|Elacytarabine|Elagolix|Elastofibroma|Elbasvir/Grazoprevir|Elbow|Electrical fire smoke|Electrocardiogram QT Corrected Interval Prolonged|Electronic Cigarette|Electronic cigarette smoke, NOS|Element 2|Element GD|Element XR|Elesclomol|Elesclomol Sodium|Elgemtumab|Elinafide|Elisidepsin|Elliptinium|Elliptinium Acetate|Elmustine|Elotuzumab|Elpamotide|Elsamitrucin|Eltanexor|Emactuzumab|Emapalumab|Embolization|Embryonal Carcinoma|Embryonal Rhabdomyosarcoma|Embryonal Tumor with Multilayered Rosettes, C19MC-Altered|Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified|Embryonal adenocarcinoma|Embryonal adenoma|Embryonal carcinoma, NOS|Embryonal carcinoma, infantile|Embryonal carcinoma, polyembryonal type|Embryonal hepatoma|Embryonal rhabdomyosarcoma, NOS|Embryonal rhabdomyosarcoma, pleomorphic|Embryonal sarcoma|Embryonal teratoma|Embryonal tumor with multilayered rosettes C19MC-altered|Embryonal tumor with multilayered rosettes, NOS|Embryonal tumor with rhabdoid features|Emepepimut-S|Emibetuzumab|Emitefur|Emofolin Sodium|Empesertib|Enadenotucirev|Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A|Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641|Enasidenib|Enasidenib Mesylate|Enavatuzumab|Encapsulated Rapamycin|Encapsulated Variant Thyroid Gland Papillary Carcinoma|Encapsulated follicular variant of papillary thyroid carcinoma, NOS (EFVPTC, NOS)|Encapsulated papillary carcinoma|Encapsulated papillary carcinoma with invasion|Encelimab|Encephalitis Infection|Encephalomyelitis Infection|Encephalopathy|Enchondroma|Enclomiphene|Enclomiphene Citrate|Encorafenib|End-stage Renal Disease|Endemic|Endemic Burkitt Lymphoma|Endo Rectal Tumor Resection|Endocarditis Infective|Endocervical Adenocarcinoma, Usual Type|Endocervical adenocarcinoma usual type|Endocervix|Endocrine Disorders - Other|Endocrine Gland|Endocrine adenomatosis|Endocrine gland, NOS|Endocrine tumor, functioning, NOS|Endodermal sinus tumor|Endolaryngeal Excision|Endolymphatic stromal myosis|Endometrial Endometrioid Adenocarcinoma, Ciliated Variant|Endometrial Endometrioid Adenocarcinoma, Secretory Variant|Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation|Endometrial Stromal Nodule|Endometrial sarcoma, NOS|Endometrial stromal nodule|Endometrial stromal sarcoma, NOS|Endometrial stromal sarcoma, high grade|Endometrial stromal sarcoma, low grade|Endometrial stromatosis|Endometrioid Adenocarcinoma|Endometrioid Stromal Sarcoma|Endometrioid adenocarcinoma, NOS|Endometrioid adenocarcinoma, ciliated cell variant|Endometrioid adenocarcinoma, secretory variant|Endometrioid adenocarcinoma, villoglandular|Endometrioid adenofibroma, NOS|Endometrioid adenofibroma, borderline malignancy|Endometrioid adenofibroma, malignant|Endometrioid adenoma, NOS|Endometrioid adenoma, borderline malignancy|Endometrioid carcinoma with squamous differentiation|Endometrioid carcinoma, NOS|Endometrioid cystadenocarcinoma|Endometrioid cystadenofibroma, NOS|Endometrioid cystadenofibroma, borderline malignancy|Endometrioid cystadenofibroma, malignant|Endometrioid cystadenoma, NOS|Endometrioid cystadenoma, borderline malignancy|Endometrioid tumor of low malignant potential|Endometriosis|Endometrium|Endophthalmitis|Endosalpingiosis|Endoscopic Biopsy|Endoscopic Mucosal Resection (EMR)|Endoscopy|Endothelin B Receptor Blocker ENB 003|Endothelin Receptor Type A Antagonist YM598|Endotheliomatous meningioma|Endovascular papillary angioendothelioma|Enfortumab Vedotin|Engineered Human Umbilical Vein Endothelial Cells AB-205|Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240|Engineered Toxin Body Targeting CD38 TAK-169|Engineered Toxin Body Targeting HER2 MT-5111|Eniluracil/5-FU Combination Tablet|Enloplatin|Enneking High Surgical Grade|Enneking Low Surgical Grade|Enneking Metastasis M0|Enneking Metastasis M1|Enoblituzumab|Enobosarm|Enoticumab|Enpromate|Ensartinib|Ensituximab|Enteric adenocarcinoma|Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride|Enterochromaffin cell carcinoid|Enterochromaffin-Like Cell Neuroendocrine Tumor G1|Enterochromaffin-like cell carcinoid, NOS|Enterochromaffin-like cell tumor, malignant|Enterococcus gallinarum Strain MRx0518|Enterocolitis|Enterocolitis Infectious|Enteroglucagonoma|Enteroglucagonoma, NOS|Enteroglucagonoma, malignant|Enteropathy associated T-cell lymphoma|Enteropathy type intestinal T-cell lymphoma|Enteropathy-Associated T-Cell Lymphoma|Enterovesical Fistula|Entinostat|Entolimod|Entospletinib|Entrectinib|Enucleation|Envafolimab|Environmental tobacco smoke|Enzalutamide|Enzastaurin|Enzastaurin Hydrochloride|Eosinophil adenocarcinoma|Eosinophil adenoma|Eosinophil carcinoma|Eosinophilic Granuloma|Eosinophilic granuloma|Eosinophilic leukemia|Epacadostat|Epcoritamab|Ependymoblastoma|Ependymoma|Ependymoma, NOS|Ependymoma, RELA Fusion-Positive|Ependymoma, RELA fusion-positive|Ependymoma, anaplastic|EphA2-targeting Bicycle Toxin Conjugate BT5528|Epidermoid carcinoma in situ with questionable stromal invasion|Epidermoid carcinoma in situ, NOS|Epidermoid carcinoma, NOS|Epidermoid carcinoma, keratinizing|Epidermoid carcinoma, large cell, nonkeratinizing|Epidermoid carcinoma, small cell, nonkeratinizing|Epidermoid carcinoma, spindle cell|Epididymis|Epidural Space|Epilepsy|Epipodophyllotoxin Analog GL331|Epipodophyllotoxin-Related Myelodysplastic Syndrome|Epipropidine|Epirubicin|Epirubicin Hydrochloride|Epistaxis|Epithelial Dysplasia|Epithelial Hyperplasia|Epithelial Neoplasm|Epithelial Neoplasms, NOS|Epithelial Synovial Sarcoma|Epithelial ependymoma|Epithelial tumor, benign|Epithelial tumor, malignant|Epithelial-Myoepithelial Carcinoma|Epithelial-myoepithelial carcinoma|Epithelioid Cell Melanoma|Epithelioid Cell Nevus|Epithelioid Cell Type Gastrointestinal Stromal Tumor|Epithelioid Glioblastoma|Epithelioid Hemangioendothelioma|Epithelioid Hemangioma|Epithelioid Leiomyosarcoma|Epithelioid MPNST|Epithelioid Malignant Peripheral Nerve Sheath Tumor|Epithelioid Mesothelioma|Epithelioid Sarcoma|Epithelioid Trophoblastic Tumor|Epithelioid and spindle cell nevus|Epithelioid cell melanoma|Epithelioid cell nevus|Epithelioid cell sarcoma|Epithelioid glioblastoma|Epithelioid hemangioendothelioma, NOS|Epithelioid hemangioendothelioma, malignant|Epithelioid hemangioma|Epithelioid leiomyoma|Epithelioid leiomyosarcoma|Epithelioid malignant peripheral nerve sheath tumor|Epithelioid mesothelioma, NOS|Epithelioid mesothelioma, benign|Epithelioid mesothelioma, malignant|Epithelioid sarcoma|Epithelioma adenoides cysticum|Epithelioma, NOS|Epithelioma, benign|Epithelioma, malignant|Epitinib Succinate|Epitiostanol|Epitrochlear|Epothilone Analog UTD1|Epothilone KOS-1584|Epratuzumab|Epratuzumab-cys-tesirine|Epstein-Barr Virus|Equatorial Guinea|Equivocal|Erastin Analogue PRLX 93936|Erbulozole|Erdafitinib|Erectile Dysfunction|Eribulin|Eribulin Mesylate|Eritrea|Erlotinib|Erlotinib Hydrochloride|Ertumaxomab|Erythema Multiforme|Erythremic myelosis, NOS|Erythrocyte-encapsulated L-asparaginase Suspension|Erythroderma|Erythroleukemia|Escherichia coli|Esophageal Anastomotic Leak|Esophageal Cancer|Esophageal Carcinoma|Esophageal Fistula|Esophageal Hemorrhage|Esophageal High Grade Intraepithelial Neoplasia|Esophageal Infection|Esophageal Necrosis|Esophageal Obstruction|Esophageal Pain|Esophageal Perforation|Esophageal Stenosis|Esophageal Ulcer|Esophageal Varices Hemorrhage|Esophageal glandular dysplasia (intraepithelial neoplasia), high grade|Esophageal glandular dysplasia (intraepithelial neoplasia), low grade|Esophageal intraepithelial neoplasia, high grade|Esophageal squamous intraepithelial neoplasia (dysplasia), high grade|Esophageal squamous intraepithelial neoplasia (dysplasia), low grade|Esophageal; Distal|Esophageal; Mid|Esophageal; Proximal|Esophagitis|Esophagogastric Junction|Esophagus|Esophagus - Mucosa Only|Esophagus, NOS|Esorubicin|Esorubicin Hydrochloride|Esperamicin A1|Essential Thrombocythemia|Essential hemorrhagic thrombocythaemia|Essential thrombocythemia|Essiac|Esterified Estrogens|Esthesioneuroblastoma|Esthesioneurocytoma|Esthesioneuroepithelioma|Estonia|Estradiol Valerate|Estramustine|Estramustine Phosphate Sodium|Estrogen Receptor Agonist GTx-758|Estrogen only|Estrogens, Conjugated|Eswatini|Etalocib|Etanercept|Etanidazole|Etaracizumab|Etarotene|Ethanol Injection Ablation|Ethaselen|Ethinyl Estradiol|Ethiopia|Ethmoid sinus|Ethyleneimine|Ethylnitrosourea|Etidronate-Cytarabine Conjugate MBC-11|Etigilimab|Etirinotecan Pegol|Etoglucid|Etoposide|Etoposide Phosphate|Etoposide Toniribate|Etoprine|Etoricoxib|Ets-family Transcription Factor Inhibitor TK216|Euphoria|Everolimus|Everolimus Tablets for Oral Suspension|Every 24 Hours|Every Hour|Every Other Day|Every day|Evofosfamide|Ewing Sarcoma|Ewing sarcoma|Ewing tumor|Ex Vivo-expanded Autologous T Cells IMA101|Exactive|Exactive Plus|Exatecan Mesylate|Exatecan Mesylate Anhydrous|Excision|Excisional Biopsy|Exemestane|Exicorilant|Exisulind|Exocervix|Exon Expression Quantification|Exoresection|Exostosis|Expanded Next Generation Cancer Model|Experiment Metadata|Extended Release Flucytosine|Extended Release Metformin Hydrochloride|Extended-release Onapristone|External Auditory Canal Ceruminous Adenoma|External Beam Radiation|External Ear Inflammation|External Ear Pain|External Lower Lip|External ear|External lip, NOS|External lower lip|External upper lip|Extra-Adrenal Paraganglioma|Extra-abdominal desmoid|Extra-adrenal paraganglioma, NOS|Extra-adrenal paraganglioma, malignant|Extraabdominal Fibromatosis|Extracompartmental (T2)|Extracompartmental Tumor|Extracutaneous Mastocytoma|Extracutaneous mastocytoma|Extrahepatic bile duct|Extramammary Paget Disease|Extramural|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Extranodal NK/T-cell lymphoma, nasal type|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extraocular Muscle Paresis|Extraosseous Plasmacytoma|Extraosseous plasmacytoma|Extrapyramidal Disorder|Extraventricular Neurocytoma|Extraventricular neurocytoma|Eye|Eye Disorders - Other|Eye Infection|Eye Pain|Eye and adnexa|Eye, NOS|Eyelid|Eyelid Function Disorder|Ezabenlimab|F16-IL2 Fusion Protein|FAB L2|FAB L3|FAB Ll|FAB M1|FAB M2, AML1(CBF-alpha)/ETO|FAB M2, NOS|FAB M2, t(8;21)(q22;q22)|FAB M3 (includes all variants)|FAB M4|FAB M4Eo|FAB M5 (includes all variants)|FAB M6|FAB M7|FAB MO|FACT Complex-targeting Curaxin CBL0137|FAK Inhibitor GSK2256098|FAK Inhibitor PF-00562271|FAK Inhibitor VS-4718|FAK/ALK/ROS1 Inhibitor APG-2449|FAP/4-1BB-targeting DARPin MP0310|FAP/4-1BB-targeting Fusion Protein RO7122290|FASN Inhibitor TVB-2640|FASTA|FASTQ|FFPE|FFPE DNA|FFPE RNA|FFPE Recurrent|FFPE Scrolls|FGF Receptor Antagonist HGS1036|FGF/FGFR Pathway Inhibitor E7090|FGFR Inhibitor ASP5878|FGFR Inhibitor AZD4547|FGFR Inhibitor CPL304110|FGFR Inhibitor Debio 1347|FGFR Inhibitor TAS-120|FGFR/CSF-1R Inhibitor 3D185|FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999|FGFR1/2/3 Inhibitor HMPL-453|FGFR2 Inhibitor RLY-4008|FGFR4 Antagonist INCB062079|FGFR4 Inhibitor BLU 9931|FGFR4 Inhibitor FGF401|FGFR4 Inhibitor H3B-6527|FGFR4 Inhibitor ICP-105|FIGO Stage IA|FIGO Stage IC1|FIGO Stage IC2|FIGO Stage IC3|FIGO Stage IIIA1(i)|FIGO Stage IIIA1(ii)|FIGO Stage IIIA2|FIRMA|FLT3 Inhibitor FF-10101 Succinate|FLT3 Inhibitor HM43239|FLT3 Inhibitor SKI-G-801|FLT3 Tyrosine Kinase Inhibitor TTT-3002|FLT3/ABL/Aurora Kinase Inhibitor KW-2449|FLT3/CDK4/6 Inhibitor FLX925|FLT3/FGFR Dual Kinase Inhibitor MAX-40279|FLT3/KIT Kinase Inhibitor AKN-028|FLT3/KIT/CSF1R Inhibitor NMS-03592088|FM Copy Number Variation|FM Simple Somatic Mutation|FM Structural Variation|FMS Inhibitor JNJ-40346527|FPV Vaccine CV301|FPV-Brachyury-TRICOM Vaccine|FTMS|Facial Muscle Weakness|Facial Nerve Disorder|Facial Pain|Factor VII-targeting Immunoconjugate Protein ICON-1|Factor VIIa Inhibitor PCI-27483|Factory smokestack smoke|Fadraciclib|Fadrozole Hydrochloride|Falimarev|Falkland Islands (Malvinas)|Fall|Fallopian Tube|Fallopian Tube Anastomotic Leak|Fallopian Tube Obstruction|Fallopian Tube Perforation|Fallopian Tube Stenosis|Fallopian tube|False|Familial Adenomatous Polyposis|Familial polyposis coli|Famitinib|Fanconi Anemia|Farletuzumab|Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778,123|Faroe Islands|Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells|Fas Receptor Agonist APO010|Fascial Fibroma|Fascial Fibrosarcoma|Fascial fibroma|Fascial fibrosarcoma|Fascin Inhibitor NP-G2-044|Fat Atrophy|Father|Father-in-law|Fatigue|Favezelimab|Favorable|Fazarabine|Fc-engineered Anti-CD40 Agonist Antibody 2141-V11|Febrile Neutropenia|Febuxostat|Fecal Incontinence|Federated States of Micronesia|Fedratinib|Fedratinib Hydrochloride|Feladilimab|Felzartamab|Female|Female Cousin|Female Genital Tract Fistula|Female Genitalia|Female Reproductive System Adenofibroma|Female Sibling of Adopted Child|Female genital tract, NOS|Feminization Acquired|Femoral Artery|Femoral Vein|Femur|Fenebrutinib|Fenretinide|Fenretinide Lipid Matrix|Fenretinide Phospholipid Suspension ST-001|Fetal Death|Fetal Growth Retardation|Fetal Rhabdomyoma|Fetal adenocarcinoma|Fetal adenoma|Fetal fat cell lipoma|Fetal lipoma, NOS|Fetal lipomatosis|Fetal rhabdomyoma|Fever|Fianlimab|Fibrillary Astrocytoma|Fibrillary astrocytoma|Fibrinogen Decreased|Fibro-osteoma|Fibroadenoma, NOS|Fibroameloblastic odontoma|Fibroblastic Liposarcoma|Fibroblastic Osteosarcoma|Fibroblastic Reticular Cell Tumor|Fibroblastic liposarcoma|Fibroblastic meningioma|Fibroblastic osteosarcoma|Fibroblastic reticular cell tumor|Fibroblasts|Fibroblasts from Bone Marrow Normal|Fibrochondrosarcoma|Fibroepithelial Neoplasms|Fibroepithelial basal cell carcinoma, Pinkus type|Fibroepithelioma of Pinkus type|Fibroepithelioma, NOS|Fibrofolliculoma|Fibroid uterus|Fibrolamellar Carcinoma|Fibrolipoma|Fibroliposarcoma|Fibroma|Fibroma, NOS|Fibromatosis-like metaplastic carcinoma|Fibromatous Neoplasms|Fibromun|Fibromyalgia|Fibromyoma|Fibromyxoid Tumor|Fibromyxolipoma|Fibromyxoma|Fibromyxosarcoma|Fibrosarcoma|Fibrosarcoma, NOS|Fibrosarcomatous Dermatofibrosarcoma Protuberans|Fibrosarcomatous dermatofibrosarcoma protuberans|Fibrosis|Fibrosis Deep Connective Tissue|Fibrous Meningioma|Fibrous astrocytoma|Fibrous histiocytoma of tendon sheath|Fibrous histiocytoma, NOS|Fibrous meningioma|Fibrous mesothelioma, NOS|Fibrous mesothelioma, benign|Fibrous mesothelioma, malignant|Fibrous papule of nose|Fibroxanthoma, NOS|Fibroxanthoma, malignant|Fibula|Ficlatuzumab|Field burning smoke|Figitumumab|Fiji|Filanesib|Filgotinib|Filgrastim|Fimaporfin A|Fimepinostat|Fine Needle Aspiration|Finger|Finland|Fire smoke, NOS|First Cousin|First Cousin Once Removed|First Patient Visit|First Treatment|Firtecan Pegol|Fisogatinib|Five Times Daily|Flank Pain|Flanvotumab|Flashing Lights|Flat Adenoma|Flat adenoma|Flat intraepithelial glandular neoplasia, high grade|Flat intraepithelial neoplasia, high grade|Flatulence|Floaters|Floor Of Mouth|Floor of Mouth|Floor of mouth|Floor of mouth, NOS|Florid osseous dysplasia|Flotetuzumab|Floxuridine|Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01|Flt3/MerTK Inhibitor MRX-2843|Flu Like Symptoms|Fludarabine|Fludarabine Phosphate|Fluid|Flumatinib|Flumatinib Mesylate|Fluorine F 18 Ara-G|Fluorodopan|Fluorouracil|Fluorouracil Implant|Fluorouracil-E Therapeutic Implant|Fluoxymesterone|Flushing|Flutamide|Fluvastatin|Fluvastatin Sodium|Fluzoparib|Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate|Focal|Folate Receptor Targeted Epothilone BMS753493|Folate Receptor-Targeted Tubulysin Conjugate EC1456|Folate Receptor-Targeted Vinca Alkaloid EC0489|Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225|Folate-FITC|Folic Acid|Folitixorin|Follicular Dendritic Cell Sarcoma|Follicular Lymphoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma, Encapsulated Subtype with Invasion|Follicular adenocarcinoma, NOS|Follicular adenocarcinoma, moderately differentiated|Follicular adenocarcinoma, trabecular|Follicular adenocarcinoma, well differentiated|Follicular adenoma|Follicular adenoma, oxyphilic cell|Follicular carcinoma, NOS|Follicular carcinoma, encapsulated|Follicular carcinoma, minimally invasive|Follicular carcinoma, moderately differentiated|Follicular carcinoma, oxyphilic cell|Follicular carcinoma, trabecular|Follicular carcinoma, well differentiated|Follicular dendritic cell sarcoma|Follicular dendritic cell tumor|Follicular fibroma|Follicular lymphoma, NOS|Follicular lymphoma, grade 1|Follicular lymphoma, grade 2|Follicular lymphoma, grade 3|Follicular lymphoma, grade 3A|Follicular lymphoma, grade 3B|Follicular lymphoma, small cleaved cell|Follicular thyroid carcinoma (FTC), encapsulated angioinvasive|Folliculome lipidique|Foot|Forced Expiratory Volume Decreased|Forearm|Forehead|Foreskin|Foretinib|Foritinib Succinate|Former User|Formestane|Forodesine Hydrochloride|Fosaprepitant|Fosbretabulin|Fosbretabulin Disodium|Fosbretabulin Tromethamine|Fosgemcitabine Palabenamide|Fosifloxuridine Nafalbenamide|Foslinanib|Foslinanib Disodium|Fosquidone|Foster Brother|Foster Daughter|Foster Father|Foster Mother|Foster Sister|Foster Son|Fostriecin|Fotemustine|Fotretamine|FoundationOne Annotation|FoundationOne Report|FoundationOne Variant Aggregation and Masking|FoundationOne XML|Four Times Daily|Fracture|France|Franklin disease|Fraternal Twin Brother|Fraternal Twin Sibling|Fraternal Twin Sister|French Guiana|French Polynesia|Fresh|Fresolimumab|Frontal Cortex|Frontal Lobe|Frontal Sinus|Frontal lobe|Frontal sinus|Frozen|Fruquintinib|Full Brother|Full Hysterectomy|Full Sister|Fulvestrant|Fumagillin-Derived Polymer Conjugate XMT-1107|Functioning Endocrine Neoplasm|Fundus Of Stomach|Fundus Uteri|Fundus of Stomach|Fundus of stomach|Fundus uteri|Furnace or boiler smoke|Fursultiamine|Fusion Catcher|Futibatinib|Futuximab|Futuximab/Modotuximab Mixture|G|G Protein-coupled Estrogen Receptor Agonist LNS8801|G cell tumor, NOS|G cell tumor, malignant|G-Quadruplex Stabilizer BMVC|G1|G2|G3|G4|GANT|GATK4 MuTect2|GATK4 MuTect2 Annotation|GB|GBM Antigens and Alloantigens Immunotherapeutic Vaccine|GC IsoLink|GCT|GCT Premier|GENIE Copy Number Variation|GENIE Report|GENIE Simple Somatic Mutation|GENIE Structural Variation|GENIE Variant Aggregation and Masking|GERD|GGT Increased|GI-4000 Vaccine|GIST, NOS|GIST, benign|GIST, malignant|GISTIC - Arm Level Copy Number|GISTIC - Copy Number Score|GISTIC - Focal Amplification|GISTIC - Focal Deletion|GITR Agonist MEDI1873|GM-CSF-encoding Oncolytic Adenovirus CGTG-102|GS/pan-Notch Inhibitor AL101|GS/pan-Notch Inhibitor BMS-986115|GSK-3 Inhibitor 9-ING-41|GSK-3 Inhibitor LY2090314|GVF|GX|Gabon|Gait Disturbance|Galamustine|Galarubicin|Galectin Inhibitor GR-MD-02|Galectin-1 Inhibitor OTX008|Galeterone|Galiximab|Gallbladder|Gallbladder Cancer|Gallbladder Fistula|Gallbladder Infection|Gallbladder Necrosis|Gallbladder Obstruction|Gallbladder Pain|Gallbladder Papillary Neoplasm with Intermediate Grade Intraepithelial Neoplasia|Gallbladder Papillary Neoplasm with Low Grade Intraepithelial Neoplasia|Gallbladder Perforation|Gallium-based Bone Resorption Inhibitor AP-002|Gallus gallus|Galocitabine|Galunisertib|Gambia|Gamboge Resin Extract TSB-9-W1|Gamma Heavy Chain Disease|Gamma heavy chain disease|Gamma-Secretase Inhibitor LY3039478|Gamma-Secretase Inhibitor RO4929097|Gamma-delta Tocotrienol|Gandotinib|Ganetespib|Ganglia|Gangliocytic paraganglioma|Gangliocytoma|Ganglioglioma|Ganglioglioma, NOS|Ganglioglioma, anaplastic|Ganglioneuroblastoma|Ganglioneuroma|Ganglioneuromatosis|Ganglioside GD2|Ganglioside GM2|Ganitumab|Ganoderma lucidum Spores Powder Capsule|Garlic|Gas burning smoke, propane|Gasterosteus aculeatus (fish)|Gastric Anastomotic Leak|Gastric Cancer|Gastric Fistula|Gastric Hemorrhage|Gastric Necrosis|Gastric Parietal Cell Adenocarcinoma|Gastric Perforation|Gastric Polyp(s)|Gastric Stenosis|Gastric Ulcer|Gastric antrum|Gastrin Immunotoxin|Gastrin cell tumor|Gastrin cell tumor, malignant|Gastrin-Producing Neuroendocrine Tumor|Gastrin/cholecystokinin Type B Receptor Inhibitor Z-360|Gastrinoma, NOS|Gastrinoma, malignant|Gastritis|Gastroesophageal Junction|Gastroesophageal Reflux Disease|Gastrointestinal Anastomotic Leak|Gastrointestinal Autonomic Nerve Tumor|Gastrointestinal Disorders - Other|Gastrointestinal Fistula|Gastrointestinal Pain|Gastrointestinal Stoma Necrosis|Gastrointestinal Stromal Tumor|Gastrointestinal Stromal Tumor of Uncertain Malignant Potential|Gastrointestinal Tract|Gastrointestinal autonomic nerve tumor|Gastrointestinal pacemaker cell tumor|Gastrointestinal stromal sarcoma|Gastrointestinal stromal tumor, NOS|Gastrointestinal stromal tumor, benign|Gastrointestinal stromal tumor, malignant|Gastrointestinal stromal tumor, uncertain malignant potential|Gastrointestinal tract, NOS|Gastrointestinal, Intestine|Gastroparesis|Gataparsen Sodium|Gatipotuzumab|Gedatolisib|Gefitinib|Gelatinous adenocarcinoma|Gelatinous carcinoma|Geldanamycin|Gelonin|Gemcitabine|Gemcitabine Elaidate|Gemcitabine Hydrochloride|Gemcitabine Hydrochloride Emulsion|Gemcitabine Prodrug LY2334737|Gemcitabine-Phosphoramidate Hydrochloride NUC-1031|Gemcitabine-Releasing Intravesical System|Gemistocytic Astrocytoma|Gemistocytic astrocytoma|Gemistocytoma|Gemtuzumab Ozogamicin|Gene Expression Quantification|Gene Level Copy Number|Gene Level Copy Number Scores|General|General Disorders and Administration Site Conditions - Other|Generalized Muscle Weakness|Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum|Genistein|Genital Edema|Genital Rhabdomyoma|Genital rhabdomyoma|Genitourinary, NOS|GenomePlex (Rubicon) Amplified DNA|Genomic Profiling|Genomplex|Genotype mismatch|Genotypes|Genotyping Array|Gentuximab|Georgia|Geranylgeranyltransferase I Inhibitor|Germ Cell Neoplasms|Germ Cell Tumor|Germ cell tumor, NOS|Germ cell tumor, nonseminomatous|Germ cell tumors with associated hematological malignancy|Germany|Germinoma|Gerota Fascia|Ghana|Ghost Cell Odontogenic Carcinoma|Ghost cell odontogenic carcinoma|Giant Cell Angiofibroma|Giant Cell Carcinoma|Giant Cell Fibroblastoma|Giant Cell Glioblastoma|Giant Cell Sarcoma|Giant Cell Tumor of Bone|Giant Cell Tumor of Soft Tissue|Giant Cell Tumors|Giant Cell and Spindle Cell Carcinoma|Giant Congenital Nevus|Giant cell and spindle cell carcinoma|Giant cell angiofibroma|Giant cell carcinoma|Giant cell fibroblastoma|Giant cell glioblastoma|Giant cell sarcoma|Giant cell sarcoma of bone|Giant cell tumor of bone, NOS|Giant cell tumor of bone, malignant|Giant cell tumor of soft parts, NOS|Giant cell tumor of tendon sheath|Giant cell tumor of tendon sheath, malignant|Giant fibroadenoma|Giant osteoid osteoma|Giant pigmented nevus, NOS|Gibraltar|Gigantiform Cementoma|Gigantiform cementoma|Gilbert's Syndrome|Giloralimab|Gilteritinib|Gilteritinib Fumarate|Gimatecan|Gimeracil|Gingival Pain|Ginsenoside Rg3 Capsule|Giredestrant|Girentuximab|Girodazole|Givinostat|Glandular Papilloma|Glandular Papillomatosis|Glandular intraepithelial neoplasia, grade I|Glandular intraepithelial neoplasia, grade II|Glandular intraepithelial neoplasia, grade III|Glandular intraepithelial neoplasia, high grade|Glandular intraepithelial neoplasia, low grade|Glandular papilloma|Glans Penis|Glans penis|Glasdegib|Glasdegib Maleate|Glassy Cell Carcinoma|Glassy cell carcinoma|Glaucarubolone|Glaucoma|Gleason Grade Group 1|Gleason Grade Group 2|Gleason Grade Group 3|Gleason Grade Group 4|Gleason Grade Group 5|Gleason Pattern 1|Gleason Pattern 2|Gleason Pattern 3|Gleason Pattern 4|Gleason Pattern 5|Glecaprevir/Pibrentasvir|Glembatumumab Vedotin|Glesatinib|Glioblastoma|Glioblastoma Cancer Vaccine ERC1671|Glioblastoma Multiforme|Glioblastoma Multiforme Multipeptide Vaccine IMA950|Glioblastoma multiforme|Glioblastoma with sarcomatous component|Glioblastoma, IDH wildtype|Glioblastoma, IDH-Mutant|Glioblastoma, IDH-Wildtype|Glioblastoma, IDH-mutant|Gliofibroma|Glioma|Glioma Lysate Vaccine GBM6-AD|Glioma, NOS|Glioma, malignant|Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701|Gliomas|Gliomatosis Cerebri|Gliomatosis cerebri|Glioneuroma|Gliosarcoma|Globo H-DT Vaccine OBI-833|Glofitamab|Glomangioma|Glomangiomyoma|Glomangiosarcoma|Glomerular Disease|Glomoid sarcoma|Glomus Tumor|Glomus jugulare tumor, NOS|Glomus tumor, NOS|Glomus tumor, malignant|Glossectomy|Glossopharyngeal Nerve Disorder|Glottis|Glucagon-like peptide-producing tumor|Glucagonoma, NOS|Glucagonoma, malignant|Glucarpidase|Glucocorticoid Receptor Antagonist ORIC-101|Glucose Intolerance|Glufosfamide|Glumetinib|Glutaminase Inhibitor CB-839|Glutaminase Inhibitor CB-839 Hydrochloride|Glutaminase Inhibitor IPN60090|Glutamine Antagonist DRP-104|Glutamyl endopeptidase|Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101|Glyco-TMT|Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01|Glycogen Storage Disease|Glycogen-Rich Carcinoma|Glycogen-rich carcinoma|Glycogenic rhabdomyoma|Glycooptimized Trastuzumab-GEX|Glycoproteome|Goblet cell carcinoid|Gold Sodium Thiomalate|Golnerminogene Pradenovec|Golotimod|Golvatinib|Gonadal Dysfunction|Gonadal stromal tumor, NOS|Gonadoblastoma|Gonadotropin-releasing Hormone Analog|Gonocytoma|Good Prognosis|Gorlin Syndrome|Goserelin|Goserelin Acetate|Goserelin Acetate Extended-release Microspheres LY01005|Gossypol|Gossypol Acetic Acid|Gout|Grade 1|Grade 1 Follicular Lymphoma|Grade 1 Nodular Sclerosis Classic Hodgkin Lymphoma|Grade 2|Grade 2 Follicular Lymphoma|Grade 2 Nodular Sclerosis Classic Hodgkin Lymphoma|Grade 3|Grade 3 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Grade 3b Follicular Lymphoma|Grade 4|Grade 5|Grade B|Grade I|Grade I Neuroendocrine Carcinoma|Grade II|Grade II Glandular Intraepithelial Neoplasia|Grade II Neuroendocrine Carcinoma|Grade II Squamous Intraepithelial Neoplasia|Grade III|Grade III Glandular Intraepithelial Neoplasia|Grade III Prostatic Intraepithelial Neoplasia|Grade IV|Grade Not Assigned|Grade X|Grand Nephew|Grand Niece|Grandchild|Granddaughter|Grandfather|Grandmother|Grandparent|Grandson|Granular Cell Carcinoma|Granular Cell Tumor|Granular Cell Tumor of the Sellar Region|Granular Cell Tumors and Alveolar Soft Part Sarcomas|Granular cell adenocarcinoma|Granular cell carcinoma|Granular cell myoblastoma, NOS|Granular cell myoblastoma, malignant|Granular cell tumor of the sellar region|Granular cell tumor, NOS|Granular cell tumor, malignant|Granulocytes|Granulocytic Sarcoma|Granulocytic leukemia, NOS|Granulocytic sarcoma|Granulosa Cell Tumor|Granulosa Cell-Theca Cell Tumor|Granulosa cell carcinoma|Granulosa cell tumor, NOS|Granulosa cell tumor, adult type|Granulosa cell tumor, juvenile|Granulosa cell tumor, malignant|Granulosa cell tumor, sarcomatoid|Granulosa cell-theca cell tumor|Grapiprant|Grawitz tumor|Gray|Grease fire smoke|Great Grandchild|Greater Curvature of the Stomach|Greater curvature of stomach, NOS|Greece|Green|Green Tea Extract-based Antioxidant Supplement|Greenland|Grenada|Grilling smoke|Groin|Gross Total Resection|Group 1|Group 2|Group 3|Group 4|Group 5|Group I|Group II|Group III|Group IIIa|Group IIIb|Group IIa|Group IIb|Group IIc|Group IV|Group Ia|Group Ib|Growth Accelerated|Growth Hormone Abnormal|Growth Suppression|Guadecitabine|Guadeloupe|Guam|Guanabenz Acetate|Guatemala|Guernsey|Guinea|Guinea-Bissau|Gum|Gum Infection|Gum, NOS|Guselkumab|Gusperimus Trihydrochloride|Gutolactone|Guyana|Gy|Gynandroblastoma|Gynecologic Cancer|Gynecomastia|H|H-ras Antisense Oligodeoxynucleotide ISIS 2503|H. pylori Infection|H1299 Tumor Cell Lysate Vaccine|H2 Blockers|HAAH Lambda phage Vaccine SNS-301|HBV Core Antibody|HBV DNA|HBV Genotype|HBV Surface Antibody|HCD|HCV DNA Vaccine INO-8000|HCV Genotype|HDAC Class I/IIb Inhibitor HG146|HDAC Inhibitor AR-42|HDAC Inhibitor CHR-2845|HDAC Inhibitor CKD-581|HDAC Inhibitor CXD101|HDAC Inhibitor MPT0E028|HDAC Inhibitor OBP-801|HDAC inhibitor CG200745|HDAC/EGFR/HER2 Inhibitor CUDC-101|HDAC6 Inhibitor KA2507|HDAC8 Inhibitor NBM-BMX|HDF5|HDM2 Inhibitor HDM201|HDM2 Inhibitor MK-8242|HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131|HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901|HER2 Inhibitor CP-724,714|HER2 Inhibitor DZD1516|HER2 Inhibitor TAS0728|HER2 Tri-specific Natural Killer Cell Engager DF1001|HER2-directed TLR8 Agonist SBT6050|HER2-targeted DARPin MP0274|HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302|HER2-targeting Antibody Fc Fragment FS102|HIF-1alpha Inhibitor PX-478|HIF-2alpha Inhibitor PT2385|HIF-2alpha Inhibitor PT2977|HIF2a RNAi ARO-HIF2|HIV|HIV / AIDS|HIV+ Tumor Molecular Characterization Project - Cervical Cancer|HIV+ Tumor Molecular Characterization Project - Lung Cancer|HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001|HLA-A*2402-Restricted Multipeptide Vaccine S-488410|HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201|HM2/MMAE Antibody-Drug Conjugate ALT-P7|HPPH|HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202|HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c|HPV DNA Plasmids Therapeutic Vaccine VGX-3100|HPV E6/E7 DNA Vaccine GX-188E|HPV E6/E7-encoding Arenavirus Vaccine HB-201|HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C|HPV-16 E6 Peptides Vaccine/Candida albicans Extract|HPV-6-targeting Immunotherapeutic Vaccine INO-3106|HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101|HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN|HPV6/11-targeted DNA Plasmid Vaccine INO-3107|HSP90-targeted SN-38 Conjugate PEN-866|HSP90alpha/beta Inhibitor TAS-116|HTSeq - Counts|HTSeq - FPKM|HTSeq - FPKM-UQ|HUS/TTP|Haemangioblastoma|Haemangiosarcoma|Hafnium Oxide-containing Nanoparticles NBTXR3|Hairy Cell Leukemia|Hairy Cell Leukemia Variant|Hairy Nevus|Hairy cell leukaemia variant|Hairy cell leukemia|Hairy cell leukemia variant|Hairy nevus|Haiti|Half Brother|Half Sibling|Half Sister|Halichondrin Analogue E7130|Halichondrin B|Haliotis rufescens|Hallucinations|Halo Nevus|Halo nevus|Halofuginone|Halofuginone Hydrobromide|Hand|Hand Assisted Laparoscopic Radical Nephrectomy|Hand-Schuller-Christian Disease|Hand-Schuller-Christian disease|HaplotypeCaller|Haptoglobin Decreased|Hard Palate|Hard palate|Hashimoto's Thyroiditis|Hashish smoke|Hay Fever|Hazel|Head & Neck|Head - Face Or Neck, Nos|Head Soft Tissue Necrosis|Head and Neck|Head and Neck Cancer|Head and Neck Lymph Node|Head and Neck Squamous Cell Carcinoma|Head of pancreas|Head of the Pancreas|Head, Face or Neck, NOS|Head, face or neck, NOS|Headache|Headaches|Hearing Impaired|Heart|Heart Disease|Heart Failure|Heart, mediastinum, and pleura|Heavy Chain Disease|Heavy Drinker|Heavy chain disease, NOS|Hedgehog Inhibitor IPI-609|Helicobacter Pylori-Associated Gastritis|Hemangioblastic Meningioma|Hemangioblastic meningioma|Hemangioblastoma|Hemangioendothelial sarcoma|Hemangioendothelioma|Hemangioendothelioma, NOS|Hemangioendothelioma, benign|Hemangioendothelioma, malignant|Hemangioma|Hemangioma simplex|Hemangioma, NOS|Hemangiopericytic meningioma|Hemangiopericytoma|Hemangiopericytoma, NOS|Hemangiopericytoma, benign|Hemangiopericytoma, malignant|Hematologic Cancer|Hematologic Disorder, NOS|Hematoma|Hematopoietic System|Hematopoietic and reticuloendothelial systems|Hematopoietic system, NOS|Hematoporphyrin Derivative|Hematosalpinx|Hematuria|Hemiasterlin Analog E7974|Hemihypertrophy|Hemochromatosis|Hemoglobin Increased|Hemoglobinuria|Hemolymphangioma|Hemolysis|Hemolytic Uremic Syndrome|Hemophiliac|Hemorrhagic Cystitis|Hemorrhoidal Hemorrhage|Hemorrhoids|Henatinib Maleate|Heparan Sulfate Glycosaminoglycan Mimetic M402|Heparin Derivative SST0001|Hepatic|Hepatic Duct|Hepatic Encephalopathy|Hepatic Failure|Hepatic Flexure|Hepatic Hemorrhage|Hepatic Infection|Hepatic Necrosis|Hepatic Pain|Hepatic Vein|Hepatic flexure of colon|Hepatitis|Hepatitis A Infection|Hepatitis B Infection|Hepatitis B Surface Antigen|Hepatitis C Antibody|Hepatitis C Infection|Hepatitis C Virus RNA|Hepatitis C virus|Hepatitis Viral|Hepatitis, Chronic|Hepatitis, NOS|Hepatobiliary Disorders - Other|Hepatoblastoma|Hepatoblastoma, epithelioid|Hepatoblastoma, mixed epithelial-mesenchymal|Hepatocarcinoma|Hepatocellular Adenoma|Hepatocellular Carcinoma|Hepatocellular adenoma|Hepatocellular carcinoma, NOS|Hepatocellular carcinoma, clear cell type|Hepatocellular carcinoma, fibrolamellar|Hepatocellular carcinoma, pleomorphic type|Hepatocellular carcinoma, sarcomatoid|Hepatocellular carcinoma, scirrhous|Hepatocellular carcinoma, spindle cell variant|Hepatocholangiocarcinoma|Hepatoid Adenocarcinoma|Hepatoid adenocarcinoma|Hepatoid carcinoma|Hepatoid yolk sac tumor|Hepatoma, NOS|Hepatoma, benign|Hepatoma, malignant|Hepatosplenic T-Cell Lymphoma|Hepatosplenic T-cell lymphoma|Hepatosplenic gamma-delta cell lymphoma|Herba Scutellaria Barbata|Herbimycin|Hereditary Breast Cancer|Hereditary Kidney Oncocytoma|Hereditary Leiomyomatosis and Renal Cell Carcinoma|Hereditary Non-polyposis Colon Cancer|Hereditary Ovarian Cancer|Hereditary Papillary Renal Cell Carcinoma|Hereditary Prostate Cancer|Hereditary Renal Cell Carcinoma|Hereditary leiomyomatosis & RCC-associated renal cell carcinoma|Herpes|Herpes Simplex Virus|Herpes Zoster|Heterodimeric Interleukin-15|Heterosexual Contact|Hexamethylene Bisacetamide|Hexaminolevulinate|Hexylresorcinol|HiChIP|HiRes ESI|HiRes MALDI|Hibernoma|Hiccups|Hidradenocarcinoma|Hidradenoma|Hidradenoma Papilliferum|Hidradenoma papilliferum|Hidradenoma, NOS|Hidrocystoma|High|High Grade|High Grade (G2)|High Grade B-Cell Lymphoma, Not Otherwise Specified|High Grade Ductal Breast Carcinoma In Situ|High Grade Dysplasia|High Grade Esophageal Glandular Intraepithelial Neoplasia|High Grade Esophageal Squamous Intraepithelial Neoplasia|High Grade Glandular Intraepithelial Neoplasia|High Grade Liver Dysplastic Nodule|High Grade Squamous Intraepithelial Neoplasia|High Grade Surface Osteosarcoma|High Risk|High Risk Gastrointestinal Stromal Tumor|High grade surface osteosarcoma|High-Intermediate Risk|High-Risk Wilms Tumor|High-grade Prostatic Intraepithelial Neoplasia (PIN)|High-grade neuroendocrine carcinoma|High-grade serous carcinoma|HighPure miRNA (Allprep DNA) FFPE RNA|Hilar|Hilar Cholangiocarcinoma|Hilar cell tumor|Hilus cell tumor|Hip|Hip Fracture|Hippocampus|Hirsutism|Hispanic or Latino|Histiocyte-rich large B-cell lymphoma|Histiocytic Sarcoma|Histiocytic medullary reticulosis|Histiocytic sarcoma|Histiocytoid hemangioma|Histiocytoma|Histiocytoma, NOS|Histiocytosis X, NOS|Histology|Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126|Histoplasmosis|History of acceptable prior treatment related to a prior/other malignancy|History of unacceptable prior treatment related to a prior/other malignancy|Histrelin Acetate|Hitachi|Hoarseness|Hodgkin Lymphoma|Hodgkin disease, NOS|Hodgkin disease, lymphocyte predominance, NOS|Hodgkin disease, lymphocyte predominance, diffuse|Hodgkin disease, lymphocytic-histiocytic predominance|Hodgkin disease, nodular sclerosis, NOS|Hodgkin disease, nodular sclerosis, lymphocyte depletion|Hodgkin disease, nodular sclerosis, lymphocyte predominance|Hodgkin disease, nodular sclerosis, mixed cellularity|Hodgkin disease, nodular sclerosis, syncytial variant|Hodgkin granuloma|Hodgkin lymphoma, NOS|Hodgkin lymphoma, lymphocyte depletion, NOS|Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis|Hodgkin lymphoma, lymphocyte depletion, reticular|Hodgkin lymphoma, lymphocyte predominance, nodular|Hodgkin lymphoma, lymphocyte-rich|Hodgkin lymphoma, mixed cellularity, NOS|Hodgkin lymphoma, nodular lymphocyte predominance|Hodgkin lymphoma, nodular sclerosis, NOS|Hodgkin lymphoma, nodular sclerosis, cellular phase|Hodgkin lymphoma, nodular sclerosis, grade 1|Hodgkin lymphoma, nodular sclerosis, grade 2|Hodgkin paragranuloma, NOS|Hodgkin paragranuloma, nodular|Hodgkin sarcoma|Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine|Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Depletion|Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Predominance|Hodgkin's Disease, Nodular Sclerosis, Mixed Cellularity|Hodgkin's Granuloma|Hodgkin's Paragranuloma|Holmium Ho 166 Poly(L-Lactic Acid) Microspheres|Holy See|Homo sapiens|Homo sapiens; Mus musculus|Homosexual Contact|Honduras|Hong Kong|Hormone Therapy|Hormones|Hot Flashes|Hsp90 Antagonist KW-2478|Hsp90 Inhibitor AB-010|Hsp90 Inhibitor BIIB021|Hsp90 Inhibitor BIIB028|Hsp90 Inhibitor DS-2248|Hsp90 Inhibitor Debio 0932|Hsp90 Inhibitor HSP990|Hsp90 Inhibitor MPC-3100|Hsp90 Inhibitor PU-H71|Hsp90 Inhibitor SNX-5422 Mesylate|Hsp90 Inhibitor SNX-5542 Mesylate|Hsp90 Inhibitor TQB3474|Hsp90 Inhibitor XL888|Hsp90-targeted Photosensitizer HS-201|Hu14.18-IL2 Fusion Protein EMD 273063|HuaChanSu|Huaier Extract Granule|Huang Lian|Human Combinatorial Antibody Library-based Monoclonal Antibody VAY736|Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104|Human MOAB LICO 28a32|Human Monoclonal Antibody 216|Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307|Human Original Cells|Human Papillomavirus 16 E7 Peptide/Padre 965.10|Human Papillomavirus Infection|Human Papillomavirus-Related Squamous Cell Carcinoma|Human Tumor Original Cells|Humerus|Hungary|Hurthle cell adenocarcinoma|Hurthle cell adenoma|Hurthle cell carcinoma|Hurthle cell tumor|Husband|Hutchinson melanotic freckle, NOS|Hyalinizing trabecular adenoma|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Hycanthone|Hydatid mole|Hydatidiform Mole|Hydatidiform mole, NOS|Hydralazine Hydrochloride|Hydrazide TMT|Hydroa Vacciniforme-Like Lymphoproliferative Disorder|Hydroa vacciniforme-like lymphoma|Hydrocephalus|Hydrocortisone Sodium Succinate|Hydroxychloroquine|Hydroxyprogesterone Caproate|Hydroxytyrosol|Hydroxyurea|Hygroma, NOS|Hypercalcemia|Hypercholesterolemia|Hypereosinophilic Syndrome|Hypereosinophilic syndrome|Hyperglycemia|Hyperhidrosis|Hypericin|Hyperkalemia|Hyperlipidemia|Hypermagnesemia|Hypernatremia|Hypernephroid tumor|Hypernephroma|Hyperparathyroidism|Hypersomnia|Hypertension|Hyperthyroidism|Hypertrichosis|Hypertriglyceridemia|Hyperuricemia|Hypoalbuminemia|Hypocalcemia|Hypoglossal Nerve Disorder|Hypoglycemia|Hypohidrosis|Hypokalemia|Hypomagnesemia|Hyponatremia|Hypoparathyroidism|Hypopharyngeal aspect of aryepiglottic fold|Hypopharynx|Hypopharynx, NOS|Hypophosphatemia|Hypospadias|Hypotension|Hypothermia|Hypothyroidism|Hypoxia|Hypoxia-activated Prodrug TH-4000|Hysterectomy NOS|Hysterectomy, NOS|I|I 131 Antiferritin Immunoglobulin|I 131 Monoclonal Antibody A33|I 131 Monoclonal Antibody CC49|I 131 Monoclonal Antibody F19|I 131 Monoclonal Antibody Lym-1|I-131 Radiation Therapy|IAP Inhibitor APG-1387|IAP Inhibitor AT-406|IAP Inhibitor HGS1029|ICAT|ICPL|ICT-121 Dendritic Cell Vaccine|IDAT|IDF|IDH1 Mutant Inhibitor LY3410738|IDH1(R132) Inhibitor IDH305|IDH1R132H-Specific Peptide Vaccine PEPIDH1M|IDO Peptide Vaccine IO102|IDO-1 Inhibitor LY3381916|IDO/TDO Inhibitor HTI-1090|IDO/TDO Inhibitor LY-01013|IDO1 Inhibitor KHK2455|IDO1 Inhibitor MK-7162|IDO1 Inhibitor PF-06840003|IDO1/TDO2 Inhibitor DN1406131|IDO1/TDO2 Inhibitor M4112|IGF-1R Inhibitor|IGF-1R Inhibitor PL225B|IGF-1R/IR Inhibitor KW-2450|IGF-methotrexate Conjugate|II|III|IL-10 Immunomodulator MK-1966|IL-12-expressing HSV-1 NSC 733972|IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051|IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000|IL-2 Recombinant Fusion Protein ALT-801|IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1|IL4-Pseudomonas Exotoxin Fusion Protein MDNA55|IMR-Immunoresponse|IMT-1012 Immunotherapeutic Vaccine|INO-1001|INR Increased|INRG Stage L1|INRG Stage L2|INRG Stage M|INRG Stage MS|INSS Stage 1|INSS Stage 2A|INSS Stage 2B|INSS Stage 3|INSS Stage 4|INSS Stage 4S|IPD-Immunoprogression|IPTL|IRAK4 Inhibitor CA-4948|ISQ|ISS 1018 CpG Oligodeoxynucleotide|ISS Stage I Plasma Cell Myeloma|ISS Stage II Plasma Cell Myeloma|ISS Stage III Plasma Cell Myeloma|ITK Inhibitor CPI-818|ITP|ITQ 1100|ITQ 700|ITQ 900|IVth Nerve Disorder|Iadademstat|Ianalumab|Ibandronate Sodium|Iberdomide|Iboctadekin|Ibritumomab Tiuxetan|Ibrutinib|Iceland|Icotinib Hydrochloride|Icrucumab|Idarubicin|Idarubicin Hydrochloride|Idarubicin-Eluting Beads|Idasanutlin|Idecabtagene Vicleucel|Idelalisib|Identical Twin Brother|Identical Twin Sibling|Identical Twin Sister|Idetrexed|Idiopathic hemorrhagic thrombocythaemia|Idiopathic thrombocythemia|Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020|Idronoxil|Idronoxil Suppository NOX66|Ieramilimab|Ifabotuzumab|Ifetroban|Ifosfamide|Ileal Fistula|Ileal Hemorrhage|Ileal Obstruction|Ileal Perforation|Ileal Stenosis|Ileal Ulcer|Ileocecal Valve|Ileum|Ileus|Ilginatinib|Ilium|Ilixadencel|Ill-Defined Anatomic Site|Ill-defined sites within respiratory system|Illumina|Illumina Human Methylation 27|Illumina Human Methylation 450|Illumina Methylation Epic|Iloprost|Ilorasertib|Imaging|Imaging Technique|Imalumab|Imaradenant|Imatinib|Imatinib Mesylate|Imetelstat|Imetelstat Sodium|Imexon|Imgatuzumab|Imidazole Mustard|Imidazole-Pyrazole|Imifoplatin|Imipramine Blue|Imiquimod|Immature Teratoma|Immature teratoma, NOS|Immature teratoma, malignant|Immediate-release Onapristone|Immediate-release Tablet Afuresertib|Immune Checkpoint Inhibitor ASP8374|Immune System Disorders - Other|Immunoblastic Lymphoma|Immunoblastic sarcoma|Immunoconjugate RO5479599|Immunocytokine NHS-IL12|Immunocytokine NHS-IL2-LT|Immunocytoma|Immunodeficiency-Related Burkitt Lymphoma|Immunodeficiency-associated, adult|Immunodeficiency-associated, pediatric|Immunoglobulin deposition disease|Immunomodulator LAM-003|Immunomodulator OHR/AVR118|Immunomodulatory Agent CC-11006|Immunomodulatory Oligonucleotide HYB2055|Immunoprogression|Immunoproliferative Diseases|Immunoproliferative disease, NOS|Immunoproliferative small intestinal disease|Immunoresponse|Immunotherapeutic Combination Product CMB305|Immunotherapeutic GSK1572932A|Immunotherapy (Including Vaccines)|Immunotherapy Regimen MKC-1106-MT|Immunotoxin CMD-193|In Situ Neoplasms|Inactivated Oncolytic Virus Particle GEN0101|Inadvertently shipped|Inalimarev|Incisional Biopsy|Incomplete Necrosis (Viable Tumor Present)|Incyclinide|Indatuximab Ravtansine|Indefinite Dysplasia|Indefinite for Dysplasia|Indeterminant|Indeterminate|Indeterminate Dendritic Cell Tumor|Indeterminate dendritic cell tumor|Index Finger|India|Indibulin|Indicine-N-Oxide|Indisulam|Individualized MVA-based Vaccine TG4050|Indocyanine Green-labeled Polymeric Micelles ONM-100|Indole-3-Carbinol|Indolent Systemic Mastocytosis|Indolent systemic mastocytosis|Indomethacin|Indonesia|Indoor stove or fireplace smoke, NOS|Indoor stove or fireplace smoke, coal burning|Indoor stove or fireplace smoke, wood burning|Indoximod|Indoximod Prodrug NLG802|Induced Abortion|Induction Failure AML (AML-IF)|Indusatumab Vedotin|Inebilizumab|Inecalcitol|Infantile Fibrosarcoma|Infantile Hemangioma|Infantile fibrosarcoma|Infantile hemangioma|Infantile myofibromatosis|Infection|Infections and Infestations - Other|Infectious Disorder|Infective Myositis|Infigratinib|Infigratinib Mesylate|Infiltrating Angiolipoma|Infiltrating Bladder Urothelial Carcinoma with Squamous Differentiation|Infiltrating Bladder Urothelial Carcinoma with Trophoblastic Differentiation|Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant|Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant|Infiltrating Bladder Urothelial Carcinoma, Microcystic Variant|Infiltrating Bladder Urothelial Carcinoma, Nested Variant|Infiltrating Lipoma|Infiltrating Papillary Adenocarcinoma|Infiltrating and papillary adenocarcinoma|Infiltrating angiolipoma|Infiltrating basal cell carcinoma, NOS|Infiltrating basal cell carcinoma, non-sclerosing|Infiltrating basal cell carcinoma, sclerosing|Infiltrating duct adenocarcinoma|Infiltrating duct and colloid carcinoma|Infiltrating duct and cribriform carcinoma|Infiltrating duct and lobular carcinoma|Infiltrating duct and lobular carcinoma in situ|Infiltrating duct and mucinous carcinoma|Infiltrating duct and tubular carcinoma|Infiltrating duct carcinoma, NOS|Infiltrating duct mixed with other types of carcinoma|Infiltrating ductular carcinoma|Infiltrating lipoma|Infiltrating lobular carcinoma and ductal carcinoma in situ|Infiltrating lobular carcinoma, NOS|Infiltrating lobular mixed with other types of carcinoma|Infiltrating papillary adenocarcinoma|Inflammation, Hyperkeratosis|Inflammatory Bowel Disease|Inflammatory Liposarcoma|Inflammatory Myofibroblastic Tumor|Inflammatory adenocarcinoma|Inflammatory carcinoma|Inflammatory liposarcoma|Inflammatory myofibroblastic tumor|Infliximab|Informed Consent|Infusion Related Reaction|Infusion Site Extravasation|Ingenol Mebutate|Ingenol Mebutate Gel|Inguinal Lymph Node|Inguinal Region|Iniparib|Initial Diagnosis|Initial Genomic Sequencing|Injected Insulin|Injection Site Reaction|Injury to Carotid Artery|Injury to Inferior Vena Cava|Injury to Jugular Vein|Injury to Superior Vena Cava|Injury, Poisoning and Procedural Complications - Other|Innate Immunostimulator rBBX-01|Inodiftagene Vixteplasmid|Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01|Inosine Monophosphate Dehydrogenase Inhibitor AVN944|Inositol|Inotuzumab Ozogamicin|Inproquone|Insomnia|Insular carcinoma|Insulin|Insulin Controlled Diabetes|Insulinoma, NOS|Insulinoma, malignant|Integrin Receptor Antagonist GLPG0187|Integrin alpha-2 Inhibitor E7820|Interdigitating Dendritic Cell Sarcoma|Interdigitating cell sarcoma|Interdigitating dendritic cell sarcoma|Interferon|Interferon Alfa-2B|Interferon Alfa-N1|Interferon Alfa-N3|Interferon Alfacon-1|Interferon Beta-1A|Interferon Gamma-1b|Interferon-gamma-expressing Adenovirus Vaccine ASN-002|Intergroup Rhabdomyosarcoma Group I|Intergroup Rhabdomyosarcoma Group II|Intergroup Rhabdomyosarcoma Group III|Intergroup Rhabdomyosarcoma Group IIIa|Intergroup Rhabdomyosarcoma Group IIIb|Intergroup Rhabdomyosarcoma Group IIa|Intergroup Rhabdomyosarcoma Group IIb|Intergroup Rhabdomyosarcoma Group IIc|Intergroup Rhabdomyosarcoma Group IV|Intergroup Rhabdomyosarcoma Group Ia|Intergroup Rhabdomyosarcoma Group Ib|Interleukin Therapy|Interleukin-12-Fc Fusion Protein DF6002|Interleukin-15 Agonist Fusion Protein SHR1501|Interleukin-15 Fusion Protein BJ-001|Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306|Interleukin-15/Interleukin-15 Receptor Alpha Sushi+ Domain Fusion Protein SO-C101|Interleukin-2 Liposome|Intermediate|Intermediate Grade|Intermediate Immature Teratoma|Intermediate Prognosis|Intermediate Risk|Intermediate and giant congenital nevus|Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230|Internal Radiation|International Prognostic Index High-Intermediate Risk Group|International Prognostic Index Low-Intermediate Risk Group|Interstitial Pneumontis or ARDS|Interstitial cell tumor, NOS|Interstitial cell tumor, benign|Interstitial cell tumor, malignant|Intestinal Metaplasia|Intestinal Stoma Leak|Intestinal Stoma Obstruction|Intestinal Stoma Site Bleeding|Intestinal T-cell lymphoma|Intestinal tract, NOS|Intestinal-Type Adenocarcinoma|Intestinal-type adenocarcinoma|Intetumumab|Intimal Sarcoma|Intimal sarcoma|Intiquinatine|Intoplicine|Intra-Abdominal Hemorrhage|Intra-Abdominal Lymph Node|Intra-abdominal lymph nodes|Intracanalicular fibroadenoma|Intracompartmental (T1)|Intracompartmental Tumor|Intracortical osteosarcoma|Intracranial Hemorrhage|Intracystic Papillary Breast Carcinoma|Intracystic Papilloma|Intracystic carcinoma, NOS|Intracystic papillary adenocarcinoma|Intracystic papillary adenoma|Intracystic papillary neoplasm with associated invasive carcinoma|Intracystic papillary neoplasm with high grade intraepithelial neoplasia|Intracystic papillary neoplasm with intermediate grade intraepithelial neoplasia|Intracystic papillary neoplasm with low grade intraepithelial neoplasia|Intracystic papillary tumor with high grade dysplasia|Intracystic papillary tumor with high grade entraepithelial neoplasia|Intracystic papillary tumor with high grade intraepithelial neoplasia|Intracystic papilloma|Intradermal nevus|Intraductal Carcinoma of the Minor Salivary Gland|Intraductal Cribriform Breast Adenocarcinoma|Intraductal Papillary Adenocarcinoma with Invasion|Intraductal Papillary Breast Carcinoma|Intraductal Papillary Mucinous Neoplasm|Intraductal Papilloma|Intraductal Papillomatosis|Intraductal adenocarcinoma, noninfiltrating, NOS|Intraductal and Lobular Carcinoma|Intraductal and lobular carcinoma|Intraductal carcinoma and lobular carcinoma in situ|Intraductal carcinoma, NOS|Intraductal carcinoma, clinging|Intraductal carcinoma, noninfiltrating, NOS|Intraductal carcinoma, solid type|Intraductal micropapillary carcinoma|Intraductal papillary adenocarcinoma with invasion|Intraductal papillary adenocarcinoma, NOS|Intraductal papillary carcinoma|Intraductal papillary mucinous neoplasm (IPMN) with an associated invasive carcinoma|Intraductal papillary mucinous neoplasm with an associated invasive carcinoma|Intraductal papillary mucinous neoplasm with high grade dysplasia|Intraductal papillary neoplasm with associated invasive carcinoma|Intraductal papillary neoplasm with high grade dysplasia|Intraductal papillary neoplasm with high grade intraepithelial neoplasia|Intraductal papillary neoplasm with intermediate grade neoplasia|Intraductal papillary neoplasm with low grade intraepithelial neoplasia|Intraductal papillary neoplasm, NOS|Intraductal papillary tumor with high grade dysplasia|Intraductal papillary tumor with high grade intraepithelial neoplasia|Intraductal papillary-mucinous adenoma|Intraductal papillary-mucinous carcinoma, invasive|Intraductal papillary-mucinous carcinoma, non-invasive|Intraductal papillary-mucinous neoplasm with low grade dysplasia|Intraductal papillary-mucinous neoplasm with moderate dysplasia|Intraductal papillary-mucinous tumor with intermediate dysplasia|Intraductal papillary-mucinous tumor with low grade dysplasia|Intraductal papillary-mucinous tumor with moderate dysplasia|Intraductal papilloma|Intraductal papilloma with ductal carcinoma in situ|Intraductal papilloma with lobular carcinoma in situ|Intraductal papillomatosis, NOS|Intraductal tubular-papillary neoplasm, high grade|Intraductal tubular-papillary neoplasm, low grade|Intraductal tubulopapillary neoplasm|Intraepidermal Epithelioma of Jadassohn|Intraepidermal carcinoma, NOS|Intraepidermal epithelioma of Jadassohn|Intraepidermal nevus|Intraepidermal squamous cell carcinoma, Bowen type|Intraepithelial carcinoma, NOS|Intraepithelial squamous cell carcinoma|Intraglandular papillary neoplasm with low grade intraepithelial neoplasia|Intrahepatic bile duct|Intramural|Intramuscular Hemangioma|Intramuscular Lipoma|Intramuscular hemangioma|Intramuscular lipoma|Intraneural Perineurioma|Intraneural perineurioma|Intraoperative Arterial Injury|Intraoperative Breast Injury|Intraoperative Cardiac Injury|Intraoperative Ear Injury|Intraoperative Endocrine Injury|Intraoperative Gastrointestinal Injury|Intraoperative Head and Neck Injury|Intraoperative Hemorrhage|Intraoperative Hepatobiliary Injury|Intraoperative Musculoskeletal Injury|Intraoperative Neurological Injury|Intraoperative Ocular Injury|Intraoperative Renal Injury|Intraoperative Reproductive Tract Injury|Intraoperative Respiratory Injury|Intraoperative Skin Injury|Intraoperative Splenic Injury|Intraoperative Urinary Injury|Intraoperative Venous Injury|Intraosseous low grade osteosarcoma|Intraosseous well differentiated osteosarcoma|Intrathecal|Intrathoracic Lymph Node|Intrathoracic lymph nodes|Intrathyroid Thymic Carcinoma|Intratubular germ cell neoplasia|Intratubular malignant germ cells|Intravascular B-cell lymphoma|Intravascular Large B-Cell Lymphoma|Intravascular bronchial alveolar tumor|Intravascular large B-cell lymphoma|Intravascular leiomyomatosis|Intravenous|Intravenous Drug User|Inulin|Invasive Breast Carcinoma|Invasive Ductal Carcinoma, Not Otherwise Specified|Invasive Ductal and Lobular Carcinoma|Invasive Ductal and Lobular Carcinoma In Situ|Invasive Hydatidiform Mole|Invasive Lobular Breast Carcinoma|Invasive Lobular Breast Carcinoma, Alveolar Variant|Invasive Lobular Breast Carcinoma, Pleomorphic Variant|Invasive Lobular Breast Carcinoma, Solid Variant|Invasive Lobular Breast Carcinoma, Tubulolobular Variant|Invasive Lung Mucinous Adenocarcinoma|Invasive Micropapillary Breast Carcinoma|Invasive carcinoma of no special type|Invasive carcinoma, NST|Invasive encapsulated follicular variant of papillary thyroid carcinoma (invasive EFVPTC)|Invasive fibroma|Invasive hydatidiform mole|Invasive lobular carcinoma|Invasive lobular carcinoma, alveolar type|Invasive lobular carcinoma, solid type|Invasive lobular carcinoma, tubulolobular variant|Invasive mammary carcinoma|Invasive micropapillary carcinoma|Invasive mole, NOS|Invasive mucinous adenocarcinoma|Inverted Squamous Cell Papilloma|Inverted Transitional Cell Papilloma|Investigations - Other|Involuting nevus|Iobenguane I-131|Iodine I 124 Monoclonal Antibody A33|Iodine I 124 Monoclonal Antibody M5A|Iodine I 125-Anti-EGFR-425 Monoclonal Antibody|Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP|Iodine I 131 Apamistamab|Iodine I 131 Derlotuximab Biotin|Iodine I 131 Ethiodized Oil|Iodine I 131 IPA|Iodine I 131 MIP-1095|Iodine I 131 Monoclonal Antibody 81C6|Iodine I 131 Monoclonal Antibody BC8|Iodine I 131 Monoclonal Antibody CC49-deltaCH2|Iodine I 131 Monoclonal Antibody F16SIP|Iodine I 131 Monoclonal Antibody G-250|Iodine I 131 Monoclonal Antibody muJ591|Iodine I 131 Omburtamab|Iodine I 131 Rituximab|Iodine I 131 TM-601|Iodine I 131 Tenatumomab|Iodine I 131 Tositumomab|Iodine I-131|IodoTMT|Iodoacetamide (IAA)|Ioflubenzamide I-131|Ion Torrent|Ionomycin|Ipafricept|Ipatasertib|Ipilimumab|Ipomeanol|Iproplatin|Iran|Iraq|Iratumumab|Ireland|Iridium Ir 192|Irinotecan|Irinotecan Hydrochloride|Irinotecan Sucrosofate|Irinotecan-Eluting Beads|Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet|Irofulven|Iron Overload|Iroplact|Irosustat|Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130|Irregular Menstruation|Irritability|Isatuximab|Ischemia Cerebrovascular|Ischemic Heart Disease|Ischium|Ishak Score 0|Ishak Score 1-2|Ishak Score 3-4|Ishak Score 5|Ishak Score 6|Isle of Man|Islet Cell Adenoma|Islet Cells|Islet cell adenocarcinoma|Islet cell adenoma|Islet cell adenomatosis|Islet cell carcinoma|Islet cell tumor, NOS|Islet cell tumor, benign|Islets of Langerhans|Iso-fludelone|IsoPrime|IsoProbe T|Isobaric label quantitation analysis|Isobrucein B|Isocoumarin NM-3|Isoform Expression Quantification|Isolated Limb Perfusion (ILP)|Isosporiasis|Isotretinoin|Ispinesib|Ispinesib Mesylate|Israel|Isthmus Uteri|Isthmus uteri|Istiratumab|Itacitinib|Itacitinib Adipate|Italy|Item Flagged Low Quality|Item does not meet study protocol|Item flagged DNU|Item in special subset|Item is noncanonical|Item may not meet study protocol|Itraconazole|Itraconazole Dispersion In Polymer Matrix|Ivaltinostat|Ivosidenib|Ivuxolimab|Ixabepilone|Ixazomib|Ixazomib Citrate|JAK Inhibitor|JAK Inhibitor INCB047986|JAK1 Inhibitor AZD4205|JAK1 Inhibitor INCB052793|JAK2 Inhibitor AZD1480|JAK2 Inhibitor BMS-911543|JAK2 Inhibitor XL019|JAK2/Src Inhibitor NS-018|JNK Inhibitor CC-401|JPEG|JPEG 2000|JSON|Jadassohn blue nevus|Jamaica|Japan|Jaw|Jejunal Fistula|Jejunal Hemorrhage|Jejunal Obstruction|Jejunal Perforation|Jejunal Stenosis|Jejunal Ulcer|Jejunum|Jersey|Jin Fu Kang|Joint|Joint Effusion|Joint Infection|Joint Range of Motion Decreased|Joint Range of Motion Decreased Cervical Spine|Joint Range of Motion Decreased Lumbar Spine|Joint Replacement|Jordan|Jugular paraganglioma|Jugulotympanic Paraganglioma|Jugulotympanic paraganglioma|Junction nevus|Junctional Nevus|Junctional nevus, NOS|Juvenile Myelomonocytic Leukemia|Juvenile Type Granulosa Cell Tumor|Juvenile angiofibroma|Juvenile astrocytoma|Juvenile carcinoma of breast|Juvenile chronic myelomonocytic leukemia|Juvenile fibroadenoma|Juvenile hemangioma|Juvenile histiocytoma|Juvenile melanoma|Juvenile myelomonocytic leukemia|Juvenile nevus|Juxtacortical chondroma|Juxtacortical chondrosarcoma|Juxtacortical osteosarcoma|Juxtaglomerular Cell Tumor|Juxtaglomerular tumor|KRAS G12C Inhibitor GDC-6036|KRAS G12C Inhibitor LY3499446|KRAS G12C Inhibitor MRTX849|KRAS Mutant-targeting AMG 510|KRAS-MAPK Signaling Pathway Inhibitor JAB-3312|KRASG12C Inhibitor JNJ-74699157|KRN5500|KSP Inhibitor AZD4877|KSP Inhibitor SB-743921|Kallisto - HDF5|Kallisto - Quantification|Kanglaite|Kanitinib|Kaposi Sarcoma|Kaposi sarcoma|Kaposiform Hemangioendothelioma|Kaposiform hemangioendothelioma|Kazakhstan|Kenya|Keratinizing Squamous Cell Carcinoma|Keratitis|Keratotoc papilloma|Ketoconazole|Ketotrexate|Kidney|Kidney Anastomotic Leak|Kidney Cancer|Kidney Chromophobe|Kidney Disease|Kidney Disorder|Kidney Infection|Kidney Medullary Carcinoma|Kidney Renal Clear Cell Carcinoma|Kidney Renal Papillary Cell Carcinoma|Kidney Wilms Tumor|Kidney, NOS|Kiribati|Klatskin tumor|Knee|Kosovo|Krukenberg Tumor|Krukenberg tumor|Kunecatechins Ointment|Kupffer cell sarcoma|Kuwait|Kyphosis|Kyrgyzstan|L-Gossypol|L-cell tumor|L-methylfolate|L1|L1 Acute Lymphoblastic Leukemia|L2|L2 Acute Lymphoblastic Leukemia|LAIR-2 Fusion Protein NC410|LC-MS label-free quantitation analysis|LCIS, NOS|LCMS-2010A|LCMS-2010EV|LCMS-2020|LCMS-8040|LCMS-8045|LCMS-8050|LCMS-8060|LCMS-9030|LCMS-IT-TOF|LCT|LCT Premier|LCT Premier XE|LECO|LMB-1 Immunotoxin|LMB-2 Immunotoxin|LMB-7 Immunotoxin|LMB-9 Immunotoxin|LMP-2:340-349 Peptide Vaccine|LMP-2:419-427 Peptide Vaccine|LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes|LMP7 Inhibitor M3258|LOH|LOXL2 Inhibitor PAT-1251|LRP5 Antagonist BI 905681|LRP5/6 Antagonist BI 905677|LS454|LSD1 Inhibitor CC-90011|LSD1 Inhibitor GSK2879552|LSD1 Inhibitor IMG-7289|LSD1 Inhibitor RO7051790|LSD1 Inhibitor SYHA1807|LTQ|LTQ FT|LTQ FT Ultra|LTQ Orbitrap|LTQ Orbitrap Classic|LTQ Orbitrap Discovery|LTQ Orbitrap Elite|LTQ Orbitrap Velos|LTQ Orbitrap XL|LTQ Orbitrap XL ETD|LTQ Velos|LTQ Velos ETD|LTQ Velos Pro|LTQ XL|LTQ XL ETD|LTQ-FT|LTQ-OT|LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1|LXQ|Label Free|Label-free gene level quantitation|Label-free peptide level quantitation|Label-free protein group level quantitation|Label-free protein level quantitation|Label-free raw feature quantitation|Labetuzumab Govitecan|Labium Majus|Labium Minus|Labium majus|Labium minus|Lacrimal Gland|Lacrimal gland|Lactating Adenoma|Lactating adenoma|Lactation Disorder|Lactoferrin-derived Lytic Peptide LTX-315|Lactotroph Adenoma|Lacutamab|Ladiratuzumab Vedotin|Ladirubicin|Laetrile|Landogrozumab|Langerhans Cell Histiocytosis|Langerhans Cell Histiocytosis, Disseminated|Langerhans Cell Histiocytosis, Monostotic|Langerhans Cell Histiocytosis, Polyostotic|Langerhans Cell Sarcoma|Langerhans cell granulomatosis|Langerhans cell granulomatosis, unifocal|Langerhans cell histiocytosis, NOS|Langerhans cell histiocytosis, disseminated|Langerhans cell histiocytosis, generalized|Langerhans cell histiocytosis, mono-ostotic|Langerhans cell histiocytosis, multifocal|Langerhans cell histiocytosis, poly-ostotic|Langerhans cell histiocytosis, unifocal|Langerhans cell sarcoma|Laniquidar|Lanreotide Acetate|Laos|Lapachone|Laparoscopic Biopsy|Laparoscopic Partial Nephrectomy|Laparoscopic Radical Nephrectomy|Laparoscopic Radical Prostatectomy with Robotics|Laparoscopic Radical Prostatectomy without Robotics|Laparoscopy|Laparotomy|Lapatinib|Lapatinib Ditosylate|Laprituximab Emtansine|Lapuleucel-T|Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease|Large Bowel|Large Cell Carcinoma|Large Cell Medulloblastoma|Large Cell Neuroendocrine Carcinoma|Large Intestinal Anastomotic Leak|Large cell (Ki-1+) lymphoma|Large cell calcifying Sertoli cell tumor|Large cell carcinoma with rhabdoid phenotype|Large cell carcinoma, NOS|Large cell medulloblastoma|Large cell neuroendocrine carcinoma|Large granular lymphocytosis, NOS|Laromustine|Larotaxel|Larotinib Mesylate|Larotrectinib|Larotrectinib Sulfate|Laryngeal Cancer|Laryngeal Cartilage|Laryngeal Edema|Laryngeal Fistula|Laryngeal Hemorrhage|Laryngeal Inflammation|Laryngeal Mucositis|Laryngeal Obstruction|Laryngeal Stenosis|Laryngeal cartilage|Laryngeal commissure|Laryngitis|Laryngopharyngeal Dysesthesia|Laryngopharyngectomy|Laryngopharynx|Laryngospasm|Larynx|Larynx, NOS|Lateral Wall of the Nasopharynx|Lateral floor of mouth|Lateral wall of bladder|Lateral wall of nasopharynx|Lateral wall of oropharynx|Latvia|Lavendustin A|Lazertinib|Lead Pb 212 TCMC-trastuzumab|Lebanon|Lefitolimod|Leflunomide|Left|Left Hemicolectomy|Left Ventricular Systolic Dysfunction|Leg|Legal Guardian|Leiomyoblastoma|Leiomyofibroma|Leiomyoma|Leiomyoma, NOS|Leiomyomatosis|Leiomyomatosis, NOS|Leiomyosarcoma|Leiomyosarcoma, NOS|Lenalidomide|Lenalidomide Analog KPG-121|Lennert lymphoma|Lentigo Maligna|Lentigo Maligna Melanoma|Lentigo maligna|Lentigo maligna melanoma|Lentinan|Lenvatinib|Lenvatinib Mesylate|Lenzilumab|Lepidic Predominant Adenocarcinoma|Lepidic adenocarcinoma|Lepidic predominant adenocarcinoma|Leptomeningeal Sarcoma|Leptomeningeal sarcoma|Leptomeninges|Lerociclib|Lesotho|Lesser Curvature of the Stomach|Lesser curvature of stomach, NOS|Lestaurtinib|Letetresgene Autoleucel|Lethargy|Letolizumab|Letrozole|Letterer-Siwe Disease|Letterer-Siwe disease|Leucovorin|Leucovorin Calcium|Leukemia|Leukemia Secondary to Oncology Chemotherapy|Leukemia, NOS|Leukemias, NOS|Leukemic reticuloendotheliosis|Leukocyte elastase|Leukocytosis|Leukoencephalopathy|Leuprolide|Leuprolide Acetate|Leuprolide Mesylate Injectable Suspension|Leurubicin|Levetiracetam|Levoleucovorin Calcium|Levothyroxine|Levothyroxine Sodium|Lexatumumab|Lexibulin|Leydig Cell Tumor|Leydig cell tumor, NOS|Leydig cell tumor, benign|Leydig cell tumor, malignant|Li-Fraumeni Syndrome|Liarozole|Liarozole Fumarate|Liarozole Hydrochloride|Liberia|Libido Decreased|Libido Increased|Libya|Licartin|Licorice|Liechtenstein|Lifastuzumab Vedotin|Lifelong Non-Drinker|Lifileucel|Lifirafenib|Liftover|Ligament|Light Chain Deposition Disease|Light-Emitting Oncolytic Vaccinia Virus GL-ONC1|Light-activated AU-011|Lilotomab|Limonene, (+)-|Limonene, (+/-)-|Lingual tonsil|Linifanib|Linitis Plastica|Linitis plastica|Linoleyl Carbonate-Paclitaxel|Linperlisib|Linrodostat|Linsitinib|Lintuzumab|Liothyronine I-131|Liothyronine Sodium|Lip|Lip Infection|Lip Pain|Lip, NOS|Lipase Increased|Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1|Lipid Nanoparticle Encapsulated OX40L mRNA-2416|Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191|Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006|Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752|Lipid cell tumor of ovary|Lipid-Rich Carcinoma|Lipid-rich Sertoli cell tumor|Lipid-rich carcinoma|Lipid-rich urothelial carcinoma|Lipidome|Lipoadenoma|Lipoblastoma|Lipoblastomatosis|Lipohypertrophy|Lipoid cell tumor of ovary|Lipoleiomyoma|Lipoma|Lipoma, NOS|Lipoma-like liposarcoma|Lipomatous Neoplasms|Lipomatous medulloblastoma|Liposarcoma|Liposarcoma, NOS|Liposarcoma, differentiated|Liposarcoma, well differentiated|Liposomal Bcl-2 Antisense Oligonucleotide  BP1002|Liposomal Curcumin|Liposomal Cytarabine|Liposomal Daunorubicin Citrate|Liposomal Docetaxel|Liposomal Eribulin Mesylate|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Liposomal Irinotecan|Liposomal MUC1/PET-lipid A Vaccine ONT-10|Liposomal Mitoxantrone Hydrochloride|Liposomal NDDP|Liposomal Rhenium Re 186|Liposomal SN-38|Liposomal Topotecan FF-10850|Liposomal Vinorelbine|Liposomal Vinorelbine Tartrate|Liposomal c-raf Antisense Oligonucleotide|Liposome|Liposome-Encapsulated Doxorubicin Citrate|Liposome-encapsulated Daunorubicin-Cytarabine|Liposome-encapsulated OSI-7904|Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94|Liposome-encapsulated TAAs mRNA Vaccine W_ova1|Liposome-encapsulated miR-34 Mimic MRX34|Liquid Biopsy|Liquid Suspension Cell Line|Liquor|Lirilumab|Lisavanbulin|Lisocabtagene Maraleucel|Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142|Lithuania|Litronesib|Live Birth|Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207|Live-attenuated Double-deleted Listeria monocytogenes Bacteria JNJ-64041809|Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623|Liver|Liver Cancer|Liver Cirrhosis (Liver Disease)|Liver Hepatocellular Carcinoma|Liver Toxicity (Non-Infectious)|Liver X Receptor beta Agonist RGX-104|Liver and intrahepatic bile ducts|Liver cell adenoma|Liver cell carcinoma|Lm-tLLO-neoantigens Vaccine ADXS-NEO|LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine ADXS31-164|Lobaplatin|Lobectomy|Lobular Breast Carcinoma|Lobular Breast Carcinoma In Situ|Lobular adenocarcinoma|Lobular and ductal carcinoma|Lobular carcinoma in situ, NOS|Lobular carcinoma, NOS|Lobular carcinoma, noninfiltrating|Local|Local Resection (Exoresection; wall resection)|Localized Edema|Localized fibrous tumor|Loco-regional recurrence/progression|Lodapolimab|Lometrexol|Lometrexol Sodium|Lomustine|Lonafarnib|Loncastuximab Tesirine|Long Peptide Vaccine 7|Long bones of lower limb and associated joints|Long bones of upper limb, scapula and associated joints|Long-acting Release Pasireotide|Lontucirev|Lordosis|Lorlatinib|Lorukafusp alfa|Lorvotuzumab Mertansine|Losatuxizumab Vedotin|Losoxantrone|Losoxantrone Hydrochloride|Lovastatin|Low|Low Grade|Low Grade (G1)|Low Grade Adenosquamous Breast Carcinoma|Low Grade Central Osteosarcoma|Low Grade Cervical Intraepithelial Neoplasia|Low Grade Dysplasia|Low Grade Endometrioid Stromal Sarcoma|Low Grade Esophageal Glandular Intraepithelial Neoplasia|Low Grade Esophageal Squamous Intraepithelial Neoplasia|Low Grade Fibromyxoid Sarcoma|Low Grade Glandular Intraepithelial Neoplasia|Low Grade Liver Dysplastic Nodule|Low Grade Myofibroblastic Sarcoma|Low Grade Squamous Intraepithelial Neoplasia|Low Risk|Low Risk Gastrointestinal Stromal Tumor|Low grade adenosquamous carcinoma|Low grade appendiceal mucinous neoplasm|Low grade cribriform cystadenocarcinoma (LGCCC)|Low-CSD Melanoma|Low-Grade Appendix Mucinous Neoplasm|Low-Intermediate Risk|Low-grade central osteosarcoma|Low-grade fibromyxoid sarcoma|Low-grade intramedullary osteosarcoma|Low-grade myofibroblastic sarcoma|Low-grade serous carcinoma|Lower Gastrointestinal Hemorrhage|Lower Gingiva|Lower gum|Lower limb, NOS|Lower lobe, lung|Lower third of esophagus|Lower-Outer Quadrant of the Breast|Lower-inner quadrant of breast|Lower-outer quadrant of breast|Lucanthone|Lucatumumab|Lucitanib|Lumbar Spine|Luminespib|Luminespib Mesylate|Lumpectomy|Lumretuzumab|Lung|Lung Adenocarcinoma|Lung Adenocarcinoma with Mixed Bronchioloalveolar and Invasive Components|Lung Cancer|Lung Cancer (all types)|Lung Colloid Adenocarcinoma|Lung Fetal Adenocarcinoma|Lung Infection|Lung Large Cell Carcinoma with Rhabdoid Phenotype|Lung Mucinous Adenocarcinoma In Situ|Lung Non-Mucinous Adenocarcinoma In Situ|Lung Papillary Adenoma|Lung Squamous Cell Carcinoma|Lung, NOS|Lung-targeted Immunomodulator QBKPN|Lupartumab Amadotin|Lupus|Lurbinectedin|Lurtotecan|Lurtotecan Liposome|Luteinoma|Luteoma, NOS|Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1|Lutetium Lu 177 DOTA-N3-CTT1403|Lutetium Lu 177 DOTA-Tetulomab|Lutetium Lu 177 DOTA-biotin|Lutetium Lu 177 Dotatate|Lutetium Lu 177 Lilotomab-satetraxetan|Lutetium Lu 177 Monoclonal Antibody CC49|Lutetium Lu 177 Monoclonal Antibody J591|Lutetium Lu 177 PP-F11N|Lutetium Lu 177 Satoreotide Tetraxetan|Lutetium Lu 177-DOTA-EB-TATE|Lutetium Lu 177-DTPA-omburtamab|Lutetium Lu 177-Edotreotide|Lutetium Lu 177-NeoB|Lutetium Lu 177-PSMA-617|Lutetium Lu-177 Capromab|Lutetium Lu-177 Girentuximab|Lutetium Lu-177 PSMA-R2|Lutetium Lu-177 Rituximab|Luxembourg|Lymph Gland Infection|Lymph Leakage|Lymph Node|Lymph Node Cancer|Lymph Node Dissection|Lymph Node Pain|Lymph Node(s) Axilla|Lymph Node(s) Cervical|Lymph Node(s) Distant|Lymph Node(s) Epitrochlear|Lymph Node(s) Femoral|Lymph Node(s) Hilar|Lymph Node(s) Iliac-Common|Lymph Node(s) Iliac-External|Lymph Node(s) Inguinal|Lymph Node(s) Internal Mammary|Lymph Node(s) Mammary|Lymph Node(s) Mediastinal|Lymph Node(s) Mesenteric|Lymph Node(s) Occipital|Lymph Node(s) Paraaortic|Lymph Node(s) Parotid|Lymph Node(s) Pelvic|Lymph Node(s) Popliteal|Lymph Node(s) Regional|Lymph Node(s) Retroperitoneal|Lymph Node(s) Scalene|Lymph Node(s) Splenic|Lymph Node(s) Subclavicular|Lymph Node(s) Submandibular|Lymph Node(s) Supraclavicular|Lymph Node, Axillary|Lymph Node, Inguinal|Lymph Node, NOS|Lymph Node, Regional|Lymph Node, Subcarinal|Lymph Nodes(s) Mediastinal|Lymph node, NOS|Lymph nodes|Lymph nodes of axilla or arm|Lymph nodes of head, face and neck|Lymph nodes of inguinal region or leg|Lymph nodes of multiple regions|Lymphadenectomy|Lymphangioendothelial sarcoma|Lymphangioendothelioma, NOS|Lymphangioendothelioma, malignant|Lymphangioleiomyoma|Lymphangioleiomyomatosis|Lymphangioma|Lymphangioma, NOS|Lymphangiomyoma|Lymphangiomyomatosis|Lymphangiosarcoma|Lymphatic Vessel Tumors|Lymphatic leukemic, NOS|Lymphedema|Lymphoblastic Lymphoma|Lymphoblastic leukemia, NOS|Lymphoblastoma|Lymphocele|Lymphocyte Count Decreased|Lymphocyte Count Increased|Lymphocyte Predominant Type Hodgkin's Disease|Lymphocyte-Depleted Classic Hodgkin Lymphoma|Lymphocyte-Rich Classic Hodgkin Lymphoma|Lymphocytes|Lymphocytic Meningitis|Lymphocytic Thyroiditis|Lymphocytic leukemia, NOS|Lymphoepithelial carcinoma|Lymphoepithelioid Variant Peripheral T-Cell Lymphoma|Lymphoepithelioid lymphoma|Lymphoepithelioma|Lymphoepithelioma-like carcinoma|Lymphoid Leukemia|Lymphoid Leukemias|Lymphoid Neoplasm Diffuse Large B-cell Lymphoma|Lymphoid Normal|Lymphoid leukemia, NOS|Lymphoma|Lymphoma, NOS|Lymphomatoid Granulomatosis|Lymphomatoid Papulosis|Lymphomatoid granulomatosis|Lymphomatoid papulosis|Lymphoplasmacyte-Rich Meningioma|Lymphoplasmacyte-rich meningioma|Lymphoplasmacytic Lymphoma|Lymphoproliferative Disorder|Lymphoproliferative disease, NOS|Lymphoproliferative disorder, NOS|Lymphosarcoma|Lymphosarcoma cell leukemia|Lymphosarcoma, NOS|Lymphosarcoma, diffuse|Lynch Syndrome|Lyophilized Black Raspberry Lozenge|Lyophilized Black Raspberry Saliva Substitute|Lys-C|Lys-C, Lys-C/P|Lysine-specific Demethylase 1 Inhibitor INCB059872|Lyso-Thermosensitive Liposome Doxorubicin|M|M0|M0 Stage Finding|M1|M1 Stage Finding|M1a|M1a Stage Finding|M1b|M1b Stage Finding|M1c|M1c Stage Finding|M1d|M2|M6A|M6B|M@LDI L|M@LDI LR|MAF|MAGE-10.A2|MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells|MAGE-A3 Multipeptide Vaccine GL-0817|MAGE-A3 Peptide Vaccine|MAGE-A3-specific Immunotherapeutic GSK 2132231A|MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201|MAGE-TAB|MAGETAB|MAI|MALDI 4800|MALDI L|MALDI LR|MALDI LTQ Orbitrap|MALDI LTQ XL|MALDI R|MALDI SYNAPT G2-Si|MALDI Synapt G2 HDMS|MALDI Synapt G2 MS|MALDI Synapt G2-S HDMS|MALDI Synapt G2-S MS|MALDI Synapt HDMS|MALDI Synapt MS|MALDI micro MX|MALT lymphoma|MALT1 Inhibitor JNJ-67856633|MANEC|MARCKS Protein Inhibitor BIO-11006|MAT2A Inhibitor AG-270|MCL-1 Inhibitor ABBV-467|MCL-1 Inhibitor AMG 176|MCL-1 inhibitor AMG 397|MDM2 Antagonist ASTX295|MDM2 Antagonist RO5045337|MDM2 Antagonist RO6839921|MDM2 Inhibitor AMG-232|MDM2 Inhibitor AMGMDS3|MDM2 Inhibitor BI 907828|MDM2 Inhibitor KRT-232|MDM2/MDMX Inhibitor ALRN-6924|MDR Modulator CBT-1|MEK 1/2 Inhibitor AS703988/MSC2015103B|MEK 1/2 Inhibitor FCN-159|MEK Inhibitor AZD8330|MEK Inhibitor CI-1040|MEK Inhibitor GDC-0623|MEK Inhibitor HL-085|MEK Inhibitor PD0325901|MEK Inhibitor RO4987655|MEK Inhibitor SHR 7390|MEK Inhibitor TAK-733|MEK Inhibitor WX-554|MEK inhibitor CS3006|MEK-1/MEKK-1 Inhibitor E6201|MEK/Aurora Kinase Inhibitor BI 847325|MELK Inhibitor OTS167|MET Kinase Inhibitor OMO-1|MET Tyrosine Kinase Inhibitor BMS-777607|MET Tyrosine Kinase Inhibitor EMD 1204831|MET Tyrosine Kinase Inhibitor PF-04217903|MET Tyrosine Kinase Inhibitor SAR125844|MET Tyrosine Kinase Inhibitor SGX523|MET x MET Bispecific Antibody REGN5093|MEX|MGUS|MK0731|MKC-1|MKNK1 Inhibitor BAY 1143269|MMP Inhibitor S-3304|MNK1/2 Inhibitor ETC-1907206|MOF Compound RiMO-301|MOv-gamma Chimeric Receptor Gene|MPNST with glandular differentiation|MPNST with mesenchymal differentiation|MPNST with rhabdomyoblastic differentiation|MPNST, NOS|MR-Minimal/Marginal Response|MR-Minimal/Marginal response|MRI|MS1 label-based analysis|MS2|MS2 tag-based analysis|MS2-based label-free quantitation|MS3|MSI|MSS|MTF-1 Inhibitor APTO-253 HCl|MUC-1/WT1 Peptide-primed Autologous Dendritic Cells|MUC1-targeted Peptide GO-203-2C|MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP|MVA-BN Smallpox Vaccine|MVA-FCU1 TG4023|MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1|MX|MX Stage Finding|MX-Mixed Response|MYC-targeting siRNA DCR-MYC|Maackia amurensis Seed Lectin|Macau|Machine smoke|Macimorelin|Macitentan|Macro|Macrocycle-bridged STING Agonist E7766|Macrofollicular adenoma|Macroscopic (2cm or less)|Macroscopic (greater than 2cm)|Macroscopic Parametrium|Madagascar|Maekmoondong-tang|Mafosfamide|Magnesium Valproate|Magnocellular nevus|Magrolimab|Main Bronchus|Main bronchus|Maintenance Therapy|Major salivary gland, NOS|Malabsorption|Malaise|Malaria|Malawi|Malaysia|Maldives|Male|Male Cousin|Male Genitalia|Male Sibling of Adopted Child|Male genital organs, NOS|Mali|Malignancy|Malignancy in Giant Cell Tumor of Bone|Malignant|Malignant Adrenal Cortex Neoplasm|Malignant Adrenal Gland Pheochromocytoma|Malignant Cell|Malignant Enteroglucagonoma|Malignant Extra-Adrenal Paraganglioma|Malignant Gastrinoma|Malignant Gastrointestinal Stromal Tumor|Malignant Giant Cell Neoplasm|Malignant Glioma|Malignant Glomus Tumor|Malignant Granular Cell Tumor|Malignant Granulosa Cell Tumor|Malignant Hemangiopericytoma|Malignant Histiocytosis|Malignant Leydig Cell Tumor|Malignant Lymphoma Centroblastic, Follicular|Malignant Lymphoma, Convoluted|Malignant Lymphoma, Histiocytic, Diffuse|Malignant Lymphoma, Large Cell Type|Malignant Lymphoma, Large Cell, Cleaved|Malignant Lymphoma, Non-Cleaved Cell Type|Malignant Lymphoma, Non-Cleaved, Diffuse|Malignant Lymphomas, NOS or Diffuse|Malignant Mastocytosis|Malignant Mediastinal Germ Cell Tumor with Associated Hematologic Malignancy|Malignant Melanoma in Precancerous Melanosis|Malignant Melanotic Peripheral Nerve Sheath Tumor|Malignant Mesenchymoma|Malignant Mesothelioma|Malignant Mixed Tumor of the Salivary Gland|Malignant Muscle Neoplasm|Malignant Myoepithelioma|Malignant Neoplasm|Malignant Neoplasm, Uncertain Whether Primary or Metastatic|Malignant Odontogenic Neoplasm|Malignant Ossifying Fibromyxoid Tumor|Malignant Ovarian Brenner Tumor|Malignant Ovarian Thecoma|Malignant PEComa|Malignant Pancreatic Glucagonoma|Malignant Pancreatic Insulinoma|Malignant Paraganglioma|Malignant Pericytic Neoplasm|Malignant Peripheral Nerve Sheath Tumor|Malignant Peripheral Nerve Sheath Tumor with Perineurial Differentiation|Malignant Phosphaturic Mesenchymal Tumor|Malignant Phyllodes Tumor|Malignant Sertoli Cell Tumor|Malignant Soft Tissue Neoplasm|Malignant Solitary Fibrous Tumor|Malignant Somatostatinoma|Malignant Spindle Cell Neoplasm|Malignant Struma Ovarii|Malignant Sweat Gland Neoplasm|Malignant Tenosynovial Giant Cell Tumor|Malignant Teratoma|Malignant Thymoma|Malignant Triton Tumor|Malignant Trophoblastic Teratoma|Malignant Tumor, Small Cell Type|Malignant Type A Thymoma|Malignant Type AB Thymoma|Malignant Type B1 Thymoma|Malignant Type B2 Thymoma|Malignant Vipoma|Malignant chondroid syringoma|Malignant cystic nephroma|Malignant eccrine spiradenoma|Malignant fibrous histiocytoma|Malignant fibrous histiocytoma (MFH) of bone|Malignant giant cell tumor of soft parts|Malignant histiocytosis|Malignant hydatidiform mole|Malignant lymphoma, Hodgkin|Malignant lymphoma, NOS|Malignant lymphoma, centroblastic, NOS|Malignant lymphoma, centroblastic, diffuse|Malignant lymphoma, centroblastic, follicular|Malignant lymphoma, centroblasticcentrocytic, NOS|Malignant lymphoma, centroblasticcentrocytic, diffuse|Malignant lymphoma, centroblasticcentrocytic, follicular|Malignant lymphoma, centrocytic|Malignant lymphoma, cleaved cell, NOS|Malignant lymphoma, convoluted cell|Malignant lymphoma, diffuse, NOS|Malignant lymphoma, follicle center, NOS|Malignant lymphoma, follicle center, follicular|Malignant lymphoma, follicular, NOS|Malignant lymphoma, histiocytic, NOS|Malignant lymphoma, histiocytic, diffuse|Malignant lymphoma, histiocytic, nodular|Malignant lymphoma, immunoblastic, NOS|Malignant lymphoma, large B-cell, NOS|Malignant lymphoma, large B-cell, diffuse, NOS|Malignant lymphoma, large B-cell, diffuse, centroblastic, NOS|Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS|Malignant lymphoma, large cell, NOS|Malignant lymphoma, large cell, cleaved and noncleaved|Malignant lymphoma, large cell, cleaved, NOS|Malignant lymphoma, large cell, cleaved, diffuse|Malignant lymphoma, large cell, diffuse, NOS|Malignant lymphoma, large cell, follicular, NOS|Malignant lymphoma, large cell, immunoblastic|Malignant lymphoma, large cell, noncleaved, NOS|Malignant lymphoma, large cell, noncleaved, diffuse|Malignant lymphoma, large cell, noncleaved, follicular|Malignant lymphoma, large cleaved cell, NOS|Malignant lymphoma, large cleaved cell, follicular|Malignant lymphoma, lymphoblastic, NOS|Malignant lymphoma, lymphocytic, NOS|Malignant lymphoma, lymphocytic, diffuse, NOS|Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse|Malignant lymphoma, lymphocytic, intermediate differentiation, nodular|Malignant lymphoma, lymphocytic, nodular, NOS|Malignant lymphoma, lymphocytic, poorly differentiated, diffuse|Malignant lymphoma, lymphocytic, poorly differentiated, nodular|Malignant lymphoma, lymphocytic, well differentiated, diffuse|Malignant lymphoma, lymphocytic, well differentiated, nodular|Malignant lymphoma, lymphoplasmacytic|Malignant lymphoma, lymphoplasmacytoid|Malignant lymphoma, mixed cell type, diffuse|Malignant lymphoma, mixed cell type, follicular|Malignant lymphoma, mixed cell type, nodular|Malignant lymphoma, mixed lymphocytic-histiocytic, diffuse|Malignant lymphoma, mixed lymphocytic-histiocytic, nodular|Malignant lymphoma, mixed small and large cell, diffuse|Malignant lymphoma, mixed small cleaved and large cell, follicular|Malignant lymphoma, nodular, NOS|Malignant lymphoma, non-Hodgkin, NOS|Malignant lymphoma, non-cleaved cell, NOS|Malignant lymphoma, noncleaved cell, follicular, NOS|Malignant lymphoma, noncleaved, NOS|Malignant lymphoma, noncleaved, diffuse, NOS|Malignant lymphoma, plasmacytoid|Malignant lymphoma, small B lymphocytic, NOS|Malignant lymphoma, small cell diffuse|Malignant lymphoma, small cell, NOS|Malignant lymphoma, small cell, noncleaved, diffuse|Malignant lymphoma, small cleaved cell, NOS|Malignant lymphoma, small cleaved cell, diffuse|Malignant lymphoma, small cleaved cell, follicular|Malignant lymphoma, small lymphocytic, NOS|Malignant lymphoma, small lymphocytic, diffuse|Malignant lymphoma, small noncleaved, Burkitt type|Malignant lymphoma, undifferentiated cell type, NOS|Malignant lymphoma, undifferentiated cell, non-Burkitt|Malignant lymphoma, undifferentiated, Burkitt type|Malignant lymphomatous polyposis|Malignant mast cell tumor|Malignant mastocytoma|Malignant mastocytosis|Malignant melanoma in Hutchinson melanotic freckle|Malignant melanoma in congenital melanocytic nevus|Malignant melanoma in giant pigmented nevus|Malignant melanoma in junctional nevus|Malignant melanoma in precancerous melanosis|Malignant melanoma, NOS|Malignant melanoma, regressing|Malignant midline reticulosis|Malignant mucinous adenofibroma|Malignant mucinous cystadenofibroma|Malignant multilocular cystic nephroma|Malignant myelosclerosis|Malignant myoepithelioma|Malignant peripheral nerve sheath tumor|Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation|Malignant perivascular epithelial cell tumor|Malignant reticulosis, NOS|Malignant rhabdoid tumor|Malignant schwannoma with rhabdomyoblastic differentiation|Malignant schwannoma, NOS|Malignant serous adenofibroma|Malignant serous cystadenofibroma|Malignant tenosynovial giant cell tumor|Malignant teratoma, anaplastic|Malignant teratoma, intermediate|Malignant teratoma, trophoblastic|Malignant teratoma, undifferentiated|Malignant tumor, clear cell type|Malignant tumor, fusiform cell type|Malignant tumor, giant cell type|Malignant tumor, small cell type|Malignant tumor, spindle cell type|Malta|Mammary carcinoma, in situ|Mandible|Mandibulectomy|Manelimab|Mania|Mannosulfan|Mannosylerythritol Lipid|Mantle|Mantle Cell Lymphoma|Mantle cell lymphoma (Includes all variants blastic, pleomorphic, small cell)|Mantle zone lymphoma|Mapatumumab|Maraba Oncolytic Virus Expressing Mutant HPV E6/E7|Marcellomycin|Margetuximab|Marginal Zone Lymphoma|Marginal zone B-cell lymphoma, NOS|Marginal zone lymphoma, NOS|Marijuana|Marijuana smoke|Marimastat|Marizomib|Marshall Islands|Martinique|Masculinovoblastoma|Masitinib Mesylate|Masked Annotated Somatic Mutation|Masked Copy Number Segment|Masked Intensities|Masked Somatic Mutation|Masoprocol|Mast Cell Leukemia|Mast Cell Neoplasm|Mast Cell Sarcoma|Mast Cell Tumors|Mast cell leukaemia|Mast cell sarcoma|Mast cell tumor, NOS|Mastocytoma|Mastocytoma, NOS|Maternal Aunt|Maternal First Cousin|Maternal First Cousin Once Removed|Maternal Grandfather|Maternal Grandmother|Maternal Grandparent|Maternal Great Aunt|Maternal Great Grandparent|Maternal Great Uncle|Maternal Half Brother|Maternal Half Sibling|Maternal Half Sister|Maternal Uncle|Matrical carcinoma|Matrix Metalloproteinase Inhibitor MMI270|Mature B-Cell Lymphomas|Mature T ALL|Mature T- and NK-Cell Lymphomas|Mature T-ALL|Mature T-cell lymphoma, NOS|Mature Teratoma|Mature teratoma|Matuzumab|Mauritania|Mauritius|Mavelertinib|Mavorixafor|Maxilla|Maxillary Sinus|Maxillary sinus|Maxillectomy|Mayotte|Maytansine|Mcl-1 Inhibitor AZD5991|Mcl-1 Inhibitor MIK665|Mechlorethamine|Mechlorethamine Hydrochloride|Mechlorethamine Hydrochloride Gel|Meckel diverticulum|Mediastinal (thymic) large B-cell lymphoma|Mediastinal Hemorrhage|Mediastinal Infection|Mediastinal Soft Tissue|Mediastinum|Mediastinum, NOS|Medical Record|Medically Treated|Mediterranean lymphoma|Medorubicin|Medroxyprogesterone|Medroxyprogesterone Acetate|Medulla of adrenal gland|Medullary Carcinoma, Not Otherwise Specified|Medullary adenocarcinoma|Medullary carcinoma with amyloid stroma|Medullary carcinoma with lymphoid stroma|Medullary carcinoma, NOS|Medullary osteosarcoma|Medulloblastoma|Medulloblastoma with Extensive Nodularity|Medulloblastoma with Melanotic Differentiation|Medulloblastoma with extensive nodularity|Medulloblastoma, NOS|Medulloblastoma, Non-WNT/Non-SHH|Medulloblastoma, Non-WNT/Non-SHH, Group 3|Medulloblastoma, Non-WNT/Non-SHH, Group 4|Medulloblastoma, Not Otherwise Specified|Medulloblastoma, SHH-Activated|Medulloblastoma, SHH-Activated, TP53-Mutant|Medulloblastoma, SHH-Activated, TP53-Wildtype|Medulloblastoma, SHH-activated and TP53-mutant|Medulloblastoma, SHH-activated and TP53-wildtype|Medulloblastoma, WNT-Activated|Medulloblastoma, WNT-activated|Medulloblastoma, classic|Medulloblastoma, group 3|Medulloblastoma, group 4|Medulloblastoma, non-WNT/non-SHH|Medullocytoma|Medulloepithelioma|Medulloepithelioma Not Otherwise Specified|Medulloepithelioma, NOS|Medulloepithelioma, benign|Medullomyoblastoma|Medullomyoblastoma with Myogenic Differentiation|Megakaryocytic leukemia|Megakaryocytic myelosclerosis|Megestrol Acetate|Melanoameloblastoma|Melanocytic Nevus|Melanocytic nevus|Melanocytoma|Melanocytoma of the Eyeball|Melanocytoma, NOS|Melanocytoma, eyeball|Melanoma|Melanoma Arising from Blue Nevus|Melanoma Monoclonal Antibody hIgG2A|Melanoma TRP2 CTL Epitope Vaccine SCIB1|Melanoma in Junctional Nevus|Melanoma in situ|Melanoma, NOS|Melanoma, malignant, of soft parts|Melanotic MPNST|Melanotic Neuroectodermal Tumor|Melanotic Neurofibroma|Melanotic Psammomatous Malignant Peripheral Nerve Sheath Tumor|Melanotic Schwannoma|Melanotic medulloblastoma|Melanotic neuroectodermal tumor|Melanotic neurofibroma|Melanotic progonoma|Melanotic psammomatous MPNST|Melanotic schwannoma|Melapuldencel-T|Melphalan|Melphalan Flufenamide|Melphalan Hydrochloride|Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex|Membrane-Disrupting Peptide EP-100|Memory Impairment|Menatetrenone|Menin-MLL Interaction Inhibitor SNDX-5613|Meningeal Melanocytoma|Meningeal Melanocytosis|Meningeal Melanoma|Meningeal Melanomatosis|Meningeal Sarcoma|Meningeal Sarcomatosis|Meningeal melanocytoma|Meningeal melanoma|Meningeal melanomatosis|Meningeal sarcoma|Meningeal sarcomatosis|Meninges|Meninges, NOS|Meningioma|Meningioma, NOS|Meningioma, anaplastic|Meningioma, malignant|Meningiomas|Meningiomatosis|Meningiomatosis, NOS|Meningismus|Meningitis|Meningothelial Meningioma|Meningothelial meningioma|Meningothelial sarcoma|Menogaril|Menopause|Menorrhagia|Merbarone|Mercaptopurine|Mercaptopurine Anhydrous|Mercaptopurine Oral Suspension|Merestinib|Merkel Cell Carcinoma|Merkel cell carcinoma|Merkel cell tumor|Mesenchymal Chondrosarcoma|Mesenchymal chondrosarcoma|Mesenchymal tumor, malignant|Mesenchymoma|Mesenchymoma, NOS|Mesenchymoma, benign|Mesenchymoma, malignant|Mesenteric fibromatosis|Mesentery|Mesna|Mesoblastic nephroma|Mesodermal mixed tumor|Mesonephric Adenocarcinoma|Mesonephric Neoplasm|Mesonephric adenocarcinoma|Mesonephric adenoma|Mesonephric tumor, NOS|Mesonephroma, NOS|Mesonephroma, benign|Mesonephroma, malignant|Mesonephromas|Mesothelial Neoplasms|Mesothelial papilloma|Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536|Mesothelioma|Mesothelioma, NOS|Mesothelioma, benign|Mesothelioma, biphasic, NOS|Mesothelioma, biphasic, malignant|Mesothelioma, malignant|Mesothelium|MetAP2 Inhibitor APL-1202|MetAP2 Inhibitor SDX-7320|Metabolic Syndrome|Metabolic labeling 14N / 15N quantitation analysis|Metabolism and Nutrition Disorders - Other|Metabolome|Metamelfalan|Metanephric Adenofibroma|Metanephric Adenoma|Metanephric adenoma|Metaplastic Carcinoma|Metaplastic Meningioma|Metaplastic carcinoma of no special type|Metaplastic carcinoma with chondroid differentiation|Metaplastic carcinoma with osseous differentiation|Metaplastic carcinoma with other types mesenchymal differentiation|Metaplastic carcinoma, NOS|Metaplastic meningioma|Metarrestin|Metastasectomy|Metastasis|Metastasis Negative|Metastasis, NOS|Metastasizing Ameloblastoma|Metastasizing leiomyoma|Metastatic|Metastatic Adenocarcinoma|Metastatic Carcinoma|Metastatic Neoplasm|Metastatic Signet Ring Cell Carcinoma|Metastatic Squamous Cell Carcinoma|Metastatic signet ring cell carcinoma|Metatinib Tromethamine|Metatypical carcinoma|Metformin|Metformin Hydrochloride|Methanol Extraction Residue of BCG|Methazolamide|Methionine Aminopeptidase 2 Inhibitor M8891|Methionine Aminopeptidase 2 Inhibitor PPI-2458|Methotrexate|Methotrexate Sodium|Methotrexate-E Therapeutic Implant|Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles|Methoxsalen|Methoxyamine|Methoxyamine Hydrochloride|Methyl Methanethiosulfonate (MMTS)|Methyl-5-Aminolevulinate Hydrochloride Cream|Methylation Array|Methylation Beta Value|Methylcantharidimide|Methylmercaptopurine Riboside|Methylprednisolone|Methylprednisolone Acetate|Methylprednisolone Sodium Succinate|Methylselenocysteine|Methyltestosterone|Metoprine|Mevociclib|Mexico|Mezagitamab|MiT Family Translocation-Associated Renal Cell Carcinoma|MiT family translocation renal cell carcinoma|Mibefradil|Mibefradil Dihydrochloride|Micellar Nanoparticle-encapsulated Epirubicin|Micro|Micro Needle Array-Doxorubicin|Microbiome GEN-001|Microbiome-derived Peptide Vaccine EO2401|Microcystic Adenoma|Microcystic Adnexal Carcinoma|Microcystic Meningioma|Microcystic adenoma|Microcystic adnexal carcinoma|Microcystic meningioma|Microcystic urothelial carcinoma|Microfollicular adenoma, NOS|Microglioma|Microinvasive Squamous Cell Carcinoma|Micropapillary Serous Carcinoma|Micropapillary Transitional Cell Carcinoma|Micropapillary adenocarcinoma|Micropapillary carcinoma, NOS|Micropapillary serous carcinoma|Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300|Microscopic|Microscopic Parametrium|Microtubule Inhibitor SCB01A|Middle Ear|Middle Ear Inflammation|Middle Finger|Middle Lobe of the Right Lung|Middle ear|Middle lobe, lung|Middle third of esophagus|Midline|Midline carcinoma of children and young adults with NUT rearrangement|Midostaurin|Mifamurtide|Mifepristone|Milademetan Tosylate|Milataxel|Milatuzumab|Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110|Milciclib Maleate|Milk Thistle|Miltefosine|Minimally Invasive Lung Adenocarcinoma|Minimally Invasive Lung Mucinous Adenocarcinoma|Minimally Invasive Lung Non-Mucinous Adenocarcinoma|Minimally invasive adenocarcinoma, NOS|Minimally invasive adenocarcinoma, mucinous|Minimally invasive adenocarcinoma, non-mucinous|Minor Response|Minretumomab|Mipsagargin|Miptenalimab|Mirabegron|Miransertib|Mirdametinib|Mirvetuximab Soravtansine|Mirzotamab Clezutoclax|Miscarriage|Miscellaneous Bone Tumors|Miscellaneous Tumors|Misonidazole|Mistletoe Extract|Mitazalimab|Mitindomide|Mitobronitol|Mitochondria|Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101|Mitoclomine|Mitoflaxone|Mitoguazone|Mitoguazone Dihydrochloride|Mitolactol|Mitomycin|Mitomycin A|Mitomycin B|Mitomycin C Analog KW-2149|Mitosis Inhibitor T 1101 Tosylate|Mitotane|Mitotenamine|Mitoxantrone|Mitoxantrone Hydrochloride|Mitozolomide|Mitral Valve Disease|Mivavotinib|Mivebresib|Mivobulin|Mivobulin Isethionate|Mixed Acinar-Ductal Carcinoma of the Pancreas|Mixed Adherent Suspension|Mixed Bacteria Vaccine|Mixed Cell Adenocarcinoma|Mixed Cell Adenoma|Mixed Cellularity Classic Hodgkin Lymphoma|Mixed Ductal and Lobular Carcinoma|Mixed Ductal-Neuroendocrine Carcinoma of the Pancreas|Mixed Embryonal Carcinoma and Teratoma|Mixed Epithelial and Mesenchymal Hepatoblastoma|Mixed Epithelioid and Spindle Cell Melanoma|Mixed Germ Cell Tumor|Mixed Glioma|Mixed Liposarcoma|Mixed Mesodermal (Mullerian) Tumor|Mixed Mucinous and Non-Mucinous Bronchioloalveolar Carcinoma|Mixed Phenotype Acute Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1|Mixed Phenotype Acute Leukemia with t(v;11q23.3); KMT2A Rearranged|Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified|Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified|Mixed Response|Mixed Teratoma and Seminoma|Mixed Testicular Sex Cord-Stromal Tumor|Mixed Tumor, Not Otherwise Specified|Mixed acidophil-basophil adenoma|Mixed acidophil-basophil carcinoma|Mixed acinar-ductal carcinoma|Mixed acinar-endocrine carcinoma|Mixed acinar-endocrine-ductal carcinoma|Mixed adenocarcinoma and epidermoid carcinoma|Mixed adenocarcinoma and squamous cell carcinoma|Mixed adenomatous and hyperplastic polyp|Mixed adenoneuroendocrine carcinoma|Mixed basal-squamous cell carcinoma|Mixed carcinoid-adenocarcinoma|Mixed cell adenocarcinoma|Mixed cell adenoma|Mixed ductal-endocrine carcinoma|Mixed embryonal carcinoma and teratoma|Mixed embryonal rhabdomyosarcoma and alveolar rhabdomyosarcoma|Mixed endocrine and exocrine adenocarcinoma|Mixed epithelioid and spindle cell melanoma|Mixed germ cell sex cord-stromal tumor, unclassified|Mixed germ cell tumor|Mixed glioma|Mixed hepatocellular and bile duct carcinoma|Mixed invasive mucinous and non-mucinous adenocarcinoma|Mixed islet cell and exocrine adenocarcinoma|Mixed liposarcoma|Mixed medullary-follicular carcinoma|Mixed medullary-papillary carcinoma|Mixed meningioma|Mixed mesenchymal sarcoma|Mixed mesenchymal tumor|Mixed pancreatic endocrine and exocrine tumor, malignant|Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1|Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged|Mixed phenotype acute leukemia, B/myeloid, NOS|Mixed phenotype acute leukemia, T/myeloid, NOS|Mixed pineal tumor|Mixed pineocytoma-pineoblastoma|Mixed small cell carcinoma|Mixed squamous cell and glandular papilloma|Mixed subependymoma-ependymoma|Mixed teratoma and seminoma|Mixed tumor, NOS|Mixed tumor, malignant, NOS|Mixed tumor, salivary gland type, NOS|Mixed tumor, salivary gland type, malignant|Mixed type rhabdomyosarcoma|Mobitz (Type) II Atrioventricular Block|Mobitz Type I|Mobocertinib|Mocetinostat|Modakafusp Alfa|Moderately Differentiated Ovarian Sertoli-Leydig Cell Tumor|Modified Radical Mastectomy|Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208|Modified Vitamin D Binding Protein Macrophage Activator EF-022|Modotuximab|Mofarotene|Mogamulizumab|Moldova|Molecular Laboratory Procedure Exon Identification Number|Molecular analysis outside specification|Molibresib|Molibresib Besylate|Momelotinib|Monaco|Monalizumab|Mongolia|Monoblastic leukemia, NOS|Monocarboxylate Transporter 1 Inhibitor AZD3965|Monoclonal Antibody 105AD7 Anti-idiotype Vaccine|Monoclonal Antibody 11D10|Monoclonal Antibody 11D10 Anti-Idiotype Vaccine|Monoclonal Antibody 14G2A|Monoclonal Antibody 1F5|Monoclonal Antibody 3622W94|Monoclonal Antibody 3F8|Monoclonal Antibody 3H1 Anti-Idiotype Vaccine|Monoclonal Antibody 4B5 Anti-Idiotype Vaccine|Monoclonal Antibody 7C11|Monoclonal Antibody 81C6|Monoclonal Antibody A1G4 Anti-Idiotype Vaccine|Monoclonal Antibody A27.15|Monoclonal Antibody A33|Monoclonal Antibody AK002|Monoclonal Antibody ASP1948|Monoclonal Antibody AbGn-7|Monoclonal Antibody CAL|Monoclonal Antibody CC49-delta CH2|Monoclonal Antibody CEP-37250/KHK2804|Monoclonal Antibody D6.12|Monoclonal Antibody E2.3|Monoclonal Antibody F19|Monoclonal Antibody GD2 Anti-Idiotype Vaccine|Monoclonal Antibody HeFi-1|Monoclonal Antibody Hu3S193|Monoclonal Antibody HuAFP31|Monoclonal Antibody HuHMFG1|Monoclonal Antibody HuPAM4|Monoclonal Antibody IMMU-14|Monoclonal Antibody L6|Monoclonal Antibody Lym-1|Monoclonal Antibody MX35 F(ab')2|Monoclonal Antibody Me1-14 F(ab')2|Monoclonal Antibody NEO-201|Monoclonal Antibody R24|Monoclonal Antibody RAV12|Monoclonal Antibody SGN-14|Monoclonal Antibody TRK-950|Monoclonal Antibody huJ591|Monoclonal Antibody m170|Monoclonal Antibody muJ591|Monoclonal Gammopathy of Undetermined Significance|Monoclonal Immunoglobulin Deposition Disease|Monoclonal Microbial EDP1503|Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100|Monoclonal gammopathy of undetermined significance|Monoclonal gammopathy, NOS|Monocytic leukemia, NOS|Monocytoid B-cell lymphoma|Monomethyl Auristatin E|Monomorphic adenoma|Mononuclear Cells from Bone Marrow Normal|Monstrocellular sarcoma|Montenegro|Montserrat|Morinda Citrifolia Fruit Extract|Morocco|Morpholinodoxorubicin|Mosedipimod|Mosunetuzumab|Motesanib|Motesanib Diphosphate|Motexafin Gadolinium|Motexafin Lutetium|Mother|Mother-in-law|Motixafortide|Motolimod|Motor / Movement Change|Motor or Movement Changes|Mouth, NOS|Movements Involuntary|Moxetumomab Pasudotox|Mozambique|Mps1 Inhibitor BAY 1217389|Mps1 Inhibitor BOS172722|Ms|Mu Heavy Chain Disease|Mu heavy chain disease|MuSE|MuSE Annotation|MuSE Variant Aggregation and Masking|MuTect2|MuTect2 Annotation|MuTect2 Variant Aggregation and Masking|Mucata mulata|Mucin-Producing Adenocarcinoma|Mucin-Producing Carcinoma|Mucin-producing adenocarcinoma|Mucin-producing carcinoma|Mucin-secreting adenocarcinoma|Mucin-secreting carcinoma|Mucinous Adenocarcinoma|Mucinous Adenocarcinoma, Endocervical Type|Mucinous Adenofibroma|Mucinous Cystadenocarcinoma|Mucinous Cystadenofibroma|Mucinous Cystadenoma|Mucinous Tubular and Spindle Cell Carcinoma of the Kidney|Mucinous adenocarcinofibroma|Mucinous adenocarcinoma|Mucinous adenocarcinoma, endocervical type|Mucinous adenofibroma of borderline malignancy|Mucinous adenofibroma, NOS|Mucinous adenoma|Mucinous carcinoid|Mucinous carcinoma|Mucinous carcinoma, gastric type|Mucinous carcinoma, intestinal type|Mucinous cystadenocarcinofibroma|Mucinous cystadenocarcinoma, NOS|Mucinous cystadenocarcinoma, non-invasive|Mucinous cystadenofibroma of borderline malignancy|Mucinous cystadenofibroma, NOS|Mucinous cystadenoma, NOS|Mucinous cystadenoma, borderline malignancy|Mucinous cystic neoplasm with an associated invasive carcinoma|Mucinous cystic neoplasm with high-grade dysplasia|Mucinous cystic neoplasm with high-grade intraepithelial neoplasia|Mucinous cystic neoplasm with intermediate-grade dysplasia|Mucinous cystic neoplasm with intermediate-grade intraepithelial neoplasia|Mucinous cystic neoplasm with low-grade dysplasia|Mucinous cystic neoplasm with low-grade intraepithelial neoplasia|Mucinous cystic tumor of borderline malignancy|Mucinous cystic tumor with an associated invasive carcinoma|Mucinous cystic tumor with high-grade dysplasia|Mucinous cystic tumor with intermediate dysplasia|Mucinous cystic tumor with low grade dysplasia|Mucinous cystic tumor with moderate dysplasia|Mucinous cystoma|Mucinous tubular and spindle cell carcinoma|Mucinous tumor, NOS, of low malignant potential|Mucoadhesive Paclitaxel Formulation|Mucocarcinoid tumor|Mucoepidermoid Carcinoma|Mucoepidermoid Neoplasms|Mucoepidermoid carcinoma|Mucoepidermoid tumor|Mucoid adenocarcinoma|Mucoid carcinoma|Mucoid cell adenocarcinoma|Mucoid cell adenoma|Mucosa of lip, NOS|Mucosa of lower lip|Mucosa of the Lip|Mucosa of the Lower Lip|Mucosa of upper lip|Mucosal Infection|Mucosal Lentiginous Melanoma|Mucosal lentiginous melanoma|Mucosal-associated lymphoid tissue lymphoma|Mucositis Oral|Mucous adenocarcinoma|Mucous carcinoma|Mullerian adenosarcoma|Mullerian mixed tumor|Multi-AGC Kinase Inhibitor AT13148|Multi-Organ Failure|Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200|Multi-epitope HER2 Peptide Vaccine H2NVAC|Multi-epitope HER2 Peptide Vaccine TPIV100|Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107|Multi-kinase Inhibitor TPX-0022|Multi-kinase Inhibitor XL092|Multi-mode Kinase Inhibitor EOC317|Multi-neo-epitope Vaccine OSE 2101|Multicentric basal cell carcinoma|Multicystic Mesothelioma|Multicystic mesothelioma, benign|Multifocal|Multifocal Lymphomatous Polyposis|Multifocal superficial basal cell carcinoma|Multifunctional/Multitargeted Anticancer Agent OMN54|Multikinase Inhibitor 4SC-203|Multikinase Inhibitor AEE788|Multikinase Inhibitor AT9283|Multikinase Inhibitor SAR103168|Multipeptide Vaccine S-588210|Multiple Adenomatous Polyps|Multiple Endocrine Neoplasia|Multiple Myeloma|Multiple Osteochondromas|Multiple adenomatous polyps|Multiple endocrine adenomas|Multiple hemorrhagic sarcoma|Multiple meningiomas|Multiple myeloma|Multiple neurofibromatosis|Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327|Muparfostat|Mureletecan|Murizatoclax|Mus musculus|Muscadine Grape Extract|Muscle|Muscle Weakness Left-Sided|Muscle Weakness Lower Limb|Muscle Weakness Right-Sided|Muscle Weakness Trunk|Muscle Weakness Upper Limb|Musculoskeletal Deformity|Musculoskeletal and Connective Tissue Disorders - Other|Mutant IDH1 Inhibitor DS-1001|Mutant p53 Activator COTI-2|Mutant-selective EGFR Inhibitor PF-06459988|Myalgia|Myanmar|Myasthenia Gravis|Mycobacterium avium Complex|Mycobacterium tuberculosis|Mycobacterium tuberculosis Arabinomannan Z-100|Mycobacterium w|Mycobacterium, NOS|Mycophenolic Acid|Mycoplasma pneumoniae|Mycosis Fungoides|Mycosis fungoides|Myelitis|Myelocytic leukemia, NOS|Myelodysplastic Syndrome|Myelodysplastic Syndrome with Excess Blasts|Myelodysplastic Syndrome with Excess Blasts-1|Myelodysplastic Syndrome with Excess Blasts-2|Myelodysplastic Syndrome with Isolated del(5q)|Myelodysplastic Syndrome with Multilineage Dysplasia|Myelodysplastic Syndrome with Ring Sideroblasts|Myelodysplastic Syndrome, Unclassifiable|Myelodysplastic Syndromes|Myelodysplastic syndrome with 5q deletion (5q-) syndrome|Myelodysplastic syndrome with isolated del (5q)|Myelodysplastic syndrome, NOS|Myelodysplastic syndrome, unclassifiable|Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Myelodysplastic/myeloproliferative neoplasm, unclassifiable|Myelofibrosis as a result of myeloproliferative disease|Myelofibrosis with myeloid metaplasia|Myelogenous leukemia, NOS|Myeloid Leukemia|Myeloid Leukemia Associated with Down Syndrome|Myeloid Leukemias|Myeloid Sarcoma|Myeloid and lymphoid neoplasms with FGFR1 abnormalities|Myeloid and lymphoid neoplasms with PDGFRA rearrangement|Myeloid leukemia associated with Down Syndrome|Myeloid leukemia, NOS|Myeloid neoplasms with PDGFRB rearrangement|Myeloid sarcoma|Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement|Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement|Myelolipoma|Myeloma, NOS|Myelomatosis|Myelomonocytic leukemia, NOS|Myeloproliferative Neoplasm|Myeloproliferative disease, NOS|Myeloproliferative neoplasm, NOS|Myelosclerosis with myeloid metaplasia|Myloproliferative neoplasm, unclassifiable|Myocardial Infarction|Myocarditis|Myoepithelial Tumor|Myoepithelial adenoma|Myoepithelial carcinoma|Myoepithelial tumor|Myoepithelioma|Myofibroblastic sarcoma|Myofibroblastic tumor, NOS|Myofibroblastic tumor, peribronchial|Myofibroblastoma|Myofibroma|Myofibromatosis|Myolipoma|Myoma|Myomatous Neoplasms|Myometrium|Myosarcoma|Myositis|Myxofibroma, NOS|Myxofibrosarcoma|Myxoid Chondrosarcoma|Myxoid Leiomyosarcoma|Myxoid Liposarcoma|Myxoid chondrosarcoma|Myxoid fibroma|Myxoid leiomyosarcoma|Myxoid liposarcoma|Myxoinflammatory Fibroblastic Sarcoma|Myxoinflammatory fibroblastic sarcoma (MIFS)|Myxolipoma|Myxoliposarcoma|Myxoma|Myxoma, NOS|Myxomatous Neoplasms|Myxopapillary Ependymoma|Myxopapillary ependymoma|Myxosarcoma|N,N-Dibenzyl Daunomycin|N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea|N-Methylformamide|N-dihydrogalactochitosan|N0|N0 (i+)|N0 (i+) Stage Finding|N0 (i-)|N0 (mol+)|N0 (mol+) Stage Finding|N0 (mol-)|N0 Stage Finding|N1|N1 Stage Finding|N1a|N1a Stage Finding|N1b|N1b Stage Finding|N1bI|N1bI Stage Finding|N1bII|N1bII Stage Finding|N1bIII|N1bIII Stage Finding|N1bIV|N1bIV Stage Finding|N1c|N1c Stage Finding|N1mi|N1mi Stage Finding|N2|N2 Stage Finding|N2a|N2a Stage Finding|N2b|N2b Stage Finding|N2c|N2c Stage Finding|N3|N3 Stage Finding|N3a|N3a Stage Finding|N3b|N3b Stage Finding|N3c|N3c Stage Finding|N4|N4 Stage Finding|NA17-A Antigen|NA17.A2 Peptide Vaccine|NAMPT Inhibitor OT-82|NEDD8 Activating Enzyme E1 Inhibitor TAS4464|NG-5400|NG-nitro-L-arginine|NHL, Burkitt lymphoma (BL)|NHL, anaplastic large cell lymphoma|NK-cell large granular lymphocytic leukemia|NK/T-cell lymphoma, nasal and nasal-type|NLRP3 Agonist BMS-986299|NOS|NPB-No Palliative Benefit|NR-No Response|NTRK/ROS1 Inhibitor DS-6051b|NUT Carcinoma|NUT carcinoma|NUT midline carcinoma|NX|NX Stage Finding|NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611|NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301|NY-ESO-1/GLA-SE Vaccine ID-G305|NY-ESO-B|Nab-paclitaxel|Nab-paclitaxel/Rituximab-coated Nanoparticle AR160|Nadofaragene Firadenovec|Nagrestipen|Nail Discoloration|Nail Infection|Nail Loss|Nail Ridging|Nails|Namibia|Namirotene|Namodenoson|Nanafrocin|Nanatinostat|Nanocell-encapsulated miR-16-based microRNA Mimic|Nanoparticle Albumin-Bound Docetaxel|Nanoparticle Albumin-Bound Rapamycin|Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404|Nanoparticle Paclitaxel Ointment SOR007|Nanoparticle-based Paclitaxel Suspension|Nanoparticle-encapsulated Doxorubicin Hydrochloride|Nanoscale Coordination Polymer Nanoparticles CPI-100|Nanosomal Docetaxel Lipid Suspension|Napabucasin|Naphthalimide Analogue UNBS5162|Naptumomab Estafenatox|Naquotinib|Naratuximab Emtansine|Narnatumab|Nasal Cavity|Nasal Congestion|Nasal Soft Tissue|Nasal Type Extranodal NK/T-Cell Lymphoma|Nasal cavity|Nasal cavity and middle ear|Nasopharyngeal-Type Undifferentiated Carcinoma|Nasopharynx|Nasopharynx, NOS|Natalizumab|Native Hawaiian or Other Pacific Islander|Natural Brother|Natural Child|Natural Daughter|Natural Father|Natural Grandchild|Natural Grandfather|Natural Grandmother|Natural Grandparent|Natural IFN-alpha OPC-18|Natural Killer Cells ZRx101|Natural Mother|Natural Parent|Natural Sibling|Natural Sister|Natural Son|Nauru|Nausea|Navarixin|Navicixizumab|Navitoclax|Navoximod|Navy Bean Powder|Naxitamab|Nazartinib|Necitumumab|Neck|Neck Edema|Neck Pain|Neck Soft Tissue Necrosis|Nedaplatin|Nedisertib|Needle Biopsy|Negative|Negative/ No Dysplasia|Nelarabine|Nelipepimut-S|Nelipepimut-S Plus GM-CSF Vaccine|Nemorubicin|Nemorubicin Hydrochloride|Neoadjuvant|Neoadjuvant therapy|Neoantigen Vaccine GEN-009|Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017|Neoantigen-based Glioblastoma Vaccine|Neoantigen-based Melanoma-Poly-ICLC Vaccine|Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine|Neoantigen-based Therapeutic Cancer Vaccine GRT-C903|Neoantigen-based Therapeutic Cancer Vaccine GRT-R904|Neoplasm|Neoplasm of the Diffuse Neuroendocrine System|Neoplasm, NOS|Neoplasm, Uncertain Whether Benign or Malignant|Neoplasm, benign|Neoplasm, malignant|Neoplasm, malignant, uncertain whether primary or metastatic|Neoplasm, metastatic|Neoplasm, secondary|Neoplasm, uncertain whether benign or malignant|Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other|Neoplasms of Histiocytes and Accessory Lymphoid Cells|Neoplasms of Uncertain and Unknown Behavior|Neoplasms, NOS|Neoplastic Cell|Nepal|Nephew|Nephroblastoma, NOS|Nephrogenic adenofibroma|Nephroma, NOS|Neratinib|Neratinib Maleate|Nerve|Nerve Sheath Myxoma|Nerve Sheath Tumors|Nerve sheath myxoma|Nerve(s) Cranial|Nervous System|Nervous System Disorders - Other|Nervous system, NOS|Nesidioblastoma|Nesidioblastosis|Nested urothelial carcinoma|Nesvacumab|Netherlands|Neuralgia|Neurilemoma, NOS|Neurilemoma, malignant|Neurilemosarcoma|Neurinoma|Neurinomatosis|Neuroastrocytoma|Neuroblastoma|Neuroblastoma (NBL)|Neuroblastoma, NOS|Neurocytoma|Neuroectodermal tumor, NOS|Neuroendocrine Carcinoma|Neuroendocrine Tumor|Neuroendocrine carcinoma, NOS|Neuroendocrine carcinoma, low grade|Neuroendocrine carcinoma, moderately differentiated|Neuroendocrine carcinoma, poorly differentiated|Neuroendocrine carcinoma, well-differentiated|Neuroendocrine tumor, grade 1|Neuroendocrine tumor, grade 2|Neuroendocrine tumor, well differentiated|Neuroepithelioma, NOS|Neuroepitheliomatous Neoplasms|Neurofibroma|Neurofibroma, NOS|Neurofibromatosis|Neurofibromatosis Type 1|Neurofibromatosis, NOS|Neurofibrosarcoma|Neurogenic sarcoma|Neurolipocytoma|Neuroma|Neuroma, NOS|Neuronevus|Neurosarcoma|Neurothekeoma|Neurotropic melanoma, malignant|Neutrophil Count Decreased|Never Used|Nevi and Melanomas|Nevus, NOS|New Caledonia|New Objective|New Zealand|New notification type|New observation type|Next Generation Cancer Model|Next Generation Cancer Model Expanded Under Non-conforming Conditions|Next Generation Targeted Sequencing|Niacinamide|Nicaragua|Niclosamide|Nicotinamide Riboside|Nidanilimab|Niece|Niece Second Degree Relative|Nifurtimox|Niger|Nigeria|Night Blindness|Night Sweats|Nilotinib|Nilotinib Hydrochloride Anhydrous|Nilotinib Hydrochloride Monohydrate|Nilutamide|Nimesulide-Hyaluronic Acid Conjugate CA102N|Nimodipine|Nimotuzumab|Nimustine|Nimustine Hydrochloride|Ningetinib Tosylate|Nintedanib|Nipple|Nipple Adenoma|Nipple Deformity|Niraparib|Niraparib Tosylate Monohydrate|Nirogacestat|Nitric Oxide-Releasing Acetylsalicylic Acid Derivative|Nitrogen Mustard Prodrug PR-104|Nitroglycerin Transdermal Patch|Niue|Nivolumab|No Known Treatment Effect|No Measurable Disease|No Metastasis|No Metastasis (M0)|No Necrosis|No Palliative Benefit|No Response|No Smoke Exposure|No Treatment|No Vascular Invasion|No cleavage|NoEnzyme|Nocardiosis|Nocodazole|Nodal Marginal Zone Lymphoma|Nodal marginal zone lymphoma|Nodular Hidradenoma|Nodular Lymphocyte Predominant Hodgkin Lymphoma|Nodular Prostatic Hyperplasia|Nodular Sclerosis Classic Hodgkin Lymphoma|Nodular Sclerosis Classic Hodgkin Lymphoma, Cellular Phase|Nodular Sclerosis Classic Hodgkin Lymphoma, Syncytial Variant|Nodular hidradenoma|Nodular hidradenoma, malignant|Nodular melanoma|Nogalamycin|Nogapendekin Alfa|Nolatrexed Dihydrochloride|Non cancerous tissue|Non-CR/Non-PD-Non-CR/Non-PD|Non-Cancer Related Death|Non-Cardiac Chest Pain|Non-Drinker|Non-Hodgkin Lymphoma|Non-Hodgkin lymphoma, NOS|Non-Invasive Papillary Squamous Cell Carcinoma|Non-Invasive Papillary Transitional Cell Carcinoma|Non-Keratinizing Large Cell Squamous Cell Carcinoma|Non-Keratinizing Sinonasal Squamous Cell Carcinoma|Non-Keratinizing Small Cell Squamous Cell Carcinoma|Non-Malignant|Non-Small Cell Carcinoma|Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201|Non-WNT/non-SHH Activated|Non-invasive EFVPTC|Non-invasive FTP|Non-invasive encapsulated follicular variant of papillary thyroid carcinoma (non-invasive EFVPTC)|Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)|Non-invasive low grade serous carcinoma|Non-invasive mammary carcinoma|Non-lymphocytic leukemia, NOS|Non-small cell carcinoma|Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis|Nonchromaffin paraganglioma, NOS|Nonchromaffin paraganglioma, malignant|None|Nonencapsulated sclerosing adenocarcinoma|Nonencapsulated sclerosing carcinoma|Nonencapsulated sclerosing tumor|Nongerminomatous Germ Cell Tumor|Noninfiltrating intracystic carcinoma|Noninfiltrating intraductal papillary adenocarcinoma|Noninfiltrating intraductal papillary carcinoma|Noninvasive pancreatobiliary papillary neoplasm with high grade dysplasia|Noninvasive pancreatobiliary papillary neoplasm with high grade intraepithelial neoplasia|Noninvasive pancreatobiliary papillary neoplasm with low grade dysplasia|Noninvasive pancreatobiliary papillary neoplasm with low grade intraepithelial neoplasia|Nonlipid reticuloendotheliosis|Nonpigmented Nevus|Nonpigmented nevus|Norgestrel|Normal|Normal Adjacent Tissue|Normal class but appears diseased|Normal tissue origin incorrect|Normal_LogR|North American Ginseng Extract AFX-2|North Korea|North Macedonia|Northern Mariana Islands|Nortopixantrone|Norway|Noscapine|Noscapine Hydrochloride|Not Allowed To Collect|Not Applicable|Not Cancer Related|Not Determined|Not Hispanic or Latino|Not Otherwise Specified|Not Performed|Not performed|Notch Signaling Inhibitor PF-06650808|Notch Signaling Pathway Inhibitor MK0752|Notification|Nuclei RNA|Nucleolin Antagonist IPP-204106N|Nucleoside Analog DFP-10917|Nucleotide Analog Prodrug NUC-3373|Nucleotide Analogue GS 9219|Numidargistat|Nurulimab|Nutlin-3a|Nutraceutical TBL-12|Nystagmus|O-Chloroacetylcarbamoylfumagillol|O6-Benzylguanine|OCT|OMEGA|OMEGA-2001|OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule|OX40L-expressing Oncolytic Adenovirus DNX-2440|Oat cell carcinoma|Obatoclax Mesylate|Obesity|Obinutuzumab|Oblimersen Sodium|Observation|Obstruction Gastric|Ocaratuzumab|Occasional Drinker|Occipital Cortex|Occipital Lobe|Occipital lobe|Ocrelizumab|Octreotide|Octreotide Acetate|Octreotide Pamoate|Ocular Orbits|Oculomotor Nerve Disorder|Odontoameloblastoma|Odontogenic Fibroma|Odontogenic Myxofibroma|Odontogenic Myxoma|Odontogenic Neoplasm|Odontogenic Tumors|Odontogenic carcinoma|Odontogenic carcinosarcoma|Odontogenic fibroma, NOS|Odontogenic fibrosarcoma|Odontogenic ghost cell tumor|Odontogenic myxofibroma|Odontogenic myxoma|Odontogenic sarcoma|Odontogenic tumor, NOS|Odontogenic tumor, benign|Odontogenic tumor, malignant|Odontoma|Odontoma, NOS|Odronextamab|Ofatumumab|Ofranergene Obadenovec|Oglufanide Disodium|Oil burning smoke, Kerosene|Oil burning smoke, NOS|Olaparib|Olaptesed Pegol|Olaratumab|Oleandrin|Oleclumab|Olfactory Nerve Disorder|Olfactory Neuroblastoma|Olfactory Neurocytoma|Olfactory Neurogenic Tumor|Olfactory nerve|Olfactory neuroblastoma|Olfactory neurocytoma|Olfactory neuroepithelioma|Olfactory neurogenic tumor|Oligo-fucoidan|Oligoastrocytoma|Oligodendroblastoma|Oligodendroglioma|Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted|Oligodendroglioma, NOS|Oligodendroglioma, Not Otherwise Specified|Oligodendroglioma, anaplastic|Oligonucleotide SPC2996|Oligospermia|Olinvacimab|Olivomycin|Olmutinib|Oltipraz|Olutasidenib|Olvimulogene Nanivacirepvec|Omacetaxine Mepesuccinate|Oman|Ombrabulin|Omentectomy|Omentum|Omipalisib|Onalespib|Onalespib Lactate|Onartuzumab|Onatasertib|Once Weekly|Oncocytic Adenoma|Oncocytic Neoplasm|Oncocytic Schneiderian papilloma|Oncocytic adenocarcinoma|Oncocytic adenoma|Oncocytic carcinoma|Oncocytoma|Oncolytic Adenovirus Ad5-DNX-2401|Oncolytic Adenovirus ORCA-010|Oncolytic HSV-1 C134|Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011|Oncolytic HSV-1 G207|Oncolytic HSV-1 NV1020|Oncolytic HSV-1 rQNestin34.5v.2|Oncolytic HSV-1 rRp450|Oncolytic HSV1716|Oncolytic Herpes Simplex Virus-1 ONCR-177|Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein|Oncolytic Newcastle Disease Virus MEDI5395|Oncolytic Newcastle Disease Virus MTH-68H|Oncolytic Newcastle Disease Virus Strain PV701|Oncolytic Virus ASP9801|Oncolytic Virus RP1|Ondansetron Hydrochloride|Ontorpacept|Ontuxizumab|Onvansertib|Onvatilimab|Oophorectomy|Opaganib|Open Craniotomy|Open Partial Nephrectomy|Open Radical Nephrectomy|Open Radical Prostatectomy|Opioid Growth Factor|Opolimogene Capmilisbac|Oportuzumab Monatox|Oprozomib|Optic Nerve|Optic Nerve Disorder|Optic nerve|OptionAnalysisPipeline2|Opucolimab|Oral|Oral Aminolevulinic Acid Hydrochloride|Oral Azacitidine|Oral Cancer Vaccine V3-OVA|Oral Cavity|Oral Cavity - Mucosa Only|Oral Cavity Fistula|Oral Contraceptives|Oral Docetaxel|Oral Dysesthesia|Oral Fludarabine Phosphate|Oral Hemorrhage|Oral Hsp90 Inhibitor IPI-493|Oral Hypoglycemic|Oral Ixabepilone|Oral Microencapsulated Diindolylmethane|Oral Milataxel|Oral Myoma Vaccine V3-myoma|Oral Pain|Oral Pancreatic Cancer Vaccine V3-P|Oral Picoplatin|Oral Sodium Phenylbutyrate|Oral Squamous Cell Carcinoma|Oral Topotecan Hydrochloride|Orantinib|Oraxol|Orbit|Orbit, NOS|Orbitrap Elite|Orbitrap Fusion|Orbitrap Fusion ETD|Orbitrap Fusion Lumos|Orbitrap Lumos|Orbitrap Velos|Orchiectomy|Orchioblastoma|Orchiopexy|Oregovomab|Orelabrutinib|Organ Transplantation|Organ transplant (site)|Ormaplatin|Oropharynx|Oropharynx, NOS|Ortataxel|Orteronel|Orvacabtagene Autoleucel|Oryza sativa|Osilodrostat|Osimertinib|Osseous and Chondromatous Neoplasms|Ossifying Fibroma|Ossifying Fibromyxoid Tumor|Ossifying fibroma|Ossifying fibromyxoid tumor|Ossifying fibromyxoid tumor, malignant|Ossifying renal tumor|Osteoarthritis|Osteoblastic Osteosarcoma|Osteoblastic sarcoma|Osteoblastoma|Osteoblastoma, NOS|Osteoblastoma, malignant|Osteocartilaginous exostosis|Osteochondroma|Osteochondromatosis, NOS|Osteochondrosarcoma|Osteofibroma|Osteofibrosarcoma|Osteogenic sarcoma, NOS|Osteoid Osteoma|Osteoid osteoma, NOS|Osteoma|Osteoma, NOS|Osteonecrosis of Jaw|Osteoporosis|Osteoporosis or Osteopenia|Osteosarcoma|Osteosarcoma (OS)|Osteosarcoma in Paget disease of bone|Osteosarcoma, NOS|Other|Other Cancer Within 5 Years|Other Hematologic Disorders|Other Leukemias|Other Nonmalignant Systemic Disease|Other Pulmonary Complications|Other Specified Parts of Pancreas|Other Surgical Resection|Other and Unspecified Female Genital Organs ICD-O-3|Other and ill-defined digestive organs|Other and ill-defined sites|Other and ill-defined sites in lip, oral cavity and pharynx|Other and ill-defined sites within respiratory system and intrathoracic organs|Other and unspecified female genital organs|Other and unspecified major salivary glands|Other and unspecified male genital organs|Other and unspecified parts of biliary tract|Other and unspecified parts of mouth|Other and unspecified parts of tongue|Other and unspecified urinary organs|Other endocrine glands and related structures|Other ill-defined sites|Other specified parts of female genital organs|Other specified parts of male genital organs|Other specified parts of pancreas|Otitis Externa|Otitis Media|Otlertuzumab|Ovapuldencel-T|Ovarian Cancer|Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006|Ovarian Capsule Fragmented|Ovarian Capsule Intact|Ovarian Capsule Ruptured|Ovarian Endometrioid Adenofibroma|Ovarian Endometrioid Cystadenofibroma|Ovarian Gynandroblastoma|Ovarian Hemorrhage|Ovarian Hilus Cell Tumor|Ovarian Infection|Ovarian Luteinized Thecoma|Ovarian Rupture|Ovarian Sclerosing Stromal Tumor|Ovarian Seromucinous Carcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord-Stromal Tumor|Ovarian Small Cell Carcinoma, Hypercalcemic Type|Ovarian Small Cell Carcinoma, Pulmonary-Type|Ovarian Steroid Cell Tumor|Ovarian Stromal Luteoma|Ovarian Stromal Tumor with Minor Sex Cord Elements|Ovarian stromal tumor|Ovary|Overlapping lesion of accessory sinuses|Overlapping lesion of biliary tract|Overlapping lesion of bladder|Overlapping lesion of bones, joints and articular cartilage|Overlapping lesion of bones, joints and articular cartilage of limbs|Overlapping lesion of brain|Overlapping lesion of brain and central nervous system|Overlapping lesion of breast|Overlapping lesion of cervix uteri|Overlapping lesion of colon|Overlapping lesion of connective, subcutaneous and other soft tissues|Overlapping lesion of corpus uteri|Overlapping lesion of digestive system|Overlapping lesion of endocrine glands and related structures|Overlapping lesion of esophagus|Overlapping lesion of eye and adnexa|Overlapping lesion of female genital organs|Overlapping lesion of floor of mouth|Overlapping lesion of heart, mediastinum and pleura|Overlapping lesion of hypopharynx|Overlapping lesion of ill-defined sites|Overlapping lesion of larynx|Overlapping lesion of lip|Overlapping lesion of lip, oral cavity and pharynx|Overlapping lesion of lung|Overlapping lesion of major salivary glands|Overlapping lesion of male genital organs|Overlapping lesion of nasopharynx|Overlapping lesion of other and unspecified parts of mouth|Overlapping lesion of palate|Overlapping lesion of pancreas|Overlapping lesion of penis|Overlapping lesion of peripheral nerves and autonomic nervous system|Overlapping lesion of rectum, anus and anal canal|Overlapping lesion of respiratory system and intrathoracic organs|Overlapping lesion of retroperitoneum and peritoneum|Overlapping lesion of skin|Overlapping lesion of small intestine|Overlapping lesion of stomach|Overlapping lesion of tongue|Overlapping lesion of tonsil|Overlapping lesion of urinary organs|Overlapping lesion of vulva|Overlapping lesions of oropharynx|Ovine Submaxillary Mucin|Ovulation Pain|OxPhos Inhibitor VLX600|Oxaliplatin|Oxaliplatin Eluting Beads|Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome|Oxcarbazepine|Oxeclosporin|Oxidative Phosphorylation Inhibitor IACS-010759|Oxidative Phosphorylation Inhibitor IM156|Oxidopamine|Oxyphilic Adenocarcinoma|Oxyphilic adenocarcinoma|Oxyphilic adenoma|Ozarelix|P-TEFb Inhibitor BAY1143572|P-cadherin Antagonist PF-03732010|P-cadherin Inhibitor PCA062|P-cadherin-targeting Agent PF-06671008|P-p68 Inhibitor RX-5902|PA-Palliative Therapy|PAK4 Inhibitor PF-03758309|PAK4/NAMPT Inhibitor KPT-9274|PARP 1/2 Inhibitor IMP4297|PARP 1/2 Inhibitor NOV1401|PARP Inhibitor AZD2461|PARP Inhibitor CEP-9722|PARP Inhibitor E7016|PARP Inhibitor NMS-03305293|PARP-1/2 Inhibitor ABT-767|PARP/Tankyrase Inhibitor 2X-121|PARP7 Inhibitor RBN-2397|PB-Palliative Benefit|PBN Derivative OKN-007|PCNU|PD-1 Directed Probody CX-188|PD-1 Inhibitor|PD-L1 Inhibitor GS-4224|PD-L1 Inhibitor INCB086550|PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480|PD-L1/PD-L2/VISTA Antagonist CA-170|PD-Progressive Disease|PDF|PDK1 Inhibitor AR-12|PDM-Persistent Distant Metastasis|PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1|PEComa, malignant|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|PEG-Proline-Interferon Alfa-2b|PEG-interleukin-2|PEOX-based Polymer Encapsulated Paclitaxel FID-007|PEP-3-KLH Conjugate Vaccine|PET|PGG Beta-Glucan|PGLA/PEG Copolymer-Based Paclitaxel|PH20 Hyaluronidase-expressing Adenovirus VCN-01|PI3K Alpha/Beta Inhibitor BAY1082439|PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate|PI3K Inhibitor ACP-319|PI3K Inhibitor BGT226|PI3K Inhibitor GDC-0084|PI3K Inhibitor GDC0077|PI3K Inhibitor GSK1059615|PI3K Inhibitor WX-037|PI3K Inhibitor ZSTK474|PI3K p110beta/delta Inhibitor KA2237|PI3K-alpha Inhibitor MEN1611|PI3K-beta Inhibitor GSK2636771|PI3K-beta Inhibitor SAR260301|PI3K-delta Inhibitor AMG 319|PI3K-delta Inhibitor HMPL 689|PI3K-delta Inhibitor INCB050465|PI3K-delta Inhibitor PWT143|PI3K-delta Inhibitor SHC014748M|PI3K-delta Inhibitor YY-20394|PI3K-gamma Inhibitor IPI-549|PI3K/BET Inhibitor LY294002|PI3K/mTOR Kinase Inhibitor DS-7423|PI3K/mTOR Kinase Inhibitor PF-04691502|PI3K/mTOR Kinase Inhibitor VS-5584|PI3K/mTOR Kinase Inhibitor WXFL10030390|PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170|PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901|PI3Ka/mTOR Inhibitor PKI-179|PI3Kalpha Inhibitor AZD8835|PI3Kbeta Inhibitor AZD8186|PI3Kdelta Inhibitor GS-9901|PIM Kinase Inhibitor LGH447|PIM Kinase Inhibitor SGI-1776|PIM Kinase Inhibitor TP-3654|PIM/FLT3 Kinase Inhibitor SEL24|PIN III|PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231|PKC-alpha Antisense Oligodeoxynucleotide ISIS 3521|PKC-beta Inhibitor MS-553|PLC|PLD-Persistent Locoregional Disease|PLK1 Inhibitor CYC140|PLK1 Inhibitor TAK-960|PNET, NOS|PP/PYY producing tumor|PPAR Alpha Antagonist TPST-1120|PPD-Pseudoprogression|PPNET|PR-Partial Response|PR1 Leukemia Peptide Vaccine|PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701|PRIMA-1 Analog APR-246|PRMT1 Inhibitor GSK3368715|PRMT5 Inhibitor JNJ-64619178|PRMT5 Inhibitor PRT811|PSA/IL-2/GM-CSF Vaccine|PSA/PSMA DNA Plasmid INO-5150|PSMA|PSMA-targeted Docetaxel Nanoparticles BIND-014|PSMA-targeted Tubulysin B-containing Conjugate EC1169|PSMA/CD3 Tri-specific T-cell Activating Construct HPN424|PSR-Pseudoresponse|PTEF-b/CDK9 Inhibitor BAY1251152|PTLD, NOS|PV-10|PVA Microporous Hydrospheres/Doxorubicin Hydrochloride|PacBio|Pacinian Neurofibroma|Pacinian tumor|Paclitaxel|Paclitaxel Ceribate|Paclitaxel Injection Concentrate for Nanodispersion|Paclitaxel Liposome|Paclitaxel PPE Microspheres|Paclitaxel Poliglumex|Paclitaxel Polymeric Micelle Formulation NANT-008|Paclitaxel Trevatide|Paclitaxel Vitamin E-Based Emulsion|Paclitaxel-Loaded Polymeric Micelle|Pacmilimab|Pacritinib|Padeliporfin|Padoporfin|Paget Disease and Intraductal Carcinoma of the Breast|Paget Disease of the Breast|Paget Disease of the Breast without Invasive Carcinoma|Paget disease and infiltrating duct carcinoma of breast|Paget disease and intraductal carcinoma of breast|Paget disease of breast|Paget disease, extramammary|Paget disease, mammary|Pagetoid Reticulosis|Pagetoid reticulosis|Pain|Pain (Various)|Pain in Extremity|Pain of Skin|Paired_LogR|Pakistan|Palate|Palate, NOS|Palatectomy|Palatine Tonsil|Palau|Palbociclib|Palbociclib Isethionate|Palifosfamide|Palifosfamide Tromethamine|Palladium Pd-103|Palliative|Palmar-Plantar Erythrodysesthesia Syndrome|Palonosetron Hydrochloride|Palpitations|Pamidronate Disodium|Pamidronic Acid|Pamiparib|Pamrevlumab|Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514|Pan-AKT Inhibitor ARQ751|Pan-AKT Kinase Inhibitor GSK690693|Pan-FGFR Inhibitor LY2874455|Pan-FLT3/Pan-BTK Multi-kinase Inhibitor CG-806|Pan-IDH Mutant Inhibitor AG-881|Pan-KRAS Inhibitor BI 1701963|Pan-Mutant-IDH1 Inhibitor Bay-1436032|Pan-PIM Inhibitor INCB053914|Pan-Procto Colectomy|Pan-RAF Inhibitor LY3009120|Pan-RAR Agonist/AP-1 Inhibitor LGD 1550|Pan-TRK Inhibitor NOV1601|Pan-TRK Inhibitor ONO-7579|Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981|Pan-mutation-selective EGFR Inhibitor CLN-081|Panama|Pancratistatin|Pancreas|Pancreas Cancer|Pancreas Infection|Pancreas, NOS|Pancreatectomy|Pancreatic Acinar Cell Cystadenocarcinoma|Pancreatic Adenocarcinoma|Pancreatic Anastomotic Leak|Pancreatic Beta Cell Adenoma|Pancreatic Duct Stenosis|Pancreatic Ductal Adenocarcinoma|Pancreatic Enzymes Decreased|Pancreatic Fistula|Pancreatic Hemorrhage|Pancreatic Insulinoma|Pancreatic Intraductal Papillary-Mucinous Neoplasm with High Grade Dysplasia|Pancreatic Intraductal Papillary-Mucinous Neoplasm with an Associated Invasive Carcinoma|Pancreatic Intraductal Tubulopapillary Neoplasm|Pancreatic Mucinous-Cystic Neoplasm with Intermediate Grade Dysplasia|Pancreatic Necrosis|Pancreatic Neuroendocrine Carcinoma|Pancreatic Neuroendocrine Neoplasm|Pancreatic duct|Pancreatic endocrine tumor, NOS|Pancreatic endocrine tumor, benign|Pancreatic endocrine tumor, malignant|Pancreatic endocrine tumor, nonfunctioning|Pancreatic microadenoma|Pancreatic neck|Pancreatic peptide and pancreatic peptide-like peptide within terminal tyrosine amide producing tumor|Pancreatitis|Pancreatobiliary neoplasm, non-invasive|Pancreatobiliary-type carcinoma|Pancreatoblastoma|Panitumumab|Panobinostat|Panobinostat Nanoparticle Formulation MTX110|Panulisib|Pap Smear|Papillary Adenocarcinoma|Papillary Adenofibroma|Papillary Carcinoma|Papillary Carcinoma In Situ|Papillary Craniopharyngioma|Papillary Cystadenocarcinoma|Papillary Cystadenoma|Papillary Cystic Neoplasm|Papillary Eccrine Adenoma|Papillary Ependymoma|Papillary Glioneuronal Tumor|Papillary Intralymphatic Angioendothelioma|Papillary Meningioma|Papillary Mucinous Cystadenocarcinoma|Papillary Mucinous Cystadenoma|Papillary Renal Cell Carcinoma|Papillary Serous Cystadenocarcinoma|Papillary Serous Cystadenoma|Papillary Squamous Cell Carcinoma|Papillary Transitional Cell Carcinoma|Papillary Tumor of the Pineal Region|Papillary adenocarcinoma, NOS|Papillary adenocarcinoma, follicular variant|Papillary adenofibroma|Papillary adenoma, NOS|Papillary and follicular adenocarcinoma|Papillary and follicular carcinoma|Papillary carcinoma in situ|Papillary carcinoma of thyroid|Papillary carcinoma, NOS|Papillary carcinoma, columnar cell|Papillary carcinoma, diffuse sclerosing|Papillary carcinoma, encapsulated|Papillary carcinoma, follicular variant|Papillary carcinoma, oxyphilic cell|Papillary carcinoma, tall cell|Papillary cystadenocarcinoma, NOS|Papillary cystadenoma lymphomatosum|Papillary cystadenoma, NOS|Papillary cystadenoma, borderline malignancy|Papillary cystic tumor|Papillary ependymoma|Papillary epidermoid carcinoma|Papillary glioneuronal tumor|Papillary hidradenoma|Papillary meningioma|Papillary microcarcinoma|Papillary mucinous cystadenocarcinoma|Papillary mucinous cystadenoma, NOS|Papillary mucinous cystadenoma, borderline malignancy|Papillary mucinous tumor of low malignant potential|Papillary neoplasm, pancreatobiliary-type, with high grade intraepithelial neoplasia|Papillary pseudomucinous cystadenocarcinoma|Papillary pseudomucinous cystadenoma, NOS|Papillary pseudomucinous cystadenoma, borderline malignancy|Papillary renal cell carcinoma|Papillary serous adenocarcinoma|Papillary serous cystadenocarcinoma|Papillary serous cystadenoma, NOS|Papillary serous cystadenoma, borderline malignancy|Papillary serous tumor of low malignant potential|Papillary squamous cell carcinoma|Papillary squamous cell carcinoma in situ|Papillary squamous cell carcinoma, non-invasive|Papillary syringadenoma|Papillary syringocystadenoma|Papillary transitional cell carcinoma|Papillary transitional cell carcinoma, non-invasive|Papillary transitional cell neoplasm of low malignant potential|Papillary tumor of the pineal region|Papillary urothelial carcinoma|Papillary urothelial carcinoma, non-invasive|Papillary urothelial neoplasm of low malignant potential|Papilledema|Papillocystic adenocarcinoma|Papilloma|Papilloma of bladder|Papilloma, NOS|Papillomatosis|Papillomatosis, NOS|Papillomatosis, glandular|Papillotubular adenocarcinoma|Papillotubular adenoma|Papua New Guinea|Papulopustular Rash|Paracentesis|Parachordoma|Parafollicular cell carcinoma|Paraganglioma|Paraganglioma, NOS|Paraganglioma, benign|Paraganglioma, malignant|Paragangliomas and Glomus Tumors|Paraguay|Parametrium|Paranasal Sinuses|Parasitic Disease of Biliary Tract|Paraspinal Ganglion|Parasympathetic Paraganglioma|Parasympathetic paraganglioma|Parathyroid|Parathyroid Gland Chief Cell Adenoma|Parathyroid Gland Water-Clear Cell Adenoma|Parathyroid gland|Paraurethral gland|Parenchyma|Parent|Paresthesia|Paricalcitol|Parietal Lobe|Parietal cell adenocarcinoma|Parietal cell carcinoma|Parietal lobe|Paronychia|Parosteal Osteosarcoma|Parosteal osteosarcoma|Parotid Gland|Parotid gland|Parotidectomy, NOS|Paroxysmal Atrial Tachycardia|Parsaclisib|Parsaclisib Hydrochloride|Parsatuzumab|Partial Hepatectomy|Partial Hydatidiform Mole|Partial Laryngectomy|Partial Maxillectomy|Partial Nephrectomy|Partial Response|Partial hydatidiform mole|Partially Engineered T-regulatory Cell Donor Graft TRGFT-201|Parvovirus H-1|Pasireotide|Pasotuxizumab|Patella|Paternal Aunt|Paternal First Cousin|Paternal First Cousin Once Removed|Paternal Grandfather|Paternal Grandmother|Paternal Grandparent|Paternal Great Aunt|Paternal Great Grandparent|Paternal Great Uncle|Paternal Half Brother|Paternal Half Sibling|Paternal Half Sister|Paternal Uncle|Pathologic Examination|Pathologic Review|Pathology|Pathology Report|Pathology outside specification|Patidegib|Patidegib Topical Gel|Patritumab|Patritumab Deruxtecan|Pattern 1|Pattern 2|Pattern 3|Pattern 4|Pattern 5|Patupilone|Paxalisib|Pazopanib|Pazopanib Hydrochloride|Pediatric Liver Cancer|Pediatric/AYA Brain Tumors|Pegargiminase|Pegaspargase|Pegasus|Pegasus 4D|Pegasus BT|Pegasus HRT|Pegasus III|Pegdinetanib|Pegfilgrastim|Pegilodecakin|Peginterferon Alfa-2a|Peginterferon Alfa-2b|Pegvisomant|Pegvorhyaluronidase Alfa|Pegylated Deoxycytidine Analogue DFP-14927|Pegylated Interferon Alfa|Pegylated Liposomal Belotecan|Pegylated Liposomal Doxorubicin Hydrochloride|Pegylated Liposomal Irinotecan|Pegylated Liposomal Mitomycin C Lipid-based Prodrug|Pegylated Liposomal Mitoxantrone Hydrochloride|Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010|Pegylated Paclitaxel|Pegylated Recombinant Human Arginase I BCT-100|Pegylated Recombinant Human Hyaluronidase PH20|Pegylated Recombinant Interleukin-2 THOR-707|Pegylated Recombinant L-asparaginase Erwinia chrysanthemi|Pegylated SN-38 Conjugate PLX038|Pegzilarginase|Pelabresib|Pelareorep|Peldesine|Pelitinib|Pelitrexol|Pelvic Floor Muscle Weakness|Pelvic Infection|Pelvic Pain|Pelvic Soft Tissue Necrosis|Pelvic bones, sacrum, coccyx and associated joints|Pelvic lymph nodes|Pelvis|Pelvis, NOS|Pembrolizumab|Pemetrexed|Pemetrexed Disodium|Pemigatinib|Pemlimogene Merolisbac|Penberol|Penclomedine|Penicillamine|Penile Carcinoma In Situ|Penile Infection|Penile Pain|Penis|Penis, NOS|Pentamethylmelamine|Pentamustine|Pentostatin|Pentoxifylline|Pepinemab|Peplomycin|Peplomycin Sulfate|Peposertib|PepsinA|Peptic Ulcer (Ulcer)|Peptichemio|Peptide 946 Melanoma Vaccine|Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine|Peretinoin|Perflenapent Emulsion|Perforation Bile Duct|Perfosfamide|Periapical cemental dysplasia|Periapical cemento-osseous dysplasia|Pericanalicular fibroadenoma|Pericardial Effusion|Pericardial Tamponade|Pericarditis|Pericardium|Periductal stromal tumor, low grade|Perifollicular Fibroma|Perifollicular fibroma|Perifosine|Perillyl Alcohol|Perimenopausal|Perineal Pain|Perinephric Fat|Perineural MPNST|Perineurioma|Perineurioma, NOS|Perineurioma, malignant|Periodontal Disease|Periorbital Edema|Periorbital Infection|Periorbital Soft Tissue|Periosteal Chondroma|Periosteal Chondrosarcoma|Periosteal Fibroma|Periosteal Fibrosarcoma|Periosteal Osteosarcoma|Periosteal chondroma|Periosteal chondrosarcoma|Periosteal fibroma|Periosteal fibrosarcoma|Periosteal osteosarcoma|Periosteal sarcoma, NOS|Peripheral Blood Components NOS|Peripheral Ischemia|Peripheral Motor Neuropathy|Peripheral Nerve Infection|Peripheral Neuropathy|Peripheral Odontogenic Fibroma|Peripheral Primitive Neuroectodermal Tumor|Peripheral Sensory Neuropathy|Peripheral T-Cell Lymphoma, Large Cell|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Peripheral T-cell lymphoma, AILD (Angioimmunoblastic Lymphadenopathy with Dysproteinemia)|Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, large cell|Peripheral T-cell lymphoma, pleomorphic medium and large cell|Peripheral T-cell lymphoma, pleomorphic small cell|Peripheral Vascular Disease|Peripheral Whole Blood|Peripheral nerves and autonomic nervous system|Peripheral nerves and autonomic nervous system of abdomen|Peripheral nerves and autonomic nervous system of head, face, and neck|Peripheral nerves and autonomic nervous system of lower limb and hip|Peripheral nerves and autonomic nervous system of pelvis|Peripheral nerves and autonomic nervous system of thorax|Peripheral nerves and autonomic nervous system of trunk, NOS|Peripheral nerves and autonomic nervous system of upper limb and shoulder|Peripheral neuroectodermal tumor|Peripheral odontogenic fibroma|Peripheral primitive neuroectodermal tumor, NOS|Peritoneal Cavity|Peritoneal Infection|Peritoneal Lavage|Peritoneal Necrosis|Peritoneum|Peritoneum, NOS|Peritumoral|Perivascular epithelioid cell tumor, malignant|Permanently missing item or object|Persistent Disease|Personality Change|Personalized ALL-specific Multi-HLA-binding Peptide Vaccine|Personalized Cancer Vaccine RO7198457|Personalized Neoantigen DNA Vaccine GNOS-PV01|Personalized Neoantigen DNA Vaccine GNOS-PVO2|Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01|Personalized Neoepitope Yeast Vaccine YE-NEO-001|Personalized Peptide Cancer Vaccine NEO-PV-01|Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC|Pertuzumab|Peru|Peutz-Jeghers Disease|Pevonedistat|Pexastimogene Devacirepvec|Pexidartinib|Pexmetinib|Phaleria macrocarpa Extract DLBS-1425|Phantom Pain|Pharmaceutical Therapy, NOS|Pharmacological Ascorbate|Pharyngeal Anastomotic Leak|Pharyngeal Fistula|Pharyngeal Hemorrhage|Pharyngeal Mucositis|Pharyngeal Necrosis|Pharyngeal Stenosis|Pharyngitis|Pharyngolaryngeal Pain|Pharynx|Pharynx, NOS|Phellodendron amurense Bark Extract|Phenesterin|Phenethyl Isothiocyanate|Phenethyl Isothiocyanate-containing Watercress Juice|Phenochromocytoma or Paraganglioma|Phenyl Acetate|Phenytoin Sodium|Pheochromoblastoma|Pheochromocytoma and Paraganglioma|Pheochromocytoma, NOS|Pheochromocytoma, malignant|Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia|Philadelphia-Negative Myelogenous Leukemia|Philippines|Phlebitis|Phlebitis Infective|Phosphaplatin PT-112|Phosphatidylcholine-Bound Silybin|Phosphaturic mesenchymal tumor, malignant|Phospholipid Ether-drug Conjugate CLR 131|Phosphoproteome|Phosphoramide Mustard|Phosphorodiamidate Morpholino Oligomer AVI-4126|Phosphorus P-32|Photodynamic Compound TLD-1433|Photophobia|Photosensitivity|Photosensitizer LUZ 11|Phyllodes Tumor|Phyllodes tumor, NOS|Phyllodes tumor, benign|Phyllodes tumor, borderline|Phyllodes tumor, malignant|Physical Exam|Physical Examination|Phytochlorin Sodium-Polyvinylpyrrolidone Complex|Pibenzimol|Pibrozelesin|Pibrozelesin Hydrobromide|Picibanil|Pick tubular adenoma|PicoFrit SELF/P|Picoplatin|Picrasinoside H|Picropodophyllin|Pictilisib|Pictilisib Bismesylate|Pidilizumab|Pigmented Adrenal Cortex Adenoma|Pigmented Dermatofibrosarcoma Protuberans|Pigmented Nevus|Pigmented Spindle Cell Nevus|Pigmented adenoma|Pigmented basal cell carcinoma|Pigmented dermatofibrosarcoma protuberans|Pigmented nevus, NOS|Pigmented schwannoma|Pigmented spindle cell nevus of Reed|Pilar tumor|Pilaralisib|Pilocytic Astrocytoma|Pilocytic astrocytoma|Piloid astrocytoma|Pilomatrical Carcinoma|Pilomatricoma|Pilomatricoma, NOS|Pilomatricoma, malignant|Pilomatrix carcinoma|Pilomatrixoma, NOS|Pilomatrixoma, malignant|Pilomyxoid Astrocytoma|Pilomyxoid astrocytoma|PilotAnalysisPipeline2|Pimasertib|Pimitespib|Pimurutamab|Pinatuzumab Vedotin|Pindborg tumor|Pindel|Pindel Annotation|Pindel Variant Aggregation and Masking|Pineal|Pineal Gland|Pineal Parenchymal Cell Neoplasm|Pineal Parenchymal Tumor of Intermediate Differentiation|Pineal Region Neoplasm|Pineal gland|Pineal parenchymal tumor of intermediate differentiation|Pinealoma|Pineoblastoma|Pineocytoma|Pingyangmycin|Pinkus tumor|Pinometostat|Pioglitazone|Pioglitazone Hydrochloride|Pipe|Pipeline|Pipendoxifene|Piperazinedione|Piperine Extract (Standardized)|Pipobroman|Piposulfan|Pirarubicin|Pirarubicin Hydrochloride|Pirfenidone|Piritrexim|Piritrexim Isethionate|Pirotinib|Piroxantrone|Piroxantrone Hydrochloride|Pituicytoma|Pituitary Gland|Pituitary Gland Acidophil Adenoma|Pituitary Gland Acidophil Carcinoma|Pituitary Gland Adenoma|Pituitary Gland Basophil Adenoma|Pituitary Gland Carcinoma|Pituitary Gland Chromophobe Adenoma|Pituitary Gland Mixed Acidophil-Basophil Adenoma|Pituitary Gland Mixed Acidophil-Basophil Carcinoma|Pituitary adenoma, NOS|Pituitary carcinoma, NOS|Pituitary gland|Pixantrone|Pixantrone Dimaleate|Pixatimod|Pizzly|Placebo|Placenta|Placental Hemangioma|Placental site trophoblastic tumor|Placental-Site Gestational Trophoblastic Tumor|Pladienolide Derivative E7107|Plamotamab|Plasma|Plasma Cell Leukemia|Plasma Cell Myeloma|Plasma Cell Neoplasm|Plasma Cell Tumors|Plasma cell leukemia|Plasma cell myeloma|Plasma cell tumor|Plasmablastic Lymphoma|Plasmablastic lymphoma|Plasmacytic leukemia|Plasmacytic lymphoma|Plasmacytoma|Plasmacytoma of bone|Plasmacytoma, NOS|Plasmacytoma, extramedullary|Plasmid DNA Vaccine pING-hHER3FL|Plasmodium falciparum|Platelet Count Decreased|Platform|Platform ICP|Platform II|Platform LCZ|Platinum|Platinum Acetylacetonate-Titanium Dioxide Nanoparticles|Platinum Compound|Pleomorphic Adenoma|Pleomorphic Carcinoma|Pleomorphic Lipoma|Pleomorphic Liposarcoma|Pleomorphic Lobular Breast Carcinoma In Situ|Pleomorphic Rhabdomyosarcoma|Pleomorphic Xanthoastrocytoma|Pleomorphic adenoma|Pleomorphic carcinoma|Pleomorphic cell sarcoma|Pleomorphic leiomyoma|Pleomorphic lipoma|Pleomorphic liposarcoma|Pleomorphic lobular carcinoma|Pleomorphic lobular carcinoma in situ|Pleomorphic rhabdomyosarcoma, NOS|Pleomorphic rhabdomyosarcoma, adult type|Pleomorphic xanthoastrocytoma|Pleura|Pleura, NOS|Pleural Effusion|Pleural Hemorrhage|Pleural Infection|Pleural Solitary Fibrous Tumor|Pleuritic Pain|Pleurodesis|Pleurodesis, NOS|Pleurodesis, Talc|Pleuropulmonary Blastoma|Pleuropulmonary blastoma|Plevitrexed|Plexiform Fibrohistiocytic Tumor|Plexiform Neurofibroma|Plexiform Schwannoma|Plexiform fibrohistiocytic tumor|Plexiform fibromyxoma|Plexiform hemangioma|Plexiform leiomyoma|Plexiform neurofibroma|Plexiform neuroma|Plexiform schwannoma|Plicamycin|Plinabulin|Plitidepsin|Plk1 Inhibitor BI 2536|Plocabulin|Plozalizumab|Pneumoblastoma|Pneumocystis Pneumonia|Pneumocystis carinii|Pneumonectomy|Pneumonia, NOS|Pneumonitis|Pneumothorax|Pol I Inhibitor CX5461|Poland|Polar Spongioblastoma|Polar spongioblastoma|Polatuzumab Vedotin|Polidocanol|Poliglusam|Polo-like Kinase 1 Inhibitor GSK461364|Polo-like Kinase 1 Inhibitor MK1496|Polo-like Kinase 1 Inhibitor NMS-1286937|Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate|Poly-alendronate Dextran-Guanidine Conjugate|Poly-gamma Glutamic Acid|Polyamine Analog SL11093|Polyamine Analogue PG11047|Polyamine Analogue SBP-101|Polyamine Transport Inhibitor AMXT-1501 Dicaprate|Polyandrol|Polycystic Ovarian Syndrome (PCOS)|Polycythemia Vera|Polycythemia rubra vera|Polycythemia vera|Polyembryoma|Polyethylene Glycol Recombinant Endostatin|Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318|Polygonal Cell Carcinoma|Polygonal cell carcinoma|Polymer-conjugated IL-15 Receptor Agonist NKTR-255|Polymer-encapsulated Luteolin Nanoparticle|Polymeric Camptothecin Prodrug XMT-1001|Polymorphic Post-Transplant Lymphoproliferative Disorder|Polymorphic post transplant lymphoproliferative disorder|Polymorphic reticulosis|Polymorphous low grade adenocarcinoma|Polypodium leucotomos Extract|Polypoid adenoma|Polysaccharide-K|Polysialic Acid|Polyunsaturated Fatty Acid|Polyvalent Melanoma Vaccine|Polyvesicular vitelline tumor|Pomalidomide|Pomegranate Juice|Pomegranate Liquid Extract|Ponatinib|Ponatinib Hydrochloride|Poor Prognosis|Poorly Differentiated|Poorly Differentiated Neuroblastoma|Poorly Differentiated Neuroendocrine Lesion|Poorly Differentiated Thyroid Gland Carcinoma|Poorly cohesive carcinoma|Popliteal Fossa|Porcupine Inhibitor CGX1321|Porcupine Inhibitor ETC-1922159|Porcupine Inhibitor RXC004|Porcupine Inhibitor WNT974|Porcupine Inhibitor XNW7201|Porfimer Sodium|Porfiromycin|Porocarcinoma|Poroma|Portal Hypertension|Portal Vein Thrombosis|Portugal|Positive|Positive Biomarker(s)|Post neo-adjuvant therapy|Post transplant lymphoproliferative disorder, NOS|Post-Transplant Lymphoproliferative Disorder|Postcricoid region|Posterior Wall of the Nasopharynx|Posterior mediastinum|Posterior wall of bladder|Posterior wall of hypopharynx|Posterior wall of nasopharynx|Posterior wall of oropharynx|Postmenopausal|Postnasal Drip|Postoperative Hemorrhage|Postoperative Thoracic Procedure Complication|Pouch|Poziotinib|Pracinostat|Pralatrexate|Pralsetinib|Praluzatamab Ravtansine|Pravastatin Sodium|Pre T-ALL|Pre-B ALL|Pre-B Acute Lymphoblastic Leukemia|Pre-Pre-B Acute Lymphoblastic Leukemia|Pre-T ALL|Pre-extracted DNA received by TSS|Pre-pre-B ALL|Precancerous Melanosis|Precancerous melanosis, NOS|Precocious Puberty|Precursor B-cell lymphoblastic leukemia|Precursor B-cell lymphoblastic lymphoma|Precursor Cell Lymphoblastic Lymphoma|Precursor T-cell lymphoblastic leukemia|Precursor T-cell lymphoblastic lymphoma|Precursor cell lymphoblastic leukemia, NOS|Precursor cell lymphoblastic leukemia, not phenotyped|Precursor cell lymphoblastic lymphoma, NOS|Prednimustine|Prednisolone|Prednisolone Acetate|Prednisolone Sodium Phosphate|Prednisone|Pregnancy in Patient or Partner|Pregnancy, Puerperium and Perinatal Conditions - Other|Preleukemia|Preleukemic syndrome|Premalignant|Premature Delivery|Premature Menopause|Premenopausal|Premier|Prepuce|Present|Presyncope|Prevention|Prexasertib|Prexigebersen|Primary|Primary Amyloidosis|Primary Blood Derived Cancer - Bone Marrow|Primary Blood Derived Cancer - Peripheral Blood|Primary Cutaneous Anaplastic Large Cell Lymphoma|Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder|Primary Cutaneous CD4-Positive Small/Medium T-Cell Lymphoproliferative Disorder|Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma|Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Primary Cutaneous Follicle Center Lymphoma|Primary Cutaneous Gamma-Delta T-Cell Lymphoma|Primary Cutaneous Lymphoma|Primary Cutaneous Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Primary Effusion Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Primary Myelofibrosis|Primary Neoplasm|Primary Peritoneal Serous Papillary Adenocarcinoma|Primary Sclerosing Cholangitis|Primary Site Unknown|Primary Tumor|Primary Tumor Field|Primary Xenograft Tissue|Primary amyloidosis|Primary cutaneous CD30+ T-cell lymphoproliferative disorder|Primary cutaneous CD30+ large T-cell lymphoma|Primary cutaneous CD4-positive small/medium T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous DLBCL, leg type|Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous follicle centre lymphoma|Primary cutaneous gamma-delta T-cell lymphoma|Primary cutaneous neuroendocrine carcinoma|Primary diffuse large B-cell lymphoma of the CNS|Primary effusion lymphoma|Primary intraosseous carcinoma|Primary myelofibrosis|Primary serous papillary carcinoma of peritoneum|Primary tumor site|Prime Cancer Vaccine MVA-BN-CV301|Primitive Neuroectodermal Tumor|Primitive neuroectodermal tumor, NOS|Primitive polar spongioblastoma|Prinomastat|Prior malignancy|Pro-B ALL|Pro-T ALL|Proapoptotic Sulindac Analog CP-461|Procarbazine|Procarbazine Hydrochloride|Procaspase Activating Compound-1 VO-100|Proctitis|Productive Cough|Progestational IUD|Progesterone and Estrogen|Progesterone only|Progestin|Progestin and Estrogen|Progression|Progressive Disease|Progressive Multifocal Leukoencephalopathy|Progressive Neoplastic Disease|Prohibitin-Targeting Peptide 1|Prolactinoma|Prolapse of Intestinal Stoma|Prolapse of Urostomy|Prolgolimab|Proliferating Trichilemmal Tumor|Proliferating trichilemmal cyst|Proliferating trichilemmal tumor|Proliferative Nodules in Congenital Melanocytic Nevus|Proliferative dermal lesion in congenital nevus|Proliferative polycythemia|Proline endopeptidase|Prolymphocytic Leukemia|Prolymphocytic leukemia, B-cell type|Prolymphocytic leukemia, NOS|Prolymphocytic leukemia, T-cell type|Prospective|Prostaglandin E2 EP4 Receptor Inhibitor AN0025|Prostaglandin E2 EP4 Receptor Inhibitor E7046|Prostate|Prostate Acinar Adenocarcinoma, Sarcomatoid Variant|Prostate Adenocarcinoma|Prostate Bed|Prostate Cancer|Prostate Cancer Vaccine ONY-P1|Prostate Gland|Prostate Health Cocktail Dietary Supplement|Prostate Infection|Prostate gland|Prostate, Seminal Vesicles and Lymph Nodes|Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024|Prostatic Hemorrhage|Prostatic Obstruction|Prostatic Pain|Prostatic intraepithelial neoplasia, grade III|Protease-activated Anti-PD-L1 Antibody Prodrug CX-072|Protein|Protein Arginine Methyltransferase 5 Inhibitor GSK3326595|Protein Arginine Methyltransferase 5 Inhibitor PF-06939999|Protein Arginine Methyltransferase 5 Inhibitor PRT543|Protein Expression Quantification|Protein Kinase C Inhibitor IDE196|Protein Phosphatase 2A Inhibitor LB-100|Protein Stabilized Liposomal Docetaxel Nanoparticles|Protein Tyrosine Kinase 2 Inhibitor IN10018|Proteinuria|Proteome|Proteome Profiling|Proton Pump Inhibitors|Protoplasmic Astrocytoma|Protoplasmic astrocytoma|Proxalutamide|Pruritus|Psammomatous Meningioma|Psammomatous meningioma|Psammomatous schwannoma|Pseudoglandular Squamous Cell Carcinoma|Pseudoisocytidine|Pseudomonas aeruginosa|Pseudomucinous adenocarcinoma|Pseudomucinous cystadenocarcinoma, NOS|Pseudomucinous cystadenoma, NOS|Pseudomucinous cystadenoma, borderline malignancy|Pseudomyxoma Peritonei|Pseudomyxoma peritonei|Pseudomyxoma peritonei with unknown primary site|Pseudoprogression|Pseudosarcomatous carcinoma|Psoriasis|Psychiatric Disorders - Other|Psychosis|Pterostilbene|Puerto Rico|Pulmonary Adenomatosis|Pulmonary Artery Intimal Sarcoma|Pulmonary Blastoma|Pulmonary Edema|Pulmonary Fibrosis|Pulmonary Fistula|Pulmonary Hemorrhage|Pulmonary Hypertension|Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Translocation|Pulmonary Valve Disease|Pulmonary adenomatosis|Pulmonary artery intimal sarcoma|Pulmonary blastoma|Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation|Pumitepa|Punch Biopsy|Puquitinib|Puquitinib Mesylate|Pure Erythroid Leukemia|Puromycin|Puromycin Hydrochloride|Purpura|Pylorus|Pyramidal Tract Syndrome|Pyrazinamide|Pyrazoloacridine|Pyridyl Cyanoguanidine CHS 828|Pyriform sinus|Pyrotinib|Pyrotinib Dimaleate|Pyroxamide|Pyruvate Kinase Inhibitor TLN-232|Pyruvate Kinase M2 Isoform Activator TP-1454|Q Exactive|Q Exactive HF|Q Exactive HF-X|Q Exactive Plus|Q TRAP|Q-Tof Premier|Q-Tof Ultima|Q-Tof micro|QA|QSTAR|QSTAR Elite|QSTAR Pulsar|QSTAR XL|QTRAP 4500|QTRAP 5500|QTRAP 6500|QTRAP 6500+m|Qatar|Qilisheng Immunoregulatory Oral Solution|Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine|Qualification metrics changed|Qualified|Qualified in error|Quarfloxin|Quattro|Quattro II|Quattro LC|Quattro Premier|Quattro Premier XE|Quattro Ultima|Quattro Ultima Pt|Quattro micro GC|Queyrat erythroplasia|Quinacrine Hydrochloride|Quinine|Quisinostat|Quizartinib|R|R-(-)-Gossypol Acetic Acid|R0|R1|R2|RAD51 Inhibitor CYT-0851|RAEB|RAEB I|RAEB II|RAEB-T|RAF Kinase Inhibitor L-779450|RAF Kinase Inhibitor XL281|RARS|RARalpha Agonist IRX5183|RD-Responsive Disease|RET Inhibitor DS-5010|RET Mutation/Fusion Inhibitor BLU-667|RET/SRC Inhibitor TPX-0046|RFT5-dgA Immunotoxin IMTOX25|RIPK1 Inhibitor GSK3145095|RNA|RNA-SeQC - Counts|RNA-SeQC - FPKM|RNA-Seq|RNR Inhibitor COH29|ROBO1-targeted BiCAR-NKT Cells|RORgamma Agonist LYC-55716|RP-Response|RPD-Radiographic Progressive Disease|RPLC|RPPA|RSEM - Quantification|RSK1-4 Inhibitor PMD-026|RX|Rabusertib|Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus SM-88|Racemose hemangioma|Racotumomab|Radgocitabine|Radgocitabine Hydrochloride|Radiation|Radiation Recall Reaction (Dermatologic)|Radiation Therapy, NOS|Radiation, 2D Conventional|Radiation, 3D Conformal|Radiation, Combination|Radiation, Cyberknife|Radiation, External Beam|Radiation, Hypofractionated|Radiation, Implants|Radiation, Intensity-Modulated Radiotherapy|Radiation, Internal|Radiation, Mixed Photon Beam|Radiation, Photon Beam|Radiation, Proton Beam|Radiation, Radioisotope|Radiation, Stereotactic/Gamma Knife/SRS|Radiation, Systemic|Radical Hysterectomy|Radical Maxillectomy|Radical Nephrectomy|Radical Prostatectomy|Radiculitis|Radioactive Iodine|Radioactive Iodine Therapy|Radioembolization|Radiographic Progressive Disease|Radiolabeled CC49|Radiology|Radiosensitizing Agent|Radium Ra 223 Dichloride|Radium Ra 224-labeled Calcium Carbonate Microparticles|Radix Angelicae Sinensis/Radix Astragali Herbal Supplement|Radotinib Hydrochloride|Raf Kinase Inhibitor HM95573|Ragifilimab|Ralaniten Acetate|Ralimetinib Mesylate|Raloxifene|Raloxifene Hydrochloride|Raltitrexed|Ramucirumab|Ranibizumab|Ranimustine|Ranolazine|Ranpirnase|Ras Inhibitor|Ras Peptide ASP|Ras Peptide CYS|Ras Peptide VAL|Rash Acneiform|Rash Maculo-Papular|Rash Pustular|Rathke pouch tumor|Rattus norvegicus|Raw CGI Variant|Raw Intensities|Raw Sequencing Data|Raw Simple Somatic Mutation|Razoxane|Read Group Quality Control|Realgar-Indigo naturalis Formulation|Rebastinib Tosylate|Rebeccamycin|Rebimastat|Receptor Tyrosine Kinase Inhibitor R1530|Recklinghausen disease|Recombinant Adenovirus-p53 SCH-58500|Recombinant Anti-WT1 Immunotherapeutic GSK2302024A|Recombinant Bacterial Minicells VAX014|Recombinant Bispecific Single-Chain Antibody rM28|Recombinant CD40-Ligand|Recombinant Erwinia asparaginase JZP-458|Recombinant Erythropoietin|Recombinant Fas Ligand|Recombinant Fractalkine|Recombinant Granulocyte-Macrophage Colony-Stimulating Factor|Recombinant Human 6Ckine|Recombinant Human Adenovirus Type 5 H101|Recombinant Human Angiotensin Converting Enzyme 2 APN01|Recombinant Human Apolipoprotein(a) Kringle V MG1102|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Recombinant Human Endostatin|Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine|Recombinant Human Papillomavirus 11-valent Vaccine|Recombinant Human Papillomavirus Bivalent Vaccine|Recombinant Human Papillomavirus Nonavalent Vaccine|Recombinant Human Plasminogen Kringle 5 Domain ABT 828|Recombinant Human TRAIL-Trimer Fusion Protein SCB-313|Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301|Recombinant Interferon|Recombinant Interferon Alfa|Recombinant Interferon Alfa-1b|Recombinant Interferon Alfa-2a|Recombinant Interferon Alfa-2b|Recombinant Interferon Alpha 2b-like Protein|Recombinant Interferon Beta|Recombinant Interferon Gamma|Recombinant Interleukin-12|Recombinant Interleukin-13|Recombinant Interleukin-18|Recombinant Interleukin-2|Recombinant Interleukin-6|Recombinant KSA Glycoprotein CO17-1A|Recombinant Leukocyte Interleukin|Recombinant Leukoregulin|Recombinant Luteinizing Hormone|Recombinant MAGE-3.1 Antigen|Recombinant MIP1-alpha Variant ECI301|Recombinant Macrophage Colony-Stimulating Factor|Recombinant Modified Vaccinia Ankara-5T4 Vaccine|Recombinant Oncolytic Poliovirus PVS-RIPO|Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A|Recombinant Platelet Factor 4|Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207|Recombinant Super-compound Interferon|Recombinant Thyroglobulin|Recombinant Thyrotropin Alfa|Recombinant Transforming Growth Factor-Beta|Recombinant Transforming Growth Factor-Beta-2|Recombinant Tumor Necrosis Factor-Alpha|Recombinant Tyrosinase-Related Protein-2|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Recreational fire smoke|Rectal Anastomotic Leak|Rectal Cancer|Rectal Fistula|Rectal Hemorrhage|Rectal Mucositis|Rectal Necrosis|Rectal Obstruction|Rectal Pain|Rectal Perforation|Rectal Stenosis|Rectal Ulcer|Rectosigmoid Junction|Rectosigmoid Region|Rectosigmoid junction|Rectum|Rectum Adenocarcinoma|Rectum, NOS|Recurrence|Recurrent Blood Derived Cancer - Bone Marrow|Recurrent Blood Derived Cancer - Peripheral Blood|Recurrent Disease|Recurrent Laryngeal Nerve Palsy|Recurrent Neoplasm|Recurrent Pyogenic Cholangitis|Recurrent Tumor|Red & Violet|Redaction|Redaporfin|Refametinib|Reflux Disease|Refractory Anemia|Refractory Anemia with Excess Blasts in Transformation|Refractory Cytopenia of Childhood|Refractory Neutropenia|Refractory Thrombocytopenia|Refractory anemia|Refractory anemia with excess blasts|Refractory anemia with excess blasts in transformation|Refractory anemia with ring sideroblasts associated with marked thrombocytosis|Refractory anemia with ringed sideroblasts|Refractory anemia with sideroblasts|Refractory anemia without sideroblasts|Refractory cytopenia of childhood|Refractory cytopenia with multilineage dysplasia|Refractory neutropenia|Refractory thrombocytopenia|Refused|Regional|Regional Metastasis|Regional Site|Regional or Distant Metastasis (M1)|Regorafenib|Regressing Melanoma|Regressing Nevus|Regressing nevus|Relacorilant|Related to Cancer|Relatlimab|Relugolix|Remetinostat|Renal|Renal Calculi|Renal Capsule|Renal Cell Carcinoma|Renal Cell Carcinoma Peptides Vaccine IMA901|Renal Colic|Renal Dialysis|Renal Disorder, NOS|Renal Failure (Requiring Dialysis)|Renal Hemorrhage|Renal Insufficiency|Renal Pelvis|Renal Sinus|Renal Vein|Renal and Urinary Disorders - Other|Renal carcinoma, collecting duct type|Renal cell adenocarcinoma|Renal cell carcinoma, NOS|Renal cell carcinoma, chromophobe type|Renal cell carcinoma, sarcomatoid|Renal cell carcinoma, spindle cell|Renal cell carcinoma, unclassified|Renal medullary carcinoma|Renal pelvis|Reninoma|Renomedullary fibroma|Renomedullary interstitial cell tumor|Reparixin|Repli-G|Repli-G (Qiagen) DNA|Repli-G Pooled (Qiagen) DNA|Repli-G X|Repli-G X (Qiagen) DNA|Repotrectinib|Reproductive System and Breast Disorders - Other|Rescinded|Reserve cell carcinoma|Residual Disease|Resiquimod|Resiquimod Topical Gel|Resistant Starch|Resminostat|Respiratory Failure|Respiratory, Thoracic and Mediastinal Disorders - Other|Responsive Disease|Restlessness|Restrictive Cardiomyopathy|Resveratrol|Resveratrol Formulation SRT501|Retaspimycin|Retaspimycin Hydrochloride|Rete Ovarii Adenocarcinoma|Retelliptine|Reticuloendothelial System|Reticuloendothelial system, NOS|Reticulohistiocytoma|Reticulosarcoma|Reticulosarcoma, NOS|Reticulosarcoma, diffuse|Reticulum cell sarcoma, NOS|Reticulum cell sarcoma, diffuse|Retifanlimab|Retina|Retinal Detachment|Retinal Tear|Retinal Vascular Disorder|Retinal anlage tumor|Retinoblastoma|Retinoblastoma, NOS|Retinoblastoma, differentiated|Retinoblastoma, diffuse|Retinoblastoma, spontaneously regressed|Retinoblastoma, undifferentiated|Retinocytoma|Retinoic Acid Agent Ro 16-9100|Retinoic Acid Syndrome|Retinoid 9cUAB30|Retinol|Retinopathy|Retinyl Acetate|Retinyl Palmitate|Retro-Orbital Region|Retromolar Trigone|Retromolar area|Retroperitoneal Hemorrhage|Retroperitoneal fibromatosis|Retroperitoneum|Retroperitoneum and peritoneum|Retrospective|Retrovector Encoding Mutant Anti-Cyclin G1|Reunion|Revdofilimab|Reverse Phase Protein Array|Reversible Posterior Leukoencephalopathy Syndrome|Rexinoid NRX 194204|Rezivertinib|Rhabdoid Meningioma|Rhabdoid Tumor|Rhabdoid meningioma|Rhabdoid sarcoma|Rhabdoid tumor (kidney) (RT)|Rhabdoid tumor, NOS|Rhabdomyoma|Rhabdomyoma, NOS|Rhabdomyosarcoma|Rhabdomyosarcoma with ganglionic differentiation|Rhabdomyosarcoma, NOS|Rhabdosarcoma|Rhenium Re 188 BMEDA-labeled Liposomes|Rhenium Re-186 Hydroxyethylidene Diphosphonate|Rhenium Re-188 Ethiodized Oil|Rhenium Re-188 Etidronate|Rheumatoid Arthritis|Rheumatologic Disease|Rhinitis Infective|Rhizoxin|RhoC Peptide Vaccine RV001V|Rib|Rib, sternum, clavicle and associated joints|Ribociclib|Ribociclib/Letrozole|Ribonuclease QBI-139|Ribosome-Inactivating Protein CY503|Ribozyme RPI.4610|Rice Bran|Ricolinostat|Ridaforolimus|Right|Right Hemicolectomy|Right Ventricular Dysfunction|Rigosertib|Rigosertib Sodium|Rilimogene Galvacirepvec|Rilimogene Galvacirepvec/Rilimogene Glafolivec|Rilimogene Glafolivec|Rilotumumab|Rindopepimut|Ring Finger|Ripertamab|Ripretinib|Risperidone Formulation in Rumenic Acid|Ritrosulfan|Rituximab|Rituximab Conjugate CON-4619|Rituximab and Hyaluronidase Human|Riviciclib|Rivoceranib|Rivoceranib Mesylate|Robatumumab|Roblitinib|Rocakinogene Sifuplasmid|Rocapuldencel-T|Rociletinib|Rodent ulcer|Rodorubicin|Roducitabine|Rofecoxib|Roflumilast|Rogaratinib|Rogletimide|Rolinsatamab Talirine|Romania|Romidepsin|Roneparstat|Roniciclib|Ropeginterferon Alfa-2B|Ropidoxuridine|Ropocamptide|Roquinimex|Rosabulin|Rose Bengal Solution PV-10|Rosette-Forming Glioneuronal Tumor|Rosette-forming glioneuronal tumor|Rosiglitazone Maleate|Rosmantuzumab|Rosopatamab|Rosuvastatin|Round Cell Liposarcoma|Round Ligament|Round cell carcinoma|Round cell liposarcoma|Round cell osteosarcoma|Round cell sarcoma|Round ligament|Rovalpituzumab Tesirine|Rubinstein-Taybi Syndrome|Rubitecan|Rucaparib|Rucaparib Camsylate|Rucaparib Phosphate|Run Metadata|Russia|Ruthenium Ru-106|Ruthenium-based Small Molecule Therapeutic BOLD-100|Ruthenium-based Transferrin Targeting Agent NKP-1339|Ruxolitinib|Ruxolitinib Phosphate|Ruxotemitide|Rwanda|S|S-Adenosylmethionine|S-equol|S1P Receptor Agonist KRP203|SALT lymphoma|SBIL-2|SCIEX|SCX|SD-Stable Disease|SDF-1 Receptor Antagonist PTX-9908|SDRF|SERD D-0502|SERD G1T48|SERD GDC-9545|SERD SAR439859|SERD SHR9549|SERD ZN-c5|SETTLE|SHH-Activated|SHP-1 Agonist SC-43|SHP2 Inhibitor JAB-3068|SHP2 Inhibitor RLY-1971|SHP2 Inhibitor RMC-4630|SHP2 Inhibitor TNO155|SILAC|SILAC quantitation analysis|SIRPa-4-1BBL Fusion Protein DSP107|SIRPa-Fc Fusion Protein TTI-621|SIRPa-Fc-CD40L Fusion Protein SL-172154|SIRPa-IgG4-Fc Fusion Protein TTI-622|SLC6A8 Inhibitor RGX-202|SLCT Inhibitor GNS561|SMAC Mimetic BI 891065|SMO Protein Inhibitor ZSP1602|SN-38-Loaded Polymeric Micelles NK012|SNS01-T Nanoparticles|SOLiD|SPD-Surgical Progression|SQ Detector 2|SR-BP1/HSI Inhibitor SR31747A|SR-T100 Gel|SRA XML|SRM quantitation analysis|SRPK1/ABCG2 Inhibitor SCO-101|SSTR2-targeting Protein/DM1 Conjugate PEN-221|STAR - Counts|STAR - FPKM|STAR - Smart-Seq2|STAR - Smart-Seq2 Filtered Counts|STAR - Smart-Seq2 Raw Counts|STAR 2-Pass|STAR 2-Pass Chimeric|STAR 2-Pass Genome|STAR 2-Pass Transcriptome|STAR-Fusion|STAT Inhibitor OPB-111077|STAT3 Inhibitor DSP-0337|STAT3 Inhibitor OPB-31121|STAT3 Inhibitor OPB-51602|STAT3 Inhibitor TTI-101|STAT3 Inhibitor WP1066|STING Agonist BMS-986301|STING Agonist GSK3745417|STING Agonist IMSA101|STING Agonist MK-1454|STING Agonist SB 11285|STING Agonist TAK-676|STING-activating Cyclic Dinucleotide Agonist MIW815|STING-expressing E. coli SYNB1891|SVS|SYNAPT G2-Si|Sabarubicin|Sabatolimab|Saccharomyces cerevisiae|Sacituzumab Govitecan|Sacrum|Sacubitril/Valsartan|Safingol|Sagopilone|Saint Helena, Ascension and Tristan da Cunha|Saint Kitts and Nevis|Saint Lucia|Saint Pierre and Miquelon|Saint Vincent and the Grenadines|Salirasib|Saliva|Salivary Duct Carcinoma|Salivary Duct Inflammation|Salivary Gland|Salivary Gland Basal Cell Adenocarcinoma|Salivary Gland Basal Cell Adenoma|Salivary Gland Fistula|Salivary Gland Infection|Salivary Gland Monomorphic Adenoma|Salivary duct carcinoma|Salmonella Septicemia|Salmonella VNP20009|Salpingectomy|Salpingo-oophorectomy|Sam68 Modulator CWP232291|Samalizumab|Samarium Sm 153-DOTMP|Samoa|Samotolisib|Sample Procurement|Sample compromised|Samrotamab Vedotin|Samuraciclib|San Marino|Sao Tome and Principe|Sapacitabine|Sapanisertib|Sapitinib|SarCNU|Saracatinib|Saracatinib Difumarate|Sarcoidosis|Sarcoma|Sarcoma botryoides|Sarcoma, NOS|Sarcomatoid Carcinoma|Sarcomatoid Mesothelioma|Sarcomatoid Renal Cell Carcinoma|Sarcomatoid Transitional Cell Carcinoma|Sarcomatoid carcinoma|Sarcomatoid mesothelioma|Sarcomatosis|Sarcomatosis, NOS|Sardomozide|Sargramostim|Sasanlimab|Satraplatin|Saudi Arabia|Savolitinib|Scalp|Scalp Pain|Scapula|Schizosaccharomyces pombe|Schmincke tumor|Schneiderian carcinoma|Schneiderian papilloma, NOS|Schneiderian papilloma, inverted|Schwannoma|Schwannoma, NOS|Schwannomatosis|Sciatic Nerve|Scirrhous Adenocarcinoma|Scirrhous Hepatocellular Carcinoma|Scirrhous adenocarcinoma|Scirrhous carcinoma|Scleral Disorder|Sclerosing Epithelioid Fibrosarcoma|Sclerosing Liposarcoma|Sclerosing Rhabdomyosarcoma|Sclerosing epithelioid fibrosarcoma|Sclerosing hemangioma|Sclerosing hepatic carcinoma|Sclerosing liposarcoma|Sclerosing rhabdomyosarcoma|Sclerosing stromal tumor|Sclerosing sweat duct carcinoma|Sclerosis|Scoliosis|Scopoletin|Scrotal Infection|Scrotal Pain|Scrotum|Scrotum, NOS|SeSAMe Methylation Beta Estimation|Sebaceous Adenoma|Sebaceous Carcinoma|Sebaceous adenocarcinoma|Sebaceous adenoma|Sebaceous carcinoma|Sebaceous epithelioma|Seclidemstat|Secondary Carcinoma|Secondary Neoplasm|Secondary carcinoma|Secretory Breast Carcinoma|Secretory Meningioma|Secretory carcinoma of breast|Secretory meningioma|Sedoxantrone Trihydrochloride|Seizure|Seizures|Selatinib Ditosilate|Selective Androgen Receptor Modulator RAD140|Selective Cytokine Inhibitory Drug CC-1088|Selective Estrogen Receptor Degrader AZD9496|Selective Estrogen Receptor Degrader AZD9833|Selective Estrogen Receptor Degrader LSZ102|Selective Estrogen Receptor Degrader LX-039|Selective Estrogen Receptor Degrader LY3484356|Selective Estrogen Receptor Degrader SRN-927|Selective Estrogen Receptor Modulator CC-8490|Selective Estrogen Receptor Modulator TAS-108|Selective Glucocorticoid Receptor Antagonist CORT125281|Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352|Seliciclib|Selicrelumab|Selinexor|Selitrectinib|Selonsertib|Selpercatinib|Selumetinib|Selumetinib Sulfate|Semaxanib|Seminal Vesicle|Seminoma|Seminoma with high mitotic index|Seminoma, NOS|Seminoma, anaplastic|Semuloparin|Semustine|Seneca Valley Virus-001|Senegal|Sensory Changes|Seocalcitol|Sepantronium Bromide|Sepsis|Sequencing Data|Sequencing Reads|Serabelisib|Serbia|Serclutamab Talirine|Serdemetan|Sergiolide|Seribantumab|Serine/Threonine Kinase Inhibitor CBP501|Serine/Threonine Kinase Inhibitor XL418|Seroma|Seromucinous carcinoma|Serotonin producing carcinoid|Serous Adenofibroma|Serous Cystadenocarcinoma|Serous Cystadenoma|Serous Endometrial Intraepithelial Carcinoma|Serous Surface Papillary Carcinoma|Serous Surface Papilloma|Serous Tubal Intraepithelial Carcinoma|Serous adenocarcinofibroma|Serous adenocarcinoma, NOS|Serous adenofibroma of borderline malignancy|Serous adenofibroma, NOS|Serous borderline tumor-micropapillary variant|Serous carcinoma, NOS|Serous cystadenocarcinofibroma|Serous cystadenocarcinoma, NOS|Serous cystadenofibroma of borderline malignancy|Serous cystadenofibroma, NOS|Serous cystadenoma, NOS|Serous cystadenoma, borderline malignancy|Serous cystoma|Serous endometrial intraepithelial carcinoma|Serous microcystic adenoma|Serous papillary cystic tumor of borderline malignancy|Serous surface papillary carcinoma|Serous surface papillary tumor of borderline malignancy|Serous surface papilloma|Serous tubal intraepithelial carcinoma|Serous tubal intraepithelial carcinoma (STIC)|Serous tumor, NOS, of low malignant potential|Serplulimab|Serrated adenocarcinoma|Serrated adenoma|Sertoli Cell Tumor|Sertoli cell adenoma|Sertoli cell carcinoma|Sertoli cell tumor with lipid storage|Sertoli cell tumor, NOS|Sertoli-Leydig cell tumor of intermediate differentiation|Sertoli-Leydig cell tumor, NOS|Sertoli-Leydig cell tumor, intermediate differentiation, with heterologous elements|Sertoli-Leydig cell tumor, poorly differentiated|Sertoli-Leydig cell tumor, poorly differentiated, with heterologous elements|Sertoli-Leydig cell tumor, retiform|Sertoli-Leydig cell tumor, retiform, with heterologous elements|Sertoli-Leydig cell tumor, sarcomatoid|Sertoli-Leydig cell tumor, well differentiated|Serum|Serum Amylase Increased|Serum Sickness|Sessile Serrated Adenoma/Polyp|Sessile serrated adenoma|Sessile serrated polyp|Seurat - 10x Chromium|Seurat - Smart-Seq2|Sevacizumab|Seviteronel|Sex Cord-Stromal Tumor|Sex cord tumor with annular tubules|Sex cord tumor, NOS|Sex cord-gonadal stromal tumor, NOS|Sex cord-gonadal stromal tumor, incompletely differentiated|Sex cord-gonadal stromal tumor, mixed forms|Seychelles|Sezary Syndrome|Sezary disease|Sezary syndrome|Shared Anti-Idiotype-AB-S006|Shared Anti-Idiotype-AB-S024A|Shark Cartilage|Shark Cartilage Extract AE-941|Shenqi Fuzheng Injection SQ001|Shimadzu|Shimadzu MALDI-7090|Shingles|Sho-Saiko-To|Short Chain Fatty Acid HQK-1004|Short bones of lower limb and associated joints|Short bones of upper limb and associated joints|Shoulder|Shu Yu Wan Formula|Sialadenitis|Sialoblastoma|Sialyl Tn Antigen|Sialyl Tn-KLH Vaccine|Sibling|Sibrotuzumab|Sick Sinus Syndrome|Sierra Leone|Sigmoid Colectomy|Sigmoid Colon|Sigmoid colon|Signet Ring Cell Carcinoma|Signet ring cell adenocarcinoma|Signet ring cell carcinoma|Silatecan AR-67|Silibinin|Silicon Phthalocyanine 4|Silmitasertib Sodium|Siltuximab|Simalikalactone D|Simeprevir|Simlukafusp Alfa|Simmitinib|Simotaxel|Simple Germline Variation|Simple Hysterectomy|Simple Mastectomy|Simple Nucleotide Variation|Simtuzumab|Simurosertib|Singapore|Single Cell Analysis|Sinonasal Inverted Schneiderian Papilloma|Sinonasal Oncocytic Schneiderian Papilloma|Sinonasal Schneiderian Papilloma|Sinonasal papilloma, NOS|Sinonasal papilloma, exophytic|Sinonasal papilloma, fungiform|Sintilimab|Sinus|Sinus Bradycardia|Sinus Disorder|Sinus Pain|Sinus Tachycardia|Sinus(es), Maxillary|Sinusitis|Siplizumab|Sipuleucel-T|Siremadlin|Sirolimus|Sister|Sister-in-law|Sitimagene Ceradenovec|Sitravatinib|Sivifene|Six Weeks or More|Sizofiran|Sjogren's Syndrome|Skeletal Muscle|Skin|Skin Adenoid Basal Cell Carcinoma|Skin Appendage Adenoma|Skin Atrophy|Skin Basal Cell Carcinoma|Skin Basal Cell Carcinoma with Sebaceous Differentiation|Skin Basosquamous Cell Carcinoma|Skin Cancer|Skin Cutaneous Melanoma|Skin Fibroepithelial Basal Cell Carcinoma|Skin Fibrous Histiocytoma|Skin Hyperpigmentation|Skin Hypopigmentation|Skin Induration|Skin Infection|Skin Infiltrating Basal Cell Carcinoma|Skin Metatypical Carcinoma|Skin Micronodular Basal Cell Carcinoma|Skin Nodular Basal Cell Carcinoma|Skin Nodulo-Ulcerative Basal Cell Carcinoma|Skin Pigmented Basal Cell Carcinoma|Skin Rash|Skin Sclerosing/Morphoeic Basal Cell Carcinoma|Skin Ulceration|Skin and Subcutaneous Tissue Disorders - Other|Skin appendage adenoma|Skin appendage carcinoma|Skin appendage tumor, benign|Skin of lip, NOS|Skin of lower limb and hip|Skin of other and unspecified parts of face|Skin of scalp and neck|Skin of the Face|Skin of the Lower Limb and Hip|Skin of the Scalp and Neck|Skin of the Upper Limb and Shoulder|Skin of trunk|Skin of upper limb and shoulder|Skin, NOS|Skin, lower extremity, local|Skin, total|Skin, trunk, local|Skin, upper extremity, local|Skin-associated lymphoid tissue lymphoma|Skull|Sleep Apnea|Sleep apnea|Slide Image|Slides|Slovakia|Slovenia|Smac Mimetic GDC-0152|Smac Mimetic GDC-0917|Smac Mimetic LCL161|Small Bowel|Small Bowel - Mucosa Only|Small Cell Carcinoma|Small Cell Carcinoma, Fusiform Cell Type|Small Cell Intermediate Cell Carcinoma|Small Cell Osteosarcoma|Small Cell Sarcoma|Small Finger|Small Intestinal Anastomotic Leak|Small Intestinal Mucositis|Small Intestinal Obstruction|Small Intestinal Perforation|Small Intestinal Stenosis|Small Intestine|Small Intestine Infection|Small Intestine Ulcer|Small Lymphocytic Lymphoma|Small cell carcinoma pulmonary type|Small cell carcinoma, NOS|Small cell carcinoma, fusiform cell|Small cell carcinoma, hypercalcemic type|Small cell carcinoma, intermediate cell|Small cell neuroendocrine carcinoma|Small cell osteosarcoma|Small cell sarcoma|Small congenital nevus|Small intestine|Small intestine, NOS|Smoke|Smoke exposure, NOS|Smokehouse smoke|Smokeless Tobacco|Smoking|Smooth Muscle Neoplasm|Smooth muscle tumor of uncertain malignant potential|Smooth muscle tumor, NOS|Smoothened Antagonist BMS-833923|Smoothened Antagonist LDE225 Topical|Smoothened Antagonist LEQ506|Smoothened Antagonist TAK-441|Snap Frozen|Sneezing|Sobuzoxane|Social Circumstances - Other|Social Security Death Index|Sodium Borocaptate|Sodium Butyrate|Sodium Dichloroacetate|Sodium Fluoride|Sodium Iodide I-131|Sodium Metaarsenite|Sodium Phenylbutyrate|Sodium Salicylate|Sodium Selenite|Sodium Stibogluconate|Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108|Sofituzumab Vedotin|Soft Tissue|Soft Tissue Infection|Soft Tissue Necrosis Lower Limb|Soft Tissue Necrosis Upper Limb|Soft Tissue Perineurioma|Soft Tissue Sarcoma|Soft Tissue Tumors and Sarcomas, NOS|Soft palate, NOS|Soft tissue perineurioma|Soft tissue sarcoma|Soft tissue sarcoma, non-rhabdomyosarcoma|Soft tissue tumor, benign|Soft tissue tumor, malignant|Solid Carcinoma|Solid Papillary Breast Carcinoma|Solid Tissue|Solid Tissue Normal|Solid adenocarcinoma with mucin formation|Solid and cystic tumor|Solid and papillary epithelial neoplasm|Solid carcinoma with mucin formation|Solid carcinoma, NOS|Solid papillary carcinoma in situ|Solid papillary carcinoma with invasion|Solid pseudopapillary carcinoma|Solid pseudopapillary tumor|Solid teratoma|Solitary Fibrous Tumor|Solitary Mastocytoma of the Skin|Solitary Osseous Plasmacytoma|Solitary Plasmacytoma|Solitary Reticulohistiocytoma|Solitary fibrous tumor|Solitary fibrous tumor, malignant|Solitary fibrous tumor/hemangiopericytoma Grade 1 (CNS)|Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS)|Solitary fibrous tumor/hemangiopericytoma Grade 3 (CNS)|Solitary mastocytoma of skin|Solitary myeloma|Solitary plasmacytoma|Solitomab|Solomon Islands|Somalia|Somatic Mutation Index|Somatic Structural Variation|SomaticSniper|SomaticSniper Annotation|SomaticSniper Variant Aggregation and Masking|Somatostatin cell tumor, NOS|Somatostatin cell tumor, malignant|Somatostatin-Producing Neuroendocrine Tumor|Somatostatinoma, NOS|Somatostatinoma, malignant|Some days|Somnolence|Son|Son-in-law|Sonepcizumab|Sonidegib|Sonolisib|Sorafenib|Sorafenib Tosylate|Sore Throat|Sorghum bicolor Supplement|Sorted Cells|Sotigalimab|Sotorasib|Sotrastaurin|Sotrastaurin Acetate|South Africa|South Korea|South Sudan|Soy Isoflavones|Soy Protein Isolate|Spain|Spanlecortemlocel|Sparfosate Sodium|Sparfosic Acid|Spartalizumab|Spasticity|Spebrutinib|Specialized Gonadal Neoplasms|Specified parts of peritoneum|Spectral counting analysis|Spermatic Cord Anastomotic Leak|Spermatic Cord Hemorrhage|Spermatic Cord Obstruction|Spermatic cord|Spermatocytic seminoma|Spermatocytoma|Sphenoid sinus|Spherical Nucleic Acid Nanoparticle NU-0129|Spinal Column|Spinal Cord|Spinal Fracture|Spinal Muscular Atrophy|Spinal cord|Spinal cord, cranial nerves, and other parts of central nervous system|Spinal meninges|Spindle Cell Hemangioma|Spindle Cell Lipoma|Spindle Cell Melanoma|Spindle Cell Oncocytoma|Spindle Cell Rhabdomyosarcoma|Spindle Cell Sarcoma|Spindle Cell Squamous Cell Carcinoma|Spindle Cell Synovial Sarcoma|Spindle cell angioendothelioma|Spindle cell carcinoma, NOS|Spindle cell hemangioendothelioma|Spindle cell lipoma|Spindle cell melanoma, NOS|Spindle cell melanoma, type A|Spindle cell melanoma, type B|Spindle cell nevus, NOS|Spindle cell oncocytoma|Spindle cell rhabdomyosarcoma|Spindle cell sarcoma|Spindle epithelial tumor with thymus-like differentiation|Spindle epithelial tumor with thymus-like element|Spindle-Cell Predominant Trichodiscoma|Spindled mesothelioma|Spine|Spiradenocarcinoma|Spiradenoma|Spiradenoma, NOS|Spirogermanium|Spiromustine|Spiroplatin|Spitz Nevus|Spitz nevus|Spleen|Spleen Cancer|Spleen Disorder|Splenic B-Cell Lymphoma/Leukemia, Unclassifiable|Splenic B-cell lymphoma/leukemia, unclassifiable|Splenic Diffuse Red Pulp Small B-Cell Lymphoma|Splenic Flexure|Splenic Infection|Splenic Marginal Zone Lymphoma|Splenic diffuse red pulp small B-cell lymphoma|Splenic flexure of colon|Splenic lymphoma with villous lymphocytes|Splenic marginal zone B-cell lymphoma|Splenic marginal zone lymphoma, NOS|Splice Junction Quantification|Splicing Inhibitor H3B-8800|Spongioblastoma multiforme|Spongioblastoma polare|Spongioblastoma, NOS|Spongioneuroblastoma|Spongistatin|Spontaneous Descent|Spontaneously Regressing Retinoblastoma|Sporadic Burkitt Lymphoma|Sporadic, adult|Sporadic, pediatric|Spouse|Sputum|Squalamine Lactate|Squamotransitional cell carcinoma|Squamous Cell Carcinoma|Squamous Cell Carcinoma In Situ with Questionable Stromal Invasion|Squamous Cell Carcinoma with Horn Formation|Squamous Cell Carcinoma, Clear Cell Type|Squamous Cell Neoplasms|Squamous Cell Papilloma|Squamous Metaplasia|Squamous Odontogenic Tumor|Squamous Papillomatosis|Squamous carcinoma|Squamous cell carcinoma in situ with questionable stromal invasion|Squamous cell carcinoma in situ, NOS|Squamous cell carcinoma with horn formation|Squamous cell carcinoma, HPV-negative|Squamous cell carcinoma, HPV-positive|Squamous cell carcinoma, NOS|Squamous cell carcinoma, acantholytic|Squamous cell carcinoma, adenoid|Squamous cell carcinoma, clear cell type|Squamous cell carcinoma, keratinizing, NOS|Squamous cell carcinoma, large cell, keratinizing|Squamous cell carcinoma, large cell, nonkeratinizing, NOS|Squamous cell carcinoma, metastatic, NOS|Squamous cell carcinoma, microinvasive|Squamous cell carcinoma, nonkeratinizing, NOS|Squamous cell carcinoma, pseudoglandular|Squamous cell carcinoma, sarcomatoid|Squamous cell carcinoma, small cell, nonkeratinizing|Squamous cell carcinoma, spindle cell|Squamous cell epithelioma|Squamous cell papilloma, NOS|Squamous cell papilloma, inverted|Squamous intraepithelial neoplasia, grade I|Squamous intraepithelial neoplasia, grade II|Squamous intraepithelial neoplasia, grade III|Squamous intraepithelial neoplasia, high grade|Squamous intraepithelial neoplasia, low grade|Squamous odontogenic tumor|Squamous papilloma|Squamous papillomatosis|Src Kinase Inhibitor AP 23846|Src Kinase Inhibitor KX2-391|Src Kinase Inhibitor KX2-391 Ointment|Src Kinase Inhibitor M475271|Src/Abl Kinase Inhibitor AZD0424|Src/tubulin Inhibitor KX02|Sri Lanka|St. John's Wort|Stable Disease|Stage 0|Stage 0 Cervical Cancer AJCC v6|Stage 0 Cutaneous Melanoma AJCC v6 and v7|Stage 0 Squamous Cell Carcinoma|Stage 0 Transitional Cell Carcinoma|Stage 0 Vaginal Cancer AJCC v6|Stage 0 Vaginal Cancer AJCC v7|Stage 0 Vulvar Cancer AJCC v6|Stage 0a|Stage 0is|Stage 1|Stage 2A|Stage 2B|Stage 3|Stage 4|Stage 4S|Stage I|Stage IA|Stage IA1|Stage IA2|Stage IA3|Stage IB|Stage IB Cervix|Stage IB1|Stage IB2|Stage IC|Stage IC1|Stage IC2|Stage IC3|Stage II|Stage II Cervix|Stage IIA|Stage IIA Cervix|Stage IIA1|Stage IIA2|Stage IIB|Stage IIC|Stage IIC1|Stage III|Stage IIIA|Stage IIIA1|Stage IIIA2|Stage IIIAi|Stage IIIAii|Stage IIIB|Stage IIIC|Stage IIIC1|Stage IIIC2|Stage IIID|Stage IIa|Stage IIb|Stage IS|Stage IV|Stage IVA|Stage IVB|Stage IVC|Stage IVa|Stage IVb|Stage Is|Stage R1|Stage R2|Stage Tis|Stage X|Stallimycin|Staphylococcal Enterotoxin A|Staphylococcal Enterotoxin B|Staphylococcus aureus|State of Palestine|Staurosporine|Steatosis|Stem Cell Transplantation, Allogeneic|Stem Cell Transplantation, Autologous|Stem Cell Transplantation, Double Autologous|Stem Cell Transplantation, Haploidentical|Stem Cell Transplantation, NOS|Stem Cell Transplantation, Non-Myeloablative|Stem Cell Transplantation, Syngenic|Stem Cell Treatment|Stem cell leukemia|Stenosis of Gastrointestinal Stoma|Step Child|Step Sibling|Stepbrother|Stepdaughter|Stepfather|Stepmother|Stepsister|Stepson|Stereotactic Radiosurgery|Sternum|Steroid Therapy|Steroid cell tumor, NOS|Steroid cell tumor, malignant|Stevens-Johnson Syndrome|Stillbirth|Stoma Site Infection|Stomach|Stomach - Mucosa Only|Stomach Adenocarcinoma|Stomach Pain|Stomach, NOS|Stomal Ulcer|Strelka2 RNA|Streptonigrin|Streptozocin|Stridor|Stroke|Stromal Neoplasm|Stromal Sarcoma|Stromal endometriosis|Stromal myosis, NOS|Stromal sarcoma, NOS|Stromal tumor with minor sex cord elements|Stromal tumor, NOS|Stromal tumor, benign|Strontium Chloride Sr-89|Structural Alteration|Structural Rearrangement|Structural Variation|Struma Ovarii|Struma ovarii and carcinoid|Struma ovarii, NOS|Struma ovarii, malignant|Strumal Carcinoid|Strumal carcinoid|Study Enrollment|Subacute granulocytic leukemia|Subacute leukemia, NOS|Subacute lymphatic leukemia|Subacute lymphocytic leukemia|Subacute lymphoid leukemia|Subacute monocytic leukemia|Subacute myelogenous leukemia|Subacute myeloid leukemia|Subareolar duct papillomatosis|Subcutaneous Panniculitis-Like T-Cell Lymphoma|Subcutaneous Tissue|Subcutaneous panniculitis-like T-cell lymphoma|Subependymal Giant Cell Astrocytoma|Subependymal astrocytoma, NOS|Subependymal giant cell astrocytoma|Subependymal glioma|Subependymoma|Subepidermal Nodular Fibrosis|Subepidermal nodular fibrosis|Subglottis|Subject identity unknown|Subject withdrew consent|Sublingual Gland|Sublingual gland|Submandibular Gland|Submandibular gland|Submicron Particle Paclitaxel Sterile Suspension|Subtotal Prostatectomy|Subtotal Resection|Succinate Dehydrogenase-Deficient Renal Cell Carcinoma|Sudan|Sudden Death NOS|Sugemalimab|Suicidal Ideation|Suicide Attempt|Sulfatinib|Sulfonylurea|Sulforaphane|Sulindac|Sulofenur|Sumoylation Inhibitor TAK-981|Sunitinib|Sunitinib Malate|Super Enhancer Inhibitor GZ17-6.02|Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803|Superficial Multifocal Basal Cell Carcinoma|Superficial Parotidectomy|Superficial Soft Tissue Fibrosis|Superficial Spreading Adenocarcinoma|Superficial Thrombophlebitis|Superficial spreading adenocarcinoma|Superficial spreading melanoma|Superficial well differentiated liposarcoma|Superior Vena Cava Syndrome|Superior Wall of the Nasopharynx|Superior wall of nasopharynx|Superoxide Dismutase Mimetic GC4711|Supplementary Files|Supracervical Hysterectomy|Supracricoid Laryngectomy|Supraglottic Laryngectomy|Supraglottis|Supratentorial Embryonal Tumor, Not Otherwise Specified|Supratentorial PNET|Supraventricular Tachycardia|Suramin|Suramin Sodium|Surgery|Surgical Complication|Surgical Complications|Surgical Resection|Surgical and Medical Procedures - Other|Surgically Treated|Suriname|Surveyor PDA|Survivin Antigen|Survivin Antigen Vaccine DPX-Survivac|Survivin mRNA Antagonist EZN-3042|Survivin-expressing CVD908ssb-TXSVN Vaccine|Sus scrofa|Sustained-release Lipid Inhaled Cisplatin|Sustained-release Mitomycin C Hydrogel Formulation UGN-101|Sustained-release Mitomycin C Hydrogel Formulation UGN-102|Svalbard & Jan Mayen Islands|Svalbard and Jan Mayen|Sweat Gland Adenoma|Sweat Gland Carcinoma|Sweat Gland Neoplasm|Sweat gland adenocarcinoma|Sweat gland adenoma|Sweat gland carcinoma|Sweat gland tumor, NOS|Sweat gland tumor, benign|Sweat gland tumor, malignant|Sweden|Switzerland|Syk Inhibitor HMPL-523|SymBiot I|SymBiot XVI|Sympathetic Paraganglioma|Sympathetic paraganglioma|Sympathicoblastoma|Symplastic leiomyoma|Synapt G2 HDMS|Synapt G2 MS|Synapt G2-S HDMS|Synapt G2-S MS|Synapt HDMS|Synapt MS|Synchronous malignancy|Synchrotope TA2M Plasmid DNA Vaccine|Synchrovax SEM Plasmid DNA Vaccine|Syncope|Syncytial meningioma|Synovial Sarcoma|Synovial sarcoma, NOS|Synovial sarcoma, biphasic|Synovial sarcoma, epithelioid cell|Synovial sarcoma, monophasic fibrous|Synovial sarcoma, spindle cell|Synovial-like Neoplasms|Synovioma, NOS|Synovioma, benign|Synovioma, malignant|Synovium|Synthetic Alkaloid PM00104|Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2|Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1|Synthetic Hypericin|Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201|Synthetic Long E6/E7 Peptides Vaccine HPV-01|Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b|Synthetic Plumbagin PCUR-101|Synthetic hTERT DNA Vaccine INO-1400|Synthetic hTERT DNA Vaccine INO-1401|Syphilis|Syria|Syringadenoma, NOS|Syringocystadenoma Papilliferum|Syringocystadenoma papilliferum|Syringofibroadenoma|Syringoma|Syringoma, NOS|Syringomatous carcinoma|Systemic EBV positive T-cell lymphoproliferative disease of childhood|Systemic EBV-Positive T-Cell Lymphoma of Childhood|Systemic Mastocytosis|Systemic Mastocytosis with an Associated Hematological Neoplasm|Systemic light chain disease|Systemic mastocytosis with AHNMD|Systemic mastocytosis with associated hematological clonal non-mast cell disorder|Systemic tissue mast cell disease|T|T Acute Lymphoblastic Leukemia|T Lymphoblastic Leukemia/Lymphoma|T Lymphoblastic Lymphoma|T lymphoblastic leukemia/lymphoma|T-Cell Large Granular Lymphocyte Leukemia|T-Cell Non-Hodgkin Lymphoma|T-Cell Prolymphocytic Leukemia|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|T-Zone Variant Peripheral T-Cell Lymphoma|T-cell large granular lymphocytic leukemia|T-cell large granular lymphocytosis|T-cell lymphoma, NOS|T-cell rich large B-cell lymphoma|T-cell rich/histiocyte-rich large B-cell lymphoma|T-gamma lymphoproliferative disease|T-zone lymphoma|T/NK-cell lymphoma|T0|T0 Stage Finding|T1|T1 Stage Finding|T1a|T1a Stage Finding|T1a1|T1a2|T1b|T1b Stage Finding|T1b1|T1b2|T1c|T1c Stage Finding|T1mi|T1mi Stage Finding|T2|T2 Stage Finding|T2a|T2a Stage Finding|T2a1|T2a2|T2b|T2b Stage Finding|T2c|T2c Stage Finding|T2d|T2d Stage Finding|T3|T3 Stage Finding|T3a|T3a Stage Finding|T3b|T3b Stage Finding|T3c|T3c Stage Finding|T3d|T3d Stage Finding|T4|T4 Stage Finding|T4a|T4a Stage Finding|T4b|T4b Stage Finding|T4c|T4c Stage Finding|T4d|T4d Stage Finding|T4e|T900607|TAM/c-Met Inhibitor RXDX-106|TARGET DCC Archive|TARGZ|TBI|TCGA DCC Archive|TE-Too Early|TF-Tumor Free|TGF-beta Receptor 1 Inhibitor PF-06952229|TGF-beta Receptor 1 Kinase Inhibitor SH3051|TGF-beta Receptor 1 Kinase Inhibitor YL-13027|TGFa-PE38 Immunotoxin|TGFbeta Inhibitor LY3200882|TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein AVID200|THL-P|TIFF|TIGIT Inhibitor M6223|TIGIT-targeting Agent MK-7684|TLC ELL-12|TLR Agonist BDB001|TLR Agonist BSG-001|TLR Agonist CADI-05|TLR-Directed Cationic Lipid-DNA Complex JVRS-100|TLR7 Agonist 852A|TLR7 Agonist LHC165|TLR7 agonist BNT411|TLR7/8/9 Antagonist IMO-8400|TLR8 Agonist DN1508052|TLR9 Agonist AST-008|TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells|TMT|TMT10|TMT11|TMT6|TORC1/2 Kinase Inhibitor DS-3078a|TP40 Immunotoxin|TRAIL Receptor Agonist ABBV-621|TRIZAIC UPLC nanoTile|TRK Inhibitor AZD6918|TRK Inhibitor TQB3558|TRPM8 Agonist D-3263|TRPV6 Calcium Channel Inhibitor SOR-C13|TSP-1 Mimetic ABT-510|TSP-1 Mimetic Fusion Protein CVX-045|TSQ 8000 Evo|TSQ 9000|TSQ Altis|TSQ Endura|TSQ Quantis|TSQ Quantiva|TSQ Quantum|TSQ Quantum Access|TSQ Quantum Ultra|TSQ Quantum Ultra AM|TSQ Vantage|TSV|TX|TX Stage Finding|TXT|Ta|Ta Stage Finding|Tabalumab|Tabelecleucel|Tacedinaline|Tafasitamab|Tag|Tagraxofusp-erzs|Tail of pancreas|Taiwan|Tajikistan|Takifugu rubripes|Talabostat|Talabostat Mesylate|Talacotuzumab|Talactoferrin Alfa|Taladegib|Talampanel|Talaporfin Sodium|Talazoparib|Taletrectinib|Talimogene Laherparepvec|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Tallimustine|Talmapimod|Talotrexin|Talotrexin Ammonium|Taltobulin|Tamibarotene|Taminadenant|Tamoxifen|Tamoxifen Citrate|Tamrintamab Pamozirine|Tandutinib|Tanespimycin|Tanibirumab|Tankyrase Inhibitor STP1002|Tanomastat|Tanycytic Ependymoma|Tanycytic ependymoma|Tanzania|Tapotoclax|Tarenflurbil|Tarextumab|Targeted Molecular Therapy|Tariquidar|Tasadenoturev|Taselisib|Tasidotin|Tasisulam|Tasisulam Sodium|Tasquinimod|Tattoo|Taurolidine|Tauromustine|Taurultam|Taurultam Analogue GP-2250|Tavokinogene Telseplasmid|Tavolimab|Taxane Analogue TPI 287|Taxane Compound|Taxol Analogue SID 530|Tazarotene|Tazemetostat|Tebentafusp|Teclistamab|Tecogalan Sodium|Tefinostat|Tegafur|Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation|Tegafur-Uracil|Tegafur-gimeracil-oteracil Potassium|Tegavivint|Teglarinad|Teglarinad Chloride|Telaglenastat|Telaglenastat Hydrochloride|Telangiectasia|Telangiectatic Osteosarcoma|Telangiectatic osteosarcoma|Telapristone|Telapristone Acetate|Telatinib Mesylate|Telisotuzumab|Telisotuzumab Vedotin|Telomerase Inhibitor FJ5002|Telomerase-specific Type 5 Adenovirus OBP-301|Teloxantrone|Teloxantrone Hydrochloride|Telratolimod|Temarotene|Temoporfin|Temozolomide|Temporal Cortex|Temporal Lobe|Temporal lobe|Temsirolimus|Tenalisib|Tendon|Tenifatecan|Teniposide|Tenosynovial Giant Cell Tumor|Tenosynovial giant cell tumor|Tepoditamab|Tepotinib|Teprotumumab|Terameprocol|Teratoblastoma, malignant|Teratocarcinoma|Teratoid medulloepithelioma|Teratoid medulloepithelioma, benign|Teratoma|Teratoma with Somatic-Type Malignancy|Teratoma with malignant transformation|Teratoma, NOS|Teratoma, benign|Teratoma, differentiated|Teratoma, malignant, NOS|Terfluranol|Tergenpumatucel-L|Terminal duct adenocarcinoma|Teroxirone|Tertomotide|Tesetaxel|Tesevatinib|Tesidolumab|Testicular Cancer|Testicular Disorder|Testicular Germ Cell Tumors|Testicular Hemorrhage|Testicular Mixed Germ Cell-Sex Cord-Stromal Tumor, Unclassified|Testicular Pain|Testicular Seminoma with High Mitotic Index|Testicular Spermatocytic Tumor|Testicular adenoma|Testicular stromal tumor|Testis|Testis Removed|Testis, NOS|Testolactone|Testosterone Enanthate|Tetanus Toxoid Vaccine|Tetradecanoylphorbol Acetate|Tetrahydrouridine|Tetraphenyl Chlorin Disulfonate|Tetrathiomolybdate|Tezacitabine|Tezacitabine Anhydrous|Thailand|Thalicarpine|Thalidomide|Theca cell tumor|Theca cell-granulosa cell tumor|Thecoma|Thecoma, NOS|Thecoma, luteinized|Thecoma, malignant|Theliatinib|Theramide|Therapeutic Angiotensin-(1-7)|Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907|Therapeutic Cancer Vaccine ATP128|Therapeutic Estradiol|Therapeutic Hydrocortisone|Therapeutic Liver Cancer Peptide Vaccine IMA970A|Therapy related myeloid neoplasm|Therapy-Related Acute Myeloid Leukemia|Therapy-Related Myelodysplastic Syndrome|Therapy-Related Myeloid Neoplasm|Therapy-related acute myeloid leukemia, NOS|Therapy-related acute myeloid leukemia, alkylating agent related|Therapy-related acute myeloid leukemia, epipodophyllotoxin-related|Therapy-related myelodysplastic syndrome, NOS|Therapy-related myelodysplastic syndrome, alkylating agent related|Therapy-related myelodysplastic syndrome, epipodophyllotoxin-related|Thermo Fisher Scientific|Thermo Orbitrap Fusion Lumos|Thermo Orbitrap Q Exactive HF-X|Thiarabine|Thiazolidinedione|Thigh|Thiodiglycol|Thioguanine|Thioguanine Anhydrous|Thioinosine|Thioredoxin-1 Inhibitor PX-12|Thiotepa|Thioureidobutyronitrile|Thoracentesis|Thoracic Esophagus|Thoracic Spine|Thoracic esophagus|Thoracoscopic Biopsy|Thorax|Thorax, NOS|Thorium Th 227 Anetumab|Thorium Th 227 Anetumab Corixetan|Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439|Thorium Th 227 Anti-PSMA Monoclonal Antibody BAY 2315497|Three Times Daily|Threonine Tyrosine Kinase Inhibitor CFI-402257|Throat|Throat Cancer|Thromboembolic Event|Thrombotic Thrombocytopenic Purpura|Thumb|Thymic Carcinoma|Thymic Epithelial Neoplasms|Thymic carcinoma with adenoid cystic carcinoma-like features|Thymic carcinoma, NOS|Thymic large B-cell lymphoma|Thymidylate Synthase Inhibitor CX1106|Thymidylate Synthase Inhibitor DFP-11207|Thymoma|Thymoma Type A|Thymoma Type AB|Thymoma Type B1|Thymoma Type B2|Thymoma Type B3|Thymoma, NOS|Thymoma, atypical, NOS|Thymoma, atypical, malignant|Thymoma, benign|Thymoma, cortical, NOS|Thymoma, cortical, malignant|Thymoma, epithelial, NOS|Thymoma, epithelial, malignant|Thymoma, lymphocyte-rich, NOS|Thymoma, lymphocyte-rich, malignant|Thymoma, lymphocytic, NOS|Thymoma, lymphocytic, malignant|Thymoma, malignant, NOS|Thymoma, medullary, NOS|Thymoma, medullary, malignant|Thymoma, mixed type, NOS|Thymoma, mixed type, malignant|Thymoma, organoid, NOS|Thymoma, organoid, malignant|Thymoma, predominantly cortical, NOS|Thymoma, predominantly cortical, malignant|Thymoma, spindle cell, NOS|Thymoma, spindle cell, malignant|Thymoma, type A, NOS|Thymoma, type A, malignant|Thymoma, type AB, NOS|Thymoma, type AB, malignant|Thymoma, type B1, NOS|Thymoma, type B1, malignant|Thymoma, type B2, NOS|Thymoma, type B2, malignant|Thymoma, type B3, NOS|Thymoma, type B3, malignant|Thymoma, type C|Thymopentin|Thymus|Thyroid|Thyroid Cancer|Thyroid Carcinoma|Thyroid Extract|Thyroid Gland|Thyroid Gland Follicular Adenoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Follicular Carcinoma, Encapsulated Angioinvasive|Thyroid Gland Hurthle (Oncocytic) Cell Neoplasm|Thyroid Gland Hurthle Cell Adenoma|Thyroid Gland Hyalinizing Trabecular Tumor|Thyroid Gland Macrofollicular Adenoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Medullary Carcinoma with Amyloid Stroma|Thyroid Gland Microfollicular Adenoma|Thyroid Gland Noninvasive Follicular Neoplasm with Papillary-Like Nuclear Features|Thyroid Gland Papillary Carcinoma|Thyroid Gland Papillary and Follicular Carcinoma|Thyroid Gland Spindle Cell Tumor with Thymus-Like Differentiation|Thyroid Gland Well-Differentiated Tumor of Uncertain Malignant Potential|Thyroid Nodular Hyperplasia|Thyroid gland|Tiazofurin|Tibia|Tibial Adamantinoma|Tibial adamantinoma|Tidutamab|Tigapotide|Tigatuzumab|Tilarginine|Tilogotamab|Tilsotolimod Sodium|Timonacic|Timor-Leste|Tin Ethyl Etiopurpurin|Tinnitus|Tinostamustine|Tinzaparin Sodium|Tiomolibdate Choline|Tiomolibdate Diammonium|Tipapkinogene Sovacivec|Tipifarnib|Tipiracil|Tipiracil Hydrochloride|Tirabrutinib|Tiragolumab|Tirapazamine|Tirbanibulin|Tis|Tis (DCIS)|Tis (LCIS)|Tis (Paget's)|Tis Stage Finding|Tisagenlecleucel|Tislelizumab|Tisotumab Vedotin|Tissue Microarray Image|Tissue Slide|Tivantinib|Tivozanib|Tobacco|Tobacco smoke, NOS|Tobacco smoke, cigar|Tobacco smoke, cigarettes|Tobacco smoke, pipe|Tobacco, NOS|Tobacco, Smokeless|Tobacco, Smoking|Tocilizumab|Tocladesine|Tocotrienol|Tocotrienol-rich Fraction|TofSpec|TofSpec 2E|TofSpec E|TofSpec SE|Togo|Tokelau|Tolebrutinib|Toll-like Receptor 7 Agonist DSP-0509|Tolnidamine|Tomaralimab|Tomato-Soy Juice|Tomivosertib|Tonga|Tongue|Tongue Cancer|Tongue, NOS|Tonsil|Tonsil (Pharyngeal)|Tonsil, NOS|Tonsillar Cancer|Tonsillar Fossa|Tonsillar fossa|Tonsillar pillar|Tonsillectomy|Tooth Development Disorder|Tooth Discoloration|Tooth Infection|Toothache|Topical Betulinic Acid|Topical Celecoxib|Topical Fluorouracil|Topical Gemcitabine Hydrochloride|Topical Potassium Dobesilate|Topical Trichloroacetic Acid|Topixantrone|Topoisomerase I Inhibitor Genz-644282|Topoisomerase I Inhibitor LMP400|Topoisomerase I Inhibitor LMP776|Topoisomerase I/II Inhibitor NEV-801|Topoisomerase-1 Inhibitor LMP744|Topoisomerase-II Inhibitor Racemic XK469|Topoisomerase-II-beta Inhibitor Racemic XK469|Topotecan|Topotecan Hydrochloride|Topotecan Hydrochloride Liposomes|Topotecan Sustained-release Episcleral Plaque|Topsalysin|Toremifene|Toremifene Citrate|Toripalimab|Tosedostat|Tositumomab|Total Androgen Blockade|Total Colectomy|Total Hepatectomy|Total Laryngectomy|Total Mastectomy|Total Nephrectomy|Total RNA|Total RNA-Seq|Tovetumab|Toxic Epidermal Necrolysis|Toxicity|Toxoplasmosis|Tozasertib Lactate|Trabectedin|Trabecular Adenocarcinoma|Trabecular Adenoma|Trabecular adenocarcinoma|Trabecular adenoma|Trabecular carcinoma|Trabedersen|Trachea|Trachea / Major Bronchi|Tracheal Fistula|Tracheal Hemorrhage|Tracheal Mucositis|Tracheal Obstruction|Tracheal Stenosis|Tracheitis|Tracheostomy Site Bleeding|Traditional Serrated Adenoma|Traditional serrated adenoma|Traditional sessile serrated adenoma|Trametinib|Trametinib Dimethyl Sulfoxide|Trans Sodium Crocetinate|Transcript Fusion|Transcriptome Profiling|Transdermal 17beta-Estradiol Gel BHR-200|Transdermal 4-Hydroxytestosterone|Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01|Transferrin Receptor-Targeted Liposomal p53 cDNA|Transferrin-CRM107|Transfusion Recipient|Transient Abnormal Myelopoiesis Associated with Down Syndrome|Transient Ischemic Attack|Transient Ischemic Attacks|Transient abnormal myelopoiesis|Transitional Cell Carcinoma|Transitional Cell Papilloma|Transitional Cell Papillomas and Carcinomas|Transitional Meningioma|Transitional carcinoma|Transitional cell carcinoma|Transitional cell carcinoma in situ|Transitional cell carcinoma, micropapillary|Transitional cell carcinoma, sarcomatoid|Transitional cell carcinoma, spindle cell|Transitional cell papilloma, NOS|Transitional cell papilloma, benign|Transitional cell papilloma, inverted, NOS|Transitional cell papilloma, inverted, benign|Transitional meningioma|Transitional papilloma|Transitional papilloma, inverted, NOS|Transitional papilloma, inverted, benign|Transitional pineal tumor|Transoral Laser Excision|Transplant|Transurethral Resection (TURP)|Transurethral resection (TURBT)|Transverse Colectomy|Transverse Colon|Transverse colon|Tranylcypromine Sulfate|Trapoxin|Trastuzumab|Trastuzumab Conjugate BI-CON-02|Trastuzumab Deruxtecan|Trastuzumab Duocarmazine|Trastuzumab Emtansine|Trastuzumab Monomethyl Auristatin F|Trastuzumab-TLR 7/8 Agonist BDC-1001|Trastuzumab/Hyaluronidase-oysk|Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502|Treatment Ongoing|Treatment Related Secondary Malignancy|Treatment Stopped Due to Toxicity|Trebananib|Tremelimumab|Tremor|Treosulfan|Treponema pallidum|Tretazicar|Tretinoin|Tretinoin Liposome|Triamcinolone Acetonide|Triamcinolone Hexacetonide|Triapine|Triazene Derivative CB10-277|Triazene Derivative TriN2755|Triazinate|Triaziquone|Tributyrin|Trichilemmal Carcinoma|Trichilemmal carcinoma|Trichilemmocarcinoma|Trichilemmoma|Trichoblastoma|Trichodiscoma|Trichoepithelioma|Trichofolliculoma|Trichomonas vaginalis|Triciribine Phosphate|Tricuspid Valve Disease|Trientine Hydrochloride|Triethylenemelamine|Trifluridine|Trifluridine and Tipiracil Hydrochloride|Trigeminal Nerve Disorder|Trigone of bladder|Trigriluzole|Trilaciclib|Trimelamol|Trimeric GITRL-Fc OMP-336B11|Trimethylcolchicinic Acid|Trimetrexate|Trimetrexate Glucuronate|Trinidad and Tobago|Trioxifene|Triplatin Tetranitrate|Triple Quad 3500|Triple Quad 4500|Triple Quad 5500|Triple Quad 6500|Triple Quad 6500+|TripleTOF 4600|TripleTOF 5600|TripleTOF 5600+|TripleTOF 6600|Triptolide Analog|Triptorelin|Triptorelin Pamoate|Tris-acryl Gelatin Microspheres|Trismus|Triton tumor, malignant|Tritylcysteine|TrkA Inhibitor VMD-928|Trodusquemine|Trofosfamide|Troglitazone|Trophoblastic neoplasms|Trophoblastic tumor, epithelioid|Tropomyosin Receptor Kinase Inhibitor AZD7451|Troriluzole|Troxacitabine|Troxacitabine Nucleotide Prodrug MIV-818|TruTOF|True|True Histiocytic Lymphoma|True histiocytic lymphoma|Trunk|TrypChymo|Trypsin|Trypsin/P|Tubercidin|Tuberculosis|Tuberous Sclerosis|Tubular Adenocarcinoma|Tubular Adenoma|Tubular adenocarcinoma|Tubular adenoma, NOS|Tubular androblastoma with lipid storage|Tubular androblastoma, NOS|Tubular carcinoid|Tubular carcinoma|Tubulin Binding Agent TTI-237|Tubulin Inhibitor ALB 109564 Dihydrochloride|Tubulin Inhibitor ALB-109564|Tubulin Polymerization Inhibitor AEZS 112|Tubulin Polymerization Inhibitor CKD-516|Tubulin Polymerization Inhibitor VERU-111|Tubulin-Binding Agent SSR97225|Tubulo-papillary adenoma|Tubulocystic Renal Cell Carcinoma|Tubulocystic renal cell carcinoma|Tubulointerstitial Disease|Tubulolobular carcinoma|Tubulopapillary adenocarcinoma|Tubulovillous Adenoma|Tubulovillous adenoma, NOS|Tucatinib|Tucidinostat|Tucotuzumab Celmoleukin|Tumor|Tumor Adjacent Normal - Post Neo-adjuvant Therapy|Tumor Debulking|Tumor Embolism|Tumor Free|Tumor Lysis Syndrome|Tumor Pain|Tumor Resection|Tumor cells, NOS|Tumor cells, benign|Tumor cells, malignant|Tumor cells, uncertain whether benign or malignant|Tumor class but appears normal|Tumor embolus|Tumor free|Tumor tissue origin incorrect|Tumor type incorrect|Tumor, NOS|Tumor, benign|Tumor, malignant, NOS|Tumor, metastatic|Tumor, secondary|Tumor-associated Lymphoid Proliferation|Tumorlet|Tumorlet, NOS|Tumorlet, benign|Tunisia|Turban Tumor|Turban tumor|Turcot Syndrome|Turkey|Turkmenistan|Tuvalu|Twice Daily|Twice Weekly|Twin Sibling|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma|Type A Spindle Cell Melanoma|Type B Spindle Cell Melanoma|Typhlitis|Typical carcinoid|Tyroserleutide|Tyrosinase Peptide|Tyrosinase-KLH|Tyrosinase:146-156 Peptide|Tyrosine Kinase Inhibitor|Tyrosine Kinase Inhibitor OSI-930|Tyrosine Kinase Inhibitor SU5402|Tyrosine Kinase Inhibitor TL-895|Tyrosine Kinase Inhibitor XL228|Tyrosinemia|UAE Inhibitor TAK-243|UHPLC|USP14/UCHL5 Inhibitor VLX1570|Ubenimex|Ubidecarenone Nanodispersion BPM31510n|Ubiquitylome|Ublituximab|Uganda|Ukraine|Ulcerative Colitis|Ulinastatin|Ulixertinib|Ulocuplumab|Ultrasound Guided Biopsy|Ultrasound-Guided Biopsy|Umbilical Cord|Umbralisib|Unaligned Reads|Uncaria tomentosa Extract|Unclassified Testicular Sex Cord-Stromal Tumor|Unclassified tumor, benign|Unclassified tumor, borderline malignancy|Unclassified tumor, malignant|Unclassified tumor, malignant, uncertain whether primary or metastatic|Unclassified tumor, uncertain whether benign or malignant|Uncle|Undescended Testis|Undescended testis|Undifferentiated|Undifferentiated (Embryonal) Sarcoma|Undifferentiated Carcinoma|Undifferentiated Epithelioid Sarcoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone|Undifferentiated Neuroblastoma|Undifferentiated Pleomorphic Sarcoma|Undifferentiated Pleomorphic Sarcoma with Osteoclast-Like Giant Cells|Undifferentiated Retinoblastoma|Undifferentiated Round Cell Sarcoma|Undifferentiated Sarcoma, Not Otherwise Specified|Undifferentiated Spindle Cell Sarcoma|Undifferentiated epithelioid sarcoma|Undifferentiated high-grade pleomorphic sarcoma|Undifferentiated leukaemia|Undifferentiated pleomorphic sarcoma|Undifferentiated round cell sarcoma|Undifferentiated sarcoma|Undifferentiated spindle cell sarcoma|Undifferentiated uterine sarcoma|Unequal Limb Length|Unfavorable|Unifocal|Unilateral|Unintended Pregnancy|United Arab Emirates|United Kingdom|United States|Unknown Tumor Status|Unknown primary site|Unknown tumor status|Unpaired_LogR|Unrelated|Unsatisfactory|Unspecific cleavage|Unspecified|Upamostat|Upifitamab|Upper Gastrointestinal Hemorrhage|Upper Gingiva|Upper Gum|Upper Respiratory Infection|Upper gum|Upper limb, NOS|Upper lobe, lung|Upper respiratory tract, NOS|Upper third of esophagus|Upper-inner quadrant of breast|Upper-outer quadrant of breast|Uproleselan|Uprosertib|Urabrelimab|Urachal carcinoma|Urachus|Uracil Ointment|Urelumab|Ureter|Ureteric Anastomotic Leak|Ureteric Orifice|Ureteric orifice|Urethra|Urethral Anastomotic Leak|Urethral Infection|Urinary Fistula|Urinary Frequency|Urinary Incontinence|Urinary Retention|Urinary System|Urinary Tract|Urinary Tract Infection|Urinary Tract Obstruction|Urinary Tract Pain|Urinary Urgency|Urinary system, NOS|Urine Discoloration|Urine Output Decreased|Uroacitides|Urokinase-Derived Peptide A6|Urostomy Leak|Urostomy Obstruction|Urostomy Site Bleeding|Urostomy Stenosis|Urothelial Carcinoma|Urothelial Papilloma|Urothelial carcinoma in situ|Urothelial carcinoma with divergent differentiation|Urothelial carcinoma with squamous differentiation|Urothelial carcinoma with trophoblastic differentiation|Urothelial carcinoma, NOS|Urothelial papilloma, NOS|Ursolic Acid|Urticaria|Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis|Urticaria pigmentosa|Uruguay|Uterine Adnexa|Uterine Anastomotic Leak|Uterine Cancer|Uterine Carcinosarcoma|Uterine Corpus Endometrial Carcinoma|Uterine Corpus Leiomyoma|Uterine Corpus Undifferentiated Sarcoma|Uterine Fistula|Uterine Hemorrhage|Uterine Infection|Uterine Obstruction|Uterine Pain|Uterine Perforation|Uterine adnexa|Uterus|Uterus, NOS|Utomilumab|Uveal Melanoma|Uveitis|Uvula|Uzansertib|Uzbekistan|V8-DE|V8-E|V930 Vaccine|VAIN III|VCF|VCF LiftOver|VEGF Inhibitor PTC299|VEGF/HGF-targeting DARPin MP0250|VEGFR Inhibitor KRN951|VEGFR-2 DNA Vaccine VXM01|VEGFR/FGFR Inhibitor ODM-203|VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593|VEGFR2 Tyrosine Kinase Inhibitor PF-00337210|VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813|VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220|VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820|VGPR-Very Good Partial Response|VIN III|VIP-Producing Neuroendocrine Tumor|VLP-encapsulated TLR9 Agonist CMP-001|Vaccine-Sensitized Draining Lymph Node Cells|Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules|Vactosertib|Vadacabtagene Leraleucel|Vadastuximab Talirine|Vadimezan|Vagina|Vagina, NOS|Vaginal Anastomotic Leak|Vaginal Discharge|Vaginal Dryness|Vaginal Fistula|Vaginal Hemorrhage|Vaginal Infection|Vaginal Inflammation|Vaginal Obstruction|Vaginal Pain|Vaginal Perforation|Vaginal Stricture|Vaginal intraepithelial neoplasia, grade III|Vaginismus|Vagus Nerve Disorder|Valecobulin|Valemetostat|Validation|Vallecula|Valproic Acid|Valrubicin|Valspodar|Vandetanib|Vandetanib-eluting Radiopaque Bead BTG-002814|Vandortuzumab Vedotin|Vantictumab|Vanuatu|Vanucizumab|Vapreotide|VarScan2|VarScan2 Annotation|VarScan2 Variant Aggregation and Masking|Varian|Varicella Zoster Virus|Varlilumab|Varlitinib|Varlitinib Tosylate|Vas Deferens|Vas Deferens Anastomotic Leak|Vascular Access Complication|Vascular Disease|Vascular Disorders - Other|Vascular Disrupting Agent BNC105|Vascular Disrupting Agent BNC105P|Vascular Disrupting Agent ZD6126|Vascular leiomyoma|Vasculitis|Vasovagal Reaction|Vatalanib|Vatalanib Succinate|Vecabrutinib|Vector-peptide Conjugated Paclitaxel|Vedolizumab|Vein|Veliparib|Velos Plus|Veltuzumab|Vemurafenib|Venetoclax|Venezuela|Venous|Venous Hemangioma|Venous Injury|Venous hemangioma|Ventral surface of tongue, NOS|Ventricle, NOS|Ventricular Arrhythmia|Ventricular Fibrillation|Ventricular Tachycardia|Verapamil|Verpasep Caltespen|Verrucous Carcinoma|Verrucous Hemangioma|Verrucous Papilloma|Verrucous carcinoma, NOS|Verrucous epidermoid carcinoma|Verrucous keratotic hemangioma|Verrucous papilloma|Verrucous squamous cell carcinoma|Vertebra|Vertebral Canal|Vertebral column|Vertical Hemilaryngectomy|Vertigo|Verubulin|Verubulin Hydrochloride|Very Good Partial Response|Vesencumab|Vesigenurtucel-L|Vestibular Disorder|Vestibule of Mouth|Vestibule of mouth|Viagenpumatucel-L|Vibecotamab|Vibostolimab|Vietnam|Vilaprisan|Villoglandular Endometrial Endometrioid Adenocarcinoma|Villoglandular adenoma|Villoglandular carcinoma|Villous Adenocarcinoma|Villous Adenoma|Villous adenocarcinoma|Villous adenoma, NOS|Villous papilloma|Vinblastine|Vinblastine Sulfate|Vincristine|Vincristine Liposomal|Vincristine Sulfate|Vincristine Sulfate Liposome|Vindesine|Vinepidine|Vinflunine|Vinflunine Ditartrate|Vinfosiltine|Vinorelbine|Vinorelbine Tartrate|Vinorelbine Tartrate Emulsion|Vinorelbine Tartrate Oral|Vintafolide|Vinzolidine|Vinzolidine Sulfate|Vipoma, NOS|Vipoma, malignant|Virgin Islands, British|Virgin Islands, U.S.|Virilization|Virulizin|Visceral Arterial Ischemia|Vision Changes|Vismodegib|Vistusertib|Visual Change|Visual Changes|Vital Capacity Abnormal|Vitamin D3 Analogue ILX23-7553|Vitamin E Compound|Vitespen|Vitreous Hemorrhage|Vocimagene Amiretrorepvec|Vofatamab|Voice Alteration|Volasertib|Volcanic smoke|Volociximab|Vomiting|Von Hippel-Lindau Syndrome|Von Recklinghausen disease|Vonlerolizumab|Vopratelimab|Vorasidenib|Vorinostat|Vorolanib|Vorsetzumab Mafodotin|Vosaroxin|Vosilasarm|Voxtalisib|Voyager-DE PRO|Voyager-DE STR|Vulinacimab|Vulva|Vulva, NOS|Vulval Infection|Vulvar Intraepithelial Neoplasia, Differentiated Type|Vulvar intraepithelial neoplasia, grade III|W|WGA Failure|WNT-Activated|WT-With Tumor|WT1 Peptide Vaccine OCV-501|WT1 Peptide Vaccine WT2725|WT1 Protein-derived Peptide Vaccine DSP-7888|WT1-A10/AS01B Immunotherapeutic GSK2130579A|WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401|WXS|Wagr Syndrome|Waldenstrom Macroglobulinemia|Waldenstrom macroglobulinemia|Waldeyer ring|Wallis and Futuna|Ward|Warfarin Sodium|Warthin Tumor|Warthin tumor|Warty carcinoma|Waste burning smoke|Wasting Syndrome|Water-Clear Cell Adenocarcinoma|Water-clear cell adenocarcinoma|Water-clear cell adenoma|Water-clear cell carcinoma|Watering Eyes|Waters|Wedge Resection|Wee1 Inhibitor ZN-c3|Wee1 Kinase Inhibitor Debio 0123|Weight Gain|Weight Loss|Well Differentiated Liposarcoma|Well Differentiated Neuroendocrine Lesion|Well differentiated liposarcoma of superficial soft tissue|Well differentiated papillary mesothelioma, benign|Well differentiated thymic carcinoma|Western Sahara|Wheezing|Whipple Procedure|White Blood Cell Decreased|White Blood Cells|White Carrot|White Matter|Whole Bone Marrow|Whole Genome Sequencing|Wife|Wilms Tumor|Wilms tumor|Wilms tumor (WT)|Wine|With Tumor|With tumor|Withdrawal by Subject|Within 5 Minutes|Wnt Signaling Inhibitor SM04755|Wnt Signaling Pathway Inhibitor SM08502|Wnt-5a Mimic Hexapeptide Foxy-5|Wobe-Mugos E|Wolff-Parkinson-White Syndrome|Wolffian duct adenoma|Wolffian duct carcinoma|Wolffian duct tumor|Wood Dust|Wood burning smoke, NOS|Wood burning smoke, factory|Work-related smoke, NOS|Work-related smoke, artificial smoke machines|Work-related smoke, fire fighting|Work-related smoke, foundry|Work-related smoke, generators|Work-related smoke, military|Work-related smoke, paint baking|Work-related smoke, plastics factory|Work-related smoke, plumbing|Work-related smoke, soldering/welding|Wound Complication|Wound Dehiscence|Wound Infection|Wrist|Wrist Fracture|X|X500R QTOF|XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410|XIAP Antisense Oligonucleotide AEG35156|XIAP/cIAP1 Antagonist ASTX660|XLSX|XML|XPO1 Inhibitor SL-801|Xanthofibroma|Xanthohumol|Xeloda|Xenograft|Xenograft Tissue|Xenopus laevis|Xentuzumab|Xevinapant|Xevo G2 Q-Tof|Xevo G2 Tof|Xevo G2 XS Tof|Xevo G2-S QTof|Xevo G2-S Tof|Xevo Q-Tof|Xevo QTof|Xevo TQ MS|Xevo TQ-S|Xevo TQD|Xiaoai Jiedu Decoction|Xiliertinib|Xisomab 3G3|Y|Y 90 Monoclonal Antibody CC49|Y 90 Monoclonal Antibody HMFG1|Y 90 Monoclonal Antibody Lym-1|Y 90 Monoclonal Antibody M195|Y 90 Monoclonal Antibody m170|Yang Yin Fu Zheng|Yangzheng Xiaoji Extract|Yemen|Yiqi-yangyin-jiedu Herbal Decoction|Yolk Sac Tumor|Yolk sac tumor|Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12|Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101|Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66|Yttrium Y 90 Basiliximab|Yttrium Y 90 Colloid|Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A|Yttrium Y 90 Daclizumab|Yttrium Y 90 Glass Microspheres|Yttrium Y 90 Monoclonal Antibody B3|Yttrium Y 90 Monoclonal Antibody BrE-3|Yttrium Y 90 Monoclonal Antibody Hu3S193|Yttrium Y 90 Monoclonal Antibody MN-14|Yttrium Y 90 Resin Microspheres|Yttrium Y 90 Tabituximab Barzuxetan|Yttrium Y 90-DOTA-Biotin|Yttrium Y 90-DOTA-di-HSG Peptide IMP-288|Yttrium Y 90-Edotreotide|Yttrium Y 90-labeled Anti-FZD10 Monoclonal Antibody OTSA101|Yttrium Y-90 Clivatuzumab Tetraxetan|Yttrium Y-90 Epratuzumab Tetraxetan|Yttrium Y-90 Ibritumomab Tiuxetan|Yttrium Y-90 Tacatuzumab Tetraxetan|Yttrium-90 Polycarbonate Brachytherapy Plaque|Z-Endoxifen Hydrochloride|ZMD|ZQ|Zalcitabine|Zalifrelimab|Zalutumumab|Zambia|Zandelisib|Zanidatamab|Zanolimumab|Zanubrutinib|Zea mays|Zebularine|Zelavespib|Zero|Zibotentan|Zimbabwe|Zinc Finger Nuclease ZFN-603|Zinc Finger Nuclease ZFN-758|Zinostatin|Zinostatin Stimalamer|Zirconium Zr 89 Panitumumab|Ziv-Aflibercept|Zolbetuximab|Zoledronic Acid|Zoptarelin Doxorubicin|Zorifertinib|Zorubicin|Zorubicin Hydrochloride|Zotatifin|Zotiraciclib Citrate|Zuclomiphene Citrate|aDNA Preparation Type|alignment_workflow|aliquot|allcnv|alleleSpecificCN|alpha-Folate Receptor-targeting Thymidylate Synthase Inhibitor ONX-0801|american indian or alaska native|analyte|asian|auxiliary|bRPLC|bRPLC (pH 10)|bRPLC (pH 7.5)|batch_effect_removed|bisulfite|black or african american|byallele|c-ALL|c-Kit Inhibitor PLX9486|c-Met Inhibitor ABN401|c-Met Inhibitor AL2846|c-Met Inhibitor AMG 208|c-Met Inhibitor AMG 337|c-Met Inhibitor GST-HG161|c-Met Inhibitor HS-10241|c-Met Inhibitor JNJ-38877605|c-Met Inhibitor MK2461|c-Met Inhibitor MK8033|c-Met Inhibitor MSC2156119J|c-raf Antisense Oligonucleotide ISIS 5132|cEt KRAS Antisense Oligonucleotide AZD4785|cFMS Tyrosine Kinase Inhibitor ARRY-382|cGy|cM0 (i+)|cM0 (i+) Stage Finding|cfDNA|cgh|cis-Urocanic Acid|cnv|control|controlled|cov|coverage|cqcf|dUTPase/DPD Inhibitor TAS-114|data_release|diagnostic_slides|drug|eIF4E Antisense Oligonucleotide ISIS 183750|explorer|false|female|follow_up|gene|germline|hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301|hTERT Vaccine V934/V935|hTERT-encoding DNA Vaccine INVAC-1|harmonized|hg18|hg19|hispanic or latino|hpv|huBC1-huIL12 Fusion Protein AS1409|iNKT Cell Agonist ABX196|iNOS Dimerization Inhibitor ASP9853|iPSC-derived CD16-expressing Natural Killer Cells FT516|iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596|iPSC-derived Natural Killer Cells FT500|iTRAQ|iTRAQ4|iTRAQ8|iTRAQH|image|indel|ismpolish|isoform|junction|lost to follow-up|lowess_normalized_smoothed|m6A RNA Methylation|mRNA-Derived Prostate Cancer Vaccine CV9103|mRNA-based Personalized Cancer Vaccine NCI-4650|mRNA-based Personalized Cancer Vaccine mRNA-4157|mRNA-based TriMix Melanoma Vaccine ECI-006|mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902|mRNA-derived KRAS-targeted Vaccine V941|mRNA-derived Lung Cancer Vaccine BI 1361849|mRNA-derived Prostate Cancer Vaccine CV9104|mTOR Inhibitor GDC-0349|mTOR Kinase Inhibitor AZD8055|mTOR Kinase Inhibitor CC-223|mTOR Kinase Inhibitor OSI-027|mTOR Kinase Inhibitor PP242|mTOR1/2 Kinase Inhibitor ME-344|mTORC 1/2 Inhibitor LXI-15029|mTORC1/2 Kinase Inhibitor BI 860585|mTORC1/mTORC2/DHFR Inhibitor ABTL0812|maXis 4G|maXis impact|male|metastasis|meth|mg|miRNA|miRNA Expression Quantification|miRNA-Seq|microOTOF focus II|microOTOF-Q II|mirVana (Allprep DNA) RNA|msi|nRNA - Melanoma Protocol|nanoACQUITY UPLC|nanoACQUITY UPLC System with 1D Technology|nanoACQUITY UPLC with HDX Technology|native hawaiian or other pacific islander|ncmtRNA Oligonucleotide Andes-1537|nocnv|normalized|not allowed to collect|not hispanic or latino|not reported|nte|omf|open|original|other|p300/CBP Bromodomain Inhibitor CCS1477|p38 MAPK Inhibitor LY3007113|p53 Peptide Vaccine MPS-128|p53-HDM2 Interaction Inhibitor MI-773|p53-HDM2 Protein-protein Interaction Inhibitor APG-115|p53/HDM2 Interaction Inhibitor CGM097|p70S6K Inhibitor LY2584702|p70S6K/Akt Inhibitor MSC2363318A|p97 Inhibitor CB-5083|p97 Inhibitor CB-5339|p97 Inhibitor CB-5339 Tosylate|pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0|pNGVL4a-CRT-E6E7L2 DNA Vaccine|pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2|pairedcn|pan FGFR Inhibitor PRN1371|pan-HER Kinase Inhibitor AC480|pan-PI3K Inhibitor CLR457|pan-PI3K/mTOR Inhibitor SF1126|pan-PIM Kinase Inhibitor AZD1208|pan-PIM Kinase Inhibitor NVP-LGB-321|pan-RAF Inhibitor LXH254|pan-RAF Kinase Inhibitor CCT3833|pan-RAF Kinase Inhibitor TAK-580|patient|pbi-shRNA STMN1 Lipoplex|portion|primary|proteomics solution 1|protocol|qc|quattro micro|radiation|raw|recurrence|root|sCR-Stringent Complete Response|sample|scATAC-Seq|scRNA-Seq|seg|segmentation|segmented|segnormal|siG12D LODER|siRNA-transfected Peripheral Blood Mononuclear Cells APN401|sif|slide|snv|solariX|somatic|ssRNA-based Immunomodulator CV8102|submitted_genomic_profile|summary|sv|tangent|timsTOF Pro|tr|tris(2-carboxyethyl)phosphine|true|ultima|unknown|unnormalized|unspecified|v1|v2|white|zUMIs - Smart-Seq2|zUMIs - Smart-Seq2 Counts|g"
vascular_invasion_present	vascular_invasion_present	False|Not Reported|True|Unknown	4/5 (both/PDC)	Not Allowed To Collect	
vascular_invasion_type	vascular_invasion_type	Extramural|Intramural|Macro|Micro|Not Reported|Unknown	6/7 (both/PDC)	No Vascular Invasion	Vascular Invasion Negative
weiss_assessment_score	weiss_assessment_score	0|1|2|3|4|5|6|7|8|9	10/10 (both/PDC)		"0 - No Fibrosis|00|01|02|03|04|05|06|07|08|09|1,2 - Portal Fibrosis|1-3|10|10-Deacetyltaxol|100|11|11C Topotecan|11D10 AluGel Anti-Idiotype Monoclonal Antibody|12|12-Allyldeoxoartemisinin|1200 series LC/MSD SL|1200 series LC/MSD VL|13|13-Deoxydoxorubicin|14|14C BMS-275183|15|16|17|17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521|18|180|1988|1995|1st|2'-F-ara-deoxyuridine|2,6-Diaminopurine|2,6-Dimethoxyquinone|2-Deoxy-D-glucose|2-Ethylhydrazide|2-Fluoroadenine|2-Fluorofucose-containing SGN-2FF|2-Hydroxyestradiol|2-Hydroxyestrone|2-Hydroxyflutamide Depot|2-Hydroxyoleic Acid|2-Methoxyestradiol|2-Methoxyestradiol Nanocrystal Colloidal Dispersion|2-Methoxyestrone|2-O, 3-O Desulfated Heparin|2-chloroacetamide (TCEP)|2-iodobenzoate|20|2000 QTRAP|2009|21|220 GC/MS Ion Trap System|240 GC/MS Ion Trap System|2500 QTRAP|26|2D Classical Conditionally Reprogrammed Cells|2D Modified Conditionally Reprogrammed Cells|2nd|3'-C-ethynylcytidine|3'-dA Phosphoramidate NUC-7738|3,4 - Fibrous Septa|30|31|31-60 Minutes|3100|32|3200 QTRAP|33|35|3500 QTRAP|39|3D Air-Liquid Interface Organoid|3D Neurosphere|3D Organoid|3rd|4 or More|4'-Iodo-4'-Deoxydoxorubicin|4-Nitroestrone 3-Methyl Ether|4-Thio-2-deoxycytidine|40|4000 QTRAP|41|42|45|4700 Proteomics Analyzer|4800 Plus MALDI TOF/TOF|4800 Proteomics Analyzer|4th|5 - Nodular Formation and Incomplete Cirrhosis|5-Aza-4'-thio-2'-deoxycytidine|5-Fluoro-2-Deoxycytidine|50|51|52|53|56|58|5800 TOF/TOF|59|5th|6 - Established Cirrhosis|6-30 Minutes|6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158|60|61|6110 Quadrupole LC/MS|6120A Quadrupole LC/MS|6120B Quadrupole LC/MS|6130 Quadrupole LC/MS|6140 Quadrupole LC/MS|6150 Quadrupole LC/MS|62|6200 Series Accurate-Mass Time-of-Flight (TOF) LC/MS|6210 Time-of-Flight LC/MS|6220 Time-of-Flight LC/MS|6224 Time-of-Flight LC/MS|6230A Time-of-Flight LC/MS|6230B Time-of-Flight LC/MS|63|6310 Ion Trap LC/MS|6320 Ion Trap LC/MS|6330 Ion Trap LC/MS|6340 Ion Trap LC/MS|64|6400 Series Triple Quadrupole LC/MS|6410 Triple Quadrupole LC/MS|6420 Triple Quadrupole LC/MS|6430 Triple Quadrupole LC/MS|6460 Triple Quadrupole LC/MS|6490 Triple Quadrupole LC/MS|6495A Triple Quadrupole LC/MS|6495B Triple Quadrupole LC/MS|65|6510 Quadrupole Time-of-Flight LC/MS|6520A Quadrupole Time-of-Flight LC/MS|6520B Q-TOF LC/MS|6530A Q-TOF LC/MS|6530B Q-TOF LC/MS|6538 Q-TOF LC/MS|6540 Q-TOF LC/MS|6542 Q-TOF LC/MS|6545 Q-TOF LC/MS|6550 iFunnel Q-TOF LC/MS|6550A iFunnel Q-TOF LC/MS|6560 Q-TOF LC/MS|6570 Q-TOF LC/MS|66|68|6th|7-Cyanoquinocarcinol|7-Ethyl-10-Hydroxycamptothecin|7-Hydroxystaurosporine|70|7000 Triple Quadrupole GC/MS System|7000A Triple Quadrupole GC/MS|7000B Triple Quadrupole GC/MS|71|7200 GC/Q-TOF|73|7800 Quadrupole ICP-MS|7th|8-Azaguanine|80|8000/0|8000/1|8000/3|8000/6|8000/9|8001/0|8001/1|8001/3|8002/3|8003/3|8004/3|8005/0|8005/3|8010/0|8010/2|8010/3|8010/6|8010/9|8011/0|8011/3|8012/3|8013/3|8014/3|8015/3|8020/3|8020/6|8021/3|8022/3|8023/3|8030/3|8031/3|8032/3|8033/3|8034/3|8035/3|8040/0|8040/1|8040/3|8041/3|8041/34|8041/6|8042/3|8043/3|8044/3|8045/3|8046/3|8046/6|8050/0|8050/2|8050/3|8051/0|8051/3|8052/0|8052/2|8052/3|8053/0|8060/0|8070/2|8070/3|8070/33|8070/6|8071/2|8071/3|8072/3|8073/3|8074/3|8075/3|8076/2|8076/3|8077/0|8077/2|8078/3|8080/2|8081/2|8082/3|8083/3|8084/3|8085/3|8086/3|8090/1|8090/3|8091/3|8092/3|8093/3|8094/3|8095/3|8096/0|8097/3|8098/3|81|8100/0|8101/0|8102/0|8102/3|8103/0|8110/0|8110/3|8120/0|8120/1|8120/2|8120/3|8121/0|8121/1|8121/3|8122/3|8123/3|8124/3|8130/1|8130/2|8130/3|8131/3|8140/0|8140/1|8140/2|8140/3|8140/33|8140/6|8141/3|8142/3|8143/3|8144/3|8145/3|8146/0|8147/0|8147/3|8148/0|8148/2|8149/0|8150/0|8150/1|8150/3|8151/0|8151/3|8152/1|8152/3|8153/1|8153/3|8154/3|8155/1|8155/3|8156/1|8156/3|8158/1|8160/0|8160/3|8161/0|8161/3|8162/3|8163/0|8163/2|8163/3|8170/0|8170/3|8171/3|8172/3|8173/3|8174/3|8175/3|8180/3|8190/0|8190/3|8191/0|82|8200/0|8200/3|8201/2|8201/3|8202/0|8204/0|8210/0|8210/2|8210/3|8211/0|8211/3|8212/0|8213/0|8213/3|8214/3|8215/3|8220/0|8220/3|8221/0|8221/3|8230/2|8230/3|8231/3|8240/1|8240/3|8240/6|8241/3|8242/1|8242/3|8243/3|8244/3|8245/1|8245/3|8246/3|8246/6|8247/3|8248/1|8249/3|8249/6|8250/1|8250/2|8250/3|8251/0|8251/3|8252/3|8253/3|8254/3|8255/3|8256/3|8257/3|8260/0|8260/3|8261/0|8261/2|8261/3|8262/3|8263/0|8263/2|8263/3|8264/0|8265/3|8270/0|8270/3|8271/0|8272/0|8272/3|8280/0|8280/3|8281/0|8281/3|8290/0|8290/3|8300/0|8300/3|8310/0|8310/3|8310/6|8311/1|8311/3|8311/6|8312/3|8313/0|8313/1|8313/3|8314/3|8315/3|8316/3|8317/3|8318/3|8319/3|8320/3|8321/0|8322/0|8322/3|8323/0|8323/3|8324/0|8325/0|8330/0|8330/1|8330/3|8331/3|8332/3|8333/0|8333/3|8334/0|8335/3|8336/0|8337/3|8339/3|8340/3|8341/3|8342/3|8343/2|8343/3|8344/3|8345/3|8346/3|8347/3|8350/3|8360/1|8361/0|8370/0|8370/1|8370/3|8371/0|8372/0|8373/0|8374/0|8375/0|8380/0|8380/1|8380/2|8380/3|8380/6|8381/0|8381/1|8381/3|8382/3|8383/3|8384/3|8390/0|8390/3|8391/0|8392/0|8400/0|8400/1|8400/3|8401/0|8401/3|8402/0|8402/3|8403/0|8403/3|8404/0|8405/0|8406/0|8407/0|8407/3|8408/0|8408/1|8408/3|8409/0|8409/3|8410/0|8410/3|8413/3|8420/0|8420/3|8430/1|8430/3|8440/0|8440/3|8441/0|8441/2|8441/3|8441/6|8442/1|8443/0|8444/1|8450/0|8450/3|8451/1|8452/1|8452/3|8453/0|8453/2|8453/3|8454/0|8460/0|8460/2|8460/3|8461/0|8461/3|8461/6|8462/1|8463/1|8470/0|8470/2|8470/3|8471/0|8471/1|8471/3|8472/1|8473/1|8474/1|8474/3|8480/0|8480/1|8480/3|8480/6|8481/3|8482/3|8482/6|8490/3|8490/6|85|8500/2|8500/3|8500/6|8501/2|8501/3|8502/3|8503/0|8503/2|8503/3|8504/0|8504/2|8504/3|8505/0|8506/0|8507/2|8507/3|8508/3|8509/2|8509/3|8510/3|8512/3|8513/3|8514/3|8519/2|8520/2|8520/3|8521/1|8521/3|8522/1|8522/2|8522/3|8522/6|8523/3|8524/3|8525/3|8530/3|8540/3|8541/3|8542/3|8543/3|8550/0|8550/1|8550/3|8551/3|8552/3|8560/0|8560/3|8561/0|8562/3|8570/3|8571/3|8572/3|8573/3|8574/3|8575/3|8576/3|8580/0|8580/1|8580/3|8581/1|8581/3|8582/1|8582/3|8583/1|8583/3|8584/1|8584/3|8585/1|8585/3|8586/3|8587/0|8588/3|8589/3|8590/1|8591/1|8592/1|8593/1|8594/1|86|8600/0|8600/3|8601/0|8602/0|8610/0|8620/1|8620/3|8621/1|8622/1|8623/1|8630/0|8630/1|8630/3|8631/0|8631/1|8631/3|8632/1|8633/1|8634/1|8634/3|8640/1|8640/3|8641/0|8642/1|8650/0|8650/1|8650/3|8660/0|8670/0|8670/3|8671/0|8680/0|8680/1|8680/3|8681/1|8682/1|8683/0|8690/1|8691/1|8692/1|8693/1|8693/3|87|8700/0|8700/3|8710/3|8711/0|8711/3|8712/0|8713/0|8714/3|8720/0|8720/2|8720/3|8720/6|8721/3|8722/0|8722/3|8723/0|8723/3|8725/0|8726/0|8727/0|8728/0|8728/1|8728/3|8730/0|8730/3|8740/0|8740/3|8741/2|8741/3|8742/2|8742/3|8743/3|8744/3|8745/3|8746/3|8750/0|8760/0|8761/0|8761/1|8761/3|8762/1|8770/0|8770/3|8771/0|8771/3|8772/0|8772/3|8773/3|8774/3|8780/0|8780/3|8790/0|8800 Triple Quadrupole ICP-MS|8800/0|8800/3|8800/6|8800/9|8801/3|8801/6|8802/3|8803/3|8804/3|8804/6|8805/3|8806/3|8806/6|8810/0|8810/1|8810/3|8811/0|8811/1|8811/3|8812/0|8812/3|8813/0|8813/3|8814/3|8815/0|8815/1|8815/3|8820/0|8821/1|8822/1|8823/0|8824/0|8824/1|8825/0|8825/1|8825/3|8826/0|8827/1|8830/0|8830/1|8830/3|8831/0|8832/0|8832/3|8833/3|8834/1|8835/1|8836/1|8840/0|8840/3|8841/1|8842/0|8842/3|8850/0|8850/1|8850/3|8851/0|8851/3|8852/0|8852/3|8853/3|8854/0|8854/3|8855/3|8856/0|8857/0|8857/3|8858/3|8860/0|8861/0|8862/0|8870/0|8880/0|8881/0|8890/0|8890/1|8890/3|8891/0|8891/3|8892/0|8893/0|8894/0|8894/3|8895/0|8895/3|8896/3|8897/1|8898/1|8900/0|8900/3|8901/3|8902/3|8903/0|8904/0|8905/0|8910/3|8912/3|8920/3|8920/6|8921/3|8930/0|8930/3|8931/3|8932/0|8933/3|8934/3|8935/0|8935/1|8935/3|8936/0|8936/1|8936/3|8940/0|8940/3|8941/3|8950/3|8950/6|8951/3|8959/0|8959/1|8959/3|8960/1|8960/3|8963/3|8964/3|8965/0|8966/0|8967/0|8970/3|8971/3|8972/3|8973/3|8974/1|8975/1|8980/3|8981/3|8982/0|8982/3|8983/0|8983/3|8990/0|8990/1|8990/3|8991/3|8th|9-Ethyl 6-Mercaptopurine|90|9000/0|9000/1|9000/3|9010/0|9011/0|9012/0|9013/0|9014/0|9014/1|9014/3|9015/0|9015/1|9015/3|9016/0|9020/0|9020/1|9020/3|9030/0|9040/0|9040/3|9041/3|9042/3|9043/3|9044/3|9045/3|9050/0|9050/3|9051/0|9051/3|9052/0|9052/3|9053/3|9054/0|9055/0|9055/1|9060/3|9061/3|9062/3|9063/3|9064/2|9064/3|9065/3|9070/3|9071/3|9072/3|9073/1|9080/0|9080/1|9080/3|9081/3|9082/3|9083/3|9084/0|9084/3|9085/3|9086/3|9090/0|9090/3|9091/1|9100/0|9100/1|9100/3|9101/3|9102/3|9103/0|9104/1|9105/3|9110/0|9110/1|9110/3|9120/0|9120/3|9121/0|9122/0|9123/0|9124/3|9125/0|9130/0|9130/1|9130/3|9131/0|9132/0|9133/1|9133/3|9135/1|9136/1|9137/3|9140/3|9141/0|9142/0|9150/0|9150/1|9150/3|9160/0|9161/0|9161/1|9170/0|9170/3|9171/0|9172/0|9173/0|9174/0|9174/1|9175/0|9180/0|9180/3|9180/6|9181/3|9182/3|9183/3|9184/3|9185/3|9186/3|9187/3|9191/0|9192/3|9193/3|9194/3|9195/3|9200/0|9200/1|9210/0|9210/1|9220/0|9220/1|9220/3|9221/0|9221/3|9230/0|9230/3|9231/3|9240/3|9241/0|9242/3|9243/3|9250/1|9250/3|9251/1|9251/3|9252/0|9252/3|9260/3|9261/3|9262/0|9270/0|9270/1|9270/3|9271/0|9272/0|9273/0|9274/0|9275/0|9280/0|9281/0|9282/0|9290/0|9290/3|9300/0|9301/0|9302/0|9302/3|9310/0|9310/3|9311/0|9312/0|9320/0|9321/0|9322/0|9330/0|9330/3|9340/0|9341/1|9341/3|9342/3|9350/1|9351/1|9352/1|9360/1|9361/1|9362/3|9363/0|9364/3|9365/3|9370/3|9371/3|9372/3|9373/0|9380/3|9381/3|9382/3|9383/1|9384/1|9385/3|9390/0|9390/1|9390/3|9391/3|9392/3|9393/3|9394/1|9395/3|9396/3|9400/3|9401/3|9410/3|9411/3|9412/1|9413/0|9420/3|9421/1|9423/3|9424/3|9425/3|9430/3|9431/1|9432/1|9440/3|9440/6|9441/3|9442/1|9442/3|9444/1|9445/3|9450/3|9451/3|9460/3|9470/3|9471/3|9472/3|9473/3|9474/3|9475/3|9476/3|9477/3|9478/3|9480/3|9490/0|9490/3|9491/0|9492/0|9493/0|9500/3|9501/0|9501/3|9502/0|9502/3|9503/3|9504/3|9505/1|9505/3|9506/1|9507/0|9508/3|9509/1|9510/0|9510/3|9511/3|9512/3|9513/3|9514/1|9520/3|9521/3|9522/3|9523/3|9530/0|9530/1|9530/3|9531/0|9532/0|9533/0|9534/0|9535/0|9537/0|9538/1|9538/3|9539/1|9539/3|9540/0|9540/1|9540/3|9541/0|9542/3|9550/0|9560/0|9560/1|9560/3|9561/3|9562/0|9570/0|9571/0|9571/3|9580/0|9580/3|9581/3|9582/0|9590/3|9591/3|9596/3|9597/3|9650/3|9651/3|9652/3|9653/3|9654/3|9655/3|9659/3|9661/3|9662/3|9663/3|9664/3|9665/3|9667/3|9670/3|9671/3|9673/3|9675/3|9678/3|9679/3|9680/3|9684/3|9687/3|9688/3|9689/3|9690/3|9691/3|9695/3|9698/3|9699/3|9700/3|9701/3|9702/3|9705/3|9708/3|9709/3|9712/3|9714/3|9716/3|9717/3|9718/3|9719/3|9724/3|9725/3|9726/3|9727/3|9728/3|9729/3|9731/3|9732/3|9733/3|9734/3|9735/3|9737/3|9738/3|9740/1|9740/3|9741/1|9741/3|9742/3|9750/3|9751/1|9751/3|9752/1|9753/1|9754/3|9755/3|9756/3|9757/3|9758/3|9759/3|9760/3|9761/3|9762/3|9764/3|9765/1|9766/1|9767/1|9768/1|9769/1|9800/3|9801/3|9805/3|9806/3|9807/3|9808/3|9809/3|9811/3|9812/3|9813/3|9814/3|9815/3|9816/3|9817/3|9818/3|9820/3|9823/3|9826/3|9827/3|9831/3|9832/3|9833/3|9834/3|9835/3|9836/3|9837/3|9840/3|9860/3|9861/3|9863/3|9865/3|9866/3|9867/3|9869/3|9870/3|9871/3|9872/3|9873/3|9874/3|9875/3|9876/3|9891/3|9895/3|9896/3|9897/3|9898/1|9898/3|99|9910/3|9911/3|9920/3|9930/3|9931/3|9940/3|9945/3|9946/3|9948/3|9950/3|9960/3|9961/3|9962/3|9963/3|9964/3|9965/3|9966/3|9967/3|9970/1|9971/1|9971/3|9975/3|9980/3|9982/3|9983/3|9984/3|9985/3|9986/3|9987/3|9989/3|9991/3|9992/3|99mTc Bone Scintigraphy|9H-Purine-6Thio-98D|A|A081105|A081801|A2A Receptor Antagonist EOS100850|A5|A6|ACQUITY UPLC|ACQUITY UPLC H-Class|ACQUITY UPLC H-Class Bio|ACQUITY UPLC I-Class|ACQUITY UPLC Systems with 2D Technology|ACTH-producing tumor|ADF|ADH-1|AE37 Peptide/GM-CSF Vaccine|AEE788|AIN III|AJ-Adjuvant Therapy|AJCC v6 Stage|AJCC v7 Stage|AJCC v8 Stage|AKR1C3-activated Prodrug OBI-3424|AKT 1/2 Inhibitor BAY1125976|AKT Inhibitor ARQ 092|ALK Inhibitor|ALK Inhibitor ASP3026|ALK Inhibitor PLB 1003|ALK Inhibitor RO5424802|ALK Inhibitor TAE684|ALK Inhibitor WX-0593|ALK positive large B-cell lymphoma|ALK-2 Inhibitor TP-0184|ALK-FAK Inhibitor CEP-37440|ALK-Positive Large B-Cell Lymphoma|ALK/FAK/Pyk2 Inhibitor CT-707|ALK/ROS1/Met Inhibitor TQ-B3101|ALK/TRK Inhibitor TSR-011|ALK/c-Met Inhibitor  TQ-B3139|AML M6|APC8015F|APE1/Ref-1 Redox Inhibitor APX3330|API 100|API 100LC|API 150EX|API 150EX Prep|API 165|API 2000|API 300|API 3000|API 3200|API 350|API 365|API 4000|API 5000|API-US|AQUA|AR Antagonist BMS-641988|ARC Fusion Protein SL-279252|ASCAT2|ASP4132|ATAC-Seq|ATM Inhibitor M 3541|ATM Kinase Inhibitor AZD0156|ATM Kinase Inhibitor AZD1390|ATR Inhibitor RP-3500|ATR Kinase Inhibitor BAY1895344|ATR Kinase Inhibitor M1774|ATR Kinase Inhibitor M6620|ATR Kinase Inhibitor VX-803|AXIMA Assurance Linear MALDI-TOF|AXIMA CFR MALDI-TOF|AXIMA Confidence MALDI-TOF|AXIMA Performance MALDI-TOF/TOF|AXIMA-CFR plus|AXIMA-QIT|AXL Inhibitor DS-1205c|AXL Inhibitor SLC-391|AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M|AXL/ FLT3/VEGFR2 Inhibitor KC1036|Abagovomab|Abarelix|Abdomen|Abdomen, NOS|Abdomen, total|Abdominal (Mesenteric) Fibromatosis|Abdominal Distension|Abdominal Infection|Abdominal Pain|Abdominal Soft Tissue Necrosis|Abdominal Wall|Abdominal desmoid|Abdominal esophagus|Abdominal fibromatosis|Abdomino-perineal Resection of Rectum|Abducens Nerve Disorder|Abemaciclib|Abemaciclib Mesylate|Abexinostat|Abexinostat Tosylate|Abiraterone|Abiraterone Acetate|Abituzumab|Ablation, Cryo|Ablation, Ethanol Injection|Ablation, Microwave|Ablation, NOS|Ablation, Radiofrequency|Ablation, Radiosurgical|Abnormal|Abnormal Glucose Level|Absent|Absolute quantitation analysis|Acai Berry Juice|Acalabrutinib|Acalisib|Accela PDA|Acceptable treatment for TCGA tumor|Accessory Nerve Disorder|Accessory sinus, NOS|Accessory sinuses|Accidental building fire smoke|Accidental fire smoke, NOS|Accidental fire smoke, grass|Accidental forest fire smoke|Accidental vehicle fire smoke|Aceglatone|Acetabulum|Acetate|Acetylcysteine|Acetylome|Achromic nevus|Acidophil adenocarcinoma|Acidophil adenoma|Acidophil carcinoma|Acidosis|Acinar Cell Adenoma|Acinar Cell Carcinoma|Acinar Cell Neoplasm|Acinar Cell Neoplasms|Acinar adenocarcinoma|Acinar adenocarcinoma, sarcomatoid|Acinar adenoma|Acinar carcinoma|Acinar cell adenoma|Acinar cell carcinoma|Acinar cell cystadenocarcinoma|Acinar cell tumor|Acinic cell adenocarcinoma|Acinic cell adenoma|Acinic cell tumor|Acitretin|Acivicin|Aclacinomycin B|Aclarubicin|Acodazole|Acodazole Hydrochloride|Acolbifene Hydrochloride|Acoustic Nerve Disorder NOS|Acoustic Schwannoma|Acoustic nerve|Acoustic neuroma|Acquired Cystic Disease-Associated Renal Cell Carcinoma|Acquired Progressive Lymphangioma|Acquired cystic disease-associated renal cell carcinoma (RCC)|Acquired tufted hemangioma|Acquity SQD|Acquity TQD|Acquity UPLC FLR|Acquity UPLC PDA|Acral Lentiginous Melanoma|Acral lentiginous melanoma, malignant|Acridine|Acridine Carboxamide|Acronine|Actinium Ac 225 Lintuzumab|Actinium Ac 225-FPI-1434|Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591|Actinomycin C2|Actinomycin C3|Actinomycin F1|Activated Partial Thromboplastin Time Prolonged|Activin Type 2B Receptor Fc Fusion Protein STM 434|Acute Basophilic Leukemia|Acute Bilineal Leukemia|Acute Biphenotypic Leukemia|Acute Coronary Syndrome|Acute Erythroid Leukemia|Acute Kidney Injury|Acute Leukemia|Acute Leukemia of Ambiguous Lineage (ALAL)|Acute Lymphoblastic Leukemia|Acute Megakaryoblastic Leukemia|Acute Monoblastic Leukemia|Acute Monoblastic and Monocytic Leukemia|Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1|Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia Not Otherwise Specified|Acute Myeloid Leukemia with Maturation|Acute Myeloid Leukemia with Minimal Differentiation|Acute Myeloid Leukemia with Multilineage Dysplasia|Acute Myeloid Leukemia with Mutated CEBPA|Acute Myeloid Leukemia with Mutated NPM1|Acute Myeloid Leukemia with Myelodysplasia-Related Changes|Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11|Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11|Acute Myeloid Leukemia with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM|Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11|Acute Myeloid Leukemia with t(6;9) (p23;q34.1); DEK-NUP214|Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A|Acute Myeloid Leukemia without Maturation|Acute Myelomonocytic Leukemia|Acute Myelomonocytic Leukemia with Abnormal Eosinophils|Acute Panmyelosis with Myelofibrosis|Acute Promyelocytic Leukemia with PML-RARA|Acute Renal Failure|Acute Undifferentiated Leukemia|Acute basophilic leukaemia|Acute bilineal leukemia|Acute biphenotypic leukemia|Acute erythremia|Acute erythremic myelosis|Acute erythroid leukaemia|Acute granulocytic leukemia|Acute leukemia, Burkitt type|Acute leukemia, NOS|Acute lymphatic leukemia|Acute lymphoblastic leukemia (ALL)|Acute lymphoblastic leukemia, L2 type, NOS|Acute lymphoblastic leukemia, NOS|Acute lymphoblastic leukemia, mature B-cell type|Acute lymphoblastic leukemia, precursor cell type|Acute lymphoblastic leukemia-lymphoma, NOS|Acute lymphocytic leukemia|Acute lymphoid leukemia|Acute megakaryoblastic leukaemia|Acute mixed lineage leukemia|Acute monoblastic and monocytic leukemia|Acute monoblastic leukemia|Acute monocytic leukemia|Acute myeloblastic leukemia|Acute myelocytic leukemia|Acute myelofibrosis|Acute myelogenous leukemia|Acute myeloid leukaemia, t(8;21)(q22;q22)|Acute myeloid leukemia (AML)|Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1|Acute myeloid leukemia with abnormal marrow eosinophils (includes all variants)|Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1|Acute myeloid leukemia with maturation|Acute myeloid leukemia with multilineage dysplasia|Acute myeloid leukemia with mutated CEBPA|Acute myeloid leukemia with mutated NPM1|Acute myeloid leukemia with myelodysplasia-related changes|Acute myeloid leukemia with prior myelodysplastic syndrome|Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214|Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1|Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL|Acute myeloid leukemia without maturation|Acute myeloid leukemia without prior myelodysplastic syndrome|Acute myeloid leukemia, AML1(CBF-alpha)/ETO|Acute myeloid leukemia, CBF-beta/MYH11|Acute myeloid leukemia, M6 type|Acute myeloid leukemia, MLL|Acute myeloid leukemia, NOS|Acute myeloid leukemia, PML/RAR-alpha|Acute myeloid leukemia, inv(16)(p13;q22)|Acute myeloid leukemia, minimal differentiation|Acute myeloid leukemia, t(15:17)(g22;q11-12)|Acute myeloid leukemia, t(16;16)(p 13;q 11)|Acute myelomonocytic leukemia|Acute myelomonocytic leukemia with abnormal eosinophils|Acute myelosclerosis, NOS|Acute myloid leukemia, 11q23 abnormalities|Acute non-lymphocytic leukemia|Acute panmyelosis with myelofibrosis|Acute panmyelosis, NOS|Acute progressive histiocytosis X|Acute promyelocytic leukaemia, PML-RAR-alpha|Acute promyelocytic leukaemia, t(15;17)(q22;q11-12)|Acute promyelocytic leukemia, NOS|Acyclic Nucleoside Phosphonate Prodrug ABI-1968|Ad-RTS-hIL-12|Adagloxad Simolenin|Adamantinoma|Adamantinoma of long bones|Adamantinoma, NOS|Adamantinoma, malignant|Adamantinomatous Craniopharyngioma|Adavosertib|Additional - New Primary|Additional Metastatic|Adecatumumab|Adenoacanthoma|Adenoameloblastoma|Adenocarcinoid tumor|Adenocarcinoma|Adenocarcinoma In Situ|Adenocarcinoma In Situ in Adenomatous Polyp|Adenocarcinoma In Situ in Tubular Adenoma|Adenocarcinoma In Situ in Tubulovillous Adenoma|Adenocarcinoma In Situ in Villous Adenoma|Adenocarcinoma In Situ in a Polyp|Adenocarcinoma admixed with neuroendocrine carcinoma|Adenocarcinoma combined with other types of carcinoma|Adenocarcinoma in Adenomatous Polyp|Adenocarcinoma in Adenomatous Polyposis Coli|Adenocarcinoma in Multiple Adenomatous Polyps|Adenocarcinoma in Tubular Adenoma|Adenocarcinoma in Tubulovillous Adenoma|Adenocarcinoma in Villous Adenoma|Adenocarcinoma in a polyp, NOS|Adenocarcinoma in adenomatous polyp|Adenocarcinoma in adenomatous polyposis coli|Adenocarcinoma in multiple adenomatous polyps|Adenocarcinoma in polypoid adenoma|Adenocarcinoma in situ in a polyp, NOS|Adenocarcinoma in situ in adenomatous polyp|Adenocarcinoma in situ in polypoid adenoma|Adenocarcinoma in situ in tubular adenoma|Adenocarcinoma in situ in tubulovillous adenoma|Adenocarcinoma in situ in villous adenoma|Adenocarcinoma in situ, NOS|Adenocarcinoma in situ, mucinous|Adenocarcinoma in situ, non-mucinous|Adenocarcinoma in tubolovillous adenoma|Adenocarcinoma in tubular adenoma|Adenocarcinoma in villous adenoma|Adenocarcinoma of anal ducts|Adenocarcinoma of anal glands|Adenocarcinoma of rete ovarii|Adenocarcinoma with Apocrine Metaplasia|Adenocarcinoma with Cartilaginous Metaplasia|Adenocarcinoma with Cartilaginous and Osseous Metaplasia|Adenocarcinoma with Neuroendocrine Differentiation|Adenocarcinoma with Osseous Metaplasia|Adenocarcinoma with Spindle Cell Metaplasia|Adenocarcinoma with Squamous Metaplasia|Adenocarcinoma with apocrine metaplasia|Adenocarcinoma with cartilaginous and osseous metaplasia|Adenocarcinoma with cartilaginous metaplasia|Adenocarcinoma with mixed subtypes|Adenocarcinoma with neuroendocrine differentiation|Adenocarcinoma with osseous metaplasia|Adenocarcinoma with spindle cell metaplasia|Adenocarcinoma with squamous metaplasia|Adenocarcinoma, Endocervical Type|Adenocarcinoma, NOS|Adenocarcinoma, cribriform comedo-type|Adenocarcinoma, cylindroid|Adenocarcinoma, diffuse type|Adenocarcinoma, endocervical type|Adenocarcinoma, intestinal type|Adenocarcinoma, metastatic, NOS|Adenocarcinoma, pancreatobiliary type|Adenocystic carcinoma|Adenofibroma, NOS|Adenoid|Adenoid Cystic Carcinoma|Adenoid basal carcinoma|Adenoid cystic carcinoma|Adenolipoma|Adenolymphoma|Adenoma|Adenoma of nipple|Adenoma, NOS|Adenomas and Adenocarcinomas|Adenomatoid Odontogenic Tumor|Adenomatoid Tumor|Adenomatoid odontogenic tumor|Adenomatoid tumor, NOS|Adenomatosis, NOS|Adenomatous Polyp|Adenomatous Polyposis Coli|Adenomatous polyp, NOS|Adenomatous polyposis coli|Adenomyoepithelioma|Adenomyoepithelioma with carcinoma|Adenomyoma|Adenosarcoma|Adenosine A2A Receptor Antagonist AZD4635|Adenosine A2A Receptor Antagonist CS3005|Adenosine A2A Receptor Antagonist NIR178|Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999|Adenosine A2A/A2B Receptor Antagonist AB928|Adenosine A2B Receptor Antagonist PBF-1129|Adenosis (Atypical Adenomatous Hyperplasia)|Adenosquamous Carcinoma|Adenosquamous carcinoma|Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201|Adenoviral Brachyury Vaccine ETBX-051|Adenoviral Cancer Vaccine PF-06936308|Adenoviral MUC1 Vaccine ETBX-061|Adenoviral PSA Vaccine ETBX-071|Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001|Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP|Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901|Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE|Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918|Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931|Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3|Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001|Aderbasib|Adherent Cell Line|Adipose|Adjacent (< or = 2cm)|Adjuvant|Administrative Compliance|Adnexal Carcinoma|Adnexal and Skin Appendage Neoplasms|Adnexal carcinoma|Adnexal tumor, benign|Adopted Brother|Adopted Daughter|Adopted Sister|Adopted Son|Adoptive Brother|Adoptive Father|Adoptive Mother|Adoptive Sister|Adrenal|Adrenal Cortex Adenoma|Adrenal Cortex Carcinoma|Adrenal Cortex Clear Cell Adenoma|Adrenal Cortex Compact Cell Adenoma|Adrenal Cortex Glomerulosa Cell Adenoma|Adrenal Cortex Mixed Cell Adenoma|Adrenal Cortex Neoplasm|Adrenal Gland|Adrenal Gland Cancer|Adrenal Gland Myelolipoma|Adrenal Gland Pheochromocytoma|Adrenal Insufficiency|Adrenal Rest Tumor|Adrenal cortical adenocarcinoma|Adrenal cortical adenoma, NOS|Adrenal cortical adenoma, clear cell|Adrenal cortical adenoma, compact cell|Adrenal cortical adenoma, glomerulosa cell|Adrenal cortical adenoma, mixed cell|Adrenal cortical adenoma, pigmented|Adrenal cortical carcinoma|Adrenal cortical tumor, NOS|Adrenal cortical tumor, benign|Adrenal cortical tumor, malignant|Adrenal gland|Adrenal gland, NOS|Adrenal medullary paraganglioma|Adrenal medullary paraganglioma, malignant|Adrenal rest tumor|Adrenocortical Carcinoma|Adrenocortical Insufficiency|Adult Cystic Nephroma|Adult Cystic Teratoma|Adult Pleomorphic Rhabdomyosarcoma|Adult Respiratory Distress Syndrome|Adult T-Cell Leukemia/Lymphoma|Adult T-cell leukemia|Adult T-cell leukemia/lymphoma (HTLV-1 positive) (includes all variants)|Adult T-cell lymphoma|Adult T-cell lymphoma/leukemia|Adult Teratoma|Adult Type Granulosa Cell Tumor|Adult cystic teratoma|Adult granulosa cell tumor|Adult rhabdomyoma|Adult teratoma, NOS|Adverse|Adverse Event|Aerosol Gemcitabine|Aerosolized Aldesleukin|Aerosolized Liposomal Rubitecan|Afatinib|Afatinib Dimaleate|Affymetrix SNP 6.0|Afghanistan|Afimoxifene|After 60 Minutes|Afuresertib|Agatolimod Sodium|Agerafenib|Aggregated Somatic Mutation|Aggressive NK-Cell Leukemia|Aggressive NK-cell leukaemia|Aggressive Osteoblastoma|Aggressive Systemic Mastocytosis|Aggressive angiomyxoma|Aggressive digital papillary adenoma|Aggressive fibromatosis|Aggressive osteoblastoma|Aggressive systemic mastocytosis|Agilent|Agitation|Aglatimagene Besadenovec|Agnogenic myeloid metaplasia|Agonistic Anti-CD40 Monoclonal Antibody ADC-1013|Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949|Agonistic Anti-OX40 Monoclonal Antibody MEDI6469|Aircraft smoke|Akathisia|Akt Inhibitor LY2780301|Akt Inhibitor MK2206|Akt Inhibitor SR13668|Akt/ERK Inhibitor ONC201|Alacizumab Pegol|Alanine Aminotransferase Increased|Alanosine|Albania|Albumin-binding Cisplatin Prodrug BTP-114|Alcohol Consumption|Alcohol Intolerance|Alcoholic Liver Disease|Aldesleukin|Aldoxorubicin|Alectinib|Alefacept|Alemtuzumab|Alestramustine|Aleukemic Chronic Lymphocytic Leukemia|Aleukemic Leukemia|Aleukemic Lymphoid Leukemia|Aleukemic granulocytic leukemia|Aleukemic leukemia, NOS|Aleukemic lymphatic leukemia|Aleukemic lymphocytic leukemia|Aleukemic lymphoid leukemia|Aleukemic monocytic leukemia|Aleukemic myelogenous leukemia|Aleukemic myeloid leukemia|Alflutinib Mesylate|Algenpantucel-L|Algeria|Aligned Reads|Aligned Reads Index|Aliquot Ensemble Somatic Variant Merging and Masking|Alisertib|Alitretinoin|Alive|Alkaline Phosphatase Increased|Alkalosis|Alkotinib|Alkylating Agent-Related Acute Myeloid Leukemia|Alkylating Agent-Related Myelodysplastic Syndrome|Allele-specific Copy Number Segment|Allergic Reaction|Allergic Rhinitis|Allergies|Allergy, Animal, NOS|Allergy, Ant|Allergy, Bee|Allergy, Cat|Allergy, Dairy or Lactose|Allergy, Dog|Allergy, Eggs|Allergy, Food, NOS|Allergy, Fruit|Allergy, Meat|Allergy, Mold or Dust|Allergy, Nuts|Allergy, Processed Foods|Allergy, Seafood|Allergy, Wasp|Allodepleted T Cell Immunotherapeutic ATIR101|Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715|Allogeneic Anti-BCMA-CAR T-cells PBCAR269A|Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells|Allogeneic Anti-CD19 CAR T-cells ALLO-501A|Allogeneic Anti-CD19 Universal CAR-T Cells CTA101|Allogeneic Anti-CD19-CAR T-cells PBCAR0191|Allogeneic Anti-CD20 CAR T-cells LUCAR-20S|Allogeneic Anti-CD20-CAR T-cells PBCAR20A|Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22|Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100|Allogeneic CD56-positive CD3-negative Natural Killer Cells CYNK-001|Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001|Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120|Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130|Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A|Allogeneic Cellular Vaccine 1650-G|Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM|Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine|Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine|Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo|Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo|Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2|Allogeneic Irradiated Melanoma Cell Vaccine CSF470|Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307|Allogeneic Melanoma Vaccine AGI-101H|Allogeneic Natural Killer Cell Line MG4101|Allogeneic Natural Killer Cell Line NK-92|Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01|Allogeneic Renal Cell Carcinoma Vaccine MGN1601|Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19|Allosteric ErbB Inhibitor BDTX-189|Allovectin-7|Allprep FFPE DNA|Allprep RNA Extraction|Almurtide|Alobresib|Alofanib|Alopecia|Alpelisib|Alpha Galactosylceramide|Alpha Heavy Chain Disease|Alpha V Beta 1 Inhibitor ATN-161|Alpha V Beta 8 Antagonist PF-06940434|Alpha cell tumor, NOS|Alpha cell tumor, malignant|Alpha heavy chain disease|Alpha-1 Antitrypsin|Alpha-1 Antitrypsin Deficiency|Alpha-Gal AGI-134|Alpha-Glucosidase Inhibitor|Alpha-Thioguanine Deoxyriboside|Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H|Alpha-tocopheryloxyacetic Acid|Alsevalimab|Altered Mental Status|Alternate sample pipeline|Altiratinib|Altretamine|Alveolar Adenoma|Alveolar Rhabdomyosarcoma|Alveolar Ridge|Alveolar Soft Part Sarcoma|Alveolar adenocarcinoma|Alveolar adenoma|Alveolar carcinoma|Alveolar cell carcinoma|Alveolar rhabdomyosarcoma|Alveolar soft part sarcoma|Alvespimycin|Alvespimycin Hydrochloride|Alvocidib|Alvocidib Hydrochloride|Alvocidib Prodrug TP-1287|Amatuximab|Ambamustine|Ambazone|Amber|Amblyomin-X|Amcasertib|Amelanotic Melanoma|Amelanotic melanoma|Ameloblastic Carcinoma|Ameloblastic Fibro-Odontoma|Ameloblastic Fibrodentinoma|Ameloblastic Fibroma|Ameloblastic Fibrosarcoma|Ameloblastic carcinoma|Ameloblastic fibro-odontoma|Ameloblastic fibro-odontosarcoma|Ameloblastic fibrodentinoma|Ameloblastic fibrodentinosarcoma|Ameloblastic fibroma|Ameloblastic fibrosarcoma|Ameloblastic odontosarcoma|Ameloblastic sarcoma|Ameloblastoma|Ameloblastoma, NOS|Ameloblastoma, malignant|American Indian or Alaska Native|Ametantrone|Amifostine|Amino Acid Injection|Aminocamptothecin|Aminocamptothecin Colloidal Dispersion|Aminoflavone Prodrug AFP464|Aminopterin|Aminopterin Sodium|AminoxyTMT|Amivantamab|Amnesia|Amniotic Fluid|Amolimogene Bepiplasmid|Amonafide L-Malate|Ampulla Of Vater|Ampulla of Vater|Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with High Grade Dysplasia|Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with Low Grade Dysplasia|Amrubicin|Amrubicin Hydrochloride|Amsacrine|Amsacrine Lactate|Amsilarotene|Amustaline|Amustaline Dihydrochloride|Amuvatinib|Amuvatinib Hydrochloride|Anakinra|Anal Canal|Anal Canal Cloacogenic Carcinoma|Anal Cancer (all types)|Anal Fistula|Anal Glands Adenocarcinoma|Anal Hemorrhage|Anal Intraepithelial Neoplasia 3|Anal Mucositis|Anal Necrosis|Anal Pain|Anal Sphincter|Anal Stenosis|Anal Ulcer|Anal canal|Anal intraepithelial neoplasia, grade III|Anal intraepithelial neoplasia, low grade|Analysis Metadata|Anaphylaxis|Anaplastic (Malignant) Meningioma|Anaplastic Astrocytoma|Anaplastic Astrocytoma, IDH-Mutant|Anaplastic Astrocytoma, IDH-Wildtype|Anaplastic Ependymoma|Anaplastic Ganglioglioma|Anaplastic Large Cell Lymphoma|Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Anaplastic Lymphoma|Anaplastic Medulloblastoma|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted|Anaplastic Pleomorphic Xanthoastrocytoma|Anaplastic astrocytoma, IDH-mutant|Anaplastic astrocytoma, IDH-wildtype|Anaplastic large B-cell lymphoma|Anaplastic large cell lymphoma, ALK negative|Anaplastic large cell lymphoma, ALK positive|Anaplastic large cell lymphoma, CD30+|Anaplastic large cell lymphoma, NOS|Anaplastic large cell lymphoma, T cell and Null cell type|Anaplastic medulloblastoma|Anaplastic oligoastrocytoma|Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted|Anaplastic pleomorphic xanthroastrocytoma|Anastrozole|Anaxirone|Ancient schwannoma|Ancillary Treatment|Ancitabine|Ancitabine Hydrochloride|Andecaliximab|Andorra|Androblastoma, NOS|Androblastoma, benign|Androblastoma, malignant|Androgen Antagonist APC-100|Androgen Deprivation Therapy (ADT)|Androgen Receptor Antagonist BAY 1161116|Androgen Receptor Antagonist SHR3680|Androgen Receptor Antagonist TAS3681|Androgen Receptor Antagonist TRC253|Androgen Receptor Antisense Oligonucleotide AZD5312|Androgen Receptor Antisense Oligonucleotide EZN-4176|Androgen Receptor Degrader ARV-110|Androgen Receptor Degrader CC-94676|Androgen Receptor Downregulator AZD3514|Androgen Receptor Inhibitor EPI-7386|Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118|Androgen Receptor/Glucocorticoid Receptor  Antagonist CB-03-10|Andrographolide|Androstane Steroid HE3235|Anemia|Anetumab Ravtansine|Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241|Angioblastic meningioma|Angioblastoma|Angiocentric Glioma|Angiocentric Immunoproliferative Lesion|Angiocentric T-cell lymphoma|Angiocentric glioma|Angiocentric immunoproliferative lesion|Angioendothelioma|Angioendotheliomatosis|Angiofibroma|Angiofibroma, NOS|Angiogenesis Inhibitor GT-111|Angiogenesis Inhibitor JI-101|Angiogenesis/Heparanase Inhibitor PG545|Angioimmunoblastic T-Cell Lymphoma|Angioimmunoblastic T-cell lymphoma|Angioimmunoblastic lymphadenopathy|Angioimmunoblastic lymphoma|Angiokeratoma|Angioleiomyoma|Angiolipoma|Angiolipoma, NOS|Angioma, NOS|Angiomatoid Fibrous Histiocytoma|Angiomatoid fibrous histiocytoma|Angiomatous Meningioma|Angiomatous meningioma|Angiomyofibroblastoma|Angiomyolipoma|Angiomyoma|Angiomyosarcoma|Angiomyxoma|Angiopoietin-2-specific Fusion Protein PF-04856884|Angiosarcoma|Angiotropic lymphoma|Angola|Anguilla|Anhydrous Enol-oxaloacetate|Anhydrovinblastine|Aniline Mustard|Ankle|Ankle Fracture|Anlotinib Hydrochloride|Annamycin|Annamycin Liposomal|Annonaceous Acetogenins|Annotated Somatic Mutation|Anopheles gambiae|Anorectal Infection|Anorectum|Anorexia|Anorgasmia|Ansamitomicin P-3|Antacids|Antecubital Fossa|Anterior 2/3 of tongue, NOS|Anterior Resection of Rectum|Anterior Surface of the Epiglottis|Anterior Wall of the Nasopharynx|Anterior floor of mouth|Anterior mediastinum|Anterior surface of epiglottis|Anterior wall of bladder|Anterior wall of nasopharynx|Anthramycin|Anthrapyrazole|Anti c-KIT Antibody-drug Conjugate LOP628|Anti-5T4 Antibody-Drug Conjugate PF-06263507|Anti-5T4 Antibody-drug Conjugate ASN004|Anti-5T4 Antibody-drug Conjugate SYD1875|Anti-A33 Monoclonal Antibody KRN330|Anti-A5B1 Integrin Monoclonal Antibody PF-04605412|Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087|Anti-AG7 Antibody Drug Conjugate AbGn-107|Anti-AGS-16 Monoclonal Antibody AGS-16M18|Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME|Anti-AGS-8 Monoclonal Antibody AGS-8M4|Anti-ANG2 Monoclonal Antibody MEDI-3617|Anti-APRIL Monoclonal Antibody BION-1301|Anti-AXL Fusion Protein AVB-S6-500|Anti-AXL/PBD Antibody-drug Conjugate ADCT-601|Anti-B7-H3 Antibody DS-5573a|Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a|Anti-B7-H4 Monoclonal Antibody FPA150|Anti-B7H3 Antibody-drug Conjugate MGC018|Anti-BCMA Antibody SEA-BCMA|Anti-BCMA Antibody-drug Conjugate AMG 224|Anti-BCMA Antibody-drug Conjugate CC-99712|Anti-BCMA Antibody-drug Conjugate GSK2857916|Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA|Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459|Anti-BCMA/CD3 BiTE Antibody AMG 420|Anti-BCMA/CD3 BiTE Antibody AMG 701|Anti-BCMA/CD3 BiTE Antibody REGN5458|Anti-BCMA/PBD ADC MEDI2228|Anti-BTLA Monoclonal Antibody TAB004|Anti-BTN3A Agonistic Monoclonal Antibody ICT01|Anti-C-met Monoclonal Antibody SAIT301|Anti-C4.4a Antibody-Drug Conjugate BAY1129980|Anti-C5aR Monoclonal Antibody IPH5401|Anti-CA19-9 Monoclonal Antibody 5B1|Anti-CA6-DM4 Immunoconjugate SAR566658|Anti-CCR7 Antibody-drug Conjugate JBH492|Anti-CD117 Monoclonal Antibody JSP191|Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1|Anti-CD123 ADC IMGN632|Anti-CD123 Monoclonal Antibody CSL360|Anti-CD123 Monoclonal Antibody KHK2823|Anti-CD123 x Anti-CD3 Bispecific Antibody XmAb1404|Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A|Anti-CD123/CD3 BiTE Antibody SAR440234|Anti-CD123/CD3 Bispecific Antibody APVO436|Anti-CD123/CD3 Bispecific Antibody JNJ-63709178|Anti-CD137 Agonistic Monoclonal Antibody ADG106|Anti-CD137 Agonistic Monoclonal Antibody AGEN2373|Anti-CD137 Agonistic Monoclonal Antibody ATOR-1017|Anti-CD137 Agonistic Monoclonal Antibody CTX-471|Anti-CD137 Agonistic Monoclonal Antibody LVGN6051|Anti-CD157 Monoclonal Antibody MEN1112|Anti-CD166 Probody-drug Conjugate CX-2009|Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003|Anti-CD19 Antibody-drug Conjugate SGN-CD19B|Anti-CD19 Monoclonal Antibody DI-B4|Anti-CD19 Monoclonal Antibody MDX-1342|Anti-CD19 Monoclonal Antibody MEDI-551|Anti-CD19 Monoclonal Antibody XmAb5574|Anti-CD19 iCAR NK Cells|Anti-CD19-DM4 Immunoconjugate SAR3419|Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL|Anti-CD19/CD22 CAR NK Cells|Anti-CD19/CD3 BiTE Antibody AMG 562|Anti-CD19/CD3 Tetravalent Antibody AFM11|Anti-CD20 Monoclonal Antibody B001|Anti-CD20 Monoclonal Antibody BAT4306F|Anti-CD20 Monoclonal Antibody MIL62|Anti-CD20 Monoclonal Antibody PRO131921|Anti-CD20 Monoclonal Antibody SCT400|Anti-CD20 Monoclonal Antibody TL011|Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002|Anti-CD20-engineered Toxin Body MT-3724|Anti-CD20/Anti-CD3 Bispecific IgM Antibody IGM2323|Anti-CD20/CD3 Monoclonal Antibody REGN1979|Anti-CD20/CD3 Monoclonal Antibody XmAb13676|Anti-CD205 Antibody-drug Conjugate OBT076|Anti-CD22 ADC TRPH-222|Anti-CD22 Monoclonal Antibody-MMAE Conjugate DCDT2980S|Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A|Anti-CD25 Monoclonal Antibody RO7296682|Anti-CD25-PBD Antibody-drug Conjugate ADCT-301|Anti-CD26 Monoclonal Antibody YS110|Anti-CD27 Agonistic Monoclonal Antibody MK-5890|Anti-CD27L Antibody-Drug Conjugate AMG 172|Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1)|Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044|Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody JNJ-64007957|Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody PF-06863135|Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05|Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564|Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119|Anti-CD3/CD20 Bispecific Antibody GEN3013|Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424|Anti-CD3/CD7-Ricin Toxin A Immunotoxin|Anti-CD30 Monoclonal Antibody MDX-1401|Anti-CD30 Monoclonal Antibody XmAb2513|Anti-CD30/CD16A Monoclonal Antibody AFM13|Anti-CD30/DM1 Antibody-drug Conjugate F0002|Anti-CD32B Monoclonal Antibody BI-1206|Anti-CD33 Antibody-drug Conjugate IMGN779|Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564|Anti-CD33 Monoclonal Antibody BI 836858|Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633|Anti-CD33/CD3 BiTE Antibody AMG 330|Anti-CD33/CD3 BiTE Antibody AMG 673|Anti-CD33/CD3 Bispecific Antibody GEM 333|Anti-CD33/CD3 Bispecific Antibody JNJ-67571244|Anti-CD352 Antibody-drug Conjugate SGN-CD352A|Anti-CD37 Antibody-Drug Conjugate IMGN529|Anti-CD37 Bispecific Monoclonal Antibody GEN3009|Anti-CD37 MMAE Antibody-drug Conjugate AGS67E|Anti-CD37 Monoclonal Antibody BI 836826|Anti-CD38 Antibody-drug Conjugate STI-6129|Anti-CD38 Monoclonal Antibody MOR03087|Anti-CD38 Monoclonal Antibody SAR442085|Anti-CD38 Monoclonal Antibody TAK-079|Anti-CD38-targeted IgG4-attenuated IFNa TAK-573|Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257|Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342|Anti-CD39 Monoclonal Antibody SRF617|Anti-CD39 Monoclonal Antibody TTX-030|Anti-CD40 Agonist Monoclonal Antibody ABBV-927|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Anti-CD40 Monoclonal Antibody Chi Lob 7/4|Anti-CD40 Monoclonal Antibody SEA-CD40|Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042|Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428|Anti-CD40L Fc-Fusion Protein BMS-986004|Anti-CD44 Monoclonal Antibody RO5429083|Anti-CD45 Monoclonal Antibody AHN-12|Anti-CD46 Antibody-drug Conjugate FOR46|Anti-CD47 ADC SGN-CD47M|Anti-CD47 Monoclonal Antibody AO-176|Anti-CD47 Monoclonal Antibody CC-90002|Anti-CD47 Monoclonal Antibody Hu5F9-G4|Anti-CD47 Monoclonal Antibody IBI188|Anti-CD47 Monoclonal Antibody IMC-002|Anti-CD47 Monoclonal Antibody SHR-1603|Anti-CD47 Monoclonal Antibody SRF231|Anti-CD47 Monoclonal Antibody TJC4|Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801|Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A|Anti-CD52 Monoclonal Antibody ALLO-647|Anti-CD70 Antibody-Drug Conjugate MDX-1203|Anti-CD70 Antibody-drug Conjugate SGN-CD70A|Anti-CD70 CAR-expressing T Lymphocytes|Anti-CD70 Monoclonal Antibody MDX-1411|Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029|Anti-CD73 Monoclonal Antibody BMS-986179|Anti-CD73 Monoclonal Antibody CPI-006|Anti-CD73 Monoclonal Antibody NZV930|Anti-CD73 Monoclonal Antibody TJ4309|Anti-CD74 Antibody-drug Conjugate STRO-001|Anti-CD98 Monoclonal Antibody IGN523|Anti-CDH6 Antibody-drug Conjugate HKT288|Anti-CEA BiTE Monoclonal Antibody AMG211|Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody|Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2|Anti-CEACAM1 Monoclonal Antibody CM-24|Anti-CEACAM5 Antibody-Drug Conjugate SAR408701|Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47|Anti-CEACAM6 Antibody BAY1834942|Anti-CLDN6 Monoclonal Antibody ASP1650|Anti-CLEC12A/CD3 Bispecific Antibody MCLA117|Anti-CLEVER-1 Monoclonal Antibody FP-1305|Anti-CSF1 Monoclonal Antibody PD-0360324|Anti-CSF1R Monoclonal Antibody IMC-CS4|Anti-CSF1R Monoclonal Antibody SNDX-6352|Anti-CTGF Monoclonal Antibody FG-3019|Anti-CTLA-4 Monoclonal Antibody ADG116|Anti-CTLA-4 Monoclonal Antibody ADU-1604|Anti-CTLA-4 Monoclonal Antibody AGEN1181|Anti-CTLA-4 Monoclonal Antibody BCD-145|Anti-CTLA-4 Monoclonal Antibody HBM4003|Anti-CTLA-4 Monoclonal Antibody MK-1308|Anti-CTLA-4 Monoclonal Antibody ONC-392|Anti-CTLA-4 Monoclonal Antibody REGN4659|Anti-CTLA-4 Probody BMS-986288|Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217|Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841|Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015|Anti-CTLA4 Antibody Fc Fusion Protein KN044|Anti-CTLA4 Monoclonal Antibody BMS-986218|Anti-CXCR4 Monoclonal Antibody PF-06747143|Anti-Claudin18.2 Monoclonal Antibody TST001|Anti-DKK-1 Monoclonal Antibody LY2812176|Anti-DKK1 Monoclonal Antibody BHQ880|Anti-DLL3/CD3 BiTE Antibody AMG 757|Anti-DLL4 Monoclonal Antibody MEDI0639|Anti-DLL4/VEGF Bispecific Monoclonal Antibody OMP-305B83|Anti-DR5 Agonist Monoclonal Antibody TRA-8|Anti-DR5 Agonistic Antibody DS-8273a|Anti-DR5 Agonistic Monoclonal Antibody INBRX-109|Anti-Denatured Collagen Monoclonal Antibody TRC093|Anti-EGFR Monoclonal Antibody CPGJ 602|Anti-EGFR Monoclonal Antibody EMD 55900|Anti-EGFR Monoclonal Antibody GC1118|Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX|Anti-EGFR Monoclonal Antibody HLX-07|Anti-EGFR Monoclonal Antibody Mixture MM-151|Anti-EGFR Monoclonal Antibody RO5083945|Anti-EGFR Monoclonal Antibody SCT200|Anti-EGFR Monoclonal Antibody SYN004|Anti-EGFR TAP Antibody-drug Conjugate IMGN289|Anti-EGFR/CD16A Bispecific Antibody AFM24|Anti-EGFR/DM1 Antibody-drug Conjugate AVID100|Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013|Anti-EGFR/PBD Antibody-drug Conjugate ABBV-321|Anti-EGFR/c-Met Bispecific Antibody EMB-01|Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372|Anti-EGFRvIII Antibody Drug Conjugate AMG 595|Anti-EGFRvIII Immunotoxin MR1-1|Anti-EGFRvIII/CD3 BiTE Antibody AMG 596|Anti-EGP-2 Immunotoxin MOC31-PE|Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F|Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F|Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A|Anti-Ep-CAM Monoclonal Antibody ING-1|Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310|Anti-EphA2 Monoclonal Antibody DS-8895a|Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547|Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111|Anti-ErbB3 Antibody ISU104|Anti-ErbB3 Monoclonal Antibody AV-203|Anti-ErbB3 Monoclonal Antibody CDX-3379|Anti-ErbB3 Monoclonal Antibody REGN1400|Anti-ErbB3/Anti-IGF-1R Bispecific Monoclonal Antibody MM-141|Anti-FAP/Interleukin-2 Fusion Protein RO6874281|Anti-FCRH5/CD3 BiTE Antibody BFCR4350A|Anti-FGFR2 Antibody BAY1179470|Anti-FGFR3 Antibody-drug Conjugate LY3076226|Anti-FGFR4 Monoclonal Antibody U3-1784|Anti-FLT3 Antibody-drug Conjugate AGS62P1|Anti-FLT3 Monoclonal Antibody 4G8-SDIEM|Anti-FLT3 Monoclonal Antibody IMC-EB10|Anti-FLT3/CD3 BiTE Antibody AMG 427|Anti-FRA/Eribulin Antibody-drug Conjugate MORAb-202|Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002|Anti-GARP Monoclonal Antibody ABBV-151|Anti-GCC Antibody-Drug Conjugate MLN0264|Anti-GCC Antibody-Drug Conjugate TAK-164|Anti-GD2 Monoclonal Antibody MORAb-028|Anti-GD2 Monoclonal Antibody hu14.18K322A|Anti-GD2 hu3F8/Anti-CD3 huOKT3 Bispecific Antibody|Anti-GD3 Antibody-drug Conjugate PF-06688992|Anti-GITR Agonistic Monoclonal Antibody ASP1951|Anti-GITR Agonistic Monoclonal Antibody BMS-986156|Anti-GITR Agonistic Monoclonal Antibody INCAGN01876|Anti-GITR Monoclonal Antibody GWN 323|Anti-GITR Monoclonal Antibody MK-4166|Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a|Anti-GRP78 Monoclonal Antibody PAT-SM6|Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962|Anti-Globo H Monoclonal Antibody OBI-888|Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999|Anti-Glypican 3/CD3 Bispecific Antibody ERY974|Anti-GnRH Vaccine PEP223|Anti-HA Epitope Monoclonal Antibody MEDI8852|Anti-HB-EGF Monoclonal Antibody KHK2866|Anti-HBEGF Monoclonal Antibody U3-1565|Anti-HER-2 Bispecific Antibody KN026|Anti-HER2 ADC DS-8201a|Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702|Anti-HER2 Antibody-drug Conjugate A166|Anti-HER2 Antibody-drug Conjugate ARX788|Anti-HER2 Antibody-drug Conjugate BAT8001|Anti-HER2 Antibody-drug Conjugate DP303c|Anti-HER2 Antibody-drug Conjugate MEDI4276|Anti-HER2 Antibody-drug Conjugate RC48|Anti-HER2 Bi-specific Monoclonal Antibody ZW25|Anti-HER2 Bispecific Antibody-drug Conjugate ZW49|Anti-HER2 Immune Stimulator-antibody Conjugate NJH395|Anti-HER2 Monoclonal Antibody B002|Anti-HER2 Monoclonal Antibody CT-P6|Anti-HER2 Monoclonal Antibody HLX22|Anti-HER2 Monoclonal Antibody/Anti-CD137Anticalin Bispecific Fusion Protein PRS-343|Anti-HER2-DM1 ADC B003|Anti-HER2-DM1 Antibody-drug Conjugate GQ1001|Anti-HER2-vc0101 ADC PF-06804103|Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A|Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302|Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128|Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522|Anti-HER2/MMAE Antibody-drug Conjugate MRG002|Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A|Anti-HER3 Antibody-drug Conjugate U3 1402|Anti-HER3 Monoclonal Antibody GSK2849330|Anti-HGF Monoclonal Antibody TAK-701|Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968|Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1|Anti-HLA-DR Monoclonal Antibody IMMU-114|Anti-HLA-G Antibody TTX-080|Anti-ICAM-1 Monoclonal Antibody BI-505|Anti-ICOS Agonist Antibody GSK3359609|Anti-ICOS Agonist Monoclonal Antibody BMS-986226|Anti-ICOS Monoclonal Antibody KY1044|Anti-ICOS Monoclonal Antibody MEDI-570|Anti-IGF-1R Monoclonal Antibody AVE1642|Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022|Anti-IL-1 alpha Monoclonal Antibody MABp1|Anti-IL-13 Humanized Monoclonal Antibody TNX-650|Anti-IL-15 Monoclonal Antibody AMG 714|Anti-IL-8 Monoclonal Antibody BMS-986253|Anti-IL-8 Monoclonal Antibody HuMax-IL8|Anti-ILDR2 Monoclonal Antibody BAY 1905254|Anti-ILT4 Monoclonal Antibody MK-4830|Anti-IRF4 Antisense Oligonucleotide ION251|Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388|Anti-KIR Monoclonal Antibody IPH 2101|Anti-KSP/Anti-VEGF siRNAs ALN-VSP02|Anti-LAG-3 Monoclonal Antibody IBI-110|Anti-LAG-3 Monoclonal Antibody INCAGN02385|Anti-LAG-3 Monoclonal Antibody LAG525|Anti-LAG-3 Monoclonal Antibody REGN3767|Anti-LAG-3/PD-L1 Bispecific Antibody FS118|Anti-LAG3 Monoclonal Antibody BI 754111|Anti-LAG3 Monoclonal Antibody MK-4280|Anti-LAG3 Monoclonal Antibody TSR-033|Anti-LAMP1 Antibody-drug Conjugate SAR428926|Anti-LGR5 Monoclonal Antibody BNC101|Anti-LIF Monoclonal Antibody MSC-1|Anti-LILRB4 Monoclonal Antibody IO-202|Anti-LIV-1 Monoclonal Antibody-MMAE Conjugate SGN-LIV1A|Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102|Anti-Ly6E Antibody-Drug Conjugate RG 7841|Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C|Anti-MMP-9 Monoclonal Antibody GS-5745|Anti-MUC1 Monoclonal Antibody BTH1704|Anti-MUC16/CD3 BiTE Antibody REGN4018|Anti-MUC16/CD3 Bispecific Antibody REGN4018|Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A|Anti-MUC17/CD3 BiTE Antibody AMG 199|Anti-Melanin Monoclonal Antibody PTI-6D2|Anti-Met Monoclonal Antibody Mixture Sym015|Anti-Met/EGFR Monoclonal Antibody LY3164530|Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062|Anti-NRP1 Antibody ASP1948|Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A|Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso|Anti-NaPi2b Antibody-drug Conjugate XMT-1592|Anti-NaPi2b Monoclonal Antibody XMT-1535|Anti-Neuropilin-1 Monoclonal Antibody MNRP1685A|Anti-Nucleolin Aptamer AS1411|Anti-OFA Immunotherapeutic BB-MPI-03|Anti-OX40 Agonist Monoclonal Antibody ABBV-368|Anti-OX40 Agonist Monoclonal Antibody BGB-A445|Anti-OX40 Agonist Monoclonal Antibody PF-04518600|Anti-OX40 Antibody BMS 986178|Anti-OX40 Hexavalent Agonist Antibody INBRX-106|Anti-OX40 Monoclonal Antibody GSK3174998|Anti-OX40 Monoclonal Antibody IBI101|Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256|Anti-PD-1 Checkpoint Inhibitor PF-06801591|Anti-PD-1 Fusion Protein AMP-224|Anti-PD-1 Monoclonal Antibody 609A|Anti-PD-1 Monoclonal Antibody AK105|Anti-PD-1 Monoclonal Antibody AMG 404|Anti-PD-1 Monoclonal Antibody BAT1306|Anti-PD-1 Monoclonal Antibody BCD-100|Anti-PD-1 Monoclonal Antibody BI 754091|Anti-PD-1 Monoclonal Antibody CS1003|Anti-PD-1 Monoclonal Antibody F520|Anti-PD-1 Monoclonal Antibody GLS-010|Anti-PD-1 Monoclonal Antibody HLX10|Anti-PD-1 Monoclonal Antibody HX008|Anti-PD-1 Monoclonal Antibody JTX-4014|Anti-PD-1 Monoclonal Antibody LZM009|Anti-PD-1 Monoclonal Antibody MEDI0680|Anti-PD-1 Monoclonal Antibody MGA012|Anti-PD-1 Monoclonal Antibody SCT-I10A|Anti-PD-1 Monoclonal Antibody Sym021|Anti-PD-1 Monoclonal Antibody TSR-042|Anti-PD-1/Anti-CTLA4 DART Protein MGD019|Anti-PD-1/Anti-HER2 Bispecific Antibody IBI315|Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669|Anti-PD-1/Anti-LAG-3 DART Protein MGD013|Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318|Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172|Anti-PD-1/CD47 Infusion Protein HX009|Anti-PD-1/CTLA-4 Bispecific Antibody AK104|Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752|Anti-PD-1/TIM-3 Bispecific Antibody RO7121661|Anti-PD-1/VEGF Bispecific Antibody AK112|Anti-PD-L1 Monoclonal Antibody A167|Anti-PD-L1 Monoclonal Antibody BCD-135|Anti-PD-L1 Monoclonal Antibody BGB-A333|Anti-PD-L1 Monoclonal Antibody CBT-502|Anti-PD-L1 Monoclonal Antibody CK-301|Anti-PD-L1 Monoclonal Antibody CS1001|Anti-PD-L1 Monoclonal Antibody FAZ053|Anti-PD-L1 Monoclonal Antibody GR1405|Anti-PD-L1 Monoclonal Antibody HLX20|Anti-PD-L1 Monoclonal Antibody IMC-001|Anti-PD-L1 Monoclonal Antibody LY3300054|Anti-PD-L1 Monoclonal Antibody MDX-1105|Anti-PD-L1 Monoclonal Antibody MSB2311|Anti-PD-L1 Monoclonal Antibody RC98|Anti-PD-L1 Monoclonal Antibody SHR-1316|Anti-PD-L1 Monoclonal Antibody TG-1501|Anti-PD-L1 Monoclonal Antibody ZKAB001|Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105|Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046|Anti-PD-L1/CD137 Bispecific Antibody MCLA-145|Anti-PD-L1/IL-15 Fusion Protein KD033|Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244|Anti-PD1 Monoclonal Antibody AGEN2034|Anti-PD1/CTLA4 Bispecific Antibody XmAb20717|Anti-PGF Monoclonal Antibody RO5323441|Anti-PKN3 siRNA Atu027|Anti-PLGF Monoclonal Antibody TB-403|Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4|Anti-PRAME Immunotherapeutic GSK2302032A|Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C|Anti-PRL-3 Monoclonal Antibody PRL3-zumab|Anti-PSCA Monoclonal Antibody AGS-1C4D4|Anti-PSMA Monoclonal Antibody MDX1201-A488|Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704|Anti-PSMA Monoclonal Antibody-MMAE Conjugate|Anti-PSMA/CD28 Bispecific Antibody REGN5678|Anti-PSMA/CD3 Bispecific Antibody CCW702|Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081|Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414|Anti-PSMA/PBD ADC MEDI3726|Anti-PTK7/Auristatin-0101 Antibody-drug Conjugate PF-06647020|Anti-PVRIG Monoclonal Antibody COM701|Anti-RANKL Monoclonal Antibody GB-223|Anti-RANKL Monoclonal Antibody JMT103|Anti-ROR1 ADC VLS-101|Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002|Anti-Ribonucleoprotein Antibody ATRC-101|Anti-S15 Monoclonal Antibody NC318|Anti-SIRPa Monoclonal Antibody CC-95251|Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E|Anti-TAG-72 Monoclonal Antibody scFV CC-49/218|Anti-TF Monoclonal Antibody ALT-836|Anti-TGF-beta Monoclonal Antibody NIS793|Anti-TGF-beta Monoclonal Antibody SAR-439459|Anti-TGF-beta RII Monoclonal Antibody IMC-TR1|Anti-TIGIT Monoclonal Antibody AB154|Anti-TIGIT Monoclonal Antibody BGB-A1217|Anti-TIGIT Monoclonal Antibody BMS-986207|Anti-TIGIT Monoclonal Antibody COM902|Anti-TIGIT Monoclonal Antibody OMP-313M32|Anti-TIGIT Monoclonal Antibody SGN-TGT|Anti-TIM-3 Antibody BMS-986258|Anti-TIM-3 Monoclonal Antibody BGB-A425|Anti-TIM-3 Monoclonal Antibody INCAGN02390|Anti-TIM-3 Monoclonal Antibody MBG453|Anti-TIM-3 Monoclonal Antibody Sym023|Anti-TIM-3 Monoclonal Antibody TSR-022|Anti-TIM3 Monoclonal Antibody LY3321367|Anti-TIM3 Monoclonal Antibody SHR-1702|Anti-TNF Therapy|Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711|Anti-TROP2 Antibody-drug Conjugate BAT8003|Anti-TROP2 Antibody-drug Conjugate SKB264|Anti-TROP2/DXd Antibody-drug Conjugate DS-1062a|Anti-TWEAK Monoclonal Antibody RG7212|Anti-Tissue Factor Monoclonal Antibody MORAb-066|Anti-VEGF Anticalin PRS-050-PEG40|Anti-VEGF Monoclonal Antibody hPV19|Anti-VEGF/ANG2 Nanobody BI 836880|Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T|Anti-VEGFC Monoclonal Antibody VGX-100|Anti-VEGFR2 Monoclonal Antibody HLX06|Anti-VEGFR2 Monoclonal Antibody MSB0254|Anti-VEGFR3 Monoclonal Antibody IMC-3C5|Anti-VISTA Monoclonal Antibody JNJ 61610588|Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B|Anti-alpha5beta1 Integrin Antibody MINT1526A|Anti-angiopoietin Monoclonal Antibody AMG 780|Anti-c-KIT Monoclonal Antibody CDX 0158|Anti-c-MET Monoclonal Antibody LY2875358|Anti-c-Met Antibody-drug Conjugate HTI-1066|Anti-c-Met Antibody-drug Conjugate TR1801|Anti-c-Met Monoclonal Antibody ABT-700|Anti-c-Met Monoclonal Antibody ARGX-111|Anti-c-Met Monoclonal Antibody HLX55|Anti-c-fms Monoclonal Antibody AMG 820|Anti-claudin18.2 Monoclonal Antibody AB011|Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012|Anti-gpA33/CD3 Monoclonal Antibody MGD007|Anti-gremlin-1 Monoclonal Antibody UCB6114|Anti-hepcidin Monoclonal Antibody LY2787106|Anti-human GITR Monoclonal Antibody AMG 228|Anti-human GITR Monoclonal Antibody TRX518|Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A|Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181|Anti-mesothelin Antibody-drug Conjugate BMS-986148|Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100|Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A|Anti-mesothelin/MMAE Antibody-drug Conjugate RC88|Anti-myostatin Monoclonal Antibody LY2495655|Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E|Anti-nf-P2X7 Antibody Ointment BIL-010t|Anti-prolactin Receptor Antibody LFA102|Anti-sCLU Monoclonal Antibody AB-16B5|Antiangiogenic Drug Combination TL-118|Antibody-Drug Conjugate DFRF4539A|Antibody-drug Conjugate ABBV-011|Antibody-drug Conjugate ABBV-085|Antibody-drug Conjugate ABBV-155|Antibody-drug Conjugate ABBV-176|Antibody-drug Conjugate ABBV-838|Antibody-drug Conjugate ADC XMT-1536|Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014|Antibody-drug Conjugate MEDI7247|Antibody-drug Conjugate PF-06647263|Antibody-drug Conjugate PF-06664178|Antibody-drug Conjugate SC-002|Antibody-drug Conjugate SC-003|Antibody-drug Conjugate SC-004|Antibody-drug Conjugate SC-005|Antibody-drug Conjugate SC-006|Antibody-drug Conjugate SC-007|Antibody-like CD95 Receptor/Fc-fusion Protein CAN-008|Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV|Antigua and Barbuda|Antimetabolite FF-10502|Antineoplastic Agent Combination SM-88|Antineoplastic Vaccine|Antineoplastic Vaccine GV-1301|Antineoplaston A10|Antineoplaston AS2-1|Antiseizure Treatment|Antisense Oligonucleotide GTI-2040|Antisense Oligonucleotide QR-313|Antitumor B Key Active Component-alpha|Antrodia cinnamomea Supplement|Antroquinonol Capsule|Antrum|Antrum Pylori|Anus|Anus and anal canal|Anus, NOS|Anxiety|Aorta|Aortic Body|Aortic Injury|Aortic Valve Disease|Aortic body and other paraganglia|Aortic body paraganglioma|Aortic body tumor|Aorticopulmonary Paraganglioma|Aorticopulmonary paraganglioma|Apalutamide|Apatorsen|Apaziquone|Aphidicoline Glycinate|Aphonia|Apilimod Dimesylate Capsule|Apitolisib|Apnea|Apocrine Adenoma|Apocrine Hidrocystoma|Apocrine adenocarcinoma|Apocrine adenoma|Apocrine cystadenoma|Apolizumab|Apomab|Apomine|Apoptosis Inducer BZL101|Apoptosis Inducer GCS-100|Apoptosis Inducer MPC-2130|Appendage of the Uterus|Appendicitis|Appendicitis Perforated|Appendix|Applied Biosystems|Approved|Apricoxib|Aprinocarsen|Aprutumab|Aprutumab Ixadotin|Apudoma|Aqueous Fluid|Arabidopsis thaliana|Arabinoxylan Compound MGN3|Arachnoiditis|Aranose|Archexin|Archive|Arcitumomab|Arfolitixorin|Arg-C, Asp-N|Argentaffinoma, NOS|Argentaffinoma, malignant|Argentina|Arginase Inhibitor INCB001158|Arginine Butyrate|Arm|Armenia|Arnebia Indigo Jade Pearl Topical Cream|Arrhenoblastoma, NOS|Arrhenoblastoma, benign|Arrhenoblastoma, malignant|Arrhythmia|Arriba|Arsenic Trioxide|Arsenic Trioxide Capsule Formulation ORH 2014|Artemether Sublingual Spray|Artemisinin Dimer|Arterial Injury|Arteriovenous Hemangioma/Malformation|Arteriovenous hemangioma|Arteritis Infective|Artery|Artesunate|Arthralgia|Arthritis|Aruba|Arugula Seed Powder|Aryl Hydrocarbon Receptor Antagonist BAY2416964|Aryl Hydrocarbon Receptor Inhibitor IK-175|Asaley|AscatNGS|Ascending Colon|Ascending Colon Hepatic Flexure|Ascending colon|Asciminib|Ascites|Ascites Drainage|Ascrinvacumab|Ashwagandha Root Powder Extract|Asian|Askin Tumor|Askin tumor|Asp-N_ambic|Aspacytarabine|Asparaginase|Asparaginase Erwinia chrysanthemi|Aspartate Aminotransferase Increased|Aspirate|Aspiration|Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10|Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10|Asthma|Astroblastoma|Astrocytic Tumor|Astrocytic glioma|Astrocytoma|Astrocytoma, NOS|Astrocytoma, anaplastic|Astrocytoma, low grade|Astroglioma|Astuprotimut-R|Asulacrine|Asulacrine Isethionate|Asunercept|Asystole|At 211 Monoclonal Antibody 81C6|Atamestane|Ataxia|Ataxia-telangiectasia|Atelectasis|Atezolizumab|Atiprimod|Atiprimod Dihydrochloride|Atiprimod Dimaleate|Atorvastatin Calcium|Atorvastatin Sodium|Atrasentan Hydrochloride|Atrial Fibrillation|Atrial Flutter|Atrioventricular Block Complete|Atrioventricular Block First Degree|Attenuated Listeria monocytogenes CRS-100|Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001|Attenuated Measles Virus Encoding SCD Transgene TMV-018|Atuveciclib|Atypical|Atypical Adenoma|Atypical Burkitt/Burkitt-Like Lymphoma|Atypical Carcinoid Tumor|Atypical Choroid Plexus Papilloma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Atypical Endometrial Hyperplasia|Atypical Fibroxanthoma|Atypical Lipomatous Tumor|Atypical Meningioma|Atypical Polypoid Adenomyoma|Atypical Teratoid/Rhabdoid Tumor|Atypical adenoma|Atypical carcinoid tumor|Atypical choroid plexus papilloma|Atypical chronic myeloid leukemia, BCR/ABL negative|Atypical chronic myeloid leukemia, Philadelphia chromosome (Ph1) negative|Atypical fibrous histiocytoma|Atypical fibroxanthoma|Atypical follicular adenoma|Atypical hyperplasia/Endometrioid intraepithelial neoplasm|Atypical leiomyoma|Atypical lipoma|Atypical medullary carcinoma|Atypical meningioma|Atypical polypoid adenomyoma|Atypical proliferating clear cell tumor|Atypical proliferating serous tumor|Atypical proliferative endometrioid tumor|Atypical proliferative mucinous tumor|Atypical proliferative papillary serous tumor|Atypical teratoid/rhabdoid tumor|Audencel|Auditory Canal|Aunt|Auranofin|Aurora A Kinase Inhibitor LY3295668|Aurora A Kinase Inhibitor LY3295668 Erbumine|Aurora A Kinase Inhibitor MK5108|Aurora A Kinase Inhibitor TAS-119|Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076|Aurora B Serine/Threonine Kinase Inhibitor TAK-901|Aurora B/C Kinase Inhibitor GSK1070916A|Aurora Kinase Inhibitor AMG 900|Aurora Kinase Inhibitor BI 811283|Aurora Kinase Inhibitor MLN8054|Aurora Kinase Inhibitor PF-03814735|Aurora Kinase Inhibitor SNS-314|Aurora Kinase Inhibitor TTP607|Aurora Kinase/VEGFR2 Inhibitor CYC116|Aurora kinase A/B inhibitor TT-00420|Australia|Austria|Auto Spec Ultima NT|Autoimmune Atrophic Chronic Gastritis|Autoimmune Disorder|Autoimmune Lymphoproliferative Syndrome (ALPS)|Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707|Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055|Autologous AXL-targeted CAR T-cells CCT301-38|Autologous Anti-BCMA CAR T-cells PHE885|Autologous Anti-BCMA CAR-transduced T-cells KITE-585|Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11|Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T-lymphocytes JCARH125|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells CT053|Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143|Autologous Anti-CD123 CAR-T Cells|Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx|Autologous Anti-CD19 CAR T-cells IM19|Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19|Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19|Autologous Anti-CD19 CAR-CD28 T-cells ET019002|Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01|Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901|Autologous Anti-CD19 Chimeric Antigen Receptor T-cells AUTO1|Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19|Autologous Anti-CD19 T-cell Receptor T cells ET190L1|Autologous Anti-CD19 TAC-T cells TAC01-CD19|Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells|Autologous Anti-CD19/CD22 CAR T-cells AUTO3|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells|Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1|Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s|Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes|Autologous Anti-FLT3 CAR T Cells AMG 553|Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202|Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1|Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100|Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794|Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes|Autologous Anti-PSMA CAR-T Cells P-PSMA-101|Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes|Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B|Autologous BCMA-targeted CAR T Cells CC-98633|Autologous BCMA-targeted CAR T Cells LCAR-B4822M|Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528|Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F|Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022|Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001|Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3005|Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3006|Autologous CD123-4SCAR-expressing T-cells 4SCAR123|Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1|Autologous CD19-targeted CAR T Cells CC-97540|Autologous CD19-targeted CAR T Cells JWCAR029|Autologous CD19-targeted CAR-T Cells GC007F|Autologous CD19/PD-1 Bispecific CAR-T Cells|Autologous CD20-4SCAR-expressing T-cells 4SCAR20|Autologous CD22-4SCAR-expressing T-cells 4SCAR22|Autologous CD38-4SCAR-expressing T-cells 4SCAR38|Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19|Autologous Clonal Neoantigen T Cells ATL001|Autologous Deep IL-15 Primed T-cells TRQ15-01|Autologous Dendritic Cell Vaccine ACT2001|Autologous Dendritic Cell-based Immunotherapeutic AV0113|Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa|Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells|Autologous Genetically-modified MAGE-A4 C1032 T Cells|Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439|Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858|Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001|Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718|Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR|Autologous Mesenchymal Stem Cells Apceth_101|Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11|Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC|Autologous Multi-lineage Potential Cells|Autologous NKG2D CAR T-cells CYAD-02|Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01|Autologous Nectin-4/FAP-targeted CAR-T Cells|Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine|Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001|Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101|Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601|Autologous ROR2-targeted CAR T-cells CCT301-59|Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201|Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1|Autologous TCR-engineered T-cells IMA201|Autologous TCR-engineered T-cells IMA202|Autologous TCR-engineered T-cells IMA203|Autologous TCRm-expressing T-cells ET140203|Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG|Autologous Tumor Infiltrating Lymphocytes LN-144|Autologous Tumor Infiltrating Lymphocytes LN-145|Autologous Tumor Infiltrating Lymphocytes LN-145-S1|Autologous Tumor Infiltrating Lymphocytes MDA-TIL|Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T|Autonomic Nervous System|Autonomic nervous system, NOS|Autopsy|Avadomide|Avadomide Hydrochloride|Avapritinib|Avascular Necrosis|Avdoralimab|Avelumab|Aviscumine|Avitinib Maleate|Axalimogene Filolisbac|Axatilimab|Axicabtagene Ciloleucel|Axilla|Axillary Lymph Node|Axillary tail of breast|Axitinib|Axl/Mer Inhibitor INCB081776|Axl/Mer Inhibitor PF-07265807|Axumin|Azacitidine|Azapicyl|Azaribine|Azaserine|Azathioprine|Azerbaijan|Azimexon|Azintuxizumab Vedotin|Aziridinylbenzoquinone RH1|Azoospermia|Azotomycin|Azurin:50-77 Cell Penetrating Peptide p28|B|B Acute Lymphoblastic Leukemia|B Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy|B Lymphoblastic Leukemia/Lymphoma with Hypodiploidy|B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1|B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)|B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH|B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1|B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged|B Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified|B Lymphoblastic Lymphoma|B cell lymphoma, NOS|B lymphoblastic leukemia/lymphoma with hyperdiploidy|B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL)|B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)|B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)|B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH|B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1|B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged|B lymphoblastic leukemia/lymphoma, NOS|B-ALL|B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|B-Cell Prolymphocytic Leukemia|B-Raf/VEGFR-2 Inhibitor RAF265|B-cell lymphocytic leukemia/small lymphocytic lymphoma|B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma|B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma|B7|B8|B9|BAI|BALT lymphoma|BAM|BAP1 Tumor Predisposition Syndrome|BC-819 Plasmid/Polyethylenimine Complex|BCG Solution|BCG Tokyo-172 Strain Solution|BCG Vaccine|BCGSC miRNA Profiling|BCMA x CD3 T-cell Engaging Antibody CC-93269|BCMA-CD19 Compound CAR T Cells|BCMA/CD3e Tri-specific T-cell Activating Construct HPN217|BCR Auxiliary XML|BCR Biotab|BCR Notification|BCR OMF XML|BCR PPS XML|BCR SSF XML|BCR XML|BCR-ABL/KIT/AKT/ERK Inhibitor HQP1351|BED-Biochemical Evidence of Disease|BEDPE|BET Bromodomain Inhibitor ZEN-3694|BET Inhibitor ABBV-744|BET Inhibitor BAY1238097|BET Inhibitor BMS-986158|BET Inhibitor CC-90010|BET Inhibitor CPI-0610|BET Inhibitor FT-1101|BET Inhibitor GS-5829|BET Inhibitor GSK2820151|BET Inhibitor INCB054329|BET Inhibitor INCB057643|BET Inhibitor RO6870810|BET inhibitor BI 894999|BET-bromodomain Inhibitor ODM-207|BF-200 Gel Formulation|BH3 Mimetic ABT-737|BL22 Immunotoxin|BMI1 Inhibitor PTC596|BMS-184476|BMS-188797|BMS-214662|BMS-275183|BP-Cx1-Platinum Complex BP-C1|BR96-Doxorubicin Immunoconjugate|BRAF Inhibitor|BRAF Inhibitor ARQ 736|BRAF Inhibitor BGB-3245|BRAF Inhibitor PLX8394|BRAF(V600E) Kinase Inhibitor ABM-1310|BRAF(V600E) Kinase Inhibitor RO5212054|BRAF/EGFR Inhibitor BGB-283|BRAFV600/PI3K Inhibitor ASN003|BRASS|BRCA Family History|BRD4 Inhibitor PLX2853|BRD4 Inhibitor PLX51107|BTK Inhibitor ARQ 531|BTK Inhibitor CT-1530|BTK Inhibitor DTRMWXHS-12|BTK Inhibitor HZ-A-018|BTK Inhibitor ICP-022|BTK Inhibitor LOXO-305|BTK Inhibitor M7583|BTK inhibitor TG-1701|BWA|BWA with BQSR|BWA with Mark Duplicates and BQSR|BWA with Mark Duplicates and Cocleaning|BWA-aln|BWA-mem|BXQ-350 Nanovesicle Formulation|B_Allele_Freq|Babaodan Capsule|Bacillus Calmette-Guerin Substrain Connaught Live Antigen|Back|Back Pain|Bacteroides fragilis|Bactobolin|Bafetinib|Bahamas|Bahrain|Balixafortide|Balloon Cell Melanoma|Balloon Cell Nevus|Balloon cell melanoma|Balloon cell nevus|Balstilimab|Baltaleucel-T|Bangladesh|Banoxantrone|Barasertib|Barbados|Barcode incorrect|Bardoxolone|Bardoxolone Methyl|Baricitinib|Barrett's Esophagus|Basal Cell Cancer|Basal Cell Carcinoma|Basal Cell Neoplasm|Basal Cell Neoplasms|Basal cell adenocarcinoma|Basal cell adenoma|Basal cell carcinoma, NOS|Basal cell carcinoma, desmoplastic type|Basal cell carcinoma, fibroepithelial|Basal cell carcinoma, micronodular|Basal cell carcinoma, morpheic|Basal cell carcinoma, nodular|Basal cell epithelioma|Basal cell tumor|Basaloid Carcinoma|Basaloid Squamous Cell Carcinoma|Basaloid carcinoma|Basaloid squamous cell carcinoma|Base of the Tongue|Base of tongue|Base of tongue, NOS|Basophil adenocarcinoma|Basophil adenoma|Basophil carcinoma|Basophilic Adenocarcinoma|Basosquamous carcinoma|Batabulin|Batabulin Sodium|Batimastat|Bavituximab|Bazedoxifene|Bazlitoran|Bcl-2 Inhibitor APG 2575|Bcl-2 Inhibitor BCL201|Bcl-2 Inhibitor BGB-11417|Bcl-2 Inhibitor LP-108|Bcl-2 Inhibitor S65487|Bcl-Xs Adenovirus Vaccine|Bcr-Abl Kinase Inhibitor K0706|Bcr-Abl Kinase Inhibitor PF-114|Beauvericin|Becatecarin|Beckwith-Wiedemann|Bednar tumor|Beer|Behcet's Disease|Belagenpumatucel-L|Belantamab Mafodotin|Belapectin|Belarus|Belgium|Belimumab|Belinostat|Belize|Bellini duct carcinoma|Belotecan Hydrochloride|Belvarafenib|Belzutifan|Bemarituzumab|Bemcentinib|Bemisia tabaci (Gennadius)|Bempegaldesleukin|Benaxibine|Bendamustine|Bendamustine Hydrochloride|Bendamustine-containing Nanoparticle-based Formulation RXDX-107|Benign Adrenal Cortex Neoplasm|Benign Epithelial Neoplasm|Benign Fibrous Histiocytoma|Benign Gastrointestinal Stromal Tumor|Benign Hemangioendothelioma|Benign Hemangiopericytoma|Benign Leydig Cell Tumor|Benign Mesenchymoma|Benign Mesonephroma|Benign Mixed Tumor of the Skin|Benign Muscle Neoplasm|Benign Myoepithelioma|Benign Neoplasm|Benign Neoplasms|Benign Odontogenic Neoplasm|Benign Paraganglioma|Benign Phyllodes Tumor|Benign Prostatic Hyperplasia|Benign Sertoli Cell Tumor|Benign Skin Appendage Neoplasm|Benign Soft Tissue Neoplasm|Benign Stromal Tumor|Benign Sweat Gland Neoplasm|Benign Synovial Neoplasm|Benign Thymoma|Benign cystic nephroma|Benign fibrous histiocytoma|Benin|Benzaldehyde Dimethane Sulfonate|Benzoylphenylurea|Berberine Chloride|Bermekimab|Bermuda|Bersanlimab|Berubicin Hydrochloride|Berzosertib|Beta Alethine|Beta cell adenoma|Beta cell tumor, malignant|Beta-Carotene|Beta-Glucan|Beta-Glucan MM-10-001|Beta-Thioguanine Deoxyriboside|Beta-elemene|Beta-lapachone Prodrug ARQ 761|Betaglucin Gel|Betulinic Acid|Bevacizumab|Bexarotene|Bexmarilimab|Bhutan|Bi-functional Alkylating Agent VAL-083|BiTE Antibody AMG 910|Bicalutamide|Biguanide|Bilateral|Bile Duct|Bile Duct Adenocarcinoma|Bile Duct Adenoma|Bile Duct Cancer|Bile Duct Carcinoma|Bile Duct Mucinous Cystic Neoplasm|Bile Duct Mucinous Cystic Neoplasm with an Associated Invasive Carcinoma|Bile Duct Papillary Neoplasm|Bile Duct Papillary Neoplasm with High Grade Intraepithelial Neoplasia|Bile Duct Papillary Neoplasm with Low Grade Intraepithelial Neoplasia|Bile Duct Stenosis|Bile duct adenocarcinoma|Bile duct adenoma|Bile duct carcinoma|Bile duct cystadenocarcinoma|Bile duct cystadenoma|Biliary Anastomotic Leak|Biliary Disorder|Biliary Fistula|Biliary Intraepithelial Neoplasia-3|Biliary Tract Infection|Biliary intraepithelial neoplasia, grade 3|Biliary intraepithelial neoplasia, high grade|Biliary intraepithelial neoplasia, low grade|Biliary papillomatosis|Biliary tract, NOS|Bimiralisib|Binetrakin|Binimetinib|Bintrafusp Alfa|Bio-Q|BioSizing|Biochemical|Biochemical Evidence of Disease without Structural Correlate|Biochemical evidence of disease without structural correlate|Biopsy|Biopsy with Histologic Confirmation|Biospecimen|Biospecimen Supplement|Biospecimen identity unknown|Biphasic Mesothelioma|Biphasic Synovial Sarcoma|Biphenotypic sinonasal sarcoma|Birabresib|Birdseed|Birinapant|Birt-Hogg-Dube Syndrome|Bis(choline)tetrathiomolybdate|Bisantrene|Bisantrene Hydrochloride|Bisnafide|Bisnafide Dimesylate|Bispecific Antibody 2B1|Bispecific Antibody AGEN1223|Bispecific Antibody AMG 509|Bispecific Antibody GS-1423|Bispecific Antibody MDX-H210|Bispecific Antibody MDX447|Bisphosphonate Therapy|Bisthianostat|Bisulfite-Seq|Bivalent BRD4 Inhibitor AZD5153|Bizalimogene Ralaplasmid|Bizarre Leiomyoma|Bizarre leiomyoma|Bizelesin|Black Cohosh|Black Raspberry Nectar|Black adenoma|Black or African American|Bladder|Bladder Anastomotic Leak|Bladder Cancer|Bladder Infection|Bladder Neck|Bladder Papillary Urothelial Neoplasm of Low Malignant Potential|Bladder Perforation|Bladder Spasm|Bladder Trigone|Bladder Urachal Carcinoma|Bladder Urothelial Carcinoma|Bladder neck|Bladder, NOS|Blast cell leukemia|Blastic NK cell lymphoma|Blastic Plasmacytoid Dendritic Cell Neoplasm|Blastic plasmacytoid dendritic cell neoplasm|Blastoma|Blastoma, NOS|Bleomycin|Bleomycin A2|Bleomycin B2|Bleomycin Sulfate|Blinatumomab|Blinded Study, Treatment Unknown|Bloating|Blocking Release|Blood|Blood Antidiuretic Hormone Abnormal|Blood Bilirubin Increased|Blood Cancer|Blood Clots|Blood Corticotrophin Decreased|Blood Derived Cancer - Bone Marrow|Blood Derived Cancer - Bone Marrow, Post-treatment|Blood Derived Cancer - Peripheral Blood|Blood Derived Cancer - Peripheral Blood, Post-treatment|Blood Derived Liquid Biopsy|Blood Derived Normal|Blood Draw|Blood Gonadotrophin Abnormal|Blood Prolactin Abnormal|Blood Vessel|Blood Vessel Tumors|Blood and Lymphatic System Disorders - Other|Blue|Blue Nevus|Blue nevus, NOS|Blue nevus, malignant|Blueberry Powder Supplement|Blurred Vision|Boanmycin Hydrochloride|Body Odor|Body of Stomach|Body of pancreas|Body of penis|Body of stomach|Body of the Penis|Body, total|Bolivia|Bomedemstat|Bone|Bone Cancer|Bone Desmoplastic Fibroma|Bone Fracture(s)|Bone Infection|Bone Marrow|Bone Marrow Aspirate|Bone Marrow Components|Bone Marrow Components NOS|Bone Marrow Hypocellular|Bone Marrow Normal|Bone Pain|Bone marrow|Bone of limb, NOS|Bone, NOS|Bone, non-spine|Bones of skull and face and associated joints|Bones, joints and articular cartilage of limbs|Bones, joints and articular cartilage of other and unspecified sites|Border of tongue|Borderline Ovarian Brenner Tumor/Atypical Proliferative Ovarian Brenner Tumor|Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor|Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor|Borderline Ovarian Serous Tumor-Micropapillary Variant/Non-Invasive Low Grade Ovarian Serous Carcinoma|Borderline Papillary Cystadenoma|Borderline Papillary Mucinous Cystadenoma|Borderline Papillary Serous Cystadenoma|Borderline Phyllodes Tumor|Borderline Serous Cystadenoma|Boronophenylalanine-Fructose Complex|Bortezomib|Bos taurus|Bosnia and Herzegovina|Bosutinib|Bosutinib Monohydrate|Botanical Agent BEL-X-HG|Botanical Agent LEAC-102|Botryoid sarcoma|Botryoid-Type Embryonal Rhabdomyosarcoma|Botswana|Bovine Cartilage|Bowel|Bowen Disease of the Skin|Bowen disease|Bozitinib|Brachial Plexopathy|Brachytherapy, High Dose|Brachytherapy, Low Dose|Brachytherapy, NOS|Brachyury-expressing Yeast Vaccine GI-6301|Brain|Brain Cancer|Brain Lower Grade Glioma|Brain Stem|Brain stem|Brain, NOS|Branchial Cleft Remnant|Branchial cleft|Brazil|Breast|Breast Atrophy|Breast Cancer|Breast Cancer pTis (DCIS) TNM Finding v8|Breast Cancer pTis (LCIS) TNM Finding v6 and v7|Breast Carcinoma with Chondroid Metaplasia|Breast Carcinoma with Osseous Metaplasia|Breast Fibroadenoma|Breast Giant Fibroadenoma|Breast Infection|Breast Intracanalicular Fibroadenoma|Breast Invasive Carcinoma|Breast Juvenile Fibroadenoma|Breast Pain|Breast Pericanalicular Fibroadenoma|Breast, NOS|Breflate|Brenner Tumor|Brenner tumor, NOS|Brenner tumor, borderline malignancy|Brenner tumor, malignant|Brenner tumor, proliferating|Brentuximab|Brentuximab Vedotin|Brequinar|Brequinar Sodium|Briciclib Sodium|Brigatinib|Brilanestrant|Brimonidine Tartrate Nanoemulsion OCU-300|Brivanib|Brivanib Alaninate|Brivudine|Brivudine Phosphoramidate|Broad Ligament|Broad ligament|Broad-Spectrum Human Papillomavirus Vaccine V505|Broccoli Sprout/Broccoli Seed Extract Supplement|Bromacrylide|Bromebric Acid|Bromocriptine Mesylate|Bronchial Fistula|Bronchial Infection|Bronchial Mucosa-Associated Lymphoid Tissue Lymphoma|Bronchial Obstruction|Bronchial Stricture|Bronchial adenoma, NOS|Bronchial adenoma, carcinoid|Bronchial adenoma, cylindroid|Bronchial-associated lymphoid tissue lymphoma|Bronchio-alveolar carcinoma, mixed mucinous and non-mucinous|Bronchio-alveolar carcinoma, mucinous|Bronchiolar adenocarcinoma|Bronchiolar carcinoma|Bronchiole|Bronchiolo-alveolar adenocarcinoma, NOS|Bronchiolo-alveolar carcinoma, Clara cell|Bronchiolo-alveolar carcinoma, Clara cell and goblet cell type|Bronchiolo-alveolar carcinoma, NOS|Bronchiolo-alveolar carcinoma, goblet cell type|Bronchiolo-alveolar carcinoma, indeterminate type|Bronchiolo-alveolar carcinoma, non-mucinous|Bronchiolo-alveolar carcinoma, type II pneumocyte and goblet cell type|Bronchiolo-alveolar carcinoma; type II pneumocyte|Bronchitis|Bronchopleural Fistula|Bronchopulmonary Hemorrhage|Bronchospasm|Bronchus|Bronchus and lung|Brontictuzumab|Brooke tumor|Brostacillin Hydrochloride|Brostallicin|Brother|Brother-in-law|Brow|Brown|Brown fat tumor|Broxuridine|Bruceanol A|Bruceanol B|Bruceanol C|Bruceanol D|Bruceanol E|Bruceanol F|Bruceanol G|Bruceanol H|Bruceantin|Bruising|Bruker|Bruker Daltonics BioTOF series|Bruker Daltonics EVOQ series|Bruker Daltonics HCT series|Bruker Daltonics SCION series|Bruker Daltonics amaZon series|Bruker Daltonics apex series|Bruker Daltonics esquire series|Bruker Daltonics flex series|Bruker Daltonics maXis series|Bruker Daltonics micrOTOF series|Bruker Daltonics solarix series|Brunei|Bryostatin 1|Buccal Cavity|Buccal Cell Normal|Buccal Cells|Buccal Mucosa|Buccal Mucosal Resection|Budigalimab|Budotitane|Bufalin|Buffy Coat|Bulgaria|Bullous Dermatitis|Buparlisib|Burixafor|Burixafor Hydrobromide|Burkina Faso|Burkitt Leukemia|Burkitt Lymphoma|Burkitt cell leukemia|Burkitt lymphoma, NOS (Includes all variants)|Burkitt tumor|Burkitt-like lymphoma|Burn|Burning tree smoke|Burosumab|Burundi|Buserelin|Bushen Culuan Decoction|Bushen-Jianpi Decoction|Busulfan|Buthionine Sulfoximine|Buttock|Buttock Pain|C|C cell carcinoma|C-VISA BikDD:Liposome|C-myb Antisense Oligonucleotide G4460|C/EBP Beta Antagonist ST101|C10|C11|C12|C18|CAB-ROR2-ADC BA3021|CAIX Inhibitor DTP348|CAIX Inhibitor SLC-0111|CAR T-Cells AMG 119|CASTLE|CBP/beta-catenin Antagonist PRI-724|CBP/beta-catenin Modulator E7386|CCR2 Antagonist CCX872-B|CCR2 Antagonist PF-04136309|CCR2/CCR5 Antagonist BMS-813160|CCR4 Inhibitor FLX475|CD11b Agonist GB1275|CD123-CD33 Compound CAR T Cells|CD123-specific Targeting Module TM123|CD20-CD19 Compound CAR T Cells|CD28/ICOS Antagonist ALPN-101|CD4 Lymphocytes Decreased|CD4-specific Telomerase Peptide Vaccine UCPVax|CD40 Agonist Monoclonal Antibody CP-870,893|CD40 Agonistic Monoclonal Antibody APX005M|CD44 Targeted Agent SPL-108|CD44v6-specific CAR T-cells|CD47 Antagonist ALX148|CD73 Inhibitor AB680|CD73 Inhibitor LY3475070|CD80-Fc Fusion Protein ALPN-202|CD80-Fc Fusion Protein FPT155|CDC JSON|CDC7 Inhibitor TAK-931|CDC7 Kinase Inhibitor BMS-863233|CDC7 Kinase Inhibitor LY3143921 Hydrate|CDC7 Kinase Inhibitor NMS-1116354|CDK Inhibitor AT7519|CDK Inhibitor R547|CDK Inhibitor SNS-032|CDK/JAK2/FLT3 Inhibitor TG02 Citrate|CDK1 Inhibitor BEY1107|CDK1/2/4 Inhibitor AG-024322|CDK2 Inhibitor PF-07104091|CDK2/4/6/FLT3 Inhibitor FN-1501|CDK2/5/9 Inhibitor CYC065|CDK4 Inhibitor P1446A-05|CDK4/6 Inhibitor|CDK4/6 Inhibitor BPI-16350|CDK4/6 Inhibitor CS3002|CDK4/6 Inhibitor FCN-437|CDK4/6 Inhibitor G1T38|CDK4/6 Inhibitor HS-10342|CDK4/6 Inhibitor SHR6390|CDK4/6 Inhibitor TQB3616|CDK7 Inhibitor CT7001|CDK7 Inhibitor SY-1365|CDK7 Inhibitor SY-5609|CDK8/19 Inhibitor SEL 120|CDK9 Inhibitor AZD4573|CEA-MUC-1-TRICOM Vaccine CV301|CEA-targeting Agent RG6123|CEBPA-targeting saRNA MTL-CEBPA Liposome|CEL|CENP-E Inhibitor GSK-923295|CHK1 Inhibitor MK-8776|CHK1 Inhibitor PF-477736|CHP-NY-ESO-1 Peptide Vaccine IMF-001|CID|CIN III with severe dysplasia|CK1alpha/CDK7/CDK9 Inhibitor BTX-A51|CK2-targeting Synthetic Peptide CIGB-300|CL 246738|CNBr, Formic_acid|CNS Cancer|CNS Embryonal tumor with rhabdoid features|CNS, ependymoma|CNS, glioblastoma (GBM)|CNS, low grade glioma (LGG)|CNS, medulloblastoma|CNS, other|CNS, rhabdoid tumor|COPD|CPD-Clinical Progression|CPK Increased|CPNET|CR-Complete Response|CRU-Complete Response Unconfirmed|CSF-1R Inhibitor BLZ945|CSF1R Inhibitor ABSK021|CSF1R Inhibitor DCC-3014|CSF1R Inhibitor PLX73086|CSV|CT Scan|CT2584 HMS|CTLA-4-directed Probody BMS-986249|CXC Chemokine Receptor 2 Antagonist AZD5069|CXCR1/2 Inhibitor SX-682|CXCR2 Antagonist QBM076|CXCR4 Antagonist BL-8040|CXCR4 Antagonist USL311|CXCR4 Inhibitor Q-122|CXCR4 Peptide Antagonist LY2510924|CXCR4/E-selectin Antagonist GMI-1359|CYL-02 Plasmid DNA|CYP11A1 Inhibitor ODM-209|CYP11A1 inhibitor ODM-208|CYP17 Inhibitor CFG920|CYP17 Lyase Inhibitor ASN001|CYP17/Androgen Receptor Inhibitor ODM 204|CYP17/CYP11B2 Inhibitor LAE001|CaVEMan|CaVEMan Annotation|CaVEMan Variant Aggregation and Masking|Cabazitaxel|Cabiralizumab|Cabozantinib|Cabozantinib S-malate|Cactinomycin|Caenorhabditis briggsae|Caenorhabditis elegans|Caenorhabditis remanei|Caffeic Acid Phenethyl Ester|Calaspargase Pegol-mknl|Calcifying Cystic Odontogenic Tumor|Calcifying Epithelial Odontogenic Tumor|Calcifying epithelial odontogenic tumor|Calcifying epithelioma of Malherbe|Calcifying nested epithelial stromal tumor|Calcifying odontogenic cyst|Calcitriol|Calcium Channel Blockers|Calcium Release-activated Channel Inhibitor CM4620|Calcium Release-activated Channels Inhibitor RP4010|Calcium Saccharate|Calculus bovis/Moschus/Olibanum/Myrrha Capsule|Calf|Calicheamicin Gamma 1I|Cambodia|Cameroon|Camidanlumab Tesirine|Camptothecin|Camptothecin Analogue TLC388|Camptothecin Glycoconjugate BAY 38-3441|Camptothecin Sodium|Camptothecin-20(S)-O-Propionate Hydrate|Camrelizumab|Camsirubicin|Canada|Canalicular adenoma|Cancell|Cancer|Cancer Control|Cancer Peptide Vaccine S-588410|Cancer Related|Candidiasis|Canerpaturev|Canertinib Dihydrochloride|Canfosfamide|Canfosfamide Hydrochloride|Canis familiaris|Cannabidiol|Cantrixil|Cantuzumab Ravtansine|Cape Verde|Capecitabine|Capecitabine Rapidly Disintegrating Tablet|Capillary|Capillary Hemangioma|Capillary Leak Syndrome|Capillary hemangioma|Capillary lymphangioma|Capivasertib|Capmatinib|Captopril|Caracemide|Carbendazim|Carbetimer|Carbogen|Carbon C 14-pamiparib|Carbon Monoxide Diffusing Capacity Decreased|Carboplatin|Carboquone|Carboxyamidotriazole|Carboxyamidotriazole Orotate|Carboxyphenyl Retinamide|Carcinofibroma|Carcinoid Tumor|Carcinoid Tumor of Uncertain Malignant Potential|Carcinoid tumor of uncertain malignant potential|Carcinoid tumor, NOS|Carcinoid tumor, NOS, of appendix|Carcinoid tumor, argentaffin, NOS|Carcinoid tumor, argentaffin, malignant|Carcinoid, NOS|Carcinoid, NOS, of appendix|Carcinoma|Carcinoma In Situ|Carcinoma In Situ in a Polyp|Carcinoma Simplex|Carcinoma ex Pleomorphic Adenoma|Carcinoma in a Polyp|Carcinoma in a polyp, NOS|Carcinoma in adenomatous polyp|Carcinoma in pleomorphic adenoma|Carcinoma in situ in a polyp, NOS|Carcinoma in situ in adenomatous polyp|Carcinoma in situ, NOS|Carcinoma showing thymus-like differentiation|Carcinoma showing thymus-like element|Carcinoma simplex|Carcinoma with apocrine metaplasia|Carcinoma with chondroid differentiation|Carcinoma with neuroendocrine differentiation|Carcinoma with osseous differentiation|Carcinoma with osteoclast-like giant cells|Carcinoma with other types mesenchymal differentiation|Carcinoma with productive fibrosis|Carcinoma, NOS|Carcinoma, anaplastic, NOS|Carcinoma, diffuse type|Carcinoma, intestinal type|Carcinoma, metastatic, NOS|Carcinoma, undifferentiated, NOS|Carcinomatosis|Carcinosarcoma|Carcinosarcoma, NOS|Carcinosarcoma, embryonal|Cardia|Cardia, NOS|Cardiac Arrest|Cardiac Disorders - Other|Cardiac Troponin I Increased|Cardiac Troponin T Increased|Cardiovascular Disorder|Cardiovascular Disorder, NOS|Carfilzomib|Caricotamide/Tretazicar|Carina|Carlumab|Carmofur|Carmustine|Carmustine Implant|Carmustine Sustained-Release Implant Wafer|Carmustine in Ethanol|Carotid Artery|Carotid Body|Carotid Body Paraganglioma|Carotid body|Carotid body paraganglioma|Carotid body tumor|Carotuximab|Cartilage|Cartilaginous exostosis|Carubicin|Carubicin Hydrochloride|Carzelesin|Carzinophilin|Case submitted is found to be a recurrence after submission|Cataract|Cataracts|Cathelicidin LL-37|Catheter Related Infection|Cationic Liposome-Encapsulated Paclitaxel|Cationic Peptide Cream Cypep-1|Catumaxomab|Cauda equina|Cavernous Hemangioma|Cavernous Lymphangioma|Cavernous hemangioma|Cavernous lymphangioma|Cayman Islands|Cecal Hemorrhage|Cecal Infection|Cecum|Cedazuridine|Cedazuridine/Azacitidine Combination Agent ASTX030|Cedazuridine/Decitabine Combination Agent ASTX727|Cedefingol|Cediranib|Cediranib Maleate|Celecoxib|Celiac Disease|Cell|Cell Culture|Cell Culture Image|Cell Cycle Checkpoint/DNA Repair Antagonist IC83|Cell Line Derived Xenograft Tissue|Cell Lines|Cell-Line|CellRanger - 10x Chromium|CellRanger - 10x Filtered Counts|CellRanger - 10x Raw Counts|Cellular Angiofibroma|Cellular Blue Nevus|Cellular Ependymoma|Cellular Fibroma|Cellular Leiomyoma|Cellular Schwannoma|Cellular angiofibroma|Cellular blue nevus|Cellular ependymoma|Cellular fibroma|Cellular leiomyoma|Cellular schwannoma|Cemadotin|Cemadotin Hydrochloride|Cementifying fibroma|Cemento-ossifying fibroma|Cementoblastoma|Cementoblastoma, benign|Cementoma, NOS|Cemiplimab|Cenersen|Cenisertib|Center QC failed|CenterNotification|Central African Republic|Central Nervous System|Central Nervous System Embryonal Tumor with Rhabdoid Features|Central Nervous System Embryonal Tumor, Not Otherwise Specified|Central Nervous System Lymphoma|Central Nervous System Necrosis|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 1|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 2|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 3|Central Neurocytoma|Central neuroblastoma|Central neurocytoma|Central odontogenic fibroma|Central osteosarcoma|Central portion of breast|Central primitive neuroectodermal tumor, NOS|Centroblastic Lymphoma|Ceralasertib|Ceramide Nanoliposome|Cerdulatinib|Cerebellar Liponeurocytoma|Cerebellar Sarcoma|Cerebellar liponeurocytoma|Cerebellar sarcoma, NOS|Cerebellum|Cerebellum, NOS|Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480|Cereblon E3 Ubiquitin Ligase Modulating Agent CC-99282|Cereblon Modulator CC-90009|Cerebral Cortex|Cerebral Hemisphere|Cerebral Meninges|Cerebral meninges|Cerebrospinal Fluid|Cerebrospinal Fluid Leakage|Cerebrovascular Disease|Cerebrum|Cergutuzumab Amunaleukin|Ceritinib|Ceruminous Adenocarcinoma|Ceruminous adenocarcinoma|Ceruminous adenoma|Ceruminous carcinoma|Cervical Adenocarcinoma Admixed with Neuroendocrine Carcinoma|Cervical Cancer|Cervical Cancer (all types)|Cervical Cancer pT1a1 TNM Finding v8|Cervical Cancer pT1a2 TNM Finding v8|Cervical Mucinous Adenocarcinoma, Gastric Type|Cervical Mucinous Adenocarcinoma, Intestinal-Type|Cervical Spine|Cervical Squamotransitional Carcinoma|Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma|Cervical Villoglandular Adenocarcinoma|Cervical esophagus|Cervical intraepithelial neoplasia, grade III|Cervical intraepithelial neoplasia, low grade|Cervicitis Infection|Cervix|Cervix Uteri|Cervix uteri|Cesalin|Cetrelimab|Cetuximab|Cetuximab Sarotalocan|Cetuximab-IR700 Conjugate RM-1929|Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY)|Cevipabulin|Cevipabulin Fumarate|Cevipabulin Succinate|Cevostamab|ChIP-Seq|Chad|Chaparrin|Chaparrinone|Checkpoint Kinase Inhibitor AZD7762|Checkpoint Kinase Inhibitor XL844|Cheek mucosa|Cheilitis|Chemical Lysis DNA Extraction|Chemodectoma|Chemoembolization|Chemoprotectant|Chemotherapy|Chest|Chest Pain - Cardiac|Chest Wall|Chest Wall Pain|ChiNing Decoction|Chiauranib|Chief cell adenoma|Child|Child-Pugh Class A|Child-Pugh Class A5|Child-Pugh Class A6|Child-Pugh Class B|Child-Pugh Class B7|Child-Pugh Class B8|Child-Pugh Class B9|Child-Pugh Class C|Child-Pugh Class C10|Child-Pugh Class C11|Child-Pugh Class C12|Childhood Astrocytic Tumor|Chile|Chills|Chimeric Monoclonal Antibody 81C6|Chin|China|Chk1 Inhibitor CCT245737|Chk1 Inhibitor GDC-0425|Chk1 Inhibitor GDC-0575|Chlamydia|Chlamydomonas reinhardtii|Chlorambucil|Chlorodihydropyrimidine|Chloroma|Chloroquine|Chloroquinoxaline Sulfonamide|Chlorotoxin|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes|Chlorozotocin|Cholangiocarcinoma|Cholangioma|Cholecystitis|Cholelithiasis|Cholesterol High|Choline|Choline Kinase Alpha Inhibitor TCD-717|Chondroblastic Osteosarcoma|Chondroblastic osteosarcoma|Chondroblastoma|Chondroblastoma, NOS|Chondroblastoma, malignant|Chondroid Chordoma|Chondroid Lipoma|Chondroid chordoma|Chondroid lipoma|Chondroid syringoma|Chondroma|Chondroma, NOS|Chondromatosis|Chondromatosis, NOS|Chondromatous giant cell tumor|Chondromyxoid Fibroma|Chondromyxoid fibroma|Chondrosarcoma|Chondrosarcoma grade 2/3|Chondrosarcoma, NOS|Chordoid Glioma of the Third Ventricle|Chordoid Meningioma|Chordoid glioma|Chordoid glioma of third ventricle|Chordoid meningioma|Chordoma|Chordoma, NOS|Chorioadenoma|Chorioadenoma destruens|Chorioangioma|Choriocarcinoma|Choriocarcinoma Combined with Other Germ Cell Elements|Choriocarcinoma combined with embryonal carcinoma|Choriocarcinoma combined with other germ cell elements|Choriocarcinoma combined with teratorna|Choriocarcinoma, NOS|Chorioepithelioma|Chorionepithelioma|Choroid|Choroid Plexus Carcinoma|Choroid Plexus Papilloma|Choroid plexus carcinoma|Choroid plexus papilloma, NOS|Choroid plexus papilloma, anaplastic|Choroid plexus papilloma, malignant|Choroidal and Ciliary Body Melanoma pT4e TNM Finding v8|Chromaffin paraganglioma|Chromaffin tumor|Chromaffinoma|Chromomycin A3|Chromophobe Renal Cell Carcinoma|Chromophobe adenocarcinoma|Chromophobe adenoma|Chromophobe carcinoma|Chromophobe cell renal carcinoma|Chronic Eosinophilic Leukemia, Not Otherwise Specified|Chronic Fatigue Syndrome|Chronic Hepatitis|Chronic Kidney Disease|Chronic Kidney Disease, Stage 5|Chronic Leukemia|Chronic Lymphocytic Leukemia|Chronic Lymphoproliferative Disorder of NK-Cells|Chronic Monocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Myeloproliferative Disorders|Chronic Neutrophilic Leukemia|Chronic Renal Failure|Chronic Systemic Steroid Use|Chronic eosinophilic leukemia, NOS|Chronic erythremia|Chronic granulocytic leukemia, BCR/ABL|Chronic granulocytic leukemia, NOS|Chronic granulocytic leukemia, Philadelphia chromosome (Ph1) positive|Chronic granulocytic leukemia, t(9;22)(q34;q11)|Chronic idiopathic myelofibrosis|Chronic leukemia, NOS|Chronic lymphatic leukemia|Chronic lymphocytic leukemia|Chronic lymphocytic leukemia, B-cell type (includes all variants of BCLL)|Chronic lymphoid leukemia|Chronic lymphoproliferative disorder of NK cells|Chronic monocytic leukemia|Chronic myelocytic leukemia, NOS|Chronic myelogenous leukemia, BCR-ABL positive|Chronic myelogenous leukemia, Philadelphia chromosome (Ph 1) positive|Chronic myelogenous leukemia, t(9;22)(q34;q11)|Chronic myeloid leukemia, NOS|Chronic myelomonocytic leukemia in transformation|Chronic myelomonocytic leukemia, NOS|Chronic myelomonocytic leukemia, Type 1|Chronic myelomonocytic leukemia, Type II|Chronic myeloproliferative disease, NOS|Chronic myeloproliferative disorder|Chronic neutrophilic leukemia|Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement|Chylothorax|Chymotrypsin|Cibisatamab|Ciclopirox Prodrug CPX-POM|Cidan Herbal Capsule|Ciforadenant|Cigar|Cigarette|Cilengitide|Ciliary Body|Ciliary body|Ciltacabtagene Autoleucel|Cimetidine|Cin III, NOS|Cinacalcet Hydrochloride|Cinobufagin|Cinobufotalin|Cinrebafusp Alfa|Cintirorgon|Cintredekin Besudotox|Circumscribed arachnoidal cerebellar sarcoma|Cirmtuzumab|Cirrhosis|Cirrhosis, Unknown Etiology|Cisplatin|Cisplatin Liposomal|Cisplatin-E Therapeutic Implant|Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6|Citarinostat|Citatuzumab Bogatox|Citius HRT|Cixutumumab|Cladribine|Clanfenur|Clarithromycin|Class 1/4 Histone Deacetylase Inhibitor OKI-179|Classic Medulloblastoma|Classical Hodgkin lymphoma, lymphocyte depletion, NOS|Classical Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis|Classical Hodgkin lymphoma, lymphocyte depletion, reticular|Classical Hodgkin lymphoma, lymphocyte-rich|Classical Hodgkin lymphoma, mixed cellularity, NOS|Classical Hodgkin lymphoma, nodular sclerosis, NOS|Classical Hodgkin lymphoma, nodular sclerosis, cellular phase|Classical Hodgkin lymphoma, nodular sclerosis, grade 1|Classical Hodgkin lymphoma, nodular sclerosis, grade 2|Clavicle|Clear Cell Adenocarcinoma|Clear Cell Adenofibroma|Clear Cell Adenoma|Clear Cell Chondrosarcoma|Clear Cell Cystadenofibroma|Clear Cell Ependymoma|Clear Cell Hidradenoma|Clear Cell Meningioma|Clear Cell Neoplasm|Clear Cell Odontogenic Carcinoma|Clear Cell Renal Cell Carcinoma|Clear Cell Sarcoma of Soft Tissue|Clear Cell Sarcoma of the Kidney|Clear cell (glycogen-rich) urothelial carcinoma|Clear cell adenocarcinofibroma|Clear cell adenocarcinoma, NOS|Clear cell adenocarcinoma, mesonephroid|Clear cell adenofibroma|Clear cell adenofibroma of borderline malignancy|Clear cell adenoma|Clear cell carcinoma|Clear cell chondrosarcoma|Clear cell cystadenocarcinofibroma|Clear cell cystadenofibroma|Clear cell cystadenofibroma of borderline malignancy|Clear cell cystadenoma|Clear cell cystic tumor of borderline malignancy|Clear cell ependymoma|Clear cell hidradenoma|Clear cell meningioma|Clear cell odontogenic carcinoma|Clear cell odontogenic tumor|Clear cell sarcoma of kidney|Clear cell sarcoma of the kidney (CCSK)|Clear cell sarcoma, NOS|Clear cell sarcoma, of tendons and aponeuroses|Clear cell tumor, NOS|Clinical|Clinical Supplement|Clinical Trial|Clinical Trial Agent|Clinical data insufficient|Clioquinol|Clitoris|Clivatuzumab|Cloacogenic carcinoma|Cloacogenic zone|Clodronate Disodium|Clodronic Acid|Clofarabine|Clomesone|Clomiphene|Clomiphene Citrate|Clonal Hematopoiesis|Clostridium Novyi-NT Spores|Coal smoke, NOS|Cobimetinib|Cobolimab|Cobomarsen|Coccidioidomycosis|Cochlear Nerve|Codman tumor|Codrituzumab|Coenzyme Q10|Cofetuzumab Pelidotin|Cognitive Disturbance|Cohort Level Copy Number Scores|Colchicine-Site Binding Agent ABT-751|Cold Contaminant-free Iobenguane I-131|Colitis|Collecting Duct Carcinoma|Collecting duct carcinoma|Colloid adenocarcinoma|Colloid adenoma|Colloid carcinoma|Colloidal Gold-Bound Tumor Necrosis Factor|Colombia|Colon|Colon - Mucosa Only|Colon Adenocarcinoma|Colon Polyps|Colon, NOS|Colonic Fistula|Colonic Hemorrhage|Colonic Obstruction|Colonic Perforation|Colonic Stenosis|Colonic Ulcer|Colonization, Bacterial|Colonization, Fungal|Colonoscopy|Colorectal|Colorectal Cancer|Colorectal Cancer Peptide Vaccine PolyPEPI1018|Colorectal Tumor-Associated Peptides Vaccine IMA910|Coltuximab Ravtansine|Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Columnar cell papilloma|Combined Carcinoid and Adenocarcinoma|Combined Hepatocellular Carcinoma and Cholangiocarcinoma|Combined Lung Large Cell Neuroendocrine Carcinoma|Combined Lung Small Cell Carcinoma|Combined Lung Small Cell Carcinoma and Lung Adenocarcinoma|Combined Nucleotide Variation|Combined carcinoid and adenocarcinoma|Combined hepatocellular carcinoma and cholangiocarcinoma|Combined large cell neuroendocrine carcinoma|Combined small cell carcinoma|Combined small cell-adenocarcinoma|Combined small cell-large carcinoma|Combined small cell-squamous cell carcinoma|Combined/mixed carcinoid and adenocarcinoma|Combretastatin|Combretastatin A-1|Combretastatin A1 Diphosphate|Comedocarcinoma|Comedocarcinoma, NOS|Comedocarcinoma, noninfiltrating|Commensal Bacterial Strain Formulation VE800|Commissure of lip|Common ALL|Common Acute Lymphoblastic Leukemia|Common Duct|Common Variable Immunodeficiency|Common precursor B ALL|Common variable immune deficiency (CVID)|Comoros|Complete Data Freeze|Complete Genomics|Complete Hydatidiform Mole|Complete Necrosis (No Viable Tumor)|Complete Remission|Complete Response|Complete Response Unconfirmed|Complete hydatidiform mole|Complex Epithelial Neoplasms|Complex Mixed and Stromal Neoplasms|Complex Odontoma|Complex odontoma|Composite Hodgkin and non-Hodgkin lymphoma|Composite Lymphoma|Composite carcinoid|Compound Kushen Injection|Compound Nevus|Compound Odontoma|Compound nevus|Compound odontoma|Conatumumab|Conbercept|Concentrated Lingzhi Mushroom Extract|Concentration Impairment|Concurrent Chemoradiation|Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011|Conduction Disorder|Condylomatous carcinoma|Confusion|Congenital Mesoblastic Nephroma|Congenital fibrosarcoma|Congenital generalized fibromatosis|Congenital peribronchial myofibroblastic tumor|Congenital, Familial and Genetic Disorders - Other|Congestive Heart Failure (CHF)|Congo|Conjunctiva|Conjunctivitis|Conjunctivitis Infective|Connective Tissue|Connective Tissue Disorder|Connective, subcutaneous and other soft tissues|Connective, subcutaneous and other soft tissues of abdomen|Connective, subcutaneous and other soft tissues of head, face, and neck|Connective, subcutaneous and other soft tissues of lower limb and hip|Connective, subcutaneous and other soft tissues of pelvis|Connective, subcutaneous and other soft tissues of thorax|Connective, subcutaneous and other soft tissues of trunk, NOS|Connective, subcutaneous and other soft tissues of upper limb and shoulder|Connective, subcutaneous and other soft tissues, NOS|Consent Exemption|Consent Waiver|Consent by Death|Constipation|Constrictive Pericarditis|Control Analyte|Conventional Osteosarcoma|Conventional central osteosarcoma|Convincing Image Source|Cook Islands|Cooking-related smoke, NOS|Copanlisib|Copanlisib Hydrochloride|Copper Cu 64-ATSM|Copper Cu 67 Tyr3-octreotate|Copper Gluconate|Copy Number Estimate|Copy Number Segment|Copy Number Variation|Cord Blood Derived CAR T-Cells|Cord Blood-derived Expanded Natural Killer Cells PNK-007|Cordycepin|Cordycepin Triphosphate|Core Biopsy|Coriolus Versicolor Extract|Cornea, NOS|Corneal Infection|Corneal Ulcer|Coronary Artery Disease|Corpus uteri|Cortex of adrenal gland|Cortical T ALL|Corticorelin Acetate|Cortisone Acetate|Cosibelimab|Cositecan|Costa Rica|Cote d'Ivoire|Cough|Course of Therapy Completed|Cousin|Cowden Syndrome|Coxsackievirus A21|Coxsackievirus V937|CpG Oligodeoxynucleotide GNKG168|Cranial Nerve Infection|Cranial nerve, NOS|Craniopharyngeal duct|Craniopharyngioma|Craniopharyngioma, adamantinomatous|Craniopharyngioma, papillary|Creatinine Increased|Crenolanib|Crenolanib Besylate|Cribriform Carcinoma|Cribriform carcinoma in situ|Cribriform carcinoma, NOS|Cribriform comedo-type carcinoma|Crizotinib|Croatia|Crohn's Disease|Crolibulin|Cryoablation|Cryopreserved|Cryptococcal Meningitis|Cryptococcosis|Cryptogenic Organizing Pneumonia|Cryptophycin|Cryptophycin 52|Cryptosporidiosis, Chronic Intestinal|Crystalline Genistein Formulation AXP107-11|Cuba|Cufflinks|Curacao|Curcumin|Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110|Cure|Current User|Cusatuzumab|Cushingoid|Custirsen Sodium|Cutaneous Mastocytosis|Cutaneous Nodular Melanoma|Cutaneous T-cell lymphoma, NOS|Cutaneous histiocytoma, NOS|Cutaneous lymphoma, NOS|Cutaneous mastocytosis|Cyclin-dependent Kinase 8/19 Inhibitor BCD 115|Cyclin-dependent Kinase Inhibitor PF-06873600|Cyclodextrin-Based Polymer-Camptothecin CRLX101|Cyclodisone|Cycloleucine|Cyclopentenyl Cytosine|Cyclophosphamide|Cyclophosphamide Anhydrous|Cyclosporine|Cylindrical cell carcinoma|Cylindrical cell papilloma|Cylindroma|Cylindroma of skin|Cylindroma, NOS|Cyproterone|Cyproterone Acetate|Cyprus|Cyst(s)|Cyst-associated renal cell carcinoma|Cystadenocarcinoma|Cystadenocarcinoma, NOS|Cystadenofibroma|Cystadenofibroma, NOS|Cystadenoma|Cystadenoma, NOS|Cystectomy|Cystic Hygroma|Cystic Partially Differentiated Kidney Nephroblastoma|Cystic Teratoma|Cystic Tumor of the Atrioventricular Node|Cystic astrocytoma|Cystic hygroma|Cystic hypersecretory carcinoma|Cystic lymphangioma|Cystic mesothelioma, NOS|Cystic mesothelioma, benign|Cystic partially differentiated nephroblastoma|Cystic teratoma, NOS|Cystic tumor of atrio-ventricular node|Cystic, Mucinous and Serous Neoplasms|Cystitis Noninfective|Cystoma, NOS|Cystosarcoma phyllodes, NOS|Cystosarcoma phyllodes, benign|Cystosarcoma phyllodes, malignant|Cystoscopy|Cytarabine|Cytarabine Monophosphate Prodrug MB07133|Cytarabine-asparagine Prodrug BST-236|Cytidine Analog RX-3117|Cytochlor|Cytokine Release Syndrome|Cytokine-based Biologic Agent IRX-2|Cytologic Atypia|Cytology|Cytomegalovirus|Cytomegalovirus (CMV)|Czech Republic (Czechia)|D|D-methionine Formulation MRX-1024|DAB389 Epidermal Growth Factor|DACH Polymer Platinate AP5346|DACH-Platin Micelle NC-4016|DCIS, NOS|DCIS, comedo type|DCIS, papillary|DDA|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|DEXSeq|DFS|DGE|DHA-Paclitaxel|DHEA Mustard|DI-Leu16-IL2 Immunocytokine|DIA|DIN 3|DKK1-Neutralizing Monoclonal Antibody DKN-01|DM-CHOC-PEN|DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015|DNA|DNA Interference Oligonucleotide PNT2258|DNA Methylation|DNA Minor Groove Binding Agent SG2000|DNA Plasmid Encoding Interleukin-12 INO-9012|DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151|DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457|DNA Vaccine VB10.16|DNA-PK inhibitor AZD7648|DNA-PK/PI3K-delta Inhibitor BR101801|DNA-PK/TOR Kinase Inhibitor CC-115|DNA-dependent Protein Kinase Inhibitor VX-984|DNAcopy|DNMT1 Inhibitor NTX-301|DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98|DPT/BCG/Measles/Serratia/Pneumococcus Vaccine|DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine|DPX-E7 HPV Vaccine|DR5 HexaBody Agonist GEN1029|DR5-targeting Tetrameric Nanobody Agonist TAS266|DSQ II|DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555|DU-Disease Unchanged|DVT/PE|Dabrafenib|Dabrafenib Mesylate|Dabska tumor|Dacarbazine|Dacetuzumab|Daclizumab|Dacomitinib|Dacplatinum|Dactinomycin|Dactolisib|Dactolisib Tosylate|Dalantercept|Dalotuzumab|Danio rerio (zebrafish)|Daniquidone|Danusertib|Danvatirsen|Daporinad|Daratumumab|Daratumumab and Hyaluronidase-fihj|Daratumumab/rHuPH20|Darinaparsin|Darleukin|Darolutamide|Daromun|Dasatinib|Daughter|Daughter-in-law|Daunorubicin|Daunorubicin Citrate|Daunorubicin Hydrochloride|Dead|Death|Death Certificate|Death NOS|Death Neonatal|Debulking|Decitabine|Decitabine and Cedazuridine|Dedifferentiated Chondrosarcoma|Dedifferentiated Chordoma|Dedifferentiated Liposarcoma|Dedifferentiated chondrosarcoma|Dedifferentiated chordoma|Dedifferentiated liposarcoma|Deep ""Aggressive"" Angiomyxoma|Deep Benign Fibrous Histiocytoma|Deep Gray (e.g. Basal Ganglia, Thalamus)|Deep Gray Matter|Deep Parotidectomy|Deep Vein Thrombosis / Thromboembolism|Deep histiocytoma|Defactinib|Defactinib Hydrochloride|Deferoxamine|Deferoxamine Mesylate|Degarelix|Degarelix Acetate|Degenerated Schwannoma|Degenerated schwannoma|Dehydration|Delanzomib|Delayed Orgasm|Delayed Puberty|Delirium|Delolimogene Mupadenorepvec|Delta_B_Allele_Freq|Delusions|Demcizumab|Demecolcine|Democratic Republic of the Congo|Demplatin Pegraglumer|Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466|Dendritic Cell Tumor, Not Otherwise Specified|Dendritic Cell Vaccine|Dendritic Cell-Autologous Lung Tumor Vaccine|Dendritic Cell-targeting Lentiviral Vector ID-LV305|Dendritic cell sarcoma, NOS|Denenicokin|Dengue Virus Adjuvant PV-001-DV|Denibulin|Denibulin Hydrochloride|Denileukin Diftitox|Denintuzumab Mafodotin|Denmark|Denosumab|Dental Caries|Dentinogenic Ghost Cell Tumor|Dentinoma|Denys-Drash Syndrome|Deoxycytidine Analogue TAS-109|Deoxycytidine Analogue TAS-109 Hydrochloride|Depatuxizumab|Depatuxizumab Mafodotin|Depressed Level of Consciousness|Depression|Derazantinib|Derived Cell Line|Dermal|Dermal Nevus|Dermal and epidermal nevus|Dermal nevus|Dermatitis Radiation|Dermatofibroma lenticulare|Dermatofibroma, NOS|Dermatofibrosarcoma Protuberans|Dermatofibrosarcoma protuberans, NOS|Dermatofibrosarcoma, NOS|Dermatomyosis|Dermoid Cyst|Dermoid cyst with malignant transformation|Dermoid cyst with secondary tumor|Dermoid cyst, NOS|Dermoid, NOS|Descended testis|Descending Colon|Descending colon|Deslorelin|Deslorelin Acetate|Desmoid, NOS|Desmoid-Type Fibromatosis|Desmoplastic Infantile Astrocytoma|Desmoplastic Infantile Ganglioglioma|Desmoplastic Melanoma|Desmoplastic Mesothelioma|Desmoplastic Small Round Cell Tumor|Desmoplastic fibroma|Desmoplastic infantile astrocytoma|Desmoplastic infantile ganglioglioma|Desmoplastic medulloblastoma|Desmoplastic melanoma, amelanotic|Desmoplastic melanoma, malignant|Desmoplastic mesothelioma|Desmoplastic nodular medulloblastoma|Desmoplastic small round cell tumor|Desmoplastic/Nodular Medulloblastoma|Detirelix|Detorubicin|Deuteporfin|Deuterated Enzalutamide|Device Related Infection|Devimistat|Dexamethason|Dexamethasone|Dexamethasone Phosphate|Dexamethasone Sodium Phosphate|Dexanabinol|Dexrazoxane|Dexrazoxane Hydrochloride|Dezaguanine|Dezaguanine Mesylate|Dezapelisib|Di Guglielmo disease|DiART|DiLeu|Diabetes|Diabetes, NOS|Diabetes, Type I|Diabetes, Type II|Diabetic Neuropathy|Diagnosis|Diagnostic Imaging|Diagnostic Slide|Dianhydrogalactitol|Diaphragm|Diarrhea|Diarylsulfonylurea Compound ILX-295501|Diazepinomicin|Diaziquone|Diazooxonorleucine|Dibrospidium Chloride|Dichloroallyl Lawsone|Dictyostelium discoideum|Dicycloplatin|Didox|Dienogest|Diet|Diet Controlled Diabetes|Diethylnorspermine|Differential Gene Expression|Differentiated Retinoblastoma|Differentiated penile intraepithelial neoplasia|Differentiated-type vulvar intraepithelial neoplasia|Differentiating|Differentiating Neuroblastoma|Diffuse|Diffuse Astrocytoma|Diffuse Astrocytoma, IDH-Mutant|Diffuse Astrocytoma, IDH-Wildtype|Diffuse Centroblastic-Centrocytic Lymphoma|Diffuse Cutaneous Mastocytosis|Diffuse Intraductal Papillomatosis|Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma (DLBCL)|Diffuse Large B-Cell Lymphoma Arising in HHV8-Positive Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation|Diffuse Leptomeningeal Glioneuronal Tumor|Diffuse Malignant Lymphoma|Diffuse Midline Glioma, H3 K27M-Mutant|Diffuse Retinoblastoma|Diffuse Sclerosing Variant Thyroid Gland Papillary Carcinoma|Diffuse Type Adenocarcinoma|Diffuse astrocytoma|Diffuse astrocytoma, IDH-mutant|Diffuse astrocytoma, IDH-wildtype|Diffuse astrocytoma, low grade|Diffuse cutaneous mastocytosis|Diffuse intraductal papillomatosis|Diffuse large B-cell lymphoma associated with chronic inflammation|Diffuse large B-cell lymphoma, NOS|Diffuse leptomeningeal glioneuronal tumor|Diffuse melanocytosis|Diffuse meningiomatosis|Diffuse midline glioma, H3 K27M-mutant|Digestive System Mixed Adenoneuroendocrine Carcinoma|Digital Papillary Adenocarcinoma|Digital papillary adenocarcinoma|Digitoxin|Digoxin|Dihydro-5-Azacytidine|Dihydrolenperone|Dihydroorotate Dehydrogenase Inhibitor AG-636|Dihydroorotate Dehydrogenase Inhibitor BAY2402234|Diindolylmethane|Diktyoma, benign|Diktyoma, malignant|Dilation and Curettage|Dilation and Curettage Procedure|Dilpacimab|Dimethylmyleran|Dinaciclib|Dinutuximab|Dionex|Dioscorea nipponica Makino Extract DNE3|Diphencyprone|Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777|Disease Progression|Disease Response|Disqualified|Disseminated Intravascular Coagulation|Distal (>2cm)|Distant|Distant Metastasis|Distant Nodes|Distant Organ|Distant Site|Distant met recurrence/progression|Ditiocarb|Diverticulitis|Dizziness|Djibouti|Docetaxel|Docetaxel Anhydrous|Docetaxel Emulsion ANX-514|Docetaxel Formulation CKD-810|Docetaxel Lipid Microspheres|Docetaxel Nanoparticle CPC634|Docetaxel Polymeric Micelles|Docetaxel-PNP|Docetaxel-loaded Nanopharmaceutical CRLX301|Docetaxel/Ritonavir|Dociparstat sodium|Dolastatin 10|Dolastatin 15|Domatinostat|Dome of bladder|Dome of the Bladder|Domestic Partner|Dominica|Dominican Republic|Donafenib|Dopamine-Somatostatin Chimeric Molecule BIM-23A760|Dorsal surface of tongue, NOS|Dostarlimab|Double-armed TMZ-CD40L/4-1BBL Oncolytic Ad5/35 Adenovirus LOAd703|Dovitinib|Dovitinib Lactate|Downstream Data Freeze|Doxazosin|Doxercalciferol|Doxifluridine|Doxorubicin|Doxorubicin Hydrochloride|Doxorubicin Prodrug L-377,202|Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370|Doxorubicin-Eluting Beads|Doxorubicin-HPMA Conjugate|Doxorubicin-Magnetic Targeted Carrier Complex|Doxorubicin-loaded EGFR-targeting Nanocells|Drinker|Dromostanolone Propionate|Drosophila melanogaster|Drozitumab|Dry Eye|Dry Mouth|Dry Skin|Dual IGF-1R/InsR Inhibitor BMS-754807|Dual Variable Domain Immunoglobulin ABT-165|Dual-affinity B7-H3/CD3-targeted Protein MGD009|Dubermatinib|Duborimycin|Duct adenocarcinoma, NOS|Duct adenoma, NOS|Duct carcinoma, NOS|Duct carcinoma, desmoplastic type|Duct cell carcinoma|Ductal Breast Carcinoma|Ductal Breast Carcinoma In Situ|Ductal Breast Carcinoma In Situ and Invasive Lobular Carcinoma|Ductal Breast Carcinoma In Situ and Lobular Carcinoma In Situ|Ductal and Lobular Neoplasms|Ductal carcinoma in situ, NOS|Ductal carcinoma in situ, comedo type|Ductal carcinoma in situ, cribriform type|Ductal carcinoma in situ, micropapillary|Ductal carcinoma in situ, papillary|Ductal carcinoma in situ, solid type|Ductal carcinoma, NOS|Ductal carcinoma, cribriform type|Ductal intraepithelial neoplasia 3|Ductal papilloma|Dulanermin|Duligotuzumab|Duodenal Fistula|Duodenal Hemorrhage|Duodenal Infection|Duodenal Obstruction|Duodenal Perforation|Duodenal Stenosis|Duodenal Ulcer|Duodenum|Dupilumab|Duplicate case|Duplicate item|Durvalumab|Dusigitumab|Duvelisib|Duvortuxizumab|Dynemicin|Dynemicin A|Dysarthria|Dysembryoplastic Neuroepithelial Tumor|Dysembryoplastic neuroepithelial tumor|Dysesthesia|Dysgerminoma|Dysgeusia|Dyslipidemia|Dysmenorrhea|Dyspareunia|Dyspepsia|Dysphagia|Dysphasia|Dysplasia Negative|Dysplastic Cerebellar Gangliocytoma|Dysplastic Nevus|Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)|Dysplastic nevus|Dyspnea|E|E2F1 Pathway Activator ARQ 171|E4512|EA5142|EBNA-1 inhibitor VK-2019|EBV Immortalized|EBV Immortalized Normal|EBV positive diffuse large B-cell lymphoma of the elderly|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EC cell carcinoid|ECD|ECL cell carcinoid, NOS|ECL cell carcinoid, malignant|EED Inhibitor MAK683|EGFR Antagonist Hemay022|EGFR Antisense DNA BB-401|EGFR Inhibitor AZD3759|EGFR Inhibitor BIBX 1382|EGFR Inhibitor DBPR112|EGFR Inhibitor PD-168393|EGFR Inhibitor TY-9591|EGFR Mutant-selective  Inhibitor TQB3804|EGFR Mutant-specific Inhibitor BPI-7711|EGFR Mutant-specific Inhibitor CK-101|EGFR Mutant-specific Inhibitor D-0316|EGFR Mutant-specific Inhibitor ZN-e4|EGFR T790M Antagonist BPI-15086|EGFR T790M Inhibitor HS-10296|EGFR/EGFRvIII Inhibitor WSD0922-FU|EGFR/FLT3/Abl Inhibitor SKLB1028|EGFR/HER1/HER2 Inhibitor PKI166|EGFR/HER2 Inhibitor AP32788|EGFR/HER2 Inhibitor AV-412|EGFR/HER2 Inhibitor DZD9008|EGFR/HER2 Kinase Inhibitor TAK-285|EGFR/TGFb Fusion Monoclonal Antibody BCA101|EGFR/VEGFR/RET Inhibitor HA121-28|EGb761|EMD 1000|EP2/EP4 Antagonist TPST-1495|EP4 Antagonist INV-1120|EP4 Antagonist ONO-4578|ER alpha Proteolysis-targeting Chimera Protein Degrader ARV-471|ERK 1/2 Inhibitor ASTX029|ERK Inhibitor CC-90003|ERK Inhibitor GDC-0994|ERK Inhibitor LTT462|ERK Inhibitor MK-8353|ERK1/2 Inhibitor ASN007|ERK1/2 Inhibitor HH2710|ERK1/2 Inhibitor JSI-1187|ERK1/2 Inhibitor KO-947|ERK1/2 Inhibitor LY3214996|ERa36 Modulator Icaritin|ETD|EVOQ Elite|EVOQ Qube|EZH1/2 Inhibitor DS-3201|EZH1/2 Inhibitor HH2853|EZH2 Inhibitor CPI-1205|EZH2 Inhibitor PF-06821497|EZH2 Inhibitor SHR2554|EZH2 inhibitor CPI-0209|Ear|Ear Canal|Ear Pain|Ear and Labyrinth Disorders - Other|Ear, Pinna (External)|Early Onset Gastric Cancer|Ecchondroma|Ecchondrosis|Eccrine Hidrocystoma|Eccrine acrospiroma|Eccrine adenocarcinoma|Eccrine cystadenoma|Eccrine dermal cylindroma|Eccrine papillary adenocarcinoma|Eccrine papillary adenoma|Eccrine poroma|Eccrine poroma, malignant|Eccrine spiradenoma|Echinomycin|Ecromeximab|Ectocervix|Ectomesenchymoma|Ectopic Hamartomatous Thymoma|Ectopic Pregnancy|Ectopic hamartomatous thymoma|Ecuador|Eczema|Edatrexate|Edelfosine|Edema Cerebral|Edema Face|Edema Limbs|Edema Trunk|Edicotinib|Edodekin alfa|Edotecarin|Edrecolomab|Efatutazone|Efatutazone Dihydrochloride|Effusion|Efizonerimod|Eflornithine|Eflornithine Hydrochloride|Eftilagimod Alpha|Eftozanermin Alfa|Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205|Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621|Egypt|Eicosapentaenoic Acid|Ejaculation Disorder|Ejection Fraction Decreased|El Salvador|Elacestrant|Elacytarabine|Elagolix|Elastofibroma|Elbasvir/Grazoprevir|Elbow|Electrical fire smoke|Electrocardiogram QT Corrected Interval Prolonged|Electronic Cigarette|Electronic cigarette smoke, NOS|Element 2|Element GD|Element XR|Elesclomol|Elesclomol Sodium|Elgemtumab|Elinafide|Elisidepsin|Elliptinium|Elliptinium Acetate|Elmustine|Elotuzumab|Elpamotide|Elsamitrucin|Eltanexor|Emactuzumab|Emapalumab|Embolization|Embryonal Carcinoma|Embryonal Rhabdomyosarcoma|Embryonal Tumor with Multilayered Rosettes, C19MC-Altered|Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified|Embryonal adenocarcinoma|Embryonal adenoma|Embryonal carcinoma, NOS|Embryonal carcinoma, infantile|Embryonal carcinoma, polyembryonal type|Embryonal hepatoma|Embryonal rhabdomyosarcoma, NOS|Embryonal rhabdomyosarcoma, pleomorphic|Embryonal sarcoma|Embryonal teratoma|Embryonal tumor with multilayered rosettes C19MC-altered|Embryonal tumor with multilayered rosettes, NOS|Embryonal tumor with rhabdoid features|Emepepimut-S|Emibetuzumab|Emitefur|Emofolin Sodium|Empesertib|Enadenotucirev|Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A|Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641|Enasidenib|Enasidenib Mesylate|Enavatuzumab|Encapsulated Rapamycin|Encapsulated Variant Thyroid Gland Papillary Carcinoma|Encapsulated follicular variant of papillary thyroid carcinoma, NOS (EFVPTC, NOS)|Encapsulated papillary carcinoma|Encapsulated papillary carcinoma with invasion|Encelimab|Encephalitis Infection|Encephalomyelitis Infection|Encephalopathy|Enchondroma|Enclomiphene|Enclomiphene Citrate|Encorafenib|End-stage Renal Disease|Endemic|Endemic Burkitt Lymphoma|Endo Rectal Tumor Resection|Endocarditis Infective|Endocervical Adenocarcinoma, Usual Type|Endocervical adenocarcinoma usual type|Endocervix|Endocrine Disorders - Other|Endocrine Gland|Endocrine adenomatosis|Endocrine gland, NOS|Endocrine tumor, functioning, NOS|Endodermal sinus tumor|Endolaryngeal Excision|Endolymphatic stromal myosis|Endometrial Endometrioid Adenocarcinoma, Ciliated Variant|Endometrial Endometrioid Adenocarcinoma, Secretory Variant|Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation|Endometrial Stromal Nodule|Endometrial sarcoma, NOS|Endometrial stromal nodule|Endometrial stromal sarcoma, NOS|Endometrial stromal sarcoma, high grade|Endometrial stromal sarcoma, low grade|Endometrial stromatosis|Endometrioid Adenocarcinoma|Endometrioid Stromal Sarcoma|Endometrioid adenocarcinoma, NOS|Endometrioid adenocarcinoma, ciliated cell variant|Endometrioid adenocarcinoma, secretory variant|Endometrioid adenocarcinoma, villoglandular|Endometrioid adenofibroma, NOS|Endometrioid adenofibroma, borderline malignancy|Endometrioid adenofibroma, malignant|Endometrioid adenoma, NOS|Endometrioid adenoma, borderline malignancy|Endometrioid carcinoma with squamous differentiation|Endometrioid carcinoma, NOS|Endometrioid cystadenocarcinoma|Endometrioid cystadenofibroma, NOS|Endometrioid cystadenofibroma, borderline malignancy|Endometrioid cystadenofibroma, malignant|Endometrioid cystadenoma, NOS|Endometrioid cystadenoma, borderline malignancy|Endometrioid tumor of low malignant potential|Endometriosis|Endometrium|Endophthalmitis|Endosalpingiosis|Endoscopic Biopsy|Endoscopic Mucosal Resection (EMR)|Endoscopy|Endothelin B Receptor Blocker ENB 003|Endothelin Receptor Type A Antagonist YM598|Endotheliomatous meningioma|Endovascular papillary angioendothelioma|Enfortumab Vedotin|Engineered Human Umbilical Vein Endothelial Cells AB-205|Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240|Engineered Toxin Body Targeting CD38 TAK-169|Engineered Toxin Body Targeting HER2 MT-5111|Eniluracil/5-FU Combination Tablet|Enloplatin|Enneking High Surgical Grade|Enneking Low Surgical Grade|Enneking Metastasis M0|Enneking Metastasis M1|Enoblituzumab|Enobosarm|Enoticumab|Enpromate|Ensartinib|Ensituximab|Enteric adenocarcinoma|Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride|Enterochromaffin cell carcinoid|Enterochromaffin-Like Cell Neuroendocrine Tumor G1|Enterochromaffin-like cell carcinoid, NOS|Enterochromaffin-like cell tumor, malignant|Enterococcus gallinarum Strain MRx0518|Enterocolitis|Enterocolitis Infectious|Enteroglucagonoma|Enteroglucagonoma, NOS|Enteroglucagonoma, malignant|Enteropathy associated T-cell lymphoma|Enteropathy type intestinal T-cell lymphoma|Enteropathy-Associated T-Cell Lymphoma|Enterovesical Fistula|Entinostat|Entolimod|Entospletinib|Entrectinib|Enucleation|Envafolimab|Environmental tobacco smoke|Enzalutamide|Enzastaurin|Enzastaurin Hydrochloride|Eosinophil adenocarcinoma|Eosinophil adenoma|Eosinophil carcinoma|Eosinophilic Granuloma|Eosinophilic granuloma|Eosinophilic leukemia|Epacadostat|Epcoritamab|Ependymoblastoma|Ependymoma|Ependymoma, NOS|Ependymoma, RELA Fusion-Positive|Ependymoma, RELA fusion-positive|Ependymoma, anaplastic|EphA2-targeting Bicycle Toxin Conjugate BT5528|Epidermoid carcinoma in situ with questionable stromal invasion|Epidermoid carcinoma in situ, NOS|Epidermoid carcinoma, NOS|Epidermoid carcinoma, keratinizing|Epidermoid carcinoma, large cell, nonkeratinizing|Epidermoid carcinoma, small cell, nonkeratinizing|Epidermoid carcinoma, spindle cell|Epididymis|Epidural Space|Epilepsy|Epipodophyllotoxin Analog GL331|Epipodophyllotoxin-Related Myelodysplastic Syndrome|Epipropidine|Epirubicin|Epirubicin Hydrochloride|Epistaxis|Epithelial Dysplasia|Epithelial Hyperplasia|Epithelial Neoplasm|Epithelial Neoplasms, NOS|Epithelial Synovial Sarcoma|Epithelial ependymoma|Epithelial tumor, benign|Epithelial tumor, malignant|Epithelial-Myoepithelial Carcinoma|Epithelial-myoepithelial carcinoma|Epithelioid Cell Melanoma|Epithelioid Cell Nevus|Epithelioid Cell Type Gastrointestinal Stromal Tumor|Epithelioid Glioblastoma|Epithelioid Hemangioendothelioma|Epithelioid Hemangioma|Epithelioid Leiomyosarcoma|Epithelioid MPNST|Epithelioid Malignant Peripheral Nerve Sheath Tumor|Epithelioid Mesothelioma|Epithelioid Sarcoma|Epithelioid Trophoblastic Tumor|Epithelioid and spindle cell nevus|Epithelioid cell melanoma|Epithelioid cell nevus|Epithelioid cell sarcoma|Epithelioid glioblastoma|Epithelioid hemangioendothelioma, NOS|Epithelioid hemangioendothelioma, malignant|Epithelioid hemangioma|Epithelioid leiomyoma|Epithelioid leiomyosarcoma|Epithelioid malignant peripheral nerve sheath tumor|Epithelioid mesothelioma, NOS|Epithelioid mesothelioma, benign|Epithelioid mesothelioma, malignant|Epithelioid sarcoma|Epithelioma adenoides cysticum|Epithelioma, NOS|Epithelioma, benign|Epithelioma, malignant|Epitinib Succinate|Epitiostanol|Epitrochlear|Epothilone Analog UTD1|Epothilone KOS-1584|Epratuzumab|Epratuzumab-cys-tesirine|Epstein-Barr Virus|Equatorial Guinea|Equivocal|Erastin Analogue PRLX 93936|Erbulozole|Erdafitinib|Erectile Dysfunction|Eribulin|Eribulin Mesylate|Eritrea|Erlotinib|Erlotinib Hydrochloride|Ertumaxomab|Erythema Multiforme|Erythremic myelosis, NOS|Erythrocyte-encapsulated L-asparaginase Suspension|Erythroderma|Erythroleukemia|Escherichia coli|Esophageal Anastomotic Leak|Esophageal Cancer|Esophageal Carcinoma|Esophageal Fistula|Esophageal Hemorrhage|Esophageal High Grade Intraepithelial Neoplasia|Esophageal Infection|Esophageal Necrosis|Esophageal Obstruction|Esophageal Pain|Esophageal Perforation|Esophageal Stenosis|Esophageal Ulcer|Esophageal Varices Hemorrhage|Esophageal glandular dysplasia (intraepithelial neoplasia), high grade|Esophageal glandular dysplasia (intraepithelial neoplasia), low grade|Esophageal intraepithelial neoplasia, high grade|Esophageal squamous intraepithelial neoplasia (dysplasia), high grade|Esophageal squamous intraepithelial neoplasia (dysplasia), low grade|Esophageal; Distal|Esophageal; Mid|Esophageal; Proximal|Esophagitis|Esophagogastric Junction|Esophagus|Esophagus - Mucosa Only|Esophagus, NOS|Esorubicin|Esorubicin Hydrochloride|Esperamicin A1|Essential Thrombocythemia|Essential hemorrhagic thrombocythaemia|Essential thrombocythemia|Essiac|Esterified Estrogens|Esthesioneuroblastoma|Esthesioneurocytoma|Esthesioneuroepithelioma|Estonia|Estradiol Valerate|Estramustine|Estramustine Phosphate Sodium|Estrogen Receptor Agonist GTx-758|Estrogen only|Estrogens, Conjugated|Eswatini|Etalocib|Etanercept|Etanidazole|Etaracizumab|Etarotene|Ethanol Injection Ablation|Ethaselen|Ethinyl Estradiol|Ethiopia|Ethmoid sinus|Ethyleneimine|Ethylnitrosourea|Etidronate-Cytarabine Conjugate MBC-11|Etigilimab|Etirinotecan Pegol|Etoglucid|Etoposide|Etoposide Phosphate|Etoposide Toniribate|Etoprine|Etoricoxib|Ets-family Transcription Factor Inhibitor TK216|Euphoria|Everolimus|Everolimus Tablets for Oral Suspension|Every 24 Hours|Every Hour|Every Other Day|Every day|Evofosfamide|Ewing Sarcoma|Ewing sarcoma|Ewing tumor|Ex Vivo-expanded Autologous T Cells IMA101|Exactive|Exactive Plus|Exatecan Mesylate|Exatecan Mesylate Anhydrous|Excision|Excisional Biopsy|Exemestane|Exicorilant|Exisulind|Exocervix|Exon Expression Quantification|Exoresection|Exostosis|Expanded Next Generation Cancer Model|Experiment Metadata|Extended Release Flucytosine|Extended Release Metformin Hydrochloride|Extended-release Onapristone|External Auditory Canal Ceruminous Adenoma|External Beam Radiation|External Ear Inflammation|External Ear Pain|External Lower Lip|External ear|External lip, NOS|External lower lip|External upper lip|Extra-Adrenal Paraganglioma|Extra-abdominal desmoid|Extra-adrenal paraganglioma, NOS|Extra-adrenal paraganglioma, malignant|Extraabdominal Fibromatosis|Extracompartmental (T2)|Extracompartmental Tumor|Extracutaneous Mastocytoma|Extracutaneous mastocytoma|Extrahepatic bile duct|Extramammary Paget Disease|Extramural|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Extranodal NK/T-cell lymphoma, nasal type|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extraocular Muscle Paresis|Extraosseous Plasmacytoma|Extraosseous plasmacytoma|Extrapyramidal Disorder|Extraventricular Neurocytoma|Extraventricular neurocytoma|Eye|Eye Disorders - Other|Eye Infection|Eye Pain|Eye and adnexa|Eye, NOS|Eyelid|Eyelid Function Disorder|Ezabenlimab|F16-IL2 Fusion Protein|FAB L2|FAB L3|FAB Ll|FAB M1|FAB M2, AML1(CBF-alpha)/ETO|FAB M2, NOS|FAB M2, t(8;21)(q22;q22)|FAB M3 (includes all variants)|FAB M4|FAB M4Eo|FAB M5 (includes all variants)|FAB M6|FAB M7|FAB MO|FACT Complex-targeting Curaxin CBL0137|FAK Inhibitor GSK2256098|FAK Inhibitor PF-00562271|FAK Inhibitor VS-4718|FAK/ALK/ROS1 Inhibitor APG-2449|FAP/4-1BB-targeting DARPin MP0310|FAP/4-1BB-targeting Fusion Protein RO7122290|FASN Inhibitor TVB-2640|FASTA|FASTQ|FFPE|FFPE DNA|FFPE RNA|FFPE Recurrent|FFPE Scrolls|FGF Receptor Antagonist HGS1036|FGF/FGFR Pathway Inhibitor E7090|FGFR Inhibitor ASP5878|FGFR Inhibitor AZD4547|FGFR Inhibitor CPL304110|FGFR Inhibitor Debio 1347|FGFR Inhibitor TAS-120|FGFR/CSF-1R Inhibitor 3D185|FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999|FGFR1/2/3 Inhibitor HMPL-453|FGFR2 Inhibitor RLY-4008|FGFR4 Antagonist INCB062079|FGFR4 Inhibitor BLU 9931|FGFR4 Inhibitor FGF401|FGFR4 Inhibitor H3B-6527|FGFR4 Inhibitor ICP-105|FIGO Stage IA|FIGO Stage IC1|FIGO Stage IC2|FIGO Stage IC3|FIGO Stage IIIA1(i)|FIGO Stage IIIA1(ii)|FIGO Stage IIIA2|FIRMA|FLT3 Inhibitor FF-10101 Succinate|FLT3 Inhibitor HM43239|FLT3 Inhibitor SKI-G-801|FLT3 Tyrosine Kinase Inhibitor TTT-3002|FLT3/ABL/Aurora Kinase Inhibitor KW-2449|FLT3/CDK4/6 Inhibitor FLX925|FLT3/FGFR Dual Kinase Inhibitor MAX-40279|FLT3/KIT Kinase Inhibitor AKN-028|FLT3/KIT/CSF1R Inhibitor NMS-03592088|FM Copy Number Variation|FM Simple Somatic Mutation|FM Structural Variation|FMS Inhibitor JNJ-40346527|FPV Vaccine CV301|FPV-Brachyury-TRICOM Vaccine|FTMS|Facial Muscle Weakness|Facial Nerve Disorder|Facial Pain|Factor VII-targeting Immunoconjugate Protein ICON-1|Factor VIIa Inhibitor PCI-27483|Factory smokestack smoke|Fadraciclib|Fadrozole Hydrochloride|Falimarev|Falkland Islands (Malvinas)|Fall|Fallopian Tube|Fallopian Tube Anastomotic Leak|Fallopian Tube Obstruction|Fallopian Tube Perforation|Fallopian Tube Stenosis|Fallopian tube|False|Familial Adenomatous Polyposis|Familial polyposis coli|Famitinib|Fanconi Anemia|Farletuzumab|Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778,123|Faroe Islands|Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells|Fas Receptor Agonist APO010|Fascial Fibroma|Fascial Fibrosarcoma|Fascial fibroma|Fascial fibrosarcoma|Fascin Inhibitor NP-G2-044|Fat Atrophy|Father|Father-in-law|Fatigue|Favezelimab|Favorable|Fazarabine|Fc-engineered Anti-CD40 Agonist Antibody 2141-V11|Febrile Neutropenia|Febuxostat|Fecal Incontinence|Federated States of Micronesia|Fedratinib|Fedratinib Hydrochloride|Feladilimab|Felzartamab|Female|Female Cousin|Female Genital Tract Fistula|Female Genitalia|Female Reproductive System Adenofibroma|Female Sibling of Adopted Child|Female genital tract, NOS|Feminization Acquired|Femoral Artery|Femoral Vein|Femur|Fenebrutinib|Fenretinide|Fenretinide Lipid Matrix|Fenretinide Phospholipid Suspension ST-001|Fetal Death|Fetal Growth Retardation|Fetal Rhabdomyoma|Fetal adenocarcinoma|Fetal adenoma|Fetal fat cell lipoma|Fetal lipoma, NOS|Fetal lipomatosis|Fetal rhabdomyoma|Fever|Fianlimab|Fibrillary Astrocytoma|Fibrillary astrocytoma|Fibrinogen Decreased|Fibro-osteoma|Fibroadenoma, NOS|Fibroameloblastic odontoma|Fibroblastic Liposarcoma|Fibroblastic Osteosarcoma|Fibroblastic Reticular Cell Tumor|Fibroblastic liposarcoma|Fibroblastic meningioma|Fibroblastic osteosarcoma|Fibroblastic reticular cell tumor|Fibroblasts|Fibroblasts from Bone Marrow Normal|Fibrochondrosarcoma|Fibroepithelial Neoplasms|Fibroepithelial basal cell carcinoma, Pinkus type|Fibroepithelioma of Pinkus type|Fibroepithelioma, NOS|Fibrofolliculoma|Fibroid uterus|Fibrolamellar Carcinoma|Fibrolipoma|Fibroliposarcoma|Fibroma|Fibroma, NOS|Fibromatosis-like metaplastic carcinoma|Fibromatous Neoplasms|Fibromun|Fibromyalgia|Fibromyoma|Fibromyxoid Tumor|Fibromyxolipoma|Fibromyxoma|Fibromyxosarcoma|Fibrosarcoma|Fibrosarcoma, NOS|Fibrosarcomatous Dermatofibrosarcoma Protuberans|Fibrosarcomatous dermatofibrosarcoma protuberans|Fibrosis|Fibrosis Deep Connective Tissue|Fibrous Meningioma|Fibrous astrocytoma|Fibrous histiocytoma of tendon sheath|Fibrous histiocytoma, NOS|Fibrous meningioma|Fibrous mesothelioma, NOS|Fibrous mesothelioma, benign|Fibrous mesothelioma, malignant|Fibrous papule of nose|Fibroxanthoma, NOS|Fibroxanthoma, malignant|Fibula|Ficlatuzumab|Field burning smoke|Figitumumab|Fiji|Filanesib|Filgotinib|Filgrastim|Fimaporfin A|Fimepinostat|Fine Needle Aspiration|Finger|Finland|Fire smoke, NOS|First Cousin|First Cousin Once Removed|First Patient Visit|First Treatment|Firtecan Pegol|Fisogatinib|Five Times Daily|Flank Pain|Flanvotumab|Flashing Lights|Flat Adenoma|Flat adenoma|Flat intraepithelial glandular neoplasia, high grade|Flat intraepithelial neoplasia, high grade|Flatulence|Floaters|Floor Of Mouth|Floor of Mouth|Floor of mouth|Floor of mouth, NOS|Florid osseous dysplasia|Flotetuzumab|Floxuridine|Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01|Flt3/MerTK Inhibitor MRX-2843|Flu Like Symptoms|Fludarabine|Fludarabine Phosphate|Fluid|Flumatinib|Flumatinib Mesylate|Fluorine F 18 Ara-G|Fluorodopan|Fluorouracil|Fluorouracil Implant|Fluorouracil-E Therapeutic Implant|Fluoxymesterone|Flushing|Flutamide|Fluvastatin|Fluvastatin Sodium|Fluzoparib|Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate|Focal|Folate Receptor Targeted Epothilone BMS753493|Folate Receptor-Targeted Tubulysin Conjugate EC1456|Folate Receptor-Targeted Vinca Alkaloid EC0489|Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225|Folate-FITC|Folic Acid|Folitixorin|Follicular Dendritic Cell Sarcoma|Follicular Lymphoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma, Encapsulated Subtype with Invasion|Follicular adenocarcinoma, NOS|Follicular adenocarcinoma, moderately differentiated|Follicular adenocarcinoma, trabecular|Follicular adenocarcinoma, well differentiated|Follicular adenoma|Follicular adenoma, oxyphilic cell|Follicular carcinoma, NOS|Follicular carcinoma, encapsulated|Follicular carcinoma, minimally invasive|Follicular carcinoma, moderately differentiated|Follicular carcinoma, oxyphilic cell|Follicular carcinoma, trabecular|Follicular carcinoma, well differentiated|Follicular dendritic cell sarcoma|Follicular dendritic cell tumor|Follicular fibroma|Follicular lymphoma, NOS|Follicular lymphoma, grade 1|Follicular lymphoma, grade 2|Follicular lymphoma, grade 3|Follicular lymphoma, grade 3A|Follicular lymphoma, grade 3B|Follicular lymphoma, small cleaved cell|Follicular thyroid carcinoma (FTC), encapsulated angioinvasive|Folliculome lipidique|Foot|Forced Expiratory Volume Decreased|Forearm|Forehead|Foreskin|Foretinib|Foritinib Succinate|Former User|Formestane|Forodesine Hydrochloride|Fosaprepitant|Fosbretabulin|Fosbretabulin Disodium|Fosbretabulin Tromethamine|Fosgemcitabine Palabenamide|Fosifloxuridine Nafalbenamide|Foslinanib|Foslinanib Disodium|Fosquidone|Foster Brother|Foster Daughter|Foster Father|Foster Mother|Foster Sister|Foster Son|Fostriecin|Fotemustine|Fotretamine|FoundationOne Annotation|FoundationOne Report|FoundationOne Variant Aggregation and Masking|FoundationOne XML|Four Times Daily|Fracture|France|Franklin disease|Fraternal Twin Brother|Fraternal Twin Sibling|Fraternal Twin Sister|French Guiana|French Polynesia|Fresh|Fresolimumab|Frontal Cortex|Frontal Lobe|Frontal Sinus|Frontal lobe|Frontal sinus|Frozen|Fruquintinib|Full Brother|Full Hysterectomy|Full Sister|Fulvestrant|Fumagillin-Derived Polymer Conjugate XMT-1107|Functioning Endocrine Neoplasm|Fundus Of Stomach|Fundus Uteri|Fundus of Stomach|Fundus of stomach|Fundus uteri|Furnace or boiler smoke|Fursultiamine|Fusion Catcher|Futibatinib|Futuximab|Futuximab/Modotuximab Mixture|G|G Protein-coupled Estrogen Receptor Agonist LNS8801|G cell tumor, NOS|G cell tumor, malignant|G-Quadruplex Stabilizer BMVC|G1|G2|G3|G4|GANT|GATK4 MuTect2|GATK4 MuTect2 Annotation|GB|GBM Antigens and Alloantigens Immunotherapeutic Vaccine|GC IsoLink|GCT|GCT Premier|GENIE Copy Number Variation|GENIE Report|GENIE Simple Somatic Mutation|GENIE Structural Variation|GENIE Variant Aggregation and Masking|GERD|GGT Increased|GI-4000 Vaccine|GIST, NOS|GIST, benign|GIST, malignant|GISTIC - Arm Level Copy Number|GISTIC - Copy Number Score|GISTIC - Focal Amplification|GISTIC - Focal Deletion|GITR Agonist MEDI1873|GM-CSF-encoding Oncolytic Adenovirus CGTG-102|GS/pan-Notch Inhibitor AL101|GS/pan-Notch Inhibitor BMS-986115|GSK-3 Inhibitor 9-ING-41|GSK-3 Inhibitor LY2090314|GVF|GX|Gabon|Gait Disturbance|Galamustine|Galarubicin|Galectin Inhibitor GR-MD-02|Galectin-1 Inhibitor OTX008|Galeterone|Galiximab|Gallbladder|Gallbladder Cancer|Gallbladder Fistula|Gallbladder Infection|Gallbladder Necrosis|Gallbladder Obstruction|Gallbladder Pain|Gallbladder Papillary Neoplasm with Intermediate Grade Intraepithelial Neoplasia|Gallbladder Papillary Neoplasm with Low Grade Intraepithelial Neoplasia|Gallbladder Perforation|Gallium-based Bone Resorption Inhibitor AP-002|Gallus gallus|Galocitabine|Galunisertib|Gambia|Gamboge Resin Extract TSB-9-W1|Gamma Heavy Chain Disease|Gamma heavy chain disease|Gamma-Secretase Inhibitor LY3039478|Gamma-Secretase Inhibitor RO4929097|Gamma-delta Tocotrienol|Gandotinib|Ganetespib|Ganglia|Gangliocytic paraganglioma|Gangliocytoma|Ganglioglioma|Ganglioglioma, NOS|Ganglioglioma, anaplastic|Ganglioneuroblastoma|Ganglioneuroma|Ganglioneuromatosis|Ganglioside GD2|Ganglioside GM2|Ganitumab|Ganoderma lucidum Spores Powder Capsule|Garlic|Gas burning smoke, propane|Gasterosteus aculeatus (fish)|Gastric Anastomotic Leak|Gastric Cancer|Gastric Fistula|Gastric Hemorrhage|Gastric Necrosis|Gastric Parietal Cell Adenocarcinoma|Gastric Perforation|Gastric Polyp(s)|Gastric Stenosis|Gastric Ulcer|Gastric antrum|Gastrin Immunotoxin|Gastrin cell tumor|Gastrin cell tumor, malignant|Gastrin-Producing Neuroendocrine Tumor|Gastrin/cholecystokinin Type B Receptor Inhibitor Z-360|Gastrinoma, NOS|Gastrinoma, malignant|Gastritis|Gastroesophageal Junction|Gastroesophageal Reflux Disease|Gastrointestinal Anastomotic Leak|Gastrointestinal Autonomic Nerve Tumor|Gastrointestinal Disorders - Other|Gastrointestinal Fistula|Gastrointestinal Pain|Gastrointestinal Stoma Necrosis|Gastrointestinal Stromal Tumor|Gastrointestinal Stromal Tumor of Uncertain Malignant Potential|Gastrointestinal Tract|Gastrointestinal autonomic nerve tumor|Gastrointestinal pacemaker cell tumor|Gastrointestinal stromal sarcoma|Gastrointestinal stromal tumor, NOS|Gastrointestinal stromal tumor, benign|Gastrointestinal stromal tumor, malignant|Gastrointestinal stromal tumor, uncertain malignant potential|Gastrointestinal tract, NOS|Gastrointestinal, Intestine|Gastroparesis|Gataparsen Sodium|Gatipotuzumab|Gedatolisib|Gefitinib|Gelatinous adenocarcinoma|Gelatinous carcinoma|Geldanamycin|Gelonin|Gemcitabine|Gemcitabine Elaidate|Gemcitabine Hydrochloride|Gemcitabine Hydrochloride Emulsion|Gemcitabine Prodrug LY2334737|Gemcitabine-Phosphoramidate Hydrochloride NUC-1031|Gemcitabine-Releasing Intravesical System|Gemistocytic Astrocytoma|Gemistocytic astrocytoma|Gemistocytoma|Gemtuzumab Ozogamicin|Gene Expression Quantification|Gene Level Copy Number|Gene Level Copy Number Scores|General|General Disorders and Administration Site Conditions - Other|Generalized Muscle Weakness|Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum|Genistein|Genital Edema|Genital Rhabdomyoma|Genital rhabdomyoma|Genitourinary, NOS|GenomePlex (Rubicon) Amplified DNA|Genomic Profiling|Genomplex|Genotype mismatch|Genotypes|Genotyping Array|Gentuximab|Georgia|Geranylgeranyltransferase I Inhibitor|Germ Cell Neoplasms|Germ Cell Tumor|Germ cell tumor, NOS|Germ cell tumor, nonseminomatous|Germ cell tumors with associated hematological malignancy|Germany|Germinoma|Gerota Fascia|Ghana|Ghost Cell Odontogenic Carcinoma|Ghost cell odontogenic carcinoma|Giant Cell Angiofibroma|Giant Cell Carcinoma|Giant Cell Fibroblastoma|Giant Cell Glioblastoma|Giant Cell Sarcoma|Giant Cell Tumor of Bone|Giant Cell Tumor of Soft Tissue|Giant Cell Tumors|Giant Cell and Spindle Cell Carcinoma|Giant Congenital Nevus|Giant cell and spindle cell carcinoma|Giant cell angiofibroma|Giant cell carcinoma|Giant cell fibroblastoma|Giant cell glioblastoma|Giant cell sarcoma|Giant cell sarcoma of bone|Giant cell tumor of bone, NOS|Giant cell tumor of bone, malignant|Giant cell tumor of soft parts, NOS|Giant cell tumor of tendon sheath|Giant cell tumor of tendon sheath, malignant|Giant fibroadenoma|Giant osteoid osteoma|Giant pigmented nevus, NOS|Gibraltar|Gigantiform Cementoma|Gigantiform cementoma|Gilbert's Syndrome|Giloralimab|Gilteritinib|Gilteritinib Fumarate|Gimatecan|Gimeracil|Gingival Pain|Ginsenoside Rg3 Capsule|Giredestrant|Girentuximab|Girodazole|Givinostat|Glandular Papilloma|Glandular Papillomatosis|Glandular intraepithelial neoplasia, grade I|Glandular intraepithelial neoplasia, grade II|Glandular intraepithelial neoplasia, grade III|Glandular intraepithelial neoplasia, high grade|Glandular intraepithelial neoplasia, low grade|Glandular papilloma|Glans Penis|Glans penis|Glasdegib|Glasdegib Maleate|Glassy Cell Carcinoma|Glassy cell carcinoma|Glaucarubolone|Glaucoma|Gleason Grade Group 1|Gleason Grade Group 2|Gleason Grade Group 3|Gleason Grade Group 4|Gleason Grade Group 5|Gleason Pattern 1|Gleason Pattern 2|Gleason Pattern 3|Gleason Pattern 4|Gleason Pattern 5|Glecaprevir/Pibrentasvir|Glembatumumab Vedotin|Glesatinib|Glioblastoma|Glioblastoma Cancer Vaccine ERC1671|Glioblastoma Multiforme|Glioblastoma Multiforme Multipeptide Vaccine IMA950|Glioblastoma multiforme|Glioblastoma with sarcomatous component|Glioblastoma, IDH wildtype|Glioblastoma, IDH-Mutant|Glioblastoma, IDH-Wildtype|Glioblastoma, IDH-mutant|Gliofibroma|Glioma|Glioma Lysate Vaccine GBM6-AD|Glioma, NOS|Glioma, malignant|Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701|Gliomas|Gliomatosis Cerebri|Gliomatosis cerebri|Glioneuroma|Gliosarcoma|Globo H-DT Vaccine OBI-833|Glofitamab|Glomangioma|Glomangiomyoma|Glomangiosarcoma|Glomerular Disease|Glomoid sarcoma|Glomus Tumor|Glomus jugulare tumor, NOS|Glomus tumor, NOS|Glomus tumor, malignant|Glossectomy|Glossopharyngeal Nerve Disorder|Glottis|Glucagon-like peptide-producing tumor|Glucagonoma, NOS|Glucagonoma, malignant|Glucarpidase|Glucocorticoid Receptor Antagonist ORIC-101|Glucose Intolerance|Glufosfamide|Glumetinib|Glutaminase Inhibitor CB-839|Glutaminase Inhibitor CB-839 Hydrochloride|Glutaminase Inhibitor IPN60090|Glutamine Antagonist DRP-104|Glutamyl endopeptidase|Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101|Glyco-TMT|Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01|Glycogen Storage Disease|Glycogen-Rich Carcinoma|Glycogen-rich carcinoma|Glycogenic rhabdomyoma|Glycooptimized Trastuzumab-GEX|Glycoproteome|Goblet cell carcinoid|Gold Sodium Thiomalate|Golnerminogene Pradenovec|Golotimod|Golvatinib|Gonadal Dysfunction|Gonadal stromal tumor, NOS|Gonadoblastoma|Gonadotropin-releasing Hormone Analog|Gonocytoma|Good Prognosis|Gorlin Syndrome|Goserelin|Goserelin Acetate|Goserelin Acetate Extended-release Microspheres LY01005|Gossypol|Gossypol Acetic Acid|Gout|Grade 1|Grade 1 Follicular Lymphoma|Grade 1 Nodular Sclerosis Classic Hodgkin Lymphoma|Grade 2|Grade 2 Follicular Lymphoma|Grade 2 Nodular Sclerosis Classic Hodgkin Lymphoma|Grade 3|Grade 3 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Grade 3b Follicular Lymphoma|Grade 4|Grade 5|Grade B|Grade I|Grade I Neuroendocrine Carcinoma|Grade II|Grade II Glandular Intraepithelial Neoplasia|Grade II Neuroendocrine Carcinoma|Grade II Squamous Intraepithelial Neoplasia|Grade III|Grade III Glandular Intraepithelial Neoplasia|Grade III Prostatic Intraepithelial Neoplasia|Grade IV|Grade Not Assigned|Grade X|Grand Nephew|Grand Niece|Grandchild|Granddaughter|Grandfather|Grandmother|Grandparent|Grandson|Granular Cell Carcinoma|Granular Cell Tumor|Granular Cell Tumor of the Sellar Region|Granular Cell Tumors and Alveolar Soft Part Sarcomas|Granular cell adenocarcinoma|Granular cell carcinoma|Granular cell myoblastoma, NOS|Granular cell myoblastoma, malignant|Granular cell tumor of the sellar region|Granular cell tumor, NOS|Granular cell tumor, malignant|Granulocytes|Granulocytic Sarcoma|Granulocytic leukemia, NOS|Granulocytic sarcoma|Granulosa Cell Tumor|Granulosa Cell-Theca Cell Tumor|Granulosa cell carcinoma|Granulosa cell tumor, NOS|Granulosa cell tumor, adult type|Granulosa cell tumor, juvenile|Granulosa cell tumor, malignant|Granulosa cell tumor, sarcomatoid|Granulosa cell-theca cell tumor|Grapiprant|Grawitz tumor|Gray|Grease fire smoke|Great Grandchild|Greater Curvature of the Stomach|Greater curvature of stomach, NOS|Greece|Green|Green Tea Extract-based Antioxidant Supplement|Greenland|Grenada|Grilling smoke|Groin|Gross Total Resection|Group 1|Group 2|Group 3|Group 4|Group 5|Group I|Group II|Group III|Group IIIa|Group IIIb|Group IIa|Group IIb|Group IIc|Group IV|Group Ia|Group Ib|Growth Accelerated|Growth Hormone Abnormal|Growth Suppression|Guadecitabine|Guadeloupe|Guam|Guanabenz Acetate|Guatemala|Guernsey|Guinea|Guinea-Bissau|Gum|Gum Infection|Gum, NOS|Guselkumab|Gusperimus Trihydrochloride|Gutolactone|Guyana|Gy|Gynandroblastoma|Gynecologic Cancer|Gynecomastia|H|H-ras Antisense Oligodeoxynucleotide ISIS 2503|H. pylori Infection|H1299 Tumor Cell Lysate Vaccine|H2 Blockers|HAAH Lambda phage Vaccine SNS-301|HBV Core Antibody|HBV DNA|HBV Genotype|HBV Surface Antibody|HCD|HCV DNA Vaccine INO-8000|HCV Genotype|HDAC Class I/IIb Inhibitor HG146|HDAC Inhibitor AR-42|HDAC Inhibitor CHR-2845|HDAC Inhibitor CKD-581|HDAC Inhibitor CXD101|HDAC Inhibitor MPT0E028|HDAC Inhibitor OBP-801|HDAC inhibitor CG200745|HDAC/EGFR/HER2 Inhibitor CUDC-101|HDAC6 Inhibitor KA2507|HDAC8 Inhibitor NBM-BMX|HDF5|HDM2 Inhibitor HDM201|HDM2 Inhibitor MK-8242|HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131|HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901|HER2 Inhibitor CP-724,714|HER2 Inhibitor DZD1516|HER2 Inhibitor TAS0728|HER2 Tri-specific Natural Killer Cell Engager DF1001|HER2-directed TLR8 Agonist SBT6050|HER2-targeted DARPin MP0274|HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302|HER2-targeting Antibody Fc Fragment FS102|HIF-1alpha Inhibitor PX-478|HIF-2alpha Inhibitor PT2385|HIF-2alpha Inhibitor PT2977|HIF2a RNAi ARO-HIF2|HIV|HIV / AIDS|HIV+ Tumor Molecular Characterization Project - Cervical Cancer|HIV+ Tumor Molecular Characterization Project - Lung Cancer|HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001|HLA-A*2402-Restricted Multipeptide Vaccine S-488410|HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201|HM2/MMAE Antibody-Drug Conjugate ALT-P7|HPPH|HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202|HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c|HPV DNA Plasmids Therapeutic Vaccine VGX-3100|HPV E6/E7 DNA Vaccine GX-188E|HPV E6/E7-encoding Arenavirus Vaccine HB-201|HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C|HPV-16 E6 Peptides Vaccine/Candida albicans Extract|HPV-6-targeting Immunotherapeutic Vaccine INO-3106|HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101|HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN|HPV6/11-targeted DNA Plasmid Vaccine INO-3107|HSP90-targeted SN-38 Conjugate PEN-866|HSP90alpha/beta Inhibitor TAS-116|HTSeq - Counts|HTSeq - FPKM|HTSeq - FPKM-UQ|HUS/TTP|Haemangioblastoma|Haemangiosarcoma|Hafnium Oxide-containing Nanoparticles NBTXR3|Hairy Cell Leukemia|Hairy Cell Leukemia Variant|Hairy Nevus|Hairy cell leukaemia variant|Hairy cell leukemia|Hairy cell leukemia variant|Hairy nevus|Haiti|Half Brother|Half Sibling|Half Sister|Halichondrin Analogue E7130|Halichondrin B|Haliotis rufescens|Hallucinations|Halo Nevus|Halo nevus|Halofuginone|Halofuginone Hydrobromide|Hand|Hand Assisted Laparoscopic Radical Nephrectomy|Hand-Schuller-Christian Disease|Hand-Schuller-Christian disease|HaplotypeCaller|Haptoglobin Decreased|Hard Palate|Hard palate|Hashimoto's Thyroiditis|Hashish smoke|Hay Fever|Hazel|Head & Neck|Head - Face Or Neck, Nos|Head Soft Tissue Necrosis|Head and Neck|Head and Neck Cancer|Head and Neck Lymph Node|Head and Neck Squamous Cell Carcinoma|Head of pancreas|Head of the Pancreas|Head, Face or Neck, NOS|Head, face or neck, NOS|Headache|Headaches|Hearing Impaired|Heart|Heart Disease|Heart Failure|Heart, mediastinum, and pleura|Heavy Chain Disease|Heavy Drinker|Heavy chain disease, NOS|Hedgehog Inhibitor IPI-609|Helicobacter Pylori-Associated Gastritis|Hemangioblastic Meningioma|Hemangioblastic meningioma|Hemangioblastoma|Hemangioendothelial sarcoma|Hemangioendothelioma|Hemangioendothelioma, NOS|Hemangioendothelioma, benign|Hemangioendothelioma, malignant|Hemangioma|Hemangioma simplex|Hemangioma, NOS|Hemangiopericytic meningioma|Hemangiopericytoma|Hemangiopericytoma, NOS|Hemangiopericytoma, benign|Hemangiopericytoma, malignant|Hematologic Cancer|Hematologic Disorder, NOS|Hematoma|Hematopoietic System|Hematopoietic and reticuloendothelial systems|Hematopoietic system, NOS|Hematoporphyrin Derivative|Hematosalpinx|Hematuria|Hemiasterlin Analog E7974|Hemihypertrophy|Hemochromatosis|Hemoglobin Increased|Hemoglobinuria|Hemolymphangioma|Hemolysis|Hemolytic Uremic Syndrome|Hemophiliac|Hemorrhagic Cystitis|Hemorrhoidal Hemorrhage|Hemorrhoids|Henatinib Maleate|Heparan Sulfate Glycosaminoglycan Mimetic M402|Heparin Derivative SST0001|Hepatic|Hepatic Duct|Hepatic Encephalopathy|Hepatic Failure|Hepatic Flexure|Hepatic Hemorrhage|Hepatic Infection|Hepatic Necrosis|Hepatic Pain|Hepatic Vein|Hepatic flexure of colon|Hepatitis|Hepatitis A Infection|Hepatitis B Infection|Hepatitis B Surface Antigen|Hepatitis C Antibody|Hepatitis C Infection|Hepatitis C Virus RNA|Hepatitis C virus|Hepatitis Viral|Hepatitis, Chronic|Hepatitis, NOS|Hepatobiliary Disorders - Other|Hepatoblastoma|Hepatoblastoma, epithelioid|Hepatoblastoma, mixed epithelial-mesenchymal|Hepatocarcinoma|Hepatocellular Adenoma|Hepatocellular Carcinoma|Hepatocellular adenoma|Hepatocellular carcinoma, NOS|Hepatocellular carcinoma, clear cell type|Hepatocellular carcinoma, fibrolamellar|Hepatocellular carcinoma, pleomorphic type|Hepatocellular carcinoma, sarcomatoid|Hepatocellular carcinoma, scirrhous|Hepatocellular carcinoma, spindle cell variant|Hepatocholangiocarcinoma|Hepatoid Adenocarcinoma|Hepatoid adenocarcinoma|Hepatoid carcinoma|Hepatoid yolk sac tumor|Hepatoma, NOS|Hepatoma, benign|Hepatoma, malignant|Hepatosplenic T-Cell Lymphoma|Hepatosplenic T-cell lymphoma|Hepatosplenic gamma-delta cell lymphoma|Herba Scutellaria Barbata|Herbimycin|Hereditary Breast Cancer|Hereditary Kidney Oncocytoma|Hereditary Leiomyomatosis and Renal Cell Carcinoma|Hereditary Non-polyposis Colon Cancer|Hereditary Ovarian Cancer|Hereditary Papillary Renal Cell Carcinoma|Hereditary Prostate Cancer|Hereditary Renal Cell Carcinoma|Hereditary leiomyomatosis & RCC-associated renal cell carcinoma|Herpes|Herpes Simplex Virus|Herpes Zoster|Heterodimeric Interleukin-15|Heterosexual Contact|Hexamethylene Bisacetamide|Hexaminolevulinate|Hexylresorcinol|HiChIP|HiRes ESI|HiRes MALDI|Hibernoma|Hiccups|Hidradenocarcinoma|Hidradenoma|Hidradenoma Papilliferum|Hidradenoma papilliferum|Hidradenoma, NOS|Hidrocystoma|High|High Grade|High Grade (G2)|High Grade B-Cell Lymphoma, Not Otherwise Specified|High Grade Ductal Breast Carcinoma In Situ|High Grade Dysplasia|High Grade Esophageal Glandular Intraepithelial Neoplasia|High Grade Esophageal Squamous Intraepithelial Neoplasia|High Grade Glandular Intraepithelial Neoplasia|High Grade Liver Dysplastic Nodule|High Grade Squamous Intraepithelial Neoplasia|High Grade Surface Osteosarcoma|High Risk|High Risk Gastrointestinal Stromal Tumor|High grade surface osteosarcoma|High-Intermediate Risk|High-Risk Wilms Tumor|High-grade Prostatic Intraepithelial Neoplasia (PIN)|High-grade neuroendocrine carcinoma|High-grade serous carcinoma|HighPure miRNA (Allprep DNA) FFPE RNA|Hilar|Hilar Cholangiocarcinoma|Hilar cell tumor|Hilus cell tumor|Hip|Hip Fracture|Hippocampus|Hirsutism|Hispanic or Latino|Histiocyte-rich large B-cell lymphoma|Histiocytic Sarcoma|Histiocytic medullary reticulosis|Histiocytic sarcoma|Histiocytoid hemangioma|Histiocytoma|Histiocytoma, NOS|Histiocytosis X, NOS|Histology|Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126|Histoplasmosis|History of acceptable prior treatment related to a prior/other malignancy|History of unacceptable prior treatment related to a prior/other malignancy|Histrelin Acetate|Hitachi|Hoarseness|Hodgkin Lymphoma|Hodgkin disease, NOS|Hodgkin disease, lymphocyte predominance, NOS|Hodgkin disease, lymphocyte predominance, diffuse|Hodgkin disease, lymphocytic-histiocytic predominance|Hodgkin disease, nodular sclerosis, NOS|Hodgkin disease, nodular sclerosis, lymphocyte depletion|Hodgkin disease, nodular sclerosis, lymphocyte predominance|Hodgkin disease, nodular sclerosis, mixed cellularity|Hodgkin disease, nodular sclerosis, syncytial variant|Hodgkin granuloma|Hodgkin lymphoma, NOS|Hodgkin lymphoma, lymphocyte depletion, NOS|Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis|Hodgkin lymphoma, lymphocyte depletion, reticular|Hodgkin lymphoma, lymphocyte predominance, nodular|Hodgkin lymphoma, lymphocyte-rich|Hodgkin lymphoma, mixed cellularity, NOS|Hodgkin lymphoma, nodular lymphocyte predominance|Hodgkin lymphoma, nodular sclerosis, NOS|Hodgkin lymphoma, nodular sclerosis, cellular phase|Hodgkin lymphoma, nodular sclerosis, grade 1|Hodgkin lymphoma, nodular sclerosis, grade 2|Hodgkin paragranuloma, NOS|Hodgkin paragranuloma, nodular|Hodgkin sarcoma|Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine|Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Depletion|Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Predominance|Hodgkin's Disease, Nodular Sclerosis, Mixed Cellularity|Hodgkin's Granuloma|Hodgkin's Paragranuloma|Holmium Ho 166 Poly(L-Lactic Acid) Microspheres|Holy See|Homo sapiens|Homo sapiens; Mus musculus|Homosexual Contact|Honduras|Hong Kong|Hormone Therapy|Hormones|Hot Flashes|Hsp90 Antagonist KW-2478|Hsp90 Inhibitor AB-010|Hsp90 Inhibitor BIIB021|Hsp90 Inhibitor BIIB028|Hsp90 Inhibitor DS-2248|Hsp90 Inhibitor Debio 0932|Hsp90 Inhibitor HSP990|Hsp90 Inhibitor MPC-3100|Hsp90 Inhibitor PU-H71|Hsp90 Inhibitor SNX-5422 Mesylate|Hsp90 Inhibitor SNX-5542 Mesylate|Hsp90 Inhibitor TQB3474|Hsp90 Inhibitor XL888|Hsp90-targeted Photosensitizer HS-201|Hu14.18-IL2 Fusion Protein EMD 273063|HuaChanSu|Huaier Extract Granule|Huang Lian|Human Combinatorial Antibody Library-based Monoclonal Antibody VAY736|Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104|Human MOAB LICO 28a32|Human Monoclonal Antibody 216|Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307|Human Original Cells|Human Papillomavirus 16 E7 Peptide/Padre 965.10|Human Papillomavirus Infection|Human Papillomavirus-Related Squamous Cell Carcinoma|Human Tumor Original Cells|Humerus|Hungary|Hurthle cell adenocarcinoma|Hurthle cell adenoma|Hurthle cell carcinoma|Hurthle cell tumor|Husband|Hutchinson melanotic freckle, NOS|Hyalinizing trabecular adenoma|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Hycanthone|Hydatid mole|Hydatidiform Mole|Hydatidiform mole, NOS|Hydralazine Hydrochloride|Hydrazide TMT|Hydroa Vacciniforme-Like Lymphoproliferative Disorder|Hydroa vacciniforme-like lymphoma|Hydrocephalus|Hydrocortisone Sodium Succinate|Hydroxychloroquine|Hydroxyprogesterone Caproate|Hydroxytyrosol|Hydroxyurea|Hygroma, NOS|Hypercalcemia|Hypercholesterolemia|Hypereosinophilic Syndrome|Hypereosinophilic syndrome|Hyperglycemia|Hyperhidrosis|Hypericin|Hyperkalemia|Hyperlipidemia|Hypermagnesemia|Hypernatremia|Hypernephroid tumor|Hypernephroma|Hyperparathyroidism|Hypersomnia|Hypertension|Hyperthyroidism|Hypertrichosis|Hypertriglyceridemia|Hyperuricemia|Hypoalbuminemia|Hypocalcemia|Hypoglossal Nerve Disorder|Hypoglycemia|Hypohidrosis|Hypokalemia|Hypomagnesemia|Hyponatremia|Hypoparathyroidism|Hypopharyngeal aspect of aryepiglottic fold|Hypopharynx|Hypopharynx, NOS|Hypophosphatemia|Hypospadias|Hypotension|Hypothermia|Hypothyroidism|Hypoxia|Hypoxia-activated Prodrug TH-4000|Hysterectomy NOS|Hysterectomy, NOS|I|I 131 Antiferritin Immunoglobulin|I 131 Monoclonal Antibody A33|I 131 Monoclonal Antibody CC49|I 131 Monoclonal Antibody F19|I 131 Monoclonal Antibody Lym-1|I-131 Radiation Therapy|IAP Inhibitor APG-1387|IAP Inhibitor AT-406|IAP Inhibitor HGS1029|ICAT|ICPL|ICT-121 Dendritic Cell Vaccine|IDAT|IDF|IDH1 Mutant Inhibitor LY3410738|IDH1(R132) Inhibitor IDH305|IDH1R132H-Specific Peptide Vaccine PEPIDH1M|IDO Peptide Vaccine IO102|IDO-1 Inhibitor LY3381916|IDO/TDO Inhibitor HTI-1090|IDO/TDO Inhibitor LY-01013|IDO1 Inhibitor KHK2455|IDO1 Inhibitor MK-7162|IDO1 Inhibitor PF-06840003|IDO1/TDO2 Inhibitor DN1406131|IDO1/TDO2 Inhibitor M4112|IGF-1R Inhibitor|IGF-1R Inhibitor PL225B|IGF-1R/IR Inhibitor KW-2450|IGF-methotrexate Conjugate|II|III|IL-10 Immunomodulator MK-1966|IL-12-expressing HSV-1 NSC 733972|IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051|IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000|IL-2 Recombinant Fusion Protein ALT-801|IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1|IL4-Pseudomonas Exotoxin Fusion Protein MDNA55|IMR-Immunoresponse|IMT-1012 Immunotherapeutic Vaccine|INO-1001|INR Increased|INRG Stage L1|INRG Stage L2|INRG Stage M|INRG Stage MS|INSS Stage 1|INSS Stage 2A|INSS Stage 2B|INSS Stage 3|INSS Stage 4|INSS Stage 4S|IPD-Immunoprogression|IPTL|IRAK4 Inhibitor CA-4948|ISQ|ISS 1018 CpG Oligodeoxynucleotide|ISS Stage I Plasma Cell Myeloma|ISS Stage II Plasma Cell Myeloma|ISS Stage III Plasma Cell Myeloma|ITK Inhibitor CPI-818|ITP|ITQ 1100|ITQ 700|ITQ 900|IVth Nerve Disorder|Iadademstat|Ianalumab|Ibandronate Sodium|Iberdomide|Iboctadekin|Ibritumomab Tiuxetan|Ibrutinib|Iceland|Icotinib Hydrochloride|Icrucumab|Idarubicin|Idarubicin Hydrochloride|Idarubicin-Eluting Beads|Idasanutlin|Idecabtagene Vicleucel|Idelalisib|Identical Twin Brother|Identical Twin Sibling|Identical Twin Sister|Idetrexed|Idiopathic hemorrhagic thrombocythaemia|Idiopathic thrombocythemia|Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020|Idronoxil|Idronoxil Suppository NOX66|Ieramilimab|Ifabotuzumab|Ifetroban|Ifosfamide|Ileal Fistula|Ileal Hemorrhage|Ileal Obstruction|Ileal Perforation|Ileal Stenosis|Ileal Ulcer|Ileocecal Valve|Ileum|Ileus|Ilginatinib|Ilium|Ilixadencel|Ill-Defined Anatomic Site|Ill-defined sites within respiratory system|Illumina|Illumina Human Methylation 27|Illumina Human Methylation 450|Illumina Methylation Epic|Iloprost|Ilorasertib|Imaging|Imaging Technique|Imalumab|Imaradenant|Imatinib|Imatinib Mesylate|Imetelstat|Imetelstat Sodium|Imexon|Imgatuzumab|Imidazole Mustard|Imidazole-Pyrazole|Imifoplatin|Imipramine Blue|Imiquimod|Immature Teratoma|Immature teratoma, NOS|Immature teratoma, malignant|Immediate-release Onapristone|Immediate-release Tablet Afuresertib|Immune Checkpoint Inhibitor ASP8374|Immune System Disorders - Other|Immunoblastic Lymphoma|Immunoblastic sarcoma|Immunoconjugate RO5479599|Immunocytokine NHS-IL12|Immunocytokine NHS-IL2-LT|Immunocytoma|Immunodeficiency-Related Burkitt Lymphoma|Immunodeficiency-associated, adult|Immunodeficiency-associated, pediatric|Immunoglobulin deposition disease|Immunomodulator LAM-003|Immunomodulator OHR/AVR118|Immunomodulatory Agent CC-11006|Immunomodulatory Oligonucleotide HYB2055|Immunoprogression|Immunoproliferative Diseases|Immunoproliferative disease, NOS|Immunoproliferative small intestinal disease|Immunoresponse|Immunotherapeutic Combination Product CMB305|Immunotherapeutic GSK1572932A|Immunotherapy (Including Vaccines)|Immunotherapy Regimen MKC-1106-MT|Immunotoxin CMD-193|In Situ Neoplasms|Inactivated Oncolytic Virus Particle GEN0101|Inadvertently shipped|Inalimarev|Incisional Biopsy|Incomplete Necrosis (Viable Tumor Present)|Incyclinide|Indatuximab Ravtansine|Indefinite Dysplasia|Indefinite for Dysplasia|Indeterminant|Indeterminate|Indeterminate Dendritic Cell Tumor|Indeterminate dendritic cell tumor|Index Finger|India|Indibulin|Indicine-N-Oxide|Indisulam|Individualized MVA-based Vaccine TG4050|Indocyanine Green-labeled Polymeric Micelles ONM-100|Indole-3-Carbinol|Indolent Systemic Mastocytosis|Indolent systemic mastocytosis|Indomethacin|Indonesia|Indoor stove or fireplace smoke, NOS|Indoor stove or fireplace smoke, coal burning|Indoor stove or fireplace smoke, wood burning|Indoximod|Indoximod Prodrug NLG802|Induced Abortion|Induction Failure AML (AML-IF)|Indusatumab Vedotin|Inebilizumab|Inecalcitol|Infantile Fibrosarcoma|Infantile Hemangioma|Infantile fibrosarcoma|Infantile hemangioma|Infantile myofibromatosis|Infection|Infections and Infestations - Other|Infectious Disorder|Infective Myositis|Infigratinib|Infigratinib Mesylate|Infiltrating Angiolipoma|Infiltrating Bladder Urothelial Carcinoma with Squamous Differentiation|Infiltrating Bladder Urothelial Carcinoma with Trophoblastic Differentiation|Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant|Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant|Infiltrating Bladder Urothelial Carcinoma, Microcystic Variant|Infiltrating Bladder Urothelial Carcinoma, Nested Variant|Infiltrating Lipoma|Infiltrating Papillary Adenocarcinoma|Infiltrating and papillary adenocarcinoma|Infiltrating angiolipoma|Infiltrating basal cell carcinoma, NOS|Infiltrating basal cell carcinoma, non-sclerosing|Infiltrating basal cell carcinoma, sclerosing|Infiltrating duct adenocarcinoma|Infiltrating duct and colloid carcinoma|Infiltrating duct and cribriform carcinoma|Infiltrating duct and lobular carcinoma|Infiltrating duct and lobular carcinoma in situ|Infiltrating duct and mucinous carcinoma|Infiltrating duct and tubular carcinoma|Infiltrating duct carcinoma, NOS|Infiltrating duct mixed with other types of carcinoma|Infiltrating ductular carcinoma|Infiltrating lipoma|Infiltrating lobular carcinoma and ductal carcinoma in situ|Infiltrating lobular carcinoma, NOS|Infiltrating lobular mixed with other types of carcinoma|Infiltrating papillary adenocarcinoma|Inflammation, Hyperkeratosis|Inflammatory Bowel Disease|Inflammatory Liposarcoma|Inflammatory Myofibroblastic Tumor|Inflammatory adenocarcinoma|Inflammatory carcinoma|Inflammatory liposarcoma|Inflammatory myofibroblastic tumor|Infliximab|Informed Consent|Infusion Related Reaction|Infusion Site Extravasation|Ingenol Mebutate|Ingenol Mebutate Gel|Inguinal Lymph Node|Inguinal Region|Iniparib|Initial Diagnosis|Initial Genomic Sequencing|Injected Insulin|Injection Site Reaction|Injury to Carotid Artery|Injury to Inferior Vena Cava|Injury to Jugular Vein|Injury to Superior Vena Cava|Injury, Poisoning and Procedural Complications - Other|Innate Immunostimulator rBBX-01|Inodiftagene Vixteplasmid|Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01|Inosine Monophosphate Dehydrogenase Inhibitor AVN944|Inositol|Inotuzumab Ozogamicin|Inproquone|Insomnia|Insular carcinoma|Insulin|Insulin Controlled Diabetes|Insulinoma, NOS|Insulinoma, malignant|Integrin Receptor Antagonist GLPG0187|Integrin alpha-2 Inhibitor E7820|Interdigitating Dendritic Cell Sarcoma|Interdigitating cell sarcoma|Interdigitating dendritic cell sarcoma|Interferon|Interferon Alfa-2B|Interferon Alfa-N1|Interferon Alfa-N3|Interferon Alfacon-1|Interferon Beta-1A|Interferon Gamma-1b|Interferon-gamma-expressing Adenovirus Vaccine ASN-002|Intergroup Rhabdomyosarcoma Group I|Intergroup Rhabdomyosarcoma Group II|Intergroup Rhabdomyosarcoma Group III|Intergroup Rhabdomyosarcoma Group IIIa|Intergroup Rhabdomyosarcoma Group IIIb|Intergroup Rhabdomyosarcoma Group IIa|Intergroup Rhabdomyosarcoma Group IIb|Intergroup Rhabdomyosarcoma Group IIc|Intergroup Rhabdomyosarcoma Group IV|Intergroup Rhabdomyosarcoma Group Ia|Intergroup Rhabdomyosarcoma Group Ib|Interleukin Therapy|Interleukin-12-Fc Fusion Protein DF6002|Interleukin-15 Agonist Fusion Protein SHR1501|Interleukin-15 Fusion Protein BJ-001|Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306|Interleukin-15/Interleukin-15 Receptor Alpha Sushi+ Domain Fusion Protein SO-C101|Interleukin-2 Liposome|Intermediate|Intermediate Grade|Intermediate Immature Teratoma|Intermediate Prognosis|Intermediate Risk|Intermediate and giant congenital nevus|Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230|Internal Radiation|International Prognostic Index High-Intermediate Risk Group|International Prognostic Index Low-Intermediate Risk Group|Interstitial Pneumontis or ARDS|Interstitial cell tumor, NOS|Interstitial cell tumor, benign|Interstitial cell tumor, malignant|Intestinal Metaplasia|Intestinal Stoma Leak|Intestinal Stoma Obstruction|Intestinal Stoma Site Bleeding|Intestinal T-cell lymphoma|Intestinal tract, NOS|Intestinal-Type Adenocarcinoma|Intestinal-type adenocarcinoma|Intetumumab|Intimal Sarcoma|Intimal sarcoma|Intiquinatine|Intoplicine|Intra-Abdominal Hemorrhage|Intra-Abdominal Lymph Node|Intra-abdominal lymph nodes|Intracanalicular fibroadenoma|Intracompartmental (T1)|Intracompartmental Tumor|Intracortical osteosarcoma|Intracranial Hemorrhage|Intracystic Papillary Breast Carcinoma|Intracystic Papilloma|Intracystic carcinoma, NOS|Intracystic papillary adenocarcinoma|Intracystic papillary adenoma|Intracystic papillary neoplasm with associated invasive carcinoma|Intracystic papillary neoplasm with high grade intraepithelial neoplasia|Intracystic papillary neoplasm with intermediate grade intraepithelial neoplasia|Intracystic papillary neoplasm with low grade intraepithelial neoplasia|Intracystic papillary tumor with high grade dysplasia|Intracystic papillary tumor with high grade entraepithelial neoplasia|Intracystic papillary tumor with high grade intraepithelial neoplasia|Intracystic papilloma|Intradermal nevus|Intraductal Carcinoma of the Minor Salivary Gland|Intraductal Cribriform Breast Adenocarcinoma|Intraductal Papillary Adenocarcinoma with Invasion|Intraductal Papillary Breast Carcinoma|Intraductal Papillary Mucinous Neoplasm|Intraductal Papilloma|Intraductal Papillomatosis|Intraductal adenocarcinoma, noninfiltrating, NOS|Intraductal and Lobular Carcinoma|Intraductal and lobular carcinoma|Intraductal carcinoma and lobular carcinoma in situ|Intraductal carcinoma, NOS|Intraductal carcinoma, clinging|Intraductal carcinoma, noninfiltrating, NOS|Intraductal carcinoma, solid type|Intraductal micropapillary carcinoma|Intraductal papillary adenocarcinoma with invasion|Intraductal papillary adenocarcinoma, NOS|Intraductal papillary carcinoma|Intraductal papillary mucinous neoplasm (IPMN) with an associated invasive carcinoma|Intraductal papillary mucinous neoplasm with an associated invasive carcinoma|Intraductal papillary mucinous neoplasm with high grade dysplasia|Intraductal papillary neoplasm with associated invasive carcinoma|Intraductal papillary neoplasm with high grade dysplasia|Intraductal papillary neoplasm with high grade intraepithelial neoplasia|Intraductal papillary neoplasm with intermediate grade neoplasia|Intraductal papillary neoplasm with low grade intraepithelial neoplasia|Intraductal papillary neoplasm, NOS|Intraductal papillary tumor with high grade dysplasia|Intraductal papillary tumor with high grade intraepithelial neoplasia|Intraductal papillary-mucinous adenoma|Intraductal papillary-mucinous carcinoma, invasive|Intraductal papillary-mucinous carcinoma, non-invasive|Intraductal papillary-mucinous neoplasm with low grade dysplasia|Intraductal papillary-mucinous neoplasm with moderate dysplasia|Intraductal papillary-mucinous tumor with intermediate dysplasia|Intraductal papillary-mucinous tumor with low grade dysplasia|Intraductal papillary-mucinous tumor with moderate dysplasia|Intraductal papilloma|Intraductal papilloma with ductal carcinoma in situ|Intraductal papilloma with lobular carcinoma in situ|Intraductal papillomatosis, NOS|Intraductal tubular-papillary neoplasm, high grade|Intraductal tubular-papillary neoplasm, low grade|Intraductal tubulopapillary neoplasm|Intraepidermal Epithelioma of Jadassohn|Intraepidermal carcinoma, NOS|Intraepidermal epithelioma of Jadassohn|Intraepidermal nevus|Intraepidermal squamous cell carcinoma, Bowen type|Intraepithelial carcinoma, NOS|Intraepithelial squamous cell carcinoma|Intraglandular papillary neoplasm with low grade intraepithelial neoplasia|Intrahepatic bile duct|Intramural|Intramuscular Hemangioma|Intramuscular Lipoma|Intramuscular hemangioma|Intramuscular lipoma|Intraneural Perineurioma|Intraneural perineurioma|Intraoperative Arterial Injury|Intraoperative Breast Injury|Intraoperative Cardiac Injury|Intraoperative Ear Injury|Intraoperative Endocrine Injury|Intraoperative Gastrointestinal Injury|Intraoperative Head and Neck Injury|Intraoperative Hemorrhage|Intraoperative Hepatobiliary Injury|Intraoperative Musculoskeletal Injury|Intraoperative Neurological Injury|Intraoperative Ocular Injury|Intraoperative Renal Injury|Intraoperative Reproductive Tract Injury|Intraoperative Respiratory Injury|Intraoperative Skin Injury|Intraoperative Splenic Injury|Intraoperative Urinary Injury|Intraoperative Venous Injury|Intraosseous low grade osteosarcoma|Intraosseous well differentiated osteosarcoma|Intrathecal|Intrathoracic Lymph Node|Intrathoracic lymph nodes|Intrathyroid Thymic Carcinoma|Intratubular germ cell neoplasia|Intratubular malignant germ cells|Intravascular B-cell lymphoma|Intravascular Large B-Cell Lymphoma|Intravascular bronchial alveolar tumor|Intravascular large B-cell lymphoma|Intravascular leiomyomatosis|Intravenous|Intravenous Drug User|Inulin|Invasive Breast Carcinoma|Invasive Ductal Carcinoma, Not Otherwise Specified|Invasive Ductal and Lobular Carcinoma|Invasive Ductal and Lobular Carcinoma In Situ|Invasive Hydatidiform Mole|Invasive Lobular Breast Carcinoma|Invasive Lobular Breast Carcinoma, Alveolar Variant|Invasive Lobular Breast Carcinoma, Pleomorphic Variant|Invasive Lobular Breast Carcinoma, Solid Variant|Invasive Lobular Breast Carcinoma, Tubulolobular Variant|Invasive Lung Mucinous Adenocarcinoma|Invasive Micropapillary Breast Carcinoma|Invasive carcinoma of no special type|Invasive carcinoma, NST|Invasive encapsulated follicular variant of papillary thyroid carcinoma (invasive EFVPTC)|Invasive fibroma|Invasive hydatidiform mole|Invasive lobular carcinoma|Invasive lobular carcinoma, alveolar type|Invasive lobular carcinoma, solid type|Invasive lobular carcinoma, tubulolobular variant|Invasive mammary carcinoma|Invasive micropapillary carcinoma|Invasive mole, NOS|Invasive mucinous adenocarcinoma|Inverted Squamous Cell Papilloma|Inverted Transitional Cell Papilloma|Investigations - Other|Involuting nevus|Iobenguane I-131|Iodine I 124 Monoclonal Antibody A33|Iodine I 124 Monoclonal Antibody M5A|Iodine I 125-Anti-EGFR-425 Monoclonal Antibody|Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP|Iodine I 131 Apamistamab|Iodine I 131 Derlotuximab Biotin|Iodine I 131 Ethiodized Oil|Iodine I 131 IPA|Iodine I 131 MIP-1095|Iodine I 131 Monoclonal Antibody 81C6|Iodine I 131 Monoclonal Antibody BC8|Iodine I 131 Monoclonal Antibody CC49-deltaCH2|Iodine I 131 Monoclonal Antibody F16SIP|Iodine I 131 Monoclonal Antibody G-250|Iodine I 131 Monoclonal Antibody muJ591|Iodine I 131 Omburtamab|Iodine I 131 Rituximab|Iodine I 131 TM-601|Iodine I 131 Tenatumomab|Iodine I 131 Tositumomab|Iodine I-131|IodoTMT|Iodoacetamide (IAA)|Ioflubenzamide I-131|Ion Torrent|Ionomycin|Ipafricept|Ipatasertib|Ipilimumab|Ipomeanol|Iproplatin|Iran|Iraq|Iratumumab|Ireland|Iridium Ir 192|Irinotecan|Irinotecan Hydrochloride|Irinotecan Sucrosofate|Irinotecan-Eluting Beads|Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet|Irofulven|Iron Overload|Iroplact|Irosustat|Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130|Irregular Menstruation|Irritability|Isatuximab|Ischemia Cerebrovascular|Ischemic Heart Disease|Ischium|Ishak Score 0|Ishak Score 1-2|Ishak Score 3-4|Ishak Score 5|Ishak Score 6|Isle of Man|Islet Cell Adenoma|Islet Cells|Islet cell adenocarcinoma|Islet cell adenoma|Islet cell adenomatosis|Islet cell carcinoma|Islet cell tumor, NOS|Islet cell tumor, benign|Islets of Langerhans|Iso-fludelone|IsoPrime|IsoProbe T|Isobaric label quantitation analysis|Isobrucein B|Isocoumarin NM-3|Isoform Expression Quantification|Isolated Limb Perfusion (ILP)|Isosporiasis|Isotretinoin|Ispinesib|Ispinesib Mesylate|Israel|Isthmus Uteri|Isthmus uteri|Istiratumab|Itacitinib|Itacitinib Adipate|Italy|Item Flagged Low Quality|Item does not meet study protocol|Item flagged DNU|Item in special subset|Item is noncanonical|Item may not meet study protocol|Itraconazole|Itraconazole Dispersion In Polymer Matrix|Ivaltinostat|Ivosidenib|Ivuxolimab|Ixabepilone|Ixazomib|Ixazomib Citrate|JAK Inhibitor|JAK Inhibitor INCB047986|JAK1 Inhibitor AZD4205|JAK1 Inhibitor INCB052793|JAK2 Inhibitor AZD1480|JAK2 Inhibitor BMS-911543|JAK2 Inhibitor XL019|JAK2/Src Inhibitor NS-018|JNK Inhibitor CC-401|JPEG|JPEG 2000|JSON|Jadassohn blue nevus|Jamaica|Japan|Jaw|Jejunal Fistula|Jejunal Hemorrhage|Jejunal Obstruction|Jejunal Perforation|Jejunal Stenosis|Jejunal Ulcer|Jejunum|Jersey|Jin Fu Kang|Joint|Joint Effusion|Joint Infection|Joint Range of Motion Decreased|Joint Range of Motion Decreased Cervical Spine|Joint Range of Motion Decreased Lumbar Spine|Joint Replacement|Jordan|Jugular paraganglioma|Jugulotympanic Paraganglioma|Jugulotympanic paraganglioma|Junction nevus|Junctional Nevus|Junctional nevus, NOS|Juvenile Myelomonocytic Leukemia|Juvenile Type Granulosa Cell Tumor|Juvenile angiofibroma|Juvenile astrocytoma|Juvenile carcinoma of breast|Juvenile chronic myelomonocytic leukemia|Juvenile fibroadenoma|Juvenile hemangioma|Juvenile histiocytoma|Juvenile melanoma|Juvenile myelomonocytic leukemia|Juvenile nevus|Juxtacortical chondroma|Juxtacortical chondrosarcoma|Juxtacortical osteosarcoma|Juxtaglomerular Cell Tumor|Juxtaglomerular tumor|KRAS G12C Inhibitor GDC-6036|KRAS G12C Inhibitor LY3499446|KRAS G12C Inhibitor MRTX849|KRAS Mutant-targeting AMG 510|KRAS-MAPK Signaling Pathway Inhibitor JAB-3312|KRASG12C Inhibitor JNJ-74699157|KRN5500|KSP Inhibitor AZD4877|KSP Inhibitor SB-743921|Kallisto - HDF5|Kallisto - Quantification|Kanglaite|Kanitinib|Kaposi Sarcoma|Kaposi sarcoma|Kaposiform Hemangioendothelioma|Kaposiform hemangioendothelioma|Kazakhstan|Kenya|Keratinizing Squamous Cell Carcinoma|Keratitis|Keratotoc papilloma|Ketoconazole|Ketotrexate|Kidney|Kidney Anastomotic Leak|Kidney Cancer|Kidney Chromophobe|Kidney Disease|Kidney Disorder|Kidney Infection|Kidney Medullary Carcinoma|Kidney Renal Clear Cell Carcinoma|Kidney Renal Papillary Cell Carcinoma|Kidney Wilms Tumor|Kidney, NOS|Kiribati|Klatskin tumor|Knee|Kosovo|Krukenberg Tumor|Krukenberg tumor|Kunecatechins Ointment|Kupffer cell sarcoma|Kuwait|Kyphosis|Kyrgyzstan|L-Gossypol|L-cell tumor|L-methylfolate|L1|L1 Acute Lymphoblastic Leukemia|L2|L2 Acute Lymphoblastic Leukemia|LAIR-2 Fusion Protein NC410|LC-MS label-free quantitation analysis|LCIS, NOS|LCMS-2010A|LCMS-2010EV|LCMS-2020|LCMS-8040|LCMS-8045|LCMS-8050|LCMS-8060|LCMS-9030|LCMS-IT-TOF|LCT|LCT Premier|LCT Premier XE|LECO|LMB-1 Immunotoxin|LMB-2 Immunotoxin|LMB-7 Immunotoxin|LMB-9 Immunotoxin|LMP-2:340-349 Peptide Vaccine|LMP-2:419-427 Peptide Vaccine|LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes|LMP7 Inhibitor M3258|LOH|LOXL2 Inhibitor PAT-1251|LRP5 Antagonist BI 905681|LRP5/6 Antagonist BI 905677|LS454|LSD1 Inhibitor CC-90011|LSD1 Inhibitor GSK2879552|LSD1 Inhibitor IMG-7289|LSD1 Inhibitor RO7051790|LSD1 Inhibitor SYHA1807|LTQ|LTQ FT|LTQ FT Ultra|LTQ Orbitrap|LTQ Orbitrap Classic|LTQ Orbitrap Discovery|LTQ Orbitrap Elite|LTQ Orbitrap Velos|LTQ Orbitrap XL|LTQ Orbitrap XL ETD|LTQ Velos|LTQ Velos ETD|LTQ Velos Pro|LTQ XL|LTQ XL ETD|LTQ-FT|LTQ-OT|LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1|LXQ|Label Free|Label-free gene level quantitation|Label-free peptide level quantitation|Label-free protein group level quantitation|Label-free protein level quantitation|Label-free raw feature quantitation|Labetuzumab Govitecan|Labium Majus|Labium Minus|Labium majus|Labium minus|Lacrimal Gland|Lacrimal gland|Lactating Adenoma|Lactating adenoma|Lactation Disorder|Lactoferrin-derived Lytic Peptide LTX-315|Lactotroph Adenoma|Lacutamab|Ladiratuzumab Vedotin|Ladirubicin|Laetrile|Landogrozumab|Langerhans Cell Histiocytosis|Langerhans Cell Histiocytosis, Disseminated|Langerhans Cell Histiocytosis, Monostotic|Langerhans Cell Histiocytosis, Polyostotic|Langerhans Cell Sarcoma|Langerhans cell granulomatosis|Langerhans cell granulomatosis, unifocal|Langerhans cell histiocytosis, NOS|Langerhans cell histiocytosis, disseminated|Langerhans cell histiocytosis, generalized|Langerhans cell histiocytosis, mono-ostotic|Langerhans cell histiocytosis, multifocal|Langerhans cell histiocytosis, poly-ostotic|Langerhans cell histiocytosis, unifocal|Langerhans cell sarcoma|Laniquidar|Lanreotide Acetate|Laos|Lapachone|Laparoscopic Biopsy|Laparoscopic Partial Nephrectomy|Laparoscopic Radical Nephrectomy|Laparoscopic Radical Prostatectomy with Robotics|Laparoscopic Radical Prostatectomy without Robotics|Laparoscopy|Laparotomy|Lapatinib|Lapatinib Ditosylate|Laprituximab Emtansine|Lapuleucel-T|Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease|Large Bowel|Large Cell Carcinoma|Large Cell Medulloblastoma|Large Cell Neuroendocrine Carcinoma|Large Intestinal Anastomotic Leak|Large cell (Ki-1+) lymphoma|Large cell calcifying Sertoli cell tumor|Large cell carcinoma with rhabdoid phenotype|Large cell carcinoma, NOS|Large cell medulloblastoma|Large cell neuroendocrine carcinoma|Large granular lymphocytosis, NOS|Laromustine|Larotaxel|Larotinib Mesylate|Larotrectinib|Larotrectinib Sulfate|Laryngeal Cancer|Laryngeal Cartilage|Laryngeal Edema|Laryngeal Fistula|Laryngeal Hemorrhage|Laryngeal Inflammation|Laryngeal Mucositis|Laryngeal Obstruction|Laryngeal Stenosis|Laryngeal cartilage|Laryngeal commissure|Laryngitis|Laryngopharyngeal Dysesthesia|Laryngopharyngectomy|Laryngopharynx|Laryngospasm|Larynx|Larynx, NOS|Lateral Wall of the Nasopharynx|Lateral floor of mouth|Lateral wall of bladder|Lateral wall of nasopharynx|Lateral wall of oropharynx|Latvia|Lavendustin A|Lazertinib|Lead Pb 212 TCMC-trastuzumab|Lebanon|Lefitolimod|Leflunomide|Left|Left Hemicolectomy|Left Ventricular Systolic Dysfunction|Leg|Legal Guardian|Leiomyoblastoma|Leiomyofibroma|Leiomyoma|Leiomyoma, NOS|Leiomyomatosis|Leiomyomatosis, NOS|Leiomyosarcoma|Leiomyosarcoma, NOS|Lenalidomide|Lenalidomide Analog KPG-121|Lennert lymphoma|Lentigo Maligna|Lentigo Maligna Melanoma|Lentigo maligna|Lentigo maligna melanoma|Lentinan|Lenvatinib|Lenvatinib Mesylate|Lenzilumab|Lepidic Predominant Adenocarcinoma|Lepidic adenocarcinoma|Lepidic predominant adenocarcinoma|Leptomeningeal Sarcoma|Leptomeningeal sarcoma|Leptomeninges|Lerociclib|Lesotho|Lesser Curvature of the Stomach|Lesser curvature of stomach, NOS|Lestaurtinib|Letetresgene Autoleucel|Lethargy|Letolizumab|Letrozole|Letterer-Siwe Disease|Letterer-Siwe disease|Leucovorin|Leucovorin Calcium|Leukemia|Leukemia Secondary to Oncology Chemotherapy|Leukemia, NOS|Leukemias, NOS|Leukemic reticuloendotheliosis|Leukocyte elastase|Leukocytosis|Leukoencephalopathy|Leuprolide|Leuprolide Acetate|Leuprolide Mesylate Injectable Suspension|Leurubicin|Levetiracetam|Levoleucovorin Calcium|Levothyroxine|Levothyroxine Sodium|Lexatumumab|Lexibulin|Leydig Cell Tumor|Leydig cell tumor, NOS|Leydig cell tumor, benign|Leydig cell tumor, malignant|Li-Fraumeni Syndrome|Liarozole|Liarozole Fumarate|Liarozole Hydrochloride|Liberia|Libido Decreased|Libido Increased|Libya|Licartin|Licorice|Liechtenstein|Lifastuzumab Vedotin|Lifelong Non-Drinker|Lifileucel|Lifirafenib|Liftover|Ligament|Light Chain Deposition Disease|Light-Emitting Oncolytic Vaccinia Virus GL-ONC1|Light-activated AU-011|Lilotomab|Limonene, (+)-|Limonene, (+/-)-|Lingual tonsil|Linifanib|Linitis Plastica|Linitis plastica|Linoleyl Carbonate-Paclitaxel|Linperlisib|Linrodostat|Linsitinib|Lintuzumab|Liothyronine I-131|Liothyronine Sodium|Lip|Lip Infection|Lip Pain|Lip, NOS|Lipase Increased|Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1|Lipid Nanoparticle Encapsulated OX40L mRNA-2416|Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191|Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006|Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752|Lipid cell tumor of ovary|Lipid-Rich Carcinoma|Lipid-rich Sertoli cell tumor|Lipid-rich carcinoma|Lipid-rich urothelial carcinoma|Lipidome|Lipoadenoma|Lipoblastoma|Lipoblastomatosis|Lipohypertrophy|Lipoid cell tumor of ovary|Lipoleiomyoma|Lipoma|Lipoma, NOS|Lipoma-like liposarcoma|Lipomatous Neoplasms|Lipomatous medulloblastoma|Liposarcoma|Liposarcoma, NOS|Liposarcoma, differentiated|Liposarcoma, well differentiated|Liposomal Bcl-2 Antisense Oligonucleotide  BP1002|Liposomal Curcumin|Liposomal Cytarabine|Liposomal Daunorubicin Citrate|Liposomal Docetaxel|Liposomal Eribulin Mesylate|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Liposomal Irinotecan|Liposomal MUC1/PET-lipid A Vaccine ONT-10|Liposomal Mitoxantrone Hydrochloride|Liposomal NDDP|Liposomal Rhenium Re 186|Liposomal SN-38|Liposomal Topotecan FF-10850|Liposomal Vinorelbine|Liposomal Vinorelbine Tartrate|Liposomal c-raf Antisense Oligonucleotide|Liposome|Liposome-Encapsulated Doxorubicin Citrate|Liposome-encapsulated Daunorubicin-Cytarabine|Liposome-encapsulated OSI-7904|Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94|Liposome-encapsulated TAAs mRNA Vaccine W_ova1|Liposome-encapsulated miR-34 Mimic MRX34|Liquid Biopsy|Liquid Suspension Cell Line|Liquor|Lirilumab|Lisavanbulin|Lisocabtagene Maraleucel|Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142|Lithuania|Litronesib|Live Birth|Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207|Live-attenuated Double-deleted Listeria monocytogenes Bacteria JNJ-64041809|Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623|Liver|Liver Cancer|Liver Cirrhosis (Liver Disease)|Liver Hepatocellular Carcinoma|Liver Toxicity (Non-Infectious)|Liver X Receptor beta Agonist RGX-104|Liver and intrahepatic bile ducts|Liver cell adenoma|Liver cell carcinoma|Lm-tLLO-neoantigens Vaccine ADXS-NEO|LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine ADXS31-164|Lobaplatin|Lobectomy|Lobular Breast Carcinoma|Lobular Breast Carcinoma In Situ|Lobular adenocarcinoma|Lobular and ductal carcinoma|Lobular carcinoma in situ, NOS|Lobular carcinoma, NOS|Lobular carcinoma, noninfiltrating|Local|Local Resection (Exoresection; wall resection)|Localized Edema|Localized fibrous tumor|Loco-regional recurrence/progression|Lodapolimab|Lometrexol|Lometrexol Sodium|Lomustine|Lonafarnib|Loncastuximab Tesirine|Long Peptide Vaccine 7|Long bones of lower limb and associated joints|Long bones of upper limb, scapula and associated joints|Long-acting Release Pasireotide|Lontucirev|Lordosis|Lorlatinib|Lorukafusp alfa|Lorvotuzumab Mertansine|Losatuxizumab Vedotin|Losoxantrone|Losoxantrone Hydrochloride|Lovastatin|Low|Low Grade|Low Grade (G1)|Low Grade Adenosquamous Breast Carcinoma|Low Grade Central Osteosarcoma|Low Grade Cervical Intraepithelial Neoplasia|Low Grade Dysplasia|Low Grade Endometrioid Stromal Sarcoma|Low Grade Esophageal Glandular Intraepithelial Neoplasia|Low Grade Esophageal Squamous Intraepithelial Neoplasia|Low Grade Fibromyxoid Sarcoma|Low Grade Glandular Intraepithelial Neoplasia|Low Grade Liver Dysplastic Nodule|Low Grade Myofibroblastic Sarcoma|Low Grade Squamous Intraepithelial Neoplasia|Low Risk|Low Risk Gastrointestinal Stromal Tumor|Low grade adenosquamous carcinoma|Low grade appendiceal mucinous neoplasm|Low grade cribriform cystadenocarcinoma (LGCCC)|Low-CSD Melanoma|Low-Grade Appendix Mucinous Neoplasm|Low-Intermediate Risk|Low-grade central osteosarcoma|Low-grade fibromyxoid sarcoma|Low-grade intramedullary osteosarcoma|Low-grade myofibroblastic sarcoma|Low-grade serous carcinoma|Lower Gastrointestinal Hemorrhage|Lower Gingiva|Lower gum|Lower limb, NOS|Lower lobe, lung|Lower third of esophagus|Lower-Outer Quadrant of the Breast|Lower-inner quadrant of breast|Lower-outer quadrant of breast|Lucanthone|Lucatumumab|Lucitanib|Lumbar Spine|Luminespib|Luminespib Mesylate|Lumpectomy|Lumretuzumab|Lung|Lung Adenocarcinoma|Lung Adenocarcinoma with Mixed Bronchioloalveolar and Invasive Components|Lung Cancer|Lung Cancer (all types)|Lung Colloid Adenocarcinoma|Lung Fetal Adenocarcinoma|Lung Infection|Lung Large Cell Carcinoma with Rhabdoid Phenotype|Lung Mucinous Adenocarcinoma In Situ|Lung Non-Mucinous Adenocarcinoma In Situ|Lung Papillary Adenoma|Lung Squamous Cell Carcinoma|Lung, NOS|Lung-targeted Immunomodulator QBKPN|Lupartumab Amadotin|Lupus|Lurbinectedin|Lurtotecan|Lurtotecan Liposome|Luteinoma|Luteoma, NOS|Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1|Lutetium Lu 177 DOTA-N3-CTT1403|Lutetium Lu 177 DOTA-Tetulomab|Lutetium Lu 177 DOTA-biotin|Lutetium Lu 177 Dotatate|Lutetium Lu 177 Lilotomab-satetraxetan|Lutetium Lu 177 Monoclonal Antibody CC49|Lutetium Lu 177 Monoclonal Antibody J591|Lutetium Lu 177 PP-F11N|Lutetium Lu 177 Satoreotide Tetraxetan|Lutetium Lu 177-DOTA-EB-TATE|Lutetium Lu 177-DTPA-omburtamab|Lutetium Lu 177-Edotreotide|Lutetium Lu 177-NeoB|Lutetium Lu 177-PSMA-617|Lutetium Lu-177 Capromab|Lutetium Lu-177 Girentuximab|Lutetium Lu-177 PSMA-R2|Lutetium Lu-177 Rituximab|Luxembourg|Lymph Gland Infection|Lymph Leakage|Lymph Node|Lymph Node Cancer|Lymph Node Dissection|Lymph Node Pain|Lymph Node(s) Axilla|Lymph Node(s) Cervical|Lymph Node(s) Distant|Lymph Node(s) Epitrochlear|Lymph Node(s) Femoral|Lymph Node(s) Hilar|Lymph Node(s) Iliac-Common|Lymph Node(s) Iliac-External|Lymph Node(s) Inguinal|Lymph Node(s) Internal Mammary|Lymph Node(s) Mammary|Lymph Node(s) Mediastinal|Lymph Node(s) Mesenteric|Lymph Node(s) Occipital|Lymph Node(s) Paraaortic|Lymph Node(s) Parotid|Lymph Node(s) Pelvic|Lymph Node(s) Popliteal|Lymph Node(s) Regional|Lymph Node(s) Retroperitoneal|Lymph Node(s) Scalene|Lymph Node(s) Splenic|Lymph Node(s) Subclavicular|Lymph Node(s) Submandibular|Lymph Node(s) Supraclavicular|Lymph Node, Axillary|Lymph Node, Inguinal|Lymph Node, NOS|Lymph Node, Regional|Lymph Node, Subcarinal|Lymph Nodes(s) Mediastinal|Lymph node, NOS|Lymph nodes|Lymph nodes of axilla or arm|Lymph nodes of head, face and neck|Lymph nodes of inguinal region or leg|Lymph nodes of multiple regions|Lymphadenectomy|Lymphangioendothelial sarcoma|Lymphangioendothelioma, NOS|Lymphangioendothelioma, malignant|Lymphangioleiomyoma|Lymphangioleiomyomatosis|Lymphangioma|Lymphangioma, NOS|Lymphangiomyoma|Lymphangiomyomatosis|Lymphangiosarcoma|Lymphatic Vessel Tumors|Lymphatic leukemic, NOS|Lymphedema|Lymphoblastic Lymphoma|Lymphoblastic leukemia, NOS|Lymphoblastoma|Lymphocele|Lymphocyte Count Decreased|Lymphocyte Count Increased|Lymphocyte Predominant Type Hodgkin's Disease|Lymphocyte-Depleted Classic Hodgkin Lymphoma|Lymphocyte-Rich Classic Hodgkin Lymphoma|Lymphocytes|Lymphocytic Meningitis|Lymphocytic Thyroiditis|Lymphocytic leukemia, NOS|Lymphoepithelial carcinoma|Lymphoepithelioid Variant Peripheral T-Cell Lymphoma|Lymphoepithelioid lymphoma|Lymphoepithelioma|Lymphoepithelioma-like carcinoma|Lymphoid Leukemia|Lymphoid Leukemias|Lymphoid Neoplasm Diffuse Large B-cell Lymphoma|Lymphoid Normal|Lymphoid leukemia, NOS|Lymphoma|Lymphoma, NOS|Lymphomatoid Granulomatosis|Lymphomatoid Papulosis|Lymphomatoid granulomatosis|Lymphomatoid papulosis|Lymphoplasmacyte-Rich Meningioma|Lymphoplasmacyte-rich meningioma|Lymphoplasmacytic Lymphoma|Lymphoproliferative Disorder|Lymphoproliferative disease, NOS|Lymphoproliferative disorder, NOS|Lymphosarcoma|Lymphosarcoma cell leukemia|Lymphosarcoma, NOS|Lymphosarcoma, diffuse|Lynch Syndrome|Lyophilized Black Raspberry Lozenge|Lyophilized Black Raspberry Saliva Substitute|Lys-C|Lys-C, Lys-C/P|Lysine-specific Demethylase 1 Inhibitor INCB059872|Lyso-Thermosensitive Liposome Doxorubicin|M|M0|M0 Stage Finding|M1|M1 Stage Finding|M1a|M1a Stage Finding|M1b|M1b Stage Finding|M1c|M1c Stage Finding|M1d|M2|M6A|M6B|M@LDI L|M@LDI LR|MAF|MAGE-10.A2|MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells|MAGE-A3 Multipeptide Vaccine GL-0817|MAGE-A3 Peptide Vaccine|MAGE-A3-specific Immunotherapeutic GSK 2132231A|MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201|MAGE-TAB|MAGETAB|MAI|MALDI 4800|MALDI L|MALDI LR|MALDI LTQ Orbitrap|MALDI LTQ XL|MALDI R|MALDI SYNAPT G2-Si|MALDI Synapt G2 HDMS|MALDI Synapt G2 MS|MALDI Synapt G2-S HDMS|MALDI Synapt G2-S MS|MALDI Synapt HDMS|MALDI Synapt MS|MALDI micro MX|MALT lymphoma|MALT1 Inhibitor JNJ-67856633|MANEC|MARCKS Protein Inhibitor BIO-11006|MAT2A Inhibitor AG-270|MCL-1 Inhibitor ABBV-467|MCL-1 Inhibitor AMG 176|MCL-1 inhibitor AMG 397|MDM2 Antagonist ASTX295|MDM2 Antagonist RO5045337|MDM2 Antagonist RO6839921|MDM2 Inhibitor AMG-232|MDM2 Inhibitor AMGMDS3|MDM2 Inhibitor BI 907828|MDM2 Inhibitor KRT-232|MDM2/MDMX Inhibitor ALRN-6924|MDR Modulator CBT-1|MEK 1/2 Inhibitor AS703988/MSC2015103B|MEK 1/2 Inhibitor FCN-159|MEK Inhibitor AZD8330|MEK Inhibitor CI-1040|MEK Inhibitor GDC-0623|MEK Inhibitor HL-085|MEK Inhibitor PD0325901|MEK Inhibitor RO4987655|MEK Inhibitor SHR 7390|MEK Inhibitor TAK-733|MEK Inhibitor WX-554|MEK inhibitor CS3006|MEK-1/MEKK-1 Inhibitor E6201|MEK/Aurora Kinase Inhibitor BI 847325|MELK Inhibitor OTS167|MET Kinase Inhibitor OMO-1|MET Tyrosine Kinase Inhibitor BMS-777607|MET Tyrosine Kinase Inhibitor EMD 1204831|MET Tyrosine Kinase Inhibitor PF-04217903|MET Tyrosine Kinase Inhibitor SAR125844|MET Tyrosine Kinase Inhibitor SGX523|MET x MET Bispecific Antibody REGN5093|MEX|MGUS|MK0731|MKC-1|MKNK1 Inhibitor BAY 1143269|MMP Inhibitor S-3304|MNK1/2 Inhibitor ETC-1907206|MOF Compound RiMO-301|MOv-gamma Chimeric Receptor Gene|MPNST with glandular differentiation|MPNST with mesenchymal differentiation|MPNST with rhabdomyoblastic differentiation|MPNST, NOS|MR-Minimal/Marginal Response|MR-Minimal/Marginal response|MRI|MS1 label-based analysis|MS2|MS2 tag-based analysis|MS2-based label-free quantitation|MS3|MSI|MSS|MTF-1 Inhibitor APTO-253 HCl|MUC-1/WT1 Peptide-primed Autologous Dendritic Cells|MUC1-targeted Peptide GO-203-2C|MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP|MVA-BN Smallpox Vaccine|MVA-FCU1 TG4023|MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1|MX|MX Stage Finding|MX-Mixed Response|MYC-targeting siRNA DCR-MYC|Maackia amurensis Seed Lectin|Macau|Machine smoke|Macimorelin|Macitentan|Macro|Macrocycle-bridged STING Agonist E7766|Macrofollicular adenoma|Macroscopic (2cm or less)|Macroscopic (greater than 2cm)|Macroscopic Parametrium|Madagascar|Maekmoondong-tang|Mafosfamide|Magnesium Valproate|Magnocellular nevus|Magrolimab|Main Bronchus|Main bronchus|Maintenance Therapy|Major salivary gland, NOS|Malabsorption|Malaise|Malaria|Malawi|Malaysia|Maldives|Male|Male Cousin|Male Genitalia|Male Sibling of Adopted Child|Male genital organs, NOS|Mali|Malignancy|Malignancy in Giant Cell Tumor of Bone|Malignant|Malignant Adrenal Cortex Neoplasm|Malignant Adrenal Gland Pheochromocytoma|Malignant Cell|Malignant Enteroglucagonoma|Malignant Extra-Adrenal Paraganglioma|Malignant Gastrinoma|Malignant Gastrointestinal Stromal Tumor|Malignant Giant Cell Neoplasm|Malignant Glioma|Malignant Glomus Tumor|Malignant Granular Cell Tumor|Malignant Granulosa Cell Tumor|Malignant Hemangiopericytoma|Malignant Histiocytosis|Malignant Leydig Cell Tumor|Malignant Lymphoma Centroblastic, Follicular|Malignant Lymphoma, Convoluted|Malignant Lymphoma, Histiocytic, Diffuse|Malignant Lymphoma, Large Cell Type|Malignant Lymphoma, Large Cell, Cleaved|Malignant Lymphoma, Non-Cleaved Cell Type|Malignant Lymphoma, Non-Cleaved, Diffuse|Malignant Lymphomas, NOS or Diffuse|Malignant Mastocytosis|Malignant Mediastinal Germ Cell Tumor with Associated Hematologic Malignancy|Malignant Melanoma in Precancerous Melanosis|Malignant Melanotic Peripheral Nerve Sheath Tumor|Malignant Mesenchymoma|Malignant Mesothelioma|Malignant Mixed Tumor of the Salivary Gland|Malignant Muscle Neoplasm|Malignant Myoepithelioma|Malignant Neoplasm|Malignant Neoplasm, Uncertain Whether Primary or Metastatic|Malignant Odontogenic Neoplasm|Malignant Ossifying Fibromyxoid Tumor|Malignant Ovarian Brenner Tumor|Malignant Ovarian Thecoma|Malignant PEComa|Malignant Pancreatic Glucagonoma|Malignant Pancreatic Insulinoma|Malignant Paraganglioma|Malignant Pericytic Neoplasm|Malignant Peripheral Nerve Sheath Tumor|Malignant Peripheral Nerve Sheath Tumor with Perineurial Differentiation|Malignant Phosphaturic Mesenchymal Tumor|Malignant Phyllodes Tumor|Malignant Sertoli Cell Tumor|Malignant Soft Tissue Neoplasm|Malignant Solitary Fibrous Tumor|Malignant Somatostatinoma|Malignant Spindle Cell Neoplasm|Malignant Struma Ovarii|Malignant Sweat Gland Neoplasm|Malignant Tenosynovial Giant Cell Tumor|Malignant Teratoma|Malignant Thymoma|Malignant Triton Tumor|Malignant Trophoblastic Teratoma|Malignant Tumor, Small Cell Type|Malignant Type A Thymoma|Malignant Type AB Thymoma|Malignant Type B1 Thymoma|Malignant Type B2 Thymoma|Malignant Vipoma|Malignant chondroid syringoma|Malignant cystic nephroma|Malignant eccrine spiradenoma|Malignant fibrous histiocytoma|Malignant fibrous histiocytoma (MFH) of bone|Malignant giant cell tumor of soft parts|Malignant histiocytosis|Malignant hydatidiform mole|Malignant lymphoma, Hodgkin|Malignant lymphoma, NOS|Malignant lymphoma, centroblastic, NOS|Malignant lymphoma, centroblastic, diffuse|Malignant lymphoma, centroblastic, follicular|Malignant lymphoma, centroblasticcentrocytic, NOS|Malignant lymphoma, centroblasticcentrocytic, diffuse|Malignant lymphoma, centroblasticcentrocytic, follicular|Malignant lymphoma, centrocytic|Malignant lymphoma, cleaved cell, NOS|Malignant lymphoma, convoluted cell|Malignant lymphoma, diffuse, NOS|Malignant lymphoma, follicle center, NOS|Malignant lymphoma, follicle center, follicular|Malignant lymphoma, follicular, NOS|Malignant lymphoma, histiocytic, NOS|Malignant lymphoma, histiocytic, diffuse|Malignant lymphoma, histiocytic, nodular|Malignant lymphoma, immunoblastic, NOS|Malignant lymphoma, large B-cell, NOS|Malignant lymphoma, large B-cell, diffuse, NOS|Malignant lymphoma, large B-cell, diffuse, centroblastic, NOS|Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS|Malignant lymphoma, large cell, NOS|Malignant lymphoma, large cell, cleaved and noncleaved|Malignant lymphoma, large cell, cleaved, NOS|Malignant lymphoma, large cell, cleaved, diffuse|Malignant lymphoma, large cell, diffuse, NOS|Malignant lymphoma, large cell, follicular, NOS|Malignant lymphoma, large cell, immunoblastic|Malignant lymphoma, large cell, noncleaved, NOS|Malignant lymphoma, large cell, noncleaved, diffuse|Malignant lymphoma, large cell, noncleaved, follicular|Malignant lymphoma, large cleaved cell, NOS|Malignant lymphoma, large cleaved cell, follicular|Malignant lymphoma, lymphoblastic, NOS|Malignant lymphoma, lymphocytic, NOS|Malignant lymphoma, lymphocytic, diffuse, NOS|Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse|Malignant lymphoma, lymphocytic, intermediate differentiation, nodular|Malignant lymphoma, lymphocytic, nodular, NOS|Malignant lymphoma, lymphocytic, poorly differentiated, diffuse|Malignant lymphoma, lymphocytic, poorly differentiated, nodular|Malignant lymphoma, lymphocytic, well differentiated, diffuse|Malignant lymphoma, lymphocytic, well differentiated, nodular|Malignant lymphoma, lymphoplasmacytic|Malignant lymphoma, lymphoplasmacytoid|Malignant lymphoma, mixed cell type, diffuse|Malignant lymphoma, mixed cell type, follicular|Malignant lymphoma, mixed cell type, nodular|Malignant lymphoma, mixed lymphocytic-histiocytic, diffuse|Malignant lymphoma, mixed lymphocytic-histiocytic, nodular|Malignant lymphoma, mixed small and large cell, diffuse|Malignant lymphoma, mixed small cleaved and large cell, follicular|Malignant lymphoma, nodular, NOS|Malignant lymphoma, non-Hodgkin, NOS|Malignant lymphoma, non-cleaved cell, NOS|Malignant lymphoma, noncleaved cell, follicular, NOS|Malignant lymphoma, noncleaved, NOS|Malignant lymphoma, noncleaved, diffuse, NOS|Malignant lymphoma, plasmacytoid|Malignant lymphoma, small B lymphocytic, NOS|Malignant lymphoma, small cell diffuse|Malignant lymphoma, small cell, NOS|Malignant lymphoma, small cell, noncleaved, diffuse|Malignant lymphoma, small cleaved cell, NOS|Malignant lymphoma, small cleaved cell, diffuse|Malignant lymphoma, small cleaved cell, follicular|Malignant lymphoma, small lymphocytic, NOS|Malignant lymphoma, small lymphocytic, diffuse|Malignant lymphoma, small noncleaved, Burkitt type|Malignant lymphoma, undifferentiated cell type, NOS|Malignant lymphoma, undifferentiated cell, non-Burkitt|Malignant lymphoma, undifferentiated, Burkitt type|Malignant lymphomatous polyposis|Malignant mast cell tumor|Malignant mastocytoma|Malignant mastocytosis|Malignant melanoma in Hutchinson melanotic freckle|Malignant melanoma in congenital melanocytic nevus|Malignant melanoma in giant pigmented nevus|Malignant melanoma in junctional nevus|Malignant melanoma in precancerous melanosis|Malignant melanoma, NOS|Malignant melanoma, regressing|Malignant midline reticulosis|Malignant mucinous adenofibroma|Malignant mucinous cystadenofibroma|Malignant multilocular cystic nephroma|Malignant myelosclerosis|Malignant myoepithelioma|Malignant peripheral nerve sheath tumor|Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation|Malignant perivascular epithelial cell tumor|Malignant reticulosis, NOS|Malignant rhabdoid tumor|Malignant schwannoma with rhabdomyoblastic differentiation|Malignant schwannoma, NOS|Malignant serous adenofibroma|Malignant serous cystadenofibroma|Malignant tenosynovial giant cell tumor|Malignant teratoma, anaplastic|Malignant teratoma, intermediate|Malignant teratoma, trophoblastic|Malignant teratoma, undifferentiated|Malignant tumor, clear cell type|Malignant tumor, fusiform cell type|Malignant tumor, giant cell type|Malignant tumor, small cell type|Malignant tumor, spindle cell type|Malta|Mammary carcinoma, in situ|Mandible|Mandibulectomy|Manelimab|Mania|Mannosulfan|Mannosylerythritol Lipid|Mantle|Mantle Cell Lymphoma|Mantle cell lymphoma (Includes all variants blastic, pleomorphic, small cell)|Mantle zone lymphoma|Mapatumumab|Maraba Oncolytic Virus Expressing Mutant HPV E6/E7|Marcellomycin|Margetuximab|Marginal Zone Lymphoma|Marginal zone B-cell lymphoma, NOS|Marginal zone lymphoma, NOS|Marijuana|Marijuana smoke|Marimastat|Marizomib|Marshall Islands|Martinique|Masculinovoblastoma|Masitinib Mesylate|Masked Annotated Somatic Mutation|Masked Copy Number Segment|Masked Intensities|Masked Somatic Mutation|Masoprocol|Mast Cell Leukemia|Mast Cell Neoplasm|Mast Cell Sarcoma|Mast Cell Tumors|Mast cell leukaemia|Mast cell sarcoma|Mast cell tumor, NOS|Mastocytoma|Mastocytoma, NOS|Maternal Aunt|Maternal First Cousin|Maternal First Cousin Once Removed|Maternal Grandfather|Maternal Grandmother|Maternal Grandparent|Maternal Great Aunt|Maternal Great Grandparent|Maternal Great Uncle|Maternal Half Brother|Maternal Half Sibling|Maternal Half Sister|Maternal Uncle|Matrical carcinoma|Matrix Metalloproteinase Inhibitor MMI270|Mature B-Cell Lymphomas|Mature T ALL|Mature T- and NK-Cell Lymphomas|Mature T-ALL|Mature T-cell lymphoma, NOS|Mature Teratoma|Mature teratoma|Matuzumab|Mauritania|Mauritius|Mavelertinib|Mavorixafor|Maxilla|Maxillary Sinus|Maxillary sinus|Maxillectomy|Mayotte|Maytansine|Mcl-1 Inhibitor AZD5991|Mcl-1 Inhibitor MIK665|Mechlorethamine|Mechlorethamine Hydrochloride|Mechlorethamine Hydrochloride Gel|Meckel diverticulum|Mediastinal (thymic) large B-cell lymphoma|Mediastinal Hemorrhage|Mediastinal Infection|Mediastinal Soft Tissue|Mediastinum|Mediastinum, NOS|Medical Record|Medically Treated|Mediterranean lymphoma|Medorubicin|Medroxyprogesterone|Medroxyprogesterone Acetate|Medulla of adrenal gland|Medullary Carcinoma, Not Otherwise Specified|Medullary adenocarcinoma|Medullary carcinoma with amyloid stroma|Medullary carcinoma with lymphoid stroma|Medullary carcinoma, NOS|Medullary osteosarcoma|Medulloblastoma|Medulloblastoma with Extensive Nodularity|Medulloblastoma with Melanotic Differentiation|Medulloblastoma with extensive nodularity|Medulloblastoma, NOS|Medulloblastoma, Non-WNT/Non-SHH|Medulloblastoma, Non-WNT/Non-SHH, Group 3|Medulloblastoma, Non-WNT/Non-SHH, Group 4|Medulloblastoma, Not Otherwise Specified|Medulloblastoma, SHH-Activated|Medulloblastoma, SHH-Activated, TP53-Mutant|Medulloblastoma, SHH-Activated, TP53-Wildtype|Medulloblastoma, SHH-activated and TP53-mutant|Medulloblastoma, SHH-activated and TP53-wildtype|Medulloblastoma, WNT-Activated|Medulloblastoma, WNT-activated|Medulloblastoma, classic|Medulloblastoma, group 3|Medulloblastoma, group 4|Medulloblastoma, non-WNT/non-SHH|Medullocytoma|Medulloepithelioma|Medulloepithelioma Not Otherwise Specified|Medulloepithelioma, NOS|Medulloepithelioma, benign|Medullomyoblastoma|Medullomyoblastoma with Myogenic Differentiation|Megakaryocytic leukemia|Megakaryocytic myelosclerosis|Megestrol Acetate|Melanoameloblastoma|Melanocytic Nevus|Melanocytic nevus|Melanocytoma|Melanocytoma of the Eyeball|Melanocytoma, NOS|Melanocytoma, eyeball|Melanoma|Melanoma Arising from Blue Nevus|Melanoma Monoclonal Antibody hIgG2A|Melanoma TRP2 CTL Epitope Vaccine SCIB1|Melanoma in Junctional Nevus|Melanoma in situ|Melanoma, NOS|Melanoma, malignant, of soft parts|Melanotic MPNST|Melanotic Neuroectodermal Tumor|Melanotic Neurofibroma|Melanotic Psammomatous Malignant Peripheral Nerve Sheath Tumor|Melanotic Schwannoma|Melanotic medulloblastoma|Melanotic neuroectodermal tumor|Melanotic neurofibroma|Melanotic progonoma|Melanotic psammomatous MPNST|Melanotic schwannoma|Melapuldencel-T|Melphalan|Melphalan Flufenamide|Melphalan Hydrochloride|Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex|Membrane-Disrupting Peptide EP-100|Memory Impairment|Menatetrenone|Menin-MLL Interaction Inhibitor SNDX-5613|Meningeal Melanocytoma|Meningeal Melanocytosis|Meningeal Melanoma|Meningeal Melanomatosis|Meningeal Sarcoma|Meningeal Sarcomatosis|Meningeal melanocytoma|Meningeal melanoma|Meningeal melanomatosis|Meningeal sarcoma|Meningeal sarcomatosis|Meninges|Meninges, NOS|Meningioma|Meningioma, NOS|Meningioma, anaplastic|Meningioma, malignant|Meningiomas|Meningiomatosis|Meningiomatosis, NOS|Meningismus|Meningitis|Meningothelial Meningioma|Meningothelial meningioma|Meningothelial sarcoma|Menogaril|Menopause|Menorrhagia|Merbarone|Mercaptopurine|Mercaptopurine Anhydrous|Mercaptopurine Oral Suspension|Merestinib|Merkel Cell Carcinoma|Merkel cell carcinoma|Merkel cell tumor|Mesenchymal Chondrosarcoma|Mesenchymal chondrosarcoma|Mesenchymal tumor, malignant|Mesenchymoma|Mesenchymoma, NOS|Mesenchymoma, benign|Mesenchymoma, malignant|Mesenteric fibromatosis|Mesentery|Mesna|Mesoblastic nephroma|Mesodermal mixed tumor|Mesonephric Adenocarcinoma|Mesonephric Neoplasm|Mesonephric adenocarcinoma|Mesonephric adenoma|Mesonephric tumor, NOS|Mesonephroma, NOS|Mesonephroma, benign|Mesonephroma, malignant|Mesonephromas|Mesothelial Neoplasms|Mesothelial papilloma|Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536|Mesothelioma|Mesothelioma, NOS|Mesothelioma, benign|Mesothelioma, biphasic, NOS|Mesothelioma, biphasic, malignant|Mesothelioma, malignant|Mesothelium|MetAP2 Inhibitor APL-1202|MetAP2 Inhibitor SDX-7320|Metabolic Syndrome|Metabolic labeling 14N / 15N quantitation analysis|Metabolism and Nutrition Disorders - Other|Metabolome|Metamelfalan|Metanephric Adenofibroma|Metanephric Adenoma|Metanephric adenoma|Metaplastic Carcinoma|Metaplastic Meningioma|Metaplastic carcinoma of no special type|Metaplastic carcinoma with chondroid differentiation|Metaplastic carcinoma with osseous differentiation|Metaplastic carcinoma with other types mesenchymal differentiation|Metaplastic carcinoma, NOS|Metaplastic meningioma|Metarrestin|Metastasectomy|Metastasis|Metastasis Negative|Metastasis, NOS|Metastasizing Ameloblastoma|Metastasizing leiomyoma|Metastatic|Metastatic Adenocarcinoma|Metastatic Carcinoma|Metastatic Neoplasm|Metastatic Signet Ring Cell Carcinoma|Metastatic Squamous Cell Carcinoma|Metastatic signet ring cell carcinoma|Metatinib Tromethamine|Metatypical carcinoma|Metformin|Metformin Hydrochloride|Methanol Extraction Residue of BCG|Methazolamide|Methionine Aminopeptidase 2 Inhibitor M8891|Methionine Aminopeptidase 2 Inhibitor PPI-2458|Methotrexate|Methotrexate Sodium|Methotrexate-E Therapeutic Implant|Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles|Methoxsalen|Methoxyamine|Methoxyamine Hydrochloride|Methyl Methanethiosulfonate (MMTS)|Methyl-5-Aminolevulinate Hydrochloride Cream|Methylation Array|Methylation Beta Value|Methylcantharidimide|Methylmercaptopurine Riboside|Methylprednisolone|Methylprednisolone Acetate|Methylprednisolone Sodium Succinate|Methylselenocysteine|Methyltestosterone|Metoprine|Mevociclib|Mexico|Mezagitamab|MiT Family Translocation-Associated Renal Cell Carcinoma|MiT family translocation renal cell carcinoma|Mibefradil|Mibefradil Dihydrochloride|Micellar Nanoparticle-encapsulated Epirubicin|Micro|Micro Needle Array-Doxorubicin|Microbiome GEN-001|Microbiome-derived Peptide Vaccine EO2401|Microcystic Adenoma|Microcystic Adnexal Carcinoma|Microcystic Meningioma|Microcystic adenoma|Microcystic adnexal carcinoma|Microcystic meningioma|Microcystic urothelial carcinoma|Microfollicular adenoma, NOS|Microglioma|Microinvasive Squamous Cell Carcinoma|Micropapillary Serous Carcinoma|Micropapillary Transitional Cell Carcinoma|Micropapillary adenocarcinoma|Micropapillary carcinoma, NOS|Micropapillary serous carcinoma|Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300|Microscopic|Microscopic Parametrium|Microtubule Inhibitor SCB01A|Middle Ear|Middle Ear Inflammation|Middle Finger|Middle Lobe of the Right Lung|Middle ear|Middle lobe, lung|Middle third of esophagus|Midline|Midline carcinoma of children and young adults with NUT rearrangement|Midostaurin|Mifamurtide|Mifepristone|Milademetan Tosylate|Milataxel|Milatuzumab|Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110|Milciclib Maleate|Milk Thistle|Miltefosine|Minimally Invasive Lung Adenocarcinoma|Minimally Invasive Lung Mucinous Adenocarcinoma|Minimally Invasive Lung Non-Mucinous Adenocarcinoma|Minimally invasive adenocarcinoma, NOS|Minimally invasive adenocarcinoma, mucinous|Minimally invasive adenocarcinoma, non-mucinous|Minor Response|Minretumomab|Mipsagargin|Miptenalimab|Mirabegron|Miransertib|Mirdametinib|Mirvetuximab Soravtansine|Mirzotamab Clezutoclax|Miscarriage|Miscellaneous Bone Tumors|Miscellaneous Tumors|Misonidazole|Mistletoe Extract|Mitazalimab|Mitindomide|Mitobronitol|Mitochondria|Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101|Mitoclomine|Mitoflaxone|Mitoguazone|Mitoguazone Dihydrochloride|Mitolactol|Mitomycin|Mitomycin A|Mitomycin B|Mitomycin C Analog KW-2149|Mitosis Inhibitor T 1101 Tosylate|Mitotane|Mitotenamine|Mitoxantrone|Mitoxantrone Hydrochloride|Mitozolomide|Mitral Valve Disease|Mivavotinib|Mivebresib|Mivobulin|Mivobulin Isethionate|Mixed Acinar-Ductal Carcinoma of the Pancreas|Mixed Adherent Suspension|Mixed Bacteria Vaccine|Mixed Cell Adenocarcinoma|Mixed Cell Adenoma|Mixed Cellularity Classic Hodgkin Lymphoma|Mixed Ductal and Lobular Carcinoma|Mixed Ductal-Neuroendocrine Carcinoma of the Pancreas|Mixed Embryonal Carcinoma and Teratoma|Mixed Epithelial and Mesenchymal Hepatoblastoma|Mixed Epithelioid and Spindle Cell Melanoma|Mixed Germ Cell Tumor|Mixed Glioma|Mixed Liposarcoma|Mixed Mesodermal (Mullerian) Tumor|Mixed Mucinous and Non-Mucinous Bronchioloalveolar Carcinoma|Mixed Phenotype Acute Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1|Mixed Phenotype Acute Leukemia with t(v;11q23.3); KMT2A Rearranged|Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified|Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified|Mixed Response|Mixed Teratoma and Seminoma|Mixed Testicular Sex Cord-Stromal Tumor|Mixed Tumor, Not Otherwise Specified|Mixed acidophil-basophil adenoma|Mixed acidophil-basophil carcinoma|Mixed acinar-ductal carcinoma|Mixed acinar-endocrine carcinoma|Mixed acinar-endocrine-ductal carcinoma|Mixed adenocarcinoma and epidermoid carcinoma|Mixed adenocarcinoma and squamous cell carcinoma|Mixed adenomatous and hyperplastic polyp|Mixed adenoneuroendocrine carcinoma|Mixed basal-squamous cell carcinoma|Mixed carcinoid-adenocarcinoma|Mixed cell adenocarcinoma|Mixed cell adenoma|Mixed ductal-endocrine carcinoma|Mixed embryonal carcinoma and teratoma|Mixed embryonal rhabdomyosarcoma and alveolar rhabdomyosarcoma|Mixed endocrine and exocrine adenocarcinoma|Mixed epithelioid and spindle cell melanoma|Mixed germ cell sex cord-stromal tumor, unclassified|Mixed germ cell tumor|Mixed glioma|Mixed hepatocellular and bile duct carcinoma|Mixed invasive mucinous and non-mucinous adenocarcinoma|Mixed islet cell and exocrine adenocarcinoma|Mixed liposarcoma|Mixed medullary-follicular carcinoma|Mixed medullary-papillary carcinoma|Mixed meningioma|Mixed mesenchymal sarcoma|Mixed mesenchymal tumor|Mixed pancreatic endocrine and exocrine tumor, malignant|Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1|Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged|Mixed phenotype acute leukemia, B/myeloid, NOS|Mixed phenotype acute leukemia, T/myeloid, NOS|Mixed pineal tumor|Mixed pineocytoma-pineoblastoma|Mixed small cell carcinoma|Mixed squamous cell and glandular papilloma|Mixed subependymoma-ependymoma|Mixed teratoma and seminoma|Mixed tumor, NOS|Mixed tumor, malignant, NOS|Mixed tumor, salivary gland type, NOS|Mixed tumor, salivary gland type, malignant|Mixed type rhabdomyosarcoma|Mobitz (Type) II Atrioventricular Block|Mobitz Type I|Mobocertinib|Mocetinostat|Modakafusp Alfa|Moderately Differentiated Ovarian Sertoli-Leydig Cell Tumor|Modified Radical Mastectomy|Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208|Modified Vitamin D Binding Protein Macrophage Activator EF-022|Modotuximab|Mofarotene|Mogamulizumab|Moldova|Molecular Laboratory Procedure Exon Identification Number|Molecular analysis outside specification|Molibresib|Molibresib Besylate|Momelotinib|Monaco|Monalizumab|Mongolia|Monoblastic leukemia, NOS|Monocarboxylate Transporter 1 Inhibitor AZD3965|Monoclonal Antibody 105AD7 Anti-idiotype Vaccine|Monoclonal Antibody 11D10|Monoclonal Antibody 11D10 Anti-Idiotype Vaccine|Monoclonal Antibody 14G2A|Monoclonal Antibody 1F5|Monoclonal Antibody 3622W94|Monoclonal Antibody 3F8|Monoclonal Antibody 3H1 Anti-Idiotype Vaccine|Monoclonal Antibody 4B5 Anti-Idiotype Vaccine|Monoclonal Antibody 7C11|Monoclonal Antibody 81C6|Monoclonal Antibody A1G4 Anti-Idiotype Vaccine|Monoclonal Antibody A27.15|Monoclonal Antibody A33|Monoclonal Antibody AK002|Monoclonal Antibody ASP1948|Monoclonal Antibody AbGn-7|Monoclonal Antibody CAL|Monoclonal Antibody CC49-delta CH2|Monoclonal Antibody CEP-37250/KHK2804|Monoclonal Antibody D6.12|Monoclonal Antibody E2.3|Monoclonal Antibody F19|Monoclonal Antibody GD2 Anti-Idiotype Vaccine|Monoclonal Antibody HeFi-1|Monoclonal Antibody Hu3S193|Monoclonal Antibody HuAFP31|Monoclonal Antibody HuHMFG1|Monoclonal Antibody HuPAM4|Monoclonal Antibody IMMU-14|Monoclonal Antibody L6|Monoclonal Antibody Lym-1|Monoclonal Antibody MX35 F(ab')2|Monoclonal Antibody Me1-14 F(ab')2|Monoclonal Antibody NEO-201|Monoclonal Antibody R24|Monoclonal Antibody RAV12|Monoclonal Antibody SGN-14|Monoclonal Antibody TRK-950|Monoclonal Antibody huJ591|Monoclonal Antibody m170|Monoclonal Antibody muJ591|Monoclonal Gammopathy of Undetermined Significance|Monoclonal Immunoglobulin Deposition Disease|Monoclonal Microbial EDP1503|Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100|Monoclonal gammopathy of undetermined significance|Monoclonal gammopathy, NOS|Monocytic leukemia, NOS|Monocytoid B-cell lymphoma|Monomethyl Auristatin E|Monomorphic adenoma|Mononuclear Cells from Bone Marrow Normal|Monstrocellular sarcoma|Montenegro|Montserrat|Morinda Citrifolia Fruit Extract|Morocco|Morpholinodoxorubicin|Mosedipimod|Mosunetuzumab|Motesanib|Motesanib Diphosphate|Motexafin Gadolinium|Motexafin Lutetium|Mother|Mother-in-law|Motixafortide|Motolimod|Motor / Movement Change|Motor or Movement Changes|Mouth, NOS|Movements Involuntary|Moxetumomab Pasudotox|Mozambique|Mps1 Inhibitor BAY 1217389|Mps1 Inhibitor BOS172722|Ms|Mu Heavy Chain Disease|Mu heavy chain disease|MuSE|MuSE Annotation|MuSE Variant Aggregation and Masking|MuTect2|MuTect2 Annotation|MuTect2 Variant Aggregation and Masking|Mucata mulata|Mucin-Producing Adenocarcinoma|Mucin-Producing Carcinoma|Mucin-producing adenocarcinoma|Mucin-producing carcinoma|Mucin-secreting adenocarcinoma|Mucin-secreting carcinoma|Mucinous Adenocarcinoma|Mucinous Adenocarcinoma, Endocervical Type|Mucinous Adenofibroma|Mucinous Cystadenocarcinoma|Mucinous Cystadenofibroma|Mucinous Cystadenoma|Mucinous Tubular and Spindle Cell Carcinoma of the Kidney|Mucinous adenocarcinofibroma|Mucinous adenocarcinoma|Mucinous adenocarcinoma, endocervical type|Mucinous adenofibroma of borderline malignancy|Mucinous adenofibroma, NOS|Mucinous adenoma|Mucinous carcinoid|Mucinous carcinoma|Mucinous carcinoma, gastric type|Mucinous carcinoma, intestinal type|Mucinous cystadenocarcinofibroma|Mucinous cystadenocarcinoma, NOS|Mucinous cystadenocarcinoma, non-invasive|Mucinous cystadenofibroma of borderline malignancy|Mucinous cystadenofibroma, NOS|Mucinous cystadenoma, NOS|Mucinous cystadenoma, borderline malignancy|Mucinous cystic neoplasm with an associated invasive carcinoma|Mucinous cystic neoplasm with high-grade dysplasia|Mucinous cystic neoplasm with high-grade intraepithelial neoplasia|Mucinous cystic neoplasm with intermediate-grade dysplasia|Mucinous cystic neoplasm with intermediate-grade intraepithelial neoplasia|Mucinous cystic neoplasm with low-grade dysplasia|Mucinous cystic neoplasm with low-grade intraepithelial neoplasia|Mucinous cystic tumor of borderline malignancy|Mucinous cystic tumor with an associated invasive carcinoma|Mucinous cystic tumor with high-grade dysplasia|Mucinous cystic tumor with intermediate dysplasia|Mucinous cystic tumor with low grade dysplasia|Mucinous cystic tumor with moderate dysplasia|Mucinous cystoma|Mucinous tubular and spindle cell carcinoma|Mucinous tumor, NOS, of low malignant potential|Mucoadhesive Paclitaxel Formulation|Mucocarcinoid tumor|Mucoepidermoid Carcinoma|Mucoepidermoid Neoplasms|Mucoepidermoid carcinoma|Mucoepidermoid tumor|Mucoid adenocarcinoma|Mucoid carcinoma|Mucoid cell adenocarcinoma|Mucoid cell adenoma|Mucosa of lip, NOS|Mucosa of lower lip|Mucosa of the Lip|Mucosa of the Lower Lip|Mucosa of upper lip|Mucosal Infection|Mucosal Lentiginous Melanoma|Mucosal lentiginous melanoma|Mucosal-associated lymphoid tissue lymphoma|Mucositis Oral|Mucous adenocarcinoma|Mucous carcinoma|Mullerian adenosarcoma|Mullerian mixed tumor|Multi-AGC Kinase Inhibitor AT13148|Multi-Organ Failure|Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200|Multi-epitope HER2 Peptide Vaccine H2NVAC|Multi-epitope HER2 Peptide Vaccine TPIV100|Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107|Multi-kinase Inhibitor TPX-0022|Multi-kinase Inhibitor XL092|Multi-mode Kinase Inhibitor EOC317|Multi-neo-epitope Vaccine OSE 2101|Multicentric basal cell carcinoma|Multicystic Mesothelioma|Multicystic mesothelioma, benign|Multifocal|Multifocal Lymphomatous Polyposis|Multifocal superficial basal cell carcinoma|Multifunctional/Multitargeted Anticancer Agent OMN54|Multikinase Inhibitor 4SC-203|Multikinase Inhibitor AEE788|Multikinase Inhibitor AT9283|Multikinase Inhibitor SAR103168|Multipeptide Vaccine S-588210|Multiple Adenomatous Polyps|Multiple Endocrine Neoplasia|Multiple Myeloma|Multiple Osteochondromas|Multiple adenomatous polyps|Multiple endocrine adenomas|Multiple hemorrhagic sarcoma|Multiple meningiomas|Multiple myeloma|Multiple neurofibromatosis|Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327|Muparfostat|Mureletecan|Murizatoclax|Mus musculus|Muscadine Grape Extract|Muscle|Muscle Weakness Left-Sided|Muscle Weakness Lower Limb|Muscle Weakness Right-Sided|Muscle Weakness Trunk|Muscle Weakness Upper Limb|Musculoskeletal Deformity|Musculoskeletal and Connective Tissue Disorders - Other|Mutant IDH1 Inhibitor DS-1001|Mutant p53 Activator COTI-2|Mutant-selective EGFR Inhibitor PF-06459988|Myalgia|Myanmar|Myasthenia Gravis|Mycobacterium avium Complex|Mycobacterium tuberculosis|Mycobacterium tuberculosis Arabinomannan Z-100|Mycobacterium w|Mycobacterium, NOS|Mycophenolic Acid|Mycoplasma pneumoniae|Mycosis Fungoides|Mycosis fungoides|Myelitis|Myelocytic leukemia, NOS|Myelodysplastic Syndrome|Myelodysplastic Syndrome with Excess Blasts|Myelodysplastic Syndrome with Excess Blasts-1|Myelodysplastic Syndrome with Excess Blasts-2|Myelodysplastic Syndrome with Isolated del(5q)|Myelodysplastic Syndrome with Multilineage Dysplasia|Myelodysplastic Syndrome with Ring Sideroblasts|Myelodysplastic Syndrome, Unclassifiable|Myelodysplastic Syndromes|Myelodysplastic syndrome with 5q deletion (5q-) syndrome|Myelodysplastic syndrome with isolated del (5q)|Myelodysplastic syndrome, NOS|Myelodysplastic syndrome, unclassifiable|Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Myelodysplastic/myeloproliferative neoplasm, unclassifiable|Myelofibrosis as a result of myeloproliferative disease|Myelofibrosis with myeloid metaplasia|Myelogenous leukemia, NOS|Myeloid Leukemia|Myeloid Leukemia Associated with Down Syndrome|Myeloid Leukemias|Myeloid Sarcoma|Myeloid and lymphoid neoplasms with FGFR1 abnormalities|Myeloid and lymphoid neoplasms with PDGFRA rearrangement|Myeloid leukemia associated with Down Syndrome|Myeloid leukemia, NOS|Myeloid neoplasms with PDGFRB rearrangement|Myeloid sarcoma|Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement|Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement|Myelolipoma|Myeloma, NOS|Myelomatosis|Myelomonocytic leukemia, NOS|Myeloproliferative Neoplasm|Myeloproliferative disease, NOS|Myeloproliferative neoplasm, NOS|Myelosclerosis with myeloid metaplasia|Myloproliferative neoplasm, unclassifiable|Myocardial Infarction|Myocarditis|Myoepithelial Tumor|Myoepithelial adenoma|Myoepithelial carcinoma|Myoepithelial tumor|Myoepithelioma|Myofibroblastic sarcoma|Myofibroblastic tumor, NOS|Myofibroblastic tumor, peribronchial|Myofibroblastoma|Myofibroma|Myofibromatosis|Myolipoma|Myoma|Myomatous Neoplasms|Myometrium|Myosarcoma|Myositis|Myxofibroma, NOS|Myxofibrosarcoma|Myxoid Chondrosarcoma|Myxoid Leiomyosarcoma|Myxoid Liposarcoma|Myxoid chondrosarcoma|Myxoid fibroma|Myxoid leiomyosarcoma|Myxoid liposarcoma|Myxoinflammatory Fibroblastic Sarcoma|Myxoinflammatory fibroblastic sarcoma (MIFS)|Myxolipoma|Myxoliposarcoma|Myxoma|Myxoma, NOS|Myxomatous Neoplasms|Myxopapillary Ependymoma|Myxopapillary ependymoma|Myxosarcoma|N,N-Dibenzyl Daunomycin|N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea|N-Methylformamide|N-dihydrogalactochitosan|N0|N0 (i+)|N0 (i+) Stage Finding|N0 (i-)|N0 (mol+)|N0 (mol+) Stage Finding|N0 (mol-)|N0 Stage Finding|N1|N1 Stage Finding|N1a|N1a Stage Finding|N1b|N1b Stage Finding|N1bI|N1bI Stage Finding|N1bII|N1bII Stage Finding|N1bIII|N1bIII Stage Finding|N1bIV|N1bIV Stage Finding|N1c|N1c Stage Finding|N1mi|N1mi Stage Finding|N2|N2 Stage Finding|N2a|N2a Stage Finding|N2b|N2b Stage Finding|N2c|N2c Stage Finding|N3|N3 Stage Finding|N3a|N3a Stage Finding|N3b|N3b Stage Finding|N3c|N3c Stage Finding|N4|N4 Stage Finding|NA17-A Antigen|NA17.A2 Peptide Vaccine|NAMPT Inhibitor OT-82|NEDD8 Activating Enzyme E1 Inhibitor TAS4464|NG-5400|NG-nitro-L-arginine|NHL, Burkitt lymphoma (BL)|NHL, anaplastic large cell lymphoma|NK-cell large granular lymphocytic leukemia|NK/T-cell lymphoma, nasal and nasal-type|NLRP3 Agonist BMS-986299|NOS|NPB-No Palliative Benefit|NR-No Response|NTRK/ROS1 Inhibitor DS-6051b|NUT Carcinoma|NUT carcinoma|NUT midline carcinoma|NX|NX Stage Finding|NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611|NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301|NY-ESO-1/GLA-SE Vaccine ID-G305|NY-ESO-B|Nab-paclitaxel|Nab-paclitaxel/Rituximab-coated Nanoparticle AR160|Nadofaragene Firadenovec|Nagrestipen|Nail Discoloration|Nail Infection|Nail Loss|Nail Ridging|Nails|Namibia|Namirotene|Namodenoson|Nanafrocin|Nanatinostat|Nanocell-encapsulated miR-16-based microRNA Mimic|Nanoparticle Albumin-Bound Docetaxel|Nanoparticle Albumin-Bound Rapamycin|Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404|Nanoparticle Paclitaxel Ointment SOR007|Nanoparticle-based Paclitaxel Suspension|Nanoparticle-encapsulated Doxorubicin Hydrochloride|Nanoscale Coordination Polymer Nanoparticles CPI-100|Nanosomal Docetaxel Lipid Suspension|Napabucasin|Naphthalimide Analogue UNBS5162|Naptumomab Estafenatox|Naquotinib|Naratuximab Emtansine|Narnatumab|Nasal Cavity|Nasal Congestion|Nasal Soft Tissue|Nasal Type Extranodal NK/T-Cell Lymphoma|Nasal cavity|Nasal cavity and middle ear|Nasopharyngeal-Type Undifferentiated Carcinoma|Nasopharynx|Nasopharynx, NOS|Natalizumab|Native Hawaiian or Other Pacific Islander|Natural Brother|Natural Child|Natural Daughter|Natural Father|Natural Grandchild|Natural Grandfather|Natural Grandmother|Natural Grandparent|Natural IFN-alpha OPC-18|Natural Killer Cells ZRx101|Natural Mother|Natural Parent|Natural Sibling|Natural Sister|Natural Son|Nauru|Nausea|Navarixin|Navicixizumab|Navitoclax|Navoximod|Navy Bean Powder|Naxitamab|Nazartinib|Necitumumab|Neck|Neck Edema|Neck Pain|Neck Soft Tissue Necrosis|Nedaplatin|Nedisertib|Needle Biopsy|Negative|Negative/ No Dysplasia|Nelarabine|Nelipepimut-S|Nelipepimut-S Plus GM-CSF Vaccine|Nemorubicin|Nemorubicin Hydrochloride|Neoadjuvant|Neoadjuvant therapy|Neoantigen Vaccine GEN-009|Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017|Neoantigen-based Glioblastoma Vaccine|Neoantigen-based Melanoma-Poly-ICLC Vaccine|Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine|Neoantigen-based Therapeutic Cancer Vaccine GRT-C903|Neoantigen-based Therapeutic Cancer Vaccine GRT-R904|Neoplasm|Neoplasm of the Diffuse Neuroendocrine System|Neoplasm, NOS|Neoplasm, Uncertain Whether Benign or Malignant|Neoplasm, benign|Neoplasm, malignant|Neoplasm, malignant, uncertain whether primary or metastatic|Neoplasm, metastatic|Neoplasm, secondary|Neoplasm, uncertain whether benign or malignant|Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other|Neoplasms of Histiocytes and Accessory Lymphoid Cells|Neoplasms of Uncertain and Unknown Behavior|Neoplasms, NOS|Neoplastic Cell|Nepal|Nephew|Nephroblastoma, NOS|Nephrogenic adenofibroma|Nephroma, NOS|Neratinib|Neratinib Maleate|Nerve|Nerve Sheath Myxoma|Nerve Sheath Tumors|Nerve sheath myxoma|Nerve(s) Cranial|Nervous System|Nervous System Disorders - Other|Nervous system, NOS|Nesidioblastoma|Nesidioblastosis|Nested urothelial carcinoma|Nesvacumab|Netherlands|Neuralgia|Neurilemoma, NOS|Neurilemoma, malignant|Neurilemosarcoma|Neurinoma|Neurinomatosis|Neuroastrocytoma|Neuroblastoma|Neuroblastoma (NBL)|Neuroblastoma, NOS|Neurocytoma|Neuroectodermal tumor, NOS|Neuroendocrine Carcinoma|Neuroendocrine Tumor|Neuroendocrine carcinoma, NOS|Neuroendocrine carcinoma, low grade|Neuroendocrine carcinoma, moderately differentiated|Neuroendocrine carcinoma, poorly differentiated|Neuroendocrine carcinoma, well-differentiated|Neuroendocrine tumor, grade 1|Neuroendocrine tumor, grade 2|Neuroendocrine tumor, well differentiated|Neuroepithelioma, NOS|Neuroepitheliomatous Neoplasms|Neurofibroma|Neurofibroma, NOS|Neurofibromatosis|Neurofibromatosis Type 1|Neurofibromatosis, NOS|Neurofibrosarcoma|Neurogenic sarcoma|Neurolipocytoma|Neuroma|Neuroma, NOS|Neuronevus|Neurosarcoma|Neurothekeoma|Neurotropic melanoma, malignant|Neutrophil Count Decreased|Never Used|Nevi and Melanomas|Nevus, NOS|New Caledonia|New Objective|New Zealand|New notification type|New observation type|Next Generation Cancer Model|Next Generation Cancer Model Expanded Under Non-conforming Conditions|Next Generation Targeted Sequencing|Niacinamide|Nicaragua|Niclosamide|Nicotinamide Riboside|Nidanilimab|Niece|Niece Second Degree Relative|Nifurtimox|Niger|Nigeria|Night Blindness|Night Sweats|Nilotinib|Nilotinib Hydrochloride Anhydrous|Nilotinib Hydrochloride Monohydrate|Nilutamide|Nimesulide-Hyaluronic Acid Conjugate CA102N|Nimodipine|Nimotuzumab|Nimustine|Nimustine Hydrochloride|Ningetinib Tosylate|Nintedanib|Nipple|Nipple Adenoma|Nipple Deformity|Niraparib|Niraparib Tosylate Monohydrate|Nirogacestat|Nitric Oxide-Releasing Acetylsalicylic Acid Derivative|Nitrogen Mustard Prodrug PR-104|Nitroglycerin Transdermal Patch|Niue|Nivolumab|No Known Treatment Effect|No Measurable Disease|No Metastasis|No Metastasis (M0)|No Necrosis|No Palliative Benefit|No Response|No Smoke Exposure|No Treatment|No Vascular Invasion|No cleavage|NoEnzyme|Nocardiosis|Nocodazole|Nodal Marginal Zone Lymphoma|Nodal marginal zone lymphoma|Nodular Hidradenoma|Nodular Lymphocyte Predominant Hodgkin Lymphoma|Nodular Prostatic Hyperplasia|Nodular Sclerosis Classic Hodgkin Lymphoma|Nodular Sclerosis Classic Hodgkin Lymphoma, Cellular Phase|Nodular Sclerosis Classic Hodgkin Lymphoma, Syncytial Variant|Nodular hidradenoma|Nodular hidradenoma, malignant|Nodular melanoma|Nogalamycin|Nogapendekin Alfa|Nolatrexed Dihydrochloride|Non cancerous tissue|Non-CR/Non-PD-Non-CR/Non-PD|Non-Cancer Related Death|Non-Cardiac Chest Pain|Non-Drinker|Non-Hodgkin Lymphoma|Non-Hodgkin lymphoma, NOS|Non-Invasive Papillary Squamous Cell Carcinoma|Non-Invasive Papillary Transitional Cell Carcinoma|Non-Keratinizing Large Cell Squamous Cell Carcinoma|Non-Keratinizing Sinonasal Squamous Cell Carcinoma|Non-Keratinizing Small Cell Squamous Cell Carcinoma|Non-Malignant|Non-Small Cell Carcinoma|Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201|Non-WNT/non-SHH Activated|Non-invasive EFVPTC|Non-invasive FTP|Non-invasive encapsulated follicular variant of papillary thyroid carcinoma (non-invasive EFVPTC)|Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)|Non-invasive low grade serous carcinoma|Non-invasive mammary carcinoma|Non-lymphocytic leukemia, NOS|Non-small cell carcinoma|Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis|Nonchromaffin paraganglioma, NOS|Nonchromaffin paraganglioma, malignant|None|Nonencapsulated sclerosing adenocarcinoma|Nonencapsulated sclerosing carcinoma|Nonencapsulated sclerosing tumor|Nongerminomatous Germ Cell Tumor|Noninfiltrating intracystic carcinoma|Noninfiltrating intraductal papillary adenocarcinoma|Noninfiltrating intraductal papillary carcinoma|Noninvasive pancreatobiliary papillary neoplasm with high grade dysplasia|Noninvasive pancreatobiliary papillary neoplasm with high grade intraepithelial neoplasia|Noninvasive pancreatobiliary papillary neoplasm with low grade dysplasia|Noninvasive pancreatobiliary papillary neoplasm with low grade intraepithelial neoplasia|Nonlipid reticuloendotheliosis|Nonpigmented Nevus|Nonpigmented nevus|Norgestrel|Normal|Normal Adjacent Tissue|Normal class but appears diseased|Normal tissue origin incorrect|Normal_LogR|North American Ginseng Extract AFX-2|North Korea|North Macedonia|Northern Mariana Islands|Nortopixantrone|Norway|Noscapine|Noscapine Hydrochloride|Not Allowed To Collect|Not Applicable|Not Cancer Related|Not Determined|Not Hispanic or Latino|Not Otherwise Specified|Not Performed|Not Reported|Not performed|Notch Signaling Inhibitor PF-06650808|Notch Signaling Pathway Inhibitor MK0752|Notification|Nuclei RNA|Nucleolin Antagonist IPP-204106N|Nucleoside Analog DFP-10917|Nucleotide Analog Prodrug NUC-3373|Nucleotide Analogue GS 9219|Numidargistat|Nurulimab|Nutlin-3a|Nutraceutical TBL-12|Nystagmus|O-Chloroacetylcarbamoylfumagillol|O6-Benzylguanine|OCT|OMEGA|OMEGA-2001|OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule|OX40L-expressing Oncolytic Adenovirus DNX-2440|Oat cell carcinoma|Obatoclax Mesylate|Obesity|Obinutuzumab|Oblimersen Sodium|Observation|Obstruction Gastric|Ocaratuzumab|Occasional Drinker|Occipital Cortex|Occipital Lobe|Occipital lobe|Ocrelizumab|Octreotide|Octreotide Acetate|Octreotide Pamoate|Ocular Orbits|Oculomotor Nerve Disorder|Odontoameloblastoma|Odontogenic Fibroma|Odontogenic Myxofibroma|Odontogenic Myxoma|Odontogenic Neoplasm|Odontogenic Tumors|Odontogenic carcinoma|Odontogenic carcinosarcoma|Odontogenic fibroma, NOS|Odontogenic fibrosarcoma|Odontogenic ghost cell tumor|Odontogenic myxofibroma|Odontogenic myxoma|Odontogenic sarcoma|Odontogenic tumor, NOS|Odontogenic tumor, benign|Odontogenic tumor, malignant|Odontoma|Odontoma, NOS|Odronextamab|Ofatumumab|Ofranergene Obadenovec|Oglufanide Disodium|Oil burning smoke, Kerosene|Oil burning smoke, NOS|Olaparib|Olaptesed Pegol|Olaratumab|Oleandrin|Oleclumab|Olfactory Nerve Disorder|Olfactory Neuroblastoma|Olfactory Neurocytoma|Olfactory Neurogenic Tumor|Olfactory nerve|Olfactory neuroblastoma|Olfactory neurocytoma|Olfactory neuroepithelioma|Olfactory neurogenic tumor|Oligo-fucoidan|Oligoastrocytoma|Oligodendroblastoma|Oligodendroglioma|Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted|Oligodendroglioma, NOS|Oligodendroglioma, Not Otherwise Specified|Oligodendroglioma, anaplastic|Oligonucleotide SPC2996|Oligospermia|Olinvacimab|Olivomycin|Olmutinib|Oltipraz|Olutasidenib|Olvimulogene Nanivacirepvec|Omacetaxine Mepesuccinate|Oman|Ombrabulin|Omentectomy|Omentum|Omipalisib|Onalespib|Onalespib Lactate|Onartuzumab|Onatasertib|Once Weekly|Oncocytic Adenoma|Oncocytic Neoplasm|Oncocytic Schneiderian papilloma|Oncocytic adenocarcinoma|Oncocytic adenoma|Oncocytic carcinoma|Oncocytoma|Oncolytic Adenovirus Ad5-DNX-2401|Oncolytic Adenovirus ORCA-010|Oncolytic HSV-1 C134|Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011|Oncolytic HSV-1 G207|Oncolytic HSV-1 NV1020|Oncolytic HSV-1 rQNestin34.5v.2|Oncolytic HSV-1 rRp450|Oncolytic HSV1716|Oncolytic Herpes Simplex Virus-1 ONCR-177|Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein|Oncolytic Newcastle Disease Virus MEDI5395|Oncolytic Newcastle Disease Virus MTH-68H|Oncolytic Newcastle Disease Virus Strain PV701|Oncolytic Virus ASP9801|Oncolytic Virus RP1|Ondansetron Hydrochloride|Ontorpacept|Ontuxizumab|Onvansertib|Onvatilimab|Oophorectomy|Opaganib|Open Craniotomy|Open Partial Nephrectomy|Open Radical Nephrectomy|Open Radical Prostatectomy|Opioid Growth Factor|Opolimogene Capmilisbac|Oportuzumab Monatox|Oprozomib|Optic Nerve|Optic Nerve Disorder|Optic nerve|OptionAnalysisPipeline2|Opucolimab|Oral|Oral Aminolevulinic Acid Hydrochloride|Oral Azacitidine|Oral Cancer Vaccine V3-OVA|Oral Cavity|Oral Cavity - Mucosa Only|Oral Cavity Fistula|Oral Contraceptives|Oral Docetaxel|Oral Dysesthesia|Oral Fludarabine Phosphate|Oral Hemorrhage|Oral Hsp90 Inhibitor IPI-493|Oral Hypoglycemic|Oral Ixabepilone|Oral Microencapsulated Diindolylmethane|Oral Milataxel|Oral Myoma Vaccine V3-myoma|Oral Pain|Oral Pancreatic Cancer Vaccine V3-P|Oral Picoplatin|Oral Sodium Phenylbutyrate|Oral Squamous Cell Carcinoma|Oral Topotecan Hydrochloride|Orantinib|Oraxol|Orbit|Orbit, NOS|Orbitrap Elite|Orbitrap Fusion|Orbitrap Fusion ETD|Orbitrap Fusion Lumos|Orbitrap Lumos|Orbitrap Velos|Orchiectomy|Orchioblastoma|Orchiopexy|Oregovomab|Orelabrutinib|Organ Transplantation|Organ transplant (site)|Ormaplatin|Oropharynx|Oropharynx, NOS|Ortataxel|Orteronel|Orvacabtagene Autoleucel|Oryza sativa|Osilodrostat|Osimertinib|Osseous and Chondromatous Neoplasms|Ossifying Fibroma|Ossifying Fibromyxoid Tumor|Ossifying fibroma|Ossifying fibromyxoid tumor|Ossifying fibromyxoid tumor, malignant|Ossifying renal tumor|Osteoarthritis|Osteoblastic Osteosarcoma|Osteoblastic sarcoma|Osteoblastoma|Osteoblastoma, NOS|Osteoblastoma, malignant|Osteocartilaginous exostosis|Osteochondroma|Osteochondromatosis, NOS|Osteochondrosarcoma|Osteofibroma|Osteofibrosarcoma|Osteogenic sarcoma, NOS|Osteoid Osteoma|Osteoid osteoma, NOS|Osteoma|Osteoma, NOS|Osteonecrosis of Jaw|Osteoporosis|Osteoporosis or Osteopenia|Osteosarcoma|Osteosarcoma (OS)|Osteosarcoma in Paget disease of bone|Osteosarcoma, NOS|Other|Other Cancer Within 5 Years|Other Hematologic Disorders|Other Leukemias|Other Nonmalignant Systemic Disease|Other Pulmonary Complications|Other Specified Parts of Pancreas|Other Surgical Resection|Other and Unspecified Female Genital Organs ICD-O-3|Other and ill-defined digestive organs|Other and ill-defined sites|Other and ill-defined sites in lip, oral cavity and pharynx|Other and ill-defined sites within respiratory system and intrathoracic organs|Other and unspecified female genital organs|Other and unspecified major salivary glands|Other and unspecified male genital organs|Other and unspecified parts of biliary tract|Other and unspecified parts of mouth|Other and unspecified parts of tongue|Other and unspecified urinary organs|Other endocrine glands and related structures|Other ill-defined sites|Other specified parts of female genital organs|Other specified parts of male genital organs|Other specified parts of pancreas|Otitis Externa|Otitis Media|Otlertuzumab|Ovapuldencel-T|Ovarian Cancer|Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006|Ovarian Capsule Fragmented|Ovarian Capsule Intact|Ovarian Capsule Ruptured|Ovarian Endometrioid Adenofibroma|Ovarian Endometrioid Cystadenofibroma|Ovarian Gynandroblastoma|Ovarian Hemorrhage|Ovarian Hilus Cell Tumor|Ovarian Infection|Ovarian Luteinized Thecoma|Ovarian Rupture|Ovarian Sclerosing Stromal Tumor|Ovarian Seromucinous Carcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord-Stromal Tumor|Ovarian Small Cell Carcinoma, Hypercalcemic Type|Ovarian Small Cell Carcinoma, Pulmonary-Type|Ovarian Steroid Cell Tumor|Ovarian Stromal Luteoma|Ovarian Stromal Tumor with Minor Sex Cord Elements|Ovarian stromal tumor|Ovary|Overlapping lesion of accessory sinuses|Overlapping lesion of biliary tract|Overlapping lesion of bladder|Overlapping lesion of bones, joints and articular cartilage|Overlapping lesion of bones, joints and articular cartilage of limbs|Overlapping lesion of brain|Overlapping lesion of brain and central nervous system|Overlapping lesion of breast|Overlapping lesion of cervix uteri|Overlapping lesion of colon|Overlapping lesion of connective, subcutaneous and other soft tissues|Overlapping lesion of corpus uteri|Overlapping lesion of digestive system|Overlapping lesion of endocrine glands and related structures|Overlapping lesion of esophagus|Overlapping lesion of eye and adnexa|Overlapping lesion of female genital organs|Overlapping lesion of floor of mouth|Overlapping lesion of heart, mediastinum and pleura|Overlapping lesion of hypopharynx|Overlapping lesion of ill-defined sites|Overlapping lesion of larynx|Overlapping lesion of lip|Overlapping lesion of lip, oral cavity and pharynx|Overlapping lesion of lung|Overlapping lesion of major salivary glands|Overlapping lesion of male genital organs|Overlapping lesion of nasopharynx|Overlapping lesion of other and unspecified parts of mouth|Overlapping lesion of palate|Overlapping lesion of pancreas|Overlapping lesion of penis|Overlapping lesion of peripheral nerves and autonomic nervous system|Overlapping lesion of rectum, anus and anal canal|Overlapping lesion of respiratory system and intrathoracic organs|Overlapping lesion of retroperitoneum and peritoneum|Overlapping lesion of skin|Overlapping lesion of small intestine|Overlapping lesion of stomach|Overlapping lesion of tongue|Overlapping lesion of tonsil|Overlapping lesion of urinary organs|Overlapping lesion of vulva|Overlapping lesions of oropharynx|Ovine Submaxillary Mucin|Ovulation Pain|OxPhos Inhibitor VLX600|Oxaliplatin|Oxaliplatin Eluting Beads|Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome|Oxcarbazepine|Oxeclosporin|Oxidative Phosphorylation Inhibitor IACS-010759|Oxidative Phosphorylation Inhibitor IM156|Oxidopamine|Oxyphilic Adenocarcinoma|Oxyphilic adenocarcinoma|Oxyphilic adenoma|Ozarelix|P-TEFb Inhibitor BAY1143572|P-cadherin Antagonist PF-03732010|P-cadherin Inhibitor PCA062|P-cadherin-targeting Agent PF-06671008|P-p68 Inhibitor RX-5902|PA-Palliative Therapy|PAK4 Inhibitor PF-03758309|PAK4/NAMPT Inhibitor KPT-9274|PARP 1/2 Inhibitor IMP4297|PARP 1/2 Inhibitor NOV1401|PARP Inhibitor AZD2461|PARP Inhibitor CEP-9722|PARP Inhibitor E7016|PARP Inhibitor NMS-03305293|PARP-1/2 Inhibitor ABT-767|PARP/Tankyrase Inhibitor 2X-121|PARP7 Inhibitor RBN-2397|PB-Palliative Benefit|PBN Derivative OKN-007|PCNU|PD-1 Directed Probody CX-188|PD-1 Inhibitor|PD-L1 Inhibitor GS-4224|PD-L1 Inhibitor INCB086550|PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480|PD-L1/PD-L2/VISTA Antagonist CA-170|PD-Progressive Disease|PDF|PDK1 Inhibitor AR-12|PDM-Persistent Distant Metastasis|PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1|PEComa, malignant|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|PEG-Proline-Interferon Alfa-2b|PEG-interleukin-2|PEOX-based Polymer Encapsulated Paclitaxel FID-007|PEP-3-KLH Conjugate Vaccine|PET|PGG Beta-Glucan|PGLA/PEG Copolymer-Based Paclitaxel|PH20 Hyaluronidase-expressing Adenovirus VCN-01|PI3K Alpha/Beta Inhibitor BAY1082439|PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate|PI3K Inhibitor ACP-319|PI3K Inhibitor BGT226|PI3K Inhibitor GDC-0084|PI3K Inhibitor GDC0077|PI3K Inhibitor GSK1059615|PI3K Inhibitor WX-037|PI3K Inhibitor ZSTK474|PI3K p110beta/delta Inhibitor KA2237|PI3K-alpha Inhibitor MEN1611|PI3K-beta Inhibitor GSK2636771|PI3K-beta Inhibitor SAR260301|PI3K-delta Inhibitor AMG 319|PI3K-delta Inhibitor HMPL 689|PI3K-delta Inhibitor INCB050465|PI3K-delta Inhibitor PWT143|PI3K-delta Inhibitor SHC014748M|PI3K-delta Inhibitor YY-20394|PI3K-gamma Inhibitor IPI-549|PI3K/BET Inhibitor LY294002|PI3K/mTOR Kinase Inhibitor DS-7423|PI3K/mTOR Kinase Inhibitor PF-04691502|PI3K/mTOR Kinase Inhibitor VS-5584|PI3K/mTOR Kinase Inhibitor WXFL10030390|PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170|PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901|PI3Ka/mTOR Inhibitor PKI-179|PI3Kalpha Inhibitor AZD8835|PI3Kbeta Inhibitor AZD8186|PI3Kdelta Inhibitor GS-9901|PIM Kinase Inhibitor LGH447|PIM Kinase Inhibitor SGI-1776|PIM Kinase Inhibitor TP-3654|PIM/FLT3 Kinase Inhibitor SEL24|PIN III|PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231|PKC-alpha Antisense Oligodeoxynucleotide ISIS 3521|PKC-beta Inhibitor MS-553|PLC|PLD-Persistent Locoregional Disease|PLK1 Inhibitor CYC140|PLK1 Inhibitor TAK-960|PNET, NOS|PP/PYY producing tumor|PPAR Alpha Antagonist TPST-1120|PPD-Pseudoprogression|PPNET|PR-Partial Response|PR1 Leukemia Peptide Vaccine|PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701|PRIMA-1 Analog APR-246|PRMT1 Inhibitor GSK3368715|PRMT5 Inhibitor JNJ-64619178|PRMT5 Inhibitor PRT811|PSA/IL-2/GM-CSF Vaccine|PSA/PSMA DNA Plasmid INO-5150|PSMA|PSMA-targeted Docetaxel Nanoparticles BIND-014|PSMA-targeted Tubulysin B-containing Conjugate EC1169|PSMA/CD3 Tri-specific T-cell Activating Construct HPN424|PSR-Pseudoresponse|PTEF-b/CDK9 Inhibitor BAY1251152|PTLD, NOS|PV-10|PVA Microporous Hydrospheres/Doxorubicin Hydrochloride|PacBio|Pacinian Neurofibroma|Pacinian tumor|Paclitaxel|Paclitaxel Ceribate|Paclitaxel Injection Concentrate for Nanodispersion|Paclitaxel Liposome|Paclitaxel PPE Microspheres|Paclitaxel Poliglumex|Paclitaxel Polymeric Micelle Formulation NANT-008|Paclitaxel Trevatide|Paclitaxel Vitamin E-Based Emulsion|Paclitaxel-Loaded Polymeric Micelle|Pacmilimab|Pacritinib|Padeliporfin|Padoporfin|Paget Disease and Intraductal Carcinoma of the Breast|Paget Disease of the Breast|Paget Disease of the Breast without Invasive Carcinoma|Paget disease and infiltrating duct carcinoma of breast|Paget disease and intraductal carcinoma of breast|Paget disease of breast|Paget disease, extramammary|Paget disease, mammary|Pagetoid Reticulosis|Pagetoid reticulosis|Pain|Pain (Various)|Pain in Extremity|Pain of Skin|Paired_LogR|Pakistan|Palate|Palate, NOS|Palatectomy|Palatine Tonsil|Palau|Palbociclib|Palbociclib Isethionate|Palifosfamide|Palifosfamide Tromethamine|Palladium Pd-103|Palliative|Palmar-Plantar Erythrodysesthesia Syndrome|Palonosetron Hydrochloride|Palpitations|Pamidronate Disodium|Pamidronic Acid|Pamiparib|Pamrevlumab|Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514|Pan-AKT Inhibitor ARQ751|Pan-AKT Kinase Inhibitor GSK690693|Pan-FGFR Inhibitor LY2874455|Pan-FLT3/Pan-BTK Multi-kinase Inhibitor CG-806|Pan-IDH Mutant Inhibitor AG-881|Pan-KRAS Inhibitor BI 1701963|Pan-Mutant-IDH1 Inhibitor Bay-1436032|Pan-PIM Inhibitor INCB053914|Pan-Procto Colectomy|Pan-RAF Inhibitor LY3009120|Pan-RAR Agonist/AP-1 Inhibitor LGD 1550|Pan-TRK Inhibitor NOV1601|Pan-TRK Inhibitor ONO-7579|Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981|Pan-mutation-selective EGFR Inhibitor CLN-081|Panama|Pancratistatin|Pancreas|Pancreas Cancer|Pancreas Infection|Pancreas, NOS|Pancreatectomy|Pancreatic Acinar Cell Cystadenocarcinoma|Pancreatic Adenocarcinoma|Pancreatic Anastomotic Leak|Pancreatic Beta Cell Adenoma|Pancreatic Duct Stenosis|Pancreatic Ductal Adenocarcinoma|Pancreatic Enzymes Decreased|Pancreatic Fistula|Pancreatic Hemorrhage|Pancreatic Insulinoma|Pancreatic Intraductal Papillary-Mucinous Neoplasm with High Grade Dysplasia|Pancreatic Intraductal Papillary-Mucinous Neoplasm with an Associated Invasive Carcinoma|Pancreatic Intraductal Tubulopapillary Neoplasm|Pancreatic Mucinous-Cystic Neoplasm with Intermediate Grade Dysplasia|Pancreatic Necrosis|Pancreatic Neuroendocrine Carcinoma|Pancreatic Neuroendocrine Neoplasm|Pancreatic duct|Pancreatic endocrine tumor, NOS|Pancreatic endocrine tumor, benign|Pancreatic endocrine tumor, malignant|Pancreatic endocrine tumor, nonfunctioning|Pancreatic microadenoma|Pancreatic neck|Pancreatic peptide and pancreatic peptide-like peptide within terminal tyrosine amide producing tumor|Pancreatitis|Pancreatobiliary neoplasm, non-invasive|Pancreatobiliary-type carcinoma|Pancreatoblastoma|Panitumumab|Panobinostat|Panobinostat Nanoparticle Formulation MTX110|Panulisib|Pap Smear|Papillary Adenocarcinoma|Papillary Adenofibroma|Papillary Carcinoma|Papillary Carcinoma In Situ|Papillary Craniopharyngioma|Papillary Cystadenocarcinoma|Papillary Cystadenoma|Papillary Cystic Neoplasm|Papillary Eccrine Adenoma|Papillary Ependymoma|Papillary Glioneuronal Tumor|Papillary Intralymphatic Angioendothelioma|Papillary Meningioma|Papillary Mucinous Cystadenocarcinoma|Papillary Mucinous Cystadenoma|Papillary Renal Cell Carcinoma|Papillary Serous Cystadenocarcinoma|Papillary Serous Cystadenoma|Papillary Squamous Cell Carcinoma|Papillary Transitional Cell Carcinoma|Papillary Tumor of the Pineal Region|Papillary adenocarcinoma, NOS|Papillary adenocarcinoma, follicular variant|Papillary adenofibroma|Papillary adenoma, NOS|Papillary and follicular adenocarcinoma|Papillary and follicular carcinoma|Papillary carcinoma in situ|Papillary carcinoma of thyroid|Papillary carcinoma, NOS|Papillary carcinoma, columnar cell|Papillary carcinoma, diffuse sclerosing|Papillary carcinoma, encapsulated|Papillary carcinoma, follicular variant|Papillary carcinoma, oxyphilic cell|Papillary carcinoma, tall cell|Papillary cystadenocarcinoma, NOS|Papillary cystadenoma lymphomatosum|Papillary cystadenoma, NOS|Papillary cystadenoma, borderline malignancy|Papillary cystic tumor|Papillary ependymoma|Papillary epidermoid carcinoma|Papillary glioneuronal tumor|Papillary hidradenoma|Papillary meningioma|Papillary microcarcinoma|Papillary mucinous cystadenocarcinoma|Papillary mucinous cystadenoma, NOS|Papillary mucinous cystadenoma, borderline malignancy|Papillary mucinous tumor of low malignant potential|Papillary neoplasm, pancreatobiliary-type, with high grade intraepithelial neoplasia|Papillary pseudomucinous cystadenocarcinoma|Papillary pseudomucinous cystadenoma, NOS|Papillary pseudomucinous cystadenoma, borderline malignancy|Papillary renal cell carcinoma|Papillary serous adenocarcinoma|Papillary serous cystadenocarcinoma|Papillary serous cystadenoma, NOS|Papillary serous cystadenoma, borderline malignancy|Papillary serous tumor of low malignant potential|Papillary squamous cell carcinoma|Papillary squamous cell carcinoma in situ|Papillary squamous cell carcinoma, non-invasive|Papillary syringadenoma|Papillary syringocystadenoma|Papillary transitional cell carcinoma|Papillary transitional cell carcinoma, non-invasive|Papillary transitional cell neoplasm of low malignant potential|Papillary tumor of the pineal region|Papillary urothelial carcinoma|Papillary urothelial carcinoma, non-invasive|Papillary urothelial neoplasm of low malignant potential|Papilledema|Papillocystic adenocarcinoma|Papilloma|Papilloma of bladder|Papilloma, NOS|Papillomatosis|Papillomatosis, NOS|Papillomatosis, glandular|Papillotubular adenocarcinoma|Papillotubular adenoma|Papua New Guinea|Papulopustular Rash|Paracentesis|Parachordoma|Parafollicular cell carcinoma|Paraganglioma|Paraganglioma, NOS|Paraganglioma, benign|Paraganglioma, malignant|Paragangliomas and Glomus Tumors|Paraguay|Parametrium|Paranasal Sinuses|Parasitic Disease of Biliary Tract|Paraspinal Ganglion|Parasympathetic Paraganglioma|Parasympathetic paraganglioma|Parathyroid|Parathyroid Gland Chief Cell Adenoma|Parathyroid Gland Water-Clear Cell Adenoma|Parathyroid gland|Paraurethral gland|Parenchyma|Parent|Paresthesia|Paricalcitol|Parietal Lobe|Parietal cell adenocarcinoma|Parietal cell carcinoma|Parietal lobe|Paronychia|Parosteal Osteosarcoma|Parosteal osteosarcoma|Parotid Gland|Parotid gland|Parotidectomy, NOS|Paroxysmal Atrial Tachycardia|Parsaclisib|Parsaclisib Hydrochloride|Parsatuzumab|Partial Hepatectomy|Partial Hydatidiform Mole|Partial Laryngectomy|Partial Maxillectomy|Partial Nephrectomy|Partial Response|Partial hydatidiform mole|Partially Engineered T-regulatory Cell Donor Graft TRGFT-201|Parvovirus H-1|Pasireotide|Pasotuxizumab|Patella|Paternal Aunt|Paternal First Cousin|Paternal First Cousin Once Removed|Paternal Grandfather|Paternal Grandmother|Paternal Grandparent|Paternal Great Aunt|Paternal Great Grandparent|Paternal Great Uncle|Paternal Half Brother|Paternal Half Sibling|Paternal Half Sister|Paternal Uncle|Pathologic Examination|Pathologic Review|Pathology|Pathology Report|Pathology outside specification|Patidegib|Patidegib Topical Gel|Patritumab|Patritumab Deruxtecan|Pattern 1|Pattern 2|Pattern 3|Pattern 4|Pattern 5|Patupilone|Paxalisib|Pazopanib|Pazopanib Hydrochloride|Pediatric Liver Cancer|Pediatric/AYA Brain Tumors|Pegargiminase|Pegaspargase|Pegasus|Pegasus 4D|Pegasus BT|Pegasus HRT|Pegasus III|Pegdinetanib|Pegfilgrastim|Pegilodecakin|Peginterferon Alfa-2a|Peginterferon Alfa-2b|Pegvisomant|Pegvorhyaluronidase Alfa|Pegylated Deoxycytidine Analogue DFP-14927|Pegylated Interferon Alfa|Pegylated Liposomal Belotecan|Pegylated Liposomal Doxorubicin Hydrochloride|Pegylated Liposomal Irinotecan|Pegylated Liposomal Mitomycin C Lipid-based Prodrug|Pegylated Liposomal Mitoxantrone Hydrochloride|Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010|Pegylated Paclitaxel|Pegylated Recombinant Human Arginase I BCT-100|Pegylated Recombinant Human Hyaluronidase PH20|Pegylated Recombinant Interleukin-2 THOR-707|Pegylated Recombinant L-asparaginase Erwinia chrysanthemi|Pegylated SN-38 Conjugate PLX038|Pegzilarginase|Pelabresib|Pelareorep|Peldesine|Pelitinib|Pelitrexol|Pelvic Floor Muscle Weakness|Pelvic Infection|Pelvic Pain|Pelvic Soft Tissue Necrosis|Pelvic bones, sacrum, coccyx and associated joints|Pelvic lymph nodes|Pelvis|Pelvis, NOS|Pembrolizumab|Pemetrexed|Pemetrexed Disodium|Pemigatinib|Pemlimogene Merolisbac|Penberol|Penclomedine|Penicillamine|Penile Carcinoma In Situ|Penile Infection|Penile Pain|Penis|Penis, NOS|Pentamethylmelamine|Pentamustine|Pentostatin|Pentoxifylline|Pepinemab|Peplomycin|Peplomycin Sulfate|Peposertib|PepsinA|Peptic Ulcer (Ulcer)|Peptichemio|Peptide 946 Melanoma Vaccine|Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine|Peretinoin|Perflenapent Emulsion|Perforation Bile Duct|Perfosfamide|Periapical cemental dysplasia|Periapical cemento-osseous dysplasia|Pericanalicular fibroadenoma|Pericardial Effusion|Pericardial Tamponade|Pericarditis|Pericardium|Periductal stromal tumor, low grade|Perifollicular Fibroma|Perifollicular fibroma|Perifosine|Perillyl Alcohol|Perimenopausal|Perineal Pain|Perinephric Fat|Perineural MPNST|Perineurioma|Perineurioma, NOS|Perineurioma, malignant|Periodontal Disease|Periorbital Edema|Periorbital Infection|Periorbital Soft Tissue|Periosteal Chondroma|Periosteal Chondrosarcoma|Periosteal Fibroma|Periosteal Fibrosarcoma|Periosteal Osteosarcoma|Periosteal chondroma|Periosteal chondrosarcoma|Periosteal fibroma|Periosteal fibrosarcoma|Periosteal osteosarcoma|Periosteal sarcoma, NOS|Peripheral Blood Components NOS|Peripheral Ischemia|Peripheral Motor Neuropathy|Peripheral Nerve Infection|Peripheral Neuropathy|Peripheral Odontogenic Fibroma|Peripheral Primitive Neuroectodermal Tumor|Peripheral Sensory Neuropathy|Peripheral T-Cell Lymphoma, Large Cell|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Peripheral T-cell lymphoma, AILD (Angioimmunoblastic Lymphadenopathy with Dysproteinemia)|Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, large cell|Peripheral T-cell lymphoma, pleomorphic medium and large cell|Peripheral T-cell lymphoma, pleomorphic small cell|Peripheral Vascular Disease|Peripheral Whole Blood|Peripheral nerves and autonomic nervous system|Peripheral nerves and autonomic nervous system of abdomen|Peripheral nerves and autonomic nervous system of head, face, and neck|Peripheral nerves and autonomic nervous system of lower limb and hip|Peripheral nerves and autonomic nervous system of pelvis|Peripheral nerves and autonomic nervous system of thorax|Peripheral nerves and autonomic nervous system of trunk, NOS|Peripheral nerves and autonomic nervous system of upper limb and shoulder|Peripheral neuroectodermal tumor|Peripheral odontogenic fibroma|Peripheral primitive neuroectodermal tumor, NOS|Peritoneal Cavity|Peritoneal Infection|Peritoneal Lavage|Peritoneal Necrosis|Peritoneum|Peritoneum, NOS|Peritumoral|Perivascular epithelioid cell tumor, malignant|Permanently missing item or object|Persistent Disease|Personality Change|Personalized ALL-specific Multi-HLA-binding Peptide Vaccine|Personalized Cancer Vaccine RO7198457|Personalized Neoantigen DNA Vaccine GNOS-PV01|Personalized Neoantigen DNA Vaccine GNOS-PVO2|Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01|Personalized Neoepitope Yeast Vaccine YE-NEO-001|Personalized Peptide Cancer Vaccine NEO-PV-01|Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC|Pertuzumab|Peru|Peutz-Jeghers Disease|Pevonedistat|Pexastimogene Devacirepvec|Pexidartinib|Pexmetinib|Phaleria macrocarpa Extract DLBS-1425|Phantom Pain|Pharmaceutical Therapy, NOS|Pharmacological Ascorbate|Pharyngeal Anastomotic Leak|Pharyngeal Fistula|Pharyngeal Hemorrhage|Pharyngeal Mucositis|Pharyngeal Necrosis|Pharyngeal Stenosis|Pharyngitis|Pharyngolaryngeal Pain|Pharynx|Pharynx, NOS|Phellodendron amurense Bark Extract|Phenesterin|Phenethyl Isothiocyanate|Phenethyl Isothiocyanate-containing Watercress Juice|Phenochromocytoma or Paraganglioma|Phenyl Acetate|Phenytoin Sodium|Pheochromoblastoma|Pheochromocytoma and Paraganglioma|Pheochromocytoma, NOS|Pheochromocytoma, malignant|Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia|Philadelphia-Negative Myelogenous Leukemia|Philippines|Phlebitis|Phlebitis Infective|Phosphaplatin PT-112|Phosphatidylcholine-Bound Silybin|Phosphaturic mesenchymal tumor, malignant|Phospholipid Ether-drug Conjugate CLR 131|Phosphoproteome|Phosphoramide Mustard|Phosphorodiamidate Morpholino Oligomer AVI-4126|Phosphorus P-32|Photodynamic Compound TLD-1433|Photophobia|Photosensitivity|Photosensitizer LUZ 11|Phyllodes Tumor|Phyllodes tumor, NOS|Phyllodes tumor, benign|Phyllodes tumor, borderline|Phyllodes tumor, malignant|Physical Exam|Physical Examination|Phytochlorin Sodium-Polyvinylpyrrolidone Complex|Pibenzimol|Pibrozelesin|Pibrozelesin Hydrobromide|Picibanil|Pick tubular adenoma|PicoFrit SELF/P|Picoplatin|Picrasinoside H|Picropodophyllin|Pictilisib|Pictilisib Bismesylate|Pidilizumab|Pigmented Adrenal Cortex Adenoma|Pigmented Dermatofibrosarcoma Protuberans|Pigmented Nevus|Pigmented Spindle Cell Nevus|Pigmented adenoma|Pigmented basal cell carcinoma|Pigmented dermatofibrosarcoma protuberans|Pigmented nevus, NOS|Pigmented schwannoma|Pigmented spindle cell nevus of Reed|Pilar tumor|Pilaralisib|Pilocytic Astrocytoma|Pilocytic astrocytoma|Piloid astrocytoma|Pilomatrical Carcinoma|Pilomatricoma|Pilomatricoma, NOS|Pilomatricoma, malignant|Pilomatrix carcinoma|Pilomatrixoma, NOS|Pilomatrixoma, malignant|Pilomyxoid Astrocytoma|Pilomyxoid astrocytoma|PilotAnalysisPipeline2|Pimasertib|Pimitespib|Pimurutamab|Pinatuzumab Vedotin|Pindborg tumor|Pindel|Pindel Annotation|Pindel Variant Aggregation and Masking|Pineal|Pineal Gland|Pineal Parenchymal Cell Neoplasm|Pineal Parenchymal Tumor of Intermediate Differentiation|Pineal Region Neoplasm|Pineal gland|Pineal parenchymal tumor of intermediate differentiation|Pinealoma|Pineoblastoma|Pineocytoma|Pingyangmycin|Pinkus tumor|Pinometostat|Pioglitazone|Pioglitazone Hydrochloride|Pipe|Pipeline|Pipendoxifene|Piperazinedione|Piperine Extract (Standardized)|Pipobroman|Piposulfan|Pirarubicin|Pirarubicin Hydrochloride|Pirfenidone|Piritrexim|Piritrexim Isethionate|Pirotinib|Piroxantrone|Piroxantrone Hydrochloride|Pituicytoma|Pituitary Gland|Pituitary Gland Acidophil Adenoma|Pituitary Gland Acidophil Carcinoma|Pituitary Gland Adenoma|Pituitary Gland Basophil Adenoma|Pituitary Gland Carcinoma|Pituitary Gland Chromophobe Adenoma|Pituitary Gland Mixed Acidophil-Basophil Adenoma|Pituitary Gland Mixed Acidophil-Basophil Carcinoma|Pituitary adenoma, NOS|Pituitary carcinoma, NOS|Pituitary gland|Pixantrone|Pixantrone Dimaleate|Pixatimod|Pizzly|Placebo|Placenta|Placental Hemangioma|Placental site trophoblastic tumor|Placental-Site Gestational Trophoblastic Tumor|Pladienolide Derivative E7107|Plamotamab|Plasma|Plasma Cell Leukemia|Plasma Cell Myeloma|Plasma Cell Neoplasm|Plasma Cell Tumors|Plasma cell leukemia|Plasma cell myeloma|Plasma cell tumor|Plasmablastic Lymphoma|Plasmablastic lymphoma|Plasmacytic leukemia|Plasmacytic lymphoma|Plasmacytoma|Plasmacytoma of bone|Plasmacytoma, NOS|Plasmacytoma, extramedullary|Plasmid DNA Vaccine pING-hHER3FL|Plasmodium falciparum|Platelet Count Decreased|Platform|Platform ICP|Platform II|Platform LCZ|Platinum|Platinum Acetylacetonate-Titanium Dioxide Nanoparticles|Platinum Compound|Pleomorphic Adenoma|Pleomorphic Carcinoma|Pleomorphic Lipoma|Pleomorphic Liposarcoma|Pleomorphic Lobular Breast Carcinoma In Situ|Pleomorphic Rhabdomyosarcoma|Pleomorphic Xanthoastrocytoma|Pleomorphic adenoma|Pleomorphic carcinoma|Pleomorphic cell sarcoma|Pleomorphic leiomyoma|Pleomorphic lipoma|Pleomorphic liposarcoma|Pleomorphic lobular carcinoma|Pleomorphic lobular carcinoma in situ|Pleomorphic rhabdomyosarcoma, NOS|Pleomorphic rhabdomyosarcoma, adult type|Pleomorphic xanthoastrocytoma|Pleura|Pleura, NOS|Pleural Effusion|Pleural Hemorrhage|Pleural Infection|Pleural Solitary Fibrous Tumor|Pleuritic Pain|Pleurodesis|Pleurodesis, NOS|Pleurodesis, Talc|Pleuropulmonary Blastoma|Pleuropulmonary blastoma|Plevitrexed|Plexiform Fibrohistiocytic Tumor|Plexiform Neurofibroma|Plexiform Schwannoma|Plexiform fibrohistiocytic tumor|Plexiform fibromyxoma|Plexiform hemangioma|Plexiform leiomyoma|Plexiform neurofibroma|Plexiform neuroma|Plexiform schwannoma|Plicamycin|Plinabulin|Plitidepsin|Plk1 Inhibitor BI 2536|Plocabulin|Plozalizumab|Pneumoblastoma|Pneumocystis Pneumonia|Pneumocystis carinii|Pneumonectomy|Pneumonia, NOS|Pneumonitis|Pneumothorax|Pol I Inhibitor CX5461|Poland|Polar Spongioblastoma|Polar spongioblastoma|Polatuzumab Vedotin|Polidocanol|Poliglusam|Polo-like Kinase 1 Inhibitor GSK461364|Polo-like Kinase 1 Inhibitor MK1496|Polo-like Kinase 1 Inhibitor NMS-1286937|Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate|Poly-alendronate Dextran-Guanidine Conjugate|Poly-gamma Glutamic Acid|Polyamine Analog SL11093|Polyamine Analogue PG11047|Polyamine Analogue SBP-101|Polyamine Transport Inhibitor AMXT-1501 Dicaprate|Polyandrol|Polycystic Ovarian Syndrome (PCOS)|Polycythemia Vera|Polycythemia rubra vera|Polycythemia vera|Polyembryoma|Polyethylene Glycol Recombinant Endostatin|Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318|Polygonal Cell Carcinoma|Polygonal cell carcinoma|Polymer-conjugated IL-15 Receptor Agonist NKTR-255|Polymer-encapsulated Luteolin Nanoparticle|Polymeric Camptothecin Prodrug XMT-1001|Polymorphic Post-Transplant Lymphoproliferative Disorder|Polymorphic post transplant lymphoproliferative disorder|Polymorphic reticulosis|Polymorphous low grade adenocarcinoma|Polypodium leucotomos Extract|Polypoid adenoma|Polysaccharide-K|Polysialic Acid|Polyunsaturated Fatty Acid|Polyvalent Melanoma Vaccine|Polyvesicular vitelline tumor|Pomalidomide|Pomegranate Juice|Pomegranate Liquid Extract|Ponatinib|Ponatinib Hydrochloride|Poor Prognosis|Poorly Differentiated|Poorly Differentiated Neuroblastoma|Poorly Differentiated Neuroendocrine Lesion|Poorly Differentiated Thyroid Gland Carcinoma|Poorly cohesive carcinoma|Popliteal Fossa|Porcupine Inhibitor CGX1321|Porcupine Inhibitor ETC-1922159|Porcupine Inhibitor RXC004|Porcupine Inhibitor WNT974|Porcupine Inhibitor XNW7201|Porfimer Sodium|Porfiromycin|Porocarcinoma|Poroma|Portal Hypertension|Portal Vein Thrombosis|Portugal|Positive|Positive Biomarker(s)|Post neo-adjuvant therapy|Post transplant lymphoproliferative disorder, NOS|Post-Transplant Lymphoproliferative Disorder|Postcricoid region|Posterior Wall of the Nasopharynx|Posterior mediastinum|Posterior wall of bladder|Posterior wall of hypopharynx|Posterior wall of nasopharynx|Posterior wall of oropharynx|Postmenopausal|Postnasal Drip|Postoperative Hemorrhage|Postoperative Thoracic Procedure Complication|Pouch|Poziotinib|Pracinostat|Pralatrexate|Pralsetinib|Praluzatamab Ravtansine|Pravastatin Sodium|Pre T-ALL|Pre-B ALL|Pre-B Acute Lymphoblastic Leukemia|Pre-Pre-B Acute Lymphoblastic Leukemia|Pre-T ALL|Pre-extracted DNA received by TSS|Pre-pre-B ALL|Precancerous Melanosis|Precancerous melanosis, NOS|Precocious Puberty|Precursor B-cell lymphoblastic leukemia|Precursor B-cell lymphoblastic lymphoma|Precursor Cell Lymphoblastic Lymphoma|Precursor T-cell lymphoblastic leukemia|Precursor T-cell lymphoblastic lymphoma|Precursor cell lymphoblastic leukemia, NOS|Precursor cell lymphoblastic leukemia, not phenotyped|Precursor cell lymphoblastic lymphoma, NOS|Prednimustine|Prednisolone|Prednisolone Acetate|Prednisolone Sodium Phosphate|Prednisone|Pregnancy in Patient or Partner|Pregnancy, Puerperium and Perinatal Conditions - Other|Preleukemia|Preleukemic syndrome|Premalignant|Premature Delivery|Premature Menopause|Premenopausal|Premier|Prepuce|Present|Presyncope|Prevention|Prexasertib|Prexigebersen|Primary|Primary Amyloidosis|Primary Blood Derived Cancer - Bone Marrow|Primary Blood Derived Cancer - Peripheral Blood|Primary Cutaneous Anaplastic Large Cell Lymphoma|Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder|Primary Cutaneous CD4-Positive Small/Medium T-Cell Lymphoproliferative Disorder|Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma|Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Primary Cutaneous Follicle Center Lymphoma|Primary Cutaneous Gamma-Delta T-Cell Lymphoma|Primary Cutaneous Lymphoma|Primary Cutaneous Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Primary Effusion Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Primary Myelofibrosis|Primary Neoplasm|Primary Peritoneal Serous Papillary Adenocarcinoma|Primary Sclerosing Cholangitis|Primary Site Unknown|Primary Tumor|Primary Tumor Field|Primary Xenograft Tissue|Primary amyloidosis|Primary cutaneous CD30+ T-cell lymphoproliferative disorder|Primary cutaneous CD30+ large T-cell lymphoma|Primary cutaneous CD4-positive small/medium T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous DLBCL, leg type|Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous follicle centre lymphoma|Primary cutaneous gamma-delta T-cell lymphoma|Primary cutaneous neuroendocrine carcinoma|Primary diffuse large B-cell lymphoma of the CNS|Primary effusion lymphoma|Primary intraosseous carcinoma|Primary myelofibrosis|Primary serous papillary carcinoma of peritoneum|Primary tumor site|Prime Cancer Vaccine MVA-BN-CV301|Primitive Neuroectodermal Tumor|Primitive neuroectodermal tumor, NOS|Primitive polar spongioblastoma|Prinomastat|Prior malignancy|Pro-B ALL|Pro-T ALL|Proapoptotic Sulindac Analog CP-461|Procarbazine|Procarbazine Hydrochloride|Procaspase Activating Compound-1 VO-100|Proctitis|Productive Cough|Progestational IUD|Progesterone and Estrogen|Progesterone only|Progestin|Progestin and Estrogen|Progression|Progressive Disease|Progressive Multifocal Leukoencephalopathy|Progressive Neoplastic Disease|Prohibitin-Targeting Peptide 1|Prolactinoma|Prolapse of Intestinal Stoma|Prolapse of Urostomy|Prolgolimab|Proliferating Trichilemmal Tumor|Proliferating trichilemmal cyst|Proliferating trichilemmal tumor|Proliferative Nodules in Congenital Melanocytic Nevus|Proliferative dermal lesion in congenital nevus|Proliferative polycythemia|Proline endopeptidase|Prolymphocytic Leukemia|Prolymphocytic leukemia, B-cell type|Prolymphocytic leukemia, NOS|Prolymphocytic leukemia, T-cell type|Prospective|Prostaglandin E2 EP4 Receptor Inhibitor AN0025|Prostaglandin E2 EP4 Receptor Inhibitor E7046|Prostate|Prostate Acinar Adenocarcinoma, Sarcomatoid Variant|Prostate Adenocarcinoma|Prostate Bed|Prostate Cancer|Prostate Cancer Vaccine ONY-P1|Prostate Gland|Prostate Health Cocktail Dietary Supplement|Prostate Infection|Prostate gland|Prostate, Seminal Vesicles and Lymph Nodes|Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024|Prostatic Hemorrhage|Prostatic Obstruction|Prostatic Pain|Prostatic intraepithelial neoplasia, grade III|Protease-activated Anti-PD-L1 Antibody Prodrug CX-072|Protein|Protein Arginine Methyltransferase 5 Inhibitor GSK3326595|Protein Arginine Methyltransferase 5 Inhibitor PF-06939999|Protein Arginine Methyltransferase 5 Inhibitor PRT543|Protein Expression Quantification|Protein Kinase C Inhibitor IDE196|Protein Phosphatase 2A Inhibitor LB-100|Protein Stabilized Liposomal Docetaxel Nanoparticles|Protein Tyrosine Kinase 2 Inhibitor IN10018|Proteinuria|Proteome|Proteome Profiling|Proton Pump Inhibitors|Protoplasmic Astrocytoma|Protoplasmic astrocytoma|Proxalutamide|Pruritus|Psammomatous Meningioma|Psammomatous meningioma|Psammomatous schwannoma|Pseudoglandular Squamous Cell Carcinoma|Pseudoisocytidine|Pseudomonas aeruginosa|Pseudomucinous adenocarcinoma|Pseudomucinous cystadenocarcinoma, NOS|Pseudomucinous cystadenoma, NOS|Pseudomucinous cystadenoma, borderline malignancy|Pseudomyxoma Peritonei|Pseudomyxoma peritonei|Pseudomyxoma peritonei with unknown primary site|Pseudoprogression|Pseudosarcomatous carcinoma|Psoriasis|Psychiatric Disorders - Other|Psychosis|Pterostilbene|Puerto Rico|Pulmonary Adenomatosis|Pulmonary Artery Intimal Sarcoma|Pulmonary Blastoma|Pulmonary Edema|Pulmonary Fibrosis|Pulmonary Fistula|Pulmonary Hemorrhage|Pulmonary Hypertension|Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Translocation|Pulmonary Valve Disease|Pulmonary adenomatosis|Pulmonary artery intimal sarcoma|Pulmonary blastoma|Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation|Pumitepa|Punch Biopsy|Puquitinib|Puquitinib Mesylate|Pure Erythroid Leukemia|Puromycin|Puromycin Hydrochloride|Purpura|Pylorus|Pyramidal Tract Syndrome|Pyrazinamide|Pyrazoloacridine|Pyridyl Cyanoguanidine CHS 828|Pyriform sinus|Pyrotinib|Pyrotinib Dimaleate|Pyroxamide|Pyruvate Kinase Inhibitor TLN-232|Pyruvate Kinase M2 Isoform Activator TP-1454|Q Exactive|Q Exactive HF|Q Exactive HF-X|Q Exactive Plus|Q TRAP|Q-Tof Premier|Q-Tof Ultima|Q-Tof micro|QA|QSTAR|QSTAR Elite|QSTAR Pulsar|QSTAR XL|QTRAP 4500|QTRAP 5500|QTRAP 6500|QTRAP 6500+m|Qatar|Qilisheng Immunoregulatory Oral Solution|Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine|Qualification metrics changed|Qualified|Qualified in error|Quarfloxin|Quattro|Quattro II|Quattro LC|Quattro Premier|Quattro Premier XE|Quattro Ultima|Quattro Ultima Pt|Quattro micro GC|Queyrat erythroplasia|Quinacrine Hydrochloride|Quinine|Quisinostat|Quizartinib|R|R-(-)-Gossypol Acetic Acid|R0|R1|R2|RAD51 Inhibitor CYT-0851|RAEB|RAEB I|RAEB II|RAEB-T|RAF Kinase Inhibitor L-779450|RAF Kinase Inhibitor XL281|RARS|RARalpha Agonist IRX5183|RD-Responsive Disease|RET Inhibitor DS-5010|RET Mutation/Fusion Inhibitor BLU-667|RET/SRC Inhibitor TPX-0046|RFT5-dgA Immunotoxin IMTOX25|RIPK1 Inhibitor GSK3145095|RNA|RNA-SeQC - Counts|RNA-SeQC - FPKM|RNA-Seq|RNR Inhibitor COH29|ROBO1-targeted BiCAR-NKT Cells|RORgamma Agonist LYC-55716|RP-Response|RPD-Radiographic Progressive Disease|RPLC|RPPA|RSEM - Quantification|RSK1-4 Inhibitor PMD-026|RX|Rabusertib|Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus SM-88|Racemose hemangioma|Racotumomab|Radgocitabine|Radgocitabine Hydrochloride|Radiation|Radiation Recall Reaction (Dermatologic)|Radiation Therapy, NOS|Radiation, 2D Conventional|Radiation, 3D Conformal|Radiation, Combination|Radiation, Cyberknife|Radiation, External Beam|Radiation, Hypofractionated|Radiation, Implants|Radiation, Intensity-Modulated Radiotherapy|Radiation, Internal|Radiation, Mixed Photon Beam|Radiation, Photon Beam|Radiation, Proton Beam|Radiation, Radioisotope|Radiation, Stereotactic/Gamma Knife/SRS|Radiation, Systemic|Radical Hysterectomy|Radical Maxillectomy|Radical Nephrectomy|Radical Prostatectomy|Radiculitis|Radioactive Iodine|Radioactive Iodine Therapy|Radioembolization|Radiographic Progressive Disease|Radiolabeled CC49|Radiology|Radiosensitizing Agent|Radium Ra 223 Dichloride|Radium Ra 224-labeled Calcium Carbonate Microparticles|Radix Angelicae Sinensis/Radix Astragali Herbal Supplement|Radotinib Hydrochloride|Raf Kinase Inhibitor HM95573|Ragifilimab|Ralaniten Acetate|Ralimetinib Mesylate|Raloxifene|Raloxifene Hydrochloride|Raltitrexed|Ramucirumab|Ranibizumab|Ranimustine|Ranolazine|Ranpirnase|Ras Inhibitor|Ras Peptide ASP|Ras Peptide CYS|Ras Peptide VAL|Rash Acneiform|Rash Maculo-Papular|Rash Pustular|Rathke pouch tumor|Rattus norvegicus|Raw CGI Variant|Raw Intensities|Raw Sequencing Data|Raw Simple Somatic Mutation|Razoxane|Read Group Quality Control|Realgar-Indigo naturalis Formulation|Rebastinib Tosylate|Rebeccamycin|Rebimastat|Receptor Tyrosine Kinase Inhibitor R1530|Recklinghausen disease|Recombinant Adenovirus-p53 SCH-58500|Recombinant Anti-WT1 Immunotherapeutic GSK2302024A|Recombinant Bacterial Minicells VAX014|Recombinant Bispecific Single-Chain Antibody rM28|Recombinant CD40-Ligand|Recombinant Erwinia asparaginase JZP-458|Recombinant Erythropoietin|Recombinant Fas Ligand|Recombinant Fractalkine|Recombinant Granulocyte-Macrophage Colony-Stimulating Factor|Recombinant Human 6Ckine|Recombinant Human Adenovirus Type 5 H101|Recombinant Human Angiotensin Converting Enzyme 2 APN01|Recombinant Human Apolipoprotein(a) Kringle V MG1102|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Recombinant Human Endostatin|Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine|Recombinant Human Papillomavirus 11-valent Vaccine|Recombinant Human Papillomavirus Bivalent Vaccine|Recombinant Human Papillomavirus Nonavalent Vaccine|Recombinant Human Plasminogen Kringle 5 Domain ABT 828|Recombinant Human TRAIL-Trimer Fusion Protein SCB-313|Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301|Recombinant Interferon|Recombinant Interferon Alfa|Recombinant Interferon Alfa-1b|Recombinant Interferon Alfa-2a|Recombinant Interferon Alfa-2b|Recombinant Interferon Alpha 2b-like Protein|Recombinant Interferon Beta|Recombinant Interferon Gamma|Recombinant Interleukin-12|Recombinant Interleukin-13|Recombinant Interleukin-18|Recombinant Interleukin-2|Recombinant Interleukin-6|Recombinant KSA Glycoprotein CO17-1A|Recombinant Leukocyte Interleukin|Recombinant Leukoregulin|Recombinant Luteinizing Hormone|Recombinant MAGE-3.1 Antigen|Recombinant MIP1-alpha Variant ECI301|Recombinant Macrophage Colony-Stimulating Factor|Recombinant Modified Vaccinia Ankara-5T4 Vaccine|Recombinant Oncolytic Poliovirus PVS-RIPO|Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A|Recombinant Platelet Factor 4|Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207|Recombinant Super-compound Interferon|Recombinant Thyroglobulin|Recombinant Thyrotropin Alfa|Recombinant Transforming Growth Factor-Beta|Recombinant Transforming Growth Factor-Beta-2|Recombinant Tumor Necrosis Factor-Alpha|Recombinant Tyrosinase-Related Protein-2|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Recreational fire smoke|Rectal Anastomotic Leak|Rectal Cancer|Rectal Fistula|Rectal Hemorrhage|Rectal Mucositis|Rectal Necrosis|Rectal Obstruction|Rectal Pain|Rectal Perforation|Rectal Stenosis|Rectal Ulcer|Rectosigmoid Junction|Rectosigmoid Region|Rectosigmoid junction|Rectum|Rectum Adenocarcinoma|Rectum, NOS|Recurrence|Recurrent Blood Derived Cancer - Bone Marrow|Recurrent Blood Derived Cancer - Peripheral Blood|Recurrent Disease|Recurrent Laryngeal Nerve Palsy|Recurrent Neoplasm|Recurrent Pyogenic Cholangitis|Recurrent Tumor|Red & Violet|Redaction|Redaporfin|Refametinib|Reflux Disease|Refractory Anemia|Refractory Anemia with Excess Blasts in Transformation|Refractory Cytopenia of Childhood|Refractory Neutropenia|Refractory Thrombocytopenia|Refractory anemia|Refractory anemia with excess blasts|Refractory anemia with excess blasts in transformation|Refractory anemia with ring sideroblasts associated with marked thrombocytosis|Refractory anemia with ringed sideroblasts|Refractory anemia with sideroblasts|Refractory anemia without sideroblasts|Refractory cytopenia of childhood|Refractory cytopenia with multilineage dysplasia|Refractory neutropenia|Refractory thrombocytopenia|Refused|Regional|Regional Metastasis|Regional Site|Regional or Distant Metastasis (M1)|Regorafenib|Regressing Melanoma|Regressing Nevus|Regressing nevus|Relacorilant|Related to Cancer|Relatlimab|Relugolix|Remetinostat|Renal|Renal Calculi|Renal Capsule|Renal Cell Carcinoma|Renal Cell Carcinoma Peptides Vaccine IMA901|Renal Colic|Renal Dialysis|Renal Disorder, NOS|Renal Failure (Requiring Dialysis)|Renal Hemorrhage|Renal Insufficiency|Renal Pelvis|Renal Sinus|Renal Vein|Renal and Urinary Disorders - Other|Renal carcinoma, collecting duct type|Renal cell adenocarcinoma|Renal cell carcinoma, NOS|Renal cell carcinoma, chromophobe type|Renal cell carcinoma, sarcomatoid|Renal cell carcinoma, spindle cell|Renal cell carcinoma, unclassified|Renal medullary carcinoma|Renal pelvis|Reninoma|Renomedullary fibroma|Renomedullary interstitial cell tumor|Reparixin|Repli-G|Repli-G (Qiagen) DNA|Repli-G Pooled (Qiagen) DNA|Repli-G X|Repli-G X (Qiagen) DNA|Repotrectinib|Reproductive System and Breast Disorders - Other|Rescinded|Reserve cell carcinoma|Residual Disease|Resiquimod|Resiquimod Topical Gel|Resistant Starch|Resminostat|Respiratory Failure|Respiratory, Thoracic and Mediastinal Disorders - Other|Responsive Disease|Restlessness|Restrictive Cardiomyopathy|Resveratrol|Resveratrol Formulation SRT501|Retaspimycin|Retaspimycin Hydrochloride|Rete Ovarii Adenocarcinoma|Retelliptine|Reticuloendothelial System|Reticuloendothelial system, NOS|Reticulohistiocytoma|Reticulosarcoma|Reticulosarcoma, NOS|Reticulosarcoma, diffuse|Reticulum cell sarcoma, NOS|Reticulum cell sarcoma, diffuse|Retifanlimab|Retina|Retinal Detachment|Retinal Tear|Retinal Vascular Disorder|Retinal anlage tumor|Retinoblastoma|Retinoblastoma, NOS|Retinoblastoma, differentiated|Retinoblastoma, diffuse|Retinoblastoma, spontaneously regressed|Retinoblastoma, undifferentiated|Retinocytoma|Retinoic Acid Agent Ro 16-9100|Retinoic Acid Syndrome|Retinoid 9cUAB30|Retinol|Retinopathy|Retinyl Acetate|Retinyl Palmitate|Retro-Orbital Region|Retromolar Trigone|Retromolar area|Retroperitoneal Hemorrhage|Retroperitoneal fibromatosis|Retroperitoneum|Retroperitoneum and peritoneum|Retrospective|Retrovector Encoding Mutant Anti-Cyclin G1|Reunion|Revdofilimab|Reverse Phase Protein Array|Reversible Posterior Leukoencephalopathy Syndrome|Rexinoid NRX 194204|Rezivertinib|Rhabdoid Meningioma|Rhabdoid Tumor|Rhabdoid meningioma|Rhabdoid sarcoma|Rhabdoid tumor (kidney) (RT)|Rhabdoid tumor, NOS|Rhabdomyoma|Rhabdomyoma, NOS|Rhabdomyosarcoma|Rhabdomyosarcoma with ganglionic differentiation|Rhabdomyosarcoma, NOS|Rhabdosarcoma|Rhenium Re 188 BMEDA-labeled Liposomes|Rhenium Re-186 Hydroxyethylidene Diphosphonate|Rhenium Re-188 Ethiodized Oil|Rhenium Re-188 Etidronate|Rheumatoid Arthritis|Rheumatologic Disease|Rhinitis Infective|Rhizoxin|RhoC Peptide Vaccine RV001V|Rib|Rib, sternum, clavicle and associated joints|Ribociclib|Ribociclib/Letrozole|Ribonuclease QBI-139|Ribosome-Inactivating Protein CY503|Ribozyme RPI.4610|Rice Bran|Ricolinostat|Ridaforolimus|Right|Right Hemicolectomy|Right Ventricular Dysfunction|Rigosertib|Rigosertib Sodium|Rilimogene Galvacirepvec|Rilimogene Galvacirepvec/Rilimogene Glafolivec|Rilimogene Glafolivec|Rilotumumab|Rindopepimut|Ring Finger|Ripertamab|Ripretinib|Risperidone Formulation in Rumenic Acid|Ritrosulfan|Rituximab|Rituximab Conjugate CON-4619|Rituximab and Hyaluronidase Human|Riviciclib|Rivoceranib|Rivoceranib Mesylate|Robatumumab|Roblitinib|Rocakinogene Sifuplasmid|Rocapuldencel-T|Rociletinib|Rodent ulcer|Rodorubicin|Roducitabine|Rofecoxib|Roflumilast|Rogaratinib|Rogletimide|Rolinsatamab Talirine|Romania|Romidepsin|Roneparstat|Roniciclib|Ropeginterferon Alfa-2B|Ropidoxuridine|Ropocamptide|Roquinimex|Rosabulin|Rose Bengal Solution PV-10|Rosette-Forming Glioneuronal Tumor|Rosette-forming glioneuronal tumor|Rosiglitazone Maleate|Rosmantuzumab|Rosopatamab|Rosuvastatin|Round Cell Liposarcoma|Round Ligament|Round cell carcinoma|Round cell liposarcoma|Round cell osteosarcoma|Round cell sarcoma|Round ligament|Rovalpituzumab Tesirine|Rubinstein-Taybi Syndrome|Rubitecan|Rucaparib|Rucaparib Camsylate|Rucaparib Phosphate|Run Metadata|Russia|Ruthenium Ru-106|Ruthenium-based Small Molecule Therapeutic BOLD-100|Ruthenium-based Transferrin Targeting Agent NKP-1339|Ruxolitinib|Ruxolitinib Phosphate|Ruxotemitide|Rwanda|S|S-Adenosylmethionine|S-equol|S1P Receptor Agonist KRP203|SALT lymphoma|SBIL-2|SCIEX|SCX|SD-Stable Disease|SDF-1 Receptor Antagonist PTX-9908|SDRF|SERD D-0502|SERD G1T48|SERD GDC-9545|SERD SAR439859|SERD SHR9549|SERD ZN-c5|SETTLE|SHH-Activated|SHP-1 Agonist SC-43|SHP2 Inhibitor JAB-3068|SHP2 Inhibitor RLY-1971|SHP2 Inhibitor RMC-4630|SHP2 Inhibitor TNO155|SILAC|SILAC quantitation analysis|SIRPa-4-1BBL Fusion Protein DSP107|SIRPa-Fc Fusion Protein TTI-621|SIRPa-Fc-CD40L Fusion Protein SL-172154|SIRPa-IgG4-Fc Fusion Protein TTI-622|SLC6A8 Inhibitor RGX-202|SLCT Inhibitor GNS561|SMAC Mimetic BI 891065|SMO Protein Inhibitor ZSP1602|SN-38-Loaded Polymeric Micelles NK012|SNS01-T Nanoparticles|SOLiD|SPD-Surgical Progression|SQ Detector 2|SR-BP1/HSI Inhibitor SR31747A|SR-T100 Gel|SRA XML|SRM quantitation analysis|SRPK1/ABCG2 Inhibitor SCO-101|SSTR2-targeting Protein/DM1 Conjugate PEN-221|STAR - Counts|STAR - FPKM|STAR - Smart-Seq2|STAR - Smart-Seq2 Filtered Counts|STAR - Smart-Seq2 Raw Counts|STAR 2-Pass|STAR 2-Pass Chimeric|STAR 2-Pass Genome|STAR 2-Pass Transcriptome|STAR-Fusion|STAT Inhibitor OPB-111077|STAT3 Inhibitor DSP-0337|STAT3 Inhibitor OPB-31121|STAT3 Inhibitor OPB-51602|STAT3 Inhibitor TTI-101|STAT3 Inhibitor WP1066|STING Agonist BMS-986301|STING Agonist GSK3745417|STING Agonist IMSA101|STING Agonist MK-1454|STING Agonist SB 11285|STING Agonist TAK-676|STING-activating Cyclic Dinucleotide Agonist MIW815|STING-expressing E. coli SYNB1891|SVS|SYNAPT G2-Si|Sabarubicin|Sabatolimab|Saccharomyces cerevisiae|Sacituzumab Govitecan|Sacrum|Sacubitril/Valsartan|Safingol|Sagopilone|Saint Helena, Ascension and Tristan da Cunha|Saint Kitts and Nevis|Saint Lucia|Saint Pierre and Miquelon|Saint Vincent and the Grenadines|Salirasib|Saliva|Salivary Duct Carcinoma|Salivary Duct Inflammation|Salivary Gland|Salivary Gland Basal Cell Adenocarcinoma|Salivary Gland Basal Cell Adenoma|Salivary Gland Fistula|Salivary Gland Infection|Salivary Gland Monomorphic Adenoma|Salivary duct carcinoma|Salmonella Septicemia|Salmonella VNP20009|Salpingectomy|Salpingo-oophorectomy|Sam68 Modulator CWP232291|Samalizumab|Samarium Sm 153-DOTMP|Samoa|Samotolisib|Sample Procurement|Sample compromised|Samrotamab Vedotin|Samuraciclib|San Marino|Sao Tome and Principe|Sapacitabine|Sapanisertib|Sapitinib|SarCNU|Saracatinib|Saracatinib Difumarate|Sarcoidosis|Sarcoma|Sarcoma botryoides|Sarcoma, NOS|Sarcomatoid Carcinoma|Sarcomatoid Mesothelioma|Sarcomatoid Renal Cell Carcinoma|Sarcomatoid Transitional Cell Carcinoma|Sarcomatoid carcinoma|Sarcomatoid mesothelioma|Sarcomatosis|Sarcomatosis, NOS|Sardomozide|Sargramostim|Sasanlimab|Satraplatin|Saudi Arabia|Savolitinib|Scalp|Scalp Pain|Scapula|Schizosaccharomyces pombe|Schmincke tumor|Schneiderian carcinoma|Schneiderian papilloma, NOS|Schneiderian papilloma, inverted|Schwannoma|Schwannoma, NOS|Schwannomatosis|Sciatic Nerve|Scirrhous Adenocarcinoma|Scirrhous Hepatocellular Carcinoma|Scirrhous adenocarcinoma|Scirrhous carcinoma|Scleral Disorder|Sclerosing Epithelioid Fibrosarcoma|Sclerosing Liposarcoma|Sclerosing Rhabdomyosarcoma|Sclerosing epithelioid fibrosarcoma|Sclerosing hemangioma|Sclerosing hepatic carcinoma|Sclerosing liposarcoma|Sclerosing rhabdomyosarcoma|Sclerosing stromal tumor|Sclerosing sweat duct carcinoma|Sclerosis|Scoliosis|Scopoletin|Scrotal Infection|Scrotal Pain|Scrotum|Scrotum, NOS|SeSAMe Methylation Beta Estimation|Sebaceous Adenoma|Sebaceous Carcinoma|Sebaceous adenocarcinoma|Sebaceous adenoma|Sebaceous carcinoma|Sebaceous epithelioma|Seclidemstat|Secondary Carcinoma|Secondary Neoplasm|Secondary carcinoma|Secretory Breast Carcinoma|Secretory Meningioma|Secretory carcinoma of breast|Secretory meningioma|Sedoxantrone Trihydrochloride|Seizure|Seizures|Selatinib Ditosilate|Selective Androgen Receptor Modulator RAD140|Selective Cytokine Inhibitory Drug CC-1088|Selective Estrogen Receptor Degrader AZD9496|Selective Estrogen Receptor Degrader AZD9833|Selective Estrogen Receptor Degrader LSZ102|Selective Estrogen Receptor Degrader LX-039|Selective Estrogen Receptor Degrader LY3484356|Selective Estrogen Receptor Degrader SRN-927|Selective Estrogen Receptor Modulator CC-8490|Selective Estrogen Receptor Modulator TAS-108|Selective Glucocorticoid Receptor Antagonist CORT125281|Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352|Seliciclib|Selicrelumab|Selinexor|Selitrectinib|Selonsertib|Selpercatinib|Selumetinib|Selumetinib Sulfate|Semaxanib|Seminal Vesicle|Seminoma|Seminoma with high mitotic index|Seminoma, NOS|Seminoma, anaplastic|Semuloparin|Semustine|Seneca Valley Virus-001|Senegal|Sensory Changes|Seocalcitol|Sepantronium Bromide|Sepsis|Sequencing Data|Sequencing Reads|Serabelisib|Serbia|Serclutamab Talirine|Serdemetan|Sergiolide|Seribantumab|Serine/Threonine Kinase Inhibitor CBP501|Serine/Threonine Kinase Inhibitor XL418|Seroma|Seromucinous carcinoma|Serotonin producing carcinoid|Serous Adenofibroma|Serous Cystadenocarcinoma|Serous Cystadenoma|Serous Endometrial Intraepithelial Carcinoma|Serous Surface Papillary Carcinoma|Serous Surface Papilloma|Serous Tubal Intraepithelial Carcinoma|Serous adenocarcinofibroma|Serous adenocarcinoma, NOS|Serous adenofibroma of borderline malignancy|Serous adenofibroma, NOS|Serous borderline tumor-micropapillary variant|Serous carcinoma, NOS|Serous cystadenocarcinofibroma|Serous cystadenocarcinoma, NOS|Serous cystadenofibroma of borderline malignancy|Serous cystadenofibroma, NOS|Serous cystadenoma, NOS|Serous cystadenoma, borderline malignancy|Serous cystoma|Serous endometrial intraepithelial carcinoma|Serous microcystic adenoma|Serous papillary cystic tumor of borderline malignancy|Serous surface papillary carcinoma|Serous surface papillary tumor of borderline malignancy|Serous surface papilloma|Serous tubal intraepithelial carcinoma|Serous tubal intraepithelial carcinoma (STIC)|Serous tumor, NOS, of low malignant potential|Serplulimab|Serrated adenocarcinoma|Serrated adenoma|Sertoli Cell Tumor|Sertoli cell adenoma|Sertoli cell carcinoma|Sertoli cell tumor with lipid storage|Sertoli cell tumor, NOS|Sertoli-Leydig cell tumor of intermediate differentiation|Sertoli-Leydig cell tumor, NOS|Sertoli-Leydig cell tumor, intermediate differentiation, with heterologous elements|Sertoli-Leydig cell tumor, poorly differentiated|Sertoli-Leydig cell tumor, poorly differentiated, with heterologous elements|Sertoli-Leydig cell tumor, retiform|Sertoli-Leydig cell tumor, retiform, with heterologous elements|Sertoli-Leydig cell tumor, sarcomatoid|Sertoli-Leydig cell tumor, well differentiated|Serum|Serum Amylase Increased|Serum Sickness|Sessile Serrated Adenoma/Polyp|Sessile serrated adenoma|Sessile serrated polyp|Seurat - 10x Chromium|Seurat - Smart-Seq2|Sevacizumab|Seviteronel|Sex Cord-Stromal Tumor|Sex cord tumor with annular tubules|Sex cord tumor, NOS|Sex cord-gonadal stromal tumor, NOS|Sex cord-gonadal stromal tumor, incompletely differentiated|Sex cord-gonadal stromal tumor, mixed forms|Seychelles|Sezary Syndrome|Sezary disease|Sezary syndrome|Shared Anti-Idiotype-AB-S006|Shared Anti-Idiotype-AB-S024A|Shark Cartilage|Shark Cartilage Extract AE-941|Shenqi Fuzheng Injection SQ001|Shimadzu|Shimadzu MALDI-7090|Shingles|Sho-Saiko-To|Short Chain Fatty Acid HQK-1004|Short bones of lower limb and associated joints|Short bones of upper limb and associated joints|Shoulder|Shu Yu Wan Formula|Sialadenitis|Sialoblastoma|Sialyl Tn Antigen|Sialyl Tn-KLH Vaccine|Sibling|Sibrotuzumab|Sick Sinus Syndrome|Sierra Leone|Sigmoid Colectomy|Sigmoid Colon|Sigmoid colon|Signet Ring Cell Carcinoma|Signet ring cell adenocarcinoma|Signet ring cell carcinoma|Silatecan AR-67|Silibinin|Silicon Phthalocyanine 4|Silmitasertib Sodium|Siltuximab|Simalikalactone D|Simeprevir|Simlukafusp Alfa|Simmitinib|Simotaxel|Simple Germline Variation|Simple Hysterectomy|Simple Mastectomy|Simple Nucleotide Variation|Simtuzumab|Simurosertib|Singapore|Single Cell Analysis|Sinonasal Inverted Schneiderian Papilloma|Sinonasal Oncocytic Schneiderian Papilloma|Sinonasal Schneiderian Papilloma|Sinonasal papilloma, NOS|Sinonasal papilloma, exophytic|Sinonasal papilloma, fungiform|Sintilimab|Sinus|Sinus Bradycardia|Sinus Disorder|Sinus Pain|Sinus Tachycardia|Sinus(es), Maxillary|Sinusitis|Siplizumab|Sipuleucel-T|Siremadlin|Sirolimus|Sister|Sister-in-law|Sitimagene Ceradenovec|Sitravatinib|Sivifene|Six Weeks or More|Sizofiran|Sjogren's Syndrome|Skeletal Muscle|Skin|Skin Adenoid Basal Cell Carcinoma|Skin Appendage Adenoma|Skin Atrophy|Skin Basal Cell Carcinoma|Skin Basal Cell Carcinoma with Sebaceous Differentiation|Skin Basosquamous Cell Carcinoma|Skin Cancer|Skin Cutaneous Melanoma|Skin Fibroepithelial Basal Cell Carcinoma|Skin Fibrous Histiocytoma|Skin Hyperpigmentation|Skin Hypopigmentation|Skin Induration|Skin Infection|Skin Infiltrating Basal Cell Carcinoma|Skin Metatypical Carcinoma|Skin Micronodular Basal Cell Carcinoma|Skin Nodular Basal Cell Carcinoma|Skin Nodulo-Ulcerative Basal Cell Carcinoma|Skin Pigmented Basal Cell Carcinoma|Skin Rash|Skin Sclerosing/Morphoeic Basal Cell Carcinoma|Skin Ulceration|Skin and Subcutaneous Tissue Disorders - Other|Skin appendage adenoma|Skin appendage carcinoma|Skin appendage tumor, benign|Skin of lip, NOS|Skin of lower limb and hip|Skin of other and unspecified parts of face|Skin of scalp and neck|Skin of the Face|Skin of the Lower Limb and Hip|Skin of the Scalp and Neck|Skin of the Upper Limb and Shoulder|Skin of trunk|Skin of upper limb and shoulder|Skin, NOS|Skin, lower extremity, local|Skin, total|Skin, trunk, local|Skin, upper extremity, local|Skin-associated lymphoid tissue lymphoma|Skull|Sleep Apnea|Sleep apnea|Slide Image|Slides|Slovakia|Slovenia|Smac Mimetic GDC-0152|Smac Mimetic GDC-0917|Smac Mimetic LCL161|Small Bowel|Small Bowel - Mucosa Only|Small Cell Carcinoma|Small Cell Carcinoma, Fusiform Cell Type|Small Cell Intermediate Cell Carcinoma|Small Cell Osteosarcoma|Small Cell Sarcoma|Small Finger|Small Intestinal Anastomotic Leak|Small Intestinal Mucositis|Small Intestinal Obstruction|Small Intestinal Perforation|Small Intestinal Stenosis|Small Intestine|Small Intestine Infection|Small Intestine Ulcer|Small Lymphocytic Lymphoma|Small cell carcinoma pulmonary type|Small cell carcinoma, NOS|Small cell carcinoma, fusiform cell|Small cell carcinoma, hypercalcemic type|Small cell carcinoma, intermediate cell|Small cell neuroendocrine carcinoma|Small cell osteosarcoma|Small cell sarcoma|Small congenital nevus|Small intestine|Small intestine, NOS|Smoke|Smoke exposure, NOS|Smokehouse smoke|Smokeless Tobacco|Smoking|Smooth Muscle Neoplasm|Smooth muscle tumor of uncertain malignant potential|Smooth muscle tumor, NOS|Smoothened Antagonist BMS-833923|Smoothened Antagonist LDE225 Topical|Smoothened Antagonist LEQ506|Smoothened Antagonist TAK-441|Snap Frozen|Sneezing|Sobuzoxane|Social Circumstances - Other|Social Security Death Index|Sodium Borocaptate|Sodium Butyrate|Sodium Dichloroacetate|Sodium Fluoride|Sodium Iodide I-131|Sodium Metaarsenite|Sodium Phenylbutyrate|Sodium Salicylate|Sodium Selenite|Sodium Stibogluconate|Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108|Sofituzumab Vedotin|Soft Tissue|Soft Tissue Infection|Soft Tissue Necrosis Lower Limb|Soft Tissue Necrosis Upper Limb|Soft Tissue Perineurioma|Soft Tissue Sarcoma|Soft Tissue Tumors and Sarcomas, NOS|Soft palate, NOS|Soft tissue perineurioma|Soft tissue sarcoma|Soft tissue sarcoma, non-rhabdomyosarcoma|Soft tissue tumor, benign|Soft tissue tumor, malignant|Solid Carcinoma|Solid Papillary Breast Carcinoma|Solid Tissue|Solid Tissue Normal|Solid adenocarcinoma with mucin formation|Solid and cystic tumor|Solid and papillary epithelial neoplasm|Solid carcinoma with mucin formation|Solid carcinoma, NOS|Solid papillary carcinoma in situ|Solid papillary carcinoma with invasion|Solid pseudopapillary carcinoma|Solid pseudopapillary tumor|Solid teratoma|Solitary Fibrous Tumor|Solitary Mastocytoma of the Skin|Solitary Osseous Plasmacytoma|Solitary Plasmacytoma|Solitary Reticulohistiocytoma|Solitary fibrous tumor|Solitary fibrous tumor, malignant|Solitary fibrous tumor/hemangiopericytoma Grade 1 (CNS)|Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS)|Solitary fibrous tumor/hemangiopericytoma Grade 3 (CNS)|Solitary mastocytoma of skin|Solitary myeloma|Solitary plasmacytoma|Solitomab|Solomon Islands|Somalia|Somatic Mutation Index|Somatic Structural Variation|SomaticSniper|SomaticSniper Annotation|SomaticSniper Variant Aggregation and Masking|Somatostatin cell tumor, NOS|Somatostatin cell tumor, malignant|Somatostatin-Producing Neuroendocrine Tumor|Somatostatinoma, NOS|Somatostatinoma, malignant|Some days|Somnolence|Son|Son-in-law|Sonepcizumab|Sonidegib|Sonolisib|Sorafenib|Sorafenib Tosylate|Sore Throat|Sorghum bicolor Supplement|Sorted Cells|Sotigalimab|Sotorasib|Sotrastaurin|Sotrastaurin Acetate|South Africa|South Korea|South Sudan|Soy Isoflavones|Soy Protein Isolate|Spain|Spanlecortemlocel|Sparfosate Sodium|Sparfosic Acid|Spartalizumab|Spasticity|Spebrutinib|Specialized Gonadal Neoplasms|Specified parts of peritoneum|Spectral counting analysis|Spermatic Cord Anastomotic Leak|Spermatic Cord Hemorrhage|Spermatic Cord Obstruction|Spermatic cord|Spermatocytic seminoma|Spermatocytoma|Sphenoid sinus|Spherical Nucleic Acid Nanoparticle NU-0129|Spinal Column|Spinal Cord|Spinal Fracture|Spinal Muscular Atrophy|Spinal cord|Spinal cord, cranial nerves, and other parts of central nervous system|Spinal meninges|Spindle Cell Hemangioma|Spindle Cell Lipoma|Spindle Cell Melanoma|Spindle Cell Oncocytoma|Spindle Cell Rhabdomyosarcoma|Spindle Cell Sarcoma|Spindle Cell Squamous Cell Carcinoma|Spindle Cell Synovial Sarcoma|Spindle cell angioendothelioma|Spindle cell carcinoma, NOS|Spindle cell hemangioendothelioma|Spindle cell lipoma|Spindle cell melanoma, NOS|Spindle cell melanoma, type A|Spindle cell melanoma, type B|Spindle cell nevus, NOS|Spindle cell oncocytoma|Spindle cell rhabdomyosarcoma|Spindle cell sarcoma|Spindle epithelial tumor with thymus-like differentiation|Spindle epithelial tumor with thymus-like element|Spindle-Cell Predominant Trichodiscoma|Spindled mesothelioma|Spine|Spiradenocarcinoma|Spiradenoma|Spiradenoma, NOS|Spirogermanium|Spiromustine|Spiroplatin|Spitz Nevus|Spitz nevus|Spleen|Spleen Cancer|Spleen Disorder|Splenic B-Cell Lymphoma/Leukemia, Unclassifiable|Splenic B-cell lymphoma/leukemia, unclassifiable|Splenic Diffuse Red Pulp Small B-Cell Lymphoma|Splenic Flexure|Splenic Infection|Splenic Marginal Zone Lymphoma|Splenic diffuse red pulp small B-cell lymphoma|Splenic flexure of colon|Splenic lymphoma with villous lymphocytes|Splenic marginal zone B-cell lymphoma|Splenic marginal zone lymphoma, NOS|Splice Junction Quantification|Splicing Inhibitor H3B-8800|Spongioblastoma multiforme|Spongioblastoma polare|Spongioblastoma, NOS|Spongioneuroblastoma|Spongistatin|Spontaneous Descent|Spontaneously Regressing Retinoblastoma|Sporadic Burkitt Lymphoma|Sporadic, adult|Sporadic, pediatric|Spouse|Sputum|Squalamine Lactate|Squamotransitional cell carcinoma|Squamous Cell Carcinoma|Squamous Cell Carcinoma In Situ with Questionable Stromal Invasion|Squamous Cell Carcinoma with Horn Formation|Squamous Cell Carcinoma, Clear Cell Type|Squamous Cell Neoplasms|Squamous Cell Papilloma|Squamous Metaplasia|Squamous Odontogenic Tumor|Squamous Papillomatosis|Squamous carcinoma|Squamous cell carcinoma in situ with questionable stromal invasion|Squamous cell carcinoma in situ, NOS|Squamous cell carcinoma with horn formation|Squamous cell carcinoma, HPV-negative|Squamous cell carcinoma, HPV-positive|Squamous cell carcinoma, NOS|Squamous cell carcinoma, acantholytic|Squamous cell carcinoma, adenoid|Squamous cell carcinoma, clear cell type|Squamous cell carcinoma, keratinizing, NOS|Squamous cell carcinoma, large cell, keratinizing|Squamous cell carcinoma, large cell, nonkeratinizing, NOS|Squamous cell carcinoma, metastatic, NOS|Squamous cell carcinoma, microinvasive|Squamous cell carcinoma, nonkeratinizing, NOS|Squamous cell carcinoma, pseudoglandular|Squamous cell carcinoma, sarcomatoid|Squamous cell carcinoma, small cell, nonkeratinizing|Squamous cell carcinoma, spindle cell|Squamous cell epithelioma|Squamous cell papilloma, NOS|Squamous cell papilloma, inverted|Squamous intraepithelial neoplasia, grade I|Squamous intraepithelial neoplasia, grade II|Squamous intraepithelial neoplasia, grade III|Squamous intraepithelial neoplasia, high grade|Squamous intraepithelial neoplasia, low grade|Squamous odontogenic tumor|Squamous papilloma|Squamous papillomatosis|Src Kinase Inhibitor AP 23846|Src Kinase Inhibitor KX2-391|Src Kinase Inhibitor KX2-391 Ointment|Src Kinase Inhibitor M475271|Src/Abl Kinase Inhibitor AZD0424|Src/tubulin Inhibitor KX02|Sri Lanka|St. John's Wort|Stable Disease|Stage 0|Stage 0 Cervical Cancer AJCC v6|Stage 0 Cutaneous Melanoma AJCC v6 and v7|Stage 0 Squamous Cell Carcinoma|Stage 0 Transitional Cell Carcinoma|Stage 0 Vaginal Cancer AJCC v6|Stage 0 Vaginal Cancer AJCC v7|Stage 0 Vulvar Cancer AJCC v6|Stage 0a|Stage 0is|Stage 1|Stage 2A|Stage 2B|Stage 3|Stage 4|Stage 4S|Stage I|Stage IA|Stage IA1|Stage IA2|Stage IA3|Stage IB|Stage IB Cervix|Stage IB1|Stage IB2|Stage IC|Stage IC1|Stage IC2|Stage IC3|Stage II|Stage II Cervix|Stage IIA|Stage IIA Cervix|Stage IIA1|Stage IIA2|Stage IIB|Stage IIC|Stage IIC1|Stage III|Stage IIIA|Stage IIIA1|Stage IIIA2|Stage IIIAi|Stage IIIAii|Stage IIIB|Stage IIIC|Stage IIIC1|Stage IIIC2|Stage IIID|Stage IIa|Stage IIb|Stage IS|Stage IV|Stage IVA|Stage IVB|Stage IVC|Stage IVa|Stage IVb|Stage Is|Stage R1|Stage R2|Stage Tis|Stage X|Stallimycin|Staphylococcal Enterotoxin A|Staphylococcal Enterotoxin B|Staphylococcus aureus|State of Palestine|Staurosporine|Steatosis|Stem Cell Transplantation, Allogeneic|Stem Cell Transplantation, Autologous|Stem Cell Transplantation, Double Autologous|Stem Cell Transplantation, Haploidentical|Stem Cell Transplantation, NOS|Stem Cell Transplantation, Non-Myeloablative|Stem Cell Transplantation, Syngenic|Stem Cell Treatment|Stem cell leukemia|Stenosis of Gastrointestinal Stoma|Step Child|Step Sibling|Stepbrother|Stepdaughter|Stepfather|Stepmother|Stepsister|Stepson|Stereotactic Radiosurgery|Sternum|Steroid Therapy|Steroid cell tumor, NOS|Steroid cell tumor, malignant|Stevens-Johnson Syndrome|Stillbirth|Stoma Site Infection|Stomach|Stomach - Mucosa Only|Stomach Adenocarcinoma|Stomach Pain|Stomach, NOS|Stomal Ulcer|Strelka2 RNA|Streptonigrin|Streptozocin|Stridor|Stroke|Stromal Neoplasm|Stromal Sarcoma|Stromal endometriosis|Stromal myosis, NOS|Stromal sarcoma, NOS|Stromal tumor with minor sex cord elements|Stromal tumor, NOS|Stromal tumor, benign|Strontium Chloride Sr-89|Structural Alteration|Structural Rearrangement|Structural Variation|Struma Ovarii|Struma ovarii and carcinoid|Struma ovarii, NOS|Struma ovarii, malignant|Strumal Carcinoid|Strumal carcinoid|Study Enrollment|Subacute granulocytic leukemia|Subacute leukemia, NOS|Subacute lymphatic leukemia|Subacute lymphocytic leukemia|Subacute lymphoid leukemia|Subacute monocytic leukemia|Subacute myelogenous leukemia|Subacute myeloid leukemia|Subareolar duct papillomatosis|Subcutaneous Panniculitis-Like T-Cell Lymphoma|Subcutaneous Tissue|Subcutaneous panniculitis-like T-cell lymphoma|Subependymal Giant Cell Astrocytoma|Subependymal astrocytoma, NOS|Subependymal giant cell astrocytoma|Subependymal glioma|Subependymoma|Subepidermal Nodular Fibrosis|Subepidermal nodular fibrosis|Subglottis|Subject identity unknown|Subject withdrew consent|Sublingual Gland|Sublingual gland|Submandibular Gland|Submandibular gland|Submicron Particle Paclitaxel Sterile Suspension|Subtotal Prostatectomy|Subtotal Resection|Succinate Dehydrogenase-Deficient Renal Cell Carcinoma|Sudan|Sudden Death NOS|Sugemalimab|Suicidal Ideation|Suicide Attempt|Sulfatinib|Sulfonylurea|Sulforaphane|Sulindac|Sulofenur|Sumoylation Inhibitor TAK-981|Sunitinib|Sunitinib Malate|Super Enhancer Inhibitor GZ17-6.02|Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803|Superficial Multifocal Basal Cell Carcinoma|Superficial Parotidectomy|Superficial Soft Tissue Fibrosis|Superficial Spreading Adenocarcinoma|Superficial Thrombophlebitis|Superficial spreading adenocarcinoma|Superficial spreading melanoma|Superficial well differentiated liposarcoma|Superior Vena Cava Syndrome|Superior Wall of the Nasopharynx|Superior wall of nasopharynx|Superoxide Dismutase Mimetic GC4711|Supplementary Files|Supracervical Hysterectomy|Supracricoid Laryngectomy|Supraglottic Laryngectomy|Supraglottis|Supratentorial Embryonal Tumor, Not Otherwise Specified|Supratentorial PNET|Supraventricular Tachycardia|Suramin|Suramin Sodium|Surgery|Surgical Complication|Surgical Complications|Surgical Resection|Surgical and Medical Procedures - Other|Surgically Treated|Suriname|Surveyor PDA|Survivin Antigen|Survivin Antigen Vaccine DPX-Survivac|Survivin mRNA Antagonist EZN-3042|Survivin-expressing CVD908ssb-TXSVN Vaccine|Sus scrofa|Sustained-release Lipid Inhaled Cisplatin|Sustained-release Mitomycin C Hydrogel Formulation UGN-101|Sustained-release Mitomycin C Hydrogel Formulation UGN-102|Svalbard & Jan Mayen Islands|Svalbard and Jan Mayen|Sweat Gland Adenoma|Sweat Gland Carcinoma|Sweat Gland Neoplasm|Sweat gland adenocarcinoma|Sweat gland adenoma|Sweat gland carcinoma|Sweat gland tumor, NOS|Sweat gland tumor, benign|Sweat gland tumor, malignant|Sweden|Switzerland|Syk Inhibitor HMPL-523|SymBiot I|SymBiot XVI|Sympathetic Paraganglioma|Sympathetic paraganglioma|Sympathicoblastoma|Symplastic leiomyoma|Synapt G2 HDMS|Synapt G2 MS|Synapt G2-S HDMS|Synapt G2-S MS|Synapt HDMS|Synapt MS|Synchronous malignancy|Synchrotope TA2M Plasmid DNA Vaccine|Synchrovax SEM Plasmid DNA Vaccine|Syncope|Syncytial meningioma|Synovial Sarcoma|Synovial sarcoma, NOS|Synovial sarcoma, biphasic|Synovial sarcoma, epithelioid cell|Synovial sarcoma, monophasic fibrous|Synovial sarcoma, spindle cell|Synovial-like Neoplasms|Synovioma, NOS|Synovioma, benign|Synovioma, malignant|Synovium|Synthetic Alkaloid PM00104|Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2|Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1|Synthetic Hypericin|Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201|Synthetic Long E6/E7 Peptides Vaccine HPV-01|Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b|Synthetic Plumbagin PCUR-101|Synthetic hTERT DNA Vaccine INO-1400|Synthetic hTERT DNA Vaccine INO-1401|Syphilis|Syria|Syringadenoma, NOS|Syringocystadenoma Papilliferum|Syringocystadenoma papilliferum|Syringofibroadenoma|Syringoma|Syringoma, NOS|Syringomatous carcinoma|Systemic EBV positive T-cell lymphoproliferative disease of childhood|Systemic EBV-Positive T-Cell Lymphoma of Childhood|Systemic Mastocytosis|Systemic Mastocytosis with an Associated Hematological Neoplasm|Systemic light chain disease|Systemic mastocytosis with AHNMD|Systemic mastocytosis with associated hematological clonal non-mast cell disorder|Systemic tissue mast cell disease|T|T Acute Lymphoblastic Leukemia|T Lymphoblastic Leukemia/Lymphoma|T Lymphoblastic Lymphoma|T lymphoblastic leukemia/lymphoma|T-Cell Large Granular Lymphocyte Leukemia|T-Cell Non-Hodgkin Lymphoma|T-Cell Prolymphocytic Leukemia|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|T-Zone Variant Peripheral T-Cell Lymphoma|T-cell large granular lymphocytic leukemia|T-cell large granular lymphocytosis|T-cell lymphoma, NOS|T-cell rich large B-cell lymphoma|T-cell rich/histiocyte-rich large B-cell lymphoma|T-gamma lymphoproliferative disease|T-zone lymphoma|T/NK-cell lymphoma|T0|T0 Stage Finding|T1|T1 Stage Finding|T1a|T1a Stage Finding|T1a1|T1a2|T1b|T1b Stage Finding|T1b1|T1b2|T1c|T1c Stage Finding|T1mi|T1mi Stage Finding|T2|T2 Stage Finding|T2a|T2a Stage Finding|T2a1|T2a2|T2b|T2b Stage Finding|T2c|T2c Stage Finding|T2d|T2d Stage Finding|T3|T3 Stage Finding|T3a|T3a Stage Finding|T3b|T3b Stage Finding|T3c|T3c Stage Finding|T3d|T3d Stage Finding|T4|T4 Stage Finding|T4a|T4a Stage Finding|T4b|T4b Stage Finding|T4c|T4c Stage Finding|T4d|T4d Stage Finding|T4e|T900607|TAM/c-Met Inhibitor RXDX-106|TARGET DCC Archive|TARGZ|TBI|TCGA DCC Archive|TE-Too Early|TF-Tumor Free|TGF-beta Receptor 1 Inhibitor PF-06952229|TGF-beta Receptor 1 Kinase Inhibitor SH3051|TGF-beta Receptor 1 Kinase Inhibitor YL-13027|TGFa-PE38 Immunotoxin|TGFbeta Inhibitor LY3200882|TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein AVID200|THL-P|TIFF|TIGIT Inhibitor M6223|TIGIT-targeting Agent MK-7684|TLC ELL-12|TLR Agonist BDB001|TLR Agonist BSG-001|TLR Agonist CADI-05|TLR-Directed Cationic Lipid-DNA Complex JVRS-100|TLR7 Agonist 852A|TLR7 Agonist LHC165|TLR7 agonist BNT411|TLR7/8/9 Antagonist IMO-8400|TLR8 Agonist DN1508052|TLR9 Agonist AST-008|TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells|TMT|TMT10|TMT11|TMT6|TORC1/2 Kinase Inhibitor DS-3078a|TP40 Immunotoxin|TRAIL Receptor Agonist ABBV-621|TRIZAIC UPLC nanoTile|TRK Inhibitor AZD6918|TRK Inhibitor TQB3558|TRPM8 Agonist D-3263|TRPV6 Calcium Channel Inhibitor SOR-C13|TSP-1 Mimetic ABT-510|TSP-1 Mimetic Fusion Protein CVX-045|TSQ 8000 Evo|TSQ 9000|TSQ Altis|TSQ Endura|TSQ Quantis|TSQ Quantiva|TSQ Quantum|TSQ Quantum Access|TSQ Quantum Ultra|TSQ Quantum Ultra AM|TSQ Vantage|TSV|TX|TX Stage Finding|TXT|Ta|Ta Stage Finding|Tabalumab|Tabelecleucel|Tacedinaline|Tafasitamab|Tag|Tagraxofusp-erzs|Tail of pancreas|Taiwan|Tajikistan|Takifugu rubripes|Talabostat|Talabostat Mesylate|Talacotuzumab|Talactoferrin Alfa|Taladegib|Talampanel|Talaporfin Sodium|Talazoparib|Taletrectinib|Talimogene Laherparepvec|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Tallimustine|Talmapimod|Talotrexin|Talotrexin Ammonium|Taltobulin|Tamibarotene|Taminadenant|Tamoxifen|Tamoxifen Citrate|Tamrintamab Pamozirine|Tandutinib|Tanespimycin|Tanibirumab|Tankyrase Inhibitor STP1002|Tanomastat|Tanycytic Ependymoma|Tanycytic ependymoma|Tanzania|Tapotoclax|Tarenflurbil|Tarextumab|Targeted Molecular Therapy|Tariquidar|Tasadenoturev|Taselisib|Tasidotin|Tasisulam|Tasisulam Sodium|Tasquinimod|Tattoo|Taurolidine|Tauromustine|Taurultam|Taurultam Analogue GP-2250|Tavokinogene Telseplasmid|Tavolimab|Taxane Analogue TPI 287|Taxane Compound|Taxol Analogue SID 530|Tazarotene|Tazemetostat|Tebentafusp|Teclistamab|Tecogalan Sodium|Tefinostat|Tegafur|Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation|Tegafur-Uracil|Tegafur-gimeracil-oteracil Potassium|Tegavivint|Teglarinad|Teglarinad Chloride|Telaglenastat|Telaglenastat Hydrochloride|Telangiectasia|Telangiectatic Osteosarcoma|Telangiectatic osteosarcoma|Telapristone|Telapristone Acetate|Telatinib Mesylate|Telisotuzumab|Telisotuzumab Vedotin|Telomerase Inhibitor FJ5002|Telomerase-specific Type 5 Adenovirus OBP-301|Teloxantrone|Teloxantrone Hydrochloride|Telratolimod|Temarotene|Temoporfin|Temozolomide|Temporal Cortex|Temporal Lobe|Temporal lobe|Temsirolimus|Tenalisib|Tendon|Tenifatecan|Teniposide|Tenosynovial Giant Cell Tumor|Tenosynovial giant cell tumor|Tepoditamab|Tepotinib|Teprotumumab|Terameprocol|Teratoblastoma, malignant|Teratocarcinoma|Teratoid medulloepithelioma|Teratoid medulloepithelioma, benign|Teratoma|Teratoma with Somatic-Type Malignancy|Teratoma with malignant transformation|Teratoma, NOS|Teratoma, benign|Teratoma, differentiated|Teratoma, malignant, NOS|Terfluranol|Tergenpumatucel-L|Terminal duct adenocarcinoma|Teroxirone|Tertomotide|Tesetaxel|Tesevatinib|Tesidolumab|Testicular Cancer|Testicular Disorder|Testicular Germ Cell Tumors|Testicular Hemorrhage|Testicular Mixed Germ Cell-Sex Cord-Stromal Tumor, Unclassified|Testicular Pain|Testicular Seminoma with High Mitotic Index|Testicular Spermatocytic Tumor|Testicular adenoma|Testicular stromal tumor|Testis|Testis Removed|Testis, NOS|Testolactone|Testosterone Enanthate|Tetanus Toxoid Vaccine|Tetradecanoylphorbol Acetate|Tetrahydrouridine|Tetraphenyl Chlorin Disulfonate|Tetrathiomolybdate|Tezacitabine|Tezacitabine Anhydrous|Thailand|Thalicarpine|Thalidomide|Theca cell tumor|Theca cell-granulosa cell tumor|Thecoma|Thecoma, NOS|Thecoma, luteinized|Thecoma, malignant|Theliatinib|Theramide|Therapeutic Angiotensin-(1-7)|Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907|Therapeutic Cancer Vaccine ATP128|Therapeutic Estradiol|Therapeutic Hydrocortisone|Therapeutic Liver Cancer Peptide Vaccine IMA970A|Therapy related myeloid neoplasm|Therapy-Related Acute Myeloid Leukemia|Therapy-Related Myelodysplastic Syndrome|Therapy-Related Myeloid Neoplasm|Therapy-related acute myeloid leukemia, NOS|Therapy-related acute myeloid leukemia, alkylating agent related|Therapy-related acute myeloid leukemia, epipodophyllotoxin-related|Therapy-related myelodysplastic syndrome, NOS|Therapy-related myelodysplastic syndrome, alkylating agent related|Therapy-related myelodysplastic syndrome, epipodophyllotoxin-related|Thermo Fisher Scientific|Thermo Orbitrap Fusion Lumos|Thermo Orbitrap Q Exactive HF-X|Thiarabine|Thiazolidinedione|Thigh|Thiodiglycol|Thioguanine|Thioguanine Anhydrous|Thioinosine|Thioredoxin-1 Inhibitor PX-12|Thiotepa|Thioureidobutyronitrile|Thoracentesis|Thoracic Esophagus|Thoracic Spine|Thoracic esophagus|Thoracoscopic Biopsy|Thorax|Thorax, NOS|Thorium Th 227 Anetumab|Thorium Th 227 Anetumab Corixetan|Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439|Thorium Th 227 Anti-PSMA Monoclonal Antibody BAY 2315497|Three Times Daily|Threonine Tyrosine Kinase Inhibitor CFI-402257|Throat|Throat Cancer|Thromboembolic Event|Thrombotic Thrombocytopenic Purpura|Thumb|Thymic Carcinoma|Thymic Epithelial Neoplasms|Thymic carcinoma with adenoid cystic carcinoma-like features|Thymic carcinoma, NOS|Thymic large B-cell lymphoma|Thymidylate Synthase Inhibitor CX1106|Thymidylate Synthase Inhibitor DFP-11207|Thymoma|Thymoma Type A|Thymoma Type AB|Thymoma Type B1|Thymoma Type B2|Thymoma Type B3|Thymoma, NOS|Thymoma, atypical, NOS|Thymoma, atypical, malignant|Thymoma, benign|Thymoma, cortical, NOS|Thymoma, cortical, malignant|Thymoma, epithelial, NOS|Thymoma, epithelial, malignant|Thymoma, lymphocyte-rich, NOS|Thymoma, lymphocyte-rich, malignant|Thymoma, lymphocytic, NOS|Thymoma, lymphocytic, malignant|Thymoma, malignant, NOS|Thymoma, medullary, NOS|Thymoma, medullary, malignant|Thymoma, mixed type, NOS|Thymoma, mixed type, malignant|Thymoma, organoid, NOS|Thymoma, organoid, malignant|Thymoma, predominantly cortical, NOS|Thymoma, predominantly cortical, malignant|Thymoma, spindle cell, NOS|Thymoma, spindle cell, malignant|Thymoma, type A, NOS|Thymoma, type A, malignant|Thymoma, type AB, NOS|Thymoma, type AB, malignant|Thymoma, type B1, NOS|Thymoma, type B1, malignant|Thymoma, type B2, NOS|Thymoma, type B2, malignant|Thymoma, type B3, NOS|Thymoma, type B3, malignant|Thymoma, type C|Thymopentin|Thymus|Thyroid|Thyroid Cancer|Thyroid Carcinoma|Thyroid Extract|Thyroid Gland|Thyroid Gland Follicular Adenoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Follicular Carcinoma, Encapsulated Angioinvasive|Thyroid Gland Hurthle (Oncocytic) Cell Neoplasm|Thyroid Gland Hurthle Cell Adenoma|Thyroid Gland Hyalinizing Trabecular Tumor|Thyroid Gland Macrofollicular Adenoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Medullary Carcinoma with Amyloid Stroma|Thyroid Gland Microfollicular Adenoma|Thyroid Gland Noninvasive Follicular Neoplasm with Papillary-Like Nuclear Features|Thyroid Gland Papillary Carcinoma|Thyroid Gland Papillary and Follicular Carcinoma|Thyroid Gland Spindle Cell Tumor with Thymus-Like Differentiation|Thyroid Gland Well-Differentiated Tumor of Uncertain Malignant Potential|Thyroid Nodular Hyperplasia|Thyroid gland|Tiazofurin|Tibia|Tibial Adamantinoma|Tibial adamantinoma|Tidutamab|Tigapotide|Tigatuzumab|Tilarginine|Tilogotamab|Tilsotolimod Sodium|Timonacic|Timor-Leste|Tin Ethyl Etiopurpurin|Tinnitus|Tinostamustine|Tinzaparin Sodium|Tiomolibdate Choline|Tiomolibdate Diammonium|Tipapkinogene Sovacivec|Tipifarnib|Tipiracil|Tipiracil Hydrochloride|Tirabrutinib|Tiragolumab|Tirapazamine|Tirbanibulin|Tis|Tis (DCIS)|Tis (LCIS)|Tis (Paget's)|Tis Stage Finding|Tisagenlecleucel|Tislelizumab|Tisotumab Vedotin|Tissue Microarray Image|Tissue Slide|Tivantinib|Tivozanib|Tobacco|Tobacco smoke, NOS|Tobacco smoke, cigar|Tobacco smoke, cigarettes|Tobacco smoke, pipe|Tobacco, NOS|Tobacco, Smokeless|Tobacco, Smoking|Tocilizumab|Tocladesine|Tocotrienol|Tocotrienol-rich Fraction|TofSpec|TofSpec 2E|TofSpec E|TofSpec SE|Togo|Tokelau|Tolebrutinib|Toll-like Receptor 7 Agonist DSP-0509|Tolnidamine|Tomaralimab|Tomato-Soy Juice|Tomivosertib|Tonga|Tongue|Tongue Cancer|Tongue, NOS|Tonsil|Tonsil (Pharyngeal)|Tonsil, NOS|Tonsillar Cancer|Tonsillar Fossa|Tonsillar fossa|Tonsillar pillar|Tonsillectomy|Tooth Development Disorder|Tooth Discoloration|Tooth Infection|Toothache|Topical Betulinic Acid|Topical Celecoxib|Topical Fluorouracil|Topical Gemcitabine Hydrochloride|Topical Potassium Dobesilate|Topical Trichloroacetic Acid|Topixantrone|Topoisomerase I Inhibitor Genz-644282|Topoisomerase I Inhibitor LMP400|Topoisomerase I Inhibitor LMP776|Topoisomerase I/II Inhibitor NEV-801|Topoisomerase-1 Inhibitor LMP744|Topoisomerase-II Inhibitor Racemic XK469|Topoisomerase-II-beta Inhibitor Racemic XK469|Topotecan|Topotecan Hydrochloride|Topotecan Hydrochloride Liposomes|Topotecan Sustained-release Episcleral Plaque|Topsalysin|Toremifene|Toremifene Citrate|Toripalimab|Tosedostat|Tositumomab|Total Androgen Blockade|Total Colectomy|Total Hepatectomy|Total Laryngectomy|Total Mastectomy|Total Nephrectomy|Total RNA|Total RNA-Seq|Tovetumab|Toxic Epidermal Necrolysis|Toxicity|Toxoplasmosis|Tozasertib Lactate|Trabectedin|Trabecular Adenocarcinoma|Trabecular Adenoma|Trabecular adenocarcinoma|Trabecular adenoma|Trabecular carcinoma|Trabedersen|Trachea|Trachea / Major Bronchi|Tracheal Fistula|Tracheal Hemorrhage|Tracheal Mucositis|Tracheal Obstruction|Tracheal Stenosis|Tracheitis|Tracheostomy Site Bleeding|Traditional Serrated Adenoma|Traditional serrated adenoma|Traditional sessile serrated adenoma|Trametinib|Trametinib Dimethyl Sulfoxide|Trans Sodium Crocetinate|Transcript Fusion|Transcriptome Profiling|Transdermal 17beta-Estradiol Gel BHR-200|Transdermal 4-Hydroxytestosterone|Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01|Transferrin Receptor-Targeted Liposomal p53 cDNA|Transferrin-CRM107|Transfusion Recipient|Transient Abnormal Myelopoiesis Associated with Down Syndrome|Transient Ischemic Attack|Transient Ischemic Attacks|Transient abnormal myelopoiesis|Transitional Cell Carcinoma|Transitional Cell Papilloma|Transitional Cell Papillomas and Carcinomas|Transitional Meningioma|Transitional carcinoma|Transitional cell carcinoma|Transitional cell carcinoma in situ|Transitional cell carcinoma, micropapillary|Transitional cell carcinoma, sarcomatoid|Transitional cell carcinoma, spindle cell|Transitional cell papilloma, NOS|Transitional cell papilloma, benign|Transitional cell papilloma, inverted, NOS|Transitional cell papilloma, inverted, benign|Transitional meningioma|Transitional papilloma|Transitional papilloma, inverted, NOS|Transitional papilloma, inverted, benign|Transitional pineal tumor|Transoral Laser Excision|Transplant|Transurethral Resection (TURP)|Transurethral resection (TURBT)|Transverse Colectomy|Transverse Colon|Transverse colon|Tranylcypromine Sulfate|Trapoxin|Trastuzumab|Trastuzumab Conjugate BI-CON-02|Trastuzumab Deruxtecan|Trastuzumab Duocarmazine|Trastuzumab Emtansine|Trastuzumab Monomethyl Auristatin F|Trastuzumab-TLR 7/8 Agonist BDC-1001|Trastuzumab/Hyaluronidase-oysk|Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502|Treatment Ongoing|Treatment Related Secondary Malignancy|Treatment Stopped Due to Toxicity|Trebananib|Tremelimumab|Tremor|Treosulfan|Treponema pallidum|Tretazicar|Tretinoin|Tretinoin Liposome|Triamcinolone Acetonide|Triamcinolone Hexacetonide|Triapine|Triazene Derivative CB10-277|Triazene Derivative TriN2755|Triazinate|Triaziquone|Tributyrin|Trichilemmal Carcinoma|Trichilemmal carcinoma|Trichilemmocarcinoma|Trichilemmoma|Trichoblastoma|Trichodiscoma|Trichoepithelioma|Trichofolliculoma|Trichomonas vaginalis|Triciribine Phosphate|Tricuspid Valve Disease|Trientine Hydrochloride|Triethylenemelamine|Trifluridine|Trifluridine and Tipiracil Hydrochloride|Trigeminal Nerve Disorder|Trigone of bladder|Trigriluzole|Trilaciclib|Trimelamol|Trimeric GITRL-Fc OMP-336B11|Trimethylcolchicinic Acid|Trimetrexate|Trimetrexate Glucuronate|Trinidad and Tobago|Trioxifene|Triplatin Tetranitrate|Triple Quad 3500|Triple Quad 4500|Triple Quad 5500|Triple Quad 6500|Triple Quad 6500+|TripleTOF 4600|TripleTOF 5600|TripleTOF 5600+|TripleTOF 6600|Triptolide Analog|Triptorelin|Triptorelin Pamoate|Tris-acryl Gelatin Microspheres|Trismus|Triton tumor, malignant|Tritylcysteine|TrkA Inhibitor VMD-928|Trodusquemine|Trofosfamide|Troglitazone|Trophoblastic neoplasms|Trophoblastic tumor, epithelioid|Tropomyosin Receptor Kinase Inhibitor AZD7451|Troriluzole|Troxacitabine|Troxacitabine Nucleotide Prodrug MIV-818|TruTOF|True|True Histiocytic Lymphoma|True histiocytic lymphoma|Trunk|TrypChymo|Trypsin|Trypsin/P|Tubercidin|Tuberculosis|Tuberous Sclerosis|Tubular Adenocarcinoma|Tubular Adenoma|Tubular adenocarcinoma|Tubular adenoma, NOS|Tubular androblastoma with lipid storage|Tubular androblastoma, NOS|Tubular carcinoid|Tubular carcinoma|Tubulin Binding Agent TTI-237|Tubulin Inhibitor ALB 109564 Dihydrochloride|Tubulin Inhibitor ALB-109564|Tubulin Polymerization Inhibitor AEZS 112|Tubulin Polymerization Inhibitor CKD-516|Tubulin Polymerization Inhibitor VERU-111|Tubulin-Binding Agent SSR97225|Tubulo-papillary adenoma|Tubulocystic Renal Cell Carcinoma|Tubulocystic renal cell carcinoma|Tubulointerstitial Disease|Tubulolobular carcinoma|Tubulopapillary adenocarcinoma|Tubulovillous Adenoma|Tubulovillous adenoma, NOS|Tucatinib|Tucidinostat|Tucotuzumab Celmoleukin|Tumor|Tumor Adjacent Normal - Post Neo-adjuvant Therapy|Tumor Debulking|Tumor Embolism|Tumor Free|Tumor Lysis Syndrome|Tumor Pain|Tumor Resection|Tumor cells, NOS|Tumor cells, benign|Tumor cells, malignant|Tumor cells, uncertain whether benign or malignant|Tumor class but appears normal|Tumor embolus|Tumor free|Tumor tissue origin incorrect|Tumor type incorrect|Tumor, NOS|Tumor, benign|Tumor, malignant, NOS|Tumor, metastatic|Tumor, secondary|Tumor-associated Lymphoid Proliferation|Tumorlet|Tumorlet, NOS|Tumorlet, benign|Tunisia|Turban Tumor|Turban tumor|Turcot Syndrome|Turkey|Turkmenistan|Tuvalu|Twice Daily|Twice Weekly|Twin Sibling|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma|Type A Spindle Cell Melanoma|Type B Spindle Cell Melanoma|Typhlitis|Typical carcinoid|Tyroserleutide|Tyrosinase Peptide|Tyrosinase-KLH|Tyrosinase:146-156 Peptide|Tyrosine Kinase Inhibitor|Tyrosine Kinase Inhibitor OSI-930|Tyrosine Kinase Inhibitor SU5402|Tyrosine Kinase Inhibitor TL-895|Tyrosine Kinase Inhibitor XL228|Tyrosinemia|UAE Inhibitor TAK-243|UHPLC|USP14/UCHL5 Inhibitor VLX1570|Ubenimex|Ubidecarenone Nanodispersion BPM31510n|Ubiquitylome|Ublituximab|Uganda|Ukraine|Ulcerative Colitis|Ulinastatin|Ulixertinib|Ulocuplumab|Ultrasound Guided Biopsy|Ultrasound-Guided Biopsy|Umbilical Cord|Umbralisib|Unaligned Reads|Uncaria tomentosa Extract|Unclassified Testicular Sex Cord-Stromal Tumor|Unclassified tumor, benign|Unclassified tumor, borderline malignancy|Unclassified tumor, malignant|Unclassified tumor, malignant, uncertain whether primary or metastatic|Unclassified tumor, uncertain whether benign or malignant|Uncle|Undescended Testis|Undescended testis|Undifferentiated|Undifferentiated (Embryonal) Sarcoma|Undifferentiated Carcinoma|Undifferentiated Epithelioid Sarcoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone|Undifferentiated Neuroblastoma|Undifferentiated Pleomorphic Sarcoma|Undifferentiated Pleomorphic Sarcoma with Osteoclast-Like Giant Cells|Undifferentiated Retinoblastoma|Undifferentiated Round Cell Sarcoma|Undifferentiated Sarcoma, Not Otherwise Specified|Undifferentiated Spindle Cell Sarcoma|Undifferentiated epithelioid sarcoma|Undifferentiated high-grade pleomorphic sarcoma|Undifferentiated leukaemia|Undifferentiated pleomorphic sarcoma|Undifferentiated round cell sarcoma|Undifferentiated sarcoma|Undifferentiated spindle cell sarcoma|Undifferentiated uterine sarcoma|Unequal Limb Length|Unfavorable|Unifocal|Unilateral|Unintended Pregnancy|United Arab Emirates|United Kingdom|United States|Unknown|Unknown Tumor Status|Unknown primary site|Unknown tumor status|Unpaired_LogR|Unrelated|Unsatisfactory|Unspecific cleavage|Unspecified|Upamostat|Upifitamab|Upper Gastrointestinal Hemorrhage|Upper Gingiva|Upper Gum|Upper Respiratory Infection|Upper gum|Upper limb, NOS|Upper lobe, lung|Upper respiratory tract, NOS|Upper third of esophagus|Upper-inner quadrant of breast|Upper-outer quadrant of breast|Uproleselan|Uprosertib|Urabrelimab|Urachal carcinoma|Urachus|Uracil Ointment|Urelumab|Ureter|Ureteric Anastomotic Leak|Ureteric Orifice|Ureteric orifice|Urethra|Urethral Anastomotic Leak|Urethral Infection|Urinary Fistula|Urinary Frequency|Urinary Incontinence|Urinary Retention|Urinary System|Urinary Tract|Urinary Tract Infection|Urinary Tract Obstruction|Urinary Tract Pain|Urinary Urgency|Urinary system, NOS|Urine Discoloration|Urine Output Decreased|Uroacitides|Urokinase-Derived Peptide A6|Urostomy Leak|Urostomy Obstruction|Urostomy Site Bleeding|Urostomy Stenosis|Urothelial Carcinoma|Urothelial Papilloma|Urothelial carcinoma in situ|Urothelial carcinoma with divergent differentiation|Urothelial carcinoma with squamous differentiation|Urothelial carcinoma with trophoblastic differentiation|Urothelial carcinoma, NOS|Urothelial papilloma, NOS|Ursolic Acid|Urticaria|Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis|Urticaria pigmentosa|Uruguay|Uterine Adnexa|Uterine Anastomotic Leak|Uterine Cancer|Uterine Carcinosarcoma|Uterine Corpus Endometrial Carcinoma|Uterine Corpus Leiomyoma|Uterine Corpus Undifferentiated Sarcoma|Uterine Fistula|Uterine Hemorrhage|Uterine Infection|Uterine Obstruction|Uterine Pain|Uterine Perforation|Uterine adnexa|Uterus|Uterus, NOS|Utomilumab|Uveal Melanoma|Uveitis|Uvula|Uzansertib|Uzbekistan|V8-DE|V8-E|V930 Vaccine|VAIN III|VCF|VCF LiftOver|VEGF Inhibitor PTC299|VEGF/HGF-targeting DARPin MP0250|VEGFR Inhibitor KRN951|VEGFR-2 DNA Vaccine VXM01|VEGFR/FGFR Inhibitor ODM-203|VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593|VEGFR2 Tyrosine Kinase Inhibitor PF-00337210|VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813|VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220|VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820|VGPR-Very Good Partial Response|VIN III|VIP-Producing Neuroendocrine Tumor|VLP-encapsulated TLR9 Agonist CMP-001|Vaccine-Sensitized Draining Lymph Node Cells|Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules|Vactosertib|Vadacabtagene Leraleucel|Vadastuximab Talirine|Vadimezan|Vagina|Vagina, NOS|Vaginal Anastomotic Leak|Vaginal Discharge|Vaginal Dryness|Vaginal Fistula|Vaginal Hemorrhage|Vaginal Infection|Vaginal Inflammation|Vaginal Obstruction|Vaginal Pain|Vaginal Perforation|Vaginal Stricture|Vaginal intraepithelial neoplasia, grade III|Vaginismus|Vagus Nerve Disorder|Valecobulin|Valemetostat|Validation|Vallecula|Valproic Acid|Valrubicin|Valspodar|Vandetanib|Vandetanib-eluting Radiopaque Bead BTG-002814|Vandortuzumab Vedotin|Vantictumab|Vanuatu|Vanucizumab|Vapreotide|VarScan2|VarScan2 Annotation|VarScan2 Variant Aggregation and Masking|Varian|Varicella Zoster Virus|Varlilumab|Varlitinib|Varlitinib Tosylate|Vas Deferens|Vas Deferens Anastomotic Leak|Vascular Access Complication|Vascular Disease|Vascular Disorders - Other|Vascular Disrupting Agent BNC105|Vascular Disrupting Agent BNC105P|Vascular Disrupting Agent ZD6126|Vascular leiomyoma|Vasculitis|Vasovagal Reaction|Vatalanib|Vatalanib Succinate|Vecabrutinib|Vector-peptide Conjugated Paclitaxel|Vedolizumab|Vein|Veliparib|Velos Plus|Veltuzumab|Vemurafenib|Venetoclax|Venezuela|Venous|Venous Hemangioma|Venous Injury|Venous hemangioma|Ventral surface of tongue, NOS|Ventricle, NOS|Ventricular Arrhythmia|Ventricular Fibrillation|Ventricular Tachycardia|Verapamil|Verpasep Caltespen|Verrucous Carcinoma|Verrucous Hemangioma|Verrucous Papilloma|Verrucous carcinoma, NOS|Verrucous epidermoid carcinoma|Verrucous keratotic hemangioma|Verrucous papilloma|Verrucous squamous cell carcinoma|Vertebra|Vertebral Canal|Vertebral column|Vertical Hemilaryngectomy|Vertigo|Verubulin|Verubulin Hydrochloride|Very Good Partial Response|Vesencumab|Vesigenurtucel-L|Vestibular Disorder|Vestibule of Mouth|Vestibule of mouth|Viagenpumatucel-L|Vibecotamab|Vibostolimab|Vietnam|Vilaprisan|Villoglandular Endometrial Endometrioid Adenocarcinoma|Villoglandular adenoma|Villoglandular carcinoma|Villous Adenocarcinoma|Villous Adenoma|Villous adenocarcinoma|Villous adenoma, NOS|Villous papilloma|Vinblastine|Vinblastine Sulfate|Vincristine|Vincristine Liposomal|Vincristine Sulfate|Vincristine Sulfate Liposome|Vindesine|Vinepidine|Vinflunine|Vinflunine Ditartrate|Vinfosiltine|Vinorelbine|Vinorelbine Tartrate|Vinorelbine Tartrate Emulsion|Vinorelbine Tartrate Oral|Vintafolide|Vinzolidine|Vinzolidine Sulfate|Vipoma, NOS|Vipoma, malignant|Virgin Islands, British|Virgin Islands, U.S.|Virilization|Virulizin|Visceral Arterial Ischemia|Vision Changes|Vismodegib|Vistusertib|Visual Change|Visual Changes|Vital Capacity Abnormal|Vitamin D3 Analogue ILX23-7553|Vitamin E Compound|Vitespen|Vitreous Hemorrhage|Vocimagene Amiretrorepvec|Vofatamab|Voice Alteration|Volasertib|Volcanic smoke|Volociximab|Vomiting|Von Hippel-Lindau Syndrome|Von Recklinghausen disease|Vonlerolizumab|Vopratelimab|Vorasidenib|Vorinostat|Vorolanib|Vorsetzumab Mafodotin|Vosaroxin|Vosilasarm|Voxtalisib|Voyager-DE PRO|Voyager-DE STR|Vulinacimab|Vulva|Vulva, NOS|Vulval Infection|Vulvar Intraepithelial Neoplasia, Differentiated Type|Vulvar intraepithelial neoplasia, grade III|W|WGA Failure|WNT-Activated|WT-With Tumor|WT1 Peptide Vaccine OCV-501|WT1 Peptide Vaccine WT2725|WT1 Protein-derived Peptide Vaccine DSP-7888|WT1-A10/AS01B Immunotherapeutic GSK2130579A|WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401|WXS|Wagr Syndrome|Waldenstrom Macroglobulinemia|Waldenstrom macroglobulinemia|Waldeyer ring|Wallis and Futuna|Ward|Warfarin Sodium|Warthin Tumor|Warthin tumor|Warty carcinoma|Waste burning smoke|Wasting Syndrome|Water-Clear Cell Adenocarcinoma|Water-clear cell adenocarcinoma|Water-clear cell adenoma|Water-clear cell carcinoma|Watering Eyes|Waters|Wedge Resection|Wee1 Inhibitor ZN-c3|Wee1 Kinase Inhibitor Debio 0123|Weight Gain|Weight Loss|Well Differentiated Liposarcoma|Well Differentiated Neuroendocrine Lesion|Well differentiated liposarcoma of superficial soft tissue|Well differentiated papillary mesothelioma, benign|Well differentiated thymic carcinoma|Western Sahara|Wheezing|Whipple Procedure|White Blood Cell Decreased|White Blood Cells|White Carrot|White Matter|Whole Bone Marrow|Whole Genome Sequencing|Wife|Wilms Tumor|Wilms tumor|Wilms tumor (WT)|Wine|With Tumor|With tumor|Withdrawal by Subject|Within 5 Minutes|Wnt Signaling Inhibitor SM04755|Wnt Signaling Pathway Inhibitor SM08502|Wnt-5a Mimic Hexapeptide Foxy-5|Wobe-Mugos E|Wolff-Parkinson-White Syndrome|Wolffian duct adenoma|Wolffian duct carcinoma|Wolffian duct tumor|Wood Dust|Wood burning smoke, NOS|Wood burning smoke, factory|Work-related smoke, NOS|Work-related smoke, artificial smoke machines|Work-related smoke, fire fighting|Work-related smoke, foundry|Work-related smoke, generators|Work-related smoke, military|Work-related smoke, paint baking|Work-related smoke, plastics factory|Work-related smoke, plumbing|Work-related smoke, soldering/welding|Wound Complication|Wound Dehiscence|Wound Infection|Wrist|Wrist Fracture|X|X500R QTOF|XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410|XIAP Antisense Oligonucleotide AEG35156|XIAP/cIAP1 Antagonist ASTX660|XLSX|XML|XPO1 Inhibitor SL-801|Xanthofibroma|Xanthohumol|Xeloda|Xenograft|Xenograft Tissue|Xenopus laevis|Xentuzumab|Xevinapant|Xevo G2 Q-Tof|Xevo G2 Tof|Xevo G2 XS Tof|Xevo G2-S QTof|Xevo G2-S Tof|Xevo Q-Tof|Xevo QTof|Xevo TQ MS|Xevo TQ-S|Xevo TQD|Xiaoai Jiedu Decoction|Xiliertinib|Xisomab 3G3|Y|Y 90 Monoclonal Antibody CC49|Y 90 Monoclonal Antibody HMFG1|Y 90 Monoclonal Antibody Lym-1|Y 90 Monoclonal Antibody M195|Y 90 Monoclonal Antibody m170|Yang Yin Fu Zheng|Yangzheng Xiaoji Extract|Yemen|Yiqi-yangyin-jiedu Herbal Decoction|Yolk Sac Tumor|Yolk sac tumor|Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12|Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101|Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66|Yttrium Y 90 Basiliximab|Yttrium Y 90 Colloid|Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A|Yttrium Y 90 Daclizumab|Yttrium Y 90 Glass Microspheres|Yttrium Y 90 Monoclonal Antibody B3|Yttrium Y 90 Monoclonal Antibody BrE-3|Yttrium Y 90 Monoclonal Antibody Hu3S193|Yttrium Y 90 Monoclonal Antibody MN-14|Yttrium Y 90 Resin Microspheres|Yttrium Y 90 Tabituximab Barzuxetan|Yttrium Y 90-DOTA-Biotin|Yttrium Y 90-DOTA-di-HSG Peptide IMP-288|Yttrium Y 90-Edotreotide|Yttrium Y 90-labeled Anti-FZD10 Monoclonal Antibody OTSA101|Yttrium Y-90 Clivatuzumab Tetraxetan|Yttrium Y-90 Epratuzumab Tetraxetan|Yttrium Y-90 Ibritumomab Tiuxetan|Yttrium Y-90 Tacatuzumab Tetraxetan|Yttrium-90 Polycarbonate Brachytherapy Plaque|Z-Endoxifen Hydrochloride|ZMD|ZQ|Zalcitabine|Zalifrelimab|Zalutumumab|Zambia|Zandelisib|Zanidatamab|Zanolimumab|Zanubrutinib|Zea mays|Zebularine|Zelavespib|Zero|Zibotentan|Zimbabwe|Zinc Finger Nuclease ZFN-603|Zinc Finger Nuclease ZFN-758|Zinostatin|Zinostatin Stimalamer|Zirconium Zr 89 Panitumumab|Ziv-Aflibercept|Zolbetuximab|Zoledronic Acid|Zoptarelin Doxorubicin|Zorifertinib|Zorubicin|Zorubicin Hydrochloride|Zotatifin|Zotiraciclib Citrate|Zuclomiphene Citrate|aDNA Preparation Type|alignment_workflow|aliquot|allcnv|alleleSpecificCN|alpha-Folate Receptor-targeting Thymidylate Synthase Inhibitor ONX-0801|american indian or alaska native|analyte|asian|auxiliary|bRPLC|bRPLC (pH 10)|bRPLC (pH 7.5)|batch_effect_removed|bisulfite|black or african american|byallele|c-ALL|c-Kit Inhibitor PLX9486|c-Met Inhibitor ABN401|c-Met Inhibitor AL2846|c-Met Inhibitor AMG 208|c-Met Inhibitor AMG 337|c-Met Inhibitor GST-HG161|c-Met Inhibitor HS-10241|c-Met Inhibitor JNJ-38877605|c-Met Inhibitor MK2461|c-Met Inhibitor MK8033|c-Met Inhibitor MSC2156119J|c-raf Antisense Oligonucleotide ISIS 5132|cEt KRAS Antisense Oligonucleotide AZD4785|cFMS Tyrosine Kinase Inhibitor ARRY-382|cGy|cM0 (i+)|cM0 (i+) Stage Finding|cfDNA|cgh|cis-Urocanic Acid|cnv|control|controlled|cov|coverage|cqcf|dUTPase/DPD Inhibitor TAS-114|data_release|diagnostic_slides|drug|eIF4E Antisense Oligonucleotide ISIS 183750|explorer|false|female|follow_up|gene|germline|hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301|hTERT Vaccine V934/V935|hTERT-encoding DNA Vaccine INVAC-1|harmonized|hg18|hg19|hispanic or latino|hpv|huBC1-huIL12 Fusion Protein AS1409|iNKT Cell Agonist ABX196|iNOS Dimerization Inhibitor ASP9853|iPSC-derived CD16-expressing Natural Killer Cells FT516|iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596|iPSC-derived Natural Killer Cells FT500|iTRAQ|iTRAQ4|iTRAQ8|iTRAQH|image|indel|ismpolish|isoform|junction|lost to follow-up|lowess_normalized_smoothed|m6A RNA Methylation|mRNA-Derived Prostate Cancer Vaccine CV9103|mRNA-based Personalized Cancer Vaccine NCI-4650|mRNA-based Personalized Cancer Vaccine mRNA-4157|mRNA-based TriMix Melanoma Vaccine ECI-006|mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902|mRNA-derived KRAS-targeted Vaccine V941|mRNA-derived Lung Cancer Vaccine BI 1361849|mRNA-derived Prostate Cancer Vaccine CV9104|mTOR Inhibitor GDC-0349|mTOR Kinase Inhibitor AZD8055|mTOR Kinase Inhibitor CC-223|mTOR Kinase Inhibitor OSI-027|mTOR Kinase Inhibitor PP242|mTOR1/2 Kinase Inhibitor ME-344|mTORC 1/2 Inhibitor LXI-15029|mTORC1/2 Kinase Inhibitor BI 860585|mTORC1/mTORC2/DHFR Inhibitor ABTL0812|maXis 4G|maXis impact|male|metastasis|meth|mg|miRNA|miRNA Expression Quantification|miRNA-Seq|microOTOF focus II|microOTOF-Q II|mirVana (Allprep DNA) RNA|msi|nRNA - Melanoma Protocol|nanoACQUITY UPLC|nanoACQUITY UPLC System with 1D Technology|nanoACQUITY UPLC with HDX Technology|native hawaiian or other pacific islander|ncmtRNA Oligonucleotide Andes-1537|nocnv|normalized|not allowed to collect|not hispanic or latino|not reported|nte|omf|open|original|other|p300/CBP Bromodomain Inhibitor CCS1477|p38 MAPK Inhibitor LY3007113|p53 Peptide Vaccine MPS-128|p53-HDM2 Interaction Inhibitor MI-773|p53-HDM2 Protein-protein Interaction Inhibitor APG-115|p53/HDM2 Interaction Inhibitor CGM097|p70S6K Inhibitor LY2584702|p70S6K/Akt Inhibitor MSC2363318A|p97 Inhibitor CB-5083|p97 Inhibitor CB-5339|p97 Inhibitor CB-5339 Tosylate|pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0|pNGVL4a-CRT-E6E7L2 DNA Vaccine|pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2|pairedcn|pan FGFR Inhibitor PRN1371|pan-HER Kinase Inhibitor AC480|pan-PI3K Inhibitor CLR457|pan-PI3K/mTOR Inhibitor SF1126|pan-PIM Kinase Inhibitor AZD1208|pan-PIM Kinase Inhibitor NVP-LGB-321|pan-RAF Inhibitor LXH254|pan-RAF Kinase Inhibitor CCT3833|pan-RAF Kinase Inhibitor TAK-580|patient|pbi-shRNA STMN1 Lipoplex|portion|primary|proteomics solution 1|protocol|qc|quattro micro|radiation|raw|recurrence|root|sCR-Stringent Complete Response|sample|scATAC-Seq|scRNA-Seq|seg|segmentation|segmented|segnormal|siG12D LODER|siRNA-transfected Peripheral Blood Mononuclear Cells APN401|sif|slide|snv|solariX|somatic|ssRNA-based Immunomodulator CV8102|submitted_genomic_profile|summary|sv|tangent|timsTOF Pro|tr|tris(2-carboxyethyl)phosphine|true|ultima|unknown|unnormalized|unspecified|v1|v2|white|zUMIs - Smart-Seq2|zUMIs - Smart-Seq2 Counts|g"
who_cns_grade	who_cns_grade	Grade I|Grade II|Grade III|Grade IV|Grade Not Assigned|Not Reported|Unknown	7/7 (both/PDC)		
who_nte_grade	who_nte_grade	Not Reported|Unknown	2/6 (both/PDC)	G1|G2|G3|GX	Grade 1|Grade 2|Grade 3|Grade X
wilms_tumor_histologic_subtype	wilms_tumor_histologic_subtype	Favorable|Not Reported|Unfavorable|Unknown	4/4 (both/PDC)		
alcohol_history	alcohol_history	False|Not Reported|True|Unknown	4/4 (both/PDC)		
alcohol_intensity	alcohol_intensity	Drinker|Heavy Drinker|Lifelong Non-Drinker|Non-Drinker|Not Reported|Occasional Drinker|Unknown	7/7 (both/PDC)		
alcohol_type	alcohol_type	Beer|Liquor|Not Reported|Other|Unknown|Wine	6/6 (both/PDC)		
asbestos_exposure	alcohol_history	False|Not Reported|True|Unknown	4/4 (both/PDC)		
coal_dust_exposure	alcohol_history	False|True|Unknown	3/3 (both/PDC)		Not Reported
environmental_tobacco_smoke_exposure	alcohol_history	False|True|Unknown	3/3 (both/PDC)		Not Reported
exposure_duration	exposure_duration	Not Reported|Six Weeks or More|Unknown	3/3 (both/PDC)		
exposure_type	exposure_type	Marijuana|Radiation|Smoke|Tobacco|Wood Dust	5/5 (both/PDC)		
parent_with_radiation_exposure	parent_with_radiation_exposure	False|Not Reported|True	3/3 (both/PDC)		
radon_exposure	alcohol_history	False|Not Reported|True|Unknown	4/4 (both/PDC)		
respirable_crystalline_silica_exposure	alcohol_history	False|True|Unknown	3/3 (both/PDC)		Not Reported
secondhand_smoke_as_child	secondhand_smoke_as_child	False|Not Reported|True|Unknown	4/4 (both/PDC)		
smoking_frequency	smoking_frequency	Unknown	1/3 (both/PDC)	Every day|Some days	Daily|Some Days
time_between_waking_and_first_smoke	time_between_waking_and_first_smoke	Unknown	1/5 (both/PDC)	31-60 Minutes|6-30 Minutes|After 60 Minutes|Within 5 Minutes	Time Between Waking and First Smoke - After 60 Minutes|Time Between Waking and First Smoke - Between 31 and 60 Minutes|Time Between Waking and First Smoke - Between 6 and 30 Minutes|Time Between Waking and First Smoke - Within 5 Minutes
tobacco_smoking_status	tobacco_smoking_status	1|2|3|4|5|6|7|Not Allowed To Collect|Not Reported|Unknown	10/10 (both/PDC)		"0|0 - No Fibrosis|00|01|02|03|04|05|06|07|08|09|1,2 - Portal Fibrosis|1-3|10|10-Deacetyltaxol|100|11|11C Topotecan|11D10 AluGel Anti-Idiotype Monoclonal Antibody|12|12-Allyldeoxoartemisinin|1200 series LC/MSD SL|1200 series LC/MSD VL|13|13-Deoxydoxorubicin|14|14C BMS-275183|15|16|17|17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521|18|180|1988|1995|1st|2'-F-ara-deoxyuridine|2,6-Diaminopurine|2,6-Dimethoxyquinone|2-Deoxy-D-glucose|2-Ethylhydrazide|2-Fluoroadenine|2-Fluorofucose-containing SGN-2FF|2-Hydroxyestradiol|2-Hydroxyestrone|2-Hydroxyflutamide Depot|2-Hydroxyoleic Acid|2-Methoxyestradiol|2-Methoxyestradiol Nanocrystal Colloidal Dispersion|2-Methoxyestrone|2-O, 3-O Desulfated Heparin|2-chloroacetamide (TCEP)|2-iodobenzoate|20|2000 QTRAP|2009|21|220 GC/MS Ion Trap System|240 GC/MS Ion Trap System|2500 QTRAP|26|2D Classical Conditionally Reprogrammed Cells|2D Modified Conditionally Reprogrammed Cells|2nd|3'-C-ethynylcytidine|3'-dA Phosphoramidate NUC-7738|3,4 - Fibrous Septa|30|31|31-60 Minutes|3100|32|3200 QTRAP|33|35|3500 QTRAP|39|3D Air-Liquid Interface Organoid|3D Neurosphere|3D Organoid|3rd|4 or More|4'-Iodo-4'-Deoxydoxorubicin|4-Nitroestrone 3-Methyl Ether|4-Thio-2-deoxycytidine|40|4000 QTRAP|41|42|45|4700 Proteomics Analyzer|4800 Plus MALDI TOF/TOF|4800 Proteomics Analyzer|4th|5 - Nodular Formation and Incomplete Cirrhosis|5-Aza-4'-thio-2'-deoxycytidine|5-Fluoro-2-Deoxycytidine|50|51|52|53|56|58|5800 TOF/TOF|59|5th|6 - Established Cirrhosis|6-30 Minutes|6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158|60|61|6110 Quadrupole LC/MS|6120A Quadrupole LC/MS|6120B Quadrupole LC/MS|6130 Quadrupole LC/MS|6140 Quadrupole LC/MS|6150 Quadrupole LC/MS|62|6200 Series Accurate-Mass Time-of-Flight (TOF) LC/MS|6210 Time-of-Flight LC/MS|6220 Time-of-Flight LC/MS|6224 Time-of-Flight LC/MS|6230A Time-of-Flight LC/MS|6230B Time-of-Flight LC/MS|63|6310 Ion Trap LC/MS|6320 Ion Trap LC/MS|6330 Ion Trap LC/MS|6340 Ion Trap LC/MS|64|6400 Series Triple Quadrupole LC/MS|6410 Triple Quadrupole LC/MS|6420 Triple Quadrupole LC/MS|6430 Triple Quadrupole LC/MS|6460 Triple Quadrupole LC/MS|6490 Triple Quadrupole LC/MS|6495A Triple Quadrupole LC/MS|6495B Triple Quadrupole LC/MS|65|6510 Quadrupole Time-of-Flight LC/MS|6520A Quadrupole Time-of-Flight LC/MS|6520B Q-TOF LC/MS|6530A Q-TOF LC/MS|6530B Q-TOF LC/MS|6538 Q-TOF LC/MS|6540 Q-TOF LC/MS|6542 Q-TOF LC/MS|6545 Q-TOF LC/MS|6550 iFunnel Q-TOF LC/MS|6550A iFunnel Q-TOF LC/MS|6560 Q-TOF LC/MS|6570 Q-TOF LC/MS|66|68|6th|7-Cyanoquinocarcinol|7-Ethyl-10-Hydroxycamptothecin|7-Hydroxystaurosporine|70|7000 Triple Quadrupole GC/MS System|7000A Triple Quadrupole GC/MS|7000B Triple Quadrupole GC/MS|71|7200 GC/Q-TOF|73|7800 Quadrupole ICP-MS|7th|8|8-Azaguanine|80|8000/0|8000/1|8000/3|8000/6|8000/9|8001/0|8001/1|8001/3|8002/3|8003/3|8004/3|8005/0|8005/3|8010/0|8010/2|8010/3|8010/6|8010/9|8011/0|8011/3|8012/3|8013/3|8014/3|8015/3|8020/3|8020/6|8021/3|8022/3|8023/3|8030/3|8031/3|8032/3|8033/3|8034/3|8035/3|8040/0|8040/1|8040/3|8041/3|8041/34|8041/6|8042/3|8043/3|8044/3|8045/3|8046/3|8046/6|8050/0|8050/2|8050/3|8051/0|8051/3|8052/0|8052/2|8052/3|8053/0|8060/0|8070/2|8070/3|8070/33|8070/6|8071/2|8071/3|8072/3|8073/3|8074/3|8075/3|8076/2|8076/3|8077/0|8077/2|8078/3|8080/2|8081/2|8082/3|8083/3|8084/3|8085/3|8086/3|8090/1|8090/3|8091/3|8092/3|8093/3|8094/3|8095/3|8096/0|8097/3|8098/3|81|8100/0|8101/0|8102/0|8102/3|8103/0|8110/0|8110/3|8120/0|8120/1|8120/2|8120/3|8121/0|8121/1|8121/3|8122/3|8123/3|8124/3|8130/1|8130/2|8130/3|8131/3|8140/0|8140/1|8140/2|8140/3|8140/33|8140/6|8141/3|8142/3|8143/3|8144/3|8145/3|8146/0|8147/0|8147/3|8148/0|8148/2|8149/0|8150/0|8150/1|8150/3|8151/0|8151/3|8152/1|8152/3|8153/1|8153/3|8154/3|8155/1|8155/3|8156/1|8156/3|8158/1|8160/0|8160/3|8161/0|8161/3|8162/3|8163/0|8163/2|8163/3|8170/0|8170/3|8171/3|8172/3|8173/3|8174/3|8175/3|8180/3|8190/0|8190/3|8191/0|82|8200/0|8200/3|8201/2|8201/3|8202/0|8204/0|8210/0|8210/2|8210/3|8211/0|8211/3|8212/0|8213/0|8213/3|8214/3|8215/3|8220/0|8220/3|8221/0|8221/3|8230/2|8230/3|8231/3|8240/1|8240/3|8240/6|8241/3|8242/1|8242/3|8243/3|8244/3|8245/1|8245/3|8246/3|8246/6|8247/3|8248/1|8249/3|8249/6|8250/1|8250/2|8250/3|8251/0|8251/3|8252/3|8253/3|8254/3|8255/3|8256/3|8257/3|8260/0|8260/3|8261/0|8261/2|8261/3|8262/3|8263/0|8263/2|8263/3|8264/0|8265/3|8270/0|8270/3|8271/0|8272/0|8272/3|8280/0|8280/3|8281/0|8281/3|8290/0|8290/3|8300/0|8300/3|8310/0|8310/3|8310/6|8311/1|8311/3|8311/6|8312/3|8313/0|8313/1|8313/3|8314/3|8315/3|8316/3|8317/3|8318/3|8319/3|8320/3|8321/0|8322/0|8322/3|8323/0|8323/3|8324/0|8325/0|8330/0|8330/1|8330/3|8331/3|8332/3|8333/0|8333/3|8334/0|8335/3|8336/0|8337/3|8339/3|8340/3|8341/3|8342/3|8343/2|8343/3|8344/3|8345/3|8346/3|8347/3|8350/3|8360/1|8361/0|8370/0|8370/1|8370/3|8371/0|8372/0|8373/0|8374/0|8375/0|8380/0|8380/1|8380/2|8380/3|8380/6|8381/0|8381/1|8381/3|8382/3|8383/3|8384/3|8390/0|8390/3|8391/0|8392/0|8400/0|8400/1|8400/3|8401/0|8401/3|8402/0|8402/3|8403/0|8403/3|8404/0|8405/0|8406/0|8407/0|8407/3|8408/0|8408/1|8408/3|8409/0|8409/3|8410/0|8410/3|8413/3|8420/0|8420/3|8430/1|8430/3|8440/0|8440/3|8441/0|8441/2|8441/3|8441/6|8442/1|8443/0|8444/1|8450/0|8450/3|8451/1|8452/1|8452/3|8453/0|8453/2|8453/3|8454/0|8460/0|8460/2|8460/3|8461/0|8461/3|8461/6|8462/1|8463/1|8470/0|8470/2|8470/3|8471/0|8471/1|8471/3|8472/1|8473/1|8474/1|8474/3|8480/0|8480/1|8480/3|8480/6|8481/3|8482/3|8482/6|8490/3|8490/6|85|8500/2|8500/3|8500/6|8501/2|8501/3|8502/3|8503/0|8503/2|8503/3|8504/0|8504/2|8504/3|8505/0|8506/0|8507/2|8507/3|8508/3|8509/2|8509/3|8510/3|8512/3|8513/3|8514/3|8519/2|8520/2|8520/3|8521/1|8521/3|8522/1|8522/2|8522/3|8522/6|8523/3|8524/3|8525/3|8530/3|8540/3|8541/3|8542/3|8543/3|8550/0|8550/1|8550/3|8551/3|8552/3|8560/0|8560/3|8561/0|8562/3|8570/3|8571/3|8572/3|8573/3|8574/3|8575/3|8576/3|8580/0|8580/1|8580/3|8581/1|8581/3|8582/1|8582/3|8583/1|8583/3|8584/1|8584/3|8585/1|8585/3|8586/3|8587/0|8588/3|8589/3|8590/1|8591/1|8592/1|8593/1|8594/1|86|8600/0|8600/3|8601/0|8602/0|8610/0|8620/1|8620/3|8621/1|8622/1|8623/1|8630/0|8630/1|8630/3|8631/0|8631/1|8631/3|8632/1|8633/1|8634/1|8634/3|8640/1|8640/3|8641/0|8642/1|8650/0|8650/1|8650/3|8660/0|8670/0|8670/3|8671/0|8680/0|8680/1|8680/3|8681/1|8682/1|8683/0|8690/1|8691/1|8692/1|8693/1|8693/3|87|8700/0|8700/3|8710/3|8711/0|8711/3|8712/0|8713/0|8714/3|8720/0|8720/2|8720/3|8720/6|8721/3|8722/0|8722/3|8723/0|8723/3|8725/0|8726/0|8727/0|8728/0|8728/1|8728/3|8730/0|8730/3|8740/0|8740/3|8741/2|8741/3|8742/2|8742/3|8743/3|8744/3|8745/3|8746/3|8750/0|8760/0|8761/0|8761/1|8761/3|8762/1|8770/0|8770/3|8771/0|8771/3|8772/0|8772/3|8773/3|8774/3|8780/0|8780/3|8790/0|8800 Triple Quadrupole ICP-MS|8800/0|8800/3|8800/6|8800/9|8801/3|8801/6|8802/3|8803/3|8804/3|8804/6|8805/3|8806/3|8806/6|8810/0|8810/1|8810/3|8811/0|8811/1|8811/3|8812/0|8812/3|8813/0|8813/3|8814/3|8815/0|8815/1|8815/3|8820/0|8821/1|8822/1|8823/0|8824/0|8824/1|8825/0|8825/1|8825/3|8826/0|8827/1|8830/0|8830/1|8830/3|8831/0|8832/0|8832/3|8833/3|8834/1|8835/1|8836/1|8840/0|8840/3|8841/1|8842/0|8842/3|8850/0|8850/1|8850/3|8851/0|8851/3|8852/0|8852/3|8853/3|8854/0|8854/3|8855/3|8856/0|8857/0|8857/3|8858/3|8860/0|8861/0|8862/0|8870/0|8880/0|8881/0|8890/0|8890/1|8890/3|8891/0|8891/3|8892/0|8893/0|8894/0|8894/3|8895/0|8895/3|8896/3|8897/1|8898/1|8900/0|8900/3|8901/3|8902/3|8903/0|8904/0|8905/0|8910/3|8912/3|8920/3|8920/6|8921/3|8930/0|8930/3|8931/3|8932/0|8933/3|8934/3|8935/0|8935/1|8935/3|8936/0|8936/1|8936/3|8940/0|8940/3|8941/3|8950/3|8950/6|8951/3|8959/0|8959/1|8959/3|8960/1|8960/3|8963/3|8964/3|8965/0|8966/0|8967/0|8970/3|8971/3|8972/3|8973/3|8974/1|8975/1|8980/3|8981/3|8982/0|8982/3|8983/0|8983/3|8990/0|8990/1|8990/3|8991/3|8th|9|9-Ethyl 6-Mercaptopurine|90|9000/0|9000/1|9000/3|9010/0|9011/0|9012/0|9013/0|9014/0|9014/1|9014/3|9015/0|9015/1|9015/3|9016/0|9020/0|9020/1|9020/3|9030/0|9040/0|9040/3|9041/3|9042/3|9043/3|9044/3|9045/3|9050/0|9050/3|9051/0|9051/3|9052/0|9052/3|9053/3|9054/0|9055/0|9055/1|9060/3|9061/3|9062/3|9063/3|9064/2|9064/3|9065/3|9070/3|9071/3|9072/3|9073/1|9080/0|9080/1|9080/3|9081/3|9082/3|9083/3|9084/0|9084/3|9085/3|9086/3|9090/0|9090/3|9091/1|9100/0|9100/1|9100/3|9101/3|9102/3|9103/0|9104/1|9105/3|9110/0|9110/1|9110/3|9120/0|9120/3|9121/0|9122/0|9123/0|9124/3|9125/0|9130/0|9130/1|9130/3|9131/0|9132/0|9133/1|9133/3|9135/1|9136/1|9137/3|9140/3|9141/0|9142/0|9150/0|9150/1|9150/3|9160/0|9161/0|9161/1|9170/0|9170/3|9171/0|9172/0|9173/0|9174/0|9174/1|9175/0|9180/0|9180/3|9180/6|9181/3|9182/3|9183/3|9184/3|9185/3|9186/3|9187/3|9191/0|9192/3|9193/3|9194/3|9195/3|9200/0|9200/1|9210/0|9210/1|9220/0|9220/1|9220/3|9221/0|9221/3|9230/0|9230/3|9231/3|9240/3|9241/0|9242/3|9243/3|9250/1|9250/3|9251/1|9251/3|9252/0|9252/3|9260/3|9261/3|9262/0|9270/0|9270/1|9270/3|9271/0|9272/0|9273/0|9274/0|9275/0|9280/0|9281/0|9282/0|9290/0|9290/3|9300/0|9301/0|9302/0|9302/3|9310/0|9310/3|9311/0|9312/0|9320/0|9321/0|9322/0|9330/0|9330/3|9340/0|9341/1|9341/3|9342/3|9350/1|9351/1|9352/1|9360/1|9361/1|9362/3|9363/0|9364/3|9365/3|9370/3|9371/3|9372/3|9373/0|9380/3|9381/3|9382/3|9383/1|9384/1|9385/3|9390/0|9390/1|9390/3|9391/3|9392/3|9393/3|9394/1|9395/3|9396/3|9400/3|9401/3|9410/3|9411/3|9412/1|9413/0|9420/3|9421/1|9423/3|9424/3|9425/3|9430/3|9431/1|9432/1|9440/3|9440/6|9441/3|9442/1|9442/3|9444/1|9445/3|9450/3|9451/3|9460/3|9470/3|9471/3|9472/3|9473/3|9474/3|9475/3|9476/3|9477/3|9478/3|9480/3|9490/0|9490/3|9491/0|9492/0|9493/0|9500/3|9501/0|9501/3|9502/0|9502/3|9503/3|9504/3|9505/1|9505/3|9506/1|9507/0|9508/3|9509/1|9510/0|9510/3|9511/3|9512/3|9513/3|9514/1|9520/3|9521/3|9522/3|9523/3|9530/0|9530/1|9530/3|9531/0|9532/0|9533/0|9534/0|9535/0|9537/0|9538/1|9538/3|9539/1|9539/3|9540/0|9540/1|9540/3|9541/0|9542/3|9550/0|9560/0|9560/1|9560/3|9561/3|9562/0|9570/0|9571/0|9571/3|9580/0|9580/3|9581/3|9582/0|9590/3|9591/3|9596/3|9597/3|9650/3|9651/3|9652/3|9653/3|9654/3|9655/3|9659/3|9661/3|9662/3|9663/3|9664/3|9665/3|9667/3|9670/3|9671/3|9673/3|9675/3|9678/3|9679/3|9680/3|9684/3|9687/3|9688/3|9689/3|9690/3|9691/3|9695/3|9698/3|9699/3|9700/3|9701/3|9702/3|9705/3|9708/3|9709/3|9712/3|9714/3|9716/3|9717/3|9718/3|9719/3|9724/3|9725/3|9726/3|9727/3|9728/3|9729/3|9731/3|9732/3|9733/3|9734/3|9735/3|9737/3|9738/3|9740/1|9740/3|9741/1|9741/3|9742/3|9750/3|9751/1|9751/3|9752/1|9753/1|9754/3|9755/3|9756/3|9757/3|9758/3|9759/3|9760/3|9761/3|9762/3|9764/3|9765/1|9766/1|9767/1|9768/1|9769/1|9800/3|9801/3|9805/3|9806/3|9807/3|9808/3|9809/3|9811/3|9812/3|9813/3|9814/3|9815/3|9816/3|9817/3|9818/3|9820/3|9823/3|9826/3|9827/3|9831/3|9832/3|9833/3|9834/3|9835/3|9836/3|9837/3|9840/3|9860/3|9861/3|9863/3|9865/3|9866/3|9867/3|9869/3|9870/3|9871/3|9872/3|9873/3|9874/3|9875/3|9876/3|9891/3|9895/3|9896/3|9897/3|9898/1|9898/3|99|9910/3|9911/3|9920/3|9930/3|9931/3|9940/3|9945/3|9946/3|9948/3|9950/3|9960/3|9961/3|9962/3|9963/3|9964/3|9965/3|9966/3|9967/3|9970/1|9971/1|9971/3|9975/3|9980/3|9982/3|9983/3|9984/3|9985/3|9986/3|9987/3|9989/3|9991/3|9992/3|99mTc Bone Scintigraphy|9H-Purine-6Thio-98D|A|A081105|A081801|A2A Receptor Antagonist EOS100850|A5|A6|ACQUITY UPLC|ACQUITY UPLC H-Class|ACQUITY UPLC H-Class Bio|ACQUITY UPLC I-Class|ACQUITY UPLC Systems with 2D Technology|ACTH-producing tumor|ADF|ADH-1|AE37 Peptide/GM-CSF Vaccine|AEE788|AIN III|AJ-Adjuvant Therapy|AJCC v6 Stage|AJCC v7 Stage|AJCC v8 Stage|AKR1C3-activated Prodrug OBI-3424|AKT 1/2 Inhibitor BAY1125976|AKT Inhibitor ARQ 092|ALK Inhibitor|ALK Inhibitor ASP3026|ALK Inhibitor PLB 1003|ALK Inhibitor RO5424802|ALK Inhibitor TAE684|ALK Inhibitor WX-0593|ALK positive large B-cell lymphoma|ALK-2 Inhibitor TP-0184|ALK-FAK Inhibitor CEP-37440|ALK-Positive Large B-Cell Lymphoma|ALK/FAK/Pyk2 Inhibitor CT-707|ALK/ROS1/Met Inhibitor TQ-B3101|ALK/TRK Inhibitor TSR-011|ALK/c-Met Inhibitor  TQ-B3139|AML M6|APC8015F|APE1/Ref-1 Redox Inhibitor APX3330|API 100|API 100LC|API 150EX|API 150EX Prep|API 165|API 2000|API 300|API 3000|API 3200|API 350|API 365|API 4000|API 5000|API-US|AQUA|AR Antagonist BMS-641988|ARC Fusion Protein SL-279252|ASCAT2|ASP4132|ATAC-Seq|ATM Inhibitor M 3541|ATM Kinase Inhibitor AZD0156|ATM Kinase Inhibitor AZD1390|ATR Inhibitor RP-3500|ATR Kinase Inhibitor BAY1895344|ATR Kinase Inhibitor M1774|ATR Kinase Inhibitor M6620|ATR Kinase Inhibitor VX-803|AXIMA Assurance Linear MALDI-TOF|AXIMA CFR MALDI-TOF|AXIMA Confidence MALDI-TOF|AXIMA Performance MALDI-TOF/TOF|AXIMA-CFR plus|AXIMA-QIT|AXL Inhibitor DS-1205c|AXL Inhibitor SLC-391|AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M|AXL/ FLT3/VEGFR2 Inhibitor KC1036|Abagovomab|Abarelix|Abdomen|Abdomen, NOS|Abdomen, total|Abdominal (Mesenteric) Fibromatosis|Abdominal Distension|Abdominal Infection|Abdominal Pain|Abdominal Soft Tissue Necrosis|Abdominal Wall|Abdominal desmoid|Abdominal esophagus|Abdominal fibromatosis|Abdomino-perineal Resection of Rectum|Abducens Nerve Disorder|Abemaciclib|Abemaciclib Mesylate|Abexinostat|Abexinostat Tosylate|Abiraterone|Abiraterone Acetate|Abituzumab|Ablation, Cryo|Ablation, Ethanol Injection|Ablation, Microwave|Ablation, NOS|Ablation, Radiofrequency|Ablation, Radiosurgical|Abnormal|Abnormal Glucose Level|Absent|Absolute quantitation analysis|Acai Berry Juice|Acalabrutinib|Acalisib|Accela PDA|Acceptable treatment for TCGA tumor|Accessory Nerve Disorder|Accessory sinus, NOS|Accessory sinuses|Accidental building fire smoke|Accidental fire smoke, NOS|Accidental fire smoke, grass|Accidental forest fire smoke|Accidental vehicle fire smoke|Aceglatone|Acetabulum|Acetate|Acetylcysteine|Acetylome|Achromic nevus|Acidophil adenocarcinoma|Acidophil adenoma|Acidophil carcinoma|Acidosis|Acinar Cell Adenoma|Acinar Cell Carcinoma|Acinar Cell Neoplasm|Acinar Cell Neoplasms|Acinar adenocarcinoma|Acinar adenocarcinoma, sarcomatoid|Acinar adenoma|Acinar carcinoma|Acinar cell adenoma|Acinar cell carcinoma|Acinar cell cystadenocarcinoma|Acinar cell tumor|Acinic cell adenocarcinoma|Acinic cell adenoma|Acinic cell tumor|Acitretin|Acivicin|Aclacinomycin B|Aclarubicin|Acodazole|Acodazole Hydrochloride|Acolbifene Hydrochloride|Acoustic Nerve Disorder NOS|Acoustic Schwannoma|Acoustic nerve|Acoustic neuroma|Acquired Cystic Disease-Associated Renal Cell Carcinoma|Acquired Progressive Lymphangioma|Acquired cystic disease-associated renal cell carcinoma (RCC)|Acquired tufted hemangioma|Acquity SQD|Acquity TQD|Acquity UPLC FLR|Acquity UPLC PDA|Acral Lentiginous Melanoma|Acral lentiginous melanoma, malignant|Acridine|Acridine Carboxamide|Acronine|Actinium Ac 225 Lintuzumab|Actinium Ac 225-FPI-1434|Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591|Actinomycin C2|Actinomycin C3|Actinomycin F1|Activated Partial Thromboplastin Time Prolonged|Activin Type 2B Receptor Fc Fusion Protein STM 434|Acute Basophilic Leukemia|Acute Bilineal Leukemia|Acute Biphenotypic Leukemia|Acute Coronary Syndrome|Acute Erythroid Leukemia|Acute Kidney Injury|Acute Leukemia|Acute Leukemia of Ambiguous Lineage (ALAL)|Acute Lymphoblastic Leukemia|Acute Megakaryoblastic Leukemia|Acute Monoblastic Leukemia|Acute Monoblastic and Monocytic Leukemia|Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1|Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia Not Otherwise Specified|Acute Myeloid Leukemia with Maturation|Acute Myeloid Leukemia with Minimal Differentiation|Acute Myeloid Leukemia with Multilineage Dysplasia|Acute Myeloid Leukemia with Mutated CEBPA|Acute Myeloid Leukemia with Mutated NPM1|Acute Myeloid Leukemia with Myelodysplasia-Related Changes|Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11|Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11|Acute Myeloid Leukemia with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM|Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11|Acute Myeloid Leukemia with t(6;9) (p23;q34.1); DEK-NUP214|Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A|Acute Myeloid Leukemia without Maturation|Acute Myelomonocytic Leukemia|Acute Myelomonocytic Leukemia with Abnormal Eosinophils|Acute Panmyelosis with Myelofibrosis|Acute Promyelocytic Leukemia with PML-RARA|Acute Renal Failure|Acute Undifferentiated Leukemia|Acute basophilic leukaemia|Acute bilineal leukemia|Acute biphenotypic leukemia|Acute erythremia|Acute erythremic myelosis|Acute erythroid leukaemia|Acute granulocytic leukemia|Acute leukemia, Burkitt type|Acute leukemia, NOS|Acute lymphatic leukemia|Acute lymphoblastic leukemia (ALL)|Acute lymphoblastic leukemia, L2 type, NOS|Acute lymphoblastic leukemia, NOS|Acute lymphoblastic leukemia, mature B-cell type|Acute lymphoblastic leukemia, precursor cell type|Acute lymphoblastic leukemia-lymphoma, NOS|Acute lymphocytic leukemia|Acute lymphoid leukemia|Acute megakaryoblastic leukaemia|Acute mixed lineage leukemia|Acute monoblastic and monocytic leukemia|Acute monoblastic leukemia|Acute monocytic leukemia|Acute myeloblastic leukemia|Acute myelocytic leukemia|Acute myelofibrosis|Acute myelogenous leukemia|Acute myeloid leukaemia, t(8;21)(q22;q22)|Acute myeloid leukemia (AML)|Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1|Acute myeloid leukemia with abnormal marrow eosinophils (includes all variants)|Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1|Acute myeloid leukemia with maturation|Acute myeloid leukemia with multilineage dysplasia|Acute myeloid leukemia with mutated CEBPA|Acute myeloid leukemia with mutated NPM1|Acute myeloid leukemia with myelodysplasia-related changes|Acute myeloid leukemia with prior myelodysplastic syndrome|Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214|Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1|Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL|Acute myeloid leukemia without maturation|Acute myeloid leukemia without prior myelodysplastic syndrome|Acute myeloid leukemia, AML1(CBF-alpha)/ETO|Acute myeloid leukemia, CBF-beta/MYH11|Acute myeloid leukemia, M6 type|Acute myeloid leukemia, MLL|Acute myeloid leukemia, NOS|Acute myeloid leukemia, PML/RAR-alpha|Acute myeloid leukemia, inv(16)(p13;q22)|Acute myeloid leukemia, minimal differentiation|Acute myeloid leukemia, t(15:17)(g22;q11-12)|Acute myeloid leukemia, t(16;16)(p 13;q 11)|Acute myelomonocytic leukemia|Acute myelomonocytic leukemia with abnormal eosinophils|Acute myelosclerosis, NOS|Acute myloid leukemia, 11q23 abnormalities|Acute non-lymphocytic leukemia|Acute panmyelosis with myelofibrosis|Acute panmyelosis, NOS|Acute progressive histiocytosis X|Acute promyelocytic leukaemia, PML-RAR-alpha|Acute promyelocytic leukaemia, t(15;17)(q22;q11-12)|Acute promyelocytic leukemia, NOS|Acyclic Nucleoside Phosphonate Prodrug ABI-1968|Ad-RTS-hIL-12|Adagloxad Simolenin|Adamantinoma|Adamantinoma of long bones|Adamantinoma, NOS|Adamantinoma, malignant|Adamantinomatous Craniopharyngioma|Adavosertib|Additional - New Primary|Additional Metastatic|Adecatumumab|Adenoacanthoma|Adenoameloblastoma|Adenocarcinoid tumor|Adenocarcinoma|Adenocarcinoma In Situ|Adenocarcinoma In Situ in Adenomatous Polyp|Adenocarcinoma In Situ in Tubular Adenoma|Adenocarcinoma In Situ in Tubulovillous Adenoma|Adenocarcinoma In Situ in Villous Adenoma|Adenocarcinoma In Situ in a Polyp|Adenocarcinoma admixed with neuroendocrine carcinoma|Adenocarcinoma combined with other types of carcinoma|Adenocarcinoma in Adenomatous Polyp|Adenocarcinoma in Adenomatous Polyposis Coli|Adenocarcinoma in Multiple Adenomatous Polyps|Adenocarcinoma in Tubular Adenoma|Adenocarcinoma in Tubulovillous Adenoma|Adenocarcinoma in Villous Adenoma|Adenocarcinoma in a polyp, NOS|Adenocarcinoma in adenomatous polyp|Adenocarcinoma in adenomatous polyposis coli|Adenocarcinoma in multiple adenomatous polyps|Adenocarcinoma in polypoid adenoma|Adenocarcinoma in situ in a polyp, NOS|Adenocarcinoma in situ in adenomatous polyp|Adenocarcinoma in situ in polypoid adenoma|Adenocarcinoma in situ in tubular adenoma|Adenocarcinoma in situ in tubulovillous adenoma|Adenocarcinoma in situ in villous adenoma|Adenocarcinoma in situ, NOS|Adenocarcinoma in situ, mucinous|Adenocarcinoma in situ, non-mucinous|Adenocarcinoma in tubolovillous adenoma|Adenocarcinoma in tubular adenoma|Adenocarcinoma in villous adenoma|Adenocarcinoma of anal ducts|Adenocarcinoma of anal glands|Adenocarcinoma of rete ovarii|Adenocarcinoma with Apocrine Metaplasia|Adenocarcinoma with Cartilaginous Metaplasia|Adenocarcinoma with Cartilaginous and Osseous Metaplasia|Adenocarcinoma with Neuroendocrine Differentiation|Adenocarcinoma with Osseous Metaplasia|Adenocarcinoma with Spindle Cell Metaplasia|Adenocarcinoma with Squamous Metaplasia|Adenocarcinoma with apocrine metaplasia|Adenocarcinoma with cartilaginous and osseous metaplasia|Adenocarcinoma with cartilaginous metaplasia|Adenocarcinoma with mixed subtypes|Adenocarcinoma with neuroendocrine differentiation|Adenocarcinoma with osseous metaplasia|Adenocarcinoma with spindle cell metaplasia|Adenocarcinoma with squamous metaplasia|Adenocarcinoma, Endocervical Type|Adenocarcinoma, NOS|Adenocarcinoma, cribriform comedo-type|Adenocarcinoma, cylindroid|Adenocarcinoma, diffuse type|Adenocarcinoma, endocervical type|Adenocarcinoma, intestinal type|Adenocarcinoma, metastatic, NOS|Adenocarcinoma, pancreatobiliary type|Adenocystic carcinoma|Adenofibroma, NOS|Adenoid|Adenoid Cystic Carcinoma|Adenoid basal carcinoma|Adenoid cystic carcinoma|Adenolipoma|Adenolymphoma|Adenoma|Adenoma of nipple|Adenoma, NOS|Adenomas and Adenocarcinomas|Adenomatoid Odontogenic Tumor|Adenomatoid Tumor|Adenomatoid odontogenic tumor|Adenomatoid tumor, NOS|Adenomatosis, NOS|Adenomatous Polyp|Adenomatous Polyposis Coli|Adenomatous polyp, NOS|Adenomatous polyposis coli|Adenomyoepithelioma|Adenomyoepithelioma with carcinoma|Adenomyoma|Adenosarcoma|Adenosine A2A Receptor Antagonist AZD4635|Adenosine A2A Receptor Antagonist CS3005|Adenosine A2A Receptor Antagonist NIR178|Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999|Adenosine A2A/A2B Receptor Antagonist AB928|Adenosine A2B Receptor Antagonist PBF-1129|Adenosis (Atypical Adenomatous Hyperplasia)|Adenosquamous Carcinoma|Adenosquamous carcinoma|Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201|Adenoviral Brachyury Vaccine ETBX-051|Adenoviral Cancer Vaccine PF-06936308|Adenoviral MUC1 Vaccine ETBX-061|Adenoviral PSA Vaccine ETBX-071|Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001|Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP|Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901|Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE|Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918|Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931|Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3|Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001|Aderbasib|Adherent Cell Line|Adipose|Adjacent (< or = 2cm)|Adjuvant|Administrative Compliance|Adnexal Carcinoma|Adnexal and Skin Appendage Neoplasms|Adnexal carcinoma|Adnexal tumor, benign|Adopted Brother|Adopted Daughter|Adopted Sister|Adopted Son|Adoptive Brother|Adoptive Father|Adoptive Mother|Adoptive Sister|Adrenal|Adrenal Cortex Adenoma|Adrenal Cortex Carcinoma|Adrenal Cortex Clear Cell Adenoma|Adrenal Cortex Compact Cell Adenoma|Adrenal Cortex Glomerulosa Cell Adenoma|Adrenal Cortex Mixed Cell Adenoma|Adrenal Cortex Neoplasm|Adrenal Gland|Adrenal Gland Cancer|Adrenal Gland Myelolipoma|Adrenal Gland Pheochromocytoma|Adrenal Insufficiency|Adrenal Rest Tumor|Adrenal cortical adenocarcinoma|Adrenal cortical adenoma, NOS|Adrenal cortical adenoma, clear cell|Adrenal cortical adenoma, compact cell|Adrenal cortical adenoma, glomerulosa cell|Adrenal cortical adenoma, mixed cell|Adrenal cortical adenoma, pigmented|Adrenal cortical carcinoma|Adrenal cortical tumor, NOS|Adrenal cortical tumor, benign|Adrenal cortical tumor, malignant|Adrenal gland|Adrenal gland, NOS|Adrenal medullary paraganglioma|Adrenal medullary paraganglioma, malignant|Adrenal rest tumor|Adrenocortical Carcinoma|Adrenocortical Insufficiency|Adult Cystic Nephroma|Adult Cystic Teratoma|Adult Pleomorphic Rhabdomyosarcoma|Adult Respiratory Distress Syndrome|Adult T-Cell Leukemia/Lymphoma|Adult T-cell leukemia|Adult T-cell leukemia/lymphoma (HTLV-1 positive) (includes all variants)|Adult T-cell lymphoma|Adult T-cell lymphoma/leukemia|Adult Teratoma|Adult Type Granulosa Cell Tumor|Adult cystic teratoma|Adult granulosa cell tumor|Adult rhabdomyoma|Adult teratoma, NOS|Adverse|Adverse Event|Aerosol Gemcitabine|Aerosolized Aldesleukin|Aerosolized Liposomal Rubitecan|Afatinib|Afatinib Dimaleate|Affymetrix SNP 6.0|Afghanistan|Afimoxifene|After 60 Minutes|Afuresertib|Agatolimod Sodium|Agerafenib|Aggregated Somatic Mutation|Aggressive NK-Cell Leukemia|Aggressive NK-cell leukaemia|Aggressive Osteoblastoma|Aggressive Systemic Mastocytosis|Aggressive angiomyxoma|Aggressive digital papillary adenoma|Aggressive fibromatosis|Aggressive osteoblastoma|Aggressive systemic mastocytosis|Agilent|Agitation|Aglatimagene Besadenovec|Agnogenic myeloid metaplasia|Agonistic Anti-CD40 Monoclonal Antibody ADC-1013|Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949|Agonistic Anti-OX40 Monoclonal Antibody MEDI6469|Aircraft smoke|Akathisia|Akt Inhibitor LY2780301|Akt Inhibitor MK2206|Akt Inhibitor SR13668|Akt/ERK Inhibitor ONC201|Alacizumab Pegol|Alanine Aminotransferase Increased|Alanosine|Albania|Albumin-binding Cisplatin Prodrug BTP-114|Alcohol Consumption|Alcohol Intolerance|Alcoholic Liver Disease|Aldesleukin|Aldoxorubicin|Alectinib|Alefacept|Alemtuzumab|Alestramustine|Aleukemic Chronic Lymphocytic Leukemia|Aleukemic Leukemia|Aleukemic Lymphoid Leukemia|Aleukemic granulocytic leukemia|Aleukemic leukemia, NOS|Aleukemic lymphatic leukemia|Aleukemic lymphocytic leukemia|Aleukemic lymphoid leukemia|Aleukemic monocytic leukemia|Aleukemic myelogenous leukemia|Aleukemic myeloid leukemia|Alflutinib Mesylate|Algenpantucel-L|Algeria|Aligned Reads|Aligned Reads Index|Aliquot Ensemble Somatic Variant Merging and Masking|Alisertib|Alitretinoin|Alive|Alkaline Phosphatase Increased|Alkalosis|Alkotinib|Alkylating Agent-Related Acute Myeloid Leukemia|Alkylating Agent-Related Myelodysplastic Syndrome|Allele-specific Copy Number Segment|Allergic Reaction|Allergic Rhinitis|Allergies|Allergy, Animal, NOS|Allergy, Ant|Allergy, Bee|Allergy, Cat|Allergy, Dairy or Lactose|Allergy, Dog|Allergy, Eggs|Allergy, Food, NOS|Allergy, Fruit|Allergy, Meat|Allergy, Mold or Dust|Allergy, Nuts|Allergy, Processed Foods|Allergy, Seafood|Allergy, Wasp|Allodepleted T Cell Immunotherapeutic ATIR101|Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715|Allogeneic Anti-BCMA-CAR T-cells PBCAR269A|Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells|Allogeneic Anti-CD19 CAR T-cells ALLO-501A|Allogeneic Anti-CD19 Universal CAR-T Cells CTA101|Allogeneic Anti-CD19-CAR T-cells PBCAR0191|Allogeneic Anti-CD20 CAR T-cells LUCAR-20S|Allogeneic Anti-CD20-CAR T-cells PBCAR20A|Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22|Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100|Allogeneic CD56-positive CD3-negative Natural Killer Cells CYNK-001|Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001|Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120|Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130|Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A|Allogeneic Cellular Vaccine 1650-G|Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM|Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine|Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine|Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo|Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo|Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2|Allogeneic Irradiated Melanoma Cell Vaccine CSF470|Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307|Allogeneic Melanoma Vaccine AGI-101H|Allogeneic Natural Killer Cell Line MG4101|Allogeneic Natural Killer Cell Line NK-92|Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01|Allogeneic Renal Cell Carcinoma Vaccine MGN1601|Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19|Allosteric ErbB Inhibitor BDTX-189|Allovectin-7|Allprep FFPE DNA|Allprep RNA Extraction|Almurtide|Alobresib|Alofanib|Alopecia|Alpelisib|Alpha Galactosylceramide|Alpha Heavy Chain Disease|Alpha V Beta 1 Inhibitor ATN-161|Alpha V Beta 8 Antagonist PF-06940434|Alpha cell tumor, NOS|Alpha cell tumor, malignant|Alpha heavy chain disease|Alpha-1 Antitrypsin|Alpha-1 Antitrypsin Deficiency|Alpha-Gal AGI-134|Alpha-Glucosidase Inhibitor|Alpha-Thioguanine Deoxyriboside|Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H|Alpha-tocopheryloxyacetic Acid|Alsevalimab|Altered Mental Status|Alternate sample pipeline|Altiratinib|Altretamine|Alveolar Adenoma|Alveolar Rhabdomyosarcoma|Alveolar Ridge|Alveolar Soft Part Sarcoma|Alveolar adenocarcinoma|Alveolar adenoma|Alveolar carcinoma|Alveolar cell carcinoma|Alveolar rhabdomyosarcoma|Alveolar soft part sarcoma|Alvespimycin|Alvespimycin Hydrochloride|Alvocidib|Alvocidib Hydrochloride|Alvocidib Prodrug TP-1287|Amatuximab|Ambamustine|Ambazone|Amber|Amblyomin-X|Amcasertib|Amelanotic Melanoma|Amelanotic melanoma|Ameloblastic Carcinoma|Ameloblastic Fibro-Odontoma|Ameloblastic Fibrodentinoma|Ameloblastic Fibroma|Ameloblastic Fibrosarcoma|Ameloblastic carcinoma|Ameloblastic fibro-odontoma|Ameloblastic fibro-odontosarcoma|Ameloblastic fibrodentinoma|Ameloblastic fibrodentinosarcoma|Ameloblastic fibroma|Ameloblastic fibrosarcoma|Ameloblastic odontosarcoma|Ameloblastic sarcoma|Ameloblastoma|Ameloblastoma, NOS|Ameloblastoma, malignant|American Indian or Alaska Native|Ametantrone|Amifostine|Amino Acid Injection|Aminocamptothecin|Aminocamptothecin Colloidal Dispersion|Aminoflavone Prodrug AFP464|Aminopterin|Aminopterin Sodium|AminoxyTMT|Amivantamab|Amnesia|Amniotic Fluid|Amolimogene Bepiplasmid|Amonafide L-Malate|Ampulla Of Vater|Ampulla of Vater|Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with High Grade Dysplasia|Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with Low Grade Dysplasia|Amrubicin|Amrubicin Hydrochloride|Amsacrine|Amsacrine Lactate|Amsilarotene|Amustaline|Amustaline Dihydrochloride|Amuvatinib|Amuvatinib Hydrochloride|Anakinra|Anal Canal|Anal Canal Cloacogenic Carcinoma|Anal Cancer (all types)|Anal Fistula|Anal Glands Adenocarcinoma|Anal Hemorrhage|Anal Intraepithelial Neoplasia 3|Anal Mucositis|Anal Necrosis|Anal Pain|Anal Sphincter|Anal Stenosis|Anal Ulcer|Anal canal|Anal intraepithelial neoplasia, grade III|Anal intraepithelial neoplasia, low grade|Analysis Metadata|Anaphylaxis|Anaplastic (Malignant) Meningioma|Anaplastic Astrocytoma|Anaplastic Astrocytoma, IDH-Mutant|Anaplastic Astrocytoma, IDH-Wildtype|Anaplastic Ependymoma|Anaplastic Ganglioglioma|Anaplastic Large Cell Lymphoma|Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Anaplastic Lymphoma|Anaplastic Medulloblastoma|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted|Anaplastic Pleomorphic Xanthoastrocytoma|Anaplastic astrocytoma, IDH-mutant|Anaplastic astrocytoma, IDH-wildtype|Anaplastic large B-cell lymphoma|Anaplastic large cell lymphoma, ALK negative|Anaplastic large cell lymphoma, ALK positive|Anaplastic large cell lymphoma, CD30+|Anaplastic large cell lymphoma, NOS|Anaplastic large cell lymphoma, T cell and Null cell type|Anaplastic medulloblastoma|Anaplastic oligoastrocytoma|Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted|Anaplastic pleomorphic xanthroastrocytoma|Anastrozole|Anaxirone|Ancient schwannoma|Ancillary Treatment|Ancitabine|Ancitabine Hydrochloride|Andecaliximab|Andorra|Androblastoma, NOS|Androblastoma, benign|Androblastoma, malignant|Androgen Antagonist APC-100|Androgen Deprivation Therapy (ADT)|Androgen Receptor Antagonist BAY 1161116|Androgen Receptor Antagonist SHR3680|Androgen Receptor Antagonist TAS3681|Androgen Receptor Antagonist TRC253|Androgen Receptor Antisense Oligonucleotide AZD5312|Androgen Receptor Antisense Oligonucleotide EZN-4176|Androgen Receptor Degrader ARV-110|Androgen Receptor Degrader CC-94676|Androgen Receptor Downregulator AZD3514|Androgen Receptor Inhibitor EPI-7386|Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118|Androgen Receptor/Glucocorticoid Receptor  Antagonist CB-03-10|Andrographolide|Androstane Steroid HE3235|Anemia|Anetumab Ravtansine|Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241|Angioblastic meningioma|Angioblastoma|Angiocentric Glioma|Angiocentric Immunoproliferative Lesion|Angiocentric T-cell lymphoma|Angiocentric glioma|Angiocentric immunoproliferative lesion|Angioendothelioma|Angioendotheliomatosis|Angiofibroma|Angiofibroma, NOS|Angiogenesis Inhibitor GT-111|Angiogenesis Inhibitor JI-101|Angiogenesis/Heparanase Inhibitor PG545|Angioimmunoblastic T-Cell Lymphoma|Angioimmunoblastic T-cell lymphoma|Angioimmunoblastic lymphadenopathy|Angioimmunoblastic lymphoma|Angiokeratoma|Angioleiomyoma|Angiolipoma|Angiolipoma, NOS|Angioma, NOS|Angiomatoid Fibrous Histiocytoma|Angiomatoid fibrous histiocytoma|Angiomatous Meningioma|Angiomatous meningioma|Angiomyofibroblastoma|Angiomyolipoma|Angiomyoma|Angiomyosarcoma|Angiomyxoma|Angiopoietin-2-specific Fusion Protein PF-04856884|Angiosarcoma|Angiotropic lymphoma|Angola|Anguilla|Anhydrous Enol-oxaloacetate|Anhydrovinblastine|Aniline Mustard|Ankle|Ankle Fracture|Anlotinib Hydrochloride|Annamycin|Annamycin Liposomal|Annonaceous Acetogenins|Annotated Somatic Mutation|Anopheles gambiae|Anorectal Infection|Anorectum|Anorexia|Anorgasmia|Ansamitomicin P-3|Antacids|Antecubital Fossa|Anterior 2/3 of tongue, NOS|Anterior Resection of Rectum|Anterior Surface of the Epiglottis|Anterior Wall of the Nasopharynx|Anterior floor of mouth|Anterior mediastinum|Anterior surface of epiglottis|Anterior wall of bladder|Anterior wall of nasopharynx|Anthramycin|Anthrapyrazole|Anti c-KIT Antibody-drug Conjugate LOP628|Anti-5T4 Antibody-Drug Conjugate PF-06263507|Anti-5T4 Antibody-drug Conjugate ASN004|Anti-5T4 Antibody-drug Conjugate SYD1875|Anti-A33 Monoclonal Antibody KRN330|Anti-A5B1 Integrin Monoclonal Antibody PF-04605412|Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087|Anti-AG7 Antibody Drug Conjugate AbGn-107|Anti-AGS-16 Monoclonal Antibody AGS-16M18|Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME|Anti-AGS-8 Monoclonal Antibody AGS-8M4|Anti-ANG2 Monoclonal Antibody MEDI-3617|Anti-APRIL Monoclonal Antibody BION-1301|Anti-AXL Fusion Protein AVB-S6-500|Anti-AXL/PBD Antibody-drug Conjugate ADCT-601|Anti-B7-H3 Antibody DS-5573a|Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a|Anti-B7-H4 Monoclonal Antibody FPA150|Anti-B7H3 Antibody-drug Conjugate MGC018|Anti-BCMA Antibody SEA-BCMA|Anti-BCMA Antibody-drug Conjugate AMG 224|Anti-BCMA Antibody-drug Conjugate CC-99712|Anti-BCMA Antibody-drug Conjugate GSK2857916|Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA|Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459|Anti-BCMA/CD3 BiTE Antibody AMG 420|Anti-BCMA/CD3 BiTE Antibody AMG 701|Anti-BCMA/CD3 BiTE Antibody REGN5458|Anti-BCMA/PBD ADC MEDI2228|Anti-BTLA Monoclonal Antibody TAB004|Anti-BTN3A Agonistic Monoclonal Antibody ICT01|Anti-C-met Monoclonal Antibody SAIT301|Anti-C4.4a Antibody-Drug Conjugate BAY1129980|Anti-C5aR Monoclonal Antibody IPH5401|Anti-CA19-9 Monoclonal Antibody 5B1|Anti-CA6-DM4 Immunoconjugate SAR566658|Anti-CCR7 Antibody-drug Conjugate JBH492|Anti-CD117 Monoclonal Antibody JSP191|Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1|Anti-CD123 ADC IMGN632|Anti-CD123 Monoclonal Antibody CSL360|Anti-CD123 Monoclonal Antibody KHK2823|Anti-CD123 x Anti-CD3 Bispecific Antibody XmAb1404|Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A|Anti-CD123/CD3 BiTE Antibody SAR440234|Anti-CD123/CD3 Bispecific Antibody APVO436|Anti-CD123/CD3 Bispecific Antibody JNJ-63709178|Anti-CD137 Agonistic Monoclonal Antibody ADG106|Anti-CD137 Agonistic Monoclonal Antibody AGEN2373|Anti-CD137 Agonistic Monoclonal Antibody ATOR-1017|Anti-CD137 Agonistic Monoclonal Antibody CTX-471|Anti-CD137 Agonistic Monoclonal Antibody LVGN6051|Anti-CD157 Monoclonal Antibody MEN1112|Anti-CD166 Probody-drug Conjugate CX-2009|Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003|Anti-CD19 Antibody-drug Conjugate SGN-CD19B|Anti-CD19 Monoclonal Antibody DI-B4|Anti-CD19 Monoclonal Antibody MDX-1342|Anti-CD19 Monoclonal Antibody MEDI-551|Anti-CD19 Monoclonal Antibody XmAb5574|Anti-CD19 iCAR NK Cells|Anti-CD19-DM4 Immunoconjugate SAR3419|Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL|Anti-CD19/CD22 CAR NK Cells|Anti-CD19/CD3 BiTE Antibody AMG 562|Anti-CD19/CD3 Tetravalent Antibody AFM11|Anti-CD20 Monoclonal Antibody B001|Anti-CD20 Monoclonal Antibody BAT4306F|Anti-CD20 Monoclonal Antibody MIL62|Anti-CD20 Monoclonal Antibody PRO131921|Anti-CD20 Monoclonal Antibody SCT400|Anti-CD20 Monoclonal Antibody TL011|Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002|Anti-CD20-engineered Toxin Body MT-3724|Anti-CD20/Anti-CD3 Bispecific IgM Antibody IGM2323|Anti-CD20/CD3 Monoclonal Antibody REGN1979|Anti-CD20/CD3 Monoclonal Antibody XmAb13676|Anti-CD205 Antibody-drug Conjugate OBT076|Anti-CD22 ADC TRPH-222|Anti-CD22 Monoclonal Antibody-MMAE Conjugate DCDT2980S|Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A|Anti-CD25 Monoclonal Antibody RO7296682|Anti-CD25-PBD Antibody-drug Conjugate ADCT-301|Anti-CD26 Monoclonal Antibody YS110|Anti-CD27 Agonistic Monoclonal Antibody MK-5890|Anti-CD27L Antibody-Drug Conjugate AMG 172|Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1)|Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044|Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody JNJ-64007957|Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody PF-06863135|Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05|Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564|Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119|Anti-CD3/CD20 Bispecific Antibody GEN3013|Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424|Anti-CD3/CD7-Ricin Toxin A Immunotoxin|Anti-CD30 Monoclonal Antibody MDX-1401|Anti-CD30 Monoclonal Antibody XmAb2513|Anti-CD30/CD16A Monoclonal Antibody AFM13|Anti-CD30/DM1 Antibody-drug Conjugate F0002|Anti-CD32B Monoclonal Antibody BI-1206|Anti-CD33 Antibody-drug Conjugate IMGN779|Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564|Anti-CD33 Monoclonal Antibody BI 836858|Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633|Anti-CD33/CD3 BiTE Antibody AMG 330|Anti-CD33/CD3 BiTE Antibody AMG 673|Anti-CD33/CD3 Bispecific Antibody GEM 333|Anti-CD33/CD3 Bispecific Antibody JNJ-67571244|Anti-CD352 Antibody-drug Conjugate SGN-CD352A|Anti-CD37 Antibody-Drug Conjugate IMGN529|Anti-CD37 Bispecific Monoclonal Antibody GEN3009|Anti-CD37 MMAE Antibody-drug Conjugate AGS67E|Anti-CD37 Monoclonal Antibody BI 836826|Anti-CD38 Antibody-drug Conjugate STI-6129|Anti-CD38 Monoclonal Antibody MOR03087|Anti-CD38 Monoclonal Antibody SAR442085|Anti-CD38 Monoclonal Antibody TAK-079|Anti-CD38-targeted IgG4-attenuated IFNa TAK-573|Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257|Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342|Anti-CD39 Monoclonal Antibody SRF617|Anti-CD39 Monoclonal Antibody TTX-030|Anti-CD40 Agonist Monoclonal Antibody ABBV-927|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Anti-CD40 Monoclonal Antibody Chi Lob 7/4|Anti-CD40 Monoclonal Antibody SEA-CD40|Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042|Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428|Anti-CD40L Fc-Fusion Protein BMS-986004|Anti-CD44 Monoclonal Antibody RO5429083|Anti-CD45 Monoclonal Antibody AHN-12|Anti-CD46 Antibody-drug Conjugate FOR46|Anti-CD47 ADC SGN-CD47M|Anti-CD47 Monoclonal Antibody AO-176|Anti-CD47 Monoclonal Antibody CC-90002|Anti-CD47 Monoclonal Antibody Hu5F9-G4|Anti-CD47 Monoclonal Antibody IBI188|Anti-CD47 Monoclonal Antibody IMC-002|Anti-CD47 Monoclonal Antibody SHR-1603|Anti-CD47 Monoclonal Antibody SRF231|Anti-CD47 Monoclonal Antibody TJC4|Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801|Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A|Anti-CD52 Monoclonal Antibody ALLO-647|Anti-CD70 Antibody-Drug Conjugate MDX-1203|Anti-CD70 Antibody-drug Conjugate SGN-CD70A|Anti-CD70 CAR-expressing T Lymphocytes|Anti-CD70 Monoclonal Antibody MDX-1411|Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029|Anti-CD73 Monoclonal Antibody BMS-986179|Anti-CD73 Monoclonal Antibody CPI-006|Anti-CD73 Monoclonal Antibody NZV930|Anti-CD73 Monoclonal Antibody TJ4309|Anti-CD74 Antibody-drug Conjugate STRO-001|Anti-CD98 Monoclonal Antibody IGN523|Anti-CDH6 Antibody-drug Conjugate HKT288|Anti-CEA BiTE Monoclonal Antibody AMG211|Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody|Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2|Anti-CEACAM1 Monoclonal Antibody CM-24|Anti-CEACAM5 Antibody-Drug Conjugate SAR408701|Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47|Anti-CEACAM6 Antibody BAY1834942|Anti-CLDN6 Monoclonal Antibody ASP1650|Anti-CLEC12A/CD3 Bispecific Antibody MCLA117|Anti-CLEVER-1 Monoclonal Antibody FP-1305|Anti-CSF1 Monoclonal Antibody PD-0360324|Anti-CSF1R Monoclonal Antibody IMC-CS4|Anti-CSF1R Monoclonal Antibody SNDX-6352|Anti-CTGF Monoclonal Antibody FG-3019|Anti-CTLA-4 Monoclonal Antibody ADG116|Anti-CTLA-4 Monoclonal Antibody ADU-1604|Anti-CTLA-4 Monoclonal Antibody AGEN1181|Anti-CTLA-4 Monoclonal Antibody BCD-145|Anti-CTLA-4 Monoclonal Antibody HBM4003|Anti-CTLA-4 Monoclonal Antibody MK-1308|Anti-CTLA-4 Monoclonal Antibody ONC-392|Anti-CTLA-4 Monoclonal Antibody REGN4659|Anti-CTLA-4 Probody BMS-986288|Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217|Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841|Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015|Anti-CTLA4 Antibody Fc Fusion Protein KN044|Anti-CTLA4 Monoclonal Antibody BMS-986218|Anti-CXCR4 Monoclonal Antibody PF-06747143|Anti-Claudin18.2 Monoclonal Antibody TST001|Anti-DKK-1 Monoclonal Antibody LY2812176|Anti-DKK1 Monoclonal Antibody BHQ880|Anti-DLL3/CD3 BiTE Antibody AMG 757|Anti-DLL4 Monoclonal Antibody MEDI0639|Anti-DLL4/VEGF Bispecific Monoclonal Antibody OMP-305B83|Anti-DR5 Agonist Monoclonal Antibody TRA-8|Anti-DR5 Agonistic Antibody DS-8273a|Anti-DR5 Agonistic Monoclonal Antibody INBRX-109|Anti-Denatured Collagen Monoclonal Antibody TRC093|Anti-EGFR Monoclonal Antibody CPGJ 602|Anti-EGFR Monoclonal Antibody EMD 55900|Anti-EGFR Monoclonal Antibody GC1118|Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX|Anti-EGFR Monoclonal Antibody HLX-07|Anti-EGFR Monoclonal Antibody Mixture MM-151|Anti-EGFR Monoclonal Antibody RO5083945|Anti-EGFR Monoclonal Antibody SCT200|Anti-EGFR Monoclonal Antibody SYN004|Anti-EGFR TAP Antibody-drug Conjugate IMGN289|Anti-EGFR/CD16A Bispecific Antibody AFM24|Anti-EGFR/DM1 Antibody-drug Conjugate AVID100|Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013|Anti-EGFR/PBD Antibody-drug Conjugate ABBV-321|Anti-EGFR/c-Met Bispecific Antibody EMB-01|Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372|Anti-EGFRvIII Antibody Drug Conjugate AMG 595|Anti-EGFRvIII Immunotoxin MR1-1|Anti-EGFRvIII/CD3 BiTE Antibody AMG 596|Anti-EGP-2 Immunotoxin MOC31-PE|Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F|Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F|Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A|Anti-Ep-CAM Monoclonal Antibody ING-1|Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310|Anti-EphA2 Monoclonal Antibody DS-8895a|Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547|Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111|Anti-ErbB3 Antibody ISU104|Anti-ErbB3 Monoclonal Antibody AV-203|Anti-ErbB3 Monoclonal Antibody CDX-3379|Anti-ErbB3 Monoclonal Antibody REGN1400|Anti-ErbB3/Anti-IGF-1R Bispecific Monoclonal Antibody MM-141|Anti-FAP/Interleukin-2 Fusion Protein RO6874281|Anti-FCRH5/CD3 BiTE Antibody BFCR4350A|Anti-FGFR2 Antibody BAY1179470|Anti-FGFR3 Antibody-drug Conjugate LY3076226|Anti-FGFR4 Monoclonal Antibody U3-1784|Anti-FLT3 Antibody-drug Conjugate AGS62P1|Anti-FLT3 Monoclonal Antibody 4G8-SDIEM|Anti-FLT3 Monoclonal Antibody IMC-EB10|Anti-FLT3/CD3 BiTE Antibody AMG 427|Anti-FRA/Eribulin Antibody-drug Conjugate MORAb-202|Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002|Anti-GARP Monoclonal Antibody ABBV-151|Anti-GCC Antibody-Drug Conjugate MLN0264|Anti-GCC Antibody-Drug Conjugate TAK-164|Anti-GD2 Monoclonal Antibody MORAb-028|Anti-GD2 Monoclonal Antibody hu14.18K322A|Anti-GD2 hu3F8/Anti-CD3 huOKT3 Bispecific Antibody|Anti-GD3 Antibody-drug Conjugate PF-06688992|Anti-GITR Agonistic Monoclonal Antibody ASP1951|Anti-GITR Agonistic Monoclonal Antibody BMS-986156|Anti-GITR Agonistic Monoclonal Antibody INCAGN01876|Anti-GITR Monoclonal Antibody GWN 323|Anti-GITR Monoclonal Antibody MK-4166|Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a|Anti-GRP78 Monoclonal Antibody PAT-SM6|Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962|Anti-Globo H Monoclonal Antibody OBI-888|Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999|Anti-Glypican 3/CD3 Bispecific Antibody ERY974|Anti-GnRH Vaccine PEP223|Anti-HA Epitope Monoclonal Antibody MEDI8852|Anti-HB-EGF Monoclonal Antibody KHK2866|Anti-HBEGF Monoclonal Antibody U3-1565|Anti-HER-2 Bispecific Antibody KN026|Anti-HER2 ADC DS-8201a|Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702|Anti-HER2 Antibody-drug Conjugate A166|Anti-HER2 Antibody-drug Conjugate ARX788|Anti-HER2 Antibody-drug Conjugate BAT8001|Anti-HER2 Antibody-drug Conjugate DP303c|Anti-HER2 Antibody-drug Conjugate MEDI4276|Anti-HER2 Antibody-drug Conjugate RC48|Anti-HER2 Bi-specific Monoclonal Antibody ZW25|Anti-HER2 Bispecific Antibody-drug Conjugate ZW49|Anti-HER2 Immune Stimulator-antibody Conjugate NJH395|Anti-HER2 Monoclonal Antibody B002|Anti-HER2 Monoclonal Antibody CT-P6|Anti-HER2 Monoclonal Antibody HLX22|Anti-HER2 Monoclonal Antibody/Anti-CD137Anticalin Bispecific Fusion Protein PRS-343|Anti-HER2-DM1 ADC B003|Anti-HER2-DM1 Antibody-drug Conjugate GQ1001|Anti-HER2-vc0101 ADC PF-06804103|Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A|Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302|Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128|Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522|Anti-HER2/MMAE Antibody-drug Conjugate MRG002|Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A|Anti-HER3 Antibody-drug Conjugate U3 1402|Anti-HER3 Monoclonal Antibody GSK2849330|Anti-HGF Monoclonal Antibody TAK-701|Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968|Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1|Anti-HLA-DR Monoclonal Antibody IMMU-114|Anti-HLA-G Antibody TTX-080|Anti-ICAM-1 Monoclonal Antibody BI-505|Anti-ICOS Agonist Antibody GSK3359609|Anti-ICOS Agonist Monoclonal Antibody BMS-986226|Anti-ICOS Monoclonal Antibody KY1044|Anti-ICOS Monoclonal Antibody MEDI-570|Anti-IGF-1R Monoclonal Antibody AVE1642|Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022|Anti-IL-1 alpha Monoclonal Antibody MABp1|Anti-IL-13 Humanized Monoclonal Antibody TNX-650|Anti-IL-15 Monoclonal Antibody AMG 714|Anti-IL-8 Monoclonal Antibody BMS-986253|Anti-IL-8 Monoclonal Antibody HuMax-IL8|Anti-ILDR2 Monoclonal Antibody BAY 1905254|Anti-ILT4 Monoclonal Antibody MK-4830|Anti-IRF4 Antisense Oligonucleotide ION251|Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388|Anti-KIR Monoclonal Antibody IPH 2101|Anti-KSP/Anti-VEGF siRNAs ALN-VSP02|Anti-LAG-3 Monoclonal Antibody IBI-110|Anti-LAG-3 Monoclonal Antibody INCAGN02385|Anti-LAG-3 Monoclonal Antibody LAG525|Anti-LAG-3 Monoclonal Antibody REGN3767|Anti-LAG-3/PD-L1 Bispecific Antibody FS118|Anti-LAG3 Monoclonal Antibody BI 754111|Anti-LAG3 Monoclonal Antibody MK-4280|Anti-LAG3 Monoclonal Antibody TSR-033|Anti-LAMP1 Antibody-drug Conjugate SAR428926|Anti-LGR5 Monoclonal Antibody BNC101|Anti-LIF Monoclonal Antibody MSC-1|Anti-LILRB4 Monoclonal Antibody IO-202|Anti-LIV-1 Monoclonal Antibody-MMAE Conjugate SGN-LIV1A|Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102|Anti-Ly6E Antibody-Drug Conjugate RG 7841|Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C|Anti-MMP-9 Monoclonal Antibody GS-5745|Anti-MUC1 Monoclonal Antibody BTH1704|Anti-MUC16/CD3 BiTE Antibody REGN4018|Anti-MUC16/CD3 Bispecific Antibody REGN4018|Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A|Anti-MUC17/CD3 BiTE Antibody AMG 199|Anti-Melanin Monoclonal Antibody PTI-6D2|Anti-Met Monoclonal Antibody Mixture Sym015|Anti-Met/EGFR Monoclonal Antibody LY3164530|Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062|Anti-NRP1 Antibody ASP1948|Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A|Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso|Anti-NaPi2b Antibody-drug Conjugate XMT-1592|Anti-NaPi2b Monoclonal Antibody XMT-1535|Anti-Neuropilin-1 Monoclonal Antibody MNRP1685A|Anti-Nucleolin Aptamer AS1411|Anti-OFA Immunotherapeutic BB-MPI-03|Anti-OX40 Agonist Monoclonal Antibody ABBV-368|Anti-OX40 Agonist Monoclonal Antibody BGB-A445|Anti-OX40 Agonist Monoclonal Antibody PF-04518600|Anti-OX40 Antibody BMS 986178|Anti-OX40 Hexavalent Agonist Antibody INBRX-106|Anti-OX40 Monoclonal Antibody GSK3174998|Anti-OX40 Monoclonal Antibody IBI101|Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256|Anti-PD-1 Checkpoint Inhibitor PF-06801591|Anti-PD-1 Fusion Protein AMP-224|Anti-PD-1 Monoclonal Antibody 609A|Anti-PD-1 Monoclonal Antibody AK105|Anti-PD-1 Monoclonal Antibody AMG 404|Anti-PD-1 Monoclonal Antibody BAT1306|Anti-PD-1 Monoclonal Antibody BCD-100|Anti-PD-1 Monoclonal Antibody BI 754091|Anti-PD-1 Monoclonal Antibody CS1003|Anti-PD-1 Monoclonal Antibody F520|Anti-PD-1 Monoclonal Antibody GLS-010|Anti-PD-1 Monoclonal Antibody HLX10|Anti-PD-1 Monoclonal Antibody HX008|Anti-PD-1 Monoclonal Antibody JTX-4014|Anti-PD-1 Monoclonal Antibody LZM009|Anti-PD-1 Monoclonal Antibody MEDI0680|Anti-PD-1 Monoclonal Antibody MGA012|Anti-PD-1 Monoclonal Antibody SCT-I10A|Anti-PD-1 Monoclonal Antibody Sym021|Anti-PD-1 Monoclonal Antibody TSR-042|Anti-PD-1/Anti-CTLA4 DART Protein MGD019|Anti-PD-1/Anti-HER2 Bispecific Antibody IBI315|Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669|Anti-PD-1/Anti-LAG-3 DART Protein MGD013|Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318|Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172|Anti-PD-1/CD47 Infusion Protein HX009|Anti-PD-1/CTLA-4 Bispecific Antibody AK104|Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752|Anti-PD-1/TIM-3 Bispecific Antibody RO7121661|Anti-PD-1/VEGF Bispecific Antibody AK112|Anti-PD-L1 Monoclonal Antibody A167|Anti-PD-L1 Monoclonal Antibody BCD-135|Anti-PD-L1 Monoclonal Antibody BGB-A333|Anti-PD-L1 Monoclonal Antibody CBT-502|Anti-PD-L1 Monoclonal Antibody CK-301|Anti-PD-L1 Monoclonal Antibody CS1001|Anti-PD-L1 Monoclonal Antibody FAZ053|Anti-PD-L1 Monoclonal Antibody GR1405|Anti-PD-L1 Monoclonal Antibody HLX20|Anti-PD-L1 Monoclonal Antibody IMC-001|Anti-PD-L1 Monoclonal Antibody LY3300054|Anti-PD-L1 Monoclonal Antibody MDX-1105|Anti-PD-L1 Monoclonal Antibody MSB2311|Anti-PD-L1 Monoclonal Antibody RC98|Anti-PD-L1 Monoclonal Antibody SHR-1316|Anti-PD-L1 Monoclonal Antibody TG-1501|Anti-PD-L1 Monoclonal Antibody ZKAB001|Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105|Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046|Anti-PD-L1/CD137 Bispecific Antibody MCLA-145|Anti-PD-L1/IL-15 Fusion Protein KD033|Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244|Anti-PD1 Monoclonal Antibody AGEN2034|Anti-PD1/CTLA4 Bispecific Antibody XmAb20717|Anti-PGF Monoclonal Antibody RO5323441|Anti-PKN3 siRNA Atu027|Anti-PLGF Monoclonal Antibody TB-403|Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4|Anti-PRAME Immunotherapeutic GSK2302032A|Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C|Anti-PRL-3 Monoclonal Antibody PRL3-zumab|Anti-PSCA Monoclonal Antibody AGS-1C4D4|Anti-PSMA Monoclonal Antibody MDX1201-A488|Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704|Anti-PSMA Monoclonal Antibody-MMAE Conjugate|Anti-PSMA/CD28 Bispecific Antibody REGN5678|Anti-PSMA/CD3 Bispecific Antibody CCW702|Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081|Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414|Anti-PSMA/PBD ADC MEDI3726|Anti-PTK7/Auristatin-0101 Antibody-drug Conjugate PF-06647020|Anti-PVRIG Monoclonal Antibody COM701|Anti-RANKL Monoclonal Antibody GB-223|Anti-RANKL Monoclonal Antibody JMT103|Anti-ROR1 ADC VLS-101|Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002|Anti-Ribonucleoprotein Antibody ATRC-101|Anti-S15 Monoclonal Antibody NC318|Anti-SIRPa Monoclonal Antibody CC-95251|Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E|Anti-TAG-72 Monoclonal Antibody scFV CC-49/218|Anti-TF Monoclonal Antibody ALT-836|Anti-TGF-beta Monoclonal Antibody NIS793|Anti-TGF-beta Monoclonal Antibody SAR-439459|Anti-TGF-beta RII Monoclonal Antibody IMC-TR1|Anti-TIGIT Monoclonal Antibody AB154|Anti-TIGIT Monoclonal Antibody BGB-A1217|Anti-TIGIT Monoclonal Antibody BMS-986207|Anti-TIGIT Monoclonal Antibody COM902|Anti-TIGIT Monoclonal Antibody OMP-313M32|Anti-TIGIT Monoclonal Antibody SGN-TGT|Anti-TIM-3 Antibody BMS-986258|Anti-TIM-3 Monoclonal Antibody BGB-A425|Anti-TIM-3 Monoclonal Antibody INCAGN02390|Anti-TIM-3 Monoclonal Antibody MBG453|Anti-TIM-3 Monoclonal Antibody Sym023|Anti-TIM-3 Monoclonal Antibody TSR-022|Anti-TIM3 Monoclonal Antibody LY3321367|Anti-TIM3 Monoclonal Antibody SHR-1702|Anti-TNF Therapy|Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711|Anti-TROP2 Antibody-drug Conjugate BAT8003|Anti-TROP2 Antibody-drug Conjugate SKB264|Anti-TROP2/DXd Antibody-drug Conjugate DS-1062a|Anti-TWEAK Monoclonal Antibody RG7212|Anti-Tissue Factor Monoclonal Antibody MORAb-066|Anti-VEGF Anticalin PRS-050-PEG40|Anti-VEGF Monoclonal Antibody hPV19|Anti-VEGF/ANG2 Nanobody BI 836880|Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T|Anti-VEGFC Monoclonal Antibody VGX-100|Anti-VEGFR2 Monoclonal Antibody HLX06|Anti-VEGFR2 Monoclonal Antibody MSB0254|Anti-VEGFR3 Monoclonal Antibody IMC-3C5|Anti-VISTA Monoclonal Antibody JNJ 61610588|Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B|Anti-alpha5beta1 Integrin Antibody MINT1526A|Anti-angiopoietin Monoclonal Antibody AMG 780|Anti-c-KIT Monoclonal Antibody CDX 0158|Anti-c-MET Monoclonal Antibody LY2875358|Anti-c-Met Antibody-drug Conjugate HTI-1066|Anti-c-Met Antibody-drug Conjugate TR1801|Anti-c-Met Monoclonal Antibody ABT-700|Anti-c-Met Monoclonal Antibody ARGX-111|Anti-c-Met Monoclonal Antibody HLX55|Anti-c-fms Monoclonal Antibody AMG 820|Anti-claudin18.2 Monoclonal Antibody AB011|Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012|Anti-gpA33/CD3 Monoclonal Antibody MGD007|Anti-gremlin-1 Monoclonal Antibody UCB6114|Anti-hepcidin Monoclonal Antibody LY2787106|Anti-human GITR Monoclonal Antibody AMG 228|Anti-human GITR Monoclonal Antibody TRX518|Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A|Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181|Anti-mesothelin Antibody-drug Conjugate BMS-986148|Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100|Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A|Anti-mesothelin/MMAE Antibody-drug Conjugate RC88|Anti-myostatin Monoclonal Antibody LY2495655|Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E|Anti-nf-P2X7 Antibody Ointment BIL-010t|Anti-prolactin Receptor Antibody LFA102|Anti-sCLU Monoclonal Antibody AB-16B5|Antiangiogenic Drug Combination TL-118|Antibody-Drug Conjugate DFRF4539A|Antibody-drug Conjugate ABBV-011|Antibody-drug Conjugate ABBV-085|Antibody-drug Conjugate ABBV-155|Antibody-drug Conjugate ABBV-176|Antibody-drug Conjugate ABBV-838|Antibody-drug Conjugate ADC XMT-1536|Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014|Antibody-drug Conjugate MEDI7247|Antibody-drug Conjugate PF-06647263|Antibody-drug Conjugate PF-06664178|Antibody-drug Conjugate SC-002|Antibody-drug Conjugate SC-003|Antibody-drug Conjugate SC-004|Antibody-drug Conjugate SC-005|Antibody-drug Conjugate SC-006|Antibody-drug Conjugate SC-007|Antibody-like CD95 Receptor/Fc-fusion Protein CAN-008|Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV|Antigua and Barbuda|Antimetabolite FF-10502|Antineoplastic Agent Combination SM-88|Antineoplastic Vaccine|Antineoplastic Vaccine GV-1301|Antineoplaston A10|Antineoplaston AS2-1|Antiseizure Treatment|Antisense Oligonucleotide GTI-2040|Antisense Oligonucleotide QR-313|Antitumor B Key Active Component-alpha|Antrodia cinnamomea Supplement|Antroquinonol Capsule|Antrum|Antrum Pylori|Anus|Anus and anal canal|Anus, NOS|Anxiety|Aorta|Aortic Body|Aortic Injury|Aortic Valve Disease|Aortic body and other paraganglia|Aortic body paraganglioma|Aortic body tumor|Aorticopulmonary Paraganglioma|Aorticopulmonary paraganglioma|Apalutamide|Apatorsen|Apaziquone|Aphidicoline Glycinate|Aphonia|Apilimod Dimesylate Capsule|Apitolisib|Apnea|Apocrine Adenoma|Apocrine Hidrocystoma|Apocrine adenocarcinoma|Apocrine adenoma|Apocrine cystadenoma|Apolizumab|Apomab|Apomine|Apoptosis Inducer BZL101|Apoptosis Inducer GCS-100|Apoptosis Inducer MPC-2130|Appendage of the Uterus|Appendicitis|Appendicitis Perforated|Appendix|Applied Biosystems|Approved|Apricoxib|Aprinocarsen|Aprutumab|Aprutumab Ixadotin|Apudoma|Aqueous Fluid|Arabidopsis thaliana|Arabinoxylan Compound MGN3|Arachnoiditis|Aranose|Archexin|Archive|Arcitumomab|Arfolitixorin|Arg-C, Asp-N|Argentaffinoma, NOS|Argentaffinoma, malignant|Argentina|Arginase Inhibitor INCB001158|Arginine Butyrate|Arm|Armenia|Arnebia Indigo Jade Pearl Topical Cream|Arrhenoblastoma, NOS|Arrhenoblastoma, benign|Arrhenoblastoma, malignant|Arrhythmia|Arriba|Arsenic Trioxide|Arsenic Trioxide Capsule Formulation ORH 2014|Artemether Sublingual Spray|Artemisinin Dimer|Arterial Injury|Arteriovenous Hemangioma/Malformation|Arteriovenous hemangioma|Arteritis Infective|Artery|Artesunate|Arthralgia|Arthritis|Aruba|Arugula Seed Powder|Aryl Hydrocarbon Receptor Antagonist BAY2416964|Aryl Hydrocarbon Receptor Inhibitor IK-175|Asaley|AscatNGS|Ascending Colon|Ascending Colon Hepatic Flexure|Ascending colon|Asciminib|Ascites|Ascites Drainage|Ascrinvacumab|Ashwagandha Root Powder Extract|Asian|Askin Tumor|Askin tumor|Asp-N_ambic|Aspacytarabine|Asparaginase|Asparaginase Erwinia chrysanthemi|Aspartate Aminotransferase Increased|Aspirate|Aspiration|Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10|Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10|Asthma|Astroblastoma|Astrocytic Tumor|Astrocytic glioma|Astrocytoma|Astrocytoma, NOS|Astrocytoma, anaplastic|Astrocytoma, low grade|Astroglioma|Astuprotimut-R|Asulacrine|Asulacrine Isethionate|Asunercept|Asystole|At 211 Monoclonal Antibody 81C6|Atamestane|Ataxia|Ataxia-telangiectasia|Atelectasis|Atezolizumab|Atiprimod|Atiprimod Dihydrochloride|Atiprimod Dimaleate|Atorvastatin Calcium|Atorvastatin Sodium|Atrasentan Hydrochloride|Atrial Fibrillation|Atrial Flutter|Atrioventricular Block Complete|Atrioventricular Block First Degree|Attenuated Listeria monocytogenes CRS-100|Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001|Attenuated Measles Virus Encoding SCD Transgene TMV-018|Atuveciclib|Atypical|Atypical Adenoma|Atypical Burkitt/Burkitt-Like Lymphoma|Atypical Carcinoid Tumor|Atypical Choroid Plexus Papilloma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Atypical Endometrial Hyperplasia|Atypical Fibroxanthoma|Atypical Lipomatous Tumor|Atypical Meningioma|Atypical Polypoid Adenomyoma|Atypical Teratoid/Rhabdoid Tumor|Atypical adenoma|Atypical carcinoid tumor|Atypical choroid plexus papilloma|Atypical chronic myeloid leukemia, BCR/ABL negative|Atypical chronic myeloid leukemia, Philadelphia chromosome (Ph1) negative|Atypical fibrous histiocytoma|Atypical fibroxanthoma|Atypical follicular adenoma|Atypical hyperplasia/Endometrioid intraepithelial neoplasm|Atypical leiomyoma|Atypical lipoma|Atypical medullary carcinoma|Atypical meningioma|Atypical polypoid adenomyoma|Atypical proliferating clear cell tumor|Atypical proliferating serous tumor|Atypical proliferative endometrioid tumor|Atypical proliferative mucinous tumor|Atypical proliferative papillary serous tumor|Atypical teratoid/rhabdoid tumor|Audencel|Auditory Canal|Aunt|Auranofin|Aurora A Kinase Inhibitor LY3295668|Aurora A Kinase Inhibitor LY3295668 Erbumine|Aurora A Kinase Inhibitor MK5108|Aurora A Kinase Inhibitor TAS-119|Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076|Aurora B Serine/Threonine Kinase Inhibitor TAK-901|Aurora B/C Kinase Inhibitor GSK1070916A|Aurora Kinase Inhibitor AMG 900|Aurora Kinase Inhibitor BI 811283|Aurora Kinase Inhibitor MLN8054|Aurora Kinase Inhibitor PF-03814735|Aurora Kinase Inhibitor SNS-314|Aurora Kinase Inhibitor TTP607|Aurora Kinase/VEGFR2 Inhibitor CYC116|Aurora kinase A/B inhibitor TT-00420|Australia|Austria|Auto Spec Ultima NT|Autoimmune Atrophic Chronic Gastritis|Autoimmune Disorder|Autoimmune Lymphoproliferative Syndrome (ALPS)|Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707|Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055|Autologous AXL-targeted CAR T-cells CCT301-38|Autologous Anti-BCMA CAR T-cells PHE885|Autologous Anti-BCMA CAR-transduced T-cells KITE-585|Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11|Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T-lymphocytes JCARH125|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells CT053|Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143|Autologous Anti-CD123 CAR-T Cells|Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx|Autologous Anti-CD19 CAR T-cells IM19|Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19|Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19|Autologous Anti-CD19 CAR-CD28 T-cells ET019002|Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01|Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901|Autologous Anti-CD19 Chimeric Antigen Receptor T-cells AUTO1|Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19|Autologous Anti-CD19 T-cell Receptor T cells ET190L1|Autologous Anti-CD19 TAC-T cells TAC01-CD19|Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells|Autologous Anti-CD19/CD22 CAR T-cells AUTO3|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells|Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1|Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s|Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes|Autologous Anti-FLT3 CAR T Cells AMG 553|Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202|Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1|Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100|Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794|Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes|Autologous Anti-PSMA CAR-T Cells P-PSMA-101|Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes|Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B|Autologous BCMA-targeted CAR T Cells CC-98633|Autologous BCMA-targeted CAR T Cells LCAR-B4822M|Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528|Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F|Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022|Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001|Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3005|Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3006|Autologous CD123-4SCAR-expressing T-cells 4SCAR123|Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1|Autologous CD19-targeted CAR T Cells CC-97540|Autologous CD19-targeted CAR T Cells JWCAR029|Autologous CD19-targeted CAR-T Cells GC007F|Autologous CD19/PD-1 Bispecific CAR-T Cells|Autologous CD20-4SCAR-expressing T-cells 4SCAR20|Autologous CD22-4SCAR-expressing T-cells 4SCAR22|Autologous CD38-4SCAR-expressing T-cells 4SCAR38|Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19|Autologous Clonal Neoantigen T Cells ATL001|Autologous Deep IL-15 Primed T-cells TRQ15-01|Autologous Dendritic Cell Vaccine ACT2001|Autologous Dendritic Cell-based Immunotherapeutic AV0113|Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa|Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells|Autologous Genetically-modified MAGE-A4 C1032 T Cells|Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439|Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858|Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001|Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718|Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR|Autologous Mesenchymal Stem Cells Apceth_101|Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11|Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC|Autologous Multi-lineage Potential Cells|Autologous NKG2D CAR T-cells CYAD-02|Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01|Autologous Nectin-4/FAP-targeted CAR-T Cells|Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine|Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001|Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101|Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601|Autologous ROR2-targeted CAR T-cells CCT301-59|Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201|Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1|Autologous TCR-engineered T-cells IMA201|Autologous TCR-engineered T-cells IMA202|Autologous TCR-engineered T-cells IMA203|Autologous TCRm-expressing T-cells ET140203|Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG|Autologous Tumor Infiltrating Lymphocytes LN-144|Autologous Tumor Infiltrating Lymphocytes LN-145|Autologous Tumor Infiltrating Lymphocytes LN-145-S1|Autologous Tumor Infiltrating Lymphocytes MDA-TIL|Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T|Autonomic Nervous System|Autonomic nervous system, NOS|Autopsy|Avadomide|Avadomide Hydrochloride|Avapritinib|Avascular Necrosis|Avdoralimab|Avelumab|Aviscumine|Avitinib Maleate|Axalimogene Filolisbac|Axatilimab|Axicabtagene Ciloleucel|Axilla|Axillary Lymph Node|Axillary tail of breast|Axitinib|Axl/Mer Inhibitor INCB081776|Axl/Mer Inhibitor PF-07265807|Axumin|Azacitidine|Azapicyl|Azaribine|Azaserine|Azathioprine|Azerbaijan|Azimexon|Azintuxizumab Vedotin|Aziridinylbenzoquinone RH1|Azoospermia|Azotomycin|Azurin:50-77 Cell Penetrating Peptide p28|B|B Acute Lymphoblastic Leukemia|B Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy|B Lymphoblastic Leukemia/Lymphoma with Hypodiploidy|B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1|B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)|B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH|B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1|B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged|B Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified|B Lymphoblastic Lymphoma|B cell lymphoma, NOS|B lymphoblastic leukemia/lymphoma with hyperdiploidy|B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL)|B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)|B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)|B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH|B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1|B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged|B lymphoblastic leukemia/lymphoma, NOS|B-ALL|B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|B-Cell Prolymphocytic Leukemia|B-Raf/VEGFR-2 Inhibitor RAF265|B-cell lymphocytic leukemia/small lymphocytic lymphoma|B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma|B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma|B7|B8|B9|BAI|BALT lymphoma|BAM|BAP1 Tumor Predisposition Syndrome|BC-819 Plasmid/Polyethylenimine Complex|BCG Solution|BCG Tokyo-172 Strain Solution|BCG Vaccine|BCGSC miRNA Profiling|BCMA x CD3 T-cell Engaging Antibody CC-93269|BCMA-CD19 Compound CAR T Cells|BCMA/CD3e Tri-specific T-cell Activating Construct HPN217|BCR Auxiliary XML|BCR Biotab|BCR Notification|BCR OMF XML|BCR PPS XML|BCR SSF XML|BCR XML|BCR-ABL/KIT/AKT/ERK Inhibitor HQP1351|BED-Biochemical Evidence of Disease|BEDPE|BET Bromodomain Inhibitor ZEN-3694|BET Inhibitor ABBV-744|BET Inhibitor BAY1238097|BET Inhibitor BMS-986158|BET Inhibitor CC-90010|BET Inhibitor CPI-0610|BET Inhibitor FT-1101|BET Inhibitor GS-5829|BET Inhibitor GSK2820151|BET Inhibitor INCB054329|BET Inhibitor INCB057643|BET Inhibitor RO6870810|BET inhibitor BI 894999|BET-bromodomain Inhibitor ODM-207|BF-200 Gel Formulation|BH3 Mimetic ABT-737|BL22 Immunotoxin|BMI1 Inhibitor PTC596|BMS-184476|BMS-188797|BMS-214662|BMS-275183|BP-Cx1-Platinum Complex BP-C1|BR96-Doxorubicin Immunoconjugate|BRAF Inhibitor|BRAF Inhibitor ARQ 736|BRAF Inhibitor BGB-3245|BRAF Inhibitor PLX8394|BRAF(V600E) Kinase Inhibitor ABM-1310|BRAF(V600E) Kinase Inhibitor RO5212054|BRAF/EGFR Inhibitor BGB-283|BRAFV600/PI3K Inhibitor ASN003|BRASS|BRCA Family History|BRD4 Inhibitor PLX2853|BRD4 Inhibitor PLX51107|BTK Inhibitor ARQ 531|BTK Inhibitor CT-1530|BTK Inhibitor DTRMWXHS-12|BTK Inhibitor HZ-A-018|BTK Inhibitor ICP-022|BTK Inhibitor LOXO-305|BTK Inhibitor M7583|BTK inhibitor TG-1701|BWA|BWA with BQSR|BWA with Mark Duplicates and BQSR|BWA with Mark Duplicates and Cocleaning|BWA-aln|BWA-mem|BXQ-350 Nanovesicle Formulation|B_Allele_Freq|Babaodan Capsule|Bacillus Calmette-Guerin Substrain Connaught Live Antigen|Back|Back Pain|Bacteroides fragilis|Bactobolin|Bafetinib|Bahamas|Bahrain|Balixafortide|Balloon Cell Melanoma|Balloon Cell Nevus|Balloon cell melanoma|Balloon cell nevus|Balstilimab|Baltaleucel-T|Bangladesh|Banoxantrone|Barasertib|Barbados|Barcode incorrect|Bardoxolone|Bardoxolone Methyl|Baricitinib|Barrett's Esophagus|Basal Cell Cancer|Basal Cell Carcinoma|Basal Cell Neoplasm|Basal Cell Neoplasms|Basal cell adenocarcinoma|Basal cell adenoma|Basal cell carcinoma, NOS|Basal cell carcinoma, desmoplastic type|Basal cell carcinoma, fibroepithelial|Basal cell carcinoma, micronodular|Basal cell carcinoma, morpheic|Basal cell carcinoma, nodular|Basal cell epithelioma|Basal cell tumor|Basaloid Carcinoma|Basaloid Squamous Cell Carcinoma|Basaloid carcinoma|Basaloid squamous cell carcinoma|Base of the Tongue|Base of tongue|Base of tongue, NOS|Basophil adenocarcinoma|Basophil adenoma|Basophil carcinoma|Basophilic Adenocarcinoma|Basosquamous carcinoma|Batabulin|Batabulin Sodium|Batimastat|Bavituximab|Bazedoxifene|Bazlitoran|Bcl-2 Inhibitor APG 2575|Bcl-2 Inhibitor BCL201|Bcl-2 Inhibitor BGB-11417|Bcl-2 Inhibitor LP-108|Bcl-2 Inhibitor S65487|Bcl-Xs Adenovirus Vaccine|Bcr-Abl Kinase Inhibitor K0706|Bcr-Abl Kinase Inhibitor PF-114|Beauvericin|Becatecarin|Beckwith-Wiedemann|Bednar tumor|Beer|Behcet's Disease|Belagenpumatucel-L|Belantamab Mafodotin|Belapectin|Belarus|Belgium|Belimumab|Belinostat|Belize|Bellini duct carcinoma|Belotecan Hydrochloride|Belvarafenib|Belzutifan|Bemarituzumab|Bemcentinib|Bemisia tabaci (Gennadius)|Bempegaldesleukin|Benaxibine|Bendamustine|Bendamustine Hydrochloride|Bendamustine-containing Nanoparticle-based Formulation RXDX-107|Benign Adrenal Cortex Neoplasm|Benign Epithelial Neoplasm|Benign Fibrous Histiocytoma|Benign Gastrointestinal Stromal Tumor|Benign Hemangioendothelioma|Benign Hemangiopericytoma|Benign Leydig Cell Tumor|Benign Mesenchymoma|Benign Mesonephroma|Benign Mixed Tumor of the Skin|Benign Muscle Neoplasm|Benign Myoepithelioma|Benign Neoplasm|Benign Neoplasms|Benign Odontogenic Neoplasm|Benign Paraganglioma|Benign Phyllodes Tumor|Benign Prostatic Hyperplasia|Benign Sertoli Cell Tumor|Benign Skin Appendage Neoplasm|Benign Soft Tissue Neoplasm|Benign Stromal Tumor|Benign Sweat Gland Neoplasm|Benign Synovial Neoplasm|Benign Thymoma|Benign cystic nephroma|Benign fibrous histiocytoma|Benin|Benzaldehyde Dimethane Sulfonate|Benzoylphenylurea|Berberine Chloride|Bermekimab|Bermuda|Bersanlimab|Berubicin Hydrochloride|Berzosertib|Beta Alethine|Beta cell adenoma|Beta cell tumor, malignant|Beta-Carotene|Beta-Glucan|Beta-Glucan MM-10-001|Beta-Thioguanine Deoxyriboside|Beta-elemene|Beta-lapachone Prodrug ARQ 761|Betaglucin Gel|Betulinic Acid|Bevacizumab|Bexarotene|Bexmarilimab|Bhutan|Bi-functional Alkylating Agent VAL-083|BiTE Antibody AMG 910|Bicalutamide|Biguanide|Bilateral|Bile Duct|Bile Duct Adenocarcinoma|Bile Duct Adenoma|Bile Duct Cancer|Bile Duct Carcinoma|Bile Duct Mucinous Cystic Neoplasm|Bile Duct Mucinous Cystic Neoplasm with an Associated Invasive Carcinoma|Bile Duct Papillary Neoplasm|Bile Duct Papillary Neoplasm with High Grade Intraepithelial Neoplasia|Bile Duct Papillary Neoplasm with Low Grade Intraepithelial Neoplasia|Bile Duct Stenosis|Bile duct adenocarcinoma|Bile duct adenoma|Bile duct carcinoma|Bile duct cystadenocarcinoma|Bile duct cystadenoma|Biliary Anastomotic Leak|Biliary Disorder|Biliary Fistula|Biliary Intraepithelial Neoplasia-3|Biliary Tract Infection|Biliary intraepithelial neoplasia, grade 3|Biliary intraepithelial neoplasia, high grade|Biliary intraepithelial neoplasia, low grade|Biliary papillomatosis|Biliary tract, NOS|Bimiralisib|Binetrakin|Binimetinib|Bintrafusp Alfa|Bio-Q|BioSizing|Biochemical|Biochemical Evidence of Disease without Structural Correlate|Biochemical evidence of disease without structural correlate|Biopsy|Biopsy with Histologic Confirmation|Biospecimen|Biospecimen Supplement|Biospecimen identity unknown|Biphasic Mesothelioma|Biphasic Synovial Sarcoma|Biphenotypic sinonasal sarcoma|Birabresib|Birdseed|Birinapant|Birt-Hogg-Dube Syndrome|Bis(choline)tetrathiomolybdate|Bisantrene|Bisantrene Hydrochloride|Bisnafide|Bisnafide Dimesylate|Bispecific Antibody 2B1|Bispecific Antibody AGEN1223|Bispecific Antibody AMG 509|Bispecific Antibody GS-1423|Bispecific Antibody MDX-H210|Bispecific Antibody MDX447|Bisphosphonate Therapy|Bisthianostat|Bisulfite-Seq|Bivalent BRD4 Inhibitor AZD5153|Bizalimogene Ralaplasmid|Bizarre Leiomyoma|Bizarre leiomyoma|Bizelesin|Black Cohosh|Black Raspberry Nectar|Black adenoma|Black or African American|Bladder|Bladder Anastomotic Leak|Bladder Cancer|Bladder Infection|Bladder Neck|Bladder Papillary Urothelial Neoplasm of Low Malignant Potential|Bladder Perforation|Bladder Spasm|Bladder Trigone|Bladder Urachal Carcinoma|Bladder Urothelial Carcinoma|Bladder neck|Bladder, NOS|Blast cell leukemia|Blastic NK cell lymphoma|Blastic Plasmacytoid Dendritic Cell Neoplasm|Blastic plasmacytoid dendritic cell neoplasm|Blastoma|Blastoma, NOS|Bleomycin|Bleomycin A2|Bleomycin B2|Bleomycin Sulfate|Blinatumomab|Blinded Study, Treatment Unknown|Bloating|Blocking Release|Blood|Blood Antidiuretic Hormone Abnormal|Blood Bilirubin Increased|Blood Cancer|Blood Clots|Blood Corticotrophin Decreased|Blood Derived Cancer - Bone Marrow|Blood Derived Cancer - Bone Marrow, Post-treatment|Blood Derived Cancer - Peripheral Blood|Blood Derived Cancer - Peripheral Blood, Post-treatment|Blood Derived Liquid Biopsy|Blood Derived Normal|Blood Draw|Blood Gonadotrophin Abnormal|Blood Prolactin Abnormal|Blood Vessel|Blood Vessel Tumors|Blood and Lymphatic System Disorders - Other|Blue|Blue Nevus|Blue nevus, NOS|Blue nevus, malignant|Blueberry Powder Supplement|Blurred Vision|Boanmycin Hydrochloride|Body Odor|Body of Stomach|Body of pancreas|Body of penis|Body of stomach|Body of the Penis|Body, total|Bolivia|Bomedemstat|Bone|Bone Cancer|Bone Desmoplastic Fibroma|Bone Fracture(s)|Bone Infection|Bone Marrow|Bone Marrow Aspirate|Bone Marrow Components|Bone Marrow Components NOS|Bone Marrow Hypocellular|Bone Marrow Normal|Bone Pain|Bone marrow|Bone of limb, NOS|Bone, NOS|Bone, non-spine|Bones of skull and face and associated joints|Bones, joints and articular cartilage of limbs|Bones, joints and articular cartilage of other and unspecified sites|Border of tongue|Borderline Ovarian Brenner Tumor/Atypical Proliferative Ovarian Brenner Tumor|Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor|Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor|Borderline Ovarian Serous Tumor-Micropapillary Variant/Non-Invasive Low Grade Ovarian Serous Carcinoma|Borderline Papillary Cystadenoma|Borderline Papillary Mucinous Cystadenoma|Borderline Papillary Serous Cystadenoma|Borderline Phyllodes Tumor|Borderline Serous Cystadenoma|Boronophenylalanine-Fructose Complex|Bortezomib|Bos taurus|Bosnia and Herzegovina|Bosutinib|Bosutinib Monohydrate|Botanical Agent BEL-X-HG|Botanical Agent LEAC-102|Botryoid sarcoma|Botryoid-Type Embryonal Rhabdomyosarcoma|Botswana|Bovine Cartilage|Bowel|Bowen Disease of the Skin|Bowen disease|Bozitinib|Brachial Plexopathy|Brachytherapy, High Dose|Brachytherapy, Low Dose|Brachytherapy, NOS|Brachyury-expressing Yeast Vaccine GI-6301|Brain|Brain Cancer|Brain Lower Grade Glioma|Brain Stem|Brain stem|Brain, NOS|Branchial Cleft Remnant|Branchial cleft|Brazil|Breast|Breast Atrophy|Breast Cancer|Breast Cancer pTis (DCIS) TNM Finding v8|Breast Cancer pTis (LCIS) TNM Finding v6 and v7|Breast Carcinoma with Chondroid Metaplasia|Breast Carcinoma with Osseous Metaplasia|Breast Fibroadenoma|Breast Giant Fibroadenoma|Breast Infection|Breast Intracanalicular Fibroadenoma|Breast Invasive Carcinoma|Breast Juvenile Fibroadenoma|Breast Pain|Breast Pericanalicular Fibroadenoma|Breast, NOS|Breflate|Brenner Tumor|Brenner tumor, NOS|Brenner tumor, borderline malignancy|Brenner tumor, malignant|Brenner tumor, proliferating|Brentuximab|Brentuximab Vedotin|Brequinar|Brequinar Sodium|Briciclib Sodium|Brigatinib|Brilanestrant|Brimonidine Tartrate Nanoemulsion OCU-300|Brivanib|Brivanib Alaninate|Brivudine|Brivudine Phosphoramidate|Broad Ligament|Broad ligament|Broad-Spectrum Human Papillomavirus Vaccine V505|Broccoli Sprout/Broccoli Seed Extract Supplement|Bromacrylide|Bromebric Acid|Bromocriptine Mesylate|Bronchial Fistula|Bronchial Infection|Bronchial Mucosa-Associated Lymphoid Tissue Lymphoma|Bronchial Obstruction|Bronchial Stricture|Bronchial adenoma, NOS|Bronchial adenoma, carcinoid|Bronchial adenoma, cylindroid|Bronchial-associated lymphoid tissue lymphoma|Bronchio-alveolar carcinoma, mixed mucinous and non-mucinous|Bronchio-alveolar carcinoma, mucinous|Bronchiolar adenocarcinoma|Bronchiolar carcinoma|Bronchiole|Bronchiolo-alveolar adenocarcinoma, NOS|Bronchiolo-alveolar carcinoma, Clara cell|Bronchiolo-alveolar carcinoma, Clara cell and goblet cell type|Bronchiolo-alveolar carcinoma, NOS|Bronchiolo-alveolar carcinoma, goblet cell type|Bronchiolo-alveolar carcinoma, indeterminate type|Bronchiolo-alveolar carcinoma, non-mucinous|Bronchiolo-alveolar carcinoma, type II pneumocyte and goblet cell type|Bronchiolo-alveolar carcinoma; type II pneumocyte|Bronchitis|Bronchopleural Fistula|Bronchopulmonary Hemorrhage|Bronchospasm|Bronchus|Bronchus and lung|Brontictuzumab|Brooke tumor|Brostacillin Hydrochloride|Brostallicin|Brother|Brother-in-law|Brow|Brown|Brown fat tumor|Broxuridine|Bruceanol A|Bruceanol B|Bruceanol C|Bruceanol D|Bruceanol E|Bruceanol F|Bruceanol G|Bruceanol H|Bruceantin|Bruising|Bruker|Bruker Daltonics BioTOF series|Bruker Daltonics EVOQ series|Bruker Daltonics HCT series|Bruker Daltonics SCION series|Bruker Daltonics amaZon series|Bruker Daltonics apex series|Bruker Daltonics esquire series|Bruker Daltonics flex series|Bruker Daltonics maXis series|Bruker Daltonics micrOTOF series|Bruker Daltonics solarix series|Brunei|Bryostatin 1|Buccal Cavity|Buccal Cell Normal|Buccal Cells|Buccal Mucosa|Buccal Mucosal Resection|Budigalimab|Budotitane|Bufalin|Buffy Coat|Bulgaria|Bullous Dermatitis|Buparlisib|Burixafor|Burixafor Hydrobromide|Burkina Faso|Burkitt Leukemia|Burkitt Lymphoma|Burkitt cell leukemia|Burkitt lymphoma, NOS (Includes all variants)|Burkitt tumor|Burkitt-like lymphoma|Burn|Burning tree smoke|Burosumab|Burundi|Buserelin|Bushen Culuan Decoction|Bushen-Jianpi Decoction|Busulfan|Buthionine Sulfoximine|Buttock|Buttock Pain|C|C cell carcinoma|C-VISA BikDD:Liposome|C-myb Antisense Oligonucleotide G4460|C/EBP Beta Antagonist ST101|C10|C11|C12|C18|CAB-ROR2-ADC BA3021|CAIX Inhibitor DTP348|CAIX Inhibitor SLC-0111|CAR T-Cells AMG 119|CASTLE|CBP/beta-catenin Antagonist PRI-724|CBP/beta-catenin Modulator E7386|CCR2 Antagonist CCX872-B|CCR2 Antagonist PF-04136309|CCR2/CCR5 Antagonist BMS-813160|CCR4 Inhibitor FLX475|CD11b Agonist GB1275|CD123-CD33 Compound CAR T Cells|CD123-specific Targeting Module TM123|CD20-CD19 Compound CAR T Cells|CD28/ICOS Antagonist ALPN-101|CD4 Lymphocytes Decreased|CD4-specific Telomerase Peptide Vaccine UCPVax|CD40 Agonist Monoclonal Antibody CP-870,893|CD40 Agonistic Monoclonal Antibody APX005M|CD44 Targeted Agent SPL-108|CD44v6-specific CAR T-cells|CD47 Antagonist ALX148|CD73 Inhibitor AB680|CD73 Inhibitor LY3475070|CD80-Fc Fusion Protein ALPN-202|CD80-Fc Fusion Protein FPT155|CDC JSON|CDC7 Inhibitor TAK-931|CDC7 Kinase Inhibitor BMS-863233|CDC7 Kinase Inhibitor LY3143921 Hydrate|CDC7 Kinase Inhibitor NMS-1116354|CDK Inhibitor AT7519|CDK Inhibitor R547|CDK Inhibitor SNS-032|CDK/JAK2/FLT3 Inhibitor TG02 Citrate|CDK1 Inhibitor BEY1107|CDK1/2/4 Inhibitor AG-024322|CDK2 Inhibitor PF-07104091|CDK2/4/6/FLT3 Inhibitor FN-1501|CDK2/5/9 Inhibitor CYC065|CDK4 Inhibitor P1446A-05|CDK4/6 Inhibitor|CDK4/6 Inhibitor BPI-16350|CDK4/6 Inhibitor CS3002|CDK4/6 Inhibitor FCN-437|CDK4/6 Inhibitor G1T38|CDK4/6 Inhibitor HS-10342|CDK4/6 Inhibitor SHR6390|CDK4/6 Inhibitor TQB3616|CDK7 Inhibitor CT7001|CDK7 Inhibitor SY-1365|CDK7 Inhibitor SY-5609|CDK8/19 Inhibitor SEL 120|CDK9 Inhibitor AZD4573|CEA-MUC-1-TRICOM Vaccine CV301|CEA-targeting Agent RG6123|CEBPA-targeting saRNA MTL-CEBPA Liposome|CEL|CENP-E Inhibitor GSK-923295|CHK1 Inhibitor MK-8776|CHK1 Inhibitor PF-477736|CHP-NY-ESO-1 Peptide Vaccine IMF-001|CID|CIN III with severe dysplasia|CK1alpha/CDK7/CDK9 Inhibitor BTX-A51|CK2-targeting Synthetic Peptide CIGB-300|CL 246738|CNBr, Formic_acid|CNS Cancer|CNS Embryonal tumor with rhabdoid features|CNS, ependymoma|CNS, glioblastoma (GBM)|CNS, low grade glioma (LGG)|CNS, medulloblastoma|CNS, other|CNS, rhabdoid tumor|COPD|CPD-Clinical Progression|CPK Increased|CPNET|CR-Complete Response|CRU-Complete Response Unconfirmed|CSF-1R Inhibitor BLZ945|CSF1R Inhibitor ABSK021|CSF1R Inhibitor DCC-3014|CSF1R Inhibitor PLX73086|CSV|CT Scan|CT2584 HMS|CTLA-4-directed Probody BMS-986249|CXC Chemokine Receptor 2 Antagonist AZD5069|CXCR1/2 Inhibitor SX-682|CXCR2 Antagonist QBM076|CXCR4 Antagonist BL-8040|CXCR4 Antagonist USL311|CXCR4 Inhibitor Q-122|CXCR4 Peptide Antagonist LY2510924|CXCR4/E-selectin Antagonist GMI-1359|CYL-02 Plasmid DNA|CYP11A1 Inhibitor ODM-209|CYP11A1 inhibitor ODM-208|CYP17 Inhibitor CFG920|CYP17 Lyase Inhibitor ASN001|CYP17/Androgen Receptor Inhibitor ODM 204|CYP17/CYP11B2 Inhibitor LAE001|CaVEMan|CaVEMan Annotation|CaVEMan Variant Aggregation and Masking|Cabazitaxel|Cabiralizumab|Cabozantinib|Cabozantinib S-malate|Cactinomycin|Caenorhabditis briggsae|Caenorhabditis elegans|Caenorhabditis remanei|Caffeic Acid Phenethyl Ester|Calaspargase Pegol-mknl|Calcifying Cystic Odontogenic Tumor|Calcifying Epithelial Odontogenic Tumor|Calcifying epithelial odontogenic tumor|Calcifying epithelioma of Malherbe|Calcifying nested epithelial stromal tumor|Calcifying odontogenic cyst|Calcitriol|Calcium Channel Blockers|Calcium Release-activated Channel Inhibitor CM4620|Calcium Release-activated Channels Inhibitor RP4010|Calcium Saccharate|Calculus bovis/Moschus/Olibanum/Myrrha Capsule|Calf|Calicheamicin Gamma 1I|Cambodia|Cameroon|Camidanlumab Tesirine|Camptothecin|Camptothecin Analogue TLC388|Camptothecin Glycoconjugate BAY 38-3441|Camptothecin Sodium|Camptothecin-20(S)-O-Propionate Hydrate|Camrelizumab|Camsirubicin|Canada|Canalicular adenoma|Cancell|Cancer|Cancer Control|Cancer Peptide Vaccine S-588410|Cancer Related|Candidiasis|Canerpaturev|Canertinib Dihydrochloride|Canfosfamide|Canfosfamide Hydrochloride|Canis familiaris|Cannabidiol|Cantrixil|Cantuzumab Ravtansine|Cape Verde|Capecitabine|Capecitabine Rapidly Disintegrating Tablet|Capillary|Capillary Hemangioma|Capillary Leak Syndrome|Capillary hemangioma|Capillary lymphangioma|Capivasertib|Capmatinib|Captopril|Caracemide|Carbendazim|Carbetimer|Carbogen|Carbon C 14-pamiparib|Carbon Monoxide Diffusing Capacity Decreased|Carboplatin|Carboquone|Carboxyamidotriazole|Carboxyamidotriazole Orotate|Carboxyphenyl Retinamide|Carcinofibroma|Carcinoid Tumor|Carcinoid Tumor of Uncertain Malignant Potential|Carcinoid tumor of uncertain malignant potential|Carcinoid tumor, NOS|Carcinoid tumor, NOS, of appendix|Carcinoid tumor, argentaffin, NOS|Carcinoid tumor, argentaffin, malignant|Carcinoid, NOS|Carcinoid, NOS, of appendix|Carcinoma|Carcinoma In Situ|Carcinoma In Situ in a Polyp|Carcinoma Simplex|Carcinoma ex Pleomorphic Adenoma|Carcinoma in a Polyp|Carcinoma in a polyp, NOS|Carcinoma in adenomatous polyp|Carcinoma in pleomorphic adenoma|Carcinoma in situ in a polyp, NOS|Carcinoma in situ in adenomatous polyp|Carcinoma in situ, NOS|Carcinoma showing thymus-like differentiation|Carcinoma showing thymus-like element|Carcinoma simplex|Carcinoma with apocrine metaplasia|Carcinoma with chondroid differentiation|Carcinoma with neuroendocrine differentiation|Carcinoma with osseous differentiation|Carcinoma with osteoclast-like giant cells|Carcinoma with other types mesenchymal differentiation|Carcinoma with productive fibrosis|Carcinoma, NOS|Carcinoma, anaplastic, NOS|Carcinoma, diffuse type|Carcinoma, intestinal type|Carcinoma, metastatic, NOS|Carcinoma, undifferentiated, NOS|Carcinomatosis|Carcinosarcoma|Carcinosarcoma, NOS|Carcinosarcoma, embryonal|Cardia|Cardia, NOS|Cardiac Arrest|Cardiac Disorders - Other|Cardiac Troponin I Increased|Cardiac Troponin T Increased|Cardiovascular Disorder|Cardiovascular Disorder, NOS|Carfilzomib|Caricotamide/Tretazicar|Carina|Carlumab|Carmofur|Carmustine|Carmustine Implant|Carmustine Sustained-Release Implant Wafer|Carmustine in Ethanol|Carotid Artery|Carotid Body|Carotid Body Paraganglioma|Carotid body|Carotid body paraganglioma|Carotid body tumor|Carotuximab|Cartilage|Cartilaginous exostosis|Carubicin|Carubicin Hydrochloride|Carzelesin|Carzinophilin|Case submitted is found to be a recurrence after submission|Cataract|Cataracts|Cathelicidin LL-37|Catheter Related Infection|Cationic Liposome-Encapsulated Paclitaxel|Cationic Peptide Cream Cypep-1|Catumaxomab|Cauda equina|Cavernous Hemangioma|Cavernous Lymphangioma|Cavernous hemangioma|Cavernous lymphangioma|Cayman Islands|Cecal Hemorrhage|Cecal Infection|Cecum|Cedazuridine|Cedazuridine/Azacitidine Combination Agent ASTX030|Cedazuridine/Decitabine Combination Agent ASTX727|Cedefingol|Cediranib|Cediranib Maleate|Celecoxib|Celiac Disease|Cell|Cell Culture|Cell Culture Image|Cell Cycle Checkpoint/DNA Repair Antagonist IC83|Cell Line Derived Xenograft Tissue|Cell Lines|Cell-Line|CellRanger - 10x Chromium|CellRanger - 10x Filtered Counts|CellRanger - 10x Raw Counts|Cellular Angiofibroma|Cellular Blue Nevus|Cellular Ependymoma|Cellular Fibroma|Cellular Leiomyoma|Cellular Schwannoma|Cellular angiofibroma|Cellular blue nevus|Cellular ependymoma|Cellular fibroma|Cellular leiomyoma|Cellular schwannoma|Cemadotin|Cemadotin Hydrochloride|Cementifying fibroma|Cemento-ossifying fibroma|Cementoblastoma|Cementoblastoma, benign|Cementoma, NOS|Cemiplimab|Cenersen|Cenisertib|Center QC failed|CenterNotification|Central African Republic|Central Nervous System|Central Nervous System Embryonal Tumor with Rhabdoid Features|Central Nervous System Embryonal Tumor, Not Otherwise Specified|Central Nervous System Lymphoma|Central Nervous System Necrosis|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 1|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 2|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 3|Central Neurocytoma|Central neuroblastoma|Central neurocytoma|Central odontogenic fibroma|Central osteosarcoma|Central portion of breast|Central primitive neuroectodermal tumor, NOS|Centroblastic Lymphoma|Ceralasertib|Ceramide Nanoliposome|Cerdulatinib|Cerebellar Liponeurocytoma|Cerebellar Sarcoma|Cerebellar liponeurocytoma|Cerebellar sarcoma, NOS|Cerebellum|Cerebellum, NOS|Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480|Cereblon E3 Ubiquitin Ligase Modulating Agent CC-99282|Cereblon Modulator CC-90009|Cerebral Cortex|Cerebral Hemisphere|Cerebral Meninges|Cerebral meninges|Cerebrospinal Fluid|Cerebrospinal Fluid Leakage|Cerebrovascular Disease|Cerebrum|Cergutuzumab Amunaleukin|Ceritinib|Ceruminous Adenocarcinoma|Ceruminous adenocarcinoma|Ceruminous adenoma|Ceruminous carcinoma|Cervical Adenocarcinoma Admixed with Neuroendocrine Carcinoma|Cervical Cancer|Cervical Cancer (all types)|Cervical Cancer pT1a1 TNM Finding v8|Cervical Cancer pT1a2 TNM Finding v8|Cervical Mucinous Adenocarcinoma, Gastric Type|Cervical Mucinous Adenocarcinoma, Intestinal-Type|Cervical Spine|Cervical Squamotransitional Carcinoma|Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma|Cervical Villoglandular Adenocarcinoma|Cervical esophagus|Cervical intraepithelial neoplasia, grade III|Cervical intraepithelial neoplasia, low grade|Cervicitis Infection|Cervix|Cervix Uteri|Cervix uteri|Cesalin|Cetrelimab|Cetuximab|Cetuximab Sarotalocan|Cetuximab-IR700 Conjugate RM-1929|Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY)|Cevipabulin|Cevipabulin Fumarate|Cevipabulin Succinate|Cevostamab|ChIP-Seq|Chad|Chaparrin|Chaparrinone|Checkpoint Kinase Inhibitor AZD7762|Checkpoint Kinase Inhibitor XL844|Cheek mucosa|Cheilitis|Chemical Lysis DNA Extraction|Chemodectoma|Chemoembolization|Chemoprotectant|Chemotherapy|Chest|Chest Pain - Cardiac|Chest Wall|Chest Wall Pain|ChiNing Decoction|Chiauranib|Chief cell adenoma|Child|Child-Pugh Class A|Child-Pugh Class A5|Child-Pugh Class A6|Child-Pugh Class B|Child-Pugh Class B7|Child-Pugh Class B8|Child-Pugh Class B9|Child-Pugh Class C|Child-Pugh Class C10|Child-Pugh Class C11|Child-Pugh Class C12|Childhood Astrocytic Tumor|Chile|Chills|Chimeric Monoclonal Antibody 81C6|Chin|China|Chk1 Inhibitor CCT245737|Chk1 Inhibitor GDC-0425|Chk1 Inhibitor GDC-0575|Chlamydia|Chlamydomonas reinhardtii|Chlorambucil|Chlorodihydropyrimidine|Chloroma|Chloroquine|Chloroquinoxaline Sulfonamide|Chlorotoxin|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes|Chlorozotocin|Cholangiocarcinoma|Cholangioma|Cholecystitis|Cholelithiasis|Cholesterol High|Choline|Choline Kinase Alpha Inhibitor TCD-717|Chondroblastic Osteosarcoma|Chondroblastic osteosarcoma|Chondroblastoma|Chondroblastoma, NOS|Chondroblastoma, malignant|Chondroid Chordoma|Chondroid Lipoma|Chondroid chordoma|Chondroid lipoma|Chondroid syringoma|Chondroma|Chondroma, NOS|Chondromatosis|Chondromatosis, NOS|Chondromatous giant cell tumor|Chondromyxoid Fibroma|Chondromyxoid fibroma|Chondrosarcoma|Chondrosarcoma grade 2/3|Chondrosarcoma, NOS|Chordoid Glioma of the Third Ventricle|Chordoid Meningioma|Chordoid glioma|Chordoid glioma of third ventricle|Chordoid meningioma|Chordoma|Chordoma, NOS|Chorioadenoma|Chorioadenoma destruens|Chorioangioma|Choriocarcinoma|Choriocarcinoma Combined with Other Germ Cell Elements|Choriocarcinoma combined with embryonal carcinoma|Choriocarcinoma combined with other germ cell elements|Choriocarcinoma combined with teratorna|Choriocarcinoma, NOS|Chorioepithelioma|Chorionepithelioma|Choroid|Choroid Plexus Carcinoma|Choroid Plexus Papilloma|Choroid plexus carcinoma|Choroid plexus papilloma, NOS|Choroid plexus papilloma, anaplastic|Choroid plexus papilloma, malignant|Choroidal and Ciliary Body Melanoma pT4e TNM Finding v8|Chromaffin paraganglioma|Chromaffin tumor|Chromaffinoma|Chromomycin A3|Chromophobe Renal Cell Carcinoma|Chromophobe adenocarcinoma|Chromophobe adenoma|Chromophobe carcinoma|Chromophobe cell renal carcinoma|Chronic Eosinophilic Leukemia, Not Otherwise Specified|Chronic Fatigue Syndrome|Chronic Hepatitis|Chronic Kidney Disease|Chronic Kidney Disease, Stage 5|Chronic Leukemia|Chronic Lymphocytic Leukemia|Chronic Lymphoproliferative Disorder of NK-Cells|Chronic Monocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Myeloproliferative Disorders|Chronic Neutrophilic Leukemia|Chronic Renal Failure|Chronic Systemic Steroid Use|Chronic eosinophilic leukemia, NOS|Chronic erythremia|Chronic granulocytic leukemia, BCR/ABL|Chronic granulocytic leukemia, NOS|Chronic granulocytic leukemia, Philadelphia chromosome (Ph1) positive|Chronic granulocytic leukemia, t(9;22)(q34;q11)|Chronic idiopathic myelofibrosis|Chronic leukemia, NOS|Chronic lymphatic leukemia|Chronic lymphocytic leukemia|Chronic lymphocytic leukemia, B-cell type (includes all variants of BCLL)|Chronic lymphoid leukemia|Chronic lymphoproliferative disorder of NK cells|Chronic monocytic leukemia|Chronic myelocytic leukemia, NOS|Chronic myelogenous leukemia, BCR-ABL positive|Chronic myelogenous leukemia, Philadelphia chromosome (Ph 1) positive|Chronic myelogenous leukemia, t(9;22)(q34;q11)|Chronic myeloid leukemia, NOS|Chronic myelomonocytic leukemia in transformation|Chronic myelomonocytic leukemia, NOS|Chronic myelomonocytic leukemia, Type 1|Chronic myelomonocytic leukemia, Type II|Chronic myeloproliferative disease, NOS|Chronic myeloproliferative disorder|Chronic neutrophilic leukemia|Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement|Chylothorax|Chymotrypsin|Cibisatamab|Ciclopirox Prodrug CPX-POM|Cidan Herbal Capsule|Ciforadenant|Cigar|Cigarette|Cilengitide|Ciliary Body|Ciliary body|Ciltacabtagene Autoleucel|Cimetidine|Cin III, NOS|Cinacalcet Hydrochloride|Cinobufagin|Cinobufotalin|Cinrebafusp Alfa|Cintirorgon|Cintredekin Besudotox|Circumscribed arachnoidal cerebellar sarcoma|Cirmtuzumab|Cirrhosis|Cirrhosis, Unknown Etiology|Cisplatin|Cisplatin Liposomal|Cisplatin-E Therapeutic Implant|Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6|Citarinostat|Citatuzumab Bogatox|Citius HRT|Cixutumumab|Cladribine|Clanfenur|Clarithromycin|Class 1/4 Histone Deacetylase Inhibitor OKI-179|Classic Medulloblastoma|Classical Hodgkin lymphoma, lymphocyte depletion, NOS|Classical Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis|Classical Hodgkin lymphoma, lymphocyte depletion, reticular|Classical Hodgkin lymphoma, lymphocyte-rich|Classical Hodgkin lymphoma, mixed cellularity, NOS|Classical Hodgkin lymphoma, nodular sclerosis, NOS|Classical Hodgkin lymphoma, nodular sclerosis, cellular phase|Classical Hodgkin lymphoma, nodular sclerosis, grade 1|Classical Hodgkin lymphoma, nodular sclerosis, grade 2|Clavicle|Clear Cell Adenocarcinoma|Clear Cell Adenofibroma|Clear Cell Adenoma|Clear Cell Chondrosarcoma|Clear Cell Cystadenofibroma|Clear Cell Ependymoma|Clear Cell Hidradenoma|Clear Cell Meningioma|Clear Cell Neoplasm|Clear Cell Odontogenic Carcinoma|Clear Cell Renal Cell Carcinoma|Clear Cell Sarcoma of Soft Tissue|Clear Cell Sarcoma of the Kidney|Clear cell (glycogen-rich) urothelial carcinoma|Clear cell adenocarcinofibroma|Clear cell adenocarcinoma, NOS|Clear cell adenocarcinoma, mesonephroid|Clear cell adenofibroma|Clear cell adenofibroma of borderline malignancy|Clear cell adenoma|Clear cell carcinoma|Clear cell chondrosarcoma|Clear cell cystadenocarcinofibroma|Clear cell cystadenofibroma|Clear cell cystadenofibroma of borderline malignancy|Clear cell cystadenoma|Clear cell cystic tumor of borderline malignancy|Clear cell ependymoma|Clear cell hidradenoma|Clear cell meningioma|Clear cell odontogenic carcinoma|Clear cell odontogenic tumor|Clear cell sarcoma of kidney|Clear cell sarcoma of the kidney (CCSK)|Clear cell sarcoma, NOS|Clear cell sarcoma, of tendons and aponeuroses|Clear cell tumor, NOS|Clinical|Clinical Supplement|Clinical Trial|Clinical Trial Agent|Clinical data insufficient|Clioquinol|Clitoris|Clivatuzumab|Cloacogenic carcinoma|Cloacogenic zone|Clodronate Disodium|Clodronic Acid|Clofarabine|Clomesone|Clomiphene|Clomiphene Citrate|Clonal Hematopoiesis|Clostridium Novyi-NT Spores|Coal smoke, NOS|Cobimetinib|Cobolimab|Cobomarsen|Coccidioidomycosis|Cochlear Nerve|Codman tumor|Codrituzumab|Coenzyme Q10|Cofetuzumab Pelidotin|Cognitive Disturbance|Cohort Level Copy Number Scores|Colchicine-Site Binding Agent ABT-751|Cold Contaminant-free Iobenguane I-131|Colitis|Collecting Duct Carcinoma|Collecting duct carcinoma|Colloid adenocarcinoma|Colloid adenoma|Colloid carcinoma|Colloidal Gold-Bound Tumor Necrosis Factor|Colombia|Colon|Colon - Mucosa Only|Colon Adenocarcinoma|Colon Polyps|Colon, NOS|Colonic Fistula|Colonic Hemorrhage|Colonic Obstruction|Colonic Perforation|Colonic Stenosis|Colonic Ulcer|Colonization, Bacterial|Colonization, Fungal|Colonoscopy|Colorectal|Colorectal Cancer|Colorectal Cancer Peptide Vaccine PolyPEPI1018|Colorectal Tumor-Associated Peptides Vaccine IMA910|Coltuximab Ravtansine|Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Columnar cell papilloma|Combined Carcinoid and Adenocarcinoma|Combined Hepatocellular Carcinoma and Cholangiocarcinoma|Combined Lung Large Cell Neuroendocrine Carcinoma|Combined Lung Small Cell Carcinoma|Combined Lung Small Cell Carcinoma and Lung Adenocarcinoma|Combined Nucleotide Variation|Combined carcinoid and adenocarcinoma|Combined hepatocellular carcinoma and cholangiocarcinoma|Combined large cell neuroendocrine carcinoma|Combined small cell carcinoma|Combined small cell-adenocarcinoma|Combined small cell-large carcinoma|Combined small cell-squamous cell carcinoma|Combined/mixed carcinoid and adenocarcinoma|Combretastatin|Combretastatin A-1|Combretastatin A1 Diphosphate|Comedocarcinoma|Comedocarcinoma, NOS|Comedocarcinoma, noninfiltrating|Commensal Bacterial Strain Formulation VE800|Commissure of lip|Common ALL|Common Acute Lymphoblastic Leukemia|Common Duct|Common Variable Immunodeficiency|Common precursor B ALL|Common variable immune deficiency (CVID)|Comoros|Complete Data Freeze|Complete Genomics|Complete Hydatidiform Mole|Complete Necrosis (No Viable Tumor)|Complete Remission|Complete Response|Complete Response Unconfirmed|Complete hydatidiform mole|Complex Epithelial Neoplasms|Complex Mixed and Stromal Neoplasms|Complex Odontoma|Complex odontoma|Composite Hodgkin and non-Hodgkin lymphoma|Composite Lymphoma|Composite carcinoid|Compound Kushen Injection|Compound Nevus|Compound Odontoma|Compound nevus|Compound odontoma|Conatumumab|Conbercept|Concentrated Lingzhi Mushroom Extract|Concentration Impairment|Concurrent Chemoradiation|Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011|Conduction Disorder|Condylomatous carcinoma|Confusion|Congenital Mesoblastic Nephroma|Congenital fibrosarcoma|Congenital generalized fibromatosis|Congenital peribronchial myofibroblastic tumor|Congenital, Familial and Genetic Disorders - Other|Congestive Heart Failure (CHF)|Congo|Conjunctiva|Conjunctivitis|Conjunctivitis Infective|Connective Tissue|Connective Tissue Disorder|Connective, subcutaneous and other soft tissues|Connective, subcutaneous and other soft tissues of abdomen|Connective, subcutaneous and other soft tissues of head, face, and neck|Connective, subcutaneous and other soft tissues of lower limb and hip|Connective, subcutaneous and other soft tissues of pelvis|Connective, subcutaneous and other soft tissues of thorax|Connective, subcutaneous and other soft tissues of trunk, NOS|Connective, subcutaneous and other soft tissues of upper limb and shoulder|Connective, subcutaneous and other soft tissues, NOS|Consent Exemption|Consent Waiver|Consent by Death|Constipation|Constrictive Pericarditis|Control Analyte|Conventional Osteosarcoma|Conventional central osteosarcoma|Convincing Image Source|Cook Islands|Cooking-related smoke, NOS|Copanlisib|Copanlisib Hydrochloride|Copper Cu 64-ATSM|Copper Cu 67 Tyr3-octreotate|Copper Gluconate|Copy Number Estimate|Copy Number Segment|Copy Number Variation|Cord Blood Derived CAR T-Cells|Cord Blood-derived Expanded Natural Killer Cells PNK-007|Cordycepin|Cordycepin Triphosphate|Core Biopsy|Coriolus Versicolor Extract|Cornea, NOS|Corneal Infection|Corneal Ulcer|Coronary Artery Disease|Corpus uteri|Cortex of adrenal gland|Cortical T ALL|Corticorelin Acetate|Cortisone Acetate|Cosibelimab|Cositecan|Costa Rica|Cote d'Ivoire|Cough|Course of Therapy Completed|Cousin|Cowden Syndrome|Coxsackievirus A21|Coxsackievirus V937|CpG Oligodeoxynucleotide GNKG168|Cranial Nerve Infection|Cranial nerve, NOS|Craniopharyngeal duct|Craniopharyngioma|Craniopharyngioma, adamantinomatous|Craniopharyngioma, papillary|Creatinine Increased|Crenolanib|Crenolanib Besylate|Cribriform Carcinoma|Cribriform carcinoma in situ|Cribriform carcinoma, NOS|Cribriform comedo-type carcinoma|Crizotinib|Croatia|Crohn's Disease|Crolibulin|Cryoablation|Cryopreserved|Cryptococcal Meningitis|Cryptococcosis|Cryptogenic Organizing Pneumonia|Cryptophycin|Cryptophycin 52|Cryptosporidiosis, Chronic Intestinal|Crystalline Genistein Formulation AXP107-11|Cuba|Cufflinks|Curacao|Curcumin|Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110|Cure|Current User|Cusatuzumab|Cushingoid|Custirsen Sodium|Cutaneous Mastocytosis|Cutaneous Nodular Melanoma|Cutaneous T-cell lymphoma, NOS|Cutaneous histiocytoma, NOS|Cutaneous lymphoma, NOS|Cutaneous mastocytosis|Cyclin-dependent Kinase 8/19 Inhibitor BCD 115|Cyclin-dependent Kinase Inhibitor PF-06873600|Cyclodextrin-Based Polymer-Camptothecin CRLX101|Cyclodisone|Cycloleucine|Cyclopentenyl Cytosine|Cyclophosphamide|Cyclophosphamide Anhydrous|Cyclosporine|Cylindrical cell carcinoma|Cylindrical cell papilloma|Cylindroma|Cylindroma of skin|Cylindroma, NOS|Cyproterone|Cyproterone Acetate|Cyprus|Cyst(s)|Cyst-associated renal cell carcinoma|Cystadenocarcinoma|Cystadenocarcinoma, NOS|Cystadenofibroma|Cystadenofibroma, NOS|Cystadenoma|Cystadenoma, NOS|Cystectomy|Cystic Hygroma|Cystic Partially Differentiated Kidney Nephroblastoma|Cystic Teratoma|Cystic Tumor of the Atrioventricular Node|Cystic astrocytoma|Cystic hygroma|Cystic hypersecretory carcinoma|Cystic lymphangioma|Cystic mesothelioma, NOS|Cystic mesothelioma, benign|Cystic partially differentiated nephroblastoma|Cystic teratoma, NOS|Cystic tumor of atrio-ventricular node|Cystic, Mucinous and Serous Neoplasms|Cystitis Noninfective|Cystoma, NOS|Cystosarcoma phyllodes, NOS|Cystosarcoma phyllodes, benign|Cystosarcoma phyllodes, malignant|Cystoscopy|Cytarabine|Cytarabine Monophosphate Prodrug MB07133|Cytarabine-asparagine Prodrug BST-236|Cytidine Analog RX-3117|Cytochlor|Cytokine Release Syndrome|Cytokine-based Biologic Agent IRX-2|Cytologic Atypia|Cytology|Cytomegalovirus|Cytomegalovirus (CMV)|Czech Republic (Czechia)|D|D-methionine Formulation MRX-1024|DAB389 Epidermal Growth Factor|DACH Polymer Platinate AP5346|DACH-Platin Micelle NC-4016|DCIS, NOS|DCIS, comedo type|DCIS, papillary|DDA|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|DEXSeq|DFS|DGE|DHA-Paclitaxel|DHEA Mustard|DI-Leu16-IL2 Immunocytokine|DIA|DIN 3|DKK1-Neutralizing Monoclonal Antibody DKN-01|DM-CHOC-PEN|DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015|DNA|DNA Interference Oligonucleotide PNT2258|DNA Methylation|DNA Minor Groove Binding Agent SG2000|DNA Plasmid Encoding Interleukin-12 INO-9012|DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151|DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457|DNA Vaccine VB10.16|DNA-PK inhibitor AZD7648|DNA-PK/PI3K-delta Inhibitor BR101801|DNA-PK/TOR Kinase Inhibitor CC-115|DNA-dependent Protein Kinase Inhibitor VX-984|DNAcopy|DNMT1 Inhibitor NTX-301|DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98|DPT/BCG/Measles/Serratia/Pneumococcus Vaccine|DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine|DPX-E7 HPV Vaccine|DR5 HexaBody Agonist GEN1029|DR5-targeting Tetrameric Nanobody Agonist TAS266|DSQ II|DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555|DU-Disease Unchanged|DVT/PE|Dabrafenib|Dabrafenib Mesylate|Dabska tumor|Dacarbazine|Dacetuzumab|Daclizumab|Dacomitinib|Dacplatinum|Dactinomycin|Dactolisib|Dactolisib Tosylate|Daily|Dalantercept|Dalotuzumab|Danio rerio (zebrafish)|Daniquidone|Danusertib|Danvatirsen|Daporinad|Daratumumab|Daratumumab and Hyaluronidase-fihj|Daratumumab/rHuPH20|Darinaparsin|Darleukin|Darolutamide|Daromun|Dasatinib|Daughter|Daughter-in-law|Daunorubicin|Daunorubicin Citrate|Daunorubicin Hydrochloride|Dead|Death|Death Certificate|Death NOS|Death Neonatal|Debulking|Decitabine|Decitabine and Cedazuridine|Dedifferentiated Chondrosarcoma|Dedifferentiated Chordoma|Dedifferentiated Liposarcoma|Dedifferentiated chondrosarcoma|Dedifferentiated chordoma|Dedifferentiated liposarcoma|Deep ""Aggressive"" Angiomyxoma|Deep Benign Fibrous Histiocytoma|Deep Gray (e.g. Basal Ganglia, Thalamus)|Deep Gray Matter|Deep Parotidectomy|Deep Vein Thrombosis / Thromboembolism|Deep histiocytoma|Defactinib|Defactinib Hydrochloride|Deferoxamine|Deferoxamine Mesylate|Degarelix|Degarelix Acetate|Degenerated Schwannoma|Degenerated schwannoma|Dehydration|Delanzomib|Delayed Orgasm|Delayed Puberty|Delirium|Delolimogene Mupadenorepvec|Delta_B_Allele_Freq|Delusions|Demcizumab|Demecolcine|Democratic Republic of the Congo|Demplatin Pegraglumer|Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466|Dendritic Cell Tumor, Not Otherwise Specified|Dendritic Cell Vaccine|Dendritic Cell-Autologous Lung Tumor Vaccine|Dendritic Cell-targeting Lentiviral Vector ID-LV305|Dendritic cell sarcoma, NOS|Denenicokin|Dengue Virus Adjuvant PV-001-DV|Denibulin|Denibulin Hydrochloride|Denileukin Diftitox|Denintuzumab Mafodotin|Denmark|Denosumab|Dental Caries|Dentinogenic Ghost Cell Tumor|Dentinoma|Denys-Drash Syndrome|Deoxycytidine Analogue TAS-109|Deoxycytidine Analogue TAS-109 Hydrochloride|Depatuxizumab|Depatuxizumab Mafodotin|Depressed Level of Consciousness|Depression|Derazantinib|Derived Cell Line|Dermal|Dermal Nevus|Dermal and epidermal nevus|Dermal nevus|Dermatitis Radiation|Dermatofibroma lenticulare|Dermatofibroma, NOS|Dermatofibrosarcoma Protuberans|Dermatofibrosarcoma protuberans, NOS|Dermatofibrosarcoma, NOS|Dermatomyosis|Dermoid Cyst|Dermoid cyst with malignant transformation|Dermoid cyst with secondary tumor|Dermoid cyst, NOS|Dermoid, NOS|Descended testis|Descending Colon|Descending colon|Deslorelin|Deslorelin Acetate|Desmoid, NOS|Desmoid-Type Fibromatosis|Desmoplastic Infantile Astrocytoma|Desmoplastic Infantile Ganglioglioma|Desmoplastic Melanoma|Desmoplastic Mesothelioma|Desmoplastic Small Round Cell Tumor|Desmoplastic fibroma|Desmoplastic infantile astrocytoma|Desmoplastic infantile ganglioglioma|Desmoplastic medulloblastoma|Desmoplastic melanoma, amelanotic|Desmoplastic melanoma, malignant|Desmoplastic mesothelioma|Desmoplastic nodular medulloblastoma|Desmoplastic small round cell tumor|Desmoplastic/Nodular Medulloblastoma|Detirelix|Detorubicin|Deuteporfin|Deuterated Enzalutamide|Device Related Infection|Devimistat|Dexamethason|Dexamethasone|Dexamethasone Phosphate|Dexamethasone Sodium Phosphate|Dexanabinol|Dexrazoxane|Dexrazoxane Hydrochloride|Dezaguanine|Dezaguanine Mesylate|Dezapelisib|Di Guglielmo disease|DiART|DiLeu|Diabetes|Diabetes, NOS|Diabetes, Type I|Diabetes, Type II|Diabetic Neuropathy|Diagnosis|Diagnostic Imaging|Diagnostic Slide|Dianhydrogalactitol|Diaphragm|Diarrhea|Diarylsulfonylurea Compound ILX-295501|Diazepinomicin|Diaziquone|Diazooxonorleucine|Dibrospidium Chloride|Dichloroallyl Lawsone|Dictyostelium discoideum|Dicycloplatin|Didox|Dienogest|Diet|Diet Controlled Diabetes|Diethylnorspermine|Differential Gene Expression|Differentiated Retinoblastoma|Differentiated penile intraepithelial neoplasia|Differentiated-type vulvar intraepithelial neoplasia|Differentiating|Differentiating Neuroblastoma|Diffuse|Diffuse Astrocytoma|Diffuse Astrocytoma, IDH-Mutant|Diffuse Astrocytoma, IDH-Wildtype|Diffuse Centroblastic-Centrocytic Lymphoma|Diffuse Cutaneous Mastocytosis|Diffuse Intraductal Papillomatosis|Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma (DLBCL)|Diffuse Large B-Cell Lymphoma Arising in HHV8-Positive Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation|Diffuse Leptomeningeal Glioneuronal Tumor|Diffuse Malignant Lymphoma|Diffuse Midline Glioma, H3 K27M-Mutant|Diffuse Retinoblastoma|Diffuse Sclerosing Variant Thyroid Gland Papillary Carcinoma|Diffuse Type Adenocarcinoma|Diffuse astrocytoma|Diffuse astrocytoma, IDH-mutant|Diffuse astrocytoma, IDH-wildtype|Diffuse astrocytoma, low grade|Diffuse cutaneous mastocytosis|Diffuse intraductal papillomatosis|Diffuse large B-cell lymphoma associated with chronic inflammation|Diffuse large B-cell lymphoma, NOS|Diffuse leptomeningeal glioneuronal tumor|Diffuse melanocytosis|Diffuse meningiomatosis|Diffuse midline glioma, H3 K27M-mutant|Digestive System Mixed Adenoneuroendocrine Carcinoma|Digital Papillary Adenocarcinoma|Digital papillary adenocarcinoma|Digitoxin|Digoxin|Dihydro-5-Azacytidine|Dihydrolenperone|Dihydroorotate Dehydrogenase Inhibitor AG-636|Dihydroorotate Dehydrogenase Inhibitor BAY2402234|Diindolylmethane|Diktyoma, benign|Diktyoma, malignant|Dilation and Curettage|Dilation and Curettage Procedure|Dilpacimab|Dimethylmyleran|Dinaciclib|Dinutuximab|Dionex|Dioscorea nipponica Makino Extract DNE3|Diphencyprone|Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777|Disease Progression|Disease Response|Disqualified|Disseminated Intravascular Coagulation|Distal (>2cm)|Distant|Distant Metastasis|Distant Nodes|Distant Organ|Distant Site|Distant met recurrence/progression|Ditiocarb|Diverticulitis|Dizziness|Djibouti|Docetaxel|Docetaxel Anhydrous|Docetaxel Emulsion ANX-514|Docetaxel Formulation CKD-810|Docetaxel Lipid Microspheres|Docetaxel Nanoparticle CPC634|Docetaxel Polymeric Micelles|Docetaxel-PNP|Docetaxel-loaded Nanopharmaceutical CRLX301|Docetaxel/Ritonavir|Dociparstat sodium|Dolastatin 10|Dolastatin 15|Domatinostat|Dome of bladder|Dome of the Bladder|Domestic Partner|Dominica|Dominican Republic|Donafenib|Dopamine-Somatostatin Chimeric Molecule BIM-23A760|Dorsal surface of tongue, NOS|Dostarlimab|Double-armed TMZ-CD40L/4-1BBL Oncolytic Ad5/35 Adenovirus LOAd703|Dovitinib|Dovitinib Lactate|Downstream Data Freeze|Doxazosin|Doxercalciferol|Doxifluridine|Doxorubicin|Doxorubicin Hydrochloride|Doxorubicin Prodrug L-377,202|Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370|Doxorubicin-Eluting Beads|Doxorubicin-HPMA Conjugate|Doxorubicin-Magnetic Targeted Carrier Complex|Doxorubicin-loaded EGFR-targeting Nanocells|Drinker|Dromostanolone Propionate|Drosophila melanogaster|Drozitumab|Dry Eye|Dry Mouth|Dry Skin|Dual IGF-1R/InsR Inhibitor BMS-754807|Dual Variable Domain Immunoglobulin ABT-165|Dual-affinity B7-H3/CD3-targeted Protein MGD009|Dubermatinib|Duborimycin|Duct adenocarcinoma, NOS|Duct adenoma, NOS|Duct carcinoma, NOS|Duct carcinoma, desmoplastic type|Duct cell carcinoma|Ductal Breast Carcinoma|Ductal Breast Carcinoma In Situ|Ductal Breast Carcinoma In Situ and Invasive Lobular Carcinoma|Ductal Breast Carcinoma In Situ and Lobular Carcinoma In Situ|Ductal and Lobular Neoplasms|Ductal carcinoma in situ, NOS|Ductal carcinoma in situ, comedo type|Ductal carcinoma in situ, cribriform type|Ductal carcinoma in situ, micropapillary|Ductal carcinoma in situ, papillary|Ductal carcinoma in situ, solid type|Ductal carcinoma, NOS|Ductal carcinoma, cribriform type|Ductal intraepithelial neoplasia 3|Ductal papilloma|Dulanermin|Duligotuzumab|Duodenal Fistula|Duodenal Hemorrhage|Duodenal Infection|Duodenal Obstruction|Duodenal Perforation|Duodenal Stenosis|Duodenal Ulcer|Duodenum|Dupilumab|Duplicate case|Duplicate item|Durvalumab|Dusigitumab|Duvelisib|Duvortuxizumab|Dynemicin|Dynemicin A|Dysarthria|Dysembryoplastic Neuroepithelial Tumor|Dysembryoplastic neuroepithelial tumor|Dysesthesia|Dysgerminoma|Dysgeusia|Dyslipidemia|Dysmenorrhea|Dyspareunia|Dyspepsia|Dysphagia|Dysphasia|Dysplasia Negative|Dysplastic Cerebellar Gangliocytoma|Dysplastic Nevus|Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)|Dysplastic nevus|Dyspnea|E|E2F1 Pathway Activator ARQ 171|E4512|EA5142|EBNA-1 inhibitor VK-2019|EBV Immortalized|EBV Immortalized Normal|EBV positive diffuse large B-cell lymphoma of the elderly|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EC cell carcinoid|ECD|ECL cell carcinoid, NOS|ECL cell carcinoid, malignant|EED Inhibitor MAK683|EGFR Antagonist Hemay022|EGFR Antisense DNA BB-401|EGFR Inhibitor AZD3759|EGFR Inhibitor BIBX 1382|EGFR Inhibitor DBPR112|EGFR Inhibitor PD-168393|EGFR Inhibitor TY-9591|EGFR Mutant-selective  Inhibitor TQB3804|EGFR Mutant-specific Inhibitor BPI-7711|EGFR Mutant-specific Inhibitor CK-101|EGFR Mutant-specific Inhibitor D-0316|EGFR Mutant-specific Inhibitor ZN-e4|EGFR T790M Antagonist BPI-15086|EGFR T790M Inhibitor HS-10296|EGFR/EGFRvIII Inhibitor WSD0922-FU|EGFR/FLT3/Abl Inhibitor SKLB1028|EGFR/HER1/HER2 Inhibitor PKI166|EGFR/HER2 Inhibitor AP32788|EGFR/HER2 Inhibitor AV-412|EGFR/HER2 Inhibitor DZD9008|EGFR/HER2 Kinase Inhibitor TAK-285|EGFR/TGFb Fusion Monoclonal Antibody BCA101|EGFR/VEGFR/RET Inhibitor HA121-28|EGb761|EMD 1000|EP2/EP4 Antagonist TPST-1495|EP4 Antagonist INV-1120|EP4 Antagonist ONO-4578|ER alpha Proteolysis-targeting Chimera Protein Degrader ARV-471|ERK 1/2 Inhibitor ASTX029|ERK Inhibitor CC-90003|ERK Inhibitor GDC-0994|ERK Inhibitor LTT462|ERK Inhibitor MK-8353|ERK1/2 Inhibitor ASN007|ERK1/2 Inhibitor HH2710|ERK1/2 Inhibitor JSI-1187|ERK1/2 Inhibitor KO-947|ERK1/2 Inhibitor LY3214996|ERa36 Modulator Icaritin|ETD|EVOQ Elite|EVOQ Qube|EZH1/2 Inhibitor DS-3201|EZH1/2 Inhibitor HH2853|EZH2 Inhibitor CPI-1205|EZH2 Inhibitor PF-06821497|EZH2 Inhibitor SHR2554|EZH2 inhibitor CPI-0209|Ear|Ear Canal|Ear Pain|Ear and Labyrinth Disorders - Other|Ear, Pinna (External)|Early Onset Gastric Cancer|Ecchondroma|Ecchondrosis|Eccrine Hidrocystoma|Eccrine acrospiroma|Eccrine adenocarcinoma|Eccrine cystadenoma|Eccrine dermal cylindroma|Eccrine papillary adenocarcinoma|Eccrine papillary adenoma|Eccrine poroma|Eccrine poroma, malignant|Eccrine spiradenoma|Echinomycin|Ecromeximab|Ectocervix|Ectomesenchymoma|Ectopic Hamartomatous Thymoma|Ectopic Pregnancy|Ectopic hamartomatous thymoma|Ecuador|Eczema|Edatrexate|Edelfosine|Edema Cerebral|Edema Face|Edema Limbs|Edema Trunk|Edicotinib|Edodekin alfa|Edotecarin|Edrecolomab|Efatutazone|Efatutazone Dihydrochloride|Effusion|Efizonerimod|Eflornithine|Eflornithine Hydrochloride|Eftilagimod Alpha|Eftozanermin Alfa|Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205|Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621|Egypt|Eicosapentaenoic Acid|Ejaculation Disorder|Ejection Fraction Decreased|El Salvador|Elacestrant|Elacytarabine|Elagolix|Elastofibroma|Elbasvir/Grazoprevir|Elbow|Electrical fire smoke|Electrocardiogram QT Corrected Interval Prolonged|Electronic Cigarette|Electronic cigarette smoke, NOS|Element 2|Element GD|Element XR|Elesclomol|Elesclomol Sodium|Elgemtumab|Elinafide|Elisidepsin|Elliptinium|Elliptinium Acetate|Elmustine|Elotuzumab|Elpamotide|Elsamitrucin|Eltanexor|Emactuzumab|Emapalumab|Embolization|Embryonal Carcinoma|Embryonal Rhabdomyosarcoma|Embryonal Tumor with Multilayered Rosettes, C19MC-Altered|Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified|Embryonal adenocarcinoma|Embryonal adenoma|Embryonal carcinoma, NOS|Embryonal carcinoma, infantile|Embryonal carcinoma, polyembryonal type|Embryonal hepatoma|Embryonal rhabdomyosarcoma, NOS|Embryonal rhabdomyosarcoma, pleomorphic|Embryonal sarcoma|Embryonal teratoma|Embryonal tumor with multilayered rosettes C19MC-altered|Embryonal tumor with multilayered rosettes, NOS|Embryonal tumor with rhabdoid features|Emepepimut-S|Emibetuzumab|Emitefur|Emofolin Sodium|Empesertib|Enadenotucirev|Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A|Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641|Enasidenib|Enasidenib Mesylate|Enavatuzumab|Encapsulated Rapamycin|Encapsulated Variant Thyroid Gland Papillary Carcinoma|Encapsulated follicular variant of papillary thyroid carcinoma, NOS (EFVPTC, NOS)|Encapsulated papillary carcinoma|Encapsulated papillary carcinoma with invasion|Encelimab|Encephalitis Infection|Encephalomyelitis Infection|Encephalopathy|Enchondroma|Enclomiphene|Enclomiphene Citrate|Encorafenib|End-stage Renal Disease|Endemic|Endemic Burkitt Lymphoma|Endo Rectal Tumor Resection|Endocarditis Infective|Endocervical Adenocarcinoma, Usual Type|Endocervical adenocarcinoma usual type|Endocervix|Endocrine Disorders - Other|Endocrine Gland|Endocrine adenomatosis|Endocrine gland, NOS|Endocrine tumor, functioning, NOS|Endodermal sinus tumor|Endolaryngeal Excision|Endolymphatic stromal myosis|Endometrial Endometrioid Adenocarcinoma, Ciliated Variant|Endometrial Endometrioid Adenocarcinoma, Secretory Variant|Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation|Endometrial Stromal Nodule|Endometrial sarcoma, NOS|Endometrial stromal nodule|Endometrial stromal sarcoma, NOS|Endometrial stromal sarcoma, high grade|Endometrial stromal sarcoma, low grade|Endometrial stromatosis|Endometrioid Adenocarcinoma|Endometrioid Stromal Sarcoma|Endometrioid adenocarcinoma, NOS|Endometrioid adenocarcinoma, ciliated cell variant|Endometrioid adenocarcinoma, secretory variant|Endometrioid adenocarcinoma, villoglandular|Endometrioid adenofibroma, NOS|Endometrioid adenofibroma, borderline malignancy|Endometrioid adenofibroma, malignant|Endometrioid adenoma, NOS|Endometrioid adenoma, borderline malignancy|Endometrioid carcinoma with squamous differentiation|Endometrioid carcinoma, NOS|Endometrioid cystadenocarcinoma|Endometrioid cystadenofibroma, NOS|Endometrioid cystadenofibroma, borderline malignancy|Endometrioid cystadenofibroma, malignant|Endometrioid cystadenoma, NOS|Endometrioid cystadenoma, borderline malignancy|Endometrioid tumor of low malignant potential|Endometriosis|Endometrium|Endophthalmitis|Endosalpingiosis|Endoscopic Biopsy|Endoscopic Mucosal Resection (EMR)|Endoscopy|Endothelin B Receptor Blocker ENB 003|Endothelin Receptor Type A Antagonist YM598|Endotheliomatous meningioma|Endovascular papillary angioendothelioma|Enfortumab Vedotin|Engineered Human Umbilical Vein Endothelial Cells AB-205|Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240|Engineered Toxin Body Targeting CD38 TAK-169|Engineered Toxin Body Targeting HER2 MT-5111|Eniluracil/5-FU Combination Tablet|Enloplatin|Enneking High Surgical Grade|Enneking Low Surgical Grade|Enneking Metastasis M0|Enneking Metastasis M1|Enoblituzumab|Enobosarm|Enoticumab|Enpromate|Ensartinib|Ensituximab|Enteric adenocarcinoma|Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride|Enterochromaffin cell carcinoid|Enterochromaffin-Like Cell Neuroendocrine Tumor G1|Enterochromaffin-like cell carcinoid, NOS|Enterochromaffin-like cell tumor, malignant|Enterococcus gallinarum Strain MRx0518|Enterocolitis|Enterocolitis Infectious|Enteroglucagonoma|Enteroglucagonoma, NOS|Enteroglucagonoma, malignant|Enteropathy associated T-cell lymphoma|Enteropathy type intestinal T-cell lymphoma|Enteropathy-Associated T-Cell Lymphoma|Enterovesical Fistula|Entinostat|Entolimod|Entospletinib|Entrectinib|Enucleation|Envafolimab|Environmental tobacco smoke|Enzalutamide|Enzastaurin|Enzastaurin Hydrochloride|Eosinophil adenocarcinoma|Eosinophil adenoma|Eosinophil carcinoma|Eosinophilic Granuloma|Eosinophilic granuloma|Eosinophilic leukemia|Epacadostat|Epcoritamab|Ependymoblastoma|Ependymoma|Ependymoma, NOS|Ependymoma, RELA Fusion-Positive|Ependymoma, RELA fusion-positive|Ependymoma, anaplastic|EphA2-targeting Bicycle Toxin Conjugate BT5528|Epidermoid carcinoma in situ with questionable stromal invasion|Epidermoid carcinoma in situ, NOS|Epidermoid carcinoma, NOS|Epidermoid carcinoma, keratinizing|Epidermoid carcinoma, large cell, nonkeratinizing|Epidermoid carcinoma, small cell, nonkeratinizing|Epidermoid carcinoma, spindle cell|Epididymis|Epidural Space|Epilepsy|Epipodophyllotoxin Analog GL331|Epipodophyllotoxin-Related Myelodysplastic Syndrome|Epipropidine|Epirubicin|Epirubicin Hydrochloride|Epistaxis|Epithelial Dysplasia|Epithelial Hyperplasia|Epithelial Neoplasm|Epithelial Neoplasms, NOS|Epithelial Synovial Sarcoma|Epithelial ependymoma|Epithelial tumor, benign|Epithelial tumor, malignant|Epithelial-Myoepithelial Carcinoma|Epithelial-myoepithelial carcinoma|Epithelioid Cell Melanoma|Epithelioid Cell Nevus|Epithelioid Cell Type Gastrointestinal Stromal Tumor|Epithelioid Glioblastoma|Epithelioid Hemangioendothelioma|Epithelioid Hemangioma|Epithelioid Leiomyosarcoma|Epithelioid MPNST|Epithelioid Malignant Peripheral Nerve Sheath Tumor|Epithelioid Mesothelioma|Epithelioid Sarcoma|Epithelioid Trophoblastic Tumor|Epithelioid and spindle cell nevus|Epithelioid cell melanoma|Epithelioid cell nevus|Epithelioid cell sarcoma|Epithelioid glioblastoma|Epithelioid hemangioendothelioma, NOS|Epithelioid hemangioendothelioma, malignant|Epithelioid hemangioma|Epithelioid leiomyoma|Epithelioid leiomyosarcoma|Epithelioid malignant peripheral nerve sheath tumor|Epithelioid mesothelioma, NOS|Epithelioid mesothelioma, benign|Epithelioid mesothelioma, malignant|Epithelioid sarcoma|Epithelioma adenoides cysticum|Epithelioma, NOS|Epithelioma, benign|Epithelioma, malignant|Epitinib Succinate|Epitiostanol|Epitrochlear|Epothilone Analog UTD1|Epothilone KOS-1584|Epratuzumab|Epratuzumab-cys-tesirine|Epstein-Barr Virus|Equatorial Guinea|Equivocal|Erastin Analogue PRLX 93936|Erbulozole|Erdafitinib|Erectile Dysfunction|Eribulin|Eribulin Mesylate|Eritrea|Erlotinib|Erlotinib Hydrochloride|Ertumaxomab|Erythema Multiforme|Erythremic myelosis, NOS|Erythrocyte-encapsulated L-asparaginase Suspension|Erythroderma|Erythroleukemia|Escherichia coli|Esophageal Anastomotic Leak|Esophageal Cancer|Esophageal Carcinoma|Esophageal Fistula|Esophageal Hemorrhage|Esophageal High Grade Intraepithelial Neoplasia|Esophageal Infection|Esophageal Necrosis|Esophageal Obstruction|Esophageal Pain|Esophageal Perforation|Esophageal Stenosis|Esophageal Ulcer|Esophageal Varices Hemorrhage|Esophageal glandular dysplasia (intraepithelial neoplasia), high grade|Esophageal glandular dysplasia (intraepithelial neoplasia), low grade|Esophageal intraepithelial neoplasia, high grade|Esophageal squamous intraepithelial neoplasia (dysplasia), high grade|Esophageal squamous intraepithelial neoplasia (dysplasia), low grade|Esophageal; Distal|Esophageal; Mid|Esophageal; Proximal|Esophagitis|Esophagogastric Junction|Esophagus|Esophagus - Mucosa Only|Esophagus, NOS|Esorubicin|Esorubicin Hydrochloride|Esperamicin A1|Essential Thrombocythemia|Essential hemorrhagic thrombocythaemia|Essential thrombocythemia|Essiac|Esterified Estrogens|Esthesioneuroblastoma|Esthesioneurocytoma|Esthesioneuroepithelioma|Estonia|Estradiol Valerate|Estramustine|Estramustine Phosphate Sodium|Estrogen Receptor Agonist GTx-758|Estrogen only|Estrogens, Conjugated|Eswatini|Etalocib|Etanercept|Etanidazole|Etaracizumab|Etarotene|Ethanol Injection Ablation|Ethaselen|Ethinyl Estradiol|Ethiopia|Ethmoid sinus|Ethyleneimine|Ethylnitrosourea|Etidronate-Cytarabine Conjugate MBC-11|Etigilimab|Etirinotecan Pegol|Etoglucid|Etoposide|Etoposide Phosphate|Etoposide Toniribate|Etoprine|Etoricoxib|Ets-family Transcription Factor Inhibitor TK216|Euphoria|Everolimus|Everolimus Tablets for Oral Suspension|Every 24 Hours|Every Hour|Every Other Day|Every day|Evofosfamide|Ewing Sarcoma|Ewing sarcoma|Ewing tumor|Ex Vivo-expanded Autologous T Cells IMA101|Exactive|Exactive Plus|Exatecan Mesylate|Exatecan Mesylate Anhydrous|Excision|Excisional Biopsy|Exemestane|Exicorilant|Exisulind|Exocervix|Exon Expression Quantification|Exoresection|Exostosis|Expanded Next Generation Cancer Model|Experiment Metadata|Extended Release Flucytosine|Extended Release Metformin Hydrochloride|Extended-release Onapristone|External Auditory Canal Ceruminous Adenoma|External Beam Radiation|External Ear Inflammation|External Ear Pain|External Lower Lip|External ear|External lip, NOS|External lower lip|External upper lip|Extra-Adrenal Paraganglioma|Extra-abdominal desmoid|Extra-adrenal paraganglioma, NOS|Extra-adrenal paraganglioma, malignant|Extraabdominal Fibromatosis|Extracompartmental (T2)|Extracompartmental Tumor|Extracutaneous Mastocytoma|Extracutaneous mastocytoma|Extrahepatic bile duct|Extramammary Paget Disease|Extramural|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Extranodal NK/T-cell lymphoma, nasal type|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extraocular Muscle Paresis|Extraosseous Plasmacytoma|Extraosseous plasmacytoma|Extrapyramidal Disorder|Extraventricular Neurocytoma|Extraventricular neurocytoma|Eye|Eye Disorders - Other|Eye Infection|Eye Pain|Eye and adnexa|Eye, NOS|Eyelid|Eyelid Function Disorder|Ezabenlimab|F16-IL2 Fusion Protein|FAB L2|FAB L3|FAB Ll|FAB M1|FAB M2, AML1(CBF-alpha)/ETO|FAB M2, NOS|FAB M2, t(8;21)(q22;q22)|FAB M3 (includes all variants)|FAB M4|FAB M4Eo|FAB M5 (includes all variants)|FAB M6|FAB M7|FAB MO|FACT Complex-targeting Curaxin CBL0137|FAK Inhibitor GSK2256098|FAK Inhibitor PF-00562271|FAK Inhibitor VS-4718|FAK/ALK/ROS1 Inhibitor APG-2449|FAP/4-1BB-targeting DARPin MP0310|FAP/4-1BB-targeting Fusion Protein RO7122290|FASN Inhibitor TVB-2640|FASTA|FASTQ|FFPE|FFPE DNA|FFPE RNA|FFPE Recurrent|FFPE Scrolls|FGF Receptor Antagonist HGS1036|FGF/FGFR Pathway Inhibitor E7090|FGFR Inhibitor ASP5878|FGFR Inhibitor AZD4547|FGFR Inhibitor CPL304110|FGFR Inhibitor Debio 1347|FGFR Inhibitor TAS-120|FGFR/CSF-1R Inhibitor 3D185|FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999|FGFR1/2/3 Inhibitor HMPL-453|FGFR2 Inhibitor RLY-4008|FGFR4 Antagonist INCB062079|FGFR4 Inhibitor BLU 9931|FGFR4 Inhibitor FGF401|FGFR4 Inhibitor H3B-6527|FGFR4 Inhibitor ICP-105|FIGO Stage IA|FIGO Stage IC1|FIGO Stage IC2|FIGO Stage IC3|FIGO Stage IIIA1(i)|FIGO Stage IIIA1(ii)|FIGO Stage IIIA2|FIRMA|FLT3 Inhibitor FF-10101 Succinate|FLT3 Inhibitor HM43239|FLT3 Inhibitor SKI-G-801|FLT3 Tyrosine Kinase Inhibitor TTT-3002|FLT3/ABL/Aurora Kinase Inhibitor KW-2449|FLT3/CDK4/6 Inhibitor FLX925|FLT3/FGFR Dual Kinase Inhibitor MAX-40279|FLT3/KIT Kinase Inhibitor AKN-028|FLT3/KIT/CSF1R Inhibitor NMS-03592088|FM Copy Number Variation|FM Simple Somatic Mutation|FM Structural Variation|FMS Inhibitor JNJ-40346527|FPV Vaccine CV301|FPV-Brachyury-TRICOM Vaccine|FTMS|Facial Muscle Weakness|Facial Nerve Disorder|Facial Pain|Factor VII-targeting Immunoconjugate Protein ICON-1|Factor VIIa Inhibitor PCI-27483|Factory smokestack smoke|Fadraciclib|Fadrozole Hydrochloride|Falimarev|Falkland Islands (Malvinas)|Fall|Fallopian Tube|Fallopian Tube Anastomotic Leak|Fallopian Tube Obstruction|Fallopian Tube Perforation|Fallopian Tube Stenosis|Fallopian tube|False|Familial Adenomatous Polyposis|Familial polyposis coli|Famitinib|Fanconi Anemia|Farletuzumab|Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778,123|Faroe Islands|Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells|Fas Receptor Agonist APO010|Fascial Fibroma|Fascial Fibrosarcoma|Fascial fibroma|Fascial fibrosarcoma|Fascin Inhibitor NP-G2-044|Fat Atrophy|Father|Father-in-law|Fatigue|Favezelimab|Favorable|Fazarabine|Fc-engineered Anti-CD40 Agonist Antibody 2141-V11|Febrile Neutropenia|Febuxostat|Fecal Incontinence|Federated States of Micronesia|Fedratinib|Fedratinib Hydrochloride|Feladilimab|Felzartamab|Female|Female Cousin|Female Genital Tract Fistula|Female Genitalia|Female Reproductive System Adenofibroma|Female Sibling of Adopted Child|Female genital tract, NOS|Feminization Acquired|Femoral Artery|Femoral Vein|Femur|Fenebrutinib|Fenretinide|Fenretinide Lipid Matrix|Fenretinide Phospholipid Suspension ST-001|Fetal Death|Fetal Growth Retardation|Fetal Rhabdomyoma|Fetal adenocarcinoma|Fetal adenoma|Fetal fat cell lipoma|Fetal lipoma, NOS|Fetal lipomatosis|Fetal rhabdomyoma|Fever|Fianlimab|Fibrillary Astrocytoma|Fibrillary astrocytoma|Fibrinogen Decreased|Fibro-osteoma|Fibroadenoma, NOS|Fibroameloblastic odontoma|Fibroblastic Liposarcoma|Fibroblastic Osteosarcoma|Fibroblastic Reticular Cell Tumor|Fibroblastic liposarcoma|Fibroblastic meningioma|Fibroblastic osteosarcoma|Fibroblastic reticular cell tumor|Fibroblasts|Fibroblasts from Bone Marrow Normal|Fibrochondrosarcoma|Fibroepithelial Neoplasms|Fibroepithelial basal cell carcinoma, Pinkus type|Fibroepithelioma of Pinkus type|Fibroepithelioma, NOS|Fibrofolliculoma|Fibroid uterus|Fibrolamellar Carcinoma|Fibrolipoma|Fibroliposarcoma|Fibroma|Fibroma, NOS|Fibromatosis-like metaplastic carcinoma|Fibromatous Neoplasms|Fibromun|Fibromyalgia|Fibromyoma|Fibromyxoid Tumor|Fibromyxolipoma|Fibromyxoma|Fibromyxosarcoma|Fibrosarcoma|Fibrosarcoma, NOS|Fibrosarcomatous Dermatofibrosarcoma Protuberans|Fibrosarcomatous dermatofibrosarcoma protuberans|Fibrosis|Fibrosis Deep Connective Tissue|Fibrous Meningioma|Fibrous astrocytoma|Fibrous histiocytoma of tendon sheath|Fibrous histiocytoma, NOS|Fibrous meningioma|Fibrous mesothelioma, NOS|Fibrous mesothelioma, benign|Fibrous mesothelioma, malignant|Fibrous papule of nose|Fibroxanthoma, NOS|Fibroxanthoma, malignant|Fibula|Ficlatuzumab|Field burning smoke|Figitumumab|Fiji|Filanesib|Filgotinib|Filgrastim|Fimaporfin A|Fimepinostat|Fine Needle Aspiration|Finger|Finland|Fire smoke, NOS|First Cousin|First Cousin Once Removed|First Patient Visit|First Treatment|Firtecan Pegol|Fisogatinib|Five Times Daily|Flank Pain|Flanvotumab|Flashing Lights|Flat Adenoma|Flat adenoma|Flat intraepithelial glandular neoplasia, high grade|Flat intraepithelial neoplasia, high grade|Flatulence|Floaters|Floor Of Mouth|Floor of Mouth|Floor of mouth|Floor of mouth, NOS|Florid osseous dysplasia|Flotetuzumab|Floxuridine|Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01|Flt3/MerTK Inhibitor MRX-2843|Flu Like Symptoms|Fludarabine|Fludarabine Phosphate|Fluid|Flumatinib|Flumatinib Mesylate|Fluorine F 18 Ara-G|Fluorodopan|Fluorouracil|Fluorouracil Implant|Fluorouracil-E Therapeutic Implant|Fluoxymesterone|Flushing|Flutamide|Fluvastatin|Fluvastatin Sodium|Fluzoparib|Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate|Focal|Folate Receptor Targeted Epothilone BMS753493|Folate Receptor-Targeted Tubulysin Conjugate EC1456|Folate Receptor-Targeted Vinca Alkaloid EC0489|Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225|Folate-FITC|Folic Acid|Folitixorin|Follicular Dendritic Cell Sarcoma|Follicular Lymphoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma, Encapsulated Subtype with Invasion|Follicular adenocarcinoma, NOS|Follicular adenocarcinoma, moderately differentiated|Follicular adenocarcinoma, trabecular|Follicular adenocarcinoma, well differentiated|Follicular adenoma|Follicular adenoma, oxyphilic cell|Follicular carcinoma, NOS|Follicular carcinoma, encapsulated|Follicular carcinoma, minimally invasive|Follicular carcinoma, moderately differentiated|Follicular carcinoma, oxyphilic cell|Follicular carcinoma, trabecular|Follicular carcinoma, well differentiated|Follicular dendritic cell sarcoma|Follicular dendritic cell tumor|Follicular fibroma|Follicular lymphoma, NOS|Follicular lymphoma, grade 1|Follicular lymphoma, grade 2|Follicular lymphoma, grade 3|Follicular lymphoma, grade 3A|Follicular lymphoma, grade 3B|Follicular lymphoma, small cleaved cell|Follicular thyroid carcinoma (FTC), encapsulated angioinvasive|Folliculome lipidique|Foot|Forced Expiratory Volume Decreased|Forearm|Forehead|Foreskin|Foretinib|Foritinib Succinate|Former User|Formestane|Forodesine Hydrochloride|Fosaprepitant|Fosbretabulin|Fosbretabulin Disodium|Fosbretabulin Tromethamine|Fosgemcitabine Palabenamide|Fosifloxuridine Nafalbenamide|Foslinanib|Foslinanib Disodium|Fosquidone|Foster Brother|Foster Daughter|Foster Father|Foster Mother|Foster Sister|Foster Son|Fostriecin|Fotemustine|Fotretamine|FoundationOne Annotation|FoundationOne Report|FoundationOne Variant Aggregation and Masking|FoundationOne XML|Four Times Daily|Fracture|France|Franklin disease|Fraternal Twin Brother|Fraternal Twin Sibling|Fraternal Twin Sister|French Guiana|French Polynesia|Fresh|Fresolimumab|Frontal Cortex|Frontal Lobe|Frontal Sinus|Frontal lobe|Frontal sinus|Frozen|Fruquintinib|Full Brother|Full Hysterectomy|Full Sister|Fulvestrant|Fumagillin-Derived Polymer Conjugate XMT-1107|Functioning Endocrine Neoplasm|Fundus Of Stomach|Fundus Uteri|Fundus of Stomach|Fundus of stomach|Fundus uteri|Furnace or boiler smoke|Fursultiamine|Fusion Catcher|Futibatinib|Futuximab|Futuximab/Modotuximab Mixture|G|G Protein-coupled Estrogen Receptor Agonist LNS8801|G cell tumor, NOS|G cell tumor, malignant|G-Quadruplex Stabilizer BMVC|G1|G2|G3|G4|GANT|GATK4 MuTect2|GATK4 MuTect2 Annotation|GB|GBM Antigens and Alloantigens Immunotherapeutic Vaccine|GC IsoLink|GCT|GCT Premier|GENIE Copy Number Variation|GENIE Report|GENIE Simple Somatic Mutation|GENIE Structural Variation|GENIE Variant Aggregation and Masking|GERD|GGT Increased|GI-4000 Vaccine|GIST, NOS|GIST, benign|GIST, malignant|GISTIC - Arm Level Copy Number|GISTIC - Copy Number Score|GISTIC - Focal Amplification|GISTIC - Focal Deletion|GITR Agonist MEDI1873|GM-CSF-encoding Oncolytic Adenovirus CGTG-102|GS/pan-Notch Inhibitor AL101|GS/pan-Notch Inhibitor BMS-986115|GSK-3 Inhibitor 9-ING-41|GSK-3 Inhibitor LY2090314|GVF|GX|Gabon|Gait Disturbance|Galamustine|Galarubicin|Galectin Inhibitor GR-MD-02|Galectin-1 Inhibitor OTX008|Galeterone|Galiximab|Gallbladder|Gallbladder Cancer|Gallbladder Fistula|Gallbladder Infection|Gallbladder Necrosis|Gallbladder Obstruction|Gallbladder Pain|Gallbladder Papillary Neoplasm with Intermediate Grade Intraepithelial Neoplasia|Gallbladder Papillary Neoplasm with Low Grade Intraepithelial Neoplasia|Gallbladder Perforation|Gallium-based Bone Resorption Inhibitor AP-002|Gallus gallus|Galocitabine|Galunisertib|Gambia|Gamboge Resin Extract TSB-9-W1|Gamma Heavy Chain Disease|Gamma heavy chain disease|Gamma-Secretase Inhibitor LY3039478|Gamma-Secretase Inhibitor RO4929097|Gamma-delta Tocotrienol|Gandotinib|Ganetespib|Ganglia|Gangliocytic paraganglioma|Gangliocytoma|Ganglioglioma|Ganglioglioma, NOS|Ganglioglioma, anaplastic|Ganglioneuroblastoma|Ganglioneuroma|Ganglioneuromatosis|Ganglioside GD2|Ganglioside GM2|Ganitumab|Ganoderma lucidum Spores Powder Capsule|Garlic|Gas burning smoke, propane|Gasterosteus aculeatus (fish)|Gastric Anastomotic Leak|Gastric Cancer|Gastric Fistula|Gastric Hemorrhage|Gastric Necrosis|Gastric Parietal Cell Adenocarcinoma|Gastric Perforation|Gastric Polyp(s)|Gastric Stenosis|Gastric Ulcer|Gastric antrum|Gastrin Immunotoxin|Gastrin cell tumor|Gastrin cell tumor, malignant|Gastrin-Producing Neuroendocrine Tumor|Gastrin/cholecystokinin Type B Receptor Inhibitor Z-360|Gastrinoma, NOS|Gastrinoma, malignant|Gastritis|Gastroesophageal Junction|Gastroesophageal Reflux Disease|Gastrointestinal Anastomotic Leak|Gastrointestinal Autonomic Nerve Tumor|Gastrointestinal Disorders - Other|Gastrointestinal Fistula|Gastrointestinal Pain|Gastrointestinal Stoma Necrosis|Gastrointestinal Stromal Tumor|Gastrointestinal Stromal Tumor of Uncertain Malignant Potential|Gastrointestinal Tract|Gastrointestinal autonomic nerve tumor|Gastrointestinal pacemaker cell tumor|Gastrointestinal stromal sarcoma|Gastrointestinal stromal tumor, NOS|Gastrointestinal stromal tumor, benign|Gastrointestinal stromal tumor, malignant|Gastrointestinal stromal tumor, uncertain malignant potential|Gastrointestinal tract, NOS|Gastrointestinal, Intestine|Gastroparesis|Gataparsen Sodium|Gatipotuzumab|Gedatolisib|Gefitinib|Gelatinous adenocarcinoma|Gelatinous carcinoma|Geldanamycin|Gelonin|Gemcitabine|Gemcitabine Elaidate|Gemcitabine Hydrochloride|Gemcitabine Hydrochloride Emulsion|Gemcitabine Prodrug LY2334737|Gemcitabine-Phosphoramidate Hydrochloride NUC-1031|Gemcitabine-Releasing Intravesical System|Gemistocytic Astrocytoma|Gemistocytic astrocytoma|Gemistocytoma|Gemtuzumab Ozogamicin|Gene Expression Quantification|Gene Level Copy Number|Gene Level Copy Number Scores|General|General Disorders and Administration Site Conditions - Other|Generalized Muscle Weakness|Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum|Genistein|Genital Edema|Genital Rhabdomyoma|Genital rhabdomyoma|Genitourinary, NOS|GenomePlex (Rubicon) Amplified DNA|Genomic Profiling|Genomplex|Genotype mismatch|Genotypes|Genotyping Array|Gentuximab|Georgia|Geranylgeranyltransferase I Inhibitor|Germ Cell Neoplasms|Germ Cell Tumor|Germ cell tumor, NOS|Germ cell tumor, nonseminomatous|Germ cell tumors with associated hematological malignancy|Germany|Germinoma|Gerota Fascia|Ghana|Ghost Cell Odontogenic Carcinoma|Ghost cell odontogenic carcinoma|Giant Cell Angiofibroma|Giant Cell Carcinoma|Giant Cell Fibroblastoma|Giant Cell Glioblastoma|Giant Cell Sarcoma|Giant Cell Tumor of Bone|Giant Cell Tumor of Soft Tissue|Giant Cell Tumors|Giant Cell and Spindle Cell Carcinoma|Giant Congenital Nevus|Giant cell and spindle cell carcinoma|Giant cell angiofibroma|Giant cell carcinoma|Giant cell fibroblastoma|Giant cell glioblastoma|Giant cell sarcoma|Giant cell sarcoma of bone|Giant cell tumor of bone, NOS|Giant cell tumor of bone, malignant|Giant cell tumor of soft parts, NOS|Giant cell tumor of tendon sheath|Giant cell tumor of tendon sheath, malignant|Giant fibroadenoma|Giant osteoid osteoma|Giant pigmented nevus, NOS|Gibraltar|Gigantiform Cementoma|Gigantiform cementoma|Gilbert's Syndrome|Giloralimab|Gilteritinib|Gilteritinib Fumarate|Gimatecan|Gimeracil|Gingival Pain|Ginsenoside Rg3 Capsule|Giredestrant|Girentuximab|Girodazole|Givinostat|Glandular Papilloma|Glandular Papillomatosis|Glandular intraepithelial neoplasia, grade I|Glandular intraepithelial neoplasia, grade II|Glandular intraepithelial neoplasia, grade III|Glandular intraepithelial neoplasia, high grade|Glandular intraepithelial neoplasia, low grade|Glandular papilloma|Glans Penis|Glans penis|Glasdegib|Glasdegib Maleate|Glassy Cell Carcinoma|Glassy cell carcinoma|Glaucarubolone|Glaucoma|Gleason Grade Group 1|Gleason Grade Group 2|Gleason Grade Group 3|Gleason Grade Group 4|Gleason Grade Group 5|Gleason Pattern 1|Gleason Pattern 2|Gleason Pattern 3|Gleason Pattern 4|Gleason Pattern 5|Glecaprevir/Pibrentasvir|Glembatumumab Vedotin|Glesatinib|Glioblastoma|Glioblastoma Cancer Vaccine ERC1671|Glioblastoma Multiforme|Glioblastoma Multiforme Multipeptide Vaccine IMA950|Glioblastoma multiforme|Glioblastoma with sarcomatous component|Glioblastoma, IDH wildtype|Glioblastoma, IDH-Mutant|Glioblastoma, IDH-Wildtype|Glioblastoma, IDH-mutant|Gliofibroma|Glioma|Glioma Lysate Vaccine GBM6-AD|Glioma, NOS|Glioma, malignant|Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701|Gliomas|Gliomatosis Cerebri|Gliomatosis cerebri|Glioneuroma|Gliosarcoma|Globo H-DT Vaccine OBI-833|Glofitamab|Glomangioma|Glomangiomyoma|Glomangiosarcoma|Glomerular Disease|Glomoid sarcoma|Glomus Tumor|Glomus jugulare tumor, NOS|Glomus tumor, NOS|Glomus tumor, malignant|Glossectomy|Glossopharyngeal Nerve Disorder|Glottis|Glucagon-like peptide-producing tumor|Glucagonoma, NOS|Glucagonoma, malignant|Glucarpidase|Glucocorticoid Receptor Antagonist ORIC-101|Glucose Intolerance|Glufosfamide|Glumetinib|Glutaminase Inhibitor CB-839|Glutaminase Inhibitor CB-839 Hydrochloride|Glutaminase Inhibitor IPN60090|Glutamine Antagonist DRP-104|Glutamyl endopeptidase|Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101|Glyco-TMT|Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01|Glycogen Storage Disease|Glycogen-Rich Carcinoma|Glycogen-rich carcinoma|Glycogenic rhabdomyoma|Glycooptimized Trastuzumab-GEX|Glycoproteome|Goblet cell carcinoid|Gold Sodium Thiomalate|Golnerminogene Pradenovec|Golotimod|Golvatinib|Gonadal Dysfunction|Gonadal stromal tumor, NOS|Gonadoblastoma|Gonadotropin-releasing Hormone Analog|Gonocytoma|Good Prognosis|Gorlin Syndrome|Goserelin|Goserelin Acetate|Goserelin Acetate Extended-release Microspheres LY01005|Gossypol|Gossypol Acetic Acid|Gout|Grade 1|Grade 1 Follicular Lymphoma|Grade 1 Nodular Sclerosis Classic Hodgkin Lymphoma|Grade 2|Grade 2 Follicular Lymphoma|Grade 2 Nodular Sclerosis Classic Hodgkin Lymphoma|Grade 3|Grade 3 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Grade 3b Follicular Lymphoma|Grade 4|Grade 5|Grade B|Grade I|Grade I Neuroendocrine Carcinoma|Grade II|Grade II Glandular Intraepithelial Neoplasia|Grade II Neuroendocrine Carcinoma|Grade II Squamous Intraepithelial Neoplasia|Grade III|Grade III Glandular Intraepithelial Neoplasia|Grade III Prostatic Intraepithelial Neoplasia|Grade IV|Grade Not Assigned|Grade X|Grand Nephew|Grand Niece|Grandchild|Granddaughter|Grandfather|Grandmother|Grandparent|Grandson|Granular Cell Carcinoma|Granular Cell Tumor|Granular Cell Tumor of the Sellar Region|Granular Cell Tumors and Alveolar Soft Part Sarcomas|Granular cell adenocarcinoma|Granular cell carcinoma|Granular cell myoblastoma, NOS|Granular cell myoblastoma, malignant|Granular cell tumor of the sellar region|Granular cell tumor, NOS|Granular cell tumor, malignant|Granulocytes|Granulocytic Sarcoma|Granulocytic leukemia, NOS|Granulocytic sarcoma|Granulosa Cell Tumor|Granulosa Cell-Theca Cell Tumor|Granulosa cell carcinoma|Granulosa cell tumor, NOS|Granulosa cell tumor, adult type|Granulosa cell tumor, juvenile|Granulosa cell tumor, malignant|Granulosa cell tumor, sarcomatoid|Granulosa cell-theca cell tumor|Grapiprant|Grawitz tumor|Gray|Grease fire smoke|Great Grandchild|Greater Curvature of the Stomach|Greater curvature of stomach, NOS|Greece|Green|Green Tea Extract-based Antioxidant Supplement|Greenland|Grenada|Grilling smoke|Groin|Gross Total Resection|Group 1|Group 2|Group 3|Group 4|Group 5|Group I|Group II|Group III|Group IIIa|Group IIIb|Group IIa|Group IIb|Group IIc|Group IV|Group Ia|Group Ib|Growth Accelerated|Growth Hormone Abnormal|Growth Suppression|Guadecitabine|Guadeloupe|Guam|Guanabenz Acetate|Guatemala|Guernsey|Guinea|Guinea-Bissau|Gum|Gum Infection|Gum, NOS|Guselkumab|Gusperimus Trihydrochloride|Gutolactone|Guyana|Gy|Gynandroblastoma|Gynecologic Cancer|Gynecomastia|H|H-ras Antisense Oligodeoxynucleotide ISIS 2503|H. pylori Infection|H1299 Tumor Cell Lysate Vaccine|H2 Blockers|HAAH Lambda phage Vaccine SNS-301|HBV Core Antibody|HBV DNA|HBV Genotype|HBV Surface Antibody|HCD|HCV DNA Vaccine INO-8000|HCV Genotype|HDAC Class I/IIb Inhibitor HG146|HDAC Inhibitor AR-42|HDAC Inhibitor CHR-2845|HDAC Inhibitor CKD-581|HDAC Inhibitor CXD101|HDAC Inhibitor MPT0E028|HDAC Inhibitor OBP-801|HDAC inhibitor CG200745|HDAC/EGFR/HER2 Inhibitor CUDC-101|HDAC6 Inhibitor KA2507|HDAC8 Inhibitor NBM-BMX|HDF5|HDM2 Inhibitor HDM201|HDM2 Inhibitor MK-8242|HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131|HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901|HER2 Inhibitor CP-724,714|HER2 Inhibitor DZD1516|HER2 Inhibitor TAS0728|HER2 Tri-specific Natural Killer Cell Engager DF1001|HER2-directed TLR8 Agonist SBT6050|HER2-targeted DARPin MP0274|HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302|HER2-targeting Antibody Fc Fragment FS102|HIF-1alpha Inhibitor PX-478|HIF-2alpha Inhibitor PT2385|HIF-2alpha Inhibitor PT2977|HIF2a RNAi ARO-HIF2|HIV|HIV / AIDS|HIV+ Tumor Molecular Characterization Project - Cervical Cancer|HIV+ Tumor Molecular Characterization Project - Lung Cancer|HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001|HLA-A*2402-Restricted Multipeptide Vaccine S-488410|HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201|HM2/MMAE Antibody-Drug Conjugate ALT-P7|HPPH|HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202|HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c|HPV DNA Plasmids Therapeutic Vaccine VGX-3100|HPV E6/E7 DNA Vaccine GX-188E|HPV E6/E7-encoding Arenavirus Vaccine HB-201|HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C|HPV-16 E6 Peptides Vaccine/Candida albicans Extract|HPV-6-targeting Immunotherapeutic Vaccine INO-3106|HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101|HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN|HPV6/11-targeted DNA Plasmid Vaccine INO-3107|HSP90-targeted SN-38 Conjugate PEN-866|HSP90alpha/beta Inhibitor TAS-116|HTSeq - Counts|HTSeq - FPKM|HTSeq - FPKM-UQ|HUS/TTP|Haemangioblastoma|Haemangiosarcoma|Hafnium Oxide-containing Nanoparticles NBTXR3|Hairy Cell Leukemia|Hairy Cell Leukemia Variant|Hairy Nevus|Hairy cell leukaemia variant|Hairy cell leukemia|Hairy cell leukemia variant|Hairy nevus|Haiti|Half Brother|Half Sibling|Half Sister|Halichondrin Analogue E7130|Halichondrin B|Haliotis rufescens|Hallucinations|Halo Nevus|Halo nevus|Halofuginone|Halofuginone Hydrobromide|Hand|Hand Assisted Laparoscopic Radical Nephrectomy|Hand-Schuller-Christian Disease|Hand-Schuller-Christian disease|HaplotypeCaller|Haptoglobin Decreased|Hard Palate|Hard palate|Hashimoto's Thyroiditis|Hashish smoke|Hay Fever|Hazel|Head & Neck|Head - Face Or Neck, Nos|Head Soft Tissue Necrosis|Head and Neck|Head and Neck Cancer|Head and Neck Lymph Node|Head and Neck Squamous Cell Carcinoma|Head of pancreas|Head of the Pancreas|Head, Face or Neck, NOS|Head, face or neck, NOS|Headache|Headaches|Hearing Impaired|Heart|Heart Disease|Heart Failure|Heart, mediastinum, and pleura|Heavy Chain Disease|Heavy Drinker|Heavy chain disease, NOS|Hedgehog Inhibitor IPI-609|Helicobacter Pylori-Associated Gastritis|Hemangioblastic Meningioma|Hemangioblastic meningioma|Hemangioblastoma|Hemangioendothelial sarcoma|Hemangioendothelioma|Hemangioendothelioma, NOS|Hemangioendothelioma, benign|Hemangioendothelioma, malignant|Hemangioma|Hemangioma simplex|Hemangioma, NOS|Hemangiopericytic meningioma|Hemangiopericytoma|Hemangiopericytoma, NOS|Hemangiopericytoma, benign|Hemangiopericytoma, malignant|Hematologic Cancer|Hematologic Disorder, NOS|Hematoma|Hematopoietic System|Hematopoietic and reticuloendothelial systems|Hematopoietic system, NOS|Hematoporphyrin Derivative|Hematosalpinx|Hematuria|Hemiasterlin Analog E7974|Hemihypertrophy|Hemochromatosis|Hemoglobin Increased|Hemoglobinuria|Hemolymphangioma|Hemolysis|Hemolytic Uremic Syndrome|Hemophiliac|Hemorrhagic Cystitis|Hemorrhoidal Hemorrhage|Hemorrhoids|Henatinib Maleate|Heparan Sulfate Glycosaminoglycan Mimetic M402|Heparin Derivative SST0001|Hepatic|Hepatic Duct|Hepatic Encephalopathy|Hepatic Failure|Hepatic Flexure|Hepatic Hemorrhage|Hepatic Infection|Hepatic Necrosis|Hepatic Pain|Hepatic Vein|Hepatic flexure of colon|Hepatitis|Hepatitis A Infection|Hepatitis B Infection|Hepatitis B Surface Antigen|Hepatitis C Antibody|Hepatitis C Infection|Hepatitis C Virus RNA|Hepatitis C virus|Hepatitis Viral|Hepatitis, Chronic|Hepatitis, NOS|Hepatobiliary Disorders - Other|Hepatoblastoma|Hepatoblastoma, epithelioid|Hepatoblastoma, mixed epithelial-mesenchymal|Hepatocarcinoma|Hepatocellular Adenoma|Hepatocellular Carcinoma|Hepatocellular adenoma|Hepatocellular carcinoma, NOS|Hepatocellular carcinoma, clear cell type|Hepatocellular carcinoma, fibrolamellar|Hepatocellular carcinoma, pleomorphic type|Hepatocellular carcinoma, sarcomatoid|Hepatocellular carcinoma, scirrhous|Hepatocellular carcinoma, spindle cell variant|Hepatocholangiocarcinoma|Hepatoid Adenocarcinoma|Hepatoid adenocarcinoma|Hepatoid carcinoma|Hepatoid yolk sac tumor|Hepatoma, NOS|Hepatoma, benign|Hepatoma, malignant|Hepatosplenic T-Cell Lymphoma|Hepatosplenic T-cell lymphoma|Hepatosplenic gamma-delta cell lymphoma|Herba Scutellaria Barbata|Herbimycin|Hereditary Breast Cancer|Hereditary Kidney Oncocytoma|Hereditary Leiomyomatosis and Renal Cell Carcinoma|Hereditary Non-polyposis Colon Cancer|Hereditary Ovarian Cancer|Hereditary Papillary Renal Cell Carcinoma|Hereditary Prostate Cancer|Hereditary Renal Cell Carcinoma|Hereditary leiomyomatosis & RCC-associated renal cell carcinoma|Herpes|Herpes Simplex Virus|Herpes Zoster|Heterodimeric Interleukin-15|Heterosexual Contact|Hexamethylene Bisacetamide|Hexaminolevulinate|Hexylresorcinol|HiChIP|HiRes ESI|HiRes MALDI|Hibernoma|Hiccups|Hidradenocarcinoma|Hidradenoma|Hidradenoma Papilliferum|Hidradenoma papilliferum|Hidradenoma, NOS|Hidrocystoma|High|High Grade|High Grade (G2)|High Grade B-Cell Lymphoma, Not Otherwise Specified|High Grade Ductal Breast Carcinoma In Situ|High Grade Dysplasia|High Grade Esophageal Glandular Intraepithelial Neoplasia|High Grade Esophageal Squamous Intraepithelial Neoplasia|High Grade Glandular Intraepithelial Neoplasia|High Grade Liver Dysplastic Nodule|High Grade Squamous Intraepithelial Neoplasia|High Grade Surface Osteosarcoma|High Risk|High Risk Gastrointestinal Stromal Tumor|High grade surface osteosarcoma|High-Intermediate Risk|High-Risk Wilms Tumor|High-grade Prostatic Intraepithelial Neoplasia (PIN)|High-grade neuroendocrine carcinoma|High-grade serous carcinoma|HighPure miRNA (Allprep DNA) FFPE RNA|Hilar|Hilar Cholangiocarcinoma|Hilar cell tumor|Hilus cell tumor|Hip|Hip Fracture|Hippocampus|Hirsutism|Hispanic or Latino|Histiocyte-rich large B-cell lymphoma|Histiocytic Sarcoma|Histiocytic medullary reticulosis|Histiocytic sarcoma|Histiocytoid hemangioma|Histiocytoma|Histiocytoma, NOS|Histiocytosis X, NOS|Histology|Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126|Histoplasmosis|History of acceptable prior treatment related to a prior/other malignancy|History of unacceptable prior treatment related to a prior/other malignancy|Histrelin Acetate|Hitachi|Hoarseness|Hodgkin Lymphoma|Hodgkin disease, NOS|Hodgkin disease, lymphocyte predominance, NOS|Hodgkin disease, lymphocyte predominance, diffuse|Hodgkin disease, lymphocytic-histiocytic predominance|Hodgkin disease, nodular sclerosis, NOS|Hodgkin disease, nodular sclerosis, lymphocyte depletion|Hodgkin disease, nodular sclerosis, lymphocyte predominance|Hodgkin disease, nodular sclerosis, mixed cellularity|Hodgkin disease, nodular sclerosis, syncytial variant|Hodgkin granuloma|Hodgkin lymphoma, NOS|Hodgkin lymphoma, lymphocyte depletion, NOS|Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis|Hodgkin lymphoma, lymphocyte depletion, reticular|Hodgkin lymphoma, lymphocyte predominance, nodular|Hodgkin lymphoma, lymphocyte-rich|Hodgkin lymphoma, mixed cellularity, NOS|Hodgkin lymphoma, nodular lymphocyte predominance|Hodgkin lymphoma, nodular sclerosis, NOS|Hodgkin lymphoma, nodular sclerosis, cellular phase|Hodgkin lymphoma, nodular sclerosis, grade 1|Hodgkin lymphoma, nodular sclerosis, grade 2|Hodgkin paragranuloma, NOS|Hodgkin paragranuloma, nodular|Hodgkin sarcoma|Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine|Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Depletion|Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Predominance|Hodgkin's Disease, Nodular Sclerosis, Mixed Cellularity|Hodgkin's Granuloma|Hodgkin's Paragranuloma|Holmium Ho 166 Poly(L-Lactic Acid) Microspheres|Holy See|Homo sapiens|Homo sapiens; Mus musculus|Homosexual Contact|Honduras|Hong Kong|Hormone Therapy|Hormones|Hot Flashes|Hsp90 Antagonist KW-2478|Hsp90 Inhibitor AB-010|Hsp90 Inhibitor BIIB021|Hsp90 Inhibitor BIIB028|Hsp90 Inhibitor DS-2248|Hsp90 Inhibitor Debio 0932|Hsp90 Inhibitor HSP990|Hsp90 Inhibitor MPC-3100|Hsp90 Inhibitor PU-H71|Hsp90 Inhibitor SNX-5422 Mesylate|Hsp90 Inhibitor SNX-5542 Mesylate|Hsp90 Inhibitor TQB3474|Hsp90 Inhibitor XL888|Hsp90-targeted Photosensitizer HS-201|Hu14.18-IL2 Fusion Protein EMD 273063|HuaChanSu|Huaier Extract Granule|Huang Lian|Human Combinatorial Antibody Library-based Monoclonal Antibody VAY736|Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104|Human MOAB LICO 28a32|Human Monoclonal Antibody 216|Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307|Human Original Cells|Human Papillomavirus 16 E7 Peptide/Padre 965.10|Human Papillomavirus Infection|Human Papillomavirus-Related Squamous Cell Carcinoma|Human Tumor Original Cells|Humerus|Hungary|Hurthle cell adenocarcinoma|Hurthle cell adenoma|Hurthle cell carcinoma|Hurthle cell tumor|Husband|Hutchinson melanotic freckle, NOS|Hyalinizing trabecular adenoma|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Hycanthone|Hydatid mole|Hydatidiform Mole|Hydatidiform mole, NOS|Hydralazine Hydrochloride|Hydrazide TMT|Hydroa Vacciniforme-Like Lymphoproliferative Disorder|Hydroa vacciniforme-like lymphoma|Hydrocephalus|Hydrocortisone Sodium Succinate|Hydroxychloroquine|Hydroxyprogesterone Caproate|Hydroxytyrosol|Hydroxyurea|Hygroma, NOS|Hypercalcemia|Hypercholesterolemia|Hypereosinophilic Syndrome|Hypereosinophilic syndrome|Hyperglycemia|Hyperhidrosis|Hypericin|Hyperkalemia|Hyperlipidemia|Hypermagnesemia|Hypernatremia|Hypernephroid tumor|Hypernephroma|Hyperparathyroidism|Hypersomnia|Hypertension|Hyperthyroidism|Hypertrichosis|Hypertriglyceridemia|Hyperuricemia|Hypoalbuminemia|Hypocalcemia|Hypoglossal Nerve Disorder|Hypoglycemia|Hypohidrosis|Hypokalemia|Hypomagnesemia|Hyponatremia|Hypoparathyroidism|Hypopharyngeal aspect of aryepiglottic fold|Hypopharynx|Hypopharynx, NOS|Hypophosphatemia|Hypospadias|Hypotension|Hypothermia|Hypothyroidism|Hypoxia|Hypoxia-activated Prodrug TH-4000|Hysterectomy NOS|Hysterectomy, NOS|I|I 131 Antiferritin Immunoglobulin|I 131 Monoclonal Antibody A33|I 131 Monoclonal Antibody CC49|I 131 Monoclonal Antibody F19|I 131 Monoclonal Antibody Lym-1|I-131 Radiation Therapy|IAP Inhibitor APG-1387|IAP Inhibitor AT-406|IAP Inhibitor HGS1029|ICAT|ICPL|ICT-121 Dendritic Cell Vaccine|IDAT|IDF|IDH1 Mutant Inhibitor LY3410738|IDH1(R132) Inhibitor IDH305|IDH1R132H-Specific Peptide Vaccine PEPIDH1M|IDO Peptide Vaccine IO102|IDO-1 Inhibitor LY3381916|IDO/TDO Inhibitor HTI-1090|IDO/TDO Inhibitor LY-01013|IDO1 Inhibitor KHK2455|IDO1 Inhibitor MK-7162|IDO1 Inhibitor PF-06840003|IDO1/TDO2 Inhibitor DN1406131|IDO1/TDO2 Inhibitor M4112|IGF-1R Inhibitor|IGF-1R Inhibitor PL225B|IGF-1R/IR Inhibitor KW-2450|IGF-methotrexate Conjugate|II|III|IL-10 Immunomodulator MK-1966|IL-12-expressing HSV-1 NSC 733972|IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051|IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000|IL-2 Recombinant Fusion Protein ALT-801|IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1|IL4-Pseudomonas Exotoxin Fusion Protein MDNA55|IMR-Immunoresponse|IMT-1012 Immunotherapeutic Vaccine|INO-1001|INR Increased|INRG Stage L1|INRG Stage L2|INRG Stage M|INRG Stage MS|INSS Stage 1|INSS Stage 2A|INSS Stage 2B|INSS Stage 3|INSS Stage 4|INSS Stage 4S|IPD-Immunoprogression|IPTL|IRAK4 Inhibitor CA-4948|ISQ|ISS 1018 CpG Oligodeoxynucleotide|ISS Stage I Plasma Cell Myeloma|ISS Stage II Plasma Cell Myeloma|ISS Stage III Plasma Cell Myeloma|ITK Inhibitor CPI-818|ITP|ITQ 1100|ITQ 700|ITQ 900|IVth Nerve Disorder|Iadademstat|Ianalumab|Ibandronate Sodium|Iberdomide|Iboctadekin|Ibritumomab Tiuxetan|Ibrutinib|Iceland|Icotinib Hydrochloride|Icrucumab|Idarubicin|Idarubicin Hydrochloride|Idarubicin-Eluting Beads|Idasanutlin|Idecabtagene Vicleucel|Idelalisib|Identical Twin Brother|Identical Twin Sibling|Identical Twin Sister|Idetrexed|Idiopathic hemorrhagic thrombocythaemia|Idiopathic thrombocythemia|Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020|Idronoxil|Idronoxil Suppository NOX66|Ieramilimab|Ifabotuzumab|Ifetroban|Ifosfamide|Ileal Fistula|Ileal Hemorrhage|Ileal Obstruction|Ileal Perforation|Ileal Stenosis|Ileal Ulcer|Ileocecal Valve|Ileum|Ileus|Ilginatinib|Ilium|Ilixadencel|Ill-Defined Anatomic Site|Ill-defined sites within respiratory system|Illumina|Illumina Human Methylation 27|Illumina Human Methylation 450|Illumina Methylation Epic|Iloprost|Ilorasertib|Imaging|Imaging Technique|Imalumab|Imaradenant|Imatinib|Imatinib Mesylate|Imetelstat|Imetelstat Sodium|Imexon|Imgatuzumab|Imidazole Mustard|Imidazole-Pyrazole|Imifoplatin|Imipramine Blue|Imiquimod|Immature Teratoma|Immature teratoma, NOS|Immature teratoma, malignant|Immediate-release Onapristone|Immediate-release Tablet Afuresertib|Immune Checkpoint Inhibitor ASP8374|Immune System Disorders - Other|Immunoblastic Lymphoma|Immunoblastic sarcoma|Immunoconjugate RO5479599|Immunocytokine NHS-IL12|Immunocytokine NHS-IL2-LT|Immunocytoma|Immunodeficiency-Related Burkitt Lymphoma|Immunodeficiency-associated, adult|Immunodeficiency-associated, pediatric|Immunoglobulin deposition disease|Immunomodulator LAM-003|Immunomodulator OHR/AVR118|Immunomodulatory Agent CC-11006|Immunomodulatory Oligonucleotide HYB2055|Immunoprogression|Immunoproliferative Diseases|Immunoproliferative disease, NOS|Immunoproliferative small intestinal disease|Immunoresponse|Immunotherapeutic Combination Product CMB305|Immunotherapeutic GSK1572932A|Immunotherapy (Including Vaccines)|Immunotherapy Regimen MKC-1106-MT|Immunotoxin CMD-193|In Situ Neoplasms|Inactivated Oncolytic Virus Particle GEN0101|Inadvertently shipped|Inalimarev|Incisional Biopsy|Incomplete Necrosis (Viable Tumor Present)|Incyclinide|Indatuximab Ravtansine|Indefinite Dysplasia|Indefinite for Dysplasia|Indeterminant|Indeterminate|Indeterminate Dendritic Cell Tumor|Indeterminate dendritic cell tumor|Index Finger|India|Indibulin|Indicine-N-Oxide|Indisulam|Individualized MVA-based Vaccine TG4050|Indocyanine Green-labeled Polymeric Micelles ONM-100|Indole-3-Carbinol|Indolent Systemic Mastocytosis|Indolent systemic mastocytosis|Indomethacin|Indonesia|Indoor stove or fireplace smoke, NOS|Indoor stove or fireplace smoke, coal burning|Indoor stove or fireplace smoke, wood burning|Indoximod|Indoximod Prodrug NLG802|Induced Abortion|Induction Failure AML (AML-IF)|Indusatumab Vedotin|Inebilizumab|Inecalcitol|Infantile Fibrosarcoma|Infantile Hemangioma|Infantile fibrosarcoma|Infantile hemangioma|Infantile myofibromatosis|Infection|Infections and Infestations - Other|Infectious Disorder|Infective Myositis|Infigratinib|Infigratinib Mesylate|Infiltrating Angiolipoma|Infiltrating Bladder Urothelial Carcinoma with Squamous Differentiation|Infiltrating Bladder Urothelial Carcinoma with Trophoblastic Differentiation|Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant|Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant|Infiltrating Bladder Urothelial Carcinoma, Microcystic Variant|Infiltrating Bladder Urothelial Carcinoma, Nested Variant|Infiltrating Lipoma|Infiltrating Papillary Adenocarcinoma|Infiltrating and papillary adenocarcinoma|Infiltrating angiolipoma|Infiltrating basal cell carcinoma, NOS|Infiltrating basal cell carcinoma, non-sclerosing|Infiltrating basal cell carcinoma, sclerosing|Infiltrating duct adenocarcinoma|Infiltrating duct and colloid carcinoma|Infiltrating duct and cribriform carcinoma|Infiltrating duct and lobular carcinoma|Infiltrating duct and lobular carcinoma in situ|Infiltrating duct and mucinous carcinoma|Infiltrating duct and tubular carcinoma|Infiltrating duct carcinoma, NOS|Infiltrating duct mixed with other types of carcinoma|Infiltrating ductular carcinoma|Infiltrating lipoma|Infiltrating lobular carcinoma and ductal carcinoma in situ|Infiltrating lobular carcinoma, NOS|Infiltrating lobular mixed with other types of carcinoma|Infiltrating papillary adenocarcinoma|Inflammation, Hyperkeratosis|Inflammatory Bowel Disease|Inflammatory Liposarcoma|Inflammatory Myofibroblastic Tumor|Inflammatory adenocarcinoma|Inflammatory carcinoma|Inflammatory liposarcoma|Inflammatory myofibroblastic tumor|Infliximab|Informed Consent|Infusion Related Reaction|Infusion Site Extravasation|Ingenol Mebutate|Ingenol Mebutate Gel|Inguinal Lymph Node|Inguinal Region|Iniparib|Initial Diagnosis|Initial Genomic Sequencing|Injected Insulin|Injection Site Reaction|Injury to Carotid Artery|Injury to Inferior Vena Cava|Injury to Jugular Vein|Injury to Superior Vena Cava|Injury, Poisoning and Procedural Complications - Other|Innate Immunostimulator rBBX-01|Inodiftagene Vixteplasmid|Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01|Inosine Monophosphate Dehydrogenase Inhibitor AVN944|Inositol|Inotuzumab Ozogamicin|Inproquone|Insomnia|Insular carcinoma|Insulin|Insulin Controlled Diabetes|Insulinoma, NOS|Insulinoma, malignant|Integrin Receptor Antagonist GLPG0187|Integrin alpha-2 Inhibitor E7820|Interdigitating Dendritic Cell Sarcoma|Interdigitating cell sarcoma|Interdigitating dendritic cell sarcoma|Interferon|Interferon Alfa-2B|Interferon Alfa-N1|Interferon Alfa-N3|Interferon Alfacon-1|Interferon Beta-1A|Interferon Gamma-1b|Interferon-gamma-expressing Adenovirus Vaccine ASN-002|Intergroup Rhabdomyosarcoma Group I|Intergroup Rhabdomyosarcoma Group II|Intergroup Rhabdomyosarcoma Group III|Intergroup Rhabdomyosarcoma Group IIIa|Intergroup Rhabdomyosarcoma Group IIIb|Intergroup Rhabdomyosarcoma Group IIa|Intergroup Rhabdomyosarcoma Group IIb|Intergroup Rhabdomyosarcoma Group IIc|Intergroup Rhabdomyosarcoma Group IV|Intergroup Rhabdomyosarcoma Group Ia|Intergroup Rhabdomyosarcoma Group Ib|Interleukin Therapy|Interleukin-12-Fc Fusion Protein DF6002|Interleukin-15 Agonist Fusion Protein SHR1501|Interleukin-15 Fusion Protein BJ-001|Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306|Interleukin-15/Interleukin-15 Receptor Alpha Sushi+ Domain Fusion Protein SO-C101|Interleukin-2 Liposome|Intermediate|Intermediate Grade|Intermediate Immature Teratoma|Intermediate Prognosis|Intermediate Risk|Intermediate and giant congenital nevus|Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230|Internal Radiation|International Prognostic Index High-Intermediate Risk Group|International Prognostic Index Low-Intermediate Risk Group|Interstitial Pneumontis or ARDS|Interstitial cell tumor, NOS|Interstitial cell tumor, benign|Interstitial cell tumor, malignant|Intestinal Metaplasia|Intestinal Stoma Leak|Intestinal Stoma Obstruction|Intestinal Stoma Site Bleeding|Intestinal T-cell lymphoma|Intestinal tract, NOS|Intestinal-Type Adenocarcinoma|Intestinal-type adenocarcinoma|Intetumumab|Intimal Sarcoma|Intimal sarcoma|Intiquinatine|Intoplicine|Intra-Abdominal Hemorrhage|Intra-Abdominal Lymph Node|Intra-abdominal lymph nodes|Intracanalicular fibroadenoma|Intracompartmental (T1)|Intracompartmental Tumor|Intracortical osteosarcoma|Intracranial Hemorrhage|Intracystic Papillary Breast Carcinoma|Intracystic Papilloma|Intracystic carcinoma, NOS|Intracystic papillary adenocarcinoma|Intracystic papillary adenoma|Intracystic papillary neoplasm with associated invasive carcinoma|Intracystic papillary neoplasm with high grade intraepithelial neoplasia|Intracystic papillary neoplasm with intermediate grade intraepithelial neoplasia|Intracystic papillary neoplasm with low grade intraepithelial neoplasia|Intracystic papillary tumor with high grade dysplasia|Intracystic papillary tumor with high grade entraepithelial neoplasia|Intracystic papillary tumor with high grade intraepithelial neoplasia|Intracystic papilloma|Intradermal nevus|Intraductal Carcinoma of the Minor Salivary Gland|Intraductal Cribriform Breast Adenocarcinoma|Intraductal Papillary Adenocarcinoma with Invasion|Intraductal Papillary Breast Carcinoma|Intraductal Papillary Mucinous Neoplasm|Intraductal Papilloma|Intraductal Papillomatosis|Intraductal adenocarcinoma, noninfiltrating, NOS|Intraductal and Lobular Carcinoma|Intraductal and lobular carcinoma|Intraductal carcinoma and lobular carcinoma in situ|Intraductal carcinoma, NOS|Intraductal carcinoma, clinging|Intraductal carcinoma, noninfiltrating, NOS|Intraductal carcinoma, solid type|Intraductal micropapillary carcinoma|Intraductal papillary adenocarcinoma with invasion|Intraductal papillary adenocarcinoma, NOS|Intraductal papillary carcinoma|Intraductal papillary mucinous neoplasm (IPMN) with an associated invasive carcinoma|Intraductal papillary mucinous neoplasm with an associated invasive carcinoma|Intraductal papillary mucinous neoplasm with high grade dysplasia|Intraductal papillary neoplasm with associated invasive carcinoma|Intraductal papillary neoplasm with high grade dysplasia|Intraductal papillary neoplasm with high grade intraepithelial neoplasia|Intraductal papillary neoplasm with intermediate grade neoplasia|Intraductal papillary neoplasm with low grade intraepithelial neoplasia|Intraductal papillary neoplasm, NOS|Intraductal papillary tumor with high grade dysplasia|Intraductal papillary tumor with high grade intraepithelial neoplasia|Intraductal papillary-mucinous adenoma|Intraductal papillary-mucinous carcinoma, invasive|Intraductal papillary-mucinous carcinoma, non-invasive|Intraductal papillary-mucinous neoplasm with low grade dysplasia|Intraductal papillary-mucinous neoplasm with moderate dysplasia|Intraductal papillary-mucinous tumor with intermediate dysplasia|Intraductal papillary-mucinous tumor with low grade dysplasia|Intraductal papillary-mucinous tumor with moderate dysplasia|Intraductal papilloma|Intraductal papilloma with ductal carcinoma in situ|Intraductal papilloma with lobular carcinoma in situ|Intraductal papillomatosis, NOS|Intraductal tubular-papillary neoplasm, high grade|Intraductal tubular-papillary neoplasm, low grade|Intraductal tubulopapillary neoplasm|Intraepidermal Epithelioma of Jadassohn|Intraepidermal carcinoma, NOS|Intraepidermal epithelioma of Jadassohn|Intraepidermal nevus|Intraepidermal squamous cell carcinoma, Bowen type|Intraepithelial carcinoma, NOS|Intraepithelial squamous cell carcinoma|Intraglandular papillary neoplasm with low grade intraepithelial neoplasia|Intrahepatic bile duct|Intramural|Intramuscular Hemangioma|Intramuscular Lipoma|Intramuscular hemangioma|Intramuscular lipoma|Intraneural Perineurioma|Intraneural perineurioma|Intraoperative Arterial Injury|Intraoperative Breast Injury|Intraoperative Cardiac Injury|Intraoperative Ear Injury|Intraoperative Endocrine Injury|Intraoperative Gastrointestinal Injury|Intraoperative Head and Neck Injury|Intraoperative Hemorrhage|Intraoperative Hepatobiliary Injury|Intraoperative Musculoskeletal Injury|Intraoperative Neurological Injury|Intraoperative Ocular Injury|Intraoperative Renal Injury|Intraoperative Reproductive Tract Injury|Intraoperative Respiratory Injury|Intraoperative Skin Injury|Intraoperative Splenic Injury|Intraoperative Urinary Injury|Intraoperative Venous Injury|Intraosseous low grade osteosarcoma|Intraosseous well differentiated osteosarcoma|Intrathecal|Intrathoracic Lymph Node|Intrathoracic lymph nodes|Intrathyroid Thymic Carcinoma|Intratubular germ cell neoplasia|Intratubular malignant germ cells|Intravascular B-cell lymphoma|Intravascular Large B-Cell Lymphoma|Intravascular bronchial alveolar tumor|Intravascular large B-cell lymphoma|Intravascular leiomyomatosis|Intravenous|Intravenous Drug User|Inulin|Invasive Breast Carcinoma|Invasive Ductal Carcinoma, Not Otherwise Specified|Invasive Ductal and Lobular Carcinoma|Invasive Ductal and Lobular Carcinoma In Situ|Invasive Hydatidiform Mole|Invasive Lobular Breast Carcinoma|Invasive Lobular Breast Carcinoma, Alveolar Variant|Invasive Lobular Breast Carcinoma, Pleomorphic Variant|Invasive Lobular Breast Carcinoma, Solid Variant|Invasive Lobular Breast Carcinoma, Tubulolobular Variant|Invasive Lung Mucinous Adenocarcinoma|Invasive Micropapillary Breast Carcinoma|Invasive carcinoma of no special type|Invasive carcinoma, NST|Invasive encapsulated follicular variant of papillary thyroid carcinoma (invasive EFVPTC)|Invasive fibroma|Invasive hydatidiform mole|Invasive lobular carcinoma|Invasive lobular carcinoma, alveolar type|Invasive lobular carcinoma, solid type|Invasive lobular carcinoma, tubulolobular variant|Invasive mammary carcinoma|Invasive micropapillary carcinoma|Invasive mole, NOS|Invasive mucinous adenocarcinoma|Inverted Squamous Cell Papilloma|Inverted Transitional Cell Papilloma|Investigations - Other|Involuting nevus|Iobenguane I-131|Iodine I 124 Monoclonal Antibody A33|Iodine I 124 Monoclonal Antibody M5A|Iodine I 125-Anti-EGFR-425 Monoclonal Antibody|Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP|Iodine I 131 Apamistamab|Iodine I 131 Derlotuximab Biotin|Iodine I 131 Ethiodized Oil|Iodine I 131 IPA|Iodine I 131 MIP-1095|Iodine I 131 Monoclonal Antibody 81C6|Iodine I 131 Monoclonal Antibody BC8|Iodine I 131 Monoclonal Antibody CC49-deltaCH2|Iodine I 131 Monoclonal Antibody F16SIP|Iodine I 131 Monoclonal Antibody G-250|Iodine I 131 Monoclonal Antibody muJ591|Iodine I 131 Omburtamab|Iodine I 131 Rituximab|Iodine I 131 TM-601|Iodine I 131 Tenatumomab|Iodine I 131 Tositumomab|Iodine I-131|IodoTMT|Iodoacetamide (IAA)|Ioflubenzamide I-131|Ion Torrent|Ionomycin|Ipafricept|Ipatasertib|Ipilimumab|Ipomeanol|Iproplatin|Iran|Iraq|Iratumumab|Ireland|Iridium Ir 192|Irinotecan|Irinotecan Hydrochloride|Irinotecan Sucrosofate|Irinotecan-Eluting Beads|Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet|Irofulven|Iron Overload|Iroplact|Irosustat|Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130|Irregular Menstruation|Irritability|Isatuximab|Ischemia Cerebrovascular|Ischemic Heart Disease|Ischium|Ishak Score 0|Ishak Score 1-2|Ishak Score 3-4|Ishak Score 5|Ishak Score 6|Isle of Man|Islet Cell Adenoma|Islet Cells|Islet cell adenocarcinoma|Islet cell adenoma|Islet cell adenomatosis|Islet cell carcinoma|Islet cell tumor, NOS|Islet cell tumor, benign|Islets of Langerhans|Iso-fludelone|IsoPrime|IsoProbe T|Isobaric label quantitation analysis|Isobrucein B|Isocoumarin NM-3|Isoform Expression Quantification|Isolated Limb Perfusion (ILP)|Isosporiasis|Isotretinoin|Ispinesib|Ispinesib Mesylate|Israel|Isthmus Uteri|Isthmus uteri|Istiratumab|Itacitinib|Itacitinib Adipate|Italy|Item Flagged Low Quality|Item does not meet study protocol|Item flagged DNU|Item in special subset|Item is noncanonical|Item may not meet study protocol|Itraconazole|Itraconazole Dispersion In Polymer Matrix|Ivaltinostat|Ivosidenib|Ivuxolimab|Ixabepilone|Ixazomib|Ixazomib Citrate|JAK Inhibitor|JAK Inhibitor INCB047986|JAK1 Inhibitor AZD4205|JAK1 Inhibitor INCB052793|JAK2 Inhibitor AZD1480|JAK2 Inhibitor BMS-911543|JAK2 Inhibitor XL019|JAK2/Src Inhibitor NS-018|JNK Inhibitor CC-401|JPEG|JPEG 2000|JSON|Jadassohn blue nevus|Jamaica|Japan|Jaw|Jejunal Fistula|Jejunal Hemorrhage|Jejunal Obstruction|Jejunal Perforation|Jejunal Stenosis|Jejunal Ulcer|Jejunum|Jersey|Jin Fu Kang|Joint|Joint Effusion|Joint Infection|Joint Range of Motion Decreased|Joint Range of Motion Decreased Cervical Spine|Joint Range of Motion Decreased Lumbar Spine|Joint Replacement|Jordan|Jugular paraganglioma|Jugulotympanic Paraganglioma|Jugulotympanic paraganglioma|Junction nevus|Junctional Nevus|Junctional nevus, NOS|Juvenile Myelomonocytic Leukemia|Juvenile Type Granulosa Cell Tumor|Juvenile angiofibroma|Juvenile astrocytoma|Juvenile carcinoma of breast|Juvenile chronic myelomonocytic leukemia|Juvenile fibroadenoma|Juvenile hemangioma|Juvenile histiocytoma|Juvenile melanoma|Juvenile myelomonocytic leukemia|Juvenile nevus|Juxtacortical chondroma|Juxtacortical chondrosarcoma|Juxtacortical osteosarcoma|Juxtaglomerular Cell Tumor|Juxtaglomerular tumor|KRAS G12C Inhibitor GDC-6036|KRAS G12C Inhibitor LY3499446|KRAS G12C Inhibitor MRTX849|KRAS Mutant-targeting AMG 510|KRAS-MAPK Signaling Pathway Inhibitor JAB-3312|KRASG12C Inhibitor JNJ-74699157|KRN5500|KSP Inhibitor AZD4877|KSP Inhibitor SB-743921|Kallisto - HDF5|Kallisto - Quantification|Kanglaite|Kanitinib|Kaposi Sarcoma|Kaposi sarcoma|Kaposiform Hemangioendothelioma|Kaposiform hemangioendothelioma|Kazakhstan|Kenya|Keratinizing Squamous Cell Carcinoma|Keratitis|Keratotoc papilloma|Ketoconazole|Ketotrexate|Kidney|Kidney Anastomotic Leak|Kidney Cancer|Kidney Chromophobe|Kidney Disease|Kidney Disorder|Kidney Infection|Kidney Medullary Carcinoma|Kidney Renal Clear Cell Carcinoma|Kidney Renal Papillary Cell Carcinoma|Kidney Wilms Tumor|Kidney, NOS|Kiribati|Klatskin tumor|Knee|Kosovo|Krukenberg Tumor|Krukenberg tumor|Kunecatechins Ointment|Kupffer cell sarcoma|Kuwait|Kyphosis|Kyrgyzstan|L-Gossypol|L-cell tumor|L-methylfolate|L1|L1 Acute Lymphoblastic Leukemia|L2|L2 Acute Lymphoblastic Leukemia|LAIR-2 Fusion Protein NC410|LC-MS label-free quantitation analysis|LCIS, NOS|LCMS-2010A|LCMS-2010EV|LCMS-2020|LCMS-8040|LCMS-8045|LCMS-8050|LCMS-8060|LCMS-9030|LCMS-IT-TOF|LCT|LCT Premier|LCT Premier XE|LECO|LMB-1 Immunotoxin|LMB-2 Immunotoxin|LMB-7 Immunotoxin|LMB-9 Immunotoxin|LMP-2:340-349 Peptide Vaccine|LMP-2:419-427 Peptide Vaccine|LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes|LMP7 Inhibitor M3258|LOH|LOXL2 Inhibitor PAT-1251|LRP5 Antagonist BI 905681|LRP5/6 Antagonist BI 905677|LS454|LSD1 Inhibitor CC-90011|LSD1 Inhibitor GSK2879552|LSD1 Inhibitor IMG-7289|LSD1 Inhibitor RO7051790|LSD1 Inhibitor SYHA1807|LTQ|LTQ FT|LTQ FT Ultra|LTQ Orbitrap|LTQ Orbitrap Classic|LTQ Orbitrap Discovery|LTQ Orbitrap Elite|LTQ Orbitrap Velos|LTQ Orbitrap XL|LTQ Orbitrap XL ETD|LTQ Velos|LTQ Velos ETD|LTQ Velos Pro|LTQ XL|LTQ XL ETD|LTQ-FT|LTQ-OT|LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1|LXQ|Label Free|Label-free gene level quantitation|Label-free peptide level quantitation|Label-free protein group level quantitation|Label-free protein level quantitation|Label-free raw feature quantitation|Labetuzumab Govitecan|Labium Majus|Labium Minus|Labium majus|Labium minus|Lacrimal Gland|Lacrimal gland|Lactating Adenoma|Lactating adenoma|Lactation Disorder|Lactoferrin-derived Lytic Peptide LTX-315|Lactotroph Adenoma|Lacutamab|Ladiratuzumab Vedotin|Ladirubicin|Laetrile|Landogrozumab|Langerhans Cell Histiocytosis|Langerhans Cell Histiocytosis, Disseminated|Langerhans Cell Histiocytosis, Monostotic|Langerhans Cell Histiocytosis, Polyostotic|Langerhans Cell Sarcoma|Langerhans cell granulomatosis|Langerhans cell granulomatosis, unifocal|Langerhans cell histiocytosis, NOS|Langerhans cell histiocytosis, disseminated|Langerhans cell histiocytosis, generalized|Langerhans cell histiocytosis, mono-ostotic|Langerhans cell histiocytosis, multifocal|Langerhans cell histiocytosis, poly-ostotic|Langerhans cell histiocytosis, unifocal|Langerhans cell sarcoma|Laniquidar|Lanreotide Acetate|Laos|Lapachone|Laparoscopic Biopsy|Laparoscopic Partial Nephrectomy|Laparoscopic Radical Nephrectomy|Laparoscopic Radical Prostatectomy with Robotics|Laparoscopic Radical Prostatectomy without Robotics|Laparoscopy|Laparotomy|Lapatinib|Lapatinib Ditosylate|Laprituximab Emtansine|Lapuleucel-T|Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease|Large Bowel|Large Cell Carcinoma|Large Cell Medulloblastoma|Large Cell Neuroendocrine Carcinoma|Large Intestinal Anastomotic Leak|Large cell (Ki-1+) lymphoma|Large cell calcifying Sertoli cell tumor|Large cell carcinoma with rhabdoid phenotype|Large cell carcinoma, NOS|Large cell medulloblastoma|Large cell neuroendocrine carcinoma|Large granular lymphocytosis, NOS|Laromustine|Larotaxel|Larotinib Mesylate|Larotrectinib|Larotrectinib Sulfate|Laryngeal Cancer|Laryngeal Cartilage|Laryngeal Edema|Laryngeal Fistula|Laryngeal Hemorrhage|Laryngeal Inflammation|Laryngeal Mucositis|Laryngeal Obstruction|Laryngeal Stenosis|Laryngeal cartilage|Laryngeal commissure|Laryngitis|Laryngopharyngeal Dysesthesia|Laryngopharyngectomy|Laryngopharynx|Laryngospasm|Larynx|Larynx, NOS|Lateral Wall of the Nasopharynx|Lateral floor of mouth|Lateral wall of bladder|Lateral wall of nasopharynx|Lateral wall of oropharynx|Latvia|Lavendustin A|Lazertinib|Lead Pb 212 TCMC-trastuzumab|Lebanon|Lefitolimod|Leflunomide|Left|Left Hemicolectomy|Left Ventricular Systolic Dysfunction|Leg|Legal Guardian|Leiomyoblastoma|Leiomyofibroma|Leiomyoma|Leiomyoma, NOS|Leiomyomatosis|Leiomyomatosis, NOS|Leiomyosarcoma|Leiomyosarcoma, NOS|Lenalidomide|Lenalidomide Analog KPG-121|Lennert lymphoma|Lentigo Maligna|Lentigo Maligna Melanoma|Lentigo maligna|Lentigo maligna melanoma|Lentinan|Lenvatinib|Lenvatinib Mesylate|Lenzilumab|Lepidic Predominant Adenocarcinoma|Lepidic adenocarcinoma|Lepidic predominant adenocarcinoma|Leptomeningeal Sarcoma|Leptomeningeal sarcoma|Leptomeninges|Lerociclib|Lesotho|Lesser Curvature of the Stomach|Lesser curvature of stomach, NOS|Lestaurtinib|Letetresgene Autoleucel|Lethargy|Letolizumab|Letrozole|Letterer-Siwe Disease|Letterer-Siwe disease|Leucovorin|Leucovorin Calcium|Leukemia|Leukemia Secondary to Oncology Chemotherapy|Leukemia, NOS|Leukemias, NOS|Leukemic reticuloendotheliosis|Leukocyte elastase|Leukocytosis|Leukoencephalopathy|Leuprolide|Leuprolide Acetate|Leuprolide Mesylate Injectable Suspension|Leurubicin|Levetiracetam|Levoleucovorin Calcium|Levothyroxine|Levothyroxine Sodium|Lexatumumab|Lexibulin|Leydig Cell Tumor|Leydig cell tumor, NOS|Leydig cell tumor, benign|Leydig cell tumor, malignant|Li-Fraumeni Syndrome|Liarozole|Liarozole Fumarate|Liarozole Hydrochloride|Liberia|Libido Decreased|Libido Increased|Libya|Licartin|Licorice|Liechtenstein|Lifastuzumab Vedotin|Lifelong Non-Drinker|Lifileucel|Lifirafenib|Liftover|Ligament|Light Chain Deposition Disease|Light-Emitting Oncolytic Vaccinia Virus GL-ONC1|Light-activated AU-011|Lilotomab|Limonene, (+)-|Limonene, (+/-)-|Lingual tonsil|Linifanib|Linitis Plastica|Linitis plastica|Linoleyl Carbonate-Paclitaxel|Linperlisib|Linrodostat|Linsitinib|Lintuzumab|Liothyronine I-131|Liothyronine Sodium|Lip|Lip Infection|Lip Pain|Lip, NOS|Lipase Increased|Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1|Lipid Nanoparticle Encapsulated OX40L mRNA-2416|Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191|Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006|Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752|Lipid cell tumor of ovary|Lipid-Rich Carcinoma|Lipid-rich Sertoli cell tumor|Lipid-rich carcinoma|Lipid-rich urothelial carcinoma|Lipidome|Lipoadenoma|Lipoblastoma|Lipoblastomatosis|Lipohypertrophy|Lipoid cell tumor of ovary|Lipoleiomyoma|Lipoma|Lipoma, NOS|Lipoma-like liposarcoma|Lipomatous Neoplasms|Lipomatous medulloblastoma|Liposarcoma|Liposarcoma, NOS|Liposarcoma, differentiated|Liposarcoma, well differentiated|Liposomal Bcl-2 Antisense Oligonucleotide  BP1002|Liposomal Curcumin|Liposomal Cytarabine|Liposomal Daunorubicin Citrate|Liposomal Docetaxel|Liposomal Eribulin Mesylate|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Liposomal Irinotecan|Liposomal MUC1/PET-lipid A Vaccine ONT-10|Liposomal Mitoxantrone Hydrochloride|Liposomal NDDP|Liposomal Rhenium Re 186|Liposomal SN-38|Liposomal Topotecan FF-10850|Liposomal Vinorelbine|Liposomal Vinorelbine Tartrate|Liposomal c-raf Antisense Oligonucleotide|Liposome|Liposome-Encapsulated Doxorubicin Citrate|Liposome-encapsulated Daunorubicin-Cytarabine|Liposome-encapsulated OSI-7904|Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94|Liposome-encapsulated TAAs mRNA Vaccine W_ova1|Liposome-encapsulated miR-34 Mimic MRX34|Liquid Biopsy|Liquid Suspension Cell Line|Liquor|Lirilumab|Lisavanbulin|Lisocabtagene Maraleucel|Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142|Lithuania|Litronesib|Live Birth|Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207|Live-attenuated Double-deleted Listeria monocytogenes Bacteria JNJ-64041809|Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623|Liver|Liver Cancer|Liver Cirrhosis (Liver Disease)|Liver Hepatocellular Carcinoma|Liver Toxicity (Non-Infectious)|Liver X Receptor beta Agonist RGX-104|Liver and intrahepatic bile ducts|Liver cell adenoma|Liver cell carcinoma|Lm-tLLO-neoantigens Vaccine ADXS-NEO|LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine ADXS31-164|Lobaplatin|Lobectomy|Lobular Breast Carcinoma|Lobular Breast Carcinoma In Situ|Lobular adenocarcinoma|Lobular and ductal carcinoma|Lobular carcinoma in situ, NOS|Lobular carcinoma, NOS|Lobular carcinoma, noninfiltrating|Local|Local Resection (Exoresection; wall resection)|Localized Edema|Localized fibrous tumor|Loco-regional recurrence/progression|Lodapolimab|Lometrexol|Lometrexol Sodium|Lomustine|Lonafarnib|Loncastuximab Tesirine|Long Peptide Vaccine 7|Long bones of lower limb and associated joints|Long bones of upper limb, scapula and associated joints|Long-acting Release Pasireotide|Lontucirev|Lordosis|Lorlatinib|Lorukafusp alfa|Lorvotuzumab Mertansine|Losatuxizumab Vedotin|Losoxantrone|Losoxantrone Hydrochloride|Lovastatin|Low|Low Grade|Low Grade (G1)|Low Grade Adenosquamous Breast Carcinoma|Low Grade Central Osteosarcoma|Low Grade Cervical Intraepithelial Neoplasia|Low Grade Dysplasia|Low Grade Endometrioid Stromal Sarcoma|Low Grade Esophageal Glandular Intraepithelial Neoplasia|Low Grade Esophageal Squamous Intraepithelial Neoplasia|Low Grade Fibromyxoid Sarcoma|Low Grade Glandular Intraepithelial Neoplasia|Low Grade Liver Dysplastic Nodule|Low Grade Myofibroblastic Sarcoma|Low Grade Squamous Intraepithelial Neoplasia|Low Risk|Low Risk Gastrointestinal Stromal Tumor|Low grade adenosquamous carcinoma|Low grade appendiceal mucinous neoplasm|Low grade cribriform cystadenocarcinoma (LGCCC)|Low-CSD Melanoma|Low-Grade Appendix Mucinous Neoplasm|Low-Intermediate Risk|Low-grade central osteosarcoma|Low-grade fibromyxoid sarcoma|Low-grade intramedullary osteosarcoma|Low-grade myofibroblastic sarcoma|Low-grade serous carcinoma|Lower Gastrointestinal Hemorrhage|Lower Gingiva|Lower gum|Lower limb, NOS|Lower lobe, lung|Lower third of esophagus|Lower-Outer Quadrant of the Breast|Lower-inner quadrant of breast|Lower-outer quadrant of breast|Lucanthone|Lucatumumab|Lucitanib|Lumbar Spine|Luminespib|Luminespib Mesylate|Lumpectomy|Lumretuzumab|Lung|Lung Adenocarcinoma|Lung Adenocarcinoma with Mixed Bronchioloalveolar and Invasive Components|Lung Cancer|Lung Cancer (all types)|Lung Colloid Adenocarcinoma|Lung Fetal Adenocarcinoma|Lung Infection|Lung Large Cell Carcinoma with Rhabdoid Phenotype|Lung Mucinous Adenocarcinoma In Situ|Lung Non-Mucinous Adenocarcinoma In Situ|Lung Papillary Adenoma|Lung Squamous Cell Carcinoma|Lung, NOS|Lung-targeted Immunomodulator QBKPN|Lupartumab Amadotin|Lupus|Lurbinectedin|Lurtotecan|Lurtotecan Liposome|Luteinoma|Luteoma, NOS|Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1|Lutetium Lu 177 DOTA-N3-CTT1403|Lutetium Lu 177 DOTA-Tetulomab|Lutetium Lu 177 DOTA-biotin|Lutetium Lu 177 Dotatate|Lutetium Lu 177 Lilotomab-satetraxetan|Lutetium Lu 177 Monoclonal Antibody CC49|Lutetium Lu 177 Monoclonal Antibody J591|Lutetium Lu 177 PP-F11N|Lutetium Lu 177 Satoreotide Tetraxetan|Lutetium Lu 177-DOTA-EB-TATE|Lutetium Lu 177-DTPA-omburtamab|Lutetium Lu 177-Edotreotide|Lutetium Lu 177-NeoB|Lutetium Lu 177-PSMA-617|Lutetium Lu-177 Capromab|Lutetium Lu-177 Girentuximab|Lutetium Lu-177 PSMA-R2|Lutetium Lu-177 Rituximab|Luxembourg|Lymph Gland Infection|Lymph Leakage|Lymph Node|Lymph Node Cancer|Lymph Node Dissection|Lymph Node Pain|Lymph Node(s) Axilla|Lymph Node(s) Cervical|Lymph Node(s) Distant|Lymph Node(s) Epitrochlear|Lymph Node(s) Femoral|Lymph Node(s) Hilar|Lymph Node(s) Iliac-Common|Lymph Node(s) Iliac-External|Lymph Node(s) Inguinal|Lymph Node(s) Internal Mammary|Lymph Node(s) Mammary|Lymph Node(s) Mediastinal|Lymph Node(s) Mesenteric|Lymph Node(s) Occipital|Lymph Node(s) Paraaortic|Lymph Node(s) Parotid|Lymph Node(s) Pelvic|Lymph Node(s) Popliteal|Lymph Node(s) Regional|Lymph Node(s) Retroperitoneal|Lymph Node(s) Scalene|Lymph Node(s) Splenic|Lymph Node(s) Subclavicular|Lymph Node(s) Submandibular|Lymph Node(s) Supraclavicular|Lymph Node, Axillary|Lymph Node, Inguinal|Lymph Node, NOS|Lymph Node, Regional|Lymph Node, Subcarinal|Lymph Nodes(s) Mediastinal|Lymph node, NOS|Lymph nodes|Lymph nodes of axilla or arm|Lymph nodes of head, face and neck|Lymph nodes of inguinal region or leg|Lymph nodes of multiple regions|Lymphadenectomy|Lymphangioendothelial sarcoma|Lymphangioendothelioma, NOS|Lymphangioendothelioma, malignant|Lymphangioleiomyoma|Lymphangioleiomyomatosis|Lymphangioma|Lymphangioma, NOS|Lymphangiomyoma|Lymphangiomyomatosis|Lymphangiosarcoma|Lymphatic Vessel Tumors|Lymphatic leukemic, NOS|Lymphedema|Lymphoblastic Lymphoma|Lymphoblastic leukemia, NOS|Lymphoblastoma|Lymphocele|Lymphocyte Count Decreased|Lymphocyte Count Increased|Lymphocyte Predominant Type Hodgkin's Disease|Lymphocyte-Depleted Classic Hodgkin Lymphoma|Lymphocyte-Rich Classic Hodgkin Lymphoma|Lymphocytes|Lymphocytic Meningitis|Lymphocytic Thyroiditis|Lymphocytic leukemia, NOS|Lymphoepithelial carcinoma|Lymphoepithelioid Variant Peripheral T-Cell Lymphoma|Lymphoepithelioid lymphoma|Lymphoepithelioma|Lymphoepithelioma-like carcinoma|Lymphoid Leukemia|Lymphoid Leukemias|Lymphoid Neoplasm Diffuse Large B-cell Lymphoma|Lymphoid Normal|Lymphoid leukemia, NOS|Lymphoma|Lymphoma, NOS|Lymphomatoid Granulomatosis|Lymphomatoid Papulosis|Lymphomatoid granulomatosis|Lymphomatoid papulosis|Lymphoplasmacyte-Rich Meningioma|Lymphoplasmacyte-rich meningioma|Lymphoplasmacytic Lymphoma|Lymphoproliferative Disorder|Lymphoproliferative disease, NOS|Lymphoproliferative disorder, NOS|Lymphosarcoma|Lymphosarcoma cell leukemia|Lymphosarcoma, NOS|Lymphosarcoma, diffuse|Lynch Syndrome|Lyophilized Black Raspberry Lozenge|Lyophilized Black Raspberry Saliva Substitute|Lys-C|Lys-C, Lys-C/P|Lysine-specific Demethylase 1 Inhibitor INCB059872|Lyso-Thermosensitive Liposome Doxorubicin|M|M0|M0 Stage Finding|M1|M1 Stage Finding|M1a|M1a Stage Finding|M1b|M1b Stage Finding|M1c|M1c Stage Finding|M1d|M2|M6A|M6B|M@LDI L|M@LDI LR|MAF|MAGE-10.A2|MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells|MAGE-A3 Multipeptide Vaccine GL-0817|MAGE-A3 Peptide Vaccine|MAGE-A3-specific Immunotherapeutic GSK 2132231A|MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201|MAGE-TAB|MAGETAB|MAI|MALDI 4800|MALDI L|MALDI LR|MALDI LTQ Orbitrap|MALDI LTQ XL|MALDI R|MALDI SYNAPT G2-Si|MALDI Synapt G2 HDMS|MALDI Synapt G2 MS|MALDI Synapt G2-S HDMS|MALDI Synapt G2-S MS|MALDI Synapt HDMS|MALDI Synapt MS|MALDI micro MX|MALT lymphoma|MALT1 Inhibitor JNJ-67856633|MANEC|MARCKS Protein Inhibitor BIO-11006|MAT2A Inhibitor AG-270|MCL-1 Inhibitor ABBV-467|MCL-1 Inhibitor AMG 176|MCL-1 inhibitor AMG 397|MDM2 Antagonist ASTX295|MDM2 Antagonist RO5045337|MDM2 Antagonist RO6839921|MDM2 Inhibitor AMG-232|MDM2 Inhibitor AMGMDS3|MDM2 Inhibitor BI 907828|MDM2 Inhibitor KRT-232|MDM2/MDMX Inhibitor ALRN-6924|MDR Modulator CBT-1|MEK 1/2 Inhibitor AS703988/MSC2015103B|MEK 1/2 Inhibitor FCN-159|MEK Inhibitor AZD8330|MEK Inhibitor CI-1040|MEK Inhibitor GDC-0623|MEK Inhibitor HL-085|MEK Inhibitor PD0325901|MEK Inhibitor RO4987655|MEK Inhibitor SHR 7390|MEK Inhibitor TAK-733|MEK Inhibitor WX-554|MEK inhibitor CS3006|MEK-1/MEKK-1 Inhibitor E6201|MEK/Aurora Kinase Inhibitor BI 847325|MELK Inhibitor OTS167|MET Kinase Inhibitor OMO-1|MET Tyrosine Kinase Inhibitor BMS-777607|MET Tyrosine Kinase Inhibitor EMD 1204831|MET Tyrosine Kinase Inhibitor PF-04217903|MET Tyrosine Kinase Inhibitor SAR125844|MET Tyrosine Kinase Inhibitor SGX523|MET x MET Bispecific Antibody REGN5093|MEX|MGUS|MK0731|MKC-1|MKNK1 Inhibitor BAY 1143269|MMP Inhibitor S-3304|MNK1/2 Inhibitor ETC-1907206|MOF Compound RiMO-301|MOv-gamma Chimeric Receptor Gene|MPNST with glandular differentiation|MPNST with mesenchymal differentiation|MPNST with rhabdomyoblastic differentiation|MPNST, NOS|MR-Minimal/Marginal Response|MR-Minimal/Marginal response|MRI|MS1 label-based analysis|MS2|MS2 tag-based analysis|MS2-based label-free quantitation|MS3|MSI|MSS|MTF-1 Inhibitor APTO-253 HCl|MUC-1/WT1 Peptide-primed Autologous Dendritic Cells|MUC1-targeted Peptide GO-203-2C|MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP|MVA-BN Smallpox Vaccine|MVA-FCU1 TG4023|MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1|MX|MX Stage Finding|MX-Mixed Response|MYC-targeting siRNA DCR-MYC|Maackia amurensis Seed Lectin|Macau|Machine smoke|Macimorelin|Macitentan|Macro|Macrocycle-bridged STING Agonist E7766|Macrofollicular adenoma|Macroscopic (2cm or less)|Macroscopic (greater than 2cm)|Macroscopic Parametrium|Madagascar|Maekmoondong-tang|Mafosfamide|Magnesium Valproate|Magnocellular nevus|Magrolimab|Main Bronchus|Main bronchus|Maintenance Therapy|Major salivary gland, NOS|Malabsorption|Malaise|Malaria|Malawi|Malaysia|Maldives|Male|Male Cousin|Male Genitalia|Male Sibling of Adopted Child|Male genital organs, NOS|Mali|Malignancy|Malignancy in Giant Cell Tumor of Bone|Malignant|Malignant Adrenal Cortex Neoplasm|Malignant Adrenal Gland Pheochromocytoma|Malignant Cell|Malignant Enteroglucagonoma|Malignant Extra-Adrenal Paraganglioma|Malignant Gastrinoma|Malignant Gastrointestinal Stromal Tumor|Malignant Giant Cell Neoplasm|Malignant Glioma|Malignant Glomus Tumor|Malignant Granular Cell Tumor|Malignant Granulosa Cell Tumor|Malignant Hemangiopericytoma|Malignant Histiocytosis|Malignant Leydig Cell Tumor|Malignant Lymphoma Centroblastic, Follicular|Malignant Lymphoma, Convoluted|Malignant Lymphoma, Histiocytic, Diffuse|Malignant Lymphoma, Large Cell Type|Malignant Lymphoma, Large Cell, Cleaved|Malignant Lymphoma, Non-Cleaved Cell Type|Malignant Lymphoma, Non-Cleaved, Diffuse|Malignant Lymphomas, NOS or Diffuse|Malignant Mastocytosis|Malignant Mediastinal Germ Cell Tumor with Associated Hematologic Malignancy|Malignant Melanoma in Precancerous Melanosis|Malignant Melanotic Peripheral Nerve Sheath Tumor|Malignant Mesenchymoma|Malignant Mesothelioma|Malignant Mixed Tumor of the Salivary Gland|Malignant Muscle Neoplasm|Malignant Myoepithelioma|Malignant Neoplasm|Malignant Neoplasm, Uncertain Whether Primary or Metastatic|Malignant Odontogenic Neoplasm|Malignant Ossifying Fibromyxoid Tumor|Malignant Ovarian Brenner Tumor|Malignant Ovarian Thecoma|Malignant PEComa|Malignant Pancreatic Glucagonoma|Malignant Pancreatic Insulinoma|Malignant Paraganglioma|Malignant Pericytic Neoplasm|Malignant Peripheral Nerve Sheath Tumor|Malignant Peripheral Nerve Sheath Tumor with Perineurial Differentiation|Malignant Phosphaturic Mesenchymal Tumor|Malignant Phyllodes Tumor|Malignant Sertoli Cell Tumor|Malignant Soft Tissue Neoplasm|Malignant Solitary Fibrous Tumor|Malignant Somatostatinoma|Malignant Spindle Cell Neoplasm|Malignant Struma Ovarii|Malignant Sweat Gland Neoplasm|Malignant Tenosynovial Giant Cell Tumor|Malignant Teratoma|Malignant Thymoma|Malignant Triton Tumor|Malignant Trophoblastic Teratoma|Malignant Tumor, Small Cell Type|Malignant Type A Thymoma|Malignant Type AB Thymoma|Malignant Type B1 Thymoma|Malignant Type B2 Thymoma|Malignant Vipoma|Malignant chondroid syringoma|Malignant cystic nephroma|Malignant eccrine spiradenoma|Malignant fibrous histiocytoma|Malignant fibrous histiocytoma (MFH) of bone|Malignant giant cell tumor of soft parts|Malignant histiocytosis|Malignant hydatidiform mole|Malignant lymphoma, Hodgkin|Malignant lymphoma, NOS|Malignant lymphoma, centroblastic, NOS|Malignant lymphoma, centroblastic, diffuse|Malignant lymphoma, centroblastic, follicular|Malignant lymphoma, centroblasticcentrocytic, NOS|Malignant lymphoma, centroblasticcentrocytic, diffuse|Malignant lymphoma, centroblasticcentrocytic, follicular|Malignant lymphoma, centrocytic|Malignant lymphoma, cleaved cell, NOS|Malignant lymphoma, convoluted cell|Malignant lymphoma, diffuse, NOS|Malignant lymphoma, follicle center, NOS|Malignant lymphoma, follicle center, follicular|Malignant lymphoma, follicular, NOS|Malignant lymphoma, histiocytic, NOS|Malignant lymphoma, histiocytic, diffuse|Malignant lymphoma, histiocytic, nodular|Malignant lymphoma, immunoblastic, NOS|Malignant lymphoma, large B-cell, NOS|Malignant lymphoma, large B-cell, diffuse, NOS|Malignant lymphoma, large B-cell, diffuse, centroblastic, NOS|Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS|Malignant lymphoma, large cell, NOS|Malignant lymphoma, large cell, cleaved and noncleaved|Malignant lymphoma, large cell, cleaved, NOS|Malignant lymphoma, large cell, cleaved, diffuse|Malignant lymphoma, large cell, diffuse, NOS|Malignant lymphoma, large cell, follicular, NOS|Malignant lymphoma, large cell, immunoblastic|Malignant lymphoma, large cell, noncleaved, NOS|Malignant lymphoma, large cell, noncleaved, diffuse|Malignant lymphoma, large cell, noncleaved, follicular|Malignant lymphoma, large cleaved cell, NOS|Malignant lymphoma, large cleaved cell, follicular|Malignant lymphoma, lymphoblastic, NOS|Malignant lymphoma, lymphocytic, NOS|Malignant lymphoma, lymphocytic, diffuse, NOS|Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse|Malignant lymphoma, lymphocytic, intermediate differentiation, nodular|Malignant lymphoma, lymphocytic, nodular, NOS|Malignant lymphoma, lymphocytic, poorly differentiated, diffuse|Malignant lymphoma, lymphocytic, poorly differentiated, nodular|Malignant lymphoma, lymphocytic, well differentiated, diffuse|Malignant lymphoma, lymphocytic, well differentiated, nodular|Malignant lymphoma, lymphoplasmacytic|Malignant lymphoma, lymphoplasmacytoid|Malignant lymphoma, mixed cell type, diffuse|Malignant lymphoma, mixed cell type, follicular|Malignant lymphoma, mixed cell type, nodular|Malignant lymphoma, mixed lymphocytic-histiocytic, diffuse|Malignant lymphoma, mixed lymphocytic-histiocytic, nodular|Malignant lymphoma, mixed small and large cell, diffuse|Malignant lymphoma, mixed small cleaved and large cell, follicular|Malignant lymphoma, nodular, NOS|Malignant lymphoma, non-Hodgkin, NOS|Malignant lymphoma, non-cleaved cell, NOS|Malignant lymphoma, noncleaved cell, follicular, NOS|Malignant lymphoma, noncleaved, NOS|Malignant lymphoma, noncleaved, diffuse, NOS|Malignant lymphoma, plasmacytoid|Malignant lymphoma, small B lymphocytic, NOS|Malignant lymphoma, small cell diffuse|Malignant lymphoma, small cell, NOS|Malignant lymphoma, small cell, noncleaved, diffuse|Malignant lymphoma, small cleaved cell, NOS|Malignant lymphoma, small cleaved cell, diffuse|Malignant lymphoma, small cleaved cell, follicular|Malignant lymphoma, small lymphocytic, NOS|Malignant lymphoma, small lymphocytic, diffuse|Malignant lymphoma, small noncleaved, Burkitt type|Malignant lymphoma, undifferentiated cell type, NOS|Malignant lymphoma, undifferentiated cell, non-Burkitt|Malignant lymphoma, undifferentiated, Burkitt type|Malignant lymphomatous polyposis|Malignant mast cell tumor|Malignant mastocytoma|Malignant mastocytosis|Malignant melanoma in Hutchinson melanotic freckle|Malignant melanoma in congenital melanocytic nevus|Malignant melanoma in giant pigmented nevus|Malignant melanoma in junctional nevus|Malignant melanoma in precancerous melanosis|Malignant melanoma, NOS|Malignant melanoma, regressing|Malignant midline reticulosis|Malignant mucinous adenofibroma|Malignant mucinous cystadenofibroma|Malignant multilocular cystic nephroma|Malignant myelosclerosis|Malignant myoepithelioma|Malignant peripheral nerve sheath tumor|Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation|Malignant perivascular epithelial cell tumor|Malignant reticulosis, NOS|Malignant rhabdoid tumor|Malignant schwannoma with rhabdomyoblastic differentiation|Malignant schwannoma, NOS|Malignant serous adenofibroma|Malignant serous cystadenofibroma|Malignant tenosynovial giant cell tumor|Malignant teratoma, anaplastic|Malignant teratoma, intermediate|Malignant teratoma, trophoblastic|Malignant teratoma, undifferentiated|Malignant tumor, clear cell type|Malignant tumor, fusiform cell type|Malignant tumor, giant cell type|Malignant tumor, small cell type|Malignant tumor, spindle cell type|Malta|Mammary carcinoma, in situ|Mandible|Mandibulectomy|Manelimab|Mania|Mannosulfan|Mannosylerythritol Lipid|Mantle|Mantle Cell Lymphoma|Mantle cell lymphoma (Includes all variants blastic, pleomorphic, small cell)|Mantle zone lymphoma|Mapatumumab|Maraba Oncolytic Virus Expressing Mutant HPV E6/E7|Marcellomycin|Margetuximab|Marginal Zone Lymphoma|Marginal zone B-cell lymphoma, NOS|Marginal zone lymphoma, NOS|Marijuana|Marijuana smoke|Marimastat|Marizomib|Marshall Islands|Martinique|Masculinovoblastoma|Masitinib Mesylate|Masked Annotated Somatic Mutation|Masked Copy Number Segment|Masked Intensities|Masked Somatic Mutation|Masoprocol|Mast Cell Leukemia|Mast Cell Neoplasm|Mast Cell Sarcoma|Mast Cell Tumors|Mast cell leukaemia|Mast cell sarcoma|Mast cell tumor, NOS|Mastocytoma|Mastocytoma, NOS|Maternal Aunt|Maternal First Cousin|Maternal First Cousin Once Removed|Maternal Grandfather|Maternal Grandmother|Maternal Grandparent|Maternal Great Aunt|Maternal Great Grandparent|Maternal Great Uncle|Maternal Half Brother|Maternal Half Sibling|Maternal Half Sister|Maternal Uncle|Matrical carcinoma|Matrix Metalloproteinase Inhibitor MMI270|Mature B-Cell Lymphomas|Mature T ALL|Mature T- and NK-Cell Lymphomas|Mature T-ALL|Mature T-cell lymphoma, NOS|Mature Teratoma|Mature teratoma|Matuzumab|Mauritania|Mauritius|Mavelertinib|Mavorixafor|Maxilla|Maxillary Sinus|Maxillary sinus|Maxillectomy|Mayotte|Maytansine|Mcl-1 Inhibitor AZD5991|Mcl-1 Inhibitor MIK665|Mechlorethamine|Mechlorethamine Hydrochloride|Mechlorethamine Hydrochloride Gel|Meckel diverticulum|Mediastinal (thymic) large B-cell lymphoma|Mediastinal Hemorrhage|Mediastinal Infection|Mediastinal Soft Tissue|Mediastinum|Mediastinum, NOS|Medical Record|Medically Treated|Mediterranean lymphoma|Medorubicin|Medroxyprogesterone|Medroxyprogesterone Acetate|Medulla of adrenal gland|Medullary Carcinoma, Not Otherwise Specified|Medullary adenocarcinoma|Medullary carcinoma with amyloid stroma|Medullary carcinoma with lymphoid stroma|Medullary carcinoma, NOS|Medullary osteosarcoma|Medulloblastoma|Medulloblastoma with Extensive Nodularity|Medulloblastoma with Melanotic Differentiation|Medulloblastoma with extensive nodularity|Medulloblastoma, NOS|Medulloblastoma, Non-WNT/Non-SHH|Medulloblastoma, Non-WNT/Non-SHH, Group 3|Medulloblastoma, Non-WNT/Non-SHH, Group 4|Medulloblastoma, Not Otherwise Specified|Medulloblastoma, SHH-Activated|Medulloblastoma, SHH-Activated, TP53-Mutant|Medulloblastoma, SHH-Activated, TP53-Wildtype|Medulloblastoma, SHH-activated and TP53-mutant|Medulloblastoma, SHH-activated and TP53-wildtype|Medulloblastoma, WNT-Activated|Medulloblastoma, WNT-activated|Medulloblastoma, classic|Medulloblastoma, group 3|Medulloblastoma, group 4|Medulloblastoma, non-WNT/non-SHH|Medullocytoma|Medulloepithelioma|Medulloepithelioma Not Otherwise Specified|Medulloepithelioma, NOS|Medulloepithelioma, benign|Medullomyoblastoma|Medullomyoblastoma with Myogenic Differentiation|Megakaryocytic leukemia|Megakaryocytic myelosclerosis|Megestrol Acetate|Melanoameloblastoma|Melanocytic Nevus|Melanocytic nevus|Melanocytoma|Melanocytoma of the Eyeball|Melanocytoma, NOS|Melanocytoma, eyeball|Melanoma|Melanoma Arising from Blue Nevus|Melanoma Monoclonal Antibody hIgG2A|Melanoma TRP2 CTL Epitope Vaccine SCIB1|Melanoma in Junctional Nevus|Melanoma in situ|Melanoma, NOS|Melanoma, malignant, of soft parts|Melanotic MPNST|Melanotic Neuroectodermal Tumor|Melanotic Neurofibroma|Melanotic Psammomatous Malignant Peripheral Nerve Sheath Tumor|Melanotic Schwannoma|Melanotic medulloblastoma|Melanotic neuroectodermal tumor|Melanotic neurofibroma|Melanotic progonoma|Melanotic psammomatous MPNST|Melanotic schwannoma|Melapuldencel-T|Melphalan|Melphalan Flufenamide|Melphalan Hydrochloride|Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex|Membrane-Disrupting Peptide EP-100|Memory Impairment|Menatetrenone|Menin-MLL Interaction Inhibitor SNDX-5613|Meningeal Melanocytoma|Meningeal Melanocytosis|Meningeal Melanoma|Meningeal Melanomatosis|Meningeal Sarcoma|Meningeal Sarcomatosis|Meningeal melanocytoma|Meningeal melanoma|Meningeal melanomatosis|Meningeal sarcoma|Meningeal sarcomatosis|Meninges|Meninges, NOS|Meningioma|Meningioma, NOS|Meningioma, anaplastic|Meningioma, malignant|Meningiomas|Meningiomatosis|Meningiomatosis, NOS|Meningismus|Meningitis|Meningothelial Meningioma|Meningothelial meningioma|Meningothelial sarcoma|Menogaril|Menopause|Menorrhagia|Merbarone|Mercaptopurine|Mercaptopurine Anhydrous|Mercaptopurine Oral Suspension|Merestinib|Merkel Cell Carcinoma|Merkel cell carcinoma|Merkel cell tumor|Mesenchymal Chondrosarcoma|Mesenchymal chondrosarcoma|Mesenchymal tumor, malignant|Mesenchymoma|Mesenchymoma, NOS|Mesenchymoma, benign|Mesenchymoma, malignant|Mesenteric fibromatosis|Mesentery|Mesna|Mesoblastic nephroma|Mesodermal mixed tumor|Mesonephric Adenocarcinoma|Mesonephric Neoplasm|Mesonephric adenocarcinoma|Mesonephric adenoma|Mesonephric tumor, NOS|Mesonephroma, NOS|Mesonephroma, benign|Mesonephroma, malignant|Mesonephromas|Mesothelial Neoplasms|Mesothelial papilloma|Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536|Mesothelioma|Mesothelioma, NOS|Mesothelioma, benign|Mesothelioma, biphasic, NOS|Mesothelioma, biphasic, malignant|Mesothelioma, malignant|Mesothelium|MetAP2 Inhibitor APL-1202|MetAP2 Inhibitor SDX-7320|Metabolic Syndrome|Metabolic labeling 14N / 15N quantitation analysis|Metabolism and Nutrition Disorders - Other|Metabolome|Metamelfalan|Metanephric Adenofibroma|Metanephric Adenoma|Metanephric adenoma|Metaplastic Carcinoma|Metaplastic Meningioma|Metaplastic carcinoma of no special type|Metaplastic carcinoma with chondroid differentiation|Metaplastic carcinoma with osseous differentiation|Metaplastic carcinoma with other types mesenchymal differentiation|Metaplastic carcinoma, NOS|Metaplastic meningioma|Metarrestin|Metastasectomy|Metastasis|Metastasis Negative|Metastasis, NOS|Metastasizing Ameloblastoma|Metastasizing leiomyoma|Metastatic|Metastatic Adenocarcinoma|Metastatic Carcinoma|Metastatic Neoplasm|Metastatic Signet Ring Cell Carcinoma|Metastatic Squamous Cell Carcinoma|Metastatic signet ring cell carcinoma|Metatinib Tromethamine|Metatypical carcinoma|Metformin|Metformin Hydrochloride|Methanol Extraction Residue of BCG|Methazolamide|Methionine Aminopeptidase 2 Inhibitor M8891|Methionine Aminopeptidase 2 Inhibitor PPI-2458|Methotrexate|Methotrexate Sodium|Methotrexate-E Therapeutic Implant|Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles|Methoxsalen|Methoxyamine|Methoxyamine Hydrochloride|Methyl Methanethiosulfonate (MMTS)|Methyl-5-Aminolevulinate Hydrochloride Cream|Methylation Array|Methylation Beta Value|Methylcantharidimide|Methylmercaptopurine Riboside|Methylprednisolone|Methylprednisolone Acetate|Methylprednisolone Sodium Succinate|Methylselenocysteine|Methyltestosterone|Metoprine|Mevociclib|Mexico|Mezagitamab|MiT Family Translocation-Associated Renal Cell Carcinoma|MiT family translocation renal cell carcinoma|Mibefradil|Mibefradil Dihydrochloride|Micellar Nanoparticle-encapsulated Epirubicin|Micro|Micro Needle Array-Doxorubicin|Microbiome GEN-001|Microbiome-derived Peptide Vaccine EO2401|Microcystic Adenoma|Microcystic Adnexal Carcinoma|Microcystic Meningioma|Microcystic adenoma|Microcystic adnexal carcinoma|Microcystic meningioma|Microcystic urothelial carcinoma|Microfollicular adenoma, NOS|Microglioma|Microinvasive Squamous Cell Carcinoma|Micropapillary Serous Carcinoma|Micropapillary Transitional Cell Carcinoma|Micropapillary adenocarcinoma|Micropapillary carcinoma, NOS|Micropapillary serous carcinoma|Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300|Microscopic|Microscopic Parametrium|Microtubule Inhibitor SCB01A|Middle Ear|Middle Ear Inflammation|Middle Finger|Middle Lobe of the Right Lung|Middle ear|Middle lobe, lung|Middle third of esophagus|Midline|Midline carcinoma of children and young adults with NUT rearrangement|Midostaurin|Mifamurtide|Mifepristone|Milademetan Tosylate|Milataxel|Milatuzumab|Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110|Milciclib Maleate|Milk Thistle|Miltefosine|Minimally Invasive Lung Adenocarcinoma|Minimally Invasive Lung Mucinous Adenocarcinoma|Minimally Invasive Lung Non-Mucinous Adenocarcinoma|Minimally invasive adenocarcinoma, NOS|Minimally invasive adenocarcinoma, mucinous|Minimally invasive adenocarcinoma, non-mucinous|Minor Response|Minretumomab|Mipsagargin|Miptenalimab|Mirabegron|Miransertib|Mirdametinib|Mirvetuximab Soravtansine|Mirzotamab Clezutoclax|Miscarriage|Miscellaneous Bone Tumors|Miscellaneous Tumors|Misonidazole|Mistletoe Extract|Mitazalimab|Mitindomide|Mitobronitol|Mitochondria|Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101|Mitoclomine|Mitoflaxone|Mitoguazone|Mitoguazone Dihydrochloride|Mitolactol|Mitomycin|Mitomycin A|Mitomycin B|Mitomycin C Analog KW-2149|Mitosis Inhibitor T 1101 Tosylate|Mitotane|Mitotenamine|Mitoxantrone|Mitoxantrone Hydrochloride|Mitozolomide|Mitral Valve Disease|Mivavotinib|Mivebresib|Mivobulin|Mivobulin Isethionate|Mixed Acinar-Ductal Carcinoma of the Pancreas|Mixed Adherent Suspension|Mixed Bacteria Vaccine|Mixed Cell Adenocarcinoma|Mixed Cell Adenoma|Mixed Cellularity Classic Hodgkin Lymphoma|Mixed Ductal and Lobular Carcinoma|Mixed Ductal-Neuroendocrine Carcinoma of the Pancreas|Mixed Embryonal Carcinoma and Teratoma|Mixed Epithelial and Mesenchymal Hepatoblastoma|Mixed Epithelioid and Spindle Cell Melanoma|Mixed Germ Cell Tumor|Mixed Glioma|Mixed Liposarcoma|Mixed Mesodermal (Mullerian) Tumor|Mixed Mucinous and Non-Mucinous Bronchioloalveolar Carcinoma|Mixed Phenotype Acute Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1|Mixed Phenotype Acute Leukemia with t(v;11q23.3); KMT2A Rearranged|Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified|Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified|Mixed Response|Mixed Teratoma and Seminoma|Mixed Testicular Sex Cord-Stromal Tumor|Mixed Tumor, Not Otherwise Specified|Mixed acidophil-basophil adenoma|Mixed acidophil-basophil carcinoma|Mixed acinar-ductal carcinoma|Mixed acinar-endocrine carcinoma|Mixed acinar-endocrine-ductal carcinoma|Mixed adenocarcinoma and epidermoid carcinoma|Mixed adenocarcinoma and squamous cell carcinoma|Mixed adenomatous and hyperplastic polyp|Mixed adenoneuroendocrine carcinoma|Mixed basal-squamous cell carcinoma|Mixed carcinoid-adenocarcinoma|Mixed cell adenocarcinoma|Mixed cell adenoma|Mixed ductal-endocrine carcinoma|Mixed embryonal carcinoma and teratoma|Mixed embryonal rhabdomyosarcoma and alveolar rhabdomyosarcoma|Mixed endocrine and exocrine adenocarcinoma|Mixed epithelioid and spindle cell melanoma|Mixed germ cell sex cord-stromal tumor, unclassified|Mixed germ cell tumor|Mixed glioma|Mixed hepatocellular and bile duct carcinoma|Mixed invasive mucinous and non-mucinous adenocarcinoma|Mixed islet cell and exocrine adenocarcinoma|Mixed liposarcoma|Mixed medullary-follicular carcinoma|Mixed medullary-papillary carcinoma|Mixed meningioma|Mixed mesenchymal sarcoma|Mixed mesenchymal tumor|Mixed pancreatic endocrine and exocrine tumor, malignant|Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1|Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged|Mixed phenotype acute leukemia, B/myeloid, NOS|Mixed phenotype acute leukemia, T/myeloid, NOS|Mixed pineal tumor|Mixed pineocytoma-pineoblastoma|Mixed small cell carcinoma|Mixed squamous cell and glandular papilloma|Mixed subependymoma-ependymoma|Mixed teratoma and seminoma|Mixed tumor, NOS|Mixed tumor, malignant, NOS|Mixed tumor, salivary gland type, NOS|Mixed tumor, salivary gland type, malignant|Mixed type rhabdomyosarcoma|Mobitz (Type) II Atrioventricular Block|Mobitz Type I|Mobocertinib|Mocetinostat|Modakafusp Alfa|Moderately Differentiated Ovarian Sertoli-Leydig Cell Tumor|Modified Radical Mastectomy|Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208|Modified Vitamin D Binding Protein Macrophage Activator EF-022|Modotuximab|Mofarotene|Mogamulizumab|Moldova|Molecular Laboratory Procedure Exon Identification Number|Molecular analysis outside specification|Molibresib|Molibresib Besylate|Momelotinib|Monaco|Monalizumab|Mongolia|Monoblastic leukemia, NOS|Monocarboxylate Transporter 1 Inhibitor AZD3965|Monoclonal Antibody 105AD7 Anti-idiotype Vaccine|Monoclonal Antibody 11D10|Monoclonal Antibody 11D10 Anti-Idiotype Vaccine|Monoclonal Antibody 14G2A|Monoclonal Antibody 1F5|Monoclonal Antibody 3622W94|Monoclonal Antibody 3F8|Monoclonal Antibody 3H1 Anti-Idiotype Vaccine|Monoclonal Antibody 4B5 Anti-Idiotype Vaccine|Monoclonal Antibody 7C11|Monoclonal Antibody 81C6|Monoclonal Antibody A1G4 Anti-Idiotype Vaccine|Monoclonal Antibody A27.15|Monoclonal Antibody A33|Monoclonal Antibody AK002|Monoclonal Antibody ASP1948|Monoclonal Antibody AbGn-7|Monoclonal Antibody CAL|Monoclonal Antibody CC49-delta CH2|Monoclonal Antibody CEP-37250/KHK2804|Monoclonal Antibody D6.12|Monoclonal Antibody E2.3|Monoclonal Antibody F19|Monoclonal Antibody GD2 Anti-Idiotype Vaccine|Monoclonal Antibody HeFi-1|Monoclonal Antibody Hu3S193|Monoclonal Antibody HuAFP31|Monoclonal Antibody HuHMFG1|Monoclonal Antibody HuPAM4|Monoclonal Antibody IMMU-14|Monoclonal Antibody L6|Monoclonal Antibody Lym-1|Monoclonal Antibody MX35 F(ab')2|Monoclonal Antibody Me1-14 F(ab')2|Monoclonal Antibody NEO-201|Monoclonal Antibody R24|Monoclonal Antibody RAV12|Monoclonal Antibody SGN-14|Monoclonal Antibody TRK-950|Monoclonal Antibody huJ591|Monoclonal Antibody m170|Monoclonal Antibody muJ591|Monoclonal Gammopathy of Undetermined Significance|Monoclonal Immunoglobulin Deposition Disease|Monoclonal Microbial EDP1503|Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100|Monoclonal gammopathy of undetermined significance|Monoclonal gammopathy, NOS|Monocytic leukemia, NOS|Monocytoid B-cell lymphoma|Monomethyl Auristatin E|Monomorphic adenoma|Mononuclear Cells from Bone Marrow Normal|Monstrocellular sarcoma|Montenegro|Montserrat|Morinda Citrifolia Fruit Extract|Morocco|Morpholinodoxorubicin|Mosedipimod|Mosunetuzumab|Motesanib|Motesanib Diphosphate|Motexafin Gadolinium|Motexafin Lutetium|Mother|Mother-in-law|Motixafortide|Motolimod|Motor / Movement Change|Motor or Movement Changes|Mouth, NOS|Movements Involuntary|Moxetumomab Pasudotox|Mozambique|Mps1 Inhibitor BAY 1217389|Mps1 Inhibitor BOS172722|Ms|Mu Heavy Chain Disease|Mu heavy chain disease|MuSE|MuSE Annotation|MuSE Variant Aggregation and Masking|MuTect2|MuTect2 Annotation|MuTect2 Variant Aggregation and Masking|Mucata mulata|Mucin-Producing Adenocarcinoma|Mucin-Producing Carcinoma|Mucin-producing adenocarcinoma|Mucin-producing carcinoma|Mucin-secreting adenocarcinoma|Mucin-secreting carcinoma|Mucinous Adenocarcinoma|Mucinous Adenocarcinoma, Endocervical Type|Mucinous Adenofibroma|Mucinous Cystadenocarcinoma|Mucinous Cystadenofibroma|Mucinous Cystadenoma|Mucinous Tubular and Spindle Cell Carcinoma of the Kidney|Mucinous adenocarcinofibroma|Mucinous adenocarcinoma|Mucinous adenocarcinoma, endocervical type|Mucinous adenofibroma of borderline malignancy|Mucinous adenofibroma, NOS|Mucinous adenoma|Mucinous carcinoid|Mucinous carcinoma|Mucinous carcinoma, gastric type|Mucinous carcinoma, intestinal type|Mucinous cystadenocarcinofibroma|Mucinous cystadenocarcinoma, NOS|Mucinous cystadenocarcinoma, non-invasive|Mucinous cystadenofibroma of borderline malignancy|Mucinous cystadenofibroma, NOS|Mucinous cystadenoma, NOS|Mucinous cystadenoma, borderline malignancy|Mucinous cystic neoplasm with an associated invasive carcinoma|Mucinous cystic neoplasm with high-grade dysplasia|Mucinous cystic neoplasm with high-grade intraepithelial neoplasia|Mucinous cystic neoplasm with intermediate-grade dysplasia|Mucinous cystic neoplasm with intermediate-grade intraepithelial neoplasia|Mucinous cystic neoplasm with low-grade dysplasia|Mucinous cystic neoplasm with low-grade intraepithelial neoplasia|Mucinous cystic tumor of borderline malignancy|Mucinous cystic tumor with an associated invasive carcinoma|Mucinous cystic tumor with high-grade dysplasia|Mucinous cystic tumor with intermediate dysplasia|Mucinous cystic tumor with low grade dysplasia|Mucinous cystic tumor with moderate dysplasia|Mucinous cystoma|Mucinous tubular and spindle cell carcinoma|Mucinous tumor, NOS, of low malignant potential|Mucoadhesive Paclitaxel Formulation|Mucocarcinoid tumor|Mucoepidermoid Carcinoma|Mucoepidermoid Neoplasms|Mucoepidermoid carcinoma|Mucoepidermoid tumor|Mucoid adenocarcinoma|Mucoid carcinoma|Mucoid cell adenocarcinoma|Mucoid cell adenoma|Mucosa of lip, NOS|Mucosa of lower lip|Mucosa of the Lip|Mucosa of the Lower Lip|Mucosa of upper lip|Mucosal Infection|Mucosal Lentiginous Melanoma|Mucosal lentiginous melanoma|Mucosal-associated lymphoid tissue lymphoma|Mucositis Oral|Mucous adenocarcinoma|Mucous carcinoma|Mullerian adenosarcoma|Mullerian mixed tumor|Multi-AGC Kinase Inhibitor AT13148|Multi-Organ Failure|Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200|Multi-epitope HER2 Peptide Vaccine H2NVAC|Multi-epitope HER2 Peptide Vaccine TPIV100|Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107|Multi-kinase Inhibitor TPX-0022|Multi-kinase Inhibitor XL092|Multi-mode Kinase Inhibitor EOC317|Multi-neo-epitope Vaccine OSE 2101|Multicentric basal cell carcinoma|Multicystic Mesothelioma|Multicystic mesothelioma, benign|Multifocal|Multifocal Lymphomatous Polyposis|Multifocal superficial basal cell carcinoma|Multifunctional/Multitargeted Anticancer Agent OMN54|Multikinase Inhibitor 4SC-203|Multikinase Inhibitor AEE788|Multikinase Inhibitor AT9283|Multikinase Inhibitor SAR103168|Multipeptide Vaccine S-588210|Multiple Adenomatous Polyps|Multiple Endocrine Neoplasia|Multiple Myeloma|Multiple Osteochondromas|Multiple adenomatous polyps|Multiple endocrine adenomas|Multiple hemorrhagic sarcoma|Multiple meningiomas|Multiple myeloma|Multiple neurofibromatosis|Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327|Muparfostat|Mureletecan|Murizatoclax|Mus musculus|Muscadine Grape Extract|Muscle|Muscle Weakness Left-Sided|Muscle Weakness Lower Limb|Muscle Weakness Right-Sided|Muscle Weakness Trunk|Muscle Weakness Upper Limb|Musculoskeletal Deformity|Musculoskeletal and Connective Tissue Disorders - Other|Mutant IDH1 Inhibitor DS-1001|Mutant p53 Activator COTI-2|Mutant-selective EGFR Inhibitor PF-06459988|Myalgia|Myanmar|Myasthenia Gravis|Mycobacterium avium Complex|Mycobacterium tuberculosis|Mycobacterium tuberculosis Arabinomannan Z-100|Mycobacterium w|Mycobacterium, NOS|Mycophenolic Acid|Mycoplasma pneumoniae|Mycosis Fungoides|Mycosis fungoides|Myelitis|Myelocytic leukemia, NOS|Myelodysplastic Syndrome|Myelodysplastic Syndrome with Excess Blasts|Myelodysplastic Syndrome with Excess Blasts-1|Myelodysplastic Syndrome with Excess Blasts-2|Myelodysplastic Syndrome with Isolated del(5q)|Myelodysplastic Syndrome with Multilineage Dysplasia|Myelodysplastic Syndrome with Ring Sideroblasts|Myelodysplastic Syndrome, Unclassifiable|Myelodysplastic Syndromes|Myelodysplastic syndrome with 5q deletion (5q-) syndrome|Myelodysplastic syndrome with isolated del (5q)|Myelodysplastic syndrome, NOS|Myelodysplastic syndrome, unclassifiable|Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Myelodysplastic/myeloproliferative neoplasm, unclassifiable|Myelofibrosis as a result of myeloproliferative disease|Myelofibrosis with myeloid metaplasia|Myelogenous leukemia, NOS|Myeloid Leukemia|Myeloid Leukemia Associated with Down Syndrome|Myeloid Leukemias|Myeloid Sarcoma|Myeloid and lymphoid neoplasms with FGFR1 abnormalities|Myeloid and lymphoid neoplasms with PDGFRA rearrangement|Myeloid leukemia associated with Down Syndrome|Myeloid leukemia, NOS|Myeloid neoplasms with PDGFRB rearrangement|Myeloid sarcoma|Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement|Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement|Myelolipoma|Myeloma, NOS|Myelomatosis|Myelomonocytic leukemia, NOS|Myeloproliferative Neoplasm|Myeloproliferative disease, NOS|Myeloproliferative neoplasm, NOS|Myelosclerosis with myeloid metaplasia|Myloproliferative neoplasm, unclassifiable|Myocardial Infarction|Myocarditis|Myoepithelial Tumor|Myoepithelial adenoma|Myoepithelial carcinoma|Myoepithelial tumor|Myoepithelioma|Myofibroblastic sarcoma|Myofibroblastic tumor, NOS|Myofibroblastic tumor, peribronchial|Myofibroblastoma|Myofibroma|Myofibromatosis|Myolipoma|Myoma|Myomatous Neoplasms|Myometrium|Myosarcoma|Myositis|Myxofibroma, NOS|Myxofibrosarcoma|Myxoid Chondrosarcoma|Myxoid Leiomyosarcoma|Myxoid Liposarcoma|Myxoid chondrosarcoma|Myxoid fibroma|Myxoid leiomyosarcoma|Myxoid liposarcoma|Myxoinflammatory Fibroblastic Sarcoma|Myxoinflammatory fibroblastic sarcoma (MIFS)|Myxolipoma|Myxoliposarcoma|Myxoma|Myxoma, NOS|Myxomatous Neoplasms|Myxopapillary Ependymoma|Myxopapillary ependymoma|Myxosarcoma|N,N-Dibenzyl Daunomycin|N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea|N-Methylformamide|N-dihydrogalactochitosan|N0|N0 (i+)|N0 (i+) Stage Finding|N0 (i-)|N0 (mol+)|N0 (mol+) Stage Finding|N0 (mol-)|N0 Stage Finding|N1|N1 Stage Finding|N1a|N1a Stage Finding|N1b|N1b Stage Finding|N1bI|N1bI Stage Finding|N1bII|N1bII Stage Finding|N1bIII|N1bIII Stage Finding|N1bIV|N1bIV Stage Finding|N1c|N1c Stage Finding|N1mi|N1mi Stage Finding|N2|N2 Stage Finding|N2a|N2a Stage Finding|N2b|N2b Stage Finding|N2c|N2c Stage Finding|N3|N3 Stage Finding|N3a|N3a Stage Finding|N3b|N3b Stage Finding|N3c|N3c Stage Finding|N4|N4 Stage Finding|NA17-A Antigen|NA17.A2 Peptide Vaccine|NAMPT Inhibitor OT-82|NEDD8 Activating Enzyme E1 Inhibitor TAS4464|NG-5400|NG-nitro-L-arginine|NHL, Burkitt lymphoma (BL)|NHL, anaplastic large cell lymphoma|NK-cell large granular lymphocytic leukemia|NK/T-cell lymphoma, nasal and nasal-type|NLRP3 Agonist BMS-986299|NOS|NPB-No Palliative Benefit|NR-No Response|NTRK/ROS1 Inhibitor DS-6051b|NUT Carcinoma|NUT carcinoma|NUT midline carcinoma|NX|NX Stage Finding|NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611|NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301|NY-ESO-1/GLA-SE Vaccine ID-G305|NY-ESO-B|Nab-paclitaxel|Nab-paclitaxel/Rituximab-coated Nanoparticle AR160|Nadofaragene Firadenovec|Nagrestipen|Nail Discoloration|Nail Infection|Nail Loss|Nail Ridging|Nails|Namibia|Namirotene|Namodenoson|Nanafrocin|Nanatinostat|Nanocell-encapsulated miR-16-based microRNA Mimic|Nanoparticle Albumin-Bound Docetaxel|Nanoparticle Albumin-Bound Rapamycin|Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404|Nanoparticle Paclitaxel Ointment SOR007|Nanoparticle-based Paclitaxel Suspension|Nanoparticle-encapsulated Doxorubicin Hydrochloride|Nanoscale Coordination Polymer Nanoparticles CPI-100|Nanosomal Docetaxel Lipid Suspension|Napabucasin|Naphthalimide Analogue UNBS5162|Naptumomab Estafenatox|Naquotinib|Naratuximab Emtansine|Narnatumab|Nasal Cavity|Nasal Congestion|Nasal Soft Tissue|Nasal Type Extranodal NK/T-Cell Lymphoma|Nasal cavity|Nasal cavity and middle ear|Nasopharyngeal-Type Undifferentiated Carcinoma|Nasopharynx|Nasopharynx, NOS|Natalizumab|Native Hawaiian or Other Pacific Islander|Natural Brother|Natural Child|Natural Daughter|Natural Father|Natural Grandchild|Natural Grandfather|Natural Grandmother|Natural Grandparent|Natural IFN-alpha OPC-18|Natural Killer Cells ZRx101|Natural Mother|Natural Parent|Natural Sibling|Natural Sister|Natural Son|Nauru|Nausea|Navarixin|Navicixizumab|Navitoclax|Navoximod|Navy Bean Powder|Naxitamab|Nazartinib|Necitumumab|Neck|Neck Edema|Neck Pain|Neck Soft Tissue Necrosis|Nedaplatin|Nedisertib|Needle Biopsy|Negative|Negative/ No Dysplasia|Nelarabine|Nelipepimut-S|Nelipepimut-S Plus GM-CSF Vaccine|Nemorubicin|Nemorubicin Hydrochloride|Neoadjuvant|Neoadjuvant therapy|Neoantigen Vaccine GEN-009|Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017|Neoantigen-based Glioblastoma Vaccine|Neoantigen-based Melanoma-Poly-ICLC Vaccine|Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine|Neoantigen-based Therapeutic Cancer Vaccine GRT-C903|Neoantigen-based Therapeutic Cancer Vaccine GRT-R904|Neoplasm|Neoplasm of the Diffuse Neuroendocrine System|Neoplasm, NOS|Neoplasm, Uncertain Whether Benign or Malignant|Neoplasm, benign|Neoplasm, malignant|Neoplasm, malignant, uncertain whether primary or metastatic|Neoplasm, metastatic|Neoplasm, secondary|Neoplasm, uncertain whether benign or malignant|Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other|Neoplasms of Histiocytes and Accessory Lymphoid Cells|Neoplasms of Uncertain and Unknown Behavior|Neoplasms, NOS|Neoplastic Cell|Nepal|Nephew|Nephroblastoma, NOS|Nephrogenic adenofibroma|Nephroma, NOS|Neratinib|Neratinib Maleate|Nerve|Nerve Sheath Myxoma|Nerve Sheath Tumors|Nerve sheath myxoma|Nerve(s) Cranial|Nervous System|Nervous System Disorders - Other|Nervous system, NOS|Nesidioblastoma|Nesidioblastosis|Nested urothelial carcinoma|Nesvacumab|Netherlands|Neuralgia|Neurilemoma, NOS|Neurilemoma, malignant|Neurilemosarcoma|Neurinoma|Neurinomatosis|Neuroastrocytoma|Neuroblastoma|Neuroblastoma (NBL)|Neuroblastoma, NOS|Neurocytoma|Neuroectodermal tumor, NOS|Neuroendocrine Carcinoma|Neuroendocrine Tumor|Neuroendocrine carcinoma, NOS|Neuroendocrine carcinoma, low grade|Neuroendocrine carcinoma, moderately differentiated|Neuroendocrine carcinoma, poorly differentiated|Neuroendocrine carcinoma, well-differentiated|Neuroendocrine tumor, grade 1|Neuroendocrine tumor, grade 2|Neuroendocrine tumor, well differentiated|Neuroepithelioma, NOS|Neuroepitheliomatous Neoplasms|Neurofibroma|Neurofibroma, NOS|Neurofibromatosis|Neurofibromatosis Type 1|Neurofibromatosis, NOS|Neurofibrosarcoma|Neurogenic sarcoma|Neurolipocytoma|Neuroma|Neuroma, NOS|Neuronevus|Neurosarcoma|Neurothekeoma|Neurotropic melanoma, malignant|Neutrophil Count Decreased|Never Used|Nevi and Melanomas|Nevus, NOS|New Caledonia|New Objective|New Zealand|New notification type|New observation type|Next Generation Cancer Model|Next Generation Cancer Model Expanded Under Non-conforming Conditions|Next Generation Targeted Sequencing|Niacinamide|Nicaragua|Niclosamide|Nicotinamide Riboside|Nidanilimab|Niece|Niece Second Degree Relative|Nifurtimox|Niger|Nigeria|Night Blindness|Night Sweats|Nilotinib|Nilotinib Hydrochloride Anhydrous|Nilotinib Hydrochloride Monohydrate|Nilutamide|Nimesulide-Hyaluronic Acid Conjugate CA102N|Nimodipine|Nimotuzumab|Nimustine|Nimustine Hydrochloride|Ningetinib Tosylate|Nintedanib|Nipple|Nipple Adenoma|Nipple Deformity|Niraparib|Niraparib Tosylate Monohydrate|Nirogacestat|Nitric Oxide-Releasing Acetylsalicylic Acid Derivative|Nitrogen Mustard Prodrug PR-104|Nitroglycerin Transdermal Patch|Niue|Nivolumab|No Known Treatment Effect|No Measurable Disease|No Metastasis|No Metastasis (M0)|No Necrosis|No Palliative Benefit|No Response|No Smoke Exposure|No Treatment|No Vascular Invasion|No cleavage|NoEnzyme|Nocardiosis|Nocodazole|Nodal Marginal Zone Lymphoma|Nodal marginal zone lymphoma|Nodular Hidradenoma|Nodular Lymphocyte Predominant Hodgkin Lymphoma|Nodular Prostatic Hyperplasia|Nodular Sclerosis Classic Hodgkin Lymphoma|Nodular Sclerosis Classic Hodgkin Lymphoma, Cellular Phase|Nodular Sclerosis Classic Hodgkin Lymphoma, Syncytial Variant|Nodular hidradenoma|Nodular hidradenoma, malignant|Nodular melanoma|Nogalamycin|Nogapendekin Alfa|Nolatrexed Dihydrochloride|Non cancerous tissue|Non-CR/Non-PD-Non-CR/Non-PD|Non-Cancer Related Death|Non-Cardiac Chest Pain|Non-Drinker|Non-Hodgkin Lymphoma|Non-Hodgkin lymphoma, NOS|Non-Invasive Papillary Squamous Cell Carcinoma|Non-Invasive Papillary Transitional Cell Carcinoma|Non-Keratinizing Large Cell Squamous Cell Carcinoma|Non-Keratinizing Sinonasal Squamous Cell Carcinoma|Non-Keratinizing Small Cell Squamous Cell Carcinoma|Non-Malignant|Non-Small Cell Carcinoma|Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201|Non-WNT/non-SHH Activated|Non-invasive EFVPTC|Non-invasive FTP|Non-invasive encapsulated follicular variant of papillary thyroid carcinoma (non-invasive EFVPTC)|Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)|Non-invasive low grade serous carcinoma|Non-invasive mammary carcinoma|Non-lymphocytic leukemia, NOS|Non-small cell carcinoma|Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis|Nonchromaffin paraganglioma, NOS|Nonchromaffin paraganglioma, malignant|None|Nonencapsulated sclerosing adenocarcinoma|Nonencapsulated sclerosing carcinoma|Nonencapsulated sclerosing tumor|Nongerminomatous Germ Cell Tumor|Noninfiltrating intracystic carcinoma|Noninfiltrating intraductal papillary adenocarcinoma|Noninfiltrating intraductal papillary carcinoma|Noninvasive pancreatobiliary papillary neoplasm with high grade dysplasia|Noninvasive pancreatobiliary papillary neoplasm with high grade intraepithelial neoplasia|Noninvasive pancreatobiliary papillary neoplasm with low grade dysplasia|Noninvasive pancreatobiliary papillary neoplasm with low grade intraepithelial neoplasia|Nonlipid reticuloendotheliosis|Nonpigmented Nevus|Nonpigmented nevus|Norgestrel|Normal|Normal Adjacent Tissue|Normal class but appears diseased|Normal tissue origin incorrect|Normal_LogR|North American Ginseng Extract AFX-2|North Korea|North Macedonia|Northern Mariana Islands|Nortopixantrone|Norway|Noscapine|Noscapine Hydrochloride|Not Applicable|Not Cancer Related|Not Determined|Not Hispanic or Latino|Not Otherwise Specified|Not Performed|Not performed|Notch Signaling Inhibitor PF-06650808|Notch Signaling Pathway Inhibitor MK0752|Notification|Nuclei RNA|Nucleolin Antagonist IPP-204106N|Nucleoside Analog DFP-10917|Nucleotide Analog Prodrug NUC-3373|Nucleotide Analogue GS 9219|Numidargistat|Nurulimab|Nutlin-3a|Nutraceutical TBL-12|Nystagmus|O-Chloroacetylcarbamoylfumagillol|O6-Benzylguanine|OCT|OMEGA|OMEGA-2001|OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule|OX40L-expressing Oncolytic Adenovirus DNX-2440|Oat cell carcinoma|Obatoclax Mesylate|Obesity|Obinutuzumab|Oblimersen Sodium|Observation|Obstruction Gastric|Ocaratuzumab|Occasional Drinker|Occipital Cortex|Occipital Lobe|Occipital lobe|Ocrelizumab|Octreotide|Octreotide Acetate|Octreotide Pamoate|Ocular Orbits|Oculomotor Nerve Disorder|Odontoameloblastoma|Odontogenic Fibroma|Odontogenic Myxofibroma|Odontogenic Myxoma|Odontogenic Neoplasm|Odontogenic Tumors|Odontogenic carcinoma|Odontogenic carcinosarcoma|Odontogenic fibroma, NOS|Odontogenic fibrosarcoma|Odontogenic ghost cell tumor|Odontogenic myxofibroma|Odontogenic myxoma|Odontogenic sarcoma|Odontogenic tumor, NOS|Odontogenic tumor, benign|Odontogenic tumor, malignant|Odontoma|Odontoma, NOS|Odronextamab|Ofatumumab|Ofranergene Obadenovec|Oglufanide Disodium|Oil burning smoke, Kerosene|Oil burning smoke, NOS|Olaparib|Olaptesed Pegol|Olaratumab|Oleandrin|Oleclumab|Olfactory Nerve Disorder|Olfactory Neuroblastoma|Olfactory Neurocytoma|Olfactory Neurogenic Tumor|Olfactory nerve|Olfactory neuroblastoma|Olfactory neurocytoma|Olfactory neuroepithelioma|Olfactory neurogenic tumor|Oligo-fucoidan|Oligoastrocytoma|Oligodendroblastoma|Oligodendroglioma|Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted|Oligodendroglioma, NOS|Oligodendroglioma, Not Otherwise Specified|Oligodendroglioma, anaplastic|Oligonucleotide SPC2996|Oligospermia|Olinvacimab|Olivomycin|Olmutinib|Oltipraz|Olutasidenib|Olvimulogene Nanivacirepvec|Omacetaxine Mepesuccinate|Oman|Ombrabulin|Omentectomy|Omentum|Omipalisib|Onalespib|Onalespib Lactate|Onartuzumab|Onatasertib|Once Weekly|Oncocytic Adenoma|Oncocytic Neoplasm|Oncocytic Schneiderian papilloma|Oncocytic adenocarcinoma|Oncocytic adenoma|Oncocytic carcinoma|Oncocytoma|Oncolytic Adenovirus Ad5-DNX-2401|Oncolytic Adenovirus ORCA-010|Oncolytic HSV-1 C134|Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011|Oncolytic HSV-1 G207|Oncolytic HSV-1 NV1020|Oncolytic HSV-1 rQNestin34.5v.2|Oncolytic HSV-1 rRp450|Oncolytic HSV1716|Oncolytic Herpes Simplex Virus-1 ONCR-177|Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein|Oncolytic Newcastle Disease Virus MEDI5395|Oncolytic Newcastle Disease Virus MTH-68H|Oncolytic Newcastle Disease Virus Strain PV701|Oncolytic Virus ASP9801|Oncolytic Virus RP1|Ondansetron Hydrochloride|Ontorpacept|Ontuxizumab|Onvansertib|Onvatilimab|Oophorectomy|Opaganib|Open Craniotomy|Open Partial Nephrectomy|Open Radical Nephrectomy|Open Radical Prostatectomy|Opioid Growth Factor|Opolimogene Capmilisbac|Oportuzumab Monatox|Oprozomib|Optic Nerve|Optic Nerve Disorder|Optic nerve|OptionAnalysisPipeline2|Opucolimab|Oral|Oral Aminolevulinic Acid Hydrochloride|Oral Azacitidine|Oral Cancer Vaccine V3-OVA|Oral Cavity|Oral Cavity - Mucosa Only|Oral Cavity Fistula|Oral Contraceptives|Oral Docetaxel|Oral Dysesthesia|Oral Fludarabine Phosphate|Oral Hemorrhage|Oral Hsp90 Inhibitor IPI-493|Oral Hypoglycemic|Oral Ixabepilone|Oral Microencapsulated Diindolylmethane|Oral Milataxel|Oral Myoma Vaccine V3-myoma|Oral Pain|Oral Pancreatic Cancer Vaccine V3-P|Oral Picoplatin|Oral Sodium Phenylbutyrate|Oral Squamous Cell Carcinoma|Oral Topotecan Hydrochloride|Orantinib|Oraxol|Orbit|Orbit, NOS|Orbitrap Elite|Orbitrap Fusion|Orbitrap Fusion ETD|Orbitrap Fusion Lumos|Orbitrap Lumos|Orbitrap Velos|Orchiectomy|Orchioblastoma|Orchiopexy|Oregovomab|Orelabrutinib|Organ Transplantation|Organ transplant (site)|Ormaplatin|Oropharynx|Oropharynx, NOS|Ortataxel|Orteronel|Orvacabtagene Autoleucel|Oryza sativa|Osilodrostat|Osimertinib|Osseous and Chondromatous Neoplasms|Ossifying Fibroma|Ossifying Fibromyxoid Tumor|Ossifying fibroma|Ossifying fibromyxoid tumor|Ossifying fibromyxoid tumor, malignant|Ossifying renal tumor|Osteoarthritis|Osteoblastic Osteosarcoma|Osteoblastic sarcoma|Osteoblastoma|Osteoblastoma, NOS|Osteoblastoma, malignant|Osteocartilaginous exostosis|Osteochondroma|Osteochondromatosis, NOS|Osteochondrosarcoma|Osteofibroma|Osteofibrosarcoma|Osteogenic sarcoma, NOS|Osteoid Osteoma|Osteoid osteoma, NOS|Osteoma|Osteoma, NOS|Osteonecrosis of Jaw|Osteoporosis|Osteoporosis or Osteopenia|Osteosarcoma|Osteosarcoma (OS)|Osteosarcoma in Paget disease of bone|Osteosarcoma, NOS|Other|Other Cancer Within 5 Years|Other Hematologic Disorders|Other Leukemias|Other Nonmalignant Systemic Disease|Other Pulmonary Complications|Other Specified Parts of Pancreas|Other Surgical Resection|Other and Unspecified Female Genital Organs ICD-O-3|Other and ill-defined digestive organs|Other and ill-defined sites|Other and ill-defined sites in lip, oral cavity and pharynx|Other and ill-defined sites within respiratory system and intrathoracic organs|Other and unspecified female genital organs|Other and unspecified major salivary glands|Other and unspecified male genital organs|Other and unspecified parts of biliary tract|Other and unspecified parts of mouth|Other and unspecified parts of tongue|Other and unspecified urinary organs|Other endocrine glands and related structures|Other ill-defined sites|Other specified parts of female genital organs|Other specified parts of male genital organs|Other specified parts of pancreas|Otitis Externa|Otitis Media|Otlertuzumab|Ovapuldencel-T|Ovarian Cancer|Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006|Ovarian Capsule Fragmented|Ovarian Capsule Intact|Ovarian Capsule Ruptured|Ovarian Endometrioid Adenofibroma|Ovarian Endometrioid Cystadenofibroma|Ovarian Gynandroblastoma|Ovarian Hemorrhage|Ovarian Hilus Cell Tumor|Ovarian Infection|Ovarian Luteinized Thecoma|Ovarian Rupture|Ovarian Sclerosing Stromal Tumor|Ovarian Seromucinous Carcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord-Stromal Tumor|Ovarian Small Cell Carcinoma, Hypercalcemic Type|Ovarian Small Cell Carcinoma, Pulmonary-Type|Ovarian Steroid Cell Tumor|Ovarian Stromal Luteoma|Ovarian Stromal Tumor with Minor Sex Cord Elements|Ovarian stromal tumor|Ovary|Overlapping lesion of accessory sinuses|Overlapping lesion of biliary tract|Overlapping lesion of bladder|Overlapping lesion of bones, joints and articular cartilage|Overlapping lesion of bones, joints and articular cartilage of limbs|Overlapping lesion of brain|Overlapping lesion of brain and central nervous system|Overlapping lesion of breast|Overlapping lesion of cervix uteri|Overlapping lesion of colon|Overlapping lesion of connective, subcutaneous and other soft tissues|Overlapping lesion of corpus uteri|Overlapping lesion of digestive system|Overlapping lesion of endocrine glands and related structures|Overlapping lesion of esophagus|Overlapping lesion of eye and adnexa|Overlapping lesion of female genital organs|Overlapping lesion of floor of mouth|Overlapping lesion of heart, mediastinum and pleura|Overlapping lesion of hypopharynx|Overlapping lesion of ill-defined sites|Overlapping lesion of larynx|Overlapping lesion of lip|Overlapping lesion of lip, oral cavity and pharynx|Overlapping lesion of lung|Overlapping lesion of major salivary glands|Overlapping lesion of male genital organs|Overlapping lesion of nasopharynx|Overlapping lesion of other and unspecified parts of mouth|Overlapping lesion of palate|Overlapping lesion of pancreas|Overlapping lesion of penis|Overlapping lesion of peripheral nerves and autonomic nervous system|Overlapping lesion of rectum, anus and anal canal|Overlapping lesion of respiratory system and intrathoracic organs|Overlapping lesion of retroperitoneum and peritoneum|Overlapping lesion of skin|Overlapping lesion of small intestine|Overlapping lesion of stomach|Overlapping lesion of tongue|Overlapping lesion of tonsil|Overlapping lesion of urinary organs|Overlapping lesion of vulva|Overlapping lesions of oropharynx|Ovine Submaxillary Mucin|Ovulation Pain|OxPhos Inhibitor VLX600|Oxaliplatin|Oxaliplatin Eluting Beads|Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome|Oxcarbazepine|Oxeclosporin|Oxidative Phosphorylation Inhibitor IACS-010759|Oxidative Phosphorylation Inhibitor IM156|Oxidopamine|Oxyphilic Adenocarcinoma|Oxyphilic adenocarcinoma|Oxyphilic adenoma|Ozarelix|P-TEFb Inhibitor BAY1143572|P-cadherin Antagonist PF-03732010|P-cadherin Inhibitor PCA062|P-cadherin-targeting Agent PF-06671008|P-p68 Inhibitor RX-5902|PA-Palliative Therapy|PAK4 Inhibitor PF-03758309|PAK4/NAMPT Inhibitor KPT-9274|PARP 1/2 Inhibitor IMP4297|PARP 1/2 Inhibitor NOV1401|PARP Inhibitor AZD2461|PARP Inhibitor CEP-9722|PARP Inhibitor E7016|PARP Inhibitor NMS-03305293|PARP-1/2 Inhibitor ABT-767|PARP/Tankyrase Inhibitor 2X-121|PARP7 Inhibitor RBN-2397|PB-Palliative Benefit|PBN Derivative OKN-007|PCNU|PD-1 Directed Probody CX-188|PD-1 Inhibitor|PD-L1 Inhibitor GS-4224|PD-L1 Inhibitor INCB086550|PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480|PD-L1/PD-L2/VISTA Antagonist CA-170|PD-Progressive Disease|PDF|PDK1 Inhibitor AR-12|PDM-Persistent Distant Metastasis|PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1|PEComa, malignant|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|PEG-Proline-Interferon Alfa-2b|PEG-interleukin-2|PEOX-based Polymer Encapsulated Paclitaxel FID-007|PEP-3-KLH Conjugate Vaccine|PET|PGG Beta-Glucan|PGLA/PEG Copolymer-Based Paclitaxel|PH20 Hyaluronidase-expressing Adenovirus VCN-01|PI3K Alpha/Beta Inhibitor BAY1082439|PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate|PI3K Inhibitor ACP-319|PI3K Inhibitor BGT226|PI3K Inhibitor GDC-0084|PI3K Inhibitor GDC0077|PI3K Inhibitor GSK1059615|PI3K Inhibitor WX-037|PI3K Inhibitor ZSTK474|PI3K p110beta/delta Inhibitor KA2237|PI3K-alpha Inhibitor MEN1611|PI3K-beta Inhibitor GSK2636771|PI3K-beta Inhibitor SAR260301|PI3K-delta Inhibitor AMG 319|PI3K-delta Inhibitor HMPL 689|PI3K-delta Inhibitor INCB050465|PI3K-delta Inhibitor PWT143|PI3K-delta Inhibitor SHC014748M|PI3K-delta Inhibitor YY-20394|PI3K-gamma Inhibitor IPI-549|PI3K/BET Inhibitor LY294002|PI3K/mTOR Kinase Inhibitor DS-7423|PI3K/mTOR Kinase Inhibitor PF-04691502|PI3K/mTOR Kinase Inhibitor VS-5584|PI3K/mTOR Kinase Inhibitor WXFL10030390|PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170|PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901|PI3Ka/mTOR Inhibitor PKI-179|PI3Kalpha Inhibitor AZD8835|PI3Kbeta Inhibitor AZD8186|PI3Kdelta Inhibitor GS-9901|PIM Kinase Inhibitor LGH447|PIM Kinase Inhibitor SGI-1776|PIM Kinase Inhibitor TP-3654|PIM/FLT3 Kinase Inhibitor SEL24|PIN III|PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231|PKC-alpha Antisense Oligodeoxynucleotide ISIS 3521|PKC-beta Inhibitor MS-553|PLC|PLD-Persistent Locoregional Disease|PLK1 Inhibitor CYC140|PLK1 Inhibitor TAK-960|PNET, NOS|PP/PYY producing tumor|PPAR Alpha Antagonist TPST-1120|PPD-Pseudoprogression|PPNET|PR-Partial Response|PR1 Leukemia Peptide Vaccine|PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701|PRIMA-1 Analog APR-246|PRMT1 Inhibitor GSK3368715|PRMT5 Inhibitor JNJ-64619178|PRMT5 Inhibitor PRT811|PSA/IL-2/GM-CSF Vaccine|PSA/PSMA DNA Plasmid INO-5150|PSMA|PSMA-targeted Docetaxel Nanoparticles BIND-014|PSMA-targeted Tubulysin B-containing Conjugate EC1169|PSMA/CD3 Tri-specific T-cell Activating Construct HPN424|PSR-Pseudoresponse|PTEF-b/CDK9 Inhibitor BAY1251152|PTLD, NOS|PV-10|PVA Microporous Hydrospheres/Doxorubicin Hydrochloride|PacBio|Pacinian Neurofibroma|Pacinian tumor|Paclitaxel|Paclitaxel Ceribate|Paclitaxel Injection Concentrate for Nanodispersion|Paclitaxel Liposome|Paclitaxel PPE Microspheres|Paclitaxel Poliglumex|Paclitaxel Polymeric Micelle Formulation NANT-008|Paclitaxel Trevatide|Paclitaxel Vitamin E-Based Emulsion|Paclitaxel-Loaded Polymeric Micelle|Pacmilimab|Pacritinib|Padeliporfin|Padoporfin|Paget Disease and Intraductal Carcinoma of the Breast|Paget Disease of the Breast|Paget Disease of the Breast without Invasive Carcinoma|Paget disease and infiltrating duct carcinoma of breast|Paget disease and intraductal carcinoma of breast|Paget disease of breast|Paget disease, extramammary|Paget disease, mammary|Pagetoid Reticulosis|Pagetoid reticulosis|Pain|Pain (Various)|Pain in Extremity|Pain of Skin|Paired_LogR|Pakistan|Palate|Palate, NOS|Palatectomy|Palatine Tonsil|Palau|Palbociclib|Palbociclib Isethionate|Palifosfamide|Palifosfamide Tromethamine|Palladium Pd-103|Palliative|Palmar-Plantar Erythrodysesthesia Syndrome|Palonosetron Hydrochloride|Palpitations|Pamidronate Disodium|Pamidronic Acid|Pamiparib|Pamrevlumab|Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514|Pan-AKT Inhibitor ARQ751|Pan-AKT Kinase Inhibitor GSK690693|Pan-FGFR Inhibitor LY2874455|Pan-FLT3/Pan-BTK Multi-kinase Inhibitor CG-806|Pan-IDH Mutant Inhibitor AG-881|Pan-KRAS Inhibitor BI 1701963|Pan-Mutant-IDH1 Inhibitor Bay-1436032|Pan-PIM Inhibitor INCB053914|Pan-Procto Colectomy|Pan-RAF Inhibitor LY3009120|Pan-RAR Agonist/AP-1 Inhibitor LGD 1550|Pan-TRK Inhibitor NOV1601|Pan-TRK Inhibitor ONO-7579|Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981|Pan-mutation-selective EGFR Inhibitor CLN-081|Panama|Pancratistatin|Pancreas|Pancreas Cancer|Pancreas Infection|Pancreas, NOS|Pancreatectomy|Pancreatic Acinar Cell Cystadenocarcinoma|Pancreatic Adenocarcinoma|Pancreatic Anastomotic Leak|Pancreatic Beta Cell Adenoma|Pancreatic Duct Stenosis|Pancreatic Ductal Adenocarcinoma|Pancreatic Enzymes Decreased|Pancreatic Fistula|Pancreatic Hemorrhage|Pancreatic Insulinoma|Pancreatic Intraductal Papillary-Mucinous Neoplasm with High Grade Dysplasia|Pancreatic Intraductal Papillary-Mucinous Neoplasm with an Associated Invasive Carcinoma|Pancreatic Intraductal Tubulopapillary Neoplasm|Pancreatic Mucinous-Cystic Neoplasm with Intermediate Grade Dysplasia|Pancreatic Necrosis|Pancreatic Neuroendocrine Carcinoma|Pancreatic Neuroendocrine Neoplasm|Pancreatic duct|Pancreatic endocrine tumor, NOS|Pancreatic endocrine tumor, benign|Pancreatic endocrine tumor, malignant|Pancreatic endocrine tumor, nonfunctioning|Pancreatic microadenoma|Pancreatic neck|Pancreatic peptide and pancreatic peptide-like peptide within terminal tyrosine amide producing tumor|Pancreatitis|Pancreatobiliary neoplasm, non-invasive|Pancreatobiliary-type carcinoma|Pancreatoblastoma|Panitumumab|Panobinostat|Panobinostat Nanoparticle Formulation MTX110|Panulisib|Pap Smear|Papillary Adenocarcinoma|Papillary Adenofibroma|Papillary Carcinoma|Papillary Carcinoma In Situ|Papillary Craniopharyngioma|Papillary Cystadenocarcinoma|Papillary Cystadenoma|Papillary Cystic Neoplasm|Papillary Eccrine Adenoma|Papillary Ependymoma|Papillary Glioneuronal Tumor|Papillary Intralymphatic Angioendothelioma|Papillary Meningioma|Papillary Mucinous Cystadenocarcinoma|Papillary Mucinous Cystadenoma|Papillary Renal Cell Carcinoma|Papillary Serous Cystadenocarcinoma|Papillary Serous Cystadenoma|Papillary Squamous Cell Carcinoma|Papillary Transitional Cell Carcinoma|Papillary Tumor of the Pineal Region|Papillary adenocarcinoma, NOS|Papillary adenocarcinoma, follicular variant|Papillary adenofibroma|Papillary adenoma, NOS|Papillary and follicular adenocarcinoma|Papillary and follicular carcinoma|Papillary carcinoma in situ|Papillary carcinoma of thyroid|Papillary carcinoma, NOS|Papillary carcinoma, columnar cell|Papillary carcinoma, diffuse sclerosing|Papillary carcinoma, encapsulated|Papillary carcinoma, follicular variant|Papillary carcinoma, oxyphilic cell|Papillary carcinoma, tall cell|Papillary cystadenocarcinoma, NOS|Papillary cystadenoma lymphomatosum|Papillary cystadenoma, NOS|Papillary cystadenoma, borderline malignancy|Papillary cystic tumor|Papillary ependymoma|Papillary epidermoid carcinoma|Papillary glioneuronal tumor|Papillary hidradenoma|Papillary meningioma|Papillary microcarcinoma|Papillary mucinous cystadenocarcinoma|Papillary mucinous cystadenoma, NOS|Papillary mucinous cystadenoma, borderline malignancy|Papillary mucinous tumor of low malignant potential|Papillary neoplasm, pancreatobiliary-type, with high grade intraepithelial neoplasia|Papillary pseudomucinous cystadenocarcinoma|Papillary pseudomucinous cystadenoma, NOS|Papillary pseudomucinous cystadenoma, borderline malignancy|Papillary renal cell carcinoma|Papillary serous adenocarcinoma|Papillary serous cystadenocarcinoma|Papillary serous cystadenoma, NOS|Papillary serous cystadenoma, borderline malignancy|Papillary serous tumor of low malignant potential|Papillary squamous cell carcinoma|Papillary squamous cell carcinoma in situ|Papillary squamous cell carcinoma, non-invasive|Papillary syringadenoma|Papillary syringocystadenoma|Papillary transitional cell carcinoma|Papillary transitional cell carcinoma, non-invasive|Papillary transitional cell neoplasm of low malignant potential|Papillary tumor of the pineal region|Papillary urothelial carcinoma|Papillary urothelial carcinoma, non-invasive|Papillary urothelial neoplasm of low malignant potential|Papilledema|Papillocystic adenocarcinoma|Papilloma|Papilloma of bladder|Papilloma, NOS|Papillomatosis|Papillomatosis, NOS|Papillomatosis, glandular|Papillotubular adenocarcinoma|Papillotubular adenoma|Papua New Guinea|Papulopustular Rash|Paracentesis|Parachordoma|Parafollicular cell carcinoma|Paraganglioma|Paraganglioma, NOS|Paraganglioma, benign|Paraganglioma, malignant|Paragangliomas and Glomus Tumors|Paraguay|Parametrium|Paranasal Sinuses|Parasitic Disease of Biliary Tract|Paraspinal Ganglion|Parasympathetic Paraganglioma|Parasympathetic paraganglioma|Parathyroid|Parathyroid Gland Chief Cell Adenoma|Parathyroid Gland Water-Clear Cell Adenoma|Parathyroid gland|Paraurethral gland|Parenchyma|Parent|Paresthesia|Paricalcitol|Parietal Lobe|Parietal cell adenocarcinoma|Parietal cell carcinoma|Parietal lobe|Paronychia|Parosteal Osteosarcoma|Parosteal osteosarcoma|Parotid Gland|Parotid gland|Parotidectomy, NOS|Paroxysmal Atrial Tachycardia|Parsaclisib|Parsaclisib Hydrochloride|Parsatuzumab|Partial Hepatectomy|Partial Hydatidiform Mole|Partial Laryngectomy|Partial Maxillectomy|Partial Nephrectomy|Partial Response|Partial hydatidiform mole|Partially Engineered T-regulatory Cell Donor Graft TRGFT-201|Parvovirus H-1|Pasireotide|Pasotuxizumab|Patella|Paternal Aunt|Paternal First Cousin|Paternal First Cousin Once Removed|Paternal Grandfather|Paternal Grandmother|Paternal Grandparent|Paternal Great Aunt|Paternal Great Grandparent|Paternal Great Uncle|Paternal Half Brother|Paternal Half Sibling|Paternal Half Sister|Paternal Uncle|Pathologic Examination|Pathologic Review|Pathology|Pathology Report|Pathology outside specification|Patidegib|Patidegib Topical Gel|Patritumab|Patritumab Deruxtecan|Pattern 1|Pattern 2|Pattern 3|Pattern 4|Pattern 5|Patupilone|Paxalisib|Pazopanib|Pazopanib Hydrochloride|Pediatric Liver Cancer|Pediatric/AYA Brain Tumors|Pegargiminase|Pegaspargase|Pegasus|Pegasus 4D|Pegasus BT|Pegasus HRT|Pegasus III|Pegdinetanib|Pegfilgrastim|Pegilodecakin|Peginterferon Alfa-2a|Peginterferon Alfa-2b|Pegvisomant|Pegvorhyaluronidase Alfa|Pegylated Deoxycytidine Analogue DFP-14927|Pegylated Interferon Alfa|Pegylated Liposomal Belotecan|Pegylated Liposomal Doxorubicin Hydrochloride|Pegylated Liposomal Irinotecan|Pegylated Liposomal Mitomycin C Lipid-based Prodrug|Pegylated Liposomal Mitoxantrone Hydrochloride|Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010|Pegylated Paclitaxel|Pegylated Recombinant Human Arginase I BCT-100|Pegylated Recombinant Human Hyaluronidase PH20|Pegylated Recombinant Interleukin-2 THOR-707|Pegylated Recombinant L-asparaginase Erwinia chrysanthemi|Pegylated SN-38 Conjugate PLX038|Pegzilarginase|Pelabresib|Pelareorep|Peldesine|Pelitinib|Pelitrexol|Pelvic Floor Muscle Weakness|Pelvic Infection|Pelvic Pain|Pelvic Soft Tissue Necrosis|Pelvic bones, sacrum, coccyx and associated joints|Pelvic lymph nodes|Pelvis|Pelvis, NOS|Pembrolizumab|Pemetrexed|Pemetrexed Disodium|Pemigatinib|Pemlimogene Merolisbac|Penberol|Penclomedine|Penicillamine|Penile Carcinoma In Situ|Penile Infection|Penile Pain|Penis|Penis, NOS|Pentamethylmelamine|Pentamustine|Pentostatin|Pentoxifylline|Pepinemab|Peplomycin|Peplomycin Sulfate|Peposertib|PepsinA|Peptic Ulcer (Ulcer)|Peptichemio|Peptide 946 Melanoma Vaccine|Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine|Peretinoin|Perflenapent Emulsion|Perforation Bile Duct|Perfosfamide|Periapical cemental dysplasia|Periapical cemento-osseous dysplasia|Pericanalicular fibroadenoma|Pericardial Effusion|Pericardial Tamponade|Pericarditis|Pericardium|Periductal stromal tumor, low grade|Perifollicular Fibroma|Perifollicular fibroma|Perifosine|Perillyl Alcohol|Perimenopausal|Perineal Pain|Perinephric Fat|Perineural MPNST|Perineurioma|Perineurioma, NOS|Perineurioma, malignant|Periodontal Disease|Periorbital Edema|Periorbital Infection|Periorbital Soft Tissue|Periosteal Chondroma|Periosteal Chondrosarcoma|Periosteal Fibroma|Periosteal Fibrosarcoma|Periosteal Osteosarcoma|Periosteal chondroma|Periosteal chondrosarcoma|Periosteal fibroma|Periosteal fibrosarcoma|Periosteal osteosarcoma|Periosteal sarcoma, NOS|Peripheral Blood Components NOS|Peripheral Ischemia|Peripheral Motor Neuropathy|Peripheral Nerve Infection|Peripheral Neuropathy|Peripheral Odontogenic Fibroma|Peripheral Primitive Neuroectodermal Tumor|Peripheral Sensory Neuropathy|Peripheral T-Cell Lymphoma, Large Cell|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Peripheral T-cell lymphoma, AILD (Angioimmunoblastic Lymphadenopathy with Dysproteinemia)|Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, large cell|Peripheral T-cell lymphoma, pleomorphic medium and large cell|Peripheral T-cell lymphoma, pleomorphic small cell|Peripheral Vascular Disease|Peripheral Whole Blood|Peripheral nerves and autonomic nervous system|Peripheral nerves and autonomic nervous system of abdomen|Peripheral nerves and autonomic nervous system of head, face, and neck|Peripheral nerves and autonomic nervous system of lower limb and hip|Peripheral nerves and autonomic nervous system of pelvis|Peripheral nerves and autonomic nervous system of thorax|Peripheral nerves and autonomic nervous system of trunk, NOS|Peripheral nerves and autonomic nervous system of upper limb and shoulder|Peripheral neuroectodermal tumor|Peripheral odontogenic fibroma|Peripheral primitive neuroectodermal tumor, NOS|Peritoneal Cavity|Peritoneal Infection|Peritoneal Lavage|Peritoneal Necrosis|Peritoneum|Peritoneum, NOS|Peritumoral|Perivascular epithelioid cell tumor, malignant|Permanently missing item or object|Persistent Disease|Personality Change|Personalized ALL-specific Multi-HLA-binding Peptide Vaccine|Personalized Cancer Vaccine RO7198457|Personalized Neoantigen DNA Vaccine GNOS-PV01|Personalized Neoantigen DNA Vaccine GNOS-PVO2|Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01|Personalized Neoepitope Yeast Vaccine YE-NEO-001|Personalized Peptide Cancer Vaccine NEO-PV-01|Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC|Pertuzumab|Peru|Peutz-Jeghers Disease|Pevonedistat|Pexastimogene Devacirepvec|Pexidartinib|Pexmetinib|Phaleria macrocarpa Extract DLBS-1425|Phantom Pain|Pharmaceutical Therapy, NOS|Pharmacological Ascorbate|Pharyngeal Anastomotic Leak|Pharyngeal Fistula|Pharyngeal Hemorrhage|Pharyngeal Mucositis|Pharyngeal Necrosis|Pharyngeal Stenosis|Pharyngitis|Pharyngolaryngeal Pain|Pharynx|Pharynx, NOS|Phellodendron amurense Bark Extract|Phenesterin|Phenethyl Isothiocyanate|Phenethyl Isothiocyanate-containing Watercress Juice|Phenochromocytoma or Paraganglioma|Phenyl Acetate|Phenytoin Sodium|Pheochromoblastoma|Pheochromocytoma and Paraganglioma|Pheochromocytoma, NOS|Pheochromocytoma, malignant|Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia|Philadelphia-Negative Myelogenous Leukemia|Philippines|Phlebitis|Phlebitis Infective|Phosphaplatin PT-112|Phosphatidylcholine-Bound Silybin|Phosphaturic mesenchymal tumor, malignant|Phospholipid Ether-drug Conjugate CLR 131|Phosphoproteome|Phosphoramide Mustard|Phosphorodiamidate Morpholino Oligomer AVI-4126|Phosphorus P-32|Photodynamic Compound TLD-1433|Photophobia|Photosensitivity|Photosensitizer LUZ 11|Phyllodes Tumor|Phyllodes tumor, NOS|Phyllodes tumor, benign|Phyllodes tumor, borderline|Phyllodes tumor, malignant|Physical Exam|Physical Examination|Phytochlorin Sodium-Polyvinylpyrrolidone Complex|Pibenzimol|Pibrozelesin|Pibrozelesin Hydrobromide|Picibanil|Pick tubular adenoma|PicoFrit SELF/P|Picoplatin|Picrasinoside H|Picropodophyllin|Pictilisib|Pictilisib Bismesylate|Pidilizumab|Pigmented Adrenal Cortex Adenoma|Pigmented Dermatofibrosarcoma Protuberans|Pigmented Nevus|Pigmented Spindle Cell Nevus|Pigmented adenoma|Pigmented basal cell carcinoma|Pigmented dermatofibrosarcoma protuberans|Pigmented nevus, NOS|Pigmented schwannoma|Pigmented spindle cell nevus of Reed|Pilar tumor|Pilaralisib|Pilocytic Astrocytoma|Pilocytic astrocytoma|Piloid astrocytoma|Pilomatrical Carcinoma|Pilomatricoma|Pilomatricoma, NOS|Pilomatricoma, malignant|Pilomatrix carcinoma|Pilomatrixoma, NOS|Pilomatrixoma, malignant|Pilomyxoid Astrocytoma|Pilomyxoid astrocytoma|PilotAnalysisPipeline2|Pimasertib|Pimitespib|Pimurutamab|Pinatuzumab Vedotin|Pindborg tumor|Pindel|Pindel Annotation|Pindel Variant Aggregation and Masking|Pineal|Pineal Gland|Pineal Parenchymal Cell Neoplasm|Pineal Parenchymal Tumor of Intermediate Differentiation|Pineal Region Neoplasm|Pineal gland|Pineal parenchymal tumor of intermediate differentiation|Pinealoma|Pineoblastoma|Pineocytoma|Pingyangmycin|Pinkus tumor|Pinometostat|Pioglitazone|Pioglitazone Hydrochloride|Pipe|Pipeline|Pipendoxifene|Piperazinedione|Piperine Extract (Standardized)|Pipobroman|Piposulfan|Pirarubicin|Pirarubicin Hydrochloride|Pirfenidone|Piritrexim|Piritrexim Isethionate|Pirotinib|Piroxantrone|Piroxantrone Hydrochloride|Pituicytoma|Pituitary Gland|Pituitary Gland Acidophil Adenoma|Pituitary Gland Acidophil Carcinoma|Pituitary Gland Adenoma|Pituitary Gland Basophil Adenoma|Pituitary Gland Carcinoma|Pituitary Gland Chromophobe Adenoma|Pituitary Gland Mixed Acidophil-Basophil Adenoma|Pituitary Gland Mixed Acidophil-Basophil Carcinoma|Pituitary adenoma, NOS|Pituitary carcinoma, NOS|Pituitary gland|Pixantrone|Pixantrone Dimaleate|Pixatimod|Pizzly|Placebo|Placenta|Placental Hemangioma|Placental site trophoblastic tumor|Placental-Site Gestational Trophoblastic Tumor|Pladienolide Derivative E7107|Plamotamab|Plasma|Plasma Cell Leukemia|Plasma Cell Myeloma|Plasma Cell Neoplasm|Plasma Cell Tumors|Plasma cell leukemia|Plasma cell myeloma|Plasma cell tumor|Plasmablastic Lymphoma|Plasmablastic lymphoma|Plasmacytic leukemia|Plasmacytic lymphoma|Plasmacytoma|Plasmacytoma of bone|Plasmacytoma, NOS|Plasmacytoma, extramedullary|Plasmid DNA Vaccine pING-hHER3FL|Plasmodium falciparum|Platelet Count Decreased|Platform|Platform ICP|Platform II|Platform LCZ|Platinum|Platinum Acetylacetonate-Titanium Dioxide Nanoparticles|Platinum Compound|Pleomorphic Adenoma|Pleomorphic Carcinoma|Pleomorphic Lipoma|Pleomorphic Liposarcoma|Pleomorphic Lobular Breast Carcinoma In Situ|Pleomorphic Rhabdomyosarcoma|Pleomorphic Xanthoastrocytoma|Pleomorphic adenoma|Pleomorphic carcinoma|Pleomorphic cell sarcoma|Pleomorphic leiomyoma|Pleomorphic lipoma|Pleomorphic liposarcoma|Pleomorphic lobular carcinoma|Pleomorphic lobular carcinoma in situ|Pleomorphic rhabdomyosarcoma, NOS|Pleomorphic rhabdomyosarcoma, adult type|Pleomorphic xanthoastrocytoma|Pleura|Pleura, NOS|Pleural Effusion|Pleural Hemorrhage|Pleural Infection|Pleural Solitary Fibrous Tumor|Pleuritic Pain|Pleurodesis|Pleurodesis, NOS|Pleurodesis, Talc|Pleuropulmonary Blastoma|Pleuropulmonary blastoma|Plevitrexed|Plexiform Fibrohistiocytic Tumor|Plexiform Neurofibroma|Plexiform Schwannoma|Plexiform fibrohistiocytic tumor|Plexiform fibromyxoma|Plexiform hemangioma|Plexiform leiomyoma|Plexiform neurofibroma|Plexiform neuroma|Plexiform schwannoma|Plicamycin|Plinabulin|Plitidepsin|Plk1 Inhibitor BI 2536|Plocabulin|Plozalizumab|Pneumoblastoma|Pneumocystis Pneumonia|Pneumocystis carinii|Pneumonectomy|Pneumonia, NOS|Pneumonitis|Pneumothorax|Pol I Inhibitor CX5461|Poland|Polar Spongioblastoma|Polar spongioblastoma|Polatuzumab Vedotin|Polidocanol|Poliglusam|Polo-like Kinase 1 Inhibitor GSK461364|Polo-like Kinase 1 Inhibitor MK1496|Polo-like Kinase 1 Inhibitor NMS-1286937|Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate|Poly-alendronate Dextran-Guanidine Conjugate|Poly-gamma Glutamic Acid|Polyamine Analog SL11093|Polyamine Analogue PG11047|Polyamine Analogue SBP-101|Polyamine Transport Inhibitor AMXT-1501 Dicaprate|Polyandrol|Polycystic Ovarian Syndrome (PCOS)|Polycythemia Vera|Polycythemia rubra vera|Polycythemia vera|Polyembryoma|Polyethylene Glycol Recombinant Endostatin|Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318|Polygonal Cell Carcinoma|Polygonal cell carcinoma|Polymer-conjugated IL-15 Receptor Agonist NKTR-255|Polymer-encapsulated Luteolin Nanoparticle|Polymeric Camptothecin Prodrug XMT-1001|Polymorphic Post-Transplant Lymphoproliferative Disorder|Polymorphic post transplant lymphoproliferative disorder|Polymorphic reticulosis|Polymorphous low grade adenocarcinoma|Polypodium leucotomos Extract|Polypoid adenoma|Polysaccharide-K|Polysialic Acid|Polyunsaturated Fatty Acid|Polyvalent Melanoma Vaccine|Polyvesicular vitelline tumor|Pomalidomide|Pomegranate Juice|Pomegranate Liquid Extract|Ponatinib|Ponatinib Hydrochloride|Poor Prognosis|Poorly Differentiated|Poorly Differentiated Neuroblastoma|Poorly Differentiated Neuroendocrine Lesion|Poorly Differentiated Thyroid Gland Carcinoma|Poorly cohesive carcinoma|Popliteal Fossa|Porcupine Inhibitor CGX1321|Porcupine Inhibitor ETC-1922159|Porcupine Inhibitor RXC004|Porcupine Inhibitor WNT974|Porcupine Inhibitor XNW7201|Porfimer Sodium|Porfiromycin|Porocarcinoma|Poroma|Portal Hypertension|Portal Vein Thrombosis|Portugal|Positive|Positive Biomarker(s)|Post neo-adjuvant therapy|Post transplant lymphoproliferative disorder, NOS|Post-Transplant Lymphoproliferative Disorder|Postcricoid region|Posterior Wall of the Nasopharynx|Posterior mediastinum|Posterior wall of bladder|Posterior wall of hypopharynx|Posterior wall of nasopharynx|Posterior wall of oropharynx|Postmenopausal|Postnasal Drip|Postoperative Hemorrhage|Postoperative Thoracic Procedure Complication|Pouch|Poziotinib|Pracinostat|Pralatrexate|Pralsetinib|Praluzatamab Ravtansine|Pravastatin Sodium|Pre T-ALL|Pre-B ALL|Pre-B Acute Lymphoblastic Leukemia|Pre-Pre-B Acute Lymphoblastic Leukemia|Pre-T ALL|Pre-extracted DNA received by TSS|Pre-pre-B ALL|Precancerous Melanosis|Precancerous melanosis, NOS|Precocious Puberty|Precursor B-cell lymphoblastic leukemia|Precursor B-cell lymphoblastic lymphoma|Precursor Cell Lymphoblastic Lymphoma|Precursor T-cell lymphoblastic leukemia|Precursor T-cell lymphoblastic lymphoma|Precursor cell lymphoblastic leukemia, NOS|Precursor cell lymphoblastic leukemia, not phenotyped|Precursor cell lymphoblastic lymphoma, NOS|Prednimustine|Prednisolone|Prednisolone Acetate|Prednisolone Sodium Phosphate|Prednisone|Pregnancy in Patient or Partner|Pregnancy, Puerperium and Perinatal Conditions - Other|Preleukemia|Preleukemic syndrome|Premalignant|Premature Delivery|Premature Menopause|Premenopausal|Premier|Prepuce|Present|Presyncope|Prevention|Prexasertib|Prexigebersen|Primary|Primary Amyloidosis|Primary Blood Derived Cancer - Bone Marrow|Primary Blood Derived Cancer - Peripheral Blood|Primary Cutaneous Anaplastic Large Cell Lymphoma|Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder|Primary Cutaneous CD4-Positive Small/Medium T-Cell Lymphoproliferative Disorder|Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma|Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Primary Cutaneous Follicle Center Lymphoma|Primary Cutaneous Gamma-Delta T-Cell Lymphoma|Primary Cutaneous Lymphoma|Primary Cutaneous Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Primary Effusion Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Primary Myelofibrosis|Primary Neoplasm|Primary Peritoneal Serous Papillary Adenocarcinoma|Primary Sclerosing Cholangitis|Primary Site Unknown|Primary Tumor|Primary Tumor Field|Primary Xenograft Tissue|Primary amyloidosis|Primary cutaneous CD30+ T-cell lymphoproliferative disorder|Primary cutaneous CD30+ large T-cell lymphoma|Primary cutaneous CD4-positive small/medium T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous DLBCL, leg type|Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous follicle centre lymphoma|Primary cutaneous gamma-delta T-cell lymphoma|Primary cutaneous neuroendocrine carcinoma|Primary diffuse large B-cell lymphoma of the CNS|Primary effusion lymphoma|Primary intraosseous carcinoma|Primary myelofibrosis|Primary serous papillary carcinoma of peritoneum|Primary tumor site|Prime Cancer Vaccine MVA-BN-CV301|Primitive Neuroectodermal Tumor|Primitive neuroectodermal tumor, NOS|Primitive polar spongioblastoma|Prinomastat|Prior malignancy|Pro-B ALL|Pro-T ALL|Proapoptotic Sulindac Analog CP-461|Procarbazine|Procarbazine Hydrochloride|Procaspase Activating Compound-1 VO-100|Proctitis|Productive Cough|Progestational IUD|Progesterone and Estrogen|Progesterone only|Progestin|Progestin and Estrogen|Progression|Progressive Disease|Progressive Multifocal Leukoencephalopathy|Progressive Neoplastic Disease|Prohibitin-Targeting Peptide 1|Prolactinoma|Prolapse of Intestinal Stoma|Prolapse of Urostomy|Prolgolimab|Proliferating Trichilemmal Tumor|Proliferating trichilemmal cyst|Proliferating trichilemmal tumor|Proliferative Nodules in Congenital Melanocytic Nevus|Proliferative dermal lesion in congenital nevus|Proliferative polycythemia|Proline endopeptidase|Prolymphocytic Leukemia|Prolymphocytic leukemia, B-cell type|Prolymphocytic leukemia, NOS|Prolymphocytic leukemia, T-cell type|Prospective|Prostaglandin E2 EP4 Receptor Inhibitor AN0025|Prostaglandin E2 EP4 Receptor Inhibitor E7046|Prostate|Prostate Acinar Adenocarcinoma, Sarcomatoid Variant|Prostate Adenocarcinoma|Prostate Bed|Prostate Cancer|Prostate Cancer Vaccine ONY-P1|Prostate Gland|Prostate Health Cocktail Dietary Supplement|Prostate Infection|Prostate gland|Prostate, Seminal Vesicles and Lymph Nodes|Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024|Prostatic Hemorrhage|Prostatic Obstruction|Prostatic Pain|Prostatic intraepithelial neoplasia, grade III|Protease-activated Anti-PD-L1 Antibody Prodrug CX-072|Protein|Protein Arginine Methyltransferase 5 Inhibitor GSK3326595|Protein Arginine Methyltransferase 5 Inhibitor PF-06939999|Protein Arginine Methyltransferase 5 Inhibitor PRT543|Protein Expression Quantification|Protein Kinase C Inhibitor IDE196|Protein Phosphatase 2A Inhibitor LB-100|Protein Stabilized Liposomal Docetaxel Nanoparticles|Protein Tyrosine Kinase 2 Inhibitor IN10018|Proteinuria|Proteome|Proteome Profiling|Proton Pump Inhibitors|Protoplasmic Astrocytoma|Protoplasmic astrocytoma|Proxalutamide|Pruritus|Psammomatous Meningioma|Psammomatous meningioma|Psammomatous schwannoma|Pseudoglandular Squamous Cell Carcinoma|Pseudoisocytidine|Pseudomonas aeruginosa|Pseudomucinous adenocarcinoma|Pseudomucinous cystadenocarcinoma, NOS|Pseudomucinous cystadenoma, NOS|Pseudomucinous cystadenoma, borderline malignancy|Pseudomyxoma Peritonei|Pseudomyxoma peritonei|Pseudomyxoma peritonei with unknown primary site|Pseudoprogression|Pseudosarcomatous carcinoma|Psoriasis|Psychiatric Disorders - Other|Psychosis|Pterostilbene|Puerto Rico|Pulmonary Adenomatosis|Pulmonary Artery Intimal Sarcoma|Pulmonary Blastoma|Pulmonary Edema|Pulmonary Fibrosis|Pulmonary Fistula|Pulmonary Hemorrhage|Pulmonary Hypertension|Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Translocation|Pulmonary Valve Disease|Pulmonary adenomatosis|Pulmonary artery intimal sarcoma|Pulmonary blastoma|Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation|Pumitepa|Punch Biopsy|Puquitinib|Puquitinib Mesylate|Pure Erythroid Leukemia|Puromycin|Puromycin Hydrochloride|Purpura|Pylorus|Pyramidal Tract Syndrome|Pyrazinamide|Pyrazoloacridine|Pyridyl Cyanoguanidine CHS 828|Pyriform sinus|Pyrotinib|Pyrotinib Dimaleate|Pyroxamide|Pyruvate Kinase Inhibitor TLN-232|Pyruvate Kinase M2 Isoform Activator TP-1454|Q Exactive|Q Exactive HF|Q Exactive HF-X|Q Exactive Plus|Q TRAP|Q-Tof Premier|Q-Tof Ultima|Q-Tof micro|QA|QSTAR|QSTAR Elite|QSTAR Pulsar|QSTAR XL|QTRAP 4500|QTRAP 5500|QTRAP 6500|QTRAP 6500+m|Qatar|Qilisheng Immunoregulatory Oral Solution|Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine|Qualification metrics changed|Qualified|Qualified in error|Quarfloxin|Quattro|Quattro II|Quattro LC|Quattro Premier|Quattro Premier XE|Quattro Ultima|Quattro Ultima Pt|Quattro micro GC|Queyrat erythroplasia|Quinacrine Hydrochloride|Quinine|Quisinostat|Quizartinib|R|R-(-)-Gossypol Acetic Acid|R0|R1|R2|RAD51 Inhibitor CYT-0851|RAEB|RAEB I|RAEB II|RAEB-T|RAF Kinase Inhibitor L-779450|RAF Kinase Inhibitor XL281|RARS|RARalpha Agonist IRX5183|RD-Responsive Disease|RET Inhibitor DS-5010|RET Mutation/Fusion Inhibitor BLU-667|RET/SRC Inhibitor TPX-0046|RFT5-dgA Immunotoxin IMTOX25|RIPK1 Inhibitor GSK3145095|RNA|RNA-SeQC - Counts|RNA-SeQC - FPKM|RNA-Seq|RNR Inhibitor COH29|ROBO1-targeted BiCAR-NKT Cells|RORgamma Agonist LYC-55716|RP-Response|RPD-Radiographic Progressive Disease|RPLC|RPPA|RSEM - Quantification|RSK1-4 Inhibitor PMD-026|RX|Rabusertib|Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus SM-88|Racemose hemangioma|Racotumomab|Radgocitabine|Radgocitabine Hydrochloride|Radiation|Radiation Recall Reaction (Dermatologic)|Radiation Therapy, NOS|Radiation, 2D Conventional|Radiation, 3D Conformal|Radiation, Combination|Radiation, Cyberknife|Radiation, External Beam|Radiation, Hypofractionated|Radiation, Implants|Radiation, Intensity-Modulated Radiotherapy|Radiation, Internal|Radiation, Mixed Photon Beam|Radiation, Photon Beam|Radiation, Proton Beam|Radiation, Radioisotope|Radiation, Stereotactic/Gamma Knife/SRS|Radiation, Systemic|Radical Hysterectomy|Radical Maxillectomy|Radical Nephrectomy|Radical Prostatectomy|Radiculitis|Radioactive Iodine|Radioactive Iodine Therapy|Radioembolization|Radiographic Progressive Disease|Radiolabeled CC49|Radiology|Radiosensitizing Agent|Radium Ra 223 Dichloride|Radium Ra 224-labeled Calcium Carbonate Microparticles|Radix Angelicae Sinensis/Radix Astragali Herbal Supplement|Radotinib Hydrochloride|Raf Kinase Inhibitor HM95573|Ragifilimab|Ralaniten Acetate|Ralimetinib Mesylate|Raloxifene|Raloxifene Hydrochloride|Raltitrexed|Ramucirumab|Ranibizumab|Ranimustine|Ranolazine|Ranpirnase|Ras Inhibitor|Ras Peptide ASP|Ras Peptide CYS|Ras Peptide VAL|Rash Acneiform|Rash Maculo-Papular|Rash Pustular|Rathke pouch tumor|Rattus norvegicus|Raw CGI Variant|Raw Intensities|Raw Sequencing Data|Raw Simple Somatic Mutation|Razoxane|Read Group Quality Control|Realgar-Indigo naturalis Formulation|Rebastinib Tosylate|Rebeccamycin|Rebimastat|Receptor Tyrosine Kinase Inhibitor R1530|Recklinghausen disease|Recombinant Adenovirus-p53 SCH-58500|Recombinant Anti-WT1 Immunotherapeutic GSK2302024A|Recombinant Bacterial Minicells VAX014|Recombinant Bispecific Single-Chain Antibody rM28|Recombinant CD40-Ligand|Recombinant Erwinia asparaginase JZP-458|Recombinant Erythropoietin|Recombinant Fas Ligand|Recombinant Fractalkine|Recombinant Granulocyte-Macrophage Colony-Stimulating Factor|Recombinant Human 6Ckine|Recombinant Human Adenovirus Type 5 H101|Recombinant Human Angiotensin Converting Enzyme 2 APN01|Recombinant Human Apolipoprotein(a) Kringle V MG1102|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Recombinant Human Endostatin|Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine|Recombinant Human Papillomavirus 11-valent Vaccine|Recombinant Human Papillomavirus Bivalent Vaccine|Recombinant Human Papillomavirus Nonavalent Vaccine|Recombinant Human Plasminogen Kringle 5 Domain ABT 828|Recombinant Human TRAIL-Trimer Fusion Protein SCB-313|Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301|Recombinant Interferon|Recombinant Interferon Alfa|Recombinant Interferon Alfa-1b|Recombinant Interferon Alfa-2a|Recombinant Interferon Alfa-2b|Recombinant Interferon Alpha 2b-like Protein|Recombinant Interferon Beta|Recombinant Interferon Gamma|Recombinant Interleukin-12|Recombinant Interleukin-13|Recombinant Interleukin-18|Recombinant Interleukin-2|Recombinant Interleukin-6|Recombinant KSA Glycoprotein CO17-1A|Recombinant Leukocyte Interleukin|Recombinant Leukoregulin|Recombinant Luteinizing Hormone|Recombinant MAGE-3.1 Antigen|Recombinant MIP1-alpha Variant ECI301|Recombinant Macrophage Colony-Stimulating Factor|Recombinant Modified Vaccinia Ankara-5T4 Vaccine|Recombinant Oncolytic Poliovirus PVS-RIPO|Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A|Recombinant Platelet Factor 4|Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207|Recombinant Super-compound Interferon|Recombinant Thyroglobulin|Recombinant Thyrotropin Alfa|Recombinant Transforming Growth Factor-Beta|Recombinant Transforming Growth Factor-Beta-2|Recombinant Tumor Necrosis Factor-Alpha|Recombinant Tyrosinase-Related Protein-2|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Recreational fire smoke|Rectal Anastomotic Leak|Rectal Cancer|Rectal Fistula|Rectal Hemorrhage|Rectal Mucositis|Rectal Necrosis|Rectal Obstruction|Rectal Pain|Rectal Perforation|Rectal Stenosis|Rectal Ulcer|Rectosigmoid Junction|Rectosigmoid Region|Rectosigmoid junction|Rectum|Rectum Adenocarcinoma|Rectum, NOS|Recurrence|Recurrent Blood Derived Cancer - Bone Marrow|Recurrent Blood Derived Cancer - Peripheral Blood|Recurrent Disease|Recurrent Laryngeal Nerve Palsy|Recurrent Neoplasm|Recurrent Pyogenic Cholangitis|Recurrent Tumor|Red & Violet|Redaction|Redaporfin|Refametinib|Reflux Disease|Refractory Anemia|Refractory Anemia with Excess Blasts in Transformation|Refractory Cytopenia of Childhood|Refractory Neutropenia|Refractory Thrombocytopenia|Refractory anemia|Refractory anemia with excess blasts|Refractory anemia with excess blasts in transformation|Refractory anemia with ring sideroblasts associated with marked thrombocytosis|Refractory anemia with ringed sideroblasts|Refractory anemia with sideroblasts|Refractory anemia without sideroblasts|Refractory cytopenia of childhood|Refractory cytopenia with multilineage dysplasia|Refractory neutropenia|Refractory thrombocytopenia|Refused|Regional|Regional Metastasis|Regional Site|Regional or Distant Metastasis (M1)|Regorafenib|Regressing Melanoma|Regressing Nevus|Regressing nevus|Relacorilant|Related to Cancer|Relatlimab|Relugolix|Remetinostat|Renal|Renal Calculi|Renal Capsule|Renal Cell Carcinoma|Renal Cell Carcinoma Peptides Vaccine IMA901|Renal Colic|Renal Dialysis|Renal Disorder, NOS|Renal Failure (Requiring Dialysis)|Renal Hemorrhage|Renal Insufficiency|Renal Pelvis|Renal Sinus|Renal Vein|Renal and Urinary Disorders - Other|Renal carcinoma, collecting duct type|Renal cell adenocarcinoma|Renal cell carcinoma, NOS|Renal cell carcinoma, chromophobe type|Renal cell carcinoma, sarcomatoid|Renal cell carcinoma, spindle cell|Renal cell carcinoma, unclassified|Renal medullary carcinoma|Renal pelvis|Reninoma|Renomedullary fibroma|Renomedullary interstitial cell tumor|Reparixin|Repli-G|Repli-G (Qiagen) DNA|Repli-G Pooled (Qiagen) DNA|Repli-G X|Repli-G X (Qiagen) DNA|Repotrectinib|Reproductive System and Breast Disorders - Other|Rescinded|Reserve cell carcinoma|Residual Disease|Resiquimod|Resiquimod Topical Gel|Resistant Starch|Resminostat|Respiratory Failure|Respiratory, Thoracic and Mediastinal Disorders - Other|Responsive Disease|Restlessness|Restrictive Cardiomyopathy|Resveratrol|Resveratrol Formulation SRT501|Retaspimycin|Retaspimycin Hydrochloride|Rete Ovarii Adenocarcinoma|Retelliptine|Reticuloendothelial System|Reticuloendothelial system, NOS|Reticulohistiocytoma|Reticulosarcoma|Reticulosarcoma, NOS|Reticulosarcoma, diffuse|Reticulum cell sarcoma, NOS|Reticulum cell sarcoma, diffuse|Retifanlimab|Retina|Retinal Detachment|Retinal Tear|Retinal Vascular Disorder|Retinal anlage tumor|Retinoblastoma|Retinoblastoma, NOS|Retinoblastoma, differentiated|Retinoblastoma, diffuse|Retinoblastoma, spontaneously regressed|Retinoblastoma, undifferentiated|Retinocytoma|Retinoic Acid Agent Ro 16-9100|Retinoic Acid Syndrome|Retinoid 9cUAB30|Retinol|Retinopathy|Retinyl Acetate|Retinyl Palmitate|Retro-Orbital Region|Retromolar Trigone|Retromolar area|Retroperitoneal Hemorrhage|Retroperitoneal fibromatosis|Retroperitoneum|Retroperitoneum and peritoneum|Retrospective|Retrovector Encoding Mutant Anti-Cyclin G1|Reunion|Revdofilimab|Reverse Phase Protein Array|Reversible Posterior Leukoencephalopathy Syndrome|Rexinoid NRX 194204|Rezivertinib|Rhabdoid Meningioma|Rhabdoid Tumor|Rhabdoid meningioma|Rhabdoid sarcoma|Rhabdoid tumor (kidney) (RT)|Rhabdoid tumor, NOS|Rhabdomyoma|Rhabdomyoma, NOS|Rhabdomyosarcoma|Rhabdomyosarcoma with ganglionic differentiation|Rhabdomyosarcoma, NOS|Rhabdosarcoma|Rhenium Re 188 BMEDA-labeled Liposomes|Rhenium Re-186 Hydroxyethylidene Diphosphonate|Rhenium Re-188 Ethiodized Oil|Rhenium Re-188 Etidronate|Rheumatoid Arthritis|Rheumatologic Disease|Rhinitis Infective|Rhizoxin|RhoC Peptide Vaccine RV001V|Rib|Rib, sternum, clavicle and associated joints|Ribociclib|Ribociclib/Letrozole|Ribonuclease QBI-139|Ribosome-Inactivating Protein CY503|Ribozyme RPI.4610|Rice Bran|Ricolinostat|Ridaforolimus|Right|Right Hemicolectomy|Right Ventricular Dysfunction|Rigosertib|Rigosertib Sodium|Rilimogene Galvacirepvec|Rilimogene Galvacirepvec/Rilimogene Glafolivec|Rilimogene Glafolivec|Rilotumumab|Rindopepimut|Ring Finger|Ripertamab|Ripretinib|Risperidone Formulation in Rumenic Acid|Ritrosulfan|Rituximab|Rituximab Conjugate CON-4619|Rituximab and Hyaluronidase Human|Riviciclib|Rivoceranib|Rivoceranib Mesylate|Robatumumab|Roblitinib|Rocakinogene Sifuplasmid|Rocapuldencel-T|Rociletinib|Rodent ulcer|Rodorubicin|Roducitabine|Rofecoxib|Roflumilast|Rogaratinib|Rogletimide|Rolinsatamab Talirine|Romania|Romidepsin|Roneparstat|Roniciclib|Ropeginterferon Alfa-2B|Ropidoxuridine|Ropocamptide|Roquinimex|Rosabulin|Rose Bengal Solution PV-10|Rosette-Forming Glioneuronal Tumor|Rosette-forming glioneuronal tumor|Rosiglitazone Maleate|Rosmantuzumab|Rosopatamab|Rosuvastatin|Round Cell Liposarcoma|Round Ligament|Round cell carcinoma|Round cell liposarcoma|Round cell osteosarcoma|Round cell sarcoma|Round ligament|Rovalpituzumab Tesirine|Rubinstein-Taybi Syndrome|Rubitecan|Rucaparib|Rucaparib Camsylate|Rucaparib Phosphate|Run Metadata|Russia|Ruthenium Ru-106|Ruthenium-based Small Molecule Therapeutic BOLD-100|Ruthenium-based Transferrin Targeting Agent NKP-1339|Ruxolitinib|Ruxolitinib Phosphate|Ruxotemitide|Rwanda|S|S-Adenosylmethionine|S-equol|S1P Receptor Agonist KRP203|SALT lymphoma|SBIL-2|SCIEX|SCX|SD-Stable Disease|SDF-1 Receptor Antagonist PTX-9908|SDRF|SERD D-0502|SERD G1T48|SERD GDC-9545|SERD SAR439859|SERD SHR9549|SERD ZN-c5|SETTLE|SHH-Activated|SHP-1 Agonist SC-43|SHP2 Inhibitor JAB-3068|SHP2 Inhibitor RLY-1971|SHP2 Inhibitor RMC-4630|SHP2 Inhibitor TNO155|SILAC|SILAC quantitation analysis|SIRPa-4-1BBL Fusion Protein DSP107|SIRPa-Fc Fusion Protein TTI-621|SIRPa-Fc-CD40L Fusion Protein SL-172154|SIRPa-IgG4-Fc Fusion Protein TTI-622|SLC6A8 Inhibitor RGX-202|SLCT Inhibitor GNS561|SMAC Mimetic BI 891065|SMO Protein Inhibitor ZSP1602|SN-38-Loaded Polymeric Micelles NK012|SNS01-T Nanoparticles|SOLiD|SPD-Surgical Progression|SQ Detector 2|SR-BP1/HSI Inhibitor SR31747A|SR-T100 Gel|SRA XML|SRM quantitation analysis|SRPK1/ABCG2 Inhibitor SCO-101|SSTR2-targeting Protein/DM1 Conjugate PEN-221|STAR - Counts|STAR - FPKM|STAR - Smart-Seq2|STAR - Smart-Seq2 Filtered Counts|STAR - Smart-Seq2 Raw Counts|STAR 2-Pass|STAR 2-Pass Chimeric|STAR 2-Pass Genome|STAR 2-Pass Transcriptome|STAR-Fusion|STAT Inhibitor OPB-111077|STAT3 Inhibitor DSP-0337|STAT3 Inhibitor OPB-31121|STAT3 Inhibitor OPB-51602|STAT3 Inhibitor TTI-101|STAT3 Inhibitor WP1066|STING Agonist BMS-986301|STING Agonist GSK3745417|STING Agonist IMSA101|STING Agonist MK-1454|STING Agonist SB 11285|STING Agonist TAK-676|STING-activating Cyclic Dinucleotide Agonist MIW815|STING-expressing E. coli SYNB1891|SVS|SYNAPT G2-Si|Sabarubicin|Sabatolimab|Saccharomyces cerevisiae|Sacituzumab Govitecan|Sacrum|Sacubitril/Valsartan|Safingol|Sagopilone|Saint Helena, Ascension and Tristan da Cunha|Saint Kitts and Nevis|Saint Lucia|Saint Pierre and Miquelon|Saint Vincent and the Grenadines|Salirasib|Saliva|Salivary Duct Carcinoma|Salivary Duct Inflammation|Salivary Gland|Salivary Gland Basal Cell Adenocarcinoma|Salivary Gland Basal Cell Adenoma|Salivary Gland Fistula|Salivary Gland Infection|Salivary Gland Monomorphic Adenoma|Salivary duct carcinoma|Salmonella Septicemia|Salmonella VNP20009|Salpingectomy|Salpingo-oophorectomy|Sam68 Modulator CWP232291|Samalizumab|Samarium Sm 153-DOTMP|Samoa|Samotolisib|Sample Procurement|Sample compromised|Samrotamab Vedotin|Samuraciclib|San Marino|Sao Tome and Principe|Sapacitabine|Sapanisertib|Sapitinib|SarCNU|Saracatinib|Saracatinib Difumarate|Sarcoidosis|Sarcoma|Sarcoma botryoides|Sarcoma, NOS|Sarcomatoid Carcinoma|Sarcomatoid Mesothelioma|Sarcomatoid Renal Cell Carcinoma|Sarcomatoid Transitional Cell Carcinoma|Sarcomatoid carcinoma|Sarcomatoid mesothelioma|Sarcomatosis|Sarcomatosis, NOS|Sardomozide|Sargramostim|Sasanlimab|Satraplatin|Saudi Arabia|Savolitinib|Scalp|Scalp Pain|Scapula|Schizosaccharomyces pombe|Schmincke tumor|Schneiderian carcinoma|Schneiderian papilloma, NOS|Schneiderian papilloma, inverted|Schwannoma|Schwannoma, NOS|Schwannomatosis|Sciatic Nerve|Scirrhous Adenocarcinoma|Scirrhous Hepatocellular Carcinoma|Scirrhous adenocarcinoma|Scirrhous carcinoma|Scleral Disorder|Sclerosing Epithelioid Fibrosarcoma|Sclerosing Liposarcoma|Sclerosing Rhabdomyosarcoma|Sclerosing epithelioid fibrosarcoma|Sclerosing hemangioma|Sclerosing hepatic carcinoma|Sclerosing liposarcoma|Sclerosing rhabdomyosarcoma|Sclerosing stromal tumor|Sclerosing sweat duct carcinoma|Sclerosis|Scoliosis|Scopoletin|Scrotal Infection|Scrotal Pain|Scrotum|Scrotum, NOS|SeSAMe Methylation Beta Estimation|Sebaceous Adenoma|Sebaceous Carcinoma|Sebaceous adenocarcinoma|Sebaceous adenoma|Sebaceous carcinoma|Sebaceous epithelioma|Seclidemstat|Secondary Carcinoma|Secondary Neoplasm|Secondary carcinoma|Secretory Breast Carcinoma|Secretory Meningioma|Secretory carcinoma of breast|Secretory meningioma|Sedoxantrone Trihydrochloride|Seizure|Seizures|Selatinib Ditosilate|Selective Androgen Receptor Modulator RAD140|Selective Cytokine Inhibitory Drug CC-1088|Selective Estrogen Receptor Degrader AZD9496|Selective Estrogen Receptor Degrader AZD9833|Selective Estrogen Receptor Degrader LSZ102|Selective Estrogen Receptor Degrader LX-039|Selective Estrogen Receptor Degrader LY3484356|Selective Estrogen Receptor Degrader SRN-927|Selective Estrogen Receptor Modulator CC-8490|Selective Estrogen Receptor Modulator TAS-108|Selective Glucocorticoid Receptor Antagonist CORT125281|Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352|Seliciclib|Selicrelumab|Selinexor|Selitrectinib|Selonsertib|Selpercatinib|Selumetinib|Selumetinib Sulfate|Semaxanib|Seminal Vesicle|Seminoma|Seminoma with high mitotic index|Seminoma, NOS|Seminoma, anaplastic|Semuloparin|Semustine|Seneca Valley Virus-001|Senegal|Sensory Changes|Seocalcitol|Sepantronium Bromide|Sepsis|Sequencing Data|Sequencing Reads|Serabelisib|Serbia|Serclutamab Talirine|Serdemetan|Sergiolide|Seribantumab|Serine/Threonine Kinase Inhibitor CBP501|Serine/Threonine Kinase Inhibitor XL418|Seroma|Seromucinous carcinoma|Serotonin producing carcinoid|Serous Adenofibroma|Serous Cystadenocarcinoma|Serous Cystadenoma|Serous Endometrial Intraepithelial Carcinoma|Serous Surface Papillary Carcinoma|Serous Surface Papilloma|Serous Tubal Intraepithelial Carcinoma|Serous adenocarcinofibroma|Serous adenocarcinoma, NOS|Serous adenofibroma of borderline malignancy|Serous adenofibroma, NOS|Serous borderline tumor-micropapillary variant|Serous carcinoma, NOS|Serous cystadenocarcinofibroma|Serous cystadenocarcinoma, NOS|Serous cystadenofibroma of borderline malignancy|Serous cystadenofibroma, NOS|Serous cystadenoma, NOS|Serous cystadenoma, borderline malignancy|Serous cystoma|Serous endometrial intraepithelial carcinoma|Serous microcystic adenoma|Serous papillary cystic tumor of borderline malignancy|Serous surface papillary carcinoma|Serous surface papillary tumor of borderline malignancy|Serous surface papilloma|Serous tubal intraepithelial carcinoma|Serous tubal intraepithelial carcinoma (STIC)|Serous tumor, NOS, of low malignant potential|Serplulimab|Serrated adenocarcinoma|Serrated adenoma|Sertoli Cell Tumor|Sertoli cell adenoma|Sertoli cell carcinoma|Sertoli cell tumor with lipid storage|Sertoli cell tumor, NOS|Sertoli-Leydig cell tumor of intermediate differentiation|Sertoli-Leydig cell tumor, NOS|Sertoli-Leydig cell tumor, intermediate differentiation, with heterologous elements|Sertoli-Leydig cell tumor, poorly differentiated|Sertoli-Leydig cell tumor, poorly differentiated, with heterologous elements|Sertoli-Leydig cell tumor, retiform|Sertoli-Leydig cell tumor, retiform, with heterologous elements|Sertoli-Leydig cell tumor, sarcomatoid|Sertoli-Leydig cell tumor, well differentiated|Serum|Serum Amylase Increased|Serum Sickness|Sessile Serrated Adenoma/Polyp|Sessile serrated adenoma|Sessile serrated polyp|Seurat - 10x Chromium|Seurat - Smart-Seq2|Sevacizumab|Seviteronel|Sex Cord-Stromal Tumor|Sex cord tumor with annular tubules|Sex cord tumor, NOS|Sex cord-gonadal stromal tumor, NOS|Sex cord-gonadal stromal tumor, incompletely differentiated|Sex cord-gonadal stromal tumor, mixed forms|Seychelles|Sezary Syndrome|Sezary disease|Sezary syndrome|Shared Anti-Idiotype-AB-S006|Shared Anti-Idiotype-AB-S024A|Shark Cartilage|Shark Cartilage Extract AE-941|Shenqi Fuzheng Injection SQ001|Shimadzu|Shimadzu MALDI-7090|Shingles|Sho-Saiko-To|Short Chain Fatty Acid HQK-1004|Short bones of lower limb and associated joints|Short bones of upper limb and associated joints|Shoulder|Shu Yu Wan Formula|Sialadenitis|Sialoblastoma|Sialyl Tn Antigen|Sialyl Tn-KLH Vaccine|Sibling|Sibrotuzumab|Sick Sinus Syndrome|Sierra Leone|Sigmoid Colectomy|Sigmoid Colon|Sigmoid colon|Signet Ring Cell Carcinoma|Signet ring cell adenocarcinoma|Signet ring cell carcinoma|Silatecan AR-67|Silibinin|Silicon Phthalocyanine 4|Silmitasertib Sodium|Siltuximab|Simalikalactone D|Simeprevir|Simlukafusp Alfa|Simmitinib|Simotaxel|Simple Germline Variation|Simple Hysterectomy|Simple Mastectomy|Simple Nucleotide Variation|Simtuzumab|Simurosertib|Singapore|Single Cell Analysis|Sinonasal Inverted Schneiderian Papilloma|Sinonasal Oncocytic Schneiderian Papilloma|Sinonasal Schneiderian Papilloma|Sinonasal papilloma, NOS|Sinonasal papilloma, exophytic|Sinonasal papilloma, fungiform|Sintilimab|Sinus|Sinus Bradycardia|Sinus Disorder|Sinus Pain|Sinus Tachycardia|Sinus(es), Maxillary|Sinusitis|Siplizumab|Sipuleucel-T|Siremadlin|Sirolimus|Sister|Sister-in-law|Sitimagene Ceradenovec|Sitravatinib|Sivifene|Six Weeks or More|Sizofiran|Sjogren's Syndrome|Skeletal Muscle|Skin|Skin Adenoid Basal Cell Carcinoma|Skin Appendage Adenoma|Skin Atrophy|Skin Basal Cell Carcinoma|Skin Basal Cell Carcinoma with Sebaceous Differentiation|Skin Basosquamous Cell Carcinoma|Skin Cancer|Skin Cutaneous Melanoma|Skin Fibroepithelial Basal Cell Carcinoma|Skin Fibrous Histiocytoma|Skin Hyperpigmentation|Skin Hypopigmentation|Skin Induration|Skin Infection|Skin Infiltrating Basal Cell Carcinoma|Skin Metatypical Carcinoma|Skin Micronodular Basal Cell Carcinoma|Skin Nodular Basal Cell Carcinoma|Skin Nodulo-Ulcerative Basal Cell Carcinoma|Skin Pigmented Basal Cell Carcinoma|Skin Rash|Skin Sclerosing/Morphoeic Basal Cell Carcinoma|Skin Ulceration|Skin and Subcutaneous Tissue Disorders - Other|Skin appendage adenoma|Skin appendage carcinoma|Skin appendage tumor, benign|Skin of lip, NOS|Skin of lower limb and hip|Skin of other and unspecified parts of face|Skin of scalp and neck|Skin of the Face|Skin of the Lower Limb and Hip|Skin of the Scalp and Neck|Skin of the Upper Limb and Shoulder|Skin of trunk|Skin of upper limb and shoulder|Skin, NOS|Skin, lower extremity, local|Skin, total|Skin, trunk, local|Skin, upper extremity, local|Skin-associated lymphoid tissue lymphoma|Skull|Sleep Apnea|Sleep apnea|Slide Image|Slides|Slovakia|Slovenia|Smac Mimetic GDC-0152|Smac Mimetic GDC-0917|Smac Mimetic LCL161|Small Bowel|Small Bowel - Mucosa Only|Small Cell Carcinoma|Small Cell Carcinoma, Fusiform Cell Type|Small Cell Intermediate Cell Carcinoma|Small Cell Osteosarcoma|Small Cell Sarcoma|Small Finger|Small Intestinal Anastomotic Leak|Small Intestinal Mucositis|Small Intestinal Obstruction|Small Intestinal Perforation|Small Intestinal Stenosis|Small Intestine|Small Intestine Infection|Small Intestine Ulcer|Small Lymphocytic Lymphoma|Small cell carcinoma pulmonary type|Small cell carcinoma, NOS|Small cell carcinoma, fusiform cell|Small cell carcinoma, hypercalcemic type|Small cell carcinoma, intermediate cell|Small cell neuroendocrine carcinoma|Small cell osteosarcoma|Small cell sarcoma|Small congenital nevus|Small intestine|Small intestine, NOS|Smoke|Smoke exposure, NOS|Smokehouse smoke|Smokeless Tobacco|Smoking|Smooth Muscle Neoplasm|Smooth muscle tumor of uncertain malignant potential|Smooth muscle tumor, NOS|Smoothened Antagonist BMS-833923|Smoothened Antagonist LDE225 Topical|Smoothened Antagonist LEQ506|Smoothened Antagonist TAK-441|Snap Frozen|Sneezing|Sobuzoxane|Social Circumstances - Other|Social Security Death Index|Sodium Borocaptate|Sodium Butyrate|Sodium Dichloroacetate|Sodium Fluoride|Sodium Iodide I-131|Sodium Metaarsenite|Sodium Phenylbutyrate|Sodium Salicylate|Sodium Selenite|Sodium Stibogluconate|Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108|Sofituzumab Vedotin|Soft Tissue|Soft Tissue Infection|Soft Tissue Necrosis Lower Limb|Soft Tissue Necrosis Upper Limb|Soft Tissue Perineurioma|Soft Tissue Sarcoma|Soft Tissue Tumors and Sarcomas, NOS|Soft palate, NOS|Soft tissue perineurioma|Soft tissue sarcoma|Soft tissue sarcoma, non-rhabdomyosarcoma|Soft tissue tumor, benign|Soft tissue tumor, malignant|Solid Carcinoma|Solid Papillary Breast Carcinoma|Solid Tissue|Solid Tissue Normal|Solid adenocarcinoma with mucin formation|Solid and cystic tumor|Solid and papillary epithelial neoplasm|Solid carcinoma with mucin formation|Solid carcinoma, NOS|Solid papillary carcinoma in situ|Solid papillary carcinoma with invasion|Solid pseudopapillary carcinoma|Solid pseudopapillary tumor|Solid teratoma|Solitary Fibrous Tumor|Solitary Mastocytoma of the Skin|Solitary Osseous Plasmacytoma|Solitary Plasmacytoma|Solitary Reticulohistiocytoma|Solitary fibrous tumor|Solitary fibrous tumor, malignant|Solitary fibrous tumor/hemangiopericytoma Grade 1 (CNS)|Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS)|Solitary fibrous tumor/hemangiopericytoma Grade 3 (CNS)|Solitary mastocytoma of skin|Solitary myeloma|Solitary plasmacytoma|Solitomab|Solomon Islands|Somalia|Somatic Mutation Index|Somatic Structural Variation|SomaticSniper|SomaticSniper Annotation|SomaticSniper Variant Aggregation and Masking|Somatostatin cell tumor, NOS|Somatostatin cell tumor, malignant|Somatostatin-Producing Neuroendocrine Tumor|Somatostatinoma, NOS|Somatostatinoma, malignant|Some Days|Some days|Somnolence|Son|Son-in-law|Sonepcizumab|Sonidegib|Sonolisib|Sorafenib|Sorafenib Tosylate|Sore Throat|Sorghum bicolor Supplement|Sorted Cells|Sotigalimab|Sotorasib|Sotrastaurin|Sotrastaurin Acetate|South Africa|South Korea|South Sudan|Soy Isoflavones|Soy Protein Isolate|Spain|Spanlecortemlocel|Sparfosate Sodium|Sparfosic Acid|Spartalizumab|Spasticity|Spebrutinib|Specialized Gonadal Neoplasms|Specified parts of peritoneum|Spectral counting analysis|Spermatic Cord Anastomotic Leak|Spermatic Cord Hemorrhage|Spermatic Cord Obstruction|Spermatic cord|Spermatocytic seminoma|Spermatocytoma|Sphenoid sinus|Spherical Nucleic Acid Nanoparticle NU-0129|Spinal Column|Spinal Cord|Spinal Fracture|Spinal Muscular Atrophy|Spinal cord|Spinal cord, cranial nerves, and other parts of central nervous system|Spinal meninges|Spindle Cell Hemangioma|Spindle Cell Lipoma|Spindle Cell Melanoma|Spindle Cell Oncocytoma|Spindle Cell Rhabdomyosarcoma|Spindle Cell Sarcoma|Spindle Cell Squamous Cell Carcinoma|Spindle Cell Synovial Sarcoma|Spindle cell angioendothelioma|Spindle cell carcinoma, NOS|Spindle cell hemangioendothelioma|Spindle cell lipoma|Spindle cell melanoma, NOS|Spindle cell melanoma, type A|Spindle cell melanoma, type B|Spindle cell nevus, NOS|Spindle cell oncocytoma|Spindle cell rhabdomyosarcoma|Spindle cell sarcoma|Spindle epithelial tumor with thymus-like differentiation|Spindle epithelial tumor with thymus-like element|Spindle-Cell Predominant Trichodiscoma|Spindled mesothelioma|Spine|Spiradenocarcinoma|Spiradenoma|Spiradenoma, NOS|Spirogermanium|Spiromustine|Spiroplatin|Spitz Nevus|Spitz nevus|Spleen|Spleen Cancer|Spleen Disorder|Splenic B-Cell Lymphoma/Leukemia, Unclassifiable|Splenic B-cell lymphoma/leukemia, unclassifiable|Splenic Diffuse Red Pulp Small B-Cell Lymphoma|Splenic Flexure|Splenic Infection|Splenic Marginal Zone Lymphoma|Splenic diffuse red pulp small B-cell lymphoma|Splenic flexure of colon|Splenic lymphoma with villous lymphocytes|Splenic marginal zone B-cell lymphoma|Splenic marginal zone lymphoma, NOS|Splice Junction Quantification|Splicing Inhibitor H3B-8800|Spongioblastoma multiforme|Spongioblastoma polare|Spongioblastoma, NOS|Spongioneuroblastoma|Spongistatin|Spontaneous Descent|Spontaneously Regressing Retinoblastoma|Sporadic Burkitt Lymphoma|Sporadic, adult|Sporadic, pediatric|Spouse|Sputum|Squalamine Lactate|Squamotransitional cell carcinoma|Squamous Cell Carcinoma|Squamous Cell Carcinoma In Situ with Questionable Stromal Invasion|Squamous Cell Carcinoma with Horn Formation|Squamous Cell Carcinoma, Clear Cell Type|Squamous Cell Neoplasms|Squamous Cell Papilloma|Squamous Metaplasia|Squamous Odontogenic Tumor|Squamous Papillomatosis|Squamous carcinoma|Squamous cell carcinoma in situ with questionable stromal invasion|Squamous cell carcinoma in situ, NOS|Squamous cell carcinoma with horn formation|Squamous cell carcinoma, HPV-negative|Squamous cell carcinoma, HPV-positive|Squamous cell carcinoma, NOS|Squamous cell carcinoma, acantholytic|Squamous cell carcinoma, adenoid|Squamous cell carcinoma, clear cell type|Squamous cell carcinoma, keratinizing, NOS|Squamous cell carcinoma, large cell, keratinizing|Squamous cell carcinoma, large cell, nonkeratinizing, NOS|Squamous cell carcinoma, metastatic, NOS|Squamous cell carcinoma, microinvasive|Squamous cell carcinoma, nonkeratinizing, NOS|Squamous cell carcinoma, pseudoglandular|Squamous cell carcinoma, sarcomatoid|Squamous cell carcinoma, small cell, nonkeratinizing|Squamous cell carcinoma, spindle cell|Squamous cell epithelioma|Squamous cell papilloma, NOS|Squamous cell papilloma, inverted|Squamous intraepithelial neoplasia, grade I|Squamous intraepithelial neoplasia, grade II|Squamous intraepithelial neoplasia, grade III|Squamous intraepithelial neoplasia, high grade|Squamous intraepithelial neoplasia, low grade|Squamous odontogenic tumor|Squamous papilloma|Squamous papillomatosis|Src Kinase Inhibitor AP 23846|Src Kinase Inhibitor KX2-391|Src Kinase Inhibitor KX2-391 Ointment|Src Kinase Inhibitor M475271|Src/Abl Kinase Inhibitor AZD0424|Src/tubulin Inhibitor KX02|Sri Lanka|St. John's Wort|Stable Disease|Stage 0|Stage 0 Cervical Cancer AJCC v6|Stage 0 Cutaneous Melanoma AJCC v6 and v7|Stage 0 Squamous Cell Carcinoma|Stage 0 Transitional Cell Carcinoma|Stage 0 Vaginal Cancer AJCC v6|Stage 0 Vaginal Cancer AJCC v7|Stage 0 Vulvar Cancer AJCC v6|Stage 0a|Stage 0is|Stage 1|Stage 2A|Stage 2B|Stage 3|Stage 4|Stage 4S|Stage I|Stage IA|Stage IA1|Stage IA2|Stage IA3|Stage IB|Stage IB Cervix|Stage IB1|Stage IB2|Stage IC|Stage IC1|Stage IC2|Stage IC3|Stage II|Stage II Cervix|Stage IIA|Stage IIA Cervix|Stage IIA1|Stage IIA2|Stage IIB|Stage IIC|Stage IIC1|Stage III|Stage IIIA|Stage IIIA1|Stage IIIA2|Stage IIIAi|Stage IIIAii|Stage IIIB|Stage IIIC|Stage IIIC1|Stage IIIC2|Stage IIID|Stage IIa|Stage IIb|Stage IS|Stage IV|Stage IVA|Stage IVB|Stage IVC|Stage IVa|Stage IVb|Stage Is|Stage R1|Stage R2|Stage Tis|Stage X|Stallimycin|Staphylococcal Enterotoxin A|Staphylococcal Enterotoxin B|Staphylococcus aureus|State of Palestine|Staurosporine|Steatosis|Stem Cell Transplantation, Allogeneic|Stem Cell Transplantation, Autologous|Stem Cell Transplantation, Double Autologous|Stem Cell Transplantation, Haploidentical|Stem Cell Transplantation, NOS|Stem Cell Transplantation, Non-Myeloablative|Stem Cell Transplantation, Syngenic|Stem Cell Treatment|Stem cell leukemia|Stenosis of Gastrointestinal Stoma|Step Child|Step Sibling|Stepbrother|Stepdaughter|Stepfather|Stepmother|Stepsister|Stepson|Stereotactic Radiosurgery|Sternum|Steroid Therapy|Steroid cell tumor, NOS|Steroid cell tumor, malignant|Stevens-Johnson Syndrome|Stillbirth|Stoma Site Infection|Stomach|Stomach - Mucosa Only|Stomach Adenocarcinoma|Stomach Pain|Stomach, NOS|Stomal Ulcer|Strelka2 RNA|Streptonigrin|Streptozocin|Stridor|Stroke|Stromal Neoplasm|Stromal Sarcoma|Stromal endometriosis|Stromal myosis, NOS|Stromal sarcoma, NOS|Stromal tumor with minor sex cord elements|Stromal tumor, NOS|Stromal tumor, benign|Strontium Chloride Sr-89|Structural Alteration|Structural Rearrangement|Structural Variation|Struma Ovarii|Struma ovarii and carcinoid|Struma ovarii, NOS|Struma ovarii, malignant|Strumal Carcinoid|Strumal carcinoid|Study Enrollment|Subacute granulocytic leukemia|Subacute leukemia, NOS|Subacute lymphatic leukemia|Subacute lymphocytic leukemia|Subacute lymphoid leukemia|Subacute monocytic leukemia|Subacute myelogenous leukemia|Subacute myeloid leukemia|Subareolar duct papillomatosis|Subcutaneous Panniculitis-Like T-Cell Lymphoma|Subcutaneous Tissue|Subcutaneous panniculitis-like T-cell lymphoma|Subependymal Giant Cell Astrocytoma|Subependymal astrocytoma, NOS|Subependymal giant cell astrocytoma|Subependymal glioma|Subependymoma|Subepidermal Nodular Fibrosis|Subepidermal nodular fibrosis|Subglottis|Subject identity unknown|Subject withdrew consent|Sublingual Gland|Sublingual gland|Submandibular Gland|Submandibular gland|Submicron Particle Paclitaxel Sterile Suspension|Subtotal Prostatectomy|Subtotal Resection|Succinate Dehydrogenase-Deficient Renal Cell Carcinoma|Sudan|Sudden Death NOS|Sugemalimab|Suicidal Ideation|Suicide Attempt|Sulfatinib|Sulfonylurea|Sulforaphane|Sulindac|Sulofenur|Sumoylation Inhibitor TAK-981|Sunitinib|Sunitinib Malate|Super Enhancer Inhibitor GZ17-6.02|Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803|Superficial Multifocal Basal Cell Carcinoma|Superficial Parotidectomy|Superficial Soft Tissue Fibrosis|Superficial Spreading Adenocarcinoma|Superficial Thrombophlebitis|Superficial spreading adenocarcinoma|Superficial spreading melanoma|Superficial well differentiated liposarcoma|Superior Vena Cava Syndrome|Superior Wall of the Nasopharynx|Superior wall of nasopharynx|Superoxide Dismutase Mimetic GC4711|Supplementary Files|Supracervical Hysterectomy|Supracricoid Laryngectomy|Supraglottic Laryngectomy|Supraglottis|Supratentorial Embryonal Tumor, Not Otherwise Specified|Supratentorial PNET|Supraventricular Tachycardia|Suramin|Suramin Sodium|Surgery|Surgical Complication|Surgical Complications|Surgical Resection|Surgical and Medical Procedures - Other|Surgically Treated|Suriname|Surveyor PDA|Survivin Antigen|Survivin Antigen Vaccine DPX-Survivac|Survivin mRNA Antagonist EZN-3042|Survivin-expressing CVD908ssb-TXSVN Vaccine|Sus scrofa|Sustained-release Lipid Inhaled Cisplatin|Sustained-release Mitomycin C Hydrogel Formulation UGN-101|Sustained-release Mitomycin C Hydrogel Formulation UGN-102|Svalbard & Jan Mayen Islands|Svalbard and Jan Mayen|Sweat Gland Adenoma|Sweat Gland Carcinoma|Sweat Gland Neoplasm|Sweat gland adenocarcinoma|Sweat gland adenoma|Sweat gland carcinoma|Sweat gland tumor, NOS|Sweat gland tumor, benign|Sweat gland tumor, malignant|Sweden|Switzerland|Syk Inhibitor HMPL-523|SymBiot I|SymBiot XVI|Sympathetic Paraganglioma|Sympathetic paraganglioma|Sympathicoblastoma|Symplastic leiomyoma|Synapt G2 HDMS|Synapt G2 MS|Synapt G2-S HDMS|Synapt G2-S MS|Synapt HDMS|Synapt MS|Synchronous malignancy|Synchrotope TA2M Plasmid DNA Vaccine|Synchrovax SEM Plasmid DNA Vaccine|Syncope|Syncytial meningioma|Synovial Sarcoma|Synovial sarcoma, NOS|Synovial sarcoma, biphasic|Synovial sarcoma, epithelioid cell|Synovial sarcoma, monophasic fibrous|Synovial sarcoma, spindle cell|Synovial-like Neoplasms|Synovioma, NOS|Synovioma, benign|Synovioma, malignant|Synovium|Synthetic Alkaloid PM00104|Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2|Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1|Synthetic Hypericin|Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201|Synthetic Long E6/E7 Peptides Vaccine HPV-01|Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b|Synthetic Plumbagin PCUR-101|Synthetic hTERT DNA Vaccine INO-1400|Synthetic hTERT DNA Vaccine INO-1401|Syphilis|Syria|Syringadenoma, NOS|Syringocystadenoma Papilliferum|Syringocystadenoma papilliferum|Syringofibroadenoma|Syringoma|Syringoma, NOS|Syringomatous carcinoma|Systemic EBV positive T-cell lymphoproliferative disease of childhood|Systemic EBV-Positive T-Cell Lymphoma of Childhood|Systemic Mastocytosis|Systemic Mastocytosis with an Associated Hematological Neoplasm|Systemic light chain disease|Systemic mastocytosis with AHNMD|Systemic mastocytosis with associated hematological clonal non-mast cell disorder|Systemic tissue mast cell disease|T|T Acute Lymphoblastic Leukemia|T Lymphoblastic Leukemia/Lymphoma|T Lymphoblastic Lymphoma|T lymphoblastic leukemia/lymphoma|T-Cell Large Granular Lymphocyte Leukemia|T-Cell Non-Hodgkin Lymphoma|T-Cell Prolymphocytic Leukemia|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|T-Zone Variant Peripheral T-Cell Lymphoma|T-cell large granular lymphocytic leukemia|T-cell large granular lymphocytosis|T-cell lymphoma, NOS|T-cell rich large B-cell lymphoma|T-cell rich/histiocyte-rich large B-cell lymphoma|T-gamma lymphoproliferative disease|T-zone lymphoma|T/NK-cell lymphoma|T0|T0 Stage Finding|T1|T1 Stage Finding|T1a|T1a Stage Finding|T1a1|T1a2|T1b|T1b Stage Finding|T1b1|T1b2|T1c|T1c Stage Finding|T1mi|T1mi Stage Finding|T2|T2 Stage Finding|T2a|T2a Stage Finding|T2a1|T2a2|T2b|T2b Stage Finding|T2c|T2c Stage Finding|T2d|T2d Stage Finding|T3|T3 Stage Finding|T3a|T3a Stage Finding|T3b|T3b Stage Finding|T3c|T3c Stage Finding|T3d|T3d Stage Finding|T4|T4 Stage Finding|T4a|T4a Stage Finding|T4b|T4b Stage Finding|T4c|T4c Stage Finding|T4d|T4d Stage Finding|T4e|T900607|TAM/c-Met Inhibitor RXDX-106|TARGET DCC Archive|TARGZ|TBI|TCGA DCC Archive|TE-Too Early|TF-Tumor Free|TGF-beta Receptor 1 Inhibitor PF-06952229|TGF-beta Receptor 1 Kinase Inhibitor SH3051|TGF-beta Receptor 1 Kinase Inhibitor YL-13027|TGFa-PE38 Immunotoxin|TGFbeta Inhibitor LY3200882|TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein AVID200|THL-P|TIFF|TIGIT Inhibitor M6223|TIGIT-targeting Agent MK-7684|TLC ELL-12|TLR Agonist BDB001|TLR Agonist BSG-001|TLR Agonist CADI-05|TLR-Directed Cationic Lipid-DNA Complex JVRS-100|TLR7 Agonist 852A|TLR7 Agonist LHC165|TLR7 agonist BNT411|TLR7/8/9 Antagonist IMO-8400|TLR8 Agonist DN1508052|TLR9 Agonist AST-008|TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells|TMT|TMT10|TMT11|TMT6|TORC1/2 Kinase Inhibitor DS-3078a|TP40 Immunotoxin|TRAIL Receptor Agonist ABBV-621|TRIZAIC UPLC nanoTile|TRK Inhibitor AZD6918|TRK Inhibitor TQB3558|TRPM8 Agonist D-3263|TRPV6 Calcium Channel Inhibitor SOR-C13|TSP-1 Mimetic ABT-510|TSP-1 Mimetic Fusion Protein CVX-045|TSQ 8000 Evo|TSQ 9000|TSQ Altis|TSQ Endura|TSQ Quantis|TSQ Quantiva|TSQ Quantum|TSQ Quantum Access|TSQ Quantum Ultra|TSQ Quantum Ultra AM|TSQ Vantage|TSV|TX|TX Stage Finding|TXT|Ta|Ta Stage Finding|Tabalumab|Tabelecleucel|Tacedinaline|Tafasitamab|Tag|Tagraxofusp-erzs|Tail of pancreas|Taiwan|Tajikistan|Takifugu rubripes|Talabostat|Talabostat Mesylate|Talacotuzumab|Talactoferrin Alfa|Taladegib|Talampanel|Talaporfin Sodium|Talazoparib|Taletrectinib|Talimogene Laherparepvec|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Tallimustine|Talmapimod|Talotrexin|Talotrexin Ammonium|Taltobulin|Tamibarotene|Taminadenant|Tamoxifen|Tamoxifen Citrate|Tamrintamab Pamozirine|Tandutinib|Tanespimycin|Tanibirumab|Tankyrase Inhibitor STP1002|Tanomastat|Tanycytic Ependymoma|Tanycytic ependymoma|Tanzania|Tapotoclax|Tarenflurbil|Tarextumab|Targeted Molecular Therapy|Tariquidar|Tasadenoturev|Taselisib|Tasidotin|Tasisulam|Tasisulam Sodium|Tasquinimod|Tattoo|Taurolidine|Tauromustine|Taurultam|Taurultam Analogue GP-2250|Tavokinogene Telseplasmid|Tavolimab|Taxane Analogue TPI 287|Taxane Compound|Taxol Analogue SID 530|Tazarotene|Tazemetostat|Tebentafusp|Teclistamab|Tecogalan Sodium|Tefinostat|Tegafur|Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation|Tegafur-Uracil|Tegafur-gimeracil-oteracil Potassium|Tegavivint|Teglarinad|Teglarinad Chloride|Telaglenastat|Telaglenastat Hydrochloride|Telangiectasia|Telangiectatic Osteosarcoma|Telangiectatic osteosarcoma|Telapristone|Telapristone Acetate|Telatinib Mesylate|Telisotuzumab|Telisotuzumab Vedotin|Telomerase Inhibitor FJ5002|Telomerase-specific Type 5 Adenovirus OBP-301|Teloxantrone|Teloxantrone Hydrochloride|Telratolimod|Temarotene|Temoporfin|Temozolomide|Temporal Cortex|Temporal Lobe|Temporal lobe|Temsirolimus|Tenalisib|Tendon|Tenifatecan|Teniposide|Tenosynovial Giant Cell Tumor|Tenosynovial giant cell tumor|Tepoditamab|Tepotinib|Teprotumumab|Terameprocol|Teratoblastoma, malignant|Teratocarcinoma|Teratoid medulloepithelioma|Teratoid medulloepithelioma, benign|Teratoma|Teratoma with Somatic-Type Malignancy|Teratoma with malignant transformation|Teratoma, NOS|Teratoma, benign|Teratoma, differentiated|Teratoma, malignant, NOS|Terfluranol|Tergenpumatucel-L|Terminal duct adenocarcinoma|Teroxirone|Tertomotide|Tesetaxel|Tesevatinib|Tesidolumab|Testicular Cancer|Testicular Disorder|Testicular Germ Cell Tumors|Testicular Hemorrhage|Testicular Mixed Germ Cell-Sex Cord-Stromal Tumor, Unclassified|Testicular Pain|Testicular Seminoma with High Mitotic Index|Testicular Spermatocytic Tumor|Testicular adenoma|Testicular stromal tumor|Testis|Testis Removed|Testis, NOS|Testolactone|Testosterone Enanthate|Tetanus Toxoid Vaccine|Tetradecanoylphorbol Acetate|Tetrahydrouridine|Tetraphenyl Chlorin Disulfonate|Tetrathiomolybdate|Tezacitabine|Tezacitabine Anhydrous|Thailand|Thalicarpine|Thalidomide|Theca cell tumor|Theca cell-granulosa cell tumor|Thecoma|Thecoma, NOS|Thecoma, luteinized|Thecoma, malignant|Theliatinib|Theramide|Therapeutic Angiotensin-(1-7)|Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907|Therapeutic Cancer Vaccine ATP128|Therapeutic Estradiol|Therapeutic Hydrocortisone|Therapeutic Liver Cancer Peptide Vaccine IMA970A|Therapy related myeloid neoplasm|Therapy-Related Acute Myeloid Leukemia|Therapy-Related Myelodysplastic Syndrome|Therapy-Related Myeloid Neoplasm|Therapy-related acute myeloid leukemia, NOS|Therapy-related acute myeloid leukemia, alkylating agent related|Therapy-related acute myeloid leukemia, epipodophyllotoxin-related|Therapy-related myelodysplastic syndrome, NOS|Therapy-related myelodysplastic syndrome, alkylating agent related|Therapy-related myelodysplastic syndrome, epipodophyllotoxin-related|Thermo Fisher Scientific|Thermo Orbitrap Fusion Lumos|Thermo Orbitrap Q Exactive HF-X|Thiarabine|Thiazolidinedione|Thigh|Thiodiglycol|Thioguanine|Thioguanine Anhydrous|Thioinosine|Thioredoxin-1 Inhibitor PX-12|Thiotepa|Thioureidobutyronitrile|Thoracentesis|Thoracic Esophagus|Thoracic Spine|Thoracic esophagus|Thoracoscopic Biopsy|Thorax|Thorax, NOS|Thorium Th 227 Anetumab|Thorium Th 227 Anetumab Corixetan|Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439|Thorium Th 227 Anti-PSMA Monoclonal Antibody BAY 2315497|Three Times Daily|Threonine Tyrosine Kinase Inhibitor CFI-402257|Throat|Throat Cancer|Thromboembolic Event|Thrombotic Thrombocytopenic Purpura|Thumb|Thymic Carcinoma|Thymic Epithelial Neoplasms|Thymic carcinoma with adenoid cystic carcinoma-like features|Thymic carcinoma, NOS|Thymic large B-cell lymphoma|Thymidylate Synthase Inhibitor CX1106|Thymidylate Synthase Inhibitor DFP-11207|Thymoma|Thymoma Type A|Thymoma Type AB|Thymoma Type B1|Thymoma Type B2|Thymoma Type B3|Thymoma, NOS|Thymoma, atypical, NOS|Thymoma, atypical, malignant|Thymoma, benign|Thymoma, cortical, NOS|Thymoma, cortical, malignant|Thymoma, epithelial, NOS|Thymoma, epithelial, malignant|Thymoma, lymphocyte-rich, NOS|Thymoma, lymphocyte-rich, malignant|Thymoma, lymphocytic, NOS|Thymoma, lymphocytic, malignant|Thymoma, malignant, NOS|Thymoma, medullary, NOS|Thymoma, medullary, malignant|Thymoma, mixed type, NOS|Thymoma, mixed type, malignant|Thymoma, organoid, NOS|Thymoma, organoid, malignant|Thymoma, predominantly cortical, NOS|Thymoma, predominantly cortical, malignant|Thymoma, spindle cell, NOS|Thymoma, spindle cell, malignant|Thymoma, type A, NOS|Thymoma, type A, malignant|Thymoma, type AB, NOS|Thymoma, type AB, malignant|Thymoma, type B1, NOS|Thymoma, type B1, malignant|Thymoma, type B2, NOS|Thymoma, type B2, malignant|Thymoma, type B3, NOS|Thymoma, type B3, malignant|Thymoma, type C|Thymopentin|Thymus|Thyroid|Thyroid Cancer|Thyroid Carcinoma|Thyroid Extract|Thyroid Gland|Thyroid Gland Follicular Adenoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Follicular Carcinoma, Encapsulated Angioinvasive|Thyroid Gland Hurthle (Oncocytic) Cell Neoplasm|Thyroid Gland Hurthle Cell Adenoma|Thyroid Gland Hyalinizing Trabecular Tumor|Thyroid Gland Macrofollicular Adenoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Medullary Carcinoma with Amyloid Stroma|Thyroid Gland Microfollicular Adenoma|Thyroid Gland Noninvasive Follicular Neoplasm with Papillary-Like Nuclear Features|Thyroid Gland Papillary Carcinoma|Thyroid Gland Papillary and Follicular Carcinoma|Thyroid Gland Spindle Cell Tumor with Thymus-Like Differentiation|Thyroid Gland Well-Differentiated Tumor of Uncertain Malignant Potential|Thyroid Nodular Hyperplasia|Thyroid gland|Tiazofurin|Tibia|Tibial Adamantinoma|Tibial adamantinoma|Tidutamab|Tigapotide|Tigatuzumab|Tilarginine|Tilogotamab|Tilsotolimod Sodium|Time Between Waking and First Smoke - After 60 Minutes|Time Between Waking and First Smoke - Between 31 and 60 Minutes|Time Between Waking and First Smoke - Between 6 and 30 Minutes|Time Between Waking and First Smoke - Within 5 Minutes|Timonacic|Timor-Leste|Tin Ethyl Etiopurpurin|Tinnitus|Tinostamustine|Tinzaparin Sodium|Tiomolibdate Choline|Tiomolibdate Diammonium|Tipapkinogene Sovacivec|Tipifarnib|Tipiracil|Tipiracil Hydrochloride|Tirabrutinib|Tiragolumab|Tirapazamine|Tirbanibulin|Tis|Tis (DCIS)|Tis (LCIS)|Tis (Paget's)|Tis Stage Finding|Tisagenlecleucel|Tislelizumab|Tisotumab Vedotin|Tissue Microarray Image|Tissue Slide|Tivantinib|Tivozanib|Tobacco|Tobacco smoke, NOS|Tobacco smoke, cigar|Tobacco smoke, cigarettes|Tobacco smoke, pipe|Tobacco, NOS|Tobacco, Smokeless|Tobacco, Smoking|Tocilizumab|Tocladesine|Tocotrienol|Tocotrienol-rich Fraction|TofSpec|TofSpec 2E|TofSpec E|TofSpec SE|Togo|Tokelau|Tolebrutinib|Toll-like Receptor 7 Agonist DSP-0509|Tolnidamine|Tomaralimab|Tomato-Soy Juice|Tomivosertib|Tonga|Tongue|Tongue Cancer|Tongue, NOS|Tonsil|Tonsil (Pharyngeal)|Tonsil, NOS|Tonsillar Cancer|Tonsillar Fossa|Tonsillar fossa|Tonsillar pillar|Tonsillectomy|Tooth Development Disorder|Tooth Discoloration|Tooth Infection|Toothache|Topical Betulinic Acid|Topical Celecoxib|Topical Fluorouracil|Topical Gemcitabine Hydrochloride|Topical Potassium Dobesilate|Topical Trichloroacetic Acid|Topixantrone|Topoisomerase I Inhibitor Genz-644282|Topoisomerase I Inhibitor LMP400|Topoisomerase I Inhibitor LMP776|Topoisomerase I/II Inhibitor NEV-801|Topoisomerase-1 Inhibitor LMP744|Topoisomerase-II Inhibitor Racemic XK469|Topoisomerase-II-beta Inhibitor Racemic XK469|Topotecan|Topotecan Hydrochloride|Topotecan Hydrochloride Liposomes|Topotecan Sustained-release Episcleral Plaque|Topsalysin|Toremifene|Toremifene Citrate|Toripalimab|Tosedostat|Tositumomab|Total Androgen Blockade|Total Colectomy|Total Hepatectomy|Total Laryngectomy|Total Mastectomy|Total Nephrectomy|Total RNA|Total RNA-Seq|Tovetumab|Toxic Epidermal Necrolysis|Toxicity|Toxoplasmosis|Tozasertib Lactate|Trabectedin|Trabecular Adenocarcinoma|Trabecular Adenoma|Trabecular adenocarcinoma|Trabecular adenoma|Trabecular carcinoma|Trabedersen|Trachea|Trachea / Major Bronchi|Tracheal Fistula|Tracheal Hemorrhage|Tracheal Mucositis|Tracheal Obstruction|Tracheal Stenosis|Tracheitis|Tracheostomy Site Bleeding|Traditional Serrated Adenoma|Traditional serrated adenoma|Traditional sessile serrated adenoma|Trametinib|Trametinib Dimethyl Sulfoxide|Trans Sodium Crocetinate|Transcript Fusion|Transcriptome Profiling|Transdermal 17beta-Estradiol Gel BHR-200|Transdermal 4-Hydroxytestosterone|Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01|Transferrin Receptor-Targeted Liposomal p53 cDNA|Transferrin-CRM107|Transfusion Recipient|Transient Abnormal Myelopoiesis Associated with Down Syndrome|Transient Ischemic Attack|Transient Ischemic Attacks|Transient abnormal myelopoiesis|Transitional Cell Carcinoma|Transitional Cell Papilloma|Transitional Cell Papillomas and Carcinomas|Transitional Meningioma|Transitional carcinoma|Transitional cell carcinoma|Transitional cell carcinoma in situ|Transitional cell carcinoma, micropapillary|Transitional cell carcinoma, sarcomatoid|Transitional cell carcinoma, spindle cell|Transitional cell papilloma, NOS|Transitional cell papilloma, benign|Transitional cell papilloma, inverted, NOS|Transitional cell papilloma, inverted, benign|Transitional meningioma|Transitional papilloma|Transitional papilloma, inverted, NOS|Transitional papilloma, inverted, benign|Transitional pineal tumor|Transoral Laser Excision|Transplant|Transurethral Resection (TURP)|Transurethral resection (TURBT)|Transverse Colectomy|Transverse Colon|Transverse colon|Tranylcypromine Sulfate|Trapoxin|Trastuzumab|Trastuzumab Conjugate BI-CON-02|Trastuzumab Deruxtecan|Trastuzumab Duocarmazine|Trastuzumab Emtansine|Trastuzumab Monomethyl Auristatin F|Trastuzumab-TLR 7/8 Agonist BDC-1001|Trastuzumab/Hyaluronidase-oysk|Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502|Treatment Ongoing|Treatment Related Secondary Malignancy|Treatment Stopped Due to Toxicity|Trebananib|Tremelimumab|Tremor|Treosulfan|Treponema pallidum|Tretazicar|Tretinoin|Tretinoin Liposome|Triamcinolone Acetonide|Triamcinolone Hexacetonide|Triapine|Triazene Derivative CB10-277|Triazene Derivative TriN2755|Triazinate|Triaziquone|Tributyrin|Trichilemmal Carcinoma|Trichilemmal carcinoma|Trichilemmocarcinoma|Trichilemmoma|Trichoblastoma|Trichodiscoma|Trichoepithelioma|Trichofolliculoma|Trichomonas vaginalis|Triciribine Phosphate|Tricuspid Valve Disease|Trientine Hydrochloride|Triethylenemelamine|Trifluridine|Trifluridine and Tipiracil Hydrochloride|Trigeminal Nerve Disorder|Trigone of bladder|Trigriluzole|Trilaciclib|Trimelamol|Trimeric GITRL-Fc OMP-336B11|Trimethylcolchicinic Acid|Trimetrexate|Trimetrexate Glucuronate|Trinidad and Tobago|Trioxifene|Triplatin Tetranitrate|Triple Quad 3500|Triple Quad 4500|Triple Quad 5500|Triple Quad 6500|Triple Quad 6500+|TripleTOF 4600|TripleTOF 5600|TripleTOF 5600+|TripleTOF 6600|Triptolide Analog|Triptorelin|Triptorelin Pamoate|Tris-acryl Gelatin Microspheres|Trismus|Triton tumor, malignant|Tritylcysteine|TrkA Inhibitor VMD-928|Trodusquemine|Trofosfamide|Troglitazone|Trophoblastic neoplasms|Trophoblastic tumor, epithelioid|Tropomyosin Receptor Kinase Inhibitor AZD7451|Troriluzole|Troxacitabine|Troxacitabine Nucleotide Prodrug MIV-818|TruTOF|True|True Histiocytic Lymphoma|True histiocytic lymphoma|Trunk|TrypChymo|Trypsin|Trypsin/P|Tubercidin|Tuberculosis|Tuberous Sclerosis|Tubular Adenocarcinoma|Tubular Adenoma|Tubular adenocarcinoma|Tubular adenoma, NOS|Tubular androblastoma with lipid storage|Tubular androblastoma, NOS|Tubular carcinoid|Tubular carcinoma|Tubulin Binding Agent TTI-237|Tubulin Inhibitor ALB 109564 Dihydrochloride|Tubulin Inhibitor ALB-109564|Tubulin Polymerization Inhibitor AEZS 112|Tubulin Polymerization Inhibitor CKD-516|Tubulin Polymerization Inhibitor VERU-111|Tubulin-Binding Agent SSR97225|Tubulo-papillary adenoma|Tubulocystic Renal Cell Carcinoma|Tubulocystic renal cell carcinoma|Tubulointerstitial Disease|Tubulolobular carcinoma|Tubulopapillary adenocarcinoma|Tubulovillous Adenoma|Tubulovillous adenoma, NOS|Tucatinib|Tucidinostat|Tucotuzumab Celmoleukin|Tumor|Tumor Adjacent Normal - Post Neo-adjuvant Therapy|Tumor Debulking|Tumor Embolism|Tumor Free|Tumor Lysis Syndrome|Tumor Pain|Tumor Resection|Tumor cells, NOS|Tumor cells, benign|Tumor cells, malignant|Tumor cells, uncertain whether benign or malignant|Tumor class but appears normal|Tumor embolus|Tumor free|Tumor tissue origin incorrect|Tumor type incorrect|Tumor, NOS|Tumor, benign|Tumor, malignant, NOS|Tumor, metastatic|Tumor, secondary|Tumor-associated Lymphoid Proliferation|Tumorlet|Tumorlet, NOS|Tumorlet, benign|Tunisia|Turban Tumor|Turban tumor|Turcot Syndrome|Turkey|Turkmenistan|Tuvalu|Twice Daily|Twice Weekly|Twin Sibling|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma|Type A Spindle Cell Melanoma|Type B Spindle Cell Melanoma|Typhlitis|Typical carcinoid|Tyroserleutide|Tyrosinase Peptide|Tyrosinase-KLH|Tyrosinase:146-156 Peptide|Tyrosine Kinase Inhibitor|Tyrosine Kinase Inhibitor OSI-930|Tyrosine Kinase Inhibitor SU5402|Tyrosine Kinase Inhibitor TL-895|Tyrosine Kinase Inhibitor XL228|Tyrosinemia|UAE Inhibitor TAK-243|UHPLC|USP14/UCHL5 Inhibitor VLX1570|Ubenimex|Ubidecarenone Nanodispersion BPM31510n|Ubiquitylome|Ublituximab|Uganda|Ukraine|Ulcerative Colitis|Ulinastatin|Ulixertinib|Ulocuplumab|Ultrasound Guided Biopsy|Ultrasound-Guided Biopsy|Umbilical Cord|Umbralisib|Unaligned Reads|Uncaria tomentosa Extract|Unclassified Testicular Sex Cord-Stromal Tumor|Unclassified tumor, benign|Unclassified tumor, borderline malignancy|Unclassified tumor, malignant|Unclassified tumor, malignant, uncertain whether primary or metastatic|Unclassified tumor, uncertain whether benign or malignant|Uncle|Undescended Testis|Undescended testis|Undifferentiated|Undifferentiated (Embryonal) Sarcoma|Undifferentiated Carcinoma|Undifferentiated Epithelioid Sarcoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone|Undifferentiated Neuroblastoma|Undifferentiated Pleomorphic Sarcoma|Undifferentiated Pleomorphic Sarcoma with Osteoclast-Like Giant Cells|Undifferentiated Retinoblastoma|Undifferentiated Round Cell Sarcoma|Undifferentiated Sarcoma, Not Otherwise Specified|Undifferentiated Spindle Cell Sarcoma|Undifferentiated epithelioid sarcoma|Undifferentiated high-grade pleomorphic sarcoma|Undifferentiated leukaemia|Undifferentiated pleomorphic sarcoma|Undifferentiated round cell sarcoma|Undifferentiated sarcoma|Undifferentiated spindle cell sarcoma|Undifferentiated uterine sarcoma|Unequal Limb Length|Unfavorable|Unifocal|Unilateral|Unintended Pregnancy|United Arab Emirates|United Kingdom|United States|Unknown Tumor Status|Unknown primary site|Unknown tumor status|Unpaired_LogR|Unrelated|Unsatisfactory|Unspecific cleavage|Unspecified|Upamostat|Upifitamab|Upper Gastrointestinal Hemorrhage|Upper Gingiva|Upper Gum|Upper Respiratory Infection|Upper gum|Upper limb, NOS|Upper lobe, lung|Upper respiratory tract, NOS|Upper third of esophagus|Upper-inner quadrant of breast|Upper-outer quadrant of breast|Uproleselan|Uprosertib|Urabrelimab|Urachal carcinoma|Urachus|Uracil Ointment|Urelumab|Ureter|Ureteric Anastomotic Leak|Ureteric Orifice|Ureteric orifice|Urethra|Urethral Anastomotic Leak|Urethral Infection|Urinary Fistula|Urinary Frequency|Urinary Incontinence|Urinary Retention|Urinary System|Urinary Tract|Urinary Tract Infection|Urinary Tract Obstruction|Urinary Tract Pain|Urinary Urgency|Urinary system, NOS|Urine Discoloration|Urine Output Decreased|Uroacitides|Urokinase-Derived Peptide A6|Urostomy Leak|Urostomy Obstruction|Urostomy Site Bleeding|Urostomy Stenosis|Urothelial Carcinoma|Urothelial Papilloma|Urothelial carcinoma in situ|Urothelial carcinoma with divergent differentiation|Urothelial carcinoma with squamous differentiation|Urothelial carcinoma with trophoblastic differentiation|Urothelial carcinoma, NOS|Urothelial papilloma, NOS|Ursolic Acid|Urticaria|Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis|Urticaria pigmentosa|Uruguay|Uterine Adnexa|Uterine Anastomotic Leak|Uterine Cancer|Uterine Carcinosarcoma|Uterine Corpus Endometrial Carcinoma|Uterine Corpus Leiomyoma|Uterine Corpus Undifferentiated Sarcoma|Uterine Fistula|Uterine Hemorrhage|Uterine Infection|Uterine Obstruction|Uterine Pain|Uterine Perforation|Uterine adnexa|Uterus|Uterus, NOS|Utomilumab|Uveal Melanoma|Uveitis|Uvula|Uzansertib|Uzbekistan|V8-DE|V8-E|V930 Vaccine|VAIN III|VCF|VCF LiftOver|VEGF Inhibitor PTC299|VEGF/HGF-targeting DARPin MP0250|VEGFR Inhibitor KRN951|VEGFR-2 DNA Vaccine VXM01|VEGFR/FGFR Inhibitor ODM-203|VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593|VEGFR2 Tyrosine Kinase Inhibitor PF-00337210|VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813|VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220|VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820|VGPR-Very Good Partial Response|VIN III|VIP-Producing Neuroendocrine Tumor|VLP-encapsulated TLR9 Agonist CMP-001|Vaccine-Sensitized Draining Lymph Node Cells|Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules|Vactosertib|Vadacabtagene Leraleucel|Vadastuximab Talirine|Vadimezan|Vagina|Vagina, NOS|Vaginal Anastomotic Leak|Vaginal Discharge|Vaginal Dryness|Vaginal Fistula|Vaginal Hemorrhage|Vaginal Infection|Vaginal Inflammation|Vaginal Obstruction|Vaginal Pain|Vaginal Perforation|Vaginal Stricture|Vaginal intraepithelial neoplasia, grade III|Vaginismus|Vagus Nerve Disorder|Valecobulin|Valemetostat|Validation|Vallecula|Valproic Acid|Valrubicin|Valspodar|Vandetanib|Vandetanib-eluting Radiopaque Bead BTG-002814|Vandortuzumab Vedotin|Vantictumab|Vanuatu|Vanucizumab|Vapreotide|VarScan2|VarScan2 Annotation|VarScan2 Variant Aggregation and Masking|Varian|Varicella Zoster Virus|Varlilumab|Varlitinib|Varlitinib Tosylate|Vas Deferens|Vas Deferens Anastomotic Leak|Vascular Access Complication|Vascular Disease|Vascular Disorders - Other|Vascular Disrupting Agent BNC105|Vascular Disrupting Agent BNC105P|Vascular Disrupting Agent ZD6126|Vascular leiomyoma|Vasculitis|Vasovagal Reaction|Vatalanib|Vatalanib Succinate|Vecabrutinib|Vector-peptide Conjugated Paclitaxel|Vedolizumab|Vein|Veliparib|Velos Plus|Veltuzumab|Vemurafenib|Venetoclax|Venezuela|Venous|Venous Hemangioma|Venous Injury|Venous hemangioma|Ventral surface of tongue, NOS|Ventricle, NOS|Ventricular Arrhythmia|Ventricular Fibrillation|Ventricular Tachycardia|Verapamil|Verpasep Caltespen|Verrucous Carcinoma|Verrucous Hemangioma|Verrucous Papilloma|Verrucous carcinoma, NOS|Verrucous epidermoid carcinoma|Verrucous keratotic hemangioma|Verrucous papilloma|Verrucous squamous cell carcinoma|Vertebra|Vertebral Canal|Vertebral column|Vertical Hemilaryngectomy|Vertigo|Verubulin|Verubulin Hydrochloride|Very Good Partial Response|Vesencumab|Vesigenurtucel-L|Vestibular Disorder|Vestibule of Mouth|Vestibule of mouth|Viagenpumatucel-L|Vibecotamab|Vibostolimab|Vietnam|Vilaprisan|Villoglandular Endometrial Endometrioid Adenocarcinoma|Villoglandular adenoma|Villoglandular carcinoma|Villous Adenocarcinoma|Villous Adenoma|Villous adenocarcinoma|Villous adenoma, NOS|Villous papilloma|Vinblastine|Vinblastine Sulfate|Vincristine|Vincristine Liposomal|Vincristine Sulfate|Vincristine Sulfate Liposome|Vindesine|Vinepidine|Vinflunine|Vinflunine Ditartrate|Vinfosiltine|Vinorelbine|Vinorelbine Tartrate|Vinorelbine Tartrate Emulsion|Vinorelbine Tartrate Oral|Vintafolide|Vinzolidine|Vinzolidine Sulfate|Vipoma, NOS|Vipoma, malignant|Virgin Islands, British|Virgin Islands, U.S.|Virilization|Virulizin|Visceral Arterial Ischemia|Vision Changes|Vismodegib|Vistusertib|Visual Change|Visual Changes|Vital Capacity Abnormal|Vitamin D3 Analogue ILX23-7553|Vitamin E Compound|Vitespen|Vitreous Hemorrhage|Vocimagene Amiretrorepvec|Vofatamab|Voice Alteration|Volasertib|Volcanic smoke|Volociximab|Vomiting|Von Hippel-Lindau Syndrome|Von Recklinghausen disease|Vonlerolizumab|Vopratelimab|Vorasidenib|Vorinostat|Vorolanib|Vorsetzumab Mafodotin|Vosaroxin|Vosilasarm|Voxtalisib|Voyager-DE PRO|Voyager-DE STR|Vulinacimab|Vulva|Vulva, NOS|Vulval Infection|Vulvar Intraepithelial Neoplasia, Differentiated Type|Vulvar intraepithelial neoplasia, grade III|W|WGA Failure|WNT-Activated|WT-With Tumor|WT1 Peptide Vaccine OCV-501|WT1 Peptide Vaccine WT2725|WT1 Protein-derived Peptide Vaccine DSP-7888|WT1-A10/AS01B Immunotherapeutic GSK2130579A|WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401|WXS|Wagr Syndrome|Waldenstrom Macroglobulinemia|Waldenstrom macroglobulinemia|Waldeyer ring|Wallis and Futuna|Ward|Warfarin Sodium|Warthin Tumor|Warthin tumor|Warty carcinoma|Waste burning smoke|Wasting Syndrome|Water-Clear Cell Adenocarcinoma|Water-clear cell adenocarcinoma|Water-clear cell adenoma|Water-clear cell carcinoma|Watering Eyes|Waters|Wedge Resection|Wee1 Inhibitor ZN-c3|Wee1 Kinase Inhibitor Debio 0123|Weight Gain|Weight Loss|Well Differentiated Liposarcoma|Well Differentiated Neuroendocrine Lesion|Well differentiated liposarcoma of superficial soft tissue|Well differentiated papillary mesothelioma, benign|Well differentiated thymic carcinoma|Western Sahara|Wheezing|Whipple Procedure|White Blood Cell Decreased|White Blood Cells|White Carrot|White Matter|Whole Bone Marrow|Whole Genome Sequencing|Wife|Wilms Tumor|Wilms tumor|Wilms tumor (WT)|Wine|With Tumor|With tumor|Withdrawal by Subject|Within 5 Minutes|Wnt Signaling Inhibitor SM04755|Wnt Signaling Pathway Inhibitor SM08502|Wnt-5a Mimic Hexapeptide Foxy-5|Wobe-Mugos E|Wolff-Parkinson-White Syndrome|Wolffian duct adenoma|Wolffian duct carcinoma|Wolffian duct tumor|Wood Dust|Wood burning smoke, NOS|Wood burning smoke, factory|Work-related smoke, NOS|Work-related smoke, artificial smoke machines|Work-related smoke, fire fighting|Work-related smoke, foundry|Work-related smoke, generators|Work-related smoke, military|Work-related smoke, paint baking|Work-related smoke, plastics factory|Work-related smoke, plumbing|Work-related smoke, soldering/welding|Wound Complication|Wound Dehiscence|Wound Infection|Wrist|Wrist Fracture|X|X500R QTOF|XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410|XIAP Antisense Oligonucleotide AEG35156|XIAP/cIAP1 Antagonist ASTX660|XLSX|XML|XPO1 Inhibitor SL-801|Xanthofibroma|Xanthohumol|Xeloda|Xenograft|Xenograft Tissue|Xenopus laevis|Xentuzumab|Xevinapant|Xevo G2 Q-Tof|Xevo G2 Tof|Xevo G2 XS Tof|Xevo G2-S QTof|Xevo G2-S Tof|Xevo Q-Tof|Xevo QTof|Xevo TQ MS|Xevo TQ-S|Xevo TQD|Xiaoai Jiedu Decoction|Xiliertinib|Xisomab 3G3|Y|Y 90 Monoclonal Antibody CC49|Y 90 Monoclonal Antibody HMFG1|Y 90 Monoclonal Antibody Lym-1|Y 90 Monoclonal Antibody M195|Y 90 Monoclonal Antibody m170|Yang Yin Fu Zheng|Yangzheng Xiaoji Extract|Yemen|Yiqi-yangyin-jiedu Herbal Decoction|Yolk Sac Tumor|Yolk sac tumor|Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12|Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101|Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66|Yttrium Y 90 Basiliximab|Yttrium Y 90 Colloid|Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A|Yttrium Y 90 Daclizumab|Yttrium Y 90 Glass Microspheres|Yttrium Y 90 Monoclonal Antibody B3|Yttrium Y 90 Monoclonal Antibody BrE-3|Yttrium Y 90 Monoclonal Antibody Hu3S193|Yttrium Y 90 Monoclonal Antibody MN-14|Yttrium Y 90 Resin Microspheres|Yttrium Y 90 Tabituximab Barzuxetan|Yttrium Y 90-DOTA-Biotin|Yttrium Y 90-DOTA-di-HSG Peptide IMP-288|Yttrium Y 90-Edotreotide|Yttrium Y 90-labeled Anti-FZD10 Monoclonal Antibody OTSA101|Yttrium Y-90 Clivatuzumab Tetraxetan|Yttrium Y-90 Epratuzumab Tetraxetan|Yttrium Y-90 Ibritumomab Tiuxetan|Yttrium Y-90 Tacatuzumab Tetraxetan|Yttrium-90 Polycarbonate Brachytherapy Plaque|Z-Endoxifen Hydrochloride|ZMD|ZQ|Zalcitabine|Zalifrelimab|Zalutumumab|Zambia|Zandelisib|Zanidatamab|Zanolimumab|Zanubrutinib|Zea mays|Zebularine|Zelavespib|Zero|Zibotentan|Zimbabwe|Zinc Finger Nuclease ZFN-603|Zinc Finger Nuclease ZFN-758|Zinostatin|Zinostatin Stimalamer|Zirconium Zr 89 Panitumumab|Ziv-Aflibercept|Zolbetuximab|Zoledronic Acid|Zoptarelin Doxorubicin|Zorifertinib|Zorubicin|Zorubicin Hydrochloride|Zotatifin|Zotiraciclib Citrate|Zuclomiphene Citrate|aDNA Preparation Type|alignment_workflow|aliquot|allcnv|alleleSpecificCN|alpha-Folate Receptor-targeting Thymidylate Synthase Inhibitor ONX-0801|american indian or alaska native|analyte|asian|auxiliary|bRPLC|bRPLC (pH 10)|bRPLC (pH 7.5)|batch_effect_removed|bisulfite|black or african american|byallele|c-ALL|c-Kit Inhibitor PLX9486|c-Met Inhibitor ABN401|c-Met Inhibitor AL2846|c-Met Inhibitor AMG 208|c-Met Inhibitor AMG 337|c-Met Inhibitor GST-HG161|c-Met Inhibitor HS-10241|c-Met Inhibitor JNJ-38877605|c-Met Inhibitor MK2461|c-Met Inhibitor MK8033|c-Met Inhibitor MSC2156119J|c-raf Antisense Oligonucleotide ISIS 5132|cEt KRAS Antisense Oligonucleotide AZD4785|cFMS Tyrosine Kinase Inhibitor ARRY-382|cGy|cM0 (i+)|cM0 (i+) Stage Finding|cfDNA|cgh|cis-Urocanic Acid|cnv|control|controlled|cov|coverage|cqcf|dUTPase/DPD Inhibitor TAS-114|data_release|diagnostic_slides|drug|eIF4E Antisense Oligonucleotide ISIS 183750|explorer|false|female|follow_up|gene|germline|hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301|hTERT Vaccine V934/V935|hTERT-encoding DNA Vaccine INVAC-1|harmonized|hg18|hg19|hispanic or latino|hpv|huBC1-huIL12 Fusion Protein AS1409|iNKT Cell Agonist ABX196|iNOS Dimerization Inhibitor ASP9853|iPSC-derived CD16-expressing Natural Killer Cells FT516|iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596|iPSC-derived Natural Killer Cells FT500|iTRAQ|iTRAQ4|iTRAQ8|iTRAQH|image|indel|ismpolish|isoform|junction|lost to follow-up|lowess_normalized_smoothed|m6A RNA Methylation|mRNA-Derived Prostate Cancer Vaccine CV9103|mRNA-based Personalized Cancer Vaccine NCI-4650|mRNA-based Personalized Cancer Vaccine mRNA-4157|mRNA-based TriMix Melanoma Vaccine ECI-006|mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902|mRNA-derived KRAS-targeted Vaccine V941|mRNA-derived Lung Cancer Vaccine BI 1361849|mRNA-derived Prostate Cancer Vaccine CV9104|mTOR Inhibitor GDC-0349|mTOR Kinase Inhibitor AZD8055|mTOR Kinase Inhibitor CC-223|mTOR Kinase Inhibitor OSI-027|mTOR Kinase Inhibitor PP242|mTOR1/2 Kinase Inhibitor ME-344|mTORC 1/2 Inhibitor LXI-15029|mTORC1/2 Kinase Inhibitor BI 860585|mTORC1/mTORC2/DHFR Inhibitor ABTL0812|maXis 4G|maXis impact|male|metastasis|meth|mg|miRNA|miRNA Expression Quantification|miRNA-Seq|microOTOF focus II|microOTOF-Q II|mirVana (Allprep DNA) RNA|msi|nRNA - Melanoma Protocol|nanoACQUITY UPLC|nanoACQUITY UPLC System with 1D Technology|nanoACQUITY UPLC with HDX Technology|native hawaiian or other pacific islander|ncmtRNA Oligonucleotide Andes-1537|nocnv|normalized|not allowed to collect|not hispanic or latino|not reported|nte|omf|open|original|other|p300/CBP Bromodomain Inhibitor CCS1477|p38 MAPK Inhibitor LY3007113|p53 Peptide Vaccine MPS-128|p53-HDM2 Interaction Inhibitor MI-773|p53-HDM2 Protein-protein Interaction Inhibitor APG-115|p53/HDM2 Interaction Inhibitor CGM097|p70S6K Inhibitor LY2584702|p70S6K/Akt Inhibitor MSC2363318A|p97 Inhibitor CB-5083|p97 Inhibitor CB-5339|p97 Inhibitor CB-5339 Tosylate|pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0|pNGVL4a-CRT-E6E7L2 DNA Vaccine|pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2|pairedcn|pan FGFR Inhibitor PRN1371|pan-HER Kinase Inhibitor AC480|pan-PI3K Inhibitor CLR457|pan-PI3K/mTOR Inhibitor SF1126|pan-PIM Kinase Inhibitor AZD1208|pan-PIM Kinase Inhibitor NVP-LGB-321|pan-RAF Inhibitor LXH254|pan-RAF Kinase Inhibitor CCT3833|pan-RAF Kinase Inhibitor TAK-580|patient|pbi-shRNA STMN1 Lipoplex|portion|primary|proteomics solution 1|protocol|qc|quattro micro|radiation|raw|recurrence|root|sCR-Stringent Complete Response|sample|scATAC-Seq|scRNA-Seq|seg|segmentation|segmented|segnormal|siG12D LODER|siRNA-transfected Peripheral Blood Mononuclear Cells APN401|sif|slide|snv|solariX|somatic|ssRNA-based Immunomodulator CV8102|submitted_genomic_profile|summary|sv|tangent|timsTOF Pro|tr|tris(2-carboxyethyl)phosphine|true|ultima|unknown|unnormalized|unspecified|v1|v2|white|zUMIs - Smart-Seq2|zUMIs - Smart-Seq2 Counts|g"
type_of_smoke_exposure	type_of_smoke_exposure	No Smoke Exposure|Tobacco smoke, NOS|Unknown	3/50 (both/PDC)	Accidental building fire smoke|Accidental fire smoke, NOS|Accidental fire smoke, grass|Accidental forest fire smoke|Accidental vehicle fire smoke|Aircraft smoke|Burning tree smoke|Coal smoke, NOS|Cooking-related smoke, NOS|Electrical fire smoke|Electronic cigarette smoke, NOS|Environmental tobacco smoke|Factory smokestack smoke|Field burning smoke|Fire smoke, NOS|Furnace or boiler smoke|Gas burning smoke, propane|Grease fire smoke|Grilling smoke|Hashish smoke|Indoor stove or fireplace smoke, NOS|Indoor stove or fireplace smoke, coal burning|Indoor stove or fireplace smoke, wood burning|Machine smoke|Marijuana smoke|Oil burning smoke, Kerosene|Oil burning smoke, NOS|Recreational fire smoke|Smoke exposure, NOS|Smokehouse smoke|Tobacco smoke, cigar|Tobacco smoke, cigarettes|Tobacco smoke, pipe|Volcanic smoke|Waste burning smoke|Wood burning smoke, NOS|Wood burning smoke, factory|Work-related smoke, NOS|Work-related smoke, artificial smoke machines|Work-related smoke, fire fighting|Work-related smoke, foundry|Work-related smoke, generators|Work-related smoke, military|Work-related smoke, paint baking|Work-related smoke, plastics factory|Work-related smoke, plumbing|Work-related smoke, soldering/welding	Accidental Building Fire Smoke Exposure|Accidental Fire Smoke Exposure|Accidental Forest Fire Smoke Exposure|Accidental Grass Fire Smoke Exposure|Accidental Vehicle Fire Smoke Exposure|Aircraft Smoke Exposure|Burning Oil Smoke Exposure|Burning Tree Smoke|Burning Waste Smoke Exposure|Burning Wood Smoke Exposure|Cigar Smoke Exposure|Cigarette Smoke Exposure|Coal Smoke Exposure|Coal-Burining Indoor Stove or Fireplace Smoke Exposure|Cooking-Related Smoke Exposure|Electrical Fire Smoke Exposure|Electronic Cigarette Smoke Exposure|Factory Smokestack Smoke Exposure|Field Burning Smoke Exposure|Fire Smoke Exposure|Furnace or Boiler Smoke Exposure|Grease Fire Smoke Exposure|Grilling Smoke Exposure|Hashish Smoke Exposure|Indoor Stove or Fireplace Smoke Exposure|Kerosene Smoke Exposure|Machine Smoke Exposure|Marijuana Smoke Exposure|Occupational Artificial Smoke Machine Smoke Exposure|Occupational Fire Fighting Smoke Exposure|Occupational Foundry Smoke Exposure|Occupational Generator Smoke Exposure|Occupational Military Smoke Exposure|Occupational Paint Baking Smoke Exposure|Occupational Plastics Factory Smoke Exposure|Occupational Plumbing Smoke Exposure|Occupational Soldering/Welding Smoke Exposure|Passive Smoke Exposure|Propane Smoke Exposue|Recreational Fire Smoke Exposure|Smoke Exposure|Smokehouse Smoke Exposure|Tobacco Pipe Smoke Exposure|Volcanic Smoke Exposure|Wood-Burning Factory Smoke Exposure|Wood-Burning Indoor Stove or Fireplace Smoke Exposure|Work-Related Smoke Exposure
type_of_tobacco_used	type_of_tobacco_used	Cigar|Cigarette|Electronic Cigarette|Other|Pipe|Smokeless Tobacco	6/6 (both/PDC)		
relationship_gender	relationship_gender	not reported|unknown	2/5 (both/PDC)	female|male|unspecified	Female|Male|Unspecified
relationship_primary_diagnosis	relationship_primary_diagnosis	Chondrosarcoma|Ewing Sarcoma|Glioblastoma|Kaposi Sarcoma|Leukemia|Lymphoma|Melanoma|Mesothelioma|Multiple Myeloma|Neuroblastoma|Not Reported|Osteosarcoma|Rhabdomyosarcoma|Sarcoma|Unknown|Wilms Tumor	16/52 (both/PDC)	Adrenal Gland Cancer|Basal Cell Cancer|Bile Duct Cancer|Bladder Cancer|Blood Cancer|Bone Cancer|Brain Cancer|Breast Cancer|CNS Cancer|Cancer|Cervical Cancer|Colorectal Cancer|Esophageal Cancer|Gallbladder Cancer|Gastric Cancer|Gynecologic Cancer|Head and Neck Cancer|Hematologic Cancer|Kidney Cancer|Laryngeal Cancer|Liver Cancer|Lung Cancer|Lymph Node Cancer|Ovarian Cancer|Pancreas Cancer|Pediatric Liver Cancer|Prostate Cancer|Rectal Cancer|Skin Cancer|Spleen Cancer|Testicular Cancer|Throat Cancer|Thyroid Cancer|Tongue Cancer|Tonsillar Cancer|Uterine Cancer	Bile Duct Carcinoma|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Childhood Malignant Liver Neoplasm|Colorectal Carcinoma|Esophageal Carcinoma|Gallbladder Carcinoma|Gastric Carcinoma|Hematopoietic and Lymphoid Cell Neoplasm|Kidney Carcinoma|Laryngeal Carcinoma|Liquid Tumor|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Malignant Adrenal Gland Neoplasm|Malignant Bone Neoplasm|Malignant Brain Neoplasm|Malignant Central Nervous System Neoplasm|Malignant Female Reproductive System Neoplasm|Malignant Head and Neck Neoplasm|Malignant Lymph Node Neoplasm|Malignant Neoplasm|Malignant Ovarian Neoplasm|Malignant Skin Neoplasm|Malignant Splenic Neoplasm|Malignant Testicular Germ Cell Tumor|Malignant Uterine Neoplasm|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Skin Basal Cell Carcinoma|Throat Carcinoma|Thyroid Gland Carcinoma|Tongue Carcinoma|Tonsillar Carcinoma
relationship_type	relationship_type	Adopted Brother|Adopted Daughter|Adopted Sister|Adopted Son|Adoptive Father|Adoptive Mother|Aunt|Brother|Brother-in-law|Child|Cousin|Daughter|Daughter-in-law|Father|Father-in-law|Female Cousin|Female Sibling of Adopted Child|First Cousin|First Cousin Once Removed|Foster Brother|Foster Daughter|Foster Father|Foster Mother|Foster Sister|Foster Son|Fraternal Twin Brother|Fraternal Twin Sister|Full Brother|Full Sister|Grandchild|Granddaughter|Grandfather|Grandmother|Grandparent|Grandson|Great Grandchild|Half Brother|Half Sibling|Half Sister|Husband|Identical Twin Brother|Identical Twin Sister|Male Cousin|Male Sibling of Adopted Child|Maternal First Cousin Once Removed|Maternal Great Aunt|Maternal Great Grandparent|Maternal Great Uncle|Maternal Half Sibling|Mother|Mother-in-law|Nephew|Niece|Not Reported|Other|Parent|Paternal First Cousin Once Removed|Paternal Great Aunt|Paternal Great Grandparent|Paternal Great Uncle|Paternal Half Sibling|Sibling|Sister|Sister-in-law|Son|Son-in-law|Spouse|Step Child|Step Sibling|Stepbrother|Stepdaughter|Stepmother|Stepsister|Stepson|Uncle|Unknown|Unrelated|Ward|Wife	79/120 (both/PDC)	Adoptive Brother|Adoptive Sister|Domestic Partner|Fraternal Twin Sibling|Grand Nephew|Grand Niece|Identical Twin Sibling|Legal Guardian|Maternal Aunt|Maternal First Cousin|Maternal Grandfather|Maternal Grandmother|Maternal Grandparent|Maternal Half Brother|Maternal Half Sister|Maternal Uncle|Natural Brother|Natural Child|Natural Daughter|Natural Father|Natural Grandchild|Natural Grandfather|Natural Grandmother|Natural Grandparent|Natural Mother|Natural Parent|Natural Sibling|Natural Sister|Natural Son|Niece Second Degree Relative|Paternal Aunt|Paternal First Cousin|Paternal Grandfather|Paternal Grandmother|Paternal Grandparent|Paternal Half Brother|Paternal Half Sister|Paternal Uncle|Refused|Stepfather|Twin Sibling	Biological Brother|Biological Child|Biological Father|Biological Grandchild|Biological Grandfather|Biological Grandmother|Biological Grandparent|Biological Maternal Aunt|Biological Maternal Cousin|Biological Maternal Grandfather|Biological Maternal Grandmother|Biological Maternal Grandparent|Biological Maternal Uncle|Biological Mother|Biological Niece|Biological Parent|Biological Paternal Aunt|Biological Paternal Cousin|Biological Paternal Grandfather|Biological Paternal Grandmother|Biological Paternal Grandparent|Biological Paternal Uncle|Biological Sibling|Biological Sister|Biological Son|Domestic Partnership|Fraternal Twin|Great Nephew|Great Niece|Guardian|Half-brother with Father as Common Parent|Half-brother with Mother as Common Parent|Half-sister with Father as Common Parent|Half-sister with Mother as Common Parent|Identical Twin|Step Father|Twin
relative_with_cancer_history	relative_with_cancer_history	False|True|not reported|unknown	4/4 (both/PDC)		
access			0/2 (both/PDC)	controlled|open	
downloadable			0/2 (both/PDC)	False|True	
adverse_event	adverse_event	Abdominal Distension|Abdominal Infection|Abdominal Pain|Abdominal Soft Tissue Necrosis|Abducens Nerve Disorder|Accessory Nerve Disorder|Acidosis|Acoustic Nerve Disorder NOS|Activated Partial Thromboplastin Time Prolonged|Acute Coronary Syndrome|Acute Kidney Injury|Adrenal Insufficiency|Adult Respiratory Distress Syndrome|Agitation|Akathisia|Alanine Aminotransferase Increased|Alcohol Intolerance|Alkaline Phosphatase Increased|Alkalosis|Allergic Reaction|Allergic Rhinitis|Alopecia|Amnesia|Anal Fistula|Anal Hemorrhage|Anal Mucositis|Anal Necrosis|Anal Pain|Anal Stenosis|Anal Ulcer|Anaphylaxis|Anemia|Ankle Fracture|Anorectal Infection|Anorexia|Anorgasmia|Anxiety|Aortic Injury|Aortic Valve Disease|Aphonia|Apnea|Appendicitis|Appendicitis Perforated|Arachnoiditis|Arterial Injury|Arteritis Infective|Arthralgia|Arthritis|Ascites|Aspartate Aminotransferase Increased|Aspiration|Asystole|Ataxia|Atelectasis|Atrial Fibrillation|Atrial Flutter|Atrioventricular Block Complete|Atrioventricular Block First Degree|Autoimmune Disorder|Avascular Necrosis|Azoospermia|Back Pain|Bile Duct Stenosis|Biliary Anastomotic Leak|Biliary Fistula|Biliary Tract Infection|Bladder Anastomotic Leak|Bladder Infection|Bladder Perforation|Bladder Spasm|Bloating|Blood Antidiuretic Hormone Abnormal|Blood Bilirubin Increased|Blood Corticotrophin Decreased|Blood Gonadotrophin Abnormal|Blood Prolactin Abnormal|Blood and Lymphatic System Disorders - Other|Blurred Vision|Body Odor|Bone Infection|Bone Marrow Hypocellular|Bone Pain|Brachial Plexopathy|Breast Atrophy|Breast Infection|Breast Pain|Bronchial Fistula|Bronchial Infection|Bronchial Obstruction|Bronchial Stricture|Bronchopleural Fistula|Bronchopulmonary Hemorrhage|Bronchospasm|Bruising|Bullous Dermatitis|Burn|Buttock Pain|CD4 Lymphocytes Decreased|CPK Increased|Capillary Leak Syndrome|Carbon Monoxide Diffusing Capacity Decreased|Cardiac Arrest|Cardiac Disorders - Other|Cardiac Troponin I Increased|Cardiac Troponin T Increased|Cataract|Catheter Related Infection|Cecal Hemorrhage|Cecal Infection|Central Nervous System Necrosis|Cerebrospinal Fluid Leakage|Cervicitis Infection|Cheilitis|Chest Pain - Cardiac|Chest Wall Pain|Chills|Cholecystitis|Cholesterol High|Chronic Kidney Disease|Chylothorax|Cognitive Disturbance|Colitis|Colonic Fistula|Colonic Hemorrhage|Colonic Obstruction|Colonic Perforation|Colonic Stenosis|Colonic Ulcer|Concentration Impairment|Conduction Disorder|Confusion|Congenital, Familial and Genetic Disorders - Other|Conjunctivitis|Conjunctivitis Infective|Constipation|Constrictive Pericarditis|Corneal Infection|Corneal Ulcer|Cough|Cranial Nerve Infection|Creatinine Increased|Cushingoid|Cystitis Noninfective|Cytokine Release Syndrome|Death NOS|Death Neonatal|Dehydration|Delayed Orgasm|Delayed Puberty|Delirium|Delusions|Dental Caries|Depressed Level of Consciousness|Depression|Dermatitis Radiation|Device Related Infection|Diarrhea|Disseminated Intravascular Coagulation|Dizziness|Dry Eye|Dry Mouth|Dry Skin|Duodenal Fistula|Duodenal Hemorrhage|Duodenal Infection|Duodenal Obstruction|Duodenal Perforation|Duodenal Stenosis|Duodenal Ulcer|Dysarthria|Dysesthesia|Dysgeusia|Dysmenorrhea|Dyspareunia|Dyspepsia|Dysphagia|Dysphasia|Dyspnea|Ear Pain|Ear and Labyrinth Disorders - Other|Edema Cerebral|Edema Face|Edema Limbs|Edema Trunk|Ejaculation Disorder|Ejection Fraction Decreased|Electrocardiogram QT Corrected Interval Prolonged|Encephalitis Infection|Encephalomyelitis Infection|Encephalopathy|Endocarditis Infective|Endocrine Disorders - Other|Endophthalmitis|Enterocolitis|Enterocolitis Infectious|Enterovesical Fistula|Epistaxis|Erectile Dysfunction|Erythema Multiforme|Erythroderma|Esophageal Anastomotic Leak|Esophageal Fistula|Esophageal Hemorrhage|Esophageal Infection|Esophageal Necrosis|Esophageal Obstruction|Esophageal Pain|Esophageal Perforation|Esophageal Stenosis|Esophageal Ulcer|Esophageal Varices Hemorrhage|Esophagitis|Euphoria|Exostosis|External Ear Inflammation|External Ear Pain|Extraocular Muscle Paresis|Extrapyramidal Disorder|Eye Disorders - Other|Eye Infection|Eye Pain|Eyelid Function Disorder|Facial Muscle Weakness|Facial Nerve Disorder|Facial Pain|Fall|Fallopian Tube Anastomotic Leak|Fallopian Tube Obstruction|Fallopian Tube Perforation|Fallopian Tube Stenosis|Fat Atrophy|Fatigue|Febrile Neutropenia|Fecal Incontinence|Female Genital Tract Fistula|Feminization Acquired|Fetal Death|Fetal Growth Retardation|Fever|Fibrinogen Decreased|Fibrosis Deep Connective Tissue|Flank Pain|Flashing Lights|Flatulence|Floaters|Flu Like Symptoms|Flushing|Forced Expiratory Volume Decreased|Fracture|GGT Increased|Gait Disturbance|Gallbladder Fistula|Gallbladder Infection|Gallbladder Necrosis|Gallbladder Obstruction|Gallbladder Pain|Gallbladder Perforation|Gastric Anastomotic Leak|Gastric Fistula|Gastric Hemorrhage|Gastric Necrosis|Gastric Perforation|Gastric Stenosis|Gastric Ulcer|Gastritis|Gastroesophageal Reflux Disease|Gastrointestinal Anastomotic Leak|Gastrointestinal Disorders - Other|Gastrointestinal Fistula|Gastrointestinal Pain|Gastrointestinal Stoma Necrosis|Gastroparesis|General Disorders and Administration Site Conditions - Other|Generalized Muscle Weakness|Genital Edema|Gingival Pain|Glaucoma|Glossopharyngeal Nerve Disorder|Glucose Intolerance|Growth Accelerated|Growth Hormone Abnormal|Growth Suppression|Gum Infection|Gynecomastia|Hallucinations|Haptoglobin Decreased|Head Soft Tissue Necrosis|Headache|Hearing Impaired|Heart Failure|Hematoma|Hematosalpinx|Hematuria|Hemoglobin Increased|Hemoglobinuria|Hemolysis|Hemolytic Uremic Syndrome|Hemorrhoidal Hemorrhage|Hemorrhoids|Hepatic Failure|Hepatic Hemorrhage|Hepatic Infection|Hepatic Necrosis|Hepatic Pain|Hepatitis Viral|Hepatobiliary Disorders - Other|Hiccups|Hip Fracture|Hirsutism|Hoarseness|Hot Flashes|Hydrocephalus|Hypercalcemia|Hyperglycemia|Hyperhidrosis|Hyperkalemia|Hypermagnesemia|Hypernatremia|Hyperparathyroidism|Hypersomnia|Hypertension|Hyperthyroidism|Hypertrichosis|Hypertriglyceridemia|Hyperuricemia|Hypoalbuminemia|Hypocalcemia|Hypoglossal Nerve Disorder|Hypoglycemia|Hypohidrosis|Hypokalemia|Hypomagnesemia|Hyponatremia|Hypoparathyroidism|Hypophosphatemia|Hypotension|Hypothermia|Hypothyroidism|Hypoxia|INR Increased|IVth Nerve Disorder|Ileal Fistula|Ileal Hemorrhage|Ileal Obstruction|Ileal Perforation|Ileal Stenosis|Ileal Ulcer|Ileus|Immune System Disorders - Other|Infections and Infestations - Other|Infective Myositis|Infusion Related Reaction|Infusion Site Extravasation|Injection Site Reaction|Injury to Carotid Artery|Injury to Inferior Vena Cava|Injury to Jugular Vein|Injury to Superior Vena Cava|Injury, Poisoning and Procedural Complications - Other|Insomnia|Intestinal Stoma Leak|Intestinal Stoma Obstruction|Intestinal Stoma Site Bleeding|Intra-Abdominal Hemorrhage|Intracranial Hemorrhage|Intraoperative Arterial Injury|Intraoperative Breast Injury|Intraoperative Cardiac Injury|Intraoperative Ear Injury|Intraoperative Endocrine Injury|Intraoperative Gastrointestinal Injury|Intraoperative Head and Neck Injury|Intraoperative Hemorrhage|Intraoperative Hepatobiliary Injury|Intraoperative Musculoskeletal Injury|Intraoperative Neurological Injury|Intraoperative Ocular Injury|Intraoperative Renal Injury|Intraoperative Reproductive Tract Injury|Intraoperative Respiratory Injury|Intraoperative Skin Injury|Intraoperative Splenic Injury|Intraoperative Urinary Injury|Intraoperative Venous Injury|Investigations - Other|Iron Overload|Irregular Menstruation|Irritability|Ischemia Cerebrovascular|Jejunal Fistula|Jejunal Hemorrhage|Jejunal Obstruction|Jejunal Perforation|Jejunal Stenosis|Jejunal Ulcer|Joint Effusion|Joint Infection|Joint Range of Motion Decreased|Joint Range of Motion Decreased Cervical Spine|Joint Range of Motion Decreased Lumbar Spine|Keratitis|Kidney Anastomotic Leak|Kidney Infection|Kyphosis|Lactation Disorder|Large Intestinal Anastomotic Leak|Laryngeal Edema|Laryngeal Fistula|Laryngeal Hemorrhage|Laryngeal Inflammation|Laryngeal Mucositis|Laryngeal Obstruction|Laryngeal Stenosis|Laryngitis|Laryngopharyngeal Dysesthesia|Laryngospasm|Left Ventricular Systolic Dysfunction|Lethargy|Leukemia Secondary to Oncology Chemotherapy|Leukocytosis|Leukoencephalopathy|Libido Decreased|Libido Increased|Lip Infection|Lip Pain|Lipase Increased|Lipohypertrophy|Localized Edema|Lordosis|Lower Gastrointestinal Hemorrhage|Lung Infection|Lymph Gland Infection|Lymph Leakage|Lymph Node Pain|Lymphedema|Lymphocele|Lymphocyte Count Decreased|Lymphocyte Count Increased|Malabsorption|Malaise|Mania|Mediastinal Hemorrhage|Mediastinal Infection|Memory Impairment|Meningismus|Meningitis|Menopause|Menorrhagia|Metabolism and Nutrition Disorders - Other|Middle Ear Inflammation|Mitral Valve Disease|Mobitz (Type) II Atrioventricular Block|Mobitz Type I|Movements Involuntary|Mucosal Infection|Mucositis Oral|Multi-Organ Failure|Muscle Weakness Left-Sided|Muscle Weakness Lower Limb|Muscle Weakness Right-Sided|Muscle Weakness Trunk|Muscle Weakness Upper Limb|Musculoskeletal Deformity|Musculoskeletal and Connective Tissue Disorders - Other|Myalgia|Myelitis|Myelodysplastic Syndrome|Myocardial Infarction|Myocarditis|Myositis|Nail Discoloration|Nail Infection|Nail Loss|Nail Ridging|Nasal Congestion|Nausea|Neck Edema|Neck Pain|Neck Soft Tissue Necrosis|Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other|Nervous System Disorders - Other|Neuralgia|Neutrophil Count Decreased|Night Blindness|Nipple Deformity|Non-Cardiac Chest Pain|Nystagmus|Obesity|Obstruction Gastric|Oculomotor Nerve Disorder|Olfactory Nerve Disorder|Oligospermia|Optic Nerve Disorder|Oral Cavity Fistula|Oral Dysesthesia|Oral Hemorrhage|Oral Pain|Osteonecrosis of Jaw|Osteoporosis|Otitis Externa|Otitis Media|Ovarian Hemorrhage|Ovarian Infection|Ovarian Rupture|Ovulation Pain|Pain|Pain in Extremity|Pain of Skin|Palmar-Plantar Erythrodysesthesia Syndrome|Palpitations|Pancreas Infection|Pancreatic Anastomotic Leak|Pancreatic Duct Stenosis|Pancreatic Enzymes Decreased|Pancreatic Fistula|Pancreatic Hemorrhage|Pancreatic Necrosis|Pancreatitis|Papilledema|Papulopustular Rash|Paresthesia|Paronychia|Paroxysmal Atrial Tachycardia|Pelvic Floor Muscle Weakness|Pelvic Infection|Pelvic Pain|Pelvic Soft Tissue Necrosis|Penile Infection|Penile Pain|Perforation Bile Duct|Pericardial Effusion|Pericardial Tamponade|Pericarditis|Perineal Pain|Periodontal Disease|Periorbital Edema|Periorbital Infection|Peripheral Ischemia|Peripheral Motor Neuropathy|Peripheral Nerve Infection|Peripheral Sensory Neuropathy|Peritoneal Infection|Peritoneal Necrosis|Personality Change|Phantom Pain|Pharyngeal Anastomotic Leak|Pharyngeal Fistula|Pharyngeal Hemorrhage|Pharyngeal Mucositis|Pharyngeal Necrosis|Pharyngeal Stenosis|Pharyngitis|Pharyngolaryngeal Pain|Phlebitis|Phlebitis Infective|Photophobia|Photosensitivity|Platelet Count Decreased|Pleural Effusion|Pleural Hemorrhage|Pleural Infection|Pleuritic Pain|Pneumonitis|Pneumothorax|Portal Hypertension|Portal Vein Thrombosis|Postnasal Drip|Postoperative Hemorrhage|Postoperative Thoracic Procedure Complication|Precocious Puberty|Pregnancy, Puerperium and Perinatal Conditions - Other|Premature Delivery|Premature Menopause|Presyncope|Proctitis|Productive Cough|Prolapse of Intestinal Stoma|Prolapse of Urostomy|Prostate Infection|Prostatic Hemorrhage|Prostatic Obstruction|Prostatic Pain|Proteinuria|Pruritus|Psychiatric Disorders - Other|Psychosis|Pulmonary Edema|Pulmonary Fibrosis|Pulmonary Fistula|Pulmonary Hypertension|Pulmonary Valve Disease|Purpura|Pyramidal Tract Syndrome|Radiation Recall Reaction (Dermatologic)|Radiculitis|Rash Acneiform|Rash Maculo-Papular|Rash Pustular|Rectal Anastomotic Leak|Rectal Fistula|Rectal Hemorrhage|Rectal Mucositis|Rectal Necrosis|Rectal Obstruction|Rectal Pain|Rectal Perforation|Rectal Stenosis|Rectal Ulcer|Recurrent Laryngeal Nerve Palsy|Renal Calculi|Renal Colic|Renal Hemorrhage|Renal and Urinary Disorders - Other|Reproductive System and Breast Disorders - Other|Respiratory Failure|Respiratory, Thoracic and Mediastinal Disorders - Other|Restlessness|Restrictive Cardiomyopathy|Retinal Detachment|Retinal Tear|Retinal Vascular Disorder|Retinoic Acid Syndrome|Retinopathy|Retroperitoneal Hemorrhage|Reversible Posterior Leukoencephalopathy Syndrome|Rhinitis Infective|Right Ventricular Dysfunction|Salivary Duct Inflammation|Salivary Gland Fistula|Salivary Gland Infection|Scalp Pain|Scleral Disorder|Scoliosis|Scrotal Infection|Scrotal Pain|Seizure|Sepsis|Seroma|Serum Amylase Increased|Serum Sickness|Sick Sinus Syndrome|Sinus Bradycardia|Sinus Disorder|Sinus Pain|Sinus Tachycardia|Sinusitis|Skin Atrophy|Skin Hyperpigmentation|Skin Hypopigmentation|Skin Induration|Skin Infection|Skin Ulceration|Skin and Subcutaneous Tissue Disorders - Other|Sleep Apnea|Small Intestinal Anastomotic Leak|Small Intestinal Mucositis|Small Intestinal Obstruction|Small Intestinal Perforation|Small Intestinal Stenosis|Small Intestine Infection|Small Intestine Ulcer|Sneezing|Social Circumstances - Other|Soft Tissue Infection|Soft Tissue Necrosis Lower Limb|Soft Tissue Necrosis Upper Limb|Somnolence|Sore Throat|Spasticity|Spermatic Cord Anastomotic Leak|Spermatic Cord Hemorrhage|Spermatic Cord Obstruction|Spinal Fracture|Spleen Disorder|Splenic Infection|Stenosis of Gastrointestinal Stoma|Stevens-Johnson Syndrome|Stoma Site Infection|Stomach Pain|Stomal Ulcer|Stridor|Stroke|Sudden Death NOS|Suicidal Ideation|Suicide Attempt|Superficial Soft Tissue Fibrosis|Superficial Thrombophlebitis|Superior Vena Cava Syndrome|Supraventricular Tachycardia|Surgical and Medical Procedures - Other|Syncope|Telangiectasia|Testicular Disorder|Testicular Hemorrhage|Testicular Pain|Thromboembolic Event|Thrombotic Thrombocytopenic Purpura|Tinnitus|Tooth Development Disorder|Tooth Discoloration|Tooth Infection|Toothache|Toxic Epidermal Necrolysis|Tracheal Fistula|Tracheal Hemorrhage|Tracheal Mucositis|Tracheal Obstruction|Tracheal Stenosis|Tracheitis|Tracheostomy Site Bleeding|Transient Ischemic Attacks|Treatment Related Secondary Malignancy|Tremor|Tricuspid Valve Disease|Trigeminal Nerve Disorder|Trismus|Tumor Lysis Syndrome|Tumor Pain|Typhlitis|Unequal Limb Length|Unintended Pregnancy|Upper Gastrointestinal Hemorrhage|Upper Respiratory Infection|Ureteric Anastomotic Leak|Urethral Anastomotic Leak|Urethral Infection|Urinary Fistula|Urinary Frequency|Urinary Incontinence|Urinary Retention|Urinary Tract Infection|Urinary Tract Obstruction|Urinary Tract Pain|Urinary Urgency|Urine Discoloration|Urine Output Decreased|Urostomy Leak|Urostomy Obstruction|Urostomy Site Bleeding|Urostomy Stenosis|Urticaria|Uterine Anastomotic Leak|Uterine Fistula|Uterine Hemorrhage|Uterine Infection|Uterine Obstruction|Uterine Pain|Uterine Perforation|Uveitis|Vaginal Anastomotic Leak|Vaginal Discharge|Vaginal Dryness|Vaginal Fistula|Vaginal Hemorrhage|Vaginal Infection|Vaginal Inflammation|Vaginal Obstruction|Vaginal Pain|Vaginal Perforation|Vaginal Stricture|Vaginismus|Vagus Nerve Disorder|Vas Deferens Anastomotic Leak|Vascular Access Complication|Vascular Disorders - Other|Vasculitis|Vasovagal Reaction|Venous Injury|Ventricular Arrhythmia|Ventricular Fibrillation|Ventricular Tachycardia|Vertigo|Vestibular Disorder|Virilization|Visceral Arterial Ischemia|Vital Capacity Abnormal|Vitreous Hemorrhage|Voice Alteration|Vomiting|Vulval Infection|Watering Eyes|Weight Gain|Weight Loss|Wheezing|White Blood Cell Decreased|Wolff-Parkinson-White Syndrome|Wound Complication|Wound Dehiscence|Wound Infection|Wrist Fracture	790/790 (both/PDC)		
adverse_event_grade	adverse_event_grade	Grade 1|Grade 2|Grade 3|Grade 4|Grade 5	5/5 (both/PDC)		
aids_risk_factors	aids_risk_factors	Candidiasis|Coccidioidomycosis|Cryptococcosis|Cryptosporidiosis, Chronic Intestinal|Cytomegalovirus|Encephalopathy|Herpes Simplex Virus|Histoplasmosis|Isosporiasis|Mycobacterium avium Complex|Mycobacterium tuberculosis|Mycobacterium, NOS|Nocardiosis|Pneumocystis Pneumonia|Pneumonia, NOS|Progressive Multifocal Leukoencephalopathy|Salmonella Septicemia|Toxoplasmosis|Wasting Syndrome	19/19 (both/PDC)		
barretts_esophagus_goblet_cells_present	barretts_esophagus_goblet_cells_present	False|Not Reported|True|Unknown	4/4 (both/PDC)		
cdc_hiv_risk_factors	cdc_hiv_risk_factors	Hemophiliac|Heterosexual Contact|Homosexual Contact|Intravenous Drug User|None|Not Reported|Transfusion Recipient|Unknown	8/8 (both/PDC)		
comorbidity	comorbidity	Abnormal Glucose Level|Acute Renal Failure|Adenocarcinoma|Adenomatous Polyposis Coli|Adrenocortical Insufficiency|Allergies|Alpha-1 Antitrypsin|Anemia|Anxiety|Arrhythmia|Arthritis|Asthma|Ataxia-telangiectasia|Atrial Fibrillation|Autoimmune Lymphoproliferative Syndrome (ALPS)|Avascular Necrosis|Bacteroides fragilis|Barrett's Esophagus|Basal Cell Carcinoma|Beckwith-Wiedemann|Behcet's Disease|Biliary Disorder|Blood Clots|Bone Fracture(s)|Bronchitis|COPD|Calcium Channel Blockers|Cataracts|Celiac Disease|Cerebrovascular Disease|Chlamydia|Cholelithiasis|Chronic Fatigue Syndrome|Chronic Renal Failure|Chronic Systemic Steroid Use|Cirrhosis, Unknown Etiology|Clonal Hematopoiesis|Colon Polyps|Common Variable Immunodeficiency|Congestive Heart Failure (CHF)|Connective Tissue Disorder|Coronary Artery Disease|Crohn's Disease|Cryptococcal Meningitis|Cryptogenic Organizing Pneumonia|Cytomegalovirus (CMV)|DVT/PE|Deep Vein Thrombosis / Thromboembolism|Denys-Drash Syndrome|Depression|Dermatomyosis|Diabetes|Diabetes, Type II|Diabetic Neuropathy|Diet Controlled Diabetes|Diverticulitis|Dyslipidemia|Eczema|Epilepsy|Familial Adenomatous Polyposis|Fanconi Anemia|Fibromyalgia|Fibrosis|GERD|Gastritis|Gastroesophageal Reflux Disease|Glaucoma|Glycogen Storage Disease|Gonadal Dysfunction|Gorlin Syndrome|Gout|H. pylori Infection|HIV / AIDS|HUS/TTP|Hashimoto's Thyroiditis|Headache|Heart Disease|Hemihypertrophy|Hemorrhagic Cystitis|Hepatitis|Hepatitis A Infection|Hepatitis B Infection|Hepatitis C Infection|Hepatitis, Chronic|Hereditary Non-polyposis Colon Cancer|Herpes|Herpes Zoster|High Grade Liver Dysplastic Nodule|Human Papillomavirus Infection|Hypercalcemia|Hypercholesterolemia|Hyperglycemia|Hyperlipidemia|Hypertension|Hypospadias|Hypothyroidism|ITP|Inflammatory Bowel Disease|Insulin Controlled Diabetes|Interstitial Pneumontis or ARDS|Intraductal Papillary Mucinous Neoplasm|Iron Overload|Ischemic Heart Disease|Joint Replacement|Kidney Disease|Li-Fraumeni Syndrome|Liver Cirrhosis (Liver Disease)|Liver Toxicity (Non-Infectious)|Low Grade Liver Dysplastic Nodule|Lupus|Lymphocytic Meningitis|Lynch Syndrome|MAI|Malaria|Metabolic Syndrome|Myasthenia Gravis|Mycobacterium avium Complex|Myocardial Infarction|Neuroendocrine Tumor|Nonalcoholic Steatohepatitis|Not Reported|Obesity|Organ transplant (site)|Osteoarthritis|Osteoporosis or Osteopenia|Other|Other Cancer Within 5 Years|Other Nonmalignant Systemic Disease|Other Pulmonary Complications|Pain (Various)|Pancreatitis|Peptic Ulcer (Ulcer)|Peripheral Neuropathy|Peripheral Vascular Disease|Peutz-Jeghers Disease|Pneumocystis Pneumonia|Polycystic Ovarian Syndrome (PCOS)|Pregnancy in Patient or Partner|Primary Sclerosing Cholangitis|Psoriasis|Pulmonary Fibrosis|Pulmonary Hemorrhage|Renal Dialysis|Renal Failure (Requiring Dialysis)|Renal Insufficiency|Rheumatoid Arthritis|Rheumatologic Disease|Rubinstein-Taybi Syndrome|Sarcoidosis|Seizure|Shingles|Sjogren's Syndrome|Sleep apnea|Smoking|Staphylococcus aureus|Steatosis|Stroke|Syphilis|Transient Ischemic Attack|Treponema pallidum|Tuberculosis|Turcot Syndrome|Tyrosinemia|Ulcerative Colitis|Unknown|Varicella Zoster Virus|Wagr Syndrome	167/169 (both/PDC)	Cancer|Epstein-Barr Virus	Epstein-Barr Virus Test|Malignant Neoplasm
comorbidity_method_of_diagnosis	comorbidity_method_of_diagnosis	Histology|Not Reported|Pathology|Radiology|Unknown	5/5 (both/PDC)		
diabetes_treatment_type	diabetes_treatment_type	Alpha-Glucosidase Inhibitor|Biguanide|Diet|Injected Insulin|Insulin|Not Reported|Oral Hypoglycemic|Other|Sulfonylurea|Thiazolidinedione|Unknown	11/11 (both/PDC)		
disease_response	disease_response	AJ-Adjuvant Therapy|BED-Biochemical Evidence of Disease|DU-Disease Unchanged|MR-Minimal/Marginal response|MX-Mixed Response|Non-CR/Non-PD-Non-CR/Non-PD|Not Reported|PA-Palliative Therapy|PB-Palliative Benefit|PDM-Persistent Distant Metastasis|PLD-Persistent Locoregional Disease|PR-Partial Response|PSR-Pseudoresponse|SPD-Surgical Progression|TE-Too Early|TF-Tumor Free|Unknown|VGPR-Very Good Partial Response|WT-With Tumor|sCR-Stringent Complete Response	20/33 (both/PDC)	CPD-Clinical Progression|CR-Complete Response|CRU-Complete Response Unconfirmed|IMR-Immunoresponse|IPD-Immunoprogression|NPB-No Palliative Benefit|NR-No Response|PD-Progressive Disease|PPD-Pseudoprogression|RD-Responsive Disease|RP-Response|RPD-Radiographic Progressive Disease|SD-Stable Disease	Complete Remission|Complete Response Unconfirmed|Disease Progression|Disease Response|Immunoprogression|Immunoresponse|No Palliative Benefit|No Response|Progressive Neoplastic Disease|Pseudoprogression|Radiographic Progressive Disease|Responsive Disease|Stable Disease
ecog_performance_status	ecog_performance_status	0|1|2|3|4|5|Not Reported|Unknown	8/8 (both/PDC)		"0 - No Fibrosis|00|01|02|03|04|05|06|07|08|09|1,2 - Portal Fibrosis|1-3|10|10-Deacetyltaxol|100|11|11C Topotecan|11D10 AluGel Anti-Idiotype Monoclonal Antibody|12|12-Allyldeoxoartemisinin|1200 series LC/MSD SL|1200 series LC/MSD VL|13|13-Deoxydoxorubicin|14|14C BMS-275183|15|16|17|17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521|18|180|1988|1995|1st|2'-F-ara-deoxyuridine|2,6-Diaminopurine|2,6-Dimethoxyquinone|2-Deoxy-D-glucose|2-Ethylhydrazide|2-Fluoroadenine|2-Fluorofucose-containing SGN-2FF|2-Hydroxyestradiol|2-Hydroxyestrone|2-Hydroxyflutamide Depot|2-Hydroxyoleic Acid|2-Methoxyestradiol|2-Methoxyestradiol Nanocrystal Colloidal Dispersion|2-Methoxyestrone|2-O, 3-O Desulfated Heparin|2-chloroacetamide (TCEP)|2-iodobenzoate|20|2000 QTRAP|2009|21|220 GC/MS Ion Trap System|240 GC/MS Ion Trap System|2500 QTRAP|26|2D Classical Conditionally Reprogrammed Cells|2D Modified Conditionally Reprogrammed Cells|2nd|3'-C-ethynylcytidine|3'-dA Phosphoramidate NUC-7738|3,4 - Fibrous Septa|30|31|31-60 Minutes|3100|32|3200 QTRAP|33|35|3500 QTRAP|39|3D Air-Liquid Interface Organoid|3D Neurosphere|3D Organoid|3rd|4 or More|4'-Iodo-4'-Deoxydoxorubicin|4-Nitroestrone 3-Methyl Ether|4-Thio-2-deoxycytidine|40|4000 QTRAP|41|42|45|4700 Proteomics Analyzer|4800 Plus MALDI TOF/TOF|4800 Proteomics Analyzer|4th|5 - Nodular Formation and Incomplete Cirrhosis|5-Aza-4'-thio-2'-deoxycytidine|5-Fluoro-2-Deoxycytidine|50|51|52|53|56|58|5800 TOF/TOF|59|5th|6|6 - Established Cirrhosis|6-30 Minutes|6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158|60|61|6110 Quadrupole LC/MS|6120A Quadrupole LC/MS|6120B Quadrupole LC/MS|6130 Quadrupole LC/MS|6140 Quadrupole LC/MS|6150 Quadrupole LC/MS|62|6200 Series Accurate-Mass Time-of-Flight (TOF) LC/MS|6210 Time-of-Flight LC/MS|6220 Time-of-Flight LC/MS|6224 Time-of-Flight LC/MS|6230A Time-of-Flight LC/MS|6230B Time-of-Flight LC/MS|63|6310 Ion Trap LC/MS|6320 Ion Trap LC/MS|6330 Ion Trap LC/MS|6340 Ion Trap LC/MS|64|6400 Series Triple Quadrupole LC/MS|6410 Triple Quadrupole LC/MS|6420 Triple Quadrupole LC/MS|6430 Triple Quadrupole LC/MS|6460 Triple Quadrupole LC/MS|6490 Triple Quadrupole LC/MS|6495A Triple Quadrupole LC/MS|6495B Triple Quadrupole LC/MS|65|6510 Quadrupole Time-of-Flight LC/MS|6520A Quadrupole Time-of-Flight LC/MS|6520B Q-TOF LC/MS|6530A Q-TOF LC/MS|6530B Q-TOF LC/MS|6538 Q-TOF LC/MS|6540 Q-TOF LC/MS|6542 Q-TOF LC/MS|6545 Q-TOF LC/MS|6550 iFunnel Q-TOF LC/MS|6550A iFunnel Q-TOF LC/MS|6560 Q-TOF LC/MS|6570 Q-TOF LC/MS|66|68|6th|7|7-Cyanoquinocarcinol|7-Ethyl-10-Hydroxycamptothecin|7-Hydroxystaurosporine|70|7000 Triple Quadrupole GC/MS System|7000A Triple Quadrupole GC/MS|7000B Triple Quadrupole GC/MS|71|7200 GC/Q-TOF|73|7800 Quadrupole ICP-MS|7th|8|8-Azaguanine|80|8000/0|8000/1|8000/3|8000/6|8000/9|8001/0|8001/1|8001/3|8002/3|8003/3|8004/3|8005/0|8005/3|8010/0|8010/2|8010/3|8010/6|8010/9|8011/0|8011/3|8012/3|8013/3|8014/3|8015/3|8020/3|8020/6|8021/3|8022/3|8023/3|8030/3|8031/3|8032/3|8033/3|8034/3|8035/3|8040/0|8040/1|8040/3|8041/3|8041/34|8041/6|8042/3|8043/3|8044/3|8045/3|8046/3|8046/6|8050/0|8050/2|8050/3|8051/0|8051/3|8052/0|8052/2|8052/3|8053/0|8060/0|8070/2|8070/3|8070/33|8070/6|8071/2|8071/3|8072/3|8073/3|8074/3|8075/3|8076/2|8076/3|8077/0|8077/2|8078/3|8080/2|8081/2|8082/3|8083/3|8084/3|8085/3|8086/3|8090/1|8090/3|8091/3|8092/3|8093/3|8094/3|8095/3|8096/0|8097/3|8098/3|81|8100/0|8101/0|8102/0|8102/3|8103/0|8110/0|8110/3|8120/0|8120/1|8120/2|8120/3|8121/0|8121/1|8121/3|8122/3|8123/3|8124/3|8130/1|8130/2|8130/3|8131/3|8140/0|8140/1|8140/2|8140/3|8140/33|8140/6|8141/3|8142/3|8143/3|8144/3|8145/3|8146/0|8147/0|8147/3|8148/0|8148/2|8149/0|8150/0|8150/1|8150/3|8151/0|8151/3|8152/1|8152/3|8153/1|8153/3|8154/3|8155/1|8155/3|8156/1|8156/3|8158/1|8160/0|8160/3|8161/0|8161/3|8162/3|8163/0|8163/2|8163/3|8170/0|8170/3|8171/3|8172/3|8173/3|8174/3|8175/3|8180/3|8190/0|8190/3|8191/0|82|8200/0|8200/3|8201/2|8201/3|8202/0|8204/0|8210/0|8210/2|8210/3|8211/0|8211/3|8212/0|8213/0|8213/3|8214/3|8215/3|8220/0|8220/3|8221/0|8221/3|8230/2|8230/3|8231/3|8240/1|8240/3|8240/6|8241/3|8242/1|8242/3|8243/3|8244/3|8245/1|8245/3|8246/3|8246/6|8247/3|8248/1|8249/3|8249/6|8250/1|8250/2|8250/3|8251/0|8251/3|8252/3|8253/3|8254/3|8255/3|8256/3|8257/3|8260/0|8260/3|8261/0|8261/2|8261/3|8262/3|8263/0|8263/2|8263/3|8264/0|8265/3|8270/0|8270/3|8271/0|8272/0|8272/3|8280/0|8280/3|8281/0|8281/3|8290/0|8290/3|8300/0|8300/3|8310/0|8310/3|8310/6|8311/1|8311/3|8311/6|8312/3|8313/0|8313/1|8313/3|8314/3|8315/3|8316/3|8317/3|8318/3|8319/3|8320/3|8321/0|8322/0|8322/3|8323/0|8323/3|8324/0|8325/0|8330/0|8330/1|8330/3|8331/3|8332/3|8333/0|8333/3|8334/0|8335/3|8336/0|8337/3|8339/3|8340/3|8341/3|8342/3|8343/2|8343/3|8344/3|8345/3|8346/3|8347/3|8350/3|8360/1|8361/0|8370/0|8370/1|8370/3|8371/0|8372/0|8373/0|8374/0|8375/0|8380/0|8380/1|8380/2|8380/3|8380/6|8381/0|8381/1|8381/3|8382/3|8383/3|8384/3|8390/0|8390/3|8391/0|8392/0|8400/0|8400/1|8400/3|8401/0|8401/3|8402/0|8402/3|8403/0|8403/3|8404/0|8405/0|8406/0|8407/0|8407/3|8408/0|8408/1|8408/3|8409/0|8409/3|8410/0|8410/3|8413/3|8420/0|8420/3|8430/1|8430/3|8440/0|8440/3|8441/0|8441/2|8441/3|8441/6|8442/1|8443/0|8444/1|8450/0|8450/3|8451/1|8452/1|8452/3|8453/0|8453/2|8453/3|8454/0|8460/0|8460/2|8460/3|8461/0|8461/3|8461/6|8462/1|8463/1|8470/0|8470/2|8470/3|8471/0|8471/1|8471/3|8472/1|8473/1|8474/1|8474/3|8480/0|8480/1|8480/3|8480/6|8481/3|8482/3|8482/6|8490/3|8490/6|85|8500/2|8500/3|8500/6|8501/2|8501/3|8502/3|8503/0|8503/2|8503/3|8504/0|8504/2|8504/3|8505/0|8506/0|8507/2|8507/3|8508/3|8509/2|8509/3|8510/3|8512/3|8513/3|8514/3|8519/2|8520/2|8520/3|8521/1|8521/3|8522/1|8522/2|8522/3|8522/6|8523/3|8524/3|8525/3|8530/3|8540/3|8541/3|8542/3|8543/3|8550/0|8550/1|8550/3|8551/3|8552/3|8560/0|8560/3|8561/0|8562/3|8570/3|8571/3|8572/3|8573/3|8574/3|8575/3|8576/3|8580/0|8580/1|8580/3|8581/1|8581/3|8582/1|8582/3|8583/1|8583/3|8584/1|8584/3|8585/1|8585/3|8586/3|8587/0|8588/3|8589/3|8590/1|8591/1|8592/1|8593/1|8594/1|86|8600/0|8600/3|8601/0|8602/0|8610/0|8620/1|8620/3|8621/1|8622/1|8623/1|8630/0|8630/1|8630/3|8631/0|8631/1|8631/3|8632/1|8633/1|8634/1|8634/3|8640/1|8640/3|8641/0|8642/1|8650/0|8650/1|8650/3|8660/0|8670/0|8670/3|8671/0|8680/0|8680/1|8680/3|8681/1|8682/1|8683/0|8690/1|8691/1|8692/1|8693/1|8693/3|87|8700/0|8700/3|8710/3|8711/0|8711/3|8712/0|8713/0|8714/3|8720/0|8720/2|8720/3|8720/6|8721/3|8722/0|8722/3|8723/0|8723/3|8725/0|8726/0|8727/0|8728/0|8728/1|8728/3|8730/0|8730/3|8740/0|8740/3|8741/2|8741/3|8742/2|8742/3|8743/3|8744/3|8745/3|8746/3|8750/0|8760/0|8761/0|8761/1|8761/3|8762/1|8770/0|8770/3|8771/0|8771/3|8772/0|8772/3|8773/3|8774/3|8780/0|8780/3|8790/0|8800 Triple Quadrupole ICP-MS|8800/0|8800/3|8800/6|8800/9|8801/3|8801/6|8802/3|8803/3|8804/3|8804/6|8805/3|8806/3|8806/6|8810/0|8810/1|8810/3|8811/0|8811/1|8811/3|8812/0|8812/3|8813/0|8813/3|8814/3|8815/0|8815/1|8815/3|8820/0|8821/1|8822/1|8823/0|8824/0|8824/1|8825/0|8825/1|8825/3|8826/0|8827/1|8830/0|8830/1|8830/3|8831/0|8832/0|8832/3|8833/3|8834/1|8835/1|8836/1|8840/0|8840/3|8841/1|8842/0|8842/3|8850/0|8850/1|8850/3|8851/0|8851/3|8852/0|8852/3|8853/3|8854/0|8854/3|8855/3|8856/0|8857/0|8857/3|8858/3|8860/0|8861/0|8862/0|8870/0|8880/0|8881/0|8890/0|8890/1|8890/3|8891/0|8891/3|8892/0|8893/0|8894/0|8894/3|8895/0|8895/3|8896/3|8897/1|8898/1|8900/0|8900/3|8901/3|8902/3|8903/0|8904/0|8905/0|8910/3|8912/3|8920/3|8920/6|8921/3|8930/0|8930/3|8931/3|8932/0|8933/3|8934/3|8935/0|8935/1|8935/3|8936/0|8936/1|8936/3|8940/0|8940/3|8941/3|8950/3|8950/6|8951/3|8959/0|8959/1|8959/3|8960/1|8960/3|8963/3|8964/3|8965/0|8966/0|8967/0|8970/3|8971/3|8972/3|8973/3|8974/1|8975/1|8980/3|8981/3|8982/0|8982/3|8983/0|8983/3|8990/0|8990/1|8990/3|8991/3|8th|9|9-Ethyl 6-Mercaptopurine|90|9000/0|9000/1|9000/3|9010/0|9011/0|9012/0|9013/0|9014/0|9014/1|9014/3|9015/0|9015/1|9015/3|9016/0|9020/0|9020/1|9020/3|9030/0|9040/0|9040/3|9041/3|9042/3|9043/3|9044/3|9045/3|9050/0|9050/3|9051/0|9051/3|9052/0|9052/3|9053/3|9054/0|9055/0|9055/1|9060/3|9061/3|9062/3|9063/3|9064/2|9064/3|9065/3|9070/3|9071/3|9072/3|9073/1|9080/0|9080/1|9080/3|9081/3|9082/3|9083/3|9084/0|9084/3|9085/3|9086/3|9090/0|9090/3|9091/1|9100/0|9100/1|9100/3|9101/3|9102/3|9103/0|9104/1|9105/3|9110/0|9110/1|9110/3|9120/0|9120/3|9121/0|9122/0|9123/0|9124/3|9125/0|9130/0|9130/1|9130/3|9131/0|9132/0|9133/1|9133/3|9135/1|9136/1|9137/3|9140/3|9141/0|9142/0|9150/0|9150/1|9150/3|9160/0|9161/0|9161/1|9170/0|9170/3|9171/0|9172/0|9173/0|9174/0|9174/1|9175/0|9180/0|9180/3|9180/6|9181/3|9182/3|9183/3|9184/3|9185/3|9186/3|9187/3|9191/0|9192/3|9193/3|9194/3|9195/3|9200/0|9200/1|9210/0|9210/1|9220/0|9220/1|9220/3|9221/0|9221/3|9230/0|9230/3|9231/3|9240/3|9241/0|9242/3|9243/3|9250/1|9250/3|9251/1|9251/3|9252/0|9252/3|9260/3|9261/3|9262/0|9270/0|9270/1|9270/3|9271/0|9272/0|9273/0|9274/0|9275/0|9280/0|9281/0|9282/0|9290/0|9290/3|9300/0|9301/0|9302/0|9302/3|9310/0|9310/3|9311/0|9312/0|9320/0|9321/0|9322/0|9330/0|9330/3|9340/0|9341/1|9341/3|9342/3|9350/1|9351/1|9352/1|9360/1|9361/1|9362/3|9363/0|9364/3|9365/3|9370/3|9371/3|9372/3|9373/0|9380/3|9381/3|9382/3|9383/1|9384/1|9385/3|9390/0|9390/1|9390/3|9391/3|9392/3|9393/3|9394/1|9395/3|9396/3|9400/3|9401/3|9410/3|9411/3|9412/1|9413/0|9420/3|9421/1|9423/3|9424/3|9425/3|9430/3|9431/1|9432/1|9440/3|9440/6|9441/3|9442/1|9442/3|9444/1|9445/3|9450/3|9451/3|9460/3|9470/3|9471/3|9472/3|9473/3|9474/3|9475/3|9476/3|9477/3|9478/3|9480/3|9490/0|9490/3|9491/0|9492/0|9493/0|9500/3|9501/0|9501/3|9502/0|9502/3|9503/3|9504/3|9505/1|9505/3|9506/1|9507/0|9508/3|9509/1|9510/0|9510/3|9511/3|9512/3|9513/3|9514/1|9520/3|9521/3|9522/3|9523/3|9530/0|9530/1|9530/3|9531/0|9532/0|9533/0|9534/0|9535/0|9537/0|9538/1|9538/3|9539/1|9539/3|9540/0|9540/1|9540/3|9541/0|9542/3|9550/0|9560/0|9560/1|9560/3|9561/3|9562/0|9570/0|9571/0|9571/3|9580/0|9580/3|9581/3|9582/0|9590/3|9591/3|9596/3|9597/3|9650/3|9651/3|9652/3|9653/3|9654/3|9655/3|9659/3|9661/3|9662/3|9663/3|9664/3|9665/3|9667/3|9670/3|9671/3|9673/3|9675/3|9678/3|9679/3|9680/3|9684/3|9687/3|9688/3|9689/3|9690/3|9691/3|9695/3|9698/3|9699/3|9700/3|9701/3|9702/3|9705/3|9708/3|9709/3|9712/3|9714/3|9716/3|9717/3|9718/3|9719/3|9724/3|9725/3|9726/3|9727/3|9728/3|9729/3|9731/3|9732/3|9733/3|9734/3|9735/3|9737/3|9738/3|9740/1|9740/3|9741/1|9741/3|9742/3|9750/3|9751/1|9751/3|9752/1|9753/1|9754/3|9755/3|9756/3|9757/3|9758/3|9759/3|9760/3|9761/3|9762/3|9764/3|9765/1|9766/1|9767/1|9768/1|9769/1|9800/3|9801/3|9805/3|9806/3|9807/3|9808/3|9809/3|9811/3|9812/3|9813/3|9814/3|9815/3|9816/3|9817/3|9818/3|9820/3|9823/3|9826/3|9827/3|9831/3|9832/3|9833/3|9834/3|9835/3|9836/3|9837/3|9840/3|9860/3|9861/3|9863/3|9865/3|9866/3|9867/3|9869/3|9870/3|9871/3|9872/3|9873/3|9874/3|9875/3|9876/3|9891/3|9895/3|9896/3|9897/3|9898/1|9898/3|99|9910/3|9911/3|9920/3|9930/3|9931/3|9940/3|9945/3|9946/3|9948/3|9950/3|9960/3|9961/3|9962/3|9963/3|9964/3|9965/3|9966/3|9967/3|9970/1|9971/1|9971/3|9975/3|9980/3|9982/3|9983/3|9984/3|9985/3|9986/3|9987/3|9989/3|9991/3|9992/3|99mTc Bone Scintigraphy|9H-Purine-6Thio-98D|A|A081105|A081801|A2A Receptor Antagonist EOS100850|A5|A6|ACQUITY UPLC|ACQUITY UPLC H-Class|ACQUITY UPLC H-Class Bio|ACQUITY UPLC I-Class|ACQUITY UPLC Systems with 2D Technology|ACTH-producing tumor|ADF|ADH-1|AE37 Peptide/GM-CSF Vaccine|AEE788|AIN III|AJ-Adjuvant Therapy|AJCC v6 Stage|AJCC v7 Stage|AJCC v8 Stage|AKR1C3-activated Prodrug OBI-3424|AKT 1/2 Inhibitor BAY1125976|AKT Inhibitor ARQ 092|ALK Inhibitor|ALK Inhibitor ASP3026|ALK Inhibitor PLB 1003|ALK Inhibitor RO5424802|ALK Inhibitor TAE684|ALK Inhibitor WX-0593|ALK positive large B-cell lymphoma|ALK-2 Inhibitor TP-0184|ALK-FAK Inhibitor CEP-37440|ALK-Positive Large B-Cell Lymphoma|ALK/FAK/Pyk2 Inhibitor CT-707|ALK/ROS1/Met Inhibitor TQ-B3101|ALK/TRK Inhibitor TSR-011|ALK/c-Met Inhibitor  TQ-B3139|AML M6|APC8015F|APE1/Ref-1 Redox Inhibitor APX3330|API 100|API 100LC|API 150EX|API 150EX Prep|API 165|API 2000|API 300|API 3000|API 3200|API 350|API 365|API 4000|API 5000|API-US|AQUA|AR Antagonist BMS-641988|ARC Fusion Protein SL-279252|ASCAT2|ASP4132|ATAC-Seq|ATM Inhibitor M 3541|ATM Kinase Inhibitor AZD0156|ATM Kinase Inhibitor AZD1390|ATR Inhibitor RP-3500|ATR Kinase Inhibitor BAY1895344|ATR Kinase Inhibitor M1774|ATR Kinase Inhibitor M6620|ATR Kinase Inhibitor VX-803|AXIMA Assurance Linear MALDI-TOF|AXIMA CFR MALDI-TOF|AXIMA Confidence MALDI-TOF|AXIMA Performance MALDI-TOF/TOF|AXIMA-CFR plus|AXIMA-QIT|AXL Inhibitor DS-1205c|AXL Inhibitor SLC-391|AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M|AXL/ FLT3/VEGFR2 Inhibitor KC1036|Abagovomab|Abarelix|Abdomen|Abdomen, NOS|Abdomen, total|Abdominal (Mesenteric) Fibromatosis|Abdominal Distension|Abdominal Infection|Abdominal Pain|Abdominal Soft Tissue Necrosis|Abdominal Wall|Abdominal desmoid|Abdominal esophagus|Abdominal fibromatosis|Abdomino-perineal Resection of Rectum|Abducens Nerve Disorder|Abemaciclib|Abemaciclib Mesylate|Abexinostat|Abexinostat Tosylate|Abiraterone|Abiraterone Acetate|Abituzumab|Ablation, Cryo|Ablation, Ethanol Injection|Ablation, Microwave|Ablation, NOS|Ablation, Radiofrequency|Ablation, Radiosurgical|Abnormal|Abnormal Glucose Level|Absent|Absolute quantitation analysis|Acai Berry Juice|Acalabrutinib|Acalisib|Accela PDA|Acceptable treatment for TCGA tumor|Accessory Nerve Disorder|Accessory sinus, NOS|Accessory sinuses|Accidental Building Fire Smoke Exposure|Accidental Fire Smoke Exposure|Accidental Forest Fire Smoke Exposure|Accidental Grass Fire Smoke Exposure|Accidental Vehicle Fire Smoke Exposure|Accidental building fire smoke|Accidental fire smoke, NOS|Accidental fire smoke, grass|Accidental forest fire smoke|Accidental vehicle fire smoke|Aceglatone|Acetabulum|Acetate|Acetylcysteine|Acetylome|Achromic nevus|Acidophil adenocarcinoma|Acidophil adenoma|Acidophil carcinoma|Acidosis|Acinar Cell Adenoma|Acinar Cell Carcinoma|Acinar Cell Neoplasm|Acinar Cell Neoplasms|Acinar adenocarcinoma|Acinar adenocarcinoma, sarcomatoid|Acinar adenoma|Acinar carcinoma|Acinar cell adenoma|Acinar cell carcinoma|Acinar cell cystadenocarcinoma|Acinar cell tumor|Acinic cell adenocarcinoma|Acinic cell adenoma|Acinic cell tumor|Acitretin|Acivicin|Aclacinomycin B|Aclarubicin|Acodazole|Acodazole Hydrochloride|Acolbifene Hydrochloride|Acoustic Nerve Disorder NOS|Acoustic Schwannoma|Acoustic nerve|Acoustic neuroma|Acquired Cystic Disease-Associated Renal Cell Carcinoma|Acquired Progressive Lymphangioma|Acquired cystic disease-associated renal cell carcinoma (RCC)|Acquired tufted hemangioma|Acquity SQD|Acquity TQD|Acquity UPLC FLR|Acquity UPLC PDA|Acral Lentiginous Melanoma|Acral lentiginous melanoma, malignant|Acridine|Acridine Carboxamide|Acronine|Actinium Ac 225 Lintuzumab|Actinium Ac 225-FPI-1434|Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591|Actinomycin C2|Actinomycin C3|Actinomycin F1|Activated Partial Thromboplastin Time Prolonged|Activin Type 2B Receptor Fc Fusion Protein STM 434|Acute Basophilic Leukemia|Acute Bilineal Leukemia|Acute Biphenotypic Leukemia|Acute Coronary Syndrome|Acute Erythroid Leukemia|Acute Kidney Injury|Acute Leukemia|Acute Leukemia of Ambiguous Lineage (ALAL)|Acute Lymphoblastic Leukemia|Acute Megakaryoblastic Leukemia|Acute Monoblastic Leukemia|Acute Monoblastic and Monocytic Leukemia|Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1|Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia Not Otherwise Specified|Acute Myeloid Leukemia with Maturation|Acute Myeloid Leukemia with Minimal Differentiation|Acute Myeloid Leukemia with Multilineage Dysplasia|Acute Myeloid Leukemia with Mutated CEBPA|Acute Myeloid Leukemia with Mutated NPM1|Acute Myeloid Leukemia with Myelodysplasia-Related Changes|Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11|Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11|Acute Myeloid Leukemia with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM|Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11|Acute Myeloid Leukemia with t(6;9) (p23;q34.1); DEK-NUP214|Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A|Acute Myeloid Leukemia without Maturation|Acute Myelomonocytic Leukemia|Acute Myelomonocytic Leukemia with Abnormal Eosinophils|Acute Panmyelosis with Myelofibrosis|Acute Promyelocytic Leukemia with PML-RARA|Acute Renal Failure|Acute Undifferentiated Leukemia|Acute basophilic leukaemia|Acute bilineal leukemia|Acute biphenotypic leukemia|Acute erythremia|Acute erythremic myelosis|Acute erythroid leukaemia|Acute granulocytic leukemia|Acute leukemia, Burkitt type|Acute leukemia, NOS|Acute lymphatic leukemia|Acute lymphoblastic leukemia (ALL)|Acute lymphoblastic leukemia, L2 type, NOS|Acute lymphoblastic leukemia, NOS|Acute lymphoblastic leukemia, mature B-cell type|Acute lymphoblastic leukemia, precursor cell type|Acute lymphoblastic leukemia-lymphoma, NOS|Acute lymphocytic leukemia|Acute lymphoid leukemia|Acute megakaryoblastic leukaemia|Acute mixed lineage leukemia|Acute monoblastic and monocytic leukemia|Acute monoblastic leukemia|Acute monocytic leukemia|Acute myeloblastic leukemia|Acute myelocytic leukemia|Acute myelofibrosis|Acute myelogenous leukemia|Acute myeloid leukaemia, t(8;21)(q22;q22)|Acute myeloid leukemia (AML)|Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1|Acute myeloid leukemia with abnormal marrow eosinophils (includes all variants)|Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1|Acute myeloid leukemia with maturation|Acute myeloid leukemia with multilineage dysplasia|Acute myeloid leukemia with mutated CEBPA|Acute myeloid leukemia with mutated NPM1|Acute myeloid leukemia with myelodysplasia-related changes|Acute myeloid leukemia with prior myelodysplastic syndrome|Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP214|Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1|Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL|Acute myeloid leukemia without maturation|Acute myeloid leukemia without prior myelodysplastic syndrome|Acute myeloid leukemia, AML1(CBF-alpha)/ETO|Acute myeloid leukemia, CBF-beta/MYH11|Acute myeloid leukemia, M6 type|Acute myeloid leukemia, MLL|Acute myeloid leukemia, NOS|Acute myeloid leukemia, PML/RAR-alpha|Acute myeloid leukemia, inv(16)(p13;q22)|Acute myeloid leukemia, minimal differentiation|Acute myeloid leukemia, t(15:17)(g22;q11-12)|Acute myeloid leukemia, t(16;16)(p 13;q 11)|Acute myelomonocytic leukemia|Acute myelomonocytic leukemia with abnormal eosinophils|Acute myelosclerosis, NOS|Acute myloid leukemia, 11q23 abnormalities|Acute non-lymphocytic leukemia|Acute panmyelosis with myelofibrosis|Acute panmyelosis, NOS|Acute progressive histiocytosis X|Acute promyelocytic leukaemia, PML-RAR-alpha|Acute promyelocytic leukaemia, t(15;17)(q22;q11-12)|Acute promyelocytic leukemia, NOS|Acyclic Nucleoside Phosphonate Prodrug ABI-1968|Ad-RTS-hIL-12|Adagloxad Simolenin|Adamantinoma|Adamantinoma of long bones|Adamantinoma, NOS|Adamantinoma, malignant|Adamantinomatous Craniopharyngioma|Adavosertib|Additional - New Primary|Additional Metastatic|Adecatumumab|Adenoacanthoma|Adenoameloblastoma|Adenocarcinoid tumor|Adenocarcinoma|Adenocarcinoma In Situ|Adenocarcinoma In Situ in Adenomatous Polyp|Adenocarcinoma In Situ in Tubular Adenoma|Adenocarcinoma In Situ in Tubulovillous Adenoma|Adenocarcinoma In Situ in Villous Adenoma|Adenocarcinoma In Situ in a Polyp|Adenocarcinoma admixed with neuroendocrine carcinoma|Adenocarcinoma combined with other types of carcinoma|Adenocarcinoma in Adenomatous Polyp|Adenocarcinoma in Adenomatous Polyposis Coli|Adenocarcinoma in Multiple Adenomatous Polyps|Adenocarcinoma in Tubular Adenoma|Adenocarcinoma in Tubulovillous Adenoma|Adenocarcinoma in Villous Adenoma|Adenocarcinoma in a polyp, NOS|Adenocarcinoma in adenomatous polyp|Adenocarcinoma in adenomatous polyposis coli|Adenocarcinoma in multiple adenomatous polyps|Adenocarcinoma in polypoid adenoma|Adenocarcinoma in situ in a polyp, NOS|Adenocarcinoma in situ in adenomatous polyp|Adenocarcinoma in situ in polypoid adenoma|Adenocarcinoma in situ in tubular adenoma|Adenocarcinoma in situ in tubulovillous adenoma|Adenocarcinoma in situ in villous adenoma|Adenocarcinoma in situ, NOS|Adenocarcinoma in situ, mucinous|Adenocarcinoma in situ, non-mucinous|Adenocarcinoma in tubolovillous adenoma|Adenocarcinoma in tubular adenoma|Adenocarcinoma in villous adenoma|Adenocarcinoma of anal ducts|Adenocarcinoma of anal glands|Adenocarcinoma of rete ovarii|Adenocarcinoma with Apocrine Metaplasia|Adenocarcinoma with Cartilaginous Metaplasia|Adenocarcinoma with Cartilaginous and Osseous Metaplasia|Adenocarcinoma with Neuroendocrine Differentiation|Adenocarcinoma with Osseous Metaplasia|Adenocarcinoma with Spindle Cell Metaplasia|Adenocarcinoma with Squamous Metaplasia|Adenocarcinoma with apocrine metaplasia|Adenocarcinoma with cartilaginous and osseous metaplasia|Adenocarcinoma with cartilaginous metaplasia|Adenocarcinoma with mixed subtypes|Adenocarcinoma with neuroendocrine differentiation|Adenocarcinoma with osseous metaplasia|Adenocarcinoma with spindle cell metaplasia|Adenocarcinoma with squamous metaplasia|Adenocarcinoma, Endocervical Type|Adenocarcinoma, NOS|Adenocarcinoma, cribriform comedo-type|Adenocarcinoma, cylindroid|Adenocarcinoma, diffuse type|Adenocarcinoma, endocervical type|Adenocarcinoma, intestinal type|Adenocarcinoma, metastatic, NOS|Adenocarcinoma, pancreatobiliary type|Adenocystic carcinoma|Adenofibroma, NOS|Adenoid|Adenoid Cystic Carcinoma|Adenoid basal carcinoma|Adenoid cystic carcinoma|Adenolipoma|Adenolymphoma|Adenoma|Adenoma of nipple|Adenoma, NOS|Adenomas and Adenocarcinomas|Adenomatoid Odontogenic Tumor|Adenomatoid Tumor|Adenomatoid odontogenic tumor|Adenomatoid tumor, NOS|Adenomatosis, NOS|Adenomatous Polyp|Adenomatous Polyposis Coli|Adenomatous polyp, NOS|Adenomatous polyposis coli|Adenomyoepithelioma|Adenomyoepithelioma with carcinoma|Adenomyoma|Adenosarcoma|Adenosine A2A Receptor Antagonist AZD4635|Adenosine A2A Receptor Antagonist CS3005|Adenosine A2A Receptor Antagonist NIR178|Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999|Adenosine A2A/A2B Receptor Antagonist AB928|Adenosine A2B Receptor Antagonist PBF-1129|Adenosis (Atypical Adenomatous Hyperplasia)|Adenosquamous Carcinoma|Adenosquamous carcinoma|Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201|Adenoviral Brachyury Vaccine ETBX-051|Adenoviral Cancer Vaccine PF-06936308|Adenoviral MUC1 Vaccine ETBX-061|Adenoviral PSA Vaccine ETBX-071|Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001|Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP|Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901|Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE|Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918|Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931|Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3|Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001|Aderbasib|Adherent Cell Line|Adipose|Adjacent (< or = 2cm)|Adjuvant|Administrative Compliance|Adnexal Carcinoma|Adnexal and Skin Appendage Neoplasms|Adnexal carcinoma|Adnexal tumor, benign|Adopted Brother|Adopted Daughter|Adopted Sister|Adopted Son|Adoptive Brother|Adoptive Father|Adoptive Mother|Adoptive Sister|Adrenal|Adrenal Cortex Adenoma|Adrenal Cortex Carcinoma|Adrenal Cortex Clear Cell Adenoma|Adrenal Cortex Compact Cell Adenoma|Adrenal Cortex Glomerulosa Cell Adenoma|Adrenal Cortex Mixed Cell Adenoma|Adrenal Cortex Neoplasm|Adrenal Gland|Adrenal Gland Cancer|Adrenal Gland Myelolipoma|Adrenal Gland Pheochromocytoma|Adrenal Insufficiency|Adrenal Rest Tumor|Adrenal cortical adenocarcinoma|Adrenal cortical adenoma, NOS|Adrenal cortical adenoma, clear cell|Adrenal cortical adenoma, compact cell|Adrenal cortical adenoma, glomerulosa cell|Adrenal cortical adenoma, mixed cell|Adrenal cortical adenoma, pigmented|Adrenal cortical carcinoma|Adrenal cortical tumor, NOS|Adrenal cortical tumor, benign|Adrenal cortical tumor, malignant|Adrenal gland|Adrenal gland, NOS|Adrenal medullary paraganglioma|Adrenal medullary paraganglioma, malignant|Adrenal rest tumor|Adrenocortical Carcinoma|Adrenocortical Insufficiency|Adult Cystic Nephroma|Adult Cystic Teratoma|Adult Pleomorphic Rhabdomyosarcoma|Adult Respiratory Distress Syndrome|Adult T-Cell Leukemia/Lymphoma|Adult T-cell leukemia|Adult T-cell leukemia/lymphoma (HTLV-1 positive) (includes all variants)|Adult T-cell lymphoma|Adult T-cell lymphoma/leukemia|Adult Teratoma|Adult Type Granulosa Cell Tumor|Adult cystic teratoma|Adult granulosa cell tumor|Adult rhabdomyoma|Adult teratoma, NOS|Adverse|Adverse Event|Aerosol Gemcitabine|Aerosolized Aldesleukin|Aerosolized Liposomal Rubitecan|Afatinib|Afatinib Dimaleate|Affymetrix SNP 6.0|Afghanistan|Afimoxifene|After 60 Minutes|Afuresertib|Agatolimod Sodium|Agerafenib|Aggregated Somatic Mutation|Aggressive NK-Cell Leukemia|Aggressive NK-cell leukaemia|Aggressive Osteoblastoma|Aggressive Systemic Mastocytosis|Aggressive angiomyxoma|Aggressive digital papillary adenoma|Aggressive fibromatosis|Aggressive osteoblastoma|Aggressive systemic mastocytosis|Agilent|Agitation|Aglatimagene Besadenovec|Agnogenic myeloid metaplasia|Agonistic Anti-CD40 Monoclonal Antibody ADC-1013|Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949|Agonistic Anti-OX40 Monoclonal Antibody MEDI6469|Aircraft Smoke Exposure|Aircraft smoke|Akathisia|Akt Inhibitor LY2780301|Akt Inhibitor MK2206|Akt Inhibitor SR13668|Akt/ERK Inhibitor ONC201|Alacizumab Pegol|Alanine Aminotransferase Increased|Alanosine|Albania|Albumin-binding Cisplatin Prodrug BTP-114|Alcohol Consumption|Alcohol Intolerance|Alcoholic Liver Disease|Aldesleukin|Aldoxorubicin|Alectinib|Alefacept|Alemtuzumab|Alestramustine|Aleukemic Chronic Lymphocytic Leukemia|Aleukemic Leukemia|Aleukemic Lymphoid Leukemia|Aleukemic granulocytic leukemia|Aleukemic leukemia, NOS|Aleukemic lymphatic leukemia|Aleukemic lymphocytic leukemia|Aleukemic lymphoid leukemia|Aleukemic monocytic leukemia|Aleukemic myelogenous leukemia|Aleukemic myeloid leukemia|Alflutinib Mesylate|Algenpantucel-L|Algeria|Aligned Reads|Aligned Reads Index|Aliquot Ensemble Somatic Variant Merging and Masking|Alisertib|Alitretinoin|Alive|Alkaline Phosphatase Increased|Alkalosis|Alkotinib|Alkylating Agent-Related Acute Myeloid Leukemia|Alkylating Agent-Related Myelodysplastic Syndrome|Allele-specific Copy Number Segment|Allergic Reaction|Allergic Rhinitis|Allergies|Allergy, Animal, NOS|Allergy, Ant|Allergy, Bee|Allergy, Cat|Allergy, Dairy or Lactose|Allergy, Dog|Allergy, Eggs|Allergy, Food, NOS|Allergy, Fruit|Allergy, Meat|Allergy, Mold or Dust|Allergy, Nuts|Allergy, Processed Foods|Allergy, Seafood|Allergy, Wasp|Allodepleted T Cell Immunotherapeutic ATIR101|Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715|Allogeneic Anti-BCMA-CAR T-cells PBCAR269A|Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells|Allogeneic Anti-CD19 CAR T-cells ALLO-501A|Allogeneic Anti-CD19 Universal CAR-T Cells CTA101|Allogeneic Anti-CD19-CAR T-cells PBCAR0191|Allogeneic Anti-CD20 CAR T-cells LUCAR-20S|Allogeneic Anti-CD20-CAR T-cells PBCAR20A|Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22|Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100|Allogeneic CD56-positive CD3-negative Natural Killer Cells CYNK-001|Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001|Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120|Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130|Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A|Allogeneic Cellular Vaccine 1650-G|Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM|Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine|Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine|Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo|Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo|Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2|Allogeneic Irradiated Melanoma Cell Vaccine CSF470|Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307|Allogeneic Melanoma Vaccine AGI-101H|Allogeneic Natural Killer Cell Line MG4101|Allogeneic Natural Killer Cell Line NK-92|Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01|Allogeneic Renal Cell Carcinoma Vaccine MGN1601|Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19|Allosteric ErbB Inhibitor BDTX-189|Allovectin-7|Allprep FFPE DNA|Allprep RNA Extraction|Almurtide|Alobresib|Alofanib|Alopecia|Alpelisib|Alpha Galactosylceramide|Alpha Heavy Chain Disease|Alpha V Beta 1 Inhibitor ATN-161|Alpha V Beta 8 Antagonist PF-06940434|Alpha cell tumor, NOS|Alpha cell tumor, malignant|Alpha heavy chain disease|Alpha-1 Antitrypsin|Alpha-1 Antitrypsin Deficiency|Alpha-Gal AGI-134|Alpha-Glucosidase Inhibitor|Alpha-Thioguanine Deoxyriboside|Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H|Alpha-tocopheryloxyacetic Acid|Alsevalimab|Altered Mental Status|Alternate sample pipeline|Altiratinib|Altretamine|Alveolar Adenoma|Alveolar Rhabdomyosarcoma|Alveolar Ridge|Alveolar Soft Part Sarcoma|Alveolar adenocarcinoma|Alveolar adenoma|Alveolar carcinoma|Alveolar cell carcinoma|Alveolar rhabdomyosarcoma|Alveolar soft part sarcoma|Alvespimycin|Alvespimycin Hydrochloride|Alvocidib|Alvocidib Hydrochloride|Alvocidib Prodrug TP-1287|Amatuximab|Ambamustine|Ambazone|Amber|Amblyomin-X|Amcasertib|Amelanotic Melanoma|Amelanotic melanoma|Ameloblastic Carcinoma|Ameloblastic Fibro-Odontoma|Ameloblastic Fibrodentinoma|Ameloblastic Fibroma|Ameloblastic Fibrosarcoma|Ameloblastic carcinoma|Ameloblastic fibro-odontoma|Ameloblastic fibro-odontosarcoma|Ameloblastic fibrodentinoma|Ameloblastic fibrodentinosarcoma|Ameloblastic fibroma|Ameloblastic fibrosarcoma|Ameloblastic odontosarcoma|Ameloblastic sarcoma|Ameloblastoma|Ameloblastoma, NOS|Ameloblastoma, malignant|American Indian or Alaska Native|Ametantrone|Amifostine|Amino Acid Injection|Aminocamptothecin|Aminocamptothecin Colloidal Dispersion|Aminoflavone Prodrug AFP464|Aminopterin|Aminopterin Sodium|AminoxyTMT|Amivantamab|Amnesia|Amniotic Fluid|Amolimogene Bepiplasmid|Amonafide L-Malate|Ampulla Of Vater|Ampulla of Vater|Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with High Grade Dysplasia|Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with Low Grade Dysplasia|Amrubicin|Amrubicin Hydrochloride|Amsacrine|Amsacrine Lactate|Amsilarotene|Amustaline|Amustaline Dihydrochloride|Amuvatinib|Amuvatinib Hydrochloride|Anakinra|Anal Canal|Anal Canal Cloacogenic Carcinoma|Anal Cancer (all types)|Anal Fistula|Anal Glands Adenocarcinoma|Anal Hemorrhage|Anal Intraepithelial Neoplasia 3|Anal Mucositis|Anal Necrosis|Anal Pain|Anal Sphincter|Anal Stenosis|Anal Ulcer|Anal canal|Anal intraepithelial neoplasia, grade III|Anal intraepithelial neoplasia, low grade|Analysis Metadata|Anaphylaxis|Anaplastic (Malignant) Meningioma|Anaplastic Astrocytoma|Anaplastic Astrocytoma, IDH-Mutant|Anaplastic Astrocytoma, IDH-Wildtype|Anaplastic Ependymoma|Anaplastic Ganglioglioma|Anaplastic Large Cell Lymphoma|Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Anaplastic Lymphoma|Anaplastic Medulloblastoma|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted|Anaplastic Pleomorphic Xanthoastrocytoma|Anaplastic astrocytoma, IDH-mutant|Anaplastic astrocytoma, IDH-wildtype|Anaplastic large B-cell lymphoma|Anaplastic large cell lymphoma, ALK negative|Anaplastic large cell lymphoma, ALK positive|Anaplastic large cell lymphoma, CD30+|Anaplastic large cell lymphoma, NOS|Anaplastic large cell lymphoma, T cell and Null cell type|Anaplastic medulloblastoma|Anaplastic oligoastrocytoma|Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted|Anaplastic pleomorphic xanthroastrocytoma|Anastrozole|Anaxirone|Ancient schwannoma|Ancillary Treatment|Ancitabine|Ancitabine Hydrochloride|Andecaliximab|Andorra|Androblastoma, NOS|Androblastoma, benign|Androblastoma, malignant|Androgen Antagonist APC-100|Androgen Deprivation Therapy (ADT)|Androgen Receptor Antagonist BAY 1161116|Androgen Receptor Antagonist SHR3680|Androgen Receptor Antagonist TAS3681|Androgen Receptor Antagonist TRC253|Androgen Receptor Antisense Oligonucleotide AZD5312|Androgen Receptor Antisense Oligonucleotide EZN-4176|Androgen Receptor Degrader ARV-110|Androgen Receptor Degrader CC-94676|Androgen Receptor Downregulator AZD3514|Androgen Receptor Inhibitor EPI-7386|Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118|Androgen Receptor/Glucocorticoid Receptor  Antagonist CB-03-10|Andrographolide|Androstane Steroid HE3235|Anemia|Anetumab Ravtansine|Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241|Angioblastic meningioma|Angioblastoma|Angiocentric Glioma|Angiocentric Immunoproliferative Lesion|Angiocentric T-cell lymphoma|Angiocentric glioma|Angiocentric immunoproliferative lesion|Angioendothelioma|Angioendotheliomatosis|Angiofibroma|Angiofibroma, NOS|Angiogenesis Inhibitor GT-111|Angiogenesis Inhibitor JI-101|Angiogenesis/Heparanase Inhibitor PG545|Angioimmunoblastic T-Cell Lymphoma|Angioimmunoblastic T-cell lymphoma|Angioimmunoblastic lymphadenopathy|Angioimmunoblastic lymphoma|Angiokeratoma|Angioleiomyoma|Angiolipoma|Angiolipoma, NOS|Angioma, NOS|Angiomatoid Fibrous Histiocytoma|Angiomatoid fibrous histiocytoma|Angiomatous Meningioma|Angiomatous meningioma|Angiomyofibroblastoma|Angiomyolipoma|Angiomyoma|Angiomyosarcoma|Angiomyxoma|Angiopoietin-2-specific Fusion Protein PF-04856884|Angiosarcoma|Angiotropic lymphoma|Angola|Anguilla|Anhydrous Enol-oxaloacetate|Anhydrovinblastine|Aniline Mustard|Ankle|Ankle Fracture|Anlotinib Hydrochloride|Annamycin|Annamycin Liposomal|Annonaceous Acetogenins|Annotated Somatic Mutation|Anopheles gambiae|Anorectal Infection|Anorectum|Anorexia|Anorgasmia|Ansamitomicin P-3|Antacids|Antecubital Fossa|Anterior 2/3 of tongue, NOS|Anterior Resection of Rectum|Anterior Surface of the Epiglottis|Anterior Wall of the Nasopharynx|Anterior floor of mouth|Anterior mediastinum|Anterior surface of epiglottis|Anterior wall of bladder|Anterior wall of nasopharynx|Anthramycin|Anthrapyrazole|Anti c-KIT Antibody-drug Conjugate LOP628|Anti-5T4 Antibody-Drug Conjugate PF-06263507|Anti-5T4 Antibody-drug Conjugate ASN004|Anti-5T4 Antibody-drug Conjugate SYD1875|Anti-A33 Monoclonal Antibody KRN330|Anti-A5B1 Integrin Monoclonal Antibody PF-04605412|Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087|Anti-AG7 Antibody Drug Conjugate AbGn-107|Anti-AGS-16 Monoclonal Antibody AGS-16M18|Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME|Anti-AGS-8 Monoclonal Antibody AGS-8M4|Anti-ANG2 Monoclonal Antibody MEDI-3617|Anti-APRIL Monoclonal Antibody BION-1301|Anti-AXL Fusion Protein AVB-S6-500|Anti-AXL/PBD Antibody-drug Conjugate ADCT-601|Anti-B7-H3 Antibody DS-5573a|Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a|Anti-B7-H4 Monoclonal Antibody FPA150|Anti-B7H3 Antibody-drug Conjugate MGC018|Anti-BCMA Antibody SEA-BCMA|Anti-BCMA Antibody-drug Conjugate AMG 224|Anti-BCMA Antibody-drug Conjugate CC-99712|Anti-BCMA Antibody-drug Conjugate GSK2857916|Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA|Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459|Anti-BCMA/CD3 BiTE Antibody AMG 420|Anti-BCMA/CD3 BiTE Antibody AMG 701|Anti-BCMA/CD3 BiTE Antibody REGN5458|Anti-BCMA/PBD ADC MEDI2228|Anti-BTLA Monoclonal Antibody TAB004|Anti-BTN3A Agonistic Monoclonal Antibody ICT01|Anti-C-met Monoclonal Antibody SAIT301|Anti-C4.4a Antibody-Drug Conjugate BAY1129980|Anti-C5aR Monoclonal Antibody IPH5401|Anti-CA19-9 Monoclonal Antibody 5B1|Anti-CA6-DM4 Immunoconjugate SAR566658|Anti-CCR7 Antibody-drug Conjugate JBH492|Anti-CD117 Monoclonal Antibody JSP191|Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1|Anti-CD123 ADC IMGN632|Anti-CD123 Monoclonal Antibody CSL360|Anti-CD123 Monoclonal Antibody KHK2823|Anti-CD123 x Anti-CD3 Bispecific Antibody XmAb1404|Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A|Anti-CD123/CD3 BiTE Antibody SAR440234|Anti-CD123/CD3 Bispecific Antibody APVO436|Anti-CD123/CD3 Bispecific Antibody JNJ-63709178|Anti-CD137 Agonistic Monoclonal Antibody ADG106|Anti-CD137 Agonistic Monoclonal Antibody AGEN2373|Anti-CD137 Agonistic Monoclonal Antibody ATOR-1017|Anti-CD137 Agonistic Monoclonal Antibody CTX-471|Anti-CD137 Agonistic Monoclonal Antibody LVGN6051|Anti-CD157 Monoclonal Antibody MEN1112|Anti-CD166 Probody-drug Conjugate CX-2009|Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003|Anti-CD19 Antibody-drug Conjugate SGN-CD19B|Anti-CD19 Monoclonal Antibody DI-B4|Anti-CD19 Monoclonal Antibody MDX-1342|Anti-CD19 Monoclonal Antibody MEDI-551|Anti-CD19 Monoclonal Antibody XmAb5574|Anti-CD19 iCAR NK Cells|Anti-CD19-DM4 Immunoconjugate SAR3419|Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL|Anti-CD19/CD22 CAR NK Cells|Anti-CD19/CD3 BiTE Antibody AMG 562|Anti-CD19/CD3 Tetravalent Antibody AFM11|Anti-CD20 Monoclonal Antibody B001|Anti-CD20 Monoclonal Antibody BAT4306F|Anti-CD20 Monoclonal Antibody MIL62|Anti-CD20 Monoclonal Antibody PRO131921|Anti-CD20 Monoclonal Antibody SCT400|Anti-CD20 Monoclonal Antibody TL011|Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002|Anti-CD20-engineered Toxin Body MT-3724|Anti-CD20/Anti-CD3 Bispecific IgM Antibody IGM2323|Anti-CD20/CD3 Monoclonal Antibody REGN1979|Anti-CD20/CD3 Monoclonal Antibody XmAb13676|Anti-CD205 Antibody-drug Conjugate OBT076|Anti-CD22 ADC TRPH-222|Anti-CD22 Monoclonal Antibody-MMAE Conjugate DCDT2980S|Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A|Anti-CD25 Monoclonal Antibody RO7296682|Anti-CD25-PBD Antibody-drug Conjugate ADCT-301|Anti-CD26 Monoclonal Antibody YS110|Anti-CD27 Agonistic Monoclonal Antibody MK-5890|Anti-CD27L Antibody-Drug Conjugate AMG 172|Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1)|Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044|Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody JNJ-64007957|Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody PF-06863135|Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05|Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564|Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119|Anti-CD3/CD20 Bispecific Antibody GEN3013|Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424|Anti-CD3/CD7-Ricin Toxin A Immunotoxin|Anti-CD30 Monoclonal Antibody MDX-1401|Anti-CD30 Monoclonal Antibody XmAb2513|Anti-CD30/CD16A Monoclonal Antibody AFM13|Anti-CD30/DM1 Antibody-drug Conjugate F0002|Anti-CD32B Monoclonal Antibody BI-1206|Anti-CD33 Antibody-drug Conjugate IMGN779|Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564|Anti-CD33 Monoclonal Antibody BI 836858|Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633|Anti-CD33/CD3 BiTE Antibody AMG 330|Anti-CD33/CD3 BiTE Antibody AMG 673|Anti-CD33/CD3 Bispecific Antibody GEM 333|Anti-CD33/CD3 Bispecific Antibody JNJ-67571244|Anti-CD352 Antibody-drug Conjugate SGN-CD352A|Anti-CD37 Antibody-Drug Conjugate IMGN529|Anti-CD37 Bispecific Monoclonal Antibody GEN3009|Anti-CD37 MMAE Antibody-drug Conjugate AGS67E|Anti-CD37 Monoclonal Antibody BI 836826|Anti-CD38 Antibody-drug Conjugate STI-6129|Anti-CD38 Monoclonal Antibody MOR03087|Anti-CD38 Monoclonal Antibody SAR442085|Anti-CD38 Monoclonal Antibody TAK-079|Anti-CD38-targeted IgG4-attenuated IFNa TAK-573|Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257|Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342|Anti-CD39 Monoclonal Antibody SRF617|Anti-CD39 Monoclonal Antibody TTX-030|Anti-CD40 Agonist Monoclonal Antibody ABBV-927|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Anti-CD40 Monoclonal Antibody Chi Lob 7/4|Anti-CD40 Monoclonal Antibody SEA-CD40|Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042|Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428|Anti-CD40L Fc-Fusion Protein BMS-986004|Anti-CD44 Monoclonal Antibody RO5429083|Anti-CD45 Monoclonal Antibody AHN-12|Anti-CD46 Antibody-drug Conjugate FOR46|Anti-CD47 ADC SGN-CD47M|Anti-CD47 Monoclonal Antibody AO-176|Anti-CD47 Monoclonal Antibody CC-90002|Anti-CD47 Monoclonal Antibody Hu5F9-G4|Anti-CD47 Monoclonal Antibody IBI188|Anti-CD47 Monoclonal Antibody IMC-002|Anti-CD47 Monoclonal Antibody SHR-1603|Anti-CD47 Monoclonal Antibody SRF231|Anti-CD47 Monoclonal Antibody TJC4|Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801|Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A|Anti-CD52 Monoclonal Antibody ALLO-647|Anti-CD70 Antibody-Drug Conjugate MDX-1203|Anti-CD70 Antibody-drug Conjugate SGN-CD70A|Anti-CD70 CAR-expressing T Lymphocytes|Anti-CD70 Monoclonal Antibody MDX-1411|Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029|Anti-CD73 Monoclonal Antibody BMS-986179|Anti-CD73 Monoclonal Antibody CPI-006|Anti-CD73 Monoclonal Antibody NZV930|Anti-CD73 Monoclonal Antibody TJ4309|Anti-CD74 Antibody-drug Conjugate STRO-001|Anti-CD98 Monoclonal Antibody IGN523|Anti-CDH6 Antibody-drug Conjugate HKT288|Anti-CEA BiTE Monoclonal Antibody AMG211|Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody|Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2|Anti-CEACAM1 Monoclonal Antibody CM-24|Anti-CEACAM5 Antibody-Drug Conjugate SAR408701|Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47|Anti-CEACAM6 Antibody BAY1834942|Anti-CLDN6 Monoclonal Antibody ASP1650|Anti-CLEC12A/CD3 Bispecific Antibody MCLA117|Anti-CLEVER-1 Monoclonal Antibody FP-1305|Anti-CSF1 Monoclonal Antibody PD-0360324|Anti-CSF1R Monoclonal Antibody IMC-CS4|Anti-CSF1R Monoclonal Antibody SNDX-6352|Anti-CTGF Monoclonal Antibody FG-3019|Anti-CTLA-4 Monoclonal Antibody ADG116|Anti-CTLA-4 Monoclonal Antibody ADU-1604|Anti-CTLA-4 Monoclonal Antibody AGEN1181|Anti-CTLA-4 Monoclonal Antibody BCD-145|Anti-CTLA-4 Monoclonal Antibody HBM4003|Anti-CTLA-4 Monoclonal Antibody MK-1308|Anti-CTLA-4 Monoclonal Antibody ONC-392|Anti-CTLA-4 Monoclonal Antibody REGN4659|Anti-CTLA-4 Probody BMS-986288|Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217|Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841|Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015|Anti-CTLA4 Antibody Fc Fusion Protein KN044|Anti-CTLA4 Monoclonal Antibody BMS-986218|Anti-CXCR4 Monoclonal Antibody PF-06747143|Anti-Claudin18.2 Monoclonal Antibody TST001|Anti-DKK-1 Monoclonal Antibody LY2812176|Anti-DKK1 Monoclonal Antibody BHQ880|Anti-DLL3/CD3 BiTE Antibody AMG 757|Anti-DLL4 Monoclonal Antibody MEDI0639|Anti-DLL4/VEGF Bispecific Monoclonal Antibody OMP-305B83|Anti-DR5 Agonist Monoclonal Antibody TRA-8|Anti-DR5 Agonistic Antibody DS-8273a|Anti-DR5 Agonistic Monoclonal Antibody INBRX-109|Anti-Denatured Collagen Monoclonal Antibody TRC093|Anti-EGFR Monoclonal Antibody CPGJ 602|Anti-EGFR Monoclonal Antibody EMD 55900|Anti-EGFR Monoclonal Antibody GC1118|Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX|Anti-EGFR Monoclonal Antibody HLX-07|Anti-EGFR Monoclonal Antibody Mixture MM-151|Anti-EGFR Monoclonal Antibody RO5083945|Anti-EGFR Monoclonal Antibody SCT200|Anti-EGFR Monoclonal Antibody SYN004|Anti-EGFR TAP Antibody-drug Conjugate IMGN289|Anti-EGFR/CD16A Bispecific Antibody AFM24|Anti-EGFR/DM1 Antibody-drug Conjugate AVID100|Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013|Anti-EGFR/PBD Antibody-drug Conjugate ABBV-321|Anti-EGFR/c-Met Bispecific Antibody EMB-01|Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372|Anti-EGFRvIII Antibody Drug Conjugate AMG 595|Anti-EGFRvIII Immunotoxin MR1-1|Anti-EGFRvIII/CD3 BiTE Antibody AMG 596|Anti-EGP-2 Immunotoxin MOC31-PE|Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F|Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F|Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A|Anti-Ep-CAM Monoclonal Antibody ING-1|Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310|Anti-EphA2 Monoclonal Antibody DS-8895a|Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547|Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111|Anti-ErbB3 Antibody ISU104|Anti-ErbB3 Monoclonal Antibody AV-203|Anti-ErbB3 Monoclonal Antibody CDX-3379|Anti-ErbB3 Monoclonal Antibody REGN1400|Anti-ErbB3/Anti-IGF-1R Bispecific Monoclonal Antibody MM-141|Anti-FAP/Interleukin-2 Fusion Protein RO6874281|Anti-FCRH5/CD3 BiTE Antibody BFCR4350A|Anti-FGFR2 Antibody BAY1179470|Anti-FGFR3 Antibody-drug Conjugate LY3076226|Anti-FGFR4 Monoclonal Antibody U3-1784|Anti-FLT3 Antibody-drug Conjugate AGS62P1|Anti-FLT3 Monoclonal Antibody 4G8-SDIEM|Anti-FLT3 Monoclonal Antibody IMC-EB10|Anti-FLT3/CD3 BiTE Antibody AMG 427|Anti-FRA/Eribulin Antibody-drug Conjugate MORAb-202|Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002|Anti-GARP Monoclonal Antibody ABBV-151|Anti-GCC Antibody-Drug Conjugate MLN0264|Anti-GCC Antibody-Drug Conjugate TAK-164|Anti-GD2 Monoclonal Antibody MORAb-028|Anti-GD2 Monoclonal Antibody hu14.18K322A|Anti-GD2 hu3F8/Anti-CD3 huOKT3 Bispecific Antibody|Anti-GD3 Antibody-drug Conjugate PF-06688992|Anti-GITR Agonistic Monoclonal Antibody ASP1951|Anti-GITR Agonistic Monoclonal Antibody BMS-986156|Anti-GITR Agonistic Monoclonal Antibody INCAGN01876|Anti-GITR Monoclonal Antibody GWN 323|Anti-GITR Monoclonal Antibody MK-4166|Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a|Anti-GRP78 Monoclonal Antibody PAT-SM6|Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962|Anti-Globo H Monoclonal Antibody OBI-888|Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999|Anti-Glypican 3/CD3 Bispecific Antibody ERY974|Anti-GnRH Vaccine PEP223|Anti-HA Epitope Monoclonal Antibody MEDI8852|Anti-HB-EGF Monoclonal Antibody KHK2866|Anti-HBEGF Monoclonal Antibody U3-1565|Anti-HER-2 Bispecific Antibody KN026|Anti-HER2 ADC DS-8201a|Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702|Anti-HER2 Antibody-drug Conjugate A166|Anti-HER2 Antibody-drug Conjugate ARX788|Anti-HER2 Antibody-drug Conjugate BAT8001|Anti-HER2 Antibody-drug Conjugate DP303c|Anti-HER2 Antibody-drug Conjugate MEDI4276|Anti-HER2 Antibody-drug Conjugate RC48|Anti-HER2 Bi-specific Monoclonal Antibody ZW25|Anti-HER2 Bispecific Antibody-drug Conjugate ZW49|Anti-HER2 Immune Stimulator-antibody Conjugate NJH395|Anti-HER2 Monoclonal Antibody B002|Anti-HER2 Monoclonal Antibody CT-P6|Anti-HER2 Monoclonal Antibody HLX22|Anti-HER2 Monoclonal Antibody/Anti-CD137Anticalin Bispecific Fusion Protein PRS-343|Anti-HER2-DM1 ADC B003|Anti-HER2-DM1 Antibody-drug Conjugate GQ1001|Anti-HER2-vc0101 ADC PF-06804103|Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A|Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302|Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128|Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522|Anti-HER2/MMAE Antibody-drug Conjugate MRG002|Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A|Anti-HER3 Antibody-drug Conjugate U3 1402|Anti-HER3 Monoclonal Antibody GSK2849330|Anti-HGF Monoclonal Antibody TAK-701|Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968|Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1|Anti-HLA-DR Monoclonal Antibody IMMU-114|Anti-HLA-G Antibody TTX-080|Anti-ICAM-1 Monoclonal Antibody BI-505|Anti-ICOS Agonist Antibody GSK3359609|Anti-ICOS Agonist Monoclonal Antibody BMS-986226|Anti-ICOS Monoclonal Antibody KY1044|Anti-ICOS Monoclonal Antibody MEDI-570|Anti-IGF-1R Monoclonal Antibody AVE1642|Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022|Anti-IL-1 alpha Monoclonal Antibody MABp1|Anti-IL-13 Humanized Monoclonal Antibody TNX-650|Anti-IL-15 Monoclonal Antibody AMG 714|Anti-IL-8 Monoclonal Antibody BMS-986253|Anti-IL-8 Monoclonal Antibody HuMax-IL8|Anti-ILDR2 Monoclonal Antibody BAY 1905254|Anti-ILT4 Monoclonal Antibody MK-4830|Anti-IRF4 Antisense Oligonucleotide ION251|Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388|Anti-KIR Monoclonal Antibody IPH 2101|Anti-KSP/Anti-VEGF siRNAs ALN-VSP02|Anti-LAG-3 Monoclonal Antibody IBI-110|Anti-LAG-3 Monoclonal Antibody INCAGN02385|Anti-LAG-3 Monoclonal Antibody LAG525|Anti-LAG-3 Monoclonal Antibody REGN3767|Anti-LAG-3/PD-L1 Bispecific Antibody FS118|Anti-LAG3 Monoclonal Antibody BI 754111|Anti-LAG3 Monoclonal Antibody MK-4280|Anti-LAG3 Monoclonal Antibody TSR-033|Anti-LAMP1 Antibody-drug Conjugate SAR428926|Anti-LGR5 Monoclonal Antibody BNC101|Anti-LIF Monoclonal Antibody MSC-1|Anti-LILRB4 Monoclonal Antibody IO-202|Anti-LIV-1 Monoclonal Antibody-MMAE Conjugate SGN-LIV1A|Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102|Anti-Ly6E Antibody-Drug Conjugate RG 7841|Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C|Anti-MMP-9 Monoclonal Antibody GS-5745|Anti-MUC1 Monoclonal Antibody BTH1704|Anti-MUC16/CD3 BiTE Antibody REGN4018|Anti-MUC16/CD3 Bispecific Antibody REGN4018|Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A|Anti-MUC17/CD3 BiTE Antibody AMG 199|Anti-Melanin Monoclonal Antibody PTI-6D2|Anti-Met Monoclonal Antibody Mixture Sym015|Anti-Met/EGFR Monoclonal Antibody LY3164530|Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062|Anti-NRP1 Antibody ASP1948|Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A|Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso|Anti-NaPi2b Antibody-drug Conjugate XMT-1592|Anti-NaPi2b Monoclonal Antibody XMT-1535|Anti-Neuropilin-1 Monoclonal Antibody MNRP1685A|Anti-Nucleolin Aptamer AS1411|Anti-OFA Immunotherapeutic BB-MPI-03|Anti-OX40 Agonist Monoclonal Antibody ABBV-368|Anti-OX40 Agonist Monoclonal Antibody BGB-A445|Anti-OX40 Agonist Monoclonal Antibody PF-04518600|Anti-OX40 Antibody BMS 986178|Anti-OX40 Hexavalent Agonist Antibody INBRX-106|Anti-OX40 Monoclonal Antibody GSK3174998|Anti-OX40 Monoclonal Antibody IBI101|Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256|Anti-PD-1 Checkpoint Inhibitor PF-06801591|Anti-PD-1 Fusion Protein AMP-224|Anti-PD-1 Monoclonal Antibody 609A|Anti-PD-1 Monoclonal Antibody AK105|Anti-PD-1 Monoclonal Antibody AMG 404|Anti-PD-1 Monoclonal Antibody BAT1306|Anti-PD-1 Monoclonal Antibody BCD-100|Anti-PD-1 Monoclonal Antibody BI 754091|Anti-PD-1 Monoclonal Antibody CS1003|Anti-PD-1 Monoclonal Antibody F520|Anti-PD-1 Monoclonal Antibody GLS-010|Anti-PD-1 Monoclonal Antibody HLX10|Anti-PD-1 Monoclonal Antibody HX008|Anti-PD-1 Monoclonal Antibody JTX-4014|Anti-PD-1 Monoclonal Antibody LZM009|Anti-PD-1 Monoclonal Antibody MEDI0680|Anti-PD-1 Monoclonal Antibody MGA012|Anti-PD-1 Monoclonal Antibody SCT-I10A|Anti-PD-1 Monoclonal Antibody Sym021|Anti-PD-1 Monoclonal Antibody TSR-042|Anti-PD-1/Anti-CTLA4 DART Protein MGD019|Anti-PD-1/Anti-HER2 Bispecific Antibody IBI315|Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669|Anti-PD-1/Anti-LAG-3 DART Protein MGD013|Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318|Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172|Anti-PD-1/CD47 Infusion Protein HX009|Anti-PD-1/CTLA-4 Bispecific Antibody AK104|Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752|Anti-PD-1/TIM-3 Bispecific Antibody RO7121661|Anti-PD-1/VEGF Bispecific Antibody AK112|Anti-PD-L1 Monoclonal Antibody A167|Anti-PD-L1 Monoclonal Antibody BCD-135|Anti-PD-L1 Monoclonal Antibody BGB-A333|Anti-PD-L1 Monoclonal Antibody CBT-502|Anti-PD-L1 Monoclonal Antibody CK-301|Anti-PD-L1 Monoclonal Antibody CS1001|Anti-PD-L1 Monoclonal Antibody FAZ053|Anti-PD-L1 Monoclonal Antibody GR1405|Anti-PD-L1 Monoclonal Antibody HLX20|Anti-PD-L1 Monoclonal Antibody IMC-001|Anti-PD-L1 Monoclonal Antibody LY3300054|Anti-PD-L1 Monoclonal Antibody MDX-1105|Anti-PD-L1 Monoclonal Antibody MSB2311|Anti-PD-L1 Monoclonal Antibody RC98|Anti-PD-L1 Monoclonal Antibody SHR-1316|Anti-PD-L1 Monoclonal Antibody TG-1501|Anti-PD-L1 Monoclonal Antibody ZKAB001|Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105|Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046|Anti-PD-L1/CD137 Bispecific Antibody MCLA-145|Anti-PD-L1/IL-15 Fusion Protein KD033|Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244|Anti-PD1 Monoclonal Antibody AGEN2034|Anti-PD1/CTLA4 Bispecific Antibody XmAb20717|Anti-PGF Monoclonal Antibody RO5323441|Anti-PKN3 siRNA Atu027|Anti-PLGF Monoclonal Antibody TB-403|Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4|Anti-PRAME Immunotherapeutic GSK2302032A|Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C|Anti-PRL-3 Monoclonal Antibody PRL3-zumab|Anti-PSCA Monoclonal Antibody AGS-1C4D4|Anti-PSMA Monoclonal Antibody MDX1201-A488|Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704|Anti-PSMA Monoclonal Antibody-MMAE Conjugate|Anti-PSMA/CD28 Bispecific Antibody REGN5678|Anti-PSMA/CD3 Bispecific Antibody CCW702|Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081|Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414|Anti-PSMA/PBD ADC MEDI3726|Anti-PTK7/Auristatin-0101 Antibody-drug Conjugate PF-06647020|Anti-PVRIG Monoclonal Antibody COM701|Anti-RANKL Monoclonal Antibody GB-223|Anti-RANKL Monoclonal Antibody JMT103|Anti-ROR1 ADC VLS-101|Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002|Anti-Ribonucleoprotein Antibody ATRC-101|Anti-S15 Monoclonal Antibody NC318|Anti-SIRPa Monoclonal Antibody CC-95251|Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E|Anti-TAG-72 Monoclonal Antibody scFV CC-49/218|Anti-TF Monoclonal Antibody ALT-836|Anti-TGF-beta Monoclonal Antibody NIS793|Anti-TGF-beta Monoclonal Antibody SAR-439459|Anti-TGF-beta RII Monoclonal Antibody IMC-TR1|Anti-TIGIT Monoclonal Antibody AB154|Anti-TIGIT Monoclonal Antibody BGB-A1217|Anti-TIGIT Monoclonal Antibody BMS-986207|Anti-TIGIT Monoclonal Antibody COM902|Anti-TIGIT Monoclonal Antibody OMP-313M32|Anti-TIGIT Monoclonal Antibody SGN-TGT|Anti-TIM-3 Antibody BMS-986258|Anti-TIM-3 Monoclonal Antibody BGB-A425|Anti-TIM-3 Monoclonal Antibody INCAGN02390|Anti-TIM-3 Monoclonal Antibody MBG453|Anti-TIM-3 Monoclonal Antibody Sym023|Anti-TIM-3 Monoclonal Antibody TSR-022|Anti-TIM3 Monoclonal Antibody LY3321367|Anti-TIM3 Monoclonal Antibody SHR-1702|Anti-TNF Therapy|Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711|Anti-TROP2 Antibody-drug Conjugate BAT8003|Anti-TROP2 Antibody-drug Conjugate SKB264|Anti-TROP2/DXd Antibody-drug Conjugate DS-1062a|Anti-TWEAK Monoclonal Antibody RG7212|Anti-Tissue Factor Monoclonal Antibody MORAb-066|Anti-VEGF Anticalin PRS-050-PEG40|Anti-VEGF Monoclonal Antibody hPV19|Anti-VEGF/ANG2 Nanobody BI 836880|Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T|Anti-VEGFC Monoclonal Antibody VGX-100|Anti-VEGFR2 Monoclonal Antibody HLX06|Anti-VEGFR2 Monoclonal Antibody MSB0254|Anti-VEGFR3 Monoclonal Antibody IMC-3C5|Anti-VISTA Monoclonal Antibody JNJ 61610588|Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B|Anti-alpha5beta1 Integrin Antibody MINT1526A|Anti-angiopoietin Monoclonal Antibody AMG 780|Anti-c-KIT Monoclonal Antibody CDX 0158|Anti-c-MET Monoclonal Antibody LY2875358|Anti-c-Met Antibody-drug Conjugate HTI-1066|Anti-c-Met Antibody-drug Conjugate TR1801|Anti-c-Met Monoclonal Antibody ABT-700|Anti-c-Met Monoclonal Antibody ARGX-111|Anti-c-Met Monoclonal Antibody HLX55|Anti-c-fms Monoclonal Antibody AMG 820|Anti-claudin18.2 Monoclonal Antibody AB011|Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012|Anti-gpA33/CD3 Monoclonal Antibody MGD007|Anti-gremlin-1 Monoclonal Antibody UCB6114|Anti-hepcidin Monoclonal Antibody LY2787106|Anti-human GITR Monoclonal Antibody AMG 228|Anti-human GITR Monoclonal Antibody TRX518|Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A|Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181|Anti-mesothelin Antibody-drug Conjugate BMS-986148|Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100|Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A|Anti-mesothelin/MMAE Antibody-drug Conjugate RC88|Anti-myostatin Monoclonal Antibody LY2495655|Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E|Anti-nf-P2X7 Antibody Ointment BIL-010t|Anti-prolactin Receptor Antibody LFA102|Anti-sCLU Monoclonal Antibody AB-16B5|Antiangiogenic Drug Combination TL-118|Antibody-Drug Conjugate DFRF4539A|Antibody-drug Conjugate ABBV-011|Antibody-drug Conjugate ABBV-085|Antibody-drug Conjugate ABBV-155|Antibody-drug Conjugate ABBV-176|Antibody-drug Conjugate ABBV-838|Antibody-drug Conjugate ADC XMT-1536|Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014|Antibody-drug Conjugate MEDI7247|Antibody-drug Conjugate PF-06647263|Antibody-drug Conjugate PF-06664178|Antibody-drug Conjugate SC-002|Antibody-drug Conjugate SC-003|Antibody-drug Conjugate SC-004|Antibody-drug Conjugate SC-005|Antibody-drug Conjugate SC-006|Antibody-drug Conjugate SC-007|Antibody-like CD95 Receptor/Fc-fusion Protein CAN-008|Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV|Antigua and Barbuda|Antimetabolite FF-10502|Antineoplastic Agent Combination SM-88|Antineoplastic Vaccine|Antineoplastic Vaccine GV-1301|Antineoplaston A10|Antineoplaston AS2-1|Antiseizure Treatment|Antisense Oligonucleotide GTI-2040|Antisense Oligonucleotide QR-313|Antitumor B Key Active Component-alpha|Antrodia cinnamomea Supplement|Antroquinonol Capsule|Antrum|Antrum Pylori|Anus|Anus and anal canal|Anus, NOS|Anxiety|Aorta|Aortic Body|Aortic Injury|Aortic Valve Disease|Aortic body and other paraganglia|Aortic body paraganglioma|Aortic body tumor|Aorticopulmonary Paraganglioma|Aorticopulmonary paraganglioma|Apalutamide|Apatorsen|Apaziquone|Aphidicoline Glycinate|Aphonia|Apilimod Dimesylate Capsule|Apitolisib|Apnea|Apocrine Adenoma|Apocrine Hidrocystoma|Apocrine adenocarcinoma|Apocrine adenoma|Apocrine cystadenoma|Apolizumab|Apomab|Apomine|Apoptosis Inducer BZL101|Apoptosis Inducer GCS-100|Apoptosis Inducer MPC-2130|Appendage of the Uterus|Appendicitis|Appendicitis Perforated|Appendix|Applied Biosystems|Approved|Apricoxib|Aprinocarsen|Aprutumab|Aprutumab Ixadotin|Apudoma|Aqueous Fluid|Arabidopsis thaliana|Arabinoxylan Compound MGN3|Arachnoiditis|Aranose|Archexin|Archive|Arcitumomab|Arfolitixorin|Arg-C, Asp-N|Argentaffinoma, NOS|Argentaffinoma, malignant|Argentina|Arginase Inhibitor INCB001158|Arginine Butyrate|Arm|Armenia|Arnebia Indigo Jade Pearl Topical Cream|Arrhenoblastoma, NOS|Arrhenoblastoma, benign|Arrhenoblastoma, malignant|Arrhythmia|Arriba|Arsenic Trioxide|Arsenic Trioxide Capsule Formulation ORH 2014|Artemether Sublingual Spray|Artemisinin Dimer|Arterial Injury|Arteriovenous Hemangioma/Malformation|Arteriovenous hemangioma|Arteritis Infective|Artery|Artesunate|Arthralgia|Arthritis|Aruba|Arugula Seed Powder|Aryl Hydrocarbon Receptor Antagonist BAY2416964|Aryl Hydrocarbon Receptor Inhibitor IK-175|Asaley|AscatNGS|Ascending Colon|Ascending Colon Hepatic Flexure|Ascending colon|Asciminib|Ascites|Ascites Drainage|Ascrinvacumab|Ashwagandha Root Powder Extract|Asian|Askin Tumor|Askin tumor|Asp-N_ambic|Aspacytarabine|Asparaginase|Asparaginase Erwinia chrysanthemi|Aspartate Aminotransferase Increased|Aspirate|Aspiration|Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10|Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10|Asthma|Astroblastoma|Astrocytic Tumor|Astrocytic glioma|Astrocytoma|Astrocytoma, NOS|Astrocytoma, anaplastic|Astrocytoma, low grade|Astroglioma|Astuprotimut-R|Asulacrine|Asulacrine Isethionate|Asunercept|Asystole|At 211 Monoclonal Antibody 81C6|Atamestane|Ataxia|Ataxia-telangiectasia|Atelectasis|Atezolizumab|Atiprimod|Atiprimod Dihydrochloride|Atiprimod Dimaleate|Atorvastatin Calcium|Atorvastatin Sodium|Atrasentan Hydrochloride|Atrial Fibrillation|Atrial Flutter|Atrioventricular Block Complete|Atrioventricular Block First Degree|Attenuated Listeria monocytogenes CRS-100|Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001|Attenuated Measles Virus Encoding SCD Transgene TMV-018|Atuveciclib|Atypical|Atypical Adenoma|Atypical Burkitt/Burkitt-Like Lymphoma|Atypical Carcinoid Tumor|Atypical Choroid Plexus Papilloma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Atypical Endometrial Hyperplasia|Atypical Fibroxanthoma|Atypical Lipomatous Tumor|Atypical Meningioma|Atypical Polypoid Adenomyoma|Atypical Teratoid/Rhabdoid Tumor|Atypical adenoma|Atypical carcinoid tumor|Atypical choroid plexus papilloma|Atypical chronic myeloid leukemia, BCR/ABL negative|Atypical chronic myeloid leukemia, Philadelphia chromosome (Ph1) negative|Atypical fibrous histiocytoma|Atypical fibroxanthoma|Atypical follicular adenoma|Atypical hyperplasia/Endometrioid intraepithelial neoplasm|Atypical leiomyoma|Atypical lipoma|Atypical medullary carcinoma|Atypical meningioma|Atypical polypoid adenomyoma|Atypical proliferating clear cell tumor|Atypical proliferating serous tumor|Atypical proliferative endometrioid tumor|Atypical proliferative mucinous tumor|Atypical proliferative papillary serous tumor|Atypical teratoid/rhabdoid tumor|Audencel|Auditory Canal|Aunt|Auranofin|Aurora A Kinase Inhibitor LY3295668|Aurora A Kinase Inhibitor LY3295668 Erbumine|Aurora A Kinase Inhibitor MK5108|Aurora A Kinase Inhibitor TAS-119|Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076|Aurora B Serine/Threonine Kinase Inhibitor TAK-901|Aurora B/C Kinase Inhibitor GSK1070916A|Aurora Kinase Inhibitor AMG 900|Aurora Kinase Inhibitor BI 811283|Aurora Kinase Inhibitor MLN8054|Aurora Kinase Inhibitor PF-03814735|Aurora Kinase Inhibitor SNS-314|Aurora Kinase Inhibitor TTP607|Aurora Kinase/VEGFR2 Inhibitor CYC116|Aurora kinase A/B inhibitor TT-00420|Australia|Austria|Auto Spec Ultima NT|Autoimmune Atrophic Chronic Gastritis|Autoimmune Disorder|Autoimmune Lymphoproliferative Syndrome (ALPS)|Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707|Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055|Autologous AXL-targeted CAR T-cells CCT301-38|Autologous Anti-BCMA CAR T-cells PHE885|Autologous Anti-BCMA CAR-transduced T-cells KITE-585|Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11|Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T-lymphocytes JCARH125|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells CT053|Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143|Autologous Anti-CD123 CAR-T Cells|Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx|Autologous Anti-CD19 CAR T-cells IM19|Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19|Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19|Autologous Anti-CD19 CAR-CD28 T-cells ET019002|Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01|Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901|Autologous Anti-CD19 Chimeric Antigen Receptor T-cells AUTO1|Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19|Autologous Anti-CD19 T-cell Receptor T cells ET190L1|Autologous Anti-CD19 TAC-T cells TAC01-CD19|Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells|Autologous Anti-CD19/CD22 CAR T-cells AUTO3|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells|Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1|Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s|Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes|Autologous Anti-FLT3 CAR T Cells AMG 553|Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202|Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1|Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100|Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794|Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes|Autologous Anti-PSMA CAR-T Cells P-PSMA-101|Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes|Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B|Autologous BCMA-targeted CAR T Cells CC-98633|Autologous BCMA-targeted CAR T Cells LCAR-B4822M|Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528|Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F|Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022|Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001|Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3005|Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3006|Autologous CD123-4SCAR-expressing T-cells 4SCAR123|Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1|Autologous CD19-targeted CAR T Cells CC-97540|Autologous CD19-targeted CAR T Cells JWCAR029|Autologous CD19-targeted CAR-T Cells GC007F|Autologous CD19/PD-1 Bispecific CAR-T Cells|Autologous CD20-4SCAR-expressing T-cells 4SCAR20|Autologous CD22-4SCAR-expressing T-cells 4SCAR22|Autologous CD38-4SCAR-expressing T-cells 4SCAR38|Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19|Autologous Clonal Neoantigen T Cells ATL001|Autologous Deep IL-15 Primed T-cells TRQ15-01|Autologous Dendritic Cell Vaccine ACT2001|Autologous Dendritic Cell-based Immunotherapeutic AV0113|Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa|Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells|Autologous Genetically-modified MAGE-A4 C1032 T Cells|Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439|Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858|Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001|Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718|Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR|Autologous Mesenchymal Stem Cells Apceth_101|Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11|Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC|Autologous Multi-lineage Potential Cells|Autologous NKG2D CAR T-cells CYAD-02|Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01|Autologous Nectin-4/FAP-targeted CAR-T Cells|Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine|Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001|Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101|Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601|Autologous ROR2-targeted CAR T-cells CCT301-59|Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201|Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1|Autologous TCR-engineered T-cells IMA201|Autologous TCR-engineered T-cells IMA202|Autologous TCR-engineered T-cells IMA203|Autologous TCRm-expressing T-cells ET140203|Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG|Autologous Tumor Infiltrating Lymphocytes LN-144|Autologous Tumor Infiltrating Lymphocytes LN-145|Autologous Tumor Infiltrating Lymphocytes LN-145-S1|Autologous Tumor Infiltrating Lymphocytes MDA-TIL|Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T|Autonomic Nervous System|Autonomic nervous system, NOS|Autopsy|Avadomide|Avadomide Hydrochloride|Avapritinib|Avascular Necrosis|Avdoralimab|Avelumab|Aviscumine|Avitinib Maleate|Axalimogene Filolisbac|Axatilimab|Axicabtagene Ciloleucel|Axilla|Axillary Lymph Node|Axillary tail of breast|Axitinib|Axl/Mer Inhibitor INCB081776|Axl/Mer Inhibitor PF-07265807|Axumin|Azacitidine|Azapicyl|Azaribine|Azaserine|Azathioprine|Azerbaijan|Azimexon|Azintuxizumab Vedotin|Aziridinylbenzoquinone RH1|Azoospermia|Azotomycin|Azurin:50-77 Cell Penetrating Peptide p28|B|B Acute Lymphoblastic Leukemia|B Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy|B Lymphoblastic Leukemia/Lymphoma with Hypodiploidy|B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1|B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)|B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH|B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1|B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged|B Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified|B Lymphoblastic Lymphoma|B cell lymphoma, NOS|B lymphoblastic leukemia/lymphoma with hyperdiploidy|B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL)|B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)|B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)|B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH|B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1|B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged|B lymphoblastic leukemia/lymphoma, NOS|B-ALL|B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|B-Cell Prolymphocytic Leukemia|B-Raf/VEGFR-2 Inhibitor RAF265|B-cell lymphocytic leukemia/small lymphocytic lymphoma|B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma|B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma|B7|B8|B9|BAI|BALT lymphoma|BAM|BAP1 Tumor Predisposition Syndrome|BC-819 Plasmid/Polyethylenimine Complex|BCG Solution|BCG Tokyo-172 Strain Solution|BCG Vaccine|BCGSC miRNA Profiling|BCMA x CD3 T-cell Engaging Antibody CC-93269|BCMA-CD19 Compound CAR T Cells|BCMA/CD3e Tri-specific T-cell Activating Construct HPN217|BCR Auxiliary XML|BCR Biotab|BCR Notification|BCR OMF XML|BCR PPS XML|BCR SSF XML|BCR XML|BCR-ABL/KIT/AKT/ERK Inhibitor HQP1351|BED-Biochemical Evidence of Disease|BEDPE|BET Bromodomain Inhibitor ZEN-3694|BET Inhibitor ABBV-744|BET Inhibitor BAY1238097|BET Inhibitor BMS-986158|BET Inhibitor CC-90010|BET Inhibitor CPI-0610|BET Inhibitor FT-1101|BET Inhibitor GS-5829|BET Inhibitor GSK2820151|BET Inhibitor INCB054329|BET Inhibitor INCB057643|BET Inhibitor RO6870810|BET inhibitor BI 894999|BET-bromodomain Inhibitor ODM-207|BF-200 Gel Formulation|BH3 Mimetic ABT-737|BL22 Immunotoxin|BMI1 Inhibitor PTC596|BMS-184476|BMS-188797|BMS-214662|BMS-275183|BP-Cx1-Platinum Complex BP-C1|BR96-Doxorubicin Immunoconjugate|BRAF Inhibitor|BRAF Inhibitor ARQ 736|BRAF Inhibitor BGB-3245|BRAF Inhibitor PLX8394|BRAF(V600E) Kinase Inhibitor ABM-1310|BRAF(V600E) Kinase Inhibitor RO5212054|BRAF/EGFR Inhibitor BGB-283|BRAFV600/PI3K Inhibitor ASN003|BRASS|BRCA Family History|BRD4 Inhibitor PLX2853|BRD4 Inhibitor PLX51107|BTK Inhibitor ARQ 531|BTK Inhibitor CT-1530|BTK Inhibitor DTRMWXHS-12|BTK Inhibitor HZ-A-018|BTK Inhibitor ICP-022|BTK Inhibitor LOXO-305|BTK Inhibitor M7583|BTK inhibitor TG-1701|BWA|BWA with BQSR|BWA with Mark Duplicates and BQSR|BWA with Mark Duplicates and Cocleaning|BWA-aln|BWA-mem|BXQ-350 Nanovesicle Formulation|B_Allele_Freq|Babaodan Capsule|Bacillus Calmette-Guerin Substrain Connaught Live Antigen|Back|Back Pain|Bacteroides fragilis|Bactobolin|Bafetinib|Bahamas|Bahrain|Balixafortide|Balloon Cell Melanoma|Balloon Cell Nevus|Balloon cell melanoma|Balloon cell nevus|Balstilimab|Baltaleucel-T|Bangladesh|Banoxantrone|Barasertib|Barbados|Barcode incorrect|Bardoxolone|Bardoxolone Methyl|Baricitinib|Barrett's Esophagus|Basal Cell Cancer|Basal Cell Carcinoma|Basal Cell Neoplasm|Basal Cell Neoplasms|Basal cell adenocarcinoma|Basal cell adenoma|Basal cell carcinoma, NOS|Basal cell carcinoma, desmoplastic type|Basal cell carcinoma, fibroepithelial|Basal cell carcinoma, micronodular|Basal cell carcinoma, morpheic|Basal cell carcinoma, nodular|Basal cell epithelioma|Basal cell tumor|Basaloid Carcinoma|Basaloid Squamous Cell Carcinoma|Basaloid carcinoma|Basaloid squamous cell carcinoma|Base of the Tongue|Base of tongue|Base of tongue, NOS|Basophil adenocarcinoma|Basophil adenoma|Basophil carcinoma|Basophilic Adenocarcinoma|Basosquamous carcinoma|Batabulin|Batabulin Sodium|Batimastat|Bavituximab|Bazedoxifene|Bazlitoran|Bcl-2 Inhibitor APG 2575|Bcl-2 Inhibitor BCL201|Bcl-2 Inhibitor BGB-11417|Bcl-2 Inhibitor LP-108|Bcl-2 Inhibitor S65487|Bcl-Xs Adenovirus Vaccine|Bcr-Abl Kinase Inhibitor K0706|Bcr-Abl Kinase Inhibitor PF-114|Beauvericin|Becatecarin|Beckwith-Wiedemann|Bednar tumor|Beer|Behcet's Disease|Belagenpumatucel-L|Belantamab Mafodotin|Belapectin|Belarus|Belgium|Belimumab|Belinostat|Belize|Bellini duct carcinoma|Belotecan Hydrochloride|Belvarafenib|Belzutifan|Bemarituzumab|Bemcentinib|Bemisia tabaci (Gennadius)|Bempegaldesleukin|Benaxibine|Bendamustine|Bendamustine Hydrochloride|Bendamustine-containing Nanoparticle-based Formulation RXDX-107|Benign Adrenal Cortex Neoplasm|Benign Epithelial Neoplasm|Benign Fibrous Histiocytoma|Benign Gastrointestinal Stromal Tumor|Benign Hemangioendothelioma|Benign Hemangiopericytoma|Benign Leydig Cell Tumor|Benign Mesenchymoma|Benign Mesonephroma|Benign Mixed Tumor of the Skin|Benign Muscle Neoplasm|Benign Myoepithelioma|Benign Neoplasm|Benign Neoplasms|Benign Odontogenic Neoplasm|Benign Paraganglioma|Benign Phyllodes Tumor|Benign Prostatic Hyperplasia|Benign Sertoli Cell Tumor|Benign Skin Appendage Neoplasm|Benign Soft Tissue Neoplasm|Benign Stromal Tumor|Benign Sweat Gland Neoplasm|Benign Synovial Neoplasm|Benign Thymoma|Benign cystic nephroma|Benign fibrous histiocytoma|Benin|Benzaldehyde Dimethane Sulfonate|Benzoylphenylurea|Berberine Chloride|Bermekimab|Bermuda|Bersanlimab|Berubicin Hydrochloride|Berzosertib|Beta Alethine|Beta cell adenoma|Beta cell tumor, malignant|Beta-Carotene|Beta-Glucan|Beta-Glucan MM-10-001|Beta-Thioguanine Deoxyriboside|Beta-elemene|Beta-lapachone Prodrug ARQ 761|Betaglucin Gel|Betulinic Acid|Bevacizumab|Bexarotene|Bexmarilimab|Bhutan|Bi-functional Alkylating Agent VAL-083|BiTE Antibody AMG 910|Bicalutamide|Biguanide|Bilateral|Bile Duct|Bile Duct Adenocarcinoma|Bile Duct Adenoma|Bile Duct Cancer|Bile Duct Carcinoma|Bile Duct Mucinous Cystic Neoplasm|Bile Duct Mucinous Cystic Neoplasm with an Associated Invasive Carcinoma|Bile Duct Papillary Neoplasm|Bile Duct Papillary Neoplasm with High Grade Intraepithelial Neoplasia|Bile Duct Papillary Neoplasm with Low Grade Intraepithelial Neoplasia|Bile Duct Stenosis|Bile duct adenocarcinoma|Bile duct adenoma|Bile duct carcinoma|Bile duct cystadenocarcinoma|Bile duct cystadenoma|Biliary Anastomotic Leak|Biliary Disorder|Biliary Fistula|Biliary Intraepithelial Neoplasia-3|Biliary Tract Infection|Biliary intraepithelial neoplasia, grade 3|Biliary intraepithelial neoplasia, high grade|Biliary intraepithelial neoplasia, low grade|Biliary papillomatosis|Biliary tract, NOS|Bimiralisib|Binetrakin|Binimetinib|Bintrafusp Alfa|Bio-Q|BioSizing|Biochemical|Biochemical Evidence of Disease without Structural Correlate|Biochemical evidence of disease without structural correlate|Biological Brother|Biological Child|Biological Father|Biological Grandchild|Biological Grandfather|Biological Grandmother|Biological Grandparent|Biological Maternal Aunt|Biological Maternal Cousin|Biological Maternal Grandfather|Biological Maternal Grandmother|Biological Maternal Grandparent|Biological Maternal Uncle|Biological Mother|Biological Niece|Biological Parent|Biological Paternal Aunt|Biological Paternal Cousin|Biological Paternal Grandfather|Biological Paternal Grandmother|Biological Paternal Grandparent|Biological Paternal Uncle|Biological Sibling|Biological Sister|Biological Son|Biopsy|Biopsy with Histologic Confirmation|Biospecimen|Biospecimen Supplement|Biospecimen identity unknown|Biphasic Mesothelioma|Biphasic Synovial Sarcoma|Biphenotypic sinonasal sarcoma|Birabresib|Birdseed|Birinapant|Birt-Hogg-Dube Syndrome|Bis(choline)tetrathiomolybdate|Bisantrene|Bisantrene Hydrochloride|Bisnafide|Bisnafide Dimesylate|Bispecific Antibody 2B1|Bispecific Antibody AGEN1223|Bispecific Antibody AMG 509|Bispecific Antibody GS-1423|Bispecific Antibody MDX-H210|Bispecific Antibody MDX447|Bisphosphonate Therapy|Bisthianostat|Bisulfite-Seq|Bivalent BRD4 Inhibitor AZD5153|Bizalimogene Ralaplasmid|Bizarre Leiomyoma|Bizarre leiomyoma|Bizelesin|Black Cohosh|Black Raspberry Nectar|Black adenoma|Black or African American|Bladder|Bladder Anastomotic Leak|Bladder Cancer|Bladder Carcinoma|Bladder Infection|Bladder Neck|Bladder Papillary Urothelial Neoplasm of Low Malignant Potential|Bladder Perforation|Bladder Spasm|Bladder Trigone|Bladder Urachal Carcinoma|Bladder Urothelial Carcinoma|Bladder neck|Bladder, NOS|Blast cell leukemia|Blastic NK cell lymphoma|Blastic Plasmacytoid Dendritic Cell Neoplasm|Blastic plasmacytoid dendritic cell neoplasm|Blastoma|Blastoma, NOS|Bleomycin|Bleomycin A2|Bleomycin B2|Bleomycin Sulfate|Blinatumomab|Blinded Study, Treatment Unknown|Bloating|Blocking Release|Blood|Blood Antidiuretic Hormone Abnormal|Blood Bilirubin Increased|Blood Cancer|Blood Clots|Blood Corticotrophin Decreased|Blood Derived Cancer - Bone Marrow|Blood Derived Cancer - Bone Marrow, Post-treatment|Blood Derived Cancer - Peripheral Blood|Blood Derived Cancer - Peripheral Blood, Post-treatment|Blood Derived Liquid Biopsy|Blood Derived Normal|Blood Draw|Blood Gonadotrophin Abnormal|Blood Prolactin Abnormal|Blood Vessel|Blood Vessel Tumors|Blood and Lymphatic System Disorders - Other|Blue|Blue Nevus|Blue nevus, NOS|Blue nevus, malignant|Blueberry Powder Supplement|Blurred Vision|Boanmycin Hydrochloride|Body Odor|Body of Stomach|Body of pancreas|Body of penis|Body of stomach|Body of the Penis|Body, total|Bolivia|Bomedemstat|Bone|Bone Cancer|Bone Desmoplastic Fibroma|Bone Fracture(s)|Bone Infection|Bone Marrow|Bone Marrow Aspirate|Bone Marrow Components|Bone Marrow Components NOS|Bone Marrow Hypocellular|Bone Marrow Normal|Bone Pain|Bone marrow|Bone of limb, NOS|Bone, NOS|Bone, non-spine|Bones of skull and face and associated joints|Bones, joints and articular cartilage of limbs|Bones, joints and articular cartilage of other and unspecified sites|Border of tongue|Borderline Ovarian Brenner Tumor/Atypical Proliferative Ovarian Brenner Tumor|Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor|Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor|Borderline Ovarian Serous Tumor-Micropapillary Variant/Non-Invasive Low Grade Ovarian Serous Carcinoma|Borderline Papillary Cystadenoma|Borderline Papillary Mucinous Cystadenoma|Borderline Papillary Serous Cystadenoma|Borderline Phyllodes Tumor|Borderline Serous Cystadenoma|Boronophenylalanine-Fructose Complex|Bortezomib|Bos taurus|Bosnia and Herzegovina|Bosutinib|Bosutinib Monohydrate|Botanical Agent BEL-X-HG|Botanical Agent LEAC-102|Botryoid sarcoma|Botryoid-Type Embryonal Rhabdomyosarcoma|Botswana|Bovine Cartilage|Bowel|Bowen Disease of the Skin|Bowen disease|Bozitinib|Brachial Plexopathy|Brachytherapy, High Dose|Brachytherapy, Low Dose|Brachytherapy, NOS|Brachyury-expressing Yeast Vaccine GI-6301|Brain|Brain Cancer|Brain Lower Grade Glioma|Brain Stem|Brain stem|Brain, NOS|Branchial Cleft Remnant|Branchial cleft|Brazil|Breast|Breast Atrophy|Breast Cancer|Breast Cancer pTis (DCIS) TNM Finding v8|Breast Cancer pTis (LCIS) TNM Finding v6 and v7|Breast Carcinoma|Breast Carcinoma with Chondroid Metaplasia|Breast Carcinoma with Osseous Metaplasia|Breast Fibroadenoma|Breast Giant Fibroadenoma|Breast Infection|Breast Intracanalicular Fibroadenoma|Breast Invasive Carcinoma|Breast Juvenile Fibroadenoma|Breast Pain|Breast Pericanalicular Fibroadenoma|Breast, NOS|Breflate|Brenner Tumor|Brenner tumor, NOS|Brenner tumor, borderline malignancy|Brenner tumor, malignant|Brenner tumor, proliferating|Brentuximab|Brentuximab Vedotin|Brequinar|Brequinar Sodium|Briciclib Sodium|Brigatinib|Brilanestrant|Brimonidine Tartrate Nanoemulsion OCU-300|Brivanib|Brivanib Alaninate|Brivudine|Brivudine Phosphoramidate|Broad Ligament|Broad ligament|Broad-Spectrum Human Papillomavirus Vaccine V505|Broccoli Sprout/Broccoli Seed Extract Supplement|Bromacrylide|Bromebric Acid|Bromocriptine Mesylate|Bronchial Fistula|Bronchial Infection|Bronchial Mucosa-Associated Lymphoid Tissue Lymphoma|Bronchial Obstruction|Bronchial Stricture|Bronchial adenoma, NOS|Bronchial adenoma, carcinoid|Bronchial adenoma, cylindroid|Bronchial-associated lymphoid tissue lymphoma|Bronchio-alveolar carcinoma, mixed mucinous and non-mucinous|Bronchio-alveolar carcinoma, mucinous|Bronchiolar adenocarcinoma|Bronchiolar carcinoma|Bronchiole|Bronchiolo-alveolar adenocarcinoma, NOS|Bronchiolo-alveolar carcinoma, Clara cell|Bronchiolo-alveolar carcinoma, Clara cell and goblet cell type|Bronchiolo-alveolar carcinoma, NOS|Bronchiolo-alveolar carcinoma, goblet cell type|Bronchiolo-alveolar carcinoma, indeterminate type|Bronchiolo-alveolar carcinoma, non-mucinous|Bronchiolo-alveolar carcinoma, type II pneumocyte and goblet cell type|Bronchiolo-alveolar carcinoma; type II pneumocyte|Bronchitis|Bronchopleural Fistula|Bronchopulmonary Hemorrhage|Bronchospasm|Bronchus|Bronchus and lung|Brontictuzumab|Brooke tumor|Brostacillin Hydrochloride|Brostallicin|Brother|Brother-in-law|Brow|Brown|Brown fat tumor|Broxuridine|Bruceanol A|Bruceanol B|Bruceanol C|Bruceanol D|Bruceanol E|Bruceanol F|Bruceanol G|Bruceanol H|Bruceantin|Bruising|Bruker|Bruker Daltonics BioTOF series|Bruker Daltonics EVOQ series|Bruker Daltonics HCT series|Bruker Daltonics SCION series|Bruker Daltonics amaZon series|Bruker Daltonics apex series|Bruker Daltonics esquire series|Bruker Daltonics flex series|Bruker Daltonics maXis series|Bruker Daltonics micrOTOF series|Bruker Daltonics solarix series|Brunei|Bryostatin 1|Buccal Cavity|Buccal Cell Normal|Buccal Cells|Buccal Mucosa|Buccal Mucosal Resection|Budigalimab|Budotitane|Bufalin|Buffy Coat|Bulgaria|Bullous Dermatitis|Buparlisib|Burixafor|Burixafor Hydrobromide|Burkina Faso|Burkitt Leukemia|Burkitt Lymphoma|Burkitt cell leukemia|Burkitt lymphoma, NOS (Includes all variants)|Burkitt tumor|Burkitt-like lymphoma|Burn|Burning Oil Smoke Exposure|Burning Tree Smoke|Burning Waste Smoke Exposure|Burning Wood Smoke Exposure|Burning tree smoke|Burosumab|Burundi|Buserelin|Bushen Culuan Decoction|Bushen-Jianpi Decoction|Busulfan|Buthionine Sulfoximine|Buttock|Buttock Pain|C|C cell carcinoma|C-VISA BikDD:Liposome|C-myb Antisense Oligonucleotide G4460|C/EBP Beta Antagonist ST101|C10|C11|C12|C18|CAB-ROR2-ADC BA3021|CAIX Inhibitor DTP348|CAIX Inhibitor SLC-0111|CAR T-Cells AMG 119|CASTLE|CBP/beta-catenin Antagonist PRI-724|CBP/beta-catenin Modulator E7386|CCR2 Antagonist CCX872-B|CCR2 Antagonist PF-04136309|CCR2/CCR5 Antagonist BMS-813160|CCR4 Inhibitor FLX475|CD11b Agonist GB1275|CD123-CD33 Compound CAR T Cells|CD123-specific Targeting Module TM123|CD20-CD19 Compound CAR T Cells|CD28/ICOS Antagonist ALPN-101|CD4 Lymphocytes Decreased|CD4-specific Telomerase Peptide Vaccine UCPVax|CD40 Agonist Monoclonal Antibody CP-870,893|CD40 Agonistic Monoclonal Antibody APX005M|CD44 Targeted Agent SPL-108|CD44v6-specific CAR T-cells|CD47 Antagonist ALX148|CD73 Inhibitor AB680|CD73 Inhibitor LY3475070|CD80-Fc Fusion Protein ALPN-202|CD80-Fc Fusion Protein FPT155|CDC JSON|CDC7 Inhibitor TAK-931|CDC7 Kinase Inhibitor BMS-863233|CDC7 Kinase Inhibitor LY3143921 Hydrate|CDC7 Kinase Inhibitor NMS-1116354|CDK Inhibitor AT7519|CDK Inhibitor R547|CDK Inhibitor SNS-032|CDK/JAK2/FLT3 Inhibitor TG02 Citrate|CDK1 Inhibitor BEY1107|CDK1/2/4 Inhibitor AG-024322|CDK2 Inhibitor PF-07104091|CDK2/4/6/FLT3 Inhibitor FN-1501|CDK2/5/9 Inhibitor CYC065|CDK4 Inhibitor P1446A-05|CDK4/6 Inhibitor|CDK4/6 Inhibitor BPI-16350|CDK4/6 Inhibitor CS3002|CDK4/6 Inhibitor FCN-437|CDK4/6 Inhibitor G1T38|CDK4/6 Inhibitor HS-10342|CDK4/6 Inhibitor SHR6390|CDK4/6 Inhibitor TQB3616|CDK7 Inhibitor CT7001|CDK7 Inhibitor SY-1365|CDK7 Inhibitor SY-5609|CDK8/19 Inhibitor SEL 120|CDK9 Inhibitor AZD4573|CEA-MUC-1-TRICOM Vaccine CV301|CEA-targeting Agent RG6123|CEBPA-targeting saRNA MTL-CEBPA Liposome|CEL|CENP-E Inhibitor GSK-923295|CHK1 Inhibitor MK-8776|CHK1 Inhibitor PF-477736|CHP-NY-ESO-1 Peptide Vaccine IMF-001|CID|CIN III with severe dysplasia|CK1alpha/CDK7/CDK9 Inhibitor BTX-A51|CK2-targeting Synthetic Peptide CIGB-300|CL 246738|CNBr, Formic_acid|CNS Cancer|CNS Embryonal tumor with rhabdoid features|CNS, ependymoma|CNS, glioblastoma (GBM)|CNS, low grade glioma (LGG)|CNS, medulloblastoma|CNS, other|CNS, rhabdoid tumor|COPD|CPD-Clinical Progression|CPK Increased|CPNET|CR-Complete Response|CRU-Complete Response Unconfirmed|CSF-1R Inhibitor BLZ945|CSF1R Inhibitor ABSK021|CSF1R Inhibitor DCC-3014|CSF1R Inhibitor PLX73086|CSV|CT Scan|CT2584 HMS|CTLA-4-directed Probody BMS-986249|CXC Chemokine Receptor 2 Antagonist AZD5069|CXCR1/2 Inhibitor SX-682|CXCR2 Antagonist QBM076|CXCR4 Antagonist BL-8040|CXCR4 Antagonist USL311|CXCR4 Inhibitor Q-122|CXCR4 Peptide Antagonist LY2510924|CXCR4/E-selectin Antagonist GMI-1359|CYL-02 Plasmid DNA|CYP11A1 Inhibitor ODM-209|CYP11A1 inhibitor ODM-208|CYP17 Inhibitor CFG920|CYP17 Lyase Inhibitor ASN001|CYP17/Androgen Receptor Inhibitor ODM 204|CYP17/CYP11B2 Inhibitor LAE001|CaVEMan|CaVEMan Annotation|CaVEMan Variant Aggregation and Masking|Cabazitaxel|Cabiralizumab|Cabozantinib|Cabozantinib S-malate|Cactinomycin|Caenorhabditis briggsae|Caenorhabditis elegans|Caenorhabditis remanei|Caffeic Acid Phenethyl Ester|Calaspargase Pegol-mknl|Calcifying Cystic Odontogenic Tumor|Calcifying Epithelial Odontogenic Tumor|Calcifying epithelial odontogenic tumor|Calcifying epithelioma of Malherbe|Calcifying nested epithelial stromal tumor|Calcifying odontogenic cyst|Calcitriol|Calcium Channel Blockers|Calcium Release-activated Channel Inhibitor CM4620|Calcium Release-activated Channels Inhibitor RP4010|Calcium Saccharate|Calculus bovis/Moschus/Olibanum/Myrrha Capsule|Calf|Calicheamicin Gamma 1I|Cambodia|Cameroon|Camidanlumab Tesirine|Camptothecin|Camptothecin Analogue TLC388|Camptothecin Glycoconjugate BAY 38-3441|Camptothecin Sodium|Camptothecin-20(S)-O-Propionate Hydrate|Camrelizumab|Camsirubicin|Canada|Canalicular adenoma|Cancell|Cancer|Cancer Control|Cancer Peptide Vaccine S-588410|Cancer Related|Candidiasis|Canerpaturev|Canertinib Dihydrochloride|Canfosfamide|Canfosfamide Hydrochloride|Canis familiaris|Cannabidiol|Cantrixil|Cantuzumab Ravtansine|Cape Verde|Capecitabine|Capecitabine Rapidly Disintegrating Tablet|Capillary|Capillary Hemangioma|Capillary Leak Syndrome|Capillary hemangioma|Capillary lymphangioma|Capivasertib|Capmatinib|Captopril|Caracemide|Carbendazim|Carbetimer|Carbogen|Carbon C 14-pamiparib|Carbon Monoxide Diffusing Capacity Decreased|Carboplatin|Carboquone|Carboxyamidotriazole|Carboxyamidotriazole Orotate|Carboxyphenyl Retinamide|Carcinofibroma|Carcinoid Tumor|Carcinoid Tumor of Uncertain Malignant Potential|Carcinoid tumor of uncertain malignant potential|Carcinoid tumor, NOS|Carcinoid tumor, NOS, of appendix|Carcinoid tumor, argentaffin, NOS|Carcinoid tumor, argentaffin, malignant|Carcinoid, NOS|Carcinoid, NOS, of appendix|Carcinoma|Carcinoma In Situ|Carcinoma In Situ in a Polyp|Carcinoma Simplex|Carcinoma ex Pleomorphic Adenoma|Carcinoma in a Polyp|Carcinoma in a polyp, NOS|Carcinoma in adenomatous polyp|Carcinoma in pleomorphic adenoma|Carcinoma in situ in a polyp, NOS|Carcinoma in situ in adenomatous polyp|Carcinoma in situ, NOS|Carcinoma showing thymus-like differentiation|Carcinoma showing thymus-like element|Carcinoma simplex|Carcinoma with apocrine metaplasia|Carcinoma with chondroid differentiation|Carcinoma with neuroendocrine differentiation|Carcinoma with osseous differentiation|Carcinoma with osteoclast-like giant cells|Carcinoma with other types mesenchymal differentiation|Carcinoma with productive fibrosis|Carcinoma, NOS|Carcinoma, anaplastic, NOS|Carcinoma, diffuse type|Carcinoma, intestinal type|Carcinoma, metastatic, NOS|Carcinoma, undifferentiated, NOS|Carcinomatosis|Carcinosarcoma|Carcinosarcoma, NOS|Carcinosarcoma, embryonal|Cardia|Cardia, NOS|Cardiac Arrest|Cardiac Disorders - Other|Cardiac Troponin I Increased|Cardiac Troponin T Increased|Cardiovascular Disorder|Cardiovascular Disorder, NOS|Carfilzomib|Caricotamide/Tretazicar|Carina|Carlumab|Carmofur|Carmustine|Carmustine Implant|Carmustine Sustained-Release Implant Wafer|Carmustine in Ethanol|Carotid Artery|Carotid Body|Carotid Body Paraganglioma|Carotid body|Carotid body paraganglioma|Carotid body tumor|Carotuximab|Cartilage|Cartilaginous exostosis|Carubicin|Carubicin Hydrochloride|Carzelesin|Carzinophilin|Case submitted is found to be a recurrence after submission|Cataract|Cataracts|Cathelicidin LL-37|Catheter Related Infection|Cationic Liposome-Encapsulated Paclitaxel|Cationic Peptide Cream Cypep-1|Catumaxomab|Cauda equina|Cavernous Hemangioma|Cavernous Lymphangioma|Cavernous hemangioma|Cavernous lymphangioma|Cayman Islands|Cecal Hemorrhage|Cecal Infection|Cecum|Cedazuridine|Cedazuridine/Azacitidine Combination Agent ASTX030|Cedazuridine/Decitabine Combination Agent ASTX727|Cedefingol|Cediranib|Cediranib Maleate|Celecoxib|Celiac Disease|Cell|Cell Culture|Cell Culture Image|Cell Cycle Checkpoint/DNA Repair Antagonist IC83|Cell Line Derived Xenograft Tissue|Cell Lines|Cell-Line|CellRanger - 10x Chromium|CellRanger - 10x Filtered Counts|CellRanger - 10x Raw Counts|Cellular Angiofibroma|Cellular Blue Nevus|Cellular Ependymoma|Cellular Fibroma|Cellular Leiomyoma|Cellular Schwannoma|Cellular angiofibroma|Cellular blue nevus|Cellular ependymoma|Cellular fibroma|Cellular leiomyoma|Cellular schwannoma|Cemadotin|Cemadotin Hydrochloride|Cementifying fibroma|Cemento-ossifying fibroma|Cementoblastoma|Cementoblastoma, benign|Cementoma, NOS|Cemiplimab|Cenersen|Cenisertib|Center QC failed|CenterNotification|Central African Republic|Central Nervous System|Central Nervous System Embryonal Tumor with Rhabdoid Features|Central Nervous System Embryonal Tumor, Not Otherwise Specified|Central Nervous System Lymphoma|Central Nervous System Necrosis|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 1|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 2|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 3|Central Neurocytoma|Central neuroblastoma|Central neurocytoma|Central odontogenic fibroma|Central osteosarcoma|Central portion of breast|Central primitive neuroectodermal tumor, NOS|Centroblastic Lymphoma|Ceralasertib|Ceramide Nanoliposome|Cerdulatinib|Cerebellar Liponeurocytoma|Cerebellar Sarcoma|Cerebellar liponeurocytoma|Cerebellar sarcoma, NOS|Cerebellum|Cerebellum, NOS|Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480|Cereblon E3 Ubiquitin Ligase Modulating Agent CC-99282|Cereblon Modulator CC-90009|Cerebral Cortex|Cerebral Hemisphere|Cerebral Meninges|Cerebral meninges|Cerebrospinal Fluid|Cerebrospinal Fluid Leakage|Cerebrovascular Disease|Cerebrum|Cergutuzumab Amunaleukin|Ceritinib|Ceruminous Adenocarcinoma|Ceruminous adenocarcinoma|Ceruminous adenoma|Ceruminous carcinoma|Cervical Adenocarcinoma Admixed with Neuroendocrine Carcinoma|Cervical Cancer|Cervical Cancer (all types)|Cervical Cancer pT1a1 TNM Finding v8|Cervical Cancer pT1a2 TNM Finding v8|Cervical Carcinoma|Cervical Mucinous Adenocarcinoma, Gastric Type|Cervical Mucinous Adenocarcinoma, Intestinal-Type|Cervical Spine|Cervical Squamotransitional Carcinoma|Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma|Cervical Villoglandular Adenocarcinoma|Cervical esophagus|Cervical intraepithelial neoplasia, grade III|Cervical intraepithelial neoplasia, low grade|Cervicitis Infection|Cervix|Cervix Uteri|Cervix uteri|Cesalin|Cetrelimab|Cetuximab|Cetuximab Sarotalocan|Cetuximab-IR700 Conjugate RM-1929|Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY)|Cevipabulin|Cevipabulin Fumarate|Cevipabulin Succinate|Cevostamab|ChIP-Seq|Chad|Chaparrin|Chaparrinone|Checkpoint Kinase Inhibitor AZD7762|Checkpoint Kinase Inhibitor XL844|Cheek mucosa|Cheilitis|Chemical Lysis DNA Extraction|Chemodectoma|Chemoembolization|Chemoprotectant|Chemotherapy|Chest|Chest Pain - Cardiac|Chest Wall|Chest Wall Pain|ChiNing Decoction|Chiauranib|Chief cell adenoma|Child|Child-Pugh Class A|Child-Pugh Class A5|Child-Pugh Class A6|Child-Pugh Class B|Child-Pugh Class B7|Child-Pugh Class B8|Child-Pugh Class B9|Child-Pugh Class C|Child-Pugh Class C10|Child-Pugh Class C11|Child-Pugh Class C12|Childhood Astrocytic Tumor|Childhood Malignant Liver Neoplasm|Chile|Chills|Chimeric Monoclonal Antibody 81C6|Chin|China|Chk1 Inhibitor CCT245737|Chk1 Inhibitor GDC-0425|Chk1 Inhibitor GDC-0575|Chlamydia|Chlamydomonas reinhardtii|Chlorambucil|Chlorodihydropyrimidine|Chloroma|Chloroquine|Chloroquinoxaline Sulfonamide|Chlorotoxin|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes|Chlorozotocin|Cholangiocarcinoma|Cholangioma|Cholecystitis|Cholelithiasis|Cholesterol High|Choline|Choline Kinase Alpha Inhibitor TCD-717|Chondroblastic Osteosarcoma|Chondroblastic osteosarcoma|Chondroblastoma|Chondroblastoma, NOS|Chondroblastoma, malignant|Chondroid Chordoma|Chondroid Lipoma|Chondroid chordoma|Chondroid lipoma|Chondroid syringoma|Chondroma|Chondroma, NOS|Chondromatosis|Chondromatosis, NOS|Chondromatous giant cell tumor|Chondromyxoid Fibroma|Chondromyxoid fibroma|Chondrosarcoma|Chondrosarcoma grade 2/3|Chondrosarcoma, NOS|Chordoid Glioma of the Third Ventricle|Chordoid Meningioma|Chordoid glioma|Chordoid glioma of third ventricle|Chordoid meningioma|Chordoma|Chordoma, NOS|Chorioadenoma|Chorioadenoma destruens|Chorioangioma|Choriocarcinoma|Choriocarcinoma Combined with Other Germ Cell Elements|Choriocarcinoma combined with embryonal carcinoma|Choriocarcinoma combined with other germ cell elements|Choriocarcinoma combined with teratorna|Choriocarcinoma, NOS|Chorioepithelioma|Chorionepithelioma|Choroid|Choroid Plexus Carcinoma|Choroid Plexus Papilloma|Choroid plexus carcinoma|Choroid plexus papilloma, NOS|Choroid plexus papilloma, anaplastic|Choroid plexus papilloma, malignant|Choroidal and Ciliary Body Melanoma pT4e TNM Finding v8|Chromaffin paraganglioma|Chromaffin tumor|Chromaffinoma|Chromomycin A3|Chromophobe Renal Cell Carcinoma|Chromophobe adenocarcinoma|Chromophobe adenoma|Chromophobe carcinoma|Chromophobe cell renal carcinoma|Chronic Eosinophilic Leukemia, Not Otherwise Specified|Chronic Fatigue Syndrome|Chronic Hepatitis|Chronic Kidney Disease|Chronic Kidney Disease, Stage 5|Chronic Leukemia|Chronic Lymphocytic Leukemia|Chronic Lymphoproliferative Disorder of NK-Cells|Chronic Monocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Myeloproliferative Disorders|Chronic Neutrophilic Leukemia|Chronic Renal Failure|Chronic Systemic Steroid Use|Chronic eosinophilic leukemia, NOS|Chronic erythremia|Chronic granulocytic leukemia, BCR/ABL|Chronic granulocytic leukemia, NOS|Chronic granulocytic leukemia, Philadelphia chromosome (Ph1) positive|Chronic granulocytic leukemia, t(9;22)(q34;q11)|Chronic idiopathic myelofibrosis|Chronic leukemia, NOS|Chronic lymphatic leukemia|Chronic lymphocytic leukemia|Chronic lymphocytic leukemia, B-cell type (includes all variants of BCLL)|Chronic lymphoid leukemia|Chronic lymphoproliferative disorder of NK cells|Chronic monocytic leukemia|Chronic myelocytic leukemia, NOS|Chronic myelogenous leukemia, BCR-ABL positive|Chronic myelogenous leukemia, Philadelphia chromosome (Ph 1) positive|Chronic myelogenous leukemia, t(9;22)(q34;q11)|Chronic myeloid leukemia, NOS|Chronic myelomonocytic leukemia in transformation|Chronic myelomonocytic leukemia, NOS|Chronic myelomonocytic leukemia, Type 1|Chronic myelomonocytic leukemia, Type II|Chronic myeloproliferative disease, NOS|Chronic myeloproliferative disorder|Chronic neutrophilic leukemia|Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement|Chylothorax|Chymotrypsin|Cibisatamab|Ciclopirox Prodrug CPX-POM|Cidan Herbal Capsule|Ciforadenant|Cigar|Cigar Smoke Exposure|Cigarette|Cigarette Smoke Exposure|Cilengitide|Ciliary Body|Ciliary body|Ciltacabtagene Autoleucel|Cimetidine|Cin III, NOS|Cinacalcet Hydrochloride|Cinobufagin|Cinobufotalin|Cinrebafusp Alfa|Cintirorgon|Cintredekin Besudotox|Circumscribed arachnoidal cerebellar sarcoma|Cirmtuzumab|Cirrhosis|Cirrhosis, Unknown Etiology|Cisplatin|Cisplatin Liposomal|Cisplatin-E Therapeutic Implant|Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6|Citarinostat|Citatuzumab Bogatox|Citius HRT|Cixutumumab|Cladribine|Clanfenur|Clarithromycin|Class 1/4 Histone Deacetylase Inhibitor OKI-179|Classic Medulloblastoma|Classical Hodgkin lymphoma, lymphocyte depletion, NOS|Classical Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis|Classical Hodgkin lymphoma, lymphocyte depletion, reticular|Classical Hodgkin lymphoma, lymphocyte-rich|Classical Hodgkin lymphoma, mixed cellularity, NOS|Classical Hodgkin lymphoma, nodular sclerosis, NOS|Classical Hodgkin lymphoma, nodular sclerosis, cellular phase|Classical Hodgkin lymphoma, nodular sclerosis, grade 1|Classical Hodgkin lymphoma, nodular sclerosis, grade 2|Clavicle|Clear Cell Adenocarcinoma|Clear Cell Adenofibroma|Clear Cell Adenoma|Clear Cell Chondrosarcoma|Clear Cell Cystadenofibroma|Clear Cell Ependymoma|Clear Cell Hidradenoma|Clear Cell Meningioma|Clear Cell Neoplasm|Clear Cell Odontogenic Carcinoma|Clear Cell Renal Cell Carcinoma|Clear Cell Sarcoma of Soft Tissue|Clear Cell Sarcoma of the Kidney|Clear cell (glycogen-rich) urothelial carcinoma|Clear cell adenocarcinofibroma|Clear cell adenocarcinoma, NOS|Clear cell adenocarcinoma, mesonephroid|Clear cell adenofibroma|Clear cell adenofibroma of borderline malignancy|Clear cell adenoma|Clear cell carcinoma|Clear cell chondrosarcoma|Clear cell cystadenocarcinofibroma|Clear cell cystadenofibroma|Clear cell cystadenofibroma of borderline malignancy|Clear cell cystadenoma|Clear cell cystic tumor of borderline malignancy|Clear cell ependymoma|Clear cell hidradenoma|Clear cell meningioma|Clear cell odontogenic carcinoma|Clear cell odontogenic tumor|Clear cell sarcoma of kidney|Clear cell sarcoma of the kidney (CCSK)|Clear cell sarcoma, NOS|Clear cell sarcoma, of tendons and aponeuroses|Clear cell tumor, NOS|Clinical|Clinical Supplement|Clinical Trial|Clinical Trial Agent|Clinical data insufficient|Clioquinol|Clitoris|Clivatuzumab|Cloacogenic carcinoma|Cloacogenic zone|Clodronate Disodium|Clodronic Acid|Clofarabine|Clomesone|Clomiphene|Clomiphene Citrate|Clonal Hematopoiesis|Clostridium Novyi-NT Spores|Coal Smoke Exposure|Coal smoke, NOS|Coal-Burining Indoor Stove or Fireplace Smoke Exposure|Cobimetinib|Cobolimab|Cobomarsen|Coccidioidomycosis|Cochlear Nerve|Codman tumor|Codrituzumab|Coenzyme Q10|Cofetuzumab Pelidotin|Cognitive Disturbance|Cohort Level Copy Number Scores|Colchicine-Site Binding Agent ABT-751|Cold Contaminant-free Iobenguane I-131|Colitis|Collecting Duct Carcinoma|Collecting duct carcinoma|Colloid adenocarcinoma|Colloid adenoma|Colloid carcinoma|Colloidal Gold-Bound Tumor Necrosis Factor|Colombia|Colon|Colon - Mucosa Only|Colon Adenocarcinoma|Colon Polyps|Colon, NOS|Colonic Fistula|Colonic Hemorrhage|Colonic Obstruction|Colonic Perforation|Colonic Stenosis|Colonic Ulcer|Colonization, Bacterial|Colonization, Fungal|Colonoscopy|Colorectal|Colorectal Cancer|Colorectal Cancer Peptide Vaccine PolyPEPI1018|Colorectal Carcinoma|Colorectal Tumor-Associated Peptides Vaccine IMA910|Coltuximab Ravtansine|Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Columnar cell papilloma|Combined Carcinoid and Adenocarcinoma|Combined Hepatocellular Carcinoma and Cholangiocarcinoma|Combined Lung Large Cell Neuroendocrine Carcinoma|Combined Lung Small Cell Carcinoma|Combined Lung Small Cell Carcinoma and Lung Adenocarcinoma|Combined Nucleotide Variation|Combined carcinoid and adenocarcinoma|Combined hepatocellular carcinoma and cholangiocarcinoma|Combined large cell neuroendocrine carcinoma|Combined small cell carcinoma|Combined small cell-adenocarcinoma|Combined small cell-large carcinoma|Combined small cell-squamous cell carcinoma|Combined/mixed carcinoid and adenocarcinoma|Combretastatin|Combretastatin A-1|Combretastatin A1 Diphosphate|Comedocarcinoma|Comedocarcinoma, NOS|Comedocarcinoma, noninfiltrating|Commensal Bacterial Strain Formulation VE800|Commissure of lip|Common ALL|Common Acute Lymphoblastic Leukemia|Common Duct|Common Variable Immunodeficiency|Common precursor B ALL|Common variable immune deficiency (CVID)|Comoros|Complete Data Freeze|Complete Genomics|Complete Hydatidiform Mole|Complete Necrosis (No Viable Tumor)|Complete Remission|Complete Response|Complete Response Unconfirmed|Complete hydatidiform mole|Complex Epithelial Neoplasms|Complex Mixed and Stromal Neoplasms|Complex Odontoma|Complex odontoma|Composite Hodgkin and non-Hodgkin lymphoma|Composite Lymphoma|Composite carcinoid|Compound Kushen Injection|Compound Nevus|Compound Odontoma|Compound nevus|Compound odontoma|Conatumumab|Conbercept|Concentrated Lingzhi Mushroom Extract|Concentration Impairment|Concurrent Chemoradiation|Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011|Conduction Disorder|Condylomatous carcinoma|Confusion|Congenital Mesoblastic Nephroma|Congenital fibrosarcoma|Congenital generalized fibromatosis|Congenital peribronchial myofibroblastic tumor|Congenital, Familial and Genetic Disorders - Other|Congestive Heart Failure (CHF)|Congo|Conjunctiva|Conjunctivitis|Conjunctivitis Infective|Connective Tissue|Connective Tissue Disorder|Connective, subcutaneous and other soft tissues|Connective, subcutaneous and other soft tissues of abdomen|Connective, subcutaneous and other soft tissues of head, face, and neck|Connective, subcutaneous and other soft tissues of lower limb and hip|Connective, subcutaneous and other soft tissues of pelvis|Connective, subcutaneous and other soft tissues of thorax|Connective, subcutaneous and other soft tissues of trunk, NOS|Connective, subcutaneous and other soft tissues of upper limb and shoulder|Connective, subcutaneous and other soft tissues, NOS|Consent Exemption|Consent Waiver|Consent by Death|Constipation|Constrictive Pericarditis|Control Analyte|Conventional Osteosarcoma|Conventional central osteosarcoma|Convincing Image Source|Cook Islands|Cooking-Related Smoke Exposure|Cooking-related smoke, NOS|Copanlisib|Copanlisib Hydrochloride|Copper Cu 64-ATSM|Copper Cu 67 Tyr3-octreotate|Copper Gluconate|Copy Number Estimate|Copy Number Segment|Copy Number Variation|Cord Blood Derived CAR T-Cells|Cord Blood-derived Expanded Natural Killer Cells PNK-007|Cordycepin|Cordycepin Triphosphate|Core Biopsy|Coriolus Versicolor Extract|Cornea, NOS|Corneal Infection|Corneal Ulcer|Coronary Artery Disease|Corpus uteri|Cortex of adrenal gland|Cortical T ALL|Corticorelin Acetate|Cortisone Acetate|Cosibelimab|Cositecan|Costa Rica|Cote d'Ivoire|Cough|Course of Therapy Completed|Cousin|Cowden Syndrome|Coxsackievirus A21|Coxsackievirus V937|CpG Oligodeoxynucleotide GNKG168|Cranial Nerve Infection|Cranial nerve, NOS|Craniopharyngeal duct|Craniopharyngioma|Craniopharyngioma, adamantinomatous|Craniopharyngioma, papillary|Creatinine Increased|Crenolanib|Crenolanib Besylate|Cribriform Carcinoma|Cribriform carcinoma in situ|Cribriform carcinoma, NOS|Cribriform comedo-type carcinoma|Crizotinib|Croatia|Crohn's Disease|Crolibulin|Cryoablation|Cryopreserved|Cryptococcal Meningitis|Cryptococcosis|Cryptogenic Organizing Pneumonia|Cryptophycin|Cryptophycin 52|Cryptosporidiosis, Chronic Intestinal|Crystalline Genistein Formulation AXP107-11|Cuba|Cufflinks|Curacao|Curcumin|Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110|Cure|Current User|Cusatuzumab|Cushingoid|Custirsen Sodium|Cutaneous Mastocytosis|Cutaneous Nodular Melanoma|Cutaneous T-cell lymphoma, NOS|Cutaneous histiocytoma, NOS|Cutaneous lymphoma, NOS|Cutaneous mastocytosis|Cyclin-dependent Kinase 8/19 Inhibitor BCD 115|Cyclin-dependent Kinase Inhibitor PF-06873600|Cyclodextrin-Based Polymer-Camptothecin CRLX101|Cyclodisone|Cycloleucine|Cyclopentenyl Cytosine|Cyclophosphamide|Cyclophosphamide Anhydrous|Cyclosporine|Cylindrical cell carcinoma|Cylindrical cell papilloma|Cylindroma|Cylindroma of skin|Cylindroma, NOS|Cyproterone|Cyproterone Acetate|Cyprus|Cyst(s)|Cyst-associated renal cell carcinoma|Cystadenocarcinoma|Cystadenocarcinoma, NOS|Cystadenofibroma|Cystadenofibroma, NOS|Cystadenoma|Cystadenoma, NOS|Cystectomy|Cystic Hygroma|Cystic Partially Differentiated Kidney Nephroblastoma|Cystic Teratoma|Cystic Tumor of the Atrioventricular Node|Cystic astrocytoma|Cystic hygroma|Cystic hypersecretory carcinoma|Cystic lymphangioma|Cystic mesothelioma, NOS|Cystic mesothelioma, benign|Cystic partially differentiated nephroblastoma|Cystic teratoma, NOS|Cystic tumor of atrio-ventricular node|Cystic, Mucinous and Serous Neoplasms|Cystitis Noninfective|Cystoma, NOS|Cystosarcoma phyllodes, NOS|Cystosarcoma phyllodes, benign|Cystosarcoma phyllodes, malignant|Cystoscopy|Cytarabine|Cytarabine Monophosphate Prodrug MB07133|Cytarabine-asparagine Prodrug BST-236|Cytidine Analog RX-3117|Cytochlor|Cytokine Release Syndrome|Cytokine-based Biologic Agent IRX-2|Cytologic Atypia|Cytology|Cytomegalovirus|Cytomegalovirus (CMV)|Czech Republic (Czechia)|D|D-methionine Formulation MRX-1024|DAB389 Epidermal Growth Factor|DACH Polymer Platinate AP5346|DACH-Platin Micelle NC-4016|DCIS, NOS|DCIS, comedo type|DCIS, papillary|DDA|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|DEXSeq|DFS|DGE|DHA-Paclitaxel|DHEA Mustard|DI-Leu16-IL2 Immunocytokine|DIA|DIN 3|DKK1-Neutralizing Monoclonal Antibody DKN-01|DM-CHOC-PEN|DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015|DNA|DNA Interference Oligonucleotide PNT2258|DNA Methylation|DNA Minor Groove Binding Agent SG2000|DNA Plasmid Encoding Interleukin-12 INO-9012|DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151|DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457|DNA Vaccine VB10.16|DNA-PK inhibitor AZD7648|DNA-PK/PI3K-delta Inhibitor BR101801|DNA-PK/TOR Kinase Inhibitor CC-115|DNA-dependent Protein Kinase Inhibitor VX-984|DNAcopy|DNMT1 Inhibitor NTX-301|DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98|DPT/BCG/Measles/Serratia/Pneumococcus Vaccine|DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine|DPX-E7 HPV Vaccine|DR5 HexaBody Agonist GEN1029|DR5-targeting Tetrameric Nanobody Agonist TAS266|DSQ II|DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555|DU-Disease Unchanged|DVT/PE|Dabrafenib|Dabrafenib Mesylate|Dabska tumor|Dacarbazine|Dacetuzumab|Daclizumab|Dacomitinib|Dacplatinum|Dactinomycin|Dactolisib|Dactolisib Tosylate|Daily|Dalantercept|Dalotuzumab|Danio rerio (zebrafish)|Daniquidone|Danusertib|Danvatirsen|Daporinad|Daratumumab|Daratumumab and Hyaluronidase-fihj|Daratumumab/rHuPH20|Darinaparsin|Darleukin|Darolutamide|Daromun|Dasatinib|Daughter|Daughter-in-law|Daunorubicin|Daunorubicin Citrate|Daunorubicin Hydrochloride|Dead|Death|Death Certificate|Death NOS|Death Neonatal|Debulking|Decitabine|Decitabine and Cedazuridine|Dedifferentiated Chondrosarcoma|Dedifferentiated Chordoma|Dedifferentiated Liposarcoma|Dedifferentiated chondrosarcoma|Dedifferentiated chordoma|Dedifferentiated liposarcoma|Deep ""Aggressive"" Angiomyxoma|Deep Benign Fibrous Histiocytoma|Deep Gray (e.g. Basal Ganglia, Thalamus)|Deep Gray Matter|Deep Parotidectomy|Deep Vein Thrombosis / Thromboembolism|Deep histiocytoma|Defactinib|Defactinib Hydrochloride|Deferoxamine|Deferoxamine Mesylate|Degarelix|Degarelix Acetate|Degenerated Schwannoma|Degenerated schwannoma|Dehydration|Delanzomib|Delayed Orgasm|Delayed Puberty|Delirium|Delolimogene Mupadenorepvec|Delta_B_Allele_Freq|Delusions|Demcizumab|Demecolcine|Democratic Republic of the Congo|Demplatin Pegraglumer|Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466|Dendritic Cell Tumor, Not Otherwise Specified|Dendritic Cell Vaccine|Dendritic Cell-Autologous Lung Tumor Vaccine|Dendritic Cell-targeting Lentiviral Vector ID-LV305|Dendritic cell sarcoma, NOS|Denenicokin|Dengue Virus Adjuvant PV-001-DV|Denibulin|Denibulin Hydrochloride|Denileukin Diftitox|Denintuzumab Mafodotin|Denmark|Denosumab|Dental Caries|Dentinogenic Ghost Cell Tumor|Dentinoma|Denys-Drash Syndrome|Deoxycytidine Analogue TAS-109|Deoxycytidine Analogue TAS-109 Hydrochloride|Depatuxizumab|Depatuxizumab Mafodotin|Depressed Level of Consciousness|Depression|Derazantinib|Derived Cell Line|Dermal|Dermal Nevus|Dermal and epidermal nevus|Dermal nevus|Dermatitis Radiation|Dermatofibroma lenticulare|Dermatofibroma, NOS|Dermatofibrosarcoma Protuberans|Dermatofibrosarcoma protuberans, NOS|Dermatofibrosarcoma, NOS|Dermatomyosis|Dermoid Cyst|Dermoid cyst with malignant transformation|Dermoid cyst with secondary tumor|Dermoid cyst, NOS|Dermoid, NOS|Descended testis|Descending Colon|Descending colon|Deslorelin|Deslorelin Acetate|Desmoid, NOS|Desmoid-Type Fibromatosis|Desmoplastic Infantile Astrocytoma|Desmoplastic Infantile Ganglioglioma|Desmoplastic Melanoma|Desmoplastic Mesothelioma|Desmoplastic Small Round Cell Tumor|Desmoplastic fibroma|Desmoplastic infantile astrocytoma|Desmoplastic infantile ganglioglioma|Desmoplastic medulloblastoma|Desmoplastic melanoma, amelanotic|Desmoplastic melanoma, malignant|Desmoplastic mesothelioma|Desmoplastic nodular medulloblastoma|Desmoplastic small round cell tumor|Desmoplastic/Nodular Medulloblastoma|Detirelix|Detorubicin|Deuteporfin|Deuterated Enzalutamide|Device Related Infection|Devimistat|Dexamethason|Dexamethasone|Dexamethasone Phosphate|Dexamethasone Sodium Phosphate|Dexanabinol|Dexrazoxane|Dexrazoxane Hydrochloride|Dezaguanine|Dezaguanine Mesylate|Dezapelisib|Di Guglielmo disease|DiART|DiLeu|Diabetes|Diabetes, NOS|Diabetes, Type I|Diabetes, Type II|Diabetic Neuropathy|Diagnosis|Diagnostic Imaging|Diagnostic Slide|Dianhydrogalactitol|Diaphragm|Diarrhea|Diarylsulfonylurea Compound ILX-295501|Diazepinomicin|Diaziquone|Diazooxonorleucine|Dibrospidium Chloride|Dichloroallyl Lawsone|Dictyostelium discoideum|Dicycloplatin|Didox|Dienogest|Diet|Diet Controlled Diabetes|Diethylnorspermine|Differential Gene Expression|Differentiated Retinoblastoma|Differentiated penile intraepithelial neoplasia|Differentiated-type vulvar intraepithelial neoplasia|Differentiating|Differentiating Neuroblastoma|Diffuse|Diffuse Astrocytoma|Diffuse Astrocytoma, IDH-Mutant|Diffuse Astrocytoma, IDH-Wildtype|Diffuse Centroblastic-Centrocytic Lymphoma|Diffuse Cutaneous Mastocytosis|Diffuse Intraductal Papillomatosis|Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma (DLBCL)|Diffuse Large B-Cell Lymphoma Arising in HHV8-Positive Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation|Diffuse Leptomeningeal Glioneuronal Tumor|Diffuse Malignant Lymphoma|Diffuse Midline Glioma, H3 K27M-Mutant|Diffuse Retinoblastoma|Diffuse Sclerosing Variant Thyroid Gland Papillary Carcinoma|Diffuse Type Adenocarcinoma|Diffuse astrocytoma|Diffuse astrocytoma, IDH-mutant|Diffuse astrocytoma, IDH-wildtype|Diffuse astrocytoma, low grade|Diffuse cutaneous mastocytosis|Diffuse intraductal papillomatosis|Diffuse large B-cell lymphoma associated with chronic inflammation|Diffuse large B-cell lymphoma, NOS|Diffuse leptomeningeal glioneuronal tumor|Diffuse melanocytosis|Diffuse meningiomatosis|Diffuse midline glioma, H3 K27M-mutant|Digestive System Mixed Adenoneuroendocrine Carcinoma|Digital Papillary Adenocarcinoma|Digital papillary adenocarcinoma|Digitoxin|Digoxin|Dihydro-5-Azacytidine|Dihydrolenperone|Dihydroorotate Dehydrogenase Inhibitor AG-636|Dihydroorotate Dehydrogenase Inhibitor BAY2402234|Diindolylmethane|Diktyoma, benign|Diktyoma, malignant|Dilation and Curettage|Dilation and Curettage Procedure|Dilpacimab|Dimethylmyleran|Dinaciclib|Dinutuximab|Dionex|Dioscorea nipponica Makino Extract DNE3|Diphencyprone|Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777|Disease Progression|Disease Response|Disqualified|Disseminated Intravascular Coagulation|Distal (>2cm)|Distant|Distant Metastasis|Distant Nodes|Distant Organ|Distant Site|Distant met recurrence/progression|Ditiocarb|Diverticulitis|Dizziness|Djibouti|Docetaxel|Docetaxel Anhydrous|Docetaxel Emulsion ANX-514|Docetaxel Formulation CKD-810|Docetaxel Lipid Microspheres|Docetaxel Nanoparticle CPC634|Docetaxel Polymeric Micelles|Docetaxel-PNP|Docetaxel-loaded Nanopharmaceutical CRLX301|Docetaxel/Ritonavir|Dociparstat sodium|Dolastatin 10|Dolastatin 15|Domatinostat|Dome of bladder|Dome of the Bladder|Domestic Partner|Domestic Partnership|Dominica|Dominican Republic|Donafenib|Dopamine-Somatostatin Chimeric Molecule BIM-23A760|Dorsal surface of tongue, NOS|Dostarlimab|Double-armed TMZ-CD40L/4-1BBL Oncolytic Ad5/35 Adenovirus LOAd703|Dovitinib|Dovitinib Lactate|Downstream Data Freeze|Doxazosin|Doxercalciferol|Doxifluridine|Doxorubicin|Doxorubicin Hydrochloride|Doxorubicin Prodrug L-377,202|Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370|Doxorubicin-Eluting Beads|Doxorubicin-HPMA Conjugate|Doxorubicin-Magnetic Targeted Carrier Complex|Doxorubicin-loaded EGFR-targeting Nanocells|Drinker|Dromostanolone Propionate|Drosophila melanogaster|Drozitumab|Dry Eye|Dry Mouth|Dry Skin|Dual IGF-1R/InsR Inhibitor BMS-754807|Dual Variable Domain Immunoglobulin ABT-165|Dual-affinity B7-H3/CD3-targeted Protein MGD009|Dubermatinib|Duborimycin|Duct adenocarcinoma, NOS|Duct adenoma, NOS|Duct carcinoma, NOS|Duct carcinoma, desmoplastic type|Duct cell carcinoma|Ductal Breast Carcinoma|Ductal Breast Carcinoma In Situ|Ductal Breast Carcinoma In Situ and Invasive Lobular Carcinoma|Ductal Breast Carcinoma In Situ and Lobular Carcinoma In Situ|Ductal and Lobular Neoplasms|Ductal carcinoma in situ, NOS|Ductal carcinoma in situ, comedo type|Ductal carcinoma in situ, cribriform type|Ductal carcinoma in situ, micropapillary|Ductal carcinoma in situ, papillary|Ductal carcinoma in situ, solid type|Ductal carcinoma, NOS|Ductal carcinoma, cribriform type|Ductal intraepithelial neoplasia 3|Ductal papilloma|Dulanermin|Duligotuzumab|Duodenal Fistula|Duodenal Hemorrhage|Duodenal Infection|Duodenal Obstruction|Duodenal Perforation|Duodenal Stenosis|Duodenal Ulcer|Duodenum|Dupilumab|Duplicate case|Duplicate item|Durvalumab|Dusigitumab|Duvelisib|Duvortuxizumab|Dynemicin|Dynemicin A|Dysarthria|Dysembryoplastic Neuroepithelial Tumor|Dysembryoplastic neuroepithelial tumor|Dysesthesia|Dysgerminoma|Dysgeusia|Dyslipidemia|Dysmenorrhea|Dyspareunia|Dyspepsia|Dysphagia|Dysphasia|Dysplasia Negative|Dysplastic Cerebellar Gangliocytoma|Dysplastic Nevus|Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)|Dysplastic nevus|Dyspnea|E|E2F1 Pathway Activator ARQ 171|E4512|EA5142|EBNA-1 inhibitor VK-2019|EBV Immortalized|EBV Immortalized Normal|EBV positive diffuse large B-cell lymphoma of the elderly|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EC cell carcinoid|ECD|ECL cell carcinoid, NOS|ECL cell carcinoid, malignant|EED Inhibitor MAK683|EGFR Antagonist Hemay022|EGFR Antisense DNA BB-401|EGFR Inhibitor AZD3759|EGFR Inhibitor BIBX 1382|EGFR Inhibitor DBPR112|EGFR Inhibitor PD-168393|EGFR Inhibitor TY-9591|EGFR Mutant-selective  Inhibitor TQB3804|EGFR Mutant-specific Inhibitor BPI-7711|EGFR Mutant-specific Inhibitor CK-101|EGFR Mutant-specific Inhibitor D-0316|EGFR Mutant-specific Inhibitor ZN-e4|EGFR T790M Antagonist BPI-15086|EGFR T790M Inhibitor HS-10296|EGFR/EGFRvIII Inhibitor WSD0922-FU|EGFR/FLT3/Abl Inhibitor SKLB1028|EGFR/HER1/HER2 Inhibitor PKI166|EGFR/HER2 Inhibitor AP32788|EGFR/HER2 Inhibitor AV-412|EGFR/HER2 Inhibitor DZD9008|EGFR/HER2 Kinase Inhibitor TAK-285|EGFR/TGFb Fusion Monoclonal Antibody BCA101|EGFR/VEGFR/RET Inhibitor HA121-28|EGb761|EMD 1000|EP2/EP4 Antagonist TPST-1495|EP4 Antagonist INV-1120|EP4 Antagonist ONO-4578|ER alpha Proteolysis-targeting Chimera Protein Degrader ARV-471|ERK 1/2 Inhibitor ASTX029|ERK Inhibitor CC-90003|ERK Inhibitor GDC-0994|ERK Inhibitor LTT462|ERK Inhibitor MK-8353|ERK1/2 Inhibitor ASN007|ERK1/2 Inhibitor HH2710|ERK1/2 Inhibitor JSI-1187|ERK1/2 Inhibitor KO-947|ERK1/2 Inhibitor LY3214996|ERa36 Modulator Icaritin|ETD|EVOQ Elite|EVOQ Qube|EZH1/2 Inhibitor DS-3201|EZH1/2 Inhibitor HH2853|EZH2 Inhibitor CPI-1205|EZH2 Inhibitor PF-06821497|EZH2 Inhibitor SHR2554|EZH2 inhibitor CPI-0209|Ear|Ear Canal|Ear Pain|Ear and Labyrinth Disorders - Other|Ear, Pinna (External)|Early Onset Gastric Cancer|Ecchondroma|Ecchondrosis|Eccrine Hidrocystoma|Eccrine acrospiroma|Eccrine adenocarcinoma|Eccrine cystadenoma|Eccrine dermal cylindroma|Eccrine papillary adenocarcinoma|Eccrine papillary adenoma|Eccrine poroma|Eccrine poroma, malignant|Eccrine spiradenoma|Echinomycin|Ecromeximab|Ectocervix|Ectomesenchymoma|Ectopic Hamartomatous Thymoma|Ectopic Pregnancy|Ectopic hamartomatous thymoma|Ecuador|Eczema|Edatrexate|Edelfosine|Edema Cerebral|Edema Face|Edema Limbs|Edema Trunk|Edicotinib|Edodekin alfa|Edotecarin|Edrecolomab|Efatutazone|Efatutazone Dihydrochloride|Effusion|Efizonerimod|Eflornithine|Eflornithine Hydrochloride|Eftilagimod Alpha|Eftozanermin Alfa|Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205|Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621|Egypt|Eicosapentaenoic Acid|Ejaculation Disorder|Ejection Fraction Decreased|El Salvador|Elacestrant|Elacytarabine|Elagolix|Elastofibroma|Elbasvir/Grazoprevir|Elbow|Electrical Fire Smoke Exposure|Electrical fire smoke|Electrocardiogram QT Corrected Interval Prolonged|Electronic Cigarette|Electronic Cigarette Smoke Exposure|Electronic cigarette smoke, NOS|Element 2|Element GD|Element XR|Elesclomol|Elesclomol Sodium|Elgemtumab|Elinafide|Elisidepsin|Elliptinium|Elliptinium Acetate|Elmustine|Elotuzumab|Elpamotide|Elsamitrucin|Eltanexor|Emactuzumab|Emapalumab|Embolization|Embryonal Carcinoma|Embryonal Rhabdomyosarcoma|Embryonal Tumor with Multilayered Rosettes, C19MC-Altered|Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified|Embryonal adenocarcinoma|Embryonal adenoma|Embryonal carcinoma, NOS|Embryonal carcinoma, infantile|Embryonal carcinoma, polyembryonal type|Embryonal hepatoma|Embryonal rhabdomyosarcoma, NOS|Embryonal rhabdomyosarcoma, pleomorphic|Embryonal sarcoma|Embryonal teratoma|Embryonal tumor with multilayered rosettes C19MC-altered|Embryonal tumor with multilayered rosettes, NOS|Embryonal tumor with rhabdoid features|Emepepimut-S|Emibetuzumab|Emitefur|Emofolin Sodium|Empesertib|Enadenotucirev|Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A|Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641|Enasidenib|Enasidenib Mesylate|Enavatuzumab|Encapsulated Rapamycin|Encapsulated Variant Thyroid Gland Papillary Carcinoma|Encapsulated follicular variant of papillary thyroid carcinoma, NOS (EFVPTC, NOS)|Encapsulated papillary carcinoma|Encapsulated papillary carcinoma with invasion|Encelimab|Encephalitis Infection|Encephalomyelitis Infection|Encephalopathy|Enchondroma|Enclomiphene|Enclomiphene Citrate|Encorafenib|End-stage Renal Disease|Endemic|Endemic Burkitt Lymphoma|Endo Rectal Tumor Resection|Endocarditis Infective|Endocervical Adenocarcinoma, Usual Type|Endocervical adenocarcinoma usual type|Endocervix|Endocrine Disorders - Other|Endocrine Gland|Endocrine adenomatosis|Endocrine gland, NOS|Endocrine tumor, functioning, NOS|Endodermal sinus tumor|Endolaryngeal Excision|Endolymphatic stromal myosis|Endometrial Endometrioid Adenocarcinoma, Ciliated Variant|Endometrial Endometrioid Adenocarcinoma, Secretory Variant|Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation|Endometrial Stromal Nodule|Endometrial sarcoma, NOS|Endometrial stromal nodule|Endometrial stromal sarcoma, NOS|Endometrial stromal sarcoma, high grade|Endometrial stromal sarcoma, low grade|Endometrial stromatosis|Endometrioid Adenocarcinoma|Endometrioid Stromal Sarcoma|Endometrioid adenocarcinoma, NOS|Endometrioid adenocarcinoma, ciliated cell variant|Endometrioid adenocarcinoma, secretory variant|Endometrioid adenocarcinoma, villoglandular|Endometrioid adenofibroma, NOS|Endometrioid adenofibroma, borderline malignancy|Endometrioid adenofibroma, malignant|Endometrioid adenoma, NOS|Endometrioid adenoma, borderline malignancy|Endometrioid carcinoma with squamous differentiation|Endometrioid carcinoma, NOS|Endometrioid cystadenocarcinoma|Endometrioid cystadenofibroma, NOS|Endometrioid cystadenofibroma, borderline malignancy|Endometrioid cystadenofibroma, malignant|Endometrioid cystadenoma, NOS|Endometrioid cystadenoma, borderline malignancy|Endometrioid tumor of low malignant potential|Endometriosis|Endometrium|Endophthalmitis|Endosalpingiosis|Endoscopic Biopsy|Endoscopic Mucosal Resection (EMR)|Endoscopy|Endothelin B Receptor Blocker ENB 003|Endothelin Receptor Type A Antagonist YM598|Endotheliomatous meningioma|Endovascular papillary angioendothelioma|Enfortumab Vedotin|Engineered Human Umbilical Vein Endothelial Cells AB-205|Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240|Engineered Toxin Body Targeting CD38 TAK-169|Engineered Toxin Body Targeting HER2 MT-5111|Eniluracil/5-FU Combination Tablet|Enloplatin|Enneking High Surgical Grade|Enneking Low Surgical Grade|Enneking Metastasis M0|Enneking Metastasis M1|Enoblituzumab|Enobosarm|Enoticumab|Enpromate|Ensartinib|Ensituximab|Enteric adenocarcinoma|Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride|Enterochromaffin cell carcinoid|Enterochromaffin-Like Cell Neuroendocrine Tumor G1|Enterochromaffin-like cell carcinoid, NOS|Enterochromaffin-like cell tumor, malignant|Enterococcus gallinarum Strain MRx0518|Enterocolitis|Enterocolitis Infectious|Enteroglucagonoma|Enteroglucagonoma, NOS|Enteroglucagonoma, malignant|Enteropathy associated T-cell lymphoma|Enteropathy type intestinal T-cell lymphoma|Enteropathy-Associated T-Cell Lymphoma|Enterovesical Fistula|Entinostat|Entolimod|Entospletinib|Entrectinib|Enucleation|Envafolimab|Environmental tobacco smoke|Enzalutamide|Enzastaurin|Enzastaurin Hydrochloride|Eosinophil adenocarcinoma|Eosinophil adenoma|Eosinophil carcinoma|Eosinophilic Granuloma|Eosinophilic granuloma|Eosinophilic leukemia|Epacadostat|Epcoritamab|Ependymoblastoma|Ependymoma|Ependymoma, NOS|Ependymoma, RELA Fusion-Positive|Ependymoma, RELA fusion-positive|Ependymoma, anaplastic|EphA2-targeting Bicycle Toxin Conjugate BT5528|Epidermoid carcinoma in situ with questionable stromal invasion|Epidermoid carcinoma in situ, NOS|Epidermoid carcinoma, NOS|Epidermoid carcinoma, keratinizing|Epidermoid carcinoma, large cell, nonkeratinizing|Epidermoid carcinoma, small cell, nonkeratinizing|Epidermoid carcinoma, spindle cell|Epididymis|Epidural Space|Epilepsy|Epipodophyllotoxin Analog GL331|Epipodophyllotoxin-Related Myelodysplastic Syndrome|Epipropidine|Epirubicin|Epirubicin Hydrochloride|Epistaxis|Epithelial Dysplasia|Epithelial Hyperplasia|Epithelial Neoplasm|Epithelial Neoplasms, NOS|Epithelial Synovial Sarcoma|Epithelial ependymoma|Epithelial tumor, benign|Epithelial tumor, malignant|Epithelial-Myoepithelial Carcinoma|Epithelial-myoepithelial carcinoma|Epithelioid Cell Melanoma|Epithelioid Cell Nevus|Epithelioid Cell Type Gastrointestinal Stromal Tumor|Epithelioid Glioblastoma|Epithelioid Hemangioendothelioma|Epithelioid Hemangioma|Epithelioid Leiomyosarcoma|Epithelioid MPNST|Epithelioid Malignant Peripheral Nerve Sheath Tumor|Epithelioid Mesothelioma|Epithelioid Sarcoma|Epithelioid Trophoblastic Tumor|Epithelioid and spindle cell nevus|Epithelioid cell melanoma|Epithelioid cell nevus|Epithelioid cell sarcoma|Epithelioid glioblastoma|Epithelioid hemangioendothelioma, NOS|Epithelioid hemangioendothelioma, malignant|Epithelioid hemangioma|Epithelioid leiomyoma|Epithelioid leiomyosarcoma|Epithelioid malignant peripheral nerve sheath tumor|Epithelioid mesothelioma, NOS|Epithelioid mesothelioma, benign|Epithelioid mesothelioma, malignant|Epithelioid sarcoma|Epithelioma adenoides cysticum|Epithelioma, NOS|Epithelioma, benign|Epithelioma, malignant|Epitinib Succinate|Epitiostanol|Epitrochlear|Epothilone Analog UTD1|Epothilone KOS-1584|Epratuzumab|Epratuzumab-cys-tesirine|Epstein-Barr Virus|Epstein-Barr Virus Test|Equatorial Guinea|Equivocal|Erastin Analogue PRLX 93936|Erbulozole|Erdafitinib|Erectile Dysfunction|Eribulin|Eribulin Mesylate|Eritrea|Erlotinib|Erlotinib Hydrochloride|Ertumaxomab|Erythema Multiforme|Erythremic myelosis, NOS|Erythrocyte-encapsulated L-asparaginase Suspension|Erythroderma|Erythroleukemia|Escherichia coli|Esophageal Anastomotic Leak|Esophageal Cancer|Esophageal Carcinoma|Esophageal Fistula|Esophageal Hemorrhage|Esophageal High Grade Intraepithelial Neoplasia|Esophageal Infection|Esophageal Necrosis|Esophageal Obstruction|Esophageal Pain|Esophageal Perforation|Esophageal Stenosis|Esophageal Ulcer|Esophageal Varices Hemorrhage|Esophageal glandular dysplasia (intraepithelial neoplasia), high grade|Esophageal glandular dysplasia (intraepithelial neoplasia), low grade|Esophageal intraepithelial neoplasia, high grade|Esophageal squamous intraepithelial neoplasia (dysplasia), high grade|Esophageal squamous intraepithelial neoplasia (dysplasia), low grade|Esophageal; Distal|Esophageal; Mid|Esophageal; Proximal|Esophagitis|Esophagogastric Junction|Esophagus|Esophagus - Mucosa Only|Esophagus, NOS|Esorubicin|Esorubicin Hydrochloride|Esperamicin A1|Essential Thrombocythemia|Essential hemorrhagic thrombocythaemia|Essential thrombocythemia|Essiac|Esterified Estrogens|Esthesioneuroblastoma|Esthesioneurocytoma|Esthesioneuroepithelioma|Estonia|Estradiol Valerate|Estramustine|Estramustine Phosphate Sodium|Estrogen Receptor Agonist GTx-758|Estrogen only|Estrogens, Conjugated|Eswatini|Etalocib|Etanercept|Etanidazole|Etaracizumab|Etarotene|Ethanol Injection Ablation|Ethaselen|Ethinyl Estradiol|Ethiopia|Ethmoid sinus|Ethyleneimine|Ethylnitrosourea|Etidronate-Cytarabine Conjugate MBC-11|Etigilimab|Etirinotecan Pegol|Etoglucid|Etoposide|Etoposide Phosphate|Etoposide Toniribate|Etoprine|Etoricoxib|Ets-family Transcription Factor Inhibitor TK216|Euphoria|Everolimus|Everolimus Tablets for Oral Suspension|Every 24 Hours|Every Hour|Every Other Day|Every day|Evofosfamide|Ewing Sarcoma|Ewing sarcoma|Ewing tumor|Ex Vivo-expanded Autologous T Cells IMA101|Exactive|Exactive Plus|Exatecan Mesylate|Exatecan Mesylate Anhydrous|Excision|Excisional Biopsy|Exemestane|Exicorilant|Exisulind|Exocervix|Exon Expression Quantification|Exoresection|Exostosis|Expanded Next Generation Cancer Model|Experiment Metadata|Extended Release Flucytosine|Extended Release Metformin Hydrochloride|Extended-release Onapristone|External Auditory Canal Ceruminous Adenoma|External Beam Radiation|External Ear Inflammation|External Ear Pain|External Lower Lip|External ear|External lip, NOS|External lower lip|External upper lip|Extra-Adrenal Paraganglioma|Extra-abdominal desmoid|Extra-adrenal paraganglioma, NOS|Extra-adrenal paraganglioma, malignant|Extraabdominal Fibromatosis|Extracompartmental (T2)|Extracompartmental Tumor|Extracutaneous Mastocytoma|Extracutaneous mastocytoma|Extrahepatic bile duct|Extramammary Paget Disease|Extramural|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Extranodal NK/T-cell lymphoma, nasal type|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extraocular Muscle Paresis|Extraosseous Plasmacytoma|Extraosseous plasmacytoma|Extrapyramidal Disorder|Extraventricular Neurocytoma|Extraventricular neurocytoma|Eye|Eye Disorders - Other|Eye Infection|Eye Pain|Eye and adnexa|Eye, NOS|Eyelid|Eyelid Function Disorder|Ezabenlimab|F16-IL2 Fusion Protein|FAB L2|FAB L3|FAB Ll|FAB M1|FAB M2, AML1(CBF-alpha)/ETO|FAB M2, NOS|FAB M2, t(8;21)(q22;q22)|FAB M3 (includes all variants)|FAB M4|FAB M4Eo|FAB M5 (includes all variants)|FAB M6|FAB M7|FAB MO|FACT Complex-targeting Curaxin CBL0137|FAK Inhibitor GSK2256098|FAK Inhibitor PF-00562271|FAK Inhibitor VS-4718|FAK/ALK/ROS1 Inhibitor APG-2449|FAP/4-1BB-targeting DARPin MP0310|FAP/4-1BB-targeting Fusion Protein RO7122290|FASN Inhibitor TVB-2640|FASTA|FASTQ|FFPE|FFPE DNA|FFPE RNA|FFPE Recurrent|FFPE Scrolls|FGF Receptor Antagonist HGS1036|FGF/FGFR Pathway Inhibitor E7090|FGFR Inhibitor ASP5878|FGFR Inhibitor AZD4547|FGFR Inhibitor CPL304110|FGFR Inhibitor Debio 1347|FGFR Inhibitor TAS-120|FGFR/CSF-1R Inhibitor 3D185|FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999|FGFR1/2/3 Inhibitor HMPL-453|FGFR2 Inhibitor RLY-4008|FGFR4 Antagonist INCB062079|FGFR4 Inhibitor BLU 9931|FGFR4 Inhibitor FGF401|FGFR4 Inhibitor H3B-6527|FGFR4 Inhibitor ICP-105|FIGO Stage IA|FIGO Stage IC1|FIGO Stage IC2|FIGO Stage IC3|FIGO Stage IIIA1(i)|FIGO Stage IIIA1(ii)|FIGO Stage IIIA2|FIRMA|FLT3 Inhibitor FF-10101 Succinate|FLT3 Inhibitor HM43239|FLT3 Inhibitor SKI-G-801|FLT3 Tyrosine Kinase Inhibitor TTT-3002|FLT3/ABL/Aurora Kinase Inhibitor KW-2449|FLT3/CDK4/6 Inhibitor FLX925|FLT3/FGFR Dual Kinase Inhibitor MAX-40279|FLT3/KIT Kinase Inhibitor AKN-028|FLT3/KIT/CSF1R Inhibitor NMS-03592088|FM Copy Number Variation|FM Simple Somatic Mutation|FM Structural Variation|FMS Inhibitor JNJ-40346527|FPV Vaccine CV301|FPV-Brachyury-TRICOM Vaccine|FTMS|Facial Muscle Weakness|Facial Nerve Disorder|Facial Pain|Factor VII-targeting Immunoconjugate Protein ICON-1|Factor VIIa Inhibitor PCI-27483|Factory Smokestack Smoke Exposure|Factory smokestack smoke|Fadraciclib|Fadrozole Hydrochloride|Falimarev|Falkland Islands (Malvinas)|Fall|Fallopian Tube|Fallopian Tube Anastomotic Leak|Fallopian Tube Obstruction|Fallopian Tube Perforation|Fallopian Tube Stenosis|Fallopian tube|False|Familial Adenomatous Polyposis|Familial polyposis coli|Famitinib|Fanconi Anemia|Farletuzumab|Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778,123|Faroe Islands|Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells|Fas Receptor Agonist APO010|Fascial Fibroma|Fascial Fibrosarcoma|Fascial fibroma|Fascial fibrosarcoma|Fascin Inhibitor NP-G2-044|Fat Atrophy|Father|Father-in-law|Fatigue|Favezelimab|Favorable|Fazarabine|Fc-engineered Anti-CD40 Agonist Antibody 2141-V11|Febrile Neutropenia|Febuxostat|Fecal Incontinence|Federated States of Micronesia|Fedratinib|Fedratinib Hydrochloride|Feladilimab|Felzartamab|Female|Female Cousin|Female Genital Tract Fistula|Female Genitalia|Female Reproductive System Adenofibroma|Female Sibling of Adopted Child|Female genital tract, NOS|Feminization Acquired|Femoral Artery|Femoral Vein|Femur|Fenebrutinib|Fenretinide|Fenretinide Lipid Matrix|Fenretinide Phospholipid Suspension ST-001|Fetal Death|Fetal Growth Retardation|Fetal Rhabdomyoma|Fetal adenocarcinoma|Fetal adenoma|Fetal fat cell lipoma|Fetal lipoma, NOS|Fetal lipomatosis|Fetal rhabdomyoma|Fever|Fianlimab|Fibrillary Astrocytoma|Fibrillary astrocytoma|Fibrinogen Decreased|Fibro-osteoma|Fibroadenoma, NOS|Fibroameloblastic odontoma|Fibroblastic Liposarcoma|Fibroblastic Osteosarcoma|Fibroblastic Reticular Cell Tumor|Fibroblastic liposarcoma|Fibroblastic meningioma|Fibroblastic osteosarcoma|Fibroblastic reticular cell tumor|Fibroblasts|Fibroblasts from Bone Marrow Normal|Fibrochondrosarcoma|Fibroepithelial Neoplasms|Fibroepithelial basal cell carcinoma, Pinkus type|Fibroepithelioma of Pinkus type|Fibroepithelioma, NOS|Fibrofolliculoma|Fibroid uterus|Fibrolamellar Carcinoma|Fibrolipoma|Fibroliposarcoma|Fibroma|Fibroma, NOS|Fibromatosis-like metaplastic carcinoma|Fibromatous Neoplasms|Fibromun|Fibromyalgia|Fibromyoma|Fibromyxoid Tumor|Fibromyxolipoma|Fibromyxoma|Fibromyxosarcoma|Fibrosarcoma|Fibrosarcoma, NOS|Fibrosarcomatous Dermatofibrosarcoma Protuberans|Fibrosarcomatous dermatofibrosarcoma protuberans|Fibrosis|Fibrosis Deep Connective Tissue|Fibrous Meningioma|Fibrous astrocytoma|Fibrous histiocytoma of tendon sheath|Fibrous histiocytoma, NOS|Fibrous meningioma|Fibrous mesothelioma, NOS|Fibrous mesothelioma, benign|Fibrous mesothelioma, malignant|Fibrous papule of nose|Fibroxanthoma, NOS|Fibroxanthoma, malignant|Fibula|Ficlatuzumab|Field Burning Smoke Exposure|Field burning smoke|Figitumumab|Fiji|Filanesib|Filgotinib|Filgrastim|Fimaporfin A|Fimepinostat|Fine Needle Aspiration|Finger|Finland|Fire Smoke Exposure|Fire smoke, NOS|First Cousin|First Cousin Once Removed|First Patient Visit|First Treatment|Firtecan Pegol|Fisogatinib|Five Times Daily|Flank Pain|Flanvotumab|Flashing Lights|Flat Adenoma|Flat adenoma|Flat intraepithelial glandular neoplasia, high grade|Flat intraepithelial neoplasia, high grade|Flatulence|Floaters|Floor Of Mouth|Floor of Mouth|Floor of mouth|Floor of mouth, NOS|Florid osseous dysplasia|Flotetuzumab|Floxuridine|Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01|Flt3/MerTK Inhibitor MRX-2843|Flu Like Symptoms|Fludarabine|Fludarabine Phosphate|Fluid|Flumatinib|Flumatinib Mesylate|Fluorine F 18 Ara-G|Fluorodopan|Fluorouracil|Fluorouracil Implant|Fluorouracil-E Therapeutic Implant|Fluoxymesterone|Flushing|Flutamide|Fluvastatin|Fluvastatin Sodium|Fluzoparib|Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate|Focal|Folate Receptor Targeted Epothilone BMS753493|Folate Receptor-Targeted Tubulysin Conjugate EC1456|Folate Receptor-Targeted Vinca Alkaloid EC0489|Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225|Folate-FITC|Folic Acid|Folitixorin|Follicular Dendritic Cell Sarcoma|Follicular Lymphoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma, Encapsulated Subtype with Invasion|Follicular adenocarcinoma, NOS|Follicular adenocarcinoma, moderately differentiated|Follicular adenocarcinoma, trabecular|Follicular adenocarcinoma, well differentiated|Follicular adenoma|Follicular adenoma, oxyphilic cell|Follicular carcinoma, NOS|Follicular carcinoma, encapsulated|Follicular carcinoma, minimally invasive|Follicular carcinoma, moderately differentiated|Follicular carcinoma, oxyphilic cell|Follicular carcinoma, trabecular|Follicular carcinoma, well differentiated|Follicular dendritic cell sarcoma|Follicular dendritic cell tumor|Follicular fibroma|Follicular lymphoma, NOS|Follicular lymphoma, grade 1|Follicular lymphoma, grade 2|Follicular lymphoma, grade 3|Follicular lymphoma, grade 3A|Follicular lymphoma, grade 3B|Follicular lymphoma, small cleaved cell|Follicular thyroid carcinoma (FTC), encapsulated angioinvasive|Folliculome lipidique|Foot|Forced Expiratory Volume Decreased|Forearm|Forehead|Foreskin|Foretinib|Foritinib Succinate|Former User|Formestane|Forodesine Hydrochloride|Fosaprepitant|Fosbretabulin|Fosbretabulin Disodium|Fosbretabulin Tromethamine|Fosgemcitabine Palabenamide|Fosifloxuridine Nafalbenamide|Foslinanib|Foslinanib Disodium|Fosquidone|Foster Brother|Foster Daughter|Foster Father|Foster Mother|Foster Sister|Foster Son|Fostriecin|Fotemustine|Fotretamine|FoundationOne Annotation|FoundationOne Report|FoundationOne Variant Aggregation and Masking|FoundationOne XML|Four Times Daily|Fracture|France|Franklin disease|Fraternal Twin|Fraternal Twin Brother|Fraternal Twin Sibling|Fraternal Twin Sister|French Guiana|French Polynesia|Fresh|Fresolimumab|Frontal Cortex|Frontal Lobe|Frontal Sinus|Frontal lobe|Frontal sinus|Frozen|Fruquintinib|Full Brother|Full Hysterectomy|Full Sister|Fulvestrant|Fumagillin-Derived Polymer Conjugate XMT-1107|Functioning Endocrine Neoplasm|Fundus Of Stomach|Fundus Uteri|Fundus of Stomach|Fundus of stomach|Fundus uteri|Furnace or Boiler Smoke Exposure|Furnace or boiler smoke|Fursultiamine|Fusion Catcher|Futibatinib|Futuximab|Futuximab/Modotuximab Mixture|G|G Protein-coupled Estrogen Receptor Agonist LNS8801|G cell tumor, NOS|G cell tumor, malignant|G-Quadruplex Stabilizer BMVC|G1|G2|G3|G4|GANT|GATK4 MuTect2|GATK4 MuTect2 Annotation|GB|GBM Antigens and Alloantigens Immunotherapeutic Vaccine|GC IsoLink|GCT|GCT Premier|GENIE Copy Number Variation|GENIE Report|GENIE Simple Somatic Mutation|GENIE Structural Variation|GENIE Variant Aggregation and Masking|GERD|GGT Increased|GI-4000 Vaccine|GIST, NOS|GIST, benign|GIST, malignant|GISTIC - Arm Level Copy Number|GISTIC - Copy Number Score|GISTIC - Focal Amplification|GISTIC - Focal Deletion|GITR Agonist MEDI1873|GM-CSF-encoding Oncolytic Adenovirus CGTG-102|GS/pan-Notch Inhibitor AL101|GS/pan-Notch Inhibitor BMS-986115|GSK-3 Inhibitor 9-ING-41|GSK-3 Inhibitor LY2090314|GVF|GX|Gabon|Gait Disturbance|Galamustine|Galarubicin|Galectin Inhibitor GR-MD-02|Galectin-1 Inhibitor OTX008|Galeterone|Galiximab|Gallbladder|Gallbladder Cancer|Gallbladder Carcinoma|Gallbladder Fistula|Gallbladder Infection|Gallbladder Necrosis|Gallbladder Obstruction|Gallbladder Pain|Gallbladder Papillary Neoplasm with Intermediate Grade Intraepithelial Neoplasia|Gallbladder Papillary Neoplasm with Low Grade Intraepithelial Neoplasia|Gallbladder Perforation|Gallium-based Bone Resorption Inhibitor AP-002|Gallus gallus|Galocitabine|Galunisertib|Gambia|Gamboge Resin Extract TSB-9-W1|Gamma Heavy Chain Disease|Gamma heavy chain disease|Gamma-Secretase Inhibitor LY3039478|Gamma-Secretase Inhibitor RO4929097|Gamma-delta Tocotrienol|Gandotinib|Ganetespib|Ganglia|Gangliocytic paraganglioma|Gangliocytoma|Ganglioglioma|Ganglioglioma, NOS|Ganglioglioma, anaplastic|Ganglioneuroblastoma|Ganglioneuroma|Ganglioneuromatosis|Ganglioside GD2|Ganglioside GM2|Ganitumab|Ganoderma lucidum Spores Powder Capsule|Garlic|Gas burning smoke, propane|Gasterosteus aculeatus (fish)|Gastric Anastomotic Leak|Gastric Cancer|Gastric Carcinoma|Gastric Fistula|Gastric Hemorrhage|Gastric Necrosis|Gastric Parietal Cell Adenocarcinoma|Gastric Perforation|Gastric Polyp(s)|Gastric Stenosis|Gastric Ulcer|Gastric antrum|Gastrin Immunotoxin|Gastrin cell tumor|Gastrin cell tumor, malignant|Gastrin-Producing Neuroendocrine Tumor|Gastrin/cholecystokinin Type B Receptor Inhibitor Z-360|Gastrinoma, NOS|Gastrinoma, malignant|Gastritis|Gastroesophageal Junction|Gastroesophageal Reflux Disease|Gastrointestinal Anastomotic Leak|Gastrointestinal Autonomic Nerve Tumor|Gastrointestinal Disorders - Other|Gastrointestinal Fistula|Gastrointestinal Pain|Gastrointestinal Stoma Necrosis|Gastrointestinal Stromal Tumor|Gastrointestinal Stromal Tumor of Uncertain Malignant Potential|Gastrointestinal Tract|Gastrointestinal autonomic nerve tumor|Gastrointestinal pacemaker cell tumor|Gastrointestinal stromal sarcoma|Gastrointestinal stromal tumor, NOS|Gastrointestinal stromal tumor, benign|Gastrointestinal stromal tumor, malignant|Gastrointestinal stromal tumor, uncertain malignant potential|Gastrointestinal tract, NOS|Gastrointestinal, Intestine|Gastroparesis|Gataparsen Sodium|Gatipotuzumab|Gedatolisib|Gefitinib|Gelatinous adenocarcinoma|Gelatinous carcinoma|Geldanamycin|Gelonin|Gemcitabine|Gemcitabine Elaidate|Gemcitabine Hydrochloride|Gemcitabine Hydrochloride Emulsion|Gemcitabine Prodrug LY2334737|Gemcitabine-Phosphoramidate Hydrochloride NUC-1031|Gemcitabine-Releasing Intravesical System|Gemistocytic Astrocytoma|Gemistocytic astrocytoma|Gemistocytoma|Gemtuzumab Ozogamicin|Gene Expression Quantification|Gene Level Copy Number|Gene Level Copy Number Scores|General|General Disorders and Administration Site Conditions - Other|Generalized Muscle Weakness|Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum|Genistein|Genital Edema|Genital Rhabdomyoma|Genital rhabdomyoma|Genitourinary, NOS|GenomePlex (Rubicon) Amplified DNA|Genomic Profiling|Genomplex|Genotype mismatch|Genotypes|Genotyping Array|Gentuximab|Georgia|Geranylgeranyltransferase I Inhibitor|Germ Cell Neoplasms|Germ Cell Tumor|Germ cell tumor, NOS|Germ cell tumor, nonseminomatous|Germ cell tumors with associated hematological malignancy|Germany|Germinoma|Gerota Fascia|Ghana|Ghost Cell Odontogenic Carcinoma|Ghost cell odontogenic carcinoma|Giant Cell Angiofibroma|Giant Cell Carcinoma|Giant Cell Fibroblastoma|Giant Cell Glioblastoma|Giant Cell Sarcoma|Giant Cell Tumor of Bone|Giant Cell Tumor of Soft Tissue|Giant Cell Tumors|Giant Cell and Spindle Cell Carcinoma|Giant Congenital Nevus|Giant cell and spindle cell carcinoma|Giant cell angiofibroma|Giant cell carcinoma|Giant cell fibroblastoma|Giant cell glioblastoma|Giant cell sarcoma|Giant cell sarcoma of bone|Giant cell tumor of bone, NOS|Giant cell tumor of bone, malignant|Giant cell tumor of soft parts, NOS|Giant cell tumor of tendon sheath|Giant cell tumor of tendon sheath, malignant|Giant fibroadenoma|Giant osteoid osteoma|Giant pigmented nevus, NOS|Gibraltar|Gigantiform Cementoma|Gigantiform cementoma|Gilbert's Syndrome|Giloralimab|Gilteritinib|Gilteritinib Fumarate|Gimatecan|Gimeracil|Gingival Pain|Ginsenoside Rg3 Capsule|Giredestrant|Girentuximab|Girodazole|Givinostat|Glandular Papilloma|Glandular Papillomatosis|Glandular intraepithelial neoplasia, grade I|Glandular intraepithelial neoplasia, grade II|Glandular intraepithelial neoplasia, grade III|Glandular intraepithelial neoplasia, high grade|Glandular intraepithelial neoplasia, low grade|Glandular papilloma|Glans Penis|Glans penis|Glasdegib|Glasdegib Maleate|Glassy Cell Carcinoma|Glassy cell carcinoma|Glaucarubolone|Glaucoma|Gleason Grade Group 1|Gleason Grade Group 2|Gleason Grade Group 3|Gleason Grade Group 4|Gleason Grade Group 5|Gleason Pattern 1|Gleason Pattern 2|Gleason Pattern 3|Gleason Pattern 4|Gleason Pattern 5|Glecaprevir/Pibrentasvir|Glembatumumab Vedotin|Glesatinib|Glioblastoma|Glioblastoma Cancer Vaccine ERC1671|Glioblastoma Multiforme|Glioblastoma Multiforme Multipeptide Vaccine IMA950|Glioblastoma multiforme|Glioblastoma with sarcomatous component|Glioblastoma, IDH wildtype|Glioblastoma, IDH-Mutant|Glioblastoma, IDH-Wildtype|Glioblastoma, IDH-mutant|Gliofibroma|Glioma|Glioma Lysate Vaccine GBM6-AD|Glioma, NOS|Glioma, malignant|Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701|Gliomas|Gliomatosis Cerebri|Gliomatosis cerebri|Glioneuroma|Gliosarcoma|Globo H-DT Vaccine OBI-833|Glofitamab|Glomangioma|Glomangiomyoma|Glomangiosarcoma|Glomerular Disease|Glomoid sarcoma|Glomus Tumor|Glomus jugulare tumor, NOS|Glomus tumor, NOS|Glomus tumor, malignant|Glossectomy|Glossopharyngeal Nerve Disorder|Glottis|Glucagon-like peptide-producing tumor|Glucagonoma, NOS|Glucagonoma, malignant|Glucarpidase|Glucocorticoid Receptor Antagonist ORIC-101|Glucose Intolerance|Glufosfamide|Glumetinib|Glutaminase Inhibitor CB-839|Glutaminase Inhibitor CB-839 Hydrochloride|Glutaminase Inhibitor IPN60090|Glutamine Antagonist DRP-104|Glutamyl endopeptidase|Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101|Glyco-TMT|Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01|Glycogen Storage Disease|Glycogen-Rich Carcinoma|Glycogen-rich carcinoma|Glycogenic rhabdomyoma|Glycooptimized Trastuzumab-GEX|Glycoproteome|Goblet cell carcinoid|Gold Sodium Thiomalate|Golnerminogene Pradenovec|Golotimod|Golvatinib|Gonadal Dysfunction|Gonadal stromal tumor, NOS|Gonadoblastoma|Gonadotropin-releasing Hormone Analog|Gonocytoma|Good Prognosis|Gorlin Syndrome|Goserelin|Goserelin Acetate|Goserelin Acetate Extended-release Microspheres LY01005|Gossypol|Gossypol Acetic Acid|Gout|Grade 1|Grade 1 Follicular Lymphoma|Grade 1 Nodular Sclerosis Classic Hodgkin Lymphoma|Grade 2|Grade 2 Follicular Lymphoma|Grade 2 Nodular Sclerosis Classic Hodgkin Lymphoma|Grade 3|Grade 3 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Grade 3b Follicular Lymphoma|Grade 4|Grade 5|Grade B|Grade I|Grade I Neuroendocrine Carcinoma|Grade II|Grade II Glandular Intraepithelial Neoplasia|Grade II Neuroendocrine Carcinoma|Grade II Squamous Intraepithelial Neoplasia|Grade III|Grade III Glandular Intraepithelial Neoplasia|Grade III Prostatic Intraepithelial Neoplasia|Grade IV|Grade Not Assigned|Grade X|Grand Nephew|Grand Niece|Grandchild|Granddaughter|Grandfather|Grandmother|Grandparent|Grandson|Granular Cell Carcinoma|Granular Cell Tumor|Granular Cell Tumor of the Sellar Region|Granular Cell Tumors and Alveolar Soft Part Sarcomas|Granular cell adenocarcinoma|Granular cell carcinoma|Granular cell myoblastoma, NOS|Granular cell myoblastoma, malignant|Granular cell tumor of the sellar region|Granular cell tumor, NOS|Granular cell tumor, malignant|Granulocytes|Granulocytic Sarcoma|Granulocytic leukemia, NOS|Granulocytic sarcoma|Granulosa Cell Tumor|Granulosa Cell-Theca Cell Tumor|Granulosa cell carcinoma|Granulosa cell tumor, NOS|Granulosa cell tumor, adult type|Granulosa cell tumor, juvenile|Granulosa cell tumor, malignant|Granulosa cell tumor, sarcomatoid|Granulosa cell-theca cell tumor|Grapiprant|Grawitz tumor|Gray|Grease Fire Smoke Exposure|Grease fire smoke|Great Grandchild|Great Nephew|Great Niece|Greater Curvature of the Stomach|Greater curvature of stomach, NOS|Greece|Green|Green Tea Extract-based Antioxidant Supplement|Greenland|Grenada|Grilling Smoke Exposure|Grilling smoke|Groin|Gross Total Resection|Group 1|Group 2|Group 3|Group 4|Group 5|Group I|Group II|Group III|Group IIIa|Group IIIb|Group IIa|Group IIb|Group IIc|Group IV|Group Ia|Group Ib|Growth Accelerated|Growth Hormone Abnormal|Growth Suppression|Guadecitabine|Guadeloupe|Guam|Guanabenz Acetate|Guardian|Guatemala|Guernsey|Guinea|Guinea-Bissau|Gum|Gum Infection|Gum, NOS|Guselkumab|Gusperimus Trihydrochloride|Gutolactone|Guyana|Gy|Gynandroblastoma|Gynecologic Cancer|Gynecomastia|H|H-ras Antisense Oligodeoxynucleotide ISIS 2503|H. pylori Infection|H1299 Tumor Cell Lysate Vaccine|H2 Blockers|HAAH Lambda phage Vaccine SNS-301|HBV Core Antibody|HBV DNA|HBV Genotype|HBV Surface Antibody|HCD|HCV DNA Vaccine INO-8000|HCV Genotype|HDAC Class I/IIb Inhibitor HG146|HDAC Inhibitor AR-42|HDAC Inhibitor CHR-2845|HDAC Inhibitor CKD-581|HDAC Inhibitor CXD101|HDAC Inhibitor MPT0E028|HDAC Inhibitor OBP-801|HDAC inhibitor CG200745|HDAC/EGFR/HER2 Inhibitor CUDC-101|HDAC6 Inhibitor KA2507|HDAC8 Inhibitor NBM-BMX|HDF5|HDM2 Inhibitor HDM201|HDM2 Inhibitor MK-8242|HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131|HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901|HER2 Inhibitor CP-724,714|HER2 Inhibitor DZD1516|HER2 Inhibitor TAS0728|HER2 Tri-specific Natural Killer Cell Engager DF1001|HER2-directed TLR8 Agonist SBT6050|HER2-targeted DARPin MP0274|HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302|HER2-targeting Antibody Fc Fragment FS102|HIF-1alpha Inhibitor PX-478|HIF-2alpha Inhibitor PT2385|HIF-2alpha Inhibitor PT2977|HIF2a RNAi ARO-HIF2|HIV|HIV / AIDS|HIV+ Tumor Molecular Characterization Project - Cervical Cancer|HIV+ Tumor Molecular Characterization Project - Lung Cancer|HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001|HLA-A*2402-Restricted Multipeptide Vaccine S-488410|HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201|HM2/MMAE Antibody-Drug Conjugate ALT-P7|HPPH|HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202|HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c|HPV DNA Plasmids Therapeutic Vaccine VGX-3100|HPV E6/E7 DNA Vaccine GX-188E|HPV E6/E7-encoding Arenavirus Vaccine HB-201|HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C|HPV-16 E6 Peptides Vaccine/Candida albicans Extract|HPV-6-targeting Immunotherapeutic Vaccine INO-3106|HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101|HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN|HPV6/11-targeted DNA Plasmid Vaccine INO-3107|HSP90-targeted SN-38 Conjugate PEN-866|HSP90alpha/beta Inhibitor TAS-116|HTSeq - Counts|HTSeq - FPKM|HTSeq - FPKM-UQ|HUS/TTP|Haemangioblastoma|Haemangiosarcoma|Hafnium Oxide-containing Nanoparticles NBTXR3|Hairy Cell Leukemia|Hairy Cell Leukemia Variant|Hairy Nevus|Hairy cell leukaemia variant|Hairy cell leukemia|Hairy cell leukemia variant|Hairy nevus|Haiti|Half Brother|Half Sibling|Half Sister|Half-brother with Father as Common Parent|Half-brother with Mother as Common Parent|Half-sister with Father as Common Parent|Half-sister with Mother as Common Parent|Halichondrin Analogue E7130|Halichondrin B|Haliotis rufescens|Hallucinations|Halo Nevus|Halo nevus|Halofuginone|Halofuginone Hydrobromide|Hand|Hand Assisted Laparoscopic Radical Nephrectomy|Hand-Schuller-Christian Disease|Hand-Schuller-Christian disease|HaplotypeCaller|Haptoglobin Decreased|Hard Palate|Hard palate|Hashimoto's Thyroiditis|Hashish Smoke Exposure|Hashish smoke|Hay Fever|Hazel|Head & Neck|Head - Face Or Neck, Nos|Head Soft Tissue Necrosis|Head and Neck|Head and Neck Cancer|Head and Neck Lymph Node|Head and Neck Squamous Cell Carcinoma|Head of pancreas|Head of the Pancreas|Head, Face or Neck, NOS|Head, face or neck, NOS|Headache|Headaches|Hearing Impaired|Heart|Heart Disease|Heart Failure|Heart, mediastinum, and pleura|Heavy Chain Disease|Heavy Drinker|Heavy chain disease, NOS|Hedgehog Inhibitor IPI-609|Helicobacter Pylori-Associated Gastritis|Hemangioblastic Meningioma|Hemangioblastic meningioma|Hemangioblastoma|Hemangioendothelial sarcoma|Hemangioendothelioma|Hemangioendothelioma, NOS|Hemangioendothelioma, benign|Hemangioendothelioma, malignant|Hemangioma|Hemangioma simplex|Hemangioma, NOS|Hemangiopericytic meningioma|Hemangiopericytoma|Hemangiopericytoma, NOS|Hemangiopericytoma, benign|Hemangiopericytoma, malignant|Hematologic Cancer|Hematologic Disorder, NOS|Hematoma|Hematopoietic System|Hematopoietic and Lymphoid Cell Neoplasm|Hematopoietic and reticuloendothelial systems|Hematopoietic system, NOS|Hematoporphyrin Derivative|Hematosalpinx|Hematuria|Hemiasterlin Analog E7974|Hemihypertrophy|Hemochromatosis|Hemoglobin Increased|Hemoglobinuria|Hemolymphangioma|Hemolysis|Hemolytic Uremic Syndrome|Hemophiliac|Hemorrhagic Cystitis|Hemorrhoidal Hemorrhage|Hemorrhoids|Henatinib Maleate|Heparan Sulfate Glycosaminoglycan Mimetic M402|Heparin Derivative SST0001|Hepatic|Hepatic Duct|Hepatic Encephalopathy|Hepatic Failure|Hepatic Flexure|Hepatic Hemorrhage|Hepatic Infection|Hepatic Necrosis|Hepatic Pain|Hepatic Vein|Hepatic flexure of colon|Hepatitis|Hepatitis A Infection|Hepatitis B Infection|Hepatitis B Surface Antigen|Hepatitis C Antibody|Hepatitis C Infection|Hepatitis C Virus RNA|Hepatitis C virus|Hepatitis Viral|Hepatitis, Chronic|Hepatitis, NOS|Hepatobiliary Disorders - Other|Hepatoblastoma|Hepatoblastoma, epithelioid|Hepatoblastoma, mixed epithelial-mesenchymal|Hepatocarcinoma|Hepatocellular Adenoma|Hepatocellular Carcinoma|Hepatocellular adenoma|Hepatocellular carcinoma, NOS|Hepatocellular carcinoma, clear cell type|Hepatocellular carcinoma, fibrolamellar|Hepatocellular carcinoma, pleomorphic type|Hepatocellular carcinoma, sarcomatoid|Hepatocellular carcinoma, scirrhous|Hepatocellular carcinoma, spindle cell variant|Hepatocholangiocarcinoma|Hepatoid Adenocarcinoma|Hepatoid adenocarcinoma|Hepatoid carcinoma|Hepatoid yolk sac tumor|Hepatoma, NOS|Hepatoma, benign|Hepatoma, malignant|Hepatosplenic T-Cell Lymphoma|Hepatosplenic T-cell lymphoma|Hepatosplenic gamma-delta cell lymphoma|Herba Scutellaria Barbata|Herbimycin|Hereditary Breast Cancer|Hereditary Kidney Oncocytoma|Hereditary Leiomyomatosis and Renal Cell Carcinoma|Hereditary Non-polyposis Colon Cancer|Hereditary Ovarian Cancer|Hereditary Papillary Renal Cell Carcinoma|Hereditary Prostate Cancer|Hereditary Renal Cell Carcinoma|Hereditary leiomyomatosis & RCC-associated renal cell carcinoma|Herpes|Herpes Simplex Virus|Herpes Zoster|Heterodimeric Interleukin-15|Heterosexual Contact|Hexamethylene Bisacetamide|Hexaminolevulinate|Hexylresorcinol|HiChIP|HiRes ESI|HiRes MALDI|Hibernoma|Hiccups|Hidradenocarcinoma|Hidradenoma|Hidradenoma Papilliferum|Hidradenoma papilliferum|Hidradenoma, NOS|Hidrocystoma|High|High Grade|High Grade (G2)|High Grade B-Cell Lymphoma, Not Otherwise Specified|High Grade Ductal Breast Carcinoma In Situ|High Grade Dysplasia|High Grade Esophageal Glandular Intraepithelial Neoplasia|High Grade Esophageal Squamous Intraepithelial Neoplasia|High Grade Glandular Intraepithelial Neoplasia|High Grade Liver Dysplastic Nodule|High Grade Squamous Intraepithelial Neoplasia|High Grade Surface Osteosarcoma|High Risk|High Risk Gastrointestinal Stromal Tumor|High grade surface osteosarcoma|High-Intermediate Risk|High-Risk Wilms Tumor|High-grade Prostatic Intraepithelial Neoplasia (PIN)|High-grade neuroendocrine carcinoma|High-grade serous carcinoma|HighPure miRNA (Allprep DNA) FFPE RNA|Hilar|Hilar Cholangiocarcinoma|Hilar cell tumor|Hilus cell tumor|Hip|Hip Fracture|Hippocampus|Hirsutism|Hispanic or Latino|Histiocyte-rich large B-cell lymphoma|Histiocytic Sarcoma|Histiocytic medullary reticulosis|Histiocytic sarcoma|Histiocytoid hemangioma|Histiocytoma|Histiocytoma, NOS|Histiocytosis X, NOS|Histology|Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126|Histoplasmosis|History of acceptable prior treatment related to a prior/other malignancy|History of unacceptable prior treatment related to a prior/other malignancy|Histrelin Acetate|Hitachi|Hoarseness|Hodgkin Lymphoma|Hodgkin disease, NOS|Hodgkin disease, lymphocyte predominance, NOS|Hodgkin disease, lymphocyte predominance, diffuse|Hodgkin disease, lymphocytic-histiocytic predominance|Hodgkin disease, nodular sclerosis, NOS|Hodgkin disease, nodular sclerosis, lymphocyte depletion|Hodgkin disease, nodular sclerosis, lymphocyte predominance|Hodgkin disease, nodular sclerosis, mixed cellularity|Hodgkin disease, nodular sclerosis, syncytial variant|Hodgkin granuloma|Hodgkin lymphoma, NOS|Hodgkin lymphoma, lymphocyte depletion, NOS|Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis|Hodgkin lymphoma, lymphocyte depletion, reticular|Hodgkin lymphoma, lymphocyte predominance, nodular|Hodgkin lymphoma, lymphocyte-rich|Hodgkin lymphoma, mixed cellularity, NOS|Hodgkin lymphoma, nodular lymphocyte predominance|Hodgkin lymphoma, nodular sclerosis, NOS|Hodgkin lymphoma, nodular sclerosis, cellular phase|Hodgkin lymphoma, nodular sclerosis, grade 1|Hodgkin lymphoma, nodular sclerosis, grade 2|Hodgkin paragranuloma, NOS|Hodgkin paragranuloma, nodular|Hodgkin sarcoma|Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine|Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Depletion|Hodgkin's Disease, Nodular Sclerosis, Lymphocyte Predominance|Hodgkin's Disease, Nodular Sclerosis, Mixed Cellularity|Hodgkin's Granuloma|Hodgkin's Paragranuloma|Holmium Ho 166 Poly(L-Lactic Acid) Microspheres|Holy See|Homo sapiens|Homo sapiens; Mus musculus|Homosexual Contact|Honduras|Hong Kong|Hormone Therapy|Hormones|Hot Flashes|Hsp90 Antagonist KW-2478|Hsp90 Inhibitor AB-010|Hsp90 Inhibitor BIIB021|Hsp90 Inhibitor BIIB028|Hsp90 Inhibitor DS-2248|Hsp90 Inhibitor Debio 0932|Hsp90 Inhibitor HSP990|Hsp90 Inhibitor MPC-3100|Hsp90 Inhibitor PU-H71|Hsp90 Inhibitor SNX-5422 Mesylate|Hsp90 Inhibitor SNX-5542 Mesylate|Hsp90 Inhibitor TQB3474|Hsp90 Inhibitor XL888|Hsp90-targeted Photosensitizer HS-201|Hu14.18-IL2 Fusion Protein EMD 273063|HuaChanSu|Huaier Extract Granule|Huang Lian|Human Combinatorial Antibody Library-based Monoclonal Antibody VAY736|Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104|Human MOAB LICO 28a32|Human Monoclonal Antibody 216|Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307|Human Original Cells|Human Papillomavirus 16 E7 Peptide/Padre 965.10|Human Papillomavirus Infection|Human Papillomavirus-Related Squamous Cell Carcinoma|Human Tumor Original Cells|Humerus|Hungary|Hurthle cell adenocarcinoma|Hurthle cell adenoma|Hurthle cell carcinoma|Hurthle cell tumor|Husband|Hutchinson melanotic freckle, NOS|Hyalinizing trabecular adenoma|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Hycanthone|Hydatid mole|Hydatidiform Mole|Hydatidiform mole, NOS|Hydralazine Hydrochloride|Hydrazide TMT|Hydroa Vacciniforme-Like Lymphoproliferative Disorder|Hydroa vacciniforme-like lymphoma|Hydrocephalus|Hydrocortisone Sodium Succinate|Hydroxychloroquine|Hydroxyprogesterone Caproate|Hydroxytyrosol|Hydroxyurea|Hygroma, NOS|Hypercalcemia|Hypercholesterolemia|Hypereosinophilic Syndrome|Hypereosinophilic syndrome|Hyperglycemia|Hyperhidrosis|Hypericin|Hyperkalemia|Hyperlipidemia|Hypermagnesemia|Hypernatremia|Hypernephroid tumor|Hypernephroma|Hyperparathyroidism|Hypersomnia|Hypertension|Hyperthyroidism|Hypertrichosis|Hypertriglyceridemia|Hyperuricemia|Hypoalbuminemia|Hypocalcemia|Hypoglossal Nerve Disorder|Hypoglycemia|Hypohidrosis|Hypokalemia|Hypomagnesemia|Hyponatremia|Hypoparathyroidism|Hypopharyngeal aspect of aryepiglottic fold|Hypopharynx|Hypopharynx, NOS|Hypophosphatemia|Hypospadias|Hypotension|Hypothermia|Hypothyroidism|Hypoxia|Hypoxia-activated Prodrug TH-4000|Hysterectomy NOS|Hysterectomy, NOS|I|I 131 Antiferritin Immunoglobulin|I 131 Monoclonal Antibody A33|I 131 Monoclonal Antibody CC49|I 131 Monoclonal Antibody F19|I 131 Monoclonal Antibody Lym-1|I-131 Radiation Therapy|IAP Inhibitor APG-1387|IAP Inhibitor AT-406|IAP Inhibitor HGS1029|ICAT|ICPL|ICT-121 Dendritic Cell Vaccine|IDAT|IDF|IDH1 Mutant Inhibitor LY3410738|IDH1(R132) Inhibitor IDH305|IDH1R132H-Specific Peptide Vaccine PEPIDH1M|IDO Peptide Vaccine IO102|IDO-1 Inhibitor LY3381916|IDO/TDO Inhibitor HTI-1090|IDO/TDO Inhibitor LY-01013|IDO1 Inhibitor KHK2455|IDO1 Inhibitor MK-7162|IDO1 Inhibitor PF-06840003|IDO1/TDO2 Inhibitor DN1406131|IDO1/TDO2 Inhibitor M4112|IGF-1R Inhibitor|IGF-1R Inhibitor PL225B|IGF-1R/IR Inhibitor KW-2450|IGF-methotrexate Conjugate|II|III|IL-10 Immunomodulator MK-1966|IL-12-expressing HSV-1 NSC 733972|IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051|IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000|IL-2 Recombinant Fusion Protein ALT-801|IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1|IL4-Pseudomonas Exotoxin Fusion Protein MDNA55|IMR-Immunoresponse|IMT-1012 Immunotherapeutic Vaccine|INO-1001|INR Increased|INRG Stage L1|INRG Stage L2|INRG Stage M|INRG Stage MS|INSS Stage 1|INSS Stage 2A|INSS Stage 2B|INSS Stage 3|INSS Stage 4|INSS Stage 4S|IPD-Immunoprogression|IPTL|IRAK4 Inhibitor CA-4948|ISQ|ISS 1018 CpG Oligodeoxynucleotide|ISS Stage I Plasma Cell Myeloma|ISS Stage II Plasma Cell Myeloma|ISS Stage III Plasma Cell Myeloma|ITK Inhibitor CPI-818|ITP|ITQ 1100|ITQ 700|ITQ 900|IVth Nerve Disorder|Iadademstat|Ianalumab|Ibandronate Sodium|Iberdomide|Iboctadekin|Ibritumomab Tiuxetan|Ibrutinib|Iceland|Icotinib Hydrochloride|Icrucumab|Idarubicin|Idarubicin Hydrochloride|Idarubicin-Eluting Beads|Idasanutlin|Idecabtagene Vicleucel|Idelalisib|Identical Twin|Identical Twin Brother|Identical Twin Sibling|Identical Twin Sister|Idetrexed|Idiopathic hemorrhagic thrombocythaemia|Idiopathic thrombocythemia|Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020|Idronoxil|Idronoxil Suppository NOX66|Ieramilimab|Ifabotuzumab|Ifetroban|Ifosfamide|Ileal Fistula|Ileal Hemorrhage|Ileal Obstruction|Ileal Perforation|Ileal Stenosis|Ileal Ulcer|Ileocecal Valve|Ileum|Ileus|Ilginatinib|Ilium|Ilixadencel|Ill-Defined Anatomic Site|Ill-defined sites within respiratory system|Illumina|Illumina Human Methylation 27|Illumina Human Methylation 450|Illumina Methylation Epic|Iloprost|Ilorasertib|Imaging|Imaging Technique|Imalumab|Imaradenant|Imatinib|Imatinib Mesylate|Imetelstat|Imetelstat Sodium|Imexon|Imgatuzumab|Imidazole Mustard|Imidazole-Pyrazole|Imifoplatin|Imipramine Blue|Imiquimod|Immature Teratoma|Immature teratoma, NOS|Immature teratoma, malignant|Immediate-release Onapristone|Immediate-release Tablet Afuresertib|Immune Checkpoint Inhibitor ASP8374|Immune System Disorders - Other|Immunoblastic Lymphoma|Immunoblastic sarcoma|Immunoconjugate RO5479599|Immunocytokine NHS-IL12|Immunocytokine NHS-IL2-LT|Immunocytoma|Immunodeficiency-Related Burkitt Lymphoma|Immunodeficiency-associated, adult|Immunodeficiency-associated, pediatric|Immunoglobulin deposition disease|Immunomodulator LAM-003|Immunomodulator OHR/AVR118|Immunomodulatory Agent CC-11006|Immunomodulatory Oligonucleotide HYB2055|Immunoprogression|Immunoproliferative Diseases|Immunoproliferative disease, NOS|Immunoproliferative small intestinal disease|Immunoresponse|Immunotherapeutic Combination Product CMB305|Immunotherapeutic GSK1572932A|Immunotherapy (Including Vaccines)|Immunotherapy Regimen MKC-1106-MT|Immunotoxin CMD-193|In Situ Neoplasms|Inactivated Oncolytic Virus Particle GEN0101|Inadvertently shipped|Inalimarev|Incisional Biopsy|Incomplete Necrosis (Viable Tumor Present)|Incyclinide|Indatuximab Ravtansine|Indefinite Dysplasia|Indefinite for Dysplasia|Indeterminant|Indeterminate|Indeterminate Dendritic Cell Tumor|Indeterminate dendritic cell tumor|Index Finger|India|Indibulin|Indicine-N-Oxide|Indisulam|Individualized MVA-based Vaccine TG4050|Indocyanine Green-labeled Polymeric Micelles ONM-100|Indole-3-Carbinol|Indolent Systemic Mastocytosis|Indolent systemic mastocytosis|Indomethacin|Indonesia|Indoor Stove or Fireplace Smoke Exposure|Indoor stove or fireplace smoke, NOS|Indoor stove or fireplace smoke, coal burning|Indoor stove or fireplace smoke, wood burning|Indoximod|Indoximod Prodrug NLG802|Induced Abortion|Induction Failure AML (AML-IF)|Indusatumab Vedotin|Inebilizumab|Inecalcitol|Infantile Fibrosarcoma|Infantile Hemangioma|Infantile fibrosarcoma|Infantile hemangioma|Infantile myofibromatosis|Infection|Infections and Infestations - Other|Infectious Disorder|Infective Myositis|Infigratinib|Infigratinib Mesylate|Infiltrating Angiolipoma|Infiltrating Bladder Urothelial Carcinoma with Squamous Differentiation|Infiltrating Bladder Urothelial Carcinoma with Trophoblastic Differentiation|Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant|Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant|Infiltrating Bladder Urothelial Carcinoma, Microcystic Variant|Infiltrating Bladder Urothelial Carcinoma, Nested Variant|Infiltrating Lipoma|Infiltrating Papillary Adenocarcinoma|Infiltrating and papillary adenocarcinoma|Infiltrating angiolipoma|Infiltrating basal cell carcinoma, NOS|Infiltrating basal cell carcinoma, non-sclerosing|Infiltrating basal cell carcinoma, sclerosing|Infiltrating duct adenocarcinoma|Infiltrating duct and colloid carcinoma|Infiltrating duct and cribriform carcinoma|Infiltrating duct and lobular carcinoma|Infiltrating duct and lobular carcinoma in situ|Infiltrating duct and mucinous carcinoma|Infiltrating duct and tubular carcinoma|Infiltrating duct carcinoma, NOS|Infiltrating duct mixed with other types of carcinoma|Infiltrating ductular carcinoma|Infiltrating lipoma|Infiltrating lobular carcinoma and ductal carcinoma in situ|Infiltrating lobular carcinoma, NOS|Infiltrating lobular mixed with other types of carcinoma|Infiltrating papillary adenocarcinoma|Inflammation, Hyperkeratosis|Inflammatory Bowel Disease|Inflammatory Liposarcoma|Inflammatory Myofibroblastic Tumor|Inflammatory adenocarcinoma|Inflammatory carcinoma|Inflammatory liposarcoma|Inflammatory myofibroblastic tumor|Infliximab|Informed Consent|Infusion Related Reaction|Infusion Site Extravasation|Ingenol Mebutate|Ingenol Mebutate Gel|Inguinal Lymph Node|Inguinal Region|Iniparib|Initial Diagnosis|Initial Genomic Sequencing|Injected Insulin|Injection Site Reaction|Injury to Carotid Artery|Injury to Inferior Vena Cava|Injury to Jugular Vein|Injury to Superior Vena Cava|Injury, Poisoning and Procedural Complications - Other|Innate Immunostimulator rBBX-01|Inodiftagene Vixteplasmid|Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01|Inosine Monophosphate Dehydrogenase Inhibitor AVN944|Inositol|Inotuzumab Ozogamicin|Inproquone|Insomnia|Insular carcinoma|Insulin|Insulin Controlled Diabetes|Insulinoma, NOS|Insulinoma, malignant|Integrin Receptor Antagonist GLPG0187|Integrin alpha-2 Inhibitor E7820|Interdigitating Dendritic Cell Sarcoma|Interdigitating cell sarcoma|Interdigitating dendritic cell sarcoma|Interferon|Interferon Alfa-2B|Interferon Alfa-N1|Interferon Alfa-N3|Interferon Alfacon-1|Interferon Beta-1A|Interferon Gamma-1b|Interferon-gamma-expressing Adenovirus Vaccine ASN-002|Intergroup Rhabdomyosarcoma Group I|Intergroup Rhabdomyosarcoma Group II|Intergroup Rhabdomyosarcoma Group III|Intergroup Rhabdomyosarcoma Group IIIa|Intergroup Rhabdomyosarcoma Group IIIb|Intergroup Rhabdomyosarcoma Group IIa|Intergroup Rhabdomyosarcoma Group IIb|Intergroup Rhabdomyosarcoma Group IIc|Intergroup Rhabdomyosarcoma Group IV|Intergroup Rhabdomyosarcoma Group Ia|Intergroup Rhabdomyosarcoma Group Ib|Interleukin Therapy|Interleukin-12-Fc Fusion Protein DF6002|Interleukin-15 Agonist Fusion Protein SHR1501|Interleukin-15 Fusion Protein BJ-001|Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306|Interleukin-15/Interleukin-15 Receptor Alpha Sushi+ Domain Fusion Protein SO-C101|Interleukin-2 Liposome|Intermediate|Intermediate Grade|Intermediate Immature Teratoma|Intermediate Prognosis|Intermediate Risk|Intermediate and giant congenital nevus|Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230|Internal Radiation|International Prognostic Index High-Intermediate Risk Group|International Prognostic Index Low-Intermediate Risk Group|Interstitial Pneumontis or ARDS|Interstitial cell tumor, NOS|Interstitial cell tumor, benign|Interstitial cell tumor, malignant|Intestinal Metaplasia|Intestinal Stoma Leak|Intestinal Stoma Obstruction|Intestinal Stoma Site Bleeding|Intestinal T-cell lymphoma|Intestinal tract, NOS|Intestinal-Type Adenocarcinoma|Intestinal-type adenocarcinoma|Intetumumab|Intimal Sarcoma|Intimal sarcoma|Intiquinatine|Intoplicine|Intra-Abdominal Hemorrhage|Intra-Abdominal Lymph Node|Intra-abdominal lymph nodes|Intracanalicular fibroadenoma|Intracompartmental (T1)|Intracompartmental Tumor|Intracortical osteosarcoma|Intracranial Hemorrhage|Intracystic Papillary Breast Carcinoma|Intracystic Papilloma|Intracystic carcinoma, NOS|Intracystic papillary adenocarcinoma|Intracystic papillary adenoma|Intracystic papillary neoplasm with associated invasive carcinoma|Intracystic papillary neoplasm with high grade intraepithelial neoplasia|Intracystic papillary neoplasm with intermediate grade intraepithelial neoplasia|Intracystic papillary neoplasm with low grade intraepithelial neoplasia|Intracystic papillary tumor with high grade dysplasia|Intracystic papillary tumor with high grade entraepithelial neoplasia|Intracystic papillary tumor with high grade intraepithelial neoplasia|Intracystic papilloma|Intradermal nevus|Intraductal Carcinoma of the Minor Salivary Gland|Intraductal Cribriform Breast Adenocarcinoma|Intraductal Papillary Adenocarcinoma with Invasion|Intraductal Papillary Breast Carcinoma|Intraductal Papillary Mucinous Neoplasm|Intraductal Papilloma|Intraductal Papillomatosis|Intraductal adenocarcinoma, noninfiltrating, NOS|Intraductal and Lobular Carcinoma|Intraductal and lobular carcinoma|Intraductal carcinoma and lobular carcinoma in situ|Intraductal carcinoma, NOS|Intraductal carcinoma, clinging|Intraductal carcinoma, noninfiltrating, NOS|Intraductal carcinoma, solid type|Intraductal micropapillary carcinoma|Intraductal papillary adenocarcinoma with invasion|Intraductal papillary adenocarcinoma, NOS|Intraductal papillary carcinoma|Intraductal papillary mucinous neoplasm (IPMN) with an associated invasive carcinoma|Intraductal papillary mucinous neoplasm with an associated invasive carcinoma|Intraductal papillary mucinous neoplasm with high grade dysplasia|Intraductal papillary neoplasm with associated invasive carcinoma|Intraductal papillary neoplasm with high grade dysplasia|Intraductal papillary neoplasm with high grade intraepithelial neoplasia|Intraductal papillary neoplasm with intermediate grade neoplasia|Intraductal papillary neoplasm with low grade intraepithelial neoplasia|Intraductal papillary neoplasm, NOS|Intraductal papillary tumor with high grade dysplasia|Intraductal papillary tumor with high grade intraepithelial neoplasia|Intraductal papillary-mucinous adenoma|Intraductal papillary-mucinous carcinoma, invasive|Intraductal papillary-mucinous carcinoma, non-invasive|Intraductal papillary-mucinous neoplasm with low grade dysplasia|Intraductal papillary-mucinous neoplasm with moderate dysplasia|Intraductal papillary-mucinous tumor with intermediate dysplasia|Intraductal papillary-mucinous tumor with low grade dysplasia|Intraductal papillary-mucinous tumor with moderate dysplasia|Intraductal papilloma|Intraductal papilloma with ductal carcinoma in situ|Intraductal papilloma with lobular carcinoma in situ|Intraductal papillomatosis, NOS|Intraductal tubular-papillary neoplasm, high grade|Intraductal tubular-papillary neoplasm, low grade|Intraductal tubulopapillary neoplasm|Intraepidermal Epithelioma of Jadassohn|Intraepidermal carcinoma, NOS|Intraepidermal epithelioma of Jadassohn|Intraepidermal nevus|Intraepidermal squamous cell carcinoma, Bowen type|Intraepithelial carcinoma, NOS|Intraepithelial squamous cell carcinoma|Intraglandular papillary neoplasm with low grade intraepithelial neoplasia|Intrahepatic bile duct|Intramural|Intramuscular Hemangioma|Intramuscular Lipoma|Intramuscular hemangioma|Intramuscular lipoma|Intraneural Perineurioma|Intraneural perineurioma|Intraoperative Arterial Injury|Intraoperative Breast Injury|Intraoperative Cardiac Injury|Intraoperative Ear Injury|Intraoperative Endocrine Injury|Intraoperative Gastrointestinal Injury|Intraoperative Head and Neck Injury|Intraoperative Hemorrhage|Intraoperative Hepatobiliary Injury|Intraoperative Musculoskeletal Injury|Intraoperative Neurological Injury|Intraoperative Ocular Injury|Intraoperative Renal Injury|Intraoperative Reproductive Tract Injury|Intraoperative Respiratory Injury|Intraoperative Skin Injury|Intraoperative Splenic Injury|Intraoperative Urinary Injury|Intraoperative Venous Injury|Intraosseous low grade osteosarcoma|Intraosseous well differentiated osteosarcoma|Intrathecal|Intrathoracic Lymph Node|Intrathoracic lymph nodes|Intrathyroid Thymic Carcinoma|Intratubular germ cell neoplasia|Intratubular malignant germ cells|Intravascular B-cell lymphoma|Intravascular Large B-Cell Lymphoma|Intravascular bronchial alveolar tumor|Intravascular large B-cell lymphoma|Intravascular leiomyomatosis|Intravenous|Intravenous Drug User|Inulin|Invasive Breast Carcinoma|Invasive Ductal Carcinoma, Not Otherwise Specified|Invasive Ductal and Lobular Carcinoma|Invasive Ductal and Lobular Carcinoma In Situ|Invasive Hydatidiform Mole|Invasive Lobular Breast Carcinoma|Invasive Lobular Breast Carcinoma, Alveolar Variant|Invasive Lobular Breast Carcinoma, Pleomorphic Variant|Invasive Lobular Breast Carcinoma, Solid Variant|Invasive Lobular Breast Carcinoma, Tubulolobular Variant|Invasive Lung Mucinous Adenocarcinoma|Invasive Micropapillary Breast Carcinoma|Invasive carcinoma of no special type|Invasive carcinoma, NST|Invasive encapsulated follicular variant of papillary thyroid carcinoma (invasive EFVPTC)|Invasive fibroma|Invasive hydatidiform mole|Invasive lobular carcinoma|Invasive lobular carcinoma, alveolar type|Invasive lobular carcinoma, solid type|Invasive lobular carcinoma, tubulolobular variant|Invasive mammary carcinoma|Invasive micropapillary carcinoma|Invasive mole, NOS|Invasive mucinous adenocarcinoma|Inverted Squamous Cell Papilloma|Inverted Transitional Cell Papilloma|Investigations - Other|Involuting nevus|Iobenguane I-131|Iodine I 124 Monoclonal Antibody A33|Iodine I 124 Monoclonal Antibody M5A|Iodine I 125-Anti-EGFR-425 Monoclonal Antibody|Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP|Iodine I 131 Apamistamab|Iodine I 131 Derlotuximab Biotin|Iodine I 131 Ethiodized Oil|Iodine I 131 IPA|Iodine I 131 MIP-1095|Iodine I 131 Monoclonal Antibody 81C6|Iodine I 131 Monoclonal Antibody BC8|Iodine I 131 Monoclonal Antibody CC49-deltaCH2|Iodine I 131 Monoclonal Antibody F16SIP|Iodine I 131 Monoclonal Antibody G-250|Iodine I 131 Monoclonal Antibody muJ591|Iodine I 131 Omburtamab|Iodine I 131 Rituximab|Iodine I 131 TM-601|Iodine I 131 Tenatumomab|Iodine I 131 Tositumomab|Iodine I-131|IodoTMT|Iodoacetamide (IAA)|Ioflubenzamide I-131|Ion Torrent|Ionomycin|Ipafricept|Ipatasertib|Ipilimumab|Ipomeanol|Iproplatin|Iran|Iraq|Iratumumab|Ireland|Iridium Ir 192|Irinotecan|Irinotecan Hydrochloride|Irinotecan Sucrosofate|Irinotecan-Eluting Beads|Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet|Irofulven|Iron Overload|Iroplact|Irosustat|Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130|Irregular Menstruation|Irritability|Isatuximab|Ischemia Cerebrovascular|Ischemic Heart Disease|Ischium|Ishak Score 0|Ishak Score 1-2|Ishak Score 3-4|Ishak Score 5|Ishak Score 6|Isle of Man|Islet Cell Adenoma|Islet Cells|Islet cell adenocarcinoma|Islet cell adenoma|Islet cell adenomatosis|Islet cell carcinoma|Islet cell tumor, NOS|Islet cell tumor, benign|Islets of Langerhans|Iso-fludelone|IsoPrime|IsoProbe T|Isobaric label quantitation analysis|Isobrucein B|Isocoumarin NM-3|Isoform Expression Quantification|Isolated Limb Perfusion (ILP)|Isosporiasis|Isotretinoin|Ispinesib|Ispinesib Mesylate|Israel|Isthmus Uteri|Isthmus uteri|Istiratumab|Itacitinib|Itacitinib Adipate|Italy|Item Flagged Low Quality|Item does not meet study protocol|Item flagged DNU|Item in special subset|Item is noncanonical|Item may not meet study protocol|Itraconazole|Itraconazole Dispersion In Polymer Matrix|Ivaltinostat|Ivosidenib|Ivuxolimab|Ixabepilone|Ixazomib|Ixazomib Citrate|JAK Inhibitor|JAK Inhibitor INCB047986|JAK1 Inhibitor AZD4205|JAK1 Inhibitor INCB052793|JAK2 Inhibitor AZD1480|JAK2 Inhibitor BMS-911543|JAK2 Inhibitor XL019|JAK2/Src Inhibitor NS-018|JNK Inhibitor CC-401|JPEG|JPEG 2000|JSON|Jadassohn blue nevus|Jamaica|Japan|Jaw|Jejunal Fistula|Jejunal Hemorrhage|Jejunal Obstruction|Jejunal Perforation|Jejunal Stenosis|Jejunal Ulcer|Jejunum|Jersey|Jin Fu Kang|Joint|Joint Effusion|Joint Infection|Joint Range of Motion Decreased|Joint Range of Motion Decreased Cervical Spine|Joint Range of Motion Decreased Lumbar Spine|Joint Replacement|Jordan|Jugular paraganglioma|Jugulotympanic Paraganglioma|Jugulotympanic paraganglioma|Junction nevus|Junctional Nevus|Junctional nevus, NOS|Juvenile Myelomonocytic Leukemia|Juvenile Type Granulosa Cell Tumor|Juvenile angiofibroma|Juvenile astrocytoma|Juvenile carcinoma of breast|Juvenile chronic myelomonocytic leukemia|Juvenile fibroadenoma|Juvenile hemangioma|Juvenile histiocytoma|Juvenile melanoma|Juvenile myelomonocytic leukemia|Juvenile nevus|Juxtacortical chondroma|Juxtacortical chondrosarcoma|Juxtacortical osteosarcoma|Juxtaglomerular Cell Tumor|Juxtaglomerular tumor|KRAS G12C Inhibitor GDC-6036|KRAS G12C Inhibitor LY3499446|KRAS G12C Inhibitor MRTX849|KRAS Mutant-targeting AMG 510|KRAS-MAPK Signaling Pathway Inhibitor JAB-3312|KRASG12C Inhibitor JNJ-74699157|KRN5500|KSP Inhibitor AZD4877|KSP Inhibitor SB-743921|Kallisto - HDF5|Kallisto - Quantification|Kanglaite|Kanitinib|Kaposi Sarcoma|Kaposi sarcoma|Kaposiform Hemangioendothelioma|Kaposiform hemangioendothelioma|Kazakhstan|Kenya|Keratinizing Squamous Cell Carcinoma|Keratitis|Keratotoc papilloma|Kerosene Smoke Exposure|Ketoconazole|Ketotrexate|Kidney|Kidney Anastomotic Leak|Kidney Cancer|Kidney Carcinoma|Kidney Chromophobe|Kidney Disease|Kidney Disorder|Kidney Infection|Kidney Medullary Carcinoma|Kidney Renal Clear Cell Carcinoma|Kidney Renal Papillary Cell Carcinoma|Kidney Wilms Tumor|Kidney, NOS|Kiribati|Klatskin tumor|Knee|Kosovo|Krukenberg Tumor|Krukenberg tumor|Kunecatechins Ointment|Kupffer cell sarcoma|Kuwait|Kyphosis|Kyrgyzstan|L-Gossypol|L-cell tumor|L-methylfolate|L1|L1 Acute Lymphoblastic Leukemia|L2|L2 Acute Lymphoblastic Leukemia|LAIR-2 Fusion Protein NC410|LC-MS label-free quantitation analysis|LCIS, NOS|LCMS-2010A|LCMS-2010EV|LCMS-2020|LCMS-8040|LCMS-8045|LCMS-8050|LCMS-8060|LCMS-9030|LCMS-IT-TOF|LCT|LCT Premier|LCT Premier XE|LECO|LMB-1 Immunotoxin|LMB-2 Immunotoxin|LMB-7 Immunotoxin|LMB-9 Immunotoxin|LMP-2:340-349 Peptide Vaccine|LMP-2:419-427 Peptide Vaccine|LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes|LMP7 Inhibitor M3258|LOH|LOXL2 Inhibitor PAT-1251|LRP5 Antagonist BI 905681|LRP5/6 Antagonist BI 905677|LS454|LSD1 Inhibitor CC-90011|LSD1 Inhibitor GSK2879552|LSD1 Inhibitor IMG-7289|LSD1 Inhibitor RO7051790|LSD1 Inhibitor SYHA1807|LTQ|LTQ FT|LTQ FT Ultra|LTQ Orbitrap|LTQ Orbitrap Classic|LTQ Orbitrap Discovery|LTQ Orbitrap Elite|LTQ Orbitrap Velos|LTQ Orbitrap XL|LTQ Orbitrap XL ETD|LTQ Velos|LTQ Velos ETD|LTQ Velos Pro|LTQ XL|LTQ XL ETD|LTQ-FT|LTQ-OT|LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1|LXQ|Label Free|Label-free gene level quantitation|Label-free peptide level quantitation|Label-free protein group level quantitation|Label-free protein level quantitation|Label-free raw feature quantitation|Labetuzumab Govitecan|Labium Majus|Labium Minus|Labium majus|Labium minus|Lacrimal Gland|Lacrimal gland|Lactating Adenoma|Lactating adenoma|Lactation Disorder|Lactoferrin-derived Lytic Peptide LTX-315|Lactotroph Adenoma|Lacutamab|Ladiratuzumab Vedotin|Ladirubicin|Laetrile|Landogrozumab|Langerhans Cell Histiocytosis|Langerhans Cell Histiocytosis, Disseminated|Langerhans Cell Histiocytosis, Monostotic|Langerhans Cell Histiocytosis, Polyostotic|Langerhans Cell Sarcoma|Langerhans cell granulomatosis|Langerhans cell granulomatosis, unifocal|Langerhans cell histiocytosis, NOS|Langerhans cell histiocytosis, disseminated|Langerhans cell histiocytosis, generalized|Langerhans cell histiocytosis, mono-ostotic|Langerhans cell histiocytosis, multifocal|Langerhans cell histiocytosis, poly-ostotic|Langerhans cell histiocytosis, unifocal|Langerhans cell sarcoma|Laniquidar|Lanreotide Acetate|Laos|Lapachone|Laparoscopic Biopsy|Laparoscopic Partial Nephrectomy|Laparoscopic Radical Nephrectomy|Laparoscopic Radical Prostatectomy with Robotics|Laparoscopic Radical Prostatectomy without Robotics|Laparoscopy|Laparotomy|Lapatinib|Lapatinib Ditosylate|Laprituximab Emtansine|Lapuleucel-T|Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease|Large Bowel|Large Cell Carcinoma|Large Cell Medulloblastoma|Large Cell Neuroendocrine Carcinoma|Large Intestinal Anastomotic Leak|Large cell (Ki-1+) lymphoma|Large cell calcifying Sertoli cell tumor|Large cell carcinoma with rhabdoid phenotype|Large cell carcinoma, NOS|Large cell medulloblastoma|Large cell neuroendocrine carcinoma|Large granular lymphocytosis, NOS|Laromustine|Larotaxel|Larotinib Mesylate|Larotrectinib|Larotrectinib Sulfate|Laryngeal Cancer|Laryngeal Carcinoma|Laryngeal Cartilage|Laryngeal Edema|Laryngeal Fistula|Laryngeal Hemorrhage|Laryngeal Inflammation|Laryngeal Mucositis|Laryngeal Obstruction|Laryngeal Stenosis|Laryngeal cartilage|Laryngeal commissure|Laryngitis|Laryngopharyngeal Dysesthesia|Laryngopharyngectomy|Laryngopharynx|Laryngospasm|Larynx|Larynx, NOS|Lateral Wall of the Nasopharynx|Lateral floor of mouth|Lateral wall of bladder|Lateral wall of nasopharynx|Lateral wall of oropharynx|Latvia|Lavendustin A|Lazertinib|Lead Pb 212 TCMC-trastuzumab|Lebanon|Lefitolimod|Leflunomide|Left|Left Hemicolectomy|Left Ventricular Systolic Dysfunction|Leg|Legal Guardian|Leiomyoblastoma|Leiomyofibroma|Leiomyoma|Leiomyoma, NOS|Leiomyomatosis|Leiomyomatosis, NOS|Leiomyosarcoma|Leiomyosarcoma, NOS|Lenalidomide|Lenalidomide Analog KPG-121|Lennert lymphoma|Lentigo Maligna|Lentigo Maligna Melanoma|Lentigo maligna|Lentigo maligna melanoma|Lentinan|Lenvatinib|Lenvatinib Mesylate|Lenzilumab|Lepidic Predominant Adenocarcinoma|Lepidic adenocarcinoma|Lepidic predominant adenocarcinoma|Leptomeningeal Sarcoma|Leptomeningeal sarcoma|Leptomeninges|Lerociclib|Lesotho|Lesser Curvature of the Stomach|Lesser curvature of stomach, NOS|Lestaurtinib|Letetresgene Autoleucel|Lethargy|Letolizumab|Letrozole|Letterer-Siwe Disease|Letterer-Siwe disease|Leucovorin|Leucovorin Calcium|Leukemia|Leukemia Secondary to Oncology Chemotherapy|Leukemia, NOS|Leukemias, NOS|Leukemic reticuloendotheliosis|Leukocyte elastase|Leukocytosis|Leukoencephalopathy|Leuprolide|Leuprolide Acetate|Leuprolide Mesylate Injectable Suspension|Leurubicin|Levetiracetam|Levoleucovorin Calcium|Levothyroxine|Levothyroxine Sodium|Lexatumumab|Lexibulin|Leydig Cell Tumor|Leydig cell tumor, NOS|Leydig cell tumor, benign|Leydig cell tumor, malignant|Li-Fraumeni Syndrome|Liarozole|Liarozole Fumarate|Liarozole Hydrochloride|Liberia|Libido Decreased|Libido Increased|Libya|Licartin|Licorice|Liechtenstein|Lifastuzumab Vedotin|Lifelong Non-Drinker|Lifileucel|Lifirafenib|Liftover|Ligament|Light Chain Deposition Disease|Light-Emitting Oncolytic Vaccinia Virus GL-ONC1|Light-activated AU-011|Lilotomab|Limonene, (+)-|Limonene, (+/-)-|Lingual tonsil|Linifanib|Linitis Plastica|Linitis plastica|Linoleyl Carbonate-Paclitaxel|Linperlisib|Linrodostat|Linsitinib|Lintuzumab|Liothyronine I-131|Liothyronine Sodium|Lip|Lip Infection|Lip Pain|Lip, NOS|Lipase Increased|Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1|Lipid Nanoparticle Encapsulated OX40L mRNA-2416|Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191|Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006|Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752|Lipid cell tumor of ovary|Lipid-Rich Carcinoma|Lipid-rich Sertoli cell tumor|Lipid-rich carcinoma|Lipid-rich urothelial carcinoma|Lipidome|Lipoadenoma|Lipoblastoma|Lipoblastomatosis|Lipohypertrophy|Lipoid cell tumor of ovary|Lipoleiomyoma|Lipoma|Lipoma, NOS|Lipoma-like liposarcoma|Lipomatous Neoplasms|Lipomatous medulloblastoma|Liposarcoma|Liposarcoma, NOS|Liposarcoma, differentiated|Liposarcoma, well differentiated|Liposomal Bcl-2 Antisense Oligonucleotide  BP1002|Liposomal Curcumin|Liposomal Cytarabine|Liposomal Daunorubicin Citrate|Liposomal Docetaxel|Liposomal Eribulin Mesylate|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Liposomal Irinotecan|Liposomal MUC1/PET-lipid A Vaccine ONT-10|Liposomal Mitoxantrone Hydrochloride|Liposomal NDDP|Liposomal Rhenium Re 186|Liposomal SN-38|Liposomal Topotecan FF-10850|Liposomal Vinorelbine|Liposomal Vinorelbine Tartrate|Liposomal c-raf Antisense Oligonucleotide|Liposome|Liposome-Encapsulated Doxorubicin Citrate|Liposome-encapsulated Daunorubicin-Cytarabine|Liposome-encapsulated OSI-7904|Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94|Liposome-encapsulated TAAs mRNA Vaccine W_ova1|Liposome-encapsulated miR-34 Mimic MRX34|Liquid Biopsy|Liquid Suspension Cell Line|Liquid Tumor|Liquor|Lirilumab|Lisavanbulin|Lisocabtagene Maraleucel|Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142|Lithuania|Litronesib|Live Birth|Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207|Live-attenuated Double-deleted Listeria monocytogenes Bacteria JNJ-64041809|Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623|Liver|Liver Cancer|Liver Cirrhosis (Liver Disease)|Liver Hepatocellular Carcinoma|Liver Toxicity (Non-Infectious)|Liver X Receptor beta Agonist RGX-104|Liver and Intrahepatic Bile Duct Carcinoma|Liver and intrahepatic bile ducts|Liver cell adenoma|Liver cell carcinoma|Lm-tLLO-neoantigens Vaccine ADXS-NEO|LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine ADXS31-164|Lobaplatin|Lobectomy|Lobular Breast Carcinoma|Lobular Breast Carcinoma In Situ|Lobular adenocarcinoma|Lobular and ductal carcinoma|Lobular carcinoma in situ, NOS|Lobular carcinoma, NOS|Lobular carcinoma, noninfiltrating|Local|Local Resection (Exoresection; wall resection)|Localized Edema|Localized fibrous tumor|Loco-regional recurrence/progression|Lodapolimab|Lometrexol|Lometrexol Sodium|Lomustine|Lonafarnib|Loncastuximab Tesirine|Long Peptide Vaccine 7|Long bones of lower limb and associated joints|Long bones of upper limb, scapula and associated joints|Long-acting Release Pasireotide|Lontucirev|Lordosis|Lorlatinib|Lorukafusp alfa|Lorvotuzumab Mertansine|Losatuxizumab Vedotin|Losoxantrone|Losoxantrone Hydrochloride|Lovastatin|Low|Low Grade|Low Grade (G1)|Low Grade Adenosquamous Breast Carcinoma|Low Grade Central Osteosarcoma|Low Grade Cervical Intraepithelial Neoplasia|Low Grade Dysplasia|Low Grade Endometrioid Stromal Sarcoma|Low Grade Esophageal Glandular Intraepithelial Neoplasia|Low Grade Esophageal Squamous Intraepithelial Neoplasia|Low Grade Fibromyxoid Sarcoma|Low Grade Glandular Intraepithelial Neoplasia|Low Grade Liver Dysplastic Nodule|Low Grade Myofibroblastic Sarcoma|Low Grade Squamous Intraepithelial Neoplasia|Low Risk|Low Risk Gastrointestinal Stromal Tumor|Low grade adenosquamous carcinoma|Low grade appendiceal mucinous neoplasm|Low grade cribriform cystadenocarcinoma (LGCCC)|Low-CSD Melanoma|Low-Grade Appendix Mucinous Neoplasm|Low-Intermediate Risk|Low-grade central osteosarcoma|Low-grade fibromyxoid sarcoma|Low-grade intramedullary osteosarcoma|Low-grade myofibroblastic sarcoma|Low-grade serous carcinoma|Lower Gastrointestinal Hemorrhage|Lower Gingiva|Lower gum|Lower limb, NOS|Lower lobe, lung|Lower third of esophagus|Lower-Outer Quadrant of the Breast|Lower-inner quadrant of breast|Lower-outer quadrant of breast|Lucanthone|Lucatumumab|Lucitanib|Lumbar Spine|Luminespib|Luminespib Mesylate|Lumpectomy|Lumretuzumab|Lung|Lung Adenocarcinoma|Lung Adenocarcinoma with Mixed Bronchioloalveolar and Invasive Components|Lung Cancer|Lung Cancer (all types)|Lung Carcinoma|Lung Colloid Adenocarcinoma|Lung Fetal Adenocarcinoma|Lung Infection|Lung Large Cell Carcinoma with Rhabdoid Phenotype|Lung Mucinous Adenocarcinoma In Situ|Lung Non-Mucinous Adenocarcinoma In Situ|Lung Papillary Adenoma|Lung Squamous Cell Carcinoma|Lung, NOS|Lung-targeted Immunomodulator QBKPN|Lupartumab Amadotin|Lupus|Lurbinectedin|Lurtotecan|Lurtotecan Liposome|Luteinoma|Luteoma, NOS|Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1|Lutetium Lu 177 DOTA-N3-CTT1403|Lutetium Lu 177 DOTA-Tetulomab|Lutetium Lu 177 DOTA-biotin|Lutetium Lu 177 Dotatate|Lutetium Lu 177 Lilotomab-satetraxetan|Lutetium Lu 177 Monoclonal Antibody CC49|Lutetium Lu 177 Monoclonal Antibody J591|Lutetium Lu 177 PP-F11N|Lutetium Lu 177 Satoreotide Tetraxetan|Lutetium Lu 177-DOTA-EB-TATE|Lutetium Lu 177-DTPA-omburtamab|Lutetium Lu 177-Edotreotide|Lutetium Lu 177-NeoB|Lutetium Lu 177-PSMA-617|Lutetium Lu-177 Capromab|Lutetium Lu-177 Girentuximab|Lutetium Lu-177 PSMA-R2|Lutetium Lu-177 Rituximab|Luxembourg|Lymph Gland Infection|Lymph Leakage|Lymph Node|Lymph Node Cancer|Lymph Node Dissection|Lymph Node Pain|Lymph Node(s) Axilla|Lymph Node(s) Cervical|Lymph Node(s) Distant|Lymph Node(s) Epitrochlear|Lymph Node(s) Femoral|Lymph Node(s) Hilar|Lymph Node(s) Iliac-Common|Lymph Node(s) Iliac-External|Lymph Node(s) Inguinal|Lymph Node(s) Internal Mammary|Lymph Node(s) Mammary|Lymph Node(s) Mediastinal|Lymph Node(s) Mesenteric|Lymph Node(s) Occipital|Lymph Node(s) Paraaortic|Lymph Node(s) Parotid|Lymph Node(s) Pelvic|Lymph Node(s) Popliteal|Lymph Node(s) Regional|Lymph Node(s) Retroperitoneal|Lymph Node(s) Scalene|Lymph Node(s) Splenic|Lymph Node(s) Subclavicular|Lymph Node(s) Submandibular|Lymph Node(s) Supraclavicular|Lymph Node, Axillary|Lymph Node, Inguinal|Lymph Node, NOS|Lymph Node, Regional|Lymph Node, Subcarinal|Lymph Nodes(s) Mediastinal|Lymph node, NOS|Lymph nodes|Lymph nodes of axilla or arm|Lymph nodes of head, face and neck|Lymph nodes of inguinal region or leg|Lymph nodes of multiple regions|Lymphadenectomy|Lymphangioendothelial sarcoma|Lymphangioendothelioma, NOS|Lymphangioendothelioma, malignant|Lymphangioleiomyoma|Lymphangioleiomyomatosis|Lymphangioma|Lymphangioma, NOS|Lymphangiomyoma|Lymphangiomyomatosis|Lymphangiosarcoma|Lymphatic Vessel Tumors|Lymphatic leukemic, NOS|Lymphedema|Lymphoblastic Lymphoma|Lymphoblastic leukemia, NOS|Lymphoblastoma|Lymphocele|Lymphocyte Count Decreased|Lymphocyte Count Increased|Lymphocyte Predominant Type Hodgkin's Disease|Lymphocyte-Depleted Classic Hodgkin Lymphoma|Lymphocyte-Rich Classic Hodgkin Lymphoma|Lymphocytes|Lymphocytic Meningitis|Lymphocytic Thyroiditis|Lymphocytic leukemia, NOS|Lymphoepithelial carcinoma|Lymphoepithelioid Variant Peripheral T-Cell Lymphoma|Lymphoepithelioid lymphoma|Lymphoepithelioma|Lymphoepithelioma-like carcinoma|Lymphoid Leukemia|Lymphoid Leukemias|Lymphoid Neoplasm Diffuse Large B-cell Lymphoma|Lymphoid Normal|Lymphoid leukemia, NOS|Lymphoma|Lymphoma, NOS|Lymphomatoid Granulomatosis|Lymphomatoid Papulosis|Lymphomatoid granulomatosis|Lymphomatoid papulosis|Lymphoplasmacyte-Rich Meningioma|Lymphoplasmacyte-rich meningioma|Lymphoplasmacytic Lymphoma|Lymphoproliferative Disorder|Lymphoproliferative disease, NOS|Lymphoproliferative disorder, NOS|Lymphosarcoma|Lymphosarcoma cell leukemia|Lymphosarcoma, NOS|Lymphosarcoma, diffuse|Lynch Syndrome|Lyophilized Black Raspberry Lozenge|Lyophilized Black Raspberry Saliva Substitute|Lys-C|Lys-C, Lys-C/P|Lysine-specific Demethylase 1 Inhibitor INCB059872|Lyso-Thermosensitive Liposome Doxorubicin|M|M0|M0 Stage Finding|M1|M1 Stage Finding|M1a|M1a Stage Finding|M1b|M1b Stage Finding|M1c|M1c Stage Finding|M1d|M2|M6A|M6B|M@LDI L|M@LDI LR|MAF|MAGE-10.A2|MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells|MAGE-A3 Multipeptide Vaccine GL-0817|MAGE-A3 Peptide Vaccine|MAGE-A3-specific Immunotherapeutic GSK 2132231A|MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201|MAGE-TAB|MAGETAB|MAI|MALDI 4800|MALDI L|MALDI LR|MALDI LTQ Orbitrap|MALDI LTQ XL|MALDI R|MALDI SYNAPT G2-Si|MALDI Synapt G2 HDMS|MALDI Synapt G2 MS|MALDI Synapt G2-S HDMS|MALDI Synapt G2-S MS|MALDI Synapt HDMS|MALDI Synapt MS|MALDI micro MX|MALT lymphoma|MALT1 Inhibitor JNJ-67856633|MANEC|MARCKS Protein Inhibitor BIO-11006|MAT2A Inhibitor AG-270|MCL-1 Inhibitor ABBV-467|MCL-1 Inhibitor AMG 176|MCL-1 inhibitor AMG 397|MDM2 Antagonist ASTX295|MDM2 Antagonist RO5045337|MDM2 Antagonist RO6839921|MDM2 Inhibitor AMG-232|MDM2 Inhibitor AMGMDS3|MDM2 Inhibitor BI 907828|MDM2 Inhibitor KRT-232|MDM2/MDMX Inhibitor ALRN-6924|MDR Modulator CBT-1|MEK 1/2 Inhibitor AS703988/MSC2015103B|MEK 1/2 Inhibitor FCN-159|MEK Inhibitor AZD8330|MEK Inhibitor CI-1040|MEK Inhibitor GDC-0623|MEK Inhibitor HL-085|MEK Inhibitor PD0325901|MEK Inhibitor RO4987655|MEK Inhibitor SHR 7390|MEK Inhibitor TAK-733|MEK Inhibitor WX-554|MEK inhibitor CS3006|MEK-1/MEKK-1 Inhibitor E6201|MEK/Aurora Kinase Inhibitor BI 847325|MELK Inhibitor OTS167|MET Kinase Inhibitor OMO-1|MET Tyrosine Kinase Inhibitor BMS-777607|MET Tyrosine Kinase Inhibitor EMD 1204831|MET Tyrosine Kinase Inhibitor PF-04217903|MET Tyrosine Kinase Inhibitor SAR125844|MET Tyrosine Kinase Inhibitor SGX523|MET x MET Bispecific Antibody REGN5093|MEX|MGUS|MK0731|MKC-1|MKNK1 Inhibitor BAY 1143269|MMP Inhibitor S-3304|MNK1/2 Inhibitor ETC-1907206|MOF Compound RiMO-301|MOv-gamma Chimeric Receptor Gene|MPNST with glandular differentiation|MPNST with mesenchymal differentiation|MPNST with rhabdomyoblastic differentiation|MPNST, NOS|MR-Minimal/Marginal Response|MR-Minimal/Marginal response|MRI|MS1 label-based analysis|MS2|MS2 tag-based analysis|MS2-based label-free quantitation|MS3|MSI|MSS|MTF-1 Inhibitor APTO-253 HCl|MUC-1/WT1 Peptide-primed Autologous Dendritic Cells|MUC1-targeted Peptide GO-203-2C|MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP|MVA-BN Smallpox Vaccine|MVA-FCU1 TG4023|MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1|MX|MX Stage Finding|MX-Mixed Response|MYC-targeting siRNA DCR-MYC|Maackia amurensis Seed Lectin|Macau|Machine Smoke Exposure|Machine smoke|Macimorelin|Macitentan|Macro|Macrocycle-bridged STING Agonist E7766|Macrofollicular adenoma|Macroscopic (2cm or less)|Macroscopic (greater than 2cm)|Macroscopic Parametrium|Madagascar|Maekmoondong-tang|Mafosfamide|Magnesium Valproate|Magnocellular nevus|Magrolimab|Main Bronchus|Main bronchus|Maintenance Therapy|Major salivary gland, NOS|Malabsorption|Malaise|Malaria|Malawi|Malaysia|Maldives|Male|Male Cousin|Male Genitalia|Male Sibling of Adopted Child|Male genital organs, NOS|Mali|Malignancy|Malignancy in Giant Cell Tumor of Bone|Malignant|Malignant Adrenal Cortex Neoplasm|Malignant Adrenal Gland Neoplasm|Malignant Adrenal Gland Pheochromocytoma|Malignant Bone Neoplasm|Malignant Brain Neoplasm|Malignant Cell|Malignant Central Nervous System Neoplasm|Malignant Enteroglucagonoma|Malignant Extra-Adrenal Paraganglioma|Malignant Female Reproductive System Neoplasm|Malignant Gastrinoma|Malignant Gastrointestinal Stromal Tumor|Malignant Giant Cell Neoplasm|Malignant Glioma|Malignant Glomus Tumor|Malignant Granular Cell Tumor|Malignant Granulosa Cell Tumor|Malignant Head and Neck Neoplasm|Malignant Hemangiopericytoma|Malignant Histiocytosis|Malignant Leydig Cell Tumor|Malignant Lymph Node Neoplasm|Malignant Lymphoma Centroblastic, Follicular|Malignant Lymphoma, Convoluted|Malignant Lymphoma, Histiocytic, Diffuse|Malignant Lymphoma, Large Cell Type|Malignant Lymphoma, Large Cell, Cleaved|Malignant Lymphoma, Non-Cleaved Cell Type|Malignant Lymphoma, Non-Cleaved, Diffuse|Malignant Lymphomas, NOS or Diffuse|Malignant Mastocytosis|Malignant Mediastinal Germ Cell Tumor with Associated Hematologic Malignancy|Malignant Melanoma in Precancerous Melanosis|Malignant Melanotic Peripheral Nerve Sheath Tumor|Malignant Mesenchymoma|Malignant Mesothelioma|Malignant Mixed Tumor of the Salivary Gland|Malignant Muscle Neoplasm|Malignant Myoepithelioma|Malignant Neoplasm|Malignant Neoplasm, Uncertain Whether Primary or Metastatic|Malignant Odontogenic Neoplasm|Malignant Ossifying Fibromyxoid Tumor|Malignant Ovarian Brenner Tumor|Malignant Ovarian Neoplasm|Malignant Ovarian Thecoma|Malignant PEComa|Malignant Pancreatic Glucagonoma|Malignant Pancreatic Insulinoma|Malignant Paraganglioma|Malignant Pericytic Neoplasm|Malignant Peripheral Nerve Sheath Tumor|Malignant Peripheral Nerve Sheath Tumor with Perineurial Differentiation|Malignant Phosphaturic Mesenchymal Tumor|Malignant Phyllodes Tumor|Malignant Sertoli Cell Tumor|Malignant Skin Neoplasm|Malignant Soft Tissue Neoplasm|Malignant Solitary Fibrous Tumor|Malignant Somatostatinoma|Malignant Spindle Cell Neoplasm|Malignant Splenic Neoplasm|Malignant Struma Ovarii|Malignant Sweat Gland Neoplasm|Malignant Tenosynovial Giant Cell Tumor|Malignant Teratoma|Malignant Testicular Germ Cell Tumor|Malignant Thymoma|Malignant Triton Tumor|Malignant Trophoblastic Teratoma|Malignant Tumor, Small Cell Type|Malignant Type A Thymoma|Malignant Type AB Thymoma|Malignant Type B1 Thymoma|Malignant Type B2 Thymoma|Malignant Uterine Neoplasm|Malignant Vipoma|Malignant chondroid syringoma|Malignant cystic nephroma|Malignant eccrine spiradenoma|Malignant fibrous histiocytoma|Malignant fibrous histiocytoma (MFH) of bone|Malignant giant cell tumor of soft parts|Malignant histiocytosis|Malignant hydatidiform mole|Malignant lymphoma, Hodgkin|Malignant lymphoma, NOS|Malignant lymphoma, centroblastic, NOS|Malignant lymphoma, centroblastic, diffuse|Malignant lymphoma, centroblastic, follicular|Malignant lymphoma, centroblasticcentrocytic, NOS|Malignant lymphoma, centroblasticcentrocytic, diffuse|Malignant lymphoma, centroblasticcentrocytic, follicular|Malignant lymphoma, centrocytic|Malignant lymphoma, cleaved cell, NOS|Malignant lymphoma, convoluted cell|Malignant lymphoma, diffuse, NOS|Malignant lymphoma, follicle center, NOS|Malignant lymphoma, follicle center, follicular|Malignant lymphoma, follicular, NOS|Malignant lymphoma, histiocytic, NOS|Malignant lymphoma, histiocytic, diffuse|Malignant lymphoma, histiocytic, nodular|Malignant lymphoma, immunoblastic, NOS|Malignant lymphoma, large B-cell, NOS|Malignant lymphoma, large B-cell, diffuse, NOS|Malignant lymphoma, large B-cell, diffuse, centroblastic, NOS|Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS|Malignant lymphoma, large cell, NOS|Malignant lymphoma, large cell, cleaved and noncleaved|Malignant lymphoma, large cell, cleaved, NOS|Malignant lymphoma, large cell, cleaved, diffuse|Malignant lymphoma, large cell, diffuse, NOS|Malignant lymphoma, large cell, follicular, NOS|Malignant lymphoma, large cell, immunoblastic|Malignant lymphoma, large cell, noncleaved, NOS|Malignant lymphoma, large cell, noncleaved, diffuse|Malignant lymphoma, large cell, noncleaved, follicular|Malignant lymphoma, large cleaved cell, NOS|Malignant lymphoma, large cleaved cell, follicular|Malignant lymphoma, lymphoblastic, NOS|Malignant lymphoma, lymphocytic, NOS|Malignant lymphoma, lymphocytic, diffuse, NOS|Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse|Malignant lymphoma, lymphocytic, intermediate differentiation, nodular|Malignant lymphoma, lymphocytic, nodular, NOS|Malignant lymphoma, lymphocytic, poorly differentiated, diffuse|Malignant lymphoma, lymphocytic, poorly differentiated, nodular|Malignant lymphoma, lymphocytic, well differentiated, diffuse|Malignant lymphoma, lymphocytic, well differentiated, nodular|Malignant lymphoma, lymphoplasmacytic|Malignant lymphoma, lymphoplasmacytoid|Malignant lymphoma, mixed cell type, diffuse|Malignant lymphoma, mixed cell type, follicular|Malignant lymphoma, mixed cell type, nodular|Malignant lymphoma, mixed lymphocytic-histiocytic, diffuse|Malignant lymphoma, mixed lymphocytic-histiocytic, nodular|Malignant lymphoma, mixed small and large cell, diffuse|Malignant lymphoma, mixed small cleaved and large cell, follicular|Malignant lymphoma, nodular, NOS|Malignant lymphoma, non-Hodgkin, NOS|Malignant lymphoma, non-cleaved cell, NOS|Malignant lymphoma, noncleaved cell, follicular, NOS|Malignant lymphoma, noncleaved, NOS|Malignant lymphoma, noncleaved, diffuse, NOS|Malignant lymphoma, plasmacytoid|Malignant lymphoma, small B lymphocytic, NOS|Malignant lymphoma, small cell diffuse|Malignant lymphoma, small cell, NOS|Malignant lymphoma, small cell, noncleaved, diffuse|Malignant lymphoma, small cleaved cell, NOS|Malignant lymphoma, small cleaved cell, diffuse|Malignant lymphoma, small cleaved cell, follicular|Malignant lymphoma, small lymphocytic, NOS|Malignant lymphoma, small lymphocytic, diffuse|Malignant lymphoma, small noncleaved, Burkitt type|Malignant lymphoma, undifferentiated cell type, NOS|Malignant lymphoma, undifferentiated cell, non-Burkitt|Malignant lymphoma, undifferentiated, Burkitt type|Malignant lymphomatous polyposis|Malignant mast cell tumor|Malignant mastocytoma|Malignant mastocytosis|Malignant melanoma in Hutchinson melanotic freckle|Malignant melanoma in congenital melanocytic nevus|Malignant melanoma in giant pigmented nevus|Malignant melanoma in junctional nevus|Malignant melanoma in precancerous melanosis|Malignant melanoma, NOS|Malignant melanoma, regressing|Malignant midline reticulosis|Malignant mucinous adenofibroma|Malignant mucinous cystadenofibroma|Malignant multilocular cystic nephroma|Malignant myelosclerosis|Malignant myoepithelioma|Malignant peripheral nerve sheath tumor|Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation|Malignant perivascular epithelial cell tumor|Malignant reticulosis, NOS|Malignant rhabdoid tumor|Malignant schwannoma with rhabdomyoblastic differentiation|Malignant schwannoma, NOS|Malignant serous adenofibroma|Malignant serous cystadenofibroma|Malignant tenosynovial giant cell tumor|Malignant teratoma, anaplastic|Malignant teratoma, intermediate|Malignant teratoma, trophoblastic|Malignant teratoma, undifferentiated|Malignant tumor, clear cell type|Malignant tumor, fusiform cell type|Malignant tumor, giant cell type|Malignant tumor, small cell type|Malignant tumor, spindle cell type|Malta|Mammary carcinoma, in situ|Mandible|Mandibulectomy|Manelimab|Mania|Mannosulfan|Mannosylerythritol Lipid|Mantle|Mantle Cell Lymphoma|Mantle cell lymphoma (Includes all variants blastic, pleomorphic, small cell)|Mantle zone lymphoma|Mapatumumab|Maraba Oncolytic Virus Expressing Mutant HPV E6/E7|Marcellomycin|Margetuximab|Marginal Zone Lymphoma|Marginal zone B-cell lymphoma, NOS|Marginal zone lymphoma, NOS|Marijuana|Marijuana Smoke Exposure|Marijuana smoke|Marimastat|Marizomib|Marshall Islands|Martinique|Masculinovoblastoma|Masitinib Mesylate|Masked Annotated Somatic Mutation|Masked Copy Number Segment|Masked Intensities|Masked Somatic Mutation|Masoprocol|Mast Cell Leukemia|Mast Cell Neoplasm|Mast Cell Sarcoma|Mast Cell Tumors|Mast cell leukaemia|Mast cell sarcoma|Mast cell tumor, NOS|Mastocytoma|Mastocytoma, NOS|Maternal Aunt|Maternal First Cousin|Maternal First Cousin Once Removed|Maternal Grandfather|Maternal Grandmother|Maternal Grandparent|Maternal Great Aunt|Maternal Great Grandparent|Maternal Great Uncle|Maternal Half Brother|Maternal Half Sibling|Maternal Half Sister|Maternal Uncle|Matrical carcinoma|Matrix Metalloproteinase Inhibitor MMI270|Mature B-Cell Lymphomas|Mature T ALL|Mature T- and NK-Cell Lymphomas|Mature T-ALL|Mature T-cell lymphoma, NOS|Mature Teratoma|Mature teratoma|Matuzumab|Mauritania|Mauritius|Mavelertinib|Mavorixafor|Maxilla|Maxillary Sinus|Maxillary sinus|Maxillectomy|Mayotte|Maytansine|Mcl-1 Inhibitor AZD5991|Mcl-1 Inhibitor MIK665|Mechlorethamine|Mechlorethamine Hydrochloride|Mechlorethamine Hydrochloride Gel|Meckel diverticulum|Mediastinal (thymic) large B-cell lymphoma|Mediastinal Hemorrhage|Mediastinal Infection|Mediastinal Soft Tissue|Mediastinum|Mediastinum, NOS|Medical Record|Medically Treated|Mediterranean lymphoma|Medorubicin|Medroxyprogesterone|Medroxyprogesterone Acetate|Medulla of adrenal gland|Medullary Carcinoma, Not Otherwise Specified|Medullary adenocarcinoma|Medullary carcinoma with amyloid stroma|Medullary carcinoma with lymphoid stroma|Medullary carcinoma, NOS|Medullary osteosarcoma|Medulloblastoma|Medulloblastoma with Extensive Nodularity|Medulloblastoma with Melanotic Differentiation|Medulloblastoma with extensive nodularity|Medulloblastoma, NOS|Medulloblastoma, Non-WNT/Non-SHH|Medulloblastoma, Non-WNT/Non-SHH, Group 3|Medulloblastoma, Non-WNT/Non-SHH, Group 4|Medulloblastoma, Not Otherwise Specified|Medulloblastoma, SHH-Activated|Medulloblastoma, SHH-Activated, TP53-Mutant|Medulloblastoma, SHH-Activated, TP53-Wildtype|Medulloblastoma, SHH-activated and TP53-mutant|Medulloblastoma, SHH-activated and TP53-wildtype|Medulloblastoma, WNT-Activated|Medulloblastoma, WNT-activated|Medulloblastoma, classic|Medulloblastoma, group 3|Medulloblastoma, group 4|Medulloblastoma, non-WNT/non-SHH|Medullocytoma|Medulloepithelioma|Medulloepithelioma Not Otherwise Specified|Medulloepithelioma, NOS|Medulloepithelioma, benign|Medullomyoblastoma|Medullomyoblastoma with Myogenic Differentiation|Megakaryocytic leukemia|Megakaryocytic myelosclerosis|Megestrol Acetate|Melanoameloblastoma|Melanocytic Nevus|Melanocytic nevus|Melanocytoma|Melanocytoma of the Eyeball|Melanocytoma, NOS|Melanocytoma, eyeball|Melanoma|Melanoma Arising from Blue Nevus|Melanoma Monoclonal Antibody hIgG2A|Melanoma TRP2 CTL Epitope Vaccine SCIB1|Melanoma in Junctional Nevus|Melanoma in situ|Melanoma, NOS|Melanoma, malignant, of soft parts|Melanotic MPNST|Melanotic Neuroectodermal Tumor|Melanotic Neurofibroma|Melanotic Psammomatous Malignant Peripheral Nerve Sheath Tumor|Melanotic Schwannoma|Melanotic medulloblastoma|Melanotic neuroectodermal tumor|Melanotic neurofibroma|Melanotic progonoma|Melanotic psammomatous MPNST|Melanotic schwannoma|Melapuldencel-T|Melphalan|Melphalan Flufenamide|Melphalan Hydrochloride|Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex|Membrane-Disrupting Peptide EP-100|Memory Impairment|Menatetrenone|Menin-MLL Interaction Inhibitor SNDX-5613|Meningeal Melanocytoma|Meningeal Melanocytosis|Meningeal Melanoma|Meningeal Melanomatosis|Meningeal Sarcoma|Meningeal Sarcomatosis|Meningeal melanocytoma|Meningeal melanoma|Meningeal melanomatosis|Meningeal sarcoma|Meningeal sarcomatosis|Meninges|Meninges, NOS|Meningioma|Meningioma, NOS|Meningioma, anaplastic|Meningioma, malignant|Meningiomas|Meningiomatosis|Meningiomatosis, NOS|Meningismus|Meningitis|Meningothelial Meningioma|Meningothelial meningioma|Meningothelial sarcoma|Menogaril|Menopause|Menorrhagia|Merbarone|Mercaptopurine|Mercaptopurine Anhydrous|Mercaptopurine Oral Suspension|Merestinib|Merkel Cell Carcinoma|Merkel cell carcinoma|Merkel cell tumor|Mesenchymal Chondrosarcoma|Mesenchymal chondrosarcoma|Mesenchymal tumor, malignant|Mesenchymoma|Mesenchymoma, NOS|Mesenchymoma, benign|Mesenchymoma, malignant|Mesenteric fibromatosis|Mesentery|Mesna|Mesoblastic nephroma|Mesodermal mixed tumor|Mesonephric Adenocarcinoma|Mesonephric Neoplasm|Mesonephric adenocarcinoma|Mesonephric adenoma|Mesonephric tumor, NOS|Mesonephroma, NOS|Mesonephroma, benign|Mesonephroma, malignant|Mesonephromas|Mesothelial Neoplasms|Mesothelial papilloma|Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536|Mesothelioma|Mesothelioma, NOS|Mesothelioma, benign|Mesothelioma, biphasic, NOS|Mesothelioma, biphasic, malignant|Mesothelioma, malignant|Mesothelium|MetAP2 Inhibitor APL-1202|MetAP2 Inhibitor SDX-7320|Metabolic Syndrome|Metabolic labeling 14N / 15N quantitation analysis|Metabolism and Nutrition Disorders - Other|Metabolome|Metamelfalan|Metanephric Adenofibroma|Metanephric Adenoma|Metanephric adenoma|Metaplastic Carcinoma|Metaplastic Meningioma|Metaplastic carcinoma of no special type|Metaplastic carcinoma with chondroid differentiation|Metaplastic carcinoma with osseous differentiation|Metaplastic carcinoma with other types mesenchymal differentiation|Metaplastic carcinoma, NOS|Metaplastic meningioma|Metarrestin|Metastasectomy|Metastasis|Metastasis Negative|Metastasis, NOS|Metastasizing Ameloblastoma|Metastasizing leiomyoma|Metastatic|Metastatic Adenocarcinoma|Metastatic Carcinoma|Metastatic Neoplasm|Metastatic Signet Ring Cell Carcinoma|Metastatic Squamous Cell Carcinoma|Metastatic signet ring cell carcinoma|Metatinib Tromethamine|Metatypical carcinoma|Metformin|Metformin Hydrochloride|Methanol Extraction Residue of BCG|Methazolamide|Methionine Aminopeptidase 2 Inhibitor M8891|Methionine Aminopeptidase 2 Inhibitor PPI-2458|Methotrexate|Methotrexate Sodium|Methotrexate-E Therapeutic Implant|Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles|Methoxsalen|Methoxyamine|Methoxyamine Hydrochloride|Methyl Methanethiosulfonate (MMTS)|Methyl-5-Aminolevulinate Hydrochloride Cream|Methylation Array|Methylation Beta Value|Methylcantharidimide|Methylmercaptopurine Riboside|Methylprednisolone|Methylprednisolone Acetate|Methylprednisolone Sodium Succinate|Methylselenocysteine|Methyltestosterone|Metoprine|Mevociclib|Mexico|Mezagitamab|MiT Family Translocation-Associated Renal Cell Carcinoma|MiT family translocation renal cell carcinoma|Mibefradil|Mibefradil Dihydrochloride|Micellar Nanoparticle-encapsulated Epirubicin|Micro|Micro Needle Array-Doxorubicin|Microbiome GEN-001|Microbiome-derived Peptide Vaccine EO2401|Microcystic Adenoma|Microcystic Adnexal Carcinoma|Microcystic Meningioma|Microcystic adenoma|Microcystic adnexal carcinoma|Microcystic meningioma|Microcystic urothelial carcinoma|Microfollicular adenoma, NOS|Microglioma|Microinvasive Squamous Cell Carcinoma|Micropapillary Serous Carcinoma|Micropapillary Transitional Cell Carcinoma|Micropapillary adenocarcinoma|Micropapillary carcinoma, NOS|Micropapillary serous carcinoma|Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300|Microscopic|Microscopic Parametrium|Microtubule Inhibitor SCB01A|Middle Ear|Middle Ear Inflammation|Middle Finger|Middle Lobe of the Right Lung|Middle ear|Middle lobe, lung|Middle third of esophagus|Midline|Midline carcinoma of children and young adults with NUT rearrangement|Midostaurin|Mifamurtide|Mifepristone|Milademetan Tosylate|Milataxel|Milatuzumab|Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110|Milciclib Maleate|Milk Thistle|Miltefosine|Minimally Invasive Lung Adenocarcinoma|Minimally Invasive Lung Mucinous Adenocarcinoma|Minimally Invasive Lung Non-Mucinous Adenocarcinoma|Minimally invasive adenocarcinoma, NOS|Minimally invasive adenocarcinoma, mucinous|Minimally invasive adenocarcinoma, non-mucinous|Minor Response|Minretumomab|Mipsagargin|Miptenalimab|Mirabegron|Miransertib|Mirdametinib|Mirvetuximab Soravtansine|Mirzotamab Clezutoclax|Miscarriage|Miscellaneous Bone Tumors|Miscellaneous Tumors|Misonidazole|Mistletoe Extract|Mitazalimab|Mitindomide|Mitobronitol|Mitochondria|Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101|Mitoclomine|Mitoflaxone|Mitoguazone|Mitoguazone Dihydrochloride|Mitolactol|Mitomycin|Mitomycin A|Mitomycin B|Mitomycin C Analog KW-2149|Mitosis Inhibitor T 1101 Tosylate|Mitotane|Mitotenamine|Mitoxantrone|Mitoxantrone Hydrochloride|Mitozolomide|Mitral Valve Disease|Mivavotinib|Mivebresib|Mivobulin|Mivobulin Isethionate|Mixed Acinar-Ductal Carcinoma of the Pancreas|Mixed Adherent Suspension|Mixed Bacteria Vaccine|Mixed Cell Adenocarcinoma|Mixed Cell Adenoma|Mixed Cellularity Classic Hodgkin Lymphoma|Mixed Ductal and Lobular Carcinoma|Mixed Ductal-Neuroendocrine Carcinoma of the Pancreas|Mixed Embryonal Carcinoma and Teratoma|Mixed Epithelial and Mesenchymal Hepatoblastoma|Mixed Epithelioid and Spindle Cell Melanoma|Mixed Germ Cell Tumor|Mixed Glioma|Mixed Liposarcoma|Mixed Mesodermal (Mullerian) Tumor|Mixed Mucinous and Non-Mucinous Bronchioloalveolar Carcinoma|Mixed Phenotype Acute Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1|Mixed Phenotype Acute Leukemia with t(v;11q23.3); KMT2A Rearranged|Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified|Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified|Mixed Response|Mixed Teratoma and Seminoma|Mixed Testicular Sex Cord-Stromal Tumor|Mixed Tumor, Not Otherwise Specified|Mixed acidophil-basophil adenoma|Mixed acidophil-basophil carcinoma|Mixed acinar-ductal carcinoma|Mixed acinar-endocrine carcinoma|Mixed acinar-endocrine-ductal carcinoma|Mixed adenocarcinoma and epidermoid carcinoma|Mixed adenocarcinoma and squamous cell carcinoma|Mixed adenomatous and hyperplastic polyp|Mixed adenoneuroendocrine carcinoma|Mixed basal-squamous cell carcinoma|Mixed carcinoid-adenocarcinoma|Mixed cell adenocarcinoma|Mixed cell adenoma|Mixed ductal-endocrine carcinoma|Mixed embryonal carcinoma and teratoma|Mixed embryonal rhabdomyosarcoma and alveolar rhabdomyosarcoma|Mixed endocrine and exocrine adenocarcinoma|Mixed epithelioid and spindle cell melanoma|Mixed germ cell sex cord-stromal tumor, unclassified|Mixed germ cell tumor|Mixed glioma|Mixed hepatocellular and bile duct carcinoma|Mixed invasive mucinous and non-mucinous adenocarcinoma|Mixed islet cell and exocrine adenocarcinoma|Mixed liposarcoma|Mixed medullary-follicular carcinoma|Mixed medullary-papillary carcinoma|Mixed meningioma|Mixed mesenchymal sarcoma|Mixed mesenchymal tumor|Mixed pancreatic endocrine and exocrine tumor, malignant|Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1|Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged|Mixed phenotype acute leukemia, B/myeloid, NOS|Mixed phenotype acute leukemia, T/myeloid, NOS|Mixed pineal tumor|Mixed pineocytoma-pineoblastoma|Mixed small cell carcinoma|Mixed squamous cell and glandular papilloma|Mixed subependymoma-ependymoma|Mixed teratoma and seminoma|Mixed tumor, NOS|Mixed tumor, malignant, NOS|Mixed tumor, salivary gland type, NOS|Mixed tumor, salivary gland type, malignant|Mixed type rhabdomyosarcoma|Mobitz (Type) II Atrioventricular Block|Mobitz Type I|Mobocertinib|Mocetinostat|Modakafusp Alfa|Moderately Differentiated Ovarian Sertoli-Leydig Cell Tumor|Modified Radical Mastectomy|Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208|Modified Vitamin D Binding Protein Macrophage Activator EF-022|Modotuximab|Mofarotene|Mogamulizumab|Moldova|Molecular Laboratory Procedure Exon Identification Number|Molecular analysis outside specification|Molibresib|Molibresib Besylate|Momelotinib|Monaco|Monalizumab|Mongolia|Monoblastic leukemia, NOS|Monocarboxylate Transporter 1 Inhibitor AZD3965|Monoclonal Antibody 105AD7 Anti-idiotype Vaccine|Monoclonal Antibody 11D10|Monoclonal Antibody 11D10 Anti-Idiotype Vaccine|Monoclonal Antibody 14G2A|Monoclonal Antibody 1F5|Monoclonal Antibody 3622W94|Monoclonal Antibody 3F8|Monoclonal Antibody 3H1 Anti-Idiotype Vaccine|Monoclonal Antibody 4B5 Anti-Idiotype Vaccine|Monoclonal Antibody 7C11|Monoclonal Antibody 81C6|Monoclonal Antibody A1G4 Anti-Idiotype Vaccine|Monoclonal Antibody A27.15|Monoclonal Antibody A33|Monoclonal Antibody AK002|Monoclonal Antibody ASP1948|Monoclonal Antibody AbGn-7|Monoclonal Antibody CAL|Monoclonal Antibody CC49-delta CH2|Monoclonal Antibody CEP-37250/KHK2804|Monoclonal Antibody D6.12|Monoclonal Antibody E2.3|Monoclonal Antibody F19|Monoclonal Antibody GD2 Anti-Idiotype Vaccine|Monoclonal Antibody HeFi-1|Monoclonal Antibody Hu3S193|Monoclonal Antibody HuAFP31|Monoclonal Antibody HuHMFG1|Monoclonal Antibody HuPAM4|Monoclonal Antibody IMMU-14|Monoclonal Antibody L6|Monoclonal Antibody Lym-1|Monoclonal Antibody MX35 F(ab')2|Monoclonal Antibody Me1-14 F(ab')2|Monoclonal Antibody NEO-201|Monoclonal Antibody R24|Monoclonal Antibody RAV12|Monoclonal Antibody SGN-14|Monoclonal Antibody TRK-950|Monoclonal Antibody huJ591|Monoclonal Antibody m170|Monoclonal Antibody muJ591|Monoclonal Gammopathy of Undetermined Significance|Monoclonal Immunoglobulin Deposition Disease|Monoclonal Microbial EDP1503|Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100|Monoclonal gammopathy of undetermined significance|Monoclonal gammopathy, NOS|Monocytic leukemia, NOS|Monocytoid B-cell lymphoma|Monomethyl Auristatin E|Monomorphic adenoma|Mononuclear Cells from Bone Marrow Normal|Monstrocellular sarcoma|Montenegro|Montserrat|Morinda Citrifolia Fruit Extract|Morocco|Morpholinodoxorubicin|Mosedipimod|Mosunetuzumab|Motesanib|Motesanib Diphosphate|Motexafin Gadolinium|Motexafin Lutetium|Mother|Mother-in-law|Motixafortide|Motolimod|Motor / Movement Change|Motor or Movement Changes|Mouth, NOS|Movements Involuntary|Moxetumomab Pasudotox|Mozambique|Mps1 Inhibitor BAY 1217389|Mps1 Inhibitor BOS172722|Ms|Mu Heavy Chain Disease|Mu heavy chain disease|MuSE|MuSE Annotation|MuSE Variant Aggregation and Masking|MuTect2|MuTect2 Annotation|MuTect2 Variant Aggregation and Masking|Mucata mulata|Mucin-Producing Adenocarcinoma|Mucin-Producing Carcinoma|Mucin-producing adenocarcinoma|Mucin-producing carcinoma|Mucin-secreting adenocarcinoma|Mucin-secreting carcinoma|Mucinous Adenocarcinoma|Mucinous Adenocarcinoma, Endocervical Type|Mucinous Adenofibroma|Mucinous Cystadenocarcinoma|Mucinous Cystadenofibroma|Mucinous Cystadenoma|Mucinous Tubular and Spindle Cell Carcinoma of the Kidney|Mucinous adenocarcinofibroma|Mucinous adenocarcinoma|Mucinous adenocarcinoma, endocervical type|Mucinous adenofibroma of borderline malignancy|Mucinous adenofibroma, NOS|Mucinous adenoma|Mucinous carcinoid|Mucinous carcinoma|Mucinous carcinoma, gastric type|Mucinous carcinoma, intestinal type|Mucinous cystadenocarcinofibroma|Mucinous cystadenocarcinoma, NOS|Mucinous cystadenocarcinoma, non-invasive|Mucinous cystadenofibroma of borderline malignancy|Mucinous cystadenofibroma, NOS|Mucinous cystadenoma, NOS|Mucinous cystadenoma, borderline malignancy|Mucinous cystic neoplasm with an associated invasive carcinoma|Mucinous cystic neoplasm with high-grade dysplasia|Mucinous cystic neoplasm with high-grade intraepithelial neoplasia|Mucinous cystic neoplasm with intermediate-grade dysplasia|Mucinous cystic neoplasm with intermediate-grade intraepithelial neoplasia|Mucinous cystic neoplasm with low-grade dysplasia|Mucinous cystic neoplasm with low-grade intraepithelial neoplasia|Mucinous cystic tumor of borderline malignancy|Mucinous cystic tumor with an associated invasive carcinoma|Mucinous cystic tumor with high-grade dysplasia|Mucinous cystic tumor with intermediate dysplasia|Mucinous cystic tumor with low grade dysplasia|Mucinous cystic tumor with moderate dysplasia|Mucinous cystoma|Mucinous tubular and spindle cell carcinoma|Mucinous tumor, NOS, of low malignant potential|Mucoadhesive Paclitaxel Formulation|Mucocarcinoid tumor|Mucoepidermoid Carcinoma|Mucoepidermoid Neoplasms|Mucoepidermoid carcinoma|Mucoepidermoid tumor|Mucoid adenocarcinoma|Mucoid carcinoma|Mucoid cell adenocarcinoma|Mucoid cell adenoma|Mucosa of lip, NOS|Mucosa of lower lip|Mucosa of the Lip|Mucosa of the Lower Lip|Mucosa of upper lip|Mucosal Infection|Mucosal Lentiginous Melanoma|Mucosal lentiginous melanoma|Mucosal-associated lymphoid tissue lymphoma|Mucositis Oral|Mucous adenocarcinoma|Mucous carcinoma|Mullerian adenosarcoma|Mullerian mixed tumor|Multi-AGC Kinase Inhibitor AT13148|Multi-Organ Failure|Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200|Multi-epitope HER2 Peptide Vaccine H2NVAC|Multi-epitope HER2 Peptide Vaccine TPIV100|Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107|Multi-kinase Inhibitor TPX-0022|Multi-kinase Inhibitor XL092|Multi-mode Kinase Inhibitor EOC317|Multi-neo-epitope Vaccine OSE 2101|Multicentric basal cell carcinoma|Multicystic Mesothelioma|Multicystic mesothelioma, benign|Multifocal|Multifocal Lymphomatous Polyposis|Multifocal superficial basal cell carcinoma|Multifunctional/Multitargeted Anticancer Agent OMN54|Multikinase Inhibitor 4SC-203|Multikinase Inhibitor AEE788|Multikinase Inhibitor AT9283|Multikinase Inhibitor SAR103168|Multipeptide Vaccine S-588210|Multiple Adenomatous Polyps|Multiple Endocrine Neoplasia|Multiple Myeloma|Multiple Osteochondromas|Multiple adenomatous polyps|Multiple endocrine adenomas|Multiple hemorrhagic sarcoma|Multiple meningiomas|Multiple myeloma|Multiple neurofibromatosis|Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327|Muparfostat|Mureletecan|Murizatoclax|Mus musculus|Muscadine Grape Extract|Muscle|Muscle Weakness Left-Sided|Muscle Weakness Lower Limb|Muscle Weakness Right-Sided|Muscle Weakness Trunk|Muscle Weakness Upper Limb|Musculoskeletal Deformity|Musculoskeletal and Connective Tissue Disorders - Other|Mutant IDH1 Inhibitor DS-1001|Mutant p53 Activator COTI-2|Mutant-selective EGFR Inhibitor PF-06459988|Myalgia|Myanmar|Myasthenia Gravis|Mycobacterium avium Complex|Mycobacterium tuberculosis|Mycobacterium tuberculosis Arabinomannan Z-100|Mycobacterium w|Mycobacterium, NOS|Mycophenolic Acid|Mycoplasma pneumoniae|Mycosis Fungoides|Mycosis fungoides|Myelitis|Myelocytic leukemia, NOS|Myelodysplastic Syndrome|Myelodysplastic Syndrome with Excess Blasts|Myelodysplastic Syndrome with Excess Blasts-1|Myelodysplastic Syndrome with Excess Blasts-2|Myelodysplastic Syndrome with Isolated del(5q)|Myelodysplastic Syndrome with Multilineage Dysplasia|Myelodysplastic Syndrome with Ring Sideroblasts|Myelodysplastic Syndrome, Unclassifiable|Myelodysplastic Syndromes|Myelodysplastic syndrome with 5q deletion (5q-) syndrome|Myelodysplastic syndrome with isolated del (5q)|Myelodysplastic syndrome, NOS|Myelodysplastic syndrome, unclassifiable|Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Myelodysplastic/myeloproliferative neoplasm, unclassifiable|Myelofibrosis as a result of myeloproliferative disease|Myelofibrosis with myeloid metaplasia|Myelogenous leukemia, NOS|Myeloid Leukemia|Myeloid Leukemia Associated with Down Syndrome|Myeloid Leukemias|Myeloid Sarcoma|Myeloid and lymphoid neoplasms with FGFR1 abnormalities|Myeloid and lymphoid neoplasms with PDGFRA rearrangement|Myeloid leukemia associated with Down Syndrome|Myeloid leukemia, NOS|Myeloid neoplasms with PDGFRB rearrangement|Myeloid sarcoma|Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement|Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement|Myelolipoma|Myeloma, NOS|Myelomatosis|Myelomonocytic leukemia, NOS|Myeloproliferative Neoplasm|Myeloproliferative disease, NOS|Myeloproliferative neoplasm, NOS|Myelosclerosis with myeloid metaplasia|Myloproliferative neoplasm, unclassifiable|Myocardial Infarction|Myocarditis|Myoepithelial Tumor|Myoepithelial adenoma|Myoepithelial carcinoma|Myoepithelial tumor|Myoepithelioma|Myofibroblastic sarcoma|Myofibroblastic tumor, NOS|Myofibroblastic tumor, peribronchial|Myofibroblastoma|Myofibroma|Myofibromatosis|Myolipoma|Myoma|Myomatous Neoplasms|Myometrium|Myosarcoma|Myositis|Myxofibroma, NOS|Myxofibrosarcoma|Myxoid Chondrosarcoma|Myxoid Leiomyosarcoma|Myxoid Liposarcoma|Myxoid chondrosarcoma|Myxoid fibroma|Myxoid leiomyosarcoma|Myxoid liposarcoma|Myxoinflammatory Fibroblastic Sarcoma|Myxoinflammatory fibroblastic sarcoma (MIFS)|Myxolipoma|Myxoliposarcoma|Myxoma|Myxoma, NOS|Myxomatous Neoplasms|Myxopapillary Ependymoma|Myxopapillary ependymoma|Myxosarcoma|N,N-Dibenzyl Daunomycin|N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea|N-Methylformamide|N-dihydrogalactochitosan|N0|N0 (i+)|N0 (i+) Stage Finding|N0 (i-)|N0 (mol+)|N0 (mol+) Stage Finding|N0 (mol-)|N0 Stage Finding|N1|N1 Stage Finding|N1a|N1a Stage Finding|N1b|N1b Stage Finding|N1bI|N1bI Stage Finding|N1bII|N1bII Stage Finding|N1bIII|N1bIII Stage Finding|N1bIV|N1bIV Stage Finding|N1c|N1c Stage Finding|N1mi|N1mi Stage Finding|N2|N2 Stage Finding|N2a|N2a Stage Finding|N2b|N2b Stage Finding|N2c|N2c Stage Finding|N3|N3 Stage Finding|N3a|N3a Stage Finding|N3b|N3b Stage Finding|N3c|N3c Stage Finding|N4|N4 Stage Finding|NA17-A Antigen|NA17.A2 Peptide Vaccine|NAMPT Inhibitor OT-82|NEDD8 Activating Enzyme E1 Inhibitor TAS4464|NG-5400|NG-nitro-L-arginine|NHL, Burkitt lymphoma (BL)|NHL, anaplastic large cell lymphoma|NK-cell large granular lymphocytic leukemia|NK/T-cell lymphoma, nasal and nasal-type|NLRP3 Agonist BMS-986299|NOS|NPB-No Palliative Benefit|NR-No Response|NTRK/ROS1 Inhibitor DS-6051b|NUT Carcinoma|NUT carcinoma|NUT midline carcinoma|NX|NX Stage Finding|NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611|NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301|NY-ESO-1/GLA-SE Vaccine ID-G305|NY-ESO-B|Nab-paclitaxel|Nab-paclitaxel/Rituximab-coated Nanoparticle AR160|Nadofaragene Firadenovec|Nagrestipen|Nail Discoloration|Nail Infection|Nail Loss|Nail Ridging|Nails|Namibia|Namirotene|Namodenoson|Nanafrocin|Nanatinostat|Nanocell-encapsulated miR-16-based microRNA Mimic|Nanoparticle Albumin-Bound Docetaxel|Nanoparticle Albumin-Bound Rapamycin|Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404|Nanoparticle Paclitaxel Ointment SOR007|Nanoparticle-based Paclitaxel Suspension|Nanoparticle-encapsulated Doxorubicin Hydrochloride|Nanoscale Coordination Polymer Nanoparticles CPI-100|Nanosomal Docetaxel Lipid Suspension|Napabucasin|Naphthalimide Analogue UNBS5162|Naptumomab Estafenatox|Naquotinib|Naratuximab Emtansine|Narnatumab|Nasal Cavity|Nasal Congestion|Nasal Soft Tissue|Nasal Type Extranodal NK/T-Cell Lymphoma|Nasal cavity|Nasal cavity and middle ear|Nasopharyngeal-Type Undifferentiated Carcinoma|Nasopharynx|Nasopharynx, NOS|Natalizumab|Native Hawaiian or Other Pacific Islander|Natural Brother|Natural Child|Natural Daughter|Natural Father|Natural Grandchild|Natural Grandfather|Natural Grandmother|Natural Grandparent|Natural IFN-alpha OPC-18|Natural Killer Cells ZRx101|Natural Mother|Natural Parent|Natural Sibling|Natural Sister|Natural Son|Nauru|Nausea|Navarixin|Navicixizumab|Navitoclax|Navoximod|Navy Bean Powder|Naxitamab|Nazartinib|Necitumumab|Neck|Neck Edema|Neck Pain|Neck Soft Tissue Necrosis|Nedaplatin|Nedisertib|Needle Biopsy|Negative|Negative/ No Dysplasia|Nelarabine|Nelipepimut-S|Nelipepimut-S Plus GM-CSF Vaccine|Nemorubicin|Nemorubicin Hydrochloride|Neoadjuvant|Neoadjuvant therapy|Neoantigen Vaccine GEN-009|Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017|Neoantigen-based Glioblastoma Vaccine|Neoantigen-based Melanoma-Poly-ICLC Vaccine|Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine|Neoantigen-based Therapeutic Cancer Vaccine GRT-C903|Neoantigen-based Therapeutic Cancer Vaccine GRT-R904|Neoplasm|Neoplasm of the Diffuse Neuroendocrine System|Neoplasm, NOS|Neoplasm, Uncertain Whether Benign or Malignant|Neoplasm, benign|Neoplasm, malignant|Neoplasm, malignant, uncertain whether primary or metastatic|Neoplasm, metastatic|Neoplasm, secondary|Neoplasm, uncertain whether benign or malignant|Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other|Neoplasms of Histiocytes and Accessory Lymphoid Cells|Neoplasms of Uncertain and Unknown Behavior|Neoplasms, NOS|Neoplastic Cell|Nepal|Nephew|Nephroblastoma, NOS|Nephrogenic adenofibroma|Nephroma, NOS|Neratinib|Neratinib Maleate|Nerve|Nerve Sheath Myxoma|Nerve Sheath Tumors|Nerve sheath myxoma|Nerve(s) Cranial|Nervous System|Nervous System Disorders - Other|Nervous system, NOS|Nesidioblastoma|Nesidioblastosis|Nested urothelial carcinoma|Nesvacumab|Netherlands|Neuralgia|Neurilemoma, NOS|Neurilemoma, malignant|Neurilemosarcoma|Neurinoma|Neurinomatosis|Neuroastrocytoma|Neuroblastoma|Neuroblastoma (NBL)|Neuroblastoma, NOS|Neurocytoma|Neuroectodermal tumor, NOS|Neuroendocrine Carcinoma|Neuroendocrine Tumor|Neuroendocrine carcinoma, NOS|Neuroendocrine carcinoma, low grade|Neuroendocrine carcinoma, moderately differentiated|Neuroendocrine carcinoma, poorly differentiated|Neuroendocrine carcinoma, well-differentiated|Neuroendocrine tumor, grade 1|Neuroendocrine tumor, grade 2|Neuroendocrine tumor, well differentiated|Neuroepithelioma, NOS|Neuroepitheliomatous Neoplasms|Neurofibroma|Neurofibroma, NOS|Neurofibromatosis|Neurofibromatosis Type 1|Neurofibromatosis, NOS|Neurofibrosarcoma|Neurogenic sarcoma|Neurolipocytoma|Neuroma|Neuroma, NOS|Neuronevus|Neurosarcoma|Neurothekeoma|Neurotropic melanoma, malignant|Neutrophil Count Decreased|Never Used|Nevi and Melanomas|Nevus, NOS|New Caledonia|New Objective|New Zealand|New notification type|New observation type|Next Generation Cancer Model|Next Generation Cancer Model Expanded Under Non-conforming Conditions|Next Generation Targeted Sequencing|Niacinamide|Nicaragua|Niclosamide|Nicotinamide Riboside|Nidanilimab|Niece|Niece Second Degree Relative|Nifurtimox|Niger|Nigeria|Night Blindness|Night Sweats|Nilotinib|Nilotinib Hydrochloride Anhydrous|Nilotinib Hydrochloride Monohydrate|Nilutamide|Nimesulide-Hyaluronic Acid Conjugate CA102N|Nimodipine|Nimotuzumab|Nimustine|Nimustine Hydrochloride|Ningetinib Tosylate|Nintedanib|Nipple|Nipple Adenoma|Nipple Deformity|Niraparib|Niraparib Tosylate Monohydrate|Nirogacestat|Nitric Oxide-Releasing Acetylsalicylic Acid Derivative|Nitrogen Mustard Prodrug PR-104|Nitroglycerin Transdermal Patch|Niue|Nivolumab|No Known Treatment Effect|No Measurable Disease|No Metastasis|No Metastasis (M0)|No Necrosis|No Palliative Benefit|No Response|No Smoke Exposure|No Treatment|No Vascular Invasion|No cleavage|NoEnzyme|Nocardiosis|Nocodazole|Nodal Marginal Zone Lymphoma|Nodal marginal zone lymphoma|Nodular Hidradenoma|Nodular Lymphocyte Predominant Hodgkin Lymphoma|Nodular Prostatic Hyperplasia|Nodular Sclerosis Classic Hodgkin Lymphoma|Nodular Sclerosis Classic Hodgkin Lymphoma, Cellular Phase|Nodular Sclerosis Classic Hodgkin Lymphoma, Syncytial Variant|Nodular hidradenoma|Nodular hidradenoma, malignant|Nodular melanoma|Nogalamycin|Nogapendekin Alfa|Nolatrexed Dihydrochloride|Non cancerous tissue|Non-CR/Non-PD-Non-CR/Non-PD|Non-Cancer Related Death|Non-Cardiac Chest Pain|Non-Drinker|Non-Hodgkin Lymphoma|Non-Hodgkin lymphoma, NOS|Non-Invasive Papillary Squamous Cell Carcinoma|Non-Invasive Papillary Transitional Cell Carcinoma|Non-Keratinizing Large Cell Squamous Cell Carcinoma|Non-Keratinizing Sinonasal Squamous Cell Carcinoma|Non-Keratinizing Small Cell Squamous Cell Carcinoma|Non-Malignant|Non-Small Cell Carcinoma|Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201|Non-WNT/non-SHH Activated|Non-invasive EFVPTC|Non-invasive FTP|Non-invasive encapsulated follicular variant of papillary thyroid carcinoma (non-invasive EFVPTC)|Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)|Non-invasive low grade serous carcinoma|Non-invasive mammary carcinoma|Non-lymphocytic leukemia, NOS|Non-small cell carcinoma|Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis|Nonchromaffin paraganglioma, NOS|Nonchromaffin paraganglioma, malignant|None|Nonencapsulated sclerosing adenocarcinoma|Nonencapsulated sclerosing carcinoma|Nonencapsulated sclerosing tumor|Nongerminomatous Germ Cell Tumor|Noninfiltrating intracystic carcinoma|Noninfiltrating intraductal papillary adenocarcinoma|Noninfiltrating intraductal papillary carcinoma|Noninvasive pancreatobiliary papillary neoplasm with high grade dysplasia|Noninvasive pancreatobiliary papillary neoplasm with high grade intraepithelial neoplasia|Noninvasive pancreatobiliary papillary neoplasm with low grade dysplasia|Noninvasive pancreatobiliary papillary neoplasm with low grade intraepithelial neoplasia|Nonlipid reticuloendotheliosis|Nonpigmented Nevus|Nonpigmented nevus|Norgestrel|Normal|Normal Adjacent Tissue|Normal class but appears diseased|Normal tissue origin incorrect|Normal_LogR|North American Ginseng Extract AFX-2|North Korea|North Macedonia|Northern Mariana Islands|Nortopixantrone|Norway|Noscapine|Noscapine Hydrochloride|Not Allowed To Collect|Not Applicable|Not Cancer Related|Not Determined|Not Hispanic or Latino|Not Otherwise Specified|Not Performed|Not performed|Notch Signaling Inhibitor PF-06650808|Notch Signaling Pathway Inhibitor MK0752|Notification|Nuclei RNA|Nucleolin Antagonist IPP-204106N|Nucleoside Analog DFP-10917|Nucleotide Analog Prodrug NUC-3373|Nucleotide Analogue GS 9219|Numidargistat|Nurulimab|Nutlin-3a|Nutraceutical TBL-12|Nystagmus|O-Chloroacetylcarbamoylfumagillol|O6-Benzylguanine|OCT|OMEGA|OMEGA-2001|OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule|OX40L-expressing Oncolytic Adenovirus DNX-2440|Oat cell carcinoma|Obatoclax Mesylate|Obesity|Obinutuzumab|Oblimersen Sodium|Observation|Obstruction Gastric|Ocaratuzumab|Occasional Drinker|Occipital Cortex|Occipital Lobe|Occipital lobe|Occupational Artificial Smoke Machine Smoke Exposure|Occupational Fire Fighting Smoke Exposure|Occupational Foundry Smoke Exposure|Occupational Generator Smoke Exposure|Occupational Military Smoke Exposure|Occupational Paint Baking Smoke Exposure|Occupational Plastics Factory Smoke Exposure|Occupational Plumbing Smoke Exposure|Occupational Soldering/Welding Smoke Exposure|Ocrelizumab|Octreotide|Octreotide Acetate|Octreotide Pamoate|Ocular Orbits|Oculomotor Nerve Disorder|Odontoameloblastoma|Odontogenic Fibroma|Odontogenic Myxofibroma|Odontogenic Myxoma|Odontogenic Neoplasm|Odontogenic Tumors|Odontogenic carcinoma|Odontogenic carcinosarcoma|Odontogenic fibroma, NOS|Odontogenic fibrosarcoma|Odontogenic ghost cell tumor|Odontogenic myxofibroma|Odontogenic myxoma|Odontogenic sarcoma|Odontogenic tumor, NOS|Odontogenic tumor, benign|Odontogenic tumor, malignant|Odontoma|Odontoma, NOS|Odronextamab|Ofatumumab|Ofranergene Obadenovec|Oglufanide Disodium|Oil burning smoke, Kerosene|Oil burning smoke, NOS|Olaparib|Olaptesed Pegol|Olaratumab|Oleandrin|Oleclumab|Olfactory Nerve Disorder|Olfactory Neuroblastoma|Olfactory Neurocytoma|Olfactory Neurogenic Tumor|Olfactory nerve|Olfactory neuroblastoma|Olfactory neurocytoma|Olfactory neuroepithelioma|Olfactory neurogenic tumor|Oligo-fucoidan|Oligoastrocytoma|Oligodendroblastoma|Oligodendroglioma|Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted|Oligodendroglioma, NOS|Oligodendroglioma, Not Otherwise Specified|Oligodendroglioma, anaplastic|Oligonucleotide SPC2996|Oligospermia|Olinvacimab|Olivomycin|Olmutinib|Oltipraz|Olutasidenib|Olvimulogene Nanivacirepvec|Omacetaxine Mepesuccinate|Oman|Ombrabulin|Omentectomy|Omentum|Omipalisib|Onalespib|Onalespib Lactate|Onartuzumab|Onatasertib|Once Weekly|Oncocytic Adenoma|Oncocytic Neoplasm|Oncocytic Schneiderian papilloma|Oncocytic adenocarcinoma|Oncocytic adenoma|Oncocytic carcinoma|Oncocytoma|Oncolytic Adenovirus Ad5-DNX-2401|Oncolytic Adenovirus ORCA-010|Oncolytic HSV-1 C134|Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011|Oncolytic HSV-1 G207|Oncolytic HSV-1 NV1020|Oncolytic HSV-1 rQNestin34.5v.2|Oncolytic HSV-1 rRp450|Oncolytic HSV1716|Oncolytic Herpes Simplex Virus-1 ONCR-177|Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein|Oncolytic Newcastle Disease Virus MEDI5395|Oncolytic Newcastle Disease Virus MTH-68H|Oncolytic Newcastle Disease Virus Strain PV701|Oncolytic Virus ASP9801|Oncolytic Virus RP1|Ondansetron Hydrochloride|Ontorpacept|Ontuxizumab|Onvansertib|Onvatilimab|Oophorectomy|Opaganib|Open Craniotomy|Open Partial Nephrectomy|Open Radical Nephrectomy|Open Radical Prostatectomy|Opioid Growth Factor|Opolimogene Capmilisbac|Oportuzumab Monatox|Oprozomib|Optic Nerve|Optic Nerve Disorder|Optic nerve|OptionAnalysisPipeline2|Opucolimab|Oral|Oral Aminolevulinic Acid Hydrochloride|Oral Azacitidine|Oral Cancer Vaccine V3-OVA|Oral Cavity|Oral Cavity - Mucosa Only|Oral Cavity Fistula|Oral Contraceptives|Oral Docetaxel|Oral Dysesthesia|Oral Fludarabine Phosphate|Oral Hemorrhage|Oral Hsp90 Inhibitor IPI-493|Oral Hypoglycemic|Oral Ixabepilone|Oral Microencapsulated Diindolylmethane|Oral Milataxel|Oral Myoma Vaccine V3-myoma|Oral Pain|Oral Pancreatic Cancer Vaccine V3-P|Oral Picoplatin|Oral Sodium Phenylbutyrate|Oral Squamous Cell Carcinoma|Oral Topotecan Hydrochloride|Orantinib|Oraxol|Orbit|Orbit, NOS|Orbitrap Elite|Orbitrap Fusion|Orbitrap Fusion ETD|Orbitrap Fusion Lumos|Orbitrap Lumos|Orbitrap Velos|Orchiectomy|Orchioblastoma|Orchiopexy|Oregovomab|Orelabrutinib|Organ Transplantation|Organ transplant (site)|Ormaplatin|Oropharynx|Oropharynx, NOS|Ortataxel|Orteronel|Orvacabtagene Autoleucel|Oryza sativa|Osilodrostat|Osimertinib|Osseous and Chondromatous Neoplasms|Ossifying Fibroma|Ossifying Fibromyxoid Tumor|Ossifying fibroma|Ossifying fibromyxoid tumor|Ossifying fibromyxoid tumor, malignant|Ossifying renal tumor|Osteoarthritis|Osteoblastic Osteosarcoma|Osteoblastic sarcoma|Osteoblastoma|Osteoblastoma, NOS|Osteoblastoma, malignant|Osteocartilaginous exostosis|Osteochondroma|Osteochondromatosis, NOS|Osteochondrosarcoma|Osteofibroma|Osteofibrosarcoma|Osteogenic sarcoma, NOS|Osteoid Osteoma|Osteoid osteoma, NOS|Osteoma|Osteoma, NOS|Osteonecrosis of Jaw|Osteoporosis|Osteoporosis or Osteopenia|Osteosarcoma|Osteosarcoma (OS)|Osteosarcoma in Paget disease of bone|Osteosarcoma, NOS|Other|Other Cancer Within 5 Years|Other Hematologic Disorders|Other Leukemias|Other Nonmalignant Systemic Disease|Other Pulmonary Complications|Other Specified Parts of Pancreas|Other Surgical Resection|Other and Unspecified Female Genital Organs ICD-O-3|Other and ill-defined digestive organs|Other and ill-defined sites|Other and ill-defined sites in lip, oral cavity and pharynx|Other and ill-defined sites within respiratory system and intrathoracic organs|Other and unspecified female genital organs|Other and unspecified major salivary glands|Other and unspecified male genital organs|Other and unspecified parts of biliary tract|Other and unspecified parts of mouth|Other and unspecified parts of tongue|Other and unspecified urinary organs|Other endocrine glands and related structures|Other ill-defined sites|Other specified parts of female genital organs|Other specified parts of male genital organs|Other specified parts of pancreas|Otitis Externa|Otitis Media|Otlertuzumab|Ovapuldencel-T|Ovarian Cancer|Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006|Ovarian Capsule Fragmented|Ovarian Capsule Intact|Ovarian Capsule Ruptured|Ovarian Endometrioid Adenofibroma|Ovarian Endometrioid Cystadenofibroma|Ovarian Gynandroblastoma|Ovarian Hemorrhage|Ovarian Hilus Cell Tumor|Ovarian Infection|Ovarian Luteinized Thecoma|Ovarian Rupture|Ovarian Sclerosing Stromal Tumor|Ovarian Seromucinous Carcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord-Stromal Tumor|Ovarian Small Cell Carcinoma, Hypercalcemic Type|Ovarian Small Cell Carcinoma, Pulmonary-Type|Ovarian Steroid Cell Tumor|Ovarian Stromal Luteoma|Ovarian Stromal Tumor with Minor Sex Cord Elements|Ovarian stromal tumor|Ovary|Overlapping lesion of accessory sinuses|Overlapping lesion of biliary tract|Overlapping lesion of bladder|Overlapping lesion of bones, joints and articular cartilage|Overlapping lesion of bones, joints and articular cartilage of limbs|Overlapping lesion of brain|Overlapping lesion of brain and central nervous system|Overlapping lesion of breast|Overlapping lesion of cervix uteri|Overlapping lesion of colon|Overlapping lesion of connective, subcutaneous and other soft tissues|Overlapping lesion of corpus uteri|Overlapping lesion of digestive system|Overlapping lesion of endocrine glands and related structures|Overlapping lesion of esophagus|Overlapping lesion of eye and adnexa|Overlapping lesion of female genital organs|Overlapping lesion of floor of mouth|Overlapping lesion of heart, mediastinum and pleura|Overlapping lesion of hypopharynx|Overlapping lesion of ill-defined sites|Overlapping lesion of larynx|Overlapping lesion of lip|Overlapping lesion of lip, oral cavity and pharynx|Overlapping lesion of lung|Overlapping lesion of major salivary glands|Overlapping lesion of male genital organs|Overlapping lesion of nasopharynx|Overlapping lesion of other and unspecified parts of mouth|Overlapping lesion of palate|Overlapping lesion of pancreas|Overlapping lesion of penis|Overlapping lesion of peripheral nerves and autonomic nervous system|Overlapping lesion of rectum, anus and anal canal|Overlapping lesion of respiratory system and intrathoracic organs|Overlapping lesion of retroperitoneum and peritoneum|Overlapping lesion of skin|Overlapping lesion of small intestine|Overlapping lesion of stomach|Overlapping lesion of tongue|Overlapping lesion of tonsil|Overlapping lesion of urinary organs|Overlapping lesion of vulva|Overlapping lesions of oropharynx|Ovine Submaxillary Mucin|Ovulation Pain|OxPhos Inhibitor VLX600|Oxaliplatin|Oxaliplatin Eluting Beads|Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome|Oxcarbazepine|Oxeclosporin|Oxidative Phosphorylation Inhibitor IACS-010759|Oxidative Phosphorylation Inhibitor IM156|Oxidopamine|Oxyphilic Adenocarcinoma|Oxyphilic adenocarcinoma|Oxyphilic adenoma|Ozarelix|P-TEFb Inhibitor BAY1143572|P-cadherin Antagonist PF-03732010|P-cadherin Inhibitor PCA062|P-cadherin-targeting Agent PF-06671008|P-p68 Inhibitor RX-5902|PA-Palliative Therapy|PAK4 Inhibitor PF-03758309|PAK4/NAMPT Inhibitor KPT-9274|PARP 1/2 Inhibitor IMP4297|PARP 1/2 Inhibitor NOV1401|PARP Inhibitor AZD2461|PARP Inhibitor CEP-9722|PARP Inhibitor E7016|PARP Inhibitor NMS-03305293|PARP-1/2 Inhibitor ABT-767|PARP/Tankyrase Inhibitor 2X-121|PARP7 Inhibitor RBN-2397|PB-Palliative Benefit|PBN Derivative OKN-007|PCNU|PD-1 Directed Probody CX-188|PD-1 Inhibitor|PD-L1 Inhibitor GS-4224|PD-L1 Inhibitor INCB086550|PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480|PD-L1/PD-L2/VISTA Antagonist CA-170|PD-Progressive Disease|PDF|PDK1 Inhibitor AR-12|PDM-Persistent Distant Metastasis|PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1|PEComa, malignant|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|PEG-Proline-Interferon Alfa-2b|PEG-interleukin-2|PEOX-based Polymer Encapsulated Paclitaxel FID-007|PEP-3-KLH Conjugate Vaccine|PET|PGG Beta-Glucan|PGLA/PEG Copolymer-Based Paclitaxel|PH20 Hyaluronidase-expressing Adenovirus VCN-01|PI3K Alpha/Beta Inhibitor BAY1082439|PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate|PI3K Inhibitor ACP-319|PI3K Inhibitor BGT226|PI3K Inhibitor GDC-0084|PI3K Inhibitor GDC0077|PI3K Inhibitor GSK1059615|PI3K Inhibitor WX-037|PI3K Inhibitor ZSTK474|PI3K p110beta/delta Inhibitor KA2237|PI3K-alpha Inhibitor MEN1611|PI3K-beta Inhibitor GSK2636771|PI3K-beta Inhibitor SAR260301|PI3K-delta Inhibitor AMG 319|PI3K-delta Inhibitor HMPL 689|PI3K-delta Inhibitor INCB050465|PI3K-delta Inhibitor PWT143|PI3K-delta Inhibitor SHC014748M|PI3K-delta Inhibitor YY-20394|PI3K-gamma Inhibitor IPI-549|PI3K/BET Inhibitor LY294002|PI3K/mTOR Kinase Inhibitor DS-7423|PI3K/mTOR Kinase Inhibitor PF-04691502|PI3K/mTOR Kinase Inhibitor VS-5584|PI3K/mTOR Kinase Inhibitor WXFL10030390|PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170|PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901|PI3Ka/mTOR Inhibitor PKI-179|PI3Kalpha Inhibitor AZD8835|PI3Kbeta Inhibitor AZD8186|PI3Kdelta Inhibitor GS-9901|PIM Kinase Inhibitor LGH447|PIM Kinase Inhibitor SGI-1776|PIM Kinase Inhibitor TP-3654|PIM/FLT3 Kinase Inhibitor SEL24|PIN III|PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231|PKC-alpha Antisense Oligodeoxynucleotide ISIS 3521|PKC-beta Inhibitor MS-553|PLC|PLD-Persistent Locoregional Disease|PLK1 Inhibitor CYC140|PLK1 Inhibitor TAK-960|PNET, NOS|PP/PYY producing tumor|PPAR Alpha Antagonist TPST-1120|PPD-Pseudoprogression|PPNET|PR-Partial Response|PR1 Leukemia Peptide Vaccine|PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701|PRIMA-1 Analog APR-246|PRMT1 Inhibitor GSK3368715|PRMT5 Inhibitor JNJ-64619178|PRMT5 Inhibitor PRT811|PSA/IL-2/GM-CSF Vaccine|PSA/PSMA DNA Plasmid INO-5150|PSMA|PSMA-targeted Docetaxel Nanoparticles BIND-014|PSMA-targeted Tubulysin B-containing Conjugate EC1169|PSMA/CD3 Tri-specific T-cell Activating Construct HPN424|PSR-Pseudoresponse|PTEF-b/CDK9 Inhibitor BAY1251152|PTLD, NOS|PV-10|PVA Microporous Hydrospheres/Doxorubicin Hydrochloride|PacBio|Pacinian Neurofibroma|Pacinian tumor|Paclitaxel|Paclitaxel Ceribate|Paclitaxel Injection Concentrate for Nanodispersion|Paclitaxel Liposome|Paclitaxel PPE Microspheres|Paclitaxel Poliglumex|Paclitaxel Polymeric Micelle Formulation NANT-008|Paclitaxel Trevatide|Paclitaxel Vitamin E-Based Emulsion|Paclitaxel-Loaded Polymeric Micelle|Pacmilimab|Pacritinib|Padeliporfin|Padoporfin|Paget Disease and Intraductal Carcinoma of the Breast|Paget Disease of the Breast|Paget Disease of the Breast without Invasive Carcinoma|Paget disease and infiltrating duct carcinoma of breast|Paget disease and intraductal carcinoma of breast|Paget disease of breast|Paget disease, extramammary|Paget disease, mammary|Pagetoid Reticulosis|Pagetoid reticulosis|Pain|Pain (Various)|Pain in Extremity|Pain of Skin|Paired_LogR|Pakistan|Palate|Palate, NOS|Palatectomy|Palatine Tonsil|Palau|Palbociclib|Palbociclib Isethionate|Palifosfamide|Palifosfamide Tromethamine|Palladium Pd-103|Palliative|Palmar-Plantar Erythrodysesthesia Syndrome|Palonosetron Hydrochloride|Palpitations|Pamidronate Disodium|Pamidronic Acid|Pamiparib|Pamrevlumab|Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514|Pan-AKT Inhibitor ARQ751|Pan-AKT Kinase Inhibitor GSK690693|Pan-FGFR Inhibitor LY2874455|Pan-FLT3/Pan-BTK Multi-kinase Inhibitor CG-806|Pan-IDH Mutant Inhibitor AG-881|Pan-KRAS Inhibitor BI 1701963|Pan-Mutant-IDH1 Inhibitor Bay-1436032|Pan-PIM Inhibitor INCB053914|Pan-Procto Colectomy|Pan-RAF Inhibitor LY3009120|Pan-RAR Agonist/AP-1 Inhibitor LGD 1550|Pan-TRK Inhibitor NOV1601|Pan-TRK Inhibitor ONO-7579|Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981|Pan-mutation-selective EGFR Inhibitor CLN-081|Panama|Pancratistatin|Pancreas|Pancreas Cancer|Pancreas Infection|Pancreas, NOS|Pancreatectomy|Pancreatic Acinar Cell Cystadenocarcinoma|Pancreatic Adenocarcinoma|Pancreatic Anastomotic Leak|Pancreatic Beta Cell Adenoma|Pancreatic Carcinoma|Pancreatic Duct Stenosis|Pancreatic Ductal Adenocarcinoma|Pancreatic Enzymes Decreased|Pancreatic Fistula|Pancreatic Hemorrhage|Pancreatic Insulinoma|Pancreatic Intraductal Papillary-Mucinous Neoplasm with High Grade Dysplasia|Pancreatic Intraductal Papillary-Mucinous Neoplasm with an Associated Invasive Carcinoma|Pancreatic Intraductal Tubulopapillary Neoplasm|Pancreatic Mucinous-Cystic Neoplasm with Intermediate Grade Dysplasia|Pancreatic Necrosis|Pancreatic Neuroendocrine Carcinoma|Pancreatic Neuroendocrine Neoplasm|Pancreatic duct|Pancreatic endocrine tumor, NOS|Pancreatic endocrine tumor, benign|Pancreatic endocrine tumor, malignant|Pancreatic endocrine tumor, nonfunctioning|Pancreatic microadenoma|Pancreatic neck|Pancreatic peptide and pancreatic peptide-like peptide within terminal tyrosine amide producing tumor|Pancreatitis|Pancreatobiliary neoplasm, non-invasive|Pancreatobiliary-type carcinoma|Pancreatoblastoma|Panitumumab|Panobinostat|Panobinostat Nanoparticle Formulation MTX110|Panulisib|Pap Smear|Papillary Adenocarcinoma|Papillary Adenofibroma|Papillary Carcinoma|Papillary Carcinoma In Situ|Papillary Craniopharyngioma|Papillary Cystadenocarcinoma|Papillary Cystadenoma|Papillary Cystic Neoplasm|Papillary Eccrine Adenoma|Papillary Ependymoma|Papillary Glioneuronal Tumor|Papillary Intralymphatic Angioendothelioma|Papillary Meningioma|Papillary Mucinous Cystadenocarcinoma|Papillary Mucinous Cystadenoma|Papillary Renal Cell Carcinoma|Papillary Serous Cystadenocarcinoma|Papillary Serous Cystadenoma|Papillary Squamous Cell Carcinoma|Papillary Transitional Cell Carcinoma|Papillary Tumor of the Pineal Region|Papillary adenocarcinoma, NOS|Papillary adenocarcinoma, follicular variant|Papillary adenofibroma|Papillary adenoma, NOS|Papillary and follicular adenocarcinoma|Papillary and follicular carcinoma|Papillary carcinoma in situ|Papillary carcinoma of thyroid|Papillary carcinoma, NOS|Papillary carcinoma, columnar cell|Papillary carcinoma, diffuse sclerosing|Papillary carcinoma, encapsulated|Papillary carcinoma, follicular variant|Papillary carcinoma, oxyphilic cell|Papillary carcinoma, tall cell|Papillary cystadenocarcinoma, NOS|Papillary cystadenoma lymphomatosum|Papillary cystadenoma, NOS|Papillary cystadenoma, borderline malignancy|Papillary cystic tumor|Papillary ependymoma|Papillary epidermoid carcinoma|Papillary glioneuronal tumor|Papillary hidradenoma|Papillary meningioma|Papillary microcarcinoma|Papillary mucinous cystadenocarcinoma|Papillary mucinous cystadenoma, NOS|Papillary mucinous cystadenoma, borderline malignancy|Papillary mucinous tumor of low malignant potential|Papillary neoplasm, pancreatobiliary-type, with high grade intraepithelial neoplasia|Papillary pseudomucinous cystadenocarcinoma|Papillary pseudomucinous cystadenoma, NOS|Papillary pseudomucinous cystadenoma, borderline malignancy|Papillary renal cell carcinoma|Papillary serous adenocarcinoma|Papillary serous cystadenocarcinoma|Papillary serous cystadenoma, NOS|Papillary serous cystadenoma, borderline malignancy|Papillary serous tumor of low malignant potential|Papillary squamous cell carcinoma|Papillary squamous cell carcinoma in situ|Papillary squamous cell carcinoma, non-invasive|Papillary syringadenoma|Papillary syringocystadenoma|Papillary transitional cell carcinoma|Papillary transitional cell carcinoma, non-invasive|Papillary transitional cell neoplasm of low malignant potential|Papillary tumor of the pineal region|Papillary urothelial carcinoma|Papillary urothelial carcinoma, non-invasive|Papillary urothelial neoplasm of low malignant potential|Papilledema|Papillocystic adenocarcinoma|Papilloma|Papilloma of bladder|Papilloma, NOS|Papillomatosis|Papillomatosis, NOS|Papillomatosis, glandular|Papillotubular adenocarcinoma|Papillotubular adenoma|Papua New Guinea|Papulopustular Rash|Paracentesis|Parachordoma|Parafollicular cell carcinoma|Paraganglioma|Paraganglioma, NOS|Paraganglioma, benign|Paraganglioma, malignant|Paragangliomas and Glomus Tumors|Paraguay|Parametrium|Paranasal Sinuses|Parasitic Disease of Biliary Tract|Paraspinal Ganglion|Parasympathetic Paraganglioma|Parasympathetic paraganglioma|Parathyroid|Parathyroid Gland Chief Cell Adenoma|Parathyroid Gland Water-Clear Cell Adenoma|Parathyroid gland|Paraurethral gland|Parenchyma|Parent|Paresthesia|Paricalcitol|Parietal Lobe|Parietal cell adenocarcinoma|Parietal cell carcinoma|Parietal lobe|Paronychia|Parosteal Osteosarcoma|Parosteal osteosarcoma|Parotid Gland|Parotid gland|Parotidectomy, NOS|Paroxysmal Atrial Tachycardia|Parsaclisib|Parsaclisib Hydrochloride|Parsatuzumab|Partial Hepatectomy|Partial Hydatidiform Mole|Partial Laryngectomy|Partial Maxillectomy|Partial Nephrectomy|Partial Response|Partial hydatidiform mole|Partially Engineered T-regulatory Cell Donor Graft TRGFT-201|Parvovirus H-1|Pasireotide|Pasotuxizumab|Passive Smoke Exposure|Patella|Paternal Aunt|Paternal First Cousin|Paternal First Cousin Once Removed|Paternal Grandfather|Paternal Grandmother|Paternal Grandparent|Paternal Great Aunt|Paternal Great Grandparent|Paternal Great Uncle|Paternal Half Brother|Paternal Half Sibling|Paternal Half Sister|Paternal Uncle|Pathologic Examination|Pathologic Review|Pathology|Pathology Report|Pathology outside specification|Patidegib|Patidegib Topical Gel|Patritumab|Patritumab Deruxtecan|Pattern 1|Pattern 2|Pattern 3|Pattern 4|Pattern 5|Patupilone|Paxalisib|Pazopanib|Pazopanib Hydrochloride|Pediatric Liver Cancer|Pediatric/AYA Brain Tumors|Pegargiminase|Pegaspargase|Pegasus|Pegasus 4D|Pegasus BT|Pegasus HRT|Pegasus III|Pegdinetanib|Pegfilgrastim|Pegilodecakin|Peginterferon Alfa-2a|Peginterferon Alfa-2b|Pegvisomant|Pegvorhyaluronidase Alfa|Pegylated Deoxycytidine Analogue DFP-14927|Pegylated Interferon Alfa|Pegylated Liposomal Belotecan|Pegylated Liposomal Doxorubicin Hydrochloride|Pegylated Liposomal Irinotecan|Pegylated Liposomal Mitomycin C Lipid-based Prodrug|Pegylated Liposomal Mitoxantrone Hydrochloride|Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010|Pegylated Paclitaxel|Pegylated Recombinant Human Arginase I BCT-100|Pegylated Recombinant Human Hyaluronidase PH20|Pegylated Recombinant Interleukin-2 THOR-707|Pegylated Recombinant L-asparaginase Erwinia chrysanthemi|Pegylated SN-38 Conjugate PLX038|Pegzilarginase|Pelabresib|Pelareorep|Peldesine|Pelitinib|Pelitrexol|Pelvic Floor Muscle Weakness|Pelvic Infection|Pelvic Pain|Pelvic Soft Tissue Necrosis|Pelvic bones, sacrum, coccyx and associated joints|Pelvic lymph nodes|Pelvis|Pelvis, NOS|Pembrolizumab|Pemetrexed|Pemetrexed Disodium|Pemigatinib|Pemlimogene Merolisbac|Penberol|Penclomedine|Penicillamine|Penile Carcinoma In Situ|Penile Infection|Penile Pain|Penis|Penis, NOS|Pentamethylmelamine|Pentamustine|Pentostatin|Pentoxifylline|Pepinemab|Peplomycin|Peplomycin Sulfate|Peposertib|PepsinA|Peptic Ulcer (Ulcer)|Peptichemio|Peptide 946 Melanoma Vaccine|Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine|Peretinoin|Perflenapent Emulsion|Perforation Bile Duct|Perfosfamide|Periapical cemental dysplasia|Periapical cemento-osseous dysplasia|Pericanalicular fibroadenoma|Pericardial Effusion|Pericardial Tamponade|Pericarditis|Pericardium|Periductal stromal tumor, low grade|Perifollicular Fibroma|Perifollicular fibroma|Perifosine|Perillyl Alcohol|Perimenopausal|Perineal Pain|Perinephric Fat|Perineural MPNST|Perineurioma|Perineurioma, NOS|Perineurioma, malignant|Periodontal Disease|Periorbital Edema|Periorbital Infection|Periorbital Soft Tissue|Periosteal Chondroma|Periosteal Chondrosarcoma|Periosteal Fibroma|Periosteal Fibrosarcoma|Periosteal Osteosarcoma|Periosteal chondroma|Periosteal chondrosarcoma|Periosteal fibroma|Periosteal fibrosarcoma|Periosteal osteosarcoma|Periosteal sarcoma, NOS|Peripheral Blood Components NOS|Peripheral Ischemia|Peripheral Motor Neuropathy|Peripheral Nerve Infection|Peripheral Neuropathy|Peripheral Odontogenic Fibroma|Peripheral Primitive Neuroectodermal Tumor|Peripheral Sensory Neuropathy|Peripheral T-Cell Lymphoma, Large Cell|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Peripheral T-cell lymphoma, AILD (Angioimmunoblastic Lymphadenopathy with Dysproteinemia)|Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, large cell|Peripheral T-cell lymphoma, pleomorphic medium and large cell|Peripheral T-cell lymphoma, pleomorphic small cell|Peripheral Vascular Disease|Peripheral Whole Blood|Peripheral nerves and autonomic nervous system|Peripheral nerves and autonomic nervous system of abdomen|Peripheral nerves and autonomic nervous system of head, face, and neck|Peripheral nerves and autonomic nervous system of lower limb and hip|Peripheral nerves and autonomic nervous system of pelvis|Peripheral nerves and autonomic nervous system of thorax|Peripheral nerves and autonomic nervous system of trunk, NOS|Peripheral nerves and autonomic nervous system of upper limb and shoulder|Peripheral neuroectodermal tumor|Peripheral odontogenic fibroma|Peripheral primitive neuroectodermal tumor, NOS|Peritoneal Cavity|Peritoneal Infection|Peritoneal Lavage|Peritoneal Necrosis|Peritoneum|Peritoneum, NOS|Peritumoral|Perivascular epithelioid cell tumor, malignant|Permanently missing item or object|Persistent Disease|Personality Change|Personalized ALL-specific Multi-HLA-binding Peptide Vaccine|Personalized Cancer Vaccine RO7198457|Personalized Neoantigen DNA Vaccine GNOS-PV01|Personalized Neoantigen DNA Vaccine GNOS-PVO2|Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01|Personalized Neoepitope Yeast Vaccine YE-NEO-001|Personalized Peptide Cancer Vaccine NEO-PV-01|Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC|Pertuzumab|Peru|Peutz-Jeghers Disease|Pevonedistat|Pexastimogene Devacirepvec|Pexidartinib|Pexmetinib|Phaleria macrocarpa Extract DLBS-1425|Phantom Pain|Pharmaceutical Therapy, NOS|Pharmacological Ascorbate|Pharyngeal Anastomotic Leak|Pharyngeal Fistula|Pharyngeal Hemorrhage|Pharyngeal Mucositis|Pharyngeal Necrosis|Pharyngeal Stenosis|Pharyngitis|Pharyngolaryngeal Pain|Pharynx|Pharynx, NOS|Phellodendron amurense Bark Extract|Phenesterin|Phenethyl Isothiocyanate|Phenethyl Isothiocyanate-containing Watercress Juice|Phenochromocytoma or Paraganglioma|Phenyl Acetate|Phenytoin Sodium|Pheochromoblastoma|Pheochromocytoma and Paraganglioma|Pheochromocytoma, NOS|Pheochromocytoma, malignant|Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia|Philadelphia-Negative Myelogenous Leukemia|Philippines|Phlebitis|Phlebitis Infective|Phosphaplatin PT-112|Phosphatidylcholine-Bound Silybin|Phosphaturic mesenchymal tumor, malignant|Phospholipid Ether-drug Conjugate CLR 131|Phosphoproteome|Phosphoramide Mustard|Phosphorodiamidate Morpholino Oligomer AVI-4126|Phosphorus P-32|Photodynamic Compound TLD-1433|Photophobia|Photosensitivity|Photosensitizer LUZ 11|Phyllodes Tumor|Phyllodes tumor, NOS|Phyllodes tumor, benign|Phyllodes tumor, borderline|Phyllodes tumor, malignant|Physical Exam|Physical Examination|Phytochlorin Sodium-Polyvinylpyrrolidone Complex|Pibenzimol|Pibrozelesin|Pibrozelesin Hydrobromide|Picibanil|Pick tubular adenoma|PicoFrit SELF/P|Picoplatin|Picrasinoside H|Picropodophyllin|Pictilisib|Pictilisib Bismesylate|Pidilizumab|Pigmented Adrenal Cortex Adenoma|Pigmented Dermatofibrosarcoma Protuberans|Pigmented Nevus|Pigmented Spindle Cell Nevus|Pigmented adenoma|Pigmented basal cell carcinoma|Pigmented dermatofibrosarcoma protuberans|Pigmented nevus, NOS|Pigmented schwannoma|Pigmented spindle cell nevus of Reed|Pilar tumor|Pilaralisib|Pilocytic Astrocytoma|Pilocytic astrocytoma|Piloid astrocytoma|Pilomatrical Carcinoma|Pilomatricoma|Pilomatricoma, NOS|Pilomatricoma, malignant|Pilomatrix carcinoma|Pilomatrixoma, NOS|Pilomatrixoma, malignant|Pilomyxoid Astrocytoma|Pilomyxoid astrocytoma|PilotAnalysisPipeline2|Pimasertib|Pimitespib|Pimurutamab|Pinatuzumab Vedotin|Pindborg tumor|Pindel|Pindel Annotation|Pindel Variant Aggregation and Masking|Pineal|Pineal Gland|Pineal Parenchymal Cell Neoplasm|Pineal Parenchymal Tumor of Intermediate Differentiation|Pineal Region Neoplasm|Pineal gland|Pineal parenchymal tumor of intermediate differentiation|Pinealoma|Pineoblastoma|Pineocytoma|Pingyangmycin|Pinkus tumor|Pinometostat|Pioglitazone|Pioglitazone Hydrochloride|Pipe|Pipeline|Pipendoxifene|Piperazinedione|Piperine Extract (Standardized)|Pipobroman|Piposulfan|Pirarubicin|Pirarubicin Hydrochloride|Pirfenidone|Piritrexim|Piritrexim Isethionate|Pirotinib|Piroxantrone|Piroxantrone Hydrochloride|Pituicytoma|Pituitary Gland|Pituitary Gland Acidophil Adenoma|Pituitary Gland Acidophil Carcinoma|Pituitary Gland Adenoma|Pituitary Gland Basophil Adenoma|Pituitary Gland Carcinoma|Pituitary Gland Chromophobe Adenoma|Pituitary Gland Mixed Acidophil-Basophil Adenoma|Pituitary Gland Mixed Acidophil-Basophil Carcinoma|Pituitary adenoma, NOS|Pituitary carcinoma, NOS|Pituitary gland|Pixantrone|Pixantrone Dimaleate|Pixatimod|Pizzly|Placebo|Placenta|Placental Hemangioma|Placental site trophoblastic tumor|Placental-Site Gestational Trophoblastic Tumor|Pladienolide Derivative E7107|Plamotamab|Plasma|Plasma Cell Leukemia|Plasma Cell Myeloma|Plasma Cell Neoplasm|Plasma Cell Tumors|Plasma cell leukemia|Plasma cell myeloma|Plasma cell tumor|Plasmablastic Lymphoma|Plasmablastic lymphoma|Plasmacytic leukemia|Plasmacytic lymphoma|Plasmacytoma|Plasmacytoma of bone|Plasmacytoma, NOS|Plasmacytoma, extramedullary|Plasmid DNA Vaccine pING-hHER3FL|Plasmodium falciparum|Platelet Count Decreased|Platform|Platform ICP|Platform II|Platform LCZ|Platinum|Platinum Acetylacetonate-Titanium Dioxide Nanoparticles|Platinum Compound|Pleomorphic Adenoma|Pleomorphic Carcinoma|Pleomorphic Lipoma|Pleomorphic Liposarcoma|Pleomorphic Lobular Breast Carcinoma In Situ|Pleomorphic Rhabdomyosarcoma|Pleomorphic Xanthoastrocytoma|Pleomorphic adenoma|Pleomorphic carcinoma|Pleomorphic cell sarcoma|Pleomorphic leiomyoma|Pleomorphic lipoma|Pleomorphic liposarcoma|Pleomorphic lobular carcinoma|Pleomorphic lobular carcinoma in situ|Pleomorphic rhabdomyosarcoma, NOS|Pleomorphic rhabdomyosarcoma, adult type|Pleomorphic xanthoastrocytoma|Pleura|Pleura, NOS|Pleural Effusion|Pleural Hemorrhage|Pleural Infection|Pleural Solitary Fibrous Tumor|Pleuritic Pain|Pleurodesis|Pleurodesis, NOS|Pleurodesis, Talc|Pleuropulmonary Blastoma|Pleuropulmonary blastoma|Plevitrexed|Plexiform Fibrohistiocytic Tumor|Plexiform Neurofibroma|Plexiform Schwannoma|Plexiform fibrohistiocytic tumor|Plexiform fibromyxoma|Plexiform hemangioma|Plexiform leiomyoma|Plexiform neurofibroma|Plexiform neuroma|Plexiform schwannoma|Plicamycin|Plinabulin|Plitidepsin|Plk1 Inhibitor BI 2536|Plocabulin|Plozalizumab|Pneumoblastoma|Pneumocystis Pneumonia|Pneumocystis carinii|Pneumonectomy|Pneumonia, NOS|Pneumonitis|Pneumothorax|Pol I Inhibitor CX5461|Poland|Polar Spongioblastoma|Polar spongioblastoma|Polatuzumab Vedotin|Polidocanol|Poliglusam|Polo-like Kinase 1 Inhibitor GSK461364|Polo-like Kinase 1 Inhibitor MK1496|Polo-like Kinase 1 Inhibitor NMS-1286937|Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate|Poly-alendronate Dextran-Guanidine Conjugate|Poly-gamma Glutamic Acid|Polyamine Analog SL11093|Polyamine Analogue PG11047|Polyamine Analogue SBP-101|Polyamine Transport Inhibitor AMXT-1501 Dicaprate|Polyandrol|Polycystic Ovarian Syndrome (PCOS)|Polycythemia Vera|Polycythemia rubra vera|Polycythemia vera|Polyembryoma|Polyethylene Glycol Recombinant Endostatin|Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318|Polygonal Cell Carcinoma|Polygonal cell carcinoma|Polymer-conjugated IL-15 Receptor Agonist NKTR-255|Polymer-encapsulated Luteolin Nanoparticle|Polymeric Camptothecin Prodrug XMT-1001|Polymorphic Post-Transplant Lymphoproliferative Disorder|Polymorphic post transplant lymphoproliferative disorder|Polymorphic reticulosis|Polymorphous low grade adenocarcinoma|Polypodium leucotomos Extract|Polypoid adenoma|Polysaccharide-K|Polysialic Acid|Polyunsaturated Fatty Acid|Polyvalent Melanoma Vaccine|Polyvesicular vitelline tumor|Pomalidomide|Pomegranate Juice|Pomegranate Liquid Extract|Ponatinib|Ponatinib Hydrochloride|Poor Prognosis|Poorly Differentiated|Poorly Differentiated Neuroblastoma|Poorly Differentiated Neuroendocrine Lesion|Poorly Differentiated Thyroid Gland Carcinoma|Poorly cohesive carcinoma|Popliteal Fossa|Porcupine Inhibitor CGX1321|Porcupine Inhibitor ETC-1922159|Porcupine Inhibitor RXC004|Porcupine Inhibitor WNT974|Porcupine Inhibitor XNW7201|Porfimer Sodium|Porfiromycin|Porocarcinoma|Poroma|Portal Hypertension|Portal Vein Thrombosis|Portugal|Positive|Positive Biomarker(s)|Post neo-adjuvant therapy|Post transplant lymphoproliferative disorder, NOS|Post-Transplant Lymphoproliferative Disorder|Postcricoid region|Posterior Wall of the Nasopharynx|Posterior mediastinum|Posterior wall of bladder|Posterior wall of hypopharynx|Posterior wall of nasopharynx|Posterior wall of oropharynx|Postmenopausal|Postnasal Drip|Postoperative Hemorrhage|Postoperative Thoracic Procedure Complication|Pouch|Poziotinib|Pracinostat|Pralatrexate|Pralsetinib|Praluzatamab Ravtansine|Pravastatin Sodium|Pre T-ALL|Pre-B ALL|Pre-B Acute Lymphoblastic Leukemia|Pre-Pre-B Acute Lymphoblastic Leukemia|Pre-T ALL|Pre-extracted DNA received by TSS|Pre-pre-B ALL|Precancerous Melanosis|Precancerous melanosis, NOS|Precocious Puberty|Precursor B-cell lymphoblastic leukemia|Precursor B-cell lymphoblastic lymphoma|Precursor Cell Lymphoblastic Lymphoma|Precursor T-cell lymphoblastic leukemia|Precursor T-cell lymphoblastic lymphoma|Precursor cell lymphoblastic leukemia, NOS|Precursor cell lymphoblastic leukemia, not phenotyped|Precursor cell lymphoblastic lymphoma, NOS|Prednimustine|Prednisolone|Prednisolone Acetate|Prednisolone Sodium Phosphate|Prednisone|Pregnancy in Patient or Partner|Pregnancy, Puerperium and Perinatal Conditions - Other|Preleukemia|Preleukemic syndrome|Premalignant|Premature Delivery|Premature Menopause|Premenopausal|Premier|Prepuce|Present|Presyncope|Prevention|Prexasertib|Prexigebersen|Primary|Primary Amyloidosis|Primary Blood Derived Cancer - Bone Marrow|Primary Blood Derived Cancer - Peripheral Blood|Primary Cutaneous Anaplastic Large Cell Lymphoma|Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder|Primary Cutaneous CD4-Positive Small/Medium T-Cell Lymphoproliferative Disorder|Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma|Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Primary Cutaneous Follicle Center Lymphoma|Primary Cutaneous Gamma-Delta T-Cell Lymphoma|Primary Cutaneous Lymphoma|Primary Cutaneous Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Primary Effusion Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Primary Myelofibrosis|Primary Neoplasm|Primary Peritoneal Serous Papillary Adenocarcinoma|Primary Sclerosing Cholangitis|Primary Site Unknown|Primary Tumor|Primary Tumor Field|Primary Xenograft Tissue|Primary amyloidosis|Primary cutaneous CD30+ T-cell lymphoproliferative disorder|Primary cutaneous CD30+ large T-cell lymphoma|Primary cutaneous CD4-positive small/medium T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous DLBCL, leg type|Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous follicle centre lymphoma|Primary cutaneous gamma-delta T-cell lymphoma|Primary cutaneous neuroendocrine carcinoma|Primary diffuse large B-cell lymphoma of the CNS|Primary effusion lymphoma|Primary intraosseous carcinoma|Primary myelofibrosis|Primary serous papillary carcinoma of peritoneum|Primary tumor site|Prime Cancer Vaccine MVA-BN-CV301|Primitive Neuroectodermal Tumor|Primitive neuroectodermal tumor, NOS|Primitive polar spongioblastoma|Prinomastat|Prior malignancy|Pro-B ALL|Pro-T ALL|Proapoptotic Sulindac Analog CP-461|Procarbazine|Procarbazine Hydrochloride|Procaspase Activating Compound-1 VO-100|Proctitis|Productive Cough|Progestational IUD|Progesterone and Estrogen|Progesterone only|Progestin|Progestin and Estrogen|Progression|Progressive Disease|Progressive Multifocal Leukoencephalopathy|Progressive Neoplastic Disease|Prohibitin-Targeting Peptide 1|Prolactinoma|Prolapse of Intestinal Stoma|Prolapse of Urostomy|Prolgolimab|Proliferating Trichilemmal Tumor|Proliferating trichilemmal cyst|Proliferating trichilemmal tumor|Proliferative Nodules in Congenital Melanocytic Nevus|Proliferative dermal lesion in congenital nevus|Proliferative polycythemia|Proline endopeptidase|Prolymphocytic Leukemia|Prolymphocytic leukemia, B-cell type|Prolymphocytic leukemia, NOS|Prolymphocytic leukemia, T-cell type|Propane Smoke Exposue|Prospective|Prostaglandin E2 EP4 Receptor Inhibitor AN0025|Prostaglandin E2 EP4 Receptor Inhibitor E7046|Prostate|Prostate Acinar Adenocarcinoma, Sarcomatoid Variant|Prostate Adenocarcinoma|Prostate Bed|Prostate Cancer|Prostate Cancer Vaccine ONY-P1|Prostate Carcinoma|Prostate Gland|Prostate Health Cocktail Dietary Supplement|Prostate Infection|Prostate gland|Prostate, Seminal Vesicles and Lymph Nodes|Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024|Prostatic Hemorrhage|Prostatic Obstruction|Prostatic Pain|Prostatic intraepithelial neoplasia, grade III|Protease-activated Anti-PD-L1 Antibody Prodrug CX-072|Protein|Protein Arginine Methyltransferase 5 Inhibitor GSK3326595|Protein Arginine Methyltransferase 5 Inhibitor PF-06939999|Protein Arginine Methyltransferase 5 Inhibitor PRT543|Protein Expression Quantification|Protein Kinase C Inhibitor IDE196|Protein Phosphatase 2A Inhibitor LB-100|Protein Stabilized Liposomal Docetaxel Nanoparticles|Protein Tyrosine Kinase 2 Inhibitor IN10018|Proteinuria|Proteome|Proteome Profiling|Proton Pump Inhibitors|Protoplasmic Astrocytoma|Protoplasmic astrocytoma|Proxalutamide|Pruritus|Psammomatous Meningioma|Psammomatous meningioma|Psammomatous schwannoma|Pseudoglandular Squamous Cell Carcinoma|Pseudoisocytidine|Pseudomonas aeruginosa|Pseudomucinous adenocarcinoma|Pseudomucinous cystadenocarcinoma, NOS|Pseudomucinous cystadenoma, NOS|Pseudomucinous cystadenoma, borderline malignancy|Pseudomyxoma Peritonei|Pseudomyxoma peritonei|Pseudomyxoma peritonei with unknown primary site|Pseudoprogression|Pseudosarcomatous carcinoma|Psoriasis|Psychiatric Disorders - Other|Psychosis|Pterostilbene|Puerto Rico|Pulmonary Adenomatosis|Pulmonary Artery Intimal Sarcoma|Pulmonary Blastoma|Pulmonary Edema|Pulmonary Fibrosis|Pulmonary Fistula|Pulmonary Hemorrhage|Pulmonary Hypertension|Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Translocation|Pulmonary Valve Disease|Pulmonary adenomatosis|Pulmonary artery intimal sarcoma|Pulmonary blastoma|Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation|Pumitepa|Punch Biopsy|Puquitinib|Puquitinib Mesylate|Pure Erythroid Leukemia|Puromycin|Puromycin Hydrochloride|Purpura|Pylorus|Pyramidal Tract Syndrome|Pyrazinamide|Pyrazoloacridine|Pyridyl Cyanoguanidine CHS 828|Pyriform sinus|Pyrotinib|Pyrotinib Dimaleate|Pyroxamide|Pyruvate Kinase Inhibitor TLN-232|Pyruvate Kinase M2 Isoform Activator TP-1454|Q Exactive|Q Exactive HF|Q Exactive HF-X|Q Exactive Plus|Q TRAP|Q-Tof Premier|Q-Tof Ultima|Q-Tof micro|QA|QSTAR|QSTAR Elite|QSTAR Pulsar|QSTAR XL|QTRAP 4500|QTRAP 5500|QTRAP 6500|QTRAP 6500+m|Qatar|Qilisheng Immunoregulatory Oral Solution|Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine|Qualification metrics changed|Qualified|Qualified in error|Quarfloxin|Quattro|Quattro II|Quattro LC|Quattro Premier|Quattro Premier XE|Quattro Ultima|Quattro Ultima Pt|Quattro micro GC|Queyrat erythroplasia|Quinacrine Hydrochloride|Quinine|Quisinostat|Quizartinib|R|R-(-)-Gossypol Acetic Acid|R0|R1|R2|RAD51 Inhibitor CYT-0851|RAEB|RAEB I|RAEB II|RAEB-T|RAF Kinase Inhibitor L-779450|RAF Kinase Inhibitor XL281|RARS|RARalpha Agonist IRX5183|RD-Responsive Disease|RET Inhibitor DS-5010|RET Mutation/Fusion Inhibitor BLU-667|RET/SRC Inhibitor TPX-0046|RFT5-dgA Immunotoxin IMTOX25|RIPK1 Inhibitor GSK3145095|RNA|RNA-SeQC - Counts|RNA-SeQC - FPKM|RNA-Seq|RNR Inhibitor COH29|ROBO1-targeted BiCAR-NKT Cells|RORgamma Agonist LYC-55716|RP-Response|RPD-Radiographic Progressive Disease|RPLC|RPPA|RSEM - Quantification|RSK1-4 Inhibitor PMD-026|RX|Rabusertib|Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus SM-88|Racemose hemangioma|Racotumomab|Radgocitabine|Radgocitabine Hydrochloride|Radiation|Radiation Recall Reaction (Dermatologic)|Radiation Therapy, NOS|Radiation, 2D Conventional|Radiation, 3D Conformal|Radiation, Combination|Radiation, Cyberknife|Radiation, External Beam|Radiation, Hypofractionated|Radiation, Implants|Radiation, Intensity-Modulated Radiotherapy|Radiation, Internal|Radiation, Mixed Photon Beam|Radiation, Photon Beam|Radiation, Proton Beam|Radiation, Radioisotope|Radiation, Stereotactic/Gamma Knife/SRS|Radiation, Systemic|Radical Hysterectomy|Radical Maxillectomy|Radical Nephrectomy|Radical Prostatectomy|Radiculitis|Radioactive Iodine|Radioactive Iodine Therapy|Radioembolization|Radiographic Progressive Disease|Radiolabeled CC49|Radiology|Radiosensitizing Agent|Radium Ra 223 Dichloride|Radium Ra 224-labeled Calcium Carbonate Microparticles|Radix Angelicae Sinensis/Radix Astragali Herbal Supplement|Radotinib Hydrochloride|Raf Kinase Inhibitor HM95573|Ragifilimab|Ralaniten Acetate|Ralimetinib Mesylate|Raloxifene|Raloxifene Hydrochloride|Raltitrexed|Ramucirumab|Ranibizumab|Ranimustine|Ranolazine|Ranpirnase|Ras Inhibitor|Ras Peptide ASP|Ras Peptide CYS|Ras Peptide VAL|Rash Acneiform|Rash Maculo-Papular|Rash Pustular|Rathke pouch tumor|Rattus norvegicus|Raw CGI Variant|Raw Intensities|Raw Sequencing Data|Raw Simple Somatic Mutation|Razoxane|Read Group Quality Control|Realgar-Indigo naturalis Formulation|Rebastinib Tosylate|Rebeccamycin|Rebimastat|Receptor Tyrosine Kinase Inhibitor R1530|Recklinghausen disease|Recombinant Adenovirus-p53 SCH-58500|Recombinant Anti-WT1 Immunotherapeutic GSK2302024A|Recombinant Bacterial Minicells VAX014|Recombinant Bispecific Single-Chain Antibody rM28|Recombinant CD40-Ligand|Recombinant Erwinia asparaginase JZP-458|Recombinant Erythropoietin|Recombinant Fas Ligand|Recombinant Fractalkine|Recombinant Granulocyte-Macrophage Colony-Stimulating Factor|Recombinant Human 6Ckine|Recombinant Human Adenovirus Type 5 H101|Recombinant Human Angiotensin Converting Enzyme 2 APN01|Recombinant Human Apolipoprotein(a) Kringle V MG1102|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Recombinant Human Endostatin|Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine|Recombinant Human Papillomavirus 11-valent Vaccine|Recombinant Human Papillomavirus Bivalent Vaccine|Recombinant Human Papillomavirus Nonavalent Vaccine|Recombinant Human Plasminogen Kringle 5 Domain ABT 828|Recombinant Human TRAIL-Trimer Fusion Protein SCB-313|Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301|Recombinant Interferon|Recombinant Interferon Alfa|Recombinant Interferon Alfa-1b|Recombinant Interferon Alfa-2a|Recombinant Interferon Alfa-2b|Recombinant Interferon Alpha 2b-like Protein|Recombinant Interferon Beta|Recombinant Interferon Gamma|Recombinant Interleukin-12|Recombinant Interleukin-13|Recombinant Interleukin-18|Recombinant Interleukin-2|Recombinant Interleukin-6|Recombinant KSA Glycoprotein CO17-1A|Recombinant Leukocyte Interleukin|Recombinant Leukoregulin|Recombinant Luteinizing Hormone|Recombinant MAGE-3.1 Antigen|Recombinant MIP1-alpha Variant ECI301|Recombinant Macrophage Colony-Stimulating Factor|Recombinant Modified Vaccinia Ankara-5T4 Vaccine|Recombinant Oncolytic Poliovirus PVS-RIPO|Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A|Recombinant Platelet Factor 4|Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207|Recombinant Super-compound Interferon|Recombinant Thyroglobulin|Recombinant Thyrotropin Alfa|Recombinant Transforming Growth Factor-Beta|Recombinant Transforming Growth Factor-Beta-2|Recombinant Tumor Necrosis Factor-Alpha|Recombinant Tyrosinase-Related Protein-2|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Recreational Fire Smoke Exposure|Recreational fire smoke|Rectal Anastomotic Leak|Rectal Cancer|Rectal Carcinoma|Rectal Fistula|Rectal Hemorrhage|Rectal Mucositis|Rectal Necrosis|Rectal Obstruction|Rectal Pain|Rectal Perforation|Rectal Stenosis|Rectal Ulcer|Rectosigmoid Junction|Rectosigmoid Region|Rectosigmoid junction|Rectum|Rectum Adenocarcinoma|Rectum, NOS|Recurrence|Recurrent Blood Derived Cancer - Bone Marrow|Recurrent Blood Derived Cancer - Peripheral Blood|Recurrent Disease|Recurrent Laryngeal Nerve Palsy|Recurrent Neoplasm|Recurrent Pyogenic Cholangitis|Recurrent Tumor|Red & Violet|Redaction|Redaporfin|Refametinib|Reflux Disease|Refractory Anemia|Refractory Anemia with Excess Blasts in Transformation|Refractory Cytopenia of Childhood|Refractory Neutropenia|Refractory Thrombocytopenia|Refractory anemia|Refractory anemia with excess blasts|Refractory anemia with excess blasts in transformation|Refractory anemia with ring sideroblasts associated with marked thrombocytosis|Refractory anemia with ringed sideroblasts|Refractory anemia with sideroblasts|Refractory anemia without sideroblasts|Refractory cytopenia of childhood|Refractory cytopenia with multilineage dysplasia|Refractory neutropenia|Refractory thrombocytopenia|Refused|Regional|Regional Metastasis|Regional Site|Regional or Distant Metastasis (M1)|Regorafenib|Regressing Melanoma|Regressing Nevus|Regressing nevus|Relacorilant|Related to Cancer|Relatlimab|Relugolix|Remetinostat|Renal|Renal Calculi|Renal Capsule|Renal Cell Carcinoma|Renal Cell Carcinoma Peptides Vaccine IMA901|Renal Colic|Renal Dialysis|Renal Disorder, NOS|Renal Failure (Requiring Dialysis)|Renal Hemorrhage|Renal Insufficiency|Renal Pelvis|Renal Sinus|Renal Vein|Renal and Urinary Disorders - Other|Renal carcinoma, collecting duct type|Renal cell adenocarcinoma|Renal cell carcinoma, NOS|Renal cell carcinoma, chromophobe type|Renal cell carcinoma, sarcomatoid|Renal cell carcinoma, spindle cell|Renal cell carcinoma, unclassified|Renal medullary carcinoma|Renal pelvis|Reninoma|Renomedullary fibroma|Renomedullary interstitial cell tumor|Reparixin|Repli-G|Repli-G (Qiagen) DNA|Repli-G Pooled (Qiagen) DNA|Repli-G X|Repli-G X (Qiagen) DNA|Repotrectinib|Reproductive System and Breast Disorders - Other|Rescinded|Reserve cell carcinoma|Residual Disease|Resiquimod|Resiquimod Topical Gel|Resistant Starch|Resminostat|Respiratory Failure|Respiratory, Thoracic and Mediastinal Disorders - Other|Responsive Disease|Restlessness|Restrictive Cardiomyopathy|Resveratrol|Resveratrol Formulation SRT501|Retaspimycin|Retaspimycin Hydrochloride|Rete Ovarii Adenocarcinoma|Retelliptine|Reticuloendothelial System|Reticuloendothelial system, NOS|Reticulohistiocytoma|Reticulosarcoma|Reticulosarcoma, NOS|Reticulosarcoma, diffuse|Reticulum cell sarcoma, NOS|Reticulum cell sarcoma, diffuse|Retifanlimab|Retina|Retinal Detachment|Retinal Tear|Retinal Vascular Disorder|Retinal anlage tumor|Retinoblastoma|Retinoblastoma, NOS|Retinoblastoma, differentiated|Retinoblastoma, diffuse|Retinoblastoma, spontaneously regressed|Retinoblastoma, undifferentiated|Retinocytoma|Retinoic Acid Agent Ro 16-9100|Retinoic Acid Syndrome|Retinoid 9cUAB30|Retinol|Retinopathy|Retinyl Acetate|Retinyl Palmitate|Retro-Orbital Region|Retromolar Trigone|Retromolar area|Retroperitoneal Hemorrhage|Retroperitoneal fibromatosis|Retroperitoneum|Retroperitoneum and peritoneum|Retrospective|Retrovector Encoding Mutant Anti-Cyclin G1|Reunion|Revdofilimab|Reverse Phase Protein Array|Reversible Posterior Leukoencephalopathy Syndrome|Rexinoid NRX 194204|Rezivertinib|Rhabdoid Meningioma|Rhabdoid Tumor|Rhabdoid meningioma|Rhabdoid sarcoma|Rhabdoid tumor (kidney) (RT)|Rhabdoid tumor, NOS|Rhabdomyoma|Rhabdomyoma, NOS|Rhabdomyosarcoma|Rhabdomyosarcoma with ganglionic differentiation|Rhabdomyosarcoma, NOS|Rhabdosarcoma|Rhenium Re 188 BMEDA-labeled Liposomes|Rhenium Re-186 Hydroxyethylidene Diphosphonate|Rhenium Re-188 Ethiodized Oil|Rhenium Re-188 Etidronate|Rheumatoid Arthritis|Rheumatologic Disease|Rhinitis Infective|Rhizoxin|RhoC Peptide Vaccine RV001V|Rib|Rib, sternum, clavicle and associated joints|Ribociclib|Ribociclib/Letrozole|Ribonuclease QBI-139|Ribosome-Inactivating Protein CY503|Ribozyme RPI.4610|Rice Bran|Ricolinostat|Ridaforolimus|Right|Right Hemicolectomy|Right Ventricular Dysfunction|Rigosertib|Rigosertib Sodium|Rilimogene Galvacirepvec|Rilimogene Galvacirepvec/Rilimogene Glafolivec|Rilimogene Glafolivec|Rilotumumab|Rindopepimut|Ring Finger|Ripertamab|Ripretinib|Risperidone Formulation in Rumenic Acid|Ritrosulfan|Rituximab|Rituximab Conjugate CON-4619|Rituximab and Hyaluronidase Human|Riviciclib|Rivoceranib|Rivoceranib Mesylate|Robatumumab|Roblitinib|Rocakinogene Sifuplasmid|Rocapuldencel-T|Rociletinib|Rodent ulcer|Rodorubicin|Roducitabine|Rofecoxib|Roflumilast|Rogaratinib|Rogletimide|Rolinsatamab Talirine|Romania|Romidepsin|Roneparstat|Roniciclib|Ropeginterferon Alfa-2B|Ropidoxuridine|Ropocamptide|Roquinimex|Rosabulin|Rose Bengal Solution PV-10|Rosette-Forming Glioneuronal Tumor|Rosette-forming glioneuronal tumor|Rosiglitazone Maleate|Rosmantuzumab|Rosopatamab|Rosuvastatin|Round Cell Liposarcoma|Round Ligament|Round cell carcinoma|Round cell liposarcoma|Round cell osteosarcoma|Round cell sarcoma|Round ligament|Rovalpituzumab Tesirine|Rubinstein-Taybi Syndrome|Rubitecan|Rucaparib|Rucaparib Camsylate|Rucaparib Phosphate|Run Metadata|Russia|Ruthenium Ru-106|Ruthenium-based Small Molecule Therapeutic BOLD-100|Ruthenium-based Transferrin Targeting Agent NKP-1339|Ruxolitinib|Ruxolitinib Phosphate|Ruxotemitide|Rwanda|S|S-Adenosylmethionine|S-equol|S1P Receptor Agonist KRP203|SALT lymphoma|SBIL-2|SCIEX|SCX|SD-Stable Disease|SDF-1 Receptor Antagonist PTX-9908|SDRF|SERD D-0502|SERD G1T48|SERD GDC-9545|SERD SAR439859|SERD SHR9549|SERD ZN-c5|SETTLE|SHH-Activated|SHP-1 Agonist SC-43|SHP2 Inhibitor JAB-3068|SHP2 Inhibitor RLY-1971|SHP2 Inhibitor RMC-4630|SHP2 Inhibitor TNO155|SILAC|SILAC quantitation analysis|SIRPa-4-1BBL Fusion Protein DSP107|SIRPa-Fc Fusion Protein TTI-621|SIRPa-Fc-CD40L Fusion Protein SL-172154|SIRPa-IgG4-Fc Fusion Protein TTI-622|SLC6A8 Inhibitor RGX-202|SLCT Inhibitor GNS561|SMAC Mimetic BI 891065|SMO Protein Inhibitor ZSP1602|SN-38-Loaded Polymeric Micelles NK012|SNS01-T Nanoparticles|SOLiD|SPD-Surgical Progression|SQ Detector 2|SR-BP1/HSI Inhibitor SR31747A|SR-T100 Gel|SRA XML|SRM quantitation analysis|SRPK1/ABCG2 Inhibitor SCO-101|SSTR2-targeting Protein/DM1 Conjugate PEN-221|STAR - Counts|STAR - FPKM|STAR - Smart-Seq2|STAR - Smart-Seq2 Filtered Counts|STAR - Smart-Seq2 Raw Counts|STAR 2-Pass|STAR 2-Pass Chimeric|STAR 2-Pass Genome|STAR 2-Pass Transcriptome|STAR-Fusion|STAT Inhibitor OPB-111077|STAT3 Inhibitor DSP-0337|STAT3 Inhibitor OPB-31121|STAT3 Inhibitor OPB-51602|STAT3 Inhibitor TTI-101|STAT3 Inhibitor WP1066|STING Agonist BMS-986301|STING Agonist GSK3745417|STING Agonist IMSA101|STING Agonist MK-1454|STING Agonist SB 11285|STING Agonist TAK-676|STING-activating Cyclic Dinucleotide Agonist MIW815|STING-expressing E. coli SYNB1891|SVS|SYNAPT G2-Si|Sabarubicin|Sabatolimab|Saccharomyces cerevisiae|Sacituzumab Govitecan|Sacrum|Sacubitril/Valsartan|Safingol|Sagopilone|Saint Helena, Ascension and Tristan da Cunha|Saint Kitts and Nevis|Saint Lucia|Saint Pierre and Miquelon|Saint Vincent and the Grenadines|Salirasib|Saliva|Salivary Duct Carcinoma|Salivary Duct Inflammation|Salivary Gland|Salivary Gland Basal Cell Adenocarcinoma|Salivary Gland Basal Cell Adenoma|Salivary Gland Fistula|Salivary Gland Infection|Salivary Gland Monomorphic Adenoma|Salivary duct carcinoma|Salmonella Septicemia|Salmonella VNP20009|Salpingectomy|Salpingo-oophorectomy|Sam68 Modulator CWP232291|Samalizumab|Samarium Sm 153-DOTMP|Samoa|Samotolisib|Sample Procurement|Sample compromised|Samrotamab Vedotin|Samuraciclib|San Marino|Sao Tome and Principe|Sapacitabine|Sapanisertib|Sapitinib|SarCNU|Saracatinib|Saracatinib Difumarate|Sarcoidosis|Sarcoma|Sarcoma botryoides|Sarcoma, NOS|Sarcomatoid Carcinoma|Sarcomatoid Mesothelioma|Sarcomatoid Renal Cell Carcinoma|Sarcomatoid Transitional Cell Carcinoma|Sarcomatoid carcinoma|Sarcomatoid mesothelioma|Sarcomatosis|Sarcomatosis, NOS|Sardomozide|Sargramostim|Sasanlimab|Satraplatin|Saudi Arabia|Savolitinib|Scalp|Scalp Pain|Scapula|Schizosaccharomyces pombe|Schmincke tumor|Schneiderian carcinoma|Schneiderian papilloma, NOS|Schneiderian papilloma, inverted|Schwannoma|Schwannoma, NOS|Schwannomatosis|Sciatic Nerve|Scirrhous Adenocarcinoma|Scirrhous Hepatocellular Carcinoma|Scirrhous adenocarcinoma|Scirrhous carcinoma|Scleral Disorder|Sclerosing Epithelioid Fibrosarcoma|Sclerosing Liposarcoma|Sclerosing Rhabdomyosarcoma|Sclerosing epithelioid fibrosarcoma|Sclerosing hemangioma|Sclerosing hepatic carcinoma|Sclerosing liposarcoma|Sclerosing rhabdomyosarcoma|Sclerosing stromal tumor|Sclerosing sweat duct carcinoma|Sclerosis|Scoliosis|Scopoletin|Scrotal Infection|Scrotal Pain|Scrotum|Scrotum, NOS|SeSAMe Methylation Beta Estimation|Sebaceous Adenoma|Sebaceous Carcinoma|Sebaceous adenocarcinoma|Sebaceous adenoma|Sebaceous carcinoma|Sebaceous epithelioma|Seclidemstat|Secondary Carcinoma|Secondary Neoplasm|Secondary carcinoma|Secretory Breast Carcinoma|Secretory Meningioma|Secretory carcinoma of breast|Secretory meningioma|Sedoxantrone Trihydrochloride|Seizure|Seizures|Selatinib Ditosilate|Selective Androgen Receptor Modulator RAD140|Selective Cytokine Inhibitory Drug CC-1088|Selective Estrogen Receptor Degrader AZD9496|Selective Estrogen Receptor Degrader AZD9833|Selective Estrogen Receptor Degrader LSZ102|Selective Estrogen Receptor Degrader LX-039|Selective Estrogen Receptor Degrader LY3484356|Selective Estrogen Receptor Degrader SRN-927|Selective Estrogen Receptor Modulator CC-8490|Selective Estrogen Receptor Modulator TAS-108|Selective Glucocorticoid Receptor Antagonist CORT125281|Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352|Seliciclib|Selicrelumab|Selinexor|Selitrectinib|Selonsertib|Selpercatinib|Selumetinib|Selumetinib Sulfate|Semaxanib|Seminal Vesicle|Seminoma|Seminoma with high mitotic index|Seminoma, NOS|Seminoma, anaplastic|Semuloparin|Semustine|Seneca Valley Virus-001|Senegal|Sensory Changes|Seocalcitol|Sepantronium Bromide|Sepsis|Sequencing Data|Sequencing Reads|Serabelisib|Serbia|Serclutamab Talirine|Serdemetan|Sergiolide|Seribantumab|Serine/Threonine Kinase Inhibitor CBP501|Serine/Threonine Kinase Inhibitor XL418|Seroma|Seromucinous carcinoma|Serotonin producing carcinoid|Serous Adenofibroma|Serous Cystadenocarcinoma|Serous Cystadenoma|Serous Endometrial Intraepithelial Carcinoma|Serous Surface Papillary Carcinoma|Serous Surface Papilloma|Serous Tubal Intraepithelial Carcinoma|Serous adenocarcinofibroma|Serous adenocarcinoma, NOS|Serous adenofibroma of borderline malignancy|Serous adenofibroma, NOS|Serous borderline tumor-micropapillary variant|Serous carcinoma, NOS|Serous cystadenocarcinofibroma|Serous cystadenocarcinoma, NOS|Serous cystadenofibroma of borderline malignancy|Serous cystadenofibroma, NOS|Serous cystadenoma, NOS|Serous cystadenoma, borderline malignancy|Serous cystoma|Serous endometrial intraepithelial carcinoma|Serous microcystic adenoma|Serous papillary cystic tumor of borderline malignancy|Serous surface papillary carcinoma|Serous surface papillary tumor of borderline malignancy|Serous surface papilloma|Serous tubal intraepithelial carcinoma|Serous tubal intraepithelial carcinoma (STIC)|Serous tumor, NOS, of low malignant potential|Serplulimab|Serrated adenocarcinoma|Serrated adenoma|Sertoli Cell Tumor|Sertoli cell adenoma|Sertoli cell carcinoma|Sertoli cell tumor with lipid storage|Sertoli cell tumor, NOS|Sertoli-Leydig cell tumor of intermediate differentiation|Sertoli-Leydig cell tumor, NOS|Sertoli-Leydig cell tumor, intermediate differentiation, with heterologous elements|Sertoli-Leydig cell tumor, poorly differentiated|Sertoli-Leydig cell tumor, poorly differentiated, with heterologous elements|Sertoli-Leydig cell tumor, retiform|Sertoli-Leydig cell tumor, retiform, with heterologous elements|Sertoli-Leydig cell tumor, sarcomatoid|Sertoli-Leydig cell tumor, well differentiated|Serum|Serum Amylase Increased|Serum Sickness|Sessile Serrated Adenoma/Polyp|Sessile serrated adenoma|Sessile serrated polyp|Seurat - 10x Chromium|Seurat - Smart-Seq2|Sevacizumab|Seviteronel|Sex Cord-Stromal Tumor|Sex cord tumor with annular tubules|Sex cord tumor, NOS|Sex cord-gonadal stromal tumor, NOS|Sex cord-gonadal stromal tumor, incompletely differentiated|Sex cord-gonadal stromal tumor, mixed forms|Seychelles|Sezary Syndrome|Sezary disease|Sezary syndrome|Shared Anti-Idiotype-AB-S006|Shared Anti-Idiotype-AB-S024A|Shark Cartilage|Shark Cartilage Extract AE-941|Shenqi Fuzheng Injection SQ001|Shimadzu|Shimadzu MALDI-7090|Shingles|Sho-Saiko-To|Short Chain Fatty Acid HQK-1004|Short bones of lower limb and associated joints|Short bones of upper limb and associated joints|Shoulder|Shu Yu Wan Formula|Sialadenitis|Sialoblastoma|Sialyl Tn Antigen|Sialyl Tn-KLH Vaccine|Sibling|Sibrotuzumab|Sick Sinus Syndrome|Sierra Leone|Sigmoid Colectomy|Sigmoid Colon|Sigmoid colon|Signet Ring Cell Carcinoma|Signet ring cell adenocarcinoma|Signet ring cell carcinoma|Silatecan AR-67|Silibinin|Silicon Phthalocyanine 4|Silmitasertib Sodium|Siltuximab|Simalikalactone D|Simeprevir|Simlukafusp Alfa|Simmitinib|Simotaxel|Simple Germline Variation|Simple Hysterectomy|Simple Mastectomy|Simple Nucleotide Variation|Simtuzumab|Simurosertib|Singapore|Single Cell Analysis|Sinonasal Inverted Schneiderian Papilloma|Sinonasal Oncocytic Schneiderian Papilloma|Sinonasal Schneiderian Papilloma|Sinonasal papilloma, NOS|Sinonasal papilloma, exophytic|Sinonasal papilloma, fungiform|Sintilimab|Sinus|Sinus Bradycardia|Sinus Disorder|Sinus Pain|Sinus Tachycardia|Sinus(es), Maxillary|Sinusitis|Siplizumab|Sipuleucel-T|Siremadlin|Sirolimus|Sister|Sister-in-law|Sitimagene Ceradenovec|Sitravatinib|Sivifene|Six Weeks or More|Sizofiran|Sjogren's Syndrome|Skeletal Muscle|Skin|Skin Adenoid Basal Cell Carcinoma|Skin Appendage Adenoma|Skin Atrophy|Skin Basal Cell Carcinoma|Skin Basal Cell Carcinoma with Sebaceous Differentiation|Skin Basosquamous Cell Carcinoma|Skin Cancer|Skin Cutaneous Melanoma|Skin Fibroepithelial Basal Cell Carcinoma|Skin Fibrous Histiocytoma|Skin Hyperpigmentation|Skin Hypopigmentation|Skin Induration|Skin Infection|Skin Infiltrating Basal Cell Carcinoma|Skin Metatypical Carcinoma|Skin Micronodular Basal Cell Carcinoma|Skin Nodular Basal Cell Carcinoma|Skin Nodulo-Ulcerative Basal Cell Carcinoma|Skin Pigmented Basal Cell Carcinoma|Skin Rash|Skin Sclerosing/Morphoeic Basal Cell Carcinoma|Skin Ulceration|Skin and Subcutaneous Tissue Disorders - Other|Skin appendage adenoma|Skin appendage carcinoma|Skin appendage tumor, benign|Skin of lip, NOS|Skin of lower limb and hip|Skin of other and unspecified parts of face|Skin of scalp and neck|Skin of the Face|Skin of the Lower Limb and Hip|Skin of the Scalp and Neck|Skin of the Upper Limb and Shoulder|Skin of trunk|Skin of upper limb and shoulder|Skin, NOS|Skin, lower extremity, local|Skin, total|Skin, trunk, local|Skin, upper extremity, local|Skin-associated lymphoid tissue lymphoma|Skull|Sleep Apnea|Sleep apnea|Slide Image|Slides|Slovakia|Slovenia|Smac Mimetic GDC-0152|Smac Mimetic GDC-0917|Smac Mimetic LCL161|Small Bowel|Small Bowel - Mucosa Only|Small Cell Carcinoma|Small Cell Carcinoma, Fusiform Cell Type|Small Cell Intermediate Cell Carcinoma|Small Cell Osteosarcoma|Small Cell Sarcoma|Small Finger|Small Intestinal Anastomotic Leak|Small Intestinal Mucositis|Small Intestinal Obstruction|Small Intestinal Perforation|Small Intestinal Stenosis|Small Intestine|Small Intestine Infection|Small Intestine Ulcer|Small Lymphocytic Lymphoma|Small cell carcinoma pulmonary type|Small cell carcinoma, NOS|Small cell carcinoma, fusiform cell|Small cell carcinoma, hypercalcemic type|Small cell carcinoma, intermediate cell|Small cell neuroendocrine carcinoma|Small cell osteosarcoma|Small cell sarcoma|Small congenital nevus|Small intestine|Small intestine, NOS|Smoke|Smoke Exposure|Smoke exposure, NOS|Smokehouse Smoke Exposure|Smokehouse smoke|Smokeless Tobacco|Smoking|Smooth Muscle Neoplasm|Smooth muscle tumor of uncertain malignant potential|Smooth muscle tumor, NOS|Smoothened Antagonist BMS-833923|Smoothened Antagonist LDE225 Topical|Smoothened Antagonist LEQ506|Smoothened Antagonist TAK-441|Snap Frozen|Sneezing|Sobuzoxane|Social Circumstances - Other|Social Security Death Index|Sodium Borocaptate|Sodium Butyrate|Sodium Dichloroacetate|Sodium Fluoride|Sodium Iodide I-131|Sodium Metaarsenite|Sodium Phenylbutyrate|Sodium Salicylate|Sodium Selenite|Sodium Stibogluconate|Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108|Sofituzumab Vedotin|Soft Tissue|Soft Tissue Infection|Soft Tissue Necrosis Lower Limb|Soft Tissue Necrosis Upper Limb|Soft Tissue Perineurioma|Soft Tissue Sarcoma|Soft Tissue Tumors and Sarcomas, NOS|Soft palate, NOS|Soft tissue perineurioma|Soft tissue sarcoma|Soft tissue sarcoma, non-rhabdomyosarcoma|Soft tissue tumor, benign|Soft tissue tumor, malignant|Solid Carcinoma|Solid Papillary Breast Carcinoma|Solid Tissue|Solid Tissue Normal|Solid adenocarcinoma with mucin formation|Solid and cystic tumor|Solid and papillary epithelial neoplasm|Solid carcinoma with mucin formation|Solid carcinoma, NOS|Solid papillary carcinoma in situ|Solid papillary carcinoma with invasion|Solid pseudopapillary carcinoma|Solid pseudopapillary tumor|Solid teratoma|Solitary Fibrous Tumor|Solitary Mastocytoma of the Skin|Solitary Osseous Plasmacytoma|Solitary Plasmacytoma|Solitary Reticulohistiocytoma|Solitary fibrous tumor|Solitary fibrous tumor, malignant|Solitary fibrous tumor/hemangiopericytoma Grade 1 (CNS)|Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS)|Solitary fibrous tumor/hemangiopericytoma Grade 3 (CNS)|Solitary mastocytoma of skin|Solitary myeloma|Solitary plasmacytoma|Solitomab|Solomon Islands|Somalia|Somatic Mutation Index|Somatic Structural Variation|SomaticSniper|SomaticSniper Annotation|SomaticSniper Variant Aggregation and Masking|Somatostatin cell tumor, NOS|Somatostatin cell tumor, malignant|Somatostatin-Producing Neuroendocrine Tumor|Somatostatinoma, NOS|Somatostatinoma, malignant|Some Days|Some days|Somnolence|Son|Son-in-law|Sonepcizumab|Sonidegib|Sonolisib|Sorafenib|Sorafenib Tosylate|Sore Throat|Sorghum bicolor Supplement|Sorted Cells|Sotigalimab|Sotorasib|Sotrastaurin|Sotrastaurin Acetate|South Africa|South Korea|South Sudan|Soy Isoflavones|Soy Protein Isolate|Spain|Spanlecortemlocel|Sparfosate Sodium|Sparfosic Acid|Spartalizumab|Spasticity|Spebrutinib|Specialized Gonadal Neoplasms|Specified parts of peritoneum|Spectral counting analysis|Spermatic Cord Anastomotic Leak|Spermatic Cord Hemorrhage|Spermatic Cord Obstruction|Spermatic cord|Spermatocytic seminoma|Spermatocytoma|Sphenoid sinus|Spherical Nucleic Acid Nanoparticle NU-0129|Spinal Column|Spinal Cord|Spinal Fracture|Spinal Muscular Atrophy|Spinal cord|Spinal cord, cranial nerves, and other parts of central nervous system|Spinal meninges|Spindle Cell Hemangioma|Spindle Cell Lipoma|Spindle Cell Melanoma|Spindle Cell Oncocytoma|Spindle Cell Rhabdomyosarcoma|Spindle Cell Sarcoma|Spindle Cell Squamous Cell Carcinoma|Spindle Cell Synovial Sarcoma|Spindle cell angioendothelioma|Spindle cell carcinoma, NOS|Spindle cell hemangioendothelioma|Spindle cell lipoma|Spindle cell melanoma, NOS|Spindle cell melanoma, type A|Spindle cell melanoma, type B|Spindle cell nevus, NOS|Spindle cell oncocytoma|Spindle cell rhabdomyosarcoma|Spindle cell sarcoma|Spindle epithelial tumor with thymus-like differentiation|Spindle epithelial tumor with thymus-like element|Spindle-Cell Predominant Trichodiscoma|Spindled mesothelioma|Spine|Spiradenocarcinoma|Spiradenoma|Spiradenoma, NOS|Spirogermanium|Spiromustine|Spiroplatin|Spitz Nevus|Spitz nevus|Spleen|Spleen Cancer|Spleen Disorder|Splenic B-Cell Lymphoma/Leukemia, Unclassifiable|Splenic B-cell lymphoma/leukemia, unclassifiable|Splenic Diffuse Red Pulp Small B-Cell Lymphoma|Splenic Flexure|Splenic Infection|Splenic Marginal Zone Lymphoma|Splenic diffuse red pulp small B-cell lymphoma|Splenic flexure of colon|Splenic lymphoma with villous lymphocytes|Splenic marginal zone B-cell lymphoma|Splenic marginal zone lymphoma, NOS|Splice Junction Quantification|Splicing Inhibitor H3B-8800|Spongioblastoma multiforme|Spongioblastoma polare|Spongioblastoma, NOS|Spongioneuroblastoma|Spongistatin|Spontaneous Descent|Spontaneously Regressing Retinoblastoma|Sporadic Burkitt Lymphoma|Sporadic, adult|Sporadic, pediatric|Spouse|Sputum|Squalamine Lactate|Squamotransitional cell carcinoma|Squamous Cell Carcinoma|Squamous Cell Carcinoma In Situ with Questionable Stromal Invasion|Squamous Cell Carcinoma with Horn Formation|Squamous Cell Carcinoma, Clear Cell Type|Squamous Cell Neoplasms|Squamous Cell Papilloma|Squamous Metaplasia|Squamous Odontogenic Tumor|Squamous Papillomatosis|Squamous carcinoma|Squamous cell carcinoma in situ with questionable stromal invasion|Squamous cell carcinoma in situ, NOS|Squamous cell carcinoma with horn formation|Squamous cell carcinoma, HPV-negative|Squamous cell carcinoma, HPV-positive|Squamous cell carcinoma, NOS|Squamous cell carcinoma, acantholytic|Squamous cell carcinoma, adenoid|Squamous cell carcinoma, clear cell type|Squamous cell carcinoma, keratinizing, NOS|Squamous cell carcinoma, large cell, keratinizing|Squamous cell carcinoma, large cell, nonkeratinizing, NOS|Squamous cell carcinoma, metastatic, NOS|Squamous cell carcinoma, microinvasive|Squamous cell carcinoma, nonkeratinizing, NOS|Squamous cell carcinoma, pseudoglandular|Squamous cell carcinoma, sarcomatoid|Squamous cell carcinoma, small cell, nonkeratinizing|Squamous cell carcinoma, spindle cell|Squamous cell epithelioma|Squamous cell papilloma, NOS|Squamous cell papilloma, inverted|Squamous intraepithelial neoplasia, grade I|Squamous intraepithelial neoplasia, grade II|Squamous intraepithelial neoplasia, grade III|Squamous intraepithelial neoplasia, high grade|Squamous intraepithelial neoplasia, low grade|Squamous odontogenic tumor|Squamous papilloma|Squamous papillomatosis|Src Kinase Inhibitor AP 23846|Src Kinase Inhibitor KX2-391|Src Kinase Inhibitor KX2-391 Ointment|Src Kinase Inhibitor M475271|Src/Abl Kinase Inhibitor AZD0424|Src/tubulin Inhibitor KX02|Sri Lanka|St. John's Wort|Stable Disease|Stage 0|Stage 0 Cervical Cancer AJCC v6|Stage 0 Cutaneous Melanoma AJCC v6 and v7|Stage 0 Squamous Cell Carcinoma|Stage 0 Transitional Cell Carcinoma|Stage 0 Vaginal Cancer AJCC v6|Stage 0 Vaginal Cancer AJCC v7|Stage 0 Vulvar Cancer AJCC v6|Stage 0a|Stage 0is|Stage 1|Stage 2A|Stage 2B|Stage 3|Stage 4|Stage 4S|Stage I|Stage IA|Stage IA1|Stage IA2|Stage IA3|Stage IB|Stage IB Cervix|Stage IB1|Stage IB2|Stage IC|Stage IC1|Stage IC2|Stage IC3|Stage II|Stage II Cervix|Stage IIA|Stage IIA Cervix|Stage IIA1|Stage IIA2|Stage IIB|Stage IIC|Stage IIC1|Stage III|Stage IIIA|Stage IIIA1|Stage IIIA2|Stage IIIAi|Stage IIIAii|Stage IIIB|Stage IIIC|Stage IIIC1|Stage IIIC2|Stage IIID|Stage IIa|Stage IIb|Stage IS|Stage IV|Stage IVA|Stage IVB|Stage IVC|Stage IVa|Stage IVb|Stage Is|Stage R1|Stage R2|Stage Tis|Stage X|Stallimycin|Staphylococcal Enterotoxin A|Staphylococcal Enterotoxin B|Staphylococcus aureus|State of Palestine|Staurosporine|Steatosis|Stem Cell Transplantation, Allogeneic|Stem Cell Transplantation, Autologous|Stem Cell Transplantation, Double Autologous|Stem Cell Transplantation, Haploidentical|Stem Cell Transplantation, NOS|Stem Cell Transplantation, Non-Myeloablative|Stem Cell Transplantation, Syngenic|Stem Cell Treatment|Stem cell leukemia|Stenosis of Gastrointestinal Stoma|Step Child|Step Father|Step Sibling|Stepbrother|Stepdaughter|Stepfather|Stepmother|Stepsister|Stepson|Stereotactic Radiosurgery|Sternum|Steroid Therapy|Steroid cell tumor, NOS|Steroid cell tumor, malignant|Stevens-Johnson Syndrome|Stillbirth|Stoma Site Infection|Stomach|Stomach - Mucosa Only|Stomach Adenocarcinoma|Stomach Pain|Stomach, NOS|Stomal Ulcer|Strelka2 RNA|Streptonigrin|Streptozocin|Stridor|Stroke|Stromal Neoplasm|Stromal Sarcoma|Stromal endometriosis|Stromal myosis, NOS|Stromal sarcoma, NOS|Stromal tumor with minor sex cord elements|Stromal tumor, NOS|Stromal tumor, benign|Strontium Chloride Sr-89|Structural Alteration|Structural Rearrangement|Structural Variation|Struma Ovarii|Struma ovarii and carcinoid|Struma ovarii, NOS|Struma ovarii, malignant|Strumal Carcinoid|Strumal carcinoid|Study Enrollment|Subacute granulocytic leukemia|Subacute leukemia, NOS|Subacute lymphatic leukemia|Subacute lymphocytic leukemia|Subacute lymphoid leukemia|Subacute monocytic leukemia|Subacute myelogenous leukemia|Subacute myeloid leukemia|Subareolar duct papillomatosis|Subcutaneous Panniculitis-Like T-Cell Lymphoma|Subcutaneous Tissue|Subcutaneous panniculitis-like T-cell lymphoma|Subependymal Giant Cell Astrocytoma|Subependymal astrocytoma, NOS|Subependymal giant cell astrocytoma|Subependymal glioma|Subependymoma|Subepidermal Nodular Fibrosis|Subepidermal nodular fibrosis|Subglottis|Subject identity unknown|Subject withdrew consent|Sublingual Gland|Sublingual gland|Submandibular Gland|Submandibular gland|Submicron Particle Paclitaxel Sterile Suspension|Subtotal Prostatectomy|Subtotal Resection|Succinate Dehydrogenase-Deficient Renal Cell Carcinoma|Sudan|Sudden Death NOS|Sugemalimab|Suicidal Ideation|Suicide Attempt|Sulfatinib|Sulfonylurea|Sulforaphane|Sulindac|Sulofenur|Sumoylation Inhibitor TAK-981|Sunitinib|Sunitinib Malate|Super Enhancer Inhibitor GZ17-6.02|Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803|Superficial Multifocal Basal Cell Carcinoma|Superficial Parotidectomy|Superficial Soft Tissue Fibrosis|Superficial Spreading Adenocarcinoma|Superficial Thrombophlebitis|Superficial spreading adenocarcinoma|Superficial spreading melanoma|Superficial well differentiated liposarcoma|Superior Vena Cava Syndrome|Superior Wall of the Nasopharynx|Superior wall of nasopharynx|Superoxide Dismutase Mimetic GC4711|Supplementary Files|Supracervical Hysterectomy|Supracricoid Laryngectomy|Supraglottic Laryngectomy|Supraglottis|Supratentorial Embryonal Tumor, Not Otherwise Specified|Supratentorial PNET|Supraventricular Tachycardia|Suramin|Suramin Sodium|Surgery|Surgical Complication|Surgical Complications|Surgical Resection|Surgical and Medical Procedures - Other|Surgically Treated|Suriname|Surveyor PDA|Survivin Antigen|Survivin Antigen Vaccine DPX-Survivac|Survivin mRNA Antagonist EZN-3042|Survivin-expressing CVD908ssb-TXSVN Vaccine|Sus scrofa|Sustained-release Lipid Inhaled Cisplatin|Sustained-release Mitomycin C Hydrogel Formulation UGN-101|Sustained-release Mitomycin C Hydrogel Formulation UGN-102|Svalbard & Jan Mayen Islands|Svalbard and Jan Mayen|Sweat Gland Adenoma|Sweat Gland Carcinoma|Sweat Gland Neoplasm|Sweat gland adenocarcinoma|Sweat gland adenoma|Sweat gland carcinoma|Sweat gland tumor, NOS|Sweat gland tumor, benign|Sweat gland tumor, malignant|Sweden|Switzerland|Syk Inhibitor HMPL-523|SymBiot I|SymBiot XVI|Sympathetic Paraganglioma|Sympathetic paraganglioma|Sympathicoblastoma|Symplastic leiomyoma|Synapt G2 HDMS|Synapt G2 MS|Synapt G2-S HDMS|Synapt G2-S MS|Synapt HDMS|Synapt MS|Synchronous malignancy|Synchrotope TA2M Plasmid DNA Vaccine|Synchrovax SEM Plasmid DNA Vaccine|Syncope|Syncytial meningioma|Synovial Sarcoma|Synovial sarcoma, NOS|Synovial sarcoma, biphasic|Synovial sarcoma, epithelioid cell|Synovial sarcoma, monophasic fibrous|Synovial sarcoma, spindle cell|Synovial-like Neoplasms|Synovioma, NOS|Synovioma, benign|Synovioma, malignant|Synovium|Synthetic Alkaloid PM00104|Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2|Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1|Synthetic Hypericin|Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201|Synthetic Long E6/E7 Peptides Vaccine HPV-01|Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b|Synthetic Plumbagin PCUR-101|Synthetic hTERT DNA Vaccine INO-1400|Synthetic hTERT DNA Vaccine INO-1401|Syphilis|Syria|Syringadenoma, NOS|Syringocystadenoma Papilliferum|Syringocystadenoma papilliferum|Syringofibroadenoma|Syringoma|Syringoma, NOS|Syringomatous carcinoma|Systemic EBV positive T-cell lymphoproliferative disease of childhood|Systemic EBV-Positive T-Cell Lymphoma of Childhood|Systemic Mastocytosis|Systemic Mastocytosis with an Associated Hematological Neoplasm|Systemic light chain disease|Systemic mastocytosis with AHNMD|Systemic mastocytosis with associated hematological clonal non-mast cell disorder|Systemic tissue mast cell disease|T|T Acute Lymphoblastic Leukemia|T Lymphoblastic Leukemia/Lymphoma|T Lymphoblastic Lymphoma|T lymphoblastic leukemia/lymphoma|T-Cell Large Granular Lymphocyte Leukemia|T-Cell Non-Hodgkin Lymphoma|T-Cell Prolymphocytic Leukemia|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|T-Zone Variant Peripheral T-Cell Lymphoma|T-cell large granular lymphocytic leukemia|T-cell large granular lymphocytosis|T-cell lymphoma, NOS|T-cell rich large B-cell lymphoma|T-cell rich/histiocyte-rich large B-cell lymphoma|T-gamma lymphoproliferative disease|T-zone lymphoma|T/NK-cell lymphoma|T0|T0 Stage Finding|T1|T1 Stage Finding|T1a|T1a Stage Finding|T1a1|T1a2|T1b|T1b Stage Finding|T1b1|T1b2|T1c|T1c Stage Finding|T1mi|T1mi Stage Finding|T2|T2 Stage Finding|T2a|T2a Stage Finding|T2a1|T2a2|T2b|T2b Stage Finding|T2c|T2c Stage Finding|T2d|T2d Stage Finding|T3|T3 Stage Finding|T3a|T3a Stage Finding|T3b|T3b Stage Finding|T3c|T3c Stage Finding|T3d|T3d Stage Finding|T4|T4 Stage Finding|T4a|T4a Stage Finding|T4b|T4b Stage Finding|T4c|T4c Stage Finding|T4d|T4d Stage Finding|T4e|T900607|TAM/c-Met Inhibitor RXDX-106|TARGET DCC Archive|TARGZ|TBI|TCGA DCC Archive|TE-Too Early|TF-Tumor Free|TGF-beta Receptor 1 Inhibitor PF-06952229|TGF-beta Receptor 1 Kinase Inhibitor SH3051|TGF-beta Receptor 1 Kinase Inhibitor YL-13027|TGFa-PE38 Immunotoxin|TGFbeta Inhibitor LY3200882|TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein AVID200|THL-P|TIFF|TIGIT Inhibitor M6223|TIGIT-targeting Agent MK-7684|TLC ELL-12|TLR Agonist BDB001|TLR Agonist BSG-001|TLR Agonist CADI-05|TLR-Directed Cationic Lipid-DNA Complex JVRS-100|TLR7 Agonist 852A|TLR7 Agonist LHC165|TLR7 agonist BNT411|TLR7/8/9 Antagonist IMO-8400|TLR8 Agonist DN1508052|TLR9 Agonist AST-008|TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells|TMT|TMT10|TMT11|TMT6|TORC1/2 Kinase Inhibitor DS-3078a|TP40 Immunotoxin|TRAIL Receptor Agonist ABBV-621|TRIZAIC UPLC nanoTile|TRK Inhibitor AZD6918|TRK Inhibitor TQB3558|TRPM8 Agonist D-3263|TRPV6 Calcium Channel Inhibitor SOR-C13|TSP-1 Mimetic ABT-510|TSP-1 Mimetic Fusion Protein CVX-045|TSQ 8000 Evo|TSQ 9000|TSQ Altis|TSQ Endura|TSQ Quantis|TSQ Quantiva|TSQ Quantum|TSQ Quantum Access|TSQ Quantum Ultra|TSQ Quantum Ultra AM|TSQ Vantage|TSV|TX|TX Stage Finding|TXT|Ta|Ta Stage Finding|Tabalumab|Tabelecleucel|Tacedinaline|Tafasitamab|Tag|Tagraxofusp-erzs|Tail of pancreas|Taiwan|Tajikistan|Takifugu rubripes|Talabostat|Talabostat Mesylate|Talacotuzumab|Talactoferrin Alfa|Taladegib|Talampanel|Talaporfin Sodium|Talazoparib|Taletrectinib|Talimogene Laherparepvec|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Tallimustine|Talmapimod|Talotrexin|Talotrexin Ammonium|Taltobulin|Tamibarotene|Taminadenant|Tamoxifen|Tamoxifen Citrate|Tamrintamab Pamozirine|Tandutinib|Tanespimycin|Tanibirumab|Tankyrase Inhibitor STP1002|Tanomastat|Tanycytic Ependymoma|Tanycytic ependymoma|Tanzania|Tapotoclax|Tarenflurbil|Tarextumab|Targeted Molecular Therapy|Tariquidar|Tasadenoturev|Taselisib|Tasidotin|Tasisulam|Tasisulam Sodium|Tasquinimod|Tattoo|Taurolidine|Tauromustine|Taurultam|Taurultam Analogue GP-2250|Tavokinogene Telseplasmid|Tavolimab|Taxane Analogue TPI 287|Taxane Compound|Taxol Analogue SID 530|Tazarotene|Tazemetostat|Tebentafusp|Teclistamab|Tecogalan Sodium|Tefinostat|Tegafur|Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation|Tegafur-Uracil|Tegafur-gimeracil-oteracil Potassium|Tegavivint|Teglarinad|Teglarinad Chloride|Telaglenastat|Telaglenastat Hydrochloride|Telangiectasia|Telangiectatic Osteosarcoma|Telangiectatic osteosarcoma|Telapristone|Telapristone Acetate|Telatinib Mesylate|Telisotuzumab|Telisotuzumab Vedotin|Telomerase Inhibitor FJ5002|Telomerase-specific Type 5 Adenovirus OBP-301|Teloxantrone|Teloxantrone Hydrochloride|Telratolimod|Temarotene|Temoporfin|Temozolomide|Temporal Cortex|Temporal Lobe|Temporal lobe|Temsirolimus|Tenalisib|Tendon|Tenifatecan|Teniposide|Tenosynovial Giant Cell Tumor|Tenosynovial giant cell tumor|Tepoditamab|Tepotinib|Teprotumumab|Terameprocol|Teratoblastoma, malignant|Teratocarcinoma|Teratoid medulloepithelioma|Teratoid medulloepithelioma, benign|Teratoma|Teratoma with Somatic-Type Malignancy|Teratoma with malignant transformation|Teratoma, NOS|Teratoma, benign|Teratoma, differentiated|Teratoma, malignant, NOS|Terfluranol|Tergenpumatucel-L|Terminal duct adenocarcinoma|Teroxirone|Tertomotide|Tesetaxel|Tesevatinib|Tesidolumab|Testicular Cancer|Testicular Disorder|Testicular Germ Cell Tumors|Testicular Hemorrhage|Testicular Mixed Germ Cell-Sex Cord-Stromal Tumor, Unclassified|Testicular Pain|Testicular Seminoma with High Mitotic Index|Testicular Spermatocytic Tumor|Testicular adenoma|Testicular stromal tumor|Testis|Testis Removed|Testis, NOS|Testolactone|Testosterone Enanthate|Tetanus Toxoid Vaccine|Tetradecanoylphorbol Acetate|Tetrahydrouridine|Tetraphenyl Chlorin Disulfonate|Tetrathiomolybdate|Tezacitabine|Tezacitabine Anhydrous|Thailand|Thalicarpine|Thalidomide|Theca cell tumor|Theca cell-granulosa cell tumor|Thecoma|Thecoma, NOS|Thecoma, luteinized|Thecoma, malignant|Theliatinib|Theramide|Therapeutic Angiotensin-(1-7)|Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907|Therapeutic Cancer Vaccine ATP128|Therapeutic Estradiol|Therapeutic Hydrocortisone|Therapeutic Liver Cancer Peptide Vaccine IMA970A|Therapy related myeloid neoplasm|Therapy-Related Acute Myeloid Leukemia|Therapy-Related Myelodysplastic Syndrome|Therapy-Related Myeloid Neoplasm|Therapy-related acute myeloid leukemia, NOS|Therapy-related acute myeloid leukemia, alkylating agent related|Therapy-related acute myeloid leukemia, epipodophyllotoxin-related|Therapy-related myelodysplastic syndrome, NOS|Therapy-related myelodysplastic syndrome, alkylating agent related|Therapy-related myelodysplastic syndrome, epipodophyllotoxin-related|Thermo Fisher Scientific|Thermo Orbitrap Fusion Lumos|Thermo Orbitrap Q Exactive HF-X|Thiarabine|Thiazolidinedione|Thigh|Thiodiglycol|Thioguanine|Thioguanine Anhydrous|Thioinosine|Thioredoxin-1 Inhibitor PX-12|Thiotepa|Thioureidobutyronitrile|Thoracentesis|Thoracic Esophagus|Thoracic Spine|Thoracic esophagus|Thoracoscopic Biopsy|Thorax|Thorax, NOS|Thorium Th 227 Anetumab|Thorium Th 227 Anetumab Corixetan|Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439|Thorium Th 227 Anti-PSMA Monoclonal Antibody BAY 2315497|Three Times Daily|Threonine Tyrosine Kinase Inhibitor CFI-402257|Throat|Throat Cancer|Throat Carcinoma|Thromboembolic Event|Thrombotic Thrombocytopenic Purpura|Thumb|Thymic Carcinoma|Thymic Epithelial Neoplasms|Thymic carcinoma with adenoid cystic carcinoma-like features|Thymic carcinoma, NOS|Thymic large B-cell lymphoma|Thymidylate Synthase Inhibitor CX1106|Thymidylate Synthase Inhibitor DFP-11207|Thymoma|Thymoma Type A|Thymoma Type AB|Thymoma Type B1|Thymoma Type B2|Thymoma Type B3|Thymoma, NOS|Thymoma, atypical, NOS|Thymoma, atypical, malignant|Thymoma, benign|Thymoma, cortical, NOS|Thymoma, cortical, malignant|Thymoma, epithelial, NOS|Thymoma, epithelial, malignant|Thymoma, lymphocyte-rich, NOS|Thymoma, lymphocyte-rich, malignant|Thymoma, lymphocytic, NOS|Thymoma, lymphocytic, malignant|Thymoma, malignant, NOS|Thymoma, medullary, NOS|Thymoma, medullary, malignant|Thymoma, mixed type, NOS|Thymoma, mixed type, malignant|Thymoma, organoid, NOS|Thymoma, organoid, malignant|Thymoma, predominantly cortical, NOS|Thymoma, predominantly cortical, malignant|Thymoma, spindle cell, NOS|Thymoma, spindle cell, malignant|Thymoma, type A, NOS|Thymoma, type A, malignant|Thymoma, type AB, NOS|Thymoma, type AB, malignant|Thymoma, type B1, NOS|Thymoma, type B1, malignant|Thymoma, type B2, NOS|Thymoma, type B2, malignant|Thymoma, type B3, NOS|Thymoma, type B3, malignant|Thymoma, type C|Thymopentin|Thymus|Thyroid|Thyroid Cancer|Thyroid Carcinoma|Thyroid Extract|Thyroid Gland|Thyroid Gland Carcinoma|Thyroid Gland Follicular Adenoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Follicular Carcinoma, Encapsulated Angioinvasive|Thyroid Gland Hurthle (Oncocytic) Cell Neoplasm|Thyroid Gland Hurthle Cell Adenoma|Thyroid Gland Hyalinizing Trabecular Tumor|Thyroid Gland Macrofollicular Adenoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Medullary Carcinoma with Amyloid Stroma|Thyroid Gland Microfollicular Adenoma|Thyroid Gland Noninvasive Follicular Neoplasm with Papillary-Like Nuclear Features|Thyroid Gland Papillary Carcinoma|Thyroid Gland Papillary and Follicular Carcinoma|Thyroid Gland Spindle Cell Tumor with Thymus-Like Differentiation|Thyroid Gland Well-Differentiated Tumor of Uncertain Malignant Potential|Thyroid Nodular Hyperplasia|Thyroid gland|Tiazofurin|Tibia|Tibial Adamantinoma|Tibial adamantinoma|Tidutamab|Tigapotide|Tigatuzumab|Tilarginine|Tilogotamab|Tilsotolimod Sodium|Time Between Waking and First Smoke - After 60 Minutes|Time Between Waking and First Smoke - Between 31 and 60 Minutes|Time Between Waking and First Smoke - Between 6 and 30 Minutes|Time Between Waking and First Smoke - Within 5 Minutes|Timonacic|Timor-Leste|Tin Ethyl Etiopurpurin|Tinnitus|Tinostamustine|Tinzaparin Sodium|Tiomolibdate Choline|Tiomolibdate Diammonium|Tipapkinogene Sovacivec|Tipifarnib|Tipiracil|Tipiracil Hydrochloride|Tirabrutinib|Tiragolumab|Tirapazamine|Tirbanibulin|Tis|Tis (DCIS)|Tis (LCIS)|Tis (Paget's)|Tis Stage Finding|Tisagenlecleucel|Tislelizumab|Tisotumab Vedotin|Tissue Microarray Image|Tissue Slide|Tivantinib|Tivozanib|Tobacco|Tobacco Pipe Smoke Exposure|Tobacco smoke, NOS|Tobacco smoke, cigar|Tobacco smoke, cigarettes|Tobacco smoke, pipe|Tobacco, NOS|Tobacco, Smokeless|Tobacco, Smoking|Tocilizumab|Tocladesine|Tocotrienol|Tocotrienol-rich Fraction|TofSpec|TofSpec 2E|TofSpec E|TofSpec SE|Togo|Tokelau|Tolebrutinib|Toll-like Receptor 7 Agonist DSP-0509|Tolnidamine|Tomaralimab|Tomato-Soy Juice|Tomivosertib|Tonga|Tongue|Tongue Cancer|Tongue Carcinoma|Tongue, NOS|Tonsil|Tonsil (Pharyngeal)|Tonsil, NOS|Tonsillar Cancer|Tonsillar Carcinoma|Tonsillar Fossa|Tonsillar fossa|Tonsillar pillar|Tonsillectomy|Tooth Development Disorder|Tooth Discoloration|Tooth Infection|Toothache|Topical Betulinic Acid|Topical Celecoxib|Topical Fluorouracil|Topical Gemcitabine Hydrochloride|Topical Potassium Dobesilate|Topical Trichloroacetic Acid|Topixantrone|Topoisomerase I Inhibitor Genz-644282|Topoisomerase I Inhibitor LMP400|Topoisomerase I Inhibitor LMP776|Topoisomerase I/II Inhibitor NEV-801|Topoisomerase-1 Inhibitor LMP744|Topoisomerase-II Inhibitor Racemic XK469|Topoisomerase-II-beta Inhibitor Racemic XK469|Topotecan|Topotecan Hydrochloride|Topotecan Hydrochloride Liposomes|Topotecan Sustained-release Episcleral Plaque|Topsalysin|Toremifene|Toremifene Citrate|Toripalimab|Tosedostat|Tositumomab|Total Androgen Blockade|Total Colectomy|Total Hepatectomy|Total Laryngectomy|Total Mastectomy|Total Nephrectomy|Total RNA|Total RNA-Seq|Tovetumab|Toxic Epidermal Necrolysis|Toxicity|Toxoplasmosis|Tozasertib Lactate|Trabectedin|Trabecular Adenocarcinoma|Trabecular Adenoma|Trabecular adenocarcinoma|Trabecular adenoma|Trabecular carcinoma|Trabedersen|Trachea|Trachea / Major Bronchi|Tracheal Fistula|Tracheal Hemorrhage|Tracheal Mucositis|Tracheal Obstruction|Tracheal Stenosis|Tracheitis|Tracheostomy Site Bleeding|Traditional Serrated Adenoma|Traditional serrated adenoma|Traditional sessile serrated adenoma|Trametinib|Trametinib Dimethyl Sulfoxide|Trans Sodium Crocetinate|Transcript Fusion|Transcriptome Profiling|Transdermal 17beta-Estradiol Gel BHR-200|Transdermal 4-Hydroxytestosterone|Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01|Transferrin Receptor-Targeted Liposomal p53 cDNA|Transferrin-CRM107|Transfusion Recipient|Transient Abnormal Myelopoiesis Associated with Down Syndrome|Transient Ischemic Attack|Transient Ischemic Attacks|Transient abnormal myelopoiesis|Transitional Cell Carcinoma|Transitional Cell Papilloma|Transitional Cell Papillomas and Carcinomas|Transitional Meningioma|Transitional carcinoma|Transitional cell carcinoma|Transitional cell carcinoma in situ|Transitional cell carcinoma, micropapillary|Transitional cell carcinoma, sarcomatoid|Transitional cell carcinoma, spindle cell|Transitional cell papilloma, NOS|Transitional cell papilloma, benign|Transitional cell papilloma, inverted, NOS|Transitional cell papilloma, inverted, benign|Transitional meningioma|Transitional papilloma|Transitional papilloma, inverted, NOS|Transitional papilloma, inverted, benign|Transitional pineal tumor|Transoral Laser Excision|Transplant|Transurethral Resection (TURP)|Transurethral resection (TURBT)|Transverse Colectomy|Transverse Colon|Transverse colon|Tranylcypromine Sulfate|Trapoxin|Trastuzumab|Trastuzumab Conjugate BI-CON-02|Trastuzumab Deruxtecan|Trastuzumab Duocarmazine|Trastuzumab Emtansine|Trastuzumab Monomethyl Auristatin F|Trastuzumab-TLR 7/8 Agonist BDC-1001|Trastuzumab/Hyaluronidase-oysk|Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502|Treatment Ongoing|Treatment Related Secondary Malignancy|Treatment Stopped Due to Toxicity|Trebananib|Tremelimumab|Tremor|Treosulfan|Treponema pallidum|Tretazicar|Tretinoin|Tretinoin Liposome|Triamcinolone Acetonide|Triamcinolone Hexacetonide|Triapine|Triazene Derivative CB10-277|Triazene Derivative TriN2755|Triazinate|Triaziquone|Tributyrin|Trichilemmal Carcinoma|Trichilemmal carcinoma|Trichilemmocarcinoma|Trichilemmoma|Trichoblastoma|Trichodiscoma|Trichoepithelioma|Trichofolliculoma|Trichomonas vaginalis|Triciribine Phosphate|Tricuspid Valve Disease|Trientine Hydrochloride|Triethylenemelamine|Trifluridine|Trifluridine and Tipiracil Hydrochloride|Trigeminal Nerve Disorder|Trigone of bladder|Trigriluzole|Trilaciclib|Trimelamol|Trimeric GITRL-Fc OMP-336B11|Trimethylcolchicinic Acid|Trimetrexate|Trimetrexate Glucuronate|Trinidad and Tobago|Trioxifene|Triplatin Tetranitrate|Triple Quad 3500|Triple Quad 4500|Triple Quad 5500|Triple Quad 6500|Triple Quad 6500+|TripleTOF 4600|TripleTOF 5600|TripleTOF 5600+|TripleTOF 6600|Triptolide Analog|Triptorelin|Triptorelin Pamoate|Tris-acryl Gelatin Microspheres|Trismus|Triton tumor, malignant|Tritylcysteine|TrkA Inhibitor VMD-928|Trodusquemine|Trofosfamide|Troglitazone|Trophoblastic neoplasms|Trophoblastic tumor, epithelioid|Tropomyosin Receptor Kinase Inhibitor AZD7451|Troriluzole|Troxacitabine|Troxacitabine Nucleotide Prodrug MIV-818|TruTOF|True|True Histiocytic Lymphoma|True histiocytic lymphoma|Trunk|TrypChymo|Trypsin|Trypsin/P|Tubercidin|Tuberculosis|Tuberous Sclerosis|Tubular Adenocarcinoma|Tubular Adenoma|Tubular adenocarcinoma|Tubular adenoma, NOS|Tubular androblastoma with lipid storage|Tubular androblastoma, NOS|Tubular carcinoid|Tubular carcinoma|Tubulin Binding Agent TTI-237|Tubulin Inhibitor ALB 109564 Dihydrochloride|Tubulin Inhibitor ALB-109564|Tubulin Polymerization Inhibitor AEZS 112|Tubulin Polymerization Inhibitor CKD-516|Tubulin Polymerization Inhibitor VERU-111|Tubulin-Binding Agent SSR97225|Tubulo-papillary adenoma|Tubulocystic Renal Cell Carcinoma|Tubulocystic renal cell carcinoma|Tubulointerstitial Disease|Tubulolobular carcinoma|Tubulopapillary adenocarcinoma|Tubulovillous Adenoma|Tubulovillous adenoma, NOS|Tucatinib|Tucidinostat|Tucotuzumab Celmoleukin|Tumor|Tumor Adjacent Normal - Post Neo-adjuvant Therapy|Tumor Debulking|Tumor Embolism|Tumor Free|Tumor Lysis Syndrome|Tumor Pain|Tumor Resection|Tumor cells, NOS|Tumor cells, benign|Tumor cells, malignant|Tumor cells, uncertain whether benign or malignant|Tumor class but appears normal|Tumor embolus|Tumor free|Tumor tissue origin incorrect|Tumor type incorrect|Tumor, NOS|Tumor, benign|Tumor, malignant, NOS|Tumor, metastatic|Tumor, secondary|Tumor-associated Lymphoid Proliferation|Tumorlet|Tumorlet, NOS|Tumorlet, benign|Tunisia|Turban Tumor|Turban tumor|Turcot Syndrome|Turkey|Turkmenistan|Tuvalu|Twice Daily|Twice Weekly|Twin|Twin Sibling|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma|Type A Spindle Cell Melanoma|Type B Spindle Cell Melanoma|Typhlitis|Typical carcinoid|Tyroserleutide|Tyrosinase Peptide|Tyrosinase-KLH|Tyrosinase:146-156 Peptide|Tyrosine Kinase Inhibitor|Tyrosine Kinase Inhibitor OSI-930|Tyrosine Kinase Inhibitor SU5402|Tyrosine Kinase Inhibitor TL-895|Tyrosine Kinase Inhibitor XL228|Tyrosinemia|UAE Inhibitor TAK-243|UHPLC|USP14/UCHL5 Inhibitor VLX1570|Ubenimex|Ubidecarenone Nanodispersion BPM31510n|Ubiquitylome|Ublituximab|Uganda|Ukraine|Ulcerative Colitis|Ulinastatin|Ulixertinib|Ulocuplumab|Ultrasound Guided Biopsy|Ultrasound-Guided Biopsy|Umbilical Cord|Umbralisib|Unaligned Reads|Uncaria tomentosa Extract|Unclassified Testicular Sex Cord-Stromal Tumor|Unclassified tumor, benign|Unclassified tumor, borderline malignancy|Unclassified tumor, malignant|Unclassified tumor, malignant, uncertain whether primary or metastatic|Unclassified tumor, uncertain whether benign or malignant|Uncle|Undescended Testis|Undescended testis|Undifferentiated|Undifferentiated (Embryonal) Sarcoma|Undifferentiated Carcinoma|Undifferentiated Epithelioid Sarcoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone|Undifferentiated Neuroblastoma|Undifferentiated Pleomorphic Sarcoma|Undifferentiated Pleomorphic Sarcoma with Osteoclast-Like Giant Cells|Undifferentiated Retinoblastoma|Undifferentiated Round Cell Sarcoma|Undifferentiated Sarcoma, Not Otherwise Specified|Undifferentiated Spindle Cell Sarcoma|Undifferentiated epithelioid sarcoma|Undifferentiated high-grade pleomorphic sarcoma|Undifferentiated leukaemia|Undifferentiated pleomorphic sarcoma|Undifferentiated round cell sarcoma|Undifferentiated sarcoma|Undifferentiated spindle cell sarcoma|Undifferentiated uterine sarcoma|Unequal Limb Length|Unfavorable|Unifocal|Unilateral|Unintended Pregnancy|United Arab Emirates|United Kingdom|United States|Unknown Tumor Status|Unknown primary site|Unknown tumor status|Unpaired_LogR|Unrelated|Unsatisfactory|Unspecific cleavage|Unspecified|Upamostat|Upifitamab|Upper Gastrointestinal Hemorrhage|Upper Gingiva|Upper Gum|Upper Respiratory Infection|Upper gum|Upper limb, NOS|Upper lobe, lung|Upper respiratory tract, NOS|Upper third of esophagus|Upper-inner quadrant of breast|Upper-outer quadrant of breast|Uproleselan|Uprosertib|Urabrelimab|Urachal carcinoma|Urachus|Uracil Ointment|Urelumab|Ureter|Ureteric Anastomotic Leak|Ureteric Orifice|Ureteric orifice|Urethra|Urethral Anastomotic Leak|Urethral Infection|Urinary Fistula|Urinary Frequency|Urinary Incontinence|Urinary Retention|Urinary System|Urinary Tract|Urinary Tract Infection|Urinary Tract Obstruction|Urinary Tract Pain|Urinary Urgency|Urinary system, NOS|Urine Discoloration|Urine Output Decreased|Uroacitides|Urokinase-Derived Peptide A6|Urostomy Leak|Urostomy Obstruction|Urostomy Site Bleeding|Urostomy Stenosis|Urothelial Carcinoma|Urothelial Papilloma|Urothelial carcinoma in situ|Urothelial carcinoma with divergent differentiation|Urothelial carcinoma with squamous differentiation|Urothelial carcinoma with trophoblastic differentiation|Urothelial carcinoma, NOS|Urothelial papilloma, NOS|Ursolic Acid|Urticaria|Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis|Urticaria pigmentosa|Uruguay|Uterine Adnexa|Uterine Anastomotic Leak|Uterine Cancer|Uterine Carcinosarcoma|Uterine Corpus Endometrial Carcinoma|Uterine Corpus Leiomyoma|Uterine Corpus Undifferentiated Sarcoma|Uterine Fistula|Uterine Hemorrhage|Uterine Infection|Uterine Obstruction|Uterine Pain|Uterine Perforation|Uterine adnexa|Uterus|Uterus, NOS|Utomilumab|Uveal Melanoma|Uveitis|Uvula|Uzansertib|Uzbekistan|V8-DE|V8-E|V930 Vaccine|VAIN III|VCF|VCF LiftOver|VEGF Inhibitor PTC299|VEGF/HGF-targeting DARPin MP0250|VEGFR Inhibitor KRN951|VEGFR-2 DNA Vaccine VXM01|VEGFR/FGFR Inhibitor ODM-203|VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593|VEGFR2 Tyrosine Kinase Inhibitor PF-00337210|VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813|VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220|VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820|VGPR-Very Good Partial Response|VIN III|VIP-Producing Neuroendocrine Tumor|VLP-encapsulated TLR9 Agonist CMP-001|Vaccine-Sensitized Draining Lymph Node Cells|Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules|Vactosertib|Vadacabtagene Leraleucel|Vadastuximab Talirine|Vadimezan|Vagina|Vagina, NOS|Vaginal Anastomotic Leak|Vaginal Discharge|Vaginal Dryness|Vaginal Fistula|Vaginal Hemorrhage|Vaginal Infection|Vaginal Inflammation|Vaginal Obstruction|Vaginal Pain|Vaginal Perforation|Vaginal Stricture|Vaginal intraepithelial neoplasia, grade III|Vaginismus|Vagus Nerve Disorder|Valecobulin|Valemetostat|Validation|Vallecula|Valproic Acid|Valrubicin|Valspodar|Vandetanib|Vandetanib-eluting Radiopaque Bead BTG-002814|Vandortuzumab Vedotin|Vantictumab|Vanuatu|Vanucizumab|Vapreotide|VarScan2|VarScan2 Annotation|VarScan2 Variant Aggregation and Masking|Varian|Varicella Zoster Virus|Varlilumab|Varlitinib|Varlitinib Tosylate|Vas Deferens|Vas Deferens Anastomotic Leak|Vascular Access Complication|Vascular Disease|Vascular Disorders - Other|Vascular Disrupting Agent BNC105|Vascular Disrupting Agent BNC105P|Vascular Disrupting Agent ZD6126|Vascular leiomyoma|Vasculitis|Vasovagal Reaction|Vatalanib|Vatalanib Succinate|Vecabrutinib|Vector-peptide Conjugated Paclitaxel|Vedolizumab|Vein|Veliparib|Velos Plus|Veltuzumab|Vemurafenib|Venetoclax|Venezuela|Venous|Venous Hemangioma|Venous Injury|Venous hemangioma|Ventral surface of tongue, NOS|Ventricle, NOS|Ventricular Arrhythmia|Ventricular Fibrillation|Ventricular Tachycardia|Verapamil|Verpasep Caltespen|Verrucous Carcinoma|Verrucous Hemangioma|Verrucous Papilloma|Verrucous carcinoma, NOS|Verrucous epidermoid carcinoma|Verrucous keratotic hemangioma|Verrucous papilloma|Verrucous squamous cell carcinoma|Vertebra|Vertebral Canal|Vertebral column|Vertical Hemilaryngectomy|Vertigo|Verubulin|Verubulin Hydrochloride|Very Good Partial Response|Vesencumab|Vesigenurtucel-L|Vestibular Disorder|Vestibule of Mouth|Vestibule of mouth|Viagenpumatucel-L|Vibecotamab|Vibostolimab|Vietnam|Vilaprisan|Villoglandular Endometrial Endometrioid Adenocarcinoma|Villoglandular adenoma|Villoglandular carcinoma|Villous Adenocarcinoma|Villous Adenoma|Villous adenocarcinoma|Villous adenoma, NOS|Villous papilloma|Vinblastine|Vinblastine Sulfate|Vincristine|Vincristine Liposomal|Vincristine Sulfate|Vincristine Sulfate Liposome|Vindesine|Vinepidine|Vinflunine|Vinflunine Ditartrate|Vinfosiltine|Vinorelbine|Vinorelbine Tartrate|Vinorelbine Tartrate Emulsion|Vinorelbine Tartrate Oral|Vintafolide|Vinzolidine|Vinzolidine Sulfate|Vipoma, NOS|Vipoma, malignant|Virgin Islands, British|Virgin Islands, U.S.|Virilization|Virulizin|Visceral Arterial Ischemia|Vision Changes|Vismodegib|Vistusertib|Visual Change|Visual Changes|Vital Capacity Abnormal|Vitamin D3 Analogue ILX23-7553|Vitamin E Compound|Vitespen|Vitreous Hemorrhage|Vocimagene Amiretrorepvec|Vofatamab|Voice Alteration|Volasertib|Volcanic Smoke Exposure|Volcanic smoke|Volociximab|Vomiting|Von Hippel-Lindau Syndrome|Von Recklinghausen disease|Vonlerolizumab|Vopratelimab|Vorasidenib|Vorinostat|Vorolanib|Vorsetzumab Mafodotin|Vosaroxin|Vosilasarm|Voxtalisib|Voyager-DE PRO|Voyager-DE STR|Vulinacimab|Vulva|Vulva, NOS|Vulval Infection|Vulvar Intraepithelial Neoplasia, Differentiated Type|Vulvar intraepithelial neoplasia, grade III|W|WGA Failure|WNT-Activated|WT-With Tumor|WT1 Peptide Vaccine OCV-501|WT1 Peptide Vaccine WT2725|WT1 Protein-derived Peptide Vaccine DSP-7888|WT1-A10/AS01B Immunotherapeutic GSK2130579A|WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401|WXS|Wagr Syndrome|Waldenstrom Macroglobulinemia|Waldenstrom macroglobulinemia|Waldeyer ring|Wallis and Futuna|Ward|Warfarin Sodium|Warthin Tumor|Warthin tumor|Warty carcinoma|Waste burning smoke|Wasting Syndrome|Water-Clear Cell Adenocarcinoma|Water-clear cell adenocarcinoma|Water-clear cell adenoma|Water-clear cell carcinoma|Watering Eyes|Waters|Wedge Resection|Wee1 Inhibitor ZN-c3|Wee1 Kinase Inhibitor Debio 0123|Weight Gain|Weight Loss|Well Differentiated Liposarcoma|Well Differentiated Neuroendocrine Lesion|Well differentiated liposarcoma of superficial soft tissue|Well differentiated papillary mesothelioma, benign|Well differentiated thymic carcinoma|Western Sahara|Wheezing|Whipple Procedure|White Blood Cell Decreased|White Blood Cells|White Carrot|White Matter|Whole Bone Marrow|Whole Genome Sequencing|Wife|Wilms Tumor|Wilms tumor|Wilms tumor (WT)|Wine|With Tumor|With tumor|Withdrawal by Subject|Within 5 Minutes|Wnt Signaling Inhibitor SM04755|Wnt Signaling Pathway Inhibitor SM08502|Wnt-5a Mimic Hexapeptide Foxy-5|Wobe-Mugos E|Wolff-Parkinson-White Syndrome|Wolffian duct adenoma|Wolffian duct carcinoma|Wolffian duct tumor|Wood Dust|Wood burning smoke, NOS|Wood burning smoke, factory|Wood-Burning Factory Smoke Exposure|Wood-Burning Indoor Stove or Fireplace Smoke Exposure|Work-Related Smoke Exposure|Work-related smoke, NOS|Work-related smoke, artificial smoke machines|Work-related smoke, fire fighting|Work-related smoke, foundry|Work-related smoke, generators|Work-related smoke, military|Work-related smoke, paint baking|Work-related smoke, plastics factory|Work-related smoke, plumbing|Work-related smoke, soldering/welding|Wound Complication|Wound Dehiscence|Wound Infection|Wrist|Wrist Fracture|X|X500R QTOF|XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410|XIAP Antisense Oligonucleotide AEG35156|XIAP/cIAP1 Antagonist ASTX660|XLSX|XML|XPO1 Inhibitor SL-801|Xanthofibroma|Xanthohumol|Xeloda|Xenograft|Xenograft Tissue|Xenopus laevis|Xentuzumab|Xevinapant|Xevo G2 Q-Tof|Xevo G2 Tof|Xevo G2 XS Tof|Xevo G2-S QTof|Xevo G2-S Tof|Xevo Q-Tof|Xevo QTof|Xevo TQ MS|Xevo TQ-S|Xevo TQD|Xiaoai Jiedu Decoction|Xiliertinib|Xisomab 3G3|Y|Y 90 Monoclonal Antibody CC49|Y 90 Monoclonal Antibody HMFG1|Y 90 Monoclonal Antibody Lym-1|Y 90 Monoclonal Antibody M195|Y 90 Monoclonal Antibody m170|Yang Yin Fu Zheng|Yangzheng Xiaoji Extract|Yemen|Yiqi-yangyin-jiedu Herbal Decoction|Yolk Sac Tumor|Yolk sac tumor|Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12|Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101|Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66|Yttrium Y 90 Basiliximab|Yttrium Y 90 Colloid|Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A|Yttrium Y 90 Daclizumab|Yttrium Y 90 Glass Microspheres|Yttrium Y 90 Monoclonal Antibody B3|Yttrium Y 90 Monoclonal Antibody BrE-3|Yttrium Y 90 Monoclonal Antibody Hu3S193|Yttrium Y 90 Monoclonal Antibody MN-14|Yttrium Y 90 Resin Microspheres|Yttrium Y 90 Tabituximab Barzuxetan|Yttrium Y 90-DOTA-Biotin|Yttrium Y 90-DOTA-di-HSG Peptide IMP-288|Yttrium Y 90-Edotreotide|Yttrium Y 90-labeled Anti-FZD10 Monoclonal Antibody OTSA101|Yttrium Y-90 Clivatuzumab Tetraxetan|Yttrium Y-90 Epratuzumab Tetraxetan|Yttrium Y-90 Ibritumomab Tiuxetan|Yttrium Y-90 Tacatuzumab Tetraxetan|Yttrium-90 Polycarbonate Brachytherapy Plaque|Z-Endoxifen Hydrochloride|ZMD|ZQ|Zalcitabine|Zalifrelimab|Zalutumumab|Zambia|Zandelisib|Zanidatamab|Zanolimumab|Zanubrutinib|Zea mays|Zebularine|Zelavespib|Zero|Zibotentan|Zimbabwe|Zinc Finger Nuclease ZFN-603|Zinc Finger Nuclease ZFN-758|Zinostatin|Zinostatin Stimalamer|Zirconium Zr 89 Panitumumab|Ziv-Aflibercept|Zolbetuximab|Zoledronic Acid|Zoptarelin Doxorubicin|Zorifertinib|Zorubicin|Zorubicin Hydrochloride|Zotatifin|Zotiraciclib Citrate|Zuclomiphene Citrate|aDNA Preparation Type|alignment_workflow|aliquot|allcnv|alleleSpecificCN|alpha-Folate Receptor-targeting Thymidylate Synthase Inhibitor ONX-0801|american indian or alaska native|analyte|asian|auxiliary|bRPLC|bRPLC (pH 10)|bRPLC (pH 7.5)|batch_effect_removed|bisulfite|black or african american|byallele|c-ALL|c-Kit Inhibitor PLX9486|c-Met Inhibitor ABN401|c-Met Inhibitor AL2846|c-Met Inhibitor AMG 208|c-Met Inhibitor AMG 337|c-Met Inhibitor GST-HG161|c-Met Inhibitor HS-10241|c-Met Inhibitor JNJ-38877605|c-Met Inhibitor MK2461|c-Met Inhibitor MK8033|c-Met Inhibitor MSC2156119J|c-raf Antisense Oligonucleotide ISIS 5132|cEt KRAS Antisense Oligonucleotide AZD4785|cFMS Tyrosine Kinase Inhibitor ARRY-382|cGy|cM0 (i+)|cM0 (i+) Stage Finding|cfDNA|cgh|cis-Urocanic Acid|cnv|control|controlled|cov|coverage|cqcf|dUTPase/DPD Inhibitor TAS-114|data_release|diagnostic_slides|drug|eIF4E Antisense Oligonucleotide ISIS 183750|explorer|false|female|follow_up|gene|germline|hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301|hTERT Vaccine V934/V935|hTERT-encoding DNA Vaccine INVAC-1|harmonized|hg18|hg19|hispanic or latino|hpv|huBC1-huIL12 Fusion Protein AS1409|iNKT Cell Agonist ABX196|iNOS Dimerization Inhibitor ASP9853|iPSC-derived CD16-expressing Natural Killer Cells FT516|iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596|iPSC-derived Natural Killer Cells FT500|iTRAQ|iTRAQ4|iTRAQ8|iTRAQH|image|indel|ismpolish|isoform|junction|lost to follow-up|lowess_normalized_smoothed|m6A RNA Methylation|mRNA-Derived Prostate Cancer Vaccine CV9103|mRNA-based Personalized Cancer Vaccine NCI-4650|mRNA-based Personalized Cancer Vaccine mRNA-4157|mRNA-based TriMix Melanoma Vaccine ECI-006|mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902|mRNA-derived KRAS-targeted Vaccine V941|mRNA-derived Lung Cancer Vaccine BI 1361849|mRNA-derived Prostate Cancer Vaccine CV9104|mTOR Inhibitor GDC-0349|mTOR Kinase Inhibitor AZD8055|mTOR Kinase Inhibitor CC-223|mTOR Kinase Inhibitor OSI-027|mTOR Kinase Inhibitor PP242|mTOR1/2 Kinase Inhibitor ME-344|mTORC 1/2 Inhibitor LXI-15029|mTORC1/2 Kinase Inhibitor BI 860585|mTORC1/mTORC2/DHFR Inhibitor ABTL0812|maXis 4G|maXis impact|male|metastasis|meth|mg|miRNA|miRNA Expression Quantification|miRNA-Seq|microOTOF focus II|microOTOF-Q II|mirVana (Allprep DNA) RNA|msi|nRNA - Melanoma Protocol|nanoACQUITY UPLC|nanoACQUITY UPLC System with 1D Technology|nanoACQUITY UPLC with HDX Technology|native hawaiian or other pacific islander|ncmtRNA Oligonucleotide Andes-1537|nocnv|normalized|not allowed to collect|not hispanic or latino|not reported|nte|omf|open|original|other|p300/CBP Bromodomain Inhibitor CCS1477|p38 MAPK Inhibitor LY3007113|p53 Peptide Vaccine MPS-128|p53-HDM2 Interaction Inhibitor MI-773|p53-HDM2 Protein-protein Interaction Inhibitor APG-115|p53/HDM2 Interaction Inhibitor CGM097|p70S6K Inhibitor LY2584702|p70S6K/Akt Inhibitor MSC2363318A|p97 Inhibitor CB-5083|p97 Inhibitor CB-5339|p97 Inhibitor CB-5339 Tosylate|pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0|pNGVL4a-CRT-E6E7L2 DNA Vaccine|pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2|pairedcn|pan FGFR Inhibitor PRN1371|pan-HER Kinase Inhibitor AC480|pan-PI3K Inhibitor CLR457|pan-PI3K/mTOR Inhibitor SF1126|pan-PIM Kinase Inhibitor AZD1208|pan-PIM Kinase Inhibitor NVP-LGB-321|pan-RAF Inhibitor LXH254|pan-RAF Kinase Inhibitor CCT3833|pan-RAF Kinase Inhibitor TAK-580|patient|pbi-shRNA STMN1 Lipoplex|portion|primary|proteomics solution 1|protocol|qc|quattro micro|radiation|raw|recurrence|root|sCR-Stringent Complete Response|sample|scATAC-Seq|scRNA-Seq|seg|segmentation|segmented|segnormal|siG12D LODER|siRNA-transfected Peripheral Blood Mononuclear Cells APN401|sif|slide|snv|solariX|somatic|ssRNA-based Immunomodulator CV8102|submitted_genomic_profile|summary|sv|tangent|timsTOF Pro|tr|tris(2-carboxyethyl)phosphine|true|ultima|unknown|unnormalized|unspecified|v1|v2|white|zUMIs - Smart-Seq2|zUMIs - Smart-Seq2 Counts|g"
evidence_of_recurrence_type	evidence_of_recurrence_type	Biopsy with Histologic Confirmation|Convincing Image Source|Physical Examination|Positive Biomarker(s)	4/4 (both/PDC)		
eye_color	eye_color	Amber|Blue|Brown|Gray|Green|Hazel|Not Reported|Other|Red & Violet	9/9 (both/PDC)		
haart_treatment_indicator	haart_treatment_indicator	False|Not Reported|True|Unknown	4/4 (both/PDC)		
hepatitis_sustained_virological_response	hepatitis_sustained_virological_response	False|Not Reported|True|Unknown	4/4 (both/PDC)		
history_of_tumor	history_of_tumor	False|Not Reported|True	3/3 (both/PDC)		
history_of_tumor_type	history_of_tumor_type	Phenochromocytoma or Paraganglioma	1/1 (both/PDC)		
hormonal_contraceptive_type	hormonal_contraceptive_type	Not Reported|Progestin|Progestin and Estrogen|Unknown	4/4 (both/PDC)		
hormonal_contraceptive_use	hormonal_contraceptive_use	Current User|Former User|Never Used|Not Reported|Unknown	5/5 (both/PDC)		
hormone_replacement_therapy_type	hormone_replacement_therapy_type	Estrogen only|Not Reported|Progesterone and Estrogen|Progesterone only|Unknown	5/5 (both/PDC)		
hysterectomy_margins_involved	hysterectomy_margins_involved	Bladder|Macroscopic Parametrium|Microscopic Parametrium|None|Not Reported|Unknown|Vagina	7/7 (both/PDC)		
hysterectomy_type	hysterectomy_type	Hysterectomy, NOS|Not Reported|Not performed|Radical Hysterectomy|Simple Hysterectomy|Unknown	6/6 (both/PDC)		
imaging_result	imaging_result	Indeterminate|Not Performed|Not Reported|Unknown	4/6 (both/PDC)	Negative|Positive	Negative Finding|Positive Finding
imaging_type	imaging_type	99mTc Bone Scintigraphy|CT Scan|MRI|PET	4/4 (both/PDC)		
immunosuppressive_treatment_type	immunosuppressive_treatment_type	Anti-TNF Therapy|Azathioprine|Cyclophosphamide|Methotrexate|None|Not Reported|Other|Unknown	8/8 (both/PDC)		
karnofsky_performance_status	karnofsky_performance_status	10|100|20|30|40|50|60|70|80|90|Not Reported|Unknown	12/13 (both/PDC)	0	Zero
menopause_status	menopause_status	Not Reported|Perimenopausal|Postmenopausal|Premenopausal|Unknown	5/5 (both/PDC)		
pregnancy_outcome	pregnancy_outcome	Ectopic Pregnancy|Induced Abortion|Live Birth|Miscarriage|Not Reported|Stillbirth|Unknown	7/7 (both/PDC)		
procedures_performed	procedures_performed	Colonoscopy|Endoscopy|Not Reported|Unknown	4/4 (both/PDC)		
progression_or_recurrence_anatomic_site	progression_or_recurrence_anatomic_site	Abdomen, NOS|Abdominal esophagus|Accessory sinus, NOS|Adrenal gland, NOS|Ampulla of Vater|Anterior 2/3 of tongue, NOS|Anterior floor of mouth|Anterior mediastinum|Anterior wall of bladder|Anus, NOS|Aortic body and other paraganglia|Appendix|Autonomic nervous system, NOS|Axillary tail of breast|Biliary tract, NOS|Bladder, NOS|Blood|Body of pancreas|Bone marrow|Bone of limb, NOS|Bone, NOS|Bones of skull and face and associated joints|Border of tongue|Brain stem|Breast, NOS|Cardia, NOS|Cauda equina|Cecum|Central portion of breast|Cervical esophagus|Cheek mucosa|Choroid|Clitoris|Cloacogenic zone|Colon, NOS|Commissure of lip|Conjunctiva|Connective, subcutaneous and other soft tissues of abdomen|Connective, subcutaneous and other soft tissues of head, face, and neck|Connective, subcutaneous and other soft tissues of lower limb and hip|Connective, subcutaneous and other soft tissues of pelvis|Connective, subcutaneous and other soft tissues of thorax|Connective, subcutaneous and other soft tissues of trunk, NOS|Connective, subcutaneous and other soft tissues of upper limb and shoulder|Connective, subcutaneous and other soft tissues, NOS|Cornea, NOS|Corpus uteri|Cortex of adrenal gland|Cranial nerve, NOS|Craniopharyngeal duct|Descended testis|Dorsal surface of tongue, NOS|Duodenum|Endocervix|Endometrium|Epididymis|Esophagus, NOS|Ethmoid sinus|External ear|External lip, NOS|External upper lip|Extrahepatic bile duct|Eyelid|Floor of mouth, NOS|Frontal lobe|Fundus of stomach|Gallbladder|Glottis|Gum, NOS|Hard palate|Head, face or neck, NOS|Heart|Hepatic flexure of colon|Hypopharyngeal aspect of aryepiglottic fold|Ileum|Ill-defined sites within respiratory system|Intestinal tract, NOS|Intrahepatic bile duct|Islets of Langerhans|Jejunum|Kidney, NOS|Lacrimal gland|Larynx, NOS|Lateral floor of mouth|Lateral wall of bladder|Lateral wall of oropharynx|Lingual tonsil|Liver|Long bones of lower limb and associated joints|Long bones of upper limb, scapula and associated joints|Lower limb, NOS|Lower lobe, lung|Lower third of esophagus|Lower-inner quadrant of breast|Lung, NOS|Lymph nodes of axilla or arm|Lymph nodes of inguinal region or leg|Lymph nodes of multiple regions|Major salivary gland, NOS|Mandible|Meckel diverticulum|Mediastinum, NOS|Medulla of adrenal gland|Middle third of esophagus|Mucosa of upper lip|Myometrium|Nasal cavity|Nipple|Not Reported|Olfactory nerve|Other specified parts of male genital organs|Ovary|Overlapping lesion of accessory sinuses|Overlapping lesion of biliary tract|Overlapping lesion of bladder|Overlapping lesion of bones, joints and articular cartilage|Overlapping lesion of bones, joints and articular cartilage of limbs|Overlapping lesion of brain|Overlapping lesion of brain and central nervous system|Overlapping lesion of breast|Overlapping lesion of cervix uteri|Overlapping lesion of colon|Overlapping lesion of connective, subcutaneous and other soft tissues|Overlapping lesion of corpus uteri|Overlapping lesion of digestive system|Overlapping lesion of endocrine glands and related structures|Overlapping lesion of esophagus|Overlapping lesion of eye and adnexa|Overlapping lesion of female genital organs|Overlapping lesion of floor of mouth|Overlapping lesion of heart, mediastinum and pleura|Overlapping lesion of hypopharynx|Overlapping lesion of ill-defined sites|Overlapping lesion of larynx|Overlapping lesion of lip|Overlapping lesion of lip, oral cavity and pharynx|Overlapping lesion of lung|Overlapping lesion of major salivary glands|Overlapping lesion of male genital organs|Overlapping lesion of nasopharynx|Overlapping lesion of other and unspecified parts of mouth|Overlapping lesion of palate|Overlapping lesion of pancreas|Overlapping lesion of penis|Overlapping lesion of peripheral nerves and autonomic nervous system|Overlapping lesion of rectum, anus and anal canal|Overlapping lesion of respiratory system and intrathoracic organs|Overlapping lesion of retroperitoneum and peritoneum|Overlapping lesion of skin|Overlapping lesion of small intestine|Overlapping lesion of stomach|Overlapping lesion of tongue|Overlapping lesion of tonsil|Overlapping lesion of urinary organs|Overlapping lesion of vulva|Overlapping lesions of oropharynx|Palate, NOS|Pancreas, NOS|Pancreatic duct|Parametrium|Parathyroid gland|Paraurethral gland|Pelvic bones, sacrum, coccyx and associated joints|Pelvic lymph nodes|Pelvis, NOS|Peripheral nerves and autonomic nervous system of abdomen|Peripheral nerves and autonomic nervous system of head, face, and neck|Peripheral nerves and autonomic nervous system of lower limb and hip|Peripheral nerves and autonomic nervous system of pelvis|Peripheral nerves and autonomic nervous system of thorax|Peripheral nerves and autonomic nervous system of trunk, NOS|Peripheral nerves and autonomic nervous system of upper limb and shoulder|Peritoneum, NOS|Pineal gland|Placenta|Pleura, NOS|Postcricoid region|Posterior mediastinum|Posterior wall of bladder|Posterior wall of hypopharynx|Posterior wall of oropharynx|Prepuce|Pylorus|Pyriform sinus|Rectum, NOS|Retina|Retroperitoneum|Rib, sternum, clavicle and associated joints|Round ligament|Short bones of lower limb and associated joints|Short bones of upper limb and associated joints|Skin of lip, NOS|Skin of trunk|Skin, NOS|Soft palate, NOS|Specified parts of peritoneum|Spermatic cord|Sphenoid sinus|Spinal meninges|Spleen|Subglottis|Sublingual gland|Supraglottis|Tail of pancreas|Thorax, NOS|Thymus|Tongue, NOS|Tonsillar pillar|Trachea|Transverse colon|Undescended testis|Unknown|Upper gum|Upper limb, NOS|Upper lobe, lung|Upper respiratory tract, NOS|Upper third of esophagus|Upper-inner quadrant of breast|Upper-outer quadrant of breast|Urachus|Ureter|Urethra|Uterus, NOS|Uvula|Vallecula|Ventral surface of tongue, NOS|Ventricle, NOS|Vertebral column|Waldeyer ring	229/332 (both/PDC)	Acoustic nerve|Anal canal|Anterior surface of epiglottis|Anterior wall of nasopharynx|Ascending colon|Base of tongue, NOS|Bladder neck|Body of penis|Body of stomach|Brain, NOS|Branchial cleft|Broad ligament|Carotid body|Cerebellum, NOS|Cerebral meninges|Cerebrum|Cervix uteri|Ciliary body|Descending colon|Dome of bladder|Endocrine gland, NOS|Exocervix|External lower lip|Eye, NOS|Fallopian tube|Female genital tract, NOS|Frontal sinus|Fundus uteri|Gastric antrum|Gastrointestinal tract, NOS|Glans penis|Greater curvature of stomach, NOS|Head of pancreas|Hematopoietic system, NOS|Hypopharynx, NOS|Intra-abdominal lymph nodes|Intrathoracic lymph nodes|Isthmus uteri|Labium majus|Labium minus|Laryngeal cartilage|Lateral wall of nasopharynx|Lesser curvature of stomach, NOS|Lip, NOS|Lower gum|Lower-outer quadrant of breast|Lymph node, NOS|Lymph nodes of head, face and neck|Main bronchus|Male genital organs, NOS|Maxillary sinus|Meninges, NOS|Middle ear|Middle lobe, lung|Mouth, NOS|Mucosa of lip, NOS|Mucosa of lower lip|Nasopharynx, NOS|Nervous system, NOS|Occipital lobe|Optic nerve|Orbit, NOS|Oropharynx, NOS|Other ill-defined sites|Other specified parts of female genital organs|Other specified parts of pancreas|Parietal lobe|Parotid gland|Penis, NOS|Pharynx, NOS|Pituitary gland|Posterior wall of nasopharynx|Prostate gland|Rectosigmoid junction|Renal pelvis|Reticuloendothelial system, NOS|Retromolar area|Scrotum, NOS|Sigmoid colon|Skin of lower limb and hip|Skin of other and unspecified parts of face|Skin of scalp and neck|Skin of upper limb and shoulder|Small intestine, NOS|Spinal cord|Splenic flexure of colon|Stomach, NOS|Submandibular gland|Superior wall of nasopharynx|Temporal lobe|Testis, NOS|Thoracic esophagus|Thyroid gland|Tonsil, NOS|Tonsillar fossa|Trigone of bladder|Unknown primary site|Ureteric orifice|Urinary system, NOS|Uterine adnexa|Vagina, NOS|Vestibule of mouth|Vulva, NOS	Anal Canal|Anterior Surface of the Epiglottis|Anterior Wall of the Nasopharynx|Antrum Pylori|Appendage of the Uterus|Ascending Colon|Base of the Tongue|Bladder Neck|Bladder Trigone|Body of Stomach|Body of the Penis|Brain|Branchial Cleft Remnant|Broad Ligament|Carotid Body|Cerebellum|Cerebral Hemisphere|Cerebral Meninges|Cervix Uteri|Ciliary Body|Cochlear Nerve|Descending Colon|Dome of the Bladder|Ectocervix|Endocrine Gland|External Lower Lip|Eye|Fallopian Tube|Female Genitalia|Frontal Sinus|Fundus Uteri|Gastrointestinal Tract|Glans Penis|Greater Curvature of the Stomach|Head and Neck Lymph Node|Head of the Pancreas|Hematopoietic System|Hypopharynx|Ill-Defined Anatomic Site|Intra-Abdominal Lymph Node|Intrathoracic Lymph Node|Isthmus Uteri|Labium Majus|Labium Minus|Laryngeal Cartilage|Lateral Wall of the Nasopharynx|Lesser Curvature of the Stomach|Lip|Lower Gingiva|Lower-Outer Quadrant of the Breast|Lymph Node|Main Bronchus|Male Genitalia|Maxillary Sinus|Meninges|Middle Ear|Middle Lobe of the Right Lung|Mucosa of the Lip|Mucosa of the Lower Lip|Nasopharynx|Nervous System|Occipital Lobe|Optic Nerve|Oral Cavity|Orbit|Oropharynx|Other Specified Parts of Pancreas|Other and Unspecified Female Genital Organs ICD-O-3|Palatine Tonsil|Parietal Lobe|Parotid Gland|Penis|Pharynx|Pituitary Gland|Posterior Wall of the Nasopharynx|Primary Site Unknown|Prostate Gland|Rectosigmoid Region|Renal Pelvis|Reticuloendothelial System|Retromolar Trigone|Scrotum|Sigmoid Colon|Skin of the Face|Skin of the Lower Limb and Hip|Skin of the Scalp and Neck|Skin of the Upper Limb and Shoulder|Small Intestine|Spinal Cord|Splenic Flexure|Stomach|Submandibular Gland|Superior Wall of the Nasopharynx|Temporal Lobe|Testis|Thoracic Esophagus|Thyroid Gland|Tonsillar Fossa|Ureteric Orifice|Urinary System|Vagina|Vestibule of Mouth|Vulva
progression_or_recurrence_type	progression_or_recurrence_type	Biochemical|Distant|Local|Not Reported|Regional|Unknown	6/6 (both/PDC)		
reflux_treatment_type	reflux_treatment_type	Antacids|H2 Blockers|Medically Treated|No Treatment|Not Applicable|Not Reported|Proton Pump Inhibitors|Surgically Treated|Unknown	9/9 (both/PDC)		
risk_factor	risk_factor	Abnormal Glucose Level|Adenosis (Atypical Adenomatous Hyperplasia)|Alcohol Consumption|Alcoholic Liver Disease|Allergy, Animal, NOS|Allergy, Ant|Allergy, Bee|Allergy, Cat|Allergy, Dairy or Lactose|Allergy, Dog|Allergy, Eggs|Allergy, Food, NOS|Allergy, Fruit|Allergy, Meat|Allergy, Mold or Dust|Allergy, Nuts|Allergy, Processed Foods|Allergy, Seafood|Allergy, Wasp|Alpha-1 Antitrypsin Deficiency|Ataxia-telangiectasia|Autoimmune Atrophic Chronic Gastritis|Autoimmune Lymphoproliferative Syndrome (ALPS)|BAP1 Tumor Predisposition Syndrome|BRCA Family History|Bacteroides fragilis|Barrett's Esophagus|Beckwith-Wiedemann|Behcet's Disease|Benign Prostatic Hyperplasia|Birt-Hogg-Dube Syndrome|Chlamydia|Cholelithiasis|Chronic Hepatitis|Chronic Kidney Disease|Chronic Systemic Steroid Use|Cirrhosis|Colon Polyps|Colonization, Bacterial|Colonization, Fungal|Common variable immune deficiency (CVID)|Cowden Syndrome|Cryptococcal Meningitis|Cyst(s)|Cytomegalovirus (CMV)|Denys-Drash Syndrome|Dermatomyosis|Diabetes, NOS|Diabetes, Type I|Diabetes, Type II|Diet|Diverticulitis|Eczema|Endometriosis|Endosalpingiosis|Epithelial Dysplasia|Epithelial Hyperplasia|Escherichia coli|Familial Adenomatous Polyposis|Fanconi Anemia|Fibrosis|Gastric Polyp(s)|Gastritis|Gilbert's Syndrome|Glomerular Disease|Gorlin Syndrome|HIV|Hashimoto's Thyroiditis|Hay Fever|Headache|Helicobacter Pylori-Associated Gastritis|Hematologic Disorder, NOS|Hemihypertrophy|Hemochromatosis|Hepatic Encephalopathy|Hepatitis B Infection|Hepatitis C Infection|Hepatitis, NOS|Hereditary Breast Cancer|Hereditary Kidney Oncocytoma|Hereditary Leiomyomatosis and Renal Cell Carcinoma|Hereditary Ovarian Cancer|Hereditary Papillary Renal Cell Carcinoma|Hereditary Prostate Cancer|Hereditary Renal Cell Carcinoma|Herpes Zoster|High Grade Dysplasia|High-grade Prostatic Intraepithelial Neoplasia (PIN)|Human Papillomavirus Infection|Hypospadias|Inflammation, Hyperkeratosis|Intestinal Metaplasia|Iron Overload|Li-Fraumeni Syndrome|Low Grade Dysplasia|Lymphocytic Meningitis|Lymphocytic Thyroiditis|Lynch Syndrome|Malaria|Metabolic Syndrome|Myasthenia Gravis|Mycobacterium avium Complex|Nodular Prostatic Hyperplasia|Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis|Not Reported|Obesity|Oral Contraceptives|Pancreatitis|Parasitic Disease of Biliary Tract|Pneumocystis Pneumonia|Polycystic Ovarian Syndrome (PCOS)|Primary Sclerosing Cholangitis|Recurrent Pyogenic Cholangitis|Reflux Disease|Rheumatoid Arthritis|Rubinstein-Taybi Syndrome|Sarcoidosis|Seizure|Sensory Changes|Serous tubal intraepithelial carcinoma (STIC)|Shingles|Sialadenitis|Sjogren's Syndrome|Skin Rash|Squamous Metaplasia|Staphylococcus aureus|Steatosis|Succinate Dehydrogenase-Deficient Renal Cell Carcinoma|Syphilis|Tattoo|Thyroid Nodular Hyperplasia|Tobacco, NOS|Tobacco, Smokeless|Tobacco, Smoking|Treponema pallidum|Tuberculosis|Tuberous Sclerosis|Tubulointerstitial Disease|Tumor-associated Lymphoid Proliferation|Turcot Syndrome|Undescended Testis|Unknown|Varicella Zoster Virus|Vascular Disease|Vision Changes|Von Hippel-Lindau Syndrome|Wagr Syndrome	148/150 (both/PDC)	Cancer|Epstein-Barr Virus	Epstein-Barr Virus Test|Inflammation|Malignant Neoplasm
risk_factor_treatment	risk_factor_treatment	False|Not Reported|True|Unknown	4/4 (both/PDC)		
scan_tracer_used	scan_tracer_used	Acetate|Axumin|Choline|PSMA|Sodium Fluoride	5/5 (both/PDC)		
undescended_testis_corrected	undescended_testis_corrected	False|Not Reported|True	3/3 (both/PDC)		
undescended_testis_corrected_laterality	undescended_testis_corrected_laterality	Bilateral|Left|Not Reported|Right	4/4 (both/PDC)		
undescended_testis_corrected_method	undescended_testis_corrected_method	Hormones|Not Reported|Orchiopexy|Spontaneous Descent|Testis Removed	5/5 (both/PDC)		
undescended_testis_history	undescended_testis_history	False|Not Reported|True	3/3 (both/PDC)		
undescended_testis_history_laterality	undescended_testis_history_laterality	Bilateral|Left|Not Reported|Right	4/4 (both/PDC)		
viral_hepatitis_serologies	viral_hepatitis_serologies	HBV Core Antibody|HBV DNA|HBV Genotype|HBV Surface Antibody|HCV Genotype|Hepatitis B Surface Antigen|Hepatitis C Antibody|Hepatitis C Virus RNA|Not Reported|Unknown	10/10 (both/PDC)		
one_d_chromatography_type			0/5 (both/PDC)	RPLC|SCX|bRPLC|bRPLC (pH 10)|bRPLC (pH 7.5)	
two_d_chromatography_type			0/2 (both/PDC)	RPLC|UHPLC	
acquisition_type			0/2 (both/PDC)	DDA|DIA	
alkylation_reagent			0/4 (both/PDC)	2-chloroacetamide (TCEP)|Iodoacetamide (IAA)|Methyl Methanethiosulfonate (MMTS)|tris(2-carboxyethyl)phosphine	
chromatography_dimensions_count			0/2 (both/PDC)	2|True	
column_type			0/3 (both/PDC)	C18|New Objective|PicoFrit SELF/P	
dia_ims			0/2 (both/PDC)	False|True	
dia_multiplexing			0/2 (both/PDC)	False|True	
digestion_reagent			0/19 (both/PDC)	2-iodobenzoate|Arg-C, Asp-N|Asp-N_ambic|CNBr, Formic_acid|Chymotrypsin|Glutamyl endopeptidase|Leukocyte elastase|Lys-C|Lys-C, Lys-C/P|No cleavage|NoEnzyme|PepsinA|Proline endopeptidase|TrypChymo|Trypsin|Trypsin/P|Unspecific cleavage|V8-DE|V8-E	
dissociation_type			0/4 (both/PDC)	CID|ECD|ETD|HCD	
enrichment_strategy			0/7 (both/PDC)	Acetylome|Glycoproteome|Lipidome|Metabolome|Phosphoproteome|Proteome|Ubiquitylome	
instrument_make			0/11 (both/PDC)	Agilent|Applied Biosystems|Bruker|Dionex|Hitachi|LECO|SCIEX|Shimadzu|Thermo Fisher Scientific|Varian|Waters	
instrument_model	instrument_model		0/284 (both/PDC)	1200 series LC/MSD SL|1200 series LC/MSD VL|2000 QTRAP|220 GC/MS Ion Trap System|240 GC/MS Ion Trap System|2500 QTRAP|3100|3200 QTRAP|3500 QTRAP|4000 QTRAP|4700 Proteomics Analyzer|4800 Plus MALDI TOF/TOF|4800 Proteomics Analyzer|5800 TOF/TOF|6110 Quadrupole LC/MS|6120A Quadrupole LC/MS|6120B Quadrupole LC/MS|6130 Quadrupole LC/MS|6140 Quadrupole LC/MS|6150 Quadrupole LC/MS|6200 Series Accurate-Mass Time-of-Flight (TOF) LC/MS|6210 Time-of-Flight LC/MS|6220 Time-of-Flight LC/MS|6224 Time-of-Flight LC/MS|6230A Time-of-Flight LC/MS|6230B Time-of-Flight LC/MS|6310 Ion Trap LC/MS|6320 Ion Trap LC/MS|6330 Ion Trap LC/MS|6340 Ion Trap LC/MS|6400 Series Triple Quadrupole LC/MS|6410 Triple Quadrupole LC/MS|6420 Triple Quadrupole LC/MS|6430 Triple Quadrupole LC/MS|6460 Triple Quadrupole LC/MS|6490 Triple Quadrupole LC/MS|6495A Triple Quadrupole LC/MS|6495B Triple Quadrupole LC/MS|6510 Quadrupole Time-of-Flight LC/MS|6520A Quadrupole Time-of-Flight LC/MS|6520B Q-TOF LC/MS|6530A Q-TOF LC/MS|6530B Q-TOF LC/MS|6538 Q-TOF LC/MS|6540 Q-TOF LC/MS|6542 Q-TOF LC/MS|6545 Q-TOF LC/MS|6550 iFunnel Q-TOF LC/MS|6550A iFunnel Q-TOF LC/MS|6560 Q-TOF LC/MS|6570 Q-TOF LC/MS|7000 Triple Quadrupole GC/MS System|7000A Triple Quadrupole GC/MS|7000B Triple Quadrupole GC/MS|7200 GC/Q-TOF|7800 Quadrupole ICP-MS|8800 Triple Quadrupole ICP-MS|ACQUITY UPLC|ACQUITY UPLC H-Class|ACQUITY UPLC H-Class Bio|ACQUITY UPLC I-Class|ACQUITY UPLC Systems with 2D Technology|API 100|API 100LC|API 150EX|API 150EX Prep|API 165|API 2000|API 300|API 3000|API 3200|API 350|API 365|API 4000|API 5000|API-US|AXIMA Assurance Linear MALDI-TOF|AXIMA CFR MALDI-TOF|AXIMA Confidence MALDI-TOF|AXIMA Performance MALDI-TOF/TOF|AXIMA-CFR plus|AXIMA-QIT|Accela PDA|Acquity SQD|Acquity TQD|Acquity UPLC FLR|Acquity UPLC PDA|Auto Spec Ultima NT|Bio-Q|Bruker Daltonics BioTOF series|Bruker Daltonics EVOQ series|Bruker Daltonics HCT series|Bruker Daltonics SCION series|Bruker Daltonics amaZon series|Bruker Daltonics apex series|Bruker Daltonics esquire series|Bruker Daltonics flex series|Bruker Daltonics maXis series|Bruker Daltonics micrOTOF series|Bruker Daltonics solarix series|Citius HRT|DFS|DSQ II|EMD 1000|EVOQ Elite|EVOQ Qube|Element 2|Element GD|Element XR|Exactive|Exactive Plus|FTMS|GC IsoLink|GCT|GCT Premier|HiRes ESI|HiRes MALDI|ISQ|ITQ 1100|ITQ 700|ITQ 900|IsoPrime|IsoProbe T|LCMS-2010A|LCMS-2010EV|LCMS-2020|LCMS-8040|LCMS-8045|LCMS-8050|LCMS-8060|LCMS-9030|LCMS-IT-TOF|LCT|LCT Premier|LCT Premier XE|LTQ|LTQ FT|LTQ FT Ultra|LTQ Orbitrap|LTQ Orbitrap Classic|LTQ Orbitrap Discovery|LTQ Orbitrap Elite|LTQ Orbitrap Velos|LTQ Orbitrap XL|LTQ Orbitrap XL ETD|LTQ Velos|LTQ Velos ETD|LTQ Velos Pro|LTQ XL|LTQ XL ETD|LTQ-FT|LTQ-OT|LXQ|M@LDI L|M@LDI LR|MALDI 4800|MALDI L|MALDI LR|MALDI LTQ Orbitrap|MALDI LTQ XL|MALDI R|MALDI SYNAPT G2-Si|MALDI Synapt G2 HDMS|MALDI Synapt G2 MS|MALDI Synapt G2-S HDMS|MALDI Synapt G2-S MS|MALDI Synapt HDMS|MALDI Synapt MS|MALDI micro MX|Micro|NG-5400|OMEGA|OMEGA-2001|Orbitrap Elite|Orbitrap Fusion|Orbitrap Fusion ETD|Orbitrap Fusion Lumos|Orbitrap Lumos|Orbitrap Velos|PLC|Pegasus|Pegasus 4D|Pegasus BT|Pegasus HRT|Pegasus III|Pipeline|Platform|Platform ICP|Platform II|Platform LCZ|Premier|Q Exactive|Q Exactive HF|Q Exactive HF-X|Q Exactive Plus|Q TRAP|Q-Tof Premier|Q-Tof Ultima|Q-Tof micro|QSTAR|QSTAR Elite|QSTAR Pulsar|QSTAR XL|QTRAP 4500|QTRAP 5500|QTRAP 6500|QTRAP 6500+m|Quattro|Quattro II|Quattro LC|Quattro Premier|Quattro Premier XE|Quattro Ultima|Quattro Ultima Pt|Quattro micro GC|SQ Detector 2|SYNAPT G2-Si|Shimadzu MALDI-7090|Surveyor PDA|SymBiot I|SymBiot XVI|Synapt G2 HDMS|Synapt G2 MS|Synapt G2-S HDMS|Synapt G2-S MS|Synapt HDMS|Synapt MS|TRIZAIC UPLC nanoTile|TSQ 8000 Evo|TSQ 9000|TSQ Altis|TSQ Endura|TSQ Quantis|TSQ Quantiva|TSQ Quantum|TSQ Quantum Access|TSQ Quantum Ultra|TSQ Quantum Ultra AM|TSQ Vantage|Thermo Orbitrap Fusion Lumos|Thermo Orbitrap Q Exactive HF-X|TofSpec|TofSpec 2E|TofSpec E|TofSpec SE|Triple Quad 3500|Triple Quad 4500|Triple Quad 5500|Triple Quad 6500|Triple Quad 6500+|TripleTOF 4600|TripleTOF 5600|TripleTOF 5600+|TripleTOF 6600|TruTOF|Velos Plus|Voyager-DE PRO|Voyager-DE STR|X500R QTOF|Xevo G2 Q-Tof|Xevo G2 Tof|Xevo G2 XS Tof|Xevo G2-S QTof|Xevo G2-S Tof|Xevo Q-Tof|Xevo QTof|Xevo TQ MS|Xevo TQ-S|Xevo TQD|ZMD|ZQ|explorer|maXis 4G|maXis impact|microOTOF focus II|microOTOF-Q II|nanoACQUITY UPLC|nanoACQUITY UPLC System with 1D Technology|nanoACQUITY UPLC with HDX Technology|proteomics solution 1|quattro micro|solariX|timsTOF Pro|ultima	454 GS FLX Titanium|AB SOLiD 2|AB SOLiD 3|AB SOLiD 4|Complete Genomics|Illumina Genome Analyzer II|Illumina Genome Analyzer IIx|Illumina HiSeq 2000|Illumina HiSeq 2500|Illumina HiSeq 4000|Illumina HiSeq X Five|Illumina HiSeq X Ten|Illumina MiSeq|Illumina NextSeq|Illumina NovaSeq 6000|Ion Torrent PGM|Ion Torrent Proton|Ion Torrent S5|Not Reported|Other|PacBio RS|Unknown
isobaric_labeling_reagent			0/10 (both/PDC)	180|AQUA|ICAT|ICPL|SILAC|TMT10|TMT11|TMT6|iTRAQ4|iTRAQ8	
label_free_quantitation			0/5 (both/PDC)	Label-free gene level quantitation|Label-free peptide level quantitation|Label-free protein group level quantitation|Label-free protein level quantitation|Label-free raw feature quantitation	
labeled_quantitation			0/10 (both/PDC)	AminoxyTMT|DiART|DiLeu|Glyco-TMT|Hydrazide TMT|IPTL|IodoTMT|TMT|iTRAQ|iTRAQH	
quantitation_strategy			0/10 (both/PDC)	Absolute quantitation analysis|Isobaric label quantitation analysis|LC-MS label-free quantitation analysis|MS1 label-based analysis|MS2 tag-based analysis|MS2-based label-free quantitation|Metabolic labeling 14N / 15N quantitation analysis|SILAC quantitation analysis|SRM quantitation analysis|Spectral counting analysis	
reporter_ion_ms_level			0/2 (both/PDC)	MS2|MS3	
starting_amount_uom			0/2 (both/PDC)	mg|g	
biospecimen_anatomic_site	biospecimen_anatomic_site	Abdomen|Abdominal Wall|Acetabulum|Adenoid|Adipose|Adrenal|Alveolar Ridge|Amniotic Fluid|Ampulla Of Vater|Anal Sphincter|Ankle|Anorectum|Antecubital Fossa|Antrum|Anus|Aorta|Aortic Body|Appendix|Aqueous Fluid|Arm|Artery|Ascending Colon|Ascending Colon Hepatic Flexure|Auditory Canal|Autonomic Nervous System|Axilla|Back|Bile Duct|Bladder|Blood|Blood Vessel|Bone|Bone Marrow|Bowel|Brain|Brain Stem|Breast|Broad Ligament|Bronchiole|Bronchus|Brow|Buccal Cavity|Buccal Mucosa|Buttock|Calf|Capillary|Cardia|Carina|Carotid Artery|Carotid Body|Cartilage|Cecum|Cell-Line|Central Nervous System|Cerebellum|Cerebral Cortex|Cerebrospinal Fluid|Cervical Spine|Cervix|Chest|Chest Wall|Chin|Clavicle|Clitoris|Colon|Colon - Mucosa Only|Common Duct|Conjunctiva|Connective Tissue|Dermal|Descending Colon|Diaphragm|Duodenum|Ear|Ear Canal|Ear, Pinna (External)|Effusion|Elbow|Endocrine Gland|Epididymis|Epidural Space|Esophageal; Distal|Esophageal; Mid|Esophageal; Proximal|Esophagogastric Junction|Esophagus|Esophagus - Mucosa Only|Eye|Fallopian Tube|Femoral Artery|Femoral Vein|Femur|Fibroblasts|Fibula|Finger|Floor Of Mouth|Fluid|Foot|Forearm|Forehead|Foreskin|Frontal Cortex|Frontal Lobe|Fundus Of Stomach|Gallbladder|Ganglia|Gastroesophageal Junction|Gastrointestinal Tract|Glottis|Gum|Hand|Hard Palate|Head & Neck|Head - Face Or Neck, Nos|Heart|Hepatic|Hepatic Duct|Hepatic Flexure|Hepatic Vein|Hip|Hippocampus|Humerus|Hypopharynx|Ileum|Ilium|Index Finger|Ischium|Islet Cells|Jaw|Jejunum|Joint|Kidney|Knee|Lacrimal Gland|Large Bowel|Laryngopharynx|Larynx|Leg|Leptomeninges|Ligament|Lip|Liver|Lumbar Spine|Lung|Lymph Node|Lymph Node(s) Axilla|Lymph Node(s) Cervical|Lymph Node(s) Distant|Lymph Node(s) Epitrochlear|Lymph Node(s) Femoral|Lymph Node(s) Hilar|Lymph Node(s) Iliac-Common|Lymph Node(s) Iliac-External|Lymph Node(s) Inguinal|Lymph Node(s) Internal Mammary|Lymph Node(s) Mammary|Lymph Node(s) Mesenteric|Lymph Node(s) Occipital|Lymph Node(s) Paraaortic|Lymph Node(s) Parotid|Lymph Node(s) Pelvic|Lymph Node(s) Popliteal|Lymph Node(s) Regional|Lymph Node(s) Retroperitoneal|Lymph Node(s) Scalene|Lymph Node(s) Splenic|Lymph Node(s) Subclavicular|Lymph Node(s) Submandibular|Lymph Node(s) Supraclavicular|Lymph Nodes(s) Mediastinal|Mandible|Maxilla|Mediastinal Soft Tissue|Mediastinum|Mesentery|Mesothelium|Middle Finger|Mitochondria|Muscle|Nails|Nasal Cavity|Nasal Soft Tissue|Nasopharynx|Neck|Nerve|Nerve(s) Cranial|Not Allowed To Collect|Not Reported|Occipital Cortex|Ocular Orbits|Omentum|Oral Cavity|Oral Cavity - Mucosa Only|Oropharynx|Other|Ovary|Palate|Pancreas|Paranasal Sinuses|Paraspinal Ganglion|Parathyroid|Parotid Gland|Patella|Pelvis|Penis|Pericardium|Periorbital Soft Tissue|Peritoneal Cavity|Peritoneum|Pharynx|Pineal|Pineal Gland|Pituitary Gland|Placenta|Pleura|Popliteal Fossa|Prostate|Pylorus|Rectosigmoid Junction|Rectum|Retina|Retro-Orbital Region|Retroperitoneum|Rib|Ring Finger|Round Ligament|Sacrum|Salivary Gland|Scalp|Scapula|Sciatic Nerve|Scrotum|Seminal Vesicle|Shoulder|Sigmoid Colon|Sinus|Sinus(es), Maxillary|Skeletal Muscle|Skin|Skull|Small Bowel|Small Bowel - Mucosa Only|Small Finger|Soft Tissue|Spinal Column|Spinal Cord|Spleen|Splenic Flexure|Sternum|Stomach|Stomach - Mucosa Only|Subcutaneous Tissue|Subglottis|Sublingual Gland|Submandibular Gland|Supraglottis|Synovium|Temporal Cortex|Tendon|Testis|Thigh|Thoracic Spine|Thorax|Throat|Thumb|Thymus|Thyroid|Tibia|Tongue|Tonsil|Tonsil (Pharyngeal)|Trachea / Major Bronchi|Transverse Colon|Trunk|Umbilical Cord|Unknown|Ureter|Urethra|Urinary Tract|Uterus|Uvula|Vagina|Vas Deferens|Vein|Venous|Vertebra|Vulva|White Blood Cells|Wrist	289/291 (both/PDC)	Cerebrum|Groin	Cerebral Hemisphere|Inguinal Region
biospecimen_laterality	biospecimen_laterality	Bilateral|Left|Not Reported|Right|Unknown	5/5 (both/PDC)		
composition	composition	2D Classical Conditionally Reprogrammed Cells|2D Modified Conditionally Reprogrammed Cells|3D Air-Liquid Interface Organoid|3D Neurosphere|3D Organoid|Adherent Cell Line|Bone Marrow Components|Bone Marrow Components NOS|Buccal Cells|Buffy Coat|Cell|Control Analyte|Derived Cell Line|EBV Immortalized|Fibroblasts from Bone Marrow Normal|Granulocytes|Human Original Cells|Liquid Suspension Cell Line|Mixed Adherent Suspension|Mononuclear Cells from Bone Marrow Normal|Not Allowed To Collect|Not Reported|Peripheral Blood Components NOS|Peripheral Whole Blood|Plasma|Pleural Effusion|Saliva|Serum|Solid Tissue|Sorted Cells|Sputum|Unknown|Whole Bone Marrow	33/34 (both/PDC)	Lymphocytes	Lymphocyte Count
diagnosis_pathologically_confirmed	diagnosis_pathologically_confirmed	False|Not Allowed To Collect|Not Reported|True|Unknown	5/5 (both/PDC)		
distance_normal_to_tumor	distance_normal_to_tumor	Adjacent (< or = 2cm)|Distal (>2cm)|Not Reported|Unknown	4/4 (both/PDC)		
method_of_sample_procurement	method_of_sample_procurement	Abdomino-perineal Resection of Rectum|Anterior Resection of Rectum|Ascites Drainage|Aspirate|Autopsy|Biopsy|Blood Draw|Bone Marrow Aspirate|Buccal Mucosal Resection|Core Biopsy|Cystectomy|Deep Parotidectomy|Endo Rectal Tumor Resection|Endolaryngeal Excision|Endoscopic Biopsy|Endoscopic Mucosal Resection (EMR)|Enucleation|Excisional Biopsy|Fine Needle Aspiration|Full Hysterectomy|Glossectomy|Gross Total Resection|Hand Assisted Laparoscopic Radical Nephrectomy|Hysterectomy NOS|Incisional Biopsy|Laparoscopic Biopsy|Laparoscopic Partial Nephrectomy|Laparoscopic Radical Nephrectomy|Laparoscopic Radical Prostatectomy with Robotics|Laparoscopic Radical Prostatectomy without Robotics|Laryngopharyngectomy|Left Hemicolectomy|Liquid Biopsy|Lobectomy|Local Resection (Exoresection; wall resection)|Lumpectomy|Lymph Node Dissection|Lymphadenectomy|Mandibulectomy|Maxillectomy|Metastasectomy|Modified Radical Mastectomy|Needle Biopsy|Not Allowed To Collect|Not Reported|Omentectomy|Oophorectomy|Open Craniotomy|Open Partial Nephrectomy|Open Radical Nephrectomy|Open Radical Prostatectomy|Orchiectomy|Other|Other Surgical Resection|Palatectomy|Pan-Procto Colectomy|Pancreatectomy|Paracentesis|Parotidectomy, NOS|Partial Hepatectomy|Partial Laryngectomy|Partial Maxillectomy|Partial Nephrectomy|Peritoneal Lavage|Pneumonectomy|Punch Biopsy|Radical Hysterectomy|Radical Maxillectomy|Radical Nephrectomy|Radical Prostatectomy|Right Hemicolectomy|Salpingectomy|Salpingo-oophorectomy|Sigmoid Colectomy|Simple Hysterectomy|Simple Mastectomy|Subtotal Prostatectomy|Subtotal Resection|Superficial Parotidectomy|Supracervical Hysterectomy|Supracricoid Laryngectomy|Supraglottic Laryngectomy|Thoracentesis|Thoracoscopic Biopsy|Tonsillectomy|Total Colectomy|Total Hepatectomy|Total Laryngectomy|Total Mastectomy|Total Nephrectomy|Transoral Laser Excision|Transplant|Transurethral Resection (TURP)|Transurethral resection (TURBT)|Transverse Colectomy|Tumor Debulking|Tumor Resection|Unknown|Vertical Hemilaryngectomy|Wedge Resection|Whipple Procedure	101/103 (both/PDC)	Indeterminant|Surgical Resection	Excision|Indeterminate
preservation_method	preservation_method	Cryopreserved|FFPE|Fresh|Frozen|Not Allowed To Collect|Not Reported|OCT|Snap Frozen|Unknown	9/9 (both/PDC)		
sample_is_ref			0/2 (both/PDC)	False|True	
sample_type	sample_type	Additional - New Primary|Additional Metastatic|Benign Neoplasms|Blood Derived Cancer - Bone Marrow|Blood Derived Cancer - Bone Marrow, Post-treatment|Blood Derived Cancer - Peripheral Blood|Blood Derived Cancer - Peripheral Blood, Post-treatment|Blood Derived Liquid Biopsy|Blood Derived Normal|Bone Marrow Normal|Buccal Cell Normal|Cell Line Derived Xenograft Tissue|Cell Lines|Control Analyte|DNA|EBV Immortalized Normal|Expanded Next Generation Cancer Model|FFPE Recurrent|FFPE Scrolls|Fibroblasts from Bone Marrow Normal|GenomePlex (Rubicon) Amplified DNA|Granulocytes|Human Tumor Original Cells|In Situ Neoplasms|Lymphoid Normal|Metastatic|Mixed Adherent Suspension|Mononuclear Cells from Bone Marrow Normal|Neoplasms of Uncertain and Unknown Behavior|Next Generation Cancer Model|Next Generation Cancer Model Expanded Under Non-conforming Conditions|Not Allowed To Collect|Not Reported|Pleural Effusion|Post neo-adjuvant therapy|Primary Blood Derived Cancer - Bone Marrow|Primary Blood Derived Cancer - Peripheral Blood|Primary Tumor|Primary Xenograft Tissue|RNA|Recurrent Blood Derived Cancer - Bone Marrow|Recurrent Blood Derived Cancer - Peripheral Blood|Recurrent Tumor|Repli-G (Qiagen) DNA|Repli-G X (Qiagen) DNA|Saliva|Slides|Solid Tissue Normal|Total RNA|Tumor|Tumor Adjacent Normal - Post Neo-adjuvant Therapy|Unknown|Xenograft Tissue	53/54 (both/PDC)	Normal Adjacent Tissue	
sample_type_id	sample_type_id	01|02|03|04|05|06|07|08|09|10|11|12|13|14|15|16|17|18|20|30|31|32|40|41|42|50|60|61|85|86|87|99	32/32 (both/PDC)		
tissue_collection_type	tissue_collection_type	Prospective|Retrospective	2/2 (both/PDC)		
tissue_type	tissue_type	Abnormal|Normal|Not Allowed To Collect|Not Reported|Peritumoral|Tumor|Unknown	7/7 (both/PDC)		
tumor_code	tumor_code	Acute Leukemia of Ambiguous Lineage (ALAL)|Acute lymphoblastic leukemia (ALL)|Acute myeloid leukemia (AML)|Anal Cancer (all types)|CNS, ependymoma|CNS, glioblastoma (GBM)|CNS, low grade glioma (LGG)|CNS, medulloblastoma|CNS, other|CNS, rhabdoid tumor|Cervical Cancer (all types)|Clear cell sarcoma of the kidney (CCSK)|Diffuse Large B-Cell Lymphoma (DLBCL)|Induction Failure AML (AML-IF)|Lung Cancer (all types)|NHL, Burkitt lymphoma (BL)|NHL, anaplastic large cell lymphoma|Neuroblastoma (NBL)|Non cancerous tissue|Osteosarcoma (OS)|Rhabdoid tumor (kidney) (RT)|Rhabdomyosarcoma|Soft tissue sarcoma, non-rhabdomyosarcoma|Wilms tumor (WT)	24/25 (both/PDC)	Ewing sarcoma	Ewing Sarcoma
tumor_code_id	tumor_code_id	00|01|02|03|04|10|15|20|21|30|40|41|50|51|52|60|61|62|63|64|65|70|71|80|81	25/25 (both/PDC)		
tumor_descriptor	tumor_descriptor	Metastatic|NOS|Not Allowed To Collect|Not Applicable|Not Reported|Premalignant|Primary|Recurrence|Unknown|Xenograft	10/10 (both/PDC)		
chemo_concurrent_to_radiation	chemo_concurrent_to_radiation	False|Not Reported|True|Unknown	4/4 (both/PDC)		
initial_disease_status	initial_disease_status	Initial Diagnosis|Not Reported|Progressive Disease|Recurrent Disease|Residual Disease|Unknown	6/6 (both/PDC)		
reason_treatment_ended	reason_treatment_ended	Adverse Event|Course of Therapy Completed|Death|Disease Progression|Other|Withdrawal by Subject	6/6 (both/PDC)		
route_of_administration	route_of_administration	Intrathecal|Intravenous|Not Reported|Oral	4/4 (both/PDC)		
therapeutic_agents	therapeutic_agents	10-Deacetyltaxol|11C Topotecan|11D10 AluGel Anti-Idiotype Monoclonal Antibody|12-Allyldeoxoartemisinin|13-Deoxydoxorubicin|14C BMS-275183|17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521|2'-F-ara-deoxyuridine|2,6-Diaminopurine|2,6-Dimethoxyquinone|2-Deoxy-D-glucose|2-Ethylhydrazide|2-Fluoroadenine|2-Fluorofucose-containing SGN-2FF|2-Hydroxyestradiol|2-Hydroxyestrone|2-Hydroxyflutamide Depot|2-Hydroxyoleic Acid|2-Methoxyestradiol|2-Methoxyestradiol Nanocrystal Colloidal Dispersion|2-Methoxyestrone|2-O, 3-O Desulfated Heparin|3'-C-ethynylcytidine|3'-dA Phosphoramidate NUC-7738|4'-Iodo-4'-Deoxydoxorubicin|4-Nitroestrone 3-Methyl Ether|4-Thio-2-deoxycytidine|5-Aza-4'-thio-2'-deoxycytidine|5-Fluoro-2-Deoxycytidine|6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158|7-Cyanoquinocarcinol|7-Ethyl-10-Hydroxycamptothecin|7-Hydroxystaurosporine|8-Azaguanine|9-Ethyl 6-Mercaptopurine|9H-Purine-6Thio-98D|A2A Receptor Antagonist EOS100850|ADH-1|AE37 Peptide/GM-CSF Vaccine|AEE788|AKR1C3-activated Prodrug OBI-3424|AKT 1/2 Inhibitor BAY1125976|AKT Inhibitor ARQ 092|ALK Inhibitor|ALK Inhibitor ASP3026|ALK Inhibitor PLB 1003|ALK Inhibitor RO5424802|ALK Inhibitor TAE684|ALK Inhibitor WX-0593|ALK-2 Inhibitor TP-0184|ALK-FAK Inhibitor CEP-37440|ALK/FAK/Pyk2 Inhibitor CT-707|ALK/ROS1/Met Inhibitor TQ-B3101|ALK/TRK Inhibitor TSR-011|ALK/c-Met Inhibitor  TQ-B3139|APC8015F|APE1/Ref-1 Redox Inhibitor APX3330|AR Antagonist BMS-641988|ARC Fusion Protein SL-279252|ASP4132|ATM Inhibitor M 3541|ATM Kinase Inhibitor AZD0156|ATM Kinase Inhibitor AZD1390|ATR Inhibitor RP-3500|ATR Kinase Inhibitor BAY1895344|ATR Kinase Inhibitor M1774|ATR Kinase Inhibitor M6620|ATR Kinase Inhibitor VX-803|AXL Inhibitor DS-1205c|AXL Inhibitor SLC-391|AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M|AXL/ FLT3/VEGFR2 Inhibitor KC1036|Abagovomab|Abarelix|Abemaciclib|Abemaciclib Mesylate|Abexinostat|Abexinostat Tosylate|Abiraterone|Abiraterone Acetate|Abituzumab|Acai Berry Juice|Acalabrutinib|Acalisib|Aceglatone|Acetylcysteine|Acitretin|Acivicin|Aclacinomycin B|Aclarubicin|Acodazole|Acodazole Hydrochloride|Acolbifene Hydrochloride|Acridine|Acridine Carboxamide|Acronine|Actinium Ac 225 Lintuzumab|Actinium Ac 225-FPI-1434|Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591|Actinomycin C2|Actinomycin C3|Actinomycin F1|Activin Type 2B Receptor Fc Fusion Protein STM 434|Acyclic Nucleoside Phosphonate Prodrug ABI-1968|Ad-RTS-hIL-12|Adagloxad Simolenin|Adavosertib|Adecatumumab|Adenosine A2A Receptor Antagonist AZD4635|Adenosine A2A Receptor Antagonist CS3005|Adenosine A2A Receptor Antagonist NIR178|Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999|Adenosine A2A/A2B Receptor Antagonist AB928|Adenosine A2B Receptor Antagonist PBF-1129|Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201|Adenoviral Brachyury Vaccine ETBX-051|Adenoviral Cancer Vaccine PF-06936308|Adenoviral MUC1 Vaccine ETBX-061|Adenoviral PSA Vaccine ETBX-071|Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001|Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP|Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901|Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE|Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918|Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931|Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3|Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001|Aderbasib|Aerosol Gemcitabine|Aerosolized Aldesleukin|Aerosolized Liposomal Rubitecan|Afatinib|Afatinib Dimaleate|Afimoxifene|Afuresertib|Agatolimod Sodium|Agerafenib|Aglatimagene Besadenovec|Agonistic Anti-CD40 Monoclonal Antibody ADC-1013|Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949|Agonistic Anti-OX40 Monoclonal Antibody MEDI6469|Akt Inhibitor LY2780301|Akt Inhibitor MK2206|Akt Inhibitor SR13668|Akt/ERK Inhibitor ONC201|Alacizumab Pegol|Alanosine|Albumin-binding Cisplatin Prodrug BTP-114|Aldesleukin|Aldoxorubicin|Alectinib|Alefacept|Alemtuzumab|Alestramustine|Alflutinib Mesylate|Algenpantucel-L|Alisertib|Alitretinoin|Alkotinib|Allodepleted T Cell Immunotherapeutic ATIR101|Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715|Allogeneic Anti-BCMA-CAR T-cells PBCAR269A|Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells|Allogeneic Anti-CD19 CAR T-cells ALLO-501A|Allogeneic Anti-CD19 Universal CAR-T Cells CTA101|Allogeneic Anti-CD19-CAR T-cells PBCAR0191|Allogeneic Anti-CD20 CAR T-cells LUCAR-20S|Allogeneic Anti-CD20-CAR T-cells PBCAR20A|Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22|Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100|Allogeneic CD56-positive CD3-negative Natural Killer Cells CYNK-001|Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001|Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120|Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130|Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A|Allogeneic Cellular Vaccine 1650-G|Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM|Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine|Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine|Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo|Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo|Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2|Allogeneic Irradiated Melanoma Cell Vaccine CSF470|Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307|Allogeneic Melanoma Vaccine AGI-101H|Allogeneic Natural Killer Cell Line MG4101|Allogeneic Natural Killer Cell Line NK-92|Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01|Allogeneic Renal Cell Carcinoma Vaccine MGN1601|Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19|Allosteric ErbB Inhibitor BDTX-189|Allovectin-7|Almurtide|Alobresib|Alofanib|Alpelisib|Alpha Galactosylceramide|Alpha V Beta 1 Inhibitor ATN-161|Alpha V Beta 8 Antagonist PF-06940434|Alpha-Gal AGI-134|Alpha-Thioguanine Deoxyriboside|Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H|Alpha-tocopheryloxyacetic Acid|Alsevalimab|Altiratinib|Altretamine|Alvespimycin|Alvespimycin Hydrochloride|Alvocidib|Alvocidib Hydrochloride|Alvocidib Prodrug TP-1287|Amatuximab|Ambamustine|Ambazone|Amblyomin-X|Amcasertib|Ametantrone|Amifostine|Amino Acid Injection|Aminocamptothecin|Aminocamptothecin Colloidal Dispersion|Aminoflavone Prodrug AFP464|Aminopterin|Aminopterin Sodium|Amivantamab|Amolimogene Bepiplasmid|Amonafide L-Malate|Amrubicin|Amrubicin Hydrochloride|Amsacrine|Amsacrine Lactate|Amsilarotene|Amustaline|Amustaline Dihydrochloride|Amuvatinib|Amuvatinib Hydrochloride|Anakinra|Anastrozole|Anaxirone|Ancitabine|Ancitabine Hydrochloride|Andecaliximab|Androgen Antagonist APC-100|Androgen Receptor Antagonist BAY 1161116|Androgen Receptor Antagonist SHR3680|Androgen Receptor Antagonist TAS3681|Androgen Receptor Antagonist TRC253|Androgen Receptor Antisense Oligonucleotide AZD5312|Androgen Receptor Antisense Oligonucleotide EZN-4176|Androgen Receptor Degrader ARV-110|Androgen Receptor Degrader CC-94676|Androgen Receptor Downregulator AZD3514|Androgen Receptor Inhibitor EPI-7386|Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118|Androgen Receptor/Glucocorticoid Receptor  Antagonist CB-03-10|Andrographolide|Androstane Steroid HE3235|Anetumab Ravtansine|Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241|Angiogenesis Inhibitor GT-111|Angiogenesis Inhibitor JI-101|Angiogenesis/Heparanase Inhibitor PG545|Angiopoietin-2-specific Fusion Protein PF-04856884|Anhydrous Enol-oxaloacetate|Anhydrovinblastine|Aniline Mustard|Anlotinib Hydrochloride|Annamycin|Annamycin Liposomal|Annonaceous Acetogenins|Ansamitomicin P-3|Anthramycin|Anthrapyrazole|Anti c-KIT Antibody-drug Conjugate LOP628|Anti-5T4 Antibody-Drug Conjugate PF-06263507|Anti-5T4 Antibody-drug Conjugate ASN004|Anti-5T4 Antibody-drug Conjugate SYD1875|Anti-A33 Monoclonal Antibody KRN330|Anti-A5B1 Integrin Monoclonal Antibody PF-04605412|Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087|Anti-AG7 Antibody Drug Conjugate AbGn-107|Anti-AGS-16 Monoclonal Antibody AGS-16M18|Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME|Anti-AGS-8 Monoclonal Antibody AGS-8M4|Anti-ANG2 Monoclonal Antibody MEDI-3617|Anti-APRIL Monoclonal Antibody BION-1301|Anti-AXL Fusion Protein AVB-S6-500|Anti-AXL/PBD Antibody-drug Conjugate ADCT-601|Anti-B7-H3 Antibody DS-5573a|Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a|Anti-B7-H4 Monoclonal Antibody FPA150|Anti-B7H3 Antibody-drug Conjugate MGC018|Anti-BCMA Antibody SEA-BCMA|Anti-BCMA Antibody-drug Conjugate AMG 224|Anti-BCMA Antibody-drug Conjugate CC-99712|Anti-BCMA Antibody-drug Conjugate GSK2857916|Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA|Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459|Anti-BCMA/CD3 BiTE Antibody AMG 420|Anti-BCMA/CD3 BiTE Antibody AMG 701|Anti-BCMA/CD3 BiTE Antibody REGN5458|Anti-BCMA/PBD ADC MEDI2228|Anti-BTLA Monoclonal Antibody TAB004|Anti-BTN3A Agonistic Monoclonal Antibody ICT01|Anti-C-met Monoclonal Antibody SAIT301|Anti-C4.4a Antibody-Drug Conjugate BAY1129980|Anti-C5aR Monoclonal Antibody IPH5401|Anti-CA19-9 Monoclonal Antibody 5B1|Anti-CA6-DM4 Immunoconjugate SAR566658|Anti-CCR7 Antibody-drug Conjugate JBH492|Anti-CD117 Monoclonal Antibody JSP191|Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1|Anti-CD123 ADC IMGN632|Anti-CD123 Monoclonal Antibody CSL360|Anti-CD123 Monoclonal Antibody KHK2823|Anti-CD123 x Anti-CD3 Bispecific Antibody XmAb1404|Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A|Anti-CD123/CD3 BiTE Antibody SAR440234|Anti-CD123/CD3 Bispecific Antibody APVO436|Anti-CD123/CD3 Bispecific Antibody JNJ-63709178|Anti-CD137 Agonistic Monoclonal Antibody ADG106|Anti-CD137 Agonistic Monoclonal Antibody AGEN2373|Anti-CD137 Agonistic Monoclonal Antibody ATOR-1017|Anti-CD137 Agonistic Monoclonal Antibody CTX-471|Anti-CD137 Agonistic Monoclonal Antibody LVGN6051|Anti-CD157 Monoclonal Antibody MEN1112|Anti-CD166 Probody-drug Conjugate CX-2009|Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003|Anti-CD19 Antibody-drug Conjugate SGN-CD19B|Anti-CD19 Monoclonal Antibody DI-B4|Anti-CD19 Monoclonal Antibody MDX-1342|Anti-CD19 Monoclonal Antibody MEDI-551|Anti-CD19 Monoclonal Antibody XmAb5574|Anti-CD19 iCAR NK Cells|Anti-CD19-DM4 Immunoconjugate SAR3419|Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL|Anti-CD19/CD22 CAR NK Cells|Anti-CD19/CD3 BiTE Antibody AMG 562|Anti-CD19/CD3 Tetravalent Antibody AFM11|Anti-CD20 Monoclonal Antibody B001|Anti-CD20 Monoclonal Antibody BAT4306F|Anti-CD20 Monoclonal Antibody MIL62|Anti-CD20 Monoclonal Antibody PRO131921|Anti-CD20 Monoclonal Antibody SCT400|Anti-CD20 Monoclonal Antibody TL011|Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002|Anti-CD20-engineered Toxin Body MT-3724|Anti-CD20/Anti-CD3 Bispecific IgM Antibody IGM2323|Anti-CD20/CD3 Monoclonal Antibody REGN1979|Anti-CD20/CD3 Monoclonal Antibody XmAb13676|Anti-CD205 Antibody-drug Conjugate OBT076|Anti-CD22 ADC TRPH-222|Anti-CD22 Monoclonal Antibody-MMAE Conjugate DCDT2980S|Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A|Anti-CD25 Monoclonal Antibody RO7296682|Anti-CD25-PBD Antibody-drug Conjugate ADCT-301|Anti-CD26 Monoclonal Antibody YS110|Anti-CD27 Agonistic Monoclonal Antibody MK-5890|Anti-CD27L Antibody-Drug Conjugate AMG 172|Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1)|Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044|Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody JNJ-64007957|Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody PF-06863135|Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05|Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564|Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119|Anti-CD3/CD20 Bispecific Antibody GEN3013|Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424|Anti-CD3/CD7-Ricin Toxin A Immunotoxin|Anti-CD30 Monoclonal Antibody MDX-1401|Anti-CD30 Monoclonal Antibody XmAb2513|Anti-CD30/CD16A Monoclonal Antibody AFM13|Anti-CD30/DM1 Antibody-drug Conjugate F0002|Anti-CD32B Monoclonal Antibody BI-1206|Anti-CD33 Antibody-drug Conjugate IMGN779|Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564|Anti-CD33 Monoclonal Antibody BI 836858|Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633|Anti-CD33/CD3 BiTE Antibody AMG 330|Anti-CD33/CD3 BiTE Antibody AMG 673|Anti-CD33/CD3 Bispecific Antibody GEM 333|Anti-CD33/CD3 Bispecific Antibody JNJ-67571244|Anti-CD352 Antibody-drug Conjugate SGN-CD352A|Anti-CD37 Antibody-Drug Conjugate IMGN529|Anti-CD37 Bispecific Monoclonal Antibody GEN3009|Anti-CD37 MMAE Antibody-drug Conjugate AGS67E|Anti-CD37 Monoclonal Antibody BI 836826|Anti-CD38 Antibody-drug Conjugate STI-6129|Anti-CD38 Monoclonal Antibody MOR03087|Anti-CD38 Monoclonal Antibody SAR442085|Anti-CD38 Monoclonal Antibody TAK-079|Anti-CD38-targeted IgG4-attenuated IFNa TAK-573|Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257|Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342|Anti-CD39 Monoclonal Antibody SRF617|Anti-CD39 Monoclonal Antibody TTX-030|Anti-CD40 Agonist Monoclonal Antibody ABBV-927|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Anti-CD40 Monoclonal Antibody Chi Lob 7/4|Anti-CD40 Monoclonal Antibody SEA-CD40|Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042|Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428|Anti-CD40L Fc-Fusion Protein BMS-986004|Anti-CD44 Monoclonal Antibody RO5429083|Anti-CD45 Monoclonal Antibody AHN-12|Anti-CD46 Antibody-drug Conjugate FOR46|Anti-CD47 ADC SGN-CD47M|Anti-CD47 Monoclonal Antibody AO-176|Anti-CD47 Monoclonal Antibody CC-90002|Anti-CD47 Monoclonal Antibody Hu5F9-G4|Anti-CD47 Monoclonal Antibody IBI188|Anti-CD47 Monoclonal Antibody IMC-002|Anti-CD47 Monoclonal Antibody SHR-1603|Anti-CD47 Monoclonal Antibody SRF231|Anti-CD47 Monoclonal Antibody TJC4|Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801|Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A|Anti-CD52 Monoclonal Antibody ALLO-647|Anti-CD70 Antibody-Drug Conjugate MDX-1203|Anti-CD70 Antibody-drug Conjugate SGN-CD70A|Anti-CD70 CAR-expressing T Lymphocytes|Anti-CD70 Monoclonal Antibody MDX-1411|Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029|Anti-CD73 Monoclonal Antibody BMS-986179|Anti-CD73 Monoclonal Antibody CPI-006|Anti-CD73 Monoclonal Antibody NZV930|Anti-CD73 Monoclonal Antibody TJ4309|Anti-CD74 Antibody-drug Conjugate STRO-001|Anti-CD98 Monoclonal Antibody IGN523|Anti-CDH6 Antibody-drug Conjugate HKT288|Anti-CEA BiTE Monoclonal Antibody AMG211|Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody|Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2|Anti-CEACAM1 Monoclonal Antibody CM-24|Anti-CEACAM5 Antibody-Drug Conjugate SAR408701|Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47|Anti-CEACAM6 Antibody BAY1834942|Anti-CLDN6 Monoclonal Antibody ASP1650|Anti-CLEC12A/CD3 Bispecific Antibody MCLA117|Anti-CLEVER-1 Monoclonal Antibody FP-1305|Anti-CSF1 Monoclonal Antibody PD-0360324|Anti-CSF1R Monoclonal Antibody IMC-CS4|Anti-CSF1R Monoclonal Antibody SNDX-6352|Anti-CTGF Monoclonal Antibody FG-3019|Anti-CTLA-4 Monoclonal Antibody ADG116|Anti-CTLA-4 Monoclonal Antibody ADU-1604|Anti-CTLA-4 Monoclonal Antibody AGEN1181|Anti-CTLA-4 Monoclonal Antibody BCD-145|Anti-CTLA-4 Monoclonal Antibody HBM4003|Anti-CTLA-4 Monoclonal Antibody MK-1308|Anti-CTLA-4 Monoclonal Antibody ONC-392|Anti-CTLA-4 Monoclonal Antibody REGN4659|Anti-CTLA-4 Probody BMS-986288|Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217|Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841|Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015|Anti-CTLA4 Antibody Fc Fusion Protein KN044|Anti-CTLA4 Monoclonal Antibody BMS-986218|Anti-CXCR4 Monoclonal Antibody PF-06747143|Anti-Claudin18.2 Monoclonal Antibody TST001|Anti-DKK-1 Monoclonal Antibody LY2812176|Anti-DKK1 Monoclonal Antibody BHQ880|Anti-DLL3/CD3 BiTE Antibody AMG 757|Anti-DLL4 Monoclonal Antibody MEDI0639|Anti-DLL4/VEGF Bispecific Monoclonal Antibody OMP-305B83|Anti-DR5 Agonist Monoclonal Antibody TRA-8|Anti-DR5 Agonistic Antibody DS-8273a|Anti-DR5 Agonistic Monoclonal Antibody INBRX-109|Anti-Denatured Collagen Monoclonal Antibody TRC093|Anti-EGFR Monoclonal Antibody CPGJ 602|Anti-EGFR Monoclonal Antibody EMD 55900|Anti-EGFR Monoclonal Antibody GC1118|Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX|Anti-EGFR Monoclonal Antibody HLX-07|Anti-EGFR Monoclonal Antibody Mixture MM-151|Anti-EGFR Monoclonal Antibody RO5083945|Anti-EGFR Monoclonal Antibody SCT200|Anti-EGFR Monoclonal Antibody SYN004|Anti-EGFR TAP Antibody-drug Conjugate IMGN289|Anti-EGFR/CD16A Bispecific Antibody AFM24|Anti-EGFR/DM1 Antibody-drug Conjugate AVID100|Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013|Anti-EGFR/PBD Antibody-drug Conjugate ABBV-321|Anti-EGFR/c-Met Bispecific Antibody EMB-01|Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372|Anti-EGFRvIII Antibody Drug Conjugate AMG 595|Anti-EGFRvIII Immunotoxin MR1-1|Anti-EGFRvIII/CD3 BiTE Antibody AMG 596|Anti-EGP-2 Immunotoxin MOC31-PE|Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F|Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F|Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A|Anti-Ep-CAM Monoclonal Antibody ING-1|Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310|Anti-EphA2 Monoclonal Antibody DS-8895a|Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547|Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111|Anti-ErbB3 Antibody ISU104|Anti-ErbB3 Monoclonal Antibody AV-203|Anti-ErbB3 Monoclonal Antibody CDX-3379|Anti-ErbB3 Monoclonal Antibody REGN1400|Anti-ErbB3/Anti-IGF-1R Bispecific Monoclonal Antibody MM-141|Anti-FAP/Interleukin-2 Fusion Protein RO6874281|Anti-FCRH5/CD3 BiTE Antibody BFCR4350A|Anti-FGFR2 Antibody BAY1179470|Anti-FGFR3 Antibody-drug Conjugate LY3076226|Anti-FGFR4 Monoclonal Antibody U3-1784|Anti-FLT3 Antibody-drug Conjugate AGS62P1|Anti-FLT3 Monoclonal Antibody 4G8-SDIEM|Anti-FLT3 Monoclonal Antibody IMC-EB10|Anti-FLT3/CD3 BiTE Antibody AMG 427|Anti-FRA/Eribulin Antibody-drug Conjugate MORAb-202|Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002|Anti-GARP Monoclonal Antibody ABBV-151|Anti-GCC Antibody-Drug Conjugate MLN0264|Anti-GCC Antibody-Drug Conjugate TAK-164|Anti-GD2 Monoclonal Antibody MORAb-028|Anti-GD2 Monoclonal Antibody hu14.18K322A|Anti-GD2 hu3F8/Anti-CD3 huOKT3 Bispecific Antibody|Anti-GD3 Antibody-drug Conjugate PF-06688992|Anti-GITR Agonistic Monoclonal Antibody ASP1951|Anti-GITR Agonistic Monoclonal Antibody BMS-986156|Anti-GITR Agonistic Monoclonal Antibody INCAGN01876|Anti-GITR Monoclonal Antibody GWN 323|Anti-GITR Monoclonal Antibody MK-4166|Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a|Anti-GRP78 Monoclonal Antibody PAT-SM6|Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962|Anti-Globo H Monoclonal Antibody OBI-888|Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999|Anti-Glypican 3/CD3 Bispecific Antibody ERY974|Anti-GnRH Vaccine PEP223|Anti-HA Epitope Monoclonal Antibody MEDI8852|Anti-HB-EGF Monoclonal Antibody KHK2866|Anti-HBEGF Monoclonal Antibody U3-1565|Anti-HER-2 Bispecific Antibody KN026|Anti-HER2 ADC DS-8201a|Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702|Anti-HER2 Antibody-drug Conjugate A166|Anti-HER2 Antibody-drug Conjugate ARX788|Anti-HER2 Antibody-drug Conjugate BAT8001|Anti-HER2 Antibody-drug Conjugate DP303c|Anti-HER2 Antibody-drug Conjugate MEDI4276|Anti-HER2 Antibody-drug Conjugate RC48|Anti-HER2 Bi-specific Monoclonal Antibody ZW25|Anti-HER2 Bispecific Antibody-drug Conjugate ZW49|Anti-HER2 Immune Stimulator-antibody Conjugate NJH395|Anti-HER2 Monoclonal Antibody B002|Anti-HER2 Monoclonal Antibody CT-P6|Anti-HER2 Monoclonal Antibody HLX22|Anti-HER2 Monoclonal Antibody/Anti-CD137Anticalin Bispecific Fusion Protein PRS-343|Anti-HER2-DM1 ADC B003|Anti-HER2-DM1 Antibody-drug Conjugate GQ1001|Anti-HER2-vc0101 ADC PF-06804103|Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A|Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302|Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128|Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522|Anti-HER2/MMAE Antibody-drug Conjugate MRG002|Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A|Anti-HER3 Antibody-drug Conjugate U3 1402|Anti-HER3 Monoclonal Antibody GSK2849330|Anti-HGF Monoclonal Antibody TAK-701|Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968|Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1|Anti-HLA-DR Monoclonal Antibody IMMU-114|Anti-HLA-G Antibody TTX-080|Anti-ICAM-1 Monoclonal Antibody BI-505|Anti-ICOS Agonist Antibody GSK3359609|Anti-ICOS Agonist Monoclonal Antibody BMS-986226|Anti-ICOS Monoclonal Antibody KY1044|Anti-ICOS Monoclonal Antibody MEDI-570|Anti-IGF-1R Monoclonal Antibody AVE1642|Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022|Anti-IL-1 alpha Monoclonal Antibody MABp1|Anti-IL-13 Humanized Monoclonal Antibody TNX-650|Anti-IL-15 Monoclonal Antibody AMG 714|Anti-IL-8 Monoclonal Antibody BMS-986253|Anti-IL-8 Monoclonal Antibody HuMax-IL8|Anti-ILDR2 Monoclonal Antibody BAY 1905254|Anti-ILT4 Monoclonal Antibody MK-4830|Anti-IRF4 Antisense Oligonucleotide ION251|Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388|Anti-KIR Monoclonal Antibody IPH 2101|Anti-KSP/Anti-VEGF siRNAs ALN-VSP02|Anti-LAG-3 Monoclonal Antibody IBI-110|Anti-LAG-3 Monoclonal Antibody INCAGN02385|Anti-LAG-3 Monoclonal Antibody LAG525|Anti-LAG-3 Monoclonal Antibody REGN3767|Anti-LAG-3/PD-L1 Bispecific Antibody FS118|Anti-LAG3 Monoclonal Antibody BI 754111|Anti-LAG3 Monoclonal Antibody MK-4280|Anti-LAG3 Monoclonal Antibody TSR-033|Anti-LAMP1 Antibody-drug Conjugate SAR428926|Anti-LGR5 Monoclonal Antibody BNC101|Anti-LIF Monoclonal Antibody MSC-1|Anti-LILRB4 Monoclonal Antibody IO-202|Anti-LIV-1 Monoclonal Antibody-MMAE Conjugate SGN-LIV1A|Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102|Anti-Ly6E Antibody-Drug Conjugate RG 7841|Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C|Anti-MMP-9 Monoclonal Antibody GS-5745|Anti-MUC1 Monoclonal Antibody BTH1704|Anti-MUC16/CD3 BiTE Antibody REGN4018|Anti-MUC16/CD3 Bispecific Antibody REGN4018|Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A|Anti-MUC17/CD3 BiTE Antibody AMG 199|Anti-Melanin Monoclonal Antibody PTI-6D2|Anti-Met Monoclonal Antibody Mixture Sym015|Anti-Met/EGFR Monoclonal Antibody LY3164530|Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062|Anti-NRP1 Antibody ASP1948|Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A|Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso|Anti-NaPi2b Antibody-drug Conjugate XMT-1592|Anti-NaPi2b Monoclonal Antibody XMT-1535|Anti-Neuropilin-1 Monoclonal Antibody MNRP1685A|Anti-Nucleolin Aptamer AS1411|Anti-OFA Immunotherapeutic BB-MPI-03|Anti-OX40 Agonist Monoclonal Antibody ABBV-368|Anti-OX40 Agonist Monoclonal Antibody BGB-A445|Anti-OX40 Agonist Monoclonal Antibody PF-04518600|Anti-OX40 Antibody BMS 986178|Anti-OX40 Hexavalent Agonist Antibody INBRX-106|Anti-OX40 Monoclonal Antibody GSK3174998|Anti-OX40 Monoclonal Antibody IBI101|Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256|Anti-PD-1 Checkpoint Inhibitor PF-06801591|Anti-PD-1 Fusion Protein AMP-224|Anti-PD-1 Monoclonal Antibody 609A|Anti-PD-1 Monoclonal Antibody AK105|Anti-PD-1 Monoclonal Antibody AMG 404|Anti-PD-1 Monoclonal Antibody BAT1306|Anti-PD-1 Monoclonal Antibody BCD-100|Anti-PD-1 Monoclonal Antibody BI 754091|Anti-PD-1 Monoclonal Antibody CS1003|Anti-PD-1 Monoclonal Antibody F520|Anti-PD-1 Monoclonal Antibody GLS-010|Anti-PD-1 Monoclonal Antibody HLX10|Anti-PD-1 Monoclonal Antibody HX008|Anti-PD-1 Monoclonal Antibody JTX-4014|Anti-PD-1 Monoclonal Antibody LZM009|Anti-PD-1 Monoclonal Antibody MEDI0680|Anti-PD-1 Monoclonal Antibody MGA012|Anti-PD-1 Monoclonal Antibody SCT-I10A|Anti-PD-1 Monoclonal Antibody Sym021|Anti-PD-1 Monoclonal Antibody TSR-042|Anti-PD-1/Anti-CTLA4 DART Protein MGD019|Anti-PD-1/Anti-HER2 Bispecific Antibody IBI315|Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669|Anti-PD-1/Anti-LAG-3 DART Protein MGD013|Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318|Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172|Anti-PD-1/CD47 Infusion Protein HX009|Anti-PD-1/CTLA-4 Bispecific Antibody AK104|Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752|Anti-PD-1/TIM-3 Bispecific Antibody RO7121661|Anti-PD-1/VEGF Bispecific Antibody AK112|Anti-PD-L1 Monoclonal Antibody A167|Anti-PD-L1 Monoclonal Antibody BCD-135|Anti-PD-L1 Monoclonal Antibody BGB-A333|Anti-PD-L1 Monoclonal Antibody CBT-502|Anti-PD-L1 Monoclonal Antibody CK-301|Anti-PD-L1 Monoclonal Antibody CS1001|Anti-PD-L1 Monoclonal Antibody FAZ053|Anti-PD-L1 Monoclonal Antibody GR1405|Anti-PD-L1 Monoclonal Antibody HLX20|Anti-PD-L1 Monoclonal Antibody IMC-001|Anti-PD-L1 Monoclonal Antibody LY3300054|Anti-PD-L1 Monoclonal Antibody MDX-1105|Anti-PD-L1 Monoclonal Antibody MSB2311|Anti-PD-L1 Monoclonal Antibody RC98|Anti-PD-L1 Monoclonal Antibody SHR-1316|Anti-PD-L1 Monoclonal Antibody TG-1501|Anti-PD-L1 Monoclonal Antibody ZKAB001|Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105|Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046|Anti-PD-L1/CD137 Bispecific Antibody MCLA-145|Anti-PD-L1/IL-15 Fusion Protein KD033|Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244|Anti-PD1 Monoclonal Antibody AGEN2034|Anti-PD1/CTLA4 Bispecific Antibody XmAb20717|Anti-PGF Monoclonal Antibody RO5323441|Anti-PKN3 siRNA Atu027|Anti-PLGF Monoclonal Antibody TB-403|Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4|Anti-PRAME Immunotherapeutic GSK2302032A|Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C|Anti-PRL-3 Monoclonal Antibody PRL3-zumab|Anti-PSCA Monoclonal Antibody AGS-1C4D4|Anti-PSMA Monoclonal Antibody MDX1201-A488|Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704|Anti-PSMA Monoclonal Antibody-MMAE Conjugate|Anti-PSMA/CD28 Bispecific Antibody REGN5678|Anti-PSMA/CD3 Bispecific Antibody CCW702|Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081|Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414|Anti-PSMA/PBD ADC MEDI3726|Anti-PTK7/Auristatin-0101 Antibody-drug Conjugate PF-06647020|Anti-PVRIG Monoclonal Antibody COM701|Anti-RANKL Monoclonal Antibody GB-223|Anti-RANKL Monoclonal Antibody JMT103|Anti-ROR1 ADC VLS-101|Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002|Anti-Ribonucleoprotein Antibody ATRC-101|Anti-S15 Monoclonal Antibody NC318|Anti-SIRPa Monoclonal Antibody CC-95251|Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E|Anti-TAG-72 Monoclonal Antibody scFV CC-49/218|Anti-TF Monoclonal Antibody ALT-836|Anti-TGF-beta Monoclonal Antibody NIS793|Anti-TGF-beta Monoclonal Antibody SAR-439459|Anti-TGF-beta RII Monoclonal Antibody IMC-TR1|Anti-TIGIT Monoclonal Antibody AB154|Anti-TIGIT Monoclonal Antibody BGB-A1217|Anti-TIGIT Monoclonal Antibody BMS-986207|Anti-TIGIT Monoclonal Antibody COM902|Anti-TIGIT Monoclonal Antibody OMP-313M32|Anti-TIGIT Monoclonal Antibody SGN-TGT|Anti-TIM-3 Antibody BMS-986258|Anti-TIM-3 Monoclonal Antibody BGB-A425|Anti-TIM-3 Monoclonal Antibody INCAGN02390|Anti-TIM-3 Monoclonal Antibody MBG453|Anti-TIM-3 Monoclonal Antibody Sym023|Anti-TIM-3 Monoclonal Antibody TSR-022|Anti-TIM3 Monoclonal Antibody LY3321367|Anti-TIM3 Monoclonal Antibody SHR-1702|Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711|Anti-TROP2 Antibody-drug Conjugate BAT8003|Anti-TROP2 Antibody-drug Conjugate SKB264|Anti-TROP2/DXd Antibody-drug Conjugate DS-1062a|Anti-TWEAK Monoclonal Antibody RG7212|Anti-Tissue Factor Monoclonal Antibody MORAb-066|Anti-VEGF Anticalin PRS-050-PEG40|Anti-VEGF Monoclonal Antibody hPV19|Anti-VEGF/ANG2 Nanobody BI 836880|Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T|Anti-VEGFC Monoclonal Antibody VGX-100|Anti-VEGFR2 Monoclonal Antibody HLX06|Anti-VEGFR2 Monoclonal Antibody MSB0254|Anti-VEGFR3 Monoclonal Antibody IMC-3C5|Anti-VISTA Monoclonal Antibody JNJ 61610588|Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B|Anti-alpha5beta1 Integrin Antibody MINT1526A|Anti-angiopoietin Monoclonal Antibody AMG 780|Anti-c-KIT Monoclonal Antibody CDX 0158|Anti-c-MET Monoclonal Antibody LY2875358|Anti-c-Met Antibody-drug Conjugate HTI-1066|Anti-c-Met Antibody-drug Conjugate TR1801|Anti-c-Met Monoclonal Antibody ABT-700|Anti-c-Met Monoclonal Antibody ARGX-111|Anti-c-Met Monoclonal Antibody HLX55|Anti-c-fms Monoclonal Antibody AMG 820|Anti-claudin18.2 Monoclonal Antibody AB011|Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012|Anti-gpA33/CD3 Monoclonal Antibody MGD007|Anti-gremlin-1 Monoclonal Antibody UCB6114|Anti-hepcidin Monoclonal Antibody LY2787106|Anti-human GITR Monoclonal Antibody AMG 228|Anti-human GITR Monoclonal Antibody TRX518|Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A|Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181|Anti-mesothelin Antibody-drug Conjugate BMS-986148|Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100|Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A|Anti-mesothelin/MMAE Antibody-drug Conjugate RC88|Anti-myostatin Monoclonal Antibody LY2495655|Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E|Anti-nf-P2X7 Antibody Ointment BIL-010t|Anti-prolactin Receptor Antibody LFA102|Anti-sCLU Monoclonal Antibody AB-16B5|Antiangiogenic Drug Combination TL-118|Antibody-Drug Conjugate DFRF4539A|Antibody-drug Conjugate ABBV-011|Antibody-drug Conjugate ABBV-085|Antibody-drug Conjugate ABBV-155|Antibody-drug Conjugate ABBV-176|Antibody-drug Conjugate ABBV-838|Antibody-drug Conjugate ADC XMT-1536|Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014|Antibody-drug Conjugate MEDI7247|Antibody-drug Conjugate PF-06647263|Antibody-drug Conjugate PF-06664178|Antibody-drug Conjugate SC-002|Antibody-drug Conjugate SC-003|Antibody-drug Conjugate SC-004|Antibody-drug Conjugate SC-005|Antibody-drug Conjugate SC-006|Antibody-drug Conjugate SC-007|Antibody-like CD95 Receptor/Fc-fusion Protein CAN-008|Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV|Antimetabolite FF-10502|Antineoplastic Agent Combination SM-88|Antineoplastic Vaccine|Antineoplastic Vaccine GV-1301|Antineoplaston A10|Antineoplaston AS2-1|Antisense Oligonucleotide GTI-2040|Antisense Oligonucleotide QR-313|Antitumor B Key Active Component-alpha|Antrodia cinnamomea Supplement|Antroquinonol Capsule|Apalutamide|Apatorsen|Apaziquone|Aphidicoline Glycinate|Apilimod Dimesylate Capsule|Apitolisib|Apolizumab|Apomab|Apomine|Apoptosis Inducer BZL101|Apoptosis Inducer GCS-100|Apoptosis Inducer MPC-2130|Apricoxib|Aprinocarsen|Aprutumab|Aprutumab Ixadotin|Arabinoxylan Compound MGN3|Aranose|Archexin|Arcitumomab|Arfolitixorin|Arginase Inhibitor INCB001158|Arginine Butyrate|Arnebia Indigo Jade Pearl Topical Cream|Arsenic Trioxide|Arsenic Trioxide Capsule Formulation ORH 2014|Artemether Sublingual Spray|Artemisinin Dimer|Artesunate|Arugula Seed Powder|Aryl Hydrocarbon Receptor Antagonist BAY2416964|Aryl Hydrocarbon Receptor Inhibitor IK-175|Asaley|Asciminib|Ascrinvacumab|Ashwagandha Root Powder Extract|Aspacytarabine|Asparaginase|Asparaginase Erwinia chrysanthemi|Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10|Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10|Astuprotimut-R|Asulacrine|Asulacrine Isethionate|Asunercept|At 211 Monoclonal Antibody 81C6|Atamestane|Atezolizumab|Atiprimod|Atiprimod Dihydrochloride|Atiprimod Dimaleate|Atorvastatin Calcium|Atorvastatin Sodium|Atrasentan Hydrochloride|Attenuated Listeria monocytogenes CRS-100|Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001|Attenuated Measles Virus Encoding SCD Transgene TMV-018|Atuveciclib|Audencel|Auranofin|Aurora A Kinase Inhibitor LY3295668|Aurora A Kinase Inhibitor LY3295668 Erbumine|Aurora A Kinase Inhibitor MK5108|Aurora A Kinase Inhibitor TAS-119|Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076|Aurora B Serine/Threonine Kinase Inhibitor TAK-901|Aurora B/C Kinase Inhibitor GSK1070916A|Aurora Kinase Inhibitor AMG 900|Aurora Kinase Inhibitor BI 811283|Aurora Kinase Inhibitor MLN8054|Aurora Kinase Inhibitor PF-03814735|Aurora Kinase Inhibitor SNS-314|Aurora Kinase Inhibitor TTP607|Aurora Kinase/VEGFR2 Inhibitor CYC116|Aurora kinase A/B inhibitor TT-00420|Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707|Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055|Autologous AXL-targeted CAR T-cells CCT301-38|Autologous Anti-BCMA CAR T-cells PHE885|Autologous Anti-BCMA CAR-transduced T-cells KITE-585|Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11|Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T-lymphocytes JCARH125|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells CT053|Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143|Autologous Anti-CD123 CAR-T Cells|Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx|Autologous Anti-CD19 CAR T-cells IM19|Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19|Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19|Autologous Anti-CD19 CAR-CD28 T-cells ET019002|Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01|Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901|Autologous Anti-CD19 Chimeric Antigen Receptor T-cells AUTO1|Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19|Autologous Anti-CD19 T-cell Receptor T cells ET190L1|Autologous Anti-CD19 TAC-T cells TAC01-CD19|Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells|Autologous Anti-CD19/CD22 CAR T-cells AUTO3|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells|Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1|Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s|Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes|Autologous Anti-FLT3 CAR T Cells AMG 553|Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202|Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1|Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100|Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794|Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes|Autologous Anti-PSMA CAR-T Cells P-PSMA-101|Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes|Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B|Autologous BCMA-targeted CAR T Cells CC-98633|Autologous BCMA-targeted CAR T Cells LCAR-B4822M|Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528|Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F|Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022|Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001|Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3005|Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3006|Autologous CD123-4SCAR-expressing T-cells 4SCAR123|Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1|Autologous CD19-targeted CAR T Cells CC-97540|Autologous CD19-targeted CAR T Cells JWCAR029|Autologous CD19-targeted CAR-T Cells GC007F|Autologous CD19/PD-1 Bispecific CAR-T Cells|Autologous CD20-4SCAR-expressing T-cells 4SCAR20|Autologous CD22-4SCAR-expressing T-cells 4SCAR22|Autologous CD38-4SCAR-expressing T-cells 4SCAR38|Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19|Autologous Clonal Neoantigen T Cells ATL001|Autologous Deep IL-15 Primed T-cells TRQ15-01|Autologous Dendritic Cell Vaccine ACT2001|Autologous Dendritic Cell-based Immunotherapeutic AV0113|Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa|Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells|Autologous Genetically-modified MAGE-A4 C1032 T Cells|Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439|Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858|Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001|Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718|Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR|Autologous Mesenchymal Stem Cells Apceth_101|Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11|Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC|Autologous Multi-lineage Potential Cells|Autologous NKG2D CAR T-cells CYAD-02|Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01|Autologous Nectin-4/FAP-targeted CAR-T Cells|Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine|Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001|Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101|Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601|Autologous ROR2-targeted CAR T-cells CCT301-59|Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201|Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1|Autologous TCR-engineered T-cells IMA201|Autologous TCR-engineered T-cells IMA202|Autologous TCR-engineered T-cells IMA203|Autologous TCRm-expressing T-cells ET140203|Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG|Autologous Tumor Infiltrating Lymphocytes LN-144|Autologous Tumor Infiltrating Lymphocytes LN-145|Autologous Tumor Infiltrating Lymphocytes LN-145-S1|Autologous Tumor Infiltrating Lymphocytes MDA-TIL|Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T|Avadomide|Avadomide Hydrochloride|Avapritinib|Avdoralimab|Avelumab|Aviscumine|Avitinib Maleate|Axalimogene Filolisbac|Axatilimab|Axicabtagene Ciloleucel|Axitinib|Axl/Mer Inhibitor INCB081776|Axl/Mer Inhibitor PF-07265807|Azacitidine|Azapicyl|Azaribine|Azaserine|Azathioprine|Azimexon|Azintuxizumab Vedotin|Aziridinylbenzoquinone RH1|Azotomycin|Azurin:50-77 Cell Penetrating Peptide p28|B-Raf/VEGFR-2 Inhibitor RAF265|BC-819 Plasmid/Polyethylenimine Complex|BCG Solution|BCG Tokyo-172 Strain Solution|BCG Vaccine|BCMA x CD3 T-cell Engaging Antibody CC-93269|BCMA-CD19 Compound CAR T Cells|BCMA/CD3e Tri-specific T-cell Activating Construct HPN217|BCR-ABL/KIT/AKT/ERK Inhibitor HQP1351|BET Bromodomain Inhibitor ZEN-3694|BET Inhibitor ABBV-744|BET Inhibitor BAY1238097|BET Inhibitor BMS-986158|BET Inhibitor CC-90010|BET Inhibitor CPI-0610|BET Inhibitor FT-1101|BET Inhibitor GS-5829|BET Inhibitor GSK2820151|BET Inhibitor INCB054329|BET Inhibitor INCB057643|BET Inhibitor RO6870810|BET inhibitor BI 894999|BET-bromodomain Inhibitor ODM-207|BF-200 Gel Formulation|BH3 Mimetic ABT-737|BL22 Immunotoxin|BMI1 Inhibitor PTC596|BMS-184476|BMS-188797|BMS-214662|BMS-275183|BP-Cx1-Platinum Complex BP-C1|BR96-Doxorubicin Immunoconjugate|BRAF Inhibitor|BRAF Inhibitor ARQ 736|BRAF Inhibitor BGB-3245|BRAF Inhibitor PLX8394|BRAF(V600E) Kinase Inhibitor ABM-1310|BRAF(V600E) Kinase Inhibitor RO5212054|BRAF/EGFR Inhibitor BGB-283|BRAFV600/PI3K Inhibitor ASN003|BRD4 Inhibitor PLX2853|BRD4 Inhibitor PLX51107|BTK Inhibitor ARQ 531|BTK Inhibitor CT-1530|BTK Inhibitor DTRMWXHS-12|BTK Inhibitor HZ-A-018|BTK Inhibitor ICP-022|BTK Inhibitor LOXO-305|BTK Inhibitor M7583|BTK inhibitor TG-1701|BXQ-350 Nanovesicle Formulation|Babaodan Capsule|Bacillus Calmette-Guerin Substrain Connaught Live Antigen|Bactobolin|Bafetinib|Balixafortide|Balstilimab|Baltaleucel-T|Banoxantrone|Barasertib|Bardoxolone|Bardoxolone Methyl|Baricitinib|Batabulin|Batabulin Sodium|Batimastat|Bavituximab|Bazedoxifene|Bazlitoran|Bcl-2 Inhibitor APG 2575|Bcl-2 Inhibitor BCL201|Bcl-2 Inhibitor BGB-11417|Bcl-2 Inhibitor LP-108|Bcl-2 Inhibitor S65487|Bcl-Xs Adenovirus Vaccine|Bcr-Abl Kinase Inhibitor K0706|Bcr-Abl Kinase Inhibitor PF-114|Beauvericin|Becatecarin|Belagenpumatucel-L|Belantamab Mafodotin|Belapectin|Belimumab|Belinostat|Belotecan Hydrochloride|Belvarafenib|Belzutifan|Bemarituzumab|Bemcentinib|Bempegaldesleukin|Benaxibine|Bendamustine|Bendamustine Hydrochloride|Bendamustine-containing Nanoparticle-based Formulation RXDX-107|Benzaldehyde Dimethane Sulfonate|Benzoylphenylurea|Berberine Chloride|Bermekimab|Bersanlimab|Berubicin Hydrochloride|Berzosertib|Beta Alethine|Beta-Carotene|Beta-Glucan|Beta-Glucan MM-10-001|Beta-Thioguanine Deoxyriboside|Beta-elemene|Beta-lapachone Prodrug ARQ 761|Betaglucin Gel|Betulinic Acid|Bevacizumab|Bexarotene|Bexmarilimab|Bi-functional Alkylating Agent VAL-083|BiTE Antibody AMG 910|Bicalutamide|Bimiralisib|Binetrakin|Binimetinib|Bintrafusp Alfa|Birabresib|Birinapant|Bis(choline)tetrathiomolybdate|Bisantrene|Bisantrene Hydrochloride|Bisnafide|Bisnafide Dimesylate|Bispecific Antibody 2B1|Bispecific Antibody AGEN1223|Bispecific Antibody AMG 509|Bispecific Antibody GS-1423|Bispecific Antibody MDX-H210|Bispecific Antibody MDX447|Bisthianostat|Bivalent BRD4 Inhibitor AZD5153|Bizalimogene Ralaplasmid|Bizelesin|Black Cohosh|Black Raspberry Nectar|Bleomycin|Bleomycin A2|Bleomycin B2|Bleomycin Sulfate|Blinatumomab|Blueberry Powder Supplement|Boanmycin Hydrochloride|Bomedemstat|Boronophenylalanine-Fructose Complex|Bortezomib|Bosutinib|Bosutinib Monohydrate|Botanical Agent BEL-X-HG|Botanical Agent LEAC-102|Bovine Cartilage|Bozitinib|Brachyury-expressing Yeast Vaccine GI-6301|Breflate|Brentuximab|Brentuximab Vedotin|Brequinar|Brequinar Sodium|Briciclib Sodium|Brigatinib|Brilanestrant|Brimonidine Tartrate Nanoemulsion OCU-300|Brivanib|Brivanib Alaninate|Brivudine|Brivudine Phosphoramidate|Broad-Spectrum Human Papillomavirus Vaccine V505|Broccoli Sprout/Broccoli Seed Extract Supplement|Bromacrylide|Bromebric Acid|Bromocriptine Mesylate|Brontictuzumab|Brostacillin Hydrochloride|Brostallicin|Broxuridine|Bruceanol A|Bruceanol B|Bruceanol C|Bruceanol D|Bruceanol E|Bruceanol F|Bruceanol G|Bruceanol H|Bruceantin|Bryostatin 1|Budigalimab|Budotitane|Bufalin|Buparlisib|Burixafor|Burixafor Hydrobromide|Burosumab|Buserelin|Bushen Culuan Decoction|Bushen-Jianpi Decoction|Busulfan|Buthionine Sulfoximine|C-VISA BikDD:Liposome|C-myb Antisense Oligonucleotide G4460|C/EBP Beta Antagonist ST101|CAB-ROR2-ADC BA3021|CAIX Inhibitor DTP348|CAIX Inhibitor SLC-0111|CAR T-Cells AMG 119|CBP/beta-catenin Antagonist PRI-724|CBP/beta-catenin Modulator E7386|CCR2 Antagonist CCX872-B|CCR2 Antagonist PF-04136309|CCR2/CCR5 Antagonist BMS-813160|CCR4 Inhibitor FLX475|CD11b Agonist GB1275|CD123-CD33 Compound CAR T Cells|CD123-specific Targeting Module TM123|CD20-CD19 Compound CAR T Cells|CD28/ICOS Antagonist ALPN-101|CD4-specific Telomerase Peptide Vaccine UCPVax|CD40 Agonist Monoclonal Antibody CP-870,893|CD40 Agonistic Monoclonal Antibody APX005M|CD44 Targeted Agent SPL-108|CD44v6-specific CAR T-cells|CD47 Antagonist ALX148|CD73 Inhibitor AB680|CD73 Inhibitor LY3475070|CD80-Fc Fusion Protein ALPN-202|CD80-Fc Fusion Protein FPT155|CDC7 Inhibitor TAK-931|CDC7 Kinase Inhibitor BMS-863233|CDC7 Kinase Inhibitor LY3143921 Hydrate|CDC7 Kinase Inhibitor NMS-1116354|CDK Inhibitor AT7519|CDK Inhibitor R547|CDK Inhibitor SNS-032|CDK/JAK2/FLT3 Inhibitor TG02 Citrate|CDK1 Inhibitor BEY1107|CDK1/2/4 Inhibitor AG-024322|CDK2 Inhibitor PF-07104091|CDK2/4/6/FLT3 Inhibitor FN-1501|CDK2/5/9 Inhibitor CYC065|CDK4 Inhibitor P1446A-05|CDK4/6 Inhibitor|CDK4/6 Inhibitor BPI-16350|CDK4/6 Inhibitor CS3002|CDK4/6 Inhibitor FCN-437|CDK4/6 Inhibitor G1T38|CDK4/6 Inhibitor HS-10342|CDK4/6 Inhibitor SHR6390|CDK4/6 Inhibitor TQB3616|CDK7 Inhibitor CT7001|CDK7 Inhibitor SY-1365|CDK7 Inhibitor SY-5609|CDK8/19 Inhibitor SEL 120|CDK9 Inhibitor AZD4573|CEA-MUC-1-TRICOM Vaccine CV301|CEA-targeting Agent RG6123|CEBPA-targeting saRNA MTL-CEBPA Liposome|CENP-E Inhibitor GSK-923295|CHK1 Inhibitor MK-8776|CHK1 Inhibitor PF-477736|CHP-NY-ESO-1 Peptide Vaccine IMF-001|CK1alpha/CDK7/CDK9 Inhibitor BTX-A51|CK2-targeting Synthetic Peptide CIGB-300|CL 246738|CSF-1R Inhibitor BLZ945|CSF1R Inhibitor ABSK021|CSF1R Inhibitor DCC-3014|CSF1R Inhibitor PLX73086|CT2584 HMS|CTLA-4-directed Probody BMS-986249|CXC Chemokine Receptor 2 Antagonist AZD5069|CXCR1/2 Inhibitor SX-682|CXCR2 Antagonist QBM076|CXCR4 Antagonist BL-8040|CXCR4 Antagonist USL311|CXCR4 Inhibitor Q-122|CXCR4 Peptide Antagonist LY2510924|CXCR4/E-selectin Antagonist GMI-1359|CYL-02 Plasmid DNA|CYP11A1 Inhibitor ODM-209|CYP11A1 inhibitor ODM-208|CYP17 Inhibitor CFG920|CYP17 Lyase Inhibitor ASN001|CYP17/Androgen Receptor Inhibitor ODM 204|CYP17/CYP11B2 Inhibitor LAE001|Cabazitaxel|Cabiralizumab|Cabozantinib|Cabozantinib S-malate|Cactinomycin|Caffeic Acid Phenethyl Ester|Calaspargase Pegol-mknl|Calcitriol|Calcium Release-activated Channel Inhibitor CM4620|Calcium Release-activated Channels Inhibitor RP4010|Calcium Saccharate|Calculus bovis/Moschus/Olibanum/Myrrha Capsule|Calicheamicin Gamma 1I|Camidanlumab Tesirine|Camptothecin|Camptothecin Analogue TLC388|Camptothecin Glycoconjugate BAY 38-3441|Camptothecin Sodium|Camptothecin-20(S)-O-Propionate Hydrate|Camrelizumab|Camsirubicin|Cancell|Cancer Peptide Vaccine S-588410|Canerpaturev|Canertinib Dihydrochloride|Canfosfamide|Canfosfamide Hydrochloride|Cannabidiol|Cantrixil|Cantuzumab Ravtansine|Capecitabine|Capecitabine Rapidly Disintegrating Tablet|Capivasertib|Capmatinib|Captopril|Caracemide|Carbendazim|Carbetimer|Carbogen|Carbon C 14-pamiparib|Carboplatin|Carboquone|Carboxyamidotriazole|Carboxyamidotriazole Orotate|Carboxyphenyl Retinamide|Carfilzomib|Caricotamide/Tretazicar|Carlumab|Carmofur|Carmustine|Carmustine Implant|Carmustine Sustained-Release Implant Wafer|Carmustine in Ethanol|Carotuximab|Carubicin|Carubicin Hydrochloride|Carzelesin|Carzinophilin|Cathelicidin LL-37|Cationic Liposome-Encapsulated Paclitaxel|Cationic Peptide Cream Cypep-1|Catumaxomab|Cedazuridine|Cedazuridine/Azacitidine Combination Agent ASTX030|Cedazuridine/Decitabine Combination Agent ASTX727|Cedefingol|Cediranib|Cediranib Maleate|Celecoxib|Cell Cycle Checkpoint/DNA Repair Antagonist IC83|Cemadotin|Cemadotin Hydrochloride|Cemiplimab|Cenersen|Cenisertib|Ceralasertib|Ceramide Nanoliposome|Cerdulatinib|Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480|Cereblon E3 Ubiquitin Ligase Modulating Agent CC-99282|Cereblon Modulator CC-90009|Cergutuzumab Amunaleukin|Ceritinib|Cesalin|Cetrelimab|Cetuximab|Cetuximab Sarotalocan|Cetuximab-IR700 Conjugate RM-1929|Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY)|Cevipabulin|Cevipabulin Fumarate|Cevipabulin Succinate|Cevostamab|Chaparrin|Chaparrinone|Checkpoint Kinase Inhibitor AZD7762|Checkpoint Kinase Inhibitor XL844|Chemotherapy|ChiNing Decoction|Chiauranib|Chimeric Monoclonal Antibody 81C6|Chk1 Inhibitor CCT245737|Chk1 Inhibitor GDC-0425|Chk1 Inhibitor GDC-0575|Chlorambucil|Chlorodihydropyrimidine|Chloroquine|Chloroquinoxaline Sulfonamide|Chlorotoxin|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes|Chlorozotocin|Choline Kinase Alpha Inhibitor TCD-717|Chromomycin A3|Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement|Cibisatamab|Ciclopirox Prodrug CPX-POM|Cidan Herbal Capsule|Ciforadenant|Cilengitide|Ciltacabtagene Autoleucel|Cimetidine|Cinacalcet Hydrochloride|Cinobufagin|Cinobufotalin|Cinrebafusp Alfa|Cintirorgon|Cintredekin Besudotox|Cirmtuzumab|Cisplatin|Cisplatin Liposomal|Cisplatin-E Therapeutic Implant|Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6|Citarinostat|Citatuzumab Bogatox|Cixutumumab|Cladribine|Clanfenur|Clarithromycin|Class 1/4 Histone Deacetylase Inhibitor OKI-179|Clinical Trial|Clinical Trial Agent|Clioquinol|Clivatuzumab|Clodronate Disodium|Clodronic Acid|Clofarabine|Clomesone|Clomiphene|Clomiphene Citrate|Clostridium Novyi-NT Spores|Cobimetinib|Cobolimab|Cobomarsen|Codrituzumab|Coenzyme Q10|Cofetuzumab Pelidotin|Colchicine-Site Binding Agent ABT-751|Cold Contaminant-free Iobenguane I-131|Colloidal Gold-Bound Tumor Necrosis Factor|Colorectal Cancer Peptide Vaccine PolyPEPI1018|Colorectal Tumor-Associated Peptides Vaccine IMA910|Coltuximab Ravtansine|Combretastatin|Combretastatin A-1|Combretastatin A1 Diphosphate|Commensal Bacterial Strain Formulation VE800|Compound Kushen Injection|Conatumumab|Conbercept|Concentrated Lingzhi Mushroom Extract|Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011|Copanlisib|Copanlisib Hydrochloride|Copper Cu 64-ATSM|Copper Cu 67 Tyr3-octreotate|Copper Gluconate|Cord Blood Derived CAR T-Cells|Cord Blood-derived Expanded Natural Killer Cells PNK-007|Cordycepin|Cordycepin Triphosphate|Coriolus Versicolor Extract|Corticorelin Acetate|Cortisone Acetate|Cosibelimab|Cositecan|Coxsackievirus A21|Coxsackievirus V937|CpG Oligodeoxynucleotide GNKG168|Crenolanib|Crenolanib Besylate|Crizotinib|Crolibulin|Cryptophycin|Cryptophycin 52|Crystalline Genistein Formulation AXP107-11|Curcumin|Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110|Cusatuzumab|Custirsen Sodium|Cyclin-dependent Kinase 8/19 Inhibitor BCD 115|Cyclin-dependent Kinase Inhibitor PF-06873600|Cyclodextrin-Based Polymer-Camptothecin CRLX101|Cyclodisone|Cycloleucine|Cyclopentenyl Cytosine|Cyclophosphamide|Cyclophosphamide Anhydrous|Cyclosporine|Cyproterone|Cyproterone Acetate|Cytarabine|Cytarabine Monophosphate Prodrug MB07133|Cytarabine-asparagine Prodrug BST-236|Cytidine Analog RX-3117|Cytochlor|Cytokine-based Biologic Agent IRX-2|D-methionine Formulation MRX-1024|DAB389 Epidermal Growth Factor|DACH Polymer Platinate AP5346|DACH-Platin Micelle NC-4016|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|DHA-Paclitaxel|DHEA Mustard|DI-Leu16-IL2 Immunocytokine|DKK1-Neutralizing Monoclonal Antibody DKN-01|DM-CHOC-PEN|DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015|DNA Interference Oligonucleotide PNT2258|DNA Minor Groove Binding Agent SG2000|DNA Plasmid Encoding Interleukin-12 INO-9012|DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151|DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457|DNA Vaccine VB10.16|DNA-PK inhibitor AZD7648|DNA-PK/PI3K-delta Inhibitor BR101801|DNA-PK/TOR Kinase Inhibitor CC-115|DNA-dependent Protein Kinase Inhibitor VX-984|DNMT1 Inhibitor NTX-301|DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98|DPT/BCG/Measles/Serratia/Pneumococcus Vaccine|DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine|DPX-E7 HPV Vaccine|DR5 HexaBody Agonist GEN1029|DR5-targeting Tetrameric Nanobody Agonist TAS266|DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555|Dabrafenib|Dabrafenib Mesylate|Dacarbazine|Dacetuzumab|Daclizumab|Dacomitinib|Dacplatinum|Dactinomycin|Dactolisib|Dactolisib Tosylate|Dalantercept|Dalotuzumab|Daniquidone|Danusertib|Danvatirsen|Daporinad|Daratumumab|Daratumumab and Hyaluronidase-fihj|Daratumumab/rHuPH20|Darinaparsin|Darleukin|Darolutamide|Daromun|Dasatinib|Daunorubicin|Daunorubicin Citrate|Daunorubicin Hydrochloride|Decitabine|Decitabine and Cedazuridine|Defactinib|Defactinib Hydrochloride|Deferoxamine|Deferoxamine Mesylate|Degarelix|Degarelix Acetate|Delanzomib|Delolimogene Mupadenorepvec|Demcizumab|Demecolcine|Demplatin Pegraglumer|Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466|Dendritic Cell Vaccine|Dendritic Cell-Autologous Lung Tumor Vaccine|Dendritic Cell-targeting Lentiviral Vector ID-LV305|Denenicokin|Dengue Virus Adjuvant PV-001-DV|Denibulin|Denibulin Hydrochloride|Denileukin Diftitox|Denintuzumab Mafodotin|Denosumab|Deoxycytidine Analogue TAS-109|Deoxycytidine Analogue TAS-109 Hydrochloride|Depatuxizumab|Depatuxizumab Mafodotin|Derazantinib|Deslorelin|Deslorelin Acetate|Detirelix|Detorubicin|Deuteporfin|Deuterated Enzalutamide|Devimistat|Dexamethason|Dexamethasone|Dexamethasone Phosphate|Dexamethasone Sodium Phosphate|Dexanabinol|Dexrazoxane|Dexrazoxane Hydrochloride|Dezaguanine|Dezaguanine Mesylate|Dezapelisib|Dianhydrogalactitol|Diarylsulfonylurea Compound ILX-295501|Diazepinomicin|Diaziquone|Diazooxonorleucine|Dibrospidium Chloride|Dichloroallyl Lawsone|Dicycloplatin|Didox|Dienogest|Diethylnorspermine|Digitoxin|Digoxin|Dihydro-5-Azacytidine|Dihydrolenperone|Dihydroorotate Dehydrogenase Inhibitor AG-636|Dihydroorotate Dehydrogenase Inhibitor BAY2402234|Diindolylmethane|Dilpacimab|Dimethylmyleran|Dinaciclib|Dinutuximab|Dioscorea nipponica Makino Extract DNE3|Diphencyprone|Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777|Ditiocarb|Docetaxel|Docetaxel Anhydrous|Docetaxel Emulsion ANX-514|Docetaxel Formulation CKD-810|Docetaxel Lipid Microspheres|Docetaxel Nanoparticle CPC634|Docetaxel Polymeric Micelles|Docetaxel-PNP|Docetaxel-loaded Nanopharmaceutical CRLX301|Docetaxel/Ritonavir|Dociparstat sodium|Dolastatin 10|Dolastatin 15|Domatinostat|Donafenib|Dopamine-Somatostatin Chimeric Molecule BIM-23A760|Dostarlimab|Double-armed TMZ-CD40L/4-1BBL Oncolytic Ad5/35 Adenovirus LOAd703|Dovitinib|Dovitinib Lactate|Doxazosin|Doxercalciferol|Doxifluridine|Doxorubicin|Doxorubicin Hydrochloride|Doxorubicin Prodrug L-377,202|Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370|Doxorubicin-Eluting Beads|Doxorubicin-HPMA Conjugate|Doxorubicin-Magnetic Targeted Carrier Complex|Doxorubicin-loaded EGFR-targeting Nanocells|Dromostanolone Propionate|Drozitumab|Dual IGF-1R/InsR Inhibitor BMS-754807|Dual Variable Domain Immunoglobulin ABT-165|Dual-affinity B7-H3/CD3-targeted Protein MGD009|Dubermatinib|Duborimycin|Dulanermin|Duligotuzumab|Dupilumab|Durvalumab|Dusigitumab|Duvelisib|Duvortuxizumab|Dynemicin|Dynemicin A|E2F1 Pathway Activator ARQ 171|EBNA-1 inhibitor VK-2019|EED Inhibitor MAK683|EGFR Antagonist Hemay022|EGFR Antisense DNA BB-401|EGFR Inhibitor AZD3759|EGFR Inhibitor BIBX 1382|EGFR Inhibitor DBPR112|EGFR Inhibitor PD-168393|EGFR Inhibitor TY-9591|EGFR Mutant-selective  Inhibitor TQB3804|EGFR Mutant-specific Inhibitor BPI-7711|EGFR Mutant-specific Inhibitor CK-101|EGFR Mutant-specific Inhibitor D-0316|EGFR Mutant-specific Inhibitor ZN-e4|EGFR T790M Antagonist BPI-15086|EGFR T790M Inhibitor HS-10296|EGFR/EGFRvIII Inhibitor WSD0922-FU|EGFR/FLT3/Abl Inhibitor SKLB1028|EGFR/HER1/HER2 Inhibitor PKI166|EGFR/HER2 Inhibitor AP32788|EGFR/HER2 Inhibitor AV-412|EGFR/HER2 Inhibitor DZD9008|EGFR/HER2 Kinase Inhibitor TAK-285|EGFR/TGFb Fusion Monoclonal Antibody BCA101|EGFR/VEGFR/RET Inhibitor HA121-28|EGb761|EP2/EP4 Antagonist TPST-1495|EP4 Antagonist INV-1120|EP4 Antagonist ONO-4578|ER alpha Proteolysis-targeting Chimera Protein Degrader ARV-471|ERK 1/2 Inhibitor ASTX029|ERK Inhibitor CC-90003|ERK Inhibitor GDC-0994|ERK Inhibitor LTT462|ERK Inhibitor MK-8353|ERK1/2 Inhibitor ASN007|ERK1/2 Inhibitor HH2710|ERK1/2 Inhibitor JSI-1187|ERK1/2 Inhibitor KO-947|ERK1/2 Inhibitor LY3214996|ERa36 Modulator Icaritin|EZH1/2 Inhibitor DS-3201|EZH1/2 Inhibitor HH2853|EZH2 Inhibitor CPI-1205|EZH2 Inhibitor PF-06821497|EZH2 Inhibitor SHR2554|EZH2 inhibitor CPI-0209|Echinomycin|Ecromeximab|Edatrexate|Edelfosine|Edicotinib|Edodekin alfa|Edotecarin|Edrecolomab|Efatutazone|Efatutazone Dihydrochloride|Efizonerimod|Eflornithine|Eflornithine Hydrochloride|Eftilagimod Alpha|Eftozanermin Alfa|Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205|Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621|Eicosapentaenoic Acid|Elacestrant|Elacytarabine|Elagolix|Elbasvir/Grazoprevir|Elesclomol|Elesclomol Sodium|Elgemtumab|Elinafide|Elisidepsin|Elliptinium|Elliptinium Acetate|Elmustine|Elotuzumab|Elpamotide|Elsamitrucin|Eltanexor|Emactuzumab|Emapalumab|Emepepimut-S|Emibetuzumab|Emitefur|Emofolin Sodium|Empesertib|Enadenotucirev|Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A|Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641|Enasidenib|Enasidenib Mesylate|Enavatuzumab|Encapsulated Rapamycin|Encelimab|Enclomiphene|Enclomiphene Citrate|Encorafenib|Endothelin B Receptor Blocker ENB 003|Endothelin Receptor Type A Antagonist YM598|Enfortumab Vedotin|Engineered Human Umbilical Vein Endothelial Cells AB-205|Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240|Engineered Toxin Body Targeting CD38 TAK-169|Engineered Toxin Body Targeting HER2 MT-5111|Eniluracil/5-FU Combination Tablet|Enloplatin|Enoblituzumab|Enobosarm|Enoticumab|Enpromate|Ensartinib|Ensituximab|Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride|Enterococcus gallinarum Strain MRx0518|Entinostat|Entolimod|Entospletinib|Entrectinib|Envafolimab|Enzalutamide|Enzastaurin|Enzastaurin Hydrochloride|Epacadostat|Epcoritamab|EphA2-targeting Bicycle Toxin Conjugate BT5528|Epipodophyllotoxin Analog GL331|Epipropidine|Epirubicin|Epirubicin Hydrochloride|Epitinib Succinate|Epitiostanol|Epothilone Analog UTD1|Epothilone KOS-1584|Epratuzumab|Epratuzumab-cys-tesirine|Erastin Analogue PRLX 93936|Erbulozole|Erdafitinib|Eribulin|Eribulin Mesylate|Erlotinib|Erlotinib Hydrochloride|Ertumaxomab|Erythrocyte-encapsulated L-asparaginase Suspension|Esorubicin|Esorubicin Hydrochloride|Esperamicin A1|Essiac|Esterified Estrogens|Estradiol Valerate|Estramustine|Estramustine Phosphate Sodium|Estrogen Receptor Agonist GTx-758|Estrogens, Conjugated|Etalocib|Etanercept|Etanidazole|Etaracizumab|Etarotene|Ethaselen|Ethinyl Estradiol|Ethyleneimine|Ethylnitrosourea|Etidronate-Cytarabine Conjugate MBC-11|Etigilimab|Etirinotecan Pegol|Etoglucid|Etoposide|Etoposide Phosphate|Etoposide Toniribate|Etoprine|Etoricoxib|Ets-family Transcription Factor Inhibitor TK216|Everolimus|Everolimus Tablets for Oral Suspension|Evofosfamide|Ex Vivo-expanded Autologous T Cells IMA101|Exatecan Mesylate|Exatecan Mesylate Anhydrous|Exemestane|Exicorilant|Exisulind|Extended Release Flucytosine|Extended Release Metformin Hydrochloride|Extended-release Onapristone|Ezabenlimab|F16-IL2 Fusion Protein|FACT Complex-targeting Curaxin CBL0137|FAK Inhibitor GSK2256098|FAK Inhibitor PF-00562271|FAK Inhibitor VS-4718|FAK/ALK/ROS1 Inhibitor APG-2449|FAP/4-1BB-targeting DARPin MP0310|FAP/4-1BB-targeting Fusion Protein RO7122290|FASN Inhibitor TVB-2640|FGF Receptor Antagonist HGS1036|FGF/FGFR Pathway Inhibitor E7090|FGFR Inhibitor ASP5878|FGFR Inhibitor AZD4547|FGFR Inhibitor CPL304110|FGFR Inhibitor Debio 1347|FGFR Inhibitor TAS-120|FGFR/CSF-1R Inhibitor 3D185|FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999|FGFR1/2/3 Inhibitor HMPL-453|FGFR2 Inhibitor RLY-4008|FGFR4 Antagonist INCB062079|FGFR4 Inhibitor BLU 9931|FGFR4 Inhibitor FGF401|FGFR4 Inhibitor H3B-6527|FGFR4 Inhibitor ICP-105|FLT3 Inhibitor FF-10101 Succinate|FLT3 Inhibitor HM43239|FLT3 Inhibitor SKI-G-801|FLT3 Tyrosine Kinase Inhibitor TTT-3002|FLT3/ABL/Aurora Kinase Inhibitor KW-2449|FLT3/CDK4/6 Inhibitor FLX925|FLT3/FGFR Dual Kinase Inhibitor MAX-40279|FLT3/KIT Kinase Inhibitor AKN-028|FLT3/KIT/CSF1R Inhibitor NMS-03592088|FMS Inhibitor JNJ-40346527|FPV Vaccine CV301|FPV-Brachyury-TRICOM Vaccine|Factor VII-targeting Immunoconjugate Protein ICON-1|Factor VIIa Inhibitor PCI-27483|Fadraciclib|Fadrozole Hydrochloride|Falimarev|Famitinib|Farletuzumab|Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778,123|Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells|Fas Receptor Agonist APO010|Fascin Inhibitor NP-G2-044|Favezelimab|Fazarabine|Fc-engineered Anti-CD40 Agonist Antibody 2141-V11|Febuxostat|Fedratinib|Fedratinib Hydrochloride|Feladilimab|Felzartamab|Fenebrutinib|Fenretinide|Fenretinide Lipid Matrix|Fenretinide Phospholipid Suspension ST-001|Fianlimab|Fibromun|Ficlatuzumab|Figitumumab|Filanesib|Filgotinib|Filgrastim|Fimaporfin A|Fimepinostat|Firtecan Pegol|Fisogatinib|Flanvotumab|Flotetuzumab|Floxuridine|Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01|Flt3/MerTK Inhibitor MRX-2843|Fludarabine|Fludarabine Phosphate|Flumatinib|Flumatinib Mesylate|Fluorine F 18 Ara-G|Fluorodopan|Fluorouracil|Fluorouracil Implant|Fluorouracil-E Therapeutic Implant|Fluoxymesterone|Flutamide|Fluvastatin|Fluvastatin Sodium|Fluzoparib|Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate|Folate Receptor Targeted Epothilone BMS753493|Folate Receptor-Targeted Tubulysin Conjugate EC1456|Folate Receptor-Targeted Vinca Alkaloid EC0489|Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225|Folate-FITC|Folic Acid|Folitixorin|Foretinib|Foritinib Succinate|Formestane|Forodesine Hydrochloride|Fosaprepitant|Fosbretabulin|Fosbretabulin Disodium|Fosbretabulin Tromethamine|Fosgemcitabine Palabenamide|Fosifloxuridine Nafalbenamide|Foslinanib|Foslinanib Disodium|Fosquidone|Fostriecin|Fotemustine|Fotretamine|Fresolimumab|Fruquintinib|Fulvestrant|Fumagillin-Derived Polymer Conjugate XMT-1107|Fursultiamine|Futibatinib|Futuximab|Futuximab/Modotuximab Mixture|G Protein-coupled Estrogen Receptor Agonist LNS8801|G-Quadruplex Stabilizer BMVC|GBM Antigens and Alloantigens Immunotherapeutic Vaccine|GI-4000 Vaccine|GITR Agonist MEDI1873|GM-CSF-encoding Oncolytic Adenovirus CGTG-102|GS/pan-Notch Inhibitor AL101|GS/pan-Notch Inhibitor BMS-986115|GSK-3 Inhibitor 9-ING-41|GSK-3 Inhibitor LY2090314|Galamustine|Galarubicin|Galectin Inhibitor GR-MD-02|Galectin-1 Inhibitor OTX008|Galeterone|Galiximab|Gallium-based Bone Resorption Inhibitor AP-002|Galocitabine|Galunisertib|Gamboge Resin Extract TSB-9-W1|Gamma-Secretase Inhibitor LY3039478|Gamma-Secretase Inhibitor RO4929097|Gamma-delta Tocotrienol|Gandotinib|Ganetespib|Ganglioside GD2|Ganglioside GM2|Ganitumab|Ganoderma lucidum Spores Powder Capsule|Garlic|Gastrin Immunotoxin|Gastrin/cholecystokinin Type B Receptor Inhibitor Z-360|Gataparsen Sodium|Gatipotuzumab|Gedatolisib|Gefitinib|Geldanamycin|Gelonin|Gemcitabine|Gemcitabine Elaidate|Gemcitabine Hydrochloride|Gemcitabine Hydrochloride Emulsion|Gemcitabine Prodrug LY2334737|Gemcitabine-Phosphoramidate Hydrochloride NUC-1031|Gemcitabine-Releasing Intravesical System|Gemtuzumab Ozogamicin|Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum|Genistein|Gentuximab|Geranylgeranyltransferase I Inhibitor|Giloralimab|Gilteritinib|Gilteritinib Fumarate|Gimatecan|Gimeracil|Ginsenoside Rg3 Capsule|Giredestrant|Girentuximab|Girodazole|Givinostat|Glasdegib|Glasdegib Maleate|Glaucarubolone|Glecaprevir/Pibrentasvir|Glembatumumab Vedotin|Glesatinib|Glioblastoma Cancer Vaccine ERC1671|Glioblastoma Multiforme Multipeptide Vaccine IMA950|Glioma Lysate Vaccine GBM6-AD|Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701|Globo H-DT Vaccine OBI-833|Glofitamab|Glucarpidase|Glucocorticoid Receptor Antagonist ORIC-101|Glufosfamide|Glumetinib|Glutaminase Inhibitor CB-839|Glutaminase Inhibitor CB-839 Hydrochloride|Glutaminase Inhibitor IPN60090|Glutamine Antagonist DRP-104|Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101|Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01|Glycooptimized Trastuzumab-GEX|Gold Sodium Thiomalate|Golnerminogene Pradenovec|Golotimod|Golvatinib|Gonadotropin-releasing Hormone Analog|Goserelin|Goserelin Acetate|Goserelin Acetate Extended-release Microspheres LY01005|Gossypol|Gossypol Acetic Acid|Grapiprant|Green Tea Extract-based Antioxidant Supplement|Guadecitabine|Guanabenz Acetate|Guselkumab|Gusperimus Trihydrochloride|Gutolactone|H-ras Antisense Oligodeoxynucleotide ISIS 2503|H1299 Tumor Cell Lysate Vaccine|HAAH Lambda phage Vaccine SNS-301|HCV DNA Vaccine INO-8000|HDAC Class I/IIb Inhibitor HG146|HDAC Inhibitor AR-42|HDAC Inhibitor CHR-2845|HDAC Inhibitor CKD-581|HDAC Inhibitor CXD101|HDAC Inhibitor MPT0E028|HDAC Inhibitor OBP-801|HDAC inhibitor CG200745|HDAC/EGFR/HER2 Inhibitor CUDC-101|HDAC6 Inhibitor KA2507|HDAC8 Inhibitor NBM-BMX|HDM2 Inhibitor HDM201|HDM2 Inhibitor MK-8242|HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131|HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901|HER2 Inhibitor CP-724,714|HER2 Inhibitor DZD1516|HER2 Inhibitor TAS0728|HER2 Tri-specific Natural Killer Cell Engager DF1001|HER2-directed TLR8 Agonist SBT6050|HER2-targeted DARPin MP0274|HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302|HER2-targeting Antibody Fc Fragment FS102|HIF-1alpha Inhibitor PX-478|HIF-2alpha Inhibitor PT2385|HIF-2alpha Inhibitor PT2977|HIF2a RNAi ARO-HIF2|HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001|HLA-A*2402-Restricted Multipeptide Vaccine S-488410|HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201|HM2/MMAE Antibody-Drug Conjugate ALT-P7|HPPH|HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202|HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c|HPV DNA Plasmids Therapeutic Vaccine VGX-3100|HPV E6/E7 DNA Vaccine GX-188E|HPV E6/E7-encoding Arenavirus Vaccine HB-201|HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C|HPV-16 E6 Peptides Vaccine/Candida albicans Extract|HPV-6-targeting Immunotherapeutic Vaccine INO-3106|HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101|HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN|HPV6/11-targeted DNA Plasmid Vaccine INO-3107|HSP90-targeted SN-38 Conjugate PEN-866|HSP90alpha/beta Inhibitor TAS-116|Hafnium Oxide-containing Nanoparticles NBTXR3|Halichondrin Analogue E7130|Halichondrin B|Halofuginone|Halofuginone Hydrobromide|Hedgehog Inhibitor IPI-609|Hematoporphyrin Derivative|Hemiasterlin Analog E7974|Henatinib Maleate|Heparan Sulfate Glycosaminoglycan Mimetic M402|Heparin Derivative SST0001|Herba Scutellaria Barbata|Herbimycin|Heterodimeric Interleukin-15|Hexamethylene Bisacetamide|Hexaminolevulinate|Hexylresorcinol|Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126|Histrelin Acetate|Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine|Holmium Ho 166 Poly(L-Lactic Acid) Microspheres|Hormone Therapy|Hsp90 Antagonist KW-2478|Hsp90 Inhibitor AB-010|Hsp90 Inhibitor BIIB021|Hsp90 Inhibitor BIIB028|Hsp90 Inhibitor DS-2248|Hsp90 Inhibitor Debio 0932|Hsp90 Inhibitor HSP990|Hsp90 Inhibitor MPC-3100|Hsp90 Inhibitor PU-H71|Hsp90 Inhibitor SNX-5422 Mesylate|Hsp90 Inhibitor SNX-5542 Mesylate|Hsp90 Inhibitor TQB3474|Hsp90 Inhibitor XL888|Hsp90-targeted Photosensitizer HS-201|Hu14.18-IL2 Fusion Protein EMD 273063|HuaChanSu|Huaier Extract Granule|Huang Lian|Human Combinatorial Antibody Library-based Monoclonal Antibody VAY736|Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104|Human MOAB LICO 28a32|Human Monoclonal Antibody 216|Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307|Human Papillomavirus 16 E7 Peptide/Padre 965.10|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Hycanthone|Hydralazine Hydrochloride|Hydrocortisone Sodium Succinate|Hydroxychloroquine|Hydroxyprogesterone Caproate|Hydroxytyrosol|Hydroxyurea|Hypericin|Hypoxia-activated Prodrug TH-4000|I 131 Antiferritin Immunoglobulin|I 131 Monoclonal Antibody A33|I 131 Monoclonal Antibody CC49|I 131 Monoclonal Antibody F19|I 131 Monoclonal Antibody Lym-1|IAP Inhibitor APG-1387|IAP Inhibitor AT-406|IAP Inhibitor HGS1029|ICT-121 Dendritic Cell Vaccine|IDH1 Mutant Inhibitor LY3410738|IDH1(R132) Inhibitor IDH305|IDH1R132H-Specific Peptide Vaccine PEPIDH1M|IDO Peptide Vaccine IO102|IDO-1 Inhibitor LY3381916|IDO/TDO Inhibitor HTI-1090|IDO/TDO Inhibitor LY-01013|IDO1 Inhibitor KHK2455|IDO1 Inhibitor MK-7162|IDO1 Inhibitor PF-06840003|IDO1/TDO2 Inhibitor DN1406131|IDO1/TDO2 Inhibitor M4112|IGF-1R Inhibitor|IGF-1R Inhibitor PL225B|IGF-1R/IR Inhibitor KW-2450|IGF-methotrexate Conjugate|IL-10 Immunomodulator MK-1966|IL-12-expressing HSV-1 NSC 733972|IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051|IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000|IL-2 Recombinant Fusion Protein ALT-801|IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1|IL4-Pseudomonas Exotoxin Fusion Protein MDNA55|IMT-1012 Immunotherapeutic Vaccine|INO-1001|IRAK4 Inhibitor CA-4948|ISS 1018 CpG Oligodeoxynucleotide|ITK Inhibitor CPI-818|Iadademstat|Ianalumab|Ibandronate Sodium|Iberdomide|Iboctadekin|Ibritumomab Tiuxetan|Ibrutinib|Icotinib Hydrochloride|Icrucumab|Idarubicin|Idarubicin Hydrochloride|Idarubicin-Eluting Beads|Idasanutlin|Idecabtagene Vicleucel|Idelalisib|Idetrexed|Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020|Idronoxil|Idronoxil Suppository NOX66|Ieramilimab|Ifabotuzumab|Ifetroban|Ifosfamide|Ilginatinib|Ilixadencel|Iloprost|Ilorasertib|Imalumab|Imaradenant|Imatinib|Imatinib Mesylate|Imetelstat|Imetelstat Sodium|Imexon|Imgatuzumab|Imidazole Mustard|Imidazole-Pyrazole|Imifoplatin|Imipramine Blue|Imiquimod|Immediate-release Onapristone|Immediate-release Tablet Afuresertib|Immune Checkpoint Inhibitor ASP8374|Immunoconjugate RO5479599|Immunocytokine NHS-IL12|Immunocytokine NHS-IL2-LT|Immunomodulator LAM-003|Immunomodulator OHR/AVR118|Immunomodulatory Agent CC-11006|Immunomodulatory Oligonucleotide HYB2055|Immunotherapeutic Combination Product CMB305|Immunotherapeutic GSK1572932A|Immunotherapy Regimen MKC-1106-MT|Immunotoxin CMD-193|Inactivated Oncolytic Virus Particle GEN0101|Inalimarev|Incyclinide|Indatuximab Ravtansine|Indibulin|Indicine-N-Oxide|Indisulam|Individualized MVA-based Vaccine TG4050|Indocyanine Green-labeled Polymeric Micelles ONM-100|Indole-3-Carbinol|Indomethacin|Indoximod|Indoximod Prodrug NLG802|Indusatumab Vedotin|Inebilizumab|Inecalcitol|Infigratinib|Infigratinib Mesylate|Infliximab|Ingenol Mebutate|Ingenol Mebutate Gel|Iniparib|Innate Immunostimulator rBBX-01|Inodiftagene Vixteplasmid|Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01|Inosine Monophosphate Dehydrogenase Inhibitor AVN944|Inositol|Inotuzumab Ozogamicin|Inproquone|Integrin Receptor Antagonist GLPG0187|Integrin alpha-2 Inhibitor E7820|Interferon|Interferon Alfa-2B|Interferon Alfa-N1|Interferon Alfa-N3|Interferon Alfacon-1|Interferon Beta-1A|Interferon Gamma-1b|Interferon-gamma-expressing Adenovirus Vaccine ASN-002|Interleukin Therapy|Interleukin-12-Fc Fusion Protein DF6002|Interleukin-15 Agonist Fusion Protein SHR1501|Interleukin-15 Fusion Protein BJ-001|Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306|Interleukin-15/Interleukin-15 Receptor Alpha Sushi+ Domain Fusion Protein SO-C101|Interleukin-2 Liposome|Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230|Intetumumab|Intiquinatine|Intoplicine|Inulin|Iobenguane I-131|Iodine I 124 Monoclonal Antibody A33|Iodine I 124 Monoclonal Antibody M5A|Iodine I 125-Anti-EGFR-425 Monoclonal Antibody|Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP|Iodine I 131 Apamistamab|Iodine I 131 Derlotuximab Biotin|Iodine I 131 Ethiodized Oil|Iodine I 131 IPA|Iodine I 131 MIP-1095|Iodine I 131 Monoclonal Antibody 81C6|Iodine I 131 Monoclonal Antibody BC8|Iodine I 131 Monoclonal Antibody CC49-deltaCH2|Iodine I 131 Monoclonal Antibody F16SIP|Iodine I 131 Monoclonal Antibody G-250|Iodine I 131 Monoclonal Antibody muJ591|Iodine I 131 Omburtamab|Iodine I 131 Rituximab|Iodine I 131 TM-601|Iodine I 131 Tenatumomab|Iodine I 131 Tositumomab|Iodine I-131|Ioflubenzamide I-131|Ionomycin|Ipafricept|Ipatasertib|Ipilimumab|Ipomeanol|Iproplatin|Iratumumab|Iridium Ir 192|Irinotecan|Irinotecan Hydrochloride|Irinotecan Sucrosofate|Irinotecan-Eluting Beads|Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet|Irofulven|Iroplact|Irosustat|Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130|Isatuximab|Iso-fludelone|Isobrucein B|Isocoumarin NM-3|Isotretinoin|Ispinesib|Ispinesib Mesylate|Istiratumab|Itacitinib|Itacitinib Adipate|Itraconazole|Itraconazole Dispersion In Polymer Matrix|Ivaltinostat|Ivosidenib|Ivuxolimab|Ixabepilone|Ixazomib|Ixazomib Citrate|JAK Inhibitor|JAK Inhibitor INCB047986|JAK1 Inhibitor AZD4205|JAK1 Inhibitor INCB052793|JAK2 Inhibitor AZD1480|JAK2 Inhibitor BMS-911543|JAK2 Inhibitor XL019|JAK2/Src Inhibitor NS-018|JNK Inhibitor CC-401|Jin Fu Kang|KRAS G12C Inhibitor GDC-6036|KRAS G12C Inhibitor LY3499446|KRAS G12C Inhibitor MRTX849|KRAS Mutant-targeting AMG 510|KRAS-MAPK Signaling Pathway Inhibitor JAB-3312|KRASG12C Inhibitor JNJ-74699157|KRN5500|KSP Inhibitor AZD4877|KSP Inhibitor SB-743921|Kanglaite|Kanitinib|Ketoconazole|Ketotrexate|Kunecatechins Ointment|L-Gossypol|L-methylfolate|LAIR-2 Fusion Protein NC410|LMB-1 Immunotoxin|LMB-2 Immunotoxin|LMB-7 Immunotoxin|LMB-9 Immunotoxin|LMP-2:340-349 Peptide Vaccine|LMP-2:419-427 Peptide Vaccine|LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes|LMP7 Inhibitor M3258|LOXL2 Inhibitor PAT-1251|LRP5 Antagonist BI 905681|LRP5/6 Antagonist BI 905677|LSD1 Inhibitor CC-90011|LSD1 Inhibitor GSK2879552|LSD1 Inhibitor IMG-7289|LSD1 Inhibitor RO7051790|LSD1 Inhibitor SYHA1807|LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1|Labetuzumab Govitecan|Lactoferrin-derived Lytic Peptide LTX-315|Lacutamab|Ladiratuzumab Vedotin|Ladirubicin|Laetrile|Landogrozumab|Laniquidar|Lanreotide Acetate|Lapachone|Lapatinib|Lapatinib Ditosylate|Laprituximab Emtansine|Lapuleucel-T|Laromustine|Larotaxel|Larotinib Mesylate|Larotrectinib|Larotrectinib Sulfate|Lavendustin A|Lazertinib|Lead Pb 212 TCMC-trastuzumab|Lefitolimod|Leflunomide|Lenalidomide|Lenalidomide Analog KPG-121|Lentinan|Lenvatinib|Lenvatinib Mesylate|Lenzilumab|Lerociclib|Lestaurtinib|Letetresgene Autoleucel|Letolizumab|Letrozole|Leucovorin|Leucovorin Calcium|Leuprolide|Leuprolide Acetate|Leuprolide Mesylate Injectable Suspension|Leurubicin|Levetiracetam|Levoleucovorin Calcium|Levothyroxine|Levothyroxine Sodium|Lexatumumab|Lexibulin|Liarozole|Liarozole Fumarate|Liarozole Hydrochloride|Licartin|Licorice|Lifastuzumab Vedotin|Lifileucel|Lifirafenib|Light-Emitting Oncolytic Vaccinia Virus GL-ONC1|Light-activated AU-011|Lilotomab|Limonene, (+)-|Limonene, (+/-)-|Linifanib|Linoleyl Carbonate-Paclitaxel|Linperlisib|Linrodostat|Linsitinib|Lintuzumab|Liothyronine I-131|Liothyronine Sodium|Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1|Lipid Nanoparticle Encapsulated OX40L mRNA-2416|Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191|Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006|Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752|Liposomal Bcl-2 Antisense Oligonucleotide  BP1002|Liposomal Curcumin|Liposomal Cytarabine|Liposomal Daunorubicin Citrate|Liposomal Docetaxel|Liposomal Eribulin Mesylate|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Liposomal Irinotecan|Liposomal MUC1/PET-lipid A Vaccine ONT-10|Liposomal Mitoxantrone Hydrochloride|Liposomal NDDP|Liposomal Rhenium Re 186|Liposomal SN-38|Liposomal Topotecan FF-10850|Liposomal Vinorelbine|Liposomal Vinorelbine Tartrate|Liposomal c-raf Antisense Oligonucleotide|Liposome|Liposome-Encapsulated Doxorubicin Citrate|Liposome-encapsulated Daunorubicin-Cytarabine|Liposome-encapsulated OSI-7904|Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94|Liposome-encapsulated TAAs mRNA Vaccine W_ova1|Liposome-encapsulated miR-34 Mimic MRX34|Lirilumab|Lisavanbulin|Lisocabtagene Maraleucel|Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142|Litronesib|Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207|Live-attenuated Double-deleted Listeria monocytogenes Bacteria JNJ-64041809|Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623|Liver X Receptor beta Agonist RGX-104|Lm-tLLO-neoantigens Vaccine ADXS-NEO|LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine ADXS31-164|Lobaplatin|Lodapolimab|Lometrexol|Lometrexol Sodium|Lomustine|Lonafarnib|Loncastuximab Tesirine|Long Peptide Vaccine 7|Long-acting Release Pasireotide|Lontucirev|Lorlatinib|Lorukafusp alfa|Lorvotuzumab Mertansine|Losatuxizumab Vedotin|Losoxantrone|Losoxantrone Hydrochloride|Lovastatin|Lucanthone|Lucatumumab|Lucitanib|Luminespib|Luminespib Mesylate|Lumretuzumab|Lung-targeted Immunomodulator QBKPN|Lupartumab Amadotin|Lurbinectedin|Lurtotecan|Lurtotecan Liposome|Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1|Lutetium Lu 177 DOTA-N3-CTT1403|Lutetium Lu 177 DOTA-Tetulomab|Lutetium Lu 177 DOTA-biotin|Lutetium Lu 177 Dotatate|Lutetium Lu 177 Lilotomab-satetraxetan|Lutetium Lu 177 Monoclonal Antibody CC49|Lutetium Lu 177 Monoclonal Antibody J591|Lutetium Lu 177 PP-F11N|Lutetium Lu 177 Satoreotide Tetraxetan|Lutetium Lu 177-DOTA-EB-TATE|Lutetium Lu 177-DTPA-omburtamab|Lutetium Lu 177-Edotreotide|Lutetium Lu 177-NeoB|Lutetium Lu 177-PSMA-617|Lutetium Lu-177 Capromab|Lutetium Lu-177 Girentuximab|Lutetium Lu-177 PSMA-R2|Lutetium Lu-177 Rituximab|Lyophilized Black Raspberry Lozenge|Lyophilized Black Raspberry Saliva Substitute|Lysine-specific Demethylase 1 Inhibitor INCB059872|Lyso-Thermosensitive Liposome Doxorubicin|MAGE-10.A2|MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells|MAGE-A3 Multipeptide Vaccine GL-0817|MAGE-A3 Peptide Vaccine|MAGE-A3-specific Immunotherapeutic GSK 2132231A|MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201|MALT1 Inhibitor JNJ-67856633|MARCKS Protein Inhibitor BIO-11006|MAT2A Inhibitor AG-270|MCL-1 Inhibitor ABBV-467|MCL-1 Inhibitor AMG 176|MCL-1 inhibitor AMG 397|MDM2 Antagonist ASTX295|MDM2 Antagonist RO5045337|MDM2 Antagonist RO6839921|MDM2 Inhibitor AMG-232|MDM2 Inhibitor AMGMDS3|MDM2 Inhibitor BI 907828|MDM2 Inhibitor KRT-232|MDM2/MDMX Inhibitor ALRN-6924|MDR Modulator CBT-1|MEK 1/2 Inhibitor AS703988/MSC2015103B|MEK 1/2 Inhibitor FCN-159|MEK Inhibitor AZD8330|MEK Inhibitor CI-1040|MEK Inhibitor GDC-0623|MEK Inhibitor HL-085|MEK Inhibitor PD0325901|MEK Inhibitor RO4987655|MEK Inhibitor SHR 7390|MEK Inhibitor TAK-733|MEK Inhibitor WX-554|MEK inhibitor CS3006|MEK-1/MEKK-1 Inhibitor E6201|MEK/Aurora Kinase Inhibitor BI 847325|MELK Inhibitor OTS167|MET Kinase Inhibitor OMO-1|MET Tyrosine Kinase Inhibitor BMS-777607|MET Tyrosine Kinase Inhibitor EMD 1204831|MET Tyrosine Kinase Inhibitor PF-04217903|MET Tyrosine Kinase Inhibitor SAR125844|MET Tyrosine Kinase Inhibitor SGX523|MET x MET Bispecific Antibody REGN5093|MK0731|MKC-1|MKNK1 Inhibitor BAY 1143269|MMP Inhibitor S-3304|MNK1/2 Inhibitor ETC-1907206|MOF Compound RiMO-301|MOv-gamma Chimeric Receptor Gene|MTF-1 Inhibitor APTO-253 HCl|MUC-1/WT1 Peptide-primed Autologous Dendritic Cells|MUC1-targeted Peptide GO-203-2C|MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP|MVA-BN Smallpox Vaccine|MVA-FCU1 TG4023|MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1|MYC-targeting siRNA DCR-MYC|Maackia amurensis Seed Lectin|Macimorelin|Macitentan|Macrocycle-bridged STING Agonist E7766|Maekmoondong-tang|Mafosfamide|Magnesium Valproate|Magrolimab|Manelimab|Mannosulfan|Mannosylerythritol Lipid|Mapatumumab|Maraba Oncolytic Virus Expressing Mutant HPV E6/E7|Marcellomycin|Margetuximab|Marimastat|Marizomib|Masitinib Mesylate|Masoprocol|Matrix Metalloproteinase Inhibitor MMI270|Matuzumab|Mavelertinib|Mavorixafor|Maytansine|Mcl-1 Inhibitor AZD5991|Mcl-1 Inhibitor MIK665|Mechlorethamine|Mechlorethamine Hydrochloride|Mechlorethamine Hydrochloride Gel|Medorubicin|Medroxyprogesterone|Medroxyprogesterone Acetate|Megestrol Acetate|Melanoma Monoclonal Antibody hIgG2A|Melanoma TRP2 CTL Epitope Vaccine SCIB1|Melapuldencel-T|Melphalan|Melphalan Flufenamide|Melphalan Hydrochloride|Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex|Membrane-Disrupting Peptide EP-100|Menatetrenone|Menin-MLL Interaction Inhibitor SNDX-5613|Menogaril|Merbarone|Mercaptopurine|Mercaptopurine Anhydrous|Mercaptopurine Oral Suspension|Merestinib|Mesna|Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536|MetAP2 Inhibitor APL-1202|MetAP2 Inhibitor SDX-7320|Metamelfalan|Metarrestin|Metatinib Tromethamine|Metformin|Metformin Hydrochloride|Methanol Extraction Residue of BCG|Methazolamide|Methionine Aminopeptidase 2 Inhibitor M8891|Methionine Aminopeptidase 2 Inhibitor PPI-2458|Methotrexate|Methotrexate Sodium|Methotrexate-E Therapeutic Implant|Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles|Methoxsalen|Methoxyamine|Methoxyamine Hydrochloride|Methyl-5-Aminolevulinate Hydrochloride Cream|Methylcantharidimide|Methylmercaptopurine Riboside|Methylprednisolone|Methylprednisolone Acetate|Methylprednisolone Sodium Succinate|Methylselenocysteine|Methyltestosterone|Metoprine|Mevociclib|Mezagitamab|Mibefradil|Mibefradil Dihydrochloride|Micellar Nanoparticle-encapsulated Epirubicin|Micro Needle Array-Doxorubicin|Microbiome GEN-001|Microbiome-derived Peptide Vaccine EO2401|Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300|Microtubule Inhibitor SCB01A|Midostaurin|Mifamurtide|Mifepristone|Milademetan Tosylate|Milataxel|Milatuzumab|Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110|Milciclib Maleate|Milk Thistle|Miltefosine|Minretumomab|Mipsagargin|Miptenalimab|Mirabegron|Miransertib|Mirdametinib|Mirvetuximab Soravtansine|Mirzotamab Clezutoclax|Misonidazole|Mistletoe Extract|Mitazalimab|Mitindomide|Mitobronitol|Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101|Mitoclomine|Mitoflaxone|Mitoguazone|Mitoguazone Dihydrochloride|Mitolactol|Mitomycin|Mitomycin A|Mitomycin B|Mitomycin C Analog KW-2149|Mitosis Inhibitor T 1101 Tosylate|Mitotane|Mitotenamine|Mitoxantrone|Mitoxantrone Hydrochloride|Mitozolomide|Mivavotinib|Mivebresib|Mivobulin|Mivobulin Isethionate|Mixed Bacteria Vaccine|Mobocertinib|Mocetinostat|Modakafusp Alfa|Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208|Modified Vitamin D Binding Protein Macrophage Activator EF-022|Modotuximab|Mofarotene|Mogamulizumab|Molibresib|Molibresib Besylate|Momelotinib|Monalizumab|Monocarboxylate Transporter 1 Inhibitor AZD3965|Monoclonal Antibody 105AD7 Anti-idiotype Vaccine|Monoclonal Antibody 11D10|Monoclonal Antibody 11D10 Anti-Idiotype Vaccine|Monoclonal Antibody 14G2A|Monoclonal Antibody 1F5|Monoclonal Antibody 3622W94|Monoclonal Antibody 3F8|Monoclonal Antibody 3H1 Anti-Idiotype Vaccine|Monoclonal Antibody 4B5 Anti-Idiotype Vaccine|Monoclonal Antibody 7C11|Monoclonal Antibody 81C6|Monoclonal Antibody A1G4 Anti-Idiotype Vaccine|Monoclonal Antibody A27.15|Monoclonal Antibody A33|Monoclonal Antibody AK002|Monoclonal Antibody ASP1948|Monoclonal Antibody AbGn-7|Monoclonal Antibody CAL|Monoclonal Antibody CC49-delta CH2|Monoclonal Antibody CEP-37250/KHK2804|Monoclonal Antibody D6.12|Monoclonal Antibody E2.3|Monoclonal Antibody F19|Monoclonal Antibody GD2 Anti-Idiotype Vaccine|Monoclonal Antibody HeFi-1|Monoclonal Antibody Hu3S193|Monoclonal Antibody HuAFP31|Monoclonal Antibody HuHMFG1|Monoclonal Antibody HuPAM4|Monoclonal Antibody IMMU-14|Monoclonal Antibody L6|Monoclonal Antibody Lym-1|Monoclonal Antibody MX35 F(ab')2|Monoclonal Antibody Me1-14 F(ab')2|Monoclonal Antibody NEO-201|Monoclonal Antibody R24|Monoclonal Antibody RAV12|Monoclonal Antibody SGN-14|Monoclonal Antibody TRK-950|Monoclonal Antibody huJ591|Monoclonal Antibody m170|Monoclonal Antibody muJ591|Monoclonal Microbial EDP1503|Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100|Monomethyl Auristatin E|Morinda Citrifolia Fruit Extract|Morpholinodoxorubicin|Mosedipimod|Mosunetuzumab|Motesanib|Motesanib Diphosphate|Motexafin Gadolinium|Motexafin Lutetium|Motixafortide|Motolimod|Moxetumomab Pasudotox|Mps1 Inhibitor BAY 1217389|Mps1 Inhibitor BOS172722|Mucoadhesive Paclitaxel Formulation|Multi-AGC Kinase Inhibitor AT13148|Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200|Multi-epitope HER2 Peptide Vaccine H2NVAC|Multi-epitope HER2 Peptide Vaccine TPIV100|Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107|Multi-kinase Inhibitor TPX-0022|Multi-kinase Inhibitor XL092|Multi-mode Kinase Inhibitor EOC317|Multi-neo-epitope Vaccine OSE 2101|Multifunctional/Multitargeted Anticancer Agent OMN54|Multikinase Inhibitor 4SC-203|Multikinase Inhibitor AEE788|Multikinase Inhibitor AT9283|Multikinase Inhibitor SAR103168|Multipeptide Vaccine S-588210|Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327|Muparfostat|Mureletecan|Murizatoclax|Muscadine Grape Extract|Mutant IDH1 Inhibitor DS-1001|Mutant p53 Activator COTI-2|Mutant-selective EGFR Inhibitor PF-06459988|Mycobacterium tuberculosis Arabinomannan Z-100|Mycobacterium w|Mycophenolic Acid|N,N-Dibenzyl Daunomycin|N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea|N-Methylformamide|N-dihydrogalactochitosan|NA17-A Antigen|NA17.A2 Peptide Vaccine|NAMPT Inhibitor OT-82|NEDD8 Activating Enzyme E1 Inhibitor TAS4464|NG-nitro-L-arginine|NLRP3 Agonist BMS-986299|NTRK/ROS1 Inhibitor DS-6051b|NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611|NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301|NY-ESO-1/GLA-SE Vaccine ID-G305|NY-ESO-B|Nab-paclitaxel|Nab-paclitaxel/Rituximab-coated Nanoparticle AR160|Nadofaragene Firadenovec|Nagrestipen|Namirotene|Namodenoson|Nanafrocin|Nanatinostat|Nanocell-encapsulated miR-16-based microRNA Mimic|Nanoparticle Albumin-Bound Docetaxel|Nanoparticle Albumin-Bound Rapamycin|Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404|Nanoparticle Paclitaxel Ointment SOR007|Nanoparticle-based Paclitaxel Suspension|Nanoparticle-encapsulated Doxorubicin Hydrochloride|Nanoscale Coordination Polymer Nanoparticles CPI-100|Nanosomal Docetaxel Lipid Suspension|Napabucasin|Naphthalimide Analogue UNBS5162|Naptumomab Estafenatox|Naquotinib|Naratuximab Emtansine|Narnatumab|Natalizumab|Natural IFN-alpha OPC-18|Natural Killer Cells ZRx101|Navarixin|Navicixizumab|Navitoclax|Navoximod|Navy Bean Powder|Naxitamab|Nazartinib|Necitumumab|Nedaplatin|Nedisertib|Nelarabine|Nelipepimut-S|Nelipepimut-S Plus GM-CSF Vaccine|Nemorubicin|Nemorubicin Hydrochloride|Neoantigen Vaccine GEN-009|Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017|Neoantigen-based Glioblastoma Vaccine|Neoantigen-based Melanoma-Poly-ICLC Vaccine|Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine|Neoantigen-based Therapeutic Cancer Vaccine GRT-C903|Neoantigen-based Therapeutic Cancer Vaccine GRT-R904|Neratinib|Neratinib Maleate|Nesvacumab|Niacinamide|Niclosamide|Nicotinamide Riboside|Nidanilimab|Nifurtimox|Nilotinib|Nilotinib Hydrochloride Anhydrous|Nilotinib Hydrochloride Monohydrate|Nilutamide|Nimesulide-Hyaluronic Acid Conjugate CA102N|Nimodipine|Nimotuzumab|Nimustine|Nimustine Hydrochloride|Ningetinib Tosylate|Nintedanib|Niraparib|Niraparib Tosylate Monohydrate|Nirogacestat|Nitric Oxide-Releasing Acetylsalicylic Acid Derivative|Nitrogen Mustard Prodrug PR-104|Nitroglycerin Transdermal Patch|Nivolumab|Nocodazole|Nogalamycin|Nogapendekin Alfa|Nolatrexed Dihydrochloride|Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201|Norgestrel|North American Ginseng Extract AFX-2|Nortopixantrone|Noscapine|Noscapine Hydrochloride|Not Otherwise Specified|Not Reported|Notch Signaling Inhibitor PF-06650808|Notch Signaling Pathway Inhibitor MK0752|Nucleolin Antagonist IPP-204106N|Nucleoside Analog DFP-10917|Nucleotide Analog Prodrug NUC-3373|Nucleotide Analogue GS 9219|Numidargistat|Nurulimab|Nutlin-3a|Nutraceutical TBL-12|O-Chloroacetylcarbamoylfumagillol|O6-Benzylguanine|OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule|OX40L-expressing Oncolytic Adenovirus DNX-2440|Obatoclax Mesylate|Obinutuzumab|Ocrelizumab|Octreotide|Octreotide Acetate|Octreotide Pamoate|Odronextamab|Ofatumumab|Ofranergene Obadenovec|Oglufanide Disodium|Olaparib|Olaptesed Pegol|Olaratumab|Oleandrin|Oleclumab|Oligo-fucoidan|Oligonucleotide SPC2996|Olinvacimab|Olivomycin|Olmutinib|Oltipraz|Olutasidenib|Olvimulogene Nanivacirepvec|Omacetaxine Mepesuccinate|Ombrabulin|Omipalisib|Onalespib|Onalespib Lactate|Onartuzumab|Onatasertib|Oncolytic Adenovirus Ad5-DNX-2401|Oncolytic Adenovirus ORCA-010|Oncolytic HSV-1 C134|Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011|Oncolytic HSV-1 G207|Oncolytic HSV-1 NV1020|Oncolytic HSV-1 rQNestin34.5v.2|Oncolytic HSV-1 rRp450|Oncolytic HSV1716|Oncolytic Herpes Simplex Virus-1 ONCR-177|Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein|Oncolytic Newcastle Disease Virus MEDI5395|Oncolytic Newcastle Disease Virus MTH-68H|Oncolytic Newcastle Disease Virus Strain PV701|Oncolytic Virus ASP9801|Oncolytic Virus RP1|Ondansetron Hydrochloride|Ontorpacept|Ontuxizumab|Onvansertib|Onvatilimab|Opaganib|Opioid Growth Factor|Opolimogene Capmilisbac|Oportuzumab Monatox|Oprozomib|Opucolimab|Oral Aminolevulinic Acid Hydrochloride|Oral Azacitidine|Oral Cancer Vaccine V3-OVA|Oral Docetaxel|Oral Fludarabine Phosphate|Oral Hsp90 Inhibitor IPI-493|Oral Ixabepilone|Oral Microencapsulated Diindolylmethane|Oral Milataxel|Oral Myoma Vaccine V3-myoma|Oral Pancreatic Cancer Vaccine V3-P|Oral Picoplatin|Oral Sodium Phenylbutyrate|Oral Topotecan Hydrochloride|Orantinib|Oraxol|Oregovomab|Orelabrutinib|Ormaplatin|Ortataxel|Orteronel|Orvacabtagene Autoleucel|Osilodrostat|Osimertinib|Other|Otlertuzumab|Ovapuldencel-T|Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006|Ovine Submaxillary Mucin|OxPhos Inhibitor VLX600|Oxaliplatin|Oxaliplatin Eluting Beads|Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome|Oxcarbazepine|Oxeclosporin|Oxidative Phosphorylation Inhibitor IACS-010759|Oxidative Phosphorylation Inhibitor IM156|Oxidopamine|Ozarelix|P-TEFb Inhibitor BAY1143572|P-cadherin Antagonist PF-03732010|P-cadherin Inhibitor PCA062|P-cadherin-targeting Agent PF-06671008|P-p68 Inhibitor RX-5902|PAK4 Inhibitor PF-03758309|PAK4/NAMPT Inhibitor KPT-9274|PARP 1/2 Inhibitor IMP4297|PARP 1/2 Inhibitor NOV1401|PARP Inhibitor AZD2461|PARP Inhibitor CEP-9722|PARP Inhibitor E7016|PARP Inhibitor NMS-03305293|PARP-1/2 Inhibitor ABT-767|PARP/Tankyrase Inhibitor 2X-121|PARP7 Inhibitor RBN-2397|PBN Derivative OKN-007|PCNU|PD-1 Directed Probody CX-188|PD-1 Inhibitor|PD-L1 Inhibitor GS-4224|PD-L1 Inhibitor INCB086550|PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480|PD-L1/PD-L2/VISTA Antagonist CA-170|PDK1 Inhibitor AR-12|PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|PEG-Proline-Interferon Alfa-2b|PEG-interleukin-2|PEOX-based Polymer Encapsulated Paclitaxel FID-007|PEP-3-KLH Conjugate Vaccine|PGG Beta-Glucan|PGLA/PEG Copolymer-Based Paclitaxel|PH20 Hyaluronidase-expressing Adenovirus VCN-01|PI3K Alpha/Beta Inhibitor BAY1082439|PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate|PI3K Inhibitor ACP-319|PI3K Inhibitor BGT226|PI3K Inhibitor GDC-0084|PI3K Inhibitor GDC0077|PI3K Inhibitor GSK1059615|PI3K Inhibitor WX-037|PI3K Inhibitor ZSTK474|PI3K p110beta/delta Inhibitor KA2237|PI3K-alpha Inhibitor MEN1611|PI3K-beta Inhibitor GSK2636771|PI3K-beta Inhibitor SAR260301|PI3K-delta Inhibitor AMG 319|PI3K-delta Inhibitor HMPL 689|PI3K-delta Inhibitor INCB050465|PI3K-delta Inhibitor PWT143|PI3K-delta Inhibitor SHC014748M|PI3K-delta Inhibitor YY-20394|PI3K-gamma Inhibitor IPI-549|PI3K/BET Inhibitor LY294002|PI3K/mTOR Kinase Inhibitor DS-7423|PI3K/mTOR Kinase Inhibitor PF-04691502|PI3K/mTOR Kinase Inhibitor VS-5584|PI3K/mTOR Kinase Inhibitor WXFL10030390|PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170|PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901|PI3Ka/mTOR Inhibitor PKI-179|PI3Kalpha Inhibitor AZD8835|PI3Kbeta Inhibitor AZD8186|PI3Kdelta Inhibitor GS-9901|PIM Kinase Inhibitor LGH447|PIM Kinase Inhibitor SGI-1776|PIM Kinase Inhibitor TP-3654|PIM/FLT3 Kinase Inhibitor SEL24|PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231|PKC-alpha Antisense Oligodeoxynucleotide ISIS 3521|PKC-beta Inhibitor MS-553|PLK1 Inhibitor CYC140|PLK1 Inhibitor TAK-960|PPAR Alpha Antagonist TPST-1120|PR1 Leukemia Peptide Vaccine|PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701|PRIMA-1 Analog APR-246|PRMT1 Inhibitor GSK3368715|PRMT5 Inhibitor JNJ-64619178|PRMT5 Inhibitor PRT811|PSA/IL-2/GM-CSF Vaccine|PSA/PSMA DNA Plasmid INO-5150|PSMA-targeted Docetaxel Nanoparticles BIND-014|PSMA-targeted Tubulysin B-containing Conjugate EC1169|PSMA/CD3 Tri-specific T-cell Activating Construct HPN424|PTEF-b/CDK9 Inhibitor BAY1251152|PV-10|PVA Microporous Hydrospheres/Doxorubicin Hydrochloride|Paclitaxel|Paclitaxel Ceribate|Paclitaxel Injection Concentrate for Nanodispersion|Paclitaxel Liposome|Paclitaxel PPE Microspheres|Paclitaxel Poliglumex|Paclitaxel Polymeric Micelle Formulation NANT-008|Paclitaxel Trevatide|Paclitaxel Vitamin E-Based Emulsion|Paclitaxel-Loaded Polymeric Micelle|Pacmilimab|Pacritinib|Padeliporfin|Padoporfin|Palbociclib|Palbociclib Isethionate|Palifosfamide|Palifosfamide Tromethamine|Palladium Pd-103|Palonosetron Hydrochloride|Pamidronate Disodium|Pamidronic Acid|Pamiparib|Pamrevlumab|Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514|Pan-AKT Inhibitor ARQ751|Pan-AKT Kinase Inhibitor GSK690693|Pan-FGFR Inhibitor LY2874455|Pan-FLT3/Pan-BTK Multi-kinase Inhibitor CG-806|Pan-IDH Mutant Inhibitor AG-881|Pan-KRAS Inhibitor BI 1701963|Pan-Mutant-IDH1 Inhibitor Bay-1436032|Pan-PIM Inhibitor INCB053914|Pan-RAF Inhibitor LY3009120|Pan-RAR Agonist/AP-1 Inhibitor LGD 1550|Pan-TRK Inhibitor NOV1601|Pan-TRK Inhibitor ONO-7579|Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981|Pan-mutation-selective EGFR Inhibitor CLN-081|Pancratistatin|Panitumumab|Panobinostat|Panobinostat Nanoparticle Formulation MTX110|Panulisib|Paricalcitol|Parsaclisib|Parsaclisib Hydrochloride|Parsatuzumab|Partially Engineered T-regulatory Cell Donor Graft TRGFT-201|Parvovirus H-1|Pasireotide|Pasotuxizumab|Patidegib|Patidegib Topical Gel|Patritumab|Patritumab Deruxtecan|Patupilone|Paxalisib|Pazopanib|Pazopanib Hydrochloride|Pegargiminase|Pegaspargase|Pegdinetanib|Pegfilgrastim|Pegilodecakin|Peginterferon Alfa-2a|Peginterferon Alfa-2b|Pegvisomant|Pegvorhyaluronidase Alfa|Pegylated Deoxycytidine Analogue DFP-14927|Pegylated Interferon Alfa|Pegylated Liposomal Belotecan|Pegylated Liposomal Doxorubicin Hydrochloride|Pegylated Liposomal Irinotecan|Pegylated Liposomal Mitomycin C Lipid-based Prodrug|Pegylated Liposomal Mitoxantrone Hydrochloride|Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010|Pegylated Paclitaxel|Pegylated Recombinant Human Arginase I BCT-100|Pegylated Recombinant Human Hyaluronidase PH20|Pegylated Recombinant Interleukin-2 THOR-707|Pegylated Recombinant L-asparaginase Erwinia chrysanthemi|Pegylated SN-38 Conjugate PLX038|Pegzilarginase|Pelabresib|Pelareorep|Peldesine|Pelitinib|Pelitrexol|Pembrolizumab|Pemetrexed|Pemetrexed Disodium|Pemigatinib|Pemlimogene Merolisbac|Penberol|Penclomedine|Penicillamine|Pentamethylmelamine|Pentamustine|Pentostatin|Pentoxifylline|Pepinemab|Peplomycin|Peplomycin Sulfate|Peposertib|Peptichemio|Peptide 946 Melanoma Vaccine|Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine|Peretinoin|Perflenapent Emulsion|Perfosfamide|Perifosine|Perillyl Alcohol|Personalized ALL-specific Multi-HLA-binding Peptide Vaccine|Personalized Cancer Vaccine RO7198457|Personalized Neoantigen DNA Vaccine GNOS-PV01|Personalized Neoantigen DNA Vaccine GNOS-PVO2|Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01|Personalized Neoepitope Yeast Vaccine YE-NEO-001|Personalized Peptide Cancer Vaccine NEO-PV-01|Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC|Pertuzumab|Pevonedistat|Pexastimogene Devacirepvec|Pexidartinib|Pexmetinib|Phaleria macrocarpa Extract DLBS-1425|Pharmacological Ascorbate|Phellodendron amurense Bark Extract|Phenesterin|Phenethyl Isothiocyanate|Phenethyl Isothiocyanate-containing Watercress Juice|Phenyl Acetate|Phenytoin Sodium|Phosphaplatin PT-112|Phosphatidylcholine-Bound Silybin|Phospholipid Ether-drug Conjugate CLR 131|Phosphoramide Mustard|Phosphorodiamidate Morpholino Oligomer AVI-4126|Phosphorus P-32|Photodynamic Compound TLD-1433|Photosensitizer LUZ 11|Phytochlorin Sodium-Polyvinylpyrrolidone Complex|Pibenzimol|Pibrozelesin|Pibrozelesin Hydrobromide|Picibanil|Picoplatin|Picrasinoside H|Picropodophyllin|Pictilisib|Pictilisib Bismesylate|Pidilizumab|Pilaralisib|Pimasertib|Pimitespib|Pimurutamab|Pinatuzumab Vedotin|Pingyangmycin|Pinometostat|Pioglitazone|Pioglitazone Hydrochloride|Pipendoxifene|Piperazinedione|Piperine Extract (Standardized)|Pipobroman|Piposulfan|Pirarubicin|Pirarubicin Hydrochloride|Pirfenidone|Piritrexim|Piritrexim Isethionate|Pirotinib|Piroxantrone|Piroxantrone Hydrochloride|Pixantrone|Pixantrone Dimaleate|Pixatimod|Placebo|Pladienolide Derivative E7107|Plamotamab|Plasmid DNA Vaccine pING-hHER3FL|Platinum|Platinum Acetylacetonate-Titanium Dioxide Nanoparticles|Platinum Compound|Plevitrexed|Plicamycin|Plinabulin|Plitidepsin|Plk1 Inhibitor BI 2536|Plocabulin|Plozalizumab|Pol I Inhibitor CX5461|Polatuzumab Vedotin|Polidocanol|Poliglusam|Polo-like Kinase 1 Inhibitor GSK461364|Polo-like Kinase 1 Inhibitor MK1496|Polo-like Kinase 1 Inhibitor NMS-1286937|Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate|Poly-alendronate Dextran-Guanidine Conjugate|Poly-gamma Glutamic Acid|Polyamine Analog SL11093|Polyamine Analogue PG11047|Polyamine Analogue SBP-101|Polyamine Transport Inhibitor AMXT-1501 Dicaprate|Polyandrol|Polyethylene Glycol Recombinant Endostatin|Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318|Polymer-conjugated IL-15 Receptor Agonist NKTR-255|Polymer-encapsulated Luteolin Nanoparticle|Polymeric Camptothecin Prodrug XMT-1001|Polypodium leucotomos Extract|Polysaccharide-K|Polysialic Acid|Polyunsaturated Fatty Acid|Polyvalent Melanoma Vaccine|Pomalidomide|Pomegranate Juice|Pomegranate Liquid Extract|Ponatinib|Ponatinib Hydrochloride|Porcupine Inhibitor CGX1321|Porcupine Inhibitor ETC-1922159|Porcupine Inhibitor RXC004|Porcupine Inhibitor WNT974|Porcupine Inhibitor XNW7201|Porfimer Sodium|Porfiromycin|Poziotinib|Pracinostat|Pralatrexate|Pralsetinib|Praluzatamab Ravtansine|Pravastatin Sodium|Prednimustine|Prednisolone|Prednisolone Acetate|Prednisolone Sodium Phosphate|Prednisone|Prexasertib|Prexigebersen|Prime Cancer Vaccine MVA-BN-CV301|Prinomastat|Proapoptotic Sulindac Analog CP-461|Procarbazine|Procarbazine Hydrochloride|Procaspase Activating Compound-1 VO-100|Progestational IUD|Prohibitin-Targeting Peptide 1|Prolgolimab|Prostaglandin E2 EP4 Receptor Inhibitor AN0025|Prostaglandin E2 EP4 Receptor Inhibitor E7046|Prostate Cancer Vaccine ONY-P1|Prostate Health Cocktail Dietary Supplement|Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024|Protease-activated Anti-PD-L1 Antibody Prodrug CX-072|Protein Arginine Methyltransferase 5 Inhibitor GSK3326595|Protein Arginine Methyltransferase 5 Inhibitor PF-06939999|Protein Arginine Methyltransferase 5 Inhibitor PRT543|Protein Kinase C Inhibitor IDE196|Protein Phosphatase 2A Inhibitor LB-100|Protein Stabilized Liposomal Docetaxel Nanoparticles|Protein Tyrosine Kinase 2 Inhibitor IN10018|Proxalutamide|Pseudoisocytidine|Pterostilbene|Pumitepa|Puquitinib|Puquitinib Mesylate|Puromycin|Puromycin Hydrochloride|Pyrazinamide|Pyrazoloacridine|Pyridyl Cyanoguanidine CHS 828|Pyrotinib|Pyrotinib Dimaleate|Pyroxamide|Pyruvate Kinase Inhibitor TLN-232|Pyruvate Kinase M2 Isoform Activator TP-1454|Qilisheng Immunoregulatory Oral Solution|Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine|Quarfloxin|Quinacrine Hydrochloride|Quinine|Quisinostat|Quizartinib|R-(-)-Gossypol Acetic Acid|RAD51 Inhibitor CYT-0851|RAF Kinase Inhibitor L-779450|RAF Kinase Inhibitor XL281|RARalpha Agonist IRX5183|RET Inhibitor DS-5010|RET Mutation/Fusion Inhibitor BLU-667|RET/SRC Inhibitor TPX-0046|RFT5-dgA Immunotoxin IMTOX25|RIPK1 Inhibitor GSK3145095|RNR Inhibitor COH29|ROBO1-targeted BiCAR-NKT Cells|RORgamma Agonist LYC-55716|RSK1-4 Inhibitor PMD-026|Rabusertib|Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus SM-88|Racotumomab|Radgocitabine|Radgocitabine Hydrochloride|Radioactive Iodine|Radiolabeled CC49|Radium Ra 223 Dichloride|Radium Ra 224-labeled Calcium Carbonate Microparticles|Radix Angelicae Sinensis/Radix Astragali Herbal Supplement|Radotinib Hydrochloride|Raf Kinase Inhibitor HM95573|Ragifilimab|Ralaniten Acetate|Ralimetinib Mesylate|Raloxifene|Raloxifene Hydrochloride|Raltitrexed|Ramucirumab|Ranibizumab|Ranimustine|Ranolazine|Ranpirnase|Ras Inhibitor|Ras Peptide ASP|Ras Peptide CYS|Ras Peptide VAL|Razoxane|Realgar-Indigo naturalis Formulation|Rebastinib Tosylate|Rebeccamycin|Rebimastat|Receptor Tyrosine Kinase Inhibitor R1530|Recombinant Adenovirus-p53 SCH-58500|Recombinant Anti-WT1 Immunotherapeutic GSK2302024A|Recombinant Bacterial Minicells VAX014|Recombinant Bispecific Single-Chain Antibody rM28|Recombinant CD40-Ligand|Recombinant Erwinia asparaginase JZP-458|Recombinant Erythropoietin|Recombinant Fas Ligand|Recombinant Fractalkine|Recombinant Granulocyte-Macrophage Colony-Stimulating Factor|Recombinant Human 6Ckine|Recombinant Human Adenovirus Type 5 H101|Recombinant Human Angiotensin Converting Enzyme 2 APN01|Recombinant Human Apolipoprotein(a) Kringle V MG1102|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Recombinant Human Endostatin|Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine|Recombinant Human Papillomavirus 11-valent Vaccine|Recombinant Human Papillomavirus Bivalent Vaccine|Recombinant Human Papillomavirus Nonavalent Vaccine|Recombinant Human Plasminogen Kringle 5 Domain ABT 828|Recombinant Human TRAIL-Trimer Fusion Protein SCB-313|Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301|Recombinant Interferon|Recombinant Interferon Alfa|Recombinant Interferon Alfa-1b|Recombinant Interferon Alfa-2a|Recombinant Interferon Alfa-2b|Recombinant Interferon Alpha 2b-like Protein|Recombinant Interferon Beta|Recombinant Interferon Gamma|Recombinant Interleukin-12|Recombinant Interleukin-13|Recombinant Interleukin-18|Recombinant Interleukin-2|Recombinant Interleukin-6|Recombinant KSA Glycoprotein CO17-1A|Recombinant Leukocyte Interleukin|Recombinant Leukoregulin|Recombinant Luteinizing Hormone|Recombinant MAGE-3.1 Antigen|Recombinant MIP1-alpha Variant ECI301|Recombinant Macrophage Colony-Stimulating Factor|Recombinant Modified Vaccinia Ankara-5T4 Vaccine|Recombinant Oncolytic Poliovirus PVS-RIPO|Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A|Recombinant Platelet Factor 4|Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207|Recombinant Super-compound Interferon|Recombinant Thyroglobulin|Recombinant Thyrotropin Alfa|Recombinant Transforming Growth Factor-Beta|Recombinant Transforming Growth Factor-Beta-2|Recombinant Tumor Necrosis Factor-Alpha|Recombinant Tyrosinase-Related Protein-2|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Redaporfin|Refametinib|Regorafenib|Relacorilant|Relatlimab|Relugolix|Remetinostat|Renal Cell Carcinoma Peptides Vaccine IMA901|Reparixin|Repotrectinib|Resiquimod|Resiquimod Topical Gel|Resistant Starch|Resminostat|Resveratrol|Resveratrol Formulation SRT501|Retaspimycin|Retaspimycin Hydrochloride|Retelliptine|Retifanlimab|Retinoic Acid Agent Ro 16-9100|Retinoid 9cUAB30|Retinol|Retinyl Acetate|Retinyl Palmitate|Retrovector Encoding Mutant Anti-Cyclin G1|Revdofilimab|Rexinoid NRX 194204|Rezivertinib|Rhenium Re 188 BMEDA-labeled Liposomes|Rhenium Re-186 Hydroxyethylidene Diphosphonate|Rhenium Re-188 Ethiodized Oil|Rhenium Re-188 Etidronate|Rhizoxin|RhoC Peptide Vaccine RV001V|Ribociclib|Ribociclib/Letrozole|Ribonuclease QBI-139|Ribosome-Inactivating Protein CY503|Ribozyme RPI.4610|Rice Bran|Ricolinostat|Ridaforolimus|Rigosertib|Rigosertib Sodium|Rilimogene Galvacirepvec|Rilimogene Galvacirepvec/Rilimogene Glafolivec|Rilimogene Glafolivec|Rilotumumab|Rindopepimut|Ripertamab|Ripretinib|Risperidone Formulation in Rumenic Acid|Ritrosulfan|Rituximab|Rituximab Conjugate CON-4619|Rituximab and Hyaluronidase Human|Riviciclib|Rivoceranib|Rivoceranib Mesylate|Robatumumab|Roblitinib|Rocakinogene Sifuplasmid|Rocapuldencel-T|Rociletinib|Rodorubicin|Roducitabine|Rofecoxib|Roflumilast|Rogaratinib|Rogletimide|Rolinsatamab Talirine|Romidepsin|Roneparstat|Roniciclib|Ropeginterferon Alfa-2B|Ropidoxuridine|Ropocamptide|Roquinimex|Rosabulin|Rose Bengal Solution PV-10|Rosiglitazone Maleate|Rosmantuzumab|Rosopatamab|Rosuvastatin|Rovalpituzumab Tesirine|Rubitecan|Rucaparib|Rucaparib Camsylate|Rucaparib Phosphate|Ruthenium Ru-106|Ruthenium-based Small Molecule Therapeutic BOLD-100|Ruthenium-based Transferrin Targeting Agent NKP-1339|Ruxolitinib|Ruxolitinib Phosphate|Ruxotemitide|S-Adenosylmethionine|S-equol|S1P Receptor Agonist KRP203|SBIL-2|SDF-1 Receptor Antagonist PTX-9908|SERD D-0502|SERD G1T48|SERD GDC-9545|SERD SAR439859|SERD SHR9549|SERD ZN-c5|SHP-1 Agonist SC-43|SHP2 Inhibitor JAB-3068|SHP2 Inhibitor RLY-1971|SHP2 Inhibitor RMC-4630|SHP2 Inhibitor TNO155|SIRPa-4-1BBL Fusion Protein DSP107|SIRPa-Fc Fusion Protein TTI-621|SIRPa-Fc-CD40L Fusion Protein SL-172154|SIRPa-IgG4-Fc Fusion Protein TTI-622|SLC6A8 Inhibitor RGX-202|SLCT Inhibitor GNS561|SMAC Mimetic BI 891065|SMO Protein Inhibitor ZSP1602|SN-38-Loaded Polymeric Micelles NK012|SNS01-T Nanoparticles|SR-BP1/HSI Inhibitor SR31747A|SR-T100 Gel|SRPK1/ABCG2 Inhibitor SCO-101|SSTR2-targeting Protein/DM1 Conjugate PEN-221|STAT Inhibitor OPB-111077|STAT3 Inhibitor DSP-0337|STAT3 Inhibitor OPB-31121|STAT3 Inhibitor OPB-51602|STAT3 Inhibitor TTI-101|STAT3 Inhibitor WP1066|STING Agonist BMS-986301|STING Agonist GSK3745417|STING Agonist IMSA101|STING Agonist MK-1454|STING Agonist SB 11285|STING Agonist TAK-676|STING-activating Cyclic Dinucleotide Agonist MIW815|STING-expressing E. coli SYNB1891|Sabarubicin|Sabatolimab|Sacituzumab Govitecan|Sacubitril/Valsartan|Safingol|Sagopilone|Salirasib|Salmonella VNP20009|Sam68 Modulator CWP232291|Samalizumab|Samarium Sm 153-DOTMP|Samotolisib|Samrotamab Vedotin|Samuraciclib|Sapacitabine|Sapanisertib|Sapitinib|SarCNU|Saracatinib|Saracatinib Difumarate|Sardomozide|Sargramostim|Sasanlimab|Satraplatin|Savolitinib|Scopoletin|Seclidemstat|Sedoxantrone Trihydrochloride|Selatinib Ditosilate|Selective Androgen Receptor Modulator RAD140|Selective Cytokine Inhibitory Drug CC-1088|Selective Estrogen Receptor Degrader AZD9496|Selective Estrogen Receptor Degrader AZD9833|Selective Estrogen Receptor Degrader LSZ102|Selective Estrogen Receptor Degrader LX-039|Selective Estrogen Receptor Degrader LY3484356|Selective Estrogen Receptor Degrader SRN-927|Selective Estrogen Receptor Modulator CC-8490|Selective Estrogen Receptor Modulator TAS-108|Selective Glucocorticoid Receptor Antagonist CORT125281|Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352|Seliciclib|Selicrelumab|Selinexor|Selitrectinib|Selonsertib|Selpercatinib|Selumetinib|Selumetinib Sulfate|Semaxanib|Semuloparin|Semustine|Seneca Valley Virus-001|Seocalcitol|Sepantronium Bromide|Serabelisib|Serclutamab Talirine|Serdemetan|Sergiolide|Seribantumab|Serine/Threonine Kinase Inhibitor CBP501|Serine/Threonine Kinase Inhibitor XL418|Serplulimab|Sevacizumab|Seviteronel|Shared Anti-Idiotype-AB-S006|Shared Anti-Idiotype-AB-S024A|Shark Cartilage|Shark Cartilage Extract AE-941|Shenqi Fuzheng Injection SQ001|Sho-Saiko-To|Short Chain Fatty Acid HQK-1004|Shu Yu Wan Formula|Sialyl Tn Antigen|Sialyl Tn-KLH Vaccine|Sibrotuzumab|Silatecan AR-67|Silibinin|Silicon Phthalocyanine 4|Silmitasertib Sodium|Siltuximab|Simalikalactone D|Simeprevir|Simlukafusp Alfa|Simmitinib|Simotaxel|Simtuzumab|Simurosertib|Sintilimab|Siplizumab|Sipuleucel-T|Siremadlin|Sirolimus|Sitimagene Ceradenovec|Sitravatinib|Sivifene|Sizofiran|Smac Mimetic GDC-0152|Smac Mimetic GDC-0917|Smac Mimetic LCL161|Smoothened Antagonist BMS-833923|Smoothened Antagonist LDE225 Topical|Smoothened Antagonist LEQ506|Smoothened Antagonist TAK-441|Sobuzoxane|Sodium Borocaptate|Sodium Butyrate|Sodium Dichloroacetate|Sodium Iodide I-131|Sodium Metaarsenite|Sodium Phenylbutyrate|Sodium Salicylate|Sodium Selenite|Sodium Stibogluconate|Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108|Sofituzumab Vedotin|Solitomab|Sonepcizumab|Sonidegib|Sonolisib|Sorafenib|Sorafenib Tosylate|Sorghum bicolor Supplement|Sotigalimab|Sotorasib|Sotrastaurin|Sotrastaurin Acetate|Soy Isoflavones|Soy Protein Isolate|Spanlecortemlocel|Sparfosate Sodium|Sparfosic Acid|Spartalizumab|Spebrutinib|Spherical Nucleic Acid Nanoparticle NU-0129|Spirogermanium|Spiromustine|Spiroplatin|Splicing Inhibitor H3B-8800|Spongistatin|Squalamine Lactate|Src Kinase Inhibitor AP 23846|Src Kinase Inhibitor KX2-391|Src Kinase Inhibitor KX2-391 Ointment|Src Kinase Inhibitor M475271|Src/Abl Kinase Inhibitor AZD0424|Src/tubulin Inhibitor KX02|St. John's Wort|Stallimycin|Staphylococcal Enterotoxin A|Staphylococcal Enterotoxin B|Staurosporine|Streptonigrin|Streptozocin|Strontium Chloride Sr-89|Submicron Particle Paclitaxel Sterile Suspension|Sugemalimab|Sulfatinib|Sulforaphane|Sulindac|Sulofenur|Sumoylation Inhibitor TAK-981|Sunitinib|Sunitinib Malate|Super Enhancer Inhibitor GZ17-6.02|Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803|Superoxide Dismutase Mimetic GC4711|Suramin|Suramin Sodium|Survivin Antigen|Survivin Antigen Vaccine DPX-Survivac|Survivin mRNA Antagonist EZN-3042|Survivin-expressing CVD908ssb-TXSVN Vaccine|Sustained-release Lipid Inhaled Cisplatin|Sustained-release Mitomycin C Hydrogel Formulation UGN-101|Sustained-release Mitomycin C Hydrogel Formulation UGN-102|Syk Inhibitor HMPL-523|Synchrotope TA2M Plasmid DNA Vaccine|Synchrovax SEM Plasmid DNA Vaccine|Synthetic Alkaloid PM00104|Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2|Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1|Synthetic Hypericin|Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201|Synthetic Long E6/E7 Peptides Vaccine HPV-01|Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b|Synthetic Plumbagin PCUR-101|Synthetic hTERT DNA Vaccine INO-1400|Synthetic hTERT DNA Vaccine INO-1401|T900607|TAM/c-Met Inhibitor RXDX-106|TGF-beta Receptor 1 Inhibitor PF-06952229|TGF-beta Receptor 1 Kinase Inhibitor SH3051|TGF-beta Receptor 1 Kinase Inhibitor YL-13027|TGFa-PE38 Immunotoxin|TGFbeta Inhibitor LY3200882|TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein AVID200|THL-P|TIGIT Inhibitor M6223|TIGIT-targeting Agent MK-7684|TLC ELL-12|TLR Agonist BDB001|TLR Agonist BSG-001|TLR Agonist CADI-05|TLR-Directed Cationic Lipid-DNA Complex JVRS-100|TLR7 Agonist 852A|TLR7 Agonist LHC165|TLR7 agonist BNT411|TLR7/8/9 Antagonist IMO-8400|TLR8 Agonist DN1508052|TLR9 Agonist AST-008|TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells|TORC1/2 Kinase Inhibitor DS-3078a|TP40 Immunotoxin|TRAIL Receptor Agonist ABBV-621|TRK Inhibitor AZD6918|TRK Inhibitor TQB3558|TRPM8 Agonist D-3263|TRPV6 Calcium Channel Inhibitor SOR-C13|TSP-1 Mimetic ABT-510|TSP-1 Mimetic Fusion Protein CVX-045|Tabalumab|Tabelecleucel|Tacedinaline|Tafasitamab|Tagraxofusp-erzs|Talabostat|Talabostat Mesylate|Talacotuzumab|Talactoferrin Alfa|Taladegib|Talampanel|Talaporfin Sodium|Talazoparib|Taletrectinib|Talimogene Laherparepvec|Tallimustine|Talmapimod|Talotrexin|Talotrexin Ammonium|Taltobulin|Tamibarotene|Taminadenant|Tamoxifen|Tamoxifen Citrate|Tamrintamab Pamozirine|Tandutinib|Tanespimycin|Tanibirumab|Tankyrase Inhibitor STP1002|Tanomastat|Tapotoclax|Tarenflurbil|Tarextumab|Tariquidar|Tasadenoturev|Taselisib|Tasidotin|Tasisulam|Tasisulam Sodium|Tasquinimod|Taurolidine|Tauromustine|Taurultam|Taurultam Analogue GP-2250|Tavokinogene Telseplasmid|Tavolimab|Taxane Analogue TPI 287|Taxane Compound|Taxol Analogue SID 530|Tazarotene|Tazemetostat|Tebentafusp|Teclistamab|Tecogalan Sodium|Tefinostat|Tegafur|Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation|Tegafur-Uracil|Tegafur-gimeracil-oteracil Potassium|Tegavivint|Teglarinad|Teglarinad Chloride|Telaglenastat|Telaglenastat Hydrochloride|Telapristone|Telapristone Acetate|Telatinib Mesylate|Telisotuzumab|Telisotuzumab Vedotin|Telomerase Inhibitor FJ5002|Telomerase-specific Type 5 Adenovirus OBP-301|Teloxantrone|Teloxantrone Hydrochloride|Telratolimod|Temarotene|Temoporfin|Temozolomide|Temsirolimus|Tenalisib|Tenifatecan|Teniposide|Tepoditamab|Tepotinib|Teprotumumab|Terameprocol|Terfluranol|Tergenpumatucel-L|Teroxirone|Tertomotide|Tesetaxel|Tesevatinib|Tesidolumab|Testolactone|Testosterone Enanthate|Tetanus Toxoid Vaccine|Tetradecanoylphorbol Acetate|Tetrahydrouridine|Tetraphenyl Chlorin Disulfonate|Tetrathiomolybdate|Tezacitabine|Tezacitabine Anhydrous|Thalicarpine|Thalidomide|Theliatinib|Theramide|Therapeutic Angiotensin-(1-7)|Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907|Therapeutic Cancer Vaccine ATP128|Therapeutic Estradiol|Therapeutic Hydrocortisone|Therapeutic Liver Cancer Peptide Vaccine IMA970A|Thiarabine|Thiodiglycol|Thioguanine|Thioguanine Anhydrous|Thioinosine|Thioredoxin-1 Inhibitor PX-12|Thiotepa|Thioureidobutyronitrile|Thorium Th 227 Anetumab|Thorium Th 227 Anetumab Corixetan|Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439|Thorium Th 227 Anti-PSMA Monoclonal Antibody BAY 2315497|Threonine Tyrosine Kinase Inhibitor CFI-402257|Thymidylate Synthase Inhibitor CX1106|Thymidylate Synthase Inhibitor DFP-11207|Thymopentin|Thyroid Extract|Tiazofurin|Tidutamab|Tigapotide|Tigatuzumab|Tilarginine|Tilogotamab|Tilsotolimod Sodium|Timonacic|Tin Ethyl Etiopurpurin|Tinostamustine|Tinzaparin Sodium|Tiomolibdate Choline|Tiomolibdate Diammonium|Tipapkinogene Sovacivec|Tipifarnib|Tipiracil|Tipiracil Hydrochloride|Tirabrutinib|Tiragolumab|Tirapazamine|Tirbanibulin|Tisagenlecleucel|Tislelizumab|Tisotumab Vedotin|Tivantinib|Tivozanib|Tocilizumab|Tocladesine|Tocotrienol|Tocotrienol-rich Fraction|Tolebrutinib|Toll-like Receptor 7 Agonist DSP-0509|Tolnidamine|Tomaralimab|Tomato-Soy Juice|Tomivosertib|Topical Betulinic Acid|Topical Celecoxib|Topical Fluorouracil|Topical Gemcitabine Hydrochloride|Topical Potassium Dobesilate|Topical Trichloroacetic Acid|Topixantrone|Topoisomerase I Inhibitor Genz-644282|Topoisomerase I Inhibitor LMP400|Topoisomerase I Inhibitor LMP776|Topoisomerase I/II Inhibitor NEV-801|Topoisomerase-1 Inhibitor LMP744|Topoisomerase-II Inhibitor Racemic XK469|Topoisomerase-II-beta Inhibitor Racemic XK469|Topotecan|Topotecan Hydrochloride|Topotecan Hydrochloride Liposomes|Topotecan Sustained-release Episcleral Plaque|Topsalysin|Toremifene|Toremifene Citrate|Toripalimab|Tosedostat|Tositumomab|Total Androgen Blockade|Tovetumab|Tozasertib Lactate|Trabectedin|Trabedersen|Trametinib|Trametinib Dimethyl Sulfoxide|Trans Sodium Crocetinate|Transdermal 17beta-Estradiol Gel BHR-200|Transdermal 4-Hydroxytestosterone|Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01|Transferrin Receptor-Targeted Liposomal p53 cDNA|Transferrin-CRM107|Tranylcypromine Sulfate|Trapoxin|Trastuzumab|Trastuzumab Conjugate BI-CON-02|Trastuzumab Deruxtecan|Trastuzumab Duocarmazine|Trastuzumab Emtansine|Trastuzumab Monomethyl Auristatin F|Trastuzumab-TLR 7/8 Agonist BDC-1001|Trastuzumab/Hyaluronidase-oysk|Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502|Trebananib|Tremelimumab|Treosulfan|Tretazicar|Tretinoin|Tretinoin Liposome|Triamcinolone Acetonide|Triamcinolone Hexacetonide|Triapine|Triazene Derivative CB10-277|Triazene Derivative TriN2755|Triazinate|Triaziquone|Tributyrin|Triciribine Phosphate|Trientine Hydrochloride|Triethylenemelamine|Trifluridine|Trifluridine and Tipiracil Hydrochloride|Trigriluzole|Trilaciclib|Trimelamol|Trimeric GITRL-Fc OMP-336B11|Trimethylcolchicinic Acid|Trimetrexate|Trimetrexate Glucuronate|Trioxifene|Triplatin Tetranitrate|Triptolide Analog|Triptorelin|Triptorelin Pamoate|Tris-acryl Gelatin Microspheres|Tritylcysteine|TrkA Inhibitor VMD-928|Trodusquemine|Trofosfamide|Troglitazone|Tropomyosin Receptor Kinase Inhibitor AZD7451|Troriluzole|Troxacitabine|Troxacitabine Nucleotide Prodrug MIV-818|Tubercidin|Tubulin Binding Agent TTI-237|Tubulin Inhibitor ALB 109564 Dihydrochloride|Tubulin Inhibitor ALB-109564|Tubulin Polymerization Inhibitor AEZS 112|Tubulin Polymerization Inhibitor CKD-516|Tubulin Polymerization Inhibitor VERU-111|Tubulin-Binding Agent SSR97225|Tucatinib|Tucidinostat|Tucotuzumab Celmoleukin|Tyroserleutide|Tyrosinase Peptide|Tyrosinase-KLH|Tyrosinase:146-156 Peptide|Tyrosine Kinase Inhibitor|Tyrosine Kinase Inhibitor OSI-930|Tyrosine Kinase Inhibitor SU5402|Tyrosine Kinase Inhibitor TL-895|Tyrosine Kinase Inhibitor XL228|UAE Inhibitor TAK-243|USP14/UCHL5 Inhibitor VLX1570|Ubenimex|Ubidecarenone Nanodispersion BPM31510n|Ublituximab|Ulinastatin|Ulixertinib|Ulocuplumab|Umbralisib|Uncaria tomentosa Extract|Unknown|Upamostat|Upifitamab|Uproleselan|Uprosertib|Urabrelimab|Uracil Ointment|Urelumab|Uroacitides|Urokinase-Derived Peptide A6|Ursolic Acid|Utomilumab|Uzansertib|V930 Vaccine|VEGF Inhibitor PTC299|VEGF/HGF-targeting DARPin MP0250|VEGFR Inhibitor KRN951|VEGFR-2 DNA Vaccine VXM01|VEGFR/FGFR Inhibitor ODM-203|VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593|VEGFR2 Tyrosine Kinase Inhibitor PF-00337210|VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813|VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220|VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820|VLP-encapsulated TLR9 Agonist CMP-001|Vaccine-Sensitized Draining Lymph Node Cells|Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules|Vactosertib|Vadacabtagene Leraleucel|Vadastuximab Talirine|Vadimezan|Valecobulin|Valemetostat|Valproic Acid|Valrubicin|Valspodar|Vandetanib|Vandetanib-eluting Radiopaque Bead BTG-002814|Vandortuzumab Vedotin|Vantictumab|Vanucizumab|Vapreotide|Varlilumab|Varlitinib|Varlitinib Tosylate|Vascular Disrupting Agent BNC105|Vascular Disrupting Agent BNC105P|Vascular Disrupting Agent ZD6126|Vatalanib|Vatalanib Succinate|Vecabrutinib|Vector-peptide Conjugated Paclitaxel|Vedolizumab|Veliparib|Veltuzumab|Vemurafenib|Venetoclax|Verapamil|Verpasep Caltespen|Verubulin|Verubulin Hydrochloride|Vesencumab|Vesigenurtucel-L|Viagenpumatucel-L|Vibecotamab|Vibostolimab|Vilaprisan|Vinblastine|Vinblastine Sulfate|Vincristine|Vincristine Liposomal|Vincristine Sulfate|Vincristine Sulfate Liposome|Vindesine|Vinepidine|Vinflunine|Vinflunine Ditartrate|Vinfosiltine|Vinorelbine|Vinorelbine Tartrate|Vinorelbine Tartrate Emulsion|Vinorelbine Tartrate Oral|Vintafolide|Vinzolidine|Vinzolidine Sulfate|Virulizin|Vismodegib|Vistusertib|Vitamin D3 Analogue ILX23-7553|Vitamin E Compound|Vitespen|Vocimagene Amiretrorepvec|Vofatamab|Volasertib|Volociximab|Vonlerolizumab|Vopratelimab|Vorasidenib|Vorinostat|Vorolanib|Vorsetzumab Mafodotin|Vosaroxin|Vosilasarm|Voxtalisib|Vulinacimab|WT1 Peptide Vaccine OCV-501|WT1 Peptide Vaccine WT2725|WT1 Protein-derived Peptide Vaccine DSP-7888|WT1-A10/AS01B Immunotherapeutic GSK2130579A|WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401|Warfarin Sodium|Wee1 Inhibitor ZN-c3|Wee1 Kinase Inhibitor Debio 0123|White Carrot|Wnt Signaling Inhibitor SM04755|Wnt Signaling Pathway Inhibitor SM08502|Wnt-5a Mimic Hexapeptide Foxy-5|Wobe-Mugos E|XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410|XIAP Antisense Oligonucleotide AEG35156|XIAP/cIAP1 Antagonist ASTX660|XPO1 Inhibitor SL-801|Xanthohumol|Xeloda|Xentuzumab|Xevinapant|Xiaoai Jiedu Decoction|Xiliertinib|Xisomab 3G3|Y 90 Monoclonal Antibody CC49|Y 90 Monoclonal Antibody HMFG1|Y 90 Monoclonal Antibody Lym-1|Y 90 Monoclonal Antibody M195|Y 90 Monoclonal Antibody m170|Yang Yin Fu Zheng|Yangzheng Xiaoji Extract|Yiqi-yangyin-jiedu Herbal Decoction|Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12|Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101|Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66|Yttrium Y 90 Basiliximab|Yttrium Y 90 Colloid|Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A|Yttrium Y 90 Daclizumab|Yttrium Y 90 Glass Microspheres|Yttrium Y 90 Monoclonal Antibody B3|Yttrium Y 90 Monoclonal Antibody BrE-3|Yttrium Y 90 Monoclonal Antibody Hu3S193|Yttrium Y 90 Monoclonal Antibody MN-14|Yttrium Y 90 Resin Microspheres|Yttrium Y 90 Tabituximab Barzuxetan|Yttrium Y 90-DOTA-Biotin|Yttrium Y 90-DOTA-di-HSG Peptide IMP-288|Yttrium Y 90-Edotreotide|Yttrium Y 90-labeled Anti-FZD10 Monoclonal Antibody OTSA101|Yttrium Y-90 Clivatuzumab Tetraxetan|Yttrium Y-90 Epratuzumab Tetraxetan|Yttrium Y-90 Ibritumomab Tiuxetan|Yttrium Y-90 Tacatuzumab Tetraxetan|Yttrium-90 Polycarbonate Brachytherapy Plaque|Z-Endoxifen Hydrochloride|Zalcitabine|Zalifrelimab|Zalutumumab|Zandelisib|Zanidatamab|Zanolimumab|Zanubrutinib|Zebularine|Zelavespib|Zibotentan|Zinc Finger Nuclease ZFN-603|Zinc Finger Nuclease ZFN-758|Zinostatin|Zinostatin Stimalamer|Zirconium Zr 89 Panitumumab|Ziv-Aflibercept|Zolbetuximab|Zoledronic Acid|Zoptarelin Doxorubicin|Zorifertinib|Zorubicin|Zorubicin Hydrochloride|Zotatifin|Zotiraciclib Citrate|Zuclomiphene Citrate|alpha-Folate Receptor-targeting Thymidylate Synthase Inhibitor ONX-0801|c-Kit Inhibitor PLX9486|c-Met Inhibitor ABN401|c-Met Inhibitor AL2846|c-Met Inhibitor AMG 208|c-Met Inhibitor AMG 337|c-Met Inhibitor GST-HG161|c-Met Inhibitor HS-10241|c-Met Inhibitor JNJ-38877605|c-Met Inhibitor MK2461|c-Met Inhibitor MK8033|c-Met Inhibitor MSC2156119J|c-raf Antisense Oligonucleotide ISIS 5132|cEt KRAS Antisense Oligonucleotide AZD4785|cFMS Tyrosine Kinase Inhibitor ARRY-382|cis-Urocanic Acid|dUTPase/DPD Inhibitor TAS-114|eIF4E Antisense Oligonucleotide ISIS 183750|hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301|hTERT Vaccine V934/V935|hTERT-encoding DNA Vaccine INVAC-1|huBC1-huIL12 Fusion Protein AS1409|iNKT Cell Agonist ABX196|iNOS Dimerization Inhibitor ASP9853|iPSC-derived CD16-expressing Natural Killer Cells FT516|iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596|iPSC-derived Natural Killer Cells FT500|mRNA-Derived Prostate Cancer Vaccine CV9103|mRNA-based Personalized Cancer Vaccine NCI-4650|mRNA-based Personalized Cancer Vaccine mRNA-4157|mRNA-based TriMix Melanoma Vaccine ECI-006|mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902|mRNA-derived KRAS-targeted Vaccine V941|mRNA-derived Lung Cancer Vaccine BI 1361849|mRNA-derived Prostate Cancer Vaccine CV9104|mTOR Inhibitor GDC-0349|mTOR Kinase Inhibitor AZD8055|mTOR Kinase Inhibitor CC-223|mTOR Kinase Inhibitor OSI-027|mTOR Kinase Inhibitor PP242|mTOR1/2 Kinase Inhibitor ME-344|mTORC 1/2 Inhibitor LXI-15029|mTORC1/2 Kinase Inhibitor BI 860585|mTORC1/mTORC2/DHFR Inhibitor ABTL0812|ncmtRNA Oligonucleotide Andes-1537|p300/CBP Bromodomain Inhibitor CCS1477|p38 MAPK Inhibitor LY3007113|p53 Peptide Vaccine MPS-128|p53-HDM2 Interaction Inhibitor MI-773|p53-HDM2 Protein-protein Interaction Inhibitor APG-115|p53/HDM2 Interaction Inhibitor CGM097|p70S6K Inhibitor LY2584702|p70S6K/Akt Inhibitor MSC2363318A|p97 Inhibitor CB-5083|p97 Inhibitor CB-5339|p97 Inhibitor CB-5339 Tosylate|pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0|pNGVL4a-CRT-E6E7L2 DNA Vaccine|pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2|pan FGFR Inhibitor PRN1371|pan-HER Kinase Inhibitor AC480|pan-PI3K Inhibitor CLR457|pan-PI3K/mTOR Inhibitor SF1126|pan-PIM Kinase Inhibitor AZD1208|pan-PIM Kinase Inhibitor NVP-LGB-321|pan-RAF Inhibitor LXH254|pan-RAF Kinase Inhibitor CCT3833|pan-RAF Kinase Inhibitor TAK-580|pbi-shRNA STMN1 Lipoplex|siG12D LODER|siRNA-transfected Peripheral Blood Mononuclear Cells APN401|ssRNA-based Immunomodulator CV8102	4473/4475 (both/PDC)	Oblimersen Sodium|Ocaratuzumab	
treatment_anatomic_site	treatment_anatomic_site	Abdomen, total|Abdominal Wall|Acetabulum|Adenoid|Adipose|Adrenal|Alveolar Ridge|Amniotic Fluid|Ampulla of Vater|Anal Sphincter|Ankle|Anorectum|Antecubital Fossa|Antrum|Anus|Aorta|Aortic Body|Appendix|Aqueous Fluid|Arm|Artery|Ascending Colon|Ascending Colon Hepatic Flexure|Ascites|Auditory Canal|Autonomic Nervous System|Axilla|Back|Bile Duct|Bladder|Blood|Blood Vessel|Body, total|Bone|Bone Marrow|Bone, non-spine|Bowel|Brain|Brain Stem|Breast|Broad Ligament|Bronchiole|Bronchus|Brow|Buccal Cavity|Buccal Mucosa|Buttock|Calf|Capillary|Cardia|Carina|Carotid Artery|Carotid Body|Cartilage|Cecum|Cell-Line|Central Nervous System|Cerebellum|Cerebral Cortex|Cerebrospinal Fluid|Cervical Spine|Cervix|Chest|Chest Wall|Chin|Clavicle|Clitoris|Colon|Colon - Mucosa Only|Common Duct|Conjunctiva|Connective Tissue|Dermal|Descending Colon|Diaphragm|Distant Site|Duodenum|Ear|Ear Canal|Ear, Pinna (External)|Elbow|Endocrine Gland|Epididymis|Epidural Space|Esophagogastric Junction|Esophagus|Esophagus - Mucosa Only|Eye|Fallopian Tube|Femoral Artery|Femoral Vein|Femur|Fibroblasts|Fibula|Finger|Floor of Mouth|Fluid|Foot|Forearm|Forehead|Foreskin|Frontal Cortex|Frontal Lobe|Fundus of Stomach|Gallbladder|Ganglia|Gastroesophageal Junction|Gastrointestinal Tract|Gastrointestinal, Intestine|Genitourinary, NOS|Gum|Hand|Hard Palate|Head - Face Or Neck, Nos|Head and Neck|Heart|Hepatic|Hepatic Duct|Hepatic Vein|Hip|Hippocampus|Humerus|Hypopharynx|Ileocecal Valve|Ileum|Ilium|Index Finger|Ischium|Islet Cells|Jaw|Jejunum|Joint|Kidney|Knee|Lacrimal Gland|Large Bowel|Laryngopharynx|Larynx|Leg|Leptomeninges|Ligament|Lip|Liver|Lumbar Spine|Lung|Lymph Node|Lymph Node(s) Axilla|Lymph Node(s) Cervical|Lymph Node(s) Distant|Lymph Node(s) Epitrochlear|Lymph Node(s) Femoral|Lymph Node(s) Hilar|Lymph Node(s) Iliac-Common|Lymph Node(s) Iliac-External|Lymph Node(s) Inguinal|Lymph Node(s) Internal Mammary|Lymph Node(s) Mammary|Lymph Node(s) Mediastinal|Lymph Node(s) Mesenteric|Lymph Node(s) Occipital|Lymph Node(s) Paraaortic|Lymph Node(s) Parotid|Lymph Node(s) Pelvic|Lymph Node(s) Popliteal|Lymph Node(s) Regional|Lymph Node(s) Retroperitoneal|Lymph Node(s) Scalene|Lymph Node(s) Splenic|Lymph Node(s) Subclavicular|Lymph Node(s) Submandibular|Lymph Node(s) Supraclavicular|Mandible|Mantle|Maxilla|Mediastinal Soft Tissue|Mediastinum|Mesentery|Mesothelium|Middle Finger|Mitochondria|Muscle|Nails|Nasal Cavity|Nasal Soft Tissue|Nasopharynx|Neck|Nerve|Nerve(s) Cranial|Not Reported|Occipital Cortex|Ocular Orbits|Omentum|Oral Cavity|Oral Cavity - Mucosa Only|Oropharynx|Other|Ovary|Palate|Pancreas|Parametrium|Paraspinal Ganglion|Parathyroid|Parotid Gland|Patella|Pelvis|Penis|Pericardium|Periorbital Soft Tissue|Peritoneal Cavity|Peritoneum|Pharynx|Pineal|Pineal Gland|Pituitary Gland|Placenta|Pleura|Popliteal Fossa|Pouch|Primary Tumor Field|Primary tumor site|Prostate|Prostate Bed|Prostate, Seminal Vesicles and Lymph Nodes|Pylorus|Rectosigmoid Junction|Rectum|Regional Site|Retina|Retro-Orbital Region|Retroperitoneum|Rib|Ring Finger|Round Ligament|Sacrum|Salivary Gland|Scalp|Scapula|Sciatic Nerve|Scrotum|Seminal Vesicle|Shoulder|Sigmoid Colon|Sinus|Sinus(es), Maxillary|Skeletal Muscle|Skin|Skin, lower extremity, local|Skin, total|Skin, trunk, local|Skin, upper extremity, local|Skull|Small Bowel|Small Bowel - Mucosa Only|Small Finger|Soft Tissue|Spinal Column|Spinal Cord|Spine|Spleen|Splenic Flexure|Sternum|Stomach|Stomach - Mucosa Only|Subcutaneous Tissue|Synovium|Temporal Cortex|Tendon|Testis|Thigh|Thoracic Spine|Thorax|Throat|Thumb|Thymus|Thyroid|Tibia|Tongue|Tonsil|Tonsil (Pharyngeal)|Trachea / Major Bronchi|Transverse Colon|Trunk|Umbilical Cord|Unknown|Ureter|Urethra|Urinary Tract|Uterus|Uvula|Vagina|Vas Deferens|Vein|Venous|Vertebra|Vulva|White Blood Cells|Wrist	297/301 (both/PDC)	Cerebrum|Epitrochlear|Groin|Hilar	Cerebral Hemisphere|Epitrochlear Lymph Node|Inguinal Region|Perihilar Lymph Node
treatment_arm	treatment_arm	A081105|A081801|E4512|EA5142	4/4 (both/PDC)		
treatment_dose_units	treatment_dose_units	Gy|cGy	2/3 (both/PDC)	mg	Milligram
treatment_effect	treatment_effect	Complete Necrosis (No Viable Tumor)|Incomplete Necrosis (Viable Tumor Present)|No Known Treatment Effect|No Necrosis|Not Reported|Unknown	6/6 (both/PDC)		
treatment_effect_indicator	treatment_effect_indicator	False|Not Reported|True|Unknown	4/4 (both/PDC)		
treatment_frequency	treatment_frequency	Every 24 Hours|Every Hour|Every Other Day|Five Times Daily|Four Times Daily|Not Reported|Once Weekly|Three Times Daily|Twice Daily|Twice Weekly|Unknown	11/11 (both/PDC)		
treatment_intent_type	treatment_intent_type	Adjuvant|Androgen Deprivation Therapy (ADT)|Cancer Control|Cure|Maintenance Therapy|Neoadjuvant|Not Reported|Palliative|Prevention|Unknown	10/10 (both/PDC)		
treatment_or_therapy	treatment_or_therapy	False|True|not reported|unknown	4/4 (both/PDC)		
treatment_outcome	treatment_outcome	Complete Response|Mixed Response|No Measurable Disease|No Response|Not Reported|Partial Response|Persistent Disease|Progressive Disease|Stable Disease|Treatment Ongoing|Treatment Stopped Due to Toxicity|Unknown|Very Good Partial Response	13/13 (both/PDC)		
treatment_type	treatment_type	Ablation, Cryo|Ablation, Ethanol Injection|Ablation, Microwave|Ablation, NOS|Ablation, Radiofrequency|Ablation, Radiosurgical|Ancillary Treatment|Antiseizure Treatment|Bisphosphonate Therapy|Blinded Study, Treatment Unknown|Brachytherapy, High Dose|Brachytherapy, Low Dose|Brachytherapy, NOS|Chemoembolization|Chemoprotectant|Chemotherapy|Concurrent Chemoradiation|Cryoablation|Embolization|Ethanol Injection Ablation|External Beam Radiation|Hormone Therapy|I-131 Radiation Therapy|Immunotherapy (Including Vaccines)|Internal Radiation|Isolated Limb Perfusion (ILP)|Not Allowed To Collect|Not Reported|Organ Transplantation|Other|Pharmaceutical Therapy, NOS|Pleurodesis|Pleurodesis, NOS|Pleurodesis, Talc|Radiation Therapy, NOS|Radiation, 2D Conventional|Radiation, 3D Conformal|Radiation, Combination|Radiation, Cyberknife|Radiation, External Beam|Radiation, Implants|Radiation, Intensity-Modulated Radiotherapy|Radiation, Internal|Radiation, Mixed Photon Beam|Radiation, Proton Beam|Radiation, Radioisotope|Radiation, Stereotactic/Gamma Knife/SRS|Radiation, Systemic|Radioactive Iodine Therapy|Radioembolization|Radiosensitizing Agent|Stem Cell Transplantation, Allogeneic|Stem Cell Transplantation, Autologous|Stem Cell Transplantation, Double Autologous|Stem Cell Transplantation, Haploidentical|Stem Cell Transplantation, NOS|Stem Cell Transplantation, Non-Myeloablative|Stem Cell Transplantation, Syngenic|Stem Cell Treatment|Stereotactic Radiosurgery|Steroid Therapy|Surgery|Targeted Molecular Therapy|Unknown	64/66 (both/PDC)	Radiation, Hypofractionated|Radiation, Photon Beam	Hypofractionated Radiation Therapy|Photon Beam Radiation Therapy
